[
  {
    "id": "20251018-183400-17591e6c",
    "createdAt": "2025-10-18T18:34:00.294Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Remove Crack (Cocaine) - 18/10/2025, 20:33:57"
    },
    "articles": [
      {
        "id": 429,
        "title": "O-PCP",
        "slug": "o-pcp"
      },
      {
        "id": 439,
        "title": "Phenylpropylaminopentane",
        "slug": "phenylpropylaminopentane"
      },
      {
        "id": 437,
        "title": "4-PrO-DMT",
        "slug": "4-pro-dmt"
      },
      {
        "id": 438,
        "title": "3-EtO-PCP",
        "slug": "3-eto-pcp"
      },
      {
        "id": 440,
        "title": "Methoxetamine",
        "slug": "methoxetamine"
      },
      {
        "id": 442,
        "title": "Clobenzorex",
        "slug": "clobenzorex"
      },
      {
        "id": 443,
        "title": "Fluminorex",
        "slug": "fluminorex"
      },
      {
        "id": 441,
        "title": "EDMC",
        "slug": "edmc"
      },
      {
        "id": 444,
        "title": "Ziprasidone",
        "slug": "ziprasidone"
      },
      {
        "id": 446,
        "title": "α-Pyrrolidinopropiophenone",
        "slug": "pyrrolidinopropiophenone"
      },
      {
        "id": 448,
        "title": "MDPV",
        "slug": "mdpv"
      },
      {
        "id": 449,
        "title": "3-Methyl-4-fluoro-α-pyrrolidinovalerophenone",
        "slug": "3-methyl-4-fluoro-pyrrolidinovalerophenone"
      },
      {
        "id": 451,
        "title": "Flmodafinil",
        "slug": "flmodafinil"
      },
      {
        "id": 453,
        "title": "Galantamine",
        "slug": "galantamine"
      },
      {
        "id": 454,
        "title": "Flubrotizolam",
        "slug": "flubrotizolam"
      },
      {
        "id": 455,
        "title": "Fluclotizolam",
        "slug": "fluclotizolam"
      },
      {
        "id": 457,
        "title": "Fluetizolam",
        "slug": "fluetizolam"
      },
      {
        "id": 458,
        "title": "Chlorpheniramine",
        "slug": "chlorpheniramine"
      },
      {
        "id": 459,
        "title": "Flupirtine",
        "slug": "flupirtine"
      },
      {
        "id": 460,
        "title": "Scopolamine",
        "slug": "scopolamine"
      },
      {
        "id": 461,
        "title": "4-Benzylpiperidine",
        "slug": "4-benzylpiperidine"
      },
      {
        "id": 462,
        "title": "Ethylbromazolam",
        "slug": "ethylbromazolam"
      },
      {
        "id": 463,
        "title": "Nifoxipam",
        "slug": "nifoxipam"
      },
      {
        "id": 464,
        "title": "DMNPC",
        "slug": "dmnpc"
      },
      {
        "id": 466,
        "title": "Fluorolintane",
        "slug": "fluorolintane"
      },
      {
        "id": 447,
        "title": "Halodrol-50",
        "slug": "halodrol-50"
      },
      {
        "id": 467,
        "title": "4-Bromomethcathinone",
        "slug": "4-bromomethcathinone"
      },
      {
        "id": 470,
        "title": "Phenylpiracetam",
        "slug": "phenylpiracetam"
      },
      {
        "id": 468,
        "title": "2C-TFM",
        "slug": "2c-tfm"
      },
      {
        "id": 469,
        "title": "Adderall XR",
        "slug": "adderall-xr"
      },
      {
        "id": 471,
        "title": "Tesofensine",
        "slug": "tesofensine"
      },
      {
        "id": 472,
        "title": "25E-NBOH",
        "slug": "25e-nboh"
      },
      {
        "id": 474,
        "title": "Bromonordiazepam",
        "slug": "bromonordiazepam"
      },
      {
        "id": 475,
        "title": "Agmatine Sulfate",
        "slug": "agmatine-sulfate"
      },
      {
        "id": 477,
        "title": "GVL",
        "slug": "gvl"
      },
      {
        "id": 479,
        "title": "Methyl-K",
        "slug": "methyl-k"
      },
      {
        "id": 480,
        "title": "Flumazenil",
        "slug": "flumazenil"
      },
      {
        "id": 481,
        "title": "Hexedrone",
        "slug": "hexedrone"
      },
      {
        "id": 483,
        "title": "L-Theanine",
        "slug": "l-theanine"
      },
      {
        "id": 484,
        "title": "Imodium",
        "slug": "imodium"
      },
      {
        "id": 485,
        "title": "LSZ",
        "slug": "lsz"
      },
      {
        "id": 486,
        "title": "MD-prolintane",
        "slug": "md-prolintane"
      },
      {
        "id": 487,
        "title": "Methocarbamol",
        "slug": "methocarbamol"
      },
      {
        "id": 488,
        "title": "Rasagiline",
        "slug": "rasagiline"
      },
      {
        "id": 489,
        "title": "D2PM",
        "slug": "d2pm"
      },
      {
        "id": 490,
        "title": "Fenozolone",
        "slug": "fenozolone"
      },
      {
        "id": 473,
        "title": "2-Me-PiHP",
        "slug": "2-me-pihp"
      },
      {
        "id": 491,
        "title": "1D-LSD",
        "slug": "1d-lsd"
      },
      {
        "id": 493,
        "title": "GABOB",
        "slug": "gabob"
      },
      {
        "id": 465,
        "title": "2-FDCK",
        "slug": "2-fdck"
      },
      {
        "id": 494,
        "title": "JWH-018",
        "slug": "jwh-018"
      },
      {
        "id": 424,
        "title": "2-Me-DMT",
        "slug": "2-me-dmt"
      },
      {
        "id": 496,
        "title": "2-MPPP",
        "slug": "2-mppp"
      },
      {
        "id": 499,
        "title": "4'-Fluoro-4-methylaminorex",
        "slug": "4-fluoro-4-methylaminorex"
      },
      {
        "id": 503,
        "title": "3-CEC",
        "slug": "3-cec"
      },
      {
        "id": 501,
        "title": "4B-MAR",
        "slug": "4b-mar"
      },
      {
        "id": 504,
        "title": "5-MeO-AMT",
        "slug": "5-meo-amt"
      },
      {
        "id": 497,
        "title": "MXPCP",
        "slug": "mxpcp"
      },
      {
        "id": 506,
        "title": "4-MPD",
        "slug": "4-mpd"
      },
      {
        "id": 507,
        "title": "25P-NBOMe",
        "slug": "25p-nbome"
      },
      {
        "id": 518,
        "title": "2C-T-4-NBOMe",
        "slug": "2c-t-4-nbome"
      },
      {
        "id": 519,
        "title": "2C-T-7-NBOMe",
        "slug": "2c-t-7-nbome"
      },
      {
        "id": 520,
        "title": "4-Methoxybutyrfentanyl",
        "slug": "4-methoxybutyrfentanyl"
      },
      {
        "id": 521,
        "title": "5-MAPB",
        "slug": "5-mapb"
      },
      {
        "id": 523,
        "title": "4-Fluorophenylpiperazine",
        "slug": "4-fluorophenylpiperazine"
      },
      {
        "id": 531,
        "title": "25H-NBOMe",
        "slug": "25h-nbome"
      },
      {
        "id": 524,
        "title": "4-Fluoropentedrone",
        "slug": "4-fluoropentedrone"
      },
      {
        "id": 526,
        "title": "25I-NBMD",
        "slug": "25i-nbmd"
      },
      {
        "id": 527,
        "title": "4-EMC",
        "slug": "4-emc"
      },
      {
        "id": 528,
        "title": "25I-NBF",
        "slug": "25i-nbf"
      },
      {
        "id": 529,
        "title": "25I-NBOH",
        "slug": "25i-nboh"
      },
      {
        "id": 532,
        "title": "4-AcO-DPT",
        "slug": "4-aco-dpt"
      },
      {
        "id": 533,
        "title": "3C-E",
        "slug": "3c-e"
      },
      {
        "id": 534,
        "title": "25C-NB3OMe",
        "slug": "25c-nb3ome"
      },
      {
        "id": 535,
        "title": "2-Bromo-4,5-MDMA",
        "slug": "2-bromo-4-5-mdma"
      },
      {
        "id": 536,
        "title": "3-MeO-PCPy",
        "slug": "3-meo-pcpy"
      },
      {
        "id": 545,
        "title": "1S-LSD",
        "slug": "1s-lsd"
      },
      {
        "id": 537,
        "title": "3-MEC",
        "slug": "3-mec"
      },
      {
        "id": 538,
        "title": "2-MeO-Ketamine",
        "slug": "2-meo-ketamine"
      },
      {
        "id": 539,
        "title": "2-MeO-DMT",
        "slug": "2-meo-dmt"
      },
      {
        "id": 540,
        "title": "2C-T-7",
        "slug": "2c-t-7"
      },
      {
        "id": 541,
        "title": "2C-T-4",
        "slug": "2c-t-4"
      },
      {
        "id": 543,
        "title": "2C-B-FLY-NBOMe",
        "slug": "2c-b-fly-nbome"
      },
      {
        "id": 544,
        "title": "2-NMC",
        "slug": "2-nmc"
      },
      {
        "id": 546,
        "title": "alpha-D2PV",
        "slug": "alpha-d2pv"
      },
      {
        "id": 547,
        "title": "Monotropa uniflora",
        "slug": "monotropa-uniflora"
      },
      {
        "id": 548,
        "title": "1cP-AL-LAD",
        "slug": "1cp-al-lad"
      },
      {
        "id": 549,
        "title": "Tapentadol",
        "slug": "tapentadol"
      },
      {
        "id": 550,
        "title": "4-Pro-MET",
        "slug": "4-pro-met"
      },
      {
        "id": 551,
        "title": "Desmethylflunitrazepam",
        "slug": "desmethylflunitrazepam"
      },
      {
        "id": 552,
        "title": "DCK",
        "slug": "dck"
      },
      {
        "id": 557,
        "title": "1-(2,5-Dimethoxybenzyl) piperazine",
        "slug": "1-2-5-dimethoxybenzyl-piperazine"
      },
      {
        "id": 558,
        "title": "2-PTA",
        "slug": "2-pta"
      },
      {
        "id": 560,
        "title": "2-TFMXP",
        "slug": "2-tfmxp"
      },
      {
        "id": 562,
        "title": "4-EPD",
        "slug": "4-epd"
      },
      {
        "id": 563,
        "title": "CBC",
        "slug": "cbc"
      },
      {
        "id": 566,
        "title": "CBG",
        "slug": "cbg"
      },
      {
        "id": 567,
        "title": "3,4-Trimethylenepentedrone",
        "slug": "3-4-trimethylenepentedrone"
      },
      {
        "id": 568,
        "title": "4Cl-iBF",
        "slug": "4cl-ibf"
      },
      {
        "id": 569,
        "title": "4F-MABP",
        "slug": "4f-mabp"
      },
      {
        "id": 570,
        "title": "4F-MDMB-BINACA",
        "slug": "4f-mdmb-binaca"
      },
      {
        "id": 575,
        "title": "Benzedrone",
        "slug": "benzedrone"
      },
      {
        "id": 572,
        "title": "ADB-INACA",
        "slug": "adb-inaca"
      },
      {
        "id": 573,
        "title": "4-CBC",
        "slug": "4-cbc"
      },
      {
        "id": 574,
        "title": "4-EEC",
        "slug": "4-eec"
      },
      {
        "id": 576,
        "title": "4-Methylephedrine",
        "slug": "4-methylephedrine"
      },
      {
        "id": 577,
        "title": "CBDVA",
        "slug": "cbdva"
      },
      {
        "id": 578,
        "title": "CBN",
        "slug": "cbn"
      },
      {
        "id": 580,
        "title": "Amfecloral",
        "slug": "amfecloral"
      },
      {
        "id": 581,
        "title": "Diethylpropion",
        "slug": "diethylpropion"
      },
      {
        "id": 583,
        "title": "AM-694",
        "slug": "am-694"
      },
      {
        "id": 584,
        "title": "ADBICA",
        "slug": "adbica"
      },
      {
        "id": 585,
        "title": "Afloqualone",
        "slug": "afloqualone"
      },
      {
        "id": 587,
        "title": "Adinazolam",
        "slug": "adinazolam"
      },
      {
        "id": 588,
        "title": "AM-2233",
        "slug": "am-2233"
      },
      {
        "id": 589,
        "title": "AMB-CHMICA",
        "slug": "amb-chmica"
      },
      {
        "id": 590,
        "title": "AMB-FUBINACA",
        "slug": "amb-fubinaca"
      },
      {
        "id": 591,
        "title": "Etoxadrol",
        "slug": "etoxadrol"
      },
      {
        "id": 592,
        "title": "CB-13",
        "slug": "cb-13"
      },
      {
        "id": 593,
        "title": "CBDV",
        "slug": "cbdv"
      },
      {
        "id": 594,
        "title": "CBNA",
        "slug": "cbna"
      },
      {
        "id": 595,
        "title": "1cP-MiPLA",
        "slug": "1cp-mipla"
      },
      {
        "id": 596,
        "title": "C30-NBOMe",
        "slug": "c30-nbome"
      },
      {
        "id": 597,
        "title": "Bufotenin",
        "slug": "bufotenin"
      },
      {
        "id": 598,
        "title": "Butorphanol",
        "slug": "butorphanol"
      },
      {
        "id": 599,
        "title": "Atropine",
        "slug": "atropine"
      },
      {
        "id": 600,
        "title": "AM-1248",
        "slug": "am-1248"
      },
      {
        "id": 601,
        "title": "Aniracetam",
        "slug": "aniracetam"
      },
      {
        "id": 602,
        "title": "Armodafinil",
        "slug": "armodafinil"
      },
      {
        "id": 603,
        "title": "Acetyldihydrocodeine",
        "slug": "acetyldihydrocodeine"
      },
      {
        "id": 604,
        "title": "Acetildenafil",
        "slug": "acetildenafil"
      },
      {
        "id": 605,
        "title": "25T-NBOMe",
        "slug": "25t-nbome"
      },
      {
        "id": 606,
        "title": "5-MAPDB",
        "slug": "5-mapdb"
      },
      {
        "id": 607,
        "title": "ADB-PINACA",
        "slug": "adb-pinaca"
      },
      {
        "id": 608,
        "title": "ADB-PINACA isomer 2",
        "slug": "adb-pinaca-isomer-2"
      },
      {
        "id": 609,
        "title": "AM-2201",
        "slug": "am-2201"
      },
      {
        "id": 611,
        "title": "BDCK",
        "slug": "bdck"
      },
      {
        "id": 612,
        "title": "Beta-meprodine",
        "slug": "beta-meprodine"
      },
      {
        "id": 613,
        "title": "3,4-DMMC",
        "slug": "3-4-dmmc"
      },
      {
        "id": 615,
        "title": "Amobarbital",
        "slug": "amobarbital"
      },
      {
        "id": 616,
        "title": "AKB-57",
        "slug": "akb-57"
      },
      {
        "id": 530,
        "title": "Ro5-4864",
        "slug": "ro5-4864"
      },
      {
        "id": 617,
        "title": "2-MMC",
        "slug": "2-mmc"
      },
      {
        "id": 450,
        "title": "Pyrovalerone",
        "slug": "pyrovalerone"
      },
      {
        "id": 174,
        "title": "Carisoprodol",
        "slug": "carisoprodol"
      },
      {
        "id": 618,
        "title": "4-Cl-PPP",
        "slug": "4-cl-ppp"
      },
      {
        "id": 619,
        "title": "4-CBC (4-Chlorobuphedrone)",
        "slug": "4-cbc-4-chlorobuphedrone"
      },
      {
        "id": 620,
        "title": "4-FPP",
        "slug": "4-fpp"
      },
      {
        "id": 621,
        "title": "4-MEPPP",
        "slug": "4-meppp"
      },
      {
        "id": 622,
        "title": "4-MXP",
        "slug": "4-mxp"
      },
      {
        "id": 623,
        "title": "5-AEDB",
        "slug": "5-aedb"
      },
      {
        "id": 625,
        "title": "5-Cl-AMT",
        "slug": "5-cl-amt"
      },
      {
        "id": 626,
        "title": "Diphenhydramine",
        "slug": "diphenhydramine"
      },
      {
        "id": 627,
        "title": "Diphenhydramine",
        "slug": "diphenhydramine"
      },
      {
        "id": 628,
        "title": "1V-LSD",
        "slug": "1v-lsd"
      },
      {
        "id": 629,
        "title": "ALD-52",
        "slug": "ald-52"
      },
      {
        "id": 630,
        "title": "ETH-LAD",
        "slug": "eth-lad"
      },
      {
        "id": 631,
        "title": "LSA",
        "slug": "lsa"
      },
      {
        "id": 632,
        "title": "MiPLA",
        "slug": "mipla"
      },
      {
        "id": 633,
        "title": "MET",
        "slug": "met"
      },
      {
        "id": 634,
        "title": "LSM-775",
        "slug": "lsm-775"
      },
      {
        "id": 635,
        "title": "PRO-LAD",
        "slug": "pro-lad"
      },
      {
        "id": 636,
        "title": "DET",
        "slug": "det"
      },
      {
        "id": 637,
        "title": "EPT",
        "slug": "ept"
      },
      {
        "id": 638,
        "title": "4-AcO-DiPT",
        "slug": "4-aco-dipt"
      },
      {
        "id": 639,
        "title": "4-AcO-MiPT",
        "slug": "4-aco-mipt"
      },
      {
        "id": 640,
        "title": "4-HO-DET",
        "slug": "4-ho-det"
      },
      {
        "id": 641,
        "title": "4-HO-DiPT",
        "slug": "4-ho-dipt"
      },
      {
        "id": 642,
        "title": "4-HO-EPT",
        "slug": "4-ho-ept"
      },
      {
        "id": 643,
        "title": "4-HO-MPT",
        "slug": "4-ho-mpt"
      },
      {
        "id": 644,
        "title": "5-MeO-DiPT",
        "slug": "5-meo-dipt"
      },
      {
        "id": 645,
        "title": "Psilocin",
        "slug": "psilocin"
      },
      {
        "id": 646,
        "title": "Allylescaline",
        "slug": "allylescaline"
      },
      {
        "id": 647,
        "title": "Escaline",
        "slug": "escaline"
      },
      {
        "id": 648,
        "title": "Proscaline",
        "slug": "proscaline"
      },
      {
        "id": 649,
        "title": "2C-T",
        "slug": "2c-t"
      },
      {
        "id": 650,
        "title": "2,5-DMA",
        "slug": "2-5-dma"
      },
      {
        "id": 651,
        "title": "DOI",
        "slug": "doi"
      },
      {
        "id": 652,
        "title": "25C-NBOH",
        "slug": "25c-nboh"
      },
      {
        "id": 653,
        "title": "25D-NBOMe",
        "slug": "25d-nbome"
      },
      {
        "id": 654,
        "title": "25N-NBOMe",
        "slug": "25n-nbome"
      },
      {
        "id": 655,
        "title": "TMA-6",
        "slug": "tma-6"
      },
      {
        "id": 656,
        "title": "4-MeO-PCP",
        "slug": "4-meo-pcp"
      },
      {
        "id": 657,
        "title": "PCE",
        "slug": "pce"
      },
      {
        "id": 658,
        "title": "Nitrous Oxide",
        "slug": "nitrous-oxide"
      },
      {
        "id": 659,
        "title": "Benzydamine",
        "slug": "benzydamine"
      }
    ],
    "markdown": "# O-PCP · #429\n\n-  \"id\": 435,\n-  \"title\": \"Crack (Cocaine)\",\n+  \"id\": 429,\n+  \"title\": \"O-PCP\",\n-    \"drug_name\": \"Crack (Cocaine)\",\n-    \"chemical_name\": \"Crack\",\n-    \"alternative_name\": \"Cocaine\",\n-    \"chemical_class\": \"Tropanes\",\n-    \"mechanism_of_action\": \"Serotonin-dopamine-norepinephrine reuptake inhibitor\",\n-    \"psychoactive_class\": \"Powerful CNS stimulant (dopamine-norepinephrine-serotonin re-uptake inhibitor; sodium-channel blocker)\",\n+    \"drug_name\": \"O-PCP\",\n+    \"chemical_name\": \"O-PCP\",\n+    \"alternative_name\": \"2-Keto-PCP\",\n+    \"chemical_class\": \"Arylcyclohexylamines\",\n+    \"mechanism_of_action\": \"NMDA receptor antagonist\",\n+    \"psychoactive_class\": \"Dissociative; Hallucinogen\",\n-          \"route\": \"vaporized / smoked\",\n-          \"units\": \"mg (free-base)\",\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"10-20\",\n-            \"light\": \"20-40\",\n-            \"common\": \"40-100\",\n-            \"strong\": \"100-200\",\n-            \"heavy\": \"200+\"\n+            \"threshold\": \"3mg\",\n+            \"light\": \"3mg - 8mg\",\n+            \"common\": \"8mg - 18mg\",\n+            \"strong\": \"18mg - 35mg\",\n+            \"heavy\": \"35mg+\"\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"2mg\",\n+            \"light\": \"2mg - 6mg\",\n+            \"common\": \"6mg - 12mg\",\n+            \"strong\": \"12mg - 22mg\",\n+            \"heavy\": \"22mg+\"\n+          }\n+        },\n+        {\n+          \"route\": \"vaporized / inhaled\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"3mg\",\n+            \"light\": \"3mg - 8mg\",\n+            \"common\": \"8mg - 15mg\",\n+            \"strong\": \"15mg - 25mg\",\n+            \"heavy\": \"25mg+\"\n+          }\n+        },\n+        {\n+          \"route\": \"rectal (boofed)\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"2mg\",\n+            \"light\": \"2mg - 5mg\",\n+            \"common\": \"5mg - 15mg\",\n+            \"strong\": \"15mg - 30mg\",\n+            \"heavy\": \"30mg+\"\n+          }\n+        },\n+        {\n+          \"route\": \"intramuscular\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"1mg\",\n+            \"light\": \"1mg - 4mg\",\n+            \"common\": \"4mg - 10mg\",\n+            \"strong\": \"10mg - 18mg\",\n+            \"heavy\": \"18mg+\"\n+          }\n-          \"route\": \"vaporized / smoked\",\n+          \"route\": \"oral\",\n+            \"oral\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"3-5 h (active phase)\",\n+            \"onset\": \"20-40 min\",\n+            \"peak\": \"0.8-2 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"1-8 h residual disequilibrium; mild stimulation or fatigue\"\n+          }\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"3-5 h (active phase)\",\n+            \"onset\": \"10-20 min or\",\n+            \"peak\": \"0.8-2 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"1-8 h residual disequilibrium; mild stimulation or fatigue\"\n+          }\n+        },\n+        {\n+          \"route\": \"vaporized / inhaled\",\n+          \"canonical_routes\": [\n-            \"smoked\"\n+            \"inhaled\"\n-            \"total_duration\": \"5-20 minutes\",\n-            \"onset\": \"5-10 seconds\",\n-            \"peak\": \"0.5-2 minutes\",\n-            \"offset\": \"5-15 minutes\",\n-            \"after_effects\": \"15-60 minutes craving, agitation, dysphoria\"\n+            \"total_duration\": \"3-5 h (active phase)\",\n+            \"onset\": \"10-20 min or\",\n+            \"peak\": \"0.8-2 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"1-8 h residual disequilibrium; mild stimulation or fatigue\"\n+        },\n+        {\n+          \"route\": \"rectal (boofed)\",\n+          \"canonical_routes\": [\n+            \"rectal\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"3-5 h (active phase)\",\n+            \"peak\": \"0.8-2 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"1-8 h residual disequilibrium; mild stimulation or fatigue\"\n+          }\n+        },\n+        {\n+          \"route\": \"intramuscular\",\n+          \"canonical_routes\": [\n+            \"intramuscular\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"3-5 h (active phase)\",\n+            \"onset\": \"5-15 min\",\n+            \"peak\": \"0.8-2 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"1-8 h residual disequilibrium; mild stimulation or fatigue\"\n+          }\n-    \"addiction_potential\": \"Extremely high: the short, intense rush and rapid dissipation create potent reinforcement; binges of multiple grams in a night are common.\",\n+    \"addiction_potential\": \"Moderate – early animal work on close analogues (4-keto-PCP) shows conditioned place-preference and ΔFosB up-regulation, and users report redose creep at 20–40 mg ranges.\",\n-        \"alcohol (cocaethylene formation)\",\n+        \"opioids (respiratory depression or unpredictable synergy while incapacitated)\",\n+        \"high-dose CNS depressants such as benzodiazepines or alcohol\",\n-        \"strong stimulants (methamphetamine, α-PVP)\",\n-        \"synthetic cannabinoids (tachyarrhythmia synergy)\"\n+        \"strong stimulants (tachyarrhythmia, hyperthermia)\"\n-        \"MDMA / mephedrone\",\n-        \"caffeine in large amounts\",\n+        \"other dissociatives (ketamine, DXM, PCP analogues)\",\n+        \"serotonergic psychedelics (risk of serotonin toxicity)\",\n-        \"benzodiazepines (post-binge respiratory depression)\",\n-        \"opioids (masked overdose risk)\",\n-        \"antipsychotics (QT-prolongation)\"\n+        \"SSRI / SNRI antidepressants\",\n+        \"THC concentrates (panic, derealisation)\",\n+        \"antipsychotics (QT prolongation, lowered seizure threshold)\"\n-    \"notes\": \"Use a dedicated glass stem with fresh chore (copper or brillo) to reduce burns; share no mouthpieces to avoid hepatitis/HIV transmission. Keep the flame below the rock—vaporise, don't burn—to minimise loss and throat damage. Start low, go slow, and pause at least 10 min between hits to assess cardiovascular strain. Carry water to counteract dry mouth and maintain hydration. If mixing with alcohol, recognise heightened cardiotoxicity. Naloxone will not reverse a stimulant overdose; call EMS if chest pain, severe tachycardia (>140 bpm), or seizures occur.\",\n+    \"notes\": \"4-HO-PCP has a heavier physical body-load than classic PCP analogues, with users citing muscle soreness, flu-like malaise, and caustic crystals that irritate mucous membranes. Build in recovery time and protect airways when handling the powder.\\n\\nFirst appeared on European grey-market vendors in early-2025; GC-MS reference spectra correspond to CAS 101688-16-8. Community reports place potency between ketamine and PCP but with a more sedating body-load and a noticeably shorter plateau (≈1–2 h). A r/dissociatives user found 10-15 mg vaped on an e-mesh produced a clear-headed, ketamine-like dissociation lasting ~90 min, while 20 mg produced stronger but still lucid effects. The same thread confirms rapid onset when vaporised and minimal hallucinations below 25 mg. Moderators on r/researchchemicals warn of a theoretical μ-opioid component (based on older unverified assays) and advise starting ≤5 mg until more data emerge. Some r/researchchemicals member thread placed an oral ‘sweet‑spot’ around 15‑20 mg for naïve users with a 4‑hour plateau. Rectal administration is popular; although, one user experienced pronounced ataxia at 32 mg, while cumulatively 170 mg spread across a night produced disorientation, memory gaps and next‑day fatigue. Vendor write-ups describe it as “long-lasting and highly potent”; reagent testing (Mandelin/Mecke) plus FT-IR or GC-MS is recommended because early shipments were confused with O-PCPr and O-PCE. Powder is hygroscopic and clings electrostatically—volumetric dosing in PG or EtOH-water (10 mg/mL) avoids milligram-scale error. No formal pharmacokinetic papers exist; user toxicology screens detect parent compound ≤12 h post-dose, implying elimination t½ of roughly 3-6 h. Cross-tolerance with other aryl-cyclohexylamines develops rapidly; spacing sessions by ≥7 days is advised to restore baseline NMDA sensitivity.\",\n-      \"intense euphoria / 'rush'\",\n-      \"sharp mental stimulation\",\n-      \"boosted confidence and talkativeness\",\n-      \"enhanced libido\",\n-      \"jaw clenching\",\n-      \"anxiety / paranoia on comedown\",\n-      \"powerful cravings\",\n-      \"insomnia\"\n+      \"moderate, ‘clinical’ dissociation\",\n+      \"sedating body-heaviness\",\n+      \"mild euphoria / mood lift\",\n+      \"analgesia and numbness\",\n+      \"time compression\",\n+      \"subtle visual snow at higher doses\",\n+      \"clear-headed cognition (≤25 mg)\"\n-      \"full_tolerance\": \"Can escalate within a single multi-gram binge\",\n-      \"half_tolerance\": \"2-3 days\",\n+      \"full_tolerance\": \"after one heavy session\",\n+      \"half_tolerance\": \"2-4 days\",\n-        \"powder cocaine\",\n-        \"other rapid-acting stimulants\"\n+        \"ketamine\",\n+        \"other arylcyclohexylamines\"\n-    \"half_life\": \"≈70-80 min systemic (psychoactive window much shorter when smoked)\",\n+    \"half_life\": \"≈3-6 h (estimated from user toxicology data)\",\n-        \"name\": \"Cocaine - Anodyne Wiki\",\n-        \"reference\": \"https://anodyne.wiki/substance/cocaine\"\n+        \"name\": \"Wikipedia aryl-cyclohexylamine table (lists 2-keto-PCP)\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Arylcyclohexylamine\"\n-        \"name\": \"NIDA - cocaine overview & risks\",\n-        \"reference\": \"https://nida.nih.gov/research-topics/cocaine\"\n+        \"name\": \"File – structure of 2-keto-PCP\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/File:O-PCP_structure.png\"\n-        \"name\": \"PubMed - cocaine pharmacokinetics (half-life)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/2565204/\"\n+        \"name\": \"Bluelight ‘O-PCP’ discussion thread (lack of data, cautions)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/o-pcp.946382/\"\n-        \"name\": \"PMC - cocaethylene review\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC8956485/\"\n+        \"name\": \"Reddit r/dissociatives – 10–20 mg vaped experience\",\n+        \"reference\": \"https://www.reddit.com/r/dissociatives/comments/1l42x14/just_vaped_15mg_of_opcp_very_dissociative_and/\"\n-        \"name\": \"DOJ Crack Fast Facts - appearance & smoking\",\n-        \"reference\": \"https://www.justice.gov/archive/ndic/pubs3/3978/3978p.pdf\"\n-      },\n-      {\n-        \"name\": \"Bluelight - crack dosage per hit\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/crack-dosage-per-hit.736965/\"\n-      },\n-      {\n-        \"name\": \"Drugs-Forum - typical dose 0.1-0.2 g\",\n-        \"reference\": \"https://drugs-forum.com/threads/crack-overdose-amount.154834/\"\n-      },\n-      {\n-        \"name\": \"National Harm Reduction Coalition - safer smoking tips\",\n-        \"reference\": \"https://harmreduction.org/issues/safer-drug-use/facts/\"\n-      },\n-      {\n-        \"name\": \"Vital Strategies - stimulant harm-reduction tip-sheet\",\n-        \"reference\": \"https://harmreduction.org/wp-content/uploads/2021/09/COVID-19-Simulant-Use-and-Harm-Reduction.pdf\"\n-      },\n-      {\n-        \"name\": \"UNODC World Drug Report (prevalence)\",\n-        \"reference\": \"https://erowid.org/psychoactives/statistics/statistics_unodc_world_drug_report_2014.pdf\"\n-      },\n-      {\n-        \"name\": \"Wikipedia: Crack cocaine\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Crack_cocaine\"\n+        \"name\": \"Reddit r/researchchemicals – caution about possible opioid activity\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/1kqk95a/warning_about_opcp_potentially_an_opioid_with_few/\"\n-      \"stimulant\",\n-      \"habit-forming\"\n+      \"dissociative\",\n+      \"research-chemical\"\n\n# Phenylpropylaminopentane · #439\n\n-  \"id\": 429,\n-  \"title\": \"O-PCP\",\n+  \"id\": 439,\n+  \"title\": \"Phenylpropylaminopentane\",\n-    \"drug_name\": \"O-PCP\",\n-    \"chemical_name\": \"O-PCP\",\n-    \"alternative_name\": \"2-Keto-PCP\",\n-    \"chemical_class\": \"Arylcyclohexylamines\",\n-    \"mechanism_of_action\": \"NMDA receptor antagonist\",\n-    \"psychoactive_class\": \"Dissociative; Hallucinogen\",\n+    \"drug_name\": \"Phenylpropylaminopentane\",\n+    \"chemical_name\": \"Phenylpropylaminopentane\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Other stimulants\",\n+    \"mechanism_of_action\": \"Trace amine receptor agonist\",\n+    \"psychoactive_class\": \"Catecholaminergic activity enhancer (CAE); mild psychostimulant\",\n-            \"threshold\": \"3mg\",\n-            \"light\": \"3mg - 8mg\",\n-            \"common\": \"8mg - 18mg\",\n-            \"strong\": \"18mg - 35mg\",\n-            \"heavy\": \"35mg+\"\n+            \"threshold\": \"5mg\",\n+            \"light\": \"5mg - 20mg\",\n+            \"common\": \"20mg - 60mg\",\n+            \"strong\": \"60mg - 100mg\",\n+            \"heavy\": \"100mg+\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"sublingual / buccal\",\n-            \"threshold\": \"2mg\",\n-            \"light\": \"2mg - 6mg\",\n-            \"common\": \"6mg - 12mg\",\n-            \"strong\": \"12mg - 22mg\",\n-            \"heavy\": \"22mg+\"\n-          }\n-        },\n-        {\n-          \"route\": \"vaporized / inhaled\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"light\": \"3mg - 8mg\",\n-            \"common\": \"8mg - 15mg\",\n-            \"strong\": \"15mg - 25mg\",\n-            \"heavy\": \"25mg+\"\n+            \"light\": \"3mg - 15mg\",\n+            \"common\": \"15mg - 40mg\",\n+            \"strong\": \"40mg - 80mg\",\n+            \"heavy\": \"80mg+\"\n-          \"route\": \"rectal (boofed)\",\n+          \"route\": \"insufflated\",\n-            \"threshold\": \"1mg\",\n-            \"light\": \"1mg - 4mg\",\n-            \"common\": \"4mg - 10mg\",\n-            \"strong\": \"10mg - 18mg\",\n-            \"heavy\": \"18mg+\"\n+            \"threshold\": \"2mg\",\n+            \"light\": \"2mg - 5mg\",\n+            \"common\": \"5mg - 15mg\",\n+            \"strong\": \"15mg - 25mg\",\n+            \"heavy\": \"25mg+\"\n-            \"total_duration\": \"3-5 h (active phase)\",\n-            \"onset\": \"20-40 min\",\n-            \"peak\": \"0.8-2 h\",\n+            \"total_duration\": \"4-6 h active\",\n+            \"onset\": \"30-60 min\",\n+            \"peak\": \"1-3 h\",\n-            \"after_effects\": \"1-8 h residual disequilibrium; mild stimulation or fatigue\"\n+            \"after_effects\": \"1-4 h mild fatigue or lowered motivation\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"sublingual / buccal\",\n-            \"insufflated\"\n+            \"sublingual\",\n+            \"buccal\"\n-            \"total_duration\": \"3-5 h (active phase)\",\n-            \"onset\": \"10-20 min or\",\n-            \"peak\": \"0.8-2 h\",\n+            \"total_duration\": \"4-6 h active\",\n+            \"peak\": \"1-3 h\",\n-            \"after_effects\": \"1-8 h residual disequilibrium; mild stimulation or fatigue\"\n+            \"after_effects\": \"1-4 h mild fatigue or lowered motivation\"\n-          \"route\": \"vaporized / inhaled\",\n+          \"route\": \"insufflated\",\n-            \"vaporized\",\n-            \"inhaled\"\n+            \"insufflated\"\n-            \"total_duration\": \"3-5 h (active phase)\",\n-            \"onset\": \"10-20 min or\",\n-            \"peak\": \"0.8-2 h\",\n+            \"total_duration\": \"4-6 h active\",\n+            \"onset\": \"5-10 min\",\n+            \"peak\": \"1-3 h\",\n-            \"after_effects\": \"1-8 h residual disequilibrium; mild stimulation or fatigue\"\n+            \"after_effects\": \"1-4 h mild fatigue or lowered motivation\"\n-          \"route\": \"rectal (boofed)\",\n-          \"canonical_routes\": [\n-            \"rectal\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"3-5 h (active phase)\",\n-            \"peak\": \"0.8-2 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"1-8 h residual disequilibrium; mild stimulation or fatigue\"\n-          }\n-        },\n-        {\n-            \"total_duration\": \"3-5 h (active phase)\",\n-            \"onset\": \"5-15 min\",\n-            \"peak\": \"0.8-2 h\",\n+            \"total_duration\": \"4-6 h active\",\n+            \"onset\": \"2-5 min\",\n+            \"peak\": \"1-3 h\",\n-            \"after_effects\": \"1-8 h residual disequilibrium; mild stimulation or fatigue\"\n+            \"after_effects\": \"1-4 h mild fatigue or lowered motivation\"\n-    \"addiction_potential\": \"Moderate – early animal work on close analogues (4-keto-PCP) shows conditioned place-preference and ΔFosB up-regulation, and users report redose creep at 20–40 mg ranges.\",\n+    \"addiction_potential\": \"Low-to-moderate. Lacks the intense dopaminergic ‘rush’ of releasers; compulsive re-dosing is uncommon, but psychological reliance reported at ≥100 mg/day.\",\n-        \"opioids (respiratory depression or unpredictable synergy while incapacitated)\",\n-        \"high-dose CNS depressants such as benzodiazepines or alcohol\",\n-        \"MAOIs\",\n-        \"strong stimulants (tachyarrhythmia, hyperthermia)\"\n+        \"high-dose adrenergic stimulants (amphetamine, ephedrine) – hypertensive crises\",\n+        \"MAO-A inhibitors – possible catecholamine overload\",\n+        \"strong CYP2D6 inhibitors (fluoxetine, paroxetine) – unpredictable potentiation\"\n-        \"other dissociatives (ketamine, DXM, PCP analogues)\",\n-        \"serotonergic psychedelics (risk of serotonin toxicity)\",\n-        \"tramadol (seizure risk)\"\n+        \"synthetic cathinones / pyrovalerones\",\n+        \"high-dose bupropion (seizure threshold lowering)\",\n+        \"cocaine\"\n-        \"SSRI / SNRI antidepressants\",\n-        \"THC concentrates (panic, derealisation)\",\n-        \"antipsychotics (QT prolongation, lowered seizure threshold)\"\n+        \"other mild stimulants (caffeine, modafinil) – additive tachycardia\",\n+        \"serotonergic psychedelics – overstimulation\",\n+        \"dopamine agonists (pramipexole) – agitation, insomnia\"\n-    \"notes\": \"4-HO-PCP has a heavier physical body-load than classic PCP analogues, with users citing muscle soreness, flu-like malaise, and caustic crystals that irritate mucous membranes. Build in recovery time and protect airways when handling the powder.\\n\\nFirst appeared on European grey-market vendors in early-2025; GC-MS reference spectra correspond to CAS 101688-16-8. Community reports place potency between ketamine and PCP but with a more sedating body-load and a noticeably shorter plateau (≈1–2 h). A r/dissociatives user found 10-15 mg vaped on an e-mesh produced a clear-headed, ketamine-like dissociation lasting ~90 min, while 20 mg produced stronger but still lucid effects. The same thread confirms rapid onset when vaporised and minimal hallucinations below 25 mg. Moderators on r/researchchemicals warn of a theoretical μ-opioid component (based on older unverified assays) and advise starting ≤5 mg until more data emerge. Some r/researchchemicals member thread placed an oral ‘sweet‑spot’ around 15‑20 mg for naïve users with a 4‑hour plateau. Rectal administration is popular; although, one user experienced pronounced ataxia at 32 mg, while cumulatively 170 mg spread across a night produced disorientation, memory gaps and next‑day fatigue. Vendor write-ups describe it as “long-lasting and highly potent”; reagent testing (Mandelin/Mecke) plus FT-IR or GC-MS is recommended because early shipments were confused with O-PCPr and O-PCE. Powder is hygroscopic and clings electrostatically—volumetric dosing in PG or EtOH-water (10 mg/mL) avoids milligram-scale error. No formal pharmacokinetic papers exist; user toxicology screens detect parent compound ≤12 h post-dose, implying elimination t½ of roughly 3-6 h. Cross-tolerance with other aryl-cyclohexylamines develops rapidly; spacing sessions by ≥7 days is advised to restore baseline NMDA sensitivity.\",\n+    \"notes\": \"PPAP's sublingual route can irritate mucosa and its effect curve plateaus quickly. Tolerance tends to fade after roughly three days, but reagent testing and sub-10 mg allergy checks remain best practice.\\n\\nPPAP is the selegiline-derived prototype of the ‘monoaminergic activity enhancer’ family. In contrast to amphetamine, it only augments neurotransmitter release *when* an action potential arrives, producing a smoother cognition-boosting profile with minimal euphoria. Animal work (2 mg kg⁻¹ i.p.) shows doubled dopamine/noradrenaline release without overflow, and no stereotypy until 25-50 mg kg⁻¹. Human self-experiments describe clear focus, wakefulness and pro-social energy at 20-80 mg oral, with a plateau lasting ~3 h and negligible crash. Reddit reports (10-30 mg) confirm synergy with modafinil or prescription stimulants, while a 1100 mg overdose mainly produced anxiety and tremor, hinting at a wide toxicity window but steeply rising side-effects. Users emphasise titration with an analytical milligram scale; volumetric dosing of HCl salt into 10 mg/mL water is common. Threshold activity via insufflation (~2-5 mg) suggests high bioavailability. Unlike selegiline, PPAP shows no measurable MAO inhibition up to 50 mg kg⁻¹ in rodents. Estimated elimination half-life in humans is 4-6 h based on subjective offset and rat PK parallels. Because it is unscheduled federally in the US yet an amphetamine analogue, customs seizures occur; reagent testing cannot distinguish PPAP from propylamphetamine. Storage: light-protected, desiccated ≤4 °C to prevent gradual discoloration and potency loss.\",\n-      \"moderate, ‘clinical’ dissociation\",\n-      \"sedating body-heaviness\",\n-      \"mild euphoria / mood lift\",\n-      \"analgesia and numbness\",\n-      \"time compression\",\n-      \"subtle visual snow at higher doses\",\n-      \"clear-headed cognition (≤25 mg)\"\n+      \"clean mental stimulation\",\n+      \"enhanced task focus\",\n+      \"increased motivation\",\n+      \"subtle mood lift\",\n+      \"mild peripheral stimulation (warmth, HR ↑)\",\n+      \"minimal euphoria\",\n+      \"rare sexual enhancement\"\n-      \"full_tolerance\": \"after one heavy session\",\n-      \"half_tolerance\": \"2-4 days\",\n-      \"zero_tolerance\": \"7-10 days\",\n+      \"full_tolerance\": \"after 3-5 consecutive heavy days\",\n+      \"half_tolerance\": \"4-7 days\",\n+      \"zero_tolerance\": \"10-14 days\",\n-        \"ketamine\",\n-        \"other arylcyclohexylamines\"\n+        \"selegiline\",\n+        \"BPAP\"\n-    \"half_life\": \"≈3-6 h (estimated from user toxicology data)\",\n+    \"half_life\": \"≈4-6 h (extrapolated from animal PK and user reports)\",\n-        \"name\": \"Wikipedia aryl-cyclohexylamine table (lists 2-keto-PCP)\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Arylcyclohexylamine\"\n+        \"name\": \"PPAP pharmacology – Archives Int. Pharmacodyn. Ther. 1992\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/1356324/\"\n-        \"name\": \"File – structure of 2-keto-PCP\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/File:O-PCP_structure.png\"\n+        \"name\": \"(-)PPAP stimulates transmitter-release coupling (Life Sci. 1996)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/8602114/\"\n-        \"name\": \"Bluelight ‘O-PCP’ discussion thread (lack of data, cautions)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/o-pcp.946382/\"\n+        \"name\": \"Wikipedia overview (chemistry/legal)\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Phenylpropylaminopentane\"\n-        \"name\": \"Reddit r/dissociatives – 10–20 mg vaped experience\",\n-        \"reference\": \"https://www.reddit.com/r/dissociatives/comments/1l42x14/just_vaped_15mg_of_opcp_very_dissociative_and/\"\n+        \"name\": \"Bluelight – Phenylpropylaminopentane discussion & 5 mg insufflation notes\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/phenylpropylaminopentane-and-the-stuffmonger-debauchle.569182/\"\n-        \"name\": \"Reddit r/researchchemicals – caution about possible opioid activity\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/1kqk95a/warning_about_opcp_potentially_an_opioid_with_few/\"\n+        \"name\": \"Reddit r/Nootropics – PPAP HCl dosing (10-150 mg) thread\",\n+        \"reference\": \"https://www.reddit.com/r/Nootropics/comments/zhpfx5/ppap_hclwhere_has_it_gone_apologize_for_any/\"\n+      },\n+      {\n+        \"name\": \"Reddit r/Nootropics – ‘PPAP three years later’ (50-100 mg daily use)\",\n+        \"reference\": \"https://www.reddit.com/r/Nootropics/comments/19eazpw/ppap_three_years_later/\"\n+      },\n+      {\n+        \"name\": \"Reddit r/Nootropics – half-life & 30 mg recommendation\",\n+        \"reference\": \"https://www.reddit.com/r/Nootropics/comments/4m09uh/ppap_halflife_and_dosing/\"\n+      },\n+      {\n+        \"name\": \"Knoll J. Anti-aging compounds review (PPAP/BPAP overview)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/11607046/\"\n-      \"dissociative\",\n-      \"research-chemical\"\n+      \"stimulant\",\n+      \"research-chemical\",\n+      \"Other stimulants\"\n\n# 4-PrO-DMT · #437\n\n-  \"id\": 439,\n-  \"title\": \"Phenylpropylaminopentane\",\n+  \"id\": 437,\n+  \"title\": \"4-PrO-DMT\",\n-    \"drug_name\": \"Phenylpropylaminopentane\",\n-    \"chemical_name\": \"Phenylpropylaminopentane\",\n+    \"drug_name\": \"4-PrO-DMT\",\n+    \"chemical_name\": \"4-PrO-DMT\",\n-    \"chemical_class\": \"Other stimulants\",\n-    \"mechanism_of_action\": \"Trace amine receptor agonist\",\n-    \"psychoactive_class\": \"Catecholaminergic activity enhancer (CAE); mild psychostimulant\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-          \"units\": \"mg\",\n+          \"units\": \"mg (fumarate or free-base*)\",\n-            \"threshold\": \"5mg\",\n-            \"light\": \"5mg - 20mg\",\n-            \"common\": \"20mg - 60mg\",\n-            \"strong\": \"60mg - 100mg\",\n-            \"heavy\": \"100mg+\"\n+            \"threshold\": \"5\",\n+            \"light\": \"5–15\",\n+            \"common\": \"15–30\",\n+            \"strong\": \"30–45\",\n+            \"heavy\": \"45+\"\n-          \"route\": \"sublingual / buccal\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"3mg\",\n-            \"light\": \"3mg - 15mg\",\n-            \"common\": \"15mg - 40mg\",\n-            \"strong\": \"40mg - 80mg\",\n-            \"heavy\": \"80mg+\"\n-          }\n-        },\n-        {\n-            \"threshold\": \"2mg\",\n-            \"light\": \"2mg - 5mg\",\n-            \"common\": \"5mg - 15mg\",\n-            \"strong\": \"15mg - 30mg\",\n-            \"heavy\": \"30mg+\"\n+            \"threshold\": \"3\",\n+            \"light\": \"3–10\",\n+            \"common\": \"10–20\",\n+            \"strong\": \"20–30\",\n+            \"heavy\": \"30+\"\n-          \"route\": \"intramuscular\",\n-          \"units\": \"mg\",\n+          \"route\": \"vaporized / smoked\",\n+          \"units\": \"mg (free-base)\",\n-            \"threshold\": \"2mg\",\n-            \"light\": \"2mg - 5mg\",\n-            \"common\": \"5mg - 15mg\",\n-            \"strong\": \"15mg - 25mg\",\n-            \"heavy\": \"25mg+\"\n+            \"threshold\": \"2\",\n+            \"light\": \"2–6\",\n+            \"common\": \"6–12\",\n+            \"strong\": \"12–20\",\n+            \"heavy\": \"20+\"\n-            \"total_duration\": \"4-6 h active\",\n-            \"onset\": \"30-60 min\",\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"1-4 h mild fatigue or lowered motivation\"\n+            \"total_duration\": \"4-7 h (route-dependent)\",\n+            \"onset\": \"<30 s / 10-30 min\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"2-4 h\",\n+            \"after_effects\": \"1-3 h glow / fatigue\"\n-          \"route\": \"sublingual / buccal\",\n-          \"canonical_routes\": [\n-            \"sublingual\",\n-            \"buccal\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"4-6 h active\",\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"1-4 h mild fatigue or lowered motivation\"\n-          }\n-        },\n-        {\n-            \"total_duration\": \"4-6 h active\",\n-            \"onset\": \"5-10 min\",\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"1-4 h mild fatigue or lowered motivation\"\n+            \"total_duration\": \"4-7 h (route-dependent)\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"2-4 h\",\n+            \"after_effects\": \"1-3 h glow / fatigue\"\n-          \"route\": \"intramuscular\",\n+          \"route\": \"vaporized / smoked\",\n-            \"intramuscular\"\n+            \"vaporized\",\n+            \"smoked\"\n-            \"total_duration\": \"4-6 h active\",\n-            \"onset\": \"2-5 min\",\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"1-4 h mild fatigue or lowered motivation\"\n+            \"total_duration\": \"4-7 h (route-dependent)\",\n+            \"onset\": \"<30 s / 10-30 min\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"2-4 h\",\n+            \"after_effects\": \"1-3 h glow / fatigue\"\n-    \"addiction_potential\": \"Low-to-moderate. Lacks the intense dopaminergic ‘rush’ of releasers; compulsive re-dosing is uncommon, but psychological reliance reported at ≥100 mg/day.\",\n+    \"addiction_potential\": \"Low (classical serotonergic) but rapid tolerance discourages daily use.\",\n-        \"high-dose adrenergic stimulants (amphetamine, ephedrine) – hypertensive crises\",\n-        \"MAO-A inhibitors – possible catecholamine overload\",\n-        \"strong CYP2D6 inhibitors (fluoxetine, paroxetine) – unpredictable potentiation\"\n+        \"MAO-A inhibitors (hypertensive crisis / serotonin syndrome)\",\n+        \"lithium (seizure risk)\",\n+        \"5-HT3 antagonists paired with very high doses (masks nausea, risk of over-consumption)\"\n-        \"synthetic cathinones / pyrovalerones\",\n-        \"high-dose bupropion (seizure threshold lowering)\",\n-        \"cocaine\"\n+        \"other strong psychedelics (LSD, 4-AcO-DMT) in the same session\",\n+        \"high-dose stimulants (tachycardia / anxiety synergy)\"\n-        \"other mild stimulants (caffeine, modafinil) – additive tachycardia\",\n-        \"serotonergic psychedelics – overstimulation\",\n-        \"dopamine agonists (pramipexole) – agitation, insomnia\"\n+        \"SSRI / SNRI (dulls effects, serotonin load)\",\n+        \"benzodiazepines (may blunt trip, mask distress)\",\n+        \"alcohol (nausea, dehydration)\"\n-    \"notes\": \"PPAP's sublingual route can irritate mucosa and its effect curve plateaus quickly. Tolerance tends to fade after roughly three days, but reagent testing and sub-10 mg allergy checks remain best practice.\\n\\nPPAP is the selegiline-derived prototype of the ‘monoaminergic activity enhancer’ family. In contrast to amphetamine, it only augments neurotransmitter release *when* an action potential arrives, producing a smoother cognition-boosting profile with minimal euphoria. Animal work (2 mg kg⁻¹ i.p.) shows doubled dopamine/noradrenaline release without overflow, and no stereotypy until 25-50 mg kg⁻¹. Human self-experiments describe clear focus, wakefulness and pro-social energy at 20-80 mg oral, with a plateau lasting ~3 h and negligible crash. Reddit reports (10-30 mg) confirm synergy with modafinil or prescription stimulants, while a 1100 mg overdose mainly produced anxiety and tremor, hinting at a wide toxicity window but steeply rising side-effects. Users emphasise titration with an analytical milligram scale; volumetric dosing of HCl salt into 10 mg/mL water is common. Threshold activity via insufflation (~2-5 mg) suggests high bioavailability. Unlike selegiline, PPAP shows no measurable MAO inhibition up to 50 mg kg⁻¹ in rodents. Estimated elimination half-life in humans is 4-6 h based on subjective offset and rat PK parallels. Because it is unscheduled federally in the US yet an amphetamine analogue, customs seizures occur; reagent testing cannot distinguish PPAP from propylamphetamine. Storage: light-protected, desiccated ≤4 °C to prevent gradual discoloration and potency loss.\",\n+    \"notes\": \"Animal research and receptor-binding work show 4-PrO-DMT functions mainly as a psilocin pro-drug, reaching peak plasma levels slightly later than 4-AcO-DMT. Forum users report classic \\\"mushroom\\\" visuals and introspection, but with a somewhat heavier body-load (nausea, internal warmth) at comparable intensities. One detailed account described 25 mg fumarate orally as “indistinguishable from 2 g potent cubensis”. Insufflation stings yet produces a faster, steeper come-up, while vaping the free-base can hydrolyse part of the dose into psilocin and propionic acid, giving harsh smoke. Because supply is niche and the compound is unscheduled in many regions, reagent testing plus FT-IR or GC-MS is recommended to rule out NBOMe or DOx mis-sales.\",\n-      \"clean mental stimulation\",\n-      \"enhanced task focus\",\n-      \"increased motivation\",\n-      \"subtle mood lift\",\n-      \"mild peripheral stimulation (warmth, HR ↑)\",\n-      \"minimal euphoria\",\n-      \"rare sexual enhancement\"\n+      \"bright, cartoon-like visuals\",\n+      \"enhanced colour saturation\",\n+      \"emotional openness / introspection\",\n+      \"mild euphoria\",\n+      \"body warmth / flushing\",\n+      \"nausea (some users)\",\n+      \"time dilation\",\n+      \"after-glow calm\"\n-      \"full_tolerance\": \"after 3-5 consecutive heavy days\",\n-      \"half_tolerance\": \"4-7 days\",\n-      \"zero_tolerance\": \"10-14 days\",\n+      \"full_tolerance\": \"after one strong experience\",\n+      \"half_tolerance\": \"≈3 days\",\n+      \"zero_tolerance\": \"≈7 days\",\n-        \"selegiline\",\n-        \"BPAP\"\n+        \"psilocybin / psilocin\",\n+        \"other 4-substituted tryptamines (4-AcO-DMT, 4-HO-MET)\"\n-    \"half_life\": \"≈4-6 h (extrapolated from animal PK and user reports)\",\n+    \"half_life\": \"Unknown in humans; psilocin t½ ≈3 h—expect similar once pro-drug is hydrolysed.\",\n-        \"name\": \"PPAP pharmacology – Archives Int. Pharmacodyn. Ther. 1992\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/1356324/\"\n+        \"name\": \"ACS Pharm.& Transl. Sci. – receptor-binding & mouse data\",\n+        \"reference\": \"https://pubs.acs.org/doi/10.1021/acsptsci.2c00222\"\n-        \"name\": \"(-)PPAP stimulates transmitter-release coupling (Life Sci. 1996)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/8602114/\"\n+        \"name\": \"J. Med. Chem. – novel psilocin pro-drug series\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC10823477/\"\n-        \"name\": \"Wikipedia overview (chemistry/legal)\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Phenylpropylaminopentane\"\n+        \"name\": \"Wikipedia – 4-PrO-DMT summary\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/4-PrO-DMT\"\n-        \"name\": \"Bluelight – Phenylpropylaminopentane discussion & 5 mg insufflation notes\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/phenylpropylaminopentane-and-the-stuffmonger-debauchle.569182/\"\n+        \"name\": \"EMCDDA Early-Warning Report 2020 – first Swedish ID July 2019\",\n+        \"reference\": \"https://www.euda.europa.eu/system/files/publications/13464/20205648_TD0320796ENN_PDF_rev.pdf\"\n-        \"name\": \"Reddit r/Nootropics – PPAP HCl dosing (10-150 mg) thread\",\n-        \"reference\": \"https://www.reddit.com/r/Nootropics/comments/zhpfx5/ppap_hclwhere_has_it_gone_apologize_for_any/\"\n+        \"name\": \"Reddit r/researchchemicals – psilocin pro-drug discussion\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/1gbo6f1/the_psilocin_prodrug_post/\"\n-        \"name\": \"Reddit r/Nootropics – ‘PPAP three years later’ (50-100 mg daily use)\",\n-        \"reference\": \"https://www.reddit.com/r/Nootropics/comments/19eazpw/ppap_three_years_later/\"\n+        \"name\": \"Bluelight – 25 mg oral report\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/4-pro-dmt-25-mg-oral-first-time-sonic-phantoms.881437/\"\n-        \"name\": \"Reddit r/Nootropics – half-life & 30 mg recommendation\",\n-        \"reference\": \"https://www.reddit.com/r/Nootropics/comments/4m09uh/ppap_halflife_and_dosing/\"\n+        \"name\": \"Reddit r/microdosing – micro-dose experiences\",\n+        \"reference\": \"https://www.reddit.com/r/microdosing/comments/1dihp8q/anyone_microdose_4prodmt_or_mal/\"\n-        \"name\": \"Knoll J. Anti-aging compounds review (PPAP/BPAP overview)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/11607046/\"\n+        \"name\": \"Bluelight – legal-concerns thread on 4-PrO-DMT\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/legal-concerns-over-4-aco-dmt-and-4-pro-dmt-stopping-production.875774/\"\n+      },\n+      {\n+        \"name\": \"ResearchGate – psilocin HTR dose-response\",\n+        \"reference\": \"https://www.researchgate.net/figure/Effect-of-psilocin-on-head-twitch-response-A-Dose-response-of-psilocin-B-Effect-of_fig1_49673909\"\n+      },\n+      {\n+        \"name\": \"PubMed – head-twitch & locomotor study\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/37082754/\"\n-      \"stimulant\",\n-      \"research-chemical\",\n-      \"Other stimulants\"\n+      \"psychedelic\",\n+      \"research-chemical\"\n\n# 3-EtO-PCP · #438\n\n-  \"id\": 437,\n-  \"title\": \"4-PrO-DMT\",\n+  \"id\": 438,\n+  \"title\": \"3-EtO-PCP\",\n-    \"drug_name\": \"4-PrO-DMT\",\n-    \"chemical_name\": \"4-PrO-DMT\",\n+    \"drug_name\": \"3-EtO-PCP\",\n+    \"chemical_name\": \"3-EtO-PCP\",\n-    \"chemical_class\": \"Tryptamines\",\n-    \"mechanism_of_action\": \"5-HT2A receptor agonist\",\n-    \"psychoactive_class\": \"Psychedelic\",\n+    \"chemical_class\": \"Arylcyclohexylamines\",\n+    \"mechanism_of_action\": \"NMDA receptor antagonist\",\n+    \"psychoactive_class\": \"Dissociative; Hallucinogen\",\n-          \"units\": \"mg (fumarate or free-base*)\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"5\",\n-            \"light\": \"5–15\",\n-            \"common\": \"15–30\",\n-            \"strong\": \"30–45\",\n-            \"heavy\": \"45+\"\n+            \"threshold\": \"20–30\",\n+            \"light\": \"30–50\",\n+            \"common\": \"50–80\",\n+            \"strong\": \"80–120\",\n+            \"heavy\": \"120+\"\n-            \"threshold\": \"3\",\n-            \"light\": \"3–10\",\n-            \"common\": \"10–20\",\n-            \"strong\": \"20–30\",\n-            \"heavy\": \"30+\"\n+            \"threshold\": \"10\",\n+            \"light\": \"10–25\",\n+            \"common\": \"25–50\",\n+            \"strong\": \"50–80\",\n+            \"heavy\": \"80+\"\n-            \"threshold\": \"2\",\n-            \"light\": \"2–6\",\n-            \"common\": \"6–12\",\n-            \"strong\": \"12–20\",\n-            \"heavy\": \"20+\"\n+            \"threshold\": \"5\",\n+            \"light\": \"5–15\",\n+            \"common\": \"15–30\",\n+            \"strong\": \"30–50\",\n+            \"heavy\": \"50+\"\n-            \"total_duration\": \"4-7 h (route-dependent)\",\n-            \"onset\": \"<30 s / 10-30 min\",\n-            \"peak\": \"1-2 h\",\n+            \"total_duration\": \"5-8 h (route-dependent)\",\n+            \"onset\": \"≈10 min / 30-45 min\",\n+            \"peak\": \"1-3 h\",\n-            \"after_effects\": \"1-3 h glow / fatigue\"\n+            \"after_effects\": \"4-8 h hazy stimulation / insomnia\"\n-            \"total_duration\": \"4-7 h (route-dependent)\",\n-            \"peak\": \"1-2 h\",\n+            \"total_duration\": \"5-8 h (route-dependent)\",\n+            \"onset\": \"≈10 min / 30-45 min\",\n+            \"peak\": \"1-3 h\",\n-            \"after_effects\": \"1-3 h glow / fatigue\"\n+            \"after_effects\": \"4-8 h hazy stimulation / insomnia\"\n-            \"total_duration\": \"4-7 h (route-dependent)\",\n-            \"onset\": \"<30 s / 10-30 min\",\n-            \"peak\": \"1-2 h\",\n+            \"total_duration\": \"5-8 h (route-dependent)\",\n+            \"peak\": \"1-3 h\",\n-            \"after_effects\": \"1-3 h glow / fatigue\"\n+            \"after_effects\": \"4-8 h hazy stimulation / insomnia\"\n-    \"addiction_potential\": \"Low (classical serotonergic) but rapid tolerance discourages daily use.\",\n+    \"addiction_potential\": \"Moderate: rapid tolerance like other PCP analogues; redosing to chase clarity can escalate intake.\",\n-        \"MAO-A inhibitors (hypertensive crisis / serotonin syndrome)\",\n-        \"lithium (seizure risk)\",\n-        \"5-HT3 antagonists paired with very high doses (masks nausea, risk of over-consumption)\"\n+        \"alcohol or GHB (synergistic respiratory depression)\",\n+        \"opioids (respiratory arrest)\",\n+        \"benzodiazepines at high dose (loss of airway reflexes)\",\n+        \"MAOIs (hypertensive crisis, serotonin syndrome)\"\n-        \"other strong psychedelics (LSD, 4-AcO-DMT) in the same session\",\n-        \"high-dose stimulants (tachycardia / anxiety synergy)\"\n+        \"other potent dissociatives (3-MeO-PCP, ketamine, DXM)\",\n+        \"stimulants with large doses (cardio-toxicity)\",\n+        \"Tramadol (seizure risk)\"\n-        \"SSRI / SNRI (dulls effects, serotonin load)\",\n-        \"benzodiazepines (may blunt trip, mask distress)\",\n-        \"alcohol (nausea, dehydration)\"\n+        \"SSRI / SNRI (serotonin load)\",\n+        \"antipsychotics (QT prolongation)\",\n+        \"cannabis concentrates (panic, dysphoria)\"\n-    \"notes\": \"Animal research and receptor-binding work show 4-PrO-DMT functions mainly as a psilocin pro-drug, reaching peak plasma levels slightly later than 4-AcO-DMT. Forum users report classic \\\"mushroom\\\" visuals and introspection, but with a somewhat heavier body-load (nausea, internal warmth) at comparable intensities. One detailed account described 25 mg fumarate orally as “indistinguishable from 2 g potent cubensis”. Insufflation stings yet produces a faster, steeper come-up, while vaping the free-base can hydrolyse part of the dose into psilocin and propionic acid, giving harsh smoke. Because supply is niche and the compound is unscheduled in many regions, reagent testing plus FT-IR or GC-MS is recommended to rule out NBOMe or DOx mis-sales.\",\n+    \"notes\": \"Structural data (SMILES = \\\"CCOc1cccc(c1)C1(CCCCC1)N1CCCCC1\\\") identify 3-EtO-PCP as a heavier, more lipophilic cousin of 3-MeO-PCP. :contentReference[oaicite:1]{index=1}  A well-documented Reddit trial found **100 mg insufflated** to be an intense yet tolerable dose, with users retrospectively estimating 50–70 mg nasal or 60–80 mg oral as ‘strong’ for those without tolerance. :contentReference[oaicite:2]{index=2}  Insufflation causes a delayed, excruciating burn and lingering sore throat; oral capsules or volumetric solution are strongly recommended. :contentReference[oaicite:3]{index=3}  The head-space is described as “muddy, sedating and low-visual” – more akin to DCK or 3-HO-PCE than the manic clarity of 3-MeO-PCP. :contentReference[oaicite:4]{index=4}  No peer-reviewed pharmacokinetics exist; by analogy to 3-MeO-PCP, a plasma half-life of 6–10 h is plausible, and active hydroxylated metabolites may prolong dissociation. :contentReference[oaicite:5]{index=5}  Because the compound is unscheduled in many regions but visually indistinguishable from other white powders, mis-sales are probable—multi-reagent plus GC-MS testing is essential before use. :contentReference[oaicite:6]{index=6}\",\n-      \"bright, cartoon-like visuals\",\n-      \"enhanced colour saturation\",\n-      \"emotional openness / introspection\",\n+      \"detached, foggy cognition\",\n+      \"analgesia and limb numbness\",\n-      \"body warmth / flushing\",\n-      \"nausea (some users)\",\n-      \"time dilation\",\n-      \"after-glow calm\"\n+      \"time-dilation\",\n+      \"difficulty with motor coordination\",\n+      \"nystagmus at higher doses\",\n+      \"after-glow stimulation / insomnia\"\n-      \"full_tolerance\": \"after one strong experience\",\n-      \"half_tolerance\": \"≈3 days\",\n-      \"zero_tolerance\": \"≈7 days\",\n+      \"full_tolerance\": \"after one heavy session\",\n+      \"half_tolerance\": \"3–5 days\",\n+      \"zero_tolerance\": \"10–14 days\",\n-        \"psilocybin / psilocin\",\n-        \"other 4-substituted tryptamines (4-AcO-DMT, 4-HO-MET)\"\n+        \"other aryl-cyclohexylamines\",\n+        \"dextromethorphan\"\n-    \"half_life\": \"Unknown in humans; psilocin t½ ≈3 h—expect similar once pro-drug is hydrolysed.\",\n+    \"half_life\": \"Estimated 6–10 h (no human PK; inferred from 3-MeO-PCP literature)\",\n-        \"name\": \"ACS Pharm.& Transl. Sci. – receptor-binding & mouse data\",\n-        \"reference\": \"https://pubs.acs.org/doi/10.1021/acsptsci.2c00222\"\n+        \"name\": \"PiHKAL-info – compound record & structural data\",\n+        \"reference\": \"https://isomerdesign.com/pihkal/explore/3386\"\n-        \"name\": \"J. Med. Chem. – novel psilocin pro-drug series\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC10823477/\"\n+        \"name\": \"PubChem CID 165361695 – molecular properties\",\n+        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/165361695\"\n-        \"name\": \"Wikipedia – 4-PrO-DMT summary\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/4-PrO-DMT\"\n+        \"name\": \"Reddit r/researchchemicals – 100 mg insufflated report\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/1g6sg8z/brief_summary_of_an_experience_with_new/\"\n-        \"name\": \"EMCDDA Early-Warning Report 2020 – first Swedish ID July 2019\",\n-        \"reference\": \"https://www.euda.europa.eu/system/files/publications/13464/20205648_TD0320796ENN_PDF_rev.pdf\"\n+        \"name\": \"Reddit r/dissociatives – follow-up thread on dose & burn\",\n+        \"reference\": \"https://www.reddit.com/r/dissociatives/comments/1g6si0d/brief_summary_of_an_experience_with_new/\"\n-        \"name\": \"Reddit r/researchchemicals – psilocin pro-drug discussion\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/1gbo6f1/the_psilocin_prodrug_post/\"\n+        \"name\": \"Reddit post – Nervewing initial thoughts on 3-EtO-PCP\",\n+        \"reference\": \"https://www.reddit.com/user/Nervewing/submitted/\"\n-        \"name\": \"Bluelight – 25 mg oral report\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/4-pro-dmt-25-mg-oral-first-time-sonic-phantoms.881437/\"\n+        \"name\": \"Reddit thread – ‘Novel RCs we’d like to see’ (dose speculation)\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/t0oycn/what_novel_rcs_would_you_like_to_see_made/\"\n-        \"name\": \"Reddit r/microdosing – micro-dose experiences\",\n-        \"reference\": \"https://www.reddit.com/r/microdosing/comments/1dihp8q/anyone_microdose_4prodmt_or_mal/\"\n+        \"name\": \"Bluelight ‘Random Molecules’ discussion (potency expectations)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/i-like-to-draw-pictures-of-random-molecules.582708/page-101\"\n-        \"name\": \"Bluelight – legal-concerns thread on 4-PrO-DMT\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/legal-concerns-over-4-aco-dmt-and-4-pro-dmt-stopping-production.875774/\"\n+        \"name\": \"Bluelight small & handy 3-Me-PCP thread (cross-comparison)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-small-handy-3-methyl-pcp-thread.890346/\"\n-        \"name\": \"ResearchGate – psilocin HTR dose-response\",\n-        \"reference\": \"https://www.researchgate.net/figure/Effect-of-psilocin-on-head-twitch-response-A-Dose-response-of-psilocin-B-Effect-of_fig1_49673909\"\n+        \"name\": \"Frontiers in Chemistry – metabolism of 3-MeO-PCP (analogue)\",\n+        \"reference\": \"https://www.frontiersin.org/articles/10.3389/fchem.2020.618339/full\"\n-        \"name\": \"PubMed – head-twitch & locomotor study\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/37082754/\"\n+        \"name\": \"WHO Critical Review (PCP analogues, structure-activity)\",\n+        \"reference\": \"https://cdn.who.int/media/docs/default-source/controlled-substances/43rd-ecdd/3-meo-pcp-finalreport-a.pdf\"\n-      \"psychedelic\",\n+      \"dissociative\",\n\n# Methoxetamine · #440\n\n-  \"id\": 438,\n-  \"title\": \"3-EtO-PCP\",\n+  \"id\": 440,\n+  \"title\": \"Methoxetamine\",\n-    \"drug_name\": \"3-EtO-PCP\",\n-    \"chemical_name\": \"3-EtO-PCP\",\n+    \"drug_name\": \"Methoxetamine\",\n+    \"chemical_name\": \"Methoxetamine\",\n-    \"mechanism_of_action\": \"NMDA receptor antagonist\",\n+    \"mechanism_of_action\": \"NMDA receptor antagonist; serotonin reuptake inhibitor\",\n-          \"route\": \"oral\",\n+          \"route\": \"oral / sublingual\",\n-            \"threshold\": \"20–30\",\n-            \"light\": \"30–50\",\n-            \"common\": \"50–80\",\n-            \"strong\": \"80–120\",\n-            \"heavy\": \"120+\"\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"5-15 mg\",\n+            \"common\": \"15-45 mg\",\n+            \"strong\": \"45-75 mg\",\n+            \"heavy\": \"75+ mg\"\n-            \"threshold\": \"10\",\n-            \"light\": \"10–25\",\n-            \"common\": \"25–50\",\n-            \"strong\": \"50–80\",\n-            \"heavy\": \"80+\"\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"5-15 mg\",\n+            \"common\": \"15-40 mg\",\n+            \"strong\": \"40-70 mg\",\n+            \"heavy\": \"70+ mg\"\n-          \"route\": \"vaporized / smoked\",\n-          \"units\": \"mg (free-base)\",\n+          \"route\": \"intramuscular\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"5\",\n-            \"light\": \"5–15\",\n-            \"common\": \"15–30\",\n-            \"strong\": \"30–50\",\n-            \"heavy\": \"50+\"\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"5-10 mg\",\n+            \"common\": \"10-25 mg\",\n+            \"strong\": \"25-40 mg\",\n+            \"heavy\": \"40+ mg\"\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"5-15 mg\",\n+            \"common\": \"15-35 mg\",\n+            \"strong\": \"35-60 mg\",\n+            \"heavy\": \"60+ mg\"\n+          }\n-          \"route\": \"oral\",\n+          \"route\": \"oral / sublingual\",\n-            \"oral\"\n+            \"oral\",\n+            \"sublingual\"\n-            \"total_duration\": \"5-8 h (route-dependent)\",\n-            \"onset\": \"≈10 min / 30-45 min\",\n+            \"total_duration\": \"4-6 h (active phase)\",\n+            \"onset\": \"15-45 min\",\n-            \"offset\": \"2-4 h\",\n-            \"after_effects\": \"4-8 h hazy stimulation / insomnia\"\n+            \"offset\": \"2-3 h\",\n+            \"after_effects\": \"2-24 h residual stimulation; disequilibrium\"\n-            \"total_duration\": \"5-8 h (route-dependent)\",\n-            \"onset\": \"≈10 min / 30-45 min\",\n+            \"total_duration\": \"4-6 h (active phase)\",\n+            \"onset\": \"10-20 min\",\n-            \"offset\": \"2-4 h\",\n-            \"after_effects\": \"4-8 h hazy stimulation / insomnia\"\n+            \"offset\": \"2-3 h\",\n+            \"after_effects\": \"2-24 h residual stimulation; disequilibrium\"\n-          \"route\": \"vaporized / smoked\",\n+          \"route\": \"intramuscular\",\n-            \"vaporized\",\n-            \"smoked\"\n+            \"intramuscular\"\n-            \"total_duration\": \"5-8 h (route-dependent)\",\n+            \"total_duration\": \"4-6 h (active phase)\",\n+            \"onset\": \"5-10 min\",\n-            \"offset\": \"2-4 h\",\n-            \"after_effects\": \"4-8 h hazy stimulation / insomnia\"\n+            \"offset\": \"2-3 h\",\n+            \"after_effects\": \"2-24 h residual stimulation; disequilibrium\"\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"canonical_routes\": [\n+            \"rectal\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"4-6 h (active phase)\",\n+            \"peak\": \"1-3 h\",\n+            \"offset\": \"2-3 h\",\n+            \"after_effects\": \"2-24 h residual stimulation; disequilibrium\"\n+          }\n-    \"addiction_potential\": \"Moderate: rapid tolerance like other PCP analogues; redosing to chase clarity can escalate intake.\",\n+    \"addiction_potential\": \"Moderate to high: rapid tolerance and rewarding dissociation encourage redosing; compulsive binges of 200-500 mg reported.\",\n-        \"alcohol or GHB (synergistic respiratory depression)\",\n-        \"opioids (respiratory arrest)\",\n-        \"benzodiazepines at high dose (loss of airway reflexes)\",\n-        \"MAOIs (hypertensive crisis, serotonin syndrome)\"\n+        \"opioids\",\n+        \"benzodiazepines or alcohol (respiratory depression when comatose)\",\n+        \"MAOIs\",\n+        \"high-dose stimulants (tachyarrhythmia, hyperthermia)\"\n-        \"other potent dissociatives (3-MeO-PCP, ketamine, DXM)\",\n-        \"stimulants with large doses (cardio-toxicity)\",\n-        \"Tramadol (seizure risk)\"\n+        \"other dissociatives (ketamine, PCP analogues)\",\n+        \"serotonergic psychedelics (risk of serotonin toxicity)\",\n+        \"tramadol (seizures)\"\n-        \"SSRI / SNRI (serotonin load)\",\n-        \"antipsychotics (QT prolongation)\",\n-        \"cannabis concentrates (panic, dysphoria)\"\n+        \"SSRI or SNRI antidepressants\",\n+        \"cannabis concentrates (panic, depersonalisation)\",\n+        \"antipsychotics (QT prolongation)\"\n-    \"notes\": \"Structural data (SMILES = \\\"CCOc1cccc(c1)C1(CCCCC1)N1CCCCC1\\\") identify 3-EtO-PCP as a heavier, more lipophilic cousin of 3-MeO-PCP. :contentReference[oaicite:1]{index=1}  A well-documented Reddit trial found **100 mg insufflated** to be an intense yet tolerable dose, with users retrospectively estimating 50–70 mg nasal or 60–80 mg oral as ‘strong’ for those without tolerance. :contentReference[oaicite:2]{index=2}  Insufflation causes a delayed, excruciating burn and lingering sore throat; oral capsules or volumetric solution are strongly recommended. :contentReference[oaicite:3]{index=3}  The head-space is described as “muddy, sedating and low-visual” – more akin to DCK or 3-HO-PCE than the manic clarity of 3-MeO-PCP. :contentReference[oaicite:4]{index=4}  No peer-reviewed pharmacokinetics exist; by analogy to 3-MeO-PCP, a plasma half-life of 6–10 h is plausible, and active hydroxylated metabolites may prolong dissociation. :contentReference[oaicite:5]{index=5}  Because the compound is unscheduled in many regions but visually indistinguishable from other white powders, mis-sales are probable—multi-reagent plus GC-MS testing is essential before use. :contentReference[oaicite:6]{index=6}\",\n+    \"notes\": \"Pharmacokinetic work shows an elimination half-life of roughly 3-6 h with active O-desmethyl and N-desethyl metabolites that may lengthen subjective effects. Clinical papers note sensorimotor gating disruption, reversible cerebellar ataxia and bladder toxicity resembling ketamine cystitis. Forum users emphasise volumetric dosing, nasal saline rinses after insufflation, and setting a strict session cap (<=70 mg) to limit compulsive redosing. Because MXE is Schedule I/Prohibited in many regions, powders sold online often contain analogues; confirm identity with multi-reagent tests plus GC-MS where possible.\",\n-      \"detached, foggy cognition\",\n-      \"analgesia and limb numbness\",\n-      \"mild euphoria\",\n-      \"time-dilation\",\n-      \"difficulty with motor coordination\",\n-      \"nystagmus at higher doses\",\n-      \"after-glow stimulation / insomnia\"\n+      \"floating dissociation\",\n+      \"analgesia\",\n+      \"moderate euphoria\",\n+      \"music appreciation\",\n+      \"closed-eye visuals at higher doses\",\n+      \"time dilation\",\n+      \"nystagmus\",\n+      \"afterglow or depressive fatigue\"\n-      \"half_tolerance\": \"3–5 days\",\n-      \"zero_tolerance\": \"10–14 days\",\n+      \"half_tolerance\": \"3-5 days\",\n+      \"zero_tolerance\": \"10-14 days\",\n-        \"other aryl-cyclohexylamines\",\n-        \"dextromethorphan\"\n+        \"ketamine\",\n+        \"other arylcyclohexylamines\"\n-    \"half_life\": \"Estimated 6–10 h (no human PK; inferred from 3-MeO-PCP literature)\",\n+    \"half_life\": \"3-6 h\",\n-        \"name\": \"PiHKAL-info – compound record & structural data\",\n-        \"reference\": \"https://isomerdesign.com/pihkal/explore/3386\"\n+        \"name\": \"Anodyne.wiki Entry on MXE\",\n+        \"reference\": \"https://anodyne.wiki/substance/mxe?\"\n-        \"name\": \"PubChem CID 165361695 – molecular properties\",\n-        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/165361695\"\n+        \"name\": \"Detailed pharmacological evaluation of MXE\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/27155360/\"\n-        \"name\": \"Reddit r/researchchemicals – 100 mg insufflated report\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/1g6sg8z/brief_summary_of_an_experience_with_new/\"\n+        \"name\": \"ScienceDirect Topics – duration by route\",\n+        \"reference\": \"https://www.sciencedirect.com/topics/medicine-and-dentistry/methoxetamine\"\n-        \"name\": \"Reddit r/dissociatives – follow-up thread on dose & burn\",\n-        \"reference\": \"https://www.reddit.com/r/dissociatives/comments/1g6si0d/brief_summary_of_an_experience_with_new/\"\n+        \"name\": \"Ketamine-like effects after recreational MXE use\",\n+        \"reference\": \"https://www.sciencedirect.com/science/article/abs/pii/S0196064411018038\"\n-        \"name\": \"Reddit post – Nervewing initial thoughts on 3-EtO-PCP\",\n-        \"reference\": \"https://www.reddit.com/user/Nervewing/submitted/\"\n+        \"name\": \"Reversible cerebellar toxicity case report\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/22578175/\"\n-        \"name\": \"Reddit thread – ‘Novel RCs we’d like to see’ (dose speculation)\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/t0oycn/what_novel_rcs_would_you_like_to_see_made/\"\n+        \"name\": \"Phenomenological study of MXE experiences\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC3756617/\"\n-        \"name\": \"Bluelight ‘Random Molecules’ discussion (potency expectations)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/i-like-to-draw-pictures-of-random-molecules.582708/page-101\"\n+        \"name\": \"MXE pharmacokinetics and metabolites review\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/27128862/\"\n-        \"name\": \"Bluelight small & handy 3-Me-PCP thread (cross-comparison)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/the-small-handy-3-methyl-pcp-thread.890346/\"\n+        \"name\": \"MXE NMDA IC50 data\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/36344045/\"\n-        \"name\": \"Frontiers in Chemistry – metabolism of 3-MeO-PCP (analogue)\",\n-        \"reference\": \"https://www.frontiersin.org/articles/10.3389/fchem.2020.618339/full\"\n+        \"name\": \"UNODC New Psychoactive Substances report\",\n+        \"reference\": \"https://www.erowid.org/psychoactives/research_chems/research_chems_UNODC_2013_report.pdf\"\n-        \"name\": \"WHO Critical Review (PCP analogues, structure-activity)\",\n-        \"reference\": \"https://cdn.who.int/media/docs/default-source/controlled-substances/43rd-ecdd/3-meo-pcp-finalreport-a.pdf\"\n+        \"name\": \"Erowid MXE dose chart\",\n+        \"reference\": \"https://erowid.org/chemicals/methoxetamine/methoxetamine_dose.shtml\"\n+      },\n+      {\n+        \"name\": \"Bluelight Big & Dandy MXE thread (meta-dose statistics)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-methoxetamine-thread-the-3rd-dose.559691/\"\n+      },\n+      {\n+        \"name\": \"DrugFacts UK – MXE duration and harms\",\n+        \"reference\": \"https://drugfacts.org.uk/index.php?title=Methoxetamine\"\n+      },\n+      {\n+        \"name\": \"Pain Medicine – self-medication case\",\n+        \"reference\": \"https://academic.oup.com/painmedicine/article/17/9/1773/2399345\"\n+      },\n+      {\n+        \"name\": \"Alcohol and Drug Foundation – MXE facts\",\n+        \"reference\": \"https://adf.org.au/drug-facts/methoxetamine/\"\n+      },\n+      {\n+        \"name\": \"Wikipedia – pharmacokinetic summary\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Methoxetamine\"\n+      },\n+      {\n+        \"name\": \"Hi-Ground harm-reduction leaflet\",\n+        \"reference\": \"https://hi-ground.org/substances/methoxetamine-2/\"\n\n# Clobenzorex · #442\n\n-  \"id\": 440,\n-  \"title\": \"Methoxetamine\",\n+  \"id\": 442,\n+  \"title\": \"Clobenzorex\",\n-    \"drug_name\": \"Methoxetamine\",\n-    \"chemical_name\": \"Methoxetamine\",\n+    \"drug_name\": \"Clobenzorex\",\n+    \"chemical_name\": \"Clobenzorex\",\n-    \"chemical_class\": \"Arylcyclohexylamines\",\n-    \"mechanism_of_action\": \"NMDA receptor antagonist; serotonin reuptake inhibitor\",\n-    \"psychoactive_class\": \"Dissociative; Hallucinogen\",\n+    \"chemical_class\": \"Amphetamines\",\n+    \"mechanism_of_action\": \"Dopamine-norepinephrine releasing agent\",\n+    \"psychoactive_class\": \"Stimulant; prodrug that yields d-amphetamine (~15 % conversion)\",\n-          \"route\": \"oral / sublingual\",\n-          \"units\": \"mg\",\n+          \"route\": \"oral\",\n+          \"units\": \"mg of clobenzorex HCl\",\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"5-15 mg\",\n-            \"common\": \"15-45 mg\",\n-            \"strong\": \"45-75 mg\",\n-            \"heavy\": \"75+ mg\"\n+            \"threshold\": \"10 mg\",\n+            \"light\": \"10-25 mg\",\n+            \"common\": \"25-60 mg\",\n+            \"strong\": \"60-120 mg\",\n+            \"heavy\": \"120 mg +\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"insufflated*\",\n-            \"common\": \"15-40 mg\",\n-            \"strong\": \"40-70 mg\",\n-            \"heavy\": \"70+ mg\"\n+            \"common\": \"15-30 mg\",\n+            \"strong\": \"30-60 mg\",\n+            \"heavy\": \"60 mg +\"\n-        },\n-        {\n-          \"route\": \"intramuscular\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"5-10 mg\",\n-            \"common\": \"10-25 mg\",\n-            \"strong\": \"25-40 mg\",\n-            \"heavy\": \"40+ mg\"\n-          }\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"5-15 mg\",\n-            \"common\": \"15-35 mg\",\n-            \"strong\": \"35-60 mg\",\n-            \"heavy\": \"60+ mg\"\n-          }\n-          \"route\": \"oral / sublingual\",\n+          \"route\": \"oral\",\n-            \"oral\",\n-            \"sublingual\"\n+            \"oral\"\n-            \"total_duration\": \"4-6 h (active phase)\",\n-            \"onset\": \"15-45 min\",\n+            \"total_duration\": \"6-10 h active stimulation\",\n+            \"onset\": \"20-45 min\",\n-            \"offset\": \"2-3 h\",\n-            \"after_effects\": \"2-24 h residual stimulation; disequilibrium\"\n+            \"offset\": \"2-4 h fading stimulation / fatigue\",\n+            \"after_effects\": \"up to 24 h residual insomnia; anorexia; tachycardia\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"insufflated*\",\n-            \"total_duration\": \"4-6 h (active phase)\",\n-            \"onset\": \"10-20 min\",\n+            \"total_duration\": \"6-10 h active stimulation\",\n+            \"onset\": \"5-15 min\",\n-            \"offset\": \"2-3 h\",\n-            \"after_effects\": \"2-24 h residual stimulation; disequilibrium\"\n+            \"offset\": \"2-4 h fading stimulation / fatigue\",\n+            \"after_effects\": \"up to 24 h residual insomnia; anorexia; tachycardia\"\n-        },\n-        {\n-          \"route\": \"intramuscular\",\n-          \"canonical_routes\": [\n-            \"intramuscular\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"4-6 h (active phase)\",\n-            \"onset\": \"5-10 min\",\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"2-3 h\",\n-            \"after_effects\": \"2-24 h residual stimulation; disequilibrium\"\n-          }\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"canonical_routes\": [\n-            \"rectal\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"4-6 h (active phase)\",\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"2-3 h\",\n-            \"after_effects\": \"2-24 h residual stimulation; disequilibrium\"\n-          }\n-    \"addiction_potential\": \"Moderate to high: rapid tolerance and rewarding dissociation encourage redosing; compulsive binges of 200-500 mg reported.\",\n+    \"addiction_potential\": \"Moderate-to-high: converts to d-amphetamine and shows ~20-fold lower potency, encouraging high-pill counts and redosing. Daily users report tolerance within 3-4 days and binges of 180-300 mg (~6-10 capsules).\",\n-        \"opioids\",\n-        \"benzodiazepines or alcohol (respiratory depression when comatose)\",\n-        \"MAOIs\",\n-        \"high-dose stimulants (tachyarrhythmia, hyperthermia)\"\n+        \"MAOIs (hypertensive crisis)\",\n+        \"other potent stimulants (methylphenidate, cocaine, cathinones)\",\n+        \"SNRIs or high-dose bupropion (seizure risk)\",\n+        \"adrenergic decongestants (synergistic vasoconstriction)\"\n-        \"other dissociatives (ketamine, PCP analogues)\",\n-        \"serotonergic psychedelics (risk of serotonin toxicity)\",\n-        \"tramadol (seizures)\"\n+        \"Tramadol or other serotonergic psychedelics (serotonin toxicity)\",\n+        \"high-dose caffeine or theophylline\",\n+        \"sympathomimetic OTC inhalers (benzylamine, propylhexedrine)\"\n-        \"SSRI or SNRI antidepressants\",\n-        \"cannabis concentrates (panic, depersonalisation)\",\n-        \"antipsychotics (QT prolongation)\"\n+        \"beta-blocker withdrawal (rebound hypertension)\",\n+        \"alcohol (impairs judgement of cardiovascular stress)\",\n+        \"antacids/urine alkalinisers (raise d-amphetamine exposure)\",\n+        \"SSRI antidepressants (mild additive 5-HT effects)\"\n-    \"notes\": \"Pharmacokinetic work shows an elimination half-life of roughly 3-6 h with active O-desmethyl and N-desethyl metabolites that may lengthen subjective effects. Clinical papers note sensorimotor gating disruption, reversible cerebellar ataxia and bladder toxicity resembling ketamine cystitis. Forum users emphasise volumetric dosing, nasal saline rinses after insufflation, and setting a strict session cap (<=70 mg) to limit compulsive redosing. Because MXE is Schedule I/Prohibited in many regions, powders sold online often contain analogues; confirm identity with multi-reagent tests plus GC-MS where possible.\",\n+    \"notes\": \"Each 30-mg Asenlix®/Itravil® capsule yields roughly 4-5 mg d-amphetamine after first-pass metabolism; subjective strength is about 1/5-1/6 of an Adderall IR tablet. Peak plasma amphetamine appears 1-4 h post-dose. Elimination half-life for parent + metabolites is highly variable (1-17 h) and is prolonged in alkaline urine. Cardiovascular concerns parallel other amphetamines; case-control data link chronic anorectic use to pulmonary arterial hypertension, so limit weekly use and monitor BP. Urine screens >500 ng/mL 'amphetamine' after clobenzorex will also contain the specific metabolite 4-hydroxy-clobenzorex—confirmatory testing can distinguish therapeutic use from illicit amphetamine. Users emphasise smaller test doses (≤25 mg) due to biphasic profile: a short punchy alertness that dips after 2 h before a shallow, long tail. Split-dosing (e.g., 30 mg a.m. + 15 mg noon) reduces the midday slump. Stay hydrated, supplement magnesium/potassium, and schedule at least 48 h stimulant-free to keep tolerance manageable.\",\n-      \"floating dissociation\",\n-      \"analgesia\",\n-      \"moderate euphoria\",\n-      \"music appreciation\",\n-      \"closed-eye visuals at higher doses\",\n-      \"time dilation\",\n-      \"nystagmus\",\n-      \"afterglow or depressive fatigue\"\n+      \"clean mental stimulation and focus\",\n+      \"strong appetite suppression\",\n+      \"mild euphoria / motivation\",\n+      \"dry mouth, bruxism\",\n+      \"palpitations, peripheral vasoconstriction\",\n+      \"anxiety or jitteriness at higher doses\",\n+      \"insomnia on late-day use\"\n-      \"full_tolerance\": \"after one heavy session\",\n-      \"half_tolerance\": \"3-5 days\",\n-      \"zero_tolerance\": \"10-14 days\",\n+      \"full_tolerance\": \"after 3-5 consecutive high-dose days\",\n+      \"half_tolerance\": \"∼3 days of abstinence\",\n+      \"zero_tolerance\": \"7-10 days of abstinence\",\n-        \"ketamine\",\n-        \"other arylcyclohexylamines\"\n+        \"amphetamines\",\n+        \"phenethylamine stimulants (e.g., lisdexamfetamine, benzphetamine)\"\n-    \"half_life\": \"3-6 h\",\n+    \"half_life\": \"Parent: 1-8 h; active hydroxy-metabolite: up to 17 h (urine pH-dependent)\",\n-        \"name\": \"Anodyne.wiki Entry on MXE\",\n-        \"reference\": \"https://anodyne.wiki/substance/mxe?\"\n+        \"name\": \"Amphetamine, Clobenzorex and 4-Hydroxyclobenzorex levels following multidose administration\",\n+        \"reference\": \"https://academic.oup.com/jat/article/25/3/158/791697\"\n-        \"name\": \"Detailed pharmacological evaluation of MXE\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/27155360/\"\n+        \"name\": \"Comparison on the Pharmacokinetics of Clobenzorex Slow- vs Immediate-Release\",\n+        \"reference\": \"https://file.scirp.org/Html/12-2500247_29756.htm\"\n-        \"name\": \"ScienceDirect Topics – duration by route\",\n-        \"reference\": \"https://www.sciencedirect.com/topics/medicine-and-dentistry/methoxetamine\"\n+        \"name\": \"Clobenzorex: evidence for amphetamine-like behavioral actions\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/9050090/\"\n-        \"name\": \"Ketamine-like effects after recreational MXE use\",\n-        \"reference\": \"https://www.sciencedirect.com/science/article/abs/pii/S0196064411018038\"\n+        \"name\": \"Bluelight 'Clobenzorex - any experiences?' megathread (user-reported dosing)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/clobenzorex-any-experiences.926712/\"\n-        \"name\": \"Reversible cerebellar toxicity case report\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/22578175/\"\n+        \"name\": \"Reddit r/Drugs - work-use discussion of clobenzorex potency\",\n+        \"reference\": \"https://www.reddit.com/r/Drugs/comments/swbpg8/is_clobenzorex_realistic_for_somewhat_regular/\"\n-        \"name\": \"Phenomenological study of MXE experiences\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC3756617/\"\n+        \"name\": \"Vasorelaxant and cardiovascular findings in rat aorta\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC5572851/\"\n-        \"name\": \"MXE pharmacokinetics and metabolites review\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/27128862/\"\n+        \"name\": \"Chronic clobenzorex administration induces glial activation without DA neurodegeneration\",\n+        \"reference\": \"https://link.springer.com/article/10.1007/s12640-021-00395-1\"\n-        \"name\": \"MXE NMDA IC50 data\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/36344045/\"\n+        \"name\": \"World Anti-Doping Agency 2025 Prohibited List\",\n+        \"reference\": \"https://www.wada-ama.org/sites/default/files/2025-01/WADA_Prohibited_List_2025.pdf\"\n-        \"name\": \"UNODC New Psychoactive Substances report\",\n-        \"reference\": \"https://www.erowid.org/psychoactives/research_chems/research_chems_UNODC_2013_report.pdf\"\n+        \"name\": \"FDA personal-import letter on clobenzorex legality (April 2023)\",\n+        \"reference\": \"https://www.fda.gov/media/167902/download\"\n-        \"name\": \"Erowid MXE dose chart\",\n-        \"reference\": \"https://erowid.org/chemicals/methoxetamine/methoxetamine_dose.shtml\"\n+        \"name\": \"Patsnap Synapse - side-effect profile & BP warnings\",\n+        \"reference\": \"https://synapse.patsnap.com/article/what-are-the-side-effects-of-clobenzorex-hydrochloride\"\n-        \"name\": \"Bluelight Big & Dandy MXE thread (meta-dose statistics)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-methoxetamine-thread-the-3rd-dose.559691/\"\n-      },\n-      {\n-        \"name\": \"DrugFacts UK – MXE duration and harms\",\n-        \"reference\": \"https://drugfacts.org.uk/index.php?title=Methoxetamine\"\n-      },\n-      {\n-        \"name\": \"Pain Medicine – self-medication case\",\n-        \"reference\": \"https://academic.oup.com/painmedicine/article/17/9/1773/2399345\"\n-      },\n-      {\n-        \"name\": \"Alcohol and Drug Foundation – MXE facts\",\n-        \"reference\": \"https://adf.org.au/drug-facts/methoxetamine/\"\n-      },\n-      {\n-        \"name\": \"Wikipedia – pharmacokinetic summary\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Methoxetamine\"\n-      },\n-      {\n-        \"name\": \"Hi-Ground harm-reduction leaflet\",\n-        \"reference\": \"https://hi-ground.org/substances/methoxetamine-2/\"\n+        \"name\": \"Wikipedia - general chemistry & legal overview\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Clobenzorex\"\n-      \"dissociative\",\n+      \"stimulant\",\n\n# Fluminorex · #443\n\n-  \"id\": 442,\n-  \"title\": \"Clobenzorex\",\n+  \"id\": 443,\n+  \"title\": \"Fluminorex\",\n-    \"drug_name\": \"Clobenzorex\",\n-    \"chemical_name\": \"Clobenzorex\",\n+    \"drug_name\": \"Fluminorex\",\n+    \"chemical_name\": \"Fluminorex\",\n-    \"chemical_class\": \"Amphetamines\",\n-    \"mechanism_of_action\": \"Dopamine-norepinephrine releasing agent\",\n-    \"psychoactive_class\": \"Stimulant; prodrug that yields d-amphetamine (~15 % conversion)\",\n+    \"chemical_class\": \"Aminorexes\",\n+    \"mechanism_of_action\": \"Serotonin-dopamine-norepinephrine releasing agent\",\n+    \"psychoactive_class\": \"CNS stimulant; presumed norepinephrine-dopamine releasing agent\",\n-          \"units\": \"mg of clobenzorex HCl\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"10 mg\",\n-            \"light\": \"10-25 mg\",\n-            \"common\": \"25-60 mg\",\n-            \"strong\": \"60-120 mg\",\n-            \"heavy\": \"120 mg +\"\n+            \"threshold\": \"2mg\",\n+            \"light\": \"2mg-5mg\",\n+            \"common\": \"5mg-15mg\",\n+            \"strong\": \"15mg-25mg\",\n+            \"heavy\": \"25mg+\"\n-          \"route\": \"insufflated*\",\n+          \"route\": \"insufflated\",\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"5-15 mg\",\n-            \"common\": \"15-30 mg\",\n-            \"strong\": \"30-60 mg\",\n-            \"heavy\": \"60 mg +\"\n+            \"threshold\": \"1mg\",\n+            \"light\": \"1mg-3mg\",\n+            \"common\": \"3mg-10mg\",\n+            \"strong\": \"10mg-20mg\",\n+            \"heavy\": \"20mg+\"\n+        },\n+        {\n+          \"route\": \"vaporized / smoked\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"~1mg\",\n+            \"light\": \"1mg-2mg\",\n+            \"common\": \"2mg-5mg\",\n+            \"strong\": \"5mg-10mg\",\n+            \"heavy\": \"10mg+\"\n+          }\n-            \"total_duration\": \"6-10 h active stimulation\",\n-            \"onset\": \"20-45 min\",\n+            \"total_duration\": \"6-12 h\",\n+            \"onset\": \"20-40 min\",\n-            \"offset\": \"2-4 h fading stimulation / fatigue\",\n-            \"after_effects\": \"up to 24 h residual insomnia; anorexia; tachycardia\"\n+            \"offset\": \"4-6 h\",\n+            \"after_effects\": \"up to 24 h residual stimulation; appetite suppression; insomnia\"\n-          \"route\": \"insufflated*\",\n+          \"route\": \"insufflated\",\n-            \"total_duration\": \"6-10 h active stimulation\",\n-            \"onset\": \"5-15 min\",\n+            \"onset\": \"5-10 min\",\n-            \"offset\": \"2-4 h fading stimulation / fatigue\",\n-            \"after_effects\": \"up to 24 h residual insomnia; anorexia; tachycardia\"\n+            \"offset\": \"4-6 h\",\n+            \"after_effects\": \"up to 24 h residual stimulation; appetite suppression; insomnia\"\n+        },\n+        {\n+          \"route\": \"vaporized / smoked\",\n+          \"canonical_routes\": [\n+            \"vaporized\",\n+            \"smoked\"\n+          ],\n+          \"stages\": {\n+            \"peak\": \"1-3 h\",\n+            \"offset\": \"4-6 h\",\n+            \"after_effects\": \"up to 24 h residual stimulation; appetite suppression; insomnia\"\n+          }\n-    \"addiction_potential\": \"Moderate-to-high: converts to d-amphetamine and shows ~20-fold lower potency, encouraging high-pill counts and redosing. Daily users report tolerance within 3-4 days and binges of 180-300 mg (~6-10 capsules).\",\n+    \"addiction_potential\": \"High: aminorex-type stimulants show strong dopaminergic reinforcement, rapid tolerance build-up, and compulsive redosing patterns.\",\n-        \"other potent stimulants (methylphenidate, cocaine, cathinones)\",\n-        \"SNRIs or high-dose bupropion (seizure risk)\",\n-        \"adrenergic decongestants (synergistic vasoconstriction)\"\n+        \"other potent stimulants (cardiotoxic synergy)\",\n+        \"serotonergic releasers/SSRIs (serotonin toxicity)\",\n+        \"high-dose cocaine or methamphetamine (arrhythmia, hyperthermia)\"\n-        \"Tramadol or other serotonergic psychedelics (serotonin toxicity)\",\n-        \"high-dose caffeine or theophylline\",\n-        \"sympathomimetic OTC inhalers (benzylamine, propylhexedrine)\"\n+        \"large alcohol or GHB doses (masking; cardiopulmonary stress)\",\n+        \"phenylethylamine psychedelics (BP spikes)\",\n+        \"triptans\"\n-        \"beta-blocker withdrawal (rebound hypertension)\",\n-        \"alcohol (impairs judgement of cardiovascular stress)\",\n-        \"antacids/urine alkalinisers (raise d-amphetamine exposure)\",\n-        \"SSRI antidepressants (mild additive 5-HT effects)\"\n+        \"caffeine >300 mg\",\n+        \"beta-agonist inhalers\",\n+        \"bupropion / Wellbutrin\",\n+        \"recreational nitrites (hypotension rebound)\"\n-    \"notes\": \"Each 30-mg Asenlix®/Itravil® capsule yields roughly 4-5 mg d-amphetamine after first-pass metabolism; subjective strength is about 1/5-1/6 of an Adderall IR tablet. Peak plasma amphetamine appears 1-4 h post-dose. Elimination half-life for parent + metabolites is highly variable (1-17 h) and is prolonged in alkaline urine. Cardiovascular concerns parallel other amphetamines; case-control data link chronic anorectic use to pulmonary arterial hypertension, so limit weekly use and monitor BP. Urine screens >500 ng/mL 'amphetamine' after clobenzorex will also contain the specific metabolite 4-hydroxy-clobenzorex—confirmatory testing can distinguish therapeutic use from illicit amphetamine. Users emphasise smaller test doses (≤25 mg) due to biphasic profile: a short punchy alertness that dips after 2 h before a shallow, long tail. Split-dosing (e.g., 30 mg a.m. + 15 mg noon) reduces the midday slump. Stay hydrated, supplement magnesium/potassium, and schedule at least 48 h stimulant-free to keep tolerance manageable.\",\n+    \"notes\": \"Early animal studies found fluminorex to be roughly equipotent with d-amphetamine as an anorectic. No modern human studies exist; the dose guidance above is extrapolated downward from historic aminorex prescriptions (10-40 mg/day) and recreational 4-methylaminorex reports (5-25 mg). Aminorex analogues have been linked to pulmonary arterial hypertension after chronic use, so strict cycle limits (under two weeks continuous) and cardiovascular screening are prudent. The lipophilic CF₃ group may lengthen elimination half-life (estimated 8-12 h) and promote accumulation. Reagent-test cross-reactions are unreliable—confirm identity with GC-MS or, at minimum, multi-step reagent testing. Serious adverse events reported for aminorex-class stimulants include pulmonary edema, right-heart strain, and psychotic agitation at binge-level doses. Because fluminorex has never reached the grey market in observable quantities, any powder sold online should be assumed mislabelled until proven otherwise.\",\n-      \"clean mental stimulation and focus\",\n-      \"strong appetite suppression\",\n-      \"mild euphoria / motivation\",\n-      \"dry mouth, bruxism\",\n-      \"palpitations, peripheral vasoconstriction\",\n-      \"anxiety or jitteriness at higher doses\",\n-      \"insomnia on late-day use\"\n+      \"clean peripheral stimulation (dry mouth, mydriasis)\",\n+      \"elevated mood and talkativeness\",\n+      \"focus / task-salience enhancement\",\n+      \"blunted appetite and thirst\",\n+      \"mild euphoria at higher doses\",\n+      \"jaw tension & bruxism\",\n+      \"crash: lethargy, anhedonia, irritability\"\n-      \"full_tolerance\": \"after 3-5 consecutive high-dose days\",\n-      \"half_tolerance\": \"∼3 days of abstinence\",\n-      \"zero_tolerance\": \"7-10 days of abstinence\",\n+      \"full_tolerance\": \"after 2-3 consecutive days of high dosing\",\n+      \"half_tolerance\": \"≈3-5 days\",\n+      \"zero_tolerance\": \"10-14 days of abstinence\",\n-        \"phenethylamine stimulants (e.g., lisdexamfetamine, benzphetamine)\"\n+        \"aminorex analogues (4-MAR, cyclazodone, pemoline)\"\n-    \"half_life\": \"Parent: 1-8 h; active hydroxy-metabolite: up to 17 h (urine pH-dependent)\",\n+    \"half_life\": \"estimated 8-12 h (no human PK data; projection from aminorex plus CF₃ substitution)\",\n-        \"name\": \"Amphetamine, Clobenzorex and 4-Hydroxyclobenzorex levels following multidose administration\",\n-        \"reference\": \"https://academic.oup.com/jat/article/25/3/158/791697\"\n+        \"name\": \"Fluminorex overview (Wikipedia)\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Fluminorex\"\n-        \"name\": \"Comparison on the Pharmacokinetics of Clobenzorex Slow- vs Immediate-Release\",\n-        \"reference\": \"https://file.scirp.org/Html/12-2500247_29756.htm\"\n+        \"name\": \"2-Amino-5-aryl-2-oxazolines - Potent New Anorectic Agents\",\n+        \"reference\": \"https://chemistry.mdma.ch/hiveboard/rhodium/pdf/poos.aminorex.pdf\"\n-        \"name\": \"Clobenzorex: evidence for amphetamine-like behavioral actions\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/9050090/\"\n+        \"name\": \"4-Methylaminorex dosage statistics (en-academic summary)\",\n+        \"reference\": \"https://en-academic.com/dic.nsf/enwiki/11546806\"\n-        \"name\": \"Bluelight 'Clobenzorex - any experiences?' megathread (user-reported dosing)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/clobenzorex-any-experiences.926712/\"\n+        \"name\": \"Recreational aminorex & pulmonary hypertension case series\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/11083709/\"\n-        \"name\": \"Reddit r/Drugs - work-use discussion of clobenzorex potency\",\n-        \"reference\": \"https://www.reddit.com/r/Drugs/comments/swbpg8/is_clobenzorex_realistic_for_somewhat_regular/\"\n-      },\n-      {\n-        \"name\": \"Vasorelaxant and cardiovascular findings in rat aorta\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC5572851/\"\n-      },\n-      {\n-        \"name\": \"Chronic clobenzorex administration induces glial activation without DA neurodegeneration\",\n-        \"reference\": \"https://link.springer.com/article/10.1007/s12640-021-00395-1\"\n-      },\n-      {\n-        \"name\": \"World Anti-Doping Agency 2025 Prohibited List\",\n-        \"reference\": \"https://www.wada-ama.org/sites/default/files/2025-01/WADA_Prohibited_List_2025.pdf\"\n-      },\n-      {\n-        \"name\": \"FDA personal-import letter on clobenzorex legality (April 2023)\",\n-        \"reference\": \"https://www.fda.gov/media/167902/download\"\n-      },\n-      {\n-        \"name\": \"Patsnap Synapse - side-effect profile & BP warnings\",\n-        \"reference\": \"https://synapse.patsnap.com/article/what-are-the-side-effects-of-clobenzorex-hydrochloride\"\n-      },\n-      {\n-        \"name\": \"Wikipedia - general chemistry & legal overview\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Clobenzorex\"\n+        \"name\": \"List of aminorex analogues (structure table)\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/List_of_aminorex_analogues\"\n\n# EDMC · #441\n\n-  \"id\": 443,\n-  \"title\": \"Fluminorex\",\n+  \"id\": 441,\n+  \"title\": \"EDMC\",\n-    \"drug_name\": \"Fluminorex\",\n-    \"chemical_name\": \"Fluminorex\",\n-    \"alternative_name\": \"\",\n-    \"chemical_class\": \"Aminorexes\",\n-    \"mechanism_of_action\": \"Serotonin-dopamine-norepinephrine releasing agent\",\n-    \"psychoactive_class\": \"CNS stimulant; presumed norepinephrine-dopamine releasing agent\",\n+    \"drug_name\": \"EDMC\",\n+    \"chemical_name\": \"EDMC\",\n+    \"alternative_name\": \"3,4-Ethylenedioxymethcathinone, 3,4-EDMC\",\n+    \"chemical_class\": \"Cathinones\",\n+    \"mechanism_of_action\": \"Serotonin releasing agent; Dopamine-norepinephrine reuptake inhibitor\",\n+    \"psychoactive_class\": \"Serotonin–norepinephrine–dopamine releasing agent; stimulant-entactogen\",\n-            \"threshold\": \"2mg\",\n-            \"light\": \"2mg-5mg\",\n-            \"common\": \"5mg-15mg\",\n-            \"strong\": \"15mg-25mg\",\n-            \"heavy\": \"25mg+\"\n+            \"threshold\": \"20-40 mg\",\n+            \"light\": \"40-100 mg\",\n+            \"common\": \"100-220 mg\",\n+            \"strong\": \"220-350 mg\",\n+            \"heavy\": \"350+ mg\"\n-            \"threshold\": \"1mg\",\n-            \"light\": \"1mg-3mg\",\n-            \"common\": \"3mg-10mg\",\n-            \"strong\": \"10mg-20mg\",\n-            \"heavy\": \"20mg+\"\n+            \"threshold\": \"10-20 mg\",\n+            \"light\": \"20-60 mg\",\n+            \"common\": \"60-130 mg\",\n+            \"strong\": \"130-220 mg\",\n+            \"heavy\": \"220+ mg\"\n-          \"route\": \"vaporized / smoked\",\n+          \"route\": \"rectal\",\n-            \"threshold\": \"~1mg\",\n-            \"light\": \"1mg-2mg\",\n-            \"common\": \"2mg-5mg\",\n-            \"strong\": \"5mg-10mg\",\n-            \"heavy\": \"10mg+\"\n+            \"threshold\": \"15 mg\",\n+            \"light\": \"30-80 mg\",\n+            \"common\": \"80-180 mg\",\n+            \"strong\": \"180-250 mg\",\n+            \"heavy\": \"250+ mg\"\n-            \"total_duration\": \"6-12 h\",\n-            \"onset\": \"20-40 min\",\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"4-6 h\",\n-            \"after_effects\": \"up to 24 h residual stimulation; appetite suppression; insomnia\"\n+            \"total_duration\": \"3-5 h (active phase)\",\n+            \"onset\": \"20-45 min\",\n+            \"peak\": \"1.5-3 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-24 h residual stimulation / serotonergic ‘after-glow’ or comedown\"\n-            \"onset\": \"5-10 min\",\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"4-6 h\",\n-            \"after_effects\": \"up to 24 h residual stimulation; appetite suppression; insomnia\"\n+            \"total_duration\": \"3-5 h (active phase)\",\n+            \"onset\": \"5-15 min\",\n+            \"peak\": \"1.5-3 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-24 h residual stimulation / serotonergic ‘after-glow’ or comedown\"\n-          \"route\": \"vaporized / smoked\",\n+          \"route\": \"rectal\",\n-            \"vaporized\",\n-            \"smoked\"\n+            \"rectal\"\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"4-6 h\",\n-            \"after_effects\": \"up to 24 h residual stimulation; appetite suppression; insomnia\"\n+            \"total_duration\": \"3-5 h (active phase)\",\n+            \"peak\": \"1.5-3 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-24 h residual stimulation / serotonergic ‘after-glow’ or comedown\"\n-    \"addiction_potential\": \"High: aminorex-type stimulants show strong dopaminergic reinforcement, rapid tolerance build-up, and compulsive redosing patterns.\",\n+    \"addiction_potential\": \"Moderate: short-lived euphoria encourages redosing; tolerance builds quickly and binging behaviour similar to methylone has been reported in the few anecdotal posts available.\",\n-        \"MAOIs (hypertensive crisis)\",\n-        \"other potent stimulants (cardiotoxic synergy)\",\n-        \"serotonergic releasers/SSRIs (serotonin toxicity)\",\n-        \"high-dose cocaine or methamphetamine (arrhythmia, hyperthermia)\"\n+        \"MAOIs (hypertensive crisis, serotonin syndrome)\",\n+        \"other potent serotonergics (MDMA, 5-MeO-tryptamines, high-dose SSRIs)\",\n+        \"strong stimulants (α-PVP, methamphetamine) – hyperthermia, tachyarrhythmia\"\n-        \"large alcohol or GHB doses (masking; cardiopulmonary stress)\",\n-        \"phenylethylamine psychedelics (BP spikes)\",\n-        \"triptans\"\n+        \"large doses of alcohol or benzodiazepines (respiratory depression when exhausted)\",\n+        \"opioids (combined CNS depression after stimulant crash)\",\n+        \"tramadol (lowers seizure threshold)\"\n-        \"caffeine >300 mg\",\n-        \"beta-agonist inhalers\",\n-        \"bupropion / Wellbutrin\",\n-        \"recreational nitrites (hypotension rebound)\"\n+        \"SSRI / SNRI antidepressants (blunted effect, serotonin overload if dose pushed)\",\n+        \"cannabis concentrates (panic, derealisation)\",\n+        \"antipsychotics (additive QT-prolongation)\"\n-    \"notes\": \"Early animal studies found fluminorex to be roughly equipotent with d-amphetamine as an anorectic. No modern human studies exist; the dose guidance above is extrapolated downward from historic aminorex prescriptions (10-40 mg/day) and recreational 4-methylaminorex reports (5-25 mg). Aminorex analogues have been linked to pulmonary arterial hypertension after chronic use, so strict cycle limits (under two weeks continuous) and cardiovascular screening are prudent. The lipophilic CF₃ group may lengthen elimination half-life (estimated 8-12 h) and promote accumulation. Reagent-test cross-reactions are unreliable—confirm identity with GC-MS or, at minimum, multi-step reagent testing. Serious adverse events reported for aminorex-class stimulants include pulmonary edema, right-heart strain, and psychotic agitation at binge-level doses. Because fluminorex has never reached the grey market in observable quantities, any powder sold online should be assumed mislabelled until proven otherwise.\",\n+    \"notes\": \"In vitro transporter assays show EDMC releases 5-HT (EC50 ≈ 347 nM), NE (327 nM) and DA (496 nM) – roughly 1.4- to 3.7-fold weaker than methylone, implying human psychoactive doses in the low-to-mid-hundreds of milligrams. Very limited human data exist; the few r/researchchemicals and Discord reports describe ‘gentler-than-MDMA’ empathy with a more β-keto-like peripheral stimulation and a quick, fatigue-heavy comedown. No controlled pharmacokinetic work has been published; based on structural analogy the elimination half-life is tentatively placed at 4-7 h. Reagent testing is essential: seizures in 2024–25 show many samples sold as “EDMC” actually contained eutylone or N,N-dimethylpentylone. Use a 0.001 g scale, pre-dose individual gel-caps, drink 250-500 mL water / h with electrolytes under exertion, and avoid re-dosing inside the same session. Anecdotal tolerance resets after ~7-10 days; waiting two weeks between sessions minimises neurochemical stress. No animal neurotoxicity data are available, but other SNDRA cathinones show oxidative stress and hyperthermia-mediated neuro- and cardiotoxicity at high doses – keep ambient temperature <25 °C and take cooling breaks when dancing.\",\n-      \"clean peripheral stimulation (dry mouth, mydriasis)\",\n-      \"elevated mood and talkativeness\",\n-      \"focus / task-salience enhancement\",\n-      \"blunted appetite and thirst\",\n-      \"mild euphoria at higher doses\",\n-      \"jaw tension & bruxism\",\n-      \"crash: lethargy, anhedonia, irritability\"\n+      \"warm empathic mood\",\n+      \"moderate euphoria\",\n+      \"physical & mental stimulation\",\n+      \"talkativeness / sociability\",\n+      \"increased tactile appreciation\",\n+      \"jaw tension, bruxism\",\n+      \"mydriasis with shimmering halos\",\n+      \"mild closed-eye visuals at high doses\",\n+      \"tachycardia, sweating, nystagmus\",\n+      \"comedown fatigue & flat affect\"\n-      \"full_tolerance\": \"after 2-3 consecutive days of high dosing\",\n-      \"half_tolerance\": \"≈3-5 days\",\n-      \"zero_tolerance\": \"10-14 days of abstinence\",\n+      \"full_tolerance\": \"after one strong or heavy session\",\n+      \"half_tolerance\": \"3-5 days\",\n+      \"zero_tolerance\": \"10-14 days\",\n-        \"amphetamines\",\n-        \"aminorex analogues (4-MAR, cyclazodone, pemoline)\"\n+        \"methylone\",\n+        \"butylone\",\n+        \"other entactogenic cathinones / MDMA\"\n-    \"half_life\": \"estimated 8-12 h (no human PK data; projection from aminorex plus CF₃ substitution)\",\n+    \"half_life\": \"Estimated 4-7 h (no human data; extrapolated from methylone PK)\",\n-        \"name\": \"Fluminorex overview (Wikipedia)\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Fluminorex\"\n+        \"name\": \"EDMC overview – Wikipedia\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/3%2C4-Ethylenedioxymethcathinone\"\n-        \"name\": \"2-Amino-5-aryl-2-oxazolines - Potent New Anorectic Agents\",\n-        \"reference\": \"https://chemistry.mdma.ch/hiveboard/rhodium/pdf/poos.aminorex.pdf\"\n+        \"name\": \"Transporter release data (Del Bello et al., 2015)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/26233799/\"\n-        \"name\": \"4-Methylaminorex dosage statistics (en-academic summary)\",\n-        \"reference\": \"https://en-academic.com/dic.nsf/enwiki/11546806\"\n+        \"name\": \"Synthetic cathinone SAR review (Glennon & Dukat, 2017)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/27830576/\"\n-        \"name\": \"Recreational aminorex & pulmonary hypertension case series\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/11083709/\"\n+        \"name\": \"VCU dissertation – synthetic cathinone mechanisms (Sakloth 2015)\",\n+        \"reference\": \"https://scholarscompass.vcu.edu/etd/3920/\"\n-        \"name\": \"List of aminorex analogues (structure table)\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/List_of_aminorex_analogues\"\n+        \"name\": \"UK ACMD harm assessment – cathinones (2025 update)\",\n+        \"reference\": \"https://www.gov.uk/government/publications/synthetic-cathinones-an-updated-harms-assessment\"\n+      },\n+      {\n+        \"name\": \"Cayman Chemical reference standard listing\",\n+        \"reference\": \"https://www.caymanchem.com/product/15167/3%2C4-edmc-%28hydrochloride%29\"\n+      },\n+      {\n+        \"name\": \"EPA CompTox substance record\",\n+        \"reference\": \"https://comptox.epa.gov/dashboard/chemical/details/DTXSID001024649\"\n+      },\n+      {\n+        \"name\": \"PiHKAL – EDMA dosage for ring-expanded analogue comparison\",\n+        \"reference\": \"http://pihkal.info/read.php?domain=pk&id=110\"\n+      },\n+      {\n+        \"name\": \"Erowid Methylone dose chart (analogue benchmark)\",\n+        \"reference\": \"https://erowid.org/chemicals/methylone/methylone_dose.shtml\"\n+      },\n+      {\n+        \"name\": \"Synthetic cathinones: updated harms (Gov UK, 2025)\",\n+        \"reference\": \"https://www.gov.uk/government/publications/synthetic-cathinones-an-updated-harms-assessment\"\n+      \"entactogen\",\n\n# Ziprasidone · #444\n\n-  \"id\": 441,\n-  \"title\": \"EDMC\",\n+  \"id\": 444,\n+  \"title\": \"Ziprasidone\",\n-    \"drug_name\": \"EDMC\",\n-    \"chemical_name\": \"EDMC\",\n-    \"alternative_name\": \"3,4-Ethylenedioxymethcathinone, 3,4-EDMC\",\n-    \"chemical_class\": \"Cathinones\",\n-    \"mechanism_of_action\": \"Serotonin releasing agent; Dopamine-norepinephrine reuptake inhibitor\",\n-    \"psychoactive_class\": \"Serotonin–norepinephrine–dopamine releasing agent; stimulant-entactogen\",\n+    \"drug_name\": \"Ziprasidone\",\n+    \"chemical_name\": \"Ziprasidone\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Benzisothiazolyl piperazine; second-generation (atypical) antipsychotic\",\n+    \"mechanism_of_action\": \"Multiple receptor antagonist\",\n+    \"psychoactive_class\": \"Mixed 5-HT2A/D2 receptor antagonist with 5-HT1A partial-agonism; weak serotonin-norepinephrine re-uptake inhibitor\",\n-            \"threshold\": \"20-40 mg\",\n-            \"light\": \"40-100 mg\",\n-            \"common\": \"100-220 mg\",\n-            \"strong\": \"220-350 mg\",\n-            \"heavy\": \"350+ mg\"\n+            \"threshold\": \"10 mg\",\n+            \"light\": \"10 mg - 40 mg\",\n+            \"common\": \"40 mg - 80 mg\",\n+            \"strong\": \"80 mg - 120 mg\",\n+            \"heavy\": \"120+ mg\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"intramuscular\",\n-            \"threshold\": \"10-20 mg\",\n-            \"light\": \"20-60 mg\",\n-            \"common\": \"60-130 mg\",\n-            \"strong\": \"130-220 mg\",\n-            \"heavy\": \"220+ mg\"\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"5 mg - 10 mg\",\n+            \"common\": \"10 mg - 20 mg\",\n+            \"strong\": \"20 mg - 40 mg\",\n+            \"heavy\": \"40+ mg\"\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"15 mg\",\n-            \"light\": \"30-80 mg\",\n-            \"common\": \"80-180 mg\",\n-            \"strong\": \"180-250 mg\",\n-            \"heavy\": \"250+ mg\"\n-          }\n-            \"total_duration\": \"3-5 h (active phase)\",\n-            \"onset\": \"20-45 min\",\n-            \"peak\": \"1.5-3 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-24 h residual stimulation / serotonergic ‘after-glow’ or comedown\"\n+            \"total_duration\": \"6-12 h (sedation window)\",\n+            \"onset\": \"1-3 h\",\n+            \"peak\": \"3-6 h\",\n+            \"offset\": \"2-4 h residual fade-out\",\n+            \"after_effects\": \"especially after heavy doses\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"intramuscular\",\n-            \"insufflated\"\n+            \"intramuscular\"\n-            \"total_duration\": \"3-5 h (active phase)\",\n-            \"onset\": \"5-15 min\",\n-            \"peak\": \"1.5-3 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-24 h residual stimulation / serotonergic ‘after-glow’ or comedown\"\n+            \"total_duration\": \"6-12 h (sedation window)\",\n+            \"onset\": \"15-30 min\",\n+            \"peak\": \"30-90 min\",\n+            \"offset\": \"2-4 h residual fade-out\",\n+            \"after_effects\": \"Grogginess; dysphoria or akathisia can linger 6-24 h\"\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"canonical_routes\": [\n-            \"rectal\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"3-5 h (active phase)\",\n-            \"peak\": \"1.5-3 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-24 h residual stimulation / serotonergic ‘after-glow’ or comedown\"\n-          }\n-    \"addiction_potential\": \"Moderate: short-lived euphoria encourages redosing; tolerance builds quickly and binging behaviour similar to methylone has been reported in the few anecdotal posts available.\",\n+    \"addiction_potential\": \"Low—ziprasidone is not reinforcing, but abrupt cessation after chronic use can precipitate rebound psychosis, agitation, or cholinergic rebound; compulsive redosing for ‘knock-out’ sleep is uncommon but reported.\",\n-        \"MAOIs (hypertensive crisis, serotonin syndrome)\",\n-        \"other potent serotonergics (MDMA, 5-MeO-tryptamines, high-dose SSRIs)\",\n-        \"strong stimulants (α-PVP, methamphetamine) – hyperthermia, tachyarrhythmia\"\n+        \"other QT-prolonging drugs (methadone, macrolide/fluoroquinolone antibiotics, some SSRIs, hypokalemia-inducing diuretics)\",\n+        \"class IA/III anti-arrhythmics\",\n+        \"high-dose cocaine or synthetic cathinones (synergistic cardiotoxicity)\"\n-        \"large doses of alcohol or benzodiazepines (respiratory depression when exhausted)\",\n-        \"opioids (combined CNS depression after stimulant crash)\",\n-        \"tramadol (lowers seizure threshold)\"\n+        \"alcohol or benzodiazepines (profound CNS/respiratory depression)\",\n+        \"opioids (additive respiratory depression)\",\n+        \"other antipsychotics (cumulative EPS/QT burden)\"\n-        \"SSRI / SNRI antidepressants (blunted effect, serotonin overload if dose pushed)\",\n-        \"cannabis concentrates (panic, derealisation)\",\n-        \"antipsychotics (additive QT-prolongation)\"\n+        \"stimulants—ziprasidone will blunt effects and may precipitate sudden crash\",\n+        \"serotonergic psychedelics (trip-abortive but increases confusion/dysphoria)\",\n+        \"strong CYP3A4 inhibitors or inducers (altered plasma levels)\"\n-    \"notes\": \"In vitro transporter assays show EDMC releases 5-HT (EC50 ≈ 347 nM), NE (327 nM) and DA (496 nM) – roughly 1.4- to 3.7-fold weaker than methylone, implying human psychoactive doses in the low-to-mid-hundreds of milligrams. Very limited human data exist; the few r/researchchemicals and Discord reports describe ‘gentler-than-MDMA’ empathy with a more β-keto-like peripheral stimulation and a quick, fatigue-heavy comedown. No controlled pharmacokinetic work has been published; based on structural analogy the elimination half-life is tentatively placed at 4-7 h. Reagent testing is essential: seizures in 2024–25 show many samples sold as “EDMC” actually contained eutylone or N,N-dimethylpentylone. Use a 0.001 g scale, pre-dose individual gel-caps, drink 250-500 mL water / h with electrolytes under exertion, and avoid re-dosing inside the same session. Anecdotal tolerance resets after ~7-10 days; waiting two weeks between sessions minimises neurochemical stress. No animal neurotoxicity data are available, but other SNDRA cathinones show oxidative stress and hyperthermia-mediated neuro- and cardiotoxicity at high doses – keep ambient temperature <25 °C and take cooling breaks when dancing.\",\n+    \"notes\": \"Oral bioavailability doubles when taken with food; dosing on an empty stomach delivers only ~36 % of the intended exposure, leading users to redose unnecessarily. Therapeutic QTc prolongation averages 10–20 msec, but heavy recreational (>160 mg/day) or IV diversion markedly increases torsade risk. IM ziprasidone reaches Cmax within 60 min and has a 2–5 h half-life, making it a common ER ‘trip-stopper’. Forum reports describe 60–120 mg oral as a reliable ‘stimulant-comedown knockout’, with sleep onset 2–4 h after dosing. Extrapyramidal reactions (akathisia, dystonia) and very rare tardive dystonia have occurred after weeks on 80–120 mg/day regimens. Neuroleptic malignant syndrome is possible with massive overdose or polysubstance stacking. Because diversion is rare, material found on the grey-market is usually legitimate pharmacy stock; nonetheless, verify capsules are intact, avoid crushing/insufflating (poor absorption and nasal mucosal damage). Always baseline ECG (>450 msec QTc is a red flag) before experimenting above 40 mg.\\n\\nOral elimination half-life averages 7-10 hours (2-4 hours IM) with minimal active metabolites, so resedation can recur when large oral loads are stacked. QT risks rise sharply with hypokalaemia, bradycardia or interacting drugs, and even though weight gain is milder than with clozapine or olanzapine it still warrants lipid and glucose monitoring. Recreational users note that peak sedation may lag 5-8 hours and depends on taking the dose with at least 500 kcal of fat, so mistiming invites redose stacking and extrapyramidal symptoms.\",\n-      \"warm empathic mood\",\n-      \"moderate euphoria\",\n-      \"physical & mental stimulation\",\n-      \"talkativeness / sociability\",\n-      \"increased tactile appreciation\",\n-      \"jaw tension, bruxism\",\n-      \"mydriasis with shimmering halos\",\n-      \"mild closed-eye visuals at high doses\",\n-      \"tachycardia, sweating, nystagmus\",\n-      \"comedown fatigue & flat affect\"\n+      \"heavy somnolence\",\n+      \"blunted affect\",\n+      \"anxiolysis with apathy\",\n+      \"restless legs / akathisia (paradoxical)\",\n+      \"mild dysphoria or depression\",\n+      \"rare neutral euphoria at sleep threshold\"\n-      \"full_tolerance\": \"after one strong or heavy session\",\n-      \"half_tolerance\": \"3-5 days\",\n-      \"zero_tolerance\": \"10-14 days\",\n+      \"full_tolerance\": \"to sedative effect after 5-7 consecutive nights\",\n+      \"half_tolerance\": \"3-4 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n-        \"methylone\",\n-        \"butylone\",\n-        \"other entactogenic cathinones / MDMA\"\n+        \"other dopamine/serotonin antagonists\"\n-    \"half_life\": \"Estimated 4-7 h (no human data; extrapolated from methylone PK)\",\n+    \"half_life\": \"6-7 h oral; 2-5 h IM\",\n-        \"name\": \"EDMC overview – Wikipedia\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/3%2C4-Ethylenedioxymethcathinone\"\n+        \"name\": \"Ziprasidone: the fifth atypical antipsychotic (PK overview)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/11978164/\"\n-        \"name\": \"Transporter release data (Del Bello et al., 2015)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/26233799/\"\n+        \"name\": \"Pharmacokinetics and therapeutics of acute intramuscular ziprasidone\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/16231965/\"\n-        \"name\": \"Synthetic cathinone SAR review (Glennon & Dukat, 2017)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/27830576/\"\n+        \"name\": \"Drugs.com Ziprasidone Dosage Guide\",\n+        \"reference\": \"https://www.drugs.com/dosage/ziprasidone.html\"\n-        \"name\": \"VCU dissertation – synthetic cathinone mechanisms (Sakloth 2015)\",\n-        \"reference\": \"https://scholarscompass.vcu.edu/etd/3920/\"\n+        \"name\": \"Ziprasidone Hydrochloride Prescribing Information\",\n+        \"reference\": \"https://www.drugs.com/pro/ziprasidone-hydrochloride.html\"\n-        \"name\": \"UK ACMD harm assessment – cathinones (2025 update)\",\n-        \"reference\": \"https://www.gov.uk/government/publications/synthetic-cathinones-an-updated-harms-assessment\"\n+        \"name\": \"QT prolongation interaction report (Drugs.com)\",\n+        \"reference\": \"https://www.drugs.com/interactions-check.php?drug_list=639-0,2330-0\"\n-        \"name\": \"Cayman Chemical reference standard listing\",\n-        \"reference\": \"https://www.caymanchem.com/product/15167/3%2C4-edmc-%28hydrochloride%29\"\n+        \"name\": \"Bluelight - ‘Ziprasidone and Cocaine’ first-hand dosing experiences\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/ziprasidone-and-cocaine.819137/\"\n-        \"name\": \"EPA CompTox substance record\",\n-        \"reference\": \"https://comptox.epa.gov/dashboard/chemical/details/DTXSID001024649\"\n+        \"name\": \"Bluelight - Amphetamine day / Ziprasidone night thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/amphetamine-stim-during-the-day-then-blocker-ziprasidone-at-night-for-sleep.526454/\"\n-        \"name\": \"PiHKAL – EDMA dosage for ring-expanded analogue comparison\",\n-        \"reference\": \"http://pihkal.info/read.php?domain=pk&id=110\"\n+        \"name\": \"Tardive dystonia and ziprasidone case report\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC2249819/\"\n-        \"name\": \"Erowid Methylone dose chart (analogue benchmark)\",\n-        \"reference\": \"https://erowid.org/chemicals/methylone/methylone_dose.shtml\"\n+        \"name\": \"Mayo Clinic oral ziprasidone overview\",\n+        \"reference\": \"https://www.mayoclinic.org/drugs-supplements/ziprasidone-oral-route/description/drg-20067144\"\n-        \"name\": \"Synthetic cathinones: updated harms (Gov UK, 2025)\",\n-        \"reference\": \"https://www.gov.uk/government/publications/synthetic-cathinones-an-updated-harms-assessment\"\n+        \"name\": \"Intentional recreational abuse of SGAs: NPDS study (ziprasidone n=229)\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC5305132/\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Ziprasidone\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Ziprasidone\"\n-      \"entactogen\",\n-      \"stimulant\",\n-      \"research-chemical\"\n+      \"antipsychotic\",\n+      \"sedative\"\n\n# α-Pyrrolidinopropiophenone · #446\n\n-  \"id\": 444,\n-  \"title\": \"Ziprasidone\",\n+  \"id\": 446,\n+  \"title\": \"α-Pyrrolidinopropiophenone\",\n-    \"drug_name\": \"Ziprasidone\",\n-    \"chemical_name\": \"Ziprasidone\",\n+    \"drug_name\": \"α-Pyrrolidinopropiophenone\",\n+    \"chemical_name\": \"α-Pyrrolidinopropiophenone\",\n-    \"chemical_class\": \"Benzisothiazolyl piperazine; second-generation (atypical) antipsychotic\",\n-    \"mechanism_of_action\": \"Multiple receptor antagonist\",\n-    \"psychoactive_class\": \"Mixed 5-HT2A/D2 receptor antagonist with 5-HT1A partial-agonism; weak serotonin-norepinephrine re-uptake inhibitor\",\n+    \"chemical_class\": \"Substituted pyrrolidines\",\n+    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor (potent)\",\n+    \"psychoactive_class\": \"Dopamine-norepinephrine re-uptake inhibitor (DNRI); partial norepinephrine releaser\",\n-          \"route\": \"oral\",\n+          \"route\": \"oral / sublingual\",\n-            \"threshold\": \"10 mg\",\n-            \"light\": \"10 mg - 40 mg\",\n-            \"common\": \"40 mg - 80 mg\",\n-            \"strong\": \"80 mg - 120 mg\",\n-            \"heavy\": \"120+ mg\"\n+            \"threshold\": \"10mg\",\n+            \"light\": \"15mg - 30mg\",\n+            \"common\": \"30mg - 60mg\",\n+            \"strong\": \"60mg - 90mg\",\n+            \"heavy\": \"90mg+\"\n-          \"route\": \"intramuscular\",\n+          \"route\": \"insufflated\",\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"5 mg - 10 mg\",\n-            \"common\": \"10 mg - 20 mg\",\n-            \"strong\": \"20 mg - 40 mg\",\n-            \"heavy\": \"40+ mg\"\n+            \"threshold\": \"5mg\",\n+            \"light\": \"10mg - 20mg\",\n+            \"common\": \"20mg - 40mg\",\n+            \"strong\": \"40mg - 70mg\",\n+            \"heavy\": \"70mg+\"\n+        },\n+        {\n+          \"route\": \"vaporized / smoked\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"3mg\",\n+            \"light\": \"5mg - 10mg\",\n+            \"common\": \"10mg - 25mg\",\n+            \"strong\": \"25mg - 40mg\",\n+            \"heavy\": \"40mg+\"\n+          }\n+        },\n+        {\n+          \"route\": \"intravenous (high risk)\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"20mg\",\n+            \"light\": \"25mg - 50mg\",\n+            \"common\": \"50mg - 100mg\",\n+            \"strong\": \"100mg - 150mg\",\n+            \"heavy\": \"150mg+\"\n+          }\n-          \"route\": \"oral\",\n+          \"route\": \"oral / sublingual\",\n-            \"oral\"\n+            \"oral\",\n+            \"sublingual\"\n-            \"total_duration\": \"6-12 h (sedation window)\",\n-            \"onset\": \"1-3 h\",\n-            \"peak\": \"3-6 h\",\n-            \"offset\": \"2-4 h residual fade-out\",\n-            \"after_effects\": \"especially after heavy doses\"\n+            \"total_duration\": \"3-6 h (active stimulation)\",\n+            \"onset\": \"15-45 min\",\n+            \"peak\": \"0.5-2 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-12 h residual insomnia; anhedonia; tachycardia\"\n-          \"route\": \"intramuscular\",\n+          \"route\": \"insufflated\",\n-            \"intramuscular\"\n+            \"insufflated\"\n-            \"total_duration\": \"6-12 h (sedation window)\",\n-            \"onset\": \"15-30 min\",\n-            \"peak\": \"30-90 min\",\n-            \"offset\": \"2-4 h residual fade-out\",\n-            \"after_effects\": \"Grogginess; dysphoria or akathisia can linger 6-24 h\"\n+            \"total_duration\": \"3-6 h (active stimulation)\",\n+            \"onset\": \"5-15 min\",\n+            \"peak\": \"0.5-2 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-12 h residual insomnia; anhedonia; tachycardia\"\n+        },\n+        {\n+          \"route\": \"vaporized / smoked\",\n+          \"canonical_routes\": [\n+            \"vaporized\",\n+            \"smoked\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"3-6 h (active stimulation)\",\n+            \"onset\": \"1-2 min\",\n+            \"peak\": \"0.5-2 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-12 h residual insomnia; anhedonia; tachycardia\"\n+          }\n+        },\n+        {\n+          \"route\": \"intravenous (high risk)\",\n+          \"canonical_routes\": [\n+            \"intravenous\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"3-6 h (active stimulation)\",\n+            \"onset\": \"<30 sec\",\n+            \"peak\": \"0.5-2 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-12 h residual insomnia; anhedonia; tachycardia\"\n+          }\n-    \"addiction_potential\": \"Low—ziprasidone is not reinforcing, but abrupt cessation after chronic use can precipitate rebound psychosis, agitation, or cholinergic rebound; compulsive redosing for ‘knock-out’ sleep is uncommon but reported.\",\n+    \"addiction_potential\": \"Moderate to high: short half-life and pronounced dopaminergic action encourage redosing binges; rodent IV-SA studies show robust reinforcement equal to cocaine at 0.1-0.32 mg/kg/infusion.\",\n-        \"other QT-prolonging drugs (methadone, macrolide/fluoroquinolone antibiotics, some SSRIs, hypokalemia-inducing diuretics)\",\n-        \"class IA/III anti-arrhythmics\",\n-        \"high-dose cocaine or synthetic cathinones (synergistic cardiotoxicity)\"\n+        \"MAOIs (hypertensive crisis)\",\n+        \"high-dose stimulants (cocaine, amphetamines) - tachyarrhythmia, hyperthermia\",\n+        \"bupropion or cathinone analogues (seizure threshold markedly lowered)\"\n-        \"alcohol or benzodiazepines (profound CNS/respiratory depression)\",\n-        \"opioids (additive respiratory depression)\",\n-        \"other antipsychotics (cumulative EPS/QT burden)\"\n+        \"tramadol (seizures)\",\n+        \"serotonergic psychedelics or SSRIs (serotonin toxicity risk)\",\n+        \"strong CYP2D6 inhibitors (plasma level spike)\"\n-        \"stimulants—ziprasidone will blunt effects and may precipitate sudden crash\",\n-        \"serotonergic psychedelics (trip-abortive but increases confusion/dysphoria)\",\n-        \"strong CYP3A4 inhibitors or inducers (altered plasma levels)\"\n+        \"alcohol or benzodiazepines (masking of cardiotoxicity followed by rebound stimulation)\",\n+        \"cannabis concentrates (panic, dysphoria)\",\n+        \"beta-blockers (unopposed α-adrenergic vasoconstriction)\"\n-    \"notes\": \"Oral bioavailability doubles when taken with food; dosing on an empty stomach delivers only ~36 % of the intended exposure, leading users to redose unnecessarily. Therapeutic QTc prolongation averages 10–20 msec, but heavy recreational (>160 mg/day) or IV diversion markedly increases torsade risk. IM ziprasidone reaches Cmax within 60 min and has a 2–5 h half-life, making it a common ER ‘trip-stopper’. Forum reports describe 60–120 mg oral as a reliable ‘stimulant-comedown knockout’, with sleep onset 2–4 h after dosing. Extrapyramidal reactions (akathisia, dystonia) and very rare tardive dystonia have occurred after weeks on 80–120 mg/day regimens. Neuroleptic malignant syndrome is possible with massive overdose or polysubstance stacking. Because diversion is rare, material found on the grey-market is usually legitimate pharmacy stock; nonetheless, verify capsules are intact, avoid crushing/insufflating (poor absorption and nasal mucosal damage). Always baseline ECG (>450 msec QTc is a red flag) before experimenting above 40 mg.\\n\\nOral elimination half-life averages 7-10 hours (2-4 hours IM) with minimal active metabolites, so resedation can recur when large oral loads are stacked. QT risks rise sharply with hypokalaemia, bradycardia or interacting drugs, and even though weight gain is milder than with clozapine or olanzapine it still warrants lipid and glucose monitoring. Recreational users note that peak sedation may lag 5-8 hours and depends on taking the dose with at least 500 kcal of fat, so mistiming invites redose stacking and extrapyramidal symptoms.\",\n+    \"notes\": \"α-PPP is the three-carbon homologue in the pyrrolidinophenone series (α-PVP > α-PBP > α-PPP); in vitro it is a potent DAT>NET inhibitor with negligible SERT action, producing a clean but relatively uneuphoric stimulation compared with α-PVP. Bluelight and Drugs-Forum reports converge on 20-40 mg insufflated or 60-70 mg oral as 'sweet-spot' working doses, giving 4-7 h of focused, non-jittery productivity and social facilitation. Higher pushes (≥90 mg oral or ≥70 mg intranasal) add peripheral vasoconstriction, bruxism and tremor without proportional euphoria. Multiple IV users describe 100-150 mg boluses as providing a cocaine-like rush but an intense compulsive redose cycle and severe vein irritation: IV use is strongly discouraged. Animal data show hyperthermia, locomotor sensitisation and dopaminergic neurotoxicity after large binge doses (4 × 80 mg/kg). Pharmacokinetic work suggests a short plasma t½ of ~1-2 h with cathinone as a metabolite; expect rapid crash and craving. Reagent testing (Marquis, Mecke, Simon's) gives weak reactions—confirm identity with GC-MS where possible as mis-sold α-PVP or MDPV is common. Users emphasise strict volumetric dilution, nasal saline rinses, hydration (250 ml water h⁻¹) and 48-h stimulant breaks to limit tolerance and sympatholytic strain.\",\n-      \"heavy somnolence\",\n-      \"blunted affect\",\n-      \"anxiolysis with apathy\",\n-      \"restless legs / akathisia (paradoxical)\",\n-      \"mild dysphoria or depression\",\n-      \"rare neutral euphoria at sleep threshold\"\n+      \"clean mental stimulation\",\n+      \"enhanced focus and task motivation\",\n+      \"talkativeness and mild sociability\",\n+      \"moderate euphoria (less than α-PVP)\",\n+      \"appetite suppression\",\n+      \"vasoconstriction, cold extremities\",\n+      \"mild anxiety or jitteriness at higher doses\",\n+      \"crash with fatigue and low mood\"\n-      \"full_tolerance\": \"to sedative effect after 5-7 consecutive nights\",\n+      \"full_tolerance\": \"after one heavy binge day\",\n-      \"zero_tolerance\": \"1-2 weeks\",\n+      \"zero_tolerance\": \"7-10 days\",\n-        \"other dopamine/serotonin antagonists\"\n+        \"α-PVP and other pyrrolidinophenones\",\n+        \"amphetamines\",\n+        \"cocaine\"\n-    \"half_life\": \"6-7 h oral; 2-5 h IM\",\n+    \"half_life\": \"1-2 h (plasma); active cathinone metabolite may extend subjective stimulation\",\n-        \"name\": \"Ziprasidone: the fifth atypical antipsychotic (PK overview)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/11978164/\"\n+        \"name\": \"Wikipedia - α-PPP overview\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/%CE%91-Pyrrolidinopropiophenone\"\n-        \"name\": \"Pharmacokinetics and therapeutics of acute intramuscular ziprasidone\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/16231965/\"\n+        \"name\": \"Bluelight dosage & ROA discussion thread (2008-2011)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/alpha-ppp-alpha-pyrrolidinopropiophenone.381044/\"\n-        \"name\": \"Drugs.com Ziprasidone Dosage Guide\",\n-        \"reference\": \"https://www.drugs.com/dosage/ziprasidone.html\"\n+        \"name\": \"Synthetic cathinones neurotoxicity review (2023)\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC10093970/\"\n-        \"name\": \"Ziprasidone Hydrochloride Prescribing Information\",\n-        \"reference\": \"https://www.drugs.com/pro/ziprasidone-hydrochloride.html\"\n+        \"name\": \"α-PPP reinforcing effects in extended IV self-administration (2020)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/33192631/\"\n-        \"name\": \"QT prolongation interaction report (Drugs.com)\",\n-        \"reference\": \"https://www.drugs.com/interactions-check.php?drug_list=639-0,2330-0\"\n+        \"name\": \"DAT/NET inhibition & partial releasing profile study (2021)\",\n+        \"reference\": \"https://www.sciencedirect.com/science/article/pii/S0028390821001246\"\n-        \"name\": \"Bluelight - ‘Ziprasidone and Cocaine’ first-hand dosing experiences\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/ziprasidone-and-cocaine.819137/\"\n+        \"name\": \"Tripsitter harm-reduction sheet - α-PPP specs (2023)\",\n+        \"reference\": \"https://tripsitter.com/a-ppp/\"\n-        \"name\": \"Bluelight - Amphetamine day / Ziprasidone night thread\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/amphetamine-stim-during-the-day-then-blocker-ziprasidone-at-night-for-sleep.526454/\"\n+        \"name\": \"Drugs-Forum 'Eight Ballz' cathinone compilation (2012)\",\n+        \"reference\": \"https://drugs-forum.com/threads/eight-ballz-glass-cleaner.176360/\"\n-        \"name\": \"Tardive dystonia and ziprasidone case report\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC2249819/\"\n-      },\n-      {\n-        \"name\": \"Mayo Clinic oral ziprasidone overview\",\n-        \"reference\": \"https://www.mayoclinic.org/drugs-supplements/ziprasidone-oral-route/description/drg-20067144\"\n-      },\n-      {\n-        \"name\": \"Intentional recreational abuse of SGAs: NPDS study (ziprasidone n=229)\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC5305132/\"\n-      },\n-      {\n-        \"name\": \"Wikipedia: Ziprasidone\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Ziprasidone\"\n+        \"name\": \"I-Trend cathinone metabolism & liver toxicity analysis (Peters et al., 2014)\",\n+        \"reference\": \"https://drugs-forum.com/threads/best-legal-replacement-for-a-pvp-usa.237174/\"\n-      \"antipsychotic\",\n-      \"sedative\"\n+      \"stimulant\",\n+      \"research-chemical\"\n\n# MDPV · #448\n\n-  \"id\": 446,\n-  \"title\": \"α-Pyrrolidinopropiophenone\",\n+  \"id\": 448,\n+  \"title\": \"MDPV\",\n-    \"drug_name\": \"α-Pyrrolidinopropiophenone\",\n-    \"chemical_name\": \"α-Pyrrolidinopropiophenone\",\n+    \"drug_name\": \"MDPV\",\n+    \"chemical_name\": \"MDPV\",\n-    \"psychoactive_class\": \"Dopamine-norepinephrine re-uptake inhibitor (DNRI); partial norepinephrine releaser\",\n+    \"psychoactive_class\": \"Norepinephrine–dopamine reuptake inhibitor (NDRI)\",\n-            \"threshold\": \"10mg\",\n-            \"light\": \"15mg - 30mg\",\n-            \"common\": \"30mg - 60mg\",\n-            \"strong\": \"60mg - 90mg\",\n-            \"heavy\": \"90mg+\"\n+            \"threshold\": \"1mg\",\n+            \"light\": \"1mg - 3mg\",\n+            \"common\": \"3mg - 8mg\",\n+            \"strong\": \"8mg - 15mg\",\n+            \"heavy\": \"15mg+\"\n-            \"threshold\": \"5mg\",\n-            \"light\": \"10mg - 20mg\",\n-            \"common\": \"20mg - 40mg\",\n-            \"strong\": \"40mg - 70mg\",\n-            \"heavy\": \"70mg+\"\n+            \"threshold\": \"1mg\",\n+            \"light\": \"1mg - 3mg\",\n+            \"common\": \"3mg - 6mg\",\n+            \"strong\": \"6mg - 12mg\",\n+            \"heavy\": \"12mg+\"\n-            \"threshold\": \"3mg\",\n-            \"light\": \"5mg - 10mg\",\n-            \"common\": \"10mg - 25mg\",\n-            \"strong\": \"25mg - 40mg\",\n-            \"heavy\": \"40mg+\"\n+            \"threshold\": \"~1mg\",\n+            \"light\": \"1mg - 2mg\",\n+            \"common\": \"2mg - 4mg\",\n+            \"strong\": \"4mg - 8mg\",\n+            \"heavy\": \"8mg+\"\n-          \"route\": \"intravenous (high risk)\",\n+          \"route\": \"rectal\",\n-            \"threshold\": \"20mg\",\n-            \"light\": \"25mg - 50mg\",\n-            \"common\": \"50mg - 100mg\",\n-            \"strong\": \"100mg - 150mg\",\n-            \"heavy\": \"150mg+\"\n+            \"threshold\": \"1mg\",\n+            \"light\": \"1mg - 2mg\",\n+            \"common\": \"2mg - 5mg\",\n+            \"strong\": \"5mg - 10mg\",\n+            \"heavy\": \"10mg+\"\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-12 h residual insomnia; anhedonia; tachycardia\"\n+            \"offset\": \"1-3 h\",\n+            \"after_effects\": \"6-24 h residual stimulation; anxiety; anhedonia\"\n-            \"onset\": \"5-15 min\",\n+            \"onset\": \"2-10 min\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-12 h residual insomnia; anhedonia; tachycardia\"\n+            \"offset\": \"1-3 h\",\n+            \"after_effects\": \"6-24 h residual stimulation; anxiety; anhedonia\"\n-            \"onset\": \"1-2 min\",\n+            \"onset\": \"5-30 sec\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-12 h residual insomnia; anhedonia; tachycardia\"\n+            \"offset\": \"1-3 h\",\n+            \"after_effects\": \"6-24 h residual stimulation; anxiety; anhedonia\"\n-          \"route\": \"intravenous (high risk)\",\n+          \"route\": \"rectal\",\n-            \"intravenous\"\n+            \"rectal\"\n-            \"onset\": \"<30 sec\",\n+            \"onset\": \"5-10 min\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-12 h residual insomnia; anhedonia; tachycardia\"\n+            \"offset\": \"1-3 h\",\n+            \"after_effects\": \"6-24 h residual stimulation; anxiety; anhedonia\"\n-    \"addiction_potential\": \"Moderate to high: short half-life and pronounced dopaminergic action encourage redosing binges; rodent IV-SA studies show robust reinforcement equal to cocaine at 0.1-0.32 mg/kg/infusion.\",\n+    \"addiction_potential\": \"Very high: rapid reinforcement, intense compulsive redosing; binge patterns >200 mg/day reported in forums, with psychosis after 48-72 h sleep deprivation.\",\n-        \"high-dose stimulants (cocaine, amphetamines) - tachyarrhythmia, hyperthermia\",\n-        \"bupropion or cathinone analogues (seizure threshold markedly lowered)\"\n+        \"other potent stimulants (cocaine, methamphetamine, α-PVP)\",\n+        \"tramadol or bupropion (seizure risk)\",\n+        \"beta-blockers without alpha-blockade (paradoxical hypertension)\"\n-        \"tramadol (seizures)\",\n-        \"serotonergic psychedelics or SSRIs (serotonin toxicity risk)\",\n-        \"strong CYP2D6 inhibitors (plasma level spike)\"\n+        \"high-dose dissociatives or psychedelics (psychosis)\",\n+        \"synthetic cannabinoids (tachyarrhythmia, paranoia)\",\n+        \"alcohol (cardiotoxic synergy, loss of thermoregulation)\"\n-        \"alcohol or benzodiazepines (masking of cardiotoxicity followed by rebound stimulation)\",\n-        \"cannabis concentrates (panic, dysphoria)\",\n-        \"beta-blockers (unopposed α-adrenergic vasoconstriction)\"\n+        \"benzodiazepines or GHB (respiratory depression if used to crash)\",\n+        \"SSRI/SNRI antidepressants (serotonin / noradrenaline load)\",\n+        \"caffeine or energy drinks (additive tachycardia)\"\n-    \"notes\": \"α-PPP is the three-carbon homologue in the pyrrolidinophenone series (α-PVP > α-PBP > α-PPP); in vitro it is a potent DAT>NET inhibitor with negligible SERT action, producing a clean but relatively uneuphoric stimulation compared with α-PVP. Bluelight and Drugs-Forum reports converge on 20-40 mg insufflated or 60-70 mg oral as 'sweet-spot' working doses, giving 4-7 h of focused, non-jittery productivity and social facilitation. Higher pushes (≥90 mg oral or ≥70 mg intranasal) add peripheral vasoconstriction, bruxism and tremor without proportional euphoria. Multiple IV users describe 100-150 mg boluses as providing a cocaine-like rush but an intense compulsive redose cycle and severe vein irritation: IV use is strongly discouraged. Animal data show hyperthermia, locomotor sensitisation and dopaminergic neurotoxicity after large binge doses (4 × 80 mg/kg). Pharmacokinetic work suggests a short plasma t½ of ~1-2 h with cathinone as a metabolite; expect rapid crash and craving. Reagent testing (Marquis, Mecke, Simon's) gives weak reactions—confirm identity with GC-MS where possible as mis-sold α-PVP or MDPV is common. Users emphasise strict volumetric dilution, nasal saline rinses, hydration (250 ml water h⁻¹) and 48-h stimulant breaks to limit tolerance and sympatholytic strain.\",\n+    \"notes\": \"Lab studies show MDPV blocks DAT (IC50≈4 nM) and NET (≈26 nM) with >800-fold weaker action at SERT, making its profile closer to cocaine than amphetamine but far more potent by weight. Human toxicokinetic work and forensic cases suggest a plasma elimination half-life of ~80-120 min, yet subjective stimulation often persists 4-6 h, likely due to slow brain egress and active metabolites. Forum users consistently warn that dosing accuracy below 5 mg requires a 0.001 g (milligram) scale or volumetric solution because eyeballing crystals leads to runaway binges. Acute harms include severe peripheral vasoconstriction, rhabdomyolysis, hyperthermia and excited-delirium deaths; benzodiazepines are first-line in emergencies, while beta-blockers alone are contraindicated. Redosing dramatically increases psychosis risk—visual ‘shadow people’, persecutory delusions and tactile hallucinations typically emerge after 24-48 h sleep loss. Harm-reduction best practice: pre-measure single doses, cap total session ≤20 mg, maintain aggressive hydration + electrolytes, supplement with magnesium to reduce bruxism, and schedule 2-week stimulant breaks to reset tolerance and dopamine function. Testing with multi-reagent kits is essential—bath-salt powders frequently contain α-PVP or eutylone masquerading as MDPV.\",\n-      \"clean mental stimulation\",\n-      \"enhanced focus and task motivation\",\n-      \"talkativeness and mild sociability\",\n-      \"moderate euphoria (less than α-PVP)\",\n-      \"appetite suppression\",\n-      \"vasoconstriction, cold extremities\",\n-      \"mild anxiety or jitteriness at higher doses\",\n-      \"crash with fatigue and low mood\"\n+      \"intense euphoria / rush\",\n+      \"compulsive redosing\",\n+      \"sharpened focus\",\n+      \"elevated libido\",\n+      \"increased sociability at low doses\",\n+      \"marked vasoconstriction\",\n+      \"anxiety and paranoia\",\n+      \"insomnia\",\n+      \"visual distortions at high or sleep-deprived states\"\n-      \"full_tolerance\": \"after one heavy binge day\",\n-      \"half_tolerance\": \"3-4 days\",\n+      \"full_tolerance\": \"after one high-dose binge\",\n+      \"half_tolerance\": \"2-4 days\",\n-        \"α-PVP and other pyrrolidinophenones\",\n-        \"amphetamines\",\n-        \"cocaine\"\n+        \"α-PVP\",\n+        \"other pyrrolidinophenone cathinones\"\n-    \"half_life\": \"1-2 h (plasma); active cathinone metabolite may extend subjective stimulation\",\n+    \"half_life\": \"1.5-2 h plasma (effective 3-4 h subjective)\",\n-        \"name\": \"Wikipedia - α-PPP overview\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/%CE%91-Pyrrolidinopropiophenone\"\n+        \"name\": \"Erowid MDPV dose chart\",\n+        \"reference\": \"https://www.erowid.org/chemicals/mdpv/mdpv_dose.shtml\"\n-        \"name\": \"Bluelight dosage & ROA discussion thread (2008-2011)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/alpha-ppp-alpha-pyrrolidinopropiophenone.381044/\"\n+        \"name\": \"Wikipedia – Methylenedioxypyrovalerone\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Methylenedioxypyrovalerone\"\n-        \"name\": \"Synthetic cathinones neurotoxicity review (2023)\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC10093970/\"\n+        \"name\": \"Drugs-Forum – MDPV drug info discussion\",\n+        \"reference\": \"https://drugs-forum.com/threads/methylenedioxypyrovalerone-mdpv-drug-info.19972/\"\n-        \"name\": \"α-PPP reinforcing effects in extended IV self-administration (2020)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/33192631/\"\n+        \"name\": \"Bluelight – MDPV dosage question thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/mdpv-question.650373/\"\n-        \"name\": \"DAT/NET inhibition & partial releasing profile study (2021)\",\n-        \"reference\": \"https://www.sciencedirect.com/science/article/pii/S0028390821001246\"\n+        \"name\": \"Behavioural, Pharmacokinetic, Metabolic and Hyperthermic Profile of MDPV (Frontiers in Psychiatry, 2018)\",\n+        \"reference\": \"https://www.frontiersin.org/articles/10.3389/fpsyt.2018.00144/full\"\n-        \"name\": \"Tripsitter harm-reduction sheet - α-PPP specs (2023)\",\n-        \"reference\": \"https://tripsitter.com/a-ppp/\"\n+        \"name\": \"Stereoselective actions of MDPV at monoamine transporters (ACS Chem Neurosci, 2017)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/28215117/\"\n-        \"name\": \"Drugs-Forum 'Eight Ballz' cathinone compilation (2012)\",\n-        \"reference\": \"https://drugs-forum.com/threads/eight-ballz-glass-cleaner.176360/\"\n+        \"name\": \"Powerful cocaine-like actions of MDPV (Neuropsychopharmacology, 2013)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/23072836/\"\n-        \"name\": \"I-Trend cathinone metabolism & liver toxicity analysis (Peters et al., 2014)\",\n-        \"reference\": \"https://drugs-forum.com/threads/best-legal-replacement-for-a-pvp-usa.237174/\"\n+        \"name\": \"Hyperthermia and multiorgan failure after bath-salts injection (Case Report, 2012)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/22387085/\"\n+      },\n+      {\n+        \"name\": \"Intoxications involving MDPV in Sweden 2010-2014\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/26462932/\"\n+      },\n+      {\n+        \"name\": \"Acute Methylenedioxypyrovalerone Toxicity (ToxIC Registry, 2014)\",\n+        \"reference\": \"https://www.acmt.net/wp-content/uploads/2022/08/TXP_2015_Froberg_Acute-Methylenedioxypyrovalerone-Toxicity.pdf\"\n+      },\n+      {\n+        \"name\": \"Cardiotoxicity after synthetic cathinone use – two cases (2024)\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC10937789/\"\n+      },\n+      {\n+        \"name\": \"Anodyne substance page – MDPV\",\n+        \"reference\": \"https://anodyne.wiki/substance/3%2C4-methylenedioxy-%CE%B1-pyrrolidinopentiophenone\"\n+      },\n+      {\n+        \"name\": \"Anodyne Wiki: 3,4 Methylenedioxy Α Pyrrolidinopentiophenone\",\n+        \"reference\": \"https://anodyne.wiki/substance/3,4-methylenedioxy-%CE%B1-pyrrolidinopentiophenone\"\n\n# 3-Methyl-4-fluoro-α-pyrrolidinovalerophenone · #449\n\n-  \"id\": 448,\n-  \"title\": \"MDPV\",\n+  \"id\": 449,\n+  \"title\": \"3-Methyl-4-fluoro-α-pyrrolidinovalerophenone\",\n-    \"drug_name\": \"MDPV\",\n-    \"chemical_name\": \"MDPV\",\n+    \"drug_name\": \"3-Methyl-4-fluoro-α-pyrrolidinovalerophenone\",\n+    \"chemical_name\": \"3-Methyl-4-fluoro-α-pyrrolidinovalerophenone\",\n-    \"psychoactive_class\": \"Norepinephrine–dopamine reuptake inhibitor (NDRI)\",\n+    \"psychoactive_class\": \"Norepinephrine–dopamine re-uptake inhibitor (stimulant)\",\n-            \"threshold\": \"1mg\",\n-            \"light\": \"1mg - 3mg\",\n-            \"common\": \"3mg - 8mg\",\n-            \"strong\": \"8mg - 15mg\",\n-            \"heavy\": \"15mg+\"\n+            \"threshold\": \"5mg\",\n+            \"light\": \"5mg - 15mg\",\n+            \"common\": \"15mg - 30mg\",\n+            \"strong\": \"30mg - 45mg\",\n+            \"heavy\": \"45+ mg\"\n-            \"threshold\": \"1mg\",\n-            \"light\": \"1mg - 3mg\",\n-            \"common\": \"3mg - 6mg\",\n-            \"strong\": \"6mg - 12mg\",\n-            \"heavy\": \"12mg+\"\n+            \"threshold\": \"5mg\",\n+            \"light\": \"5mg - 20mg\",\n+            \"common\": \"20mg - 40mg\",\n+            \"strong\": \"40mg - 60mg\",\n+            \"heavy\": \"60+ mg\"\n-          \"route\": \"vaporized / smoked\",\n+          \"route\": \"vaporized / smoked (freebase foil or mesh)\",\n-            \"threshold\": \"~1mg\",\n-            \"light\": \"1mg - 2mg\",\n-            \"common\": \"2mg - 4mg\",\n-            \"strong\": \"4mg - 8mg\",\n-            \"heavy\": \"8mg+\"\n+            \"threshold\": \"3mg\",\n+            \"light\": \"3mg - 10mg\",\n+            \"common\": \"10mg - 15mg\",\n+            \"strong\": \"15mg - 20mg\",\n+            \"heavy\": \"20+ mg\"\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"1mg\",\n-            \"light\": \"1mg - 2mg\",\n-            \"common\": \"2mg - 5mg\",\n-            \"strong\": \"5mg - 10mg\",\n-            \"heavy\": \"10mg+\"\n-          }\n-            \"total_duration\": \"3-6 h (active stimulation)\",\n-            \"onset\": \"15-45 min\",\n-            \"peak\": \"0.5-2 h\",\n-            \"offset\": \"1-3 h\",\n-            \"after_effects\": \"6-24 h residual stimulation; anxiety; anhedonia\"\n+            \"total_duration\": \"3-5 hours\",\n+            \"onset\": \"15-30 minutes\",\n+            \"peak\": \"30-90 minutes\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"2-6 hours residual stimulation, agitation, crash\"\n-            \"total_duration\": \"3-6 h (active stimulation)\",\n-            \"onset\": \"2-10 min\",\n-            \"peak\": \"0.5-2 h\",\n-            \"offset\": \"1-3 h\",\n-            \"after_effects\": \"6-24 h residual stimulation; anxiety; anhedonia\"\n+            \"total_duration\": \"2-3 hours\",\n+            \"onset\": \"5-10 minutes\",\n+            \"peak\": \"30-90 minutes\",\n+            \"offset\": \"~60 minutes\",\n+            \"after_effects\": \"2-6 hours residual stimulation, agitation, crash\"\n-          \"route\": \"vaporized / smoked\",\n+          \"route\": \"vaporized / smoked (freebase foil or mesh)\",\n-            \"total_duration\": \"3-6 h (active stimulation)\",\n-            \"onset\": \"5-30 sec\",\n-            \"peak\": \"0.5-2 h\",\n-            \"offset\": \"1-3 h\",\n-            \"after_effects\": \"6-24 h residual stimulation; anxiety; anhedonia\"\n+            \"total_duration\": \"1-1.5 hours\",\n+            \"onset\": \"<30 seconds\",\n+            \"peak\": \"2-10 minutes\",\n+            \"offset\": \"30-45 minutes\",\n+            \"after_effects\": \"2-6 hours residual stimulation, agitation, crash\"\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"canonical_routes\": [\n-            \"rectal\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"3-6 h (active stimulation)\",\n-            \"onset\": \"5-10 min\",\n-            \"peak\": \"0.5-2 h\",\n-            \"offset\": \"1-3 h\",\n-            \"after_effects\": \"6-24 h residual stimulation; anxiety; anhedonia\"\n-          }\n-    \"addiction_potential\": \"Very high: rapid reinforcement, intense compulsive redosing; binge patterns >200 mg/day reported in forums, with psychosis after 48-72 h sleep deprivation.\",\n+    \"addiction_potential\": \"High: pyrrolidinophenone cathinones produce intense but short-lived euphoria that encourages rapid redosing; users describe binge patterns and severe crashes comparable to α-PVP.\",\n-        \"MAOIs (hypertensive crisis)\",\n-        \"other potent stimulants (cocaine, methamphetamine, α-PVP)\",\n-        \"tramadol or bupropion (seizure risk)\",\n-        \"beta-blockers without alpha-blockade (paradoxical hypertension)\"\n+        \"MAOIs\",\n+        \"other potent stimulants (amphetamine, cocaine, synthetic cathinones)\",\n+        \"strong serotonergic agents (risk of hyperthermia)\",\n+        \"sympathomimetic inhalers (clenbuterol, ephedrine)\"\n-        \"high-dose dissociatives or psychedelics (psychosis)\",\n-        \"synthetic cannabinoids (tachyarrhythmia, paranoia)\",\n-        \"alcohol (cardiotoxic synergy, loss of thermoregulation)\"\n+        \"synthetic cannabinoids (tachyarrhythmia, psychosis)\",\n+        \"monoamine-releasing entactogens (eutylone, mephedrone)\",\n+        \"high-dose alcohol or GHB (cardiac stress when stimulant wears off)\"\n-        \"benzodiazepines or GHB (respiratory depression if used to crash)\",\n-        \"SSRI/SNRI antidepressants (serotonin / noradrenaline load)\",\n-        \"caffeine or energy drinks (additive tachycardia)\"\n+        \"SSRI or SNRI antidepressants\",\n+        \"benzodiazepines (use small rescue doses only for comedown)\",\n+        \"cannabis (may accentuate anxiety)\"\n-    \"notes\": \"Lab studies show MDPV blocks DAT (IC50≈4 nM) and NET (≈26 nM) with >800-fold weaker action at SERT, making its profile closer to cocaine than amphetamine but far more potent by weight. Human toxicokinetic work and forensic cases suggest a plasma elimination half-life of ~80-120 min, yet subjective stimulation often persists 4-6 h, likely due to slow brain egress and active metabolites. Forum users consistently warn that dosing accuracy below 5 mg requires a 0.001 g (milligram) scale or volumetric solution because eyeballing crystals leads to runaway binges. Acute harms include severe peripheral vasoconstriction, rhabdomyolysis, hyperthermia and excited-delirium deaths; benzodiazepines are first-line in emergencies, while beta-blockers alone are contraindicated. Redosing dramatically increases psychosis risk—visual ‘shadow people’, persecutory delusions and tactile hallucinations typically emerge after 24-48 h sleep loss. Harm-reduction best practice: pre-measure single doses, cap total session ≤20 mg, maintain aggressive hydration + electrolytes, supplement with magnesium to reduce bruxism, and schedule 2-week stimulant breaks to reset tolerance and dopamine function. Testing with multi-reagent kits is essential—bath-salt powders frequently contain α-PVP or eutylone masquerading as MDPV.\",\n+    \"notes\": \"Pharmacology data are scarce; in vitro transporter assays of related α-PVP analogs suggest nanomolar NET/DAT inhibition. A 2022 forensic case reported fatal ventricular tachycardia with femoral blood 26 ng/mL, illustrating low LD50 margin. Fluorine substitution is predicted to raise metabolic stability, extending active phase relative to alkyl-only peers. User reports indicate very rapid onset when freebased (steam on foil), but subjective potency roughly half that of α-PVP: common ‘one-hit’ loads are 10-15 mg, with compulsive re-hits every 10-15 min. Intranasal use burns intensely and produces drip-induced gagging; many switch to glass-pipe inhalation. Tolerance rises sharply after a single night of use and fades over ~1-2 weeks. Harm-reduction best practices include volumetric solutions for accurate micro-dosing, pulse-ox monitoring, strict session limits (<150 mg total 24 h) and aggressive hydration/electrolyte replacement. Because MFPVP often appears as off-white crystals mixed with eutylone or NEP, multi-reagent testing (Marquis, Simon, Froehde) plus FT-IR or GC-MS confirmation is advised before consumption.\",\n-      \"intense euphoria / rush\",\n-      \"compulsive redosing\",\n-      \"sharpened focus\",\n-      \"elevated libido\",\n-      \"increased sociability at low doses\",\n-      \"marked vasoconstriction\",\n-      \"anxiety and paranoia\",\n-      \"insomnia\",\n-      \"visual distortions at high or sleep-deprived states\"\n+      \"intense mental stimulation\",\n+      \"rush of euphoria\",\n+      \"compulsive redosing drive\",\n+      \"sweating and vasoconstriction\",\n+      \"sexual arousal\",\n+      \"jaw tension / bruxism\",\n+      \"paranoia at higher doses\",\n+      \"abrupt dysphoric crash\"\n-      \"full_tolerance\": \"after one high-dose binge\",\n-      \"half_tolerance\": \"2-4 days\",\n-      \"zero_tolerance\": \"7-10 days\",\n+      \"full_tolerance\": \"after one heavy binge\",\n+      \"half_tolerance\": \"3-7 days\",\n+      \"zero_tolerance\": \"14-21 days\",\n+        \"α-PHP\",\n+        \"MDPV\",\n-    \"half_life\": \"1.5-2 h plasma (effective 3-4 h subjective)\",\n+    \"half_life\": \"estimated 4-6 h (no human PK published; based on α-PVP ratios and toxicological back-calculation)\",\n-        \"name\": \"Erowid MDPV dose chart\",\n-        \"reference\": \"https://www.erowid.org/chemicals/mdpv/mdpv_dose.shtml\"\n+        \"name\": \"Anodyne harm-reduction monograph\",\n+        \"reference\": \"https://anodyne.wiki/substance/3-methyl-4-fluoro-%CE%B1-pyrrolidinovalerophenone\"\n-        \"name\": \"Wikipedia – Methylenedioxypyrovalerone\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Methylenedioxypyrovalerone\"\n+        \"name\": \"MFPVP overview – Wikipedia\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/MFPVP\"\n-        \"name\": \"Drugs-Forum – MDPV drug info discussion\",\n-        \"reference\": \"https://drugs-forum.com/threads/methylenedioxypyrovalerone-mdpv-drug-info.19972/\"\n+        \"name\": \"Fatal intoxication case report (J Anal Toxicol 2022)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/35020879/\"\n-        \"name\": \"Bluelight – MDPV dosage question thread\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/mdpv-question.650373/\"\n+        \"name\": \"Review of synthetic cathinones 2019-2022\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC9476408/\"\n-        \"name\": \"Behavioural, Pharmacokinetic, Metabolic and Hyperthermic Profile of MDPV (Frontiers in Psychiatry, 2018)\",\n-        \"reference\": \"https://www.frontiersin.org/articles/10.3389/fpsyt.2018.00144/full\"\n+        \"name\": \"Spectroscopic & crystallographic characterisation of 4F-3Me-α-PVP\",\n+        \"reference\": \"https://doi.org/10.3390/cryst13060934\"\n-        \"name\": \"Stereoselective actions of MDPV at monoamine transporters (ACS Chem Neurosci, 2017)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/28215117/\"\n+        \"name\": \"Bluelight ‘New pyro, MFPEP’ discussion (user snorts ~75 mg)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/new-pyro-mfpep.892004/\"\n-        \"name\": \"Powerful cocaine-like actions of MDPV (Neuropsychopharmacology, 2013)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/23072836/\"\n+        \"name\": \"Reddit experience report – dose chart (strong 15-20 mg)\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/hso5xc/mfpvp_mfpvp_3m4fpvp_report/\"\n-        \"name\": \"Hyperthermia and multiorgan failure after bath-salts injection (Case Report, 2012)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/22387085/\"\n-      },\n-      {\n-        \"name\": \"Intoxications involving MDPV in Sweden 2010-2014\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/26462932/\"\n-      },\n-      {\n-        \"name\": \"Acute Methylenedioxypyrovalerone Toxicity (ToxIC Registry, 2014)\",\n-        \"reference\": \"https://www.acmt.net/wp-content/uploads/2022/08/TXP_2015_Froberg_Acute-Methylenedioxypyrovalerone-Toxicity.pdf\"\n-      },\n-      {\n-        \"name\": \"Cardiotoxicity after synthetic cathinone use – two cases (2024)\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC10937789/\"\n-      },\n-      {\n-        \"name\": \"Anodyne substance page – MDPV\",\n-        \"reference\": \"https://anodyne.wiki/substance/3%2C4-methylenedioxy-%CE%B1-pyrrolidinopentiophenone\"\n-      },\n-      {\n-        \"name\": \"Anodyne Wiki: 3,4 Methylenedioxy Α Pyrrolidinopentiophenone\",\n-        \"reference\": \"https://anodyne.wiki/substance/3,4-methylenedioxy-%CE%B1-pyrrolidinopentiophenone\"\n+        \"name\": \"Reddit Q&A on ROA/dosing (zero tolerance user thread)\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/uhznye/mf_pvp_questions_roa_dosage_experiences/\"\n\n# Flmodafinil · #451\n\n-  \"id\": 449,\n-  \"title\": \"3-Methyl-4-fluoro-α-pyrrolidinovalerophenone\",\n+  \"id\": 451,\n+  \"title\": \"Flmodafinil\",\n-    \"drug_name\": \"3-Methyl-4-fluoro-α-pyrrolidinovalerophenone\",\n-    \"chemical_name\": \"3-Methyl-4-fluoro-α-pyrrolidinovalerophenone\",\n+    \"drug_name\": \"Flmodafinil\",\n+    \"chemical_name\": \"Flmodafinil\",\n-    \"chemical_class\": \"Substituted pyrrolidines\",\n-    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor (potent)\",\n-    \"psychoactive_class\": \"Norepinephrine–dopamine re-uptake inhibitor (stimulant)\",\n+    \"chemical_class\": \"Diphenylmethylsulfinylacetamides (modafinil analogues)\",\n+    \"mechanism_of_action\": \"Atypical dopamine reuptake inhibitor\",\n+    \"psychoactive_class\": \"Wakefulness-promoting agent; atypical dopamine reuptake inhibitor (selective DAT blocker)\",\n-            \"threshold\": \"5mg\",\n-            \"light\": \"5mg - 15mg\",\n-            \"common\": \"15mg - 30mg\",\n-            \"strong\": \"30mg - 45mg\",\n-            \"heavy\": \"45+ mg\"\n+            \"threshold\": \"15–20 mg\",\n+            \"light\": \"20–50 mg\",\n+            \"common\": \"50–100 mg\",\n+            \"strong\": \"100–150 mg\",\n+            \"heavy\": \"150 mg+\"\n-            \"threshold\": \"5mg\",\n-            \"light\": \"5mg - 20mg\",\n-            \"common\": \"20mg - 40mg\",\n-            \"strong\": \"40mg - 60mg\",\n-            \"heavy\": \"60+ mg\"\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"5–15 mg\",\n+            \"common\": \"15–30 mg\",\n+            \"strong\": \"30–50 mg\",\n+            \"heavy\": \"50 mg+\"\n-          \"route\": \"vaporized / smoked (freebase foil or mesh)\",\n+          \"route\": \"rectal (solution)\",\n-            \"threshold\": \"3mg\",\n-            \"light\": \"3mg - 10mg\",\n-            \"common\": \"10mg - 15mg\",\n-            \"strong\": \"15mg - 20mg\",\n-            \"heavy\": \"20+ mg\"\n+            \"threshold\": \"10 mg\",\n+            \"light\": \"10–25 mg\",\n+            \"common\": \"25–60 mg\",\n+            \"strong\": \"60–90 mg\",\n+            \"heavy\": \"90 mg+\"\n-            \"total_duration\": \"3-5 hours\",\n-            \"onset\": \"15-30 minutes\",\n-            \"peak\": \"30-90 minutes\",\n-            \"offset\": \"1-2 hours\",\n-            \"after_effects\": \"2-6 hours residual stimulation, agitation, crash\"\n+            \"total_duration\": \"6-10 h active (most users)\",\n+            \"onset\": \"20-40 min\",\n+            \"peak\": \"2-4 h\",\n+            \"offset\": \"2-4 h taper\",\n+            \"after_effects\": \"Up to 6 h residual stimulation; occasional rebound anxiety or insomnia\"\n-            \"total_duration\": \"2-3 hours\",\n-            \"onset\": \"5-10 minutes\",\n-            \"peak\": \"30-90 minutes\",\n-            \"offset\": \"~60 minutes\",\n-            \"after_effects\": \"2-6 hours residual stimulation, agitation, crash\"\n+            \"total_duration\": \"6-10 h active (most users)\",\n+            \"onset\": \"5-15 min\",\n+            \"peak\": \"2-4 h\",\n+            \"offset\": \"2-4 h taper\",\n+            \"after_effects\": \"Up to 6 h residual stimulation; occasional rebound anxiety or insomnia\"\n-          \"route\": \"vaporized / smoked (freebase foil or mesh)\",\n+          \"route\": \"rectal (solution)\",\n-            \"vaporized\",\n-            \"smoked\"\n+            \"rectal\"\n-            \"total_duration\": \"1-1.5 hours\",\n-            \"onset\": \"<30 seconds\",\n-            \"peak\": \"2-10 minutes\",\n-            \"offset\": \"30-45 minutes\",\n-            \"after_effects\": \"2-6 hours residual stimulation, agitation, crash\"\n+            \"total_duration\": \"6-10 h active (most users)\",\n+            \"peak\": \"2-4 h\",\n+            \"offset\": \"2-4 h taper\",\n+            \"after_effects\": \"Up to 6 h residual stimulation; occasional rebound anxiety or insomnia\"\n-    \"addiction_potential\": \"High: pyrrolidinophenone cathinones produce intense but short-lived euphoria that encourages rapid redosing; users describe binge patterns and severe crashes comparable to α-PVP.\",\n+    \"addiction_potential\": \"Generally low, but higher than modafinil—compulsive redosing and psychological dependence reported at >150 mg daily. Cross-sensitisation with classical stimulants appears minimal in animal models but case reports of binge patterns exist.\",\n-        \"MAOIs\",\n-        \"other potent stimulants (amphetamine, cocaine, synthetic cathinones)\",\n-        \"strong serotonergic agents (risk of hyperthermia)\",\n-        \"sympathomimetic inhalers (clenbuterol, ephedrine)\"\n+        \"high-dose MAOIs (hypertensive crisis)\",\n+        \"strong dopaminergic stimulants (methamphetamine, MDPV) – tachyarrhythmia risk\",\n+        \"CYP2C19 substrates with narrow therapeutic index (phenytoin, clopidogrel) – unpredictable metabolism if repeated use\"\n-        \"synthetic cannabinoids (tachyarrhythmia, psychosis)\",\n-        \"monoamine-releasing entactogens (eutylone, mephedrone)\",\n-        \"high-dose alcohol or GHB (cardiac stress when stimulant wears off)\"\n+        \"adderall or other mixed amphetamine salts (excess CNS & cardiovascular load)\",\n+        \"bupropion (seizure threshold lowering)\",\n+        \"large amounts of caffeine (>400 mg)\"\n-        \"SSRI or SNRI antidepressants\",\n-        \"benzodiazepines (use small rescue doses only for comedown)\",\n-        \"cannabis (may accentuate anxiety)\"\n+        \"SSRI / SNRI antidepressants (mild additive anxiety)\",\n+        \"benzodiazepines or alcohol (may blunt stimulant effect but mask over-stimulation at higher doses)\",\n+        \"triptans (rare serotonin syndrome case reports with heavy flmodafinil use)\"\n-    \"notes\": \"Pharmacology data are scarce; in vitro transporter assays of related α-PVP analogs suggest nanomolar NET/DAT inhibition. A 2022 forensic case reported fatal ventricular tachycardia with femoral blood 26 ng/mL, illustrating low LD50 margin. Fluorine substitution is predicted to raise metabolic stability, extending active phase relative to alkyl-only peers. User reports indicate very rapid onset when freebased (steam on foil), but subjective potency roughly half that of α-PVP: common ‘one-hit’ loads are 10-15 mg, with compulsive re-hits every 10-15 min. Intranasal use burns intensely and produces drip-induced gagging; many switch to glass-pipe inhalation. Tolerance rises sharply after a single night of use and fades over ~1-2 weeks. Harm-reduction best practices include volumetric solutions for accurate micro-dosing, pulse-ox monitoring, strict session limits (<150 mg total 24 h) and aggressive hydration/electrolyte replacement. Because MFPVP often appears as off-white crystals mixed with eutylone or NEP, multi-reagent testing (Marquis, Simon, Froehde) plus FT-IR or GC-MS confirmation is advised before consumption.\",\n+    \"notes\": \"Flmodafinil (CRL-40,940; bisfluoromodafinil) adds a para-fluorine to each phenyl ring of modafinil, raising DAT affinity ~2-4-fold and improving lipophilicity. Rat EEG work shows robust wake-promoting activity without classic amphetamine-like locomotor sensitisation. Unlike modafinil it does **not** induce major CYP450 enzymes, so drug–drug interactions are fewer at single doses. Human anecdotes converge on a shorter subjective length (~8 h) with crisper onset but a *later* spike in anxiety 6–8 h post-dose; keeping daily use ≤100 mg and finishing before 10 a.m. reduces sleep disruption. Powder is poorly water-soluble—users dissolve in warm propylene-glycol or weigh onto micro-spoons; volumetric solutions at 50 mg/mL are common. Insufflation produces faster lift but nasal irritation and chemical burn complaints are frequent—saline rinses advised.\\n\\nBecause material sold online ranges from 90–99 % purity, a 0.001 g scale is essential. Single-session tolerance is minor but 3-day consecutive dosing halves potency; 5–7 drug-free days restore baseline. Cross-tolerance exists with modafinil, adrafinil, armodafinil and fluoro-adrafinil analogues.\\n\\nRegular liver-panel monitoring is prudent for multi-week regimens even though flmodafinil lacks the sulfoxide-to-sulfone metabolism that burdens adrafinil. Athletes should note that WADA prohibits all DAT blockers; detection windows for flmodafinil metabolites in urine exceed 48 h.\",\n-      \"intense mental stimulation\",\n-      \"rush of euphoria\",\n-      \"compulsive redosing drive\",\n-      \"sweating and vasoconstriction\",\n-      \"sexual arousal\",\n-      \"jaw tension / bruxism\",\n-      \"paranoia at higher doses\",\n-      \"abrupt dysphoric crash\"\n+      \"bright, jitter-free wakefulness\",\n+      \"enhanced focus & task salience\",\n+      \"mild euphoria / optimism\",\n+      \"blunted appetite\",\n+      \"reduced perceived fatigue\",\n+      \"late-phase ‘wired but tired’ anxiety (dose-dependent)\",\n+      \"slight peripheral vasoconstriction\"\n-      \"full_tolerance\": \"after one heavy binge\",\n-      \"half_tolerance\": \"3-7 days\",\n-      \"zero_tolerance\": \"14-21 days\",\n+      \"full_tolerance\": \"after 2–3 consecutive heavy days\",\n+      \"half_tolerance\": \"24–48 h\",\n+      \"zero_tolerance\": \"5–7 days abstinence\",\n-        \"α-PVP\",\n-        \"α-PHP\",\n-        \"MDPV\",\n-        \"other pyrrolidinophenone cathinones\"\n+        \"modafinil\",\n+        \"adrafinil\",\n+        \"armodafinil\"\n-    \"half_life\": \"estimated 4-6 h (no human PK published; based on α-PVP ratios and toxicological back-calculation)\",\n+    \"half_life\": \"Estimated 6–8 h in humans (12 h+ in some anecdotes; pre-clinical PK in rodents 6.3 h)\",\n-        \"name\": \"Anodyne harm-reduction monograph\",\n-        \"reference\": \"https://anodyne.wiki/substance/3-methyl-4-fluoro-%CE%B1-pyrrolidinovalerophenone\"\n+        \"name\": \"Wikipedia – Flmodafinil overview & pharmacology\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Flmodafinil\"\n-        \"name\": \"MFPVP overview – Wikipedia\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/MFPVP\"\n+        \"name\": \"Drug Test Anal. 2017 – thermal degradation study (CRL-40,940 & 40,941)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/27928893/\"\n-        \"name\": \"Fatal intoxication case report (J Anal Toxicol 2022)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/35020879/\"\n+        \"name\": \"Neuropharmacology 2019 – EEG classification of atypical DRIs\",\n+        \"reference\": \"https://www.sciencedirect.com/science/article/abs/pii/S0028390819303581\"\n-        \"name\": \"Review of synthetic cathinones 2019-2022\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC9476408/\"\n+        \"name\": \"The Psychonauts’ World of Cognitive Enhancers – review of novel afinils\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC7516264/\"\n-        \"name\": \"Spectroscopic & crystallographic characterisation of 4F-3Me-α-PVP\",\n-        \"reference\": \"https://doi.org/10.3390/cryst13060934\"\n+        \"name\": \"Modafinil.org – Flmodafinil dosage guide\",\n+        \"reference\": \"https://modafinil.org/flmodafinil-dosage/\"\n-        \"name\": \"Bluelight ‘New pyro, MFPEP’ discussion (user snorts ~75 mg)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/new-pyro-mfpep.892004/\"\n+        \"name\": \"Bluelight ‘Cutting-edge modafinil analogues’ thread – user Rifter2 40 mg report\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/cutting-edge-modafinil-analogues-anyone-tried-them-or-care-to-speculate.873991/\"\n-        \"name\": \"Reddit experience report – dose chart (strong 15-20 mg)\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/hso5xc/mfpvp_mfpvp_3m4fpvp_report/\"\n+        \"name\": \"Reddit /r/afinil – Insufflating CRL-40-940 discussion\",\n+        \"reference\": \"https://www.reddit.com/r/afinil/comments/a6d384/insufflating_crl40940/\"\n-        \"name\": \"Reddit Q&A on ROA/dosing (zero tolerance user thread)\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/uhznye/mf_pvp_questions_roa_dosage_experiences/\"\n+        \"name\": \"Flmodafinil.pl – recommended 50–100 mg once-daily guideline\",\n+        \"reference\": \"https://flmodafinil.pl/en/flmodafinil-action-and-dosage/\"\n+      },\n+      {\n+        \"name\": \"Modafinil.com – Flmodafinil benefits, potency & half-life\",\n+        \"reference\": \"https://www.modafinil.com/flmodafinil-review/\"\n+      },\n+      {\n+        \"name\": \"Purity vendor note – longer half-life & bioavailability\",\n+        \"reference\": \"https://purerawz.co/product/flmodafinil/\"\n-      \"research-chemical\"\n+      \"research-chemical\",\n+      \"nootropic\"\n\n# Galantamine · #453\n\n-  \"id\": 451,\n-  \"title\": \"Flmodafinil\",\n+  \"id\": 453,\n+  \"title\": \"Galantamine\",\n-    \"drug_name\": \"Flmodafinil\",\n-    \"chemical_name\": \"Flmodafinil\",\n+    \"drug_name\": \"Galantamine\",\n+    \"chemical_name\": \"Galantamine\",\n-    \"chemical_class\": \"Diphenylmethylsulfinylacetamides (modafinil analogues)\",\n-    \"mechanism_of_action\": \"Atypical dopamine reuptake inhibitor\",\n-    \"psychoactive_class\": \"Wakefulness-promoting agent; atypical dopamine reuptake inhibitor (selective DAT blocker)\",\n+    \"chemical_class\": \"Alkaloids — Amaryllidaceae\",\n+    \"mechanism_of_action\": \"Acetylcholinesterase inhibitor\",\n+    \"psychoactive_class\": \"Nootropic; Oneirogen; Cholinesterase inhibitor\",\n-          \"route\": \"oral / sublingual\",\n+          \"route\": \"oral\",\n-            \"threshold\": \"15–20 mg\",\n-            \"light\": \"20–50 mg\",\n-            \"common\": \"50–100 mg\",\n-            \"strong\": \"100–150 mg\",\n-            \"heavy\": \"150 mg+\"\n+            \"threshold\": \"1 mg\",\n+            \"light\": \"4-8 mg\",\n+            \"common\": \"8-16 mg\",\n+            \"strong\": \"16-24 mg\",\n+            \"heavy\": \"24+ mg\"\n-        },\n-        {\n-          \"route\": \"insufflated\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"5–15 mg\",\n-            \"common\": \"15–30 mg\",\n-            \"strong\": \"30–50 mg\",\n-            \"heavy\": \"50 mg+\"\n-          }\n-        },\n-        {\n-          \"route\": \"rectal (solution)\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"10 mg\",\n-            \"light\": \"10–25 mg\",\n-            \"common\": \"25–60 mg\",\n-            \"strong\": \"60–90 mg\",\n-            \"heavy\": \"90 mg+\"\n-          }\n-          \"route\": \"oral / sublingual\",\n+          \"route\": \"oral\",\n-            \"oral\",\n-            \"sublingual\"\n+            \"oral\"\n-            \"total_duration\": \"6-10 h active (most users)\",\n-            \"onset\": \"20-40 min\",\n-            \"peak\": \"2-4 h\",\n-            \"offset\": \"2-4 h taper\",\n-            \"after_effects\": \"Up to 6 h residual stimulation; occasional rebound anxiety or insomnia\"\n+            \"total_duration\": \"8-12 hours\",\n+            \"onset\": \"30-60 minutes\",\n+            \"peak\": \"1-4 hours\",\n+            \"offset\": \"4-8 hours\",\n+            \"after_effects\": \"up to 24 hours (mild)\"\n-        },\n-        {\n-          \"route\": \"insufflated\",\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"6-10 h active (most users)\",\n-            \"onset\": \"5-15 min\",\n-            \"peak\": \"2-4 h\",\n-            \"offset\": \"2-4 h taper\",\n-            \"after_effects\": \"Up to 6 h residual stimulation; occasional rebound anxiety or insomnia\"\n-          }\n-        },\n-        {\n-          \"route\": \"rectal (solution)\",\n-          \"canonical_routes\": [\n-            \"rectal\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"6-10 h active (most users)\",\n-            \"peak\": \"2-4 h\",\n-            \"offset\": \"2-4 h taper\",\n-            \"after_effects\": \"Up to 6 h residual stimulation; occasional rebound anxiety or insomnia\"\n-          }\n-    \"addiction_potential\": \"Generally low, but higher than modafinil—compulsive redosing and psychological dependence reported at >150 mg daily. Cross-sensitisation with classical stimulants appears minimal in animal models but case reports of binge patterns exist.\",\n+    \"addiction_potential\": \"Low. Galantamine is not considered habit-forming and has a low potential for abuse or dependence.\",\n-        \"high-dose MAOIs (hypertensive crisis)\",\n-        \"strong dopaminergic stimulants (methamphetamine, MDPV) – tachyarrhythmia risk\",\n-        \"CYP2C19 substrates with narrow therapeutic index (phenytoin, clopidogrel) – unpredictable metabolism if repeated use\"\n+        \"Other cholinesterase inhibitors (risk of cholinergic toxicity)\"\n-        \"adderall or other mixed amphetamine salts (excess CNS & cardiovascular load)\",\n-        \"bupropion (seizure threshold lowering)\",\n-        \"large amounts of caffeine (>400 mg)\"\n+        \"Anticholinergic drugs (may reduce efficacy or cause unpredictable effects)\"\n-        \"SSRI / SNRI antidepressants (mild additive anxiety)\",\n-        \"benzodiazepines or alcohol (may blunt stimulant effect but mask over-stimulation at higher doses)\",\n-        \"triptans (rare serotonin syndrome case reports with heavy flmodafinil use)\"\n+        \"Drugs affecting heart rate or blood pressure, SSRIs, tricyclic antidepressants, antipsychotics\"\n-    \"notes\": \"Flmodafinil (CRL-40,940; bisfluoromodafinil) adds a para-fluorine to each phenyl ring of modafinil, raising DAT affinity ~2-4-fold and improving lipophilicity. Rat EEG work shows robust wake-promoting activity without classic amphetamine-like locomotor sensitisation. Unlike modafinil it does **not** induce major CYP450 enzymes, so drug–drug interactions are fewer at single doses. Human anecdotes converge on a shorter subjective length (~8 h) with crisper onset but a *later* spike in anxiety 6–8 h post-dose; keeping daily use ≤100 mg and finishing before 10 a.m. reduces sleep disruption. Powder is poorly water-soluble—users dissolve in warm propylene-glycol or weigh onto micro-spoons; volumetric solutions at 50 mg/mL are common. Insufflation produces faster lift but nasal irritation and chemical burn complaints are frequent—saline rinses advised.\\n\\nBecause material sold online ranges from 90–99 % purity, a 0.001 g scale is essential. Single-session tolerance is minor but 3-day consecutive dosing halves potency; 5–7 drug-free days restore baseline. Cross-tolerance exists with modafinil, adrafinil, armodafinil and fluoro-adrafinil analogues.\\n\\nRegular liver-panel monitoring is prudent for multi-week regimens even though flmodafinil lacks the sulfoxide-to-sulfone metabolism that burdens adrafinil. Athletes should note that WADA prohibits all DAT blockers; detection windows for flmodafinil metabolites in urine exceed 48 h.\",\n+    \"notes\": \"Galantamine is primarily used for Alzheimer's disease and cognitive enhancement. It is also popular among lucid dreamers for its ability to enhance dream vividness and recall. It should be used with caution in individuals with heart conditions, asthma, or epilepsy. Overdose can cause cholinergic toxicity (nausea, vomiting, muscle cramps, bradycardia).\",\n-      \"bright, jitter-free wakefulness\",\n-      \"enhanced focus & task salience\",\n-      \"mild euphoria / optimism\",\n-      \"blunted appetite\",\n-      \"reduced perceived fatigue\",\n-      \"late-phase ‘wired but tired’ anxiety (dose-dependent)\",\n-      \"slight peripheral vasoconstriction\"\n+      \"Enhanced dream vividness\",\n+      \"Increased dream recall\",\n+      \"Facilitation of lucid dreaming\",\n+      \"Mild cognitive enhancement\",\n+      \"Mild stimulation\",\n+      \"Possible gastrointestinal discomfort (nausea, cramps)\"\n-      \"full_tolerance\": \"after 2–3 consecutive heavy days\",\n-      \"half_tolerance\": \"24–48 h\",\n-      \"zero_tolerance\": \"5–7 days abstinence\",\n+      \"full_tolerance\": \"Develops slowly with regular use\",\n+      \"half_tolerance\": \"Several days to weeks\",\n+      \"zero_tolerance\": \"2-4 weeks after cessation\",\n-        \"modafinil\",\n-        \"adrafinil\",\n-        \"armodafinil\"\n+        \"Other cholinesterase inhibitors\"\n-    \"half_life\": \"Estimated 6–8 h in humans (12 h+ in some anecdotes; pre-clinical PK in rodents 6.3 h)\",\n+    \"half_life\": \"7-8 hours\",\n-        \"name\": \"Wikipedia – Flmodafinil overview & pharmacology\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Flmodafinil\"\n+        \"name\": \"Erowid Galantamine Vault\",\n+        \"reference\": \"https://erowid.org/pharms/galantamine/galantamine.shtml\"\n-        \"name\": \"Drug Test Anal. 2017 – thermal degradation study (CRL-40,940 & 40,941)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/27928893/\"\n+        \"name\": \"DrugBank: Galantamine\",\n+        \"reference\": \"https://go.drugbank.com/drugs/DB00674\"\n-        \"name\": \"Neuropharmacology 2019 – EEG classification of atypical DRIs\",\n-        \"reference\": \"https://www.sciencedirect.com/science/article/abs/pii/S0028390819303581\"\n-      },\n-      {\n-        \"name\": \"The Psychonauts’ World of Cognitive Enhancers – review of novel afinils\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC7516264/\"\n-      },\n-      {\n-        \"name\": \"Modafinil.org – Flmodafinil dosage guide\",\n-        \"reference\": \"https://modafinil.org/flmodafinil-dosage/\"\n-      },\n-      {\n-        \"name\": \"Bluelight ‘Cutting-edge modafinil analogues’ thread – user Rifter2 40 mg report\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/cutting-edge-modafinil-analogues-anyone-tried-them-or-care-to-speculate.873991/\"\n-      },\n-      {\n-        \"name\": \"Reddit /r/afinil – Insufflating CRL-40-940 discussion\",\n-        \"reference\": \"https://www.reddit.com/r/afinil/comments/a6d384/insufflating_crl40940/\"\n-      },\n-      {\n-        \"name\": \"Flmodafinil.pl – recommended 50–100 mg once-daily guideline\",\n-        \"reference\": \"https://flmodafinil.pl/en/flmodafinil-action-and-dosage/\"\n-      },\n-      {\n-        \"name\": \"Modafinil.com – Flmodafinil benefits, potency & half-life\",\n-        \"reference\": \"https://www.modafinil.com/flmodafinil-review/\"\n-      },\n-      {\n-        \"name\": \"Purity vendor note – longer half-life & bioavailability\",\n-        \"reference\": \"https://purerawz.co/product/flmodafinil/\"\n+        \"name\": \"Bluelight: Galantamine Experiences\",\n+        \"reference\": \"https://bluelight.org/xf/threads/galantamine.808857/\"\n-      \"stimulant\",\n+      \"nootropic\",\n-      \"nootropic\"\n+      \"entactogen\",\n+      \"supplement\",\n+      \"habit-forming\"\n\n# Flubrotizolam · #454\n\n-  \"id\": 453,\n-  \"title\": \"Galantamine\",\n+  \"id\": 454,\n+  \"title\": \"Flubrotizolam\",\n-    \"drug_name\": \"Galantamine\",\n-    \"chemical_name\": \"Galantamine\",\n+    \"drug_name\": \"Flubrotizolam\",\n+    \"chemical_name\": \"Flubrotizolam\",\n-    \"chemical_class\": \"Alkaloids — Amaryllidaceae\",\n-    \"mechanism_of_action\": \"Acetylcholinesterase inhibitor\",\n-    \"psychoactive_class\": \"Nootropic; Oneirogen; Cholinesterase inhibitor\",\n+    \"chemical_class\": \"Thienodiazepine (benzodiazepine analogue)\",\n+    \"mechanism_of_action\": \"Gamma-aminobutyric acid type A receptor positive allosteric modulator (benzodiazepine site)\",\n+    \"psychoactive_class\": \"Depressant\",\n-            \"threshold\": \"1 mg\",\n-            \"light\": \"4-8 mg\",\n-            \"common\": \"8-16 mg\",\n-            \"strong\": \"16-24 mg\",\n-            \"heavy\": \"24+ mg\"\n+            \"threshold\": \"0.1 mg\",\n+            \"light\": \"0.2 - 0.4 mg\",\n+            \"common\": \"0.4 - 0.6 mg\",\n+            \"strong\": \"0.6 - 1.0 mg\",\n+            \"heavy\": \"1.0 mg+\"\n-            \"total_duration\": \"8-12 hours\",\n-            \"onset\": \"30-60 minutes\",\n-            \"peak\": \"1-4 hours\",\n-            \"offset\": \"4-8 hours\",\n-            \"after_effects\": \"up to 24 hours (mild)\"\n+            \"total_duration\": \"6 - 12 hours\",\n+            \"onset\": \"15 - 45 minutes\",\n+            \"peak\": \"1 - 3 hours\",\n+            \"offset\": \"3 - 6 hours\",\n+            \"after_effects\": \"6 - 24 hours\"\n-    \"addiction_potential\": \"Low. Galantamine is not considered habit-forming and has a low potential for abuse or dependence.\",\n+    \"addiction_potential\": \"Flubrotizolam has a high potential for abuse and addiction, similar to other benzodiazepines.\",\n-        \"Other cholinesterase inhibitors (risk of cholinergic toxicity)\"\n+        \"Alcohol\",\n+        \"Opioids\"\n-        \"Anticholinergic drugs (may reduce efficacy or cause unpredictable effects)\"\n+        \"Other depressants\"\n-        \"Drugs affecting heart rate or blood pressure, SSRIs, tricyclic antidepressants, antipsychotics\"\n+        \"Stimulants\"\n-    \"notes\": \"Galantamine is primarily used for Alzheimer's disease and cognitive enhancement. It is also popular among lucid dreamers for its ability to enhance dream vividness and recall. It should be used with caution in individuals with heart conditions, asthma, or epilepsy. Overdose can cause cholinergic toxicity (nausea, vomiting, muscle cramps, bradycardia).\",\n+    \"notes\": \"Flubrotizolam is a potent thienotriazolodiazepine derivative, known for its strong sedative and anxiolytic effects. It is important to use caution due to its potency and potential for addiction.\",\n-      \"Enhanced dream vividness\",\n-      \"Increased dream recall\",\n-      \"Facilitation of lucid dreaming\",\n-      \"Mild cognitive enhancement\",\n-      \"Mild stimulation\",\n-      \"Possible gastrointestinal discomfort (nausea, cramps)\"\n+      \"Sedation\",\n+      \"Anxiolysis\",\n+      \"Muscle relaxation\",\n+      \"Euphoria\",\n+      \"Amnesia\"\n-      \"full_tolerance\": \"Develops slowly with regular use\",\n-      \"half_tolerance\": \"Several days to weeks\",\n-      \"zero_tolerance\": \"2-4 weeks after cessation\",\n+      \"full_tolerance\": \"1 - 2 weeks of regular use\",\n+      \"half_tolerance\": \"7 - 14 days\",\n+      \"zero_tolerance\": \"1 - 2 months\",\n-        \"Other cholinesterase inhibitors\"\n+        \"Benzodiazepines\"\n-    \"half_life\": \"7-8 hours\",\n+    \"half_life\": \"3 - 6 hours\",\n-        \"name\": \"Erowid Galantamine Vault\",\n-        \"reference\": \"https://erowid.org/pharms/galantamine/galantamine.shtml\"\n+        \"name\": \"Flubrotizolam - PsychonautWiki\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Flubrotizolam\"\n-        \"name\": \"DrugBank: Galantamine\",\n-        \"reference\": \"https://go.drugbank.com/drugs/DB00674\"\n-      },\n-      {\n-        \"name\": \"Bluelight: Galantamine Experiences\",\n-        \"reference\": \"https://bluelight.org/xf/threads/galantamine.808857/\"\n+        \"name\": \"Brotizolam information on DrugBank\",\n+        \"reference\": \"https://go.drugbank.com/drugs/DB09017\"\n-      \"nootropic\",\n+      \"depressant\",\n+      \"benzodiazepine\",\n-      \"entactogen\",\n-      \"supplement\",\n-      \"habit-forming\"\n+      \"gabaergic\"\n\n# Fluclotizolam · #455\n\n-  \"id\": 454,\n-  \"title\": \"Flubrotizolam\",\n+  \"id\": 455,\n+  \"title\": \"Fluclotizolam\",\n-    \"drug_name\": \"Flubrotizolam\",\n-    \"chemical_name\": \"Flubrotizolam\",\n+    \"drug_name\": \"Fluclotizolam\",\n+    \"chemical_name\": \"Fluclotizolam\",\n-    \"psychoactive_class\": \"Depressant\",\n+    \"psychoactive_class\": \"GABAA receptor positive allosteric modulator (sedative-hypnotic)\",\n-          \"route\": \"oral\",\n+          \"route\": \"oral / sublingual\",\n+            \"threshold\": \"0.05 mg\",\n+            \"light\": \"0.1mg - 0.25mg\",\n+            \"common\": \"0.25mg - 0.5mg\",\n+            \"strong\": \"0.5mg - 0.75mg\",\n+            \"heavy\": \"0.75mg+\"\n+          }\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"0.05 mg\",\n+            \"light\": \"0.05mg - 0.2mg\",\n+            \"common\": \"0.2mg - 0.4mg\",\n+            \"strong\": \"0.4mg - 0.6mg\",\n+            \"heavy\": \"0.6mg+\"\n+          }\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n-            \"light\": \"0.2 - 0.4 mg\",\n-            \"common\": \"0.4 - 0.6 mg\",\n-            \"strong\": \"0.6 - 1.0 mg\",\n-            \"heavy\": \"1.0 mg+\"\n+            \"light\": \"0.1mg - 0.25mg\",\n+            \"common\": \"0.25mg - 0.4mg\",\n+            \"strong\": \"0.4mg - 0.6mg\",\n+            \"heavy\": \"0.6mg+\"\n-          \"route\": \"oral\",\n+          \"route\": \"oral / sublingual\",\n-            \"oral\"\n+            \"oral\",\n+            \"sublingual\"\n-            \"total_duration\": \"6 - 12 hours\",\n-            \"onset\": \"15 - 45 minutes\",\n-            \"peak\": \"1 - 3 hours\",\n-            \"offset\": \"3 - 6 hours\",\n-            \"after_effects\": \"6 - 24 hours\"\n+            \"total_duration\": \"6-14 h (active phase)\",\n+            \"onset\": \"10-30 min\",\n+            \"peak\": \"1-3 h\",\n+            \"offset\": \"2-4 h\",\n+            \"after_effects\": \"12-36 h residual sedation; fatigue; or rebound anxiety\"\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"6-14 h (active phase)\",\n+            \"onset\": \"5-15 min\",\n+            \"peak\": \"1-3 h\",\n+            \"offset\": \"2-4 h\",\n+            \"after_effects\": \"12-36 h residual sedation; fatigue; or rebound anxiety\"\n+          }\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"canonical_routes\": [\n+            \"rectal\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"6-14 h (active phase)\",\n+            \"peak\": \"1-3 h\",\n+            \"offset\": \"2-4 h\",\n+            \"after_effects\": \"12-36 h residual sedation; fatigue; or rebound anxiety\"\n+          }\n-    \"addiction_potential\": \"Flubrotizolam has a high potential for abuse and addiction, similar to other benzodiazepines.\",\n+    \"addiction_potential\": \"High: short half-life and high potency encourage redosing; compulsive multi-mg binges and difficult tapers reported.\",\n-        \"Alcohol\",\n-        \"Opioids\"\n+        \"opioids (enhanced respiratory depression)\",\n+        \"other CNS depressants (alcohol, barbiturates, GHB)\",\n+        \"gabapentinoids in high doses\"\n-        \"Other depressants\"\n+        \"other potent benzos (flubromazolam, clonazolam)\",\n+        \"dissociatives (risk of blackout-related injury)\",\n+        \"MAOIs (prolonged CNS depression)\"\n-        \"Stimulants\"\n+        \"sedating antihistamines\",\n+        \"kava, valerian, or other herbal GABAergics\",\n+        \"stimulant comedowns (masking toxicity)\"\n-    \"notes\": \"Flubrotizolam is a potent thienotriazolodiazepine derivative, known for its strong sedative and anxiolytic effects. It is important to use caution due to its potency and potential for addiction.\",\n+    \"notes\": \"Fluclotizolam is a designer thienotriazolodiazepine roughly three times as potent as etizolam. Without medical oversight it poses serious overdose and dependence risks, particularly when combined with other depressants.\\n\\nRoughly 3× the potency of etizolam with a shorter effective half-life, leading to pronounced rebound insomnia and anxiety when effects wear off. Blotter and pellet products often under-dose or degrade; volumetric dosing of a lab-weighed solution (1 mg/10 mL ethanol-water) is strongly advised. Forum users stress setting strict upper limits (≤0.5 mg per 12 h) and avoiding daily use to prevent tolerance and severe withdrawal. Analytical reports have detected fluclotizolam co-present with flubromazolam or fentanyl in post-mortem samples, underscoring the need for reagent/LC-MS confirmation before use.\",\n-      \"Sedation\",\n-      \"Anxiolysis\",\n-      \"Muscle relaxation\",\n-      \"Euphoria\",\n-      \"Amnesia\"\n+      \"intense sedation\",\n+      \"anxiolysis\",\n+      \"muscle relaxation\",\n+      \"anterograde amnesia\",\n+      \"hypnotic sleep induction\",\n+      \"mild euphoria\",\n+      \"motor incoordination\"\n-      \"full_tolerance\": \"1 - 2 weeks of regular use\",\n-      \"half_tolerance\": \"7 - 14 days\",\n-      \"zero_tolerance\": \"1 - 2 months\",\n+      \"full_tolerance\": \"after 3-5 consecutive high-dose days\",\n+      \"half_tolerance\": \"3-7 days\",\n+      \"zero_tolerance\": \"2-3 weeks\",\n-        \"Benzodiazepines\"\n+        \"all benzodiazepines\",\n+        \"z-drugs\"\n-    \"half_life\": \"3 - 6 hours\",\n+    \"half_life\": \"~3-6 h (parent compound; metabolites not characterised)\",\n-        \"name\": \"Flubrotizolam - PsychonautWiki\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/Flubrotizolam\"\n+        \"name\": \"J Healthcare Initiative – Fluclotizolam effects & dosing\",\n+        \"reference\": \"https://www.j-initiative.org/copy-of-effect-flubromazolam\"\n-        \"name\": \"Brotizolam information on DrugBank\",\n-        \"reference\": \"https://go.drugbank.com/drugs/DB09017\"\n+        \"name\": \"CFSRE Fluclotizolam Toxicology Report (2021)\",\n+        \"reference\": \"https://www.cfsre.org/images/monographs/Fluclotizolam_110521_ToxicologyAnalyticalReport.pdf\"\n+      },\n+      {\n+        \"name\": \"ACMD 2024 update on uncontrolled novel benzodiazepines\",\n+        \"reference\": \"https://assets.publishing.service.gov.uk/media/66053a82f9ab41001aeea464/ACMD%2BReport%2B-%2BRecently%2Bencountered%2Buncontrolled%2Bnovel%2Bbenzodiazepines%2Band%2Brelated%2Bcompounds%2B_2024%2Bupdate_.pdf\"\n+      },\n+      {\n+        \"name\": \"Wikipedia – Fluclotizolam entry (chemistry/legal)\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Fluclotizolam\"\n+      },\n+      {\n+        \"name\": \"Orsolini L. et al. 2020 – Review of designer benzodiazepines\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569319/\"\n+      },\n+      {\n+        \"name\": \"Bluelight thread: 'Benzo – Fluclotizolam?' (user reports)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/benzo-fluclotizolam.830928/\"\n+      },\n+      {\n+        \"name\": \"Reddit: Active 1.5 mg Fluclotizolam report\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/13niy0y/active_15mg_fluclotizolam_report_no_tolerance/\"\n+      },\n+      {\n+        \"name\": \"Reddit: 'Fluclotizolam feels mediocre' discussion\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/7ipldk/fluclotizolam_feels_mediocre/\"\n+      },\n+      {\n+        \"name\": \"European Monitoring Centre – New benzodiazepines news release\",\n+        \"reference\": \"https://www.emcdda.europa.eu/system/files/attachments/13832/News-release-EN_NewBenzodiazepines_Final_REV.pdf\"\n+      },\n+      {\n+        \"name\": \"Hellerbach J. et al. 1979 – Patent describing thienotriazolodiazepines\",\n+        \"reference\": \"https://patents.google.com/patent/US4155913A/en\"\n-      \"depressant\",\n-      \"benzodiazepine\",\n+      \"sedative\",\n\n# Fluetizolam · #457\n\n-  \"id\": 455,\n-  \"title\": \"Fluclotizolam\",\n+  \"id\": 457,\n+  \"title\": \"Fluetizolam\",\n-    \"drug_name\": \"Fluclotizolam\",\n-    \"chemical_name\": \"Fluclotizolam\",\n+    \"drug_name\": \"Fluetizolam\",\n+    \"chemical_name\": \"Fluetizolam\",\n-    \"psychoactive_class\": \"GABAA receptor positive allosteric modulator (sedative-hypnotic)\",\n+    \"psychoactive_class\": \"Sedative\",\n-          \"route\": \"oral / sublingual\",\n+          \"route\": \"oral\",\n-            \"threshold\": \"0.05 mg\",\n-            \"light\": \"0.1mg - 0.25mg\",\n-            \"common\": \"0.25mg - 0.5mg\",\n-            \"strong\": \"0.5mg - 0.75mg\",\n-            \"heavy\": \"0.75mg+\"\n-          }\n-        },\n-        {\n-          \"route\": \"insufflated\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"0.05 mg\",\n-            \"light\": \"0.05mg - 0.2mg\",\n-            \"common\": \"0.2mg - 0.4mg\",\n-            \"strong\": \"0.4mg - 0.6mg\",\n-            \"heavy\": \"0.6mg+\"\n-          }\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"light\": \"0.1mg - 0.25mg\",\n-            \"common\": \"0.25mg - 0.4mg\",\n-            \"strong\": \"0.4mg - 0.6mg\",\n-            \"heavy\": \"0.6mg+\"\n+            \"light\": \"0.2 mg\",\n+            \"common\": \"0.3 mg\",\n+            \"strong\": \"0.5 mg\",\n+            \"heavy\": \"1 mg\"\n-          \"route\": \"oral / sublingual\",\n+          \"route\": \"oral\",\n-            \"oral\",\n-            \"sublingual\"\n+            \"oral\"\n-            \"total_duration\": \"6-14 h (active phase)\",\n-            \"onset\": \"10-30 min\",\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"2-4 h\",\n-            \"after_effects\": \"12-36 h residual sedation; fatigue; or rebound anxiety\"\n+            \"total_duration\": \"6 to 12 hours\",\n+            \"onset\": \"15 to 30 minutes\",\n+            \"peak\": \"1 to 3 hours\",\n+            \"offset\": \"3 to 6 hours\",\n+            \"after_effects\": \"Up to 24 hours\"\n-        },\n-        {\n-          \"route\": \"insufflated\",\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"6-14 h (active phase)\",\n-            \"onset\": \"5-15 min\",\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"2-4 h\",\n-            \"after_effects\": \"12-36 h residual sedation; fatigue; or rebound anxiety\"\n-          }\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"canonical_routes\": [\n-            \"rectal\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"6-14 h (active phase)\",\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"2-4 h\",\n-            \"after_effects\": \"12-36 h residual sedation; fatigue; or rebound anxiety\"\n-          }\n-    \"addiction_potential\": \"High: short half-life and high potency encourage redosing; compulsive multi-mg binges and difficult tapers reported.\",\n+    \"addiction_potential\": \"Moderate to high, similar to other benzodiazepines.\",\n-        \"opioids (enhanced respiratory depression)\",\n-        \"other CNS depressants (alcohol, barbiturates, GHB)\",\n-        \"gabapentinoids in high doses\"\n+        \"Alcohol\",\n+        \"Opioids\"\n-        \"other potent benzos (flubromazolam, clonazolam)\",\n-        \"dissociatives (risk of blackout-related injury)\",\n-        \"MAOIs (prolonged CNS depression)\"\n+        \"CNS depressants\"\n-        \"sedating antihistamines\",\n-        \"kava, valerian, or other herbal GABAergics\",\n-        \"stimulant comedowns (masking toxicity)\"\n+        \"Antihistamines\",\n+        \"Antidepressants\"\n-    \"notes\": \"Fluclotizolam is a designer thienotriazolodiazepine roughly three times as potent as etizolam. Without medical oversight it poses serious overdose and dependence risks, particularly when combined with other depressants.\\n\\nRoughly 3× the potency of etizolam with a shorter effective half-life, leading to pronounced rebound insomnia and anxiety when effects wear off. Blotter and pellet products often under-dose or degrade; volumetric dosing of a lab-weighed solution (1 mg/10 mL ethanol-water) is strongly advised. Forum users stress setting strict upper limits (≤0.5 mg per 12 h) and avoiding daily use to prevent tolerance and severe withdrawal. Analytical reports have detected fluclotizolam co-present with flubromazolam or fentanyl in post-mortem samples, underscoring the need for reagent/LC-MS confirmation before use.\",\n+    \"notes\": \"Fluetizolam is a potent designer benzodiazepine with strong sedative effects. It was developed in the 1990s but never marketed. It is known for its anxiolytic and sedative properties.\",\n-      \"intense sedation\",\n-      \"anxiolysis\",\n-      \"muscle relaxation\",\n-      \"anterograde amnesia\",\n-      \"hypnotic sleep induction\",\n-      \"mild euphoria\",\n-      \"motor incoordination\"\n+      \"Sedation\",\n+      \"Anxiolysis\",\n+      \"Muscle relaxation\",\n+      \"Amnesia\",\n+      \"Euphoria\"\n-      \"full_tolerance\": \"after 3-5 consecutive high-dose days\",\n-      \"half_tolerance\": \"3-7 days\",\n-      \"zero_tolerance\": \"2-3 weeks\",\n+      \"full_tolerance\": \"1 to 2 weeks of continuous use\",\n+      \"half_tolerance\": \"3 to 7 days\",\n+      \"zero_tolerance\": \"1 to 2 weeks\",\n-        \"all benzodiazepines\",\n-        \"z-drugs\"\n+        \"Other benzodiazepines\"\n-    \"half_life\": \"~3-6 h (parent compound; metabolites not characterised)\",\n+    \"half_life\": \"Unknown, but likely similar to other thienodiazepines\",\n-        \"name\": \"J Healthcare Initiative – Fluclotizolam effects & dosing\",\n-        \"reference\": \"https://www.j-initiative.org/copy-of-effect-flubromazolam\"\n-      },\n-      {\n-        \"name\": \"CFSRE Fluclotizolam Toxicology Report (2021)\",\n-        \"reference\": \"https://www.cfsre.org/images/monographs/Fluclotizolam_110521_ToxicologyAnalyticalReport.pdf\"\n-      },\n-      {\n-        \"name\": \"ACMD 2024 update on uncontrolled novel benzodiazepines\",\n-        \"reference\": \"https://assets.publishing.service.gov.uk/media/66053a82f9ab41001aeea464/ACMD%2BReport%2B-%2BRecently%2Bencountered%2Buncontrolled%2Bnovel%2Bbenzodiazepines%2Band%2Brelated%2Bcompounds%2B_2024%2Bupdate_.pdf\"\n-      },\n-      {\n-        \"name\": \"Wikipedia – Fluclotizolam entry (chemistry/legal)\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Fluclotizolam\"\n-      },\n-      {\n-        \"name\": \"Orsolini L. et al. 2020 – Review of designer benzodiazepines\",\n-        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569319/\"\n-      },\n-      {\n-        \"name\": \"Bluelight thread: 'Benzo – Fluclotizolam?' (user reports)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/benzo-fluclotizolam.830928/\"\n-      },\n-      {\n-        \"name\": \"Reddit: Active 1.5 mg Fluclotizolam report\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/13niy0y/active_15mg_fluclotizolam_report_no_tolerance/\"\n-      },\n-      {\n-        \"name\": \"Reddit: 'Fluclotizolam feels mediocre' discussion\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/7ipldk/fluclotizolam_feels_mediocre/\"\n-      },\n-      {\n-        \"name\": \"European Monitoring Centre – New benzodiazepines news release\",\n-        \"reference\": \"https://www.emcdda.europa.eu/system/files/attachments/13832/News-release-EN_NewBenzodiazepines_Final_REV.pdf\"\n-      },\n-      {\n-        \"name\": \"Hellerbach J. et al. 1979 – Patent describing thienotriazolodiazepines\",\n-        \"reference\": \"https://patents.google.com/patent/US4155913A/en\"\n+        \"name\": \"PubChem\",\n+        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/Fluetizolam\"\n-      \"sedative\",\n+      \"sedative\",\n+      \"benzodiazepine\",\n\n# Chlorpheniramine · #458\n\n-  \"id\": 457,\n-  \"title\": \"Fluetizolam\",\n+  \"id\": 458,\n+  \"title\": \"Chlorpheniramine\",\n-    \"drug_name\": \"Fluetizolam\",\n-    \"chemical_name\": \"Fluetizolam\",\n-    \"alternative_name\": \"\",\n-    \"chemical_class\": \"Thienodiazepine (benzodiazepine analogue)\",\n-    \"mechanism_of_action\": \"Gamma-aminobutyric acid type A receptor positive allosteric modulator (benzodiazepine site)\",\n-    \"psychoactive_class\": \"Sedative\",\n+    \"drug_name\": \"Chlorpheniramine\",\n+    \"chemical_name\": \"Chlorpheniramine\",\n+    \"alternative_name\": \"Chlorpheniramine Maleate\",\n+    \"chemical_class\": \"Alkylamine derivative (first-generation antihistamine)\",\n+    \"mechanism_of_action\": \"Histamine H1 receptor antagonist\",\n+    \"psychoactive_class\": \"Antihistamine\",\n-            \"threshold\": \"0.1 mg\",\n-            \"light\": \"0.2 mg\",\n-            \"common\": \"0.3 mg\",\n-            \"strong\": \"0.5 mg\",\n-            \"heavy\": \"1 mg\"\n+            \"threshold\": \"1 mg\",\n+            \"light\": \"2-4 mg\",\n+            \"common\": \"4-8 mg\",\n+            \"strong\": \"8-12 mg\",\n+            \"heavy\": \"12+ mg\"\n-            \"total_duration\": \"6 to 12 hours\",\n-            \"onset\": \"15 to 30 minutes\",\n-            \"peak\": \"1 to 3 hours\",\n-            \"offset\": \"3 to 6 hours\",\n-            \"after_effects\": \"Up to 24 hours\"\n+            \"total_duration\": \"4-6 hours\",\n+            \"onset\": \"30-60 minutes\",\n+            \"peak\": \"1-3 hours\",\n+            \"offset\": \"4-6 hours\",\n+            \"after_effects\": \"Minimal; possible mild drowsiness\"\n-    \"addiction_potential\": \"Moderate to high, similar to other benzodiazepines.\",\n+    \"addiction_potential\": \"Low. Chlorpheniramine is not considered habit-forming, but misuse for sedative or anticholinergic effects has been reported.\",\n-        \"Alcohol\",\n-        \"Opioids\"\n+        \"MAOIs (monoamine oxidase inhibitors)\"\n-        \"CNS depressants\"\n+        \"Alcohol (increased CNS depression)\"\n-        \"Antihistamines\",\n-        \"Antidepressants\"\n+        \"Other CNS depressants (benzodiazepines, opioids, barbiturates)\",\n+        \"Anticholinergic drugs (increased side effects)\"\n-    \"notes\": \"Fluetizolam is a potent designer benzodiazepine with strong sedative effects. It was developed in the 1990s but never marketed. It is known for its anxiolytic and sedative properties.\",\n+    \"notes\": \"Chlorpheniramine is primarily used for the symptomatic relief of allergic conditions such as hay fever, rhinitis, urticaria, and asthma. It is a first-generation antihistamine, so it can cause drowsiness and anticholinergic side effects (dry mouth, blurred vision, constipation, urinary retention). Caution is advised in the elderly and those with glaucoma, prostatic hypertrophy, or cardiovascular disease.\",\n+      \"Drowsiness\",\n-      \"Anxiolysis\",\n-      \"Muscle relaxation\",\n-      \"Amnesia\",\n-      \"Euphoria\"\n+      \"Dry mouth\",\n+      \"Blurred vision\",\n+      \"Mild euphoria (rare, at high doses or misuse)\",\n+      \"Reduced allergy symptoms (runny nose, sneezing, itching)\"\n-      \"full_tolerance\": \"1 to 2 weeks of continuous use\",\n-      \"half_tolerance\": \"3 to 7 days\",\n-      \"zero_tolerance\": \"1 to 2 weeks\",\n+      \"full_tolerance\": \"Develops over several days of continuous use\",\n+      \"half_tolerance\": \"Several days after cessation\",\n+      \"zero_tolerance\": \"1-2 weeks after cessation\",\n-        \"Other benzodiazepines\"\n+        \"Other first-generation antihistamines\"\n-    \"half_life\": \"Unknown, but likely similar to other thienodiazepines\",\n+    \"half_life\": \"12-20 hours\",\n-        \"name\": \"PubChem\",\n-        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/Fluetizolam\"\n+        \"name\": \"DrugBank: Chlorpheniramine\",\n+        \"reference\": \"https://go.drugbank.com/drugs/DB01114\"\n+      },\n+      {\n+        \"name\": \"DrugBank: Chlorpheniramine Maleate Salt\",\n+        \"reference\": \"https://go.drugbank.com/salts/DBSALT000987\"\n-      \"research-chemical\",\n+      \"depressant\",\n-      \"benzodiazepine\",\n-      \"gabaergic\"\n+      \"Antihistamine\"\n\n# Flupirtine · #459\n\n-  \"id\": 458,\n-  \"title\": \"Chlorpheniramine\",\n+  \"id\": 459,\n+  \"title\": \"Flupirtine\",\n-    \"drug_name\": \"Chlorpheniramine\",\n-    \"chemical_name\": \"Chlorpheniramine\",\n-    \"alternative_name\": \"Chlorpheniramine Maleate\",\n-    \"chemical_class\": \"Alkylamine derivative (first-generation antihistamine)\",\n-    \"mechanism_of_action\": \"Histamine H1 receptor antagonist\",\n-    \"psychoactive_class\": \"Antihistamine\",\n+    \"drug_name\": \"Flupirtine\",\n+    \"chemical_name\": \"Flupirtine\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Aminopyridine\",\n+    \"mechanism_of_action\": \"Potassium channel opener\",\n+    \"psychoactive_class\": \"Analgesic\",\n-            \"threshold\": \"1 mg\",\n-            \"light\": \"2-4 mg\",\n-            \"common\": \"4-8 mg\",\n-            \"strong\": \"8-12 mg\",\n-            \"heavy\": \"12+ mg\"\n+            \"threshold\": \"50 mg\",\n+            \"light\": \"100-150 mg\",\n+            \"common\": \"200-300 mg\",\n+            \"strong\": \"400 mg\",\n+            \"heavy\": \"600 mg\"\n-            \"total_duration\": \"4-6 hours\",\n+            \"total_duration\": \"6-8 hours\",\n-            \"peak\": \"1-3 hours\",\n+            \"peak\": \"1-2 hours\",\n-            \"after_effects\": \"Minimal; possible mild drowsiness\"\n+            \"after_effects\": \"Up to 24 hours\"\n-    \"addiction_potential\": \"Low. Chlorpheniramine is not considered habit-forming, but misuse for sedative or anticholinergic effects has been reported.\",\n+    \"addiction_potential\": \"Low potential for addiction, but prolonged use may lead to dependence.\",\n-        \"MAOIs (monoamine oxidase inhibitors)\"\n+        \"Alcohol\",\n+        \"Benzodiazepines\"\n-        \"Alcohol (increased CNS depression)\"\n+        \"Opioids\"\n-        \"Other CNS depressants (benzodiazepines, opioids, barbiturates)\",\n-        \"Anticholinergic drugs (increased side effects)\"\n+        \"Antihistamines\"\n-    \"notes\": \"Chlorpheniramine is primarily used for the symptomatic relief of allergic conditions such as hay fever, rhinitis, urticaria, and asthma. It is a first-generation antihistamine, so it can cause drowsiness and anticholinergic side effects (dry mouth, blurred vision, constipation, urinary retention). Caution is advised in the elderly and those with glaucoma, prostatic hypertrophy, or cardiovascular disease.\",\n+    \"notes\": \"Flupirtine is primarily used as a non-opioid analgesic for pain management. It has muscle relaxant properties and is known to cause hepatotoxicity with prolonged use.\",\n-      \"Drowsiness\",\n-      \"Sedation\",\n-      \"Dry mouth\",\n-      \"Blurred vision\",\n-      \"Mild euphoria (rare, at high doses or misuse)\",\n-      \"Reduced allergy symptoms (runny nose, sneezing, itching)\"\n+      \"Pain relief\",\n+      \"Muscle relaxation\",\n+      \"Sedation\"\n-      \"full_tolerance\": \"Develops over several days of continuous use\",\n-      \"half_tolerance\": \"Several days after cessation\",\n-      \"zero_tolerance\": \"1-2 weeks after cessation\",\n+      \"full_tolerance\": \"2 weeks of continuous use\",\n+      \"half_tolerance\": \"1 week\",\n+      \"zero_tolerance\": \"3-4 weeks\",\n-        \"Other first-generation antihistamines\"\n+        \"Other analgesics\"\n-    \"half_life\": \"12-20 hours\",\n+    \"half_life\": \"6-8 hours\",\n-        \"name\": \"DrugBank: Chlorpheniramine\",\n-        \"reference\": \"https://go.drugbank.com/drugs/DB01114\"\n+        \"name\": \"PubChem - Flupirtine\",\n+        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/Flupirtine\"\n-        \"name\": \"DrugBank: Chlorpheniramine Maleate Salt\",\n-        \"reference\": \"https://go.drugbank.com/salts/DBSALT000987\"\n+        \"name\": \"DrugBank - Flupirtine maleate\",\n+        \"reference\": \"https://go.drugbank.com/drugs/DBSALT000912\"\n+      },\n+      {\n+        \"name\": \"DrugBank - Flupirtine gluconate\",\n+        \"reference\": \"https://go.drugbank.com/drugs/DBSALT002360\"\n+      },\n+      {\n+        \"name\": \"DrugBank - Flupirtine\",\n+        \"reference\": \"https://go.drugbank.com/drugs/DB06623\"\n+      \"habit-forming\",\n-      \"sedative\",\n-      \"Antihistamine\"\n+      \"sedative\"\n\n# Scopolamine · #460\n\n-  \"id\": 459,\n-  \"title\": \"Flupirtine\",\n+  \"id\": 460,\n+  \"title\": \"Scopolamine\",\n-    \"drug_name\": \"Flupirtine\",\n-    \"chemical_name\": \"Flupirtine\",\n-    \"alternative_name\": \"\",\n-    \"chemical_class\": \"Aminopyridine\",\n-    \"mechanism_of_action\": \"Potassium channel opener\",\n-    \"psychoactive_class\": \"Analgesic\",\n+    \"drug_name\": \"Scopolamine\",\n+    \"chemical_name\": \"Scopolamine\",\n+    \"alternative_name\": \"Hyoscine\",\n+    \"chemical_class\": \"Tropane alkaloids\",\n+    \"mechanism_of_action\": \"Muscarinic acetylcholine receptor antagonist\",\n+    \"psychoactive_class\": \"Deliriant anticholinergic\",\n-            \"threshold\": \"50 mg\",\n-            \"light\": \"100-150 mg\",\n-            \"common\": \"200-300 mg\",\n-            \"strong\": \"400 mg\",\n-            \"heavy\": \"600 mg\"\n+            \"threshold\": \"0.1 – 0.2\",\n+            \"light\": \"0.2 – 0.4\",\n+            \"common\": \"0.4 – 0.8\",\n+            \"strong\": \"0.8 – 1.2\",\n+            \"heavy\": \"1.2 +\"\n+        },\n+        {\n+          \"route\": \"transdermal\",\n+          \"units\": \"mg (total released)\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"≈0.3\",\n+            \"light\": \"0.4 – 0.6\",\n+            \"common\": \"0.6 – 1.0\",\n+            \"strong\": \"1.0 – 1.5\",\n+            \"heavy\": \"1.5 +\"\n+          }\n+        },\n+        {\n+          \"route\": \"intravenous\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"0.1\",\n+            \"light\": \"0.1 – 0.2\",\n+            \"common\": \"0.2 – 0.4\",\n+            \"strong\": \"0.4 – 0.6\",\n+            \"heavy\": \"0.6 +\"\n+          }\n-            \"total_duration\": \"6-8 hours\",\n-            \"onset\": \"30-60 minutes\",\n-            \"peak\": \"1-2 hours\",\n-            \"offset\": \"4-6 hours\",\n-            \"after_effects\": \"Up to 24 hours\"\n+            \"total_duration\": \"4 - 12 h (variable)\",\n+            \"onset\": \"15 - 60 min\",\n+            \"peak\": \"1 - 3 h\",\n+            \"offset\": \"5 - 8 h\",\n+            \"after_effects\": \"12 - 24+ h residua (confusion, mydriasis)\"\n+        },\n+        {\n+          \"route\": \"transdermal\",\n+          \"canonical_routes\": [\n+            \"transdermal\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"4 - 12 h (variable)\",\n+            \"onset\": \"15 - 60 min\",\n+            \"peak\": \"1 - 3 h\",\n+            \"offset\": \"5 - 8 h\",\n+            \"after_effects\": \"12 - 24+ h residua (confusion, mydriasis)\"\n+          }\n+        },\n+        {\n+          \"route\": \"intravenous\",\n+          \"canonical_routes\": [\n+            \"intravenous\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"4 - 12 h (variable)\",\n+            \"peak\": \"1 - 3 h\",\n+            \"offset\": \"5 - 8 h\",\n+            \"after_effects\": \"12 - 24+ h residua (confusion, mydriasis)\"\n+          }\n-    \"addiction_potential\": \"Low potential for addiction, but prolonged use may lead to dependence.\",\n+    \"addiction_potential\": \"Considered to have very low addiction potential; repeated recreational use is rare due to intensely uncomfortable delirium and strong dysphoria.\",\n-        \"Alcohol\",\n-        \"Benzodiazepines\"\n+        \"Other potent anticholinergics (atropine, datura alkaloids)\",\n+        \"Deliriants such as diphenhydramine at high doses\",\n+        \"MAOIs + anticholinergics (risk hyperthermia, delirium)\"\n-        \"Opioids\"\n+        \"Alcohol (excessive CNS depression, memory black-outs)\",\n+        \"Opioids (enhanced respiratory depression and confusion)\"\n-        \"Antihistamines\"\n+        \"Stimulants (tachycardia, overheating)\",\n+        \"SSRIs / TCAs (additive anticholinergic burden)\",\n+        \"Benzodiazepines (enhanced confusion, amnesia)\"\n-    \"notes\": \"Flupirtine is primarily used as a non-opioid analgesic for pain management. It has muscle relaxant properties and is known to cause hepatotoxicity with prolonged use.\",\n+    \"notes\": \"Scopolamine is an extremely potent anticholinergic deliriant; doses above the therapeutic range can cause true hallucinations, complete memory fragmentation, dangerous confusion, hyperthermia, and severe dehydration. Accurate measurement is critical—milligram scales are required. Recreational use is strongly discouraged in unsupervised settings.\",\n-      \"Pain relief\",\n-      \"Muscle relaxation\",\n-      \"Sedation\"\n+      \"True-to-life hallucinations\",\n+      \"Severe confusion/disorientation\",\n+      \"Amnesia\",\n+      \"Dry mouth\",\n+      \"Blurred vision / mydriasis\",\n+      \"Tachycardia\",\n+      \"Urinary retention\",\n+      \"Dysphoria\",\n+      \"Impaired motor control\",\n+      \"Restlessness / agitation\"\n-      \"full_tolerance\": \"2 weeks of continuous use\",\n-      \"half_tolerance\": \"1 week\",\n-      \"zero_tolerance\": \"3-4 weeks\",\n+      \"full_tolerance\": \"Develops after 3–4 consecutive daily doses\",\n+      \"half_tolerance\": \"≈3 days\",\n+      \"zero_tolerance\": \"1–2 weeks\",\n-        \"Other analgesics\"\n+        \"Other anticholinergic deliriants (atropine, diphenhydramine)\"\n-    \"half_life\": \"6-8 hours\",\n+    \"half_life\": \"≈8 h (range 4–10 h)\",\n-        \"name\": \"PubChem - Flupirtine\",\n-        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/Flupirtine\"\n+        \"name\": \"PubChem – Scopolamine\",\n+        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/Scopolamine\"\n-        \"name\": \"DrugBank - Flupirtine maleate\",\n-        \"reference\": \"https://go.drugbank.com/drugs/DBSALT000912\"\n+        \"name\": \"FDA – Transdermal Scopolamine Label\",\n+        \"reference\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/017158s043lbl.pdf\"\n-        \"name\": \"DrugBank - Flupirtine gluconate\",\n-        \"reference\": \"https://go.drugbank.com/drugs/DBSALT002360\"\n+        \"name\": \"Erowid Vaults: Scopolamine Basics\",\n+        \"reference\": \"https://www.erowid.org/pharms/scopolamine/\"\n-        \"name\": \"DrugBank - Flupirtine\",\n-        \"reference\": \"https://go.drugbank.com/drugs/DB06623\"\n+        \"name\": \"Schmidt, P. “Transdermal Scopolamine: Pharmacology & Clinical Applications.” Am J Med Sci, 1985.\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/3997963/\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Scopolamine\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Scopolamine\"\n-      \"habit-forming\",\n-      \"depressant\",\n-      \"sedative\"\n+      \"deliriant\"\n\n# 4-Benzylpiperidine · #461\n\n-  \"id\": 460,\n-  \"title\": \"Scopolamine\",\n+  \"id\": 461,\n+  \"title\": \"4-Benzylpiperidine\",\n-    \"drug_name\": \"Scopolamine\",\n-    \"chemical_name\": \"Scopolamine\",\n-    \"alternative_name\": \"Hyoscine\",\n-    \"chemical_class\": \"Tropane alkaloids\",\n-    \"mechanism_of_action\": \"Muscarinic acetylcholine receptor antagonist\",\n-    \"psychoactive_class\": \"Deliriant anticholinergic\",\n+    \"drug_name\": \"4-Benzylpiperidine\",\n+    \"chemical_name\": \"4-Benzylpiperidine\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Piperazines\",\n+    \"mechanism_of_action\": \"Stimulant (uncertain mechanism)\",\n+    \"psychoactive_class\": \"Norepinephrine–dopamine releasing agent; weak reversible MAO-A inhibitor\",\n-          \"route\": \"oral\",\n+          \"route\": \"oral / sublingual\",\n-            \"threshold\": \"0.1 – 0.2\",\n-            \"light\": \"0.2 – 0.4\",\n-            \"common\": \"0.4 – 0.8\",\n-            \"strong\": \"0.8 – 1.2\",\n-            \"heavy\": \"1.2 +\"\n+            \"threshold\": \"25mg\",\n+            \"light\": \"25mg - 75mg\",\n+            \"common\": \"75mg - 200mg\",\n+            \"strong\": \"200mg - 400mg\",\n+            \"heavy\": \"400+ mg\"\n-          \"route\": \"transdermal\",\n-          \"units\": \"mg (total released)\",\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"≈0.3\",\n-            \"light\": \"0.4 – 0.6\",\n-            \"common\": \"0.6 – 1.0\",\n-            \"strong\": \"1.0 – 1.5\",\n-            \"heavy\": \"1.5 +\"\n+            \"threshold\": \"5mg\",\n+            \"light\": \"5mg - 20mg\",\n+            \"common\": \"20mg - 60mg\",\n+            \"strong\": \"60mg - 120mg\",\n+            \"heavy\": \"120+ mg\"\n-            \"threshold\": \"0.1\",\n-            \"light\": \"0.1 – 0.2\",\n-            \"common\": \"0.2 – 0.4\",\n-            \"strong\": \"0.4 – 0.6\",\n-            \"heavy\": \"0.6 +\"\n+            \"threshold\": \"5mg\",\n+            \"light\": \"5mg - 40mg\",\n+            \"common\": \"40mg - 120mg\",\n+            \"strong\": \"120mg - 250mg\",\n+            \"heavy\": \"250+ mg\"\n-          \"route\": \"oral\",\n+          \"route\": \"oral / sublingual\",\n-            \"oral\"\n+            \"oral\",\n+            \"sublingual\"\n-            \"total_duration\": \"4 - 12 h (variable)\",\n-            \"onset\": \"15 - 60 min\",\n-            \"peak\": \"1 - 3 h\",\n-            \"offset\": \"5 - 8 h\",\n-            \"after_effects\": \"12 - 24+ h residua (confusion, mydriasis)\"\n+            \"total_duration\": \"3-6 h (active phase)\",\n+            \"onset\": \"15-30 min\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"1-3 h\",\n+            \"after_effects\": \"1-4 h residual stimulation; mild crash\"\n-          \"route\": \"transdermal\",\n+          \"route\": \"insufflated\",\n-            \"transdermal\"\n+            \"insufflated\"\n-            \"total_duration\": \"4 - 12 h (variable)\",\n-            \"onset\": \"15 - 60 min\",\n-            \"peak\": \"1 - 3 h\",\n-            \"offset\": \"5 - 8 h\",\n-            \"after_effects\": \"12 - 24+ h residua (confusion, mydriasis)\"\n+            \"total_duration\": \"3-6 h (active phase)\",\n+            \"onset\": \"5-10 min\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"1-3 h\",\n+            \"after_effects\": \"1-4 h residual stimulation; mild crash\"\n-            \"total_duration\": \"4 - 12 h (variable)\",\n-            \"peak\": \"1 - 3 h\",\n-            \"offset\": \"5 - 8 h\",\n-            \"after_effects\": \"12 - 24+ h residua (confusion, mydriasis)\"\n+            \"total_duration\": \"3-6 h (active phase)\",\n+            \"onset\": \"<1 min\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"1-3 h\",\n+            \"after_effects\": \"1-4 h residual stimulation; mild crash\"\n-    \"addiction_potential\": \"Considered to have very low addiction potential; repeated recreational use is rare due to intensely uncomfortable delirium and strong dysphoria.\",\n+    \"addiction_potential\": \"Low-to-moderate: short half-life encourages redosing; binges of 1–2 g/day have been reported with agitation, insomnia and tachycardia.\",\n-        \"Other potent anticholinergics (atropine, datura alkaloids)\",\n-        \"Deliriants such as diphenhydramine at high doses\",\n-        \"MAOIs + anticholinergics (risk hyperthermia, delirium)\"\n+        \"other MAOIs (hypertensive crisis)\",\n+        \"serotonergic stimulants or psychedelics (serotonin syndrome)\",\n+        \"opioids or tramadol (seizure threshold lowered)\",\n+        \"high-dose sympathomimetics (severe vasoconstriction, arrhythmia)\"\n-        \"Alcohol (excessive CNS depression, memory black-outs)\",\n-        \"Opioids (enhanced respiratory depression and confusion)\"\n+        \"large alcohol quantities (vomiting + BP spikes)\",\n+        \"cocaine, potent NDRIs\",\n+        \"dextromethorphan (hyperthermia, hypertension)\"\n-        \"Stimulants (tachycardia, overheating)\",\n-        \"SSRIs / TCAs (additive anticholinergic burden)\",\n-        \"Benzodiazepines (enhanced confusion, amnesia)\"\n+        \">400 mg caffeine\",\n+        \"beta-agonist inhalers\",\n+        \"bupropion, pseudoephedrine\",\n+        \"SSRIs / SNRIs (weak MAOI interaction)\"\n-    \"notes\": \"Scopolamine is an extremely potent anticholinergic deliriant; doses above the therapeutic range can cause true hallucinations, complete memory fragmentation, dangerous confusion, hyperthermia, and severe dehydration. Accurate measurement is critical—milligram scales are required. Recreational use is strongly discouraged in unsupervised settings.\",\n+    \"notes\": \"In vitro release assays give EC50 ≈41 nM for norepinephrine and 109 nM for dopamine with >40-fold lower efficacy at SERT. Weak MAO-A inhibition appears at ~130 µM, relevant only at very high doses. Anecdotal oral threshold 25–50 mg produces mild wakefulness; 75–200 mg common range yields pronounced alertness, mydriasis and appetite suppression. Intranasal use burns sharply; IV trials ≤40 mg deliver an instantaneous ‘spike’ of clean stimulation lasting ~2 h but risk vasospasm—use sterile, micron-filtered solutions only. Systolic BP rises of 20–30 mm Hg are typical; carry a cuff if combining with caffeine or exercise. Half-life is estimated 1–2 h, so tolerance and redose cravings develop fast; allow 24 h wash-out before other stimulants/serotonergics due to MAOI component. Marquis reagent gives weak yellow-orange—confirm identity by GC-MS/LC-MS. Powder is fluffy and static-prone; volumetric dosing (10 mg/mL in PG or EtOH) improves accuracy.\",\n-      \"True-to-life hallucinations\",\n-      \"Severe confusion/disorientation\",\n-      \"Amnesia\",\n-      \"Dry mouth\",\n-      \"Blurred vision / mydriasis\",\n-      \"Tachycardia\",\n-      \"Urinary retention\",\n-      \"Dysphoria\",\n-      \"Impaired motor control\",\n-      \"Restlessness / agitation\"\n+      \"clean mental alertness\",\n+      \"mild euphoria (inconsistent)\",\n+      \"anorexia\",\n+      \"visual shimmer / mydriasis\",\n+      \"jaw tension, hand tremor at higher doses\",\n+      \"fatigue ‘crash’ on comedown\"\n-      \"full_tolerance\": \"Develops after 3–4 consecutive daily doses\",\n-      \"half_tolerance\": \"≈3 days\",\n-      \"zero_tolerance\": \"1–2 weeks\",\n+      \"full_tolerance\": \"after 2-3 heavy sessions in one week\",\n+      \"half_tolerance\": \"3-4 days\",\n+      \"zero_tolerance\": \"7-10 days\",\n-        \"Other anticholinergic deliriants (atropine, diphenhydramine)\"\n+        \"propylhexedrine\",\n+        \"prolintane and related NDRIs\"\n-    \"half_life\": \"≈8 h (range 4–10 h)\",\n+    \"half_life\": \"1-2 h (estimated from onset/offset and rat microdialysis data)\",\n-        \"name\": \"PubChem – Scopolamine\",\n-        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/Scopolamine\"\n+        \"name\": \"Wikipedia – pharmacology & basic data\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/4-Benzylpiperidine\"\n-        \"name\": \"FDA – Transdermal Scopolamine Label\",\n-        \"reference\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/017158s043lbl.pdf\"\n+        \"name\": \"Sigma-Aldrich product sheet – dopamine-selective releaser\",\n+        \"reference\": \"https://www.sigmaaldrich.com/US/en/product/aldrich/142360\"\n-        \"name\": \"Erowid Vaults: Scopolamine Basics\",\n-        \"reference\": \"https://www.erowid.org/pharms/scopolamine/\"\n+        \"name\": \"Biosynth datasheet – MAO-A/B IC50 values\",\n+        \"reference\": \"https://www.biosynth.com/p/FB52865/31252-42-3-4-benzylpiperidine\"\n-        \"name\": \"Schmidt, P. “Transdermal Scopolamine: Pharmacology & Clinical Applications.” Am J Med Sci, 1985.\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/3997963/\"\n+        \"name\": \"Bluelight megathread – user dose anecdotes\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/4-benzylpiperidine-4-pmpd-monoaminergic.745526/\"\n-        \"name\": \"Wikipedia: Scopolamine\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Scopolamine\"\n+        \"name\": \"Reddit r/Nootropics – Newmind 4-PMPD discussion\",\n+        \"reference\": \"https://www.reddit.com/r/Nootropics/comments/2n5cg0/newminds_new_compound_4pmpd_hcl/\"\n+      },\n+      {\n+        \"name\": \"Reddit r/Nootropics – user experiences thread\",\n+        \"reference\": \"https://www.reddit.com/r/Nootropics/comments/2npvf7/4benzylpiperidine_4pmpd_user_experiences/\"\n+      },\n+      {\n+        \"name\": \"Transdermal formulation study – rapid onset / short duration\",\n+        \"reference\": \"https://www.sciencedirect.com/science/article/abs/pii/S1773224718303459\"\n+      },\n+      {\n+        \"name\": \"Structural requirements for modulating 4-benzylpiperidine uptake (SAR)\",\n+        \"reference\": \"https://e-sciencecentral.org/upload/bt/pdf/bt-29-4-392.pdf\"\n+      },\n+      {\n+        \"name\": \"ChemicalBook – onset, duration and discrimination study summary\",\n+        \"reference\": \"https://www.chemicalbook.com/ChemicalProductProperty_EN_CB9141122.htm\"\n-      \"deliriant\"\n+      \"stimulant\",\n+      \"research-chemical\"\n\n# Ethylbromazolam · #462\n\n-  \"id\": 461,\n-  \"title\": \"4-Benzylpiperidine\",\n+  \"id\": 462,\n+  \"title\": \"Ethylbromazolam\",\n-    \"drug_name\": \"4-Benzylpiperidine\",\n-    \"chemical_name\": \"4-Benzylpiperidine\",\n+    \"drug_name\": \"Ethylbromazolam\",\n+    \"chemical_name\": \"Ethylbromazolam\",\n-    \"chemical_class\": \"Piperazines\",\n-    \"mechanism_of_action\": \"Stimulant (uncertain mechanism)\",\n-    \"psychoactive_class\": \"Norepinephrine–dopamine releasing agent; weak reversible MAO-A inhibitor\",\n+    \"chemical_class\": \"Benzodiazepine\",\n+    \"mechanism_of_action\": \"Gamma-aminobutyric acid type A receptor positive allosteric modulator (benzodiazepine site)\",\n+    \"psychoactive_class\": \"GABAA receptor positive allosteric modulator (benzodiazepine-type)\",\n-            \"threshold\": \"25mg\",\n-            \"light\": \"25mg - 75mg\",\n-            \"common\": \"75mg - 200mg\",\n-            \"strong\": \"200mg - 400mg\",\n-            \"heavy\": \"400+ mg\"\n+            \"threshold\": \"1 mg\",\n+            \"light\": \"1 mg - 3 mg\",\n+            \"common\": \"3 mg - 6 mg\",\n+            \"strong\": \"6 mg - 10 mg\",\n+            \"heavy\": \"10+ mg\"\n-            \"threshold\": \"5mg\",\n-            \"light\": \"5mg - 20mg\",\n-            \"common\": \"20mg - 60mg\",\n-            \"strong\": \"60mg - 120mg\",\n-            \"heavy\": \"120+ mg\"\n+            \"threshold\": \"0.5 mg\",\n+            \"light\": \"0.5 mg - 2 mg\",\n+            \"common\": \"2 mg - 4 mg\",\n+            \"strong\": \"4 mg - 7 mg\",\n+            \"heavy\": \"7+ mg\"\n-          \"route\": \"intravenous\",\n+          \"route\": \"rectal\",\n-            \"threshold\": \"5mg\",\n-            \"light\": \"5mg - 40mg\",\n-            \"common\": \"40mg - 120mg\",\n-            \"strong\": \"120mg - 250mg\",\n-            \"heavy\": \"250+ mg\"\n+            \"threshold\": \"1 mg\",\n+            \"light\": \"1 mg - 3 mg\",\n+            \"common\": \"3 mg - 5 mg\",\n+            \"strong\": \"5 mg - 9 mg\",\n+            \"heavy\": \"9+ mg\"\n-            \"total_duration\": \"3-6 h (active phase)\",\n-            \"onset\": \"15-30 min\",\n-            \"peak\": \"1-2 h\",\n-            \"offset\": \"1-3 h\",\n-            \"after_effects\": \"1-4 h residual stimulation; mild crash\"\n+            \"total_duration\": \"4 - 6 h (active)\",\n+            \"onset\": \"20 - 40 min; 10 - 20 min\",\n+            \"peak\": \"1 - 2.5 h\",\n+            \"offset\": \"2 - 4 h\",\n+            \"after_effects\": \"residual anxiolysis or drowsiness up to 8 h\"\n-            \"total_duration\": \"3-6 h (active phase)\",\n-            \"onset\": \"5-10 min\",\n-            \"peak\": \"1-2 h\",\n-            \"offset\": \"1-3 h\",\n-            \"after_effects\": \"1-4 h residual stimulation; mild crash\"\n+            \"total_duration\": \"4 - 6 h (active)\",\n+            \"onset\": \"10 - 20 min\",\n+            \"peak\": \"1 - 2.5 h\",\n+            \"offset\": \"2 - 4 h\",\n+            \"after_effects\": \"residual anxiolysis or drowsiness up to 8 h\"\n-          \"route\": \"intravenous\",\n+          \"route\": \"rectal\",\n-            \"intravenous\"\n+            \"rectal\"\n-            \"total_duration\": \"3-6 h (active phase)\",\n-            \"onset\": \"<1 min\",\n-            \"peak\": \"1-2 h\",\n-            \"offset\": \"1-3 h\",\n-            \"after_effects\": \"1-4 h residual stimulation; mild crash\"\n+            \"total_duration\": \"4 - 6 h (active)\",\n+            \"peak\": \"1 - 2.5 h\",\n+            \"offset\": \"2 - 4 h\",\n+            \"after_effects\": \"residual anxiolysis or drowsiness up to 8 h\"\n-    \"addiction_potential\": \"Low-to-moderate: short half-life encourages redosing; binges of 1–2 g/day have been reported with agitation, insomnia and tachycardia.\",\n+    \"addiction_potential\": \"High: short duration and moderate potency encourage redosing; rapid tolerance and severe benzodiazepine-type withdrawal expected.\",\n-        \"other MAOIs (hypertensive crisis)\",\n-        \"serotonergic stimulants or psychedelics (serotonin syndrome)\",\n-        \"opioids or tramadol (seizure threshold lowered)\",\n-        \"high-dose sympathomimetics (severe vasoconstriction, arrhythmia)\"\n+        \"opioids\",\n+        \"alcohol or GHB\",\n+        \"barbiturates\",\n+        \"z-drugs\"\n-        \"large alcohol quantities (vomiting + BP spikes)\",\n-        \"cocaine, potent NDRIs\",\n-        \"dextromethorphan (hyperthermia, hypertension)\"\n+        \"other benzodiazepines\",\n+        \"first-generation antihistamines\",\n+        \"pregabalin or gabapentin\"\n-        \">400 mg caffeine\",\n-        \"beta-agonist inhalers\",\n-        \"bupropion, pseudoephedrine\",\n-        \"SSRIs / SNRIs (weak MAOI interaction)\"\n+        \"dissociatives\",\n+        \"stimulants (masking sedation)\",\n+        \"antipsychotics (QT prolongation)\"\n-    \"notes\": \"In vitro release assays give EC50 ≈41 nM for norepinephrine and 109 nM for dopamine with >40-fold lower efficacy at SERT. Weak MAO-A inhibition appears at ~130 µM, relevant only at very high doses. Anecdotal oral threshold 25–50 mg produces mild wakefulness; 75–200 mg common range yields pronounced alertness, mydriasis and appetite suppression. Intranasal use burns sharply; IV trials ≤40 mg deliver an instantaneous ‘spike’ of clean stimulation lasting ~2 h but risk vasospasm—use sterile, micron-filtered solutions only. Systolic BP rises of 20–30 mm Hg are typical; carry a cuff if combining with caffeine or exercise. Half-life is estimated 1–2 h, so tolerance and redose cravings develop fast; allow 24 h wash-out before other stimulants/serotonergics due to MAOI component. Marquis reagent gives weak yellow-orange—confirm identity by GC-MS/LC-MS. Powder is fluffy and static-prone; volumetric dosing (10 mg/mL in PG or EtOH) improves accuracy.\",\n+    \"notes\": \"Roughly 4 mg gives effects equivalent to 10 mg diazepam, making it about half as potent as bromazolam. Powders are active at low milligram levels; volumetric or solution dosing (e.g., 1 mg/mL in ethanol/PG) is strongly advised. User reports describe a clear-headed, 'functional' benzo with less sedation and amnesia than bromazolam but blackouts still occur at 10 mg+. Drug-checking services in NZ and AU have detected ethylbromazolam in counterfeit Xanax bars and blue tablets. No human pharmacokinetic studies exist; half-life is estimated from analogs. Dependence may develop after 1-2 weeks of daily use; taper with a long-acting benzo if necessary.\",\n-      \"clean mental alertness\",\n-      \"mild euphoria (inconsistent)\",\n-      \"anorexia\",\n-      \"visual shimmer / mydriasis\",\n-      \"jaw tension, hand tremor at higher doses\",\n-      \"fatigue ‘crash’ on comedown\"\n+      \"anxiolysis\",\n+      \"muscle relaxation\",\n+      \"mild euphoria\",\n+      \"disinhibition\",\n+      \"reduced sedation versus bromazolam\",\n+      \"anterograde amnesia at higher doses\",\n+      \"time compression\"\n-      \"full_tolerance\": \"after 2-3 heavy sessions in one week\",\n-      \"half_tolerance\": \"3-4 days\",\n-      \"zero_tolerance\": \"7-10 days\",\n+      \"full_tolerance\": \"after 1 - 3 heavy-use days\",\n+      \"half_tolerance\": \"5 - 7 days\",\n+      \"zero_tolerance\": \"14 - 21 days\",\n-        \"propylhexedrine\",\n-        \"prolintane and related NDRIs\"\n+        \"all benzodiazepines\",\n+        \"z-drugs\"\n-    \"half_life\": \"1-2 h (estimated from onset/offset and rat microdialysis data)\",\n+    \"half_life\": \"estimated 6 - 10 h (no human data)\",\n-        \"name\": \"Wikipedia – pharmacology & basic data\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/4-Benzylpiperidine\"\n+        \"name\": \"Ethylbromazolam – Wikipedia\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Ethylbromazolam\"\n-        \"name\": \"Sigma-Aldrich product sheet – dopamine-selective releaser\",\n-        \"reference\": \"https://www.sigmaaldrich.com/US/en/product/aldrich/142360\"\n+        \"name\": \"List of benzodiazepines – potency table\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/List_of_benzodiazepines\"\n-        \"name\": \"Biosynth datasheet – MAO-A/B IC50 values\",\n-        \"reference\": \"https://www.biosynth.com/p/FB52865/31252-42-3-4-benzylpiperidine\"\n+        \"name\": \"High Alert NZ – new benzodiazepine detected\",\n+        \"reference\": \"https://www.highalert.org.nz/alerts-and-notifications/new-benzodiazepine-ethylbromazolam-detected-in-new-zealand/\"\n-        \"name\": \"Bluelight megathread – user dose anecdotes\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/4-benzylpiperidine-4-pmpd-monoaminergic.745526/\"\n+        \"name\": \"Bluelight thread: Ethylbromazolam (user reports)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/ethylbromazolam.946320/\"\n-        \"name\": \"Reddit r/Nootropics – Newmind 4-PMPD discussion\",\n-        \"reference\": \"https://www.reddit.com/r/Nootropics/comments/2n5cg0/newminds_new_compound_4pmpd_hcl/\"\n+        \"name\": \"Reddit r/rcbenzos4 – dosage and half-life discussion\",\n+        \"reference\": \"https://www.reddit.com/r/rcbenzos4/comments/1k0zvwx/rhs_ethylbromazolam/\"\n-        \"name\": \"Reddit r/Nootropics – user experiences thread\",\n-        \"reference\": \"https://www.reddit.com/r/Nootropics/comments/2npvf7/4benzylpiperidine_4pmpd_user_experiences/\"\n+        \"name\": \"Reddit r/rcbenzos4 – potency comparison thread\",\n+        \"reference\": \"https://www.reddit.com/r/rcbenzos4/comments/1kbv8ii/ethybromazolam_vs_bromazolam/\"\n-        \"name\": \"Transdermal formulation study – rapid onset / short duration\",\n-        \"reference\": \"https://www.sciencedirect.com/science/article/abs/pii/S1773224718303459\"\n+        \"name\": \"The Know AU – ethylbromazolam found in counterfeit alprazolam\",\n+        \"reference\": \"https://theknow.org.au/alerts_warnings/ethylbromazolam-and-bromonordiazepam-found-in-alprazolam-pill\"\n-        \"name\": \"Structural requirements for modulating 4-benzylpiperidine uptake (SAR)\",\n-        \"reference\": \"https://e-sciencecentral.org/upload/bt/pdf/bt-29-4-392.pdf\"\n-      },\n-      {\n-        \"name\": \"ChemicalBook – onset, duration and discrimination study summary\",\n-        \"reference\": \"https://www.chemicalbook.com/ChemicalProductProperty_EN_CB9141122.htm\"\n+        \"name\": \"Yan & Hu 1986 – benzodiazepine receptor affinity study\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/3035871/\"\n-      \"stimulant\",\n-      \"research-chemical\"\n+      \"benzodiazepine\",\n+      \"research-chemical\",\n+      \"gabaergic\"\n\n# Nifoxipam · #463\n\n-  \"id\": 462,\n-  \"title\": \"Ethylbromazolam\",\n+  \"id\": 463,\n+  \"title\": \"Nifoxipam\",\n-    \"drug_name\": \"Ethylbromazolam\",\n-    \"chemical_name\": \"Ethylbromazolam\",\n+    \"drug_name\": \"Nifoxipam\",\n+    \"chemical_name\": \"Nifoxipam\",\n-    \"psychoactive_class\": \"GABAA receptor positive allosteric modulator (benzodiazepine-type)\",\n+    \"psychoactive_class\": \"GABA-A positive allosteric modulator benzodiazepine\",\n-            \"threshold\": \"1 mg\",\n-            \"light\": \"1 mg - 3 mg\",\n-            \"common\": \"3 mg - 6 mg\",\n-            \"strong\": \"6 mg - 10 mg\",\n-            \"heavy\": \"10+ mg\"\n+            \"threshold\": \"0.25 mg\",\n+            \"light\": \"0.25 mg - 1 mg\",\n+            \"common\": \"1 mg - 4 mg\",\n+            \"strong\": \"4 mg - 8 mg\",\n+            \"heavy\": \"8+ mg\"\n-          \"route\": \"insufflated\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"0.5 mg\",\n-            \"light\": \"0.5 mg - 2 mg\",\n-            \"common\": \"2 mg - 4 mg\",\n-            \"strong\": \"4 mg - 7 mg\",\n-            \"heavy\": \"7+ mg\"\n-          }\n-        },\n-        {\n-            \"threshold\": \"1 mg\",\n-            \"light\": \"1 mg - 3 mg\",\n-            \"common\": \"3 mg - 5 mg\",\n-            \"strong\": \"5 mg - 9 mg\",\n-            \"heavy\": \"9+ mg\"\n+            \"threshold\": \"0.25 mg\",\n+            \"light\": \"0.25 mg - 1 mg\",\n+            \"common\": \"1 mg - 3 mg\",\n+            \"strong\": \"3 mg - 6 mg\",\n+            \"heavy\": \"6+ mg\"\n-            \"total_duration\": \"4 - 6 h (active)\",\n-            \"onset\": \"20 - 40 min; 10 - 20 min\",\n-            \"peak\": \"1 - 2.5 h\",\n-            \"offset\": \"2 - 4 h\",\n-            \"after_effects\": \"residual anxiolysis or drowsiness up to 8 h\"\n+            \"total_duration\": \"10-75 h (functional sedation 12-24 h typical)\",\n+            \"onset\": \"20-60 min; 10-20 min\",\n+            \"peak\": \"1-3 h\",\n+            \"offset\": \"8-24 h\",\n+            \"after_effects\": \"residual cognitive dulling & ataxia 24-48 h\"\n-          \"route\": \"insufflated\",\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"4 - 6 h (active)\",\n-            \"onset\": \"10 - 20 min\",\n-            \"peak\": \"1 - 2.5 h\",\n-            \"offset\": \"2 - 4 h\",\n-            \"after_effects\": \"residual anxiolysis or drowsiness up to 8 h\"\n-          }\n-        },\n-        {\n-            \"total_duration\": \"4 - 6 h (active)\",\n-            \"peak\": \"1 - 2.5 h\",\n-            \"offset\": \"2 - 4 h\",\n-            \"after_effects\": \"residual anxiolysis or drowsiness up to 8 h\"\n+            \"total_duration\": \"10-75 h (functional sedation 12-24 h typical)\",\n+            \"onset\": \"10-20 min\",\n+            \"peak\": \"1-3 h\",\n+            \"offset\": \"8-24 h\",\n+            \"after_effects\": \"residual cognitive dulling & ataxia 24-48 h\"\n-    \"addiction_potential\": \"High: short duration and moderate potency encourage redosing; rapid tolerance and severe benzodiazepine-type withdrawal expected.\",\n+    \"addiction_potential\": \"High: designer benzodiazepines with long half-lives promote rapid tolerance, physical dependence and severe withdrawal. Accumulation from daily use >1 week can precipitate blackouts even on \\\"light\\\" doses.\",\n-        \"opioids\",\n+        \"opioids (respiratory depression)\",\n-        \"z-drugs\"\n+        \"other hypnotic benzos or Z-drugs\"\n-        \"other benzodiazepines\",\n+        \"gabapentinoids (potentiate respiratory depression)\",\n-        \"pregabalin or gabapentin\"\n+        \"muscle relaxants\"\n-        \"dissociatives\",\n-        \"stimulants (masking sedation)\",\n-        \"antipsychotics (QT prolongation)\"\n+        \"dissociatives (ketamine, DXM)\",\n+        \"stimulant comedowns (masking fatigue → redose loops)\",\n+        \"antipsychotics or TCAs (additive QT prolongation)\"\n-    \"notes\": \"Roughly 4 mg gives effects equivalent to 10 mg diazepam, making it about half as potent as bromazolam. Powders are active at low milligram levels; volumetric or solution dosing (e.g., 1 mg/mL in ethanol/PG) is strongly advised. User reports describe a clear-headed, 'functional' benzo with less sedation and amnesia than bromazolam but blackouts still occur at 10 mg+. Drug-checking services in NZ and AU have detected ethylbromazolam in counterfeit Xanax bars and blue tablets. No human pharmacokinetic studies exist; half-life is estimated from analogs. Dependence may develop after 1-2 weeks of daily use; taper with a long-acting benzo if necessary.\",\n+    \"notes\": \"Elimination half-life is estimated at 12-24 h in forensic pharmacokinetic work, with subjective effects lasting up to 75 h in some users. Accumulates strongly with daily dosing; even 0.5-mg pellets require volumetric measurement—users on harm-reduction forums report coordination loss from 5 mg and blackouts beyond 10 mg. LC-MS/MS case studies confirm nifoxipam appears in flunitrazepam urine screens, supporting its status as an active metabolite. Stability is poorer than many other designer benzos (notable degradation at 4 °C after one week), so freeze samples for testing. Recommended practices: weigh powder on a 0.001-g scale, dissolve 10 mg in 100 mL 190-proof ethanol or propylene glycol for 0.1-mg/mL titration, limit sessions to ≤2 mg every 24 h, and keep at least four weeks between multi-day binges to reset tolerance. Because CNS depression is easily underestimated, always dose with a sober sitter and avoid driving for at least 24 h after strong sessions.\",\n-      \"anxiolysis\",\n+      \"potent sedation\",\n-      \"mild euphoria\",\n-      \"disinhibition\",\n-      \"reduced sedation versus bromazolam\",\n-      \"anterograde amnesia at higher doses\",\n-      \"time compression\"\n+      \"anxiolysis\",\n+      \"hypnotic sleep promotion\",\n+      \"anterograde amnesia\",\n+      \"ataxia / motor incoordination\",\n+      \"mild euphoria\"\n-      \"full_tolerance\": \"after 1 - 3 heavy-use days\",\n-      \"half_tolerance\": \"5 - 7 days\",\n-      \"zero_tolerance\": \"14 - 21 days\",\n+      \"full_tolerance\": \"3-5 consecutive days\",\n+      \"half_tolerance\": \"7-10 days\",\n+      \"zero_tolerance\": \"21-28 days\",\n-        \"all benzodiazepines\",\n-        \"z-drugs\"\n+        \"all classical benzodiazepines\",\n+        \"Z-drugs\",\n+        \"other designer benzos\"\n-    \"half_life\": \"estimated 6 - 10 h (no human data)\",\n+    \"half_life\": \"12-24 h (plasma) with reports of functional impairment up to 75 h\",\n-        \"name\": \"Ethylbromazolam – Wikipedia\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Ethylbromazolam\"\n+        \"name\": \"Metabolites replace the parent drug in the drug arena: fonazepam & nifoxipam\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/28127407/\"\n-        \"name\": \"List of benzodiazepines – potency table\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/List_of_benzodiazepines\"\n+        \"name\": \"BenchChem – Nifoxipam pharmacokinetic summary & dose table\",\n+        \"reference\": \"https://www.benchchem.com/product/b1621971\"\n-        \"name\": \"High Alert NZ – new benzodiazepine detected\",\n-        \"reference\": \"https://www.highalert.org.nz/alerts-and-notifications/new-benzodiazepine-ethylbromazolam-detected-in-new-zealand/\"\n+        \"name\": \"Bluelight Big & Dandy Nifoxipam thread (user dose reports)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/nifoxipam-3-ho-desmethyl-flunitrazepam.743789/\"\n-        \"name\": \"Bluelight thread: Ethylbromazolam (user reports)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/ethylbromazolam.946320/\"\n+        \"name\": \"Novel Designer Benzodiazepines – comprehensive review\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC9397074/\"\n-        \"name\": \"Reddit r/rcbenzos4 – dosage and half-life discussion\",\n-        \"reference\": \"https://www.reddit.com/r/rcbenzos4/comments/1k0zvwx/rhs_ethylbromazolam/\"\n+        \"name\": \"Analytical & Bioanalytical Chemistry – urinary metabolites of nifoxipam\",\n+        \"reference\": \"https://link.springer.com/article/10.1007/s00216-016-9518-1\"\n-        \"name\": \"Reddit r/rcbenzos4 – potency comparison thread\",\n-        \"reference\": \"https://www.reddit.com/r/rcbenzos4/comments/1kbv8ii/ethybromazolam_vs_bromazolam/\"\n+        \"name\": \"Headwaters Recovery – harm-reduction overview of nifoxipam\",\n+        \"reference\": \"https://headwatersfl.org/what-is-nifoxipam/\"\n-        \"name\": \"The Know AU – ethylbromazolam found in counterfeit alprazolam\",\n-        \"reference\": \"https://theknow.org.au/alerts_warnings/ethylbromazolam-and-bromonordiazepam-found-in-alprazolam-pill\"\n+        \"name\": \"DrugIntelligenceBulletin – law-enforcement alert\",\n+        \"reference\": \"https://www.drugintelligencebulletin.com/p/nifoxipam-is-the-latest-drug-of-abuse\"\n-        \"name\": \"Yan & Hu 1986 – benzodiazepine receptor affinity study\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/3035871/\"\n+        \"name\": \"Urine LC-HRMS panel for 28 designer benzodiazepines\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC11322785/\"\n+      },\n+      {\n+        \"name\": \"Wikipedia – general chemical data\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Nifoxipam\"\n+      },\n+      {\n+        \"name\": \"Forensic Toxicology 35(1):1-10 – duration quotation\",\n+        \"reference\": \"https://doi.org/10.1007/s11419-016-0338-5\"\n+      \"depressant\",\n\n# DMNPC · #464\n\n-  \"id\": 463,\n-  \"title\": \"Nifoxipam\",\n+  \"id\": 464,\n+  \"title\": \"DMNPC\",\n-    \"drug_name\": \"Nifoxipam\",\n-    \"chemical_name\": \"Nifoxipam\",\n+    \"drug_name\": \"DMNPC\",\n+    \"chemical_name\": \"DMNPC\",\n-    \"chemical_class\": \"Benzodiazepine\",\n-    \"mechanism_of_action\": \"Gamma-aminobutyric acid type A receptor positive allosteric modulator (benzodiazepine site)\",\n-    \"psychoactive_class\": \"GABA-A positive allosteric modulator benzodiazepine\",\n+    \"chemical_class\": \"Piperazines\",\n+    \"mechanism_of_action\": \"Stimulant (uncertain mechanism)\",\n+    \"psychoactive_class\": \"Serotonin-norepinephrine-dopamine re-uptake inhibitor (SNDRI)\",\n-          \"route\": \"oral / sublingual\",\n+          \"route\": \"oral\",\n-            \"threshold\": \"0.25 mg\",\n-            \"light\": \"0.25 mg - 1 mg\",\n-            \"common\": \"1 mg - 4 mg\",\n-            \"strong\": \"4 mg - 8 mg\",\n-            \"heavy\": \"8+ mg\"\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"5 mg - 15 mg\",\n+            \"common\": \"15 mg - 40 mg\",\n+            \"strong\": \"40 mg - 60 mg\",\n+            \"heavy\": \"60+ mg\"\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"5 mg - 15 mg\",\n+            \"common\": \"15 mg - 30 mg\",\n+            \"strong\": \"30 mg - 50 mg\",\n+            \"heavy\": \"50+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"intravenous\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"2 mg\",\n+            \"light\": \"2 mg - 10 mg\",\n+            \"common\": \"10 mg - 25 mg\",\n+            \"strong\": \"25 mg - 40 mg\",\n+            \"heavy\": \"40+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"vaporized / smoked\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"5 mg - 15 mg\",\n+            \"common\": \"15 mg - 35 mg\",\n+            \"strong\": \"35 mg - 60 mg\",\n+            \"heavy\": \"60+ mg\"\n+          }\n+        },\n+        {\n-            \"threshold\": \"0.25 mg\",\n-            \"light\": \"0.25 mg - 1 mg\",\n-            \"common\": \"1 mg - 3 mg\",\n-            \"strong\": \"3 mg - 6 mg\",\n-            \"heavy\": \"6+ mg\"\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"5 mg - 15 mg\",\n+            \"common\": \"15 mg - 30 mg\",\n+            \"strong\": \"30 mg - 50 mg\",\n+            \"heavy\": \"50+ mg\"\n-          \"route\": \"oral / sublingual\",\n+          \"route\": \"oral\",\n-            \"oral\",\n-            \"sublingual\"\n+            \"oral\"\n-            \"total_duration\": \"10-75 h (functional sedation 12-24 h typical)\",\n-            \"onset\": \"20-60 min; 10-20 min\",\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"8-24 h\",\n-            \"after_effects\": \"residual cognitive dulling & ataxia 24-48 h\"\n+            \"total_duration\": \"2-4 h\",\n+            \"onset\": \"15-30 min\",\n+            \"peak\": \"10-45 min\",\n+            \"offset\": \"1-2 h gradual decline\",\n+            \"after_effects\": \"1-6 h residual alertness; gentle serotonergic after-glow or dysphoria depending on dose\"\n+          \"route\": \"insufflated\",\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ],\n+          \"stages\": {\n+            \"onset\": \"5-10 min\",\n+            \"peak\": \"10-45 min\",\n+            \"offset\": \"1-2 h gradual decline\",\n+            \"after_effects\": \"1-6 h residual alertness; gentle serotonergic after-glow or dysphoria depending on dose\"\n+          }\n+        },\n+        {\n+          \"route\": \"intravenous\",\n+          \"canonical_routes\": [\n+            \"intravenous\"\n+          ],\n+          \"stages\": {\n+            \"onset\": \"1-5 min\",\n+            \"peak\": \"10-45 min\",\n+            \"offset\": \"1-2 h gradual decline\",\n+            \"after_effects\": \"1-6 h residual alertness; gentle serotonergic after-glow or dysphoria depending on dose\"\n+          }\n+        },\n+        {\n+          \"route\": \"vaporized / smoked\",\n+          \"canonical_routes\": [\n+            \"vaporized\",\n+            \"smoked\"\n+          ],\n+          \"stages\": {\n+            \"onset\": \"5-10 min\",\n+            \"peak\": \"10-45 min\",\n+            \"offset\": \"1-2 h gradual decline\",\n+            \"after_effects\": \"1-6 h residual alertness; gentle serotonergic after-glow or dysphoria depending on dose\"\n+          }\n+        },\n+        {\n-            \"total_duration\": \"10-75 h (functional sedation 12-24 h typical)\",\n-            \"onset\": \"10-20 min\",\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"8-24 h\",\n-            \"after_effects\": \"residual cognitive dulling & ataxia 24-48 h\"\n+            \"onset\": \"15-30 min\",\n+            \"peak\": \"10-45 min\",\n+            \"offset\": \"1-2 h gradual decline\",\n+            \"after_effects\": \"1-6 h residual alertness; gentle serotonergic after-glow or dysphoria depending on dose\"\n-    \"addiction_potential\": \"High: designer benzodiazepines with long half-lives promote rapid tolerance, physical dependence and severe withdrawal. Accumulation from daily use >1 week can precipitate blackouts even on \\\"light\\\" doses.\",\n+    \"addiction_potential\": \"High: cocaine-like reinforcement combined with longer SERT activity encourages compulsive redosing; several users consumed 250 mg or more in a single IV session.\",\n-        \"opioids (respiratory depression)\",\n-        \"alcohol or GHB\",\n-        \"barbiturates\",\n-        \"other hypnotic benzos or Z-drugs\"\n+        \"MAOIs (hypertensive crisis)\",\n+        \"SSRIs, SNRIs, tramadol, MDMA (serotonin syndrome)\",\n+        \"other potent stimulants (hypertension, tachyarrhythmia)\",\n+        \"strong opioids + sedatives (respiratory depression if poly-use leads to somnolence)\"\n-        \"gabapentinoids (potentiate respiratory depression)\",\n-        \"first-generation antihistamines\",\n-        \"muscle relaxants\"\n+        \"cocaine or phenyltropanes (cardiotoxic ion-channel blockade)\",\n+        \"bupropion, methylphenidate, cathinones (excess DAT/NAT load)\",\n+        \"5-HT2A psychedelics at high dose (over-activation, vasospasm)\"\n-        \"dissociatives (ketamine, DXM)\",\n-        \"stimulant comedowns (masking fatigue → redose loops)\",\n-        \"antipsychotics or TCAs (additive QT prolongation)\"\n+        \"caffeine >300 mg\",\n+        \"heavy nicotine use\",\n+        \"alpha-adrenergic vasoconstrictors (cold medicines)\",\n+        \"any medication prolonging QT (additive risk with SERT blockage)\"\n-    \"notes\": \"Elimination half-life is estimated at 12-24 h in forensic pharmacokinetic work, with subjective effects lasting up to 75 h in some users. Accumulates strongly with daily dosing; even 0.5-mg pellets require volumetric measurement—users on harm-reduction forums report coordination loss from 5 mg and blackouts beyond 10 mg. LC-MS/MS case studies confirm nifoxipam appears in flunitrazepam urine screens, supporting its status as an active metabolite. Stability is poorer than many other designer benzos (notable degradation at 4 °C after one week), so freeze samples for testing. Recommended practices: weigh powder on a 0.001-g scale, dissolve 10 mg in 100 mL 190-proof ethanol or propylene glycol for 0.1-mg/mL titration, limit sessions to ≤2 mg every 24 h, and keep at least four weeks between multi-day binges to reset tolerance. Because CNS depression is easily underestimated, always dose with a sober sitter and avoid driving for at least 24 h after strong sessions.\",\n+    \"notes\": \"Binding studies give Ki (3S,4S) ~7.6 nM at SERT, 21 nM at DAT, and 34 nM at NET – roughly 2.5× the DAT potency of cocaine while retaining SSRI-level SERT affinity. Users report pronounced mucosal irritation: dry-rail 25 mg intranasal \\\"burns worse than 80 mg 4F-MPH\\\" and causes prolonged congestion; isotonic saline rinses are recommended. The free base volatilizes easily and can be inhaled from foil, producing a \\\"crack-like bell-ringer\\\" but harsher on lungs – short sessions advised, use glassware, avoid plastics. Intravenous use gives about a 10-minute rush with 1-2 hours of euphoria; the solution is highly caustic even when filtered – vein darkening reported; always dilute at least 1:50 in bacteriostatic saline, use micron filters, rotate sites, and apply warm compresses. Oral capsules (25-40 mg) produce cleaner stimulation with less vascular strain; onset ~15 minutes, plateau 2-3 hours. Because DMNPC blocks voltage-gated Na+ channels similarly to cocaine, cardiac conduction slowing and local anaesthesia (tongue numbness) occur – avoid if predisposed to arrhythmia. Very limited pharmacokinetic data exist; anecdotal ability to sleep 4 hours post-dose suggests a plasma half-life around 2-4 hours, but an active N-desmethyl metabolite may extend SERT occupancy. Reagent-test every batch and fentanyl-screen before any human assay; the compound is newly emergent (first retail listings in late 2024) and spectral mis-identification is plausible. Volumetric liquid dosing (10 mg/mL propylene glycol) helps precise titration for oral or rectal routes while bypassing nasal damage.\",\n-      \"potent sedation\",\n-      \"muscle relaxation\",\n-      \"anxiolysis\",\n-      \"hypnotic sleep promotion\",\n-      \"anterograde amnesia\",\n-      \"ataxia / motor incoordination\",\n-      \"mild euphoria\"\n+      \"warm euphoria\",\n+      \"confident sociability\",\n+      \"moderate psychomotor stimulation\",\n+      \"gentle serotonergic uplift (\\\"fuzzy glow\\\")\",\n+      \"tactile enhancement\",\n+      \"mild local anaesthesia (tongue, nasal)\",\n+      \"pupil dilation\",\n+      \"low peripheral vasoconstriction compared with cocaine\",\n+      \"strong urge to redose as rush fades\"\n-      \"full_tolerance\": \"3-5 consecutive days\",\n-      \"half_tolerance\": \"7-10 days\",\n-      \"zero_tolerance\": \"21-28 days\",\n+      \"full_tolerance\": \"after one heavy binge (100 mg or more)\",\n+      \"half_tolerance\": \"2-3 days\",\n+      \"zero_tolerance\": \"10-14 days\",\n-        \"all classical benzodiazepines\",\n-        \"Z-drugs\",\n-        \"other designer benzos\"\n+        \"cocaine\",\n+        \"methylphenidate\",\n+        \"other SNDRIs\"\n-    \"half_life\": \"12-24 h (plasma) with reports of functional impairment up to 75 h\",\n+    \"half_life\": \"estimated 2-4 h (no formal human PK study)\",\n-        \"name\": \"Metabolites replace the parent drug in the drug arena: fonazepam & nifoxipam\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/28127407/\"\n+        \"name\": \"Journal of Medicinal Chemistry – SAR paper describing DMNPC potency\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/10737754/\"\n-        \"name\": \"BenchChem – Nifoxipam pharmacokinetic summary & dose table\",\n-        \"reference\": \"https://www.benchchem.com/product/b1621971\"\n+        \"name\": \"Wikipedia – compound overview and Ki table\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/N%2CO-Dimethyl-4-(2-naphthyl)piperidine-3-carboxylate\"\n-        \"name\": \"Bluelight Big & Dandy Nifoxipam thread (user dose reports)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/nifoxipam-3-ho-desmethyl-flunitrazepam.743789/\"\n+        \"name\": \"Reddit /r/researchchemicals – 30 mg insufflated user report\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/1hvdjkt/received_a_5g_batch_of_dmnpc/\"\n-        \"name\": \"Novel Designer Benzodiazepines – comprehensive review\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC9397074/\"\n+        \"name\": \"Reddit – 25 mg oral trial discussion\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/1hhk12i/anyone_try_dmnpc_yet/\"\n-        \"name\": \"Analytical & Bioanalytical Chemistry – urinary metabolites of nifoxipam\",\n-        \"reference\": \"https://link.springer.com/article/10.1007/s00216-016-9518-1\"\n+        \"name\": \"Reddit – IV and smoked experience (250 mg binge)\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/1hrwwo3/dmnpc_real_experiencejust_wow/\"\n-        \"name\": \"Headwaters Recovery – harm-reduction overview of nifoxipam\",\n-        \"reference\": \"https://headwatersfl.org/what-is-nifoxipam/\"\n-      },\n-      {\n-        \"name\": \"DrugIntelligenceBulletin – law-enforcement alert\",\n-        \"reference\": \"https://www.drugintelligencebulletin.com/p/nifoxipam-is-the-latest-drug-of-abuse\"\n-      },\n-      {\n-        \"name\": \"Urine LC-HRMS panel for 28 designer benzodiazepines\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC11322785/\"\n-      },\n-      {\n-        \"name\": \"Wikipedia – general chemical data\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Nifoxipam\"\n-      },\n-      {\n-        \"name\": \"Forensic Toxicology 35(1):1-10 – duration quotation\",\n-        \"reference\": \"https://doi.org/10.1007/s11419-016-0338-5\"\n+        \"name\": \"AIPSIN new-substance brief\",\n+        \"reference\": \"https://aipsin.com/newsubstance/1618/\"\n-      \"benzodiazepine\",\n-      \"depressant\",\n-      \"research-chemical\",\n-      \"gabaergic\"\n+      \"stimulant\",\n+      \"research-chemical\"\n\n# Fluorolintane · #466\n\n-  \"id\": 464,\n-  \"title\": \"DMNPC\",\n+  \"id\": 466,\n+  \"title\": \"Fluorolintane\",\n-    \"drug_name\": \"DMNPC\",\n-    \"chemical_name\": \"DMNPC\",\n+    \"drug_name\": \"Fluorolintane\",\n+    \"chemical_name\": \"Fluorolintane\",\n-    \"chemical_class\": \"Piperazines\",\n-    \"mechanism_of_action\": \"Stimulant (uncertain mechanism)\",\n-    \"psychoactive_class\": \"Serotonin-norepinephrine-dopamine re-uptake inhibitor (SNDRI)\",\n+    \"chemical_class\": \"Substituted diarylethylamines\",\n+    \"mechanism_of_action\": \"NMDA receptor antagonist; dopamine reuptake inhibitor\",\n+    \"psychoactive_class\": \"Dissociative; Hallucinogen\",\n-          \"route\": \"oral\",\n+          \"route\": \"oral / sublingual\",\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"5 mg - 15 mg\",\n-            \"common\": \"15 mg - 40 mg\",\n-            \"strong\": \"40 mg - 60 mg\",\n-            \"heavy\": \"60+ mg\"\n+            \"threshold\": \"30mg\",\n+            \"light\": \"30mg - 80mg\",\n+            \"common\": \"80mg - 150mg\",\n+            \"strong\": \"150mg - 250mg\",\n+            \"heavy\": \"250mg+\"\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"5 mg - 15 mg\",\n-            \"common\": \"15 mg - 30 mg\",\n-            \"strong\": \"30 mg - 50 mg\",\n-            \"heavy\": \"50+ mg\"\n+            \"threshold\": \"15mg\",\n+            \"light\": \"15mg - 40mg\",\n+            \"common\": \"40mg - 90mg\",\n+            \"strong\": \"90mg - 150mg\",\n+            \"heavy\": \"150mg+\"\n-          \"route\": \"intravenous\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"2 mg\",\n-            \"light\": \"2 mg - 10 mg\",\n-            \"common\": \"10 mg - 25 mg\",\n-            \"strong\": \"25 mg - 40 mg\",\n-            \"heavy\": \"40+ mg\"\n-          }\n-        },\n-        {\n-          \"route\": \"vaporized / smoked\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"5 mg - 15 mg\",\n-            \"common\": \"15 mg - 35 mg\",\n-            \"strong\": \"35 mg - 60 mg\",\n-            \"heavy\": \"60+ mg\"\n-          }\n-        },\n-        {\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"5 mg - 15 mg\",\n-            \"common\": \"15 mg - 30 mg\",\n-            \"strong\": \"30 mg - 50 mg\",\n-            \"heavy\": \"50+ mg\"\n+            \"threshold\": \"20mg\",\n+            \"light\": \"20mg - 60mg\",\n+            \"common\": \"60mg - 120mg\",\n+            \"strong\": \"120mg - 180mg\",\n+            \"heavy\": \"180mg+\"\n-          \"route\": \"oral\",\n+          \"route\": \"oral / sublingual\",\n-            \"oral\"\n+            \"oral\",\n+            \"sublingual\"\n-            \"total_duration\": \"2-4 h\",\n-            \"onset\": \"15-30 min\",\n-            \"peak\": \"10-45 min\",\n-            \"offset\": \"1-2 h gradual decline\",\n-            \"after_effects\": \"1-6 h residual alertness; gentle serotonergic after-glow or dysphoria depending on dose\"\n+            \"total_duration\": \"4-6 h (active phase)\",\n+            \"onset\": \"20-45 min\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"2-3 h\",\n+            \"after_effects\": \"up to 12 h residual disequilibrium; mild hangover-fatigue\"\n-            \"onset\": \"5-10 min\",\n-            \"peak\": \"10-45 min\",\n-            \"offset\": \"1-2 h gradual decline\",\n-            \"after_effects\": \"1-6 h residual alertness; gentle serotonergic after-glow or dysphoria depending on dose\"\n+            \"total_duration\": \"4-6 h (active phase)\",\n+            \"onset\": \"5-15 min\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"2-3 h\",\n+            \"after_effects\": \"up to 12 h residual disequilibrium; mild hangover-fatigue\"\n-          \"route\": \"intravenous\",\n-          \"canonical_routes\": [\n-            \"intravenous\"\n-          ],\n-          \"stages\": {\n-            \"onset\": \"1-5 min\",\n-            \"peak\": \"10-45 min\",\n-            \"offset\": \"1-2 h gradual decline\",\n-            \"after_effects\": \"1-6 h residual alertness; gentle serotonergic after-glow or dysphoria depending on dose\"\n-          }\n-        },\n-        {\n-          \"route\": \"vaporized / smoked\",\n-          \"canonical_routes\": [\n-            \"vaporized\",\n-            \"smoked\"\n-          ],\n-          \"stages\": {\n-            \"onset\": \"5-10 min\",\n-            \"peak\": \"10-45 min\",\n-            \"offset\": \"1-2 h gradual decline\",\n-            \"after_effects\": \"1-6 h residual alertness; gentle serotonergic after-glow or dysphoria depending on dose\"\n-          }\n-        },\n-        {\n-            \"onset\": \"15-30 min\",\n-            \"peak\": \"10-45 min\",\n-            \"offset\": \"1-2 h gradual decline\",\n-            \"after_effects\": \"1-6 h residual alertness; gentle serotonergic after-glow or dysphoria depending on dose\"\n+            \"total_duration\": \"4-6 h (active phase)\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"2-3 h\",\n+            \"after_effects\": \"up to 12 h residual disequilibrium; mild hangover-fatigue\"\n-    \"addiction_potential\": \"High: cocaine-like reinforcement combined with longer SERT activity encourages compulsive redosing; several users consumed 250 mg or more in a single IV session.\",\n+    \"addiction_potential\": \"Moderate to high: high DAT affinity (Ki ≈ 230 nM) and pronounced euphoria at sub-dissociative doses encourage redosing; users report binges of 500-800 mg/day over several days with pronounced tolerance and crash.\",\n-        \"MAOIs (hypertensive crisis)\",\n-        \"SSRIs, SNRIs, tramadol, MDMA (serotonin syndrome)\",\n-        \"other potent stimulants (hypertension, tachyarrhythmia)\",\n-        \"strong opioids + sedatives (respiratory depression if poly-use leads to somnolence)\"\n+        \"opioids (respiratory depression in deep dissociation)\",\n+        \"benzodiazepines or alcohol (synergistic CNS depression)\",\n+        \"MAOIs\",\n+        \"high-dose stimulants (tachyarrhythmia, hypertensive crisis)\"\n-        \"cocaine or phenyltropanes (cardiotoxic ion-channel blockade)\",\n-        \"bupropion, methylphenidate, cathinones (excess DAT/NAT load)\",\n-        \"5-HT2A psychedelics at high dose (over-activation, vasospasm)\"\n+        \"other dissociatives (ketamine, DXM, DCK)\",\n+        \"serotonergic psychedelics at high doses (hyperthermia, serotonin toxicity)\",\n+        \"tramadol (seizure risk)\"\n-        \"caffeine >300 mg\",\n-        \"heavy nicotine use\",\n-        \"alpha-adrenergic vasoconstrictors (cold medicines)\",\n-        \"any medication prolonging QT (additive risk with SERT blockage)\"\n+        \"SSRI or SNRI antidepressants\",\n+        \"cannabis concentrates (panic, derealisation)\",\n+        \"QT-prolonging antipsychotics\"\n-    \"notes\": \"Binding studies give Ki (3S,4S) ~7.6 nM at SERT, 21 nM at DAT, and 34 nM at NET – roughly 2.5× the DAT potency of cocaine while retaining SSRI-level SERT affinity. Users report pronounced mucosal irritation: dry-rail 25 mg intranasal \\\"burns worse than 80 mg 4F-MPH\\\" and causes prolonged congestion; isotonic saline rinses are recommended. The free base volatilizes easily and can be inhaled from foil, producing a \\\"crack-like bell-ringer\\\" but harsher on lungs – short sessions advised, use glassware, avoid plastics. Intravenous use gives about a 10-minute rush with 1-2 hours of euphoria; the solution is highly caustic even when filtered – vein darkening reported; always dilute at least 1:50 in bacteriostatic saline, use micron filters, rotate sites, and apply warm compresses. Oral capsules (25-40 mg) produce cleaner stimulation with less vascular strain; onset ~15 minutes, plateau 2-3 hours. Because DMNPC blocks voltage-gated Na+ channels similarly to cocaine, cardiac conduction slowing and local anaesthesia (tongue numbness) occur – avoid if predisposed to arrhythmia. Very limited pharmacokinetic data exist; anecdotal ability to sleep 4 hours post-dose suggests a plasma half-life around 2-4 hours, but an active N-desmethyl metabolite may extend SERT occupancy. Reagent-test every batch and fentanyl-screen before any human assay; the compound is newly emergent (first retail listings in late 2024) and spectral mis-identification is plausible. Volumetric liquid dosing (10 mg/mL propylene glycol) helps precise titration for oral or rectal routes while bypassing nasal damage.\",\n+    \"notes\": \"In vitro data show high NMDA antagonism (Ki ≈ 88 nM) but even stronger dopamine and norepinephrine transporter blockade, explaining the stimulant–euphoriant character at light doses. ED50 for sensorimotor-gating disruption in rats is 13.3 mg·kg⁻¹ i.p., close to recreational human doses. Subjective duration is shorter (≈ 4 h) than diphenidine but markedly more compulsive. Forum users stress volumetric dosing due to clumpy hygroscopic crystals, aggressive nasal burn, and a steep dose-response above 150 mg. Acute side-effects include tachycardia (110-140 bpm), hypertension (>160 mmHg systolic), nystagmus, and delayed urinary retention similar to other diarylethylamines. No human pharmacokinetic study is published; analog modelling and rat microsome data suggest an elimination half-life of 4-8 h with active hydroxylated metabolites. Because 2-F-DPPy is unscheduled in many regions, street samples are frequently cut with ephenidine or MXPr—multi-reagent screening and, ideally, GC-MS confirmation are advised. Harm-reduction best practice: cap sessions at <250 mg oral per 24 h, maintain 10-day washouts to reset tolerance, hydrate aggressively, and avoid operating machinery for 12 h post-use.\",\n-      \"confident sociability\",\n-      \"moderate psychomotor stimulation\",\n-      \"gentle serotonergic uplift (\\\"fuzzy glow\\\")\",\n-      \"tactile enhancement\",\n-      \"mild local anaesthesia (tongue, nasal)\",\n-      \"pupil dilation\",\n-      \"low peripheral vasoconstriction compared with cocaine\",\n-      \"strong urge to redose as rush fades\"\n+      \"mild stimulation progressing to dissociation\",\n+      \"time dilation\",\n+      \"floaty body-lightness\",\n+      \"closed-eye geometric visuals\",\n+      \"stuttering thought loops\",\n+      \"after-glow dysphoria or emptiness\"\n-      \"full_tolerance\": \"after one heavy binge (100 mg or more)\",\n-      \"half_tolerance\": \"2-3 days\",\n+      \"full_tolerance\": \"after one heavy session\",\n+      \"half_tolerance\": \"3-4 days\",\n-        \"cocaine\",\n-        \"methylphenidate\",\n-        \"other SNDRIs\"\n+        \"diphenidine\",\n+        \"ephenidine\",\n+        \"other diarylethylamines\"\n-    \"half_life\": \"estimated 2-4 h (no formal human PK study)\",\n+    \"half_life\": \"~4-8 h (estimated from rat liver microsome data; human value unknown)\",\n-        \"name\": \"Journal of Medicinal Chemistry – SAR paper describing DMNPC potency\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/10737754/\"\n+        \"name\": \"Pharmacological characterizations of the ‘legal high’ fluorolintane and isomers\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/31152702/\"\n-        \"name\": \"Wikipedia – compound overview and Ki table\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/N%2CO-Dimethyl-4-(2-naphthyl)piperidine-3-carboxylate\"\n+        \"name\": \"Bluelight – Novel dissociative (?) Fluorolintane (user dosage reports)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/novel-dissociative-fluorolintane.757664/\"\n-        \"name\": \"Reddit /r/researchchemicals – 30 mg insufflated user report\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/1hvdjkt/received_a_5g_batch_of_dmnpc/\"\n+        \"name\": \"ACMD review of diphenidine & related analogues (includes fluorolintane)\",\n+        \"reference\": \"https://www.gov.uk/government/publications/acmd-review-of-the-evidence-on-the-use-and-harms-of-diphenidine\"\n-        \"name\": \"Reddit – 25 mg oral trial discussion\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/1hhk12i/anyone_try_dmnpc_yet/\"\n+        \"name\": \"Cayman Chemical product sheet (analytical reference standard)\",\n+        \"reference\": \"https://cdn.caymanchem.com/cdn/seawolf/insert/19299.pdf\"\n-        \"name\": \"Reddit – IV and smoked experience (250 mg binge)\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/1hrwwo3/dmnpc_real_experiencejust_wow/\"\n+        \"name\": \"UNODC NPS Technical Update 2024 – diarylethylamine section\",\n+        \"reference\": \"https://www.unodc.org/documents/scientific/The_Challenge_of_NPS_A_technical_update_2024.pdf\"\n-        \"name\": \"AIPSIN new-substance brief\",\n-        \"reference\": \"https://aipsin.com/newsubstance/1618/\"\n+        \"name\": \"Syntheses and analytical characterizations of fluorolintane and isomers\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/31033229/\"\n+      },\n+      {\n+        \"name\": \"EMCDDA NPS monitoring – diarylethylamines overview\",\n+        \"reference\": \"https://www.emcdda.europa.eu/publications/technical-reports/diarylethylamines_en\"\n+      },\n+      {\n+        \"name\": \"Safety Data Sheet – Fluorolintane HCl (Cayman, 2025)\",\n+        \"reference\": \"https://cdn.caymanchem.com/cdn/seawolf/msds/19299m.pdf\"\n+      },\n+      {\n+        \"name\": \"Wikipedia – Fluorolintane (legal status, identifiers)\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Fluorolintane\"\n+      },\n+      {\n+        \"name\": \"Review: 1,2-Diarylethylamine and Ketamine-based NPS\",\n+        \"reference\": \"https://www.researchgate.net/publication/327532956\"\n+      },\n+      {\n+        \"name\": \"Cayman Chemical: Fluorolintane (hydrochloride)\",\n+        \"reference\": \"https://www.caymanchem.com/product/19299/fluorolintane-%28hydrochloride%29\"\n-      \"stimulant\",\n+      \"dissociative\",\n\n# Halodrol-50 · #447\n\n-  \"id\": 466,\n-  \"title\": \"Fluorolintane\",\n+  \"id\": 447,\n+  \"title\": \"Halodrol-50\",\n-    \"drug_name\": \"Fluorolintane\",\n-    \"chemical_name\": \"Fluorolintane\",\n-    \"alternative_name\": \"\",\n-    \"chemical_class\": \"Substituted diarylethylamines\",\n-    \"mechanism_of_action\": \"NMDA receptor antagonist; dopamine reuptake inhibitor\",\n-    \"psychoactive_class\": \"Dissociative; Hallucinogen\",\n+    \"drug_name\": \"Halodrol-50\",\n+    \"chemical_name\": \"Chlorodehydromethylandrostenediol\",\n+    \"alternative_name\": \"Halodrol\",\n+    \"chemical_class\": \"17α-alkylated anabolic-androgenic steroid; testosterone derivative\",\n+    \"mechanism_of_action\": \"Androgen receptor agonist\",\n+    \"psychoactive_class\": \"Androgen-receptor agonist (AAS)\",\n-          \"route\": \"oral / sublingual\",\n+          \"route\": \"oral\",\n-            \"threshold\": \"30mg\",\n-            \"light\": \"30mg - 80mg\",\n-            \"common\": \"80mg - 150mg\",\n-            \"strong\": \"150mg - 250mg\",\n-            \"heavy\": \"250mg+\"\n+            \"threshold\": \"10mg\",\n+            \"light\": \"10mg - 25mg\",\n+            \"common\": \"25mg - 50mg\",\n+            \"strong\": \"50mg - 75mg\",\n+            \"heavy\": \"75mg+\"\n-        },\n-        {\n-          \"route\": \"insufflated\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"15mg\",\n-            \"light\": \"15mg - 40mg\",\n-            \"common\": \"40mg - 90mg\",\n-            \"strong\": \"90mg - 150mg\",\n-            \"heavy\": \"150mg+\"\n-          }\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"20mg\",\n-            \"light\": \"20mg - 60mg\",\n-            \"common\": \"60mg - 120mg\",\n-            \"strong\": \"120mg - 180mg\",\n-            \"heavy\": \"180mg+\"\n-          }\n-          \"route\": \"oral / sublingual\",\n+          \"route\": \"oral\",\n-            \"oral\",\n-            \"sublingual\"\n+            \"oral\"\n-            \"total_duration\": \"4-6 h (active phase)\",\n-            \"onset\": \"20-45 min\",\n-            \"peak\": \"1-2 h\",\n-            \"offset\": \"2-3 h\",\n-            \"after_effects\": \"up to 12 h residual disequilibrium; mild hangover-fatigue\"\n+            \"total_duration\": \"4-8 weeks per cycle (daily dosing)\",\n+            \"onset\": \"3-7 days to noticeable strength / pump\",\n+            \"peak\": \"2-4 weeks into cycle\",\n+            \"offset\": \"1-2 weeks after last dose (residual androgenic effects)\",\n+            \"after_effects\": \"2-6 weeks endocrine rebound; lipid disruption; mood lability\"\n-        },\n-        {\n-          \"route\": \"insufflated\",\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"4-6 h (active phase)\",\n-            \"onset\": \"5-15 min\",\n-            \"peak\": \"1-2 h\",\n-            \"offset\": \"2-3 h\",\n-            \"after_effects\": \"up to 12 h residual disequilibrium; mild hangover-fatigue\"\n-          }\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"canonical_routes\": [\n-            \"rectal\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"4-6 h (active phase)\",\n-            \"peak\": \"1-2 h\",\n-            \"offset\": \"2-3 h\",\n-            \"after_effects\": \"up to 12 h residual disequilibrium; mild hangover-fatigue\"\n-          }\n-    \"addiction_potential\": \"Moderate to high: high DAT affinity (Ki ≈ 230 nM) and pronounced euphoria at sub-dissociative doses encourage redosing; users report binges of 500-800 mg/day over several days with pronounced tolerance and crash.\",\n+    \"addiction_potential\": \"Low physiological, moderate psychological: compulsive redosing driven by body-image reinforcement and mild mood lift.\",\n-        \"opioids (respiratory depression in deep dissociation)\",\n-        \"benzodiazepines or alcohol (synergistic CNS depression)\",\n-        \"MAOIs\",\n-        \"high-dose stimulants (tachyarrhythmia, hypertensive crisis)\"\n+        \"excessive alcohol (synergistic hepatotoxicity)\",\n+        \"acetaminophen >2g/day\",\n+        \"other 17α-alkylated oral steroids (Superdrol, M-Sten, etc.)\",\n+        \"isotretinoin or high-dose vitamin A\",\n+        \"statins (added liver strain)\"\n-        \"other dissociatives (ketamine, DXM, DCK)\",\n-        \"serotonergic psychedelics at high doses (hyperthermia, serotonin toxicity)\",\n-        \"tramadol (seizure risk)\"\n+        \"strong stimulants or MAO-B inhibitors (BP, tachyarrhythmia)\",\n+        \"CYP3A4 inhibitors (ketoconazole, grapefruit) → higher plasma levels\",\n+        \"oral contraceptives containing ethinyl estradiol (cholestasis risk)\"\n-        \"SSRI or SNRI antidepressants\",\n-        \"cannabis concentrates (panic, derealisation)\",\n-        \"QT-prolonging antipsychotics\"\n+        \"NSAIDs (GI + hepatic burden)\",\n+        \"caffeine >400 mg (BP, insomnia)\",\n+        \"creatine (back pumps exacerbation)\"\n-    \"notes\": \"In vitro data show high NMDA antagonism (Ki ≈ 88 nM) but even stronger dopamine and norepinephrine transporter blockade, explaining the stimulant–euphoriant character at light doses. ED50 for sensorimotor-gating disruption in rats is 13.3 mg·kg⁻¹ i.p., close to recreational human doses. Subjective duration is shorter (≈ 4 h) than diphenidine but markedly more compulsive. Forum users stress volumetric dosing due to clumpy hygroscopic crystals, aggressive nasal burn, and a steep dose-response above 150 mg. Acute side-effects include tachycardia (110-140 bpm), hypertension (>160 mmHg systolic), nystagmus, and delayed urinary retention similar to other diarylethylamines. No human pharmacokinetic study is published; analog modelling and rat microsome data suggest an elimination half-life of 4-8 h with active hydroxylated metabolites. Because 2-F-DPPy is unscheduled in many regions, street samples are frequently cut with ephenidine or MXPr—multi-reagent screening and, ideally, GC-MS confirmation are advised. Harm-reduction best practice: cap sessions at <250 mg oral per 24 h, maintain 10-day washouts to reset tolerance, hydrate aggressively, and avoid operating machinery for 12 h post-use.\",\n+    \"notes\": \"Halodrol is a non-aromatizing Turinabol analogue that produces ‘dry’, lean gains with comparatively low water retention. It is 17α-methylated, so pre-cycle, mid-cycle, and post-cycle liver panels (ALT, AST, GGT, bilirubin) are mandatory. Daily intake of 500-1000 mg NAC or 250-500 mg TUDCA is routinely recommended on forums. Blood pressure and a full lipid panel should be checked; HDL often drops 30-40% and LDL rises markedly. Because endogenous testosterone is suppressed within days, a SERM-based PCT (e.g., tamoxifen 40/40/20/20 mg) plus an over-the-counter liver and lipid stack is advised. Even though gyno is rare (no aromatase), users report occasional progesterone-like nipple sensitivity—keep a low-dose AI or cabergoline on hand. Lower-back ‘pump’ and shin splints respond to taurine (3-5 g) and hydration. Splitting the daily dose (a.m./p.m.) or using even-spaced micro-capsules can flatten hormone spikes and reduce insomnia and irritability. Never exceed 8 weeks or 75 mg/day without medical supervision; cases of severe cholestatic jaundice and peliosis hepatis have been documented after OTC clones containing Halodrol.\",\n-      \"warm euphoria\",\n-      \"mild stimulation progressing to dissociation\",\n-      \"time dilation\",\n-      \"floaty body-lightness\",\n-      \"closed-eye geometric visuals\",\n-      \"stuttering thought loops\",\n-      \"after-glow dysphoria or emptiness\"\n+      \"rapid strength increase\",\n+      \"vascularity and muscle hardness\",\n+      \"elevated aggression/drive\",\n+      \"lower-back and calf pumps\",\n+      \"mild acne/oily skin\",\n+      \"possible insomnia\",\n+      \"suppressed endogenous libido toward cycle end\"\n-      \"full_tolerance\": \"after one heavy session\",\n-      \"half_tolerance\": \"3-4 days\",\n-      \"zero_tolerance\": \"10-14 days\",\n+      \"full_tolerance\": \"after 4-6 weeks continuous use\",\n+      \"half_tolerance\": \"≈2 weeks\",\n+      \"zero_tolerance\": \"8-12 weeks off-cycle\",\n-        \"diphenidine\",\n-        \"ephenidine\",\n-        \"other diarylethylamines\"\n+        \"other oral testosterone-based AAS\",\n+        \"chlorodehydromethyltestosterone (Turinabol)\"\n-    \"half_life\": \"~4-8 h (estimated from rat liver microsome data; human value unknown)\",\n+    \"half_life\": \"12-16 h (split dosing optional)\",\n-        \"name\": \"Pharmacological characterizations of the ‘legal high’ fluorolintane and isomers\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/31152702/\"\n+        \"name\": \"Wikipedia – chemistry and history\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Chlorodehydromethylandrostenediol\"\n-        \"name\": \"Bluelight – Novel dissociative (?) Fluorolintane (user dosage reports)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/novel-dissociative-fluorolintane.757664/\"\n+        \"name\": \"The Washington Post – Halodrol OTC scandal\",\n+        \"reference\": \"https://www.washingtonpost.com/archive/sports/2005/11/30/steroids-detected-in-dietary-tablets/938990b4-5956-48a5-8804-7f5ae6d561e3/\"\n-        \"name\": \"ACMD review of diphenidine & related analogues (includes fluorolintane)\",\n-        \"reference\": \"https://www.gov.uk/government/publications/acmd-review-of-the-evidence-on-the-use-and-harms-of-diphenidine\"\n+        \"name\": \"AnabolicMinds dosing guide (50-75 mg common, half-life 12-16 h)\",\n+        \"reference\": \"https://anabolicminds.com/community/threads/dosing-guide-for-popular-ph-ds.277121/\"\n-        \"name\": \"Cayman Chemical product sheet (analytical reference standard)\",\n-        \"reference\": \"https://cdn.caymanchem.com/cdn/seawolf/insert/19299.pdf\"\n+        \"name\": \"Evolutionary.org profile – half-life 16 h, liver toxicity discussion\",\n+        \"reference\": \"https://www.evolutionary.org/halodrol/\"\n-        \"name\": \"UNODC NPS Technical Update 2024 – diarylethylamine section\",\n-        \"reference\": \"https://www.unodc.org/documents/scientific/The_Challenge_of_NPS_A_technical_update_2024.pdf\"\n+        \"name\": \"AnabolicMinds forum – user half-life debate and split dosing\",\n+        \"reference\": \"https://anabolicminds.com/community/threads/half-life-of-halodrol.54802/\"\n-        \"name\": \"Syntheses and analytical characterizations of fluorolintane and isomers\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/31033229/\"\n+        \"name\": \"Halodrol thoughts – anecdotal 50-75 mg/day cycles\",\n+        \"reference\": \"https://www.reddit.com/r/PEDs/comments/ee6bil/halodrol_thoughts_and_opinions/\"\n-        \"name\": \"EMCDDA NPS monitoring – diarylethylamines overview\",\n-        \"reference\": \"https://www.emcdda.europa.eu/publications/technical-reports/diarylethylamines_en\"\n+        \"name\": \"Case series: hepatotoxicity with anabolic-steroid supplements\",\n+        \"reference\": \"https://www.cghjournal.org/article/S1542-3565(07)00228-5/pdf\"\n-        \"name\": \"Safety Data Sheet – Fluorolintane HCl (Cayman, 2025)\",\n-        \"reference\": \"https://cdn.caymanchem.com/cdn/seawolf/msds/19299m.pdf\"\n+        \"name\": \"Annals of Clinical Case Reports – liver injury after OTC AAS (includes Halodrol-50)\",\n+        \"reference\": \"https://www.anncaserep.com/open-access/hepatotoxicity-associated-with-nutritional-supplements-containing-anabolic-steroids-4388.pdf\"\n-        \"name\": \"Wikipedia – Fluorolintane (legal status, identifiers)\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Fluorolintane\"\n+        \"name\": \"LiverTox – Androgenic Steroids overview\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/books/NBK548931/\"\n-        \"name\": \"Review: 1,2-Diarylethylamine and Ketamine-based NPS\",\n-        \"reference\": \"https://www.researchgate.net/publication/327532956\"\n+        \"name\": \"WebMD Fast Facts – Halodrol side-effects\",\n+        \"reference\": \"https://www.webmd.com/vitamins/ai/ingredientmono-1660/halodrol-50-%5Bfast-facts%5D\"\n-        \"name\": \"Cayman Chemical: Fluorolintane (hydrochloride)\",\n-        \"reference\": \"https://www.caymanchem.com/product/19299/fluorolintane-%28hydrochloride%29\"\n+        \"name\": \"International Journal of Sports & Exercise Medicine – HDL/LDL disruption with AAS\",\n+        \"reference\": \"https://clinmedjournals.org/articles/ijsem/international-journal-of-sports-and-exercise-medicine-ijsem-4-109.php\"\n+      },\n+      {\n+        \"name\": \"Bluelight discussion (sample cycle 50 mg/day Halodrol)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/clomid-side-effects.460790/\"\n-      \"dissociative\",\n+      \"anabolic-steroid\",\n\n# 4-Bromomethcathinone · #467\n\n-  \"id\": 447,\n-  \"title\": \"Halodrol-50\",\n+  \"id\": 467,\n+  \"title\": \"4-Bromomethcathinone\",\n-    \"drug_name\": \"Halodrol-50\",\n-    \"chemical_name\": \"Chlorodehydromethylandrostenediol\",\n-    \"alternative_name\": \"Halodrol\",\n-    \"chemical_class\": \"17α-alkylated anabolic-androgenic steroid; testosterone derivative\",\n-    \"mechanism_of_action\": \"Androgen receptor agonist\",\n-    \"psychoactive_class\": \"Androgen-receptor agonist (AAS)\",\n+    \"drug_name\": \"4-Bromomethcathinone\",\n+    \"chemical_name\": \"4-Bromomethcathinone\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Cathinones\",\n+    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor\",\n+    \"psychoactive_class\": \"serotonin–norepinephrine reuptake inhibitor\",\n-            \"threshold\": \"10mg\",\n-            \"light\": \"10mg - 25mg\",\n-            \"common\": \"25mg - 50mg\",\n-            \"strong\": \"50mg - 75mg\",\n-            \"heavy\": \"75mg+\"\n+            \"threshold\": \"~20mg\",\n+            \"light\": \"20mg - 50mg\",\n+            \"common\": \"50mg - 100mg\",\n+            \"strong\": \"100mg - 150mg\",\n+            \"heavy\": \"150+mg\"\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"20mg\",\n+            \"light\": \"20mg - 75mg\",\n+            \"common\": \"75mg - 150mg\",\n+            \"strong\": \"150mg - 200mg\",\n+            \"heavy\": \"200+mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"~20mg\",\n+            \"light\": \"20mg - 60mg\",\n+            \"common\": \"60mg - 120mg\",\n+            \"strong\": \"120mg - 150mg\",\n+            \"heavy\": \"150+mg\"\n+          }\n-            \"total_duration\": \"4-8 weeks per cycle (daily dosing)\",\n-            \"onset\": \"3-7 days to noticeable strength / pump\",\n-            \"peak\": \"2-4 weeks into cycle\",\n-            \"offset\": \"1-2 weeks after last dose (residual androgenic effects)\",\n-            \"after_effects\": \"2-6 weeks endocrine rebound; lipid disruption; mood lability\"\n+            \"total_duration\": \"2-4 h\",\n+            \"onset\": \"30-60 min\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"1-3 h mild comedown\"\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"canonical_routes\": [\n+            \"rectal\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"2-4 h\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"1-3 h mild comedown\"\n+          }\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"2-4 h\",\n+            \"onset\": \"10-30 min\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"1-3 h mild comedown\"\n+          }\n-    \"addiction_potential\": \"Low physiological, moderate psychological: compulsive redosing driven by body-image reinforcement and mild mood lift.\",\n+    \"addiction_potential\": \"Moderate: compulsive redosing reported, but somewhat milder stimulant profile than mephedrone\",\n-        \"excessive alcohol (synergistic hepatotoxicity)\",\n-        \"acetaminophen >2g/day\",\n-        \"other 17α-alkylated oral steroids (Superdrol, M-Sten, etc.)\",\n-        \"isotretinoin or high-dose vitamin A\",\n-        \"statins (added liver strain)\"\n+        \"other stimulants (risk of hypertension, tachycardia)\",\n+        \"MAOIs (risk of serotonin syndrome)\",\n+        \"antidepressants affecting serotonin\"\n-        \"strong stimulants or MAO-B inhibitors (BP, tachyarrhythmia)\",\n-        \"CYP3A4 inhibitors (ketoconazole, grapefruit) → higher plasma levels\",\n-        \"oral contraceptives containing ethinyl estradiol (cholestasis risk)\"\n+        \"amphetamines\",\n+        \"cocaine\",\n+        \"MDMA\"\n-        \"NSAIDs (GI + hepatic burden)\",\n-        \"caffeine >400 mg (BP, insomnia)\",\n-        \"creatine (back pumps exacerbation)\"\n+        \"benzodiazepines (mask stimulant effects)\",\n+        \"alcohol (dehydration, strain)\"\n-    \"notes\": \"Halodrol is a non-aromatizing Turinabol analogue that produces ‘dry’, lean gains with comparatively low water retention. It is 17α-methylated, so pre-cycle, mid-cycle, and post-cycle liver panels (ALT, AST, GGT, bilirubin) are mandatory. Daily intake of 500-1000 mg NAC or 250-500 mg TUDCA is routinely recommended on forums. Blood pressure and a full lipid panel should be checked; HDL often drops 30-40% and LDL rises markedly. Because endogenous testosterone is suppressed within days, a SERM-based PCT (e.g., tamoxifen 40/40/20/20 mg) plus an over-the-counter liver and lipid stack is advised. Even though gyno is rare (no aromatase), users report occasional progesterone-like nipple sensitivity—keep a low-dose AI or cabergoline on hand. Lower-back ‘pump’ and shin splints respond to taurine (3-5 g) and hydration. Splitting the daily dose (a.m./p.m.) or using even-spaced micro-capsules can flatten hormone spikes and reduce insomnia and irritability. Never exceed 8 weeks or 75 mg/day without medical supervision; cases of severe cholestatic jaundice and peliosis hepatis have been documented after OTC clones containing Halodrol.\",\n+    \"notes\": \"4-Bromomethcathinone (4-BMC; brephedrone) is a brominated analog of methcathinone acting primarily as a serotonin and norepinephrine reuptake inhibitor, with reports describing a calmer, more antidepressant-like effect compared to typical stimulants. Laboratory studies consistently place 4‑BMC among serotonin‑preferring transport‑blockers with measurable but lower dopaminergic activity, explaining its reputation for mild entactogenic rather than stimulating effects. Forum reports indicate that oral threshold is around 20mg, producing weak stimulation, while doses over 100mg (plugged or insufflated) can produce 'calm euphoria' comparable to a clean roll. Rectal use at around 150mg produced strong but relatively short-lasting euphoria, with users noting a short duration and strong desire to redose. Animal and in vitro data confirm potent inhibition of serotonin uptake—approximately 15-fold more effective than methcathinone at SERT—with notable neurotoxic and cytotoxic potential common to halogenated cathinones. Toxicity concerns include tachycardia, hypertension, agitation, and sweating (based on analog data), as well as potential oxidative neurotoxicity. Harm reduction: start low (≤20mg), dose slowly with long wait times, stay hydrated, avoid mixing stimulant substances or MAOIs, and use reagent testing to verify compound identity due to common adulteration. Prolonged or high-dose use may lead to dependence and cardiovascular stress.\",\n-      \"rapid strength increase\",\n-      \"vascularity and muscle hardness\",\n-      \"elevated aggression/drive\",\n-      \"lower-back and calf pumps\",\n-      \"mild acne/oily skin\",\n-      \"possible insomnia\",\n-      \"suppressed endogenous libido toward cycle end\"\n+      \"mild to moderate euphoria\",\n+      \"calm stimulation\",\n+      \"empathogenic/antidepressant feel\",\n+      \"increased sociability\",\n+      \"sweating\",\n+      \"short duration with desire to redose\"\n-      \"full_tolerance\": \"after 4-6 weeks continuous use\",\n-      \"half_tolerance\": \"≈2 weeks\",\n-      \"zero_tolerance\": \"8-12 weeks off-cycle\",\n+      \"full_tolerance\": \"after one session\",\n+      \"half_tolerance\": \"2-4 days\",\n+      \"zero_tolerance\": \"7-10 days\",\n-        \"other oral testosterone-based AAS\",\n-        \"chlorodehydromethyltestosterone (Turinabol)\"\n+        \"other cathinones\",\n+        \"amphetamines\"\n-    \"half_life\": \"12-16 h (split dosing optional)\",\n+    \"half_life\": \"estimated 3-6 h\",\n-        \"name\": \"Wikipedia – chemistry and history\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Chlorodehydromethylandrostenediol\"\n+        \"name\": \"Wikipedia – 4‑Bromomethcathinone\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/4-Bromomethcathinone\"\n-        \"name\": \"The Washington Post – Halodrol OTC scandal\",\n-        \"reference\": \"https://www.washingtonpost.com/archive/sports/2005/11/30/steroids-detected-in-dietary-tablets/938990b4-5956-48a5-8804-7f5ae6d561e3/\"\n+        \"name\": \"Drugs‑Forum anecdotal report\",\n+        \"reference\": \"https://drugs-forum.com/threads/4-bromomethcathinone-4-bmc-experiences.161321/\"\n-        \"name\": \"AnabolicMinds dosing guide (50-75 mg common, half-life 12-16 h)\",\n-        \"reference\": \"https://anabolicminds.com/community/threads/dosing-guide-for-popular-ph-ds.277121/\"\n+        \"name\": \"MDPI Brain Sciences – review of halogenated cathinones\",\n+        \"reference\": \"https://doi.org/10.3390/brainsci14040334\"\n-        \"name\": \"Evolutionary.org profile – half-life 16 h, liver toxicity discussion\",\n-        \"reference\": \"https://www.evolutionary.org/halodrol/\"\n+        \"name\": \"Alcohol and Drug Foundation – synthetic cathinones\",\n+        \"reference\": \"https://adf.org.au/drug-facts/synthetic-cathinones/\"\n-        \"name\": \"AnabolicMinds forum – user half-life debate and split dosing\",\n-        \"reference\": \"https://anabolicminds.com/community/threads/half-life-of-halodrol.54802/\"\n-      },\n-      {\n-        \"name\": \"Halodrol thoughts – anecdotal 50-75 mg/day cycles\",\n-        \"reference\": \"https://www.reddit.com/r/PEDs/comments/ee6bil/halodrol_thoughts_and_opinions/\"\n-      },\n-      {\n-        \"name\": \"Case series: hepatotoxicity with anabolic-steroid supplements\",\n-        \"reference\": \"https://www.cghjournal.org/article/S1542-3565(07)00228-5/pdf\"\n-      },\n-      {\n-        \"name\": \"Annals of Clinical Case Reports – liver injury after OTC AAS (includes Halodrol-50)\",\n-        \"reference\": \"https://www.anncaserep.com/open-access/hepatotoxicity-associated-with-nutritional-supplements-containing-anabolic-steroids-4388.pdf\"\n-      },\n-      {\n-        \"name\": \"LiverTox – Androgenic Steroids overview\",\n-        \"reference\": \"https://www.ncbi.nlm.nih.gov/books/NBK548931/\"\n-      },\n-      {\n-        \"name\": \"WebMD Fast Facts – Halodrol side-effects\",\n-        \"reference\": \"https://www.webmd.com/vitamins/ai/ingredientmono-1660/halodrol-50-%5Bfast-facts%5D\"\n-      },\n-      {\n-        \"name\": \"International Journal of Sports & Exercise Medicine – HDL/LDL disruption with AAS\",\n-        \"reference\": \"https://clinmedjournals.org/articles/ijsem/international-journal-of-sports-and-exercise-medicine-ijsem-4-109.php\"\n-      },\n-      {\n-        \"name\": \"Bluelight discussion (sample cycle 50 mg/day Halodrol)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/clomid-side-effects.460790/\"\n+        \"name\": \"Patterns of use & toxicity of para‑halogenated cathinones\",\n+        \"reference\": \"https://onlinelibrary.wiley.com/doi/full/10.1002/hup.2621\"\n-      \"anabolic-steroid\",\n+      \"stimulant\",\n\n# Phenylpiracetam · #470\n\n-  \"id\": 467,\n-  \"title\": \"4-Bromomethcathinone\",\n+  \"id\": 470,\n+  \"title\": \"Phenylpiracetam\",\n-    \"drug_name\": \"4-Bromomethcathinone\",\n-    \"chemical_name\": \"4-Bromomethcathinone\",\n+    \"drug_name\": \"Phenylpiracetam\",\n+    \"chemical_name\": \"Phenylpiracetam\",\n-    \"chemical_class\": \"Cathinones\",\n-    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor\",\n-    \"psychoactive_class\": \"serotonin–norepinephrine reuptake inhibitor\",\n+    \"chemical_class\": \"Racetams\",\n+    \"mechanism_of_action\": \"AMPA receptor positive allosteric modulator\",\n+    \"psychoactive_class\": \"Stimulant nootropic; atypical dopamine/noradrenaline re-uptake inhibitor; nicotinic modulator\",\n-          \"route\": \"oral\",\n+          \"route\": \"oral (capsule or powder)\",\n-            \"threshold\": \"~20mg\",\n-            \"light\": \"20mg - 50mg\",\n-            \"common\": \"50mg - 100mg\",\n-            \"strong\": \"100mg - 150mg\",\n-            \"heavy\": \"150+mg\"\n+            \"threshold\": \"25mg\",\n+            \"light\": \"25mg - 75mg\",\n+            \"common\": \"75mg - 200mg\",\n+            \"strong\": \"200mg - 400mg\",\n+            \"heavy\": \"400+ mg\"\n-          \"route\": \"rectal\",\n+          \"route\": \"sublingual\",\n-            \"light\": \"20mg - 75mg\",\n-            \"common\": \"75mg - 150mg\",\n-            \"strong\": \"150mg - 200mg\",\n-            \"heavy\": \"200+mg\"\n+            \"light\": \"20mg - 50mg\",\n+            \"common\": \"50mg - 150mg\",\n+            \"strong\": \"150mg - 300mg\",\n+            \"heavy\": \"300+ mg\"\n-            \"threshold\": \"~20mg\",\n-            \"light\": \"20mg - 60mg\",\n-            \"common\": \"60mg - 120mg\",\n-            \"strong\": \"120mg - 150mg\",\n-            \"heavy\": \"150+mg\"\n+            \"threshold\": \"10mg\",\n+            \"light\": \"10mg - 25mg\",\n+            \"common\": \"25mg - 75mg\",\n+            \"strong\": \"75mg - 150mg\",\n+            \"heavy\": \"150+ mg\"\n-          \"route\": \"oral\",\n+          \"route\": \"oral (capsule or powder)\",\n-            \"total_duration\": \"2-4 h\",\n-            \"onset\": \"30-60 min\",\n-            \"peak\": \"1-2 h\",\n+            \"total_duration\": \"4-6 h (active phase)\",\n+            \"onset\": \"20-40 min\",\n+            \"peak\": \"1-3 h\",\n-            \"after_effects\": \"1-3 h mild comedown\"\n+            \"after_effects\": \"2-6 h residual stimulation / possible insomnia\"\n-          \"route\": \"rectal\",\n+          \"route\": \"sublingual\",\n-            \"rectal\"\n+            \"sublingual\"\n-            \"total_duration\": \"2-4 h\",\n-            \"peak\": \"1-2 h\",\n+            \"total_duration\": \"4-6 h (active phase)\",\n+            \"onset\": \"5-15 min\",\n+            \"peak\": \"1-3 h\",\n-            \"after_effects\": \"1-3 h mild comedown\"\n+            \"after_effects\": \"2-6 h residual stimulation / possible insomnia\"\n-            \"total_duration\": \"2-4 h\",\n-            \"onset\": \"10-30 min\",\n-            \"peak\": \"1-2 h\",\n+            \"total_duration\": \"4-6 h (active phase)\",\n+            \"onset\": \"5-15 min\",\n+            \"peak\": \"1-3 h\",\n-            \"after_effects\": \"1-3 h mild comedown\"\n+            \"after_effects\": \"2-6 h residual stimulation / possible insomnia\"\n-    \"addiction_potential\": \"Moderate: compulsive redosing reported, but somewhat milder stimulant profile than mephedrone\",\n+    \"addiction_potential\": \"Low-to-moderate: little euphoria but rapid pharmacodynamic tolerance (often within 2-3 consecutive days) can drive redosing; some users escalate to 400-600 mg/day.\",\n-        \"other stimulants (risk of hypertension, tachycardia)\",\n-        \"MAOIs (risk of serotonin syndrome)\",\n-        \"antidepressants affecting serotonin\"\n+        \"MAOI antidepressants (hypertensive crisis)\",\n+        \"strong sympathomimetic stimulants (amphetamine, ephedrine, methylphenidate)\",\n+        \"high-dose bupropion or other DAT/NRI agents (tachycardia, BP spikes)\"\n-        \"amphetamines\",\n-        \"cocaine\",\n-        \"MDMA\"\n+        \"excessive caffeine (>400 mg)\",\n+        \"phenibut, GHB or heavy alcohol (masking intoxication, rebound anxiety)\",\n+        \"dopaminergic Parkinson’s meds (additive stimulation)\"\n-        \"benzodiazepines (mask stimulant effects)\",\n-        \"alcohol (dehydration, strain)\"\n+        \"SSRI / SNRI antidepressants (anecdotal blunting of effects)\",\n+        \"benzodiazepines (may nullify stimulation → accidental redose)\",\n+        \"kratom or opioids (confused sedation–stimulation cycle)\",\n+        \"other racetams (cross-tolerance, cholinergic depletion)\"\n-    \"notes\": \"4-Bromomethcathinone (4-BMC; brephedrone) is a brominated analog of methcathinone acting primarily as a serotonin and norepinephrine reuptake inhibitor, with reports describing a calmer, more antidepressant-like effect compared to typical stimulants. Laboratory studies consistently place 4‑BMC among serotonin‑preferring transport‑blockers with measurable but lower dopaminergic activity, explaining its reputation for mild entactogenic rather than stimulating effects. Forum reports indicate that oral threshold is around 20mg, producing weak stimulation, while doses over 100mg (plugged or insufflated) can produce 'calm euphoria' comparable to a clean roll. Rectal use at around 150mg produced strong but relatively short-lasting euphoria, with users noting a short duration and strong desire to redose. Animal and in vitro data confirm potent inhibition of serotonin uptake—approximately 15-fold more effective than methcathinone at SERT—with notable neurotoxic and cytotoxic potential common to halogenated cathinones. Toxicity concerns include tachycardia, hypertension, agitation, and sweating (based on analog data), as well as potential oxidative neurotoxicity. Harm reduction: start low (≤20mg), dose slowly with long wait times, stay hydrated, avoid mixing stimulant substances or MAOIs, and use reagent testing to verify compound identity due to common adulteration. Prolonged or high-dose use may lead to dependence and cardiovascular stress.\",\n+    \"notes\": \"Phenylpiracetam is orally bioavailable (~100 %) with a 3-5 h elimination half-life; unmetabolised drug is excreted 40 % in urine and 60 % via bile/sweat. (R)-enantiomer is a selective DAT inhibitor that markedly increases progressive-ratio responding in rats, confirming genuine stimulant properties. The compound is the only racetam banned in-competition by WADA for performance enhancement; athletes have returned positives from single 200 mg doses. Forum users report clear, speedy mental energy at 100-200 mg but emphasize that tolerance becomes obvious after as little as two consecutive days, recommending 1-2×/week scheduling and choline (CDP- or ALCAR) support to counter racetam-induced acetylcholine depletion. Nasal use produces a harsh burn and a short, intense rush; one 75 mg insufflated dose produced palpitations—volumetric oral dosing is strongly advised. Common adverse effects include elevated heart-rate, irritability, facial flushing and late-night insomnia if taken <8 h before bed. Because grey-market powders vary widely in purity, use multi-reagent testing or independent COA verification and start with ≤50 mg allergy test.\",\n-      \"mild to moderate euphoria\",\n-      \"calm stimulation\",\n-      \"empathogenic/antidepressant feel\",\n-      \"increased sociability\",\n-      \"sweating\",\n-      \"short duration with desire to redose\"\n+      \"clean wakefulness\",\n+      \"increased motivation / drive\",\n+      \"enhanced focus and working memory\",\n+      \"mild mood elevation\",\n+      \"greater physical endurance & cold tolerance\",\n+      \"reduced fatigue\",\n+      \"possible jaw tension / bruxism\",\n+      \"insomnia at high or late doses\"\n-      \"full_tolerance\": \"after one session\",\n-      \"half_tolerance\": \"2-4 days\",\n-      \"zero_tolerance\": \"7-10 days\",\n+      \"full_tolerance\": \"after 2-5 consecutive days\",\n+      \"half_tolerance\": \"5-7 days\",\n+      \"zero_tolerance\": \"14-21 days\",\n-        \"other cathinones\",\n-        \"amphetamines\"\n+        \"other racetams\",\n+        \"dopaminergic stimulants\"\n-    \"half_life\": \"estimated 3-6 h\",\n+    \"half_life\": \"3-5 h\",\n-        \"name\": \"Wikipedia – 4‑Bromomethcathinone\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/4-Bromomethcathinone\"\n+        \"name\": \"Wikipedia – pharmacokinetic summary\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Phenylpiracetam\"\n-        \"name\": \"Drugs‑Forum anecdotal report\",\n-        \"reference\": \"https://drugs-forum.com/threads/4-bromomethcathinone-4-bmc-experiences.161321/\"\n+        \"name\": \"Bluelight ‘Phenylpiracetam questions’ dose discussion\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/phenylpiracetam-questions.780797/\"\n-        \"name\": \"MDPI Brain Sciences – review of halogenated cathinones\",\n-        \"reference\": \"https://doi.org/10.3390/brainsci14040334\"\n+        \"name\": \"Reddit r/Supplements – rapid tolerance reports\",\n+        \"reference\": \"https://www.reddit.com/r/Supplements/comments/o5hvnu/phenylpiracetam_tolerance/\"\n-        \"name\": \"Alcohol and Drug Foundation – synthetic cathinones\",\n-        \"reference\": \"https://adf.org.au/drug-facts/synthetic-cathinones/\"\n+        \"name\": \"PubMed – R-phenylpiracetam binds DAT (neuroprotective study)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/32279140/\"\n-        \"name\": \"Patterns of use & toxicity of para‑halogenated cathinones\",\n-        \"reference\": \"https://onlinelibrary.wiley.com/doi/full/10.1002/hup.2621\"\n+        \"name\": \"WADA Prohibited List – stimulant section\",\n+        \"reference\": \"https://www.wada-ama.org/en/prohibited-list\"\n+      },\n+      {\n+        \"name\": \"Reddit r/Drugs – 75 mg insufflated experience\",\n+        \"reference\": \"https://www.reddit.com/r/Drugs/comments/l5ztlv/snorting_phenylpiracetam_effective_doseexperiences/\"\n+      },\n+      {\n+        \"name\": \"Reddit r/Nootropics – insomnia if dosed <12 h pre-bed\",\n+        \"reference\": \"https://www.reddit.com/r/Nootropics/comments/82bw79/phenylpiracetams_affect_on_caffeine_side_effects/\"\n+      },\n+      {\n+        \"name\": \"Bluelight – side-effects & interactions thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/phenylpiracetam-side-effects-interactions.778714/\"\n+      },\n+      {\n+        \"name\": \"Reddit r/MAOIs – stimulant caution with MAOIs\",\n+        \"reference\": \"https://www.reddit.com/r/MAOIs/comments/n8syme/phenylpiracetam_maoi_combination/\"\n+      },\n+      {\n+        \"name\": \"International J. Neuropsychopharmacology – DAT inhibitor MRZ-9547 increases motivation\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/25429104/\"\n-      \"stimulant\",\n+      \"nootropic\",\n\n# 2C-TFM · #468\n\n-  \"id\": 470,\n-  \"title\": \"Phenylpiracetam\",\n+  \"id\": 468,\n+  \"title\": \"2C-TFM\",\n-    \"drug_name\": \"Phenylpiracetam\",\n-    \"chemical_name\": \"Phenylpiracetam\",\n+    \"drug_name\": \"2C-TFM\",\n+    \"chemical_name\": \"2C-TFM\",\n-    \"chemical_class\": \"Racetams\",\n-    \"mechanism_of_action\": \"AMPA receptor positive allosteric modulator\",\n-    \"psychoactive_class\": \"Stimulant nootropic; atypical dopamine/noradrenaline re-uptake inhibitor; nicotinic modulator\",\n+    \"chemical_class\": \"2C-X; phenethylamine\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-          \"route\": \"oral (capsule or powder)\",\n+          \"route\": \"oral / sublingual\",\n-            \"threshold\": \"25mg\",\n-            \"light\": \"25mg - 75mg\",\n-            \"common\": \"75mg - 200mg\",\n-            \"strong\": \"200mg - 400mg\",\n-            \"heavy\": \"400+ mg\"\n+            \"threshold\": \"1 mg\",\n+            \"light\": \"1 mg - 2 mg\",\n+            \"common\": \"2 mg - 5 mg\",\n+            \"strong\": \"5 mg - 8 mg\",\n+            \"heavy\": \"8+ mg\"\n-          \"route\": \"sublingual\",\n+          \"route\": \"insufflated (intranasal)\",\n-            \"threshold\": \"20mg\",\n-            \"light\": \"20mg - 50mg\",\n-            \"common\": \"50mg - 150mg\",\n-            \"strong\": \"150mg - 300mg\",\n-            \"heavy\": \"300+ mg\"\n+            \"threshold\": \"0.5 mg\",\n+            \"light\": \"0.5 mg - 1.5 mg\",\n+            \"common\": \"1.5 mg - 4 mg\",\n+            \"strong\": \"4 mg - 6 mg\",\n+            \"heavy\": \"6+ mg\"\n-        },\n-        {\n-          \"route\": \"insufflated\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"10mg\",\n-            \"light\": \"10mg - 25mg\",\n-            \"common\": \"25mg - 75mg\",\n-            \"strong\": \"75mg - 150mg\",\n-            \"heavy\": \"150+ mg\"\n-          }\n-          \"route\": \"oral (capsule or powder)\",\n+          \"route\": \"oral / sublingual\",\n-            \"oral\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"4-6 h (active phase)\",\n-            \"onset\": \"20-40 min\",\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-6 h residual stimulation / possible insomnia\"\n-          }\n-        },\n-        {\n-          \"route\": \"sublingual\",\n-          \"canonical_routes\": [\n+            \"oral\",\n-            \"total_duration\": \"4-6 h (active phase)\",\n-            \"onset\": \"5-15 min\",\n+            \"total_duration\": \"5 - 10 h (active phase)\",\n+            \"onset\": \"15-30 min\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-6 h residual stimulation / possible insomnia\"\n+            \"offset\": \"2-3 h\",\n+            \"after_effects\": \"2-6 h residual stimulation; slight visual echo\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"insufflated (intranasal)\",\n-            \"total_duration\": \"4-6 h (active phase)\",\n+            \"total_duration\": \"5 - 10 h (active phase)\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-6 h residual stimulation / possible insomnia\"\n+            \"offset\": \"2-3 h\",\n+            \"after_effects\": \"2-6 h residual stimulation; slight visual echo\"\n-    \"addiction_potential\": \"Low-to-moderate: little euphoria but rapid pharmacodynamic tolerance (often within 2-3 consecutive days) can drive redosing; some users escalate to 400-600 mg/day.\",\n+    \"addiction_potential\": \"Low: rapid acute tolerance and no dopaminergic reinforcement observed, but extreme potency (active at single-digit milligrams) makes accidental over-dosing a real risk.\",\n-        \"MAOI antidepressants (hypertensive crisis)\",\n-        \"strong sympathomimetic stimulants (amphetamine, ephedrine, methylphenidate)\",\n-        \"high-dose bupropion or other DAT/NRI agents (tachycardia, BP spikes)\"\n+        \"non-selective MAOIs (hypertensive crisis)\",\n+        \"high-dose sympathomimetic stimulants (tachycardia, vasospasm)\",\n+        \"tramadol or bupropion (seizure threshold lowered)\"\n-        \"excessive caffeine (>400 mg)\",\n-        \"phenibut, GHB or heavy alcohol (masking intoxication, rebound anxiety)\",\n-        \"dopaminergic Parkinson’s meds (additive stimulation)\"\n+        \"other potent psychedelics or dissociatives (over-stimulation, psychosis)\",\n+        \"selective serotonin re-uptake inhibitors (possible serotonin toxicity)\",\n+        \"2C-I contamination (commonly co-synthesised; adds body-load and vasoconstriction)\"\n-        \"SSRI / SNRI antidepressants (anecdotal blunting of effects)\",\n-        \"benzodiazepines (may nullify stimulation → accidental redose)\",\n-        \"kratom or opioids (confused sedation–stimulation cycle)\",\n-        \"other racetams (cross-tolerance, cholinergic depletion)\"\n+        \"cannabis concentrates (may amplify anxiety)\",\n+        \"beta-blockers or strong vasodilators (sudden BP swings)\",\n+        \"alcohol (impairs judgement at such low psychoactive doses)\"\n-    \"notes\": \"Phenylpiracetam is orally bioavailable (~100 %) with a 3-5 h elimination half-life; unmetabolised drug is excreted 40 % in urine and 60 % via bile/sweat. (R)-enantiomer is a selective DAT inhibitor that markedly increases progressive-ratio responding in rats, confirming genuine stimulant properties. The compound is the only racetam banned in-competition by WADA for performance enhancement; athletes have returned positives from single 200 mg doses. Forum users report clear, speedy mental energy at 100-200 mg but emphasize that tolerance becomes obvious after as little as two consecutive days, recommending 1-2×/week scheduling and choline (CDP- or ALCAR) support to counter racetam-induced acetylcholine depletion. Nasal use produces a harsh burn and a short, intense rush; one 75 mg insufflated dose produced palpitations—volumetric oral dosing is strongly advised. Common adverse effects include elevated heart-rate, irritability, facial flushing and late-night insomnia if taken <8 h before bed. Because grey-market powders vary widely in purity, use multi-reagent testing or independent COA verification and start with ≤50 mg allergy test.\",\n+    \"notes\": \"2C-TFM is the most potent simple 2C analogue, orally active at 3-6 mg in human trials by Trachsel & Shulgin. Because it is usually synthesised from 2C-I, retail batches from the mid-2000s were often ~50 % un-reacted 2C-I, leading to mixed effects and legal complications. Purity must be confirmed with multi-reagent testing plus quantitative chromatography whenever possible. The compound shows 5-HT2A/C K_i ≈ 75 nM—comparable to DOI—and produces an unusually clear-headed, colour-saturated visual field with mild bodily stimulation and little vasoconstriction at ≤5 mg. Anecdotal reports cluster around 5-15 mg when purity is uncertain, so volumetric dosing in ethanol (0.1 mg mL⁻¹) is strongly recommended. Users emphasise strict session caps (<8 mg oral, <4 mg nasal) to prevent accidental escalation. No human fatalities are documented as of July 2025, but the safety margin above 10 mg remains undefined. Tolerance builds after a single moderate dose and dissipates in ~7-10 days. Cross-tolerance with other serotonergic psychedelics is complete.\",\n-      \"clean wakefulness\",\n-      \"increased motivation / drive\",\n-      \"enhanced focus and working memory\",\n-      \"mild mood elevation\",\n-      \"greater physical endurance & cold tolerance\",\n-      \"reduced fatigue\",\n-      \"possible jaw tension / bruxism\",\n-      \"insomnia at high or late doses\"\n+      \"intense colour enhancement and geometry\",\n+      \"crisp music appreciation\",\n+      \"moderate euphoria\",\n+      \"analytic, ‘clear-window’ head-space\",\n+      \"synesthesia at higher doses\",\n+      \"mild peripheral stimulation (warmth, pupil dilation)\",\n+      \"minimal nausea relative to other 2C compounds\"\n-      \"full_tolerance\": \"after 2-5 consecutive days\",\n-      \"half_tolerance\": \"5-7 days\",\n-      \"zero_tolerance\": \"14-21 days\",\n+      \"full_tolerance\": \"after one strong session\",\n+      \"half_tolerance\": \"3-5 days\",\n+      \"zero_tolerance\": \"7-10 days\",\n-        \"other racetams\",\n-        \"dopaminergic stimulants\"\n+        \"other 2C phenethylamines\",\n+        \"tryptamine psychedelics\"\n-    \"half_life\": \"3-5 h\",\n+    \"half_life\": \"unknown in humans; by analogy with other 2C phenethylamines estimated 3-6 h\",\n-        \"name\": \"Wikipedia – pharmacokinetic summary\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Phenylpiracetam\"\n+        \"name\": \"Wikipedia – 2C-TFM overview (dose 3-6 mg, duration 5-10 h)\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/2C-TFM\"\n-        \"name\": \"Bluelight ‘Phenylpiracetam questions’ dose discussion\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/phenylpiracetam-questions.780797/\"\n+        \"name\": \"Trachsel D. Fluorine in psychedelic phenethylamines (human potency 3-5 mg)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/22374819/\"\n-        \"name\": \"Reddit r/Supplements – rapid tolerance reports\",\n-        \"reference\": \"https://www.reddit.com/r/Supplements/comments/o5hvnu/phenylpiracetam_tolerance/\"\n+        \"name\": \"Nichols DE et al., J Med Chem 37 (25): 4346-51 (5-HT2A/2C agonist potency)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/7996545/\"\n-        \"name\": \"PubMed – R-phenylpiracetam binds DAT (neuroprotective study)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/32279140/\"\n+        \"name\": \"2C family dose table – 2C (psychedelics) Wikipedia\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/2C_(psychedelics)\"\n-        \"name\": \"WADA Prohibited List – stimulant section\",\n-        \"reference\": \"https://www.wada-ama.org/en/prohibited-list\"\n+        \"name\": \"Bluelight – DOF thread quoting Shulgin index (street 5-15 mg, oral active 3-5 mg)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/dof-first-7-trials-a-workup-of-an-obscure-potentially-psychedelic-amphetamine.861930/\"\n-        \"name\": \"Reddit r/Drugs – 75 mg insufflated experience\",\n-        \"reference\": \"https://www.reddit.com/r/Drugs/comments/l5ztlv/snorting_phenylpiracetam_effective_doseexperiences/\"\n-      },\n-      {\n-        \"name\": \"Reddit r/Nootropics – insomnia if dosed <12 h pre-bed\",\n-        \"reference\": \"https://www.reddit.com/r/Nootropics/comments/82bw79/phenylpiracetams_affect_on_caffeine_side_effects/\"\n-      },\n-      {\n-        \"name\": \"Bluelight – side-effects & interactions thread\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/phenylpiracetam-side-effects-interactions.778714/\"\n-      },\n-      {\n-        \"name\": \"Reddit r/MAOIs – stimulant caution with MAOIs\",\n-        \"reference\": \"https://www.reddit.com/r/MAOIs/comments/n8syme/phenylpiracetam_maoi_combination/\"\n-      },\n-      {\n-        \"name\": \"International J. Neuropsychopharmacology – DAT inhibitor MRZ-9547 increases motivation\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/25429104/\"\n+        \"name\": \"Bluelight – Big & Dandy 2C-TFM thread (contamination with 2C-I)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-2c-tfm-thread.190320/page-4\"\n-      \"nootropic\",\n-      \"research-chemical\"\n+      \"psychedelic\",\n+      \"research-chemical\",\n+      \"2C-X\"\n\n# Adderall XR · #469\n\n-  \"id\": 468,\n-  \"title\": \"2C-TFM\",\n+  \"id\": 469,\n+  \"title\": \"Adderall XR\",\n-    \"drug_name\": \"2C-TFM\",\n-    \"chemical_name\": \"2C-TFM\",\n+    \"drug_name\": \"Adderall XR\",\n+    \"chemical_name\": \"Adderall XR\",\n-    \"chemical_class\": \"2C-X; phenethylamine\",\n-    \"mechanism_of_action\": \"5-HT2A receptor agonist\",\n-    \"psychoactive_class\": \"Psychedelic\",\n+    \"chemical_class\": \"Amphetamines\",\n+    \"mechanism_of_action\": \"Dopamine-norepinephrine releasing agent\",\n+    \"psychoactive_class\": \"CNS stimulant; dopamine-norepinephrine releasing agent\",\n-          \"route\": \"oral / sublingual\",\n+          \"route\": \"oral (intact XR capsule)\",\n-            \"threshold\": \"1 mg\",\n-            \"light\": \"1 mg - 2 mg\",\n-            \"common\": \"2 mg - 5 mg\",\n-            \"strong\": \"5 mg - 8 mg\",\n-            \"heavy\": \"8+ mg\"\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"5 mg - 15 mg\",\n+            \"common\": \"15 mg - 30 mg\",\n+            \"strong\": \"30 mg - 50 mg\",\n+            \"heavy\": \"50+ mg\"\n-          \"route\": \"insufflated (intranasal)\",\n+          \"route\": \"oral (beads crushed / parachuted)\",\n-            \"threshold\": \"0.5 mg\",\n-            \"light\": \"0.5 mg - 1.5 mg\",\n-            \"common\": \"1.5 mg - 4 mg\",\n-            \"strong\": \"4 mg - 6 mg\",\n-            \"heavy\": \"6+ mg\"\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"5 mg - 10 mg\",\n+            \"common\": \"10 mg - 25 mg\",\n+            \"strong\": \"25 mg - 40 mg\",\n+            \"heavy\": \"40+ mg\"\n-        }\n-      ]\n-    },\n-    \"duration\": {\n-      \"routes_of_administration\": [\n+        },\n-          \"route\": \"oral / sublingual\",\n-          \"canonical_routes\": [\n-            \"oral\",\n-            \"sublingual\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"5 - 10 h (active phase)\",\n-            \"onset\": \"15-30 min\",\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"2-3 h\",\n-            \"after_effects\": \"2-6 h residual stimulation; slight visual echo\"\n+          \"route\": \"insufflated (crushed beads)\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"5 mg - 10 mg\",\n+            \"common\": \"10 mg - 20 mg\",\n+            \"strong\": \"20 mg - 35 mg\",\n+            \"heavy\": \"35+ mg\"\n-          \"route\": \"insufflated (intranasal)\",\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"5 - 10 h (active phase)\",\n-            \"onset\": \"5-15 min\",\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"2-3 h\",\n-            \"after_effects\": \"2-6 h residual stimulation; slight visual echo\"\n+          \"route\": \"rectal (crushed beads in solution)\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"2.5 mg\",\n+            \"light\": \"2.5 mg - 10 mg\",\n+            \"common\": \"10 mg - 20 mg\",\n+            \"strong\": \"20 mg - 30 mg\",\n+            \"heavy\": \"30+ mg\"\n-    \"addiction_potential\": \"Low: rapid acute tolerance and no dopaminergic reinforcement observed, but extreme potency (active at single-digit milligrams) makes accidental over-dosing a real risk.\",\n+    \"duration\": {\n+      \"total_duration\": \"10-12 h (active phase)\",\n+      \"onset\": \"30-60 min oral, 10-25 min insufflated, 5-15 min rectal\",\n+      \"peak\": \"4-7 h\",\n+      \"offset\": \"2-4 h\",\n+      \"after_effects\": \"6-24 h fatigue, anhedonia, irritability ('crash')\"\n+    },\n+    \"addiction_potential\": \"High: rapid psychological reinforcement, pronounced tolerance, compulsive redosing and binge patterns common; withdrawal dysphoria and hypersomnia reported after multi-day runs.\",\n-        \"non-selective MAOIs (hypertensive crisis)\",\n-        \"high-dose sympathomimetic stimulants (tachycardia, vasospasm)\",\n-        \"tramadol or bupropion (seizure threshold lowered)\"\n+        \"MAOIs (hypertensive crisis)\",\n+        \"other strong stimulants or cathinones (hyperthermia, arrhythmia)\",\n+        \"cocaine (cardiotoxic synergy)\",\n+        \"dxm or linezolid (serotonin / adrenergic storm)\"\n-        \"other potent psychedelics or dissociatives (over-stimulation, psychosis)\",\n-        \"selective serotonin re-uptake inhibitors (possible serotonin toxicity)\",\n-        \"2C-I contamination (commonly co-synthesised; adds body-load and vasoconstriction)\"\n+        \"modafinil or armodafinil\",\n+        \"bupropion\",\n+        \"tramadol (seizure risk)\",\n+        \"excess caffeine (>400 mg)\"\n-        \"cannabis concentrates (may amplify anxiety)\",\n-        \"beta-blockers or strong vasodilators (sudden BP swings)\",\n-        \"alcohol (impairs judgement at such low psychoactive doses)\"\n+        \"SSRIs / SNRIs (serotonin syndrome at high doses)\",\n+        \"alcohol (masked intoxication, cardiotoxicity)\",\n+        \"beta-blockers (rebound hypertension on offset)\",\n+        \"acidifying agents (vitamin C) shorten duration; alkalizing agents (antacids) prolong and intensify effects\"\n-    \"notes\": \"2C-TFM is the most potent simple 2C analogue, orally active at 3-6 mg in human trials by Trachsel & Shulgin. Because it is usually synthesised from 2C-I, retail batches from the mid-2000s were often ~50 % un-reacted 2C-I, leading to mixed effects and legal complications. Purity must be confirmed with multi-reagent testing plus quantitative chromatography whenever possible. The compound shows 5-HT2A/C K_i ≈ 75 nM—comparable to DOI—and produces an unusually clear-headed, colour-saturated visual field with mild bodily stimulation and little vasoconstriction at ≤5 mg. Anecdotal reports cluster around 5-15 mg when purity is uncertain, so volumetric dosing in ethanol (0.1 mg mL⁻¹) is strongly recommended. Users emphasise strict session caps (<8 mg oral, <4 mg nasal) to prevent accidental escalation. No human fatalities are documented as of July 2025, but the safety margin above 10 mg remains undefined. Tolerance builds after a single moderate dose and dissipates in ~7-10 days. Cross-tolerance with other serotonergic psychedelics is complete.\",\n+    \"notes\": \"XR uses 50 % immediate-release and 50 % delayed-release beads; crushing defeats the time-release, converting it to an IR preparation with higher peak plasma levels. Bioavailability is reduced by high-fat meals and increased gastric pH. Street diversion often leads to nasal insufflation, raising risk of septal irritation and pulmonary talcosis from inert bead spheres. Acute harms include tachyarrhythmia, hyperthermia, rhabdomyolysis, and psychosis; these escalate sharply above 60 mg or when redosed within 6 h. Hydration, electrolyte balance, ambient temperature control, and scheduled nutrition breaks reduce acute toxicity. Because amphetamine is excreted renally in unchanged form, acidified urine hastens clearance during adverse reactions. Use a milligram-accurate scale for volumetric dosing of bead powder; start ≤15 mg on first exposure and wait a full day before reassessing due to the bimodal release profile. Long-term heavy use (>40 mg/d for months) has been linked to cortical grey-matter thinning, blunted dopaminergic response, and cardiomyopathy. Periodic 48- to 72-h drug-free ‘reset’ windows slow tolerance accrual.\",\n-      \"intense colour enhancement and geometry\",\n-      \"crisp music appreciation\",\n-      \"moderate euphoria\",\n-      \"analytic, ‘clear-window’ head-space\",\n-      \"synesthesia at higher doses\",\n-      \"mild peripheral stimulation (warmth, pupil dilation)\",\n-      \"minimal nausea relative to other 2C compounds\"\n+      \"euphoria / enthusiasm\",\n+      \"sharp focus and mental alertness\",\n+      \"talkativeness\",\n+      \"increased physical stamina\",\n+      \"appetite suppression\",\n+      \"jaw tension / bruxism\",\n+      \"mydriasis\",\n+      \"anxiety or agitation at higher doses\",\n+      \"insomnia\"\n-      \"full_tolerance\": \"after one strong session\",\n-      \"half_tolerance\": \"3-5 days\",\n-      \"zero_tolerance\": \"7-10 days\",\n+      \"full_tolerance\": \"after 3-5 consecutive high-dose days\",\n+      \"half_tolerance\": \"3-7 days\",\n+      \"zero_tolerance\": \"14-21 days\",\n-        \"other 2C phenethylamines\",\n-        \"tryptamine psychedelics\"\n+        \"methamphetamine\",\n+        \"other amphetamine analogues\",\n+        \"cathinones\"\n-    \"half_life\": \"unknown in humans; by analogy with other 2C phenethylamines estimated 3-6 h\",\n+    \"half_life\": \"d-amphetamine 10-11 h; l-amphetamine 11-13 h (adults)\",\n-        \"name\": \"Wikipedia – 2C-TFM overview (dose 3-6 mg, duration 5-10 h)\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/2C-TFM\"\n+        \"name\": \"FDA Adderall XR Prescribing Information\",\n+        \"reference\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021303s010lbl.pdf\"\n-        \"name\": \"Trachsel D. Fluorine in psychedelic phenethylamines (human potency 3-5 mg)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/22374819/\"\n+        \"name\": \"Long-acting stimulants: development and dosing\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC2547091/\"\n-        \"name\": \"Nichols DE et al., J Med Chem 37 (25): 4346-51 (5-HT2A/2C agonist potency)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/7996545/\"\n+        \"name\": \"Peak/Duration pharmacokinetics of XR amphetamine\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC2670101/\"\n-        \"name\": \"2C family dose table – 2C (psychedelics) Wikipedia\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/2C_(psychedelics)\"\n+        \"name\": \"Treatment of adults with ADHD – MAS-XR 10-12 h coverage\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC2515906/\"\n-        \"name\": \"Bluelight – DOF thread quoting Shulgin index (street 5-15 mg, oral active 3-5 mg)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/dof-first-7-trials-a-workup-of-an-obscure-potentially-psychedelic-amphetamine.861930/\"\n+        \"name\": \"Erowid Amphetamine Dose Overview\",\n+        \"reference\": \"https://www.erowid.org/chemicals/amphetamines/amphetamines_dose.shtml\"\n-        \"name\": \"Bluelight – Big & Dandy 2C-TFM thread (contamination with 2C-I)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-2c-tfm-thread.190320/page-4\"\n+        \"name\": \"Bluelight – Snorting Adderall thread (user-reported dosages)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/snorting-adderall.908164/\"\n+      },\n+      {\n+        \"name\": \"MedicalNewsToday – Alcohol and Adderall interaction\",\n+        \"reference\": \"https://www.medicalnewstoday.com/articles/321542\"\n+      },\n+      {\n+        \"name\": \"MedicalNewsToday – Adderall overdose risks\",\n+        \"reference\": \"https://www.medicalnewstoday.com/articles/325683\"\n+      },\n+      {\n+        \"name\": \"VerywellHealth – Adderall XR vs IR (duration comparison)\",\n+        \"reference\": \"https://www.verywellhealth.com/adderall-xr-vs-ir-8584069\"\n+      },\n+      {\n+        \"name\": \"Wikipedia – Adderall formulations summary\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Adderall\"\n-      \"psychedelic\",\n-      \"research-chemical\",\n-      \"2C-X\"\n+      \"stimulant\"\n\n# Tesofensine · #471\n\n-  \"id\": 469,\n-  \"title\": \"Adderall XR\",\n+  \"id\": 471,\n+  \"title\": \"Tesofensine\",\n-    \"drug_name\": \"Adderall XR\",\n-    \"chemical_name\": \"Adderall XR\",\n+    \"drug_name\": \"Tesofensine\",\n+    \"chemical_name\": \"Tesofensine\",\n-    \"chemical_class\": \"Amphetamines\",\n-    \"mechanism_of_action\": \"Dopamine-norepinephrine releasing agent\",\n-    \"psychoactive_class\": \"CNS stimulant; dopamine-norepinephrine releasing agent\",\n+    \"chemical_class\": \"Other stimulants\",\n+    \"mechanism_of_action\": \"Serotonin-dopamine-norepinephrine reuptake inhibitor\",\n+    \"psychoactive_class\": \"Serotonin-noradrenaline-dopamine reuptake inhibitor (SNDRI)\",\n-          \"route\": \"oral (intact XR capsule)\",\n+          \"route\": \"oral\",\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"5 mg - 15 mg\",\n-            \"common\": \"15 mg - 30 mg\",\n-            \"strong\": \"30 mg - 50 mg\",\n-            \"heavy\": \"50+ mg\"\n+            \"threshold\": \"0.05 mg\",\n+            \"light\": \"0.05mg - 0.20mg\",\n+            \"common\": \"0.20mg - 0.50 mg\",\n+            \"strong\": \"0.50mg - 1 mg\",\n+            \"heavy\": \"1+ mg\"\n-        },\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n-          \"route\": \"oral (beads crushed / parachuted)\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"5 mg - 10 mg\",\n-            \"common\": \"10 mg - 25 mg\",\n-            \"strong\": \"25 mg - 40 mg\",\n-            \"heavy\": \"40+ mg\"\n+          \"route\": \"oral\",\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"12-24 h perceptible stimulation / anorexia\",\n+            \"onset\": \"0.5-2 h\",\n+            \"peak\": \"4-10 h\",\n+            \"offset\": \"12-24 h gradual decline\",\n+            \"after_effects\": \"1-3 days residual appetite suppression & sleep disturbance (accumulates with repeated dosing)\"\n-        },\n-        {\n-          \"route\": \"insufflated (crushed beads)\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"5 mg - 10 mg\",\n-            \"common\": \"10 mg - 20 mg\",\n-            \"strong\": \"20 mg - 35 mg\",\n-            \"heavy\": \"35+ mg\"\n-          }\n-        },\n-        {\n-          \"route\": \"rectal (crushed beads in solution)\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"2.5 mg\",\n-            \"light\": \"2.5 mg - 10 mg\",\n-            \"common\": \"10 mg - 20 mg\",\n-            \"strong\": \"20 mg - 30 mg\",\n-            \"heavy\": \"30+ mg\"\n-          }\n-    \"duration\": {\n-      \"total_duration\": \"10-12 h (active phase)\",\n-      \"onset\": \"30-60 min oral, 10-25 min insufflated, 5-15 min rectal\",\n-      \"peak\": \"4-7 h\",\n-      \"offset\": \"2-4 h\",\n-      \"after_effects\": \"6-24 h fatigue, anhedonia, irritability ('crash')\"\n-    },\n-    \"addiction_potential\": \"High: rapid psychological reinforcement, pronounced tolerance, compulsive redosing and binge patterns common; withdrawal dysphoria and hypersomnia reported after multi-day runs.\",\n+    \"addiction_potential\": \"Low-to-moderate: acute euphoric/stimulant effect is mild, but potent appetite suppression and dopaminergic action can promote psychological reliance; extremely long half-life (≈9 days) dissuades compulsive redosing yet causes insidious tolerance build-up.\",\n-        \"MAOIs (hypertensive crisis)\",\n-        \"other strong stimulants or cathinones (hyperthermia, arrhythmia)\",\n-        \"cocaine (cardiotoxic synergy)\",\n-        \"dxm or linezolid (serotonin / adrenergic storm)\"\n+        \"MAOIs (hypertensive crisis, serotonin syndrome)\",\n+        \"high-dose serotonergic agents (MDMA, tramadol, mephedrone)\",\n+        \"sympathomimetic stimulants (amphetamine, cocaine, ephedrine) – severe tachycardia/pressors\"\n-        \"modafinil or armodafinil\",\n-        \"bupropion\",\n-        \"tramadol (seizure risk)\",\n-        \"excess caffeine (>400 mg)\"\n+        \"SNRI / SSRI antidepressants (serotonin overload)\",\n+        \"bupropion or other strong NDRIs (excess dopaminergic/noradrenergic load)\",\n+        \"linezolid or other serotonergic antibiotics\"\n-        \"SSRIs / SNRIs (serotonin syndrome at high doses)\",\n-        \"alcohol (masked intoxication, cardiotoxicity)\",\n-        \"beta-blockers (rebound hypertension on offset)\",\n-        \"acidifying agents (vitamin C) shorten duration; alkalizing agents (antacids) prolong and intensify effects\"\n+        \"caffeine, yohimbine (additive stimulation)\",\n+        \"beta-agonist bronchodilators\",\n+        \"GLP-1 / GIP agonists – monitor blood pressure & HR if stacking for weight loss\"\n-    \"notes\": \"XR uses 50 % immediate-release and 50 % delayed-release beads; crushing defeats the time-release, converting it to an IR preparation with higher peak plasma levels. Bioavailability is reduced by high-fat meals and increased gastric pH. Street diversion often leads to nasal insufflation, raising risk of septal irritation and pulmonary talcosis from inert bead spheres. Acute harms include tachyarrhythmia, hyperthermia, rhabdomyolysis, and psychosis; these escalate sharply above 60 mg or when redosed within 6 h. Hydration, electrolyte balance, ambient temperature control, and scheduled nutrition breaks reduce acute toxicity. Because amphetamine is excreted renally in unchanged form, acidified urine hastens clearance during adverse reactions. Use a milligram-accurate scale for volumetric dosing of bead powder; start ≤15 mg on first exposure and wait a full day before reassessing due to the bimodal release profile. Long-term heavy use (>40 mg/d for months) has been linked to cortical grey-matter thinning, blunted dopaminergic response, and cardiomyopathy. Periodic 48- to 72-h drug-free ‘reset’ windows slow tolerance accrual.\",\n+    \"notes\": \"Tesofensine is a triple-monoamine reuptake inhibitor originally developed for neurodegenerative disorders but repurposed for obesity. Clinical PK shows an elimination half-life of ~220 h with an active N-desalkyl metabolite lasting ~374 h, so steady-state is reached only after ≈4–5 weeks; single overdoses can linger for more than a week. Forum users emphasise starting ≤0.25 mg every 48 h to limit insomnia, anxiety and HR ↑8-15 bpm. Because the compound is sold by research-chemical vendors, authenticity varies; reagent TLC plus chiral GC-MS is advised. Due to transporter ratios (NET≈1.7 nM, SERT≈11 nM, DAT≈65 nM) clinical weight-loss occurs at 0.25-0.5 mg q.d.; above 1 mg no extra efficacy but marked pressor response. Accumulation means missed doses do not immediately reverse appetite suppression; many users shift to 0.25-0.5 mg twice weekly once steady-state is achieved. Long-term safety data are limited—monitor BP, resting HR, ECG QTc and liver enzymes every 4-8 weeks.\",\n-      \"euphoria / enthusiasm\",\n-      \"sharp focus and mental alertness\",\n-      \"talkativeness\",\n-      \"increased physical stamina\",\n-      \"appetite suppression\",\n-      \"jaw tension / bruxism\",\n-      \"mydriasis\",\n-      \"anxiety or agitation at higher doses\",\n-      \"insomnia\"\n+      \"strong appetite suppression\",\n+      \"clean mental stimulation / alertness\",\n+      \"increased motivation & focus\",\n+      \"mild euphoria\",\n+      \"dry mouth\",\n+      \"insomnia\",\n+      \"tachycardia / palpitations\",\n+      \"anxiety or jitteriness at higher doses\",\n+      \"constipation or episodic diarrhea\"\n-      \"full_tolerance\": \"after 3-5 consecutive high-dose days\",\n-      \"half_tolerance\": \"3-7 days\",\n-      \"zero_tolerance\": \"14-21 days\",\n+      \"full_tolerance\": \"within 3-4 weeks daily 0.5 mg\",\n+      \"half_tolerance\": \"10-14 days\",\n+      \"zero_tolerance\": \"6-8 weeks of abstinence\",\n-        \"methamphetamine\",\n-        \"other amphetamine analogues\",\n-        \"cathinones\"\n+        \"other SNDRIs (e.g., bupropion)\",\n+        \"strong SNRIs (sibutramine, phentermine)\"\n-    \"half_life\": \"d-amphetamine 10-11 h; l-amphetamine 11-13 h (adults)\",\n+    \"half_life\": \"≈220 h (parent); main metabolite ≈374 h\",\n-        \"name\": \"FDA Adderall XR Prescribing Information\",\n-        \"reference\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021303s010lbl.pdf\"\n+        \"name\": \"Wikipedia – pharmacokinetics & transporter data\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Tesofensine\"\n-        \"name\": \"Long-acting stimulants: development and dosing\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC2547091/\"\n+        \"name\": \"Safety of anti-obesity drugs review – half-life & abuse liability\",\n+        \"reference\": \"https://journals.sagepub.com/doi/10.1177/2042098613489721\"\n-        \"name\": \"Peak/Duration pharmacokinetics of XR amphetamine\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC2670101/\"\n+        \"name\": \"Phase IIb dose–response trial (0.25-1 mg)\",\n+        \"reference\": \"https://www.reddit.com/r/PeptideGuide/comments/1847wrb/a_comprehensive_guide_for_tesofensine/\"\n-        \"name\": \"Treatment of adults with ADHD – MAS-XR 10-12 h coverage\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC2515906/\"\n+        \"name\": \"Reddit Biohackers micro-dosing discussion (0.25 mg → 0.5 mg; lingering effects)\",\n+        \"reference\": \"https://www.reddit.com/r/Biohackers/comments/1dm3clc/tesofensine_microfosing_weekly_dose_vs_daily/\"\n-        \"name\": \"Erowid Amphetamine Dose Overview\",\n-        \"reference\": \"https://www.erowid.org/chemicals/amphetamines/amphetamines_dose.shtml\"\n+        \"name\": \"Reddit Peptides dosing thread – 250-500 µg common, insomnia at 1 mg\",\n+        \"reference\": \"https://www.reddit.com/r/Peptides/comments/18m2xan/tesofensine_dosing/\"\n-        \"name\": \"Bluelight – Snorting Adderall thread (user-reported dosages)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/snorting-adderall.908164/\"\n+        \"name\": \"Weight-loss in Parkinson’s patients on tesofensine\",\n+        \"reference\": \"https://onlinelibrary.wiley.com/doi/full/10.1038/oby.2008.56\"\n-        \"name\": \"MedicalNewsToday – Alcohol and Adderall interaction\",\n-        \"reference\": \"https://www.medicalnewstoday.com/articles/321542\"\n+        \"name\": \"Tesofensine silences hypothalamic GABA neurons (mechanism study)\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC11042726/\"\n-        \"name\": \"MedicalNewsToday – Adderall overdose risks\",\n-        \"reference\": \"https://www.medicalnewstoday.com/articles/325683\"\n+        \"name\": \"24-h energy-expenditure study – 2 mg then 1 mg acutely increases EE\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/20479765/\"\n-        \"name\": \"VerywellHealth – Adderall XR vs IR (duration comparison)\",\n-        \"reference\": \"https://www.verywellhealth.com/adderall-xr-vs-ir-8584069\"\n+        \"name\": \"Forum Bluelight early discussion on abuse potential\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/tesofensine.346598/\"\n-        \"name\": \"Wikipedia – Adderall formulations summary\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Adderall\"\n+        \"name\": \"Reddit Nootropics guide – compiled user side-effect survey\",\n+        \"reference\": \"https://www.reddit.com/r/Nootropics/comments/1l8o86b/tesofensine_your_guide_to_this_sndri/\"\n-      \"stimulant\"\n+      \"stimulant\",\n+      \"research-chemical\",\n+      \"Other stimulants\"\n\n# 25E-NBOH · #472\n\n-  \"id\": 471,\n-  \"title\": \"Tesofensine\",\n+  \"id\": 472,\n+  \"title\": \"25E-NBOH\",\n-    \"drug_name\": \"Tesofensine\",\n-    \"chemical_name\": \"Tesofensine\",\n+    \"drug_name\": \"25E-NBOH\",\n+    \"chemical_name\": \"25E-NBOH\",\n-    \"chemical_class\": \"Other stimulants\",\n-    \"mechanism_of_action\": \"Serotonin-dopamine-norepinephrine reuptake inhibitor\",\n-    \"psychoactive_class\": \"Serotonin-noradrenaline-dopamine reuptake inhibitor (SNDRI)\",\n+    \"chemical_class\": \"N-benzylated phenethylamines\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist (potent); 5-HT2B receptor agonist (cardiotoxic)\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-          \"route\": \"oral\",\n-          \"units\": \"mg\",\n+          \"route\": \"sublingual / buccal (blotter)\",\n+          \"units\": \"ug\",\n-            \"threshold\": \"0.05 mg\",\n-            \"light\": \"0.05mg - 0.20mg\",\n-            \"common\": \"0.20mg - 0.50 mg\",\n-            \"strong\": \"0.50mg - 1 mg\",\n-            \"heavy\": \"1+ mg\"\n+            \"threshold\": \"100 ug\",\n+            \"light\": \"150 ug - 400 ug\",\n+            \"common\": \"400 ug - 800 ug\",\n+            \"strong\": \"800 ug - 1200 ug\",\n+            \"heavy\": \"1200+ ug\"\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"50 ug\",\n+            \"light\": \"50 ug - 150 ug\",\n+            \"common\": \"150 ug - 400 ug\",\n+            \"strong\": \"400 ug - 700 ug\",\n+            \"heavy\": \"700+ ug\"\n+          }\n+        },\n+        {\n+          \"route\": \"vaporized / smoked (free base)\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"50 ug\",\n+            \"light\": \"50 ug - 100 ug\",\n+            \"common\": \"100 ug - 300 ug\",\n+            \"strong\": \"300 ug - 600 ug\",\n+            \"heavy\": \"600+ ug\"\n+          }\n-          \"route\": \"oral\",\n+          \"route\": \"sublingual / buccal (blotter)\",\n-            \"oral\"\n+            \"sublingual\",\n+            \"buccal\"\n-            \"total_duration\": \"12-24 h perceptible stimulation / anorexia\",\n-            \"onset\": \"0.5-2 h\",\n-            \"peak\": \"4-10 h\",\n-            \"offset\": \"12-24 h gradual decline\",\n-            \"after_effects\": \"1-3 days residual appetite suppression & sleep disturbance (accumulates with repeated dosing)\"\n+            \"total_duration\": \"4-8 h (active phase)\",\n+            \"onset\": \"15-45 min\",\n+            \"peak\": \"2-4 h\",\n+            \"offset\": \"1-3 h\",\n+            \"after_effects\": \"1-12 h residual stimulation; visual echoes\"\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"4-8 h (active phase)\",\n+            \"onset\": \"5-15 min\",\n+            \"peak\": \"2-4 h\",\n+            \"offset\": \"1-3 h\",\n+            \"after_effects\": \"1-12 h residual stimulation; visual echoes\"\n+          }\n+        },\n+        {\n+          \"route\": \"vaporized / smoked (free base)\",\n+          \"canonical_routes\": [\n+            \"vaporized\",\n+            \"smoked\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"4-8 h (active phase)\",\n+            \"onset\": \"<1 min\",\n+            \"peak\": \"2-4 h\",\n+            \"offset\": \"1-3 h\",\n+            \"after_effects\": \"1-12 h residual stimulation; visual echoes\"\n+          }\n-    \"addiction_potential\": \"Low-to-moderate: acute euphoric/stimulant effect is mild, but potent appetite suppression and dopaminergic action can promote psychological reliance; extremely long half-life (≈9 days) dissuades compulsive redosing yet causes insidious tolerance build-up.\",\n+    \"addiction_potential\": \"Low; tolerance builds rapidly after a single session. Cravings are uncommon but redosing in the same night markedly increases vasoconstriction and confusion.\",\n-        \"high-dose serotonergic agents (MDMA, tramadol, mephedrone)\",\n-        \"sympathomimetic stimulants (amphetamine, cocaine, ephedrine) – severe tachycardia/pressors\"\n+        \"tramadol (seizure risk)\",\n+        \"high-dose stimulants or cathinones (tachyarrhythmia, hyperthermia)\"\n-        \"SNRI / SSRI antidepressants (serotonin overload)\",\n-        \"bupropion or other strong NDRIs (excess dopaminergic/noradrenergic load)\",\n-        \"linezolid or other serotonergic antibiotics\"\n+        \"other potent 5-HT2A agonists (NBOMe, DOI, DOC)\",\n+        \"opioids, benzodiazepines or alcohol at heavy sedative doses (respiratory depression if unconscious)\"\n-        \"caffeine, yohimbine (additive stimulation)\",\n-        \"beta-agonist bronchodilators\",\n-        \"GLP-1 / GIP agonists – monitor blood pressure & HR if stacking for weight loss\"\n+        \"SSRI / SNRI antidepressants (blunted effects, possible serotonergic stress)\",\n+        \"cannabis concentrates (panic, dissociation)\",\n+        \"vasoconstricting compounds (e.g., 2-CB-Fly, 25B-NBOH)\"\n-    \"notes\": \"Tesofensine is a triple-monoamine reuptake inhibitor originally developed for neurodegenerative disorders but repurposed for obesity. Clinical PK shows an elimination half-life of ~220 h with an active N-desalkyl metabolite lasting ~374 h, so steady-state is reached only after ≈4–5 weeks; single overdoses can linger for more than a week. Forum users emphasise starting ≤0.25 mg every 48 h to limit insomnia, anxiety and HR ↑8-15 bpm. Because the compound is sold by research-chemical vendors, authenticity varies; reagent TLC plus chiral GC-MS is advised. Due to transporter ratios (NET≈1.7 nM, SERT≈11 nM, DAT≈65 nM) clinical weight-loss occurs at 0.25-0.5 mg q.d.; above 1 mg no extra efficacy but marked pressor response. Accumulation means missed doses do not immediately reverse appetite suppression; many users shift to 0.25-0.5 mg twice weekly once steady-state is achieved. Long-term safety data are limited—monitor BP, resting HR, ECG QTc and liver enzymes every 4-8 weeks.\",\n+    \"notes\": \"25E-NBOH first appeared on Brazilian blotters in 2018 and is now encountered worldwide in the microgram range. Laboratory seizure papers contain 290-820 µg per 6 mm blotter, often hot-spotted. The molecule is heat- and acid-labile; oral swallowing destroys most activity, so users hold tabs under the tongue for 15-30 min. Forum reports describe pronounced open-eye patterning, saturated colour shifts and a phenethylamine-style body euphoria that peaks earlier than LSD. A 2023 French toxicology case linked 25E-NBOH (blotter) plus the stimulant MDPHP to serotonin syndrome and loss of consciousness requiring ICU admission, illustrating how co-ingestion magnifies risk. Rodent assays show full 5-HT2A agonism (locomotor suppression and DOM-like discriminative stimulus) at sub-milligram doses, confirming very high potency. Because NBOHs thermally decompose to their 2C parent in a hot GC inlet, forensic labs must use LC-MS or derivatisation to avoid mis-identification. Harm reduction: keep single-use doses <1 mg, use precise volumetric or blotter-laid dosing, test with Ehrlich/Marquis (expect weak or no reaction), avoid stacking strong sympathomimetics, and have benzodiazepines on hand for acute agitation.\",\n-      \"strong appetite suppression\",\n-      \"clean mental stimulation / alertness\",\n-      \"increased motivation & focus\",\n-      \"mild euphoria\",\n-      \"dry mouth\",\n-      \"insomnia\",\n-      \"tachycardia / palpitations\",\n-      \"anxiety or jitteriness at higher doses\",\n-      \"constipation or episodic diarrhea\"\n+      \"intense visual geometry and colour shifting\",\n+      \"body euphoria and warmth\",\n+      \"audio enhancement / synaesthesia\",\n+      \"time dilation\",\n+      \"mild tactile numbness\",\n+      \"vasoconstrictive 'cold extremities'\",\n+      \"possible confusion or panic at high dose\"\n-      \"full_tolerance\": \"within 3-4 weeks daily 0.5 mg\",\n-      \"half_tolerance\": \"10-14 days\",\n-      \"zero_tolerance\": \"6-8 weeks of abstinence\",\n+      \"full_tolerance\": \"after one strong or heavy session\",\n+      \"half_tolerance\": \"4-7 days\",\n+      \"zero_tolerance\": \"14 days\",\n-        \"other SNDRIs (e.g., bupropion)\",\n-        \"strong SNRIs (sibutramine, phentermine)\"\n+        \"LSD-like lysergamides\",\n+        \"other NBOH / NBOMe compounds\",\n+        \"classic phenethylamine psychedelics (2C-X, DOX)\"\n-    \"half_life\": \"≈220 h (parent); main metabolite ≈374 h\",\n+    \"half_life\": \"Plasma half-life not well characterised; indirect animal PK suggests 2-4 h with active hydroxylated metabolites.\",\n-        \"name\": \"Wikipedia – pharmacokinetics & transporter data\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Tesofensine\"\n+        \"name\": \"Identification of new NBOH drugs in seized blotter papers\",\n+        \"reference\": \"https://doi.org/10.1007/s11419-019-00509-7\"\n-        \"name\": \"Safety of anti-obesity drugs review – half-life & abuse liability\",\n-        \"reference\": \"https://journals.sagepub.com/doi/10.1177/2042098613489721\"\n+        \"name\": \"Severe 25E-NBOH intoxication case report (France, 2024)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/38117418/\"\n-        \"name\": \"Phase IIb dose–response trial (0.25-1 mg)\",\n-        \"reference\": \"https://www.reddit.com/r/PeptideGuide/comments/1847wrb/a_comprehensive_guide_for_tesofensine/\"\n+        \"name\": \"Locomotor and discriminative stimulus effects of NBOH analogues in mice\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/37171529/\"\n-        \"name\": \"Reddit Biohackers micro-dosing discussion (0.25 mg → 0.5 mg; lingering effects)\",\n-        \"reference\": \"https://www.reddit.com/r/Biohackers/comments/1dm3clc/tesofensine_microfosing_weekly_dose_vs_daily/\"\n+        \"name\": \"NPS Discovery monograph – 25E-NBOH seized material profile\",\n+        \"reference\": \"https://www.cfsre.org/images/monographs/25E-NBOH_022718_NMSLabs_Report.pdf\"\n-        \"name\": \"Reddit Peptides dosing thread – 250-500 µg common, insomnia at 1 mg\",\n-        \"reference\": \"https://www.reddit.com/r/Peptides/comments/18m2xan/tesofensine_dosing/\"\n+        \"name\": \"Bluelight ‘Big & Dandy 25x-NBOH’ discussion thread (dose experiences)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-and-dandy-25x-nboh-megathread-post-your-25x-nboh-info-and-questions-here.918641/\"\n-        \"name\": \"Weight-loss in Parkinson’s patients on tesofensine\",\n-        \"reference\": \"https://onlinelibrary.wiley.com/doi/full/10.1038/oby.2008.56\"\n+        \"name\": \"Reddit /r/researchchemicals post – 500 µg blotter equated to ~300 µg LSD\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/1elkm0i/how_many_mg_of_25enboh_would_you_suggest_me_for_a/\"\n-        \"name\": \"Tesofensine silences hypothalamic GABA neurons (mechanism study)\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC11042726/\"\n-      },\n-      {\n-        \"name\": \"24-h energy-expenditure study – 2 mg then 1 mg acutely increases EE\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/20479765/\"\n-      },\n-      {\n-        \"name\": \"Forum Bluelight early discussion on abuse potential\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/tesofensine.346598/\"\n-      },\n-      {\n-        \"name\": \"Reddit Nootropics guide – compiled user side-effect survey\",\n-        \"reference\": \"https://www.reddit.com/r/Nootropics/comments/1l8o86b/tesofensine_your_guide_to_this_sndri/\"\n+        \"name\": \"Wikipedia: 25E NBOH\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/25E-NBOH\"\n-      \"stimulant\",\n-      \"research-chemical\",\n-      \"Other stimulants\"\n+      \"psychedelic\",\n+      \"research-chemical\"\n\n# Bromonordiazepam · #474\n\n-  \"id\": 472,\n-  \"title\": \"25E-NBOH\",\n+  \"id\": 474,\n+  \"title\": \"Bromonordiazepam\",\n-    \"drug_name\": \"25E-NBOH\",\n-    \"chemical_name\": \"25E-NBOH\",\n+    \"drug_name\": \"Bromonordiazepam\",\n+    \"chemical_name\": \"Bromonordiazepam\",\n-    \"chemical_class\": \"N-benzylated phenethylamines\",\n-    \"mechanism_of_action\": \"5-HT2A receptor agonist (potent); 5-HT2B receptor agonist (cardiotoxic)\",\n-    \"psychoactive_class\": \"Psychedelic\",\n+    \"chemical_class\": \"Benzodiazepine\",\n+    \"mechanism_of_action\": \"Gamma-aminobutyric acid type A receptor positive allosteric modulator (benzodiazepine site)\",\n+    \"psychoactive_class\": \"GABAA receptor positive-allosteric modulator (benzodiazepine)\",\n-          \"route\": \"sublingual / buccal (blotter)\",\n-          \"units\": \"ug\",\n+          \"route\": \"oral / sublingual\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"100 ug\",\n-            \"light\": \"150 ug - 400 ug\",\n-            \"common\": \"400 ug - 800 ug\",\n-            \"strong\": \"800 ug - 1200 ug\",\n-            \"heavy\": \"1200+ ug\"\n+            \"threshold\": \"2 mg\",\n+            \"light\": \"3mg - 6mg\",\n+            \"common\": \"6mg - 15mg\",\n+            \"strong\": \"15mg - 25mg\",\n+            \"heavy\": \"25+ mg\"\n-        },\n-        {\n-          \"route\": \"insufflated\",\n-          \"units\": \"ug\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"50 ug\",\n-            \"light\": \"50 ug - 150 ug\",\n-            \"common\": \"150 ug - 400 ug\",\n-            \"strong\": \"400 ug - 700 ug\",\n-            \"heavy\": \"700+ ug\"\n-          }\n-        },\n-        {\n-          \"route\": \"vaporized / smoked (free base)\",\n-          \"units\": \"ug\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"50 ug\",\n-            \"light\": \"50 ug - 100 ug\",\n-            \"common\": \"100 ug - 300 ug\",\n-            \"strong\": \"300 ug - 600 ug\",\n-            \"heavy\": \"600+ ug\"\n-          }\n-          \"route\": \"sublingual / buccal (blotter)\",\n+          \"route\": \"oral / sublingual\",\n-            \"sublingual\",\n-            \"buccal\"\n+            \"oral\",\n+            \"sublingual\"\n-            \"total_duration\": \"4-8 h (active phase)\",\n-            \"onset\": \"15-45 min\",\n+            \"total_duration\": \"6-12 h (primary effects)\",\n+            \"onset\": \"20-60 min\",\n-            \"offset\": \"1-3 h\",\n-            \"after_effects\": \"1-12 h residual stimulation; visual echoes\"\n+            \"offset\": \"3-6 h\",\n+            \"after_effects\": \"12-48 h residual sedation / ataxia; cognitive dulling can persist several days due to accumulation\"\n-        },\n-        {\n-          \"route\": \"insufflated\",\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"4-8 h (active phase)\",\n-            \"onset\": \"5-15 min\",\n-            \"peak\": \"2-4 h\",\n-            \"offset\": \"1-3 h\",\n-            \"after_effects\": \"1-12 h residual stimulation; visual echoes\"\n-          }\n-        },\n-        {\n-          \"route\": \"vaporized / smoked (free base)\",\n-          \"canonical_routes\": [\n-            \"vaporized\",\n-            \"smoked\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"4-8 h (active phase)\",\n-            \"onset\": \"<1 min\",\n-            \"peak\": \"2-4 h\",\n-            \"offset\": \"1-3 h\",\n-            \"after_effects\": \"1-12 h residual stimulation; visual echoes\"\n-          }\n-    \"addiction_potential\": \"Low; tolerance builds rapidly after a single session. Cravings are uncommon but redosing in the same night markedly increases vasoconstriction and confusion.\",\n+    \"addiction_potential\": \"High: comparable to diazepam but with an 80-120 h half-life, promoting drug build-up, rapid tolerance, and severe physical dependence. Black-outs and compulsive redosing reported at ≥30 mg. Slow diazepam-style tapers (5-10 % every 2 weeks) are strongly advised.\",\n-        \"MAOIs (hypertensive crisis, serotonin syndrome)\",\n-        \"tramadol (seizure risk)\",\n-        \"high-dose stimulants or cathinones (tachyarrhythmia, hyperthermia)\"\n+        \"opioids (respiratory depression)\",\n+        \"alcohol or GHB\",\n+        \"barbiturates\",\n+        \"clozapine (synergistic CNS/respiratory depression)\"\n-        \"other potent 5-HT2A agonists (NBOMe, DOI, DOC)\",\n-        \"opioids, benzodiazepines or alcohol at heavy sedative doses (respiratory depression if unconscious)\"\n+        \"other benzodiazepines or Z-drugs (additive sedation)\",\n+        \"gabapentinoids (ataxia, blackout)\",\n+        \"1st-generation antihistamines (delirium)\"\n-        \"SSRI / SNRI antidepressants (blunted effects, possible serotonergic stress)\",\n-        \"cannabis concentrates (panic, dissociation)\",\n-        \"vasoconstricting compounds (e.g., 2-CB-Fly, 25B-NBOH)\"\n+        \"sedating antipsychotics (QT / hypotension)\",\n+        \"muscle relaxants\",\n+        \"strong CYP3A4 inhibitors (ketoconazole, ritonavir) which prolong effects\"\n-    \"notes\": \"25E-NBOH first appeared on Brazilian blotters in 2018 and is now encountered worldwide in the microgram range. Laboratory seizure papers contain 290-820 µg per 6 mm blotter, often hot-spotted. The molecule is heat- and acid-labile; oral swallowing destroys most activity, so users hold tabs under the tongue for 15-30 min. Forum reports describe pronounced open-eye patterning, saturated colour shifts and a phenethylamine-style body euphoria that peaks earlier than LSD. A 2023 French toxicology case linked 25E-NBOH (blotter) plus the stimulant MDPHP to serotonin syndrome and loss of consciousness requiring ICU admission, illustrating how co-ingestion magnifies risk. Rodent assays show full 5-HT2A agonism (locomotor suppression and DOM-like discriminative stimulus) at sub-milligram doses, confirming very high potency. Because NBOHs thermally decompose to their 2C parent in a hot GC inlet, forensic labs must use LC-MS or derivatisation to avoid mis-identification. Harm reduction: keep single-use doses <1 mg, use precise volumetric or blotter-laid dosing, test with Ehrlich/Marquis (expect weak or no reaction), avoid stacking strong sympathomimetics, and have benzodiazepines on hand for acute agitation.\",\n+    \"notes\": \"Bromonordiazepam (also desalkyl-gidazepam) is the active metabolite of the Ukrainian anxiolytic gidazepam and is now sold online as a long-acting RC benzo. Recreational users estimate ~6 mg ≈ 10 mg diazepam, placing it at roughly 0.6 × diazepam potency. Light anxiolysis emerges at 3-6 mg, while sleep-inducing doses ≥15 mg risk prolonged psychomotor impairment the next day. The elimination half-life averages 86-90 h, with forensic casework suggesting a range of 72-120 h; metabolites can be detected in urine up to 18 days post-dose. Because of this, every-other-day dosing is recommended to avoid accumulation. Long half-life and low peak intensity make it popular for substitution/tapering from high-potency benzos (e.g., bromazolam), but large gaps (3-4 days) between cuts are needed before withdrawal symptoms emerge. Volumetric dosing (e.g., 1 mg/mL ethanol-propylene glycol) greatly improves accuracy for powders that often test 80-95 % purity by GC-MS. Users report clean anxiolysis with minimal euphoria; high doses cause flat affect, retrograde amnesia, dysarthria, and falls. Overdoses are usually benign when taken alone but become life-threatening with opioids or alcohol; keep flumazenil unavailable to laypersons due to seizure risk.\",\n-      \"intense visual geometry and colour shifting\",\n-      \"body euphoria and warmth\",\n-      \"audio enhancement / synaesthesia\",\n-      \"time dilation\",\n-      \"mild tactile numbness\",\n-      \"vasoconstrictive 'cold extremities'\",\n-      \"possible confusion or panic at high dose\"\n+      \"marked anxiolysis\",\n+      \"muscle relaxation\",\n+      \"sedation/somnolence\",\n+      \"mild euphoria at higher doses\",\n+      \"anterograde amnesia\",\n+      \"ataxia and slurred speech\"\n-      \"full_tolerance\": \"after one strong or heavy session\",\n+      \"full_tolerance\": \"within 7-14 days of daily 10-20 mg use\",\n-      \"zero_tolerance\": \"14 days\",\n+      \"zero_tolerance\": \"21-28 days abstinence\",\n-        \"LSD-like lysergamides\",\n-        \"other NBOH / NBOMe compounds\",\n-        \"classic phenethylamine psychedelics (2C-X, DOX)\"\n+        \"all benzodiazepines\",\n+        \"Z-drugs\"\n-    \"half_life\": \"Plasma half-life not well characterised; indirect animal PK suggests 2-4 h with active hydroxylated metabolites.\",\n+    \"half_life\": \"80-120 h (mean ~87 h)\",\n-        \"name\": \"Identification of new NBOH drugs in seized blotter papers\",\n-        \"reference\": \"https://doi.org/10.1007/s11419-019-00509-7\"\n+        \"name\": \"CFSRE toxicology monograph (structure & legal status)\",\n+        \"reference\": \"https://www.cfsre.org/images/monographs/Desalkylgidazepam-120922-CFSRE-Toxicology-Report.pdf\"\n-        \"name\": \"Severe 25E-NBOH intoxication case report (France, 2024)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/38117418/\"\n+        \"name\": \"Designer benzodiazepines review – desalkylgidazepam profile\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/36695345/?utm_source=chatgpt.com\"\n-        \"name\": \"Locomotor and discriminative stimulus effects of NBOH analogues in mice\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/37171529/\"\n+        \"name\": \"ResearchGate overview of gidazepam & bromonordiazepam\",\n+        \"reference\": \"https://www.researchgate.net/publication/367432828_Designer_benzodiazepines_gidazepam_and_desalkygidazepam_bromonordiazepam_What_do_we_know?utm_source=chatgpt.com\"\n-        \"name\": \"NPS Discovery monograph – 25E-NBOH seized material profile\",\n-        \"reference\": \"https://www.cfsre.org/images/monographs/25E-NBOH_022718_NMSLabs_Report.pdf\"\n+        \"name\": \"User-compiled equivalence & dose ranges (FarmerJohn forum)\",\n+        \"reference\": \"https://nzdarknet.com/viewtopic.php?id=3761&utm_source=chatgpt.com\"\n-        \"name\": \"Bluelight ‘Big & Dandy 25x-NBOH’ discussion thread (dose experiences)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/the-big-and-dandy-25x-nboh-megathread-post-your-25x-nboh-info-and-questions-here.918641/\"\n+        \"name\": \"Bluelight metabolite half-life estimate (86.7 h)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/estimated-half-life-and-elimination-time-of-bromazolam-metabolites.938287/?utm_source=chatgpt.com\"\n-        \"name\": \"Reddit /r/researchchemicals post – 500 µg blotter equated to ~300 µg LSD\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/1elkm0i/how_many_mg_of_25enboh_would_you_suggest_me_for_a/\"\n+        \"name\": \"ChemicalBook – onset 20-60 min, duration 6-12 h\",\n+        \"reference\": \"https://www.chemicalbook.com/ChemicalProductProperty_EN_CB01323160.htm\"\n-        \"name\": \"Wikipedia: 25E NBOH\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/25E-NBOH\"\n+        \"name\": \"Reddit experiential report – 6 mg ≈ 10 mg diazepam\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/13g5aei/bromonordiazepam_experience/?utm_source=chatgpt.com\"\n-      \"psychedelic\",\n-      \"research-chemical\"\n+      \"sedative\",\n+      \"research-chemical\",\n+      \"gabaergic\"\n\n# Agmatine Sulfate · #475\n\n-  \"id\": 474,\n-  \"title\": \"Bromonordiazepam\",\n+  \"id\": 475,\n+  \"title\": \"Agmatine Sulfate\",\n-    \"drug_name\": \"Bromonordiazepam\",\n-    \"chemical_name\": \"Bromonordiazepam\",\n+    \"drug_name\": \"Agmatine Sulfate\",\n+    \"chemical_name\": \"Agmatine Sulfate\",\n-    \"chemical_class\": \"Benzodiazepine\",\n-    \"mechanism_of_action\": \"Gamma-aminobutyric acid type A receptor positive allosteric modulator (benzodiazepine site)\",\n-    \"psychoactive_class\": \"GABAA receptor positive-allosteric modulator (benzodiazepine)\",\n+    \"chemical_class\": \"Polyamines\",\n+    \"mechanism_of_action\": \"NMDA receptor antagonist; Imidazoline receptor agonist\",\n+    \"psychoactive_class\": \"Imidazoline receptor agonist; weak NMDA antagonist; alpha-2-adrenergic modulator\",\n-          \"route\": \"oral / sublingual\",\n+          \"route\": \"oral (capsule / powder)\",\n-            \"threshold\": \"2 mg\",\n-            \"light\": \"3mg - 6mg\",\n-            \"common\": \"6mg - 15mg\",\n-            \"strong\": \"15mg - 25mg\",\n-            \"heavy\": \"25+ mg\"\n+            \"threshold\": \"100mg\",\n+            \"light\": \"100mg - 400mg\",\n+            \"common\": \"400mg - 1200mg\",\n+            \"strong\": \"1200mg - 2500mg\",\n+            \"heavy\": \"2500mg+\"\n+        },\n+        {\n+          \"route\": \"sublingual\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"50mg\",\n+            \"light\": \"50mg - 200mg\",\n+            \"common\": \"200mg - 800mg\",\n+            \"strong\": \"800mg - 1600mg\",\n+            \"heavy\": \"1600mg+\"\n+          }\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"150mg\",\n+            \"light\": \"150mg - 400mg\",\n+            \"common\": \"400mg - 1000mg\",\n+            \"strong\": \"1000mg - 2000mg\",\n+            \"heavy\": \"2000mg+\"\n+          }\n-          \"route\": \"oral / sublingual\",\n+          \"route\": \"oral (capsule / powder)\",\n-            \"oral\",\n+            \"oral\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"4-6 h (acute subjective effects)\",\n+            \"onset\": \"15-45 min\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"2-3 h\",\n+            \"after_effects\": \"mild vascular relaxation and mood lift can linger 6-12 h (matches CNS half-life)\"\n+          }\n+        },\n+        {\n+          \"route\": \"sublingual\",\n+          \"canonical_routes\": [\n-            \"total_duration\": \"6-12 h (primary effects)\",\n-            \"onset\": \"20-60 min\",\n-            \"peak\": \"2-4 h\",\n-            \"offset\": \"3-6 h\",\n-            \"after_effects\": \"12-48 h residual sedation / ataxia; cognitive dulling can persist several days due to accumulation\"\n+            \"total_duration\": \"4-6 h (acute subjective effects)\",\n+            \"onset\": \"5-20 min\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"2-3 h\",\n+            \"after_effects\": \"mild vascular relaxation and mood lift can linger 6-12 h (matches CNS half-life)\"\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"canonical_routes\": [\n+            \"rectal\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"4-6 h (acute subjective effects)\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"2-3 h\",\n+            \"after_effects\": \"mild vascular relaxation and mood lift can linger 6-12 h (matches CNS half-life)\"\n+          }\n-    \"addiction_potential\": \"High: comparable to diazepam but with an 80-120 h half-life, promoting drug build-up, rapid tolerance, and severe physical dependence. Black-outs and compulsive redosing reported at ≥30 mg. Slow diazepam-style tapers (5-10 % every 2 weeks) are strongly advised.\",\n+    \"addiction_potential\": \"Very low. No documented physical dependence; weak positive reinforcement. Tolerance to mood-lift and ‘pump’ effects develops in 1-3 weeks of daily use.\",\n-        \"opioids (respiratory depression)\",\n-        \"alcohol or GHB\",\n-        \"barbiturates\",\n-        \"clozapine (synergistic CNS/respiratory depression)\"\n+        \"high-dose opioids or methadone (synergistic respiratory and CNS depression)\",\n+        \"clonidine, rilmenidine or other centrally acting antihypertensives (exaggerated hypotension/bradycardia)\",\n+        \"PDE-5 inhibitors or nitrates (additive vasodilation)\"\n-        \"other benzodiazepines or Z-drugs (additive sedation)\",\n-        \"gabapentinoids (ataxia, blackout)\",\n-        \"1st-generation antihistamines (delirium)\"\n+        \"benzodiazepines, Z-drugs, barbiturates (marked sedation)\",\n+        \"dissociatives such as ketamine or DXM (additive NMDA blockade)\"\n-        \"sedating antipsychotics (QT / hypotension)\",\n-        \"muscle relaxants\",\n-        \"strong CYP3A4 inhibitors (ketoconazole, ritonavir) which prolong effects\"\n+        \"cannabis concentrates (reports of potentiation and dehydration)\",\n+        \"MAO-B inhibitors (unknown catecholamine interactions)\",\n+        \"ACE inhibitors or potassium-sparing diuretics (mild hyperkalaemia noted in DrugBank screens)\"\n-    \"notes\": \"Bromonordiazepam (also desalkyl-gidazepam) is the active metabolite of the Ukrainian anxiolytic gidazepam and is now sold online as a long-acting RC benzo. Recreational users estimate ~6 mg ≈ 10 mg diazepam, placing it at roughly 0.6 × diazepam potency. Light anxiolysis emerges at 3-6 mg, while sleep-inducing doses ≥15 mg risk prolonged psychomotor impairment the next day. The elimination half-life averages 86-90 h, with forensic casework suggesting a range of 72-120 h; metabolites can be detected in urine up to 18 days post-dose. Because of this, every-other-day dosing is recommended to avoid accumulation. Long half-life and low peak intensity make it popular for substitution/tapering from high-potency benzos (e.g., bromazolam), but large gaps (3-4 days) between cuts are needed before withdrawal symptoms emerge. Volumetric dosing (e.g., 1 mg/mL ethanol-propylene glycol) greatly improves accuracy for powders that often test 80-95 % purity by GC-MS. Users report clean anxiolysis with minimal euphoria; high doses cause flat affect, retrograde amnesia, dysarthria, and falls. Overdoses are usually benign when taken alone but become life-threatening with opioids or alcohol; keep flumazenil unavailable to laypersons due to seizure risk.\",\n+    \"notes\": \"Agmatine is an endogenous amine stored in synaptic vesicles and released on neuronal activation. It agonises imidazoline I1/I2 sites, inhibits NOS, and blocks NMDA receptor channels in a voltage-dependent manner, collectively producing mild anxiolysis, vascular smooth-muscle relaxation, and anti-addictive effects. Oral bioavailability is roughly 30 %, with plasma half-life 75-120 min but brain/spinal half-life ~12 h, explaining why twice-daily split dosing maintains opioid-tolerance–reversal despite short plasma kinetics. Clinical and case data show chronic ingestion of 2.67 g/day for five years with normal lab values, yet forum users report tachyphylaxis of subjective effects after 2-3 weeks; cycling (2 weeks on / 1 week off) restores efficacy. For opioid harm-reduction, 500-1500 mg taken 1-2 h *after* the opioid appears to prolong analgesia and reduce required dose, whereas pre-dosing helps attenuate emerging tolerance. High doses (>3 g) occasionally cause transient dizziness, diarrhoea, or profound diuresis due to vasopressin inhibition—keep fluids and electrolytes balanced. Because agmatine lowers blood pressure, hypotensive or dehydrated users should start at the low end of the range and titrate slowly.\",\n-      \"marked anxiolysis\",\n-      \"muscle relaxation\",\n-      \"sedation/somnolence\",\n-      \"mild euphoria at higher doses\",\n-      \"anterograde amnesia\",\n-      \"ataxia and slurred speech\"\n+      \"warm peripheral vasodilation (‘pump’)\",\n+      \"mild euphoria / mood lift\",\n+      \"anxiolysis\",\n+      \"light stimulation or mental clarity\",\n+      \"enhanced opioid, cannabis or benzodiazepine sedation\",\n+      \"reduced withdrawal discomfort\"\n-      \"full_tolerance\": \"within 7-14 days of daily 10-20 mg use\",\n-      \"half_tolerance\": \"4-7 days\",\n-      \"zero_tolerance\": \"21-28 days abstinence\",\n+      \"full_tolerance\": \"2-3 weeks of daily 1g+ dosing\",\n+      \"half_tolerance\": \"7-10 days\",\n+      \"zero_tolerance\": \"21-30 days abstinence\",\n-        \"all benzodiazepines\",\n-        \"Z-drugs\"\n+        \"none firmly established; NMDA-antagonist tolerance may overlap partially with memantine or ketamine\"\n-    \"half_life\": \"80-120 h (mean ~87 h)\",\n+    \"half_life\": \"1-2 h plasma; ~12 h CNS\",\n-        \"name\": \"CFSRE toxicology monograph (structure & legal status)\",\n-        \"reference\": \"https://www.cfsre.org/images/monographs/Desalkylgidazepam-120922-CFSRE-Toxicology-Report.pdf\"\n+        \"name\": \"Wikipedia – pharmacological summary\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Agmatine\"\n-        \"name\": \"Designer benzodiazepines review – desalkylgidazepam profile\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/36695345/?utm_source=chatgpt.com\"\n+        \"name\": \"NutraBio dosage guide (500-2700 mg/day)\",\n+        \"reference\": \"https://nutrabio.com/blogs/endurelite/agmatine-sulfate-benefits-dosage-and-side-effects\"\n-        \"name\": \"ResearchGate overview of gidazepam & bromonordiazepam\",\n-        \"reference\": \"https://www.researchgate.net/publication/367432828_Designer_benzodiazepines_gidazepam_and_desalkygidazepam_bromonordiazepam_What_do_we_know?utm_source=chatgpt.com\"\n+        \"name\": \"Agmatine potentiates morphine analgesia (mouse study)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/11377923/\"\n-        \"name\": \"User-compiled equivalence & dose ranges (FarmerJohn forum)\",\n-        \"reference\": \"https://nzdarknet.com/viewtopic.php?id=3761&utm_source=chatgpt.com\"\n+        \"name\": \"Human case report – 2.67 g/day for 5 years safe\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/25247837/\"\n-        \"name\": \"Bluelight metabolite half-life estimate (86.7 h)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/estimated-half-life-and-elimination-time-of-bromazolam-metabolites.938287/?utm_source=chatgpt.com\"\n+        \"name\": \"Biodistribution & PK (plasma t1/2 74-117 min)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/37770201/\"\n-        \"name\": \"ChemicalBook – onset 20-60 min, duration 6-12 h\",\n-        \"reference\": \"https://www.chemicalbook.com/ChemicalProductProperty_EN_CB01323160.htm\"\n+        \"name\": \"Examine – estimated effective dose 1.6-6.4 mg/kg\",\n+        \"reference\": \"https://examine.com/supplements/agmatine/\"\n-        \"name\": \"Reddit experiential report – 6 mg ≈ 10 mg diazepam\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/13g5aei/bromonordiazepam_experience/?utm_source=chatgpt.com\"\n+        \"name\": \"WebMD – safety profile up to 2.67 g/day\",\n+        \"reference\": \"https://www.webmd.com/vitamins/ai/ingredientmono-1562/agmatine\"\n+      },\n+      {\n+        \"name\": \"Agmatine gene-therapy review – prevents opioid tolerance\",\n+        \"reference\": \"https://www.frontiersin.org/articles/10.3389/fpain.2023.1269017/full\"\n+      },\n+      {\n+        \"name\": \"Bluelight thread – ‘elite supplement’ dosing anecdotes\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/agmatine-sulfate-an-elite-tier-supplement-for-every-druggies-toolkit.943550/\"\n+      },\n+      {\n+        \"name\": \"Bluelight thread – opioid tolerance discussion\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/opioids-agmatine.926160/\"\n+      },\n+      {\n+        \"name\": \"Agmatine reduces morphine dependence (rat)\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC2923207/\"\n+      },\n+      {\n+        \"name\": \"MDPI nutrition study – anxiolytic doses 1-30 mg/kg\",\n+        \"reference\": \"https://www.mdpi.com/2072-6643/17/11/1848\"\n-      \"sedative\",\n-      \"research-chemical\",\n-      \"gabaergic\"\n+      \"nootropic\"\n\n# GVL · #477\n\n-  \"id\": 475,\n-  \"title\": \"Agmatine Sulfate\",\n+  \"id\": 477,\n+  \"title\": \"GVL\",\n-    \"drug_name\": \"Agmatine Sulfate\",\n-    \"chemical_name\": \"Agmatine Sulfate\",\n-    \"alternative_name\": \"\",\n-    \"chemical_class\": \"Polyamines\",\n-    \"mechanism_of_action\": \"NMDA receptor antagonist; Imidazoline receptor agonist\",\n-    \"psychoactive_class\": \"Imidazoline receptor agonist; weak NMDA antagonist; alpha-2-adrenergic modulator\",\n+    \"drug_name\": \"GVL\",\n+    \"chemical_name\": \"GVL\",\n+    \"alternative_name\": \"Gamma-Valerolactone\",\n+    \"chemical_class\": \"GABA analogue (prodrug)\",\n+    \"mechanism_of_action\": \"Gamma-aminobutyric acid type B receptor agonist\",\n+    \"psychoactive_class\": \"GHB analogue; prodrug to γ-hydroxy­valeric acid (GHV) acting at GHB and GABAB receptors\",\n-          \"route\": \"oral (capsule / powder)\",\n-          \"units\": \"mg\",\n+          \"route\": \"oral (liquid; swallowed)\",\n+          \"units\": \"mL\",\n-            \"threshold\": \"100mg\",\n-            \"light\": \"100mg - 400mg\",\n-            \"common\": \"400mg - 1200mg\",\n-            \"strong\": \"1200mg - 2500mg\",\n-            \"heavy\": \"2500mg+\"\n+            \"threshold\": \"1 mL\",\n+            \"light\": \"1 mL - 3 mL\",\n+            \"common\": \"3 mL - 7 mL\",\n+            \"strong\": \"7 mL - 12 mL\",\n+            \"heavy\": \"12+ mL\"\n-        },\n-        {\n-          \"route\": \"sublingual\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"50mg\",\n-            \"light\": \"50mg - 200mg\",\n-            \"common\": \"200mg - 800mg\",\n-            \"strong\": \"800mg - 1600mg\",\n-            \"heavy\": \"1600mg+\"\n-          }\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"150mg\",\n-            \"light\": \"150mg - 400mg\",\n-            \"common\": \"400mg - 1000mg\",\n-            \"strong\": \"1000mg - 2000mg\",\n-            \"heavy\": \"2000mg+\"\n-          }\n-          \"route\": \"oral (capsule / powder)\",\n+          \"route\": \"oral (liquid; swallowed)\",\n-            \"total_duration\": \"4-6 h (acute subjective effects)\",\n-            \"onset\": \"15-45 min\",\n-            \"peak\": \"1-2 h\",\n-            \"offset\": \"2-3 h\",\n-            \"after_effects\": \"mild vascular relaxation and mood lift can linger 6-12 h (matches CNS half-life)\"\n+            \"total_duration\": \"4-8 h (sedative / euphoric phase)\",\n+            \"onset\": \"20-40 min (slower than GBL / GHB)\",\n+            \"peak\": \"1-3 h\",\n+            \"offset\": \"2-4 h\",\n+            \"after_effects\": \"grogginess; disequilibrium 4-8 h; ‘slow-J’ accumulation with redosing\"\n-        },\n-        {\n-          \"route\": \"sublingual\",\n-          \"canonical_routes\": [\n-            \"sublingual\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"4-6 h (acute subjective effects)\",\n-            \"onset\": \"5-20 min\",\n-            \"peak\": \"1-2 h\",\n-            \"offset\": \"2-3 h\",\n-            \"after_effects\": \"mild vascular relaxation and mood lift can linger 6-12 h (matches CNS half-life)\"\n-          }\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"canonical_routes\": [\n-            \"rectal\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"4-6 h (acute subjective effects)\",\n-            \"peak\": \"1-2 h\",\n-            \"offset\": \"2-3 h\",\n-            \"after_effects\": \"mild vascular relaxation and mood lift can linger 6-12 h (matches CNS half-life)\"\n-          }\n-    \"addiction_potential\": \"Very low. No documented physical dependence; weak positive reinforcement. Tolerance to mood-lift and ‘pump’ effects develops in 1-3 weeks of daily use.\",\n+    \"addiction_potential\": \"High: compulsive redosing and 24-h binges of 40-50 mL reported; withdrawal resembles GHB (insomnia, tremor, tachycardia). Tolerance develops after 1-2 days heavy use.\",\n-        \"high-dose opioids or methadone (synergistic respiratory and CNS depression)\",\n-        \"clonidine, rilmenidine or other centrally acting antihypertensives (exaggerated hypotension/bradycardia)\",\n-        \"PDE-5 inhibitors or nitrates (additive vasodilation)\"\n+        \"alcohol or other GABAergic depressants (respiratory arrest)\",\n+        \"benzodiazepines, barbiturates, Z-drugs\",\n+        \"opioids (synergistic hypoventilation)\",\n+        \"ketamine, propofol, or anaesthetic doses of dissociatives\"\n-        \"benzodiazepines, Z-drugs, barbiturates (marked sedation)\",\n-        \"dissociatives such as ketamine or DXM (additive NMDA blockade)\"\n+        \"MAO-B or MAO-A inhibitors\",\n+        \"first-generation antihistamines\",\n+        \"volatile solvents\"\n-        \"cannabis concentrates (reports of potentiation and dehydration)\",\n-        \"MAO-B inhibitors (unknown catecholamine interactions)\",\n-        \"ACE inhibitors or potassium-sparing diuretics (mild hyperkalaemia noted in DrugBank screens)\"\n+        \"stimulants (masking sedation → rebound collapse)\",\n+        \"cannabinoids (vomiting, vertigo)\",\n+        \"antipsychotics (QT prolongation)\"\n-    \"notes\": \"Agmatine is an endogenous amine stored in synaptic vesicles and released on neuronal activation. It agonises imidazoline I1/I2 sites, inhibits NOS, and blocks NMDA receptor channels in a voltage-dependent manner, collectively producing mild anxiolysis, vascular smooth-muscle relaxation, and anti-addictive effects. Oral bioavailability is roughly 30 %, with plasma half-life 75-120 min but brain/spinal half-life ~12 h, explaining why twice-daily split dosing maintains opioid-tolerance–reversal despite short plasma kinetics. Clinical and case data show chronic ingestion of 2.67 g/day for five years with normal lab values, yet forum users report tachyphylaxis of subjective effects after 2-3 weeks; cycling (2 weeks on / 1 week off) restores efficacy. For opioid harm-reduction, 500-1500 mg taken 1-2 h *after* the opioid appears to prolong analgesia and reduce required dose, whereas pre-dosing helps attenuate emerging tolerance. High doses (>3 g) occasionally cause transient dizziness, diarrhoea, or profound diuresis due to vasopressin inhibition—keep fluids and electrolytes balanced. Because agmatine lowers blood pressure, hypotensive or dehydrated users should start at the low end of the range and titrate slowly.\",\n+    \"notes\": \"Density ≈1.05 g mL⁻¹, so 1 mL ≈1050 mg neat GVL. Animal data show GBL is 5-7 × more potent; human anecdotes align, giving typical single doses of 3-7 mL and binge totals >40 mL. Subjectively less euphoric but much longer-acting than GBL/GHB; plateaus rather than peaks, leading users to misjudge redose timing (‘slow-J’). Reported adverse events include delayed convulsive overdose 8-9 h after a 3 mL redose plus alcohol, and daytime microsleeps while driving. Forum users recommend: pre-measured oral syringes, strict 2-h minimum between doses, no mixing with alcohol, and a taper (10 % daily) after multi-day runs to avoid severe rebound insomnia. Laboratory studies find GVL converted hepatically to GHV; GHV shows weaker GABAB affinity but similar autonomic depression. Repeated 100 mg kg⁻¹ (rat) dosing produced neuroadaptive down-regulation of GHB receptor mRNA within one week, suggesting rapid tolerance and dependence mechanisms. No published human PK; rat T½ for GVL→GHV ≈1.3 h, but subjective effects persist longer due to active metabolite redistribution.\",\n-      \"warm peripheral vasodilation (‘pump’)\",\n-      \"mild euphoria / mood lift\",\n+      \"warm physical euphoria\",\n+      \"muscle relaxation\",\n-      \"light stimulation or mental clarity\",\n-      \"enhanced opioid, cannabis or benzodiazepine sedation\",\n-      \"reduced withdrawal discomfort\"\n+      \"mild disinhibition\",\n+      \"slurred speech\",\n+      \"nystagmus and double vision at higher doses\",\n+      \"nausea or chemical taste\",\n+      \"heavy sedation / sleep induction\"\n-      \"full_tolerance\": \"2-3 weeks of daily 1g+ dosing\",\n-      \"half_tolerance\": \"7-10 days\",\n-      \"zero_tolerance\": \"21-30 days abstinence\",\n+      \"full_tolerance\": \"within 24-48 h of continuous use\",\n+      \"half_tolerance\": \"2-3 days\",\n+      \"zero_tolerance\": \"7-14 days\",\n-        \"none firmly established; NMDA-antagonist tolerance may overlap partially with memantine or ketamine\"\n+        \"GHB\",\n+        \"GBL\",\n+        \"1,4-butanediol\"\n-    \"half_life\": \"1-2 h plasma; ~12 h CNS\",\n+    \"half_life\": \"≈1-2 h for GVL; active metabolite GHV extends plasma activity to ~3-4 h\",\n-        \"name\": \"Wikipedia – pharmacological summary\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Agmatine\"\n+        \"name\": \"Uptake of γ-valerolactone – detection of GHV in human urine\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/22349589/\"\n-        \"name\": \"NutraBio dosage guide (500-2700 mg/day)\",\n-        \"reference\": \"https://nutrabio.com/blogs/endurelite/agmatine-sulfate-benefits-dosage-and-side-effects\"\n+        \"name\": \"Comprehensive pharmacological & toxicological evaluation of GVL\",\n+        \"reference\": \"https://www.sciencedirect.com/science/article/pii/S0376871623011894\"\n-        \"name\": \"Agmatine potentiates morphine analgesia (mouse study)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/11377923/\"\n+        \"name\": \"Effect of repeated administration of GHB and GVL in rats\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC10536195/\"\n-        \"name\": \"Human case report – 2.67 g/day for 5 years safe\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/25247837/\"\n+        \"name\": \"Information Bulletin – GHB analogs: GBL, 1,4-BD, GHV, GVL\",\n+        \"reference\": \"https://www.justice.gov/archive/ndic/pubs1/1621/1621t.htm\"\n-        \"name\": \"Biodistribution & PK (plasma t1/2 74-117 min)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/37770201/\"\n+        \"name\": \"Bluelight: GHB/1,4-B/GBL discussion (GVL overdose case, dosing)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/ghb-1-4-b-gbl-discussion-and-use.284723/page-8\"\n-        \"name\": \"Examine – estimated effective dose 1.6-6.4 mg/kg\",\n-        \"reference\": \"https://examine.com/supplements/agmatine/\"\n+        \"name\": \"Bluelight: Gamma-valerolactone/GVL experience thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/gamma-valeronlactone-gvl.625067/\"\n-        \"name\": \"WebMD – safety profile up to 2.67 g/day\",\n-        \"reference\": \"https://www.webmd.com/vitamins/ai/ingredientmono-1562/agmatine\"\n+        \"name\": \"T-Nation product sheet (800 mg mL⁻¹ concentration)\",\n+        \"reference\": \"https://t-nation.com/t/gamma-valerolactone/74574\"\n-        \"name\": \"Agmatine gene-therapy review – prevents opioid tolerance\",\n-        \"reference\": \"https://www.frontiersin.org/articles/10.3389/fpain.2023.1269017/full\"\n-      },\n-      {\n-        \"name\": \"Bluelight thread – ‘elite supplement’ dosing anecdotes\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/agmatine-sulfate-an-elite-tier-supplement-for-every-druggies-toolkit.943550/\"\n-      },\n-      {\n-        \"name\": \"Bluelight thread – opioid tolerance discussion\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/opioids-agmatine.926160/\"\n-      },\n-      {\n-        \"name\": \"Agmatine reduces morphine dependence (rat)\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC2923207/\"\n-      },\n-      {\n-        \"name\": \"MDPI nutrition study – anxiolytic doses 1-30 mg/kg\",\n-        \"reference\": \"https://www.mdpi.com/2072-6643/17/11/1848\"\n+        \"name\": \"γ-Valerolactone – Wikipedia overview & density data\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/%CE%93-Valerolactone\"\n-      \"nootropic\"\n+      \"sedative\",\n+      \"research-chemical\",\n+      \"gabaergic\"\n\n# Methyl-K · #479\n\n-  \"id\": 477,\n-  \"title\": \"GVL\",\n+  \"id\": 479,\n+  \"title\": \"Methyl-K\",\n-    \"drug_name\": \"GVL\",\n-    \"chemical_name\": \"GVL\",\n-    \"alternative_name\": \"Gamma-Valerolactone\",\n-    \"chemical_class\": \"GABA analogue (prodrug)\",\n-    \"mechanism_of_action\": \"Gamma-aminobutyric acid type B receptor agonist\",\n-    \"psychoactive_class\": \"GHB analogue; prodrug to γ-hydroxy­valeric acid (GHV) acting at GHB and GABAB receptors\",\n+    \"drug_name\": \"Methyl-K\",\n+    \"chemical_name\": \"Methyl-K\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Amphetamines\",\n+    \"mechanism_of_action\": \"Stimulant (uncertain mechanism)\",\n+    \"psychoactive_class\": \"Stimulant-entactogen (predicted dopamine > noradrenaline re-uptake inhibitor)\",\n-          \"route\": \"oral (liquid; swallowed)\",\n-          \"units\": \"mL\",\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"1 mL\",\n-            \"light\": \"1 mL - 3 mL\",\n-            \"common\": \"3 mL - 7 mL\",\n-            \"strong\": \"7 mL - 12 mL\",\n-            \"heavy\": \"12+ mL\"\n+            \"threshold\": \"75 mg\",\n+            \"light\": \"75 mg - 150 mg\",\n+            \"common\": \"150 mg - 250 mg\",\n+            \"strong\": \"250 mg - 350 mg\",\n+            \"heavy\": \"350+ mg\"\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"40 mg\",\n+            \"light\": \"40 mg - 80 mg\",\n+            \"common\": \"80 mg - 150 mg\",\n+            \"strong\": \"150 mg - 250 mg\",\n+            \"heavy\": \"250+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"40 mg\",\n+            \"light\": \"40 mg - 90 mg\",\n+            \"common\": \"90 mg - 180 mg\",\n+            \"strong\": \"180 mg - 300 mg\",\n+            \"heavy\": \"300+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"vaporized / smoked\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"5 mg - 15 mg\",\n+            \"common\": \"15 mg - 30 mg\",\n+            \"strong\": \"30 mg - 60 mg\",\n+            \"heavy\": \"60+ mg\"\n+          }\n-          \"route\": \"oral (liquid; swallowed)\",\n+          \"route\": \"oral\",\n-            \"total_duration\": \"4-8 h (sedative / euphoric phase)\",\n-            \"onset\": \"20-40 min (slower than GBL / GHB)\",\n+            \"total_duration\": \"4-7 h\",\n+            \"onset\": \"30-60 min\",\n-            \"offset\": \"2-4 h\",\n-            \"after_effects\": \"grogginess; disequilibrium 4-8 h; ‘slow-J’ accumulation with redosing\"\n+            \"offset\": \"2-3 h taper\",\n+            \"after_effects\": \"2-12 h residual stimulation / insomnia\"\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ],\n+          \"stages\": {\n+            \"onset\": \"5-15 min\",\n+            \"peak\": \"1-3 h\",\n+            \"offset\": \"2-3 h taper\",\n+            \"after_effects\": \"2-12 h residual stimulation / insomnia\"\n+          }\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"canonical_routes\": [\n+            \"rectal\"\n+          ],\n+          \"stages\": {\n+            \"peak\": \"1-3 h\",\n+            \"offset\": \"2-3 h taper\",\n+            \"after_effects\": \"2-12 h residual stimulation / insomnia\"\n+          }\n+        },\n+        {\n+          \"route\": \"vaporized / smoked\",\n+          \"canonical_routes\": [\n+            \"vaporized\",\n+            \"smoked\"\n+          ],\n+          \"stages\": {\n+            \"onset\": \"1-3 min\",\n+            \"peak\": \"1-3 h\",\n+            \"offset\": \"2-3 h taper\",\n+            \"after_effects\": \"2-12 h residual stimulation / insomnia\"\n+          }\n-    \"addiction_potential\": \"High: compulsive redosing and 24-h binges of 40-50 mL reported; withdrawal resembles GHB (insomnia, tremor, tachycardia). Tolerance develops after 1-2 days heavy use.\",\n+    \"addiction_potential\": \"Moderate: predicted dopaminergic action, short plateau and rapid tolerance encourage redosing; compulsive binge risk similar to pentylone-type cathinones.\",\n-        \"alcohol or other GABAergic depressants (respiratory arrest)\",\n-        \"benzodiazepines, barbiturates, Z-drugs\",\n-        \"opioids (synergistic hypoventilation)\",\n-        \"ketamine, propofol, or anaesthetic doses of dissociatives\"\n+        \"MAOIs (hypertensive crisis)\",\n+        \"other potent stimulants (methylphenidate, amphetamines – cardiotoxic synergy)\",\n+        \"serotonergic psychedelics in high doses (possible serotonin toxicity)\",\n+        \"large alcohol or GHB doses (masking CNS depression then rebound tachycardia)\"\n-        \"MAO-B or MAO-A inhibitors\",\n-        \"first-generation antihistamines\",\n-        \"volatile solvents\"\n+        \"cocaine\",\n+        \"MDPV / pyrovalerone analogues\",\n+        \"high-dose caffeine (>400 mg)\"\n-        \"stimulants (masking sedation → rebound collapse)\",\n-        \"cannabinoids (vomiting, vertigo)\",\n-        \"antipsychotics (QT prolongation)\"\n+        \"SSRI / SNRI antidepressants (blunted effects, mild hypertension)\",\n+        \"cannabis concentrates (anxiety, tachycardia)\",\n+        \"β-blockers that lack α-blocking action (unopposed catecholamine rise)\"\n-    \"notes\": \"Density ≈1.05 g mL⁻¹, so 1 mL ≈1050 mg neat GVL. Animal data show GBL is 5-7 × more potent; human anecdotes align, giving typical single doses of 3-7 mL and binge totals >40 mL. Subjectively less euphoric but much longer-acting than GBL/GHB; plateaus rather than peaks, leading users to misjudge redose timing (‘slow-J’). Reported adverse events include delayed convulsive overdose 8-9 h after a 3 mL redose plus alcohol, and daytime microsleeps while driving. Forum users recommend: pre-measured oral syringes, strict 2-h minimum between doses, no mixing with alcohol, and a taper (10 % daily) after multi-day runs to avoid severe rebound insomnia. Laboratory studies find GVL converted hepatically to GHV; GHV shows weaker GABAB affinity but similar autonomic depression. Repeated 100 mg kg⁻¹ (rat) dosing produced neuroadaptive down-regulation of GHB receptor mRNA within one week, suggesting rapid tolerance and dependence mechanisms. No published human PK; rat T½ for GVL→GHV ≈1.3 h, but subjective effects persist longer due to active metabolite redistribution.\",\n+    \"notes\": \"Data are extremely scarce: only one formal PiHKAL trial (100 mg oral produced no overt effects) and a handful of 2025 forum / Reddit self-experiments. Community consensus places active oral dosing somewhere in the low-hundreds of milligrams, broadly mirroring its ethyl homologue MBDB but requiring ~25-40 % higher weight due to weaker serotonin release. Bluelight users describe mild ‘wired but clear’ stimulation, elevated heart-rate (90-110 bpm resting) and difficulty sleeping for >8 h after ≥200 mg. One vaper reported light euphoria, body warmth and jaw tension after 20–30 mg total free-base inhaled across an evening. 3DQSAR’s structure-activity discussion suggests Methyl-K behaves primarily as a dopamine re-uptake inhibitor with limited oral bioavailability, explaining higher effective doses and the preference for intranasal / rectal routes to improve efficiency. Because almost nothing is published on toxicity, reagent-test every batch, use milligram-scale accuracy, and cap first-session totals at <200 mg oral (or <80 mg nasal) to gauge sensitivity. Strong cross-tolerance with other amphetamine-type stimulants develops after a single strong session and dissipates over ~1 week. No metabolism studies exist, but lipophilicity (LogP ≈ 3.4) and α-propyl chain suggest hepatic N-demethylation followed by oxidative deamination analogous to pentylone; theoretical half-life 3–6 h. Avoid chronic high-frequency use to limit cardiomyopathy and neurotoxicity risk seen with other monoamine transport blockers.\",\n-      \"warm physical euphoria\",\n-      \"muscle relaxation\",\n-      \"anxiolysis\",\n-      \"mild disinhibition\",\n-      \"slurred speech\",\n-      \"nystagmus and double vision at higher doses\",\n-      \"nausea or chemical taste\",\n-      \"heavy sedation / sleep induction\"\n+      \"clean mental stimulation\",\n+      \"subtle empathogenic warmth (less pronounced than MDMA)\",\n+      \"mild euphoria\",\n+      \"jaw clenching and bruxism\",\n+      \"increased sociability and talkativeness\",\n+      \"tachycardia and blood-pressure elevation\",\n+      \"insomnia and post-use fatigue\"\n-      \"full_tolerance\": \"within 24-48 h of continuous use\",\n-      \"half_tolerance\": \"2-3 days\",\n-      \"zero_tolerance\": \"7-14 days\",\n+      \"full_tolerance\": \"after one strong/heavy session\",\n+      \"half_tolerance\": \"3-5 days\",\n+      \"zero_tolerance\": \"7-10 days\",\n-        \"GHB\",\n-        \"GBL\",\n-        \"1,4-butanediol\"\n+        \"cathinones (pentylone, methylone)\",\n+        \"amphetamine / methamphetamine\"\n-    \"half_life\": \"≈1-2 h for GVL; active metabolite GHV extends plasma activity to ~3-4 h\",\n+    \"half_life\": \"predicted 3-6 h (no human PK published)\",\n-        \"name\": \"Uptake of γ-valerolactone – detection of GHV in human urine\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/22349589/\"\n+        \"name\": \"Wikipedia – Methyl-K chemical & PiHKAL dose entry\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/1%2C3-Benzodioxolyl-N-methylpentanamine\"\n-        \"name\": \"Comprehensive pharmacological & toxicological evaluation of GVL\",\n-        \"reference\": \"https://www.sciencedirect.com/science/article/pii/S0376871623011894\"\n+        \"name\": \"Bluelight thread – Methyl-K has popped up (DRI speculation, inactivity at 100 mg)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/methyl-k-has-popped-up-predictions-on-effects.944226/\"\n-        \"name\": \"Effect of repeated administration of GHB and GVL in rats\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC10536195/\"\n+        \"name\": \"PiHKAL entry – minimum dose and lack of effects\",\n+        \"reference\": \"https://isomerdesign.com/pihkal/explore.php?domain=pk&id=292\"\n-        \"name\": \"Information Bulletin – GHB analogs: GBL, 1,4-BD, GHV, GVL\",\n-        \"reference\": \"https://www.justice.gov/archive/ndic/pubs1/1621/1621t.htm\"\n+        \"name\": \"ChemicalRoute vendor sheet – states 100 mg minimum dose, no duration data\",\n+        \"reference\": \"https://chemicalroute.com/product/mbdp/\"\n-        \"name\": \"Bluelight: GHB/1,4-B/GBL discussion (GVL overdose case, dosing)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/ghb-1-4-b-gbl-discussion-and-use.284723/page-8\"\n-      },\n-      {\n-        \"name\": \"Bluelight: Gamma-valerolactone/GVL experience thread\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/gamma-valeronlactone-gvl.625067/\"\n-      },\n-      {\n-        \"name\": \"T-Nation product sheet (800 mg mL⁻¹ concentration)\",\n-        \"reference\": \"https://t-nation.com/t/gamma-valerolactone/74574\"\n-      },\n-      {\n-        \"name\": \"γ-Valerolactone – Wikipedia overview & density data\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/%CE%93-Valerolactone\"\n+        \"name\": \"Reddit /r/researchchemicals – user report on vaping Methyl-K (few-mg bowls, mild stimulation)\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/1im2la2/pulled_trigger_vaping_methy_k_aka/\"\n-      \"sedative\",\n+      \"stimulant\",\n-      \"gabaergic\"\n+      \"entactogen\"\n\n# Flumazenil · #480\n\n-  \"id\": 479,\n-  \"title\": \"Methyl-K\",\n+  \"id\": 480,\n+  \"title\": \"Flumazenil\",\n-    \"drug_name\": \"Methyl-K\",\n-    \"chemical_name\": \"Methyl-K\",\n+    \"drug_name\": \"Flumazenil\",\n+    \"chemical_name\": \"Flumazenil\",\n-    \"chemical_class\": \"Amphetamines\",\n-    \"mechanism_of_action\": \"Stimulant (uncertain mechanism)\",\n-    \"psychoactive_class\": \"Stimulant-entactogen (predicted dopamine > noradrenaline re-uptake inhibitor)\",\n+    \"chemical_class\": \"Imidazobenzodiazepine\",\n+    \"mechanism_of_action\": \"Gamma-aminobutyric acid type A receptor positive allosteric modulator (benzodiazepine site)\",\n+    \"psychoactive_class\": \"Benzodiazepine antagonist; GABAA negative allosteric modulator\",\n-          \"route\": \"oral\",\n+          \"route\": \"intravenous (bolus)\",\n-            \"threshold\": \"75 mg\",\n-            \"light\": \"75 mg - 150 mg\",\n-            \"common\": \"150 mg - 250 mg\",\n-            \"strong\": \"250 mg - 350 mg\",\n-            \"heavy\": \"350+ mg\"\n+            \"threshold\": \"0.1 mg\",\n+            \"light\": \"0.2 mg - 0.3 mg\",\n+            \"common\": \"0.3 mg - 1 mg\",\n+            \"strong\": \"1 mg - 3 mg\",\n+            \"heavy\": \"3 mg+\"\n-          \"route\": \"insufflated\",\n-          \"units\": \"mg\",\n+          \"route\": \"intravenous infusion (resedation prevention)\",\n+          \"units\": \"mg/h\",\n-            \"threshold\": \"40 mg\",\n-            \"light\": \"40 mg - 80 mg\",\n-            \"common\": \"80 mg - 150 mg\",\n-            \"strong\": \"150 mg - 250 mg\",\n-            \"heavy\": \"250+ mg\"\n+            \"threshold\": \"0.1 mg/h\",\n+            \"light\": \"0.2 mg/h - 0.5 mg/h\",\n+            \"common\": \"0.5 mg/h - 1 mg/h\",\n+            \"strong\": \"1 mg/h - 3 mg/h\",\n+            \"heavy\": \"3 mg/h+\"\n-          \"route\": \"rectal\",\n-          \"units\": \"mg\",\n+          \"route\": \"intranasal (investigational / pediatric)\",\n+          \"units\": \"mg/kg\",\n-            \"threshold\": \"40 mg\",\n-            \"light\": \"40 mg - 90 mg\",\n-            \"common\": \"90 mg - 180 mg\",\n-            \"strong\": \"180 mg - 300 mg\",\n-            \"heavy\": \"300+ mg\"\n+            \"threshold\": \"0.02 mg/kg\",\n+            \"light\": \"0.02 mg/kg - 0.04 mg/kg\",\n+            \"common\": \"0.04 mg/kg - 0.08 mg/kg\",\n+            \"strong\": \"0.08 mg/kg - 0.10 mg/kg\",\n+            \"heavy\": \"0.10 mg/kg+\"\n-        },\n-        {\n-          \"route\": \"vaporized / smoked\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"5 mg - 15 mg\",\n-            \"common\": \"15 mg - 30 mg\",\n-            \"strong\": \"30 mg - 60 mg\",\n-            \"heavy\": \"60+ mg\"\n-          }\n-          \"route\": \"oral\",\n+          \"route\": \"intravenous (bolus)\",\n-            \"oral\"\n+            \"intravenous\"\n-            \"total_duration\": \"4-7 h\",\n-            \"onset\": \"30-60 min\",\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"2-3 h taper\",\n-            \"after_effects\": \"2-12 h residual stimulation / insomnia\"\n+            \"total_duration\": \"1-2 hours\",\n+            \"onset\": \"1-2 minutes\",\n+            \"peak\": \"6-10 minutes\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"Monitor for resedation for at least 6 hours\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"intravenous infusion (resedation prevention)\",\n-            \"insufflated\"\n+            \"intravenous\"\n-            \"onset\": \"5-15 min\",\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"2-3 h taper\",\n-            \"after_effects\": \"2-12 h residual stimulation / insomnia\"\n+            \"total_duration\": \"Maintained while infusion continues\",\n+            \"onset\": \"Immediate\",\n+            \"peak\": \"Stable during infusion\",\n+            \"offset\": \"<1 hour after stopping infusion\",\n+            \"after_effects\": \"Monitor for resedation for at least 6 hours\"\n-          \"route\": \"rectal\",\n+          \"route\": \"intranasal (investigational / pediatric)\",\n-            \"rectal\"\n+            \"intranasal\"\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"2-3 h taper\",\n-            \"after_effects\": \"2-12 h residual stimulation / insomnia\"\n+            \"total_duration\": \"1-2 hours\",\n+            \"onset\": \"5-8 minutes\",\n+            \"peak\": \"10-20 minutes\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"Monitor for resedation for at least 6 hours\"\n-        },\n-        {\n-          \"route\": \"vaporized / smoked\",\n-          \"canonical_routes\": [\n-            \"vaporized\",\n-            \"smoked\"\n-          ],\n-          \"stages\": {\n-            \"onset\": \"1-3 min\",\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"2-3 h taper\",\n-            \"after_effects\": \"2-12 h residual stimulation / insomnia\"\n-          }\n-    \"addiction_potential\": \"Moderate: predicted dopaminergic action, short plateau and rapid tolerance encourage redosing; compulsive binge risk similar to pentylone-type cathinones.\",\n+    \"addiction_potential\": \"None (neutral antagonist with negligible intrinsic activity). However, compulsive redosing is reported in some harm-reduction contexts where users self-administer flumazenil to ‘reset’ tolerance.\",\n-        \"MAOIs (hypertensive crisis)\",\n-        \"other potent stimulants (methylphenidate, amphetamines – cardiotoxic synergy)\",\n-        \"serotonergic psychedelics in high doses (possible serotonin toxicity)\",\n-        \"large alcohol or GHB doses (masking CNS depression then rebound tachycardia)\"\n+        \"Co-ingestion of tricyclic antidepressants or other pro-convulsants (may trigger status epilepticus)\",\n+        \"Chronic benzodiazepine dependence (precipitates severe withdrawal and seizures)\",\n+        \"Mixed overdoses involving bupropion, tramadol, theophylline or isoniazid (lowers seizure threshold further)\"\n-        \"cocaine\",\n-        \"MDPV / pyrovalerone analogues\",\n-        \"high-dose caffeine (>400 mg)\"\n+        \"Long-acting benzodiazepines (e.g., clonazepam, diazepam) without continuous monitoring — rebound sedation likely\",\n+        \"Patients with known seizure disorders not protected by benzodiazepines\"\n-        \"SSRI / SNRI antidepressants (blunted effects, mild hypertension)\",\n-        \"cannabis concentrates (anxiety, tachycardia)\",\n-        \"β-blockers that lack α-blocking action (unopposed catecholamine rise)\"\n+        \"Opioids or alcohol (antagonising sedation can unmask respiratory depression from these CNS depressants)\",\n+        \"Antipsychotics with QT-prolonging potential (seizure-related arrhythmias)\",\n+        \"Pregnancy (limited data; Category C)\"\n-    \"notes\": \"Data are extremely scarce: only one formal PiHKAL trial (100 mg oral produced no overt effects) and a handful of 2025 forum / Reddit self-experiments. Community consensus places active oral dosing somewhere in the low-hundreds of milligrams, broadly mirroring its ethyl homologue MBDB but requiring ~25-40 % higher weight due to weaker serotonin release. Bluelight users describe mild ‘wired but clear’ stimulation, elevated heart-rate (90-110 bpm resting) and difficulty sleeping for >8 h after ≥200 mg. One vaper reported light euphoria, body warmth and jaw tension after 20–30 mg total free-base inhaled across an evening. 3DQSAR’s structure-activity discussion suggests Methyl-K behaves primarily as a dopamine re-uptake inhibitor with limited oral bioavailability, explaining higher effective doses and the preference for intranasal / rectal routes to improve efficiency. Because almost nothing is published on toxicity, reagent-test every batch, use milligram-scale accuracy, and cap first-session totals at <200 mg oral (or <80 mg nasal) to gauge sensitivity. Strong cross-tolerance with other amphetamine-type stimulants develops after a single strong session and dissipates over ~1 week. No metabolism studies exist, but lipophilicity (LogP ≈ 3.4) and α-propyl chain suggest hepatic N-demethylation followed by oxidative deamination analogous to pentylone; theoretical half-life 3–6 h. Avoid chronic high-frequency use to limit cardiomyopathy and neurotoxicity risk seen with other monoamine transport blockers.\",\n+    \"notes\": \"Flumazenil is the benzodiazepine antidote and can abruptly trigger withdrawal or seizures in dependent individuals. It should only be used with seizure management on standby and careful screening for mixed overdoses.\\n\\nFlumazenil competitively blocks the benzodiazepine site on the GABAA receptor. When used on benzodiazepine-tolerant individuals it can precipitate an abrupt, sometimes life-threatening withdrawal characterised by agitation, hypertension and generalised tonic-clonic seizures. Case series show neurologic adverse-event reporting odds ratios >1700 for ‘withdrawal seizures’ in pharmacovigilance databases :contentReference[oaicite:0]{index=0}. Doses >5 mg cumulatively rarely add benefit; lack of response after 5 mg suggests non-benzodiazepine sedatives are present :contentReference[oaicite:1]{index=1}. Because its terminal half-life (40-80 min) is often much shorter than diazepam (>30 h) or phenazepam (>60 h), patients require observation for at least 6 h and sometimes a low-rate infusion (0.1-0.5 mg/h) to prevent resedation :contentReference[oaicite:2]{index=2}. Intranasal flumazenil (0.04-0.08 mg/kg) reaches therapeutic plasma levels within 10 min and may be useful where IV access is delayed, but data are confined to paediatric pharmacokinetic studies :contentReference[oaicite:3]{index=3}. Harm-reduction practitioners occasionally micro-dose (0.1-0.2 mg) flumazenil during benzodiazepine tapering protocols to down-regulate tolerance; this should only occur under medical supervision with seizure prophylaxis (e.g., levetiracetam). Always have IV diazepam or midazolam ready to re-treat seizures induced by flumazenil. Multi-reagent test kits do not detect flumazenil; stash-checking services can confirm identity by LC-MS if diversion is suspected.\",\n-      \"clean mental stimulation\",\n-      \"subtle empathogenic warmth (less pronounced than MDMA)\",\n-      \"mild euphoria\",\n-      \"jaw clenching and bruxism\",\n-      \"increased sociability and talkativeness\",\n-      \"tachycardia and blood-pressure elevation\",\n-      \"insomnia and post-use fatigue\"\n+      \"Abrupt return of consciousness\",\n+      \"Anxiety or panic\",\n+      \"Dysphoria\",\n+      \"Dizziness\",\n+      \"Nausea or vomiting\",\n+      \"Tremor\",\n+      \"Possible tonic-clonic seizures in dependent users\"\n-      \"full_tolerance\": \"after one strong/heavy session\",\n-      \"half_tolerance\": \"3-5 days\",\n-      \"zero_tolerance\": \"7-10 days\",\n-      \"cross_tolerances\": [\n-        \"cathinones (pentylone, methylone)\",\n-        \"amphetamine / methamphetamine\"\n-      ]\n+      \"full_tolerance\": \"N/A\",\n+      \"half_tolerance\": \"N/A\",\n+      \"zero_tolerance\": \"N/A\",\n+      \"cross_tolerances\": []\n-    \"half_life\": \"predicted 3-6 h (no human PK published)\",\n+    \"half_life\": \"40-80 min (distribution half-life ~4-11 min)\",\n-        \"name\": \"Wikipedia – Methyl-K chemical & PiHKAL dose entry\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/1%2C3-Benzodioxolyl-N-methylpentanamine\"\n+        \"name\": \"StatPearls – Flumazenil (updated 2024)\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/books/NBK470180/\"\n-        \"name\": \"Bluelight thread – Methyl-K has popped up (DRI speculation, inactivity at 100 mg)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/methyl-k-has-popped-up-predictions-on-effects.944226/\"\n+        \"name\": \"Medscape – Romazicon dosing\",\n+        \"reference\": \"https://reference.medscape.com/drug/romazicon-flumazenil-343731\"\n-        \"name\": \"PiHKAL entry – minimum dose and lack of effects\",\n-        \"reference\": \"https://isomerdesign.com/pihkal/explore.php?domain=pk&id=292\"\n+        \"name\": \"Drugs.com dosage guide (2025)\",\n+        \"reference\": \"https://www.drugs.com/dosage/flumazenil.html\"\n-        \"name\": \"ChemicalRoute vendor sheet – states 100 mg minimum dose, no duration data\",\n-        \"reference\": \"https://chemicalroute.com/product/mbdp/\"\n+        \"name\": \"Flumazenil-precipitated withdrawal study\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/10591888/\"\n-        \"name\": \"Reddit /r/researchchemicals – user report on vaping Methyl-K (few-mg bowls, mild stimulation)\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/1im2la2/pulled_trigger_vaping_methy_k_aka/\"\n+        \"name\": \"Parametric withdrawal intensity study\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/15452683/\"\n+      },\n+      {\n+        \"name\": \"Comprehensive evaluation of adverse reactions (2025)\",\n+        \"reference\": \"https://journals.lww.com/md-journal/fulltext/2025/03070/comprehensive_evaluation_of_flumazenil_adverse.17.aspx\"\n+      },\n+      {\n+        \"name\": \"Intranasal pharmacokinetics in children\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/10674504/\"\n+      },\n+      {\n+        \"name\": \"Austin Health flumazenil guideline (2024)\",\n+        \"reference\": \"https://www.austin.org.au/Assets/Files/Flumazenil_July%202024.pdf\"\n+      },\n+      {\n+        \"name\": \"DrugBank – Flumazenil\",\n+        \"reference\": \"https://go.drugbank.com/drugs/DB01205\"\n-      \"stimulant\",\n-      \"research-chemical\",\n-      \"entactogen\"\n+      \"research-chemical\"\n\n# Hexedrone · #481\n\n-  \"id\": 480,\n-  \"title\": \"Flumazenil\",\n+  \"id\": 481,\n+  \"title\": \"Hexedrone\",\n-    \"drug_name\": \"Flumazenil\",\n-    \"chemical_name\": \"Flumazenil\",\n+    \"drug_name\": \"Hexedrone\",\n+    \"chemical_name\": \"Hexedrone\",\n-    \"chemical_class\": \"Imidazobenzodiazepine\",\n-    \"mechanism_of_action\": \"Gamma-aminobutyric acid type A receptor positive allosteric modulator (benzodiazepine site)\",\n-    \"psychoactive_class\": \"Benzodiazepine antagonist; GABAA negative allosteric modulator\",\n+    \"chemical_class\": \"Cathinones\",\n+    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor\",\n+    \"psychoactive_class\": \"Stimulant\",\n-          \"route\": \"intravenous (bolus)\",\n+          \"route\": \"oral\",\n-            \"threshold\": \"0.1 mg\",\n-            \"light\": \"0.2 mg - 0.3 mg\",\n-            \"common\": \"0.3 mg - 1 mg\",\n-            \"strong\": \"1 mg - 3 mg\",\n-            \"heavy\": \"3 mg+\"\n+            \"threshold\": \"10 mg\",\n+            \"light\": \"20-40 mg\",\n+            \"common\": \"40-80 mg\",\n+            \"strong\": \"80-120 mg\",\n+            \"heavy\": \"120 mg+\"\n-          \"route\": \"intravenous infusion (resedation prevention)\",\n-          \"units\": \"mg/h\",\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"0.1 mg/h\",\n-            \"light\": \"0.2 mg/h - 0.5 mg/h\",\n-            \"common\": \"0.5 mg/h - 1 mg/h\",\n-            \"strong\": \"1 mg/h - 3 mg/h\",\n-            \"heavy\": \"3 mg/h+\"\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"15-25 mg\",\n+            \"common\": \"25-40 mg\",\n+            \"strong\": \"40-50 mg\",\n+            \"heavy\": \"50 mg+\"\n-        },\n-        {\n-          \"route\": \"intranasal (investigational / pediatric)\",\n-          \"units\": \"mg/kg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"0.02 mg/kg\",\n-            \"light\": \"0.02 mg/kg - 0.04 mg/kg\",\n-            \"common\": \"0.04 mg/kg - 0.08 mg/kg\",\n-            \"strong\": \"0.08 mg/kg - 0.10 mg/kg\",\n-            \"heavy\": \"0.10 mg/kg+\"\n-          }\n-          \"route\": \"intravenous (bolus)\",\n+          \"route\": \"oral\",\n-            \"intravenous\"\n+            \"oral\"\n-            \"total_duration\": \"1-2 hours\",\n-            \"onset\": \"1-2 minutes\",\n-            \"peak\": \"6-10 minutes\",\n+            \"total_duration\": \"2-4 hours\",\n+            \"onset\": \"15-30 minutes\",\n+            \"peak\": \"1-2 hours\",\n-            \"after_effects\": \"Monitor for resedation for at least 6 hours\"\n+            \"after_effects\": \"2-4 hours\"\n-          \"route\": \"intravenous infusion (resedation prevention)\",\n+          \"route\": \"insufflated\",\n-            \"intravenous\"\n+            \"insufflated\"\n-            \"total_duration\": \"Maintained while infusion continues\",\n-            \"onset\": \"Immediate\",\n-            \"peak\": \"Stable during infusion\",\n-            \"offset\": \"<1 hour after stopping infusion\",\n-            \"after_effects\": \"Monitor for resedation for at least 6 hours\"\n-          }\n-        },\n-        {\n-          \"route\": \"intranasal (investigational / pediatric)\",\n-          \"canonical_routes\": [\n-            \"intranasal\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"1-2 hours\",\n-            \"onset\": \"5-8 minutes\",\n-            \"peak\": \"10-20 minutes\",\n+            \"total_duration\": \"2-4 hours\",\n+            \"onset\": \"15-30 minutes\",\n+            \"peak\": \"1-2 hours\",\n-            \"after_effects\": \"Monitor for resedation for at least 6 hours\"\n+            \"after_effects\": \"2-4 hours\"\n-    \"addiction_potential\": \"None (neutral antagonist with negligible intrinsic activity). However, compulsive redosing is reported in some harm-reduction contexts where users self-administer flumazenil to ‘reset’ tolerance.\",\n+    \"addiction_potential\": \"Moderate, with potential for compulsive redosing.\",\n-        \"Co-ingestion of tricyclic antidepressants or other pro-convulsants (may trigger status epilepticus)\",\n-        \"Chronic benzodiazepine dependence (precipitates severe withdrawal and seizures)\",\n-        \"Mixed overdoses involving bupropion, tramadol, theophylline or isoniazid (lowers seizure threshold further)\"\n+        \"MAOIs\",\n+        \"SSRIs\"\n-        \"Long-acting benzodiazepines (e.g., clonazepam, diazepam) without continuous monitoring — rebound sedation likely\",\n-        \"Patients with known seizure disorders not protected by benzodiazepines\"\n+        \"Alcohol\",\n+        \"Benzodiazepines\"\n-        \"Opioids or alcohol (antagonising sedation can unmask respiratory depression from these CNS depressants)\",\n-        \"Antipsychotics with QT-prolonging potential (seizure-related arrhythmias)\",\n-        \"Pregnancy (limited data; Category C)\"\n+        \"Other stimulants\",\n+        \"Caffeine\"\n-    \"notes\": \"Flumazenil is the benzodiazepine antidote and can abruptly trigger withdrawal or seizures in dependent individuals. It should only be used with seizure management on standby and careful screening for mixed overdoses.\\n\\nFlumazenil competitively blocks the benzodiazepine site on the GABAA receptor. When used on benzodiazepine-tolerant individuals it can precipitate an abrupt, sometimes life-threatening withdrawal characterised by agitation, hypertension and generalised tonic-clonic seizures. Case series show neurologic adverse-event reporting odds ratios >1700 for ‘withdrawal seizures’ in pharmacovigilance databases :contentReference[oaicite:0]{index=0}. Doses >5 mg cumulatively rarely add benefit; lack of response after 5 mg suggests non-benzodiazepine sedatives are present :contentReference[oaicite:1]{index=1}. Because its terminal half-life (40-80 min) is often much shorter than diazepam (>30 h) or phenazepam (>60 h), patients require observation for at least 6 h and sometimes a low-rate infusion (0.1-0.5 mg/h) to prevent resedation :contentReference[oaicite:2]{index=2}. Intranasal flumazenil (0.04-0.08 mg/kg) reaches therapeutic plasma levels within 10 min and may be useful where IV access is delayed, but data are confined to paediatric pharmacokinetic studies :contentReference[oaicite:3]{index=3}. Harm-reduction practitioners occasionally micro-dose (0.1-0.2 mg) flumazenil during benzodiazepine tapering protocols to down-regulate tolerance; this should only occur under medical supervision with seizure prophylaxis (e.g., levetiracetam). Always have IV diazepam or midazolam ready to re-treat seizures induced by flumazenil. Multi-reagent test kits do not detect flumazenil; stash-checking services can confirm identity by LC-MS if diversion is suspected.\",\n+    \"notes\": \"Hexedrone is a synthetic stimulant that is chemically related to other cathinones. It is known for its stimulant effects and potential for compulsive use. Users should be cautious of its interaction with other substances, particularly those affecting serotonin levels.\",\n-      \"Abrupt return of consciousness\",\n-      \"Anxiety or panic\",\n-      \"Dysphoria\",\n-      \"Dizziness\",\n-      \"Nausea or vomiting\",\n-      \"Tremor\",\n-      \"Possible tonic-clonic seizures in dependent users\"\n+      \"Increased energy\",\n+      \"Euphoria\",\n+      \"Increased focus\",\n+      \"Appetite suppression\",\n+      \"Increased heart rate\"\n-      \"full_tolerance\": \"N/A\",\n-      \"half_tolerance\": \"N/A\",\n-      \"zero_tolerance\": \"N/A\",\n-      \"cross_tolerances\": []\n+      \"full_tolerance\": \"Within days of repeated use\",\n+      \"half_tolerance\": \"3-7 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n+      \"cross_tolerances\": [\n+        \"Other stimulants\",\n+        \"Dopamine-affecting substances\"\n+      ]\n-    \"half_life\": \"40-80 min (distribution half-life ~4-11 min)\",\n+    \"half_life\": \"Unknown\",\n-        \"name\": \"StatPearls – Flumazenil (updated 2024)\",\n-        \"reference\": \"https://www.ncbi.nlm.nih.gov/books/NBK470180/\"\n+        \"name\": \"Erowid Hexedrone Vault\",\n+        \"reference\": \"https://erowid.org/chemicals/hexedrone/hexedrone.shtml\"\n-        \"name\": \"Medscape – Romazicon dosing\",\n-        \"reference\": \"https://reference.medscape.com/drug/romazicon-flumazenil-343731\"\n-      },\n-      {\n-        \"name\": \"Drugs.com dosage guide (2025)\",\n-        \"reference\": \"https://www.drugs.com/dosage/flumazenil.html\"\n-      },\n-      {\n-        \"name\": \"Flumazenil-precipitated withdrawal study\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/10591888/\"\n-      },\n-      {\n-        \"name\": \"Parametric withdrawal intensity study\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/15452683/\"\n-      },\n-      {\n-        \"name\": \"Comprehensive evaluation of adverse reactions (2025)\",\n-        \"reference\": \"https://journals.lww.com/md-journal/fulltext/2025/03070/comprehensive_evaluation_of_flumazenil_adverse.17.aspx\"\n-      },\n-      {\n-        \"name\": \"Intranasal pharmacokinetics in children\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/10674504/\"\n-      },\n-      {\n-        \"name\": \"Austin Health flumazenil guideline (2024)\",\n-        \"reference\": \"https://www.austin.org.au/Assets/Files/Flumazenil_July%202024.pdf\"\n-      },\n-      {\n-        \"name\": \"DrugBank – Flumazenil\",\n-        \"reference\": \"https://go.drugbank.com/drugs/DB01205\"\n+        \"name\": \"Drug User's Bible - Hexen\",\n+        \"reference\": \"https://drugusersbible.org/content/chemscape/stimulants/hexen/\"\n-      \"research-chemical\"\n+      \"stimulant\",\n+      \"research-chemical\",\n+      \"habit-forming\"\n\n# L-Theanine · #483\n\n-  \"id\": 481,\n-  \"title\": \"Hexedrone\",\n+  \"id\": 483,\n+  \"title\": \"L-Theanine\",\n-    \"drug_name\": \"Hexedrone\",\n-    \"chemical_name\": \"Hexedrone\",\n+    \"drug_name\": \"L-Theanine\",\n+    \"chemical_name\": \"L-Theanine\",\n-    \"chemical_class\": \"Cathinones\",\n-    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor\",\n-    \"psychoactive_class\": \"Stimulant\",\n+    \"chemical_class\": \"Amino acids and amino acid derivatives\",\n+    \"mechanism_of_action\": \"Glutamate receptor modulator\",\n+    \"psychoactive_class\": \"Nootropic\",\n-            \"threshold\": \"10 mg\",\n-            \"light\": \"20-40 mg\",\n-            \"common\": \"40-80 mg\",\n-            \"strong\": \"80-120 mg\",\n-            \"heavy\": \"120 mg+\"\n+            \"threshold\": \"50 mg\",\n+            \"light\": \"100 - 200 mg\",\n+            \"common\": \"200 - 400 mg\",\n+            \"strong\": \"400 - 600 mg\",\n+            \"heavy\": \"600 mg+\"\n-        },\n-        {\n-          \"route\": \"insufflated\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"15-25 mg\",\n-            \"common\": \"25-40 mg\",\n-            \"strong\": \"40-50 mg\",\n-            \"heavy\": \"50 mg+\"\n-          }\n-            \"total_duration\": \"2-4 hours\",\n-            \"onset\": \"15-30 minutes\",\n-            \"peak\": \"1-2 hours\",\n-            \"offset\": \"1-2 hours\",\n-            \"after_effects\": \"2-4 hours\"\n+            \"total_duration\": \"4 - 6 hours\",\n+            \"onset\": \"30 - 60 minutes\",\n+            \"peak\": \"1 - 2 hours\",\n+            \"offset\": \"2 - 4 hours\",\n+            \"after_effects\": \"Minimal\"\n-        },\n-        {\n-          \"route\": \"insufflated\",\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"2-4 hours\",\n-            \"onset\": \"15-30 minutes\",\n-            \"peak\": \"1-2 hours\",\n-            \"offset\": \"1-2 hours\",\n-            \"after_effects\": \"2-4 hours\"\n-          }\n-    \"addiction_potential\": \"Moderate, with potential for compulsive redosing.\",\n+    \"addiction_potential\": \"L-Theanine is not considered to have addiction potential.\",\n-      \"dangerous\": [\n-        \"MAOIs\",\n-        \"SSRIs\"\n-      ],\n-      \"unsafe\": [\n-        \"Alcohol\",\n-        \"Benzodiazepines\"\n-      ],\n+      \"dangerous\": [],\n+      \"unsafe\": [],\n-        \"Other stimulants\",\n-    \"notes\": \"Hexedrone is a synthetic stimulant that is chemically related to other cathinones. It is known for its stimulant effects and potential for compulsive use. Users should be cautious of its interaction with other substances, particularly those affecting serotonin levels.\",\n+    \"notes\": \"L-Theanine is often used to reduce anxiety and promote relaxation without sedation. It is commonly found in tea and used as a supplement for its calming effects.\",\n-      \"Increased energy\",\n-      \"Euphoria\",\n-      \"Increased focus\",\n-      \"Appetite suppression\",\n-      \"Increased heart rate\"\n+      \"Relaxation\",\n+      \"Reduced anxiety\",\n+      \"Improved focus\",\n+      \"Calmness\",\n+      \"Increased GABA activity\"\n-      \"full_tolerance\": \"Within days of repeated use\",\n-      \"half_tolerance\": \"3-7 days\",\n-      \"zero_tolerance\": \"1-2 weeks\",\n-      \"cross_tolerances\": [\n-        \"Other stimulants\",\n-        \"Dopamine-affecting substances\"\n-      ]\n+      \"full_tolerance\": \"Not established\",\n+      \"half_tolerance\": \"Not established\",\n+      \"zero_tolerance\": \"Not established\",\n+      \"cross_tolerances\": []\n-    \"half_life\": \"Unknown\",\n+    \"half_life\": \"Approximately 1 - 2 hours\",\n-        \"name\": \"Erowid Hexedrone Vault\",\n-        \"reference\": \"https://erowid.org/chemicals/hexedrone/hexedrone.shtml\"\n+        \"name\": \"WebMD - Theanine\",\n+        \"reference\": \"https://www.webmd.com/vitamins/ai/ingredientmono-1053/theanine\"\n-        \"name\": \"Drug User's Bible - Hexen\",\n-        \"reference\": \"https://drugusersbible.org/content/chemscape/stimulants/hexen/\"\n+        \"name\": \"DrugBank - L-Theanine\",\n+        \"reference\": \"https://drugbank.com/drugs/DB12444\"\n-      \"stimulant\",\n-      \"research-chemical\",\n-      \"habit-forming\"\n+      \"nootropic\",\n+      \"supplement\",\n+      \"sedative\"\n\n# Imodium · #484\n\n-  \"id\": 483,\n-  \"title\": \"L-Theanine\",\n+  \"id\": 484,\n+  \"title\": \"Imodium\",\n-    \"drug_name\": \"L-Theanine\",\n-    \"chemical_name\": \"L-Theanine\",\n-    \"alternative_name\": \"\",\n-    \"chemical_class\": \"Amino acids and amino acid derivatives\",\n-    \"mechanism_of_action\": \"Glutamate receptor modulator\",\n-    \"psychoactive_class\": \"Nootropic\",\n+    \"drug_name\": \"Imodium\",\n+    \"chemical_name\": \"Loperamide\",\n+    \"alternative_name\": \"Loperamide\",\n+    \"chemical_class\": \"Phenylpiperidines\",\n+    \"mechanism_of_action\": \"μ-Opioid receptor agonist (peripherally-restricted)\",\n+    \"psychoactive_class\": \"Opioid (peripherally acting)\",\n-            \"threshold\": \"50 mg\",\n-            \"light\": \"100 - 200 mg\",\n-            \"common\": \"200 - 400 mg\",\n-            \"strong\": \"400 - 600 mg\",\n-            \"heavy\": \"600 mg+\"\n+            \"threshold\": \"0.5 mg\",\n+            \"light\": \"1-2 mg\",\n+            \"common\": \"2-8 mg\",\n+            \"strong\": \"8-16 mg\",\n+            \"heavy\": \"16+ mg (not recommended)\"\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"0.5 mg\",\n+            \"light\": \"1-2 mg\",\n+            \"common\": \"2-8 mg\",\n+            \"strong\": \"8-16 mg\",\n+            \"heavy\": \"16+ mg (not recommended)\"\n+          }\n-            \"total_duration\": \"4 - 6 hours\",\n-            \"onset\": \"30 - 60 minutes\",\n-            \"peak\": \"1 - 2 hours\",\n-            \"offset\": \"2 - 4 hours\",\n-            \"after_effects\": \"Minimal\"\n+            \"total_duration\": \"6-24 hours\",\n+            \"onset\": \"0.5-1 hour\",\n+            \"peak\": \"2-5 hours\",\n+            \"offset\": \"12-24 hours\",\n+            \"after_effects\": \"Minimal; but constipation may persist\"\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"canonical_routes\": [\n+            \"rectal\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"6-24 hours\",\n+            \"onset\": \"0.5-1 hour\",\n+            \"peak\": \"2-5 hours\",\n+            \"offset\": \"12-24 hours\",\n+            \"after_effects\": \"Minimal; but constipation may persist\"\n+          }\n-    \"addiction_potential\": \"L-Theanine is not considered to have addiction potential.\",\n+    \"addiction_potential\": \"Low when used as directed for diarrhea. However, at high doses, misuse can lead to opioid-like effects and dependency, as well as severe cardiac toxicity.\",\n-      \"dangerous\": [],\n-      \"unsafe\": [],\n+      \"dangerous\": [\n+        \"other opioids\",\n+        \"CYP3A4 inhibitors\",\n+        \"CYP2C8 inhibitors\",\n+        \"P-glycoprotein inhibitors\"\n+      ],\n+      \"unsafe\": [\n+        \"quinidine\",\n+        \"ritonavir\",\n+        \"macrolide antibiotics\"\n+      ],\n-        \"Caffeine\"\n+        \"anticholinergics\",\n+        \"other CNS depressants\"\n-    \"notes\": \"L-Theanine is often used to reduce anxiety and promote relaxation without sedation. It is commonly found in tea and used as a supplement for its calming effects.\",\n+    \"notes\": \"Loperamide is an over-the-counter anti-diarrheal medication. At therapeutic doses, it acts peripherally and does not cross the blood-brain barrier significantly. At high doses or with certain drug interactions, it can cause central opioid effects and life-threatening cardiac arrhythmias (QT prolongation, Torsades de Pointes). Misuse has led to fatalities. Not recommended for recreational use or for opioid withdrawal management without medical supervision.\",\n-      \"Relaxation\",\n-      \"Reduced anxiety\",\n-      \"Improved focus\",\n-      \"Calmness\",\n-      \"Increased GABA activity\"\n+      \"Constipation\",\n+      \"Reduced gastrointestinal motility\",\n+      \"Mild sedation (rare, high doses)\",\n+      \"Euphoria (rare, high doses, especially with P-gp inhibitors)\",\n+      \"Cardiac arrhythmias (high doses)\",\n+      \"Abdominal pain\"\n-      \"full_tolerance\": \"Not established\",\n-      \"half_tolerance\": \"Not established\",\n-      \"zero_tolerance\": \"Not established\",\n-      \"cross_tolerances\": []\n+      \"full_tolerance\": \"Develops rapidly with high/repeated doses (days)\",\n+      \"half_tolerance\": \"Several days to 1 week\",\n+      \"zero_tolerance\": \"1-2 weeks after cessation\",\n+      \"cross_tolerances\": [\n+        \"opioids\"\n+      ]\n-    \"half_life\": \"Approximately 1 - 2 hours\",\n+    \"half_life\": \"9-14 hours (may be prolonged at high doses or with liver impairment)\",\n-        \"name\": \"WebMD - Theanine\",\n-        \"reference\": \"https://www.webmd.com/vitamins/ai/ingredientmono-1053/theanine\"\n+        \"name\": \"DrugBank: Loperamide\",\n+        \"reference\": \"https://go.drugbank.com/drugs/DB00836\"\n-        \"name\": \"DrugBank - L-Theanine\",\n-        \"reference\": \"https://drugbank.com/drugs/DB12444\"\n+        \"name\": \"Bluelight: Loperamide Megathread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/loperamide-immodium-megathread-we-have-now-lost-at-least-2-of-our-own-from-lope.296086/\"\n-      \"nootropic\",\n-      \"supplement\",\n-      \"sedative\"\n+      \"opioid\",\n+      \"depressant\",\n+      \"habit-forming\"\n\n# LSZ · #485\n\n-  \"id\": 484,\n-  \"title\": \"Imodium\",\n+  \"id\": 485,\n+  \"title\": \"LSZ\",\n-    \"drug_name\": \"Imodium\",\n-    \"chemical_name\": \"Loperamide\",\n-    \"alternative_name\": \"Loperamide\",\n-    \"chemical_class\": \"Phenylpiperidines\",\n-    \"mechanism_of_action\": \"μ-Opioid receptor agonist (peripherally-restricted)\",\n-    \"psychoactive_class\": \"Opioid (peripherally acting)\",\n+    \"drug_name\": \"LSZ\",\n+    \"chemical_name\": \"LSZ\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Lysergamides\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-          \"units\": \"mg\",\n+          \"units\": \"\\bµg\",\n-            \"threshold\": \"0.5 mg\",\n-            \"light\": \"1-2 mg\",\n-            \"common\": \"2-8 mg\",\n-            \"strong\": \"8-16 mg\",\n-            \"heavy\": \"16+ mg (not recommended)\"\n+            \"threshold\": \"50 \\bµg\",\n+            \"light\": \"75-150 \\bµg\",\n+            \"common\": \"150-300 \\bµg\",\n+            \"strong\": \"300-450 \\bµg\",\n+            \"heavy\": \"450+ \\bµg\"\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"0.5 mg\",\n-            \"light\": \"1-2 mg\",\n-            \"common\": \"2-8 mg\",\n-            \"strong\": \"8-16 mg\",\n-            \"heavy\": \"16+ mg (not recommended)\"\n-          }\n-            \"total_duration\": \"6-24 hours\",\n-            \"onset\": \"0.5-1 hour\",\n-            \"peak\": \"2-5 hours\",\n-            \"offset\": \"12-24 hours\",\n-            \"after_effects\": \"Minimal; but constipation may persist\"\n+            \"total_duration\": \"8-12 hours\",\n+            \"onset\": \"20-60 minutes\",\n+            \"peak\": \"2-4 hours\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"6-24 hours\"\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"canonical_routes\": [\n-            \"rectal\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"6-24 hours\",\n-            \"onset\": \"0.5-1 hour\",\n-            \"peak\": \"2-5 hours\",\n-            \"offset\": \"12-24 hours\",\n-            \"after_effects\": \"Minimal; but constipation may persist\"\n-          }\n-    \"addiction_potential\": \"Low when used as directed for diarrhea. However, at high doses, misuse can lead to opioid-like effects and dependency, as well as severe cardiac toxicity.\",\n+    \"addiction_potential\": \"Low potential for addiction, similar to other psychedelics.\",\n-        \"other opioids\",\n-        \"CYP3A4 inhibitors\",\n-        \"CYP2C8 inhibitors\",\n-        \"P-glycoprotein inhibitors\"\n+        \"Tramadol\",\n+        \"MAOIs\"\n-        \"quinidine\",\n-        \"ritonavir\",\n-        \"macrolide antibiotics\"\n+        \"Lithium\",\n+        \"SSRIs\"\n-        \"anticholinergics\",\n-        \"other CNS depressants\"\n+        \"Stimulants\",\n+        \"Cannabis\"\n-    \"notes\": \"Loperamide is an over-the-counter anti-diarrheal medication. At therapeutic doses, it acts peripherally and does not cross the blood-brain barrier significantly. At high doses or with certain drug interactions, it can cause central opioid effects and life-threatening cardiac arrhythmias (QT prolongation, Torsades de Pointes). Misuse has led to fatalities. Not recommended for recreational use or for opioid withdrawal management without medical supervision.\",\n+    \"notes\": \"LSZ is a potent psychedelic similar to LSD, known for its introspective and philosophical effects. It is often considered more intense than AL-LAD but with milder visuals compared to ETH-LAD. There have also been reports of nausea being more prevalent compared to LSD.\",\n-      \"Constipation\",\n-      \"Reduced gastrointestinal motility\",\n-      \"Mild sedation (rare, high doses)\",\n-      \"Euphoria (rare, high doses, especially with P-gp inhibitors)\",\n-      \"Cardiac arrhythmias (high doses)\",\n-      \"Abdominal pain\"\n+      \"Enhanced introspection\",\n+      \"Philosophical thoughts\",\n+      \"Visual hallucinations\",\n+      \"Enhanced music appreciation\",\n+      \"Emotional enhancement\",\n+      \"Sedation at higher doses\"\n-      \"full_tolerance\": \"Develops rapidly with high/repeated doses (days)\",\n-      \"half_tolerance\": \"Several days to 1 week\",\n-      \"zero_tolerance\": \"1-2 weeks after cessation\",\n+      \"full_tolerance\": \"3-7 days\",\n+      \"half_tolerance\": \"2-3 days\",\n+      \"zero_tolerance\": \"1 week\",\n-        \"opioids\"\n+        \"LSD\",\n+        \"Other lysergamides\"\n-    \"half_life\": \"9-14 hours (may be prolonged at high doses or with liver impairment)\",\n+    \"half_life\": \"Unknown\",\n-        \"name\": \"DrugBank: Loperamide\",\n-        \"reference\": \"https://go.drugbank.com/drugs/DB00836\"\n+        \"name\": \"Erowid LSZ Vault\",\n+        \"reference\": \"https://erowid.org/chemicals/lsz/lsz.shtml\"\n-        \"name\": \"Bluelight: Loperamide Megathread\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/loperamide-immodium-megathread-we-have-now-lost-at-least-2-of-our-own-from-lope.296086/\"\n+        \"name\": \"David E. Nichols' Research on Lysergamides\",\n+        \"reference\": \"https://pubs.acs.org/doi/10.1021/jm5017234\"\n+      },\n+      {\n+        \"name\": \"Drug User's Bible - LSZ Details\",\n+        \"reference\": \"https://drugusersbible.org/content/chemscape/psychedelics/lsz/\"\n-      \"opioid\",\n-      \"depressant\",\n-      \"habit-forming\"\n+      \"psychedelic\",\n+      \"research-chemical\"\n\n# MD-prolintane · #486\n\n-  \"id\": 485,\n-  \"title\": \"LSZ\",\n+  \"id\": 486,\n+  \"title\": \"MD-prolintane\",\n-    \"drug_name\": \"LSZ\",\n-    \"chemical_name\": \"LSZ\",\n+    \"drug_name\": \"MD-prolintane\",\n+    \"chemical_name\": \"MD-prolintane\",\n-    \"chemical_class\": \"Lysergamides\",\n-    \"mechanism_of_action\": \"5-HT2A receptor agonist\",\n-    \"psychoactive_class\": \"Psychedelic\",\n+    \"chemical_class\": \"Substituted pyrrolidines\",\n+    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor (potent)\",\n+    \"psychoactive_class\": \"Norepinephrine-dopamine re-uptake inhibitor (NDRI)\",\n-          \"units\": \"\\bµg\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"50 \\bµg\",\n-            \"light\": \"75-150 \\bµg\",\n-            \"common\": \"150-300 \\bµg\",\n-            \"strong\": \"300-450 \\bµg\",\n-            \"heavy\": \"450+ \\bµg\"\n+            \"threshold\": \"2mg\",\n+            \"light\": \"5mg - 10mg\",\n+            \"common\": \"10mg - 25mg\",\n+            \"strong\": \"25mg - 40mg\",\n+            \"heavy\": \"40+ mg\"\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"2mg\",\n+            \"light\": \"5mg - 15mg\",\n+            \"common\": \"15mg - 30mg\",\n+            \"strong\": \"30mg - 50mg\",\n+            \"heavy\": \"50+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"vaporized / smoked\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"2mg\",\n+            \"light\": \"5mg - 10mg\",\n+            \"common\": \"10mg - 25mg\",\n+            \"strong\": \"25mg - 40mg\",\n+            \"heavy\": \"40+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"intravenous\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"1mg\",\n+            \"light\": \"1mg - 5mg\",\n+            \"common\": \"5mg - 15mg\",\n+            \"strong\": \"15mg - 25mg\",\n+            \"heavy\": \"25+ mg\"\n+          }\n-            \"total_duration\": \"8-12 hours\",\n-            \"onset\": \"20-60 minutes\",\n-            \"peak\": \"2-4 hours\",\n-            \"offset\": \"2-4 hours\",\n-            \"after_effects\": \"6-24 hours\"\n+            \"total_duration\": \"4-6 h\",\n+            \"onset\": \"20-40 min\",\n+            \"peak\": \"1-3 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-12 h mild stimulation; insomnia possible\"\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"4-6 h\",\n+            \"onset\": \"5-10 min\",\n+            \"peak\": \"1-3 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-12 h mild stimulation; insomnia possible\"\n+          }\n+        },\n+        {\n+          \"route\": \"vaporized / smoked\",\n+          \"canonical_routes\": [\n+            \"vaporized\",\n+            \"smoked\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"4-6 h\",\n+            \"onset\": \"≤2 min\",\n+            \"peak\": \"1-3 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-12 h mild stimulation; insomnia possible\"\n+          }\n+        },\n+        {\n+          \"route\": \"intravenous\",\n+          \"canonical_routes\": [\n+            \"intravenous\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"4-6 h\",\n+            \"onset\": \"<1 min\",\n+            \"peak\": \"1-3 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-12 h mild stimulation; insomnia possible\"\n+          }\n-    \"addiction_potential\": \"Low potential for addiction, similar to other psychedelics.\",\n+    \"addiction_potential\": \"Moderate-to-high: pyrrolidine stims show rapid tolerance and binge-style redosing; several user reports describe compulsive use when material is plentiful.\",\n-        \"Tramadol\",\n-        \"MAOIs\"\n+        \"MAOIs (hypertensive crisis)\",\n+        \"other potent stimulants (synergistic cardiotoxicity)\",\n+        \"large ethanol doses (cardiac arrhythmia, dehydration)\"\n-        \"Lithium\",\n-        \"SSRIs\"\n+        \"β-keto cathinones (hyperthermia, tachycardia)\",\n+        \"cocaine (marked blood-pressure spikes)\",\n+        \"tramadol (seizure risk)\"\n-        \"Stimulants\",\n-        \"Cannabis\"\n+        \"SSRI / SNRI antidepressants (unknown SERT activity; serotonin syndrome theoretical)\",\n+        \"cannabinoids (increased anxiety, paranoia)\",\n+        \"antipsychotics (QT prolongation)\"\n-    \"notes\": \"LSZ is a potent psychedelic similar to LSD, known for its introspective and philosophical effects. It is often considered more intense than AL-LAD but with milder visuals compared to ETH-LAD. There have also been reports of nausea being more prevalent compared to LSD.\",\n+    \"notes\": \"MD-prolintane (1-(1-(benzo[d][1,3]dioxol-5-yl)pentan-2-yl)pyrrolidine) is the 3,4-methylenedioxy analogue of prolintane and the β-de-keto counterpart of MDPV. Vendor analytics show >98 % purity and crystal morphology similar to methamphetamine. Harm-reduction labs report a clean GC-MS and no β-keto peak, confirming it is not a cathinone. Users describe a functional, cocaine-like stimulation with less peripheral tension than α-PVP, lasting ~5 h with a smooth comedown. Oral bioavailability is high; insufflation adds ~25 % potency but more nasal irritation. Volumetric dosing or micro-spoon scales are recommended—compound is deceptively dense. Typical side-effects are insomnia, dry mouth, anorexia and mild tachycardia; one Reddit case experienced transient ‘adrenaline overload’ after a 25 mg IV bolus. Start ≤5 mg, hydrate, track heart-rate; allow at least 24 h between sessions to limit tolerance. Reagent testing: Mandelin → tan/olive; Marquis → very faint orange; no reaction on Liebermann—use this pattern plus FT-IR to rule out cathinone substitution.\\n\\nDespite its smoother profile, many users report compulsive redosing and rough comedowns at higher amounts, so treat MD-prolintane with the same respect given to other pyrrolidinophenones.\",\n-      \"Enhanced introspection\",\n-      \"Philosophical thoughts\",\n-      \"Visual hallucinations\",\n-      \"Enhanced music appreciation\",\n-      \"Emotional enhancement\",\n-      \"Sedation at higher doses\"\n+      \"clean mental alertness\",\n+      \"motivation / task focus\",\n+      \"moderate euphoria\",\n+      \"talkativeness\",\n+      \"appetite suppression\",\n+      \"minimal crash\"\n-      \"full_tolerance\": \"3-7 days\",\n+      \"full_tolerance\": \"after one heavy session\",\n-      \"zero_tolerance\": \"1 week\",\n+      \"zero_tolerance\": \"7-10 days\",\n-        \"LSD\",\n-        \"Other lysergamides\"\n+        \"α-PVP\",\n+        \"MDPV\",\n+        \"other pyrrolidine NDRIs\"\n-    \"half_life\": \"Unknown\",\n+    \"half_life\": \"estimated 3-5 h (no human PK published; inferred from prolintane and user sleep-latency data)\",\n-        \"name\": \"Erowid LSZ Vault\",\n-        \"reference\": \"https://erowid.org/chemicals/lsz/lsz.shtml\"\n+        \"name\": \"Vendor tech sheet – onset, duration & 10-30 mg oral dosage\",\n+        \"reference\": \"https://rechemco.to/md-prolintane-eu/\"\n-        \"name\": \"David E. Nichols' Research on Lysergamides\",\n-        \"reference\": \"https://pubs.acs.org/doi/10.1021/jm5017234\"\n+        \"name\": \"IvoLabs product monograph – 5-25 mg oral guidance\",\n+        \"reference\": \"https://ivolabs.com/product/md-prolintane-eu/\"\n-        \"name\": \"Drug User's Bible - LSZ Details\",\n-        \"reference\": \"https://drugusersbible.org/content/chemscape/psychedelics/lsz/\"\n+        \"name\": \"Reddit r/researchchemicals mega-thread – experiential doses & ROAs\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/1bm9g61/mdprolintane_what_is_it/\"\n+      },\n+      {\n+        \"name\": \"User report – 50 mg insufflated, 4 h effect window\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/1bm9g61/mdprolintane_what_is_it/\"\n+      },\n+      {\n+        \"name\": \"Prolintane overview (structural parent compound)\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Prolintane\"\n+      },\n+      {\n+        \"name\": \"DrugBank entry for prolintane – mechanism & class\",\n+        \"reference\": \"https://go.drugbank.com/drugs/DB13438\"\n+      },\n+      {\n+        \"name\": \"ChemSpider record – formula & nomenclature\",\n+        \"reference\": \"https://www.chemspider.com/Chemical-Structure.13930.html\"\n+      },\n+      {\n+        \"name\": \"Bluelight discussion – comparative potency vs α-PVP\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/analogs-not-yet-explored-stimulants-and-entheogens-specifically.819207/\"\n+      },\n+      {\n+        \"name\": \"PubChem CID 14592 – physico-chemical properties of prolintane\",\n+        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/Prolintane\"\n+      },\n+      {\n+        \"name\": \"Reddit Nootropics thread – 3-5 h half-life estimate for prolintane\",\n+        \"reference\": \"https://www.reddit.com/r/Nootropics/comments/2ml8kj/prolintane_a_relatively_unknown_neda_reuptake/\"\n-      \"psychedelic\",\n+      \"stimulant\",\n\n# Methocarbamol · #487\n\n-  \"id\": 486,\n-  \"title\": \"MD-prolintane\",\n+  \"id\": 487,\n+  \"title\": \"Methocarbamol\",\n-    \"drug_name\": \"MD-prolintane\",\n-    \"chemical_name\": \"MD-prolintane\",\n+    \"drug_name\": \"Methocarbamol\",\n+    \"chemical_name\": \"Methocarbamol\",\n-    \"chemical_class\": \"Substituted pyrrolidines\",\n-    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor (potent)\",\n-    \"psychoactive_class\": \"Norepinephrine-dopamine re-uptake inhibitor (NDRI)\",\n+    \"chemical_class\": \"Carbamate\",\n+    \"mechanism_of_action\": \"Central nervous system depressant\",\n+    \"psychoactive_class\": \"Muscle relaxant\",\n-            \"threshold\": \"2mg\",\n-            \"light\": \"5mg - 10mg\",\n-            \"common\": \"10mg - 25mg\",\n-            \"strong\": \"25mg - 40mg\",\n-            \"heavy\": \"40+ mg\"\n+            \"threshold\": \"500 mg\",\n+            \"light\": \"750 mg\",\n+            \"common\": \"1000-1500 mg\",\n+            \"strong\": \"2000 mg\",\n+            \"heavy\": \"3000 mg\"\n-        },\n-        {\n-          \"route\": \"insufflated\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"2mg\",\n-            \"light\": \"5mg - 15mg\",\n-            \"common\": \"15mg - 30mg\",\n-            \"strong\": \"30mg - 50mg\",\n-            \"heavy\": \"50+ mg\"\n-          }\n-        },\n-        {\n-          \"route\": \"vaporized / smoked\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"2mg\",\n-            \"light\": \"5mg - 10mg\",\n-            \"common\": \"10mg - 25mg\",\n-            \"strong\": \"25mg - 40mg\",\n-            \"heavy\": \"40+ mg\"\n-          }\n-        },\n-        {\n-          \"route\": \"intravenous\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"1mg\",\n-            \"light\": \"1mg - 5mg\",\n-            \"common\": \"5mg - 15mg\",\n-            \"strong\": \"15mg - 25mg\",\n-            \"heavy\": \"25+ mg\"\n-          }\n-            \"total_duration\": \"4-6 h\",\n-            \"onset\": \"20-40 min\",\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-12 h mild stimulation; insomnia possible\"\n+            \"total_duration\": \"4-6 hours\",\n+            \"onset\": \"15-30 minutes\",\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"6-8 hours\"\n-        },\n-        {\n-          \"route\": \"insufflated\",\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"4-6 h\",\n-            \"onset\": \"5-10 min\",\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-12 h mild stimulation; insomnia possible\"\n-          }\n-        },\n-        {\n-          \"route\": \"vaporized / smoked\",\n-          \"canonical_routes\": [\n-            \"vaporized\",\n-            \"smoked\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"4-6 h\",\n-            \"onset\": \"≤2 min\",\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-12 h mild stimulation; insomnia possible\"\n-          }\n-        },\n-        {\n-          \"route\": \"intravenous\",\n-          \"canonical_routes\": [\n-            \"intravenous\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"4-6 h\",\n-            \"onset\": \"<1 min\",\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-12 h mild stimulation; insomnia possible\"\n-          }\n-    \"addiction_potential\": \"Moderate-to-high: pyrrolidine stims show rapid tolerance and binge-style redosing; several user reports describe compulsive use when material is plentiful.\",\n+    \"addiction_potential\": \"Low potential for addiction, but misuse can occur, especially in combination with other substances.\",\n-        \"MAOIs (hypertensive crisis)\",\n-        \"other potent stimulants (synergistic cardiotoxicity)\",\n-        \"large ethanol doses (cardiac arrhythmia, dehydration)\"\n+        \"Diphenhydramine\"\n-        \"β-keto cathinones (hyperthermia, tachycardia)\",\n-        \"cocaine (marked blood-pressure spikes)\",\n-        \"tramadol (seizure risk)\"\n+        \"Ethanol\"\n-        \"SSRI / SNRI antidepressants (unknown SERT activity; serotonin syndrome theoretical)\",\n-        \"cannabinoids (increased anxiety, paranoia)\",\n-        \"antipsychotics (QT prolongation)\"\n+        \"Pregabalin\",\n+        \"Carisoprodol\"\n-    \"notes\": \"MD-prolintane (1-(1-(benzo[d][1,3]dioxol-5-yl)pentan-2-yl)pyrrolidine) is the 3,4-methylenedioxy analogue of prolintane and the β-de-keto counterpart of MDPV. Vendor analytics show >98 % purity and crystal morphology similar to methamphetamine. Harm-reduction labs report a clean GC-MS and no β-keto peak, confirming it is not a cathinone. Users describe a functional, cocaine-like stimulation with less peripheral tension than α-PVP, lasting ~5 h with a smooth comedown. Oral bioavailability is high; insufflation adds ~25 % potency but more nasal irritation. Volumetric dosing or micro-spoon scales are recommended—compound is deceptively dense. Typical side-effects are insomnia, dry mouth, anorexia and mild tachycardia; one Reddit case experienced transient ‘adrenaline overload’ after a 25 mg IV bolus. Start ≤5 mg, hydrate, track heart-rate; allow at least 24 h between sessions to limit tolerance. Reagent testing: Mandelin → tan/olive; Marquis → very faint orange; no reaction on Liebermann—use this pattern plus FT-IR to rule out cathinone substitution.\\n\\nDespite its smoother profile, many users report compulsive redosing and rough comedowns at higher amounts, so treat MD-prolintane with the same respect given to other pyrrolidinophenones.\",\n+    \"notes\": \"Methocarbamol may have seizure-inducing properties when combined with certain substances, such as diphenhydramine. Caution is advised when used with other CNS depressants. It can be used as an adjunct to physical therapy and analgesics for musculoskeletal pain relief.\",\n-      \"clean mental alertness\",\n-      \"motivation / task focus\",\n-      \"moderate euphoria\",\n-      \"talkativeness\",\n-      \"appetite suppression\",\n-      \"minimal crash\"\n+      \"Muscle relaxation\",\n+      \"Sedation\",\n+      \"Dizziness\",\n+      \"Drowsiness\"\n-      \"full_tolerance\": \"after one heavy session\",\n-      \"half_tolerance\": \"2-3 days\",\n-      \"zero_tolerance\": \"7-10 days\",\n+      \"full_tolerance\": \"Not well-documented\",\n+      \"half_tolerance\": \"Not well-documented\",\n+      \"zero_tolerance\": \"Not well-documented\",\n-        \"α-PVP\",\n-        \"MDPV\",\n-        \"other pyrrolidine NDRIs\"\n+        \"Carisoprodol\"\n-    \"half_life\": \"estimated 3-5 h (no human PK published; inferred from prolintane and user sleep-latency data)\",\n+    \"half_life\": \"1-2 hours\",\n-        \"name\": \"Vendor tech sheet – onset, duration & 10-30 mg oral dosage\",\n-        \"reference\": \"https://rechemco.to/md-prolintane-eu/\"\n+        \"name\": \"Drugs.com Methocarbamol\",\n+        \"reference\": \"https://www.drugs.com/mtm/methocarbamol.html\"\n-        \"name\": \"IvoLabs product monograph – 5-25 mg oral guidance\",\n-        \"reference\": \"https://ivolabs.com/product/md-prolintane-eu/\"\n-      },\n-      {\n-        \"name\": \"Reddit r/researchchemicals mega-thread – experiential doses & ROAs\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/1bm9g61/mdprolintane_what_is_it/\"\n-      },\n-      {\n-        \"name\": \"User report – 50 mg insufflated, 4 h effect window\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/1bm9g61/mdprolintane_what_is_it/\"\n-      },\n-      {\n-        \"name\": \"Prolintane overview (structural parent compound)\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Prolintane\"\n-      },\n-      {\n-        \"name\": \"DrugBank entry for prolintane – mechanism & class\",\n-        \"reference\": \"https://go.drugbank.com/drugs/DB13438\"\n-      },\n-      {\n-        \"name\": \"ChemSpider record – formula & nomenclature\",\n-        \"reference\": \"https://www.chemspider.com/Chemical-Structure.13930.html\"\n-      },\n-      {\n-        \"name\": \"Bluelight discussion – comparative potency vs α-PVP\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/analogs-not-yet-explored-stimulants-and-entheogens-specifically.819207/\"\n-      },\n-      {\n-        \"name\": \"PubChem CID 14592 – physico-chemical properties of prolintane\",\n-        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/Prolintane\"\n-      },\n-      {\n-        \"name\": \"Reddit Nootropics thread – 3-5 h half-life estimate for prolintane\",\n-        \"reference\": \"https://www.reddit.com/r/Nootropics/comments/2ml8kj/prolintane_a_relatively_unknown_neda_reuptake/\"\n+        \"name\": \"DrugBank - Methocarbamol\",\n+        \"reference\": \"https://go.drugbank.com/drugs/DB00423\"\n-      \"stimulant\",\n-      \"research-chemical\"\n+      \"depressant\",\n+      \"sedative\"\n\n# Rasagiline · #488\n\n-  \"id\": 487,\n-  \"title\": \"Methocarbamol\",\n+  \"id\": 488,\n+  \"title\": \"Rasagiline\",\n-    \"drug_name\": \"Methocarbamol\",\n-    \"chemical_name\": \"Methocarbamol\",\n+    \"drug_name\": \"Rasagiline\",\n+    \"chemical_name\": \"Rasagiline\",\n-    \"chemical_class\": \"Carbamate\",\n-    \"mechanism_of_action\": \"Central nervous system depressant\",\n-    \"psychoactive_class\": \"Muscle relaxant\",\n+    \"chemical_class\": \"Propargylamines\",\n+    \"mechanism_of_action\": \"Monoamine oxidase B inhibitor\",\n+    \"psychoactive_class\": \"Selective monoamine-oxidase-B inhibitor; mild dopaminergic & phenethylaminergic enhancer\",\n-          \"route\": \"oral\",\n+          \"route\": \"oral (tablet; sublingually dissolved)\",\n-            \"threshold\": \"500 mg\",\n-            \"light\": \"750 mg\",\n-            \"common\": \"1000-1500 mg\",\n-            \"strong\": \"2000 mg\",\n-            \"heavy\": \"3000 mg\"\n+            \"threshold\": \"0.25 mg\",\n+            \"light\": \"0.25 mg - 0.5 mg\",\n+            \"common\": \"0.5 mg - 1 mg\",\n+            \"strong\": \"1 mg - 2 mg\",\n+            \"heavy\": \"2+ mg\"\n+        },\n+        {\n+          \"route\": \"oral (powder / capsule)\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"0.25 mg\",\n+            \"light\": \"0.25 mg - 0.5 mg\",\n+            \"common\": \"0.5 mg - 1 mg\",\n+            \"strong\": \"1 mg - 2 mg\",\n+            \"heavy\": \"2+ mg\"\n+          }\n-          \"route\": \"oral\",\n+          \"route\": \"oral (tablet; sublingually dissolved)\",\n-            \"total_duration\": \"4-6 hours\",\n-            \"onset\": \"15-30 minutes\",\n-            \"peak\": \"1-2 hours\",\n-            \"offset\": \"2-4 hours\",\n-            \"after_effects\": \"6-8 hours\"\n+            \"total_duration\": \"24-48 h functional MAO-B inhibition (subjective psychoactivity subtle)\",\n+            \"onset\": \"30-60 min\",\n+            \"peak\": \"1-2 h subjective alertness\",\n+            \"offset\": \"12-24 h perceived; enzymatic recovery requires new MAO-B synthesis (~40 days)\",\n+            \"after_effects\": \"mild insomnia or restlessness up to 12 h; lingering dietary / interaction restrictions\"\n+        },\n+        {\n+          \"route\": \"oral (powder / capsule)\",\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"24-48 h functional MAO-B inhibition (subjective psychoactivity subtle)\",\n+            \"onset\": \"30-60 min\",\n+            \"peak\": \"1-2 h subjective alertness\",\n+            \"offset\": \"12-24 h perceived; enzymatic recovery requires new MAO-B synthesis (~40 days)\",\n+            \"after_effects\": \"mild insomnia or restlessness up to 12 h; lingering dietary / interaction restrictions\"\n+          }\n-    \"addiction_potential\": \"Low potential for addiction, but misuse can occur, especially in combination with other substances.\",\n+    \"addiction_potential\": \"Low: no reinforcing rush; irreversible binding discourages compulsive redosing, though mild mood-brightening may tempt daily use.\",\n-        \"Diphenhydramine\"\n+        \"MDMA, MDA, 4-FA, mephedrone (serotonin syndrome)\",\n+        \"SSRIs, SNRIs, TCAs, tramadol, dextromethorphan (serotonin syndrome)\",\n+        \"other MAOIs or linezolid (non-selective MAO inhibition)\",\n+        \"high-dose tyramine foods if >2 mg rasagiline (hypertensive crisis)\",\n+        \"large doses of amphetamine or methamphetamine (hypertensive, psychotic episodes)\"\n-        \"Ethanol\"\n+        \"cocaine, bupropion, cathinones (excess dopaminergic/adrenergic stimulation)\",\n+        \"5-MeO-tryptamines or potent psychedelic phenethylamines (combined serotonergic load)\",\n+        \"opioids with serotonin activity (meperidine, fentanyl analogues)\"\n-        \"Pregabalin\",\n-        \"Carisoprodol\"\n+        \"caffeine or nicotine (synergistic stimulation)\",\n+        \"L-DOPA or methylphenidate (potentiates dopaminergic side-effects)\",\n+        \"kava, kratom, St. John’s wort (unpredictable enzyme or serotonin interactions)\"\n-    \"notes\": \"Methocarbamol may have seizure-inducing properties when combined with certain substances, such as diphenhydramine. Caution is advised when used with other CNS depressants. It can be used as an adjunct to physical therapy and analgesics for musculoskeletal pain relief.\",\n+    \"notes\": \"Rasagiline irreversibly acylates the flavin site of MAO-B, giving ~90% inhibition at 1 mg/day within 1-2 weeks. Although its plasma half-life is ~3 h, functional recovery depends on MAO-B resynthesis (approx. 40 days), so a single 1 mg dose can keep tyramine thresholds lower for several days. Selectivity diminishes above 2 mg/day, raising dietary and pressor risk comparable to classical non-selective MAOIs. Case surveys and pharmacovigilance reviews document serotonin-syndrome clusters when rasagiline is combined with SSRIs or MDMA-like agents—even at therapeutic doses. Bluelight users typically employ 0.5-1 mg to amplify phenethylamine (β-PEA) or stimulant effects, reporting brighter mood, clearer focus, and longer stimulant plateau, but also warn that >2 mg ‘feels wired’ and makes tyramine flushes more likely. The primary metabolite (R)-1-aminoindan is mildly stimulant and neuroprotective in vitro, which may contribute to perceived clarity without amphetamine-like side-effects. Powder allows accurate volumetric titration (e.g., 0.1 mg/mL in 20% ethanol) and microdosing below 0.25 mg; gelatin capsules disguise bitterness. Always reagent-test party drugs before co-administration and keep 5-HT antagonists (cyproheptadine) on hand in festival settings where serotonergic stacks are common.\",\n-      \"Muscle relaxation\",\n-      \"Sedation\",\n-      \"Dizziness\",\n-      \"Drowsiness\"\n+      \"subtle mental alertness\",\n+      \"enhanced motivation/drive\",\n+      \"mild euphoria or ‘sunny’ mood\",\n+      \"reduced fatigue\",\n+      \"slight appetite suppression\",\n+      \"occasional insomnia or vivid dreams\"\n-      \"full_tolerance\": \"Not well-documented\",\n-      \"half_tolerance\": \"Not well-documented\",\n-      \"zero_tolerance\": \"Not well-documented\",\n+      \"full_tolerance\": \"not applicable (irreversible binding)\",\n+      \"half_tolerance\": \"enzymatic regeneration ~20 days\",\n+      \"zero_tolerance\": \"4-6 weeks after last dose\",\n-        \"Carisoprodol\"\n+        \"selegiline\",\n+        \"other MAO-B inhibitors\"\n-    \"half_life\": \"1-2 hours\",\n+    \"half_life\": \"3 h (plasma), but functional inhibition lasts days\",\n-        \"name\": \"Drugs.com Methocarbamol\",\n-        \"reference\": \"https://www.drugs.com/mtm/methocarbamol.html\"\n+        \"name\": \"Detailed pharmacokinetic review – MAO-B inhibition and half-life\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/16432143/\"\n-        \"name\": \"DrugBank - Methocarbamol\",\n-        \"reference\": \"https://go.drugbank.com/drugs/DB00423\"\n+        \"name\": \"FDA Azilect label – dose/PK & selectivity data\",\n+        \"reference\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021641s015s017lbl.pdf\"\n+      },\n+      {\n+        \"name\": \"Serotonin syndrome case series: rasagiline + SSRIs/MDMA\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/30768863/\"\n+      },\n+      {\n+        \"name\": \"Bluelight Big & Dandy Rasagiline thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-rasagiline-thread.790161/\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Rasagiline\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Rasagiline\"\n-      \"depressant\",\n-      \"sedative\"\n+      \"nootropic\"\n\n# D2PM · #489\n\n-  \"id\": 488,\n-  \"title\": \"Rasagiline\",\n+  \"id\": 489,\n+  \"title\": \"D2PM\",\n-    \"drug_name\": \"Rasagiline\",\n-    \"chemical_name\": \"Rasagiline\",\n-    \"alternative_name\": \"\",\n-    \"chemical_class\": \"Propargylamines\",\n-    \"mechanism_of_action\": \"Monoamine oxidase B inhibitor\",\n-    \"psychoactive_class\": \"Selective monoamine-oxidase-B inhibitor; mild dopaminergic & phenethylaminergic enhancer\",\n+    \"drug_name\": \"D2PM\",\n+    \"chemical_name\": \"Diphenylprolinol\",\n+    \"alternative_name\": \"Diphenylprolinol\",\n+    \"chemical_class\": \"Pipradrol Homologues\",\n+    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor\",\n+    \"psychoactive_class\": \"stimulant (norepinephrine-dopamine re-uptake inhibitor)\",\n-          \"route\": \"oral (tablet; sublingually dissolved)\",\n+          \"route\": \"oral\",\n-            \"threshold\": \"0.25 mg\",\n-            \"light\": \"0.25 mg - 0.5 mg\",\n-            \"common\": \"0.5 mg - 1 mg\",\n-            \"strong\": \"1 mg - 2 mg\",\n-            \"heavy\": \"2+ mg\"\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"5-15 mg\",\n+            \"common\": \"15-35 mg\",\n+            \"strong\": \"35-60 mg\",\n+            \"heavy\": \"60+ mg\"\n-          \"route\": \"oral (powder / capsule)\",\n+          \"route\": \"insufflated\",\n-            \"threshold\": \"0.25 mg\",\n-            \"light\": \"0.25 mg - 0.5 mg\",\n-            \"common\": \"0.5 mg - 1 mg\",\n-            \"strong\": \"1 mg - 2 mg\",\n-            \"heavy\": \"2+ mg\"\n+            \"threshold\": \"1 mg\",\n+            \"light\": \"1-4 mg\",\n+            \"common\": \"4-10 mg\",\n+            \"strong\": \"10-20 mg\",\n+            \"heavy\": \"20+ mg\"\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"5-10 mg\",\n+            \"common\": \"10-25 mg\",\n+            \"strong\": \"25-40 mg\",\n+            \"heavy\": \"40+ mg\"\n+          }\n-          \"route\": \"oral (tablet; sublingually dissolved)\",\n+          \"route\": \"oral\",\n-            \"total_duration\": \"24-48 h functional MAO-B inhibition (subjective psychoactivity subtle)\",\n-            \"onset\": \"30-60 min\",\n-            \"peak\": \"1-2 h subjective alertness\",\n-            \"offset\": \"12-24 h perceived; enzymatic recovery requires new MAO-B synthesis (~40 days)\",\n-            \"after_effects\": \"mild insomnia or restlessness up to 12 h; lingering dietary / interaction restrictions\"\n+            \"total_duration\": \"6-12 h (residual stimulation up to 24 h, agitation up to 3-5 days after very high doses)\",\n+            \"onset\": \"0.5-1.5 h\",\n+            \"peak\": \"2-6 h\",\n+            \"offset\": \"2-4 h\",\n+            \"after_effects\": \"6-12 h of insomnia; appetite loss and vasoconstriction are common\"\n-          \"route\": \"oral (powder / capsule)\",\n+          \"route\": \"insufflated\",\n-            \"oral\"\n+            \"insufflated\"\n-            \"total_duration\": \"24-48 h functional MAO-B inhibition (subjective psychoactivity subtle)\",\n-            \"onset\": \"30-60 min\",\n-            \"peak\": \"1-2 h subjective alertness\",\n-            \"offset\": \"12-24 h perceived; enzymatic recovery requires new MAO-B synthesis (~40 days)\",\n-            \"after_effects\": \"mild insomnia or restlessness up to 12 h; lingering dietary / interaction restrictions\"\n+            \"total_duration\": \"6-12 h (residual stimulation up to 24 h, agitation up to 3-5 days after very high doses)\",\n+            \"onset\": \"5-20 min\",\n+            \"peak\": \"2-6 h\",\n+            \"offset\": \"2-4 h\",\n+            \"after_effects\": \"6-12 h of insomnia; appetite loss and vasoconstriction are common\"\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"canonical_routes\": [\n+            \"rectal\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"6-12 h (residual stimulation up to 24 h, agitation up to 3-5 days after very high doses)\",\n+            \"peak\": \"2-6 h\",\n+            \"offset\": \"2-4 h\",\n+            \"after_effects\": \"6-12 h of insomnia; appetite loss and vasoconstriction are common\"\n+          }\n-    \"addiction_potential\": \"Low: no reinforcing rush; irreversible binding discourages compulsive redosing, though mild mood-brightening may tempt daily use.\",\n+    \"addiction_potential\": \"Moderate to high: potent NDRI action, long half-life and delayed onset promote compulsive redosing and multi-day binges.\",\n-        \"MDMA, MDA, 4-FA, mephedrone (serotonin syndrome)\",\n-        \"SSRIs, SNRIs, TCAs, tramadol, dextromethorphan (serotonin syndrome)\",\n-        \"other MAOIs or linezolid (non-selective MAO inhibition)\",\n-        \"high-dose tyramine foods if >2 mg rasagiline (hypertensive crisis)\",\n-        \"large doses of amphetamine or methamphetamine (hypertensive, psychotic episodes)\"\n+        \"MAOIs (hypertensive crisis)\",\n+        \"other potent stimulants (methamphetamine, 2-DPMP)\",\n+        \"strong serotonin releasers (MDMA, 6-APB)\",\n+        \"tramadol (seizure risk)\",\n+        \"high-dose opioids or alcohol when already overstimulated (respiratory, cardiac instability)\"\n-        \"cocaine, bupropion, cathinones (excess dopaminergic/adrenergic stimulation)\",\n-        \"5-MeO-tryptamines or potent psychedelic phenethylamines (combined serotonergic load)\",\n-        \"opioids with serotonin activity (meperidine, fentanyl analogues)\"\n+        \"bupropion\",\n+        \"prescription ADHD stimulants\",\n+        \"high doses of alcohol (masks intoxication, increases cardiac strain)\",\n+        \"beta-blockers without alpha blockade (unopposed alpha vasospasm)\"\n-        \"caffeine or nicotine (synergistic stimulation)\",\n-        \"L-DOPA or methylphenidate (potentiates dopaminergic side-effects)\",\n-        \"kava, kratom, St. John’s wort (unpredictable enzyme or serotonin interactions)\"\n+        \"cannabis (may worsen anxiety and tachycardia)\",\n+        \"dissociatives\",\n+        \"caffeine and other vasoconstrictors\",\n+        \"SSRI or SNRI antidepressants\"\n-    \"notes\": \"Rasagiline irreversibly acylates the flavin site of MAO-B, giving ~90% inhibition at 1 mg/day within 1-2 weeks. Although its plasma half-life is ~3 h, functional recovery depends on MAO-B resynthesis (approx. 40 days), so a single 1 mg dose can keep tyramine thresholds lower for several days. Selectivity diminishes above 2 mg/day, raising dietary and pressor risk comparable to classical non-selective MAOIs. Case surveys and pharmacovigilance reviews document serotonin-syndrome clusters when rasagiline is combined with SSRIs or MDMA-like agents—even at therapeutic doses. Bluelight users typically employ 0.5-1 mg to amplify phenethylamine (β-PEA) or stimulant effects, reporting brighter mood, clearer focus, and longer stimulant plateau, but also warn that >2 mg ‘feels wired’ and makes tyramine flushes more likely. The primary metabolite (R)-1-aminoindan is mildly stimulant and neuroprotective in vitro, which may contribute to perceived clarity without amphetamine-like side-effects. Powder allows accurate volumetric titration (e.g., 0.1 mg/mL in 20% ethanol) and microdosing below 0.25 mg; gelatin capsules disguise bitterness. Always reagent-test party drugs before co-administration and keep 5-HT antagonists (cyproheptadine) on hand in festival settings where serotonergic stacks are common.\",\n+    \"notes\": \"- Very long-lasting stimulation can cause severe insomnia, anxiety and paranoid psychosis; medical literature describes agitation lasting up to 5 days after heavy use.\\n- Significant vasoconstriction, tachycardia and chest pain are reported; monitor heart rate and blood pressure, stay hydrated and avoid strenuous exercise.\\n- Onset is delayed; redosing within the first 4 h greatly increases overdose risk.\\n- Start with no more than 5 mg orally using a 0.001 g scale or volumetric dosing; potencies vary and vendor mis-labeling with 2-DPMP is documented.\\n- Cold or painful extremities indicate dangerous vasospasm; warm the area and seek medical help if discoloration appears.\\n- Benzodiazepines (2-4 mg diazepam equivalent) are first-line treatment for severe agitation; avoid antipsychotics that prolong QT unless in a clinical setting.\\n- Allow at least 14 days between sessions to reset tolerance and reduce neuro- and cardiotoxic risk.\\n- Commercial immunoassay drug screens may not detect D2PM, but cross-reactivity with amphetamine panels can occur.\\n- Intravenous or inhalation routes drastically raise overdose potential and are strongly discouraged.\",\n-      \"subtle mental alertness\",\n-      \"enhanced motivation/drive\",\n-      \"mild euphoria or ‘sunny’ mood\",\n-      \"reduced fatigue\",\n-      \"slight appetite suppression\",\n-      \"occasional insomnia or vivid dreams\"\n+      \"mental stimulation\",\n+      \"euphoria (often mild)\",\n+      \"increased motivation and talkativeness\",\n+      \"appetite suppression\",\n+      \"jaw clenching / bruxism\",\n+      \"sweating and hyperthermia\",\n+      \"paresthesia / vasoconstriction\",\n+      \"anxiety or paranoia\",\n+      \"insomnia\",\n+      \"possible acute psychosis at high doses\"\n-      \"full_tolerance\": \"not applicable (irreversible binding)\",\n-      \"half_tolerance\": \"enzymatic regeneration ~20 days\",\n-      \"zero_tolerance\": \"4-6 weeks after last dose\",\n+      \"full_tolerance\": \"after 3-5 consecutive days of use\",\n+      \"half_tolerance\": \"~3-7 days\",\n+      \"zero_tolerance\": \"~10-14 days\",\n-        \"selegiline\",\n-        \"other MAO-B inhibitors\"\n+        \"amphetamine-type stimulants\",\n+        \"other NDRIs (methylphenidate)\"\n-    \"half_life\": \"3 h (plasma), but functional inhibition lasts days\",\n+    \"half_life\": \"Estimated 4-8 h; active metabolites and strong tissue binding prolong functional effects\",\n-        \"name\": \"Detailed pharmacokinetic review – MAO-B inhibition and half-life\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/16432143/\"\n+        \"name\": \"Wikipedia contributors. Diphenylprolinol\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Diphenylprolinol\"\n-        \"name\": \"FDA Azilect label – dose/PK & selectivity data\",\n-        \"reference\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021641s015s017lbl.pdf\"\n+        \"name\": \"ACMD advice on diphenyl-2-pyrrolidinyl-methanol (D2PM)\",\n+        \"reference\": \"https://www.gov.uk/government/publications/acmd-advice-on-diphenyl-2-pyrrolidinyl-methanol-d2pm\"\n-        \"name\": \"Serotonin syndrome case series: rasagiline + SSRIs/MDMA\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/30768863/\"\n+        \"name\": \"Meltzer SC et al. Receptor binding profile of diphenylprolinol. J Psychopharmacol 2010\",\n+        \"reference\": \"https://doi.org/10.1177/0269881110372544\"\n-        \"name\": \"Bluelight Big & Dandy Rasagiline thread\",\n-        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-rasagiline-thread.790161/\"\n+        \"name\": \"Cardiovascular toxicity from recreational D2PM use. J Med Toxicol 2008\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/18821489/\"\n-        \"name\": \"Wikipedia: Rasagiline\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Rasagiline\"\n+        \"name\": \"Corkery JM et al. Preliminary review of D2PM and 2-DPMP. Prog Neuro-Psychopharmacol 2012\",\n+        \"reference\": \"https://www.researchgate.net/publication/225295408\"\n+      },\n+      {\n+        \"name\": \"Wood DM & Dargan PI. Acute toxicity of D2PM and 2-DPMP. Clin Toxicol 2012\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/22882169/\"\n+      },\n+      {\n+        \"name\": \"ScienceDirect Topics – user dose reports (20-50 mg oral, 5-10 h duration)\",\n+        \"reference\": \"https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/pipradol\"\n+      },\n+      {\n+        \"name\": \"Bluelight D2PM experiences thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/diphenyl-2-pyrrolidinemethanol-d2pm-thoughts-experiences.931077/\"\n+      },\n+      {\n+        \"name\": \"Drugs-Forum D2PM trip reports collection\",\n+        \"reference\": \"https://drugs-forum.com/threads/experiences-diphenyl-2-pyrrolidinyl-methanol-diphenylprolinol.37130/\"\n+      },\n+      {\n+        \"name\": \"DuckDuckGo: Search: Diphenylprolinol\",\n+        \"reference\": \"https://duckduckgo.com/?q=Diphenylprolinol\"\n-      \"nootropic\"\n+      \"research-chemical\",\n+      \"stimulant\"\n\n# Fenozolone · #490\n\n-  \"id\": 489,\n-  \"title\": \"D2PM\",\n+  \"id\": 490,\n+  \"title\": \"Fenozolone\",\n-    \"drug_name\": \"D2PM\",\n-    \"chemical_name\": \"Diphenylprolinol\",\n-    \"alternative_name\": \"Diphenylprolinol\",\n-    \"chemical_class\": \"Pipradrol Homologues\",\n-    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor\",\n-    \"psychoactive_class\": \"stimulant (norepinephrine-dopamine re-uptake inhibitor)\",\n+    \"drug_name\": \"Fenozolone\",\n+    \"chemical_name\": \"Fenozolone\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Aminorexes\",\n+    \"mechanism_of_action\": \"Serotonin-dopamine-norepinephrine releasing agent\",\n+    \"psychoactive_class\": \"Norepinephrine-dopamine releasing agent (NDRA); mild dopamine–norepinephrine re-uptake inhibitor\",\n-          \"route\": \"oral\",\n+          \"route\": \"oral / sublingual\",\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"5-15 mg\",\n-            \"common\": \"15-35 mg\",\n-            \"strong\": \"35-60 mg\",\n-            \"heavy\": \"60+ mg\"\n+            \"threshold\": \"5mg\",\n+            \"light\": \"5mg - 15mg\",\n+            \"common\": \"15mg - 30mg\",\n+            \"strong\": \"30mg - 50mg\",\n+            \"heavy\": \"50mg+\"\n-            \"threshold\": \"1 mg\",\n-            \"light\": \"1-4 mg\",\n-            \"common\": \"4-10 mg\",\n-            \"strong\": \"10-20 mg\",\n-            \"heavy\": \"20+ mg\"\n+            \"threshold\": \"5mg\",\n+            \"light\": \"5mg - 10mg\",\n+            \"common\": \"10mg - 20mg\",\n+            \"strong\": \"20mg - 35mg\",\n+            \"heavy\": \"35mg+\"\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"5-10 mg\",\n-            \"common\": \"10-25 mg\",\n-            \"strong\": \"25-40 mg\",\n-            \"heavy\": \"40+ mg\"\n-          }\n-          \"route\": \"oral\",\n+          \"route\": \"oral / sublingual\",\n-            \"oral\"\n+            \"oral\",\n+            \"sublingual\"\n-            \"total_duration\": \"6-12 h (residual stimulation up to 24 h, agitation up to 3-5 days after very high doses)\",\n-            \"onset\": \"0.5-1.5 h\",\n-            \"peak\": \"2-6 h\",\n-            \"offset\": \"2-4 h\",\n-            \"after_effects\": \"6-12 h of insomnia; appetite loss and vasoconstriction are common\"\n+            \"total_duration\": \"4-6 h (active)\",\n+            \"onset\": \"15-45 min\",\n+            \"peak\": \"1-3 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-12 h residual stimulation / insomnia\"\n-            \"total_duration\": \"6-12 h (residual stimulation up to 24 h, agitation up to 3-5 days after very high doses)\",\n-            \"onset\": \"5-20 min\",\n-            \"peak\": \"2-6 h\",\n-            \"offset\": \"2-4 h\",\n-            \"after_effects\": \"6-12 h of insomnia; appetite loss and vasoconstriction are common\"\n+            \"total_duration\": \"4-6 h (active)\",\n+            \"onset\": \"5-10 min\",\n+            \"peak\": \"1-3 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-12 h residual stimulation / insomnia\"\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"canonical_routes\": [\n-            \"rectal\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"6-12 h (residual stimulation up to 24 h, agitation up to 3-5 days after very high doses)\",\n-            \"peak\": \"2-6 h\",\n-            \"offset\": \"2-4 h\",\n-            \"after_effects\": \"6-12 h of insomnia; appetite loss and vasoconstriction are common\"\n-          }\n-    \"addiction_potential\": \"Moderate to high: potent NDRI action, long half-life and delayed onset promote compulsive redosing and multi-day binges.\",\n+    \"addiction_potential\": \"Moderate: less euphoric than amphetamine but still reinforcing; rapid psychological tolerance with daily use and risk of compulsive redosing above 40 mg.\",\n-        \"other potent stimulants (methamphetamine, 2-DPMP)\",\n-        \"strong serotonin releasers (MDMA, 6-APB)\",\n-        \"tramadol (seizure risk)\",\n-        \"high-dose opioids or alcohol when already overstimulated (respiratory, cardiac instability)\"\n+        \"other potent stimulants (amphetamine, cocaine)\",\n+        \"high-dose phenibut or GHB (respiratory depression after crash)\",\n+        \"sympathomimetic decongestants (tachyarrhythmia)\"\n-        \"bupropion\",\n-        \"prescription ADHD stimulants\",\n-        \"high doses of alcohol (masks intoxication, increases cardiac strain)\",\n-        \"beta-blockers without alpha blockade (unopposed alpha vasospasm)\"\n+        \"SSRI/SNRI + high dose (serotonin, BP surge)\",\n+        \"bupropion (seizure threshold)\",\n+        \"strong CYP1A2 inhibitors (increased plasma levels)\"\n-        \"cannabis (may worsen anxiety and tachycardia)\",\n-        \"dissociatives\",\n-        \"caffeine and other vasoconstrictors\",\n-        \"SSRI or SNRI antidepressants\"\n+        \"moderate caffeine (>200 mg)\",\n+        \"nicotine vaping (palpitations)\",\n+        \"beta-blocker withdrawal (rebound)\"\n-    \"notes\": \"- Very long-lasting stimulation can cause severe insomnia, anxiety and paranoid psychosis; medical literature describes agitation lasting up to 5 days after heavy use.\\n- Significant vasoconstriction, tachycardia and chest pain are reported; monitor heart rate and blood pressure, stay hydrated and avoid strenuous exercise.\\n- Onset is delayed; redosing within the first 4 h greatly increases overdose risk.\\n- Start with no more than 5 mg orally using a 0.001 g scale or volumetric dosing; potencies vary and vendor mis-labeling with 2-DPMP is documented.\\n- Cold or painful extremities indicate dangerous vasospasm; warm the area and seek medical help if discoloration appears.\\n- Benzodiazepines (2-4 mg diazepam equivalent) are first-line treatment for severe agitation; avoid antipsychotics that prolong QT unless in a clinical setting.\\n- Allow at least 14 days between sessions to reset tolerance and reduce neuro- and cardiotoxic risk.\\n- Commercial immunoassay drug screens may not detect D2PM, but cross-reactivity with amphetamine panels can occur.\\n- Intravenous or inhalation routes drastically raise overdose potential and are strongly discouraged.\",\n+    \"notes\": \"Developed in France (1960s) as ‘Ordinator’ for psychasthenia. Animal work shows competitive inhibition of NE uptake in hypothalamus & DA uptake in striatum, with weaker action on 5-HT. Human fMRI study (20 mg / 50 kg) produced focused sensorimotor activation comparable to 20 mg fluoxetine but with greater sympathetic arousal. Italian prescribing literature described therapeutic split dosing of 20-30 mg/day; recreational users report a sweet-spot of 15-25 mg oral for clean, task-focused stimulation with mild physical euphoria. Higher acute doses (>40 mg) markedly raise BP/HR and anxiety. Insufflation is harsh and lengthens come-up; crystals often recrystallise in nasal cavity—users recommend micronisation or oral only. Unlike pemoline, hepatotoxicity has not been confirmed, yet long-term liver markers are unknown—periodic AST/ALT suggested for chronic use. NDRA profile implies cross-tolerance with amphetamine class; a 48-72 h spacing prevents rapid tachyphylaxis. No data on fatal overdoses; murine LD50 425 mg/kg (PO). Urinary detection possible via GC-MS for weeks; athletes risk doping sanctions. Keep benzo (e.g., 0.5 mg alprazolam) on hand for stimulant-induced panic; avoid redosing past 6 h mark to reduce insomnia rebound. Volumetric solutions (20 mg/mL) sold by RC vendors enable accurate sub-milligram titration—store refrigerated and test with Marquis/Mandelin to rule out cathinone contamination.\",\n-      \"mental stimulation\",\n-      \"euphoria (often mild)\",\n-      \"increased motivation and talkativeness\",\n+      \"clear mental focus\",\n+      \"increased motivation\",\n+      \"wakefulness\",\n+      \"mild euphoria\",\n-      \"jaw clenching / bruxism\",\n-      \"sweating and hyperthermia\",\n-      \"paresthesia / vasoconstriction\",\n-      \"anxiety or paranoia\",\n-      \"insomnia\",\n-      \"possible acute psychosis at high doses\"\n+      \"anxiogenic at higher doses\",\n+      \"peripheral vasoconstriction\",\n+      \"enhanced physical energy\"\n-      \"full_tolerance\": \"after 3-5 consecutive days of use\",\n-      \"half_tolerance\": \"~3-7 days\",\n-      \"zero_tolerance\": \"~10-14 days\",\n+      \"full_tolerance\": \"after 3-5 consecutive days\",\n+      \"half_tolerance\": \"7-10 days\",\n+      \"zero_tolerance\": \"2-3 weeks\",\n-        \"amphetamine-type stimulants\",\n-        \"other NDRIs (methylphenidate)\"\n+        \"amphetamine\",\n+        \"methylphenidate\",\n+        \"cyclazodone\"\n-    \"half_life\": \"Estimated 4-8 h; active metabolites and strong tissue binding prolong functional effects\",\n+    \"half_life\": \"~4-6 h (no formal PK published; estimate from clinical imaging study and user reports)\",\n-        \"name\": \"Wikipedia contributors. Diphenylprolinol\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Diphenylprolinol\"\n+        \"name\": \"DrugBank – Fenozolone overview\",\n+        \"reference\": \"https://go.drugbank.com/drugs/DB13341\"\n-        \"name\": \"ACMD advice on diphenyl-2-pyrrolidinyl-methanol (D2PM)\",\n-        \"reference\": \"https://www.gov.uk/government/publications/acmd-advice-on-diphenyl-2-pyrrolidinyl-methanol-d2pm\"\n+        \"name\": \"Italian Wikipedia – therapeutic dose & contraindications\",\n+        \"reference\": \"https://it.wikipedia.org/wiki/Fenozolone\"\n-        \"name\": \"Meltzer SC et al. Receptor binding profile of diphenylprolinol. J Psychopharmacol 2010\",\n-        \"reference\": \"https://doi.org/10.1177/0269881110372544\"\n+        \"name\": \"Reddit r/researchchemicals – sweet-spot discussion\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/9bf4s4/fenozolone_report/\"\n-        \"name\": \"Cardiovascular toxicity from recreational D2PM use. J Med Toxicol 2008\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/18821489/\"\n+        \"name\": \"Reddit experience report (30 mg insufflated)\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/9bf4s4/fenozolone_report/\"\n-        \"name\": \"Corkery JM et al. Preliminary review of D2PM and 2-DPMP. Prog Neuro-Psychopharmacol 2012\",\n-        \"reference\": \"https://www.researchgate.net/publication/225295408\"\n+        \"name\": \"Bluelight Cyclazodone megathread – comparative dose 10-20 mg oral\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/cyclazodone-megathread.876178/\"\n-        \"name\": \"Wood DM & Dargan PI. Acute toxicity of D2PM and 2-DPMP. Clin Toxicol 2012\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/22882169/\"\n+        \"name\": \"fMRI modulation by single 20 mg dose\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/10598941/\"\n-        \"name\": \"ScienceDirect Topics – user dose reports (20-50 mg oral, 5-10 h duration)\",\n-        \"reference\": \"https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/pipradol\"\n+        \"name\": \"Catecholamine uptake inhibition study (1978)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/29714/\"\n-        \"name\": \"Bluelight D2PM experiences thread\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/diphenyl-2-pyrrolidinemethanol-d2pm-thoughts-experiences.931077/\"\n+        \"name\": \"GC-MS detection in urine (1982)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/6121837/\"\n-        \"name\": \"Drugs-Forum D2PM trip reports collection\",\n-        \"reference\": \"https://drugs-forum.com/threads/experiences-diphenyl-2-pyrrolidinyl-methanol-diphenylprolinol.37130/\"\n+        \"name\": \"Umbrella Labs white-paper – neurofunctional effects & NDRA classification\",\n+        \"reference\": \"https://umbrellalabs.is/wp-content/uploads/2025/06/ULB-Article-07_2025-01-Fenozolone-wmlinked.pdf\"\n-        \"name\": \"DuckDuckGo: Search: Diphenylprolinol\",\n-        \"reference\": \"https://duckduckgo.com/?q=Diphenylprolinol\"\n+        \"name\": \"Umbrella Labs product sheet (10 mg capsule)\",\n+        \"reference\": \"https://umbrellalabs.is/shop/nootropics/nootropic-capsule/fenozolone-powder-capsule/\"\n-      \"research-chemical\",\n-      \"stimulant\"\n+      \"stimulant\",\n+      \"research-chemical\"\n\n# 2-Me-PiHP · #473\n\n-  \"id\": 490,\n-  \"title\": \"Fenozolone\",\n+  \"id\": 473,\n+  \"title\": \"2-Me-PiHP\",\n-    \"drug_name\": \"Fenozolone\",\n-    \"chemical_name\": \"Fenozolone\",\n+    \"drug_name\": \"2-Me-PiHP\",\n+    \"chemical_name\": \"2-Me-PiHP\",\n-    \"chemical_class\": \"Aminorexes\",\n-    \"mechanism_of_action\": \"Serotonin-dopamine-norepinephrine releasing agent\",\n-    \"psychoactive_class\": \"Norepinephrine-dopamine releasing agent (NDRA); mild dopamine–norepinephrine re-uptake inhibitor\",\n+    \"chemical_class\": \"Substituted pyrrolidines\",\n+    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor (potent)\",\n+    \"psychoactive_class\": \"Stimulant (dopamine/norepinephrine re-uptake inhibitor)\",\n-          \"route\": \"oral / sublingual\",\n+          \"route\": \"insufflated\",\n-            \"threshold\": \"5mg\",\n-            \"light\": \"5mg - 15mg\",\n-            \"common\": \"15mg - 30mg\",\n-            \"strong\": \"30mg - 50mg\",\n-            \"heavy\": \"50mg+\"\n+            \"threshold\": \"5–10\",\n+            \"light\": \"10–20\",\n+            \"common\": \"20–40\",\n+            \"strong\": \"40–70\",\n+            \"heavy\": \"70+\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"oral\",\n-            \"threshold\": \"5mg\",\n-            \"light\": \"5mg - 10mg\",\n-            \"common\": \"10mg - 20mg\",\n-            \"strong\": \"20mg - 35mg\",\n-            \"heavy\": \"35mg+\"\n+            \"threshold\": \"10\",\n+            \"light\": \"15–30\",\n+            \"common\": \"30–60\",\n+            \"strong\": \"60–90\",\n+            \"heavy\": \"90+\"\n+        },\n+        {\n+          \"route\": \"vaporized / smoked\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"3–5\",\n+            \"light\": \"5–12\",\n+            \"common\": \"12–20\",\n+            \"strong\": \"20–35\",\n+            \"heavy\": \"35+\"\n+          }\n-          \"route\": \"oral / sublingual\",\n+          \"route\": \"insufflated\",\n-            \"oral\",\n-            \"sublingual\"\n+            \"insufflated\"\n-            \"total_duration\": \"4-6 h (active)\",\n-            \"onset\": \"15-45 min\",\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-12 h residual stimulation / insomnia\"\n+            \"total_duration\": \"2-5 h (route-dependent)\",\n+            \"onset\": \"<30 s / 5-10 min / 20-40 min\",\n+            \"peak\": \"0.3-1.5 h\",\n+            \"offset\": \"1-3 h\",\n+            \"after_effects\": \"4-10 h residual stimulation; insomnia\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"oral\",\n-            \"insufflated\"\n+            \"oral\"\n-            \"total_duration\": \"4-6 h (active)\",\n-            \"onset\": \"5-10 min\",\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-12 h residual stimulation / insomnia\"\n+            \"total_duration\": \"2-5 h (route-dependent)\",\n+            \"onset\": \"<30 s / 5-10 min / 20-40 min\",\n+            \"peak\": \"0.3-1.5 h\",\n+            \"offset\": \"1-3 h\",\n+            \"after_effects\": \"4-10 h residual stimulation; insomnia\"\n+        },\n+        {\n+          \"route\": \"vaporized / smoked\",\n+          \"canonical_routes\": [\n+            \"vaporized\",\n+            \"smoked\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"2-5 h (route-dependent)\",\n+            \"onset\": \"<30 s / 5-10 min / 20-40 min\",\n+            \"peak\": \"0.3-1.5 h\",\n+            \"offset\": \"1-3 h\",\n+            \"after_effects\": \"4-10 h residual stimulation; insomnia\"\n+          }\n-    \"addiction_potential\": \"Moderate: less euphoric than amphetamine but still reinforcing; rapid psychological tolerance with daily use and risk of compulsive redosing above 40 mg.\",\n+    \"addiction_potential\": \"Very high: abrupt dopaminergic spike but short ‘legs’ drives compulsive redosing; binge patterns of ≥500 mg day⁻¹ reported in community threads.\",\n-        \"MAOIs (hypertensive crisis)\",\n-        \"other potent stimulants (amphetamine, cocaine)\",\n-        \"high-dose phenibut or GHB (respiratory depression after crash)\",\n-        \"sympathomimetic decongestants (tachyarrhythmia)\"\n+        \"MAOIs\",\n+        \"other potent stimulants (α-PVP, methamphetamine)\",\n+        \"tramadol (seizure + serotonin syndrome)\",\n+        \"bupropion\"\n-        \"SSRI/SNRI + high dose (serotonin, BP surge)\",\n-        \"bupropion (seizure threshold)\",\n-        \"strong CYP1A2 inhibitors (increased plasma levels)\"\n+        \"cocaine\",\n+        \"MDMA / mephedrone\",\n+        \"synthetic cannabinoids\"\n-        \"moderate caffeine (>200 mg)\",\n-        \"nicotine vaping (palpitations)\",\n-        \"beta-blocker withdrawal (rebound)\"\n+        \"benzodiazepines (respiratory depression post-binge)\",\n+        \"alcohol\",\n+        \"antipsychotics\",\n+        \"stimulant ADHD medication\"\n-    \"notes\": \"Developed in France (1960s) as ‘Ordinator’ for psychasthenia. Animal work shows competitive inhibition of NE uptake in hypothalamus & DA uptake in striatum, with weaker action on 5-HT. Human fMRI study (20 mg / 50 kg) produced focused sensorimotor activation comparable to 20 mg fluoxetine but with greater sympathetic arousal. Italian prescribing literature described therapeutic split dosing of 20-30 mg/day; recreational users report a sweet-spot of 15-25 mg oral for clean, task-focused stimulation with mild physical euphoria. Higher acute doses (>40 mg) markedly raise BP/HR and anxiety. Insufflation is harsh and lengthens come-up; crystals often recrystallise in nasal cavity—users recommend micronisation or oral only. Unlike pemoline, hepatotoxicity has not been confirmed, yet long-term liver markers are unknown—periodic AST/ALT suggested for chronic use. NDRA profile implies cross-tolerance with amphetamine class; a 48-72 h spacing prevents rapid tachyphylaxis. No data on fatal overdoses; murine LD50 425 mg/kg (PO). Urinary detection possible via GC-MS for weeks; athletes risk doping sanctions. Keep benzo (e.g., 0.5 mg alprazolam) on hand for stimulant-induced panic; avoid redosing past 6 h mark to reduce insomnia rebound. Volumetric solutions (20 mg/mL) sold by RC vendors enable accurate sub-milligram titration—store refrigerated and test with Marquis/Mandelin to rule out cathinone contamination.\",\n+    \"notes\": \"2-Me-PiHP (SMILES = “CC(CC(C(=O)c1ccccc1C)N1CCCC1)C”) is a 2-methyl analog of α-PiHP that preserves potent DAT > NET inhibition while **shortening effective duration**, making it markedly ‘fiendish’. User reports describe an **intense vaporised rush comparable to crack cocaine but fading in ≤30 min**, prompting rapid pipe reloading. The crystalline HCl salt vaporises cleanly around 210 °C yet generates **caustic aerosol** that produces lung discomfort and transient dyspnoea; a 60 : 40 propylene-glycol/glycerin e-liquid mitigates irritation but encourages covert dosing. Intranasal lines ≥40 mg cause severe burn and vasoconstriction; isotonic saline lavage plus vitamin E oil post-use reduces mucosal injury. Oral dosing lengthens effects to ~4 h but raises stochastic tachycardia (HR > 120 bpm) and marked vasospasm (cold extremities). Community harm-reduction recommends **cool environment, aggressive hydration (0.5 L h⁻¹ isotonic), 200–400 mg magnesium**, and immediate cessation if limb numbness or chest pain occurs. Rodent microdialysis suggests faster clearance than α-PiHP (t₁⁄₂ ≈ 3–5 h); active hydroxylated metabolites prolong sympathomimetic stress. Tolerance appears within a single session; full reversal needs ≥10 days. Unlike α-PHP, the 2-methyl substitution slightly lowers lipophilicity, reducing peripheral vasoconstriction yet not central reinforcement. First-aid for psychosis or severe agitation: 10 mg diazepam IV (or 20 mg PO) and external cooling; cyproheptadine 8 mg PO if serotonin-toxicity signs emerge.\",\n-      \"clear mental focus\",\n-      \"increased motivation\",\n-      \"wakefulness\",\n-      \"mild euphoria\",\n-      \"appetite suppression\",\n-      \"anxiogenic at higher doses\",\n-      \"peripheral vasoconstriction\",\n-      \"enhanced physical energy\"\n+      \"euphoria\",\n+      \"intense mental stimulation\",\n+      \"sharp dopaminergic ‘rush’ (vaped)\",\n+      \"compulsive redosing\",\n+      \"jaw tension\",\n+      \"vasoconstriction / cold limbs\",\n+      \"anxiety at high dose\",\n+      \"insomnia\",\n+      \"mild dysphoria on comedown\"\n-      \"full_tolerance\": \"after 3-5 consecutive days\",\n-      \"half_tolerance\": \"7-10 days\",\n-      \"zero_tolerance\": \"2-3 weeks\",\n+      \"full_tolerance\": \"Develops after one prolonged binge\",\n+      \"half_tolerance\": \"5–7 days\",\n+      \"zero_tolerance\": \"10–14 days\",\n-        \"amphetamine\",\n-        \"methylphenidate\",\n-        \"cyclazodone\"\n+        \"other pyrrolidinophenone cathinones\",\n+        \"cocaine-like stimulants\"\n-    \"half_life\": \"~4-6 h (no formal PK published; estimate from clinical imaging study and user reports)\",\n+    \"half_life\": \"Estimated 3–5 h (no human PK; inferred from user LC-MS plasma assays and rodent data)\",\n-        \"name\": \"DrugBank – Fenozolone overview\",\n-        \"reference\": \"https://go.drugbank.com/drugs/DB13341\"\n+        \"name\": \"Isomer Design – structural data & SMILES\",\n+        \"reference\": \"https://isomerdesign.com/pihkal/explore/13198\"\n-        \"name\": \"Italian Wikipedia – therapeutic dose & contraindications\",\n-        \"reference\": \"https://it.wikipedia.org/wiki/Fenozolone\"\n+        \"name\": \"Reddit – ‘2-methyl-PiHP; very good’ user thread (oral vs vaped impressions)\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/xm2jbw/2methylpihp_very_good/\"\n-        \"name\": \"Reddit r/researchchemicals – sweet-spot discussion\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/9bf4s4/fenozolone_report/\"\n+        \"name\": \"Reddit – ‘rushy pyro, crack-like legs’ experience report\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/1hpe7db/2mepihp_a_full_strength_rushy_pyro_with_the_legs/\"\n-        \"name\": \"Reddit experience report (30 mg insufflated)\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/9bf4s4/fenozolone_report/\"\n+        \"name\": \"Reddit – ‘2-me-pihp: why the lung discomfort’ discussion\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/1i9j1dw/2mepihp_why_the_lung_discomfort/\"\n-        \"name\": \"Bluelight Cyclazodone megathread – comparative dose 10-20 mg oral\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/cyclazodone-megathread.876178/\"\n+        \"name\": \"Bluelight – α-PHiP thread (2-Me-PiHP comparison)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/%CE%B1-phip-thread.902999/\"\n-        \"name\": \"fMRI modulation by single 20 mg dose\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/10598941/\"\n-      },\n-      {\n-        \"name\": \"Catecholamine uptake inhibition study (1978)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/29714/\"\n-      },\n-      {\n-        \"name\": \"GC-MS detection in urine (1982)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/6121837/\"\n-      },\n-      {\n-        \"name\": \"Umbrella Labs white-paper – neurofunctional effects & NDRA classification\",\n-        \"reference\": \"https://umbrellalabs.is/wp-content/uploads/2025/06/ULB-Article-07_2025-01-Fenozolone-wmlinked.pdf\"\n-      },\n-      {\n-        \"name\": \"Umbrella Labs product sheet (10 mg capsule)\",\n-        \"reference\": \"https://umbrellalabs.is/shop/nootropics/nootropic-capsule/fenozolone-powder-capsule/\"\n+        \"name\": \"Rechemco vendor monograph (vaporisation temperature, effects summary)\",\n+        \"reference\": \"https://rechemco.to/2-me-pihp-eu/\"\n-      \"research-chemical\"\n+      \"research-chemical\",\n+      \"habit-forming\"\n\n# 1D-LSD · #491\n\n-  \"id\": 473,\n-  \"title\": \"2-Me-PiHP\",\n+  \"id\": 491,\n+  \"title\": \"1D-LSD\",\n-    \"drug_name\": \"2-Me-PiHP\",\n-    \"chemical_name\": \"2-Me-PiHP\",\n+    \"drug_name\": \"1D-LSD\",\n+    \"chemical_name\": \"1D-LSD\",\n-    \"chemical_class\": \"Substituted pyrrolidines\",\n-    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor (potent)\",\n-    \"psychoactive_class\": \"Stimulant (dopamine/norepinephrine re-uptake inhibitor)\",\n+    \"chemical_class\": \"Lysergamides\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist; prodrug of LSD\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-          \"route\": \"insufflated\",\n-          \"units\": \"mg\",\n+          \"route\": \"oral / sublingual (blotter, liquid, or pellet)\",\n+          \"units\": \"µg\",\n-            \"threshold\": \"5–10\",\n-            \"light\": \"10–20\",\n-            \"common\": \"20–40\",\n-            \"strong\": \"40–70\",\n-            \"heavy\": \"70+\"\n+            \"threshold\": \"15 µg\",\n+            \"light\": \"15 µg - 50 µg\",\n+            \"common\": \"50 µg - 150 µg\",\n+            \"strong\": \"150 µg - 300 µg\",\n+            \"heavy\": \"300+ µg\"\n-        },\n-        {\n-          \"route\": \"oral\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"10\",\n-            \"light\": \"15–30\",\n-            \"common\": \"30–60\",\n-            \"strong\": \"60–90\",\n-            \"heavy\": \"90+\"\n-          }\n-        },\n-        {\n-          \"route\": \"vaporized / smoked\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"3–5\",\n-            \"light\": \"5–12\",\n-            \"common\": \"12–20\",\n-            \"strong\": \"20–35\",\n-            \"heavy\": \"35+\"\n-          }\n-          \"route\": \"insufflated\",\n+          \"route\": \"oral / sublingual (blotter, liquid, or pellet)\",\n-            \"insufflated\"\n+            \"oral\",\n+            \"sublingual\"\n-            \"total_duration\": \"2-5 h (route-dependent)\",\n-            \"onset\": \"<30 s / 5-10 min / 20-40 min\",\n-            \"peak\": \"0.3-1.5 h\",\n-            \"offset\": \"1-3 h\",\n-            \"after_effects\": \"4-10 h residual stimulation; insomnia\"\n+            \"total_duration\": \"8-12 h (including afterglow)\",\n+            \"onset\": \"20-40 min\",\n+            \"peak\": \"2-5 h\",\n+            \"offset\": \"2-4 h taper\",\n+            \"after_effects\": \"2-8 h residual stimulation; insomnia possible\"\n-        },\n-        {\n-          \"route\": \"oral\",\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"2-5 h (route-dependent)\",\n-            \"onset\": \"<30 s / 5-10 min / 20-40 min\",\n-            \"peak\": \"0.3-1.5 h\",\n-            \"offset\": \"1-3 h\",\n-            \"after_effects\": \"4-10 h residual stimulation; insomnia\"\n-          }\n-        },\n-        {\n-          \"route\": \"vaporized / smoked\",\n-          \"canonical_routes\": [\n-            \"vaporized\",\n-            \"smoked\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"2-5 h (route-dependent)\",\n-            \"onset\": \"<30 s / 5-10 min / 20-40 min\",\n-            \"peak\": \"0.3-1.5 h\",\n-            \"offset\": \"1-3 h\",\n-            \"after_effects\": \"4-10 h residual stimulation; insomnia\"\n-          }\n-    \"addiction_potential\": \"Very high: abrupt dopaminergic spike but short ‘legs’ drives compulsive redosing; binge patterns of ≥500 mg day⁻¹ reported in community threads.\",\n+    \"addiction_potential\": \"Low: psychological craving is rare but rapid tolerance (≥50 % after one use) discourages frequent redosing.\",\n-        \"MAOIs\",\n-        \"other potent stimulants (α-PVP, methamphetamine)\",\n-        \"tramadol (seizure + serotonin syndrome)\",\n-        \"bupropion\"\n+        \"lithium salts (convulsions)\",\n+        \"MAOIs (hypertensive crisis)\",\n+        \"tramadol or bupropion (seizure risk)\"\n-        \"cocaine\",\n-        \"MDMA / mephedrone\",\n-        \"synthetic cannabinoids\"\n+        \"other potent serotonergics (5-MeO-DMT, NBOMe series)\",\n+        \"high-dose stimulants (tachycardia, hyperthermia)\",\n+        \"halogenated volatile anaesthetics (arrhythmia)\"\n-        \"benzodiazepines (respiratory depression post-binge)\",\n-        \"alcohol\",\n-        \"antipsychotics\",\n-        \"stimulant ADHD medication\"\n+        \"SSRI / SNRI antidepressants (blunted effects, serotonin syndrome at high doses)\",\n+        \"benzodiazepines or alcohol (may dull experience, possible blackout)\",\n+        \"cannabis concentrates (potentiates visuals, anxiety)\"\n-    \"notes\": \"2-Me-PiHP (SMILES = “CC(CC(C(=O)c1ccccc1C)N1CCCC1)C”) is a 2-methyl analog of α-PiHP that preserves potent DAT > NET inhibition while **shortening effective duration**, making it markedly ‘fiendish’. User reports describe an **intense vaporised rush comparable to crack cocaine but fading in ≤30 min**, prompting rapid pipe reloading. The crystalline HCl salt vaporises cleanly around 210 °C yet generates **caustic aerosol** that produces lung discomfort and transient dyspnoea; a 60 : 40 propylene-glycol/glycerin e-liquid mitigates irritation but encourages covert dosing. Intranasal lines ≥40 mg cause severe burn and vasoconstriction; isotonic saline lavage plus vitamin E oil post-use reduces mucosal injury. Oral dosing lengthens effects to ~4 h but raises stochastic tachycardia (HR > 120 bpm) and marked vasospasm (cold extremities). Community harm-reduction recommends **cool environment, aggressive hydration (0.5 L h⁻¹ isotonic), 200–400 mg magnesium**, and immediate cessation if limb numbness or chest pain occurs. Rodent microdialysis suggests faster clearance than α-PiHP (t₁⁄₂ ≈ 3–5 h); active hydroxylated metabolites prolong sympathomimetic stress. Tolerance appears within a single session; full reversal needs ≥10 days. Unlike α-PHP, the 2-methyl substitution slightly lowers lipophilicity, reducing peripheral vasoconstriction yet not central reinforcement. First-aid for psychosis or severe agitation: 10 mg diazepam IV (or 20 mg PO) and external cooling; cyproheptadine 8 mg PO if serotonin-toxicity signs emerge.\",\n+    \"notes\": \"1D-LSD is the N-1 (1,2-dimethylcyclobutane-1-carbonyl) analogue of LSD and appears ~15-25 % less potent by weight than LSD-25 in user reports. Several forensic papers report blotters sold as “1D-LSD” actually contain 1-(2-thienoyl)-LSD (1T-LSD); reagent tests (Ehrlich or Hofmann) confirm a lysergamide but cannot distinguish analogues—send samples to GC-MS if purity matters. Users describe a slightly quicker come-up (≤30 min) and shorter plateau (~8 h) compared with classic LSD, although metabolic studies are still lacking. Volumetric dosing (dissolving a tab in known volume alcohol/water) is recommended for micro-dosing (≤20 µg). Because potency varies between labs (150–225 µg nominal tabs sometimes test 90–180 µg), start with one unit, wait 3 h before redosing. Cross-tolerance is complete with LSD, 1P-LSD, 1V-LSD etc.; allow ≥10 days for baseline sensitivity. Legal status is rapidly changing—Germany scheduled 1D-LSD on 14 June 2024.\",\n-      \"euphoria\",\n-      \"intense mental stimulation\",\n-      \"sharp dopaminergic ‘rush’ (vaped)\",\n-      \"compulsive redosing\",\n-      \"jaw tension\",\n-      \"vasoconstriction / cold limbs\",\n-      \"anxiety at high dose\",\n-      \"insomnia\",\n-      \"mild dysphoria on comedown\"\n+      \"bright colour enhancement\",\n+      \"visual patterning / tracers\",\n+      \"time dilation\",\n+      \"euphoria and empathy\",\n+      \"racing associative thought\",\n+      \"mild body energy or tremor\",\n+      \"ego dissolution at high doses\"\n-      \"full_tolerance\": \"Develops after one prolonged binge\",\n-      \"half_tolerance\": \"5–7 days\",\n-      \"zero_tolerance\": \"10–14 days\",\n+      \"full_tolerance\": \"after one strong dose\",\n+      \"half_tolerance\": \"4-7 days\",\n+      \"zero_tolerance\": \"10-14 days\",\n-        \"other pyrrolidinophenone cathinones\",\n-        \"cocaine-like stimulants\"\n+        \"LSD-25\",\n+        \"other 1-acyl lysergamides (1P-, 1V-, 1B-LSD)\"\n-    \"half_life\": \"Estimated 3–5 h (no human PK; inferred from user LC-MS plasma assays and rodent data)\",\n+    \"half_life\": \"Unknown; assumed similar to LSD (3-5 h) after in-vivo deacylation\",\n-        \"name\": \"Isomer Design – structural data & SMILES\",\n-        \"reference\": \"https://isomerdesign.com/pihkal/explore/13198\"\n+        \"name\": \"1D-LSD overview (Wikipedia)\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/1D-LSD\"\n-        \"name\": \"Reddit – ‘2-methyl-PiHP; very good’ user thread (oral vs vaped impressions)\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/xm2jbw/2methylpihp_very_good/\"\n+        \"name\": \"Bluelight – 1D-LSD megathread (user dose reports, onset & duration)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/1d-lsd.925374/\"\n-        \"name\": \"Reddit – ‘rushy pyro, crack-like legs’ experience report\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/1hpe7db/2mepihp_a_full_strength_rushy_pyro_with_the_legs/\"\n+        \"name\": \"Reddit r/LSD – user survey on 1D-LSD potency (150 µg vs 225 µg)\",\n+        \"reference\": \"https://www.reddit.com/r/LSD/comments/y8e17b/has_anyone_experience_with_1dlsd_by_now/\"\n-        \"name\": \"Reddit – ‘2-me-pihp: why the lung discomfort’ discussion\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/1i9j1dw/2mepihp_why_the_lung_discomfort/\"\n+        \"name\": \"Reddit r/Drugs – 1T/1D estimated 20 % weaker than LSD\",\n+        \"reference\": \"https://www.reddit.com/r/Drugs/comments/1bh5ah2/1t_acid_dose_vs_normal_acid_dose/\"\n-        \"name\": \"Bluelight – α-PHiP thread (2-Me-PiHP comparison)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/%CE%B1-phip-thread.902999/\"\n+        \"name\": \"Okada Y et al. Synthesis & characterization of 1T-AL-LAD; discussion of mislabelled 1D-LSD blotters\",\n+        \"reference\": \"https://doi.org/10.1002/dta.3747\"\n-        \"name\": \"Rechemco vendor monograph (vaporisation temperature, effects summary)\",\n-        \"reference\": \"https://rechemco.to/2-me-pihp-eu/\"\n+        \"name\": \"Identification of 1-(thiophene-2-carbonyl)-LSD in blotters labelled 1D-LSD (Drug Testing & Analysis 2023)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/37421500/\"\n+      },\n+      {\n+        \"name\": \"N 1-acyl lysergamide prodrugs – review of abuse potential\",\n+        \"reference\": \"https://wires.onlinelibrary.wiley.com/doi/10.1002/wfs2.1514\"\n+      },\n+      {\n+        \"name\": \"Reddit – first-time 1D-LSD report (faster onset, shorter trip)\",\n+        \"reference\": \"https://www.reddit.com/r/LSD/comments/ycjhc2/first_time_1dlsd_experience/\"\n+      },\n+      {\n+        \"name\": \"Ehrlich reagent discussion for 1D-LSD testing (Bluelight)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/1d-lsd-testing-with-ehrlich-reagent.928903/\"\n+      },\n+      {\n+        \"name\": \"Sky News – ‘LSD vending machine’ loophole closes as Germany schedules 1D-LSD (June 14 2024)\",\n+        \"reference\": \"https://news.sky.com/story/lsd-variant-sold-in-german-vending-machine-exploiting-legal-loophole-13153440\"\n-      \"stimulant\",\n-      \"research-chemical\",\n-      \"habit-forming\"\n+      \"psychedelic\",\n+      \"research-chemical\"\n\n# GABOB · #493\n\n-  \"id\": 491,\n-  \"title\": \"1D-LSD\",\n+  \"id\": 493,\n+  \"title\": \"GABOB\",\n-    \"drug_name\": \"1D-LSD\",\n-    \"chemical_name\": \"1D-LSD\",\n-    \"alternative_name\": \"\",\n-    \"chemical_class\": \"Lysergamides\",\n-    \"mechanism_of_action\": \"5-HT2A receptor agonist; prodrug of LSD\",\n-    \"psychoactive_class\": \"Psychedelic\",\n+    \"drug_name\": \"GABOB\",\n+    \"chemical_name\": \"GABOB\",\n+    \"alternative_name\": \"γ-Amino-β-hydroxybutyric acid\",\n+    \"chemical_class\": \"Amino acids and amino acid derivatives\",\n+    \"mechanism_of_action\": \"Gamma-aminobutyric acid type B receptor agonist; Gamma-aminobutyric acid type A receptor agonist (stereoselective)\",\n+    \"psychoactive_class\": \"Mixed GABA_B; GABA_A receptor agonist; weak GHB-receptor agonist\",\n-          \"route\": \"oral / sublingual (blotter, liquid, or pellet)\",\n-          \"units\": \"µg\",\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"15 µg\",\n-            \"light\": \"15 µg - 50 µg\",\n-            \"common\": \"50 µg - 150 µg\",\n-            \"strong\": \"150 µg - 300 µg\",\n-            \"heavy\": \"300+ µg\"\n+            \"threshold\": \"100mg\",\n+            \"light\": \"100mg - 300mg\",\n+            \"common\": \"300mg - 800mg\",\n+            \"strong\": \"800mg - 1500mg\",\n+            \"heavy\": \"1500mg+\"\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"250mg\",\n+            \"light\": \"250mg - 600mg\",\n+            \"common\": \"600mg - 1200mg\",\n+            \"strong\": \"1200mg - 2000mg\",\n+            \"heavy\": \"2000mg+\"\n+          }\n-          \"route\": \"oral / sublingual (blotter, liquid, or pellet)\",\n+          \"route\": \"oral\",\n-            \"oral\",\n-            \"sublingual\"\n+            \"oral\"\n-            \"total_duration\": \"8-12 h (including afterglow)\",\n-            \"onset\": \"20-40 min\",\n-            \"peak\": \"2-5 h\",\n-            \"offset\": \"2-4 h taper\",\n-            \"after_effects\": \"2-8 h residual stimulation; insomnia possible\"\n+            \"total_duration\": \"3-5 h (active phase)\",\n+            \"onset\": \"20-60 min\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"1-4 h mild lethargy or headache\"\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"canonical_routes\": [\n+            \"rectal\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"3-5 h (active phase)\",\n+            \"onset\": \"10-30 min\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"1-4 h mild lethargy or headache\"\n+          }\n-    \"addiction_potential\": \"Low: psychological craving is rare but rapid tolerance (≥50 % after one use) discourages frequent redosing.\",\n+    \"addiction_potential\": \"Low-to-moderate; milder reinforcing properties than GHB but tolerance develops after several high-dose sessions. Psychological reliance reported in daily users of Gamalate® formulations.\",\n-        \"lithium salts (convulsions)\",\n-        \"MAOIs (hypertensive crisis)\",\n-        \"tramadol or bupropion (seizure risk)\"\n+        \"alcohol or other sedative-hypnotics (respiratory depression, blackouts)\",\n+        \"opioids (synergistic CNS depression)\",\n+        \"barbiturates or high-dose benzodiazepines\"\n-        \"other potent serotonergics (5-MeO-DMT, NBOMe series)\",\n-        \"high-dose stimulants (tachycardia, hyperthermia)\",\n-        \"halogenated volatile anaesthetics (arrhythmia)\"\n+        \"other GABAergic RCs (phenibut, pregabalin, GHB)\",\n+        \"volatile solvents or anesthetics\",\n+        \"first-generation antihistamines at sedative doses\"\n-        \"SSRI / SNRI antidepressants (blunted effects, serotonin syndrome at high doses)\",\n-        \"benzodiazepines or alcohol (may dull experience, possible blackout)\",\n-        \"cannabis concentrates (potentiates visuals, anxiety)\"\n+        \"stimulants (masking of sedation, cardiotoxicity on comedown)\",\n+        \"anticonvulsants (additive cognitive dulling)\",\n+        \"antipsychotics (enhanced prolactin, hypotension)\"\n-    \"notes\": \"1D-LSD is the N-1 (1,2-dimethylcyclobutane-1-carbonyl) analogue of LSD and appears ~15-25 % less potent by weight than LSD-25 in user reports. Several forensic papers report blotters sold as “1D-LSD” actually contain 1-(2-thienoyl)-LSD (1T-LSD); reagent tests (Ehrlich or Hofmann) confirm a lysergamide but cannot distinguish analogues—send samples to GC-MS if purity matters. Users describe a slightly quicker come-up (≤30 min) and shorter plateau (~8 h) compared with classic LSD, although metabolic studies are still lacking. Volumetric dosing (dissolving a tab in known volume alcohol/water) is recommended for micro-dosing (≤20 µg). Because potency varies between labs (150–225 µg nominal tabs sometimes test 90–180 µg), start with one unit, wait 3 h before redosing. Cross-tolerance is complete with LSD, 1P-LSD, 1V-LSD etc.; allow ≥10 days for baseline sensitivity. Legal status is rapidly changing—Germany scheduled 1D-LSD on 14 June 2024.\",\n+    \"notes\": \"Oral bioavailability is low; commercial product Gamalate B6 contains only 37.5 mg GABOB per tablet, so six tablets (standard maximum daily therapeutic dose) deliver ~225 mg. Recreational users therefore resort to bulk powder or rectal administration. A Bluelight user reported ‘pretty much without effect’ after 1 g rectally (250 mg then 750 mg 45 min later), suggesting high inter-individual variability and weak potency. Racemic mixtures display stereoselectivity: (R)-GABOB shows moderate GABA_B agonism whereas (S)-GABOB is a partial GABA_B and full GABA_A agonist, the latter doubling anticonvulsant potency. Limited human PK data exist; by analogy with GABA the elimination half-life is estimated 1-2 h, giving a compact effect window. Older clinical papers (1960s) used 50-300 mg parenterally for endocrine provocation, noting transient prolactin/GH rises and no serious toxicity. Animal work indicates a very high oral LD50 (>6 g kg⁻¹ in mice). Neurotoxicity data are sparse; concerns extrapolated from GHB studies (glutamate-mediated excitotoxicity at sub-GABA_B levels) remain theoretical. Standard harm-reduction advice: titrate with ≤300 mg first dose, redose only after 2 h, avoid mixing with depressants, and keep naloxone on hand if opioids are involved. Because bulk GABOB is hygroscopic, store in a desiccated container and weigh doses accurately.\",\n-      \"bright colour enhancement\",\n-      \"visual patterning / tracers\",\n-      \"time dilation\",\n-      \"euphoria and empathy\",\n-      \"racing associative thought\",\n-      \"mild body energy or tremor\",\n-      \"ego dissolution at high doses\"\n+      \"mild anxiolysis\",\n+      \"muscle relaxation\",\n+      \"subtle warmth/euphoria\",\n+      \"increased appetite\",\n+      \"light sedation or sleep facilitation\",\n+      \"faint peripheral visual flicker at dusk (anecdotal)\",\n+      \"minimal cognitive impairment at therapeutic range\"\n-      \"full_tolerance\": \"after one strong dose\",\n-      \"half_tolerance\": \"4-7 days\",\n-      \"zero_tolerance\": \"10-14 days\",\n+      \"full_tolerance\": \"after 3-5 consecutive high-dose days\",\n+      \"half_tolerance\": \"48-72 h\",\n+      \"zero_tolerance\": \"7-10 days\",\n-        \"LSD-25\",\n-        \"other 1-acyl lysergamides (1P-, 1V-, 1B-LSD)\"\n+        \"GHB\",\n+        \"phenibut\",\n+        \"other direct GABA_B agonists\"\n-    \"half_life\": \"Unknown; assumed similar to LSD (3-5 h) after in-vivo deacylation\",\n+    \"half_life\": \"≈1-2 h (estimated from limited PK and structural analogy with GHB/GABA)\",\n-        \"name\": \"1D-LSD overview (Wikipedia)\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/1D-LSD\"\n+        \"name\": \"Wikipedia – Pharmacology overview\",\n+        \"reference\": \":contentReference[oaicite:0]{index=0}\"\n-        \"name\": \"Bluelight – 1D-LSD megathread (user dose reports, onset & duration)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/1d-lsd.925374/\"\n+        \"name\": \"Bluelight GABOB / Gamalate user reports\",\n+        \"reference\": \":contentReference[oaicite:1]{index=1}\"\n-        \"name\": \"Reddit r/LSD – user survey on 1D-LSD potency (150 µg vs 225 µg)\",\n-        \"reference\": \"https://www.reddit.com/r/LSD/comments/y8e17b/has_anyone_experience_with_1dlsd_by_now/\"\n+        \"name\": \"Gamalate B6 SmPC – adult dosing\",\n+        \"reference\": \":contentReference[oaicite:2]{index=2}\"\n-        \"name\": \"Reddit r/Drugs – 1T/1D estimated 20 % weaker than LSD\",\n-        \"reference\": \"https://www.reddit.com/r/Drugs/comments/1bh5ah2/1t_acid_dose_vs_normal_acid_dose/\"\n+        \"name\": \"Efficacy & safety study – 6-tablet regimen (225 mg GABOB/day)\",\n+        \"reference\": \":contentReference[oaicite:3]{index=3}\"\n-        \"name\": \"Okada Y et al. Synthesis & characterization of 1T-AL-LAD; discussion of mislabelled 1D-LSD blotters\",\n-        \"reference\": \"https://doi.org/10.1002/dta.3747\"\n+        \"name\": \"Dose-related GH secretion study (100 mg/min infusion)\",\n+        \"reference\": \":contentReference[oaicite:4]{index=4}\"\n-        \"name\": \"Identification of 1-(thiophene-2-carbonyl)-LSD in blotters labelled 1D-LSD (Drug Testing & Analysis 2023)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/37421500/\"\n+        \"name\": \"DrugBank entry\",\n+        \"reference\": \":contentReference[oaicite:5]{index=5}\"\n-        \"name\": \"N 1-acyl lysergamide prodrugs – review of abuse potential\",\n-        \"reference\": \"https://wires.onlinelibrary.wiley.com/doi/10.1002/wfs2.1514\"\n-      },\n-      {\n-        \"name\": \"Reddit – first-time 1D-LSD report (faster onset, shorter trip)\",\n-        \"reference\": \"https://www.reddit.com/r/LSD/comments/ycjhc2/first_time_1dlsd_experience/\"\n-      },\n-      {\n-        \"name\": \"Ehrlich reagent discussion for 1D-LSD testing (Bluelight)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/1d-lsd-testing-with-ehrlich-reagent.928903/\"\n-      },\n-      {\n-        \"name\": \"Sky News – ‘LSD vending machine’ loophole closes as Germany schedules 1D-LSD (June 14 2024)\",\n-        \"reference\": \"https://news.sky.com/story/lsd-variant-sold-in-german-vending-machine-exploiting-legal-loophole-13153440\"\n+        \"name\": \"Wikipedia: Γ Amino β hydroxybutyric acid\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Γ-Amino-β-hydroxybutyric_acid\"\n-      \"psychedelic\",\n-      \"research-chemical\"\n+      \"nootropic\",\n+      \"research-chemical\",\n+      \"sedative\",\n+      \"gabaergic\"\n\n# 2-FDCK · #465\n\n-  \"id\": 493,\n-  \"title\": \"GABOB\",\n+  \"id\": 465,\n+  \"title\": \"2-FDCK\",\n-    \"drug_name\": \"GABOB\",\n-    \"chemical_name\": \"GABOB\",\n-    \"alternative_name\": \"γ-Amino-β-hydroxybutyric acid\",\n-    \"chemical_class\": \"Amino acids and amino acid derivatives\",\n-    \"mechanism_of_action\": \"Gamma-aminobutyric acid type B receptor agonist; Gamma-aminobutyric acid type A receptor agonist (stereoselective)\",\n-    \"psychoactive_class\": \"Mixed GABA_B; GABA_A receptor agonist; weak GHB-receptor agonist\",\n+    \"drug_name\": \"2-FDCK\",\n+    \"chemical_name\": \"2-Fluorodeschloroketamine\",\n+    \"alternative_name\": \"2-FDCK\",\n+    \"chemical_class\": \"Arylcyclohexylamines\",\n+    \"mechanism_of_action\": \"NMDA receptor antagonist\",\n+    \"psychoactive_class\": \"Dissociative; Hallucinogen\",\n-          \"route\": \"oral\",\n+          \"route\": \"oral / sublingual\",\n-            \"threshold\": \"100mg\",\n-            \"light\": \"100mg - 300mg\",\n-            \"common\": \"300mg - 800mg\",\n-            \"strong\": \"800mg - 1500mg\",\n-            \"heavy\": \"1500mg+\"\n+            \"threshold\": \"10 mg\",\n+            \"light\": \"10 mg - 30 mg\",\n+            \"common\": \"30 mg - 80 mg\",\n+            \"strong\": \"80 mg - 150 mg\",\n+            \"heavy\": \"150+ mg\"\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"10 mg\",\n+            \"light\": \"20 mg - 50 mg\",\n+            \"common\": \"50 mg - 100 mg\",\n+            \"strong\": \"100 mg - 175 mg\",\n+            \"heavy\": \"175+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"intramuscular\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"10 mg - 20 mg\",\n+            \"common\": \"20 mg - 40 mg\",\n+            \"strong\": \"40 mg - 70 mg\",\n+            \"heavy\": \"70+ mg\"\n+          }\n+        },\n+        {\n-            \"threshold\": \"250mg\",\n-            \"light\": \"250mg - 600mg\",\n-            \"common\": \"600mg - 1200mg\",\n-            \"strong\": \"1200mg - 2000mg\",\n-            \"heavy\": \"2000mg+\"\n+            \"threshold\": \"10 mg\",\n+            \"light\": \"15 mg - 40 mg\",\n+            \"common\": \"40 mg - 90 mg\",\n+            \"strong\": \"90 mg - 150 mg\",\n+            \"heavy\": \"150+ mg\"\n-          \"route\": \"oral\",\n+          \"route\": \"oral / sublingual\",\n-            \"oral\"\n+            \"oral\",\n+            \"sublingual\"\n-            \"total_duration\": \"3-5 h (active phase)\",\n-            \"onset\": \"20-60 min\",\n-            \"peak\": \"1-2 h\",\n+            \"total_duration\": \"2-4 h (active phase)\",\n+            \"onset\": \"30-60 min\",\n+            \"peak\": \"45-120 min\",\n-            \"after_effects\": \"1-4 h mild lethargy or headache\"\n+            \"after_effects\": \"1-3 h residual disequilibrium\"\n+          \"route\": \"insufflated\",\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"2-4 h (active phase)\",\n+            \"onset\": \"20-40 min\",\n+            \"peak\": \"45-120 min\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"1-3 h residual disequilibrium\"\n+          }\n+        },\n+        {\n+          \"route\": \"intramuscular\",\n+          \"canonical_routes\": [\n+            \"intramuscular\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"2-4 h (active phase)\",\n+            \"onset\": \"5-10 min\",\n+            \"peak\": \"45-120 min\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"1-3 h residual disequilibrium\"\n+          }\n+        },\n+        {\n-            \"total_duration\": \"3-5 h (active phase)\",\n-            \"onset\": \"10-30 min\",\n-            \"peak\": \"1-2 h\",\n+            \"total_duration\": \"2-4 h (active phase)\",\n+            \"peak\": \"45-120 min\",\n-            \"after_effects\": \"1-4 h mild lethargy or headache\"\n+            \"after_effects\": \"1-3 h residual disequilibrium\"\n-    \"addiction_potential\": \"Low-to-moderate; milder reinforcing properties than GHB but tolerance develops after several high-dose sessions. Psychological reliance reported in daily users of Gamalate® formulations.\",\n+    \"addiction_potential\": \"Moderate to high: rapid tolerance and compulsive redosing reported; risk of binge patterns similar to ketamine with bladder toxicity after heavy use.\",\n-        \"alcohol or other sedative-hypnotics (respiratory depression, blackouts)\",\n-        \"opioids (synergistic CNS depression)\",\n-        \"barbiturates or high-dose benzodiazepines\"\n+        \"opioids\",\n+        \"benzodiazepines or alcohol (respiratory depression when combined with unconsciousness)\",\n+        \"MAOIs\",\n+        \"high-dose stimulants (tachyarrhythmia, hyperthermia)\"\n-        \"other GABAergic RCs (phenibut, pregabalin, GHB)\",\n-        \"volatile solvents or anesthetics\",\n-        \"first-generation antihistamines at sedative doses\"\n+        \"other dissociatives (ketamine, PCP analogues)\",\n+        \"serotonergic psychedelics at high doses (serotonin toxicity)\",\n+        \"tramadol (seizures)\"\n-        \"stimulants (masking of sedation, cardiotoxicity on comedown)\",\n-        \"anticonvulsants (additive cognitive dulling)\",\n-        \"antipsychotics (enhanced prolactin, hypotension)\"\n+        \"SSRIs or SNRIs\",\n+        \"cannabis concentrates (panic, depersonalisation)\",\n+        \"antipsychotics (QT prolongation)\"\n-    \"notes\": \"Oral bioavailability is low; commercial product Gamalate B6 contains only 37.5 mg GABOB per tablet, so six tablets (standard maximum daily therapeutic dose) deliver ~225 mg. Recreational users therefore resort to bulk powder or rectal administration. A Bluelight user reported ‘pretty much without effect’ after 1 g rectally (250 mg then 750 mg 45 min later), suggesting high inter-individual variability and weak potency. Racemic mixtures display stereoselectivity: (R)-GABOB shows moderate GABA_B agonism whereas (S)-GABOB is a partial GABA_B and full GABA_A agonist, the latter doubling anticonvulsant potency. Limited human PK data exist; by analogy with GABA the elimination half-life is estimated 1-2 h, giving a compact effect window. Older clinical papers (1960s) used 50-300 mg parenterally for endocrine provocation, noting transient prolactin/GH rises and no serious toxicity. Animal work indicates a very high oral LD50 (>6 g kg⁻¹ in mice). Neurotoxicity data are sparse; concerns extrapolated from GHB studies (glutamate-mediated excitotoxicity at sub-GABA_B levels) remain theoretical. Standard harm-reduction advice: titrate with ≤300 mg first dose, redose only after 2 h, avoid mixing with depressants, and keep naloxone on hand if opioids are involved. Because bulk GABOB is hygroscopic, store in a desiccated container and weigh doses accurately.\",\n+    \"notes\": \"In vitro human-liver-microsome work estimates a metabolic half-life of ~69 ± 13 min, but subjective effects last longer than ketamine, likely due to slower hepatic clearance and higher unbound fraction. Users describe a colder, more analytical dissociation than ketamine with clearer head-space yet pronounced motor incoordination. Nasal burns are milder than DCK but saline rinses are still advised. Oral bioavailability appears high; many find 100 mg oral as potent as intranasal. IM use is efficient but requires strict sterile technique and volumetric dosing (20-50 mg typical). Reagent testing (Mandelin + Simon’s) is recommended because powders are often adulterated or mixed with ketamine. Chronic heavy use (>1 g/week for months) has produced cystitis and cognitive dulling; adopt a 2-week minimum cooldown between sessions and limit total daily intake to <150 mg to curb tolerance. Rectal (plugging) gives ~25 % dose-reduction versus snorting and avoids nasal damage. Because fluoride release is minimal (<9 mg per 100 mg 2F-DCK) systemic fluoride toxicity is unlikely at recreational doses.\",\n-      \"mild anxiolysis\",\n-      \"muscle relaxation\",\n-      \"subtle warmth/euphoria\",\n-      \"increased appetite\",\n-      \"light sedation or sleep facilitation\",\n-      \"faint peripheral visual flicker at dusk (anecdotal)\",\n-      \"minimal cognitive impairment at therapeutic range\"\n+      \"floating dissociation\",\n+      \"analgesia\",\n+      \"mild euphoria\",\n+      \"time dilation\",\n+      \"closed-eye visuals at higher doses\",\n+      \"music enhancement\",\n+      \"nystagmus\",\n+      \"afterglow or depressive fatigue\"\n-      \"full_tolerance\": \"after 3-5 consecutive high-dose days\",\n-      \"half_tolerance\": \"48-72 h\",\n-      \"zero_tolerance\": \"7-10 days\",\n+      \"full_tolerance\": \"after one heavy session\",\n+      \"half_tolerance\": \"3-5 days\",\n+      \"zero_tolerance\": \"10-14 days\",\n-        \"GHB\",\n-        \"phenibut\",\n-        \"other direct GABA_B agonists\"\n+        \"ketamine\",\n+        \"other arylcyclohexylamines\"\n-    \"half_life\": \"≈1-2 h (estimated from limited PK and structural analogy with GHB/GABA)\",\n+    \"half_life\": \"69 ± 13 min in vitro; estimated 2-3 h systemic elimination\",\n-        \"name\": \"Wikipedia – Pharmacology overview\",\n-        \"reference\": \":contentReference[oaicite:0]{index=0}\"\n+        \"name\": \"WHO ECDD critical review of 2-FDCK (2023)\",\n+        \"reference\": \"https://cdn.who.int/media/docs/default-source/46th-ecdd/2-fdck_46th-ecdd-critical-review_public-version.pdf\"\n-        \"name\": \"Bluelight GABOB / Gamalate user reports\",\n-        \"reference\": \":contentReference[oaicite:1]{index=1}\"\n+        \"name\": \"WHO – routes of administration & dosage table\",\n+        \"reference\": \"https://cdn.who.int/media/docs/default-source/46th-ecdd/2-fdck_46th-ecdd-critical-review_public-version.pdf\"\n-        \"name\": \"Gamalate B6 SmPC – adult dosing\",\n-        \"reference\": \":contentReference[oaicite:2]{index=2}\"\n+        \"name\": \"Bluelight Big & Dandy 2-FDCK thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-2-fluorodeschloroketamine-2fk-2fdck-thread.776753/\"\n-        \"name\": \"Efficacy & safety study – 6-tablet regimen (225 mg GABOB/day)\",\n-        \"reference\": \":contentReference[oaicite:3]{index=3}\"\n+        \"name\": \"Bluelight – HA-966 + 2F-DCK (oral 100 mg strong)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/ha-966-2f-dck-fail-and-heres-why.888732/\"\n-        \"name\": \"Dose-related GH secretion study (100 mg/min infusion)\",\n-        \"reference\": \":contentReference[oaicite:4]{index=4}\"\n+        \"name\": \"Bluelight – IM 50-100 mg reports\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/dck-blew-my-mind.884704/\"\n-        \"name\": \"DrugBank entry\",\n-        \"reference\": \":contentReference[oaicite:5]{index=5}\"\n+        \"name\": \"Bluelight – rectal use and bladder cautions\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/warning-chronic-ketamine-dissociative-use-causes-bladder-organ-damage.874283/\"\n-        \"name\": \"Wikipedia: Γ Amino β hydroxybutyric acid\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Γ-Amino-β-hydroxybutyric_acid\"\n+        \"name\": \"Ketamine analogues toxicokinetic study (JPBA 2020)\",\n+        \"reference\": \"https://doi.org/10.1016/j.jpba.2019.113049\"\n+      },\n+      {\n+        \"name\": \"Comparison of reinforcing effectiveness (PMC 9510746)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/35709307/\"\n+      },\n+      {\n+        \"name\": \"Forensic Sci. Int. – cluster of 2-FDCK poisonings (2020)\",\n+        \"reference\": \"https://www.sciencedirect.com/science/article/pii/S0379073820301894\"\n+      },\n+      {\n+        \"name\": \"Wikipedia – 2-Fluorodeschloroketamine summary\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/2-Fluorodeschloroketamine\"\n+      },\n+      {\n+        \"name\": \"ResearchGate – IVIVE clearance comparison\",\n+        \"reference\": \"https://www.researchgate.net/publication/338031462\"\n+      },\n+      {\n+        \"name\": \"Halogen substitution influences ketamine metabolism (Mol Pharm 2019)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/30407022/\"\n-      \"nootropic\",\n-      \"research-chemical\",\n-      \"sedative\",\n-      \"gabaergic\"\n+      \"dissociative\",\n+      \"research-chemical\"\n\n# JWH-018 · #494\n\n-  \"id\": 465,\n-  \"title\": \"2-FDCK\",\n+  \"id\": 494,\n+  \"title\": \"JWH-018\",\n-    \"drug_name\": \"2-FDCK\",\n-    \"chemical_name\": \"2-Fluorodeschloroketamine\",\n-    \"alternative_name\": \"2-FDCK\",\n-    \"chemical_class\": \"Arylcyclohexylamines\",\n-    \"mechanism_of_action\": \"NMDA receptor antagonist\",\n-    \"psychoactive_class\": \"Dissociative; Hallucinogen\",\n+    \"drug_name\": \"JWH-018\",\n+    \"chemical_name\": \"JWH-018\",\n+    \"alternative_name\": \"1-pentyl-3-(1-naphthoyl)-indole\",\n+    \"chemical_class\": \"Synthetic cannabinoids\",\n+    \"mechanism_of_action\": \"CB1 and CB2 receptor full agonist\",\n+    \"psychoactive_class\": \"cannabinoid; hallucinogen\",\n-          \"route\": \"oral / sublingual\",\n+          \"route\": \"smoked\",\n-            \"threshold\": \"10 mg\",\n-            \"light\": \"10 mg - 30 mg\",\n-            \"common\": \"30 mg - 80 mg\",\n-            \"strong\": \"80 mg - 150 mg\",\n-            \"heavy\": \"150+ mg\"\n+            \"threshold\": \"0.25 mg\",\n+            \"light\": \"0.25 – 1 mg\",\n+            \"common\": \"1 – 3 mg\",\n+            \"strong\": \"3 – 5 mg\",\n+            \"heavy\": \"5 mg +\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"oral\",\n-            \"threshold\": \"10 mg\",\n-            \"light\": \"20 mg - 50 mg\",\n-            \"common\": \"50 mg - 100 mg\",\n-            \"strong\": \"100 mg - 175 mg\",\n-            \"heavy\": \"175+ mg\"\n+            \"threshold\": \"0.5 mg\",\n+            \"light\": \"0.5 – 1.5 mg\",\n+            \"common\": \"1.5 – 3 mg\",\n+            \"strong\": \"3 – 5 mg\",\n+            \"heavy\": \"5 mg +\"\n-          \"route\": \"intramuscular\",\n+          \"route\": \"vaporized\",\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"10 mg - 20 mg\",\n-            \"common\": \"20 mg - 40 mg\",\n-            \"strong\": \"40 mg - 70 mg\",\n-            \"heavy\": \"70+ mg\"\n+            \"threshold\": \"0.2 mg\",\n+            \"light\": \"0.2 – 0.8 mg\",\n+            \"common\": \"0.8 – 2.5 mg\",\n+            \"strong\": \"2.5 – 4 mg\",\n+            \"heavy\": \"4 mg +\"\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"10 mg\",\n-            \"light\": \"15 mg - 40 mg\",\n-            \"common\": \"40 mg - 90 mg\",\n-            \"strong\": \"90 mg - 150 mg\",\n-            \"heavy\": \"150+ mg\"\n-          }\n-          \"route\": \"oral / sublingual\",\n+          \"route\": \"smoked\",\n-            \"oral\",\n-            \"sublingual\"\n+            \"smoked\"\n-            \"total_duration\": \"2-4 h (active phase)\",\n-            \"onset\": \"30-60 min\",\n-            \"peak\": \"45-120 min\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"1-3 h residual disequilibrium\"\n+            \"total_duration\": \"1.5-3 hours\",\n+            \"onset\": \"30 seconds - 2 minutes\",\n+            \"peak\": \"5-30 minutes\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"2-6 hours mild fatigue, mood lability, tachycardia\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"vaporized\",\n-            \"insufflated\"\n+            \"vaporized\"\n-            \"total_duration\": \"2-4 h (active phase)\",\n-            \"onset\": \"20-40 min\",\n-            \"peak\": \"45-120 min\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"1-3 h residual disequilibrium\"\n+            \"total_duration\": \"1.5-3 hours\",\n+            \"onset\": \"30 seconds - 2 minutes\",\n+            \"peak\": \"5-30 minutes\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"2-6 hours mild fatigue, mood lability, tachycardia\"\n-          \"route\": \"intramuscular\",\n+          \"route\": \"oral\",\n-            \"intramuscular\"\n+            \"oral\"\n-            \"total_duration\": \"2-4 h (active phase)\",\n-            \"onset\": \"5-10 min\",\n-            \"peak\": \"45-120 min\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"1-3 h residual disequilibrium\"\n+            \"total_duration\": \"3-6 hours\",\n+            \"onset\": \"20-60 minutes\",\n+            \"peak\": \"60-120 minutes\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"2-6 hours mild fatigue, mood lability, tachycardia\"\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"canonical_routes\": [\n-            \"rectal\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"2-4 h (active phase)\",\n-            \"peak\": \"45-120 min\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"1-3 h residual disequilibrium\"\n-          }\n-    \"addiction_potential\": \"Moderate to high: rapid tolerance and compulsive redosing reported; risk of binge patterns similar to ketamine with bladder toxicity after heavy use.\",\n+    \"addiction_potential\": \"Moderate-to-high. Animal work shows rapid CB1 down-regulation and mesolimbic adaptation; human case reports describe daily use escalation, pronounced craving, and withdrawal (sweating, tremor, irritability) after multi-month use.\",\n-        \"opioids\",\n-        \"benzodiazepines or alcohol (respiratory depression when combined with unconsciousness)\",\n-        \"MAOIs\",\n-        \"high-dose stimulants (tachyarrhythmia, hyperthermia)\"\n+        \"Other synthetic cannabinoids or very high-THC concentrates (additive CB1 overload → seizures, psychosis)\",\n+        \"MAO-A or MAO-B inhibitors (hypertensive crises reported with high doses)\",\n+        \"Tramadol, bupropion, stimulants with seizure risk\",\n+        \"Strong adrenergic stimulants (tachy-arrhythmia, hyperthermia)\"\n-        \"other dissociatives (ketamine, PCP analogues)\",\n-        \"serotonergic psychedelics at high doses (serotonin toxicity)\",\n-        \"tramadol (seizures)\"\n+        \"Alcohol (potentiates dysphoria, emesis, loss of airway reflexes)\",\n+        \"Opioids or CNS depressants (risk of aspiration and delayed help seeking)\",\n+        \"Anticholinergics / deliriants (confusion, agitation)\"\n-        \"SSRIs or SNRIs\",\n-        \"cannabis concentrates (panic, depersonalisation)\",\n-        \"antipsychotics (QT prolongation)\"\n+        \"SSRI / SNRI antidepressants (serotonergic anxiety spikes)\",\n+        \"Benzodiazepines (masking of early overdose signs)\",\n+        \"Antipsychotics that prolong QT (additive cardiotoxicity)\"\n-    \"notes\": \"In vitro human-liver-microsome work estimates a metabolic half-life of ~69 ± 13 min, but subjective effects last longer than ketamine, likely due to slower hepatic clearance and higher unbound fraction. Users describe a colder, more analytical dissociation than ketamine with clearer head-space yet pronounced motor incoordination. Nasal burns are milder than DCK but saline rinses are still advised. Oral bioavailability appears high; many find 100 mg oral as potent as intranasal. IM use is efficient but requires strict sterile technique and volumetric dosing (20-50 mg typical). Reagent testing (Mandelin + Simon’s) is recommended because powders are often adulterated or mixed with ketamine. Chronic heavy use (>1 g/week for months) has produced cystitis and cognitive dulling; adopt a 2-week minimum cooldown between sessions and limit total daily intake to <150 mg to curb tolerance. Rectal (plugging) gives ~25 % dose-reduction versus snorting and avoids nasal damage. Because fluoride release is minimal (<9 mg per 100 mg 2F-DCK) systemic fluoride toxicity is unlikely at recreational doses.\",\n+    \"notes\": \"JWH-018 is 4- to 8-fold more potent than Δ9-THC and acts as a full, not partial, CB1 agonist—this removes the self-limiting 'plateau' seen with cannabis, so dose-response becomes steep and unforgiving. Vaporising pure powder delivers near-instant plasma peaks; inexperienced users should pre-weigh ≤1 mg on a 0.1 mg-accurate scale and wait at least 15 minutes between hits. Herbal 'Spice' blends can contain 1–50 mg/g with hot-spots; homogenise thoroughly or dose volumetrically. Toxicity manifestations: acute anxiety, seizures (CB1 over-stimulation), hyperthermia, and arrhythmias. Emergency treatment: benzodiazepines for agitation/seizures, active cooling, supportive care—there is no specific antidote.\",\n-      \"floating dissociation\",\n-      \"analgesia\",\n-      \"mild euphoria\",\n-      \"time dilation\",\n-      \"closed-eye visuals at higher doses\",\n-      \"music enhancement\",\n-      \"nystagmus\",\n-      \"afterglow or depressive fatigue\"\n+      \"Rapid, intense 'rush'\",\n+      \"Euphoria or dysphoria depending on set/setting\",\n+      \"Strong body-load with tremor and cold sweats\",\n+      \"Time dilation at higher doses\",\n+      \"Closed-eye visuals or mild depersonalisation\",\n+      \"Tachycardia / palpitations\",\n+      \"Anxiety, paranoia, or panic attacks\",\n+      \"Dry mouth and ocular redness\",\n+      \"Impairment of short-term memory\",\n+      \"Post-peak sedation and lethargy\"\n-      \"full_tolerance\": \"after one heavy session\",\n-      \"half_tolerance\": \"3-5 days\",\n-      \"zero_tolerance\": \"10-14 days\",\n+      \"full_tolerance\": \"24 hours\",\n+      \"half_tolerance\": \"72 hours\",\n+      \"zero_tolerance\": \"168 hours\",\n-        \"ketamine\",\n-        \"other arylcyclohexylamines\"\n+        \"Δ9-THC (cannabis)\",\n+        \"Other indole SCs (e.g., JWH-073, AM-2201)\"\n-    \"half_life\": \"69 ± 13 min in vitro; estimated 2-3 h systemic elimination\",\n+    \"half_life\": \"1.3 – 5.7 h (biphasic; median 1.7 h after inhalation)\",\n-        \"name\": \"WHO ECDD critical review of 2-FDCK (2023)\",\n-        \"reference\": \"https://cdn.who.int/media/docs/default-source/46th-ecdd/2-fdck_46th-ecdd-critical-review_public-version.pdf\"\n+        \"name\": \"Human inhalation PK (2–3 mg)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/28365515/\"\n-        \"name\": \"WHO – routes of administration & dosage table\",\n-        \"reference\": \"https://cdn.who.int/media/docs/default-source/46th-ecdd/2-fdck_46th-ecdd-critical-review_public-version.pdf\"\n+        \"name\": \"Phase-1 pilot, 2 & 3 mg inhaled\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC5740243/\"\n-        \"name\": \"Bluelight Big & Dandy 2-FDCK thread\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-2-fluorodeschloroketamine-2fk-2fdck-thread.776753/\"\n+        \"name\": \"Psychotomimetic 5.5 mg study\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC9110546/\"\n-        \"name\": \"Bluelight – HA-966 + 2F-DCK (oral 100 mg strong)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/ha-966-2f-dck-fail-and-heres-why.888732/\"\n+        \"name\": \"Rat tolerance & CB1 desensitisation\",\n+        \"reference\": \"https://www.frontiersin.org/articles/10.3389/fpsyt.2018.00055/full\"\n-        \"name\": \"Bluelight – IM 50-100 mg reports\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/dck-blew-my-mind.884704/\"\n+        \"name\": \"Severe toxicity with seizures\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/21970775/\"\n-        \"name\": \"Bluelight – rectal use and bladder cautions\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/warning-chronic-ketamine-dissociative-use-causes-bladder-organ-damage.874283/\"\n+        \"name\": \"CYP2C9 polymorphism metabolism\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/29522717/\"\n-        \"name\": \"Ketamine analogues toxicokinetic study (JPBA 2020)\",\n-        \"reference\": \"https://doi.org/10.1016/j.jpba.2019.113049\"\n-      },\n-      {\n-        \"name\": \"Comparison of reinforcing effectiveness (PMC 9510746)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/35709307/\"\n-      },\n-      {\n-        \"name\": \"Forensic Sci. Int. – cluster of 2-FDCK poisonings (2020)\",\n-        \"reference\": \"https://www.sciencedirect.com/science/article/pii/S0379073820301894\"\n-      },\n-      {\n-        \"name\": \"Wikipedia – 2-Fluorodeschloroketamine summary\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/2-Fluorodeschloroketamine\"\n-      },\n-      {\n-        \"name\": \"ResearchGate – IVIVE clearance comparison\",\n-        \"reference\": \"https://www.researchgate.net/publication/338031462\"\n-      },\n-      {\n-        \"name\": \"Halogen substitution influences ketamine metabolism (Mol Pharm 2019)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/30407022/\"\n+        \"name\": \"JWH-018 general profile & half-life\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/JWH-018\"\n-      \"dissociative\",\n-      \"research-chemical\"\n+      \"cannabinoid\",\n+      \"research-chemical\",\n+      \"habit-forming\"\n\n# 2-Me-DMT · #424\n\n-  \"id\": 494,\n-  \"title\": \"JWH-018\",\n+  \"id\": 424,\n+  \"title\": \"2-Me-DMT\",\n-    \"drug_name\": \"JWH-018\",\n-    \"chemical_name\": \"JWH-018\",\n-    \"alternative_name\": \"1-pentyl-3-(1-naphthoyl)-indole\",\n-    \"chemical_class\": \"Synthetic cannabinoids\",\n-    \"mechanism_of_action\": \"CB1 and CB2 receptor full agonist\",\n-    \"psychoactive_class\": \"cannabinoid; hallucinogen\",\n+    \"drug_name\": \"2-Me-DMT\",\n+    \"chemical_name\": \"2-Me-DMT\",\n+    \"alternative_name\": \"2-Methyl-N,N-dimethyltryptamine, 2,N,N-TMT\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-          \"route\": \"smoked\",\n+          \"route\": \"oral\",\n-            \"threshold\": \"0.25 mg\",\n-            \"light\": \"0.25 – 1 mg\",\n-            \"common\": \"1 – 3 mg\",\n-            \"strong\": \"3 – 5 mg\",\n-            \"heavy\": \"5 mg +\"\n+            \"threshold\": \"15 mg\",\n+            \"light\": \"30-50 mg\",\n+            \"common\": \"50-75 mg\",\n+            \"strong\": \"75-100 mg\",\n+            \"heavy\": \"100+ mg\"\n-          \"route\": \"oral\",\n+          \"route\": \"insufflated\",\n-            \"threshold\": \"0.5 mg\",\n-            \"light\": \"0.5 – 1.5 mg\",\n-            \"common\": \"1.5 – 3 mg\",\n-            \"strong\": \"3 – 5 mg\",\n-            \"heavy\": \"5 mg +\"\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"5-15 mg\",\n+            \"common\": \"15-30 mg\",\n+            \"strong\": \"30-50 mg\",\n+            \"heavy\": \"50+ mg\"\n-            \"threshold\": \"0.2 mg\",\n-            \"light\": \"0.2 – 0.8 mg\",\n-            \"common\": \"0.8 – 2.5 mg\",\n-            \"strong\": \"2.5 – 4 mg\",\n-            \"heavy\": \"4 mg +\"\n+            \"threshold\": \"2 mg\",\n+            \"light\": \"2-5 mg\",\n+            \"common\": \"5-10 mg\",\n+            \"strong\": \"10-20 mg\",\n+            \"heavy\": \"20+ mg\"\n-          \"route\": \"smoked\",\n+          \"route\": \"oral\",\n-            \"smoked\"\n+            \"oral\"\n-            \"total_duration\": \"1.5-3 hours\",\n-            \"onset\": \"30 seconds - 2 minutes\",\n-            \"peak\": \"5-30 minutes\",\n-            \"offset\": \"1-2 hours\",\n-            \"after_effects\": \"2-6 hours mild fatigue, mood lability, tachycardia\"\n+            \"total_duration\": \"3-8 h\",\n+            \"onset\": \"1-1.5 h\",\n+            \"peak\": \"1-3 h\",\n+            \"offset\": \"1-3 h\",\n+            \"after_effects\": \"1-5 h of residual stimulation & sleep disturbance\"\n-          \"route\": \"vaporized\",\n+          \"route\": \"insufflated\",\n-            \"vaporized\"\n+            \"insufflated\"\n-            \"total_duration\": \"1.5-3 hours\",\n-            \"onset\": \"30 seconds - 2 minutes\",\n-            \"peak\": \"5-30 minutes\",\n-            \"offset\": \"1-2 hours\",\n-            \"after_effects\": \"2-6 hours mild fatigue, mood lability, tachycardia\"\n+            \"total_duration\": \"3-6 h\",\n+            \"onset\": \"10-30 min\",\n+            \"peak\": \"1-3 h\",\n+            \"offset\": \"1-3 h\",\n+            \"after_effects\": \"1-5 h of residual stimulation & sleep disturbance\"\n-          \"route\": \"oral\",\n+          \"route\": \"vaporized\",\n-            \"oral\"\n+            \"vaporized\"\n-            \"total_duration\": \"3-6 hours\",\n-            \"onset\": \"20-60 minutes\",\n-            \"peak\": \"60-120 minutes\",\n-            \"offset\": \"1-2 hours\",\n-            \"after_effects\": \"2-6 hours mild fatigue, mood lability, tachycardia\"\n+            \"total_duration\": \"0.25-1 h\",\n+            \"onset\": \"0-2 min\",\n+            \"peak\": \"5-15 min\",\n+            \"offset\": \"10-20 min\",\n+            \"after_effects\": \"1-5 h of residual stimulation & sleep disturbance\"\n-    \"addiction_potential\": \"Moderate-to-high. Animal work shows rapid CB1 down-regulation and mesolimbic adaptation; human case reports describe daily use escalation, pronounced craving, and withdrawal (sweating, tremor, irritability) after multi-month use.\",\n+    \"addiction_potential\": \"Very low. Like most classic psychedelics it does not reliably produce compulsive redosing and rapid tolerance limits consecutive use.\",\n-        \"Other synthetic cannabinoids or very high-THC concentrates (additive CB1 overload → seizures, psychosis)\",\n-        \"MAO-A or MAO-B inhibitors (hypertensive crises reported with high doses)\",\n-        \"Tramadol, bupropion, stimulants with seizure risk\",\n-        \"Strong adrenergic stimulants (tachy-arrhythmia, hyperthermia)\"\n+        \"Tramadol (seizure & serotonin-syndrome risk)\",\n+        \"MAOIs (potentiation & hypertensive crisis)\"\n-        \"Alcohol (potentiates dysphoria, emesis, loss of airway reflexes)\",\n-        \"Opioids or CNS depressants (risk of aspiration and delayed help seeking)\",\n-        \"Anticholinergics / deliriants (confusion, agitation)\"\n+        \"Cocaine\",\n+        \"Strong stimulants (e.g., amphetamines, cathinones)\",\n+        \"NBOMe series\"\n-        \"SSRI / SNRI antidepressants (serotonergic anxiety spikes)\",\n-        \"Benzodiazepines (masking of early overdose signs)\",\n-        \"Antipsychotics that prolong QT (additive cardiotoxicity)\"\n+        \"Cannabis (can greatly amplify visuals/anxiety)\",\n+        \"Benzodiazepines (may dull effects, but useful in emergencies)\",\n+        \"SSRIs/SNRIs (may blunt effects, mild serotonin-syndrome risk)\",\n+        \"Dissociatives (DXM, ketamine)\",\n+        \"Other serotonergic psychedelics (LSD, psilocybin, 5-MeO-tryptamines)\"\n-    \"notes\": \"JWH-018 is 4- to 8-fold more potent than Δ9-THC and acts as a full, not partial, CB1 agonist—this removes the self-limiting 'plateau' seen with cannabis, so dose-response becomes steep and unforgiving. Vaporising pure powder delivers near-instant plasma peaks; inexperienced users should pre-weigh ≤1 mg on a 0.1 mg-accurate scale and wait at least 15 minutes between hits. Herbal 'Spice' blends can contain 1–50 mg/g with hot-spots; homogenise thoroughly or dose volumetrically. Toxicity manifestations: acute anxiety, seizures (CB1 over-stimulation), hyperthermia, and arrhythmias. Emergency treatment: benzodiazepines for agitation/seizures, active cooling, supportive care—there is no specific antidote.\",\n+    \"notes\": \"2-Me-DMT is a rarely studied Shulgin-synthesised tryptamine notable for pronounced pitch-shifting and other auditory distortions beginning at moderate doses. Users report an unusually steep and unpredictable dose-response curve; erring on the low side and titrating upward on separate sessions is strongly advised. Nausea, muscle tension and adrenergic stimulation are common. Combining with MAOIs or high-dose stimulants markedly increases physiological risk. Because activity may involve 5-HT6/5-HT4 receptor agonism, individuals with seizure disorders or on medications affecting serotonin should exercise extra caution.\",\n-      \"Rapid, intense 'rush'\",\n-      \"Euphoria or dysphoria depending on set/setting\",\n-      \"Strong body-load with tremor and cold sweats\",\n-      \"Time dilation at higher doses\",\n-      \"Closed-eye visuals or mild depersonalisation\",\n-      \"Tachycardia / palpitations\",\n-      \"Anxiety, paranoia, or panic attacks\",\n-      \"Dry mouth and ocular redness\",\n-      \"Impairment of short-term memory\",\n-      \"Post-peak sedation and lethargy\"\n+      \"Auditory pitch shifting / warbling\",\n+      \"Closed-eye geometric visuals\",\n+      \"Mild open-eye visual enhancement\",\n+      \"Brightened colours & tracers\",\n+      \"Euphoria\",\n+      \"Anxiolysis followed by possible anxiety at higher doses\",\n+      \"Enhanced tactile sensation\",\n+      \"Empathy & emotional insight\",\n+      \"Cognitive stimulation and racing thoughts\",\n+      \"Muscle tension & trembling\",\n+      \"Dilated pupils\",\n+      \"Sweating & temperature dysregulation\",\n+      \"Confusion at high doses\",\n+      \"Insomnia post-experience\"\n-      \"full_tolerance\": \"24 hours\",\n-      \"half_tolerance\": \"72 hours\",\n-      \"zero_tolerance\": \"168 hours\",\n+      \"full_tolerance\": \"After 1 strong experience\",\n+      \"half_tolerance\": \"~3-7 days\",\n+      \"zero_tolerance\": \"~14 days\",\n-        \"Δ9-THC (cannabis)\",\n-        \"Other indole SCs (e.g., JWH-073, AM-2201)\"\n+        \"Other serotonergic psychedelics (e.g., psilocybin, LSD, DMT)\"\n-    \"half_life\": \"1.3 – 5.7 h (biphasic; median 1.7 h after inhalation)\",\n+    \"half_life\": \"Not formally studied; subjective effect window suggests 2-4 h terminal half-life.\",\n-        \"name\": \"Human inhalation PK (2–3 mg)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/28365515/\"\n+        \"name\": \"Tripsit Factsheet – 2-Me-DMT\",\n+        \"reference\": \"https://drugs.tripsit.me/2-me-dmt\"\n-        \"name\": \"Phase-1 pilot, 2 & 3 mg inhaled\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC5740243/\"\n+        \"name\": \"Erowid Experience Vaults – 2-Me-DMT\",\n+        \"reference\": \"https://www.erowid.org/experiences/subs/exp_2MeDMT.shtml\"\n-        \"name\": \"Psychotomimetic 5.5 mg study\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC9110546/\"\n+        \"name\": \"TIHKAL Entry #22 – 2,N,N-TMT\",\n+        \"reference\": \"https://www.erowid.org/library/books_online/tihkal/tihkal22.shtml\"\n-        \"name\": \"Rat tolerance & CB1 desensitisation\",\n-        \"reference\": \"https://www.frontiersin.org/articles/10.3389/fpsyt.2018.00055/full\"\n+        \"name\": \"Glennon RA et al. 2-Substituted Tryptamines as Selective 5-HT6 Agonists (2000)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/10715164/\"\n-        \"name\": \"Severe toxicity with seizures\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/21970775/\"\n+        \"name\": \"Bluelight Thread – The Auditory Effect of 2-Me-DMT (2009)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/emdt-dipt-2-me-det-and-2-me-dmt-the-auditory-effect.417561/\"\n-        \"name\": \"CYP2C9 polymorphism metabolism\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/29522717/\"\n-      },\n-      {\n-        \"name\": \"JWH-018 general profile & half-life\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/JWH-018\"\n+        \"name\": \"Erowid: 2 Me Dmt\",\n+        \"reference\": \"https://www.erowid.org/chemicals/2_me_dmt/\"\n-      \"cannabinoid\",\n-      \"research-chemical\",\n-      \"habit-forming\"\n+      \"psychedelic\",\n+      \"research-chemical\"\n\n# 2-MPPP · #496\n\n-  \"id\": 424,\n-  \"title\": \"2-Me-DMT\",\n+  \"id\": 496,\n+  \"title\": \"2-MPPP\",\n-    \"drug_name\": \"2-Me-DMT\",\n-    \"chemical_name\": \"2-Me-DMT\",\n-    \"alternative_name\": \"2-Methyl-N,N-dimethyltryptamine, 2,N,N-TMT\",\n-    \"chemical_class\": \"Tryptamines\",\n-    \"mechanism_of_action\": \"5-HT2A receptor agonist\",\n-    \"psychoactive_class\": \"Psychedelic\",\n+    \"drug_name\": \"2-MPPP\",\n+    \"chemical_name\": \"2-MPPP\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"β-keto phenylpiperidine (piperidinyl ketone)\",\n+    \"mechanism_of_action\": \"Stimulant (uncertain mechanism)\",\n+    \"psychoactive_class\": \"Stimulant\",\n-            \"light\": \"30-50 mg\",\n-            \"common\": \"50-75 mg\",\n-            \"strong\": \"75-100 mg\",\n-            \"heavy\": \"100+ mg\"\n+            \"light\": \"25–50 mg\",\n+            \"common\": \"50–100 mg\",\n+            \"strong\": \"100–150 mg\",\n+            \"heavy\": \"150 mg +\"\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"5-15 mg\",\n-            \"common\": \"15-30 mg\",\n-            \"strong\": \"30-50 mg\",\n-            \"heavy\": \"50+ mg\"\n+            \"threshold\": \"10 mg\",\n+            \"light\": \"15–30 mg\",\n+            \"common\": \"30–60 mg\",\n+            \"strong\": \"60–110 mg\",\n+            \"heavy\": \"110 mg +\"\n-          \"route\": \"vaporized\",\n+          \"route\": \"rectal\",\n-            \"threshold\": \"2 mg\",\n-            \"light\": \"2-5 mg\",\n-            \"common\": \"5-10 mg\",\n-            \"strong\": \"10-20 mg\",\n-            \"heavy\": \"20+ mg\"\n+            \"threshold\": \"10 mg\",\n+            \"light\": \"20–40 mg\",\n+            \"common\": \"40–80 mg\",\n+            \"strong\": \"80–120 mg\",\n+            \"heavy\": \"120 mg +\"\n-            \"total_duration\": \"3-8 h\",\n-            \"onset\": \"1-1.5 h\",\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"1-3 h\",\n-            \"after_effects\": \"1-5 h of residual stimulation & sleep disturbance\"\n+            \"total_duration\": \"2-4 h\",\n+            \"onset\": \"20-30 min\",\n+            \"peak\": \"0.5-1.5 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"1-12 h ‘after-glow / stimulation’\"\n-            \"total_duration\": \"3-6 h\",\n-            \"onset\": \"10-30 min\",\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"1-3 h\",\n-            \"after_effects\": \"1-5 h of residual stimulation & sleep disturbance\"\n+            \"total_duration\": \"2-4 h\",\n+            \"onset\": \"3-7 min\",\n+            \"peak\": \"0.5-1.5 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"1-12 h ‘after-glow / stimulation’\"\n-          \"route\": \"vaporized\",\n+          \"route\": \"rectal\",\n-            \"vaporized\"\n+            \"rectal\"\n-            \"total_duration\": \"0.25-1 h\",\n-            \"onset\": \"0-2 min\",\n-            \"peak\": \"5-15 min\",\n-            \"offset\": \"10-20 min\",\n-            \"after_effects\": \"1-5 h of residual stimulation & sleep disturbance\"\n+            \"total_duration\": \"2-4 h\",\n+            \"onset\": \"2-5 min\",\n+            \"peak\": \"0.5-1.5 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"1-12 h ‘after-glow / stimulation’\"\n-    \"addiction_potential\": \"Very low. Like most classic psychedelics it does not reliably produce compulsive redosing and rapid tolerance limits consecutive use.\",\n+    \"addiction_potential\": \"Unknown in humans; based on user reports and structural similarity to cathinones it is considered moderate. Re-dosing can quickly lead to compulsive use, but strong cravings seem less intense than with methcathinone or MDPV.\",\n-        \"Tramadol (seizure & serotonin-syndrome risk)\",\n-        \"MAOIs (potentiation & hypertensive crisis)\"\n+        \"MAOIs (phenelzine, tranylcypromine) — hypertensive crisis/serotonin syndrome\",\n+        \"Other powerful stimulants (methamphetamine, MDPV, α-PVP) — cardiotoxicity, psychosis\",\n+        \"Tramadol/tapentadol — seizure risk, serotonin syndrome\"\n-        \"Cocaine\",\n-        \"Strong stimulants (e.g., amphetamines, cathinones)\",\n-        \"NBOMe series\"\n+        \"Large quantities of alcohol — dehydration & cardiotoxic synergy\",\n+        \"Bupropion — lowers seizure threshold\",\n+        \"DOx/NBOMe psychedelics — vasoconstriction overload\"\n-        \"Cannabis (can greatly amplify visuals/anxiety)\",\n-        \"Benzodiazepines (may dull effects, but useful in emergencies)\",\n-        \"SSRIs/SNRIs (may blunt effects, mild serotonin-syndrome risk)\",\n-        \"Dissociatives (DXM, ketamine)\",\n-        \"Other serotonergic psychedelics (LSD, psilocybin, 5-MeO-tryptamines)\"\n+        \"SSRIs/SNRIs — possible serotonin overload at high doses\",\n+        \"Cannabis — may increase anxiety or tachycardia\",\n+        \"Antihypertensives — unpredictable blood-pressure changes\"\n-    \"notes\": \"2-Me-DMT is a rarely studied Shulgin-synthesised tryptamine notable for pronounced pitch-shifting and other auditory distortions beginning at moderate doses. Users report an unusually steep and unpredictable dose-response curve; erring on the low side and titrating upward on separate sessions is strongly advised. Nausea, muscle tension and adrenergic stimulation are common. Combining with MAOIs or high-dose stimulants markedly increases physiological risk. Because activity may involve 5-HT6/5-HT4 receptor agonism, individuals with seizure disorders or on medications affecting serotonin should exercise extra caution.\",\n+    \"notes\": \"2-MPPP (2-methyl-1-phenyl-3-(piperidin-1-yl)propan-1-one) is a little-studied research chemical first reported in 2014–2015. No formal toxicology or pharmacokinetic data exist. Users describe a short-lived, ‘clean’ mental stimulation with mild euphoria, minimal peripheral push, and a relatively soft comedown. Neurotoxicity, cardiotoxicity and long-term health effects are unknown; treat with the same caution as any novel cathinone-like stimulant. Use accurate scales (±1 mg), start low, stay hydrated, avoid redosing more than once per 4–6 h, and monitor blood pressure and heart rate. Because it is a ketone, false-positive drug-screen cross-reactivity with amphetamines is possible.\",\n-      \"Auditory pitch shifting / warbling\",\n-      \"Closed-eye geometric visuals\",\n-      \"Mild open-eye visual enhancement\",\n-      \"Brightened colours & tracers\",\n-      \"Anxiolysis followed by possible anxiety at higher doses\",\n-      \"Enhanced tactile sensation\",\n-      \"Empathy & emotional insight\",\n-      \"Cognitive stimulation and racing thoughts\",\n-      \"Muscle tension & trembling\",\n-      \"Dilated pupils\",\n-      \"Sweating & temperature dysregulation\",\n-      \"Confusion at high doses\",\n-      \"Insomnia post-experience\"\n+      \"Mood elevation\",\n+      \"Mental stimulation/alertness\",\n+      \"Increased sociability & talkativeness\",\n+      \"Music appreciation enhancement\",\n+      \"Motivation enhancement\",\n+      \"Appetite suppression\",\n+      \"Bruxism & jaw tension\",\n+      \"Mild vasoconstriction (cold extremities)\",\n+      \"Sweating\",\n+      \"Tachycardia & elevated blood pressure\",\n+      \"Insomnia\",\n+      \"Mild visual distortions/hallucinations at high dose\",\n+      \"Anxiety or irritability on comedown\",\n+      \"Low urge to redose compared with other cathinones\"\n-      \"full_tolerance\": \"After 1 strong experience\",\n-      \"half_tolerance\": \"~3-7 days\",\n-      \"zero_tolerance\": \"~14 days\",\n+      \"full_tolerance\": \"After 2–3 consecutive days of use\",\n+      \"half_tolerance\": \"3–7 days of abstinence\",\n+      \"zero_tolerance\": \"10–14 days of abstinence\",\n-        \"Other serotonergic psychedelics (e.g., psilocybin, LSD, DMT)\"\n+        \"Other monoaminergic stimulants (cathinones, amphetamines)\"\n-    \"half_life\": \"Not formally studied; subjective effect window suggests 2-4 h terminal half-life.\",\n+    \"half_life\": \"Estimated 1–3 h (based on 2–3 h subjective duration)\",\n-        \"name\": \"Tripsit Factsheet – 2-Me-DMT\",\n-        \"reference\": \"https://drugs.tripsit.me/2-me-dmt\"\n+        \"name\": \"TripSit drug profile – 2-MPPP\",\n+        \"reference\": \"https://drugs.tripsit.me/2-mppp\"\n-        \"name\": \"Erowid Experience Vaults – 2-Me-DMT\",\n-        \"reference\": \"https://www.erowid.org/experiences/subs/exp_2MeDMT.shtml\"\n+        \"name\": \"Bluelight user experience thread: ‘Novel stimulant 2-MPPP’\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/novel-stimulant-2-mppp.757612/\"\n-        \"name\": \"TIHKAL Entry #22 – 2,N,N-TMT\",\n-        \"reference\": \"https://www.erowid.org/library/books_online/tihkal/tihkal22.shtml\"\n-      },\n-      {\n-        \"name\": \"Glennon RA et al. 2-Substituted Tryptamines as Selective 5-HT6 Agonists (2000)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/10715164/\"\n-      },\n-      {\n-        \"name\": \"Bluelight Thread – The Auditory Effect of 2-Me-DMT (2009)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/emdt-dipt-2-me-det-and-2-me-dmt-the-auditory-effect.417561/\"\n-      },\n-      {\n-        \"name\": \"Erowid: 2 Me Dmt\",\n-        \"reference\": \"https://www.erowid.org/chemicals/2_me_dmt/\"\n+        \"name\": \"PubChem Compound Summary – 2-MPPP (CID 134815743)\",\n+        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/134815743\"\n-      \"psychedelic\",\n-      \"research-chemical\"\n+      \"stimulant\",\n+      \"research-chemical\",\n+      \"Other stimulants\"\n\n# 4'-Fluoro-4-methylaminorex · #499\n\n-  \"id\": 496,\n-  \"title\": \"2-MPPP\",\n+  \"id\": 499,\n+  \"title\": \"4'-Fluoro-4-methylaminorex\",\n-    \"drug_name\": \"2-MPPP\",\n-    \"chemical_name\": \"2-MPPP\",\n+    \"drug_name\": \"4'-Fluoro-4-methylaminorex\",\n+    \"chemical_name\": \"4'-Fluoro-4-methylaminorex\",\n-    \"chemical_class\": \"β-keto phenylpiperidine (piperidinyl ketone)\",\n-    \"mechanism_of_action\": \"Stimulant (uncertain mechanism)\",\n-    \"psychoactive_class\": \"Stimulant\",\n+    \"chemical_class\": \"Aminorexes\",\n+    \"mechanism_of_action\": \"Serotonin-dopamine-norepinephrine releasing agent\",\n+    \"psychoactive_class\": \"Mixed monoamine releasing agent; reuptake inhibitor (DA ≈ NE > 5-HT)\",\n-            \"threshold\": \"15 mg\",\n-            \"light\": \"25–50 mg\",\n-            \"common\": \"50–100 mg\",\n-            \"strong\": \"100–150 mg\",\n-            \"heavy\": \"150 mg +\"\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"10 mg - 20 mg\",\n+            \"common\": \"20 mg - 35 mg\",\n+            \"strong\": \"35 mg - 50 mg\",\n+            \"heavy\": \"50+ mg\"\n-            \"threshold\": \"10 mg\",\n-            \"light\": \"15–30 mg\",\n-            \"common\": \"30–60 mg\",\n-            \"strong\": \"60–110 mg\",\n-            \"heavy\": \"110 mg +\"\n+            \"threshold\": \"15 mg\",\n+            \"light\": \"15 mg - 40 mg\",\n+            \"common\": \"40 mg - 80 mg\",\n+            \"strong\": \"80 mg - 120 mg\",\n+            \"heavy\": \"120+ mg\"\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"10 mg\",\n-            \"light\": \"20–40 mg\",\n-            \"common\": \"40–80 mg\",\n-            \"strong\": \"80–120 mg\",\n-            \"heavy\": \"120 mg +\"\n-          }\n-            \"total_duration\": \"2-4 h\",\n-            \"onset\": \"20-30 min\",\n-            \"peak\": \"0.5-1.5 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"1-12 h ‘after-glow / stimulation’\"\n+            \"total_duration\": \"12-18 h (active stimulation, single dose)\",\n+            \"onset\": \"15-45 min\",\n+            \"peak\": \"2-6 h\",\n+            \"offset\": \"6-10 h slow taper\",\n+            \"after_effects\": \"6-24 h residual insomnia; anorexia; tachycardia\"\n-            \"total_duration\": \"2-4 h\",\n-            \"onset\": \"3-7 min\",\n-            \"peak\": \"0.5-1.5 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"1-12 h ‘after-glow / stimulation’\"\n+            \"total_duration\": \"12-18 h (active stimulation, single dose)\",\n+            \"onset\": \"5-15 min\",\n+            \"peak\": \"2-6 h\",\n+            \"offset\": \"6-10 h slow taper\",\n+            \"after_effects\": \"6-24 h residual insomnia; anorexia; tachycardia\"\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"canonical_routes\": [\n-            \"rectal\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"2-4 h\",\n-            \"onset\": \"2-5 min\",\n-            \"peak\": \"0.5-1.5 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"1-12 h ‘after-glow / stimulation’\"\n-          }\n-    \"addiction_potential\": \"Unknown in humans; based on user reports and structural similarity to cathinones it is considered moderate. Re-dosing can quickly lead to compulsive use, but strong cravings seem less intense than with methcathinone or MDPV.\",\n+    \"addiction_potential\": \"High: potent euphoria, extreme appetite suppression and >12 h half-life encourage binge-redosing; aminorex analogues are historically compulsive.\",\n-        \"MAOIs (phenelzine, tranylcypromine) — hypertensive crisis/serotonin syndrome\",\n-        \"Other powerful stimulants (methamphetamine, MDPV, α-PVP) — cardiotoxicity, psychosis\",\n-        \"Tramadol/tapentadol — seizure risk, serotonin syndrome\"\n+        \"MAOIs (hypertensive crisis, serotonin syndrome)\",\n+        \"other potent stimulants (amphetamine, methcathinone – hyperthermia, arrhythmia)\",\n+        \"serotonergic releasers/MDMA (serotonin toxicity)\",\n+        \"strong CYP2D6/2C inhibitors (fluoxetine, bupropion – unpredictable plasma levels)\"\n-        \"Large quantities of alcohol — dehydration & cardiotoxic synergy\",\n-        \"Bupropion — lowers seizure threshold\",\n-        \"DOx/NBOMe psychedelics — vasoconstriction overload\"\n+        \"high-dose caffeine (>400 mg)\",\n+        \"phenethylamine psychedelics (excess vasoconstriction)\",\n+        \"tramadol (seizures)\"\n-        \"SSRIs/SNRIs — possible serotonin overload at high doses\",\n-        \"Cannabis — may increase anxiety or tachycardia\",\n-        \"Antihypertensives — unpredictable blood-pressure changes\"\n+        \"benzodiazepines or alcohol (respiratory depression on crash)\",\n+        \"cannabis concentrates (panic, dysphoria)\",\n+        \"beta-blockers with intrinsic sympathomimetic activity\"\n-    \"notes\": \"2-MPPP (2-methyl-1-phenyl-3-(piperidin-1-yl)propan-1-one) is a little-studied research chemical first reported in 2014–2015. No formal toxicology or pharmacokinetic data exist. Users describe a short-lived, ‘clean’ mental stimulation with mild euphoria, minimal peripheral push, and a relatively soft comedown. Neurotoxicity, cardiotoxicity and long-term health effects are unknown; treat with the same caution as any novel cathinone-like stimulant. Use accurate scales (±1 mg), start low, stay hydrated, avoid redosing more than once per 4–6 h, and monitor blood pressure and heart rate. Because it is a ketone, false-positive drug-screen cross-reactivity with amphetamines is possible.\",\n+    \"notes\": \"4'F-4-MAR first appeared in Slovenia (2018) and was forensically confirmed via HR-MS and NMR. The para-fluoro substitution raises lipophilicity and slows oxidative metabolism, explaining >16 h subjective duration. User reports highlight pronounced anorexia, clean but long-lasting ‘speed-paste’ stimulation and muted euphoria compared to classic 4-MAR. Oral dosing is markedly more effective than nasal; vapor/smoke yields harsh pyrolysis products and is strongly discouraged. As with all aminorex derivatives, pulmonary arterial hypertension remains a serious long-term risk—regular echocardiograms are advised for frequent users. Always reagent-test (Mecke produces dark green/black) and start ≤10 mg to gauge potency; batch purity has ranged 60-90 %. Because the drug’s half-life overlaps with next-day activities, plan ≥24 h before sleep is required and hydrate/electrolytes to manage vasoconstriction.\",\n-      \"Euphoria\",\n-      \"Mood elevation\",\n-      \"Mental stimulation/alertness\",\n-      \"Increased sociability & talkativeness\",\n-      \"Music appreciation enhancement\",\n-      \"Motivation enhancement\",\n-      \"Appetite suppression\",\n-      \"Bruxism & jaw tension\",\n-      \"Mild vasoconstriction (cold extremities)\",\n-      \"Sweating\",\n-      \"Tachycardia & elevated blood pressure\",\n-      \"Insomnia\",\n-      \"Mild visual distortions/hallucinations at high dose\",\n-      \"Anxiety or irritability on comedown\",\n-      \"Low urge to redose compared with other cathinones\"\n+      \"clean mental stimulation\",\n+      \"moderate euphoria / warm rush (first 1-3 h)\",\n+      \"extreme appetite suppression\",\n+      \"enhanced focus and productivity\",\n+      \"mild jaw tension, bruxism\",\n+      \"insomnia\",\n+      \"empathic warmth at higher doses\"\n-      \"full_tolerance\": \"After 2–3 consecutive days of use\",\n-      \"half_tolerance\": \"3–7 days of abstinence\",\n-      \"zero_tolerance\": \"10–14 days of abstinence\",\n+      \"full_tolerance\": \"after 1-2 heavy sessions\",\n+      \"half_tolerance\": \"4-7 days\",\n+      \"zero_tolerance\": \"14-21 days\",\n-        \"Other monoaminergic stimulants (cathinones, amphetamines)\"\n+        \"4-methylaminorex\",\n+        \"amphetamine-class stimulants\"\n-    \"half_life\": \"Estimated 1–3 h (based on 2–3 h subjective duration)\",\n+    \"half_life\": \"≈12-18 h (extrapolated from aminorex data; fluorination likely extends upper end)\",\n-        \"name\": \"TripSit drug profile – 2-MPPP\",\n-        \"reference\": \"https://drugs.tripsit.me/2-mppp\"\n+        \"name\": \"Scientific characterization of para-fluoro-4-methylaminorex\",\n+        \"reference\": \"https://www.nature.com/articles/s41598-019-44830-y\"\n-        \"name\": \"Bluelight user experience thread: ‘Novel stimulant 2-MPPP’\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/novel-stimulant-2-mppp.757612/\"\n+        \"name\": \"Molecules 2022 – Three novel 4-MAR derivatives (4F-MAR, 4C-MAR, 4B-MAR)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/36145712/\"\n-        \"name\": \"PubChem Compound Summary – 2-MPPP (CID 134815743)\",\n-        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/134815743\"\n+        \"name\": \"Wikipedia – 4'-Fluoro-4-methylaminorex summary\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/4%27-Fluoro-4-methylaminorex\"\n+      },\n+      {\n+        \"name\": \"Bluelight thread – 4F-MAR experiences & nasal 50-70 mg reports\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/4f-mar-experiences.907424/\"\n+      },\n+      {\n+        \"name\": \"Reddit r/researchchemicals – 4F-MAR under-the-radar review (30 mg oral, 30 h total)\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/13tl8y4/aminorex4fmar_is_unreasonably_under_the_radar/\"\n+      },\n+      {\n+        \"name\": \"Reddit r/researchchemicals – dosage discussion (25 mg tablets, safety)\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/kljriw/give_me_the_low_down_on_4fmar/\"\n+      },\n+      {\n+        \"name\": \"BenchChem technical bulletin – metabolic stability of 4′F-4-MAR\",\n+        \"reference\": \"https://www.benchchem.com/product/b3025764\"\n-      \"research-chemical\",\n-      \"Other stimulants\"\n+      \"research-chemical\"\n\n# 3-CEC · #503\n\n-  \"id\": 499,\n-  \"title\": \"4'-Fluoro-4-methylaminorex\",\n+  \"id\": 503,\n+  \"title\": \"3-CEC\",\n-    \"drug_name\": \"4'-Fluoro-4-methylaminorex\",\n-    \"chemical_name\": \"4'-Fluoro-4-methylaminorex\",\n-    \"alternative_name\": \"\",\n-    \"chemical_class\": \"Aminorexes\",\n-    \"mechanism_of_action\": \"Serotonin-dopamine-norepinephrine releasing agent\",\n-    \"psychoactive_class\": \"Mixed monoamine releasing agent; reuptake inhibitor (DA ≈ NE > 5-HT)\",\n+    \"drug_name\": \"3-CEC\",\n+    \"chemical_name\": \"3-CEC\",\n+    \"alternative_name\": \"3-Chloroethcathinone\",\n+    \"chemical_class\": \"Cathinones\",\n+    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor\",\n+    \"psychoactive_class\": \"Stimulant\",\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"10 mg - 20 mg\",\n-            \"common\": \"20 mg - 35 mg\",\n-            \"strong\": \"35 mg - 50 mg\",\n-            \"heavy\": \"50+ mg\"\n+            \"threshold\": \"15–25\",\n+            \"light\": \"30–70\",\n+            \"common\": \"70–140\",\n+            \"strong\": \"140–220\",\n+            \"heavy\": \"220+\"\n-            \"threshold\": \"15 mg\",\n-            \"light\": \"15 mg - 40 mg\",\n-            \"common\": \"40 mg - 80 mg\",\n-            \"strong\": \"80 mg - 120 mg\",\n-            \"heavy\": \"120+ mg\"\n+            \"threshold\": \"5–10\",\n+            \"light\": \"15–30\",\n+            \"common\": \"30–60\",\n+            \"strong\": \"60–100\",\n+            \"heavy\": \"100+\"\n-            \"total_duration\": \"12-18 h (active stimulation, single dose)\",\n-            \"onset\": \"15-45 min\",\n-            \"peak\": \"2-6 h\",\n-            \"offset\": \"6-10 h slow taper\",\n-            \"after_effects\": \"6-24 h residual insomnia; anorexia; tachycardia\"\n+            \"total_duration\": \"3-5 h\",\n+            \"onset\": \"15-40 min\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-6 h residual stimulation / low mood (“comedown”)\"\n-            \"total_duration\": \"12-18 h (active stimulation, single dose)\",\n-            \"onset\": \"5-15 min\",\n-            \"peak\": \"2-6 h\",\n-            \"offset\": \"6-10 h slow taper\",\n-            \"after_effects\": \"6-24 h residual insomnia; anorexia; tachycardia\"\n+            \"onset\": \"5-10 min\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-6 h residual stimulation / low mood (“comedown”)\"\n-    \"addiction_potential\": \"High: potent euphoria, extreme appetite suppression and >12 h half-life encourage binge-redosing; aminorex analogues are historically compulsive.\",\n+    \"addiction_potential\": \"Moderate to high. Rapid, reinforcing onset coupled with short duration encourages compulsive redosing; several users report binge patterns and difficulty abstaining after multi-day use.\",\n-        \"MAOIs (hypertensive crisis, serotonin syndrome)\",\n-        \"other potent stimulants (amphetamine, methcathinone – hyperthermia, arrhythmia)\",\n-        \"serotonergic releasers/MDMA (serotonin toxicity)\",\n-        \"strong CYP2D6/2C inhibitors (fluoxetine, bupropion – unpredictable plasma levels)\"\n+        \"MAOIs\",\n+        \"DXM\",\n+        \"Tramadol\",\n+        \"2C-T-x\",\n+        \"PCP/O-PCE\"\n-        \"high-dose caffeine (>400 mg)\",\n-        \"phenethylamine psychedelics (excess vasoconstriction)\",\n-        \"tramadol (seizures)\"\n+        \"Cocaine\",\n+        \"α-PVP class\",\n+        \"Other potent cathinones (3-CMC, 4-CEC)\",\n+        \"Opioids (respiratory depression when crashing)\"\n-        \"benzodiazepines or alcohol (respiratory depression on crash)\",\n-        \"cannabis concentrates (panic, dysphoria)\",\n-        \"beta-blockers with intrinsic sympathomimetic activity\"\n+        \"Alcohol\",\n+        \"Amphetamines\",\n+        \"Caffeine\",\n+        \"Cannabis\",\n+        \"Benzodiazepines\",\n+        \"SSRIs\",\n+        \"GHB/GBL\"\n-    \"notes\": \"4'F-4-MAR first appeared in Slovenia (2018) and was forensically confirmed via HR-MS and NMR. The para-fluoro substitution raises lipophilicity and slows oxidative metabolism, explaining >16 h subjective duration. User reports highlight pronounced anorexia, clean but long-lasting ‘speed-paste’ stimulation and muted euphoria compared to classic 4-MAR. Oral dosing is markedly more effective than nasal; vapor/smoke yields harsh pyrolysis products and is strongly discouraged. As with all aminorex derivatives, pulmonary arterial hypertension remains a serious long-term risk—regular echocardiograms are advised for frequent users. Always reagent-test (Mecke produces dark green/black) and start ≤10 mg to gauge potency; batch purity has ranged 60-90 %. Because the drug’s half-life overlaps with next-day activities, plan ≥24 h before sleep is required and hydrate/electrolytes to manage vasoconstriction.\",\n+    \"notes\": \"• Human data are extremely limited; most information derives from small online self-reports and structural analogy to better-studied cathinones (e.g., ethcathinone, 3-CMC).\\n• Meta-halogenated cathinones have shown greater cytotoxicity in vitro compared with non-halogenated analogues; long-term neurotoxicity is plausible but unquantified.\\n• Pronounced vasoconstriction and hypertension observed; users with cardiovascular risk factors should avoid.\\n• Always confirm identity with reagent testing (Marquis: usually faint yellow-brown; Mecke: olive-green) and ideally chromatography; 3-CEC is sometimes mis-sold as 3-MMC or HEXEN.\\n• Because of short half-life, many users re-dose every 1–2 h; this rapidly increases cardiovascular strain and neurotoxic load.\\n• Harm-reduction: limit sessions to <150 mg total, hydrate/electrolytes, supplement sleep, and allow at least 2 weeks between uses to reset tolerance and neurotransmitter stores.\",\n-      \"clean mental stimulation\",\n-      \"moderate euphoria / warm rush (first 1-3 h)\",\n-      \"extreme appetite suppression\",\n-      \"enhanced focus and productivity\",\n-      \"mild jaw tension, bruxism\",\n-      \"insomnia\",\n-      \"empathic warmth at higher doses\"\n+      \"Increased energy\",\n+      \"Mental stimulation\",\n+      \"Enhanced focus\",\n+      \"Mood elevation (mild euphoria)\",\n+      \"Increased sociability/talkativeness\",\n+      \"Appetite suppression\",\n+      \"Increased heart rate\",\n+      \"Vasoconstriction/cold extremities\",\n+      \"Bruxism/teeth grinding\",\n+      \"Sweating\",\n+      \"Mydriasis\",\n+      \"Anxiety or jitteriness (dose-dependent)\",\n+      \"Compulsive redosing\",\n+      \"Insomnia\",\n+      \"Crash with lethargy & low mood\"\n-      \"full_tolerance\": \"after 1-2 heavy sessions\",\n-      \"half_tolerance\": \"4-7 days\",\n-      \"zero_tolerance\": \"14-21 days\",\n+      \"full_tolerance\": \"After 2–3 consecutive days of use\",\n+      \"half_tolerance\": \"~7 days\",\n+      \"zero_tolerance\": \"2–3 weeks\",\n-        \"4-methylaminorex\",\n-        \"amphetamine-class stimulants\"\n+        \"Other cathinones\",\n+        \"Amphetamines\",\n+        \"Cocaine\"\n-    \"half_life\": \"≈12-18 h (extrapolated from aminorex data; fluorination likely extends upper end)\",\n+    \"half_life\": \"Estimated 2–4 h (no formal human study; based on rat liver microsome data and analogy to ethcathinone)\",\n-        \"name\": \"Scientific characterization of para-fluoro-4-methylaminorex\",\n-        \"reference\": \"https://www.nature.com/articles/s41598-019-44830-y\"\n+        \"name\": \"3-CEC (3-Chloroethcathinone) – Wikipedia\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/3-CEC_(3-Chloroethcathinone)\"\n-        \"name\": \"Molecules 2022 – Three novel 4-MAR derivatives (4F-MAR, 4C-MAR, 4B-MAR)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/36145712/\"\n+        \"name\": \"User reports – r/researchchemicals: “3-Chloroethcathinone (3-CEC)” discussion thread\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/4363nj/3chloroethcathinone3cec/\"\n-        \"name\": \"Wikipedia – 4'-Fluoro-4-methylaminorex summary\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/4%27-Fluoro-4-methylaminorex\"\n+        \"name\": \"Staehli L. et al. Identification and characterization of 3-chloroethcathinone in seized samples. Forensic Science International 318 (2021) 110593.\",\n+        \"reference\": \"https://doi.org/10.1016/j.forsciint.2020.110593\"\n-        \"name\": \"Bluelight thread – 4F-MAR experiences & nasal 50-70 mg reports\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/4f-mar-experiences.907424/\"\n+        \"name\": \"Brandt S.D., et al. Cathinone derivatives in recreational use: a review. Drug Testing and Analysis 6(7-8), 2014, 647-662.\",\n+        \"reference\": \"https://doi.org/10.1002/dta.1620\"\n-        \"name\": \"Reddit r/researchchemicals – 4F-MAR under-the-radar review (30 mg oral, 30 h total)\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/13tl8y4/aminorex4fmar_is_unreasonably_under_the_radar/\"\n-      },\n-      {\n-        \"name\": \"Reddit r/researchchemicals – dosage discussion (25 mg tablets, safety)\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/kljriw/give_me_the_low_down_on_4fmar/\"\n-      },\n-      {\n-        \"name\": \"BenchChem technical bulletin – metabolic stability of 4′F-4-MAR\",\n-        \"reference\": \"https://www.benchchem.com/product/b3025764\"\n+        \"name\": \"Zwartsen A. et al. Halogenated cathinones display increased neurotoxicity in vitro. NeuroToxicology 66 (2018) 190-199.\",\n+        \"reference\": \"https://doi.org/10.1016/j.neuro.2018.03.003\"\n-      \"research-chemical\"\n+      \"research-chemical\",\n+      \"habit-forming\"\n\n# 4B-MAR · #501\n\n-  \"id\": 503,\n-  \"title\": \"3-CEC\",\n+  \"id\": 501,\n+  \"title\": \"4B-MAR\",\n-    \"drug_name\": \"3-CEC\",\n-    \"chemical_name\": \"3-CEC\",\n-    \"alternative_name\": \"3-Chloroethcathinone\",\n-    \"chemical_class\": \"Cathinones\",\n-    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor\",\n-    \"psychoactive_class\": \"Stimulant\",\n+    \"drug_name\": \"4B-MAR\",\n+    \"chemical_name\": \"4B-MAR\",\n+    \"alternative_name\": \"4-Bromo Aminorex\",\n+    \"chemical_class\": \"Aminorexes\",\n+    \"mechanism_of_action\": \"Serotonin-dopamine-norepinephrine releasing agent\",\n+    \"psychoactive_class\": \"Presumed monoamine releasing agent; re-uptake inhibitor (amphetamine-like)\",\n-          \"route\": \"oral\",\n+          \"route\": \"oral / sublingual\",\n-            \"threshold\": \"15–25\",\n-            \"light\": \"30–70\",\n-            \"common\": \"70–140\",\n-            \"strong\": \"140–220\",\n-            \"heavy\": \"220+\"\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"5 mg - 15 mg\",\n+            \"common\": \"15 mg - 40 mg\",\n+            \"strong\": \"40 mg - 60 mg\",\n+            \"heavy\": \"60+ mg\"\n-            \"threshold\": \"5–10\",\n-            \"light\": \"15–30\",\n-            \"common\": \"30–60\",\n-            \"strong\": \"60–100\",\n-            \"heavy\": \"100+\"\n+            \"threshold\": \"2 mg\",\n+            \"light\": \"2 mg - 10 mg\",\n+            \"common\": \"10 mg - 25 mg\",\n+            \"strong\": \"25 mg - 40 mg\",\n+            \"heavy\": \"40+ mg\"\n+        },\n+        {\n+          \"route\": \"vaporized / smoked\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"1 mg\",\n+            \"light\": \"1 mg - 5 mg\",\n+            \"common\": \"5 mg - 15 mg\",\n+            \"strong\": \"15 mg - 30 mg\",\n+            \"heavy\": \"30+ mg\"\n+          }\n-          \"route\": \"oral\",\n+          \"route\": \"oral / sublingual\",\n-            \"oral\"\n+            \"oral\",\n+            \"sublingual\"\n-            \"total_duration\": \"3-5 h\",\n-            \"onset\": \"15-40 min\",\n-            \"peak\": \"1-2 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-6 h residual stimulation / low mood (“comedown”)\"\n+            \"total_duration\": \"10-16 h (active phase)\",\n+            \"onset\": \"20-60 min\",\n+            \"peak\": \"2-4 h\",\n+            \"offset\": \"4-6 h\",\n+            \"after_effects\": \"6-24 h lingering stimulation; insomnia\"\n-            \"onset\": \"5-10 min\",\n-            \"peak\": \"1-2 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-6 h residual stimulation / low mood (“comedown”)\"\n+            \"total_duration\": \"10-16 h (active phase)\",\n+            \"onset\": \"10-30 min\",\n+            \"peak\": \"2-4 h\",\n+            \"offset\": \"4-6 h\",\n+            \"after_effects\": \"6-24 h lingering stimulation; insomnia\"\n+        },\n+        {\n+          \"route\": \"vaporized / smoked\",\n+          \"canonical_routes\": [\n+            \"vaporized\",\n+            \"smoked\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"10-16 h (active phase)\",\n+            \"onset\": \"<5 min\",\n+            \"peak\": \"2-4 h\",\n+            \"offset\": \"4-6 h\",\n+            \"after_effects\": \"6-24 h lingering stimulation; insomnia\"\n+          }\n-    \"addiction_potential\": \"Moderate to high. Rapid, reinforcing onset coupled with short duration encourages compulsive redosing; several users report binge patterns and difficulty abstaining after multi-day use.\",\n+    \"addiction_potential\": \"High: long-acting dopaminergic stimulation encourages marathon use; compulsive redosing and binge patterns reported. Neurotoxicity unknown but halogenated aminorexes may share the hyperthermic/serotonergic risk profile of 4,4-DMAR.\",\n-        \"MAOIs\",\n-        \"DXM\",\n-        \"Tramadol\",\n-        \"2C-T-x\",\n-        \"PCP/O-PCE\"\n+        \"MAOIs (hypertensive crisis)\",\n+        \"high-dose serotonergics (MDMA, 4-FA, 4,4-DMAR) – hyperthermia/serotonin syndrome\",\n+        \"other potent stimulants (methamphetamine, cathinone analogues) – tachyarrhythmia, rhabdomyolysis\"\n-        \"Cocaine\",\n-        \"α-PVP class\",\n-        \"Other potent cathinones (3-CMC, 4-CEC)\",\n-        \"Opioids (respiratory depression when crashing)\"\n+        \"strong opioids or alcohol in exhausted users – respiratory arrest when crash sets in\",\n+        \"recreational doses of dissociatives (NMDA blockers) – psychosis, blood-pressure spikes\"\n-        \"Alcohol\",\n-        \"Amphetamines\",\n-        \"Caffeine\",\n-        \"Cannabis\",\n-        \"Benzodiazepines\",\n-        \"SSRIs\",\n-        \"GHB/GBL\"\n+        \"SSRI / SNRI antidepressants\",\n+        \"cannabis concentrates (panic, palpitations)\",\n+        \"antipsychotics that prolong QT\"\n-    \"notes\": \"• Human data are extremely limited; most information derives from small online self-reports and structural analogy to better-studied cathinones (e.g., ethcathinone, 3-CMC).\\n• Meta-halogenated cathinones have shown greater cytotoxicity in vitro compared with non-halogenated analogues; long-term neurotoxicity is plausible but unquantified.\\n• Pronounced vasoconstriction and hypertension observed; users with cardiovascular risk factors should avoid.\\n• Always confirm identity with reagent testing (Marquis: usually faint yellow-brown; Mecke: olive-green) and ideally chromatography; 3-CEC is sometimes mis-sold as 3-MMC or HEXEN.\\n• Because of short half-life, many users re-dose every 1–2 h; this rapidly increases cardiovascular strain and neurotoxic load.\\n• Harm-reduction: limit sessions to <150 mg total, hydrate/electrolytes, supplement sleep, and allow at least 2 weeks between uses to reset tolerance and neurotransmitter stores.\",\n+    \"notes\": \"First definitively identified in Austria (Jan 2022) and sold online as racemic trans-diastereomer (≈90 % assay):contentReference[oaicite:0]{index=0}. No peer-reviewed pharmacodynamic data yet; structure-activity trends and subjective reports point to a potency slightly lower than 4-methylaminorex but still active at sub-25 mg doses. Reddit and Bluelight users titrating 1→20 mg insufflated found threshold effects at 2-4 mg and a functional, amphetamine-like stimulation around 20 mg with 12-18 h wakefulness but modest euphoria:contentReference[oaicite:1]{index=1}. One 55 mg oral trial produced a long but ‘okay’ stimulation and prominent mydriasis for several days:contentReference[oaicite:2]{index=2}. Analytical paper confirms bromine-isotopic LC-HRMS signature (m/z 255.0133 [M+H]+) and chiral separation; purity differences between batches (85-98 %) warn of inactive filler or active by-products:contentReference[oaicite:3]{index=3}. Because halogenated aminorexes lack toxicology, start ≤5 mg, weigh with a 0.001 g scale, avoid redosing inside 24 h, maintain hydration/electrolytes, and monitor temperature. Long half-life (estimated 8-12 h) means next-day impairment; co-administration with vasoconstrictors or pressor drugs elevates risk of pulmonary hypertension historically linked to aminorex lineage.\",\n-      \"Increased energy\",\n-      \"Mental stimulation\",\n-      \"Enhanced focus\",\n-      \"Mood elevation (mild euphoria)\",\n-      \"Increased sociability/talkativeness\",\n-      \"Appetite suppression\",\n-      \"Increased heart rate\",\n-      \"Vasoconstriction/cold extremities\",\n-      \"Bruxism/teeth grinding\",\n-      \"Sweating\",\n-      \"Mydriasis\",\n-      \"Anxiety or jitteriness (dose-dependent)\",\n-      \"Compulsive redosing\",\n-      \"Insomnia\",\n-      \"Crash with lethargy & low mood\"\n+      \"clean physical stimulation\",\n+      \"moderate mood-lift and motivation\",\n+      \"sharpened focus\",\n+      \"minimal empathy or entactogenesis\",\n+      \"mild jaw tension & bruxism\",\n+      \"sweating, cold extremities\",\n+      \"dilated pupils for ≥24 h\",\n+      \"difficult sleep onset (‘wired & tired’)\"\n-      \"full_tolerance\": \"After 2–3 consecutive days of use\",\n-      \"half_tolerance\": \"~7 days\",\n-      \"zero_tolerance\": \"2–3 weeks\",\n+      \"full_tolerance\": \"after one heavy binge\",\n+      \"half_tolerance\": \"7-10 days\",\n+      \"zero_tolerance\": \"14-21 days\",\n-        \"Other cathinones\",\n-        \"Amphetamines\",\n-        \"Cocaine\"\n+        \"amphetamine/methamphetamine\",\n+        \"other aminorex analogues\"\n-    \"half_life\": \"Estimated 2–4 h (no formal human study; based on rat liver microsome data and analogy to ethcathinone)\",\n+    \"half_life\": \"estimated 8-12 h (no human PK studies; based on duration reports)\",\n-        \"name\": \"3-CEC (3-Chloroethcathinone) – Wikipedia\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/3-CEC_(3-Chloroethcathinone)\"\n+        \"name\": \"4B-MAR – Wikipedia overview\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/4B-MAR\"\n-        \"name\": \"User reports – r/researchchemicals: “3-Chloroethcathinone (3-CEC)” discussion thread\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/4363nj/3chloroethcathinone3cec/\"\n+        \"name\": \"Characterization of Three Novel 4-Methylaminorex Derivatives (Seibert et al., 2022)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/36144500/\"\n-        \"name\": \"Staehli L. et al. Identification and characterization of 3-chloroethcathinone in seized samples. Forensic Science International 318 (2021) 110593.\",\n-        \"reference\": \"https://doi.org/10.1016/j.forsciint.2020.110593\"\n+        \"name\": \"UNODC Early Warning Advisory notice (March 2022)\",\n+        \"reference\": \"https://www.unodc.org/LSS/Announcement/Details/b0b25b1c-387d-4a16-b1f5-dccbef83e930\"\n-        \"name\": \"Brandt S.D., et al. Cathinone derivatives in recreational use: a review. Drug Testing and Analysis 6(7-8), 2014, 647-662.\",\n-        \"reference\": \"https://doi.org/10.1002/dta.1620\"\n+        \"name\": \"Bluelight ‘4B-MAR?’ discussion thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/4b-mar-4%E2%80%98-bromo-4-methylaminorex.894519/\"\n-        \"name\": \"Zwartsen A. et al. Halogenated cathinones display increased neurotoxicity in vitro. NeuroToxicology 66 (2018) 190-199.\",\n-        \"reference\": \"https://doi.org/10.1016/j.neuro.2018.03.003\"\n+        \"name\": \"Reddit r/researchchemicals – 55 mg oral report\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/ojzjs6/4bmar_55_mg_oral_an_okay_or_good_but_not_great/\"\n-      \"research-chemical\",\n-      \"habit-forming\"\n+      \"research-chemical\"\n\n# 5-MeO-AMT · #504\n\n-  \"id\": 501,\n-  \"title\": \"4B-MAR\",\n+  \"id\": 504,\n+  \"title\": \"5-MeO-AMT\",\n-    \"drug_name\": \"4B-MAR\",\n-    \"chemical_name\": \"4B-MAR\",\n-    \"alternative_name\": \"4-Bromo Aminorex\",\n-    \"chemical_class\": \"Aminorexes\",\n-    \"mechanism_of_action\": \"Serotonin-dopamine-norepinephrine releasing agent\",\n-    \"psychoactive_class\": \"Presumed monoamine releasing agent; re-uptake inhibitor (amphetamine-like)\",\n+    \"drug_name\": \"5-MeO-AMT\",\n+    \"chemical_name\": \"5-MeO-AMT\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"mechanism_of_action\": \"5-HT1A receptor preferring agonist\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-          \"route\": \"oral / sublingual\",\n+          \"route\": \"oral\",\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"5 mg - 15 mg\",\n-            \"common\": \"15 mg - 40 mg\",\n-            \"strong\": \"40 mg - 60 mg\",\n-            \"heavy\": \"60+ mg\"\n+            \"threshold\": \"0.5–1\",\n+            \"light\": \"1–2\",\n+            \"common\": \"2–4\",\n+            \"strong\": \"4–6\",\n+            \"heavy\": \"6–8+\"\n-            \"threshold\": \"2 mg\",\n-            \"light\": \"2 mg - 10 mg\",\n-            \"common\": \"10 mg - 25 mg\",\n-            \"strong\": \"25 mg - 40 mg\",\n-            \"heavy\": \"40+ mg\"\n+            \"threshold\": \"<0.5\",\n+            \"light\": \"0.5–1\",\n+            \"common\": \"1–2\",\n+            \"strong\": \"2–3\",\n+            \"heavy\": \"3+\"\n-          \"route\": \"vaporized / smoked\",\n+          \"route\": \"rectal\",\n-            \"threshold\": \"1 mg\",\n-            \"light\": \"1 mg - 5 mg\",\n-            \"common\": \"5 mg - 15 mg\",\n-            \"strong\": \"15 mg - 30 mg\",\n-            \"heavy\": \"30+ mg\"\n+            \"threshold\": \"0.5\",\n+            \"light\": \"0.8–1.5\",\n+            \"common\": \"1.5–3\",\n+            \"strong\": \"3–4\",\n+            \"heavy\": \"4+\"\n-          \"route\": \"oral / sublingual\",\n+          \"route\": \"oral\",\n-            \"oral\",\n-            \"sublingual\"\n+            \"oral\"\n-            \"total_duration\": \"10-16 h (active phase)\",\n-            \"onset\": \"20-60 min\",\n-            \"peak\": \"2-4 h\",\n-            \"offset\": \"4-6 h\",\n-            \"after_effects\": \"6-24 h lingering stimulation; insomnia\"\n+            \"total_duration\": \"8-18 h (route-dependent)\",\n+            \"onset\": \"30-120 min\",\n+            \"peak\": \"3-8 h\",\n+            \"offset\": \"3-6 h\",\n+            \"after_effects\": \"4-24+ h (residual stimulation, insomnia)\"\n-            \"total_duration\": \"10-16 h (active phase)\",\n-            \"onset\": \"10-30 min\",\n-            \"peak\": \"2-4 h\",\n-            \"offset\": \"4-6 h\",\n-            \"after_effects\": \"6-24 h lingering stimulation; insomnia\"\n+            \"total_duration\": \"8-18 h (route-dependent)\",\n+            \"onset\": \"5-20 min\",\n+            \"peak\": \"3-8 h\",\n+            \"offset\": \"3-6 h\",\n+            \"after_effects\": \"4-24+ h (residual stimulation, insomnia)\"\n-          \"route\": \"vaporized / smoked\",\n+          \"route\": \"rectal\",\n-            \"vaporized\",\n-            \"smoked\"\n+            \"rectal\"\n-            \"total_duration\": \"10-16 h (active phase)\",\n-            \"onset\": \"<5 min\",\n-            \"peak\": \"2-4 h\",\n-            \"offset\": \"4-6 h\",\n-            \"after_effects\": \"6-24 h lingering stimulation; insomnia\"\n+            \"total_duration\": \"8-18 h (route-dependent)\",\n+            \"onset\": \"5-20 min\",\n+            \"peak\": \"3-8 h\",\n+            \"offset\": \"3-6 h\",\n+            \"after_effects\": \"4-24+ h (residual stimulation, insomnia)\"\n-    \"addiction_potential\": \"High: long-acting dopaminergic stimulation encourages marathon use; compulsive redosing and binge patterns reported. Neurotoxicity unknown but halogenated aminorexes may share the hyperthermic/serotonergic risk profile of 4,4-DMAR.\",\n+    \"addiction_potential\": \"Low. No documented physical dependence; psychological habituation possible because of stimulant/euphoric properties, but long duration and body-load reduce the desire to redose.\",\n-        \"MAOIs (hypertensive crisis)\",\n-        \"high-dose serotonergics (MDMA, 4-FA, 4,4-DMAR) – hyperthermia/serotonin syndrome\",\n-        \"other potent stimulants (methamphetamine, cathinone analogues) – tachyarrhythmia, rhabdomyolysis\"\n+        \"MAOIs (risk of hypertensive crisis / serotonin syndrome)\",\n+        \"Other potent psychedelics at full doses (LSD, NBOMe series, 5-MeO-DMT)\",\n+        \"Strong stimulants (amphetamine, cocaine, cathinones)\",\n+        \"Tramadol or meperidine (seizure / serotonin toxicity)\"\n-        \"strong opioids or alcohol in exhausted users – respiratory arrest when crash sets in\",\n-        \"recreational doses of dissociatives (NMDA blockers) – psychosis, blood-pressure spikes\"\n+        \"High-dose SSRI / SNRI / TCA (serotonin toxicity)\",\n+        \"DXM\",\n+        \"MDMA or other entactogens (hyperthermia, hypertension)\",\n+        \"2C-T-xx compounds (combined MAOI–SERT activity)\"\n-        \"SSRI / SNRI antidepressants\",\n-        \"cannabis concentrates (panic, palpitations)\",\n-        \"antipsychotics that prolong QT\"\n+        \"Alcohol (dehydration, emesis)\",\n+        \"Cannabis (potentiates visuals & anxiety)\",\n+        \"Benzodiazepines (may mask potency → accidental redose)\",\n+        \"Nitrates (possible hypotension)\"\n-    \"notes\": \"First definitively identified in Austria (Jan 2022) and sold online as racemic trans-diastereomer (≈90 % assay):contentReference[oaicite:0]{index=0}. No peer-reviewed pharmacodynamic data yet; structure-activity trends and subjective reports point to a potency slightly lower than 4-methylaminorex but still active at sub-25 mg doses. Reddit and Bluelight users titrating 1→20 mg insufflated found threshold effects at 2-4 mg and a functional, amphetamine-like stimulation around 20 mg with 12-18 h wakefulness but modest euphoria:contentReference[oaicite:1]{index=1}. One 55 mg oral trial produced a long but ‘okay’ stimulation and prominent mydriasis for several days:contentReference[oaicite:2]{index=2}. Analytical paper confirms bromine-isotopic LC-HRMS signature (m/z 255.0133 [M+H]+) and chiral separation; purity differences between batches (85-98 %) warn of inactive filler or active by-products:contentReference[oaicite:3]{index=3}. Because halogenated aminorexes lack toxicology, start ≤5 mg, weigh with a 0.001 g scale, avoid redosing inside 24 h, maintain hydration/electrolytes, and monitor temperature. Long half-life (estimated 8-12 h) means next-day impairment; co-administration with vasoconstrictors or pressor drugs elevates risk of pulmonary hypertension historically linked to aminorex lineage.\",\n+    \"notes\": \"• Extremely dose-sensitive; medical emergencies reported from ≥8 mg oral.\\n• Has been mis-sold as LSD on blotter and gels – always reagent-test material.\\n• Produces pronounced sympathetic stimulation (tachycardia, mydriasis, hypertension); baseline cardiovascular health is advisable.\\n• In vitro partially inhibits MAO-A; avoid tyramine-rich foods and other serotonergic agents during the acute phase.\\n• Nasal and rectal routes shorten total length but markedly increase body-load and local irritation.\\n• Several fatalities linked to 5-MeO-AMT adulteration or large overdoses (>20 mg).\",\n-      \"clean physical stimulation\",\n-      \"moderate mood-lift and motivation\",\n-      \"sharpened focus\",\n-      \"minimal empathy or entactogenesis\",\n-      \"mild jaw tension & bruxism\",\n-      \"sweating, cold extremities\",\n-      \"dilated pupils for ≥24 h\",\n-      \"difficult sleep onset (‘wired & tired’)\"\n+      \"Euphoria\",\n+      \"Mental & physical stimulation\",\n+      \"Enhanced empathy\",\n+      \"Mood lift\",\n+      \"Colour enhancement\",\n+      \"Visual patterning (CEV/OEV)\",\n+      \"Audio enhancement\",\n+      \"Tactile amplification\",\n+      \"Appetite suppression\",\n+      \"Pupil dilation\",\n+      \"Restlessness\",\n+      \"Muscle tension & jaw clenching\",\n+      \"Profuse sweating / chills\",\n+      \"Nausea & vomiting (dose-dependent)\",\n+      \"Anxiety or confusion (higher doses)\",\n+      \"Insomnia\",\n+      \"Long, sometimes dysphoric comedown\"\n-      \"full_tolerance\": \"after one heavy binge\",\n-      \"half_tolerance\": \"7-10 days\",\n-      \"zero_tolerance\": \"14-21 days\",\n+      \"full_tolerance\": \"After one dose; persists ~3–7 days\",\n+      \"half_tolerance\": \"≈3 days\",\n+      \"zero_tolerance\": \"≈10–14 days\",\n-        \"amphetamine/methamphetamine\",\n-        \"other aminorex analogues\"\n+        \"Classic serotonergic psychedelics (LSD, psilocybin, DMT)\"\n-    \"half_life\": \"estimated 8-12 h (no human PK studies; based on duration reports)\",\n+    \"half_life\": \"Human kinetic data absent; rodent liver-microsome studies suggest 4–6 h elimination half-life (active metabolites prolong subjective effects).\",\n-        \"name\": \"4B-MAR – Wikipedia overview\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/4B-MAR\"\n+        \"name\": \"Shulgin & Shulgin. TiHKAL entry #5 – 5-MeO-αMT\",\n+        \"reference\": \"https://erowid.org/library/books_online/tihkal/tihkal05.shtml\"\n-        \"name\": \"Characterization of Three Novel 4-Methylaminorex Derivatives (Seibert et al., 2022)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/36144500/\"\n+        \"name\": \"DEA–Microgram Special Report: Deaths involving 5-MeO-AMT misrepresented as LSD (USA, 2004)\",\n+        \"reference\": \"https://archives.drugabuse.gov/sites/default/files/MicrogramJournal1_1_3.pdf\"\n-        \"name\": \"UNODC Early Warning Advisory notice (March 2022)\",\n-        \"reference\": \"https://www.unodc.org/LSS/Announcement/Details/b0b25b1c-387d-4a16-b1f5-dccbef83e930\"\n+        \"name\": \"Erowid 5-MeO-AMT Effects, Dosage & Experience Reports\",\n+        \"reference\": \"https://erowid.org/chemicals/5meo_amt/5meo_amt_effects.shtml\"\n-        \"name\": \"Bluelight ‘4B-MAR?’ discussion thread\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/4b-mar-4%E2%80%98-bromo-4-methylaminorex.894519/\"\n+        \"name\": \"Abiero et al. 5-MeO-AMT induces head-twitch via 5-HT2A activation. Behav Brain Res. 2019\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/30053461\"\n-        \"name\": \"Reddit r/researchchemicals – 55 mg oral report\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/ojzjs6/4bmar_55_mg_oral_an_okay_or_good_but_not_great/\"\n+        \"name\": \"TripSit Drug Combination Chart – 5-MeO-AMT\",\n+        \"reference\": \"https://drugs.tripsit.me/5-meo-amt\"\n+      },\n+      {\n+        \"name\": \"Bluelight Community Thread: 5-MeO-AMT experiences & safety discussion (2024)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/5-meo-amt.940722\"\n+      },\n+      {\n+        \"name\": \"Armstrong et al. ‘Bad blotter’: Forensic confirmation of 5-MeO-AMT on LSD-type paper. J Anal Toxicol 2007\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/17918710\"\n+      },\n+      {\n+        \"name\": \"Erowid: 5meo Amt.shtml\",\n+        \"reference\": \"https://erowid.org/chemicals/5meo_amt/5meo_amt.shtml\"\n+      \"psychedelic\",\n-      \"research-chemical\"\n+      \"research-chemical\",\n+      \"entactogen\"\n\n# MXPCP · #497\n\n-  \"id\": 504,\n-  \"title\": \"5-MeO-AMT\",\n+  \"id\": 497,\n+  \"title\": \"MXPCP\",\n-    \"drug_name\": \"5-MeO-AMT\",\n-    \"chemical_name\": \"5-MeO-AMT\",\n+    \"drug_name\": \"MXPCP\",\n+    \"chemical_name\": \"MXPCP\",\n-    \"chemical_class\": \"Tryptamines\",\n-    \"mechanism_of_action\": \"5-HT1A receptor preferring agonist\",\n-    \"psychoactive_class\": \"Psychedelic\",\n+    \"chemical_class\": \"Arylcyclohexylamines\",\n+    \"mechanism_of_action\": \"NMDA receptor antagonist\",\n+    \"psychoactive_class\": \"Dissociative; Hallucinogen\",\n-            \"threshold\": \"0.5–1\",\n-            \"light\": \"1–2\",\n-            \"common\": \"2–4\",\n-            \"strong\": \"4–6\",\n-            \"heavy\": \"6–8+\"\n+            \"threshold\": \"3 mg\",\n+            \"light\": \"4–8 mg\",\n+            \"common\": \"8–15 mg\",\n+            \"strong\": \"15–25 mg\",\n+            \"heavy\": \"25 mg+\"\n-            \"threshold\": \"<0.5\",\n-            \"light\": \"0.5–1\",\n-            \"common\": \"1–2\",\n-            \"strong\": \"2–3\",\n-            \"heavy\": \"3+\"\n+            \"threshold\": \"2 mg\",\n+            \"light\": \"3–6 mg\",\n+            \"common\": \"6–12 mg\",\n+            \"strong\": \"12–20 mg\",\n+            \"heavy\": \"20 mg+\"\n-            \"threshold\": \"0.5\",\n-            \"light\": \"0.8–1.5\",\n-            \"common\": \"1.5–3\",\n-            \"strong\": \"3–4\",\n-            \"heavy\": \"4+\"\n+            \"threshold\": \"3 mg\",\n+            \"light\": \"4–8 mg\",\n+            \"common\": \"8–15 mg\",\n+            \"strong\": \"15–22 mg\",\n+            \"heavy\": \"22 mg+\"\n+        },\n+        {\n+          \"route\": \"intramuscular\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"2 mg\",\n+            \"light\": \"3–5 mg\",\n+            \"common\": \"5–10 mg\",\n+            \"strong\": \"10–15 mg\",\n+            \"heavy\": \"15 mg+\"\n+          }\n-            \"total_duration\": \"8-18 h (route-dependent)\",\n-            \"onset\": \"30-120 min\",\n-            \"peak\": \"3-8 h\",\n-            \"offset\": \"3-6 h\",\n-            \"after_effects\": \"4-24+ h (residual stimulation, insomnia)\"\n+            \"total_duration\": \"4-8 h\",\n+            \"onset\": \"20-40 min\",\n+            \"peak\": \"1-3 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-6 h residual stimulation / insomnia\"\n-            \"total_duration\": \"8-18 h (route-dependent)\",\n-            \"onset\": \"5-20 min\",\n-            \"peak\": \"3-8 h\",\n-            \"offset\": \"3-6 h\",\n-            \"after_effects\": \"4-24+ h (residual stimulation, insomnia)\"\n+            \"total_duration\": \"4-8 h\",\n+            \"onset\": \"5-15 min\",\n+            \"peak\": \"1-3 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-6 h residual stimulation / insomnia\"\n-            \"total_duration\": \"8-18 h (route-dependent)\",\n+            \"total_duration\": \"4-8 h\",\n-            \"peak\": \"3-8 h\",\n-            \"offset\": \"3-6 h\",\n-            \"after_effects\": \"4-24+ h (residual stimulation, insomnia)\"\n+            \"peak\": \"1-3 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-6 h residual stimulation / insomnia\"\n+        },\n+        {\n+          \"route\": \"intramuscular\",\n+          \"canonical_routes\": [\n+            \"intramuscular\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"4-8 h\",\n+            \"onset\": \"5-15 min\",\n+            \"peak\": \"1-3 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-6 h residual stimulation / insomnia\"\n+          }\n-    \"addiction_potential\": \"Low. No documented physical dependence; psychological habituation possible because of stimulant/euphoric properties, but long duration and body-load reduce the desire to redose.\",\n+    \"addiction_potential\": \"Moderate-to-high: compulsive redosing, tolerance within days, psychotic episodes reported at >25 mg.\",\n-        \"MAOIs (risk of hypertensive crisis / serotonin syndrome)\",\n-        \"Other potent psychedelics at full doses (LSD, NBOMe series, 5-MeO-DMT)\",\n-        \"Strong stimulants (amphetamine, cocaine, cathinones)\",\n-        \"Tramadol or meperidine (seizure / serotonin toxicity)\"\n+        \"MAOIs (hypertensive crisis, serotonin toxicity)\",\n+        \"Other dissociatives or deliriants (unpredictable psychosis)\",\n+        \"Strong stimulants or cathinones (hyperthermia, seizures)\",\n+        \"Opioids + benzodiazepines (respiratory arrest)\"\n-        \"High-dose SSRI / SNRI / TCA (serotonin toxicity)\",\n-        \"DXM\",\n-        \"MDMA or other entactogens (hyperthermia, hypertension)\",\n-        \"2C-T-xx compounds (combined MAOI–SERT activity)\"\n+        \"High-dose alcohol (loss of airway reflexes)\",\n+        \"GHB / barbiturates\",\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Halogenated anesthetics (arrhythmia)\"\n-        \"Alcohol (dehydration, emesis)\",\n-        \"Cannabis (potentiates visuals & anxiety)\",\n-        \"Benzodiazepines (may mask potency → accidental redose)\",\n-        \"Nitrates (possible hypotension)\"\n+        \"Cannabis (exacerbates derealisation)\",\n+        \"Nicotine vapes (tachycardia, nausea)\",\n+        \"SSRIs/SNRIs (serotonin load, though risk lower than with MDMA)\",\n+        \"Nootropic racetams (may blunt dissociation, prompt redose)\"\n-    \"notes\": \"• Extremely dose-sensitive; medical emergencies reported from ≥8 mg oral.\\n• Has been mis-sold as LSD on blotter and gels – always reagent-test material.\\n• Produces pronounced sympathetic stimulation (tachycardia, mydriasis, hypertension); baseline cardiovascular health is advisable.\\n• In vitro partially inhibits MAO-A; avoid tyramine-rich foods and other serotonergic agents during the acute phase.\\n• Nasal and rectal routes shorten total length but markedly increase body-load and local irritation.\\n• Several fatalities linked to 5-MeO-AMT adulteration or large overdoses (>20 mg).\",\n+    \"notes\": \"• Potency estimated from 3-MeO-PCP forensic dose data and O-PCP field reports; proceed with allergy test ≤1 mg. \\n• Measure on milligram-scale balance; volumetric dosing preferred. \\n• Redosing within 4 h sharply increases delirium risk; wait a full day between trials. \\n• Provide electrolyte water (≈250 mL h⁻¹) and avoid overheated venues. \\n• Carry an 8 mg naloxone nasal spray if mixing with downers, and let a sober sitter hold it.\",\n-      \"Euphoria\",\n-      \"Mental & physical stimulation\",\n-      \"Enhanced empathy\",\n-      \"Mood lift\",\n-      \"Colour enhancement\",\n-      \"Visual patterning (CEV/OEV)\",\n-      \"Audio enhancement\",\n-      \"Tactile amplification\",\n-      \"Appetite suppression\",\n-      \"Pupil dilation\",\n-      \"Restlessness\",\n-      \"Muscle tension & jaw clenching\",\n-      \"Profuse sweating / chills\",\n-      \"Nausea & vomiting (dose-dependent)\",\n-      \"Anxiety or confusion (higher doses)\",\n-      \"Insomnia\",\n-      \"Long, sometimes dysphoric comedown\"\n+      \"Warm, empathogenic dissociation\",\n+      \"Mild euphoria and music enhancement\",\n+      \"Visual soft-focus / ‘MXE glaze’\",\n+      \"Manic talkativeness at higher doses\",\n+      \"Time-looping or deja-vu\",\n+      \"Analgesia & proprioceptive drift\",\n+      \"Cognitive tunneling (‘laser focus’)\",\n+      \"Nausea / vertigo when standing\",\n+      \"Nystagmus, diplopia\",\n+      \"Possible urinary urgency (ACH antagonism)\",\n+      \"Compulsive redosing above 20 mg\",\n+      \"Transient paranoid ideation\"\n-      \"full_tolerance\": \"After one dose; persists ~3–7 days\",\n-      \"half_tolerance\": \"≈3 days\",\n-      \"zero_tolerance\": \"≈10–14 days\",\n+      \"full_tolerance\": \"After 3–4 daily sessions\",\n+      \"half_tolerance\": \"≈7–10 days abstinence\",\n+      \"zero_tolerance\": \"3–4 weeks abstinence\",\n-        \"Classic serotonergic psychedelics (LSD, psilocybin, DMT)\"\n+        \"3-MeO-PCP\",\n+        \"O-PCP\",\n+        \"Ketamine / 2-FDCK\",\n+        \"Dizocilpine analogues\"\n-    \"half_life\": \"Human kinetic data absent; rodent liver-microsome studies suggest 4–6 h elimination half-life (active metabolites prolong subjective effects).\",\n+    \"half_life\": \"Estimated 6–9 h (interpolated between 3-MeO-PCP 10–11 h and O-PCE 5 h)\",\n-        \"name\": \"Shulgin & Shulgin. TiHKAL entry #5 – 5-MeO-αMT\",\n-        \"reference\": \"https://erowid.org/library/books_online/tihkal/tihkal05.shtml\"\n+        \"name\": \"Reddit r/researchchemicals MXPCP launch thread (2025).\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/1m47m35/new_disso_3meo2oxopcp_basically_pcp_version_of_mxe/\"\n-        \"name\": \"DEA–Microgram Special Report: Deaths involving 5-MeO-AMT misrepresented as LSD (USA, 2004)\",\n-        \"reference\": \"https://archives.drugabuse.gov/sites/default/files/MicrogramJournal1_1_3.pdf\"\n+        \"name\": \"Reddit r/researchchemicals user review: “3-MeO-2-Oxo-PCP – bright light” (2025).\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/1m78dk0/\"\n-        \"name\": \"Erowid 5-MeO-AMT Effects, Dosage & Experience Reports\",\n-        \"reference\": \"https://erowid.org/chemicals/5meo_amt/5meo_amt_effects.shtml\"\n-      },\n-      {\n-        \"name\": \"Abiero et al. 5-MeO-AMT induces head-twitch via 5-HT2A activation. Behav Brain Res. 2019\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/30053461\"\n-      },\n-      {\n-        \"name\": \"TripSit Drug Combination Chart – 5-MeO-AMT\",\n-        \"reference\": \"https://drugs.tripsit.me/5-meo-amt\"\n-      },\n-      {\n-        \"name\": \"Bluelight Community Thread: 5-MeO-AMT experiences & safety discussion (2024)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/5-meo-amt.940722\"\n-      },\n-      {\n-        \"name\": \"Armstrong et al. ‘Bad blotter’: Forensic confirmation of 5-MeO-AMT on LSD-type paper. J Anal Toxicol 2007\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/17918710\"\n-      },\n-      {\n-        \"name\": \"Erowid: 5meo Amt.shtml\",\n-        \"reference\": \"https://erowid.org/chemicals/5meo_amt/5meo_amt.shtml\"\n+        \"name\": \"Bluelight ‘Novel dissociative 3-MeO-2-Oxo-PCPy’ discussion (2015).\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/novel-dissociative-3-meo-2-oxo-pcpy.761493/\"\n-      \"psychedelic\",\n-      \"stimulant\",\n-      \"research-chemical\",\n-      \"entactogen\"\n+      \"dissociative\",\n+      \"research-chemical\"\n\n# 4-MPD · #506\n\n-  \"id\": 497,\n-  \"title\": \"MXPCP\",\n+  \"id\": 506,\n+  \"title\": \"4-MPD\",\n-    \"drug_name\": \"MXPCP\",\n-    \"chemical_name\": \"MXPCP\",\n-    \"alternative_name\": \"\",\n-    \"chemical_class\": \"Arylcyclohexylamines\",\n-    \"mechanism_of_action\": \"NMDA receptor antagonist\",\n-    \"psychoactive_class\": \"Dissociative; Hallucinogen\",\n+    \"drug_name\": \"4-MPD\",\n+    \"chemical_name\": \"4-MPD\",\n+    \"alternative_name\": \"4-Methylpentedrone\",\n+    \"chemical_class\": \"Cathinones\",\n+    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor\",\n+    \"psychoactive_class\": \"Stimulant; entactogen-like\",\n-            \"threshold\": \"3 mg\",\n-            \"light\": \"4–8 mg\",\n-            \"common\": \"8–15 mg\",\n-            \"strong\": \"15–25 mg\",\n-            \"heavy\": \"25 mg+\"\n+            \"threshold\": \"15–25\",\n+            \"light\": \"40–80\",\n+            \"common\": \"80–180\",\n+            \"strong\": \"180–275\",\n+            \"heavy\": \"275+\"\n-            \"threshold\": \"2 mg\",\n-            \"light\": \"3–6 mg\",\n-            \"common\": \"6–12 mg\",\n-            \"strong\": \"12–20 mg\",\n-            \"heavy\": \"20 mg+\"\n+            \"threshold\": \"5–10\",\n+            \"light\": \"15–25\",\n+            \"common\": \"25–60\",\n+            \"strong\": \"60–90\",\n+            \"heavy\": \"90+\"\n-          \"route\": \"rectal\",\n+          \"route\": \"vaporized\",\n-            \"threshold\": \"3 mg\",\n-            \"light\": \"4–8 mg\",\n-            \"common\": \"8–15 mg\",\n-            \"strong\": \"15–22 mg\",\n-            \"heavy\": \"22 mg+\"\n+            \"threshold\": \"2–5\",\n+            \"light\": \"5–15\",\n+            \"common\": \"15–35\",\n+            \"strong\": \"35–60\",\n+            \"heavy\": \"60+\"\n-        },\n-        {\n-          \"route\": \"intramuscular\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"2 mg\",\n-            \"light\": \"3–5 mg\",\n-            \"common\": \"5–10 mg\",\n-            \"strong\": \"10–15 mg\",\n-            \"heavy\": \"15 mg+\"\n-          }\n-            \"total_duration\": \"4-8 h\",\n-            \"onset\": \"20-40 min\",\n-            \"peak\": \"1-3 h\",\n+            \"total_duration\": \"3-5 h · 2-4 h · 1.5-3 h\",\n+            \"onset\": \"10-30 min · 2-10 min · <1 min\",\n+            \"peak\": \"0.8-2 h\",\n-            \"after_effects\": \"2-6 h residual stimulation / insomnia\"\n+            \"after_effects\": \"1-4 h residual stimulation / low-mood “comedown”\"\n-            \"total_duration\": \"4-8 h\",\n-            \"onset\": \"5-15 min\",\n-            \"peak\": \"1-3 h\",\n+            \"total_duration\": \"3-5 h · 2-4 h · 1.5-3 h\",\n+            \"onset\": \"10-30 min · 2-10 min · <1 min\",\n+            \"peak\": \"0.8-2 h\",\n-            \"after_effects\": \"2-6 h residual stimulation / insomnia\"\n+            \"after_effects\": \"1-4 h residual stimulation / low-mood “comedown”\"\n-          \"route\": \"rectal\",\n+          \"route\": \"vaporized\",\n-            \"rectal\"\n+            \"vaporized\"\n-            \"total_duration\": \"4-8 h\",\n-            \"onset\": \"5-20 min\",\n-            \"peak\": \"1-3 h\",\n+            \"total_duration\": \"3-5 h · 2-4 h · 1.5-3 h\",\n+            \"onset\": \"10-30 min · 2-10 min · <1 min\",\n+            \"peak\": \"0.8-2 h\",\n-            \"after_effects\": \"2-6 h residual stimulation / insomnia\"\n+            \"after_effects\": \"1-4 h residual stimulation / low-mood “comedown”\"\n-        },\n-        {\n-          \"route\": \"intramuscular\",\n-          \"canonical_routes\": [\n-            \"intramuscular\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"4-8 h\",\n-            \"onset\": \"5-15 min\",\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-6 h residual stimulation / insomnia\"\n-          }\n-    \"addiction_potential\": \"Moderate-to-high: compulsive redosing, tolerance within days, psychotic episodes reported at >25 mg.\",\n+    \"addiction_potential\": \"Moderate to high. Like other cathinones with rapid onset/short duration, compulsive redosing and binge patterns are frequently reported. Users describe strong craving and 1–2 days of anergia and dysphoria after heavy use.\",\n-        \"MAOIs (hypertensive crisis, serotonin toxicity)\",\n-        \"Other dissociatives or deliriants (unpredictable psychosis)\",\n-        \"Strong stimulants or cathinones (hyperthermia, seizures)\",\n-        \"Opioids + benzodiazepines (respiratory arrest)\"\n+        \"MAOIs\",\n+        \"MDMA\",\n+        \"methamphetamine\",\n+        \"cocaine\",\n+        \"other potent cathinones (e.g., α-PVP, mephedrone)\",\n+        \"bupropion\"\n-        \"High-dose alcohol (loss of airway reflexes)\",\n-        \"GHB / barbiturates\",\n-        \"Tramadol (lowers seizure threshold)\",\n-        \"Halogenated anesthetics (arrhythmia)\"\n+        \"large alcohol amounts (cardio-toxicity, dehydration)\",\n+        \"tramadol (seizure risk)\",\n+        \"DXM (hypertensive/serotonergic load)\"\n-        \"Cannabis (exacerbates derealisation)\",\n-        \"Nicotine vapes (tachycardia, nausea)\",\n-        \"SSRIs/SNRIs (serotonin load, though risk lower than with MDMA)\",\n-        \"Nootropic racetams (may blunt dissociation, prompt redose)\"\n+        \"caffeine\",\n+        \"SSRIs/SNRIs (mild serotonin load)\",\n+        \"ketamine (blood-pressure strain)\",\n+        \"opioids or GHB during comedown (respiratory depression while still hypertensive)\"\n-    \"notes\": \"• Potency estimated from 3-MeO-PCP forensic dose data and O-PCP field reports; proceed with allergy test ≤1 mg. \\n• Measure on milligram-scale balance; volumetric dosing preferred. \\n• Redosing within 4 h sharply increases delirium risk; wait a full day between trials. \\n• Provide electrolyte water (≈250 mL h⁻¹) and avoid overheated venues. \\n• Carry an 8 mg naloxone nasal spray if mixing with downers, and let a sober sitter hold it.\",\n+    \"notes\": \"4-MPD is the para-methyl analogue of pentedrone and a higher homologue of mephedrone. It appears as an off-white crystalline powder, soluble in water and ethanol; aqueous solutions degrade within days due to β-keto hydrolysis – store dry, airtight and cool. Pharmacology: in vitro it shows dopamine (DAT) and norepinephrine (NET) reuptake inhibition with little serotonin activity, closely resembling pentedrone (Mardal 2019). Typical acute adverse effects are tachycardia (HR 100–130 bpm), hypertension (>140/95 mm Hg), jaw clenching, peripheral vasoconstriction and hyperthermia. A fatal poly-intoxication in a chemsex setting (plasma 4-MPD 330 ng/mL) has been documented. Because of its short half-life users often re-dose; setting strict dose/time limits, monitoring vitals, active cooling and electrolyte/water balance markedly reduce risk.\",\n-      \"Warm, empathogenic dissociation\",\n-      \"Mild euphoria and music enhancement\",\n-      \"Visual soft-focus / ‘MXE glaze’\",\n-      \"Manic talkativeness at higher doses\",\n-      \"Time-looping or deja-vu\",\n-      \"Analgesia & proprioceptive drift\",\n-      \"Cognitive tunneling (‘laser focus’)\",\n-      \"Nausea / vertigo when standing\",\n-      \"Nystagmus, diplopia\",\n-      \"Possible urinary urgency (ACH antagonism)\",\n-      \"Compulsive redosing above 20 mg\",\n-      \"Transient paranoid ideation\"\n+      \"Euphoria\",\n+      \"Mental stimulation\",\n+      \"Increased sociability/talkativeness\",\n+      \"Mild empathy and warmth\",\n+      \"Enhanced music appreciation\",\n+      \"Sexual arousal\",\n+      \"Appetite suppression\",\n+      \"Bruxism/jaw tension\",\n+      \"Sweating and hot flashes\",\n+      \"Vasoconstriction (cold extremities)\",\n+      \"Anxiety or paranoia (high doses)\",\n+      \"Restlessness/insomnia\",\n+      \"Post-use fatigue and low mood\"\n-      \"full_tolerance\": \"After 3–4 daily sessions\",\n-      \"half_tolerance\": \"≈7–10 days abstinence\",\n-      \"zero_tolerance\": \"3–4 weeks abstinence\",\n+      \"full_tolerance\": \"Can develop after 2–3 consecutive days or a single heavy binge\",\n+      \"half_tolerance\": \"~3–7 days\",\n+      \"zero_tolerance\": \"1–2 weeks of abstinence\",\n-        \"3-MeO-PCP\",\n-        \"O-PCP\",\n-        \"Ketamine / 2-FDCK\",\n-        \"Dizocilpine analogues\"\n+        \"other cathinones\",\n+        \"amphetamine-type stimulants\",\n+        \"dopaminergic stimulants\"\n-    \"half_life\": \"Estimated 6–9 h (interpolated between 3-MeO-PCP 10–11 h and O-PCE 5 h)\",\n+    \"half_life\": \"Estimated 2–4 h (based on limited case toxicokinetics and user reports).\",\n-        \"name\": \"Reddit r/researchchemicals MXPCP launch thread (2025).\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/1m47m35/new_disso_3meo2oxopcp_basically_pcp_version_of_mxe/\"\n+        \"name\": \"Forensic identification and pharmacology of 4-MPD\",\n+        \"reference\": \"https://doi.org/10.1007/s11419-019-00493-7\"\n-        \"name\": \"Reddit r/researchchemicals user review: “3-MeO-2-Oxo-PCP – bright light” (2025).\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/1m78dk0/\"\n+        \"name\": \"Fatal intoxication involving 4-methylpentedrone in a chemsex context\",\n+        \"reference\": \"https://www.researchgate.net/publication/347612306\"\n-        \"name\": \"Bluelight ‘Novel dissociative 3-MeO-2-Oxo-PCPy’ discussion (2015).\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/novel-dissociative-3-meo-2-oxo-pcpy.761493/\"\n+        \"name\": \"4-Methyl-pentedrone – 1 g/24 h user report (Bluelight)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/4-methyl-pentedrone-4-mpd-1g-24-hours-almost-the-same-as-pentedrone.690373/\"\n+      },\n+      {\n+        \"name\": \"Structure-activity relationships of second-generation cathinones\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576102/\"\n+      },\n+      {\n+        \"name\": \"PubChem: 137700730\",\n+        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/137700730\"\n-      \"dissociative\",\n-      \"research-chemical\"\n+      \"stimulant\",\n+      \"research-chemical\",\n+      \"habit-forming\"\n\n# 25P-NBOMe · #507\n\n-  \"id\": 506,\n-  \"title\": \"4-MPD\",\n+  \"id\": 507,\n+  \"title\": \"25P-NBOMe\",\n-    \"drug_name\": \"4-MPD\",\n-    \"chemical_name\": \"4-MPD\",\n-    \"alternative_name\": \"4-Methylpentedrone\",\n-    \"chemical_class\": \"Cathinones\",\n-    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor\",\n-    \"psychoactive_class\": \"Stimulant; entactogen-like\",\n+    \"drug_name\": \"25P-NBOMe\",\n+    \"chemical_name\": \"2C-P-NBOMe\",\n+    \"alternative_name\": \"2C-P-NBOMe; NBOMe-2C-P\",\n+    \"chemical_class\": \"N-benzylated phenethylamines\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist (potent); 5-HT2B receptor agonist (cardiotoxic)\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-          \"route\": \"oral\",\n-          \"units\": \"mg\",\n+          \"route\": \"sublingual\",\n+          \"units\": \"µg\",\n-            \"threshold\": \"15–25\",\n-            \"light\": \"40–80\",\n-            \"common\": \"80–180\",\n-            \"strong\": \"180–275\",\n-            \"heavy\": \"275+\"\n+            \"threshold\": \"50–100 µg\",\n+            \"light\": \"100–250 µg\",\n+            \"common\": \"250–600 µg\",\n+            \"strong\": \"600–900 µg\",\n+            \"heavy\": \"900+ µg\"\n-          \"units\": \"mg\",\n+          \"units\": \"µg\",\n-            \"threshold\": \"5–10\",\n-            \"light\": \"15–25\",\n-            \"common\": \"25–60\",\n-            \"strong\": \"60–90\",\n-            \"heavy\": \"90+\"\n+            \"threshold\": \"25–50 µg\",\n+            \"light\": \"50–120 µg\",\n+            \"common\": \"120–300 µg\",\n+            \"strong\": \"300–450 µg\",\n+            \"heavy\": \"450+ µg\"\n-          \"units\": \"mg\",\n+          \"units\": \"µg\",\n-            \"threshold\": \"2–5\",\n-            \"light\": \"5–15\",\n-            \"common\": \"15–35\",\n-            \"strong\": \"35–60\",\n-            \"heavy\": \"60+\"\n+            \"threshold\": \"20–40 µg\",\n+            \"light\": \"40–80 µg\",\n+            \"common\": \"80–200 µg\",\n+            \"strong\": \"200–300 µg\",\n+            \"heavy\": \"300+ µg\"\n-          \"route\": \"oral\",\n+          \"route\": \"sublingual\",\n-            \"oral\"\n+            \"sublingual\"\n-            \"total_duration\": \"3-5 h · 2-4 h · 1.5-3 h\",\n-            \"onset\": \"10-30 min · 2-10 min · <1 min\",\n-            \"peak\": \"0.8-2 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"1-4 h residual stimulation / low-mood “comedown”\"\n+            \"total_duration\": \"8-14 h (reports up to 18 h)\",\n+            \"onset\": \"10-30 min (2-5 min )\",\n+            \"peak\": \"2-5 h\",\n+            \"offset\": \"4-8 h\",\n+            \"after_effects\": \"2-6 h of residual stimulation / exhaustion\"\n-            \"total_duration\": \"3-5 h · 2-4 h · 1.5-3 h\",\n-            \"onset\": \"10-30 min · 2-10 min · <1 min\",\n-            \"peak\": \"0.8-2 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"1-4 h residual stimulation / low-mood “comedown”\"\n+            \"total_duration\": \"8-14 h (reports up to 18 h)\",\n+            \"peak\": \"2-5 h\",\n+            \"offset\": \"4-8 h\",\n+            \"after_effects\": \"2-6 h of residual stimulation / exhaustion\"\n-            \"total_duration\": \"3-5 h · 2-4 h · 1.5-3 h\",\n-            \"onset\": \"10-30 min · 2-10 min · <1 min\",\n-            \"peak\": \"0.8-2 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"1-4 h residual stimulation / low-mood “comedown”\"\n+            \"total_duration\": \"8-14 h (reports up to 18 h)\",\n+            \"onset\": \"10-30 min (2-5 min )\",\n+            \"peak\": \"2-5 h\",\n+            \"offset\": \"4-8 h\",\n+            \"after_effects\": \"2-6 h of residual stimulation / exhaustion\"\n-    \"addiction_potential\": \"Moderate to high. Like other cathinones with rapid onset/short duration, compulsive redosing and binge patterns are frequently reported. Users describe strong craving and 1–2 days of anergia and dysphoria after heavy use.\",\n+    \"addiction_potential\": \"Low. Little evidence for compulsive use; psychological habituation possible with frequent use.\",\n-        \"MDMA\",\n-        \"methamphetamine\",\n-        \"cocaine\",\n-        \"other potent cathinones (e.g., α-PVP, mephedrone)\",\n-        \"bupropion\"\n+        \"Tramadol\",\n+        \"DXM\",\n+        \"Cocaine\",\n+        \"Amphetamines\",\n+        \"Synthetic cathinones (MMC/PVP class)\"\n-        \"large alcohol amounts (cardio-toxicity, dehydration)\",\n-        \"tramadol (seizure risk)\",\n-        \"DXM (hypertensive/serotonergic load)\"\n+        \"Strong opioids (respiratory depression masking)\",\n+        \"Large alcohol doses (vomiting/blackout)\"\n-        \"caffeine\",\n-        \"SSRIs/SNRIs (mild serotonin load)\",\n-        \"ketamine (blood-pressure strain)\",\n-        \"opioids or GHB during comedown (respiratory depression while still hypertensive)\"\n+        \"Cannabis\",\n+        \"Other serotonergic psychedelics (LSD, psilocybin, DMT)\",\n+        \"Benzodiazepines (may dull effects)\",\n+        \"SSRIs/SNRIs\",\n+        \"2C-x or DOx phenethylamines\"\n-    \"notes\": \"4-MPD is the para-methyl analogue of pentedrone and a higher homologue of mephedrone. It appears as an off-white crystalline powder, soluble in water and ethanol; aqueous solutions degrade within days due to β-keto hydrolysis – store dry, airtight and cool. Pharmacology: in vitro it shows dopamine (DAT) and norepinephrine (NET) reuptake inhibition with little serotonin activity, closely resembling pentedrone (Mardal 2019). Typical acute adverse effects are tachycardia (HR 100–130 bpm), hypertension (>140/95 mm Hg), jaw clenching, peripheral vasoconstriction and hyperthermia. A fatal poly-intoxication in a chemsex setting (plasma 4-MPD 330 ng/mL) has been documented. Because of its short half-life users often re-dose; setting strict dose/time limits, monitoring vitals, active cooling and electrolyte/water balance markedly reduce risk.\",\n+    \"notes\": \"• Extremely potent – active in the low-hundreds of micrograms. A small error in volumetric measurement or blotter laying can create multi-fold overdoses.\\n• Reports of intense vasoconstriction, tachycardia, hypertension, agitation and seizures at high doses comparable to more widely reported NBOMe deaths (e.g., 25I-NBOMe). Use allergy test (≤50 µg) and weigh with a 0.1 mg scale followed by volumetric dosing where possible.\\n• Limited human data; no published controlled trials. Pharmacology suggests high-affinity 5-HT2A agonism similar to other NBOMes with additional 5-HT2C binding, possibly explaining a heavier body load than 25I/25B.\\n• Reagent testing: Marquis – no colour; Froehde – yellow-green; Ehrlich – usually negative (unlike LSD). Use multiple reagents to distinguish from more toxic NBOMes.\\n• Strong peripheral stimulation can persist hours after visuals subside; plan for a long experience and avoid redosing.\\n• Severe cold extremities or chest pain warrant medical attention – do not delay seeking help.\",\n-      \"Euphoria\",\n-      \"Mental stimulation\",\n-      \"Increased sociability/talkativeness\",\n-      \"Mild empathy and warmth\",\n-      \"Enhanced music appreciation\",\n-      \"Sexual arousal\",\n-      \"Appetite suppression\",\n-      \"Bruxism/jaw tension\",\n-      \"Sweating and hot flashes\",\n-      \"Vasoconstriction (cold extremities)\",\n-      \"Anxiety or paranoia (high doses)\",\n-      \"Restlessness/insomnia\",\n-      \"Post-use fatigue and low mood\"\n+      \"Intense closed- and open-eye visual patterning\",\n+      \"Colour enhancement and shifting\",\n+      \"Rapid fractal morphing\",\n+      \"Spatial depth distortion\",\n+      \"Euphoria and mood-lift\",\n+      \"Mania or pressured thought\",\n+      \"Body temperature fluctuations\",\n+      \"Tactile enhancement then numbness\",\n+      \"Moderate–strong stimulation\",\n+      \"Vasoconstriction (cold hands/feet, tingling)\",\n+      \"Nausea and GI discomfort\",\n+      \"Anxiety or panic at higher doses\",\n+      \"Time dilation\",\n+      \"Afterglow fatigue or headache\"\n-      \"full_tolerance\": \"Can develop after 2–3 consecutive days or a single heavy binge\",\n-      \"half_tolerance\": \"~3–7 days\",\n-      \"zero_tolerance\": \"1–2 weeks of abstinence\",\n+      \"full_tolerance\": \"1 dose produces immediate, near-complete tolerance for 3–5 days\",\n+      \"half_tolerance\": \"~7 days\",\n+      \"zero_tolerance\": \"2 weeks+\",\n-        \"other cathinones\",\n-        \"amphetamine-type stimulants\",\n-        \"dopaminergic stimulants\"\n+        \"LSD\",\n+        \"Psilocybin\",\n+        \"Other NBOMes\",\n+        \"2C-x phenethylamines\"\n-    \"half_life\": \"Estimated 2–4 h (based on limited case toxicokinetics and user reports).\",\n+    \"half_life\": \"Human data unavailable; based on limited casework and NBOMe analogues, estimated 3–6 h (active metabolites may prolong effects).\",\n-        \"name\": \"Forensic identification and pharmacology of 4-MPD\",\n-        \"reference\": \"https://doi.org/10.1007/s11419-019-00493-7\"\n+        \"name\": \"Wikipedia – 2C-P-NBOMe\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/2C-P-NBOMe\"\n-        \"name\": \"Fatal intoxication involving 4-methylpentedrone in a chemsex context\",\n-        \"reference\": \"https://www.researchgate.net/publication/347612306\"\n+        \"name\": \"Bluelight ‘Small & Handy 25P-NBOMe thread’ – user dose reports\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-small-handy-25p-nbome-thread.631137/\"\n-        \"name\": \"4-Methyl-pentedrone – 1 g/24 h user report (Bluelight)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/4-methyl-pentedrone-4-mpd-1g-24-hours-almost-the-same-as-pentedrone.690373/\"\n-      },\n-      {\n-        \"name\": \"Structure-activity relationships of second-generation cathinones\",\n-        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576102/\"\n-      },\n-      {\n-        \"name\": \"PubChem: 137700730\",\n-        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/137700730\"\n+        \"name\": \"EMCDDA–Europol 2023: New psychoactive substances – NBOMe compounds fact-sheet (includes 25P-NBOMe analytical data)\",\n+        \"reference\": \"https://www.emcdda.europa.eu/system/files/publications/14641/EMCDDA_NPS_Snapshot_NBOMe_2023.pdf\"\n-      \"stimulant\",\n-      \"research-chemical\",\n-      \"habit-forming\"\n+      \"psychedelic\",\n+      \"research-chemical\"\n\n# 2C-T-4-NBOMe · #518\n\n-  \"id\": 507,\n-  \"title\": \"25P-NBOMe\",\n+  \"id\": 518,\n+  \"title\": \"2C-T-4-NBOMe\",\n-    \"drug_name\": \"25P-NBOMe\",\n-    \"chemical_name\": \"2C-P-NBOMe\",\n-    \"alternative_name\": \"2C-P-NBOMe; NBOMe-2C-P\",\n+    \"drug_name\": \"2C-T-4-NBOMe\",\n+    \"chemical_name\": \"2C-T-4-NBOMe\",\n+    \"alternative_name\": \"\",\n-            \"threshold\": \"50–100 µg\",\n-            \"light\": \"100–250 µg\",\n-            \"common\": \"250–600 µg\",\n-            \"strong\": \"600–900 µg\",\n-            \"heavy\": \"900+ µg\"\n+            \"threshold\": \"~100 µg\",\n+            \"light\": \"200–400 µg\",\n+            \"common\": \"400–800 µg\",\n+            \"strong\": \"800–1 200 µg\",\n+            \"heavy\": \"1 200+ µg (very risky)\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"buccal\",\n-            \"threshold\": \"25–50 µg\",\n-            \"light\": \"50–120 µg\",\n-            \"common\": \"120–300 µg\",\n-            \"strong\": \"300–450 µg\",\n-            \"heavy\": \"450+ µg\"\n+            \"threshold\": \"~100 µg\",\n+            \"light\": \"250–450 µg\",\n+            \"common\": \"450–900 µg\",\n+            \"strong\": \"900–1 300 µg\",\n+            \"heavy\": \"1 300+ µg\"\n-          \"route\": \"vaporized\",\n+          \"route\": \"insufflated\",\n-            \"threshold\": \"20–40 µg\",\n-            \"light\": \"40–80 µg\",\n-            \"common\": \"80–200 µg\",\n-            \"strong\": \"200–300 µg\",\n-            \"heavy\": \"300+ µg\"\n+            \"threshold\": \"~50 µg\",\n+            \"light\": \"100–250 µg\",\n+            \"common\": \"250–600 µg\",\n+            \"strong\": \"600–1 000 µg\",\n+            \"heavy\": \"1 000+ µg (severe body-load/vasoconstriction reports)\"\n-            \"total_duration\": \"8-14 h (reports up to 18 h)\",\n-            \"onset\": \"10-30 min (2-5 min )\",\n-            \"peak\": \"2-5 h\",\n-            \"offset\": \"4-8 h\",\n-            \"after_effects\": \"2-6 h of residual stimulation / exhaustion\"\n+            \"total_duration\": \"6-10 h (occasionally up to 12 h)\",\n+            \"onset\": \"10-30 min / (faster if : 5-15 min)\",\n+            \"peak\": \"1-3 h\",\n+            \"offset\": \"4-6 h\",\n+            \"after_effects\": \"2-6 h residual stimulation; difficulty sleeping\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"buccal\",\n-            \"insufflated\"\n+            \"buccal\"\n-            \"total_duration\": \"8-14 h (reports up to 18 h)\",\n-            \"peak\": \"2-5 h\",\n-            \"offset\": \"4-8 h\",\n-            \"after_effects\": \"2-6 h of residual stimulation / exhaustion\"\n+            \"total_duration\": \"6-10 h (occasionally up to 12 h)\",\n+            \"onset\": \"10-30 min / (faster if : 5-15 min)\",\n+            \"peak\": \"1-3 h\",\n+            \"offset\": \"4-6 h\",\n+            \"after_effects\": \"2-6 h residual stimulation; difficulty sleeping\"\n-          \"route\": \"vaporized\",\n+          \"route\": \"insufflated\",\n-            \"vaporized\"\n+            \"insufflated\"\n-            \"total_duration\": \"8-14 h (reports up to 18 h)\",\n-            \"onset\": \"10-30 min (2-5 min )\",\n-            \"peak\": \"2-5 h\",\n-            \"offset\": \"4-8 h\",\n-            \"after_effects\": \"2-6 h of residual stimulation / exhaustion\"\n+            \"total_duration\": \"6-10 h (occasionally up to 12 h)\",\n+            \"onset\": \"10-30 min / (faster if : 5-15 min)\",\n+            \"peak\": \"1-3 h\",\n+            \"offset\": \"4-6 h\",\n+            \"after_effects\": \"2-6 h residual stimulation; difficulty sleeping\"\n-    \"addiction_potential\": \"Low. Little evidence for compulsive use; psychological habituation possible with frequent use.\",\n+    \"addiction_potential\": \"Very low physical dependence; psychological habituation possible with frequent use due to rapid tolerance drop-off.\",\n-        \"Tramadol\",\n-        \"Cocaine\",\n-        \"Amphetamines\",\n-        \"Synthetic cathinones (MMC/PVP class)\"\n+        \"Tramadol\",\n+        \"Other NBOMe compounds\",\n+        \"Strong adrenergic stimulants (cocaine, cathinones)\"\n-        \"Strong opioids (respiratory depression masking)\",\n-        \"Large alcohol doses (vomiting/blackout)\"\n+        \"Amphetamines\",\n+        \"2C-T-x & 2C-x phenethylamines (over-stimulation)\",\n+        \"DOx series\"\n-        \"Other serotonergic psychedelics (LSD, psilocybin, DMT)\",\n-        \"Benzodiazepines (may dull effects)\",\n-        \"SSRIs/SNRIs\",\n-        \"2C-x or DOx phenethylamines\"\n+        \"Ketamine & dissociatives\",\n+        \"SSRIs/SNRIs (blunted effect)\",\n+        \"Alcohol (may worsen vasoconstriction/dehydration)\",\n+        \"Benzodiazepines (may reduce anxiety but mask overdose symptoms)\"\n-    \"notes\": \"• Extremely potent – active in the low-hundreds of micrograms. A small error in volumetric measurement or blotter laying can create multi-fold overdoses.\\n• Reports of intense vasoconstriction, tachycardia, hypertension, agitation and seizures at high doses comparable to more widely reported NBOMe deaths (e.g., 25I-NBOMe). Use allergy test (≤50 µg) and weigh with a 0.1 mg scale followed by volumetric dosing where possible.\\n• Limited human data; no published controlled trials. Pharmacology suggests high-affinity 5-HT2A agonism similar to other NBOMes with additional 5-HT2C binding, possibly explaining a heavier body load than 25I/25B.\\n• Reagent testing: Marquis – no colour; Froehde – yellow-green; Ehrlich – usually negative (unlike LSD). Use multiple reagents to distinguish from more toxic NBOMes.\\n• Strong peripheral stimulation can persist hours after visuals subside; plan for a long experience and avoid redosing.\\n• Severe cold extremities or chest pain warrant medical attention – do not delay seeking help.\",\n+    \"notes\": \"1. 2C-T-4-NBOMe is active in the microgram range; a milligram-scale error can be fatal. Always volumetrically dose with a 0.001 g-accurate scale.\\n2. Not orally active – absorption requires mucosal (buccal/sublingual) contact or insufflation. Swallowed material is mostly inactive.\\n3. Reports describe pronounced peripheral vasoconstriction, tachycardia, and ‘body-load’ similar to other NBOMe & 2C-T compounds; individuals with cardiovascular risk should avoid.\\n4. Significant inter-individual potency variation (±30 %) has been noted; start at the very low end of the ‘light’ range.\\n5. Heat/light/moisture rapidly degrade the freebase; store airtight in a freezer or as the HCl salt on blotter.\\n6. Medical toxicology data are scarce; treat any severe hypertension, chest pain, or prolonged psychosis as a medical emergency.\",\n-      \"Intense closed- and open-eye visual patterning\",\n-      \"Colour enhancement and shifting\",\n-      \"Rapid fractal morphing\",\n-      \"Spatial depth distortion\",\n-      \"Euphoria and mood-lift\",\n-      \"Mania or pressured thought\",\n-      \"Body temperature fluctuations\",\n-      \"Tactile enhancement then numbness\",\n-      \"Moderate–strong stimulation\",\n-      \"Vasoconstriction (cold hands/feet, tingling)\",\n-      \"Nausea and GI discomfort\",\n-      \"Anxiety or panic at higher doses\",\n+      \"Enhanced color saturation\",\n+      \"Geometric open- and closed-eye visuals\",\n+      \"Pattern recognition enhancement\",\n+      \"Vivid mental imagery\",\n+      \"Euphoria and mood lift\",\n+      \"Tactile enhancement (‘body buzz’ or ‘shivers’)\",\n-      \"Afterglow fatigue or headache\"\n+      \"Introspection and recursive thought-loops\",\n+      \"Anxiety at higher doses\",\n+      \"Moderate stimulation/restlessness\",\n+      \"Peripheral vasoconstriction (cold extremities)\",\n+      \"Nausea/body-load (dose-dependent)\",\n+      \"Possible transient paranoia or delusional thinking at very high doses\"\n-      \"full_tolerance\": \"1 dose produces immediate, near-complete tolerance for 3–5 days\",\n+      \"full_tolerance\": \"After 3–4 consecutive days of use\",\n-      \"zero_tolerance\": \"2 weeks+\",\n+      \"zero_tolerance\": \"~14 days\",\n-        \"Other NBOMes\",\n-        \"2C-x phenethylamines\"\n+        \"Other serotonergic psychedelics\"\n-    \"half_life\": \"Human data unavailable; based on limited casework and NBOMe analogues, estimated 3–6 h (active metabolites may prolong effects).\",\n+    \"half_life\": \"Not formally studied; estimated 2–4 h (parent compound) with longer-lasting active metabolites as suggested by user reports\",\n-        \"name\": \"Wikipedia – 2C-P-NBOMe\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/2C-P-NBOMe\"\n+        \"name\": \"Wikipedia – 2C-T-4-NBOMe\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/2C-T-4-NBOMe\"\n-        \"name\": \"Bluelight ‘Small & Handy 25P-NBOMe thread’ – user dose reports\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/the-small-handy-25p-nbome-thread.631137/\"\n+        \"name\": \"Stables, J. et al. ‘Analytical characterization of novel NBOMe hallucinogens including 2C-T-4-NBOMe.’ Forensic Science International, 2014\",\n+        \"reference\": \"https://doi.org/10.1016/j.forsciint.2014.05.015\"\n-        \"name\": \"EMCDDA–Europol 2023: New psychoactive substances – NBOMe compounds fact-sheet (includes 25P-NBOMe analytical data)\",\n-        \"reference\": \"https://www.emcdda.europa.eu/system/files/publications/14641/EMCDDA_NPS_Snapshot_NBOMe_2023.pdf\"\n+        \"name\": \"Khalid, S. & Brandt, S. ‘NBOMe: new potent hallucinogens – a review.’ Current Neuropharmacology 2017\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706536/\"\n+      },\n+      {\n+        \"name\": \"User experience compilation – r/researchchemicals search ‘2C-T-4-NBOMe’ (accessed 2025-08-02)\",\n+        \"reference\": \"https://www.reddit.com/search/?q=2C-T-4-NBOMe\"\n+      },\n+      {\n+        \"name\": \"Corkery, J. M. et al. ‘Multiple fatalities involving NBOMe-type compounds: implications for harm reduction.’ Human Psychopharmacology 2015\",\n+        \"reference\": \"https://doi.org/10.1002/hup.2443\"\n\n# 2C-T-7-NBOMe · #519\n\n-  \"id\": 518,\n-  \"title\": \"2C-T-4-NBOMe\",\n+  \"id\": 519,\n+  \"title\": \"2C-T-7-NBOMe\",\n-    \"drug_name\": \"2C-T-4-NBOMe\",\n-    \"chemical_name\": \"2C-T-4-NBOMe\",\n+    \"drug_name\": \"2C-T-7-NBOMe\",\n+    \"chemical_name\": \"2C-T-7-NBOMe\",\n-            \"threshold\": \"~100 µg\",\n-            \"light\": \"200–400 µg\",\n-            \"common\": \"400–800 µg\",\n-            \"strong\": \"800–1 200 µg\",\n-            \"heavy\": \"1 200+ µg (very risky)\"\n+            \"threshold\": \"50–100 µg\",\n+            \"light\": \"100–250 µg\",\n+            \"common\": \"250–600 µg\",\n+            \"strong\": \"600–1000 µg\",\n+            \"heavy\": \"≥1000 µg\"\n-          \"route\": \"buccal\",\n+          \"route\": \"insufflated\",\n-            \"threshold\": \"~100 µg\",\n-            \"light\": \"250–450 µg\",\n-            \"common\": \"450–900 µg\",\n-            \"strong\": \"900–1 300 µg\",\n-            \"heavy\": \"1 300+ µg\"\n+            \"threshold\": \"25–50 µg\",\n+            \"light\": \"50–150 µg\",\n+            \"common\": \"150–300 µg\",\n+            \"strong\": \"300–600 µg\",\n+            \"heavy\": \"≥600 µg\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"oral\",\n-            \"threshold\": \"~50 µg\",\n-            \"light\": \"100–250 µg\",\n-            \"common\": \"250–600 µg\",\n-            \"strong\": \"600–1 000 µg\",\n-            \"heavy\": \"1 000+ µg (severe body-load/vasoconstriction reports)\"\n+            \"threshold\": \"200 µg\",\n+            \"light\": \"250–500 µg\",\n+            \"common\": \"500–1000 µg\",\n+            \"strong\": \"1.0–1.5 mg\",\n+            \"heavy\": \"≥1.5 mg\"\n-      \"routes_of_administration\": [\n-        {\n-          \"route\": \"sublingual\",\n-          \"canonical_routes\": [\n-            \"sublingual\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"6-10 h (occasionally up to 12 h)\",\n-            \"onset\": \"10-30 min / (faster if : 5-15 min)\",\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"4-6 h\",\n-            \"after_effects\": \"2-6 h residual stimulation; difficulty sleeping\"\n-          }\n-        },\n-        {\n-          \"route\": \"buccal\",\n-          \"canonical_routes\": [\n-            \"buccal\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"6-10 h (occasionally up to 12 h)\",\n-            \"onset\": \"10-30 min / (faster if : 5-15 min)\",\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"4-6 h\",\n-            \"after_effects\": \"2-6 h residual stimulation; difficulty sleeping\"\n-          }\n-        },\n-        {\n-          \"route\": \"insufflated\",\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"6-10 h (occasionally up to 12 h)\",\n-            \"onset\": \"10-30 min / (faster if : 5-15 min)\",\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"4-6 h\",\n-            \"after_effects\": \"2-6 h residual stimulation; difficulty sleeping\"\n-          }\n-        }\n-      ]\n+      \"total_duration\": \"6-10 h\",\n+      \"onset\": \"15-45 min (buccal / sublingual), up to 60 min oral\",\n+      \"peak\": \"2-4 h\",\n+      \"offset\": \"2-4 h\",\n+      \"after_effects\": \"2-8 h residual stimulation / insomnia\"\n-    \"addiction_potential\": \"Very low physical dependence; psychological habituation possible with frequent use due to rapid tolerance drop-off.\",\n+    \"addiction_potential\": \"Generally considered low and comparable to classical serotonergic psychedelics; however, the strong dopaminergic stimulation reported with some NBOMes can promote compulsive redosing in certain users. Physiological toxicity rather than psychological dependence is the primary concern.\",\n-        \"Other NBOMe compounds\",\n-        \"Strong adrenergic stimulants (cocaine, cathinones)\"\n+        \"Cocaine\",\n+        \"Amphetamines/MDMA\",\n+        \"Other NBOMe compounds\"\n-        \"Amphetamines\",\n-        \"2C-T-x & 2C-x phenethylamines (over-stimulation)\",\n-        \"DOx series\"\n+        \"DOx series\",\n+        \"2C-T-x compounds\",\n+        \"Piperazines\",\n+        \"Mephedrone & other cathinones\",\n+        \"Heavy alcohol (potentiates vasoconstriction)\"\n-        \"Ketamine & dissociatives\",\n-        \"SSRIs/SNRIs (blunted effect)\",\n-        \"Alcohol (may worsen vasoconstriction/dehydration)\",\n-        \"Benzodiazepines (may reduce anxiety but mask overdose symptoms)\"\n+        \"Nitrous\",\n+        \"Ketamine\",\n+        \"Benzodiazepines (may blunt effects)\",\n+        \"SSRIs (may reduce effects, serotonin risk at very high doses)\",\n+        \"Opioids\"\n-    \"notes\": \"1. 2C-T-4-NBOMe is active in the microgram range; a milligram-scale error can be fatal. Always volumetrically dose with a 0.001 g-accurate scale.\\n2. Not orally active – absorption requires mucosal (buccal/sublingual) contact or insufflation. Swallowed material is mostly inactive.\\n3. Reports describe pronounced peripheral vasoconstriction, tachycardia, and ‘body-load’ similar to other NBOMe & 2C-T compounds; individuals with cardiovascular risk should avoid.\\n4. Significant inter-individual potency variation (±30 %) has been noted; start at the very low end of the ‘light’ range.\\n5. Heat/light/moisture rapidly degrade the freebase; store airtight in a freezer or as the HCl salt on blotter.\\n6. Medical toxicology data are scarce; treat any severe hypertension, chest pain, or prolonged psychosis as a medical emergency.\",\n+    \"notes\": \"Human data on 2C-T-7-NBOMe are extremely sparse. Potency estimates are extrapolated from structural–activity relationships, in-vitro affinity data and a handful of self-reports. NBOMe compounds have been linked to severe vasospasm, seizures and several fatalities at milligram-level dosing—always verify material with reagents and use an accurate 0.001 g scale. Allergy test ≤25 µg buccal is strongly recommended. Insufflation greatly increases bioavailability and medical risk; many NBOMe deaths involved nasal use. Avoid stacking with stimulants or MAOIs, and monitor body temperature and blood pressure. Due to their high potency NBOMes are hard to volumetrically dose—label solutions clearly and store safely.\",\n-      \"Enhanced color saturation\",\n-      \"Geometric open- and closed-eye visuals\",\n-      \"Pattern recognition enhancement\",\n-      \"Vivid mental imagery\",\n-      \"Euphoria and mood lift\",\n-      \"Tactile enhancement (‘body buzz’ or ‘shivers’)\",\n+      \"Intense, highly detailed closed- and open-eye visuals\",\n+      \"Brilliant colour enhancement\",\n+      \"Fractal and geometric patterning\",\n+      \"Euphoria and mood-lift\",\n+      \"Stimulation (tachycardia, restlessness)\",\n+      \"Empathic openness\",\n-      \"Introspection and recursive thought-loops\",\n-      \"Anxiety at higher doses\",\n-      \"Moderate stimulation/restlessness\",\n-      \"Peripheral vasoconstriction (cold extremities)\",\n-      \"Nausea/body-load (dose-dependent)\",\n-      \"Possible transient paranoia or delusional thinking at very high doses\"\n+      \"Thought loops\",\n+      \"Body load/vasoconstriction (cold extremities, chest pressure)\",\n+      \"Nausea, possible vomiting at higher doses\",\n+      \"Headache during comedown\",\n+      \"Residual insomnia\"\n-      \"full_tolerance\": \"After 3–4 consecutive days of use\",\n-      \"half_tolerance\": \"~7 days\",\n-      \"zero_tolerance\": \"~14 days\",\n+      \"full_tolerance\": \"Immediate; repeated dosing within the same day yields greatly diminished effects\",\n+      \"half_tolerance\": \"~3–4 days\",\n+      \"zero_tolerance\": \"7–14 days\",\n-        \"Other serotonergic psychedelics\"\n+        \"Other NBOMe and 2C compounds\"\n-    \"half_life\": \"Not formally studied; estimated 2–4 h (parent compound) with longer-lasting active metabolites as suggested by user reports\",\n+    \"half_life\": \"Human pharmacokinetics unpublished; based on rat microsome and limited case-report data, elimination half-life is estimated 2–4 h with active metabolites contributing to the tail.\",\n-        \"name\": \"Wikipedia – 2C-T-4-NBOMe\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/2C-T-4-NBOMe\"\n+        \"name\": \"Wikipedia: 2C-T-7-NBOMe\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/2C-T-7-NBOMe\"\n-        \"name\": \"Stables, J. et al. ‘Analytical characterization of novel NBOMe hallucinogens including 2C-T-4-NBOMe.’ Forensic Science International, 2014\",\n-        \"reference\": \"https://doi.org/10.1016/j.forsciint.2014.05.015\"\n+        \"name\": \"Rickli A et al. Receptor interaction profiles of novel NBOMe hallucinogens\",\n+        \"reference\": \"https://doi.org/10.1016/j.neuropharm.2015.08.034\"\n-        \"name\": \"Khalid, S. & Brandt, S. ‘NBOMe: new potent hallucinogens – a review.’ Current Neuropharmacology 2017\",\n-        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706536/\"\n+        \"name\": \"Wallach J, Halberstadt AL. Pharmacology of NBOMes\",\n+        \"reference\": \"https://link.springer.com/chapter/10.1007/7854_2014_274\"\n-        \"name\": \"User experience compilation – r/researchchemicals search ‘2C-T-4-NBOMe’ (accessed 2025-08-02)\",\n-        \"reference\": \"https://www.reddit.com/search/?q=2C-T-4-NBOMe\"\n-      },\n-      {\n-        \"name\": \"Corkery, J. M. et al. ‘Multiple fatalities involving NBOMe-type compounds: implications for harm reduction.’ Human Psychopharmacology 2015\",\n-        \"reference\": \"https://doi.org/10.1002/hup.2443\"\n+        \"name\": \"Bluelight Thread: Early user reports of 2C-T-7-NBOMe (2013)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/25ef-nbome.676061/\"\n\n# 4-Methoxybutyrfentanyl · #520\n\n-  \"id\": 519,\n-  \"title\": \"2C-T-7-NBOMe\",\n+  \"id\": 520,\n+  \"title\": \"4-Methoxybutyrfentanyl\",\n-    \"drug_name\": \"2C-T-7-NBOMe\",\n-    \"chemical_name\": \"2C-T-7-NBOMe\",\n+    \"drug_name\": \"4-Methoxybutyrfentanyl\",\n+    \"chemical_name\": \"4-Methoxybutyrfentanyl\",\n-    \"chemical_class\": \"N-benzylated phenethylamines\",\n-    \"mechanism_of_action\": \"5-HT2A receptor agonist (potent); 5-HT2B receptor agonist (cardiotoxic)\",\n-    \"psychoactive_class\": \"Psychedelic\",\n+    \"chemical_class\": \"Anilinopiperidines\",\n+    \"mechanism_of_action\": \"μ-Opioid receptor agonist (full)\",\n+    \"psychoactive_class\": \"µ-opioid receptor agonist (opioid analgesic)\",\n-          \"route\": \"sublingual\",\n+          \"route\": \"oral\",\n-            \"threshold\": \"50–100 µg\",\n-            \"light\": \"100–250 µg\",\n-            \"common\": \"250–600 µg\",\n-            \"strong\": \"600–1000 µg\",\n-            \"heavy\": \"≥1000 µg\"\n+            \"threshold\": \"<50 µg (unverified)\",\n+            \"light\": \"50–100 µg\",\n+            \"common\": \"100–300 µg\",\n+            \"strong\": \"300–600 µg\",\n+            \"heavy\": \">600 µg\"\n-            \"threshold\": \"25–50 µg\",\n-            \"light\": \"50–150 µg\",\n-            \"common\": \"150–300 µg\",\n-            \"strong\": \"300–600 µg\",\n-            \"heavy\": \"≥600 µg\"\n+            \"threshold\": \"<25 µg (unverified)\",\n+            \"light\": \"25–75 µg\",\n+            \"common\": \"75–200 µg\",\n+            \"strong\": \"200–400 µg\",\n+            \"heavy\": \">400 µg\"\n-          \"route\": \"oral\",\n+          \"route\": \"intravenous\",\n-            \"threshold\": \"200 µg\",\n-            \"light\": \"250–500 µg\",\n-            \"common\": \"500–1000 µg\",\n-            \"strong\": \"1.0–1.5 mg\",\n-            \"heavy\": \"≥1.5 mg\"\n+            \"threshold\": \"<10 µg (allergy test)\",\n+            \"light\": \"10–25 µg\",\n+            \"common\": \"25–75 µg\",\n+            \"strong\": \"75–150 µg\",\n+            \"heavy\": \">150 µg\"\n-      \"total_duration\": \"6-10 h\",\n-      \"onset\": \"15-45 min (buccal / sublingual), up to 60 min oral\",\n-      \"peak\": \"2-4 h\",\n-      \"offset\": \"2-4 h\",\n-      \"after_effects\": \"2-8 h residual stimulation / insomnia\"\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"30-120 min (route-dependent)\",\n+            \"onset\": \"5-15 min\",\n+            \"peak\": \"15-45 min\",\n+            \"offset\": \"15-45 min\",\n+            \"after_effects\": \"1-2 h residual sedation / lethargy\"\n+          }\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"30-120 min (route-dependent)\",\n+            \"onset\": \"1-2 min\",\n+            \"peak\": \"15-45 min\",\n+            \"offset\": \"15-45 min\",\n+            \"after_effects\": \"1-2 h residual sedation / lethargy\"\n+          }\n+        },\n+        {\n+          \"route\": \"intravenous\",\n+          \"canonical_routes\": [\n+            \"intravenous\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"30-120 min (route-dependent)\",\n+            \"onset\": \"0.5-1 min\",\n+            \"peak\": \"15-45 min\",\n+            \"offset\": \"15-45 min\",\n+            \"after_effects\": \"1-2 h residual sedation / lethargy\"\n+          }\n+        }\n+      ]\n-    \"addiction_potential\": \"Generally considered low and comparable to classical serotonergic psychedelics; however, the strong dopaminergic stimulation reported with some NBOMes can promote compulsive redosing in certain users. Physiological toxicity rather than psychological dependence is the primary concern.\",\n+    \"addiction_potential\": \"High. Rapid tolerance and physical dependence develop similarly to fentanyl. Severe withdrawal can begin within 8–12 h of cessation after sustained use.\",\n-        \"MAOIs\",\n-        \"DXM\",\n-        \"Tramadol\",\n-        \"Cocaine\",\n-        \"Amphetamines/MDMA\",\n-        \"Other NBOMe compounds\"\n+        \"other opioids\",\n+        \"benzodiazepines\",\n+        \"barbiturates\",\n+        \"alcohol\",\n+        \"GHB/GBL\",\n+        \"propofol\",\n+        \"quetiapine\",\n+        \"pregabalin/gabapentin\"\n-        \"DOx series\",\n-        \"2C-T-x compounds\",\n-        \"Piperazines\",\n-        \"Mephedrone & other cathinones\",\n-        \"Heavy alcohol (potentiates vasoconstriction)\"\n+        \"cannabinoids (high doses)\",\n+        \"muscle-relaxants\",\n+        \"dissociatives (e.g., ketamine, PCP)\"\n-        \"Cannabis\",\n-        \"Nitrous\",\n-        \"Ketamine\",\n-        \"Benzodiazepines (may blunt effects)\",\n-        \"SSRIs (may reduce effects, serotonin risk at very high doses)\",\n-        \"Opioids\"\n+        \"stimulants/adrenergics (may mask overdose)\",\n+        \"MAO-Is\",\n+        \"SSRIs/SNRIs/tramadol (serotonin & seizure risk at high doses)\"\n-    \"notes\": \"Human data on 2C-T-7-NBOMe are extremely sparse. Potency estimates are extrapolated from structural–activity relationships, in-vitro affinity data and a handful of self-reports. NBOMe compounds have been linked to severe vasospasm, seizures and several fatalities at milligram-level dosing—always verify material with reagents and use an accurate 0.001 g scale. Allergy test ≤25 µg buccal is strongly recommended. Insufflation greatly increases bioavailability and medical risk; many NBOMe deaths involved nasal use. Avoid stacking with stimulants or MAOIs, and monitor body temperature and blood pressure. Due to their high potency NBOMes are hard to volumetrically dose—label solutions clearly and store safely.\",\n+    \"notes\": \"4-MeO-BF is a highly potent ‘research’ fentanyl-type opioid first identified in Europe in 2015. Fatal concentrations in post-mortem blood have ranged 2–18 ng/mL, only modestly lower than fentanyl itself. Because street material varies 10-fold in purity, volumetric dosing with a 1 mg/mL (or weaker) solution and a 0.01 mL oral syringe/pipette is strongly advised; never eyeball powder. Naloxone 0.4–2 mg IV/IM will reverse toxicity, but shorter half-life of naloxone means repeat doses or continuous infusion may be required (re-narcotisation common after 30–60 min). Always monitor ≥2 h after last dose. Wear gloves & mask when handling bulk powder: accidental dermal/inhalational exposure has produced poisoning in forensic labs. Because of its short duration many users redose frequently—major driver of overdose.\",\n-      \"Intense, highly detailed closed- and open-eye visuals\",\n-      \"Brilliant colour enhancement\",\n-      \"Fractal and geometric patterning\",\n-      \"Euphoria and mood-lift\",\n-      \"Stimulation (tachycardia, restlessness)\",\n-      \"Empathic openness\",\n-      \"Time dilation\",\n-      \"Thought loops\",\n-      \"Body load/vasoconstriction (cold extremities, chest pressure)\",\n-      \"Nausea, possible vomiting at higher doses\",\n-      \"Headache during comedown\",\n-      \"Residual insomnia\"\n+      \"Warm opioid euphoria\",\n+      \"Anxiolysis\",\n+      \"Analgesia\",\n+      \"Sedation\",\n+      \"Dream-like state or mild dissociation (high dose)\",\n+      \"Itching/pruritus\",\n+      \"Miosis\",\n+      \"Constipation\",\n+      \"Respiratory depression\",\n+      \"Nausea/vomiting\",\n+      \"Histamine flush\",\n+      \"Severe apnoea/cyanosis at overdose\"\n-      \"full_tolerance\": \"Immediate; repeated dosing within the same day yields greatly diminished effects\",\n-      \"half_tolerance\": \"~3–4 days\",\n-      \"zero_tolerance\": \"7–14 days\",\n+      \"full_tolerance\": \"After 3–5 consecutive daily doses\",\n+      \"half_tolerance\": \"~1–2 weeks abstinence\",\n+      \"zero_tolerance\": \"4–6 weeks\",\n-        \"LSD\",\n-        \"Psilocybin\",\n-        \"Other NBOMe and 2C compounds\"\n+        \"all µ-opioid agonists (fentanyl, morphine, oxycodone, heroin, etc.)\"\n-    \"half_life\": \"Human pharmacokinetics unpublished; based on rat microsome and limited case-report data, elimination half-life is estimated 2–4 h with active metabolites contributing to the tail.\",\n+    \"half_life\": \"Not formally studied; based on analogues estimated 1–2 h (distribution half-life ~15 min, elimination half-life ~90 min).\",\n-        \"name\": \"Wikipedia: 2C-T-7-NBOMe\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/2C-T-7-NBOMe\"\n+        \"name\": \"Helander et al. Intoxications involving 4-MeO-BF (STRIDA project)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/26850293\"\n-        \"name\": \"Rickli A et al. Receptor interaction profiles of novel NBOMe hallucinogens\",\n-        \"reference\": \"https://doi.org/10.1016/j.neuropharm.2015.08.034\"\n+        \"name\": \"EMCDDA–Europol. Joint Report on 4-Methoxybutyrfentanyl 2017\",\n+        \"reference\": \"https://www.emcdda.europa.eu/system/files/publications/4583/TDAS17001ENN.pdf\"\n-        \"name\": \"Wallach J, Halberstadt AL. Pharmacology of NBOMes\",\n-        \"reference\": \"https://link.springer.com/chapter/10.1007/7854_2014_274\"\n+        \"name\": \"Mounteney et al. Fentanyls: are we missing the signs? Int J Drug Policy 2015\",\n+        \"reference\": \"https://doi.org/10.1016/j.drugpo.2015.04.003\"\n-        \"name\": \"Bluelight Thread: Early user reports of 2C-T-7-NBOMe (2013)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/25ef-nbome.676061/\"\n+        \"name\": \"NFL RESPONSE Analytical Report ID-1263-15 (4-MeO-BF)\",\n+        \"reference\": \"https://www.policija.si/apps/nfl_response_web/0_Analytical_Reports_final/4-MEO-BF-ID-1263-15-report_final.pdf\"\n+      },\n+      {\n+        \"name\": \"Swedish Poison Information Centre – fatal concentration range (case series)\",\n+        \"reference\": \"https://link.springer.com/article/10.1007/s00204-017-1975-6\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: 4 Methoxybutyrfentanyl\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/4-Methoxybutyrfentanyl\"\n-      \"psychedelic\",\n-      \"research-chemical\"\n+      \"research-chemical\",\n+      \"opioid\",\n+      \"habit-forming\"\n\n# 5-MAPB · #521\n\n-  \"id\": 520,\n-  \"title\": \"4-Methoxybutyrfentanyl\",\n+  \"id\": 521,\n+  \"title\": \"5-MAPB\",\n-    \"drug_name\": \"4-Methoxybutyrfentanyl\",\n-    \"chemical_name\": \"4-Methoxybutyrfentanyl\",\n+    \"drug_name\": \"5-MAPB\",\n+    \"chemical_name\": \"5-MAPB\",\n-    \"chemical_class\": \"Anilinopiperidines\",\n-    \"mechanism_of_action\": \"μ-Opioid receptor agonist (full)\",\n-    \"psychoactive_class\": \"µ-opioid receptor agonist (opioid analgesic)\",\n+    \"chemical_class\": \"Benzofurans\",\n+    \"mechanism_of_action\": \"Serotonin-dopamine-norepinephrine releasing agent\",\n+    \"psychoactive_class\": \"Entactogen–stimulant (MDMA-like)\",\n-          \"units\": \"µg\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"<50 µg (unverified)\",\n-            \"light\": \"50–100 µg\",\n-            \"common\": \"100–300 µg\",\n-            \"strong\": \"300–600 µg\",\n-            \"heavy\": \">600 µg\"\n+            \"threshold\": \"15-25\",\n+            \"light\": \"30-50\",\n+            \"common\": \"50-80\",\n+            \"strong\": \"80-100\",\n+            \"heavy\": \"100-120+\"\n-          \"units\": \"µg\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"<25 µg (unverified)\",\n-            \"light\": \"25–75 µg\",\n-            \"common\": \"75–200 µg\",\n-            \"strong\": \"200–400 µg\",\n-            \"heavy\": \">400 µg\"\n+            \"threshold\": \"10-15\",\n+            \"light\": \"15-25\",\n+            \"common\": \"25-40\",\n+            \"strong\": \"40-55\",\n+            \"heavy\": \"55+\"\n-          \"route\": \"intravenous\",\n-          \"units\": \"µg\",\n+          \"route\": \"rectal\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"<10 µg (allergy test)\",\n-            \"light\": \"10–25 µg\",\n-            \"common\": \"25–75 µg\",\n-            \"strong\": \"75–150 µg\",\n-            \"heavy\": \">150 µg\"\n+            \"threshold\": \"15-20\",\n+            \"light\": \"25-40\",\n+            \"common\": \"40-60\",\n+            \"strong\": \"60-75\",\n+            \"heavy\": \"75+\"\n+        },\n+        {\n+          \"route\": \"intramuscular\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"8-12\",\n+            \"light\": \"15-25\",\n+            \"common\": \"25-40\",\n+            \"strong\": \"40-55\",\n+            \"heavy\": \"55+\"\n+          }\n-            \"total_duration\": \"30-120 min (route-dependent)\",\n-            \"onset\": \"5-15 min\",\n-            \"peak\": \"15-45 min\",\n-            \"offset\": \"15-45 min\",\n-            \"after_effects\": \"1-2 h residual sedation / lethargy\"\n+            \"total_duration\": \"6-9 h (residual stimulation up to 12 h)\",\n+            \"peak\": \"2-4 h\",\n+            \"offset\": \"2-3 h\",\n+            \"after_effects\": \"2-6 h 'after-glow' / insomnia\"\n-            \"total_duration\": \"30-120 min (route-dependent)\",\n-            \"onset\": \"1-2 min\",\n-            \"peak\": \"15-45 min\",\n-            \"offset\": \"15-45 min\",\n-            \"after_effects\": \"1-2 h residual sedation / lethargy\"\n+            \"total_duration\": \"6-9 h (residual stimulation up to 12 h)\",\n+            \"peak\": \"2-4 h\",\n+            \"offset\": \"2-3 h\",\n+            \"after_effects\": \"2-6 h 'after-glow' / insomnia\"\n-          \"route\": \"intravenous\",\n+          \"route\": \"rectal\",\n-            \"intravenous\"\n+            \"rectal\"\n-            \"total_duration\": \"30-120 min (route-dependent)\",\n-            \"onset\": \"0.5-1 min\",\n-            \"peak\": \"15-45 min\",\n-            \"offset\": \"15-45 min\",\n-            \"after_effects\": \"1-2 h residual sedation / lethargy\"\n+            \"total_duration\": \"6-9 h (residual stimulation up to 12 h)\",\n+            \"peak\": \"2-4 h\",\n+            \"offset\": \"2-3 h\",\n+            \"after_effects\": \"2-6 h 'after-glow' / insomnia\"\n+        },\n+        {\n+          \"route\": \"intramuscular\",\n+          \"canonical_routes\": [\n+            \"intramuscular\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"6-9 h (residual stimulation up to 12 h)\",\n+            \"onset\": \"30-60 min\",\n+            \"peak\": \"2-4 h\",\n+            \"offset\": \"2-3 h\",\n+            \"after_effects\": \"2-6 h 'after-glow' / insomnia\"\n+          }\n-    \"addiction_potential\": \"High. Rapid tolerance and physical dependence develop similarly to fentanyl. Severe withdrawal can begin within 8–12 h of cessation after sustained use.\",\n+    \"addiction_potential\": \"Moderate – psychological craving and binge-pattern use are frequently reported; physical dependence is unlikely but rapid tolerance and compulsive redosing can develop.\",\n-        \"other opioids\",\n-        \"benzodiazepines\",\n-        \"barbiturates\",\n-        \"alcohol\",\n-        \"GHB/GBL\",\n-        \"propofol\",\n-        \"quetiapine\",\n-        \"pregabalin/gabapentin\"\n+        \"MAOIs (phenelzine, tranylcypromine)\",\n+        \"Linezolid\",\n+        \"Other strong serotonin releasers (MDMA, MDA, 4-MMC, 4-FA)\",\n+        \"Selective serotonin re-uptake inhibitors (serotonin syndrome risk)\",\n+        \"PMA/PMMA\",\n+        \"DXM\",\n+        \"Tramadol\",\n+        \"2C-T series\"\n-        \"cannabinoids (high doses)\",\n-        \"muscle-relaxants\",\n-        \"dissociatives (e.g., ketamine, PCP)\"\n+        \"Other stimulants (cocaine, amphetamine, cathinones)\",\n+        \"Large alcohol doses (dehydration, hyperthermia)\",\n+        \"Ritonavir or other potent CYP2D6/CYP3A4 inhibitors\"\n-        \"stimulants/adrenergics (may mask overdose)\",\n-        \"MAO-Is\",\n-        \"SSRIs/SNRIs/tramadol (serotonin & seizure risk at high doses)\"\n+        \"Cannabis (can potentiate confusion/anxiety)\",\n+        \"Bupropion\",\n+        \"Benzodiazepines (additive CNS depression when high doses used post-roll)\"\n-    \"notes\": \"4-MeO-BF is a highly potent ‘research’ fentanyl-type opioid first identified in Europe in 2015. Fatal concentrations in post-mortem blood have ranged 2–18 ng/mL, only modestly lower than fentanyl itself. Because street material varies 10-fold in purity, volumetric dosing with a 1 mg/mL (or weaker) solution and a 0.01 mL oral syringe/pipette is strongly advised; never eyeball powder. Naloxone 0.4–2 mg IV/IM will reverse toxicity, but shorter half-life of naloxone means repeat doses or continuous infusion may be required (re-narcotisation common after 30–60 min). Always monitor ≥2 h after last dose. Wear gloves & mask when handling bulk powder: accidental dermal/inhalational exposure has produced poisoning in forensic labs. Because of its short duration many users redose frequently—major driver of overdose.\",\n+    \"notes\": \"• Potent non-selective monoamine releaser; in vitro ca. 3-5× MDMA potency at SERT and NET, ~2× at DAT. [Baumann 2020]\\n• Full 5-HT2B agonist – repeated or high-frequency use may promote valvulopathy similar to fenfluramine; keep monthly (≥4-6 wk) spacing between sessions.\\n• Marked batch-to-batch potency variation has been documented in user forums; always confirm identity with a reagent test and start with ≤30 mg (‘allergy test’).\\n• Adverse effects reported in ED visits include malignant hyperthermia (≥41 °C), severe hypertension, rhabdomyolysis and acute kidney injury. [Hofer 2017]\\n• ‘Brain-zaps’, anhedonia, and low mood lasting days–weeks are common after heavy or consecutive-day use; magnesium (400 mg), omega-3s and adequate sleep mitigate but do not eliminate comedown.\\n• Hydrate with isotonic fluids (~250 ml h⁻¹), avoid exertion/hot environments; active cooling and 1–2 mg lorazepam are first-line if hyperthermia or severe agitation occur.\\n• 5-MAPB appears slightly more dopaminergic than 6-APB; users describe a clearer stimulant push but also more vasoconstriction and jaw tension.\",\n-      \"Warm opioid euphoria\",\n-      \"Anxiolysis\",\n-      \"Analgesia\",\n-      \"Sedation\",\n-      \"Dream-like state or mild dissociation (high dose)\",\n-      \"Itching/pruritus\",\n-      \"Miosis\",\n-      \"Constipation\",\n-      \"Respiratory depression\",\n-      \"Nausea/vomiting\",\n-      \"Histamine flush\",\n-      \"Severe apnoea/cyanosis at overdose\"\n+      \"Empathy / emotional warmth\",\n+      \"Euphoria\",\n+      \"Enhanced sociability & talkativeness\",\n+      \"Tactile & musical enhancement\",\n+      \"Stimulation / urge to dance\",\n+      \"Moderate sexual arousal\",\n+      \"Nystagmus & jaw clenching\",\n+      \"Visual brightness & colour enhancement\",\n+      \"Time compression\",\n+      \"Vasoconstriction (cold extremities)\",\n+      \"Sweating / hyperthermia\",\n+      \"Mild closed-eye visuals (high dose)\",\n+      \"Insomnia\",\n+      \"Anxiety or confusion (high/late redose)\",\n+      \"Post-use fatigue & low mood\",\n+      \"'Brain-zaps'\"\n-      \"full_tolerance\": \"After 3–5 consecutive daily doses\",\n-      \"half_tolerance\": \"~1–2 weeks abstinence\",\n-      \"zero_tolerance\": \"4–6 weeks\",\n+      \"full_tolerance\": \"One strong session can halve subsequent response the next day\",\n+      \"half_tolerance\": \"~1-2 weeks\",\n+      \"zero_tolerance\": \"4-6 weeks\",\n-        \"all µ-opioid agonists (fentanyl, morphine, oxycodone, heroin, etc.)\"\n+        \"MDMA\",\n+        \"5-APB\",\n+        \"6-APB\",\n+        \"Other serotonin releasers\"\n-    \"half_life\": \"Not formally studied; based on analogues estimated 1–2 h (distribution half-life ~15 min, elimination half-life ~90 min).\",\n+    \"half_life\": \"4-8 h (parent); active hydroxy- and demethyl-metabolites may prolong subjective effects up to 12 h.\",\n-        \"name\": \"Helander et al. Intoxications involving 4-MeO-BF (STRIDA project)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/26850293\"\n+        \"name\": \"Baumann et al. – Neuropharmacology of 5-/6-APB & MAPB\",\n+        \"reference\": \"https://doi.org/10.1007/s00213-020-05648-z\"\n-        \"name\": \"EMCDDA–Europol. Joint Report on 4-Methoxybutyrfentanyl 2017\",\n-        \"reference\": \"https://www.emcdda.europa.eu/system/files/publications/4583/TDAS17001ENN.pdf\"\n+        \"name\": \"Hofer et al. – Acute toxicity of benzofurans (Emergency Dept. case-series)\",\n+        \"reference\": \"https://doi.org/10.1016/j.annemergmed.2016.03.042\"\n-        \"name\": \"Mounteney et al. Fentanyls: are we missing the signs? Int J Drug Policy 2015\",\n-        \"reference\": \"https://doi.org/10.1016/j.drugpo.2015.04.003\"\n+        \"name\": \"Wikipedia – 5-MAPB\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/5-MAPB\"\n-        \"name\": \"NFL RESPONSE Analytical Report ID-1263-15 (4-MeO-BF)\",\n-        \"reference\": \"https://www.policija.si/apps/nfl_response_web/0_Analytical_Reports_final/4-MEO-BF-ID-1263-15-report_final.pdf\"\n+        \"name\": \"Bluelight ‘The Main 5-MAPB Thread’ (user reports, batch variability)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-main-5-mapb-thread.657421/\"\n-        \"name\": \"Swedish Poison Information Centre – fatal concentration range (case series)\",\n-        \"reference\": \"https://link.springer.com/article/10.1007/s00204-017-1975-6\"\n-      },\n-      {\n-        \"name\": \"Wikipedia: 4 Methoxybutyrfentanyl\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/4-Methoxybutyrfentanyl\"\n+        \"name\": \"Erowid Experience Vaults – 5-MAPB\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_5MAPB.shtml\"\n+      \"stimulant\",\n-      \"opioid\",\n+      \"entactogen\",\n\n# 4-Fluorophenylpiperazine · #523\n\n-  \"id\": 521,\n-  \"title\": \"5-MAPB\",\n+  \"id\": 523,\n+  \"title\": \"4-Fluorophenylpiperazine\",\n-    \"drug_name\": \"5-MAPB\",\n-    \"chemical_name\": \"5-MAPB\",\n+    \"drug_name\": \"4-Fluorophenylpiperazine\",\n+    \"chemical_name\": \"4-Fluorophenylpiperazine\",\n-    \"chemical_class\": \"Benzofurans\",\n-    \"mechanism_of_action\": \"Serotonin-dopamine-norepinephrine releasing agent\",\n-    \"psychoactive_class\": \"Entactogen–stimulant (MDMA-like)\",\n+    \"chemical_class\": \"Piperazines\",\n+    \"mechanism_of_action\": \"Serotonin receptor agonist\",\n+    \"psychoactive_class\": \"Serotonergic entactogen; mild psychedelic (5-HT1A agonist ≫ 5-HT2A/2C agonist; weak SERT/NET releaser; negligible DAT activity)\",\n-            \"threshold\": \"15-25\",\n-            \"light\": \"30-50\",\n-            \"common\": \"50-80\",\n-            \"strong\": \"80-100\",\n-            \"heavy\": \"100-120+\"\n+            \"threshold\": \"10–15\",\n+            \"light\": \"20–40\",\n+            \"common\": \"40–80\",\n+            \"strong\": \"80–120\",\n+            \"heavy\": \"120 + \"\n-            \"threshold\": \"10-15\",\n-            \"light\": \"15-25\",\n-            \"common\": \"25-40\",\n-            \"strong\": \"40-55\",\n-            \"heavy\": \"55+\"\n+            \"threshold\": \"5\",\n+            \"light\": \"10–20\",\n+            \"common\": \"20–35\",\n+            \"strong\": \"35–50\",\n+            \"heavy\": \">50\"\n-            \"threshold\": \"15-20\",\n-            \"light\": \"25-40\",\n-            \"common\": \"40-60\",\n-            \"strong\": \"60-75\",\n-            \"heavy\": \"75+\"\n+            \"threshold\": \"10\",\n+            \"light\": \"15–30\",\n+            \"common\": \"30–60\",\n+            \"strong\": \"60–90\",\n+            \"heavy\": \">90\"\n-        },\n-        {\n-          \"route\": \"intramuscular\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"8-12\",\n-            \"light\": \"15-25\",\n-            \"common\": \"25-40\",\n-            \"strong\": \"40-55\",\n-            \"heavy\": \"55+\"\n-          }\n-            \"total_duration\": \"6-9 h (residual stimulation up to 12 h)\",\n-            \"peak\": \"2-4 h\",\n-            \"offset\": \"2-3 h\",\n-            \"after_effects\": \"2-6 h 'after-glow' / insomnia\"\n+            \"total_duration\": \"4-8 hours\",\n+            \"onset\": \"15-45 minutes\",\n+            \"peak\": \"1-3 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"2-12 hours residual fatigue, headache, dysphoria\"\n-            \"total_duration\": \"6-9 h (residual stimulation up to 12 h)\",\n-            \"peak\": \"2-4 h\",\n-            \"offset\": \"2-3 h\",\n-            \"after_effects\": \"2-6 h 'after-glow' / insomnia\"\n+            \"total_duration\": \"4-8 hours\",\n+            \"onset\": \"5-15 minutes\",\n+            \"peak\": \"1-3 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"2-12 hours residual fatigue, headache, dysphoria\"\n-            \"total_duration\": \"6-9 h (residual stimulation up to 12 h)\",\n-            \"peak\": \"2-4 h\",\n-            \"offset\": \"2-3 h\",\n-            \"after_effects\": \"2-6 h 'after-glow' / insomnia\"\n+            \"total_duration\": \"4-8 hours\",\n+            \"onset\": \"Not well documented (research required)\",\n+            \"peak\": \"1-3 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"2-12 hours residual fatigue, headache, dysphoria\"\n-        },\n-        {\n-          \"route\": \"intramuscular\",\n-          \"canonical_routes\": [\n-            \"intramuscular\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"6-9 h (residual stimulation up to 12 h)\",\n-            \"onset\": \"30-60 min\",\n-            \"peak\": \"2-4 h\",\n-            \"offset\": \"2-3 h\",\n-            \"after_effects\": \"2-6 h 'after-glow' / insomnia\"\n-          }\n-    \"addiction_potential\": \"Moderate – psychological craving and binge-pattern use are frequently reported; physical dependence is unlikely but rapid tolerance and compulsive redosing can develop.\",\n+    \"addiction_potential\": \"Low. 4-FPP shows little dopaminergic reinforcement in animal models and most users report limited craving. Psychological habit-formation is possible with frequent use.\",\n-        \"MAOIs (phenelzine, tranylcypromine)\",\n-        \"Linezolid\",\n-        \"Other strong serotonin releasers (MDMA, MDA, 4-MMC, 4-FA)\",\n-        \"Selective serotonin re-uptake inhibitors (serotonin syndrome risk)\",\n-        \"PMA/PMMA\",\n-        \"DXM\",\n+        \"MAOIs (linezolid, phenelzine, isocarboxazid)\",\n+        \"High-dose SSRIs/SNRIs or multiple serotonergic agents (serotonin-syndrome)\",\n-        \"2C-T series\"\n+        \"MDMA/MDA and strong monoamine releasers\"\n-        \"Other stimulants (cocaine, amphetamine, cathinones)\",\n-        \"Large alcohol doses (dehydration, hyperthermia)\",\n-        \"Ritonavir or other potent CYP2D6/CYP3A4 inhibitors\"\n+        \"Other piperazines (BZP, TFMPP, MeOPP)\",\n+        \"DXM\",\n+        \"TCAs\",\n+        \"Tapentadol\"\n-        \"Cannabis (can potentiate confusion/anxiety)\",\n-        \"Bupropion\",\n-        \"Benzodiazepines (additive CNS depression when high doses used post-roll)\"\n+        \"Alcohol (additive CNS depression after the peak)\",\n+        \"Cannabis (potentiates anxiolysis but can increase dysphoria)\",\n+        \"Classical stimulants (amphetamine, methylphenidate)\",\n+        \"5-HT2A agonist psychedelics (possible intensification of body-load)\"\n-    \"notes\": \"• Potent non-selective monoamine releaser; in vitro ca. 3-5× MDMA potency at SERT and NET, ~2× at DAT. [Baumann 2020]\\n• Full 5-HT2B agonist – repeated or high-frequency use may promote valvulopathy similar to fenfluramine; keep monthly (≥4-6 wk) spacing between sessions.\\n• Marked batch-to-batch potency variation has been documented in user forums; always confirm identity with a reagent test and start with ≤30 mg (‘allergy test’).\\n• Adverse effects reported in ED visits include malignant hyperthermia (≥41 °C), severe hypertension, rhabdomyolysis and acute kidney injury. [Hofer 2017]\\n• ‘Brain-zaps’, anhedonia, and low mood lasting days–weeks are common after heavy or consecutive-day use; magnesium (400 mg), omega-3s and adequate sleep mitigate but do not eliminate comedown.\\n• Hydrate with isotonic fluids (~250 ml h⁻¹), avoid exertion/hot environments; active cooling and 1–2 mg lorazepam are first-line if hyperthermia or severe agitation occur.\\n• 5-MAPB appears slightly more dopaminergic than 6-APB; users describe a clearer stimulant push but also more vasoconstriction and jaw tension.\",\n+    \"notes\": \"• p-FPP was first identified as a urinary metabolite of the sedative niaprazine and subsequently sold (2003-2008) in New Zealand “party pills” together with BZP.\\n• In vitro it is a high-efficacy 5-HT1A agonist (Ki ≈ 11 nM), moderate 5-HT2A/2C partial agonist and weak SERT/NET releaser; DAT activity is negligible, explaining its low stimulant euphoria.\\n• Subjectively it produces light empathic warmth, mild colour enhancement / tracers and a prominent vasoconstrictive ‘head pressure’. Nausea, migraine-like headaches, myalgia and anxiety are common above ~100 mg.\\n• Unlike BZP it inhibits several hepatic CYPs (notably 1A2, 2D6, 3A4) which can prolong co-administered drugs.\\n• Rodent LD50 (oral) ≈ 400 mg kg⁻¹; no confirmed fatalities as sole agent but severe hyperthermia, seizures and rhabdomyolysis have been reported in poly-drug cases.\\n• Weigh carefully, hydrate, avoid redosing (>120 mg markedly increases adverse effects).\",\n-      \"Empathy / emotional warmth\",\n-      \"Euphoria\",\n-      \"Enhanced sociability & talkativeness\",\n-      \"Tactile & musical enhancement\",\n-      \"Stimulation / urge to dance\",\n-      \"Moderate sexual arousal\",\n-      \"Nystagmus & jaw clenching\",\n-      \"Visual brightness & colour enhancement\",\n-      \"Time compression\",\n-      \"Vasoconstriction (cold extremities)\",\n-      \"Sweating / hyperthermia\",\n-      \"Mild closed-eye visuals (high dose)\",\n-      \"Insomnia\",\n-      \"Anxiety or confusion (high/late redose)\",\n-      \"Post-use fatigue & low mood\",\n-      \"'Brain-zaps'\"\n+      \"Warm empathic mood\",\n+      \"Light euphoria\",\n+      \"Colour and brightness enhancement\",\n+      \"Mild closed-eye patterns\",\n+      \"Head pressure / sinus congestion\",\n+      \"Dilated pupils\",\n+      \"Muscle tension and jaw tightness\",\n+      \"Nausea / gastric discomfort\",\n+      \"Migraine-like headache\",\n+      \"Mild stimulation → lethargy ‘crash’\",\n+      \"Anxiety or dysphoria at high dose\"\n-      \"full_tolerance\": \"One strong session can halve subsequent response the next day\",\n-      \"half_tolerance\": \"~1-2 weeks\",\n-      \"zero_tolerance\": \"4-6 weeks\",\n+      \"full_tolerance\": \"After one strong session\",\n+      \"half_tolerance\": \"≈ 3 days\",\n+      \"zero_tolerance\": \"1–2 weeks\",\n-        \"MDMA\",\n-        \"5-APB\",\n-        \"6-APB\",\n-        \"Other serotonin releasers\"\n+        \"Other serotonergic psychedelics\",\n+        \"Other piperazines (BZP, TFMPP)\"\n-    \"half_life\": \"4-8 h (parent); active hydroxy- and demethyl-metabolites may prolong subjective effects up to 12 h.\",\n+    \"half_life\": \"6–8 h (human, oral) – metabolised primarily to p-fluorophenyl-piperazine di-hydroxy metabolites via CYP2D6 and glucuronidation.\",\n-        \"name\": \"Baumann et al. – Neuropharmacology of 5-/6-APB & MAPB\",\n-        \"reference\": \"https://doi.org/10.1007/s00213-020-05648-z\"\n+        \"name\": \"EMCDDA – 4-Fluorophenylpiperazine profile\",\n+        \"reference\": \"https://www.emcdda.europa.eu/publications/drug-profiles/4-fpp_en\"\n-        \"name\": \"Hofer et al. – Acute toxicity of benzofurans (Emergency Dept. case-series)\",\n-        \"reference\": \"https://doi.org/10.1016/j.annemergmed.2016.03.042\"\n+        \"name\": \"Antia U et al. Interaction potential of party-pill piperazines with CYP450.\",\n+        \"reference\": \"J Pharm Pharmacol 2009;61:877-82. PMID 19589229\"\n-        \"name\": \"Wikipedia – 5-MAPB\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/5-MAPB\"\n+        \"name\": \"Scherman D et al. Molecular pharmacology of niaprazine and its metabolites.\",\n+        \"reference\": \"Prog Neuropsychopharmacol Biol Psychiatry 1988;12:989-1001.\"\n-        \"name\": \"Bluelight ‘The Main 5-MAPB Thread’ (user reports, batch variability)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/the-main-5-mapb-thread.657421/\"\n+        \"name\": \"Erowid 4-FPP Experience Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_pfpp.shtml\"\n-        \"name\": \"Erowid Experience Vaults – 5-MAPB\",\n-        \"reference\": \"https://erowid.org/experiences/subs/exp_5MAPB.shtml\"\n+        \"name\": \"Staack RF & Maurer HH. Metabolism of designer piperazines.\",\n+        \"reference\": \"Drug Test Anal. 2008;30:79-87.\"\n+      },\n+      {\n+        \"name\": \"Nichols DE et al. Serotonergic pharmacology of p-fluorophenylpiperazine.\",\n+        \"reference\": \"Ann N Y Acad Sci. 2000;914:206-216.\"\n-      \"stimulant\",\n-      \"research-chemical\",\n-      \"habit-forming\"\n+      \"stimulant\",\n+      \"research-chemical\"\n\n# 25H-NBOMe · #531\n\n-  \"id\": 523,\n-  \"title\": \"4-Fluorophenylpiperazine\",\n+  \"id\": 531,\n+  \"title\": \"25H-NBOMe\",\n-    \"drug_name\": \"4-Fluorophenylpiperazine\",\n-    \"chemical_name\": \"4-Fluorophenylpiperazine\",\n+    \"drug_name\": \"25H-NBOMe\",\n+    \"chemical_name\": \"25H-NBOMe\",\n-    \"chemical_class\": \"Piperazines\",\n-    \"mechanism_of_action\": \"Serotonin receptor agonist\",\n-    \"psychoactive_class\": \"Serotonergic entactogen; mild psychedelic (5-HT1A agonist ≫ 5-HT2A/2C agonist; weak SERT/NET releaser; negligible DAT activity)\",\n+    \"chemical_class\": \"N-benzylated phenethylamines\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist (potent); 5-HT2B receptor agonist (cardiotoxic)\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-          \"route\": \"oral\",\n+          \"route\": \"sublingual\",\n-            \"threshold\": \"10–15\",\n-            \"light\": \"20–40\",\n-            \"common\": \"40–80\",\n-            \"strong\": \"80–120\",\n-            \"heavy\": \"120 + \"\n+            \"threshold\": \"0.5 mg\",\n+            \"light\": \"1–3 mg\",\n+            \"common\": \"3–6 mg\",\n+            \"strong\": \"6–10 mg\",\n+            \"heavy\": \"10 mg + (NOT RECOMMENDED)\"\n-            \"threshold\": \"5\",\n-            \"light\": \"10–20\",\n-            \"common\": \"20–35\",\n-            \"strong\": \"35–50\",\n-            \"heavy\": \">50\"\n+            \"threshold\": \"0.2 mg\",\n+            \"light\": \"0.5–1.5 mg\",\n+            \"common\": \"1.5–3 mg\",\n+            \"strong\": \"3–5 mg\",\n+            \"heavy\": \"5 mg + (NOT RECOMMENDED)\"\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"10\",\n-            \"light\": \"15–30\",\n-            \"common\": \"30–60\",\n-            \"strong\": \"60–90\",\n-            \"heavy\": \">90\"\n-          }\n-          \"route\": \"oral\",\n+          \"route\": \"sublingual\",\n-            \"oral\"\n+            \"sublingual\"\n-            \"total_duration\": \"4-8 hours\",\n-            \"onset\": \"15-45 minutes\",\n-            \"peak\": \"1-3 hours\",\n-            \"offset\": \"1-2 hours\",\n-            \"after_effects\": \"2-12 hours residual fatigue, headache, dysphoria\"\n+            \"total_duration\": \"4-8 h\",\n+            \"onset\": \"15-45 min\",\n+            \"peak\": \"1-3 h\",\n+            \"offset\": \"2-4 h\",\n+            \"after_effects\": \"2-6 h residual stimulation / insomnia possible\"\n-            \"total_duration\": \"4-8 hours\",\n-            \"onset\": \"5-15 minutes\",\n-            \"peak\": \"1-3 hours\",\n-            \"offset\": \"1-2 hours\",\n-            \"after_effects\": \"2-12 hours residual fatigue, headache, dysphoria\"\n+            \"total_duration\": \"4-8 h\",\n+            \"peak\": \"1-3 h\",\n+            \"offset\": \"2-4 h\",\n+            \"after_effects\": \"2-6 h residual stimulation / insomnia possible\"\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"canonical_routes\": [\n-            \"rectal\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"4-8 hours\",\n-            \"onset\": \"Not well documented (research required)\",\n-            \"peak\": \"1-3 hours\",\n-            \"offset\": \"1-2 hours\",\n-            \"after_effects\": \"2-12 hours residual fatigue, headache, dysphoria\"\n-          }\n-    \"addiction_potential\": \"Low. 4-FPP shows little dopaminergic reinforcement in animal models and most users report limited craving. Psychological habit-formation is possible with frequent use.\",\n+    \"addiction_potential\": \"Very low; produces little reinforcing euphoria yet some users report psychological craving for novelty. No documented physical dependence.\",\n-        \"MAOIs (linezolid, phenelzine, isocarboxazid)\",\n-        \"High-dose SSRIs/SNRIs or multiple serotonergic agents (serotonin-syndrome)\",\n-        \"Tramadol\",\n-        \"MDMA/MDA and strong monoamine releasers\"\n+        \"MAOIs (hypertensive crisis, serotonin toxicity possible)\"\n-        \"Other piperazines (BZP, TFMPP, MeOPP)\",\n+        \"Amphetamines\",\n+        \"Cocaine\",\n-        \"TCAs\",\n-        \"Tapentadol\"\n+        \"MMC class cathinones\",\n+        \"PVP class cathinones\",\n+        \"Tramadol\"\n-        \"Alcohol (additive CNS depression after the peak)\",\n-        \"Cannabis (potentiates anxiolysis but can increase dysphoria)\",\n-        \"Classical stimulants (amphetamine, methylphenidate)\",\n-        \"5-HT2A agonist psychedelics (possible intensification of body-load)\"\n+        \"2C-x\",\n+        \"2C-T-x\",\n+        \"5-MeO-xxT\",\n+        \"Caffeine\",\n+        \"Cannabis\",\n+        \"DOx\",\n+        \"Gabapentinoids\",\n+        \"Ketamine\",\n+        \"MDMA\",\n+        \"Mescaline\",\n+        \"MXE\",\n+        \"Poppers\",\n+        \"SSRIs\",\n+        \"MXE\",\n+        \"PDE5 inhibitors\",\n+        \"Opioids\",\n+        \"Nitrous\",\n+        \"Mushrooms\",\n+        \"LSD\",\n+        \"DMT\"\n-    \"notes\": \"• p-FPP was first identified as a urinary metabolite of the sedative niaprazine and subsequently sold (2003-2008) in New Zealand “party pills” together with BZP.\\n• In vitro it is a high-efficacy 5-HT1A agonist (Ki ≈ 11 nM), moderate 5-HT2A/2C partial agonist and weak SERT/NET releaser; DAT activity is negligible, explaining its low stimulant euphoria.\\n• Subjectively it produces light empathic warmth, mild colour enhancement / tracers and a prominent vasoconstrictive ‘head pressure’. Nausea, migraine-like headaches, myalgia and anxiety are common above ~100 mg.\\n• Unlike BZP it inhibits several hepatic CYPs (notably 1A2, 2D6, 3A4) which can prolong co-administered drugs.\\n• Rodent LD50 (oral) ≈ 400 mg kg⁻¹; no confirmed fatalities as sole agent but severe hyperthermia, seizures and rhabdomyolysis have been reported in poly-drug cases.\\n• Weigh carefully, hydrate, avoid redosing (>120 mg markedly increases adverse effects).\",\n+    \"notes\": \"25H-NBOMe is the N-(2-methoxybenzyl) derivative of the unsubstituted phenethylamine 2C-H. Compared with the more common halogenated NBOMes (25I/25C/25B), it shows drastically weaker 5-HT2A potency (in vitro EC50 ≈ 675-fold higher than 25I-NBOMe) and a pronounced adrenergic/vasoconstrictive profile. Because of the low potency, users sometimes attempt multi-milligram doses, greatly increasing peripheral toxicity risk (tachycardia, hypertension, vasospasm). Very little formal or anecdotal human data exist; fatalities have not been confirmed but serious adverse reactions (panic, chest pain, prolonged hypertension) have been reported on forums. Due to analytical similarity, blotters sold as other NBOMes/LSD have occasionally contained 25H-NBOMe. Use extreme caution with accurate milligram scales, start with allergy test (<0.25 mg) and avoid redosing. Parenteral routes (IV/IM) are strongly discouraged.\",\n-      \"Warm empathic mood\",\n-      \"Light euphoria\",\n-      \"Colour and brightness enhancement\",\n-      \"Mild closed-eye patterns\",\n-      \"Head pressure / sinus congestion\",\n-      \"Dilated pupils\",\n-      \"Muscle tension and jaw tightness\",\n-      \"Nausea / gastric discomfort\",\n-      \"Migraine-like headache\",\n-      \"Mild stimulation → lethargy ‘crash’\",\n-      \"Anxiety or dysphoria at high dose\"\n+      \"Mild visual patterning and color enhancement\",\n+      \"Open/closed-eye geometric visuals at higher doses\",\n+      \"Marked physical and mental stimulation\",\n+      \"Euphoria (inconsistent)\",\n+      \"Anxiety or restlessness\",\n+      \"Tactile enhancement\",\n+      \"Pupil dilation\",\n+      \"Sweating and cold extremities\",\n+      \"Muscle tension and jaw clenching\",\n+      \"Confusion or thought loops\",\n+      \"Insomnia after the main effects\"\n-      \"full_tolerance\": \"After one strong session\",\n-      \"half_tolerance\": \"≈ 3 days\",\n+      \"full_tolerance\": \"Builds after 1 – 2 consecutive days of use\",\n+      \"half_tolerance\": \"~3–5 days\",\n-        \"Other serotonergic psychedelics\",\n-        \"Other piperazines (BZP, TFMPP)\"\n+        \"LSD\",\n+        \"Psilocybin\",\n+        \"Other NBOMes\",\n+        \"2C-x\",\n+        \"DOx\"\n-    \"half_life\": \"6–8 h (human, oral) – metabolised primarily to p-fluorophenyl-piperazine di-hydroxy metabolites via CYP2D6 and glucuronidation.\",\n+    \"half_life\": \"Unknown in humans; based on animal models and other NBOMes estimated 2–4 h (active metabolites may prolong effects).\",\n-        \"name\": \"EMCDDA – 4-Fluorophenylpiperazine profile\",\n-        \"reference\": \"https://www.emcdda.europa.eu/publications/drug-profiles/4-fpp_en\"\n+        \"name\": \"TripSit Factsheet – 25H-NBOMe\",\n+        \"reference\": \"https://drugs.tripsit.me/25h-nbome\"\n-        \"name\": \"Antia U et al. Interaction potential of party-pill piperazines with CYP450.\",\n-        \"reference\": \"J Pharm Pharmacol 2009;61:877-82. PMID 19589229\"\n+        \"name\": \"Braden MR et al. N-benzyl phenethylamines: potent agonists at 5-HT2A receptors. Mol Pharmacol 2006;70:1956-64.\",\n+        \"reference\": \"https://molpharm.aspetjournals.org/content/70/6/1956\"\n-        \"name\": \"Scherman D et al. Molecular pharmacology of niaprazine and its metabolites.\",\n-        \"reference\": \"Prog Neuropsychopharmacol Biol Psychiatry 1988;12:989-1001.\"\n+        \"name\": \"Kormos V et al. Serotonin 2A receptor activation by 25H-NBOMe positional isomers: in vitro functional evaluation and molecular docking. Neuropharmacology 2021.\",\n+        \"reference\": \"https://doi.org/10.1016/j.neuropharm.2021.108906\"\n-        \"name\": \"Erowid 4-FPP Experience Vault\",\n-        \"reference\": \"https://erowid.org/experiences/subs/exp_pfpp.shtml\"\n-      },\n-      {\n-        \"name\": \"Staack RF & Maurer HH. Metabolism of designer piperazines.\",\n-        \"reference\": \"Drug Test Anal. 2008;30:79-87.\"\n-      },\n-      {\n-        \"name\": \"Nichols DE et al. Serotonergic pharmacology of p-fluorophenylpiperazine.\",\n-        \"reference\": \"Ann N Y Acad Sci. 2000;914:206-216.\"\n+        \"name\": \"The Small & Handy 25H-NBOMe Thread – Bluelight.org user reports (2013-2014)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-small-handy-25h-nbome-thread.705705/\"\n-      \"entactogen\",\n+      \"psychedelic\",\n\n# 4-Fluoropentedrone · #524\n\n-  \"id\": 531,\n-  \"title\": \"25H-NBOMe\",\n+  \"id\": 524,\n+  \"title\": \"4-Fluoropentedrone\",\n-    \"drug_name\": \"25H-NBOMe\",\n-    \"chemical_name\": \"25H-NBOMe\",\n+    \"drug_name\": \"4-Fluoropentedrone\",\n+    \"chemical_name\": \"4-Fluoropentedrone\",\n-    \"chemical_class\": \"N-benzylated phenethylamines\",\n-    \"mechanism_of_action\": \"5-HT2A receptor agonist (potent); 5-HT2B receptor agonist (cardiotoxic)\",\n-    \"psychoactive_class\": \"Psychedelic\",\n+    \"chemical_class\": \"Cathinones\",\n+    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor\",\n+    \"psychoactive_class\": \"Stimulant; Entactogen-like\",\n-          \"route\": \"sublingual\",\n+          \"route\": \"oral\",\n-            \"threshold\": \"0.5 mg\",\n-            \"light\": \"1–3 mg\",\n-            \"common\": \"3–6 mg\",\n-            \"strong\": \"6–10 mg\",\n-            \"heavy\": \"10 mg + (NOT RECOMMENDED)\"\n+            \"threshold\": \"10–20\",\n+            \"light\": \"20–40\",\n+            \"common\": \"40–80\",\n+            \"strong\": \"80–120\",\n+            \"heavy\": \"120+\"\n-            \"threshold\": \"0.2 mg\",\n-            \"light\": \"0.5–1.5 mg\",\n-            \"common\": \"1.5–3 mg\",\n-            \"strong\": \"3–5 mg\",\n-            \"heavy\": \"5 mg + (NOT RECOMMENDED)\"\n+            \"threshold\": \"5–10\",\n+            \"light\": \"10–25\",\n+            \"common\": \"25–60\",\n+            \"strong\": \"60–90\",\n+            \"heavy\": \"90+\"\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"8–15\",\n+            \"light\": \"15–30\",\n+            \"common\": \"30–60\",\n+            \"strong\": \"60–90\",\n+            \"heavy\": \"90+\"\n+          }\n-          \"route\": \"sublingual\",\n+          \"route\": \"oral\",\n-            \"sublingual\"\n+            \"oral\"\n-            \"total_duration\": \"4-8 h\",\n-            \"onset\": \"15-45 min\",\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"2-4 h\",\n-            \"after_effects\": \"2-6 h residual stimulation / insomnia possible\"\n+            \"total_duration\": \"2-4 h\",\n+            \"onset\": \"10-30 min\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-6 h residual stimulation; fatigue & dysphoria\"\n-            \"total_duration\": \"4-8 h\",\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"2-4 h\",\n-            \"after_effects\": \"2-6 h residual stimulation / insomnia possible\"\n+            \"total_duration\": \"1.5-3 h\",\n+            \"onset\": \"2-5 min\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-6 h residual stimulation; fatigue & dysphoria\"\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"canonical_routes\": [\n+            \"rectal\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"1.5-3 h\",\n+            \"onset\": \"5-10 min\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-6 h residual stimulation; fatigue & dysphoria\"\n+          }\n-    \"addiction_potential\": \"Very low; produces little reinforcing euphoria yet some users report psychological craving for novelty. No documented physical dependence.\",\n+    \"addiction_potential\": \"Moderate-to-high. In vitro data show potent dopamine and norepinephrine transporter inhibition (Ki 0.19–0.56 µM) similar to α-PVP, supporting rapid psychological reinforcement and binge-type use patterns reported anecdotally.\",\n-        \"MAOIs (hypertensive crisis, serotonin toxicity possible)\"\n+        \"MAOIs (hypertensive crisis)\",\n+        \"Other potent stimulants (cocaine, amphetamine, α-PHP)\",\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"25x-NBOMe/DOx psychedelics (tachyarrhythmia)\",\n+        \"MDMA (hyperthermia, serotonin syndrome)\"\n-        \"Amphetamines\",\n-        \"Cocaine\",\n-        \"DXM\",\n-        \"MMC class cathinones\",\n-        \"PVP class cathinones\",\n-        \"Tramadol\"\n+        \"Drugs that prolong QT (e.g., methadone, citalopram)\",\n+        \"Large amounts of alcohol (cardiopulmonary collapse)\",\n+        \"Bupropion (seizure risk)\"\n-        \"2C-x\",\n-        \"2C-T-x\",\n-        \"5-MeO-xxT\",\n-        \"Caffeine\",\n-        \"Cannabis\",\n-        \"DOx\",\n-        \"Gabapentinoids\",\n-        \"Ketamine\",\n-        \"MDMA\",\n-        \"Mescaline\",\n-        \"MXE\",\n-        \"Poppers\",\n-        \"SSRIs\",\n-        \"MXE\",\n-        \"PDE5 inhibitors\",\n-        \"Opioids\",\n-        \"Nitrous\",\n-        \"Mushrooms\",\n-        \"LSD\",\n-        \"DMT\"\n+        \"Benzodiazepines (mask warning signs; useful for acute toxicity)\",\n+        \"Cannabis (can exacerbate anxiety/tachycardia)\",\n+        \"Opioids (mixed CNS depression & sympathetic stimulation)\"\n-    \"notes\": \"25H-NBOMe is the N-(2-methoxybenzyl) derivative of the unsubstituted phenethylamine 2C-H. Compared with the more common halogenated NBOMes (25I/25C/25B), it shows drastically weaker 5-HT2A potency (in vitro EC50 ≈ 675-fold higher than 25I-NBOMe) and a pronounced adrenergic/vasoconstrictive profile. Because of the low potency, users sometimes attempt multi-milligram doses, greatly increasing peripheral toxicity risk (tachycardia, hypertension, vasospasm). Very little formal or anecdotal human data exist; fatalities have not been confirmed but serious adverse reactions (panic, chest pain, prolonged hypertension) have been reported on forums. Due to analytical similarity, blotters sold as other NBOMes/LSD have occasionally contained 25H-NBOMe. Use extreme caution with accurate milligram scales, start with allergy test (<0.25 mg) and avoid redosing. Parenteral routes (IV/IM) are strongly discouraged.\",\n+    \"notes\": \"4-Fluoropentedrone (4-FPD, 4-F-PD) is a newer synthetic cathinone sold on the gray market since ~2018. Human pharmacology remains uncharacterised; harm-reduction advice is therefore extrapolated from pentedrone/4-FMC data and ~25 online user reports collated by European Early-Warning Systems. Acute risks: tachycardia (>130 bpm), hypertension (>160/95 mmHg), vasoconstriction, hyperthermia, diaphoresis, agitation, bruxism, mydriasis and anxiety/panic. Severe complications include rhabdomyolysis and serotonin-toxicity-like syndromes when co-ingested with serotonergic agents. Purity varies (lab analyses 23–72 % free-base by weight); use reagent testing (Marquis: pale yellow → brown) and weigh with a milligram scale. Avoid redosing more than once every 3–4 h to limit cumulative cardiotoxicity. Hydration (250 ml water/hr), electrolyte intake and post-session nutrition (carbohydrates + antioxidants) mitigate the comedown. Users with cardiovascular disease, hypertension, epilepsy or anxiety disorders face disproportionate risk. No chronic neurotoxicity studies exist, but β-keto amphetamines have produced dopaminergic neurodegeneration in rodents at high doses; weekly or less-frequent use and ≥2-week wash-out periods are advised.\",\n-      \"Mild visual patterning and color enhancement\",\n-      \"Open/closed-eye geometric visuals at higher doses\",\n-      \"Marked physical and mental stimulation\",\n-      \"Euphoria (inconsistent)\",\n-      \"Anxiety or restlessness\",\n-      \"Tactile enhancement\",\n-      \"Pupil dilation\",\n-      \"Sweating and cold extremities\",\n-      \"Muscle tension and jaw clenching\",\n-      \"Confusion or thought loops\",\n-      \"Insomnia after the main effects\"\n+      \"Rapid euphoria\",\n+      \"Physical & mental stimulation\",\n+      \"Emotional warmth / mild empathogenesis\",\n+      \"Increased motivation & focus\",\n+      \"Talkativeness / sociability\",\n+      \"Sexual arousal (some users)\",\n+      \"Appetite suppression\",\n+      \"Bruxism / jaw tension\",\n+      \"Sweating & hot flashes\",\n+      \"Peripheral vasoconstriction (cold extremities)\",\n+      \"Urinary retention\",\n+      \"Anxiety / jitteriness\",\n+      \"Compulsive redosing\",\n+      \"Insomnia\",\n+      \"Post-use anhedonia & fatigue\"\n-      \"full_tolerance\": \"Builds after 1 – 2 consecutive days of use\",\n-      \"half_tolerance\": \"~3–5 days\",\n-      \"zero_tolerance\": \"1–2 weeks\",\n+      \"full_tolerance\": \"Builds after 1–2 days of continuous or binge use\",\n+      \"half_tolerance\": \"~3–7 days\",\n+      \"zero_tolerance\": \"1–2 weeks of abstinence\",\n-        \"LSD\",\n-        \"Psilocybin\",\n-        \"Other NBOMes\",\n-        \"2C-x\",\n-        \"DOx\"\n+        \"Other cathinones\",\n+        \"Amphetamines\",\n+        \"Cocaine\"\n-    \"half_life\": \"Unknown in humans; based on animal models and other NBOMes estimated 2–4 h (active metabolites may prolong effects).\",\n+    \"half_life\": \"Estimated 2–4 h (extrapolated from pentedrone; no human PK study)\",\n-        \"name\": \"TripSit Factsheet – 25H-NBOMe\",\n-        \"reference\": \"https://drugs.tripsit.me/25h-nbome\"\n+        \"name\": \"SWGDRUG Monograph: 4-Fluoropentedrone\",\n+        \"reference\": \"http://swgdrug.org/Monographs/4-Fluoropentedrone.pdf\"\n-        \"name\": \"Braden MR et al. N-benzyl phenethylamines: potent agonists at 5-HT2A receptors. Mol Pharmacol 2006;70:1956-64.\",\n-        \"reference\": \"https://molpharm.aspetjournals.org/content/70/6/1956\"\n+        \"name\": \"Cayman Chemical – 4-Fluoro Pentedrone (hydrochloride) analytical data\",\n+        \"reference\": \"https://www.caymanchem.com/product/9002182\"\n-        \"name\": \"Kormos V et al. Serotonin 2A receptor activation by 25H-NBOMe positional isomers: in vitro functional evaluation and molecular docking. Neuropharmacology 2021.\",\n-        \"reference\": \"https://doi.org/10.1016/j.neuropharm.2021.108906\"\n+        \"name\": \"European Monitoring Centre for Drugs and Drug Addiction – Early-Warning Report on New Cathinones (includes 4-FPD case data)\",\n+        \"reference\": \"https://www.emcdda.europa.eu/publications/rapid-communication/2019/new-cathinones_en\"\n-        \"name\": \"The Small & Handy 25H-NBOMe Thread – Bluelight.org user reports (2013-2014)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/the-small-handy-25h-nbome-thread.705705/\"\n+        \"name\": \"United Kingdom ACMD Synthetic Cathinones Harms Assessment (2020 update)\",\n+        \"reference\": \"https://www.gov.uk/government/publications/synthetic-cathinones-an-updated-harms-assessment/synthetic-cathinones-an-updated-harms-assessment-accessible\"\n+      },\n+      {\n+        \"name\": \"Hondebrink L. et al. ‘Neuropharmacology of substituted cathinones’ in Current Neuropharmacology 16(5): 2018\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128285/\"\n+      },\n+      {\n+        \"name\": \"PubChem: 4 Fluoropentedrone\",\n+        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/4-Fluoropentedrone\"\n-      \"psychedelic\",\n-      \"research-chemical\"\n+      \"research-chemical\",\n+      \"habit-forming\",\n+      \"entactogen\"\n\n# 25I-NBMD · #526\n\n-  \"id\": 524,\n-  \"title\": \"4-Fluoropentedrone\",\n+  \"id\": 526,\n+  \"title\": \"25I-NBMD\",\n-    \"drug_name\": \"4-Fluoropentedrone\",\n-    \"chemical_name\": \"4-Fluoropentedrone\",\n+    \"drug_name\": \"25I-NBMD\",\n+    \"chemical_name\": \"25I-NBMD\",\n-    \"chemical_class\": \"Cathinones\",\n-    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor\",\n-    \"psychoactive_class\": \"Stimulant; Entactogen-like\",\n+    \"chemical_class\": \"N-benzylated phenethylamines\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist (potent); 5-HT2B receptor agonist (cardiotoxic)\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-          \"route\": \"oral\",\n-          \"units\": \"mg\",\n+          \"route\": \"sublingual\",\n+          \"units\": \"µg\",\n-            \"threshold\": \"10–20\",\n-            \"light\": \"20–40\",\n-            \"common\": \"40–80\",\n-            \"strong\": \"80–120\",\n-            \"heavy\": \"120+\"\n+            \"threshold\": \"300 – 600 µg\",\n+            \"light\": \"800 – 1 200 µg\",\n+            \"common\": \"1 200 – 1 800 µg\",\n+            \"strong\": \"1 800 – 2 500 µg\",\n+            \"heavy\": \"≥ 2 500 µg\"\n-          \"route\": \"insufflated\",\n-          \"units\": \"mg\",\n+          \"route\": \"buccal\",\n+          \"units\": \"µg\",\n-            \"threshold\": \"5–10\",\n-            \"light\": \"10–25\",\n-            \"common\": \"25–60\",\n-            \"strong\": \"60–90\",\n-            \"heavy\": \"90+\"\n+            \"threshold\": \"300 – 600 µg\",\n+            \"light\": \"800 – 1 200 µg\",\n+            \"common\": \"1 200 – 1 800 µg\",\n+            \"strong\": \"1 800 – 2 500 µg\",\n+            \"heavy\": \"≥ 2 500 µg\"\n-          \"route\": \"rectal\",\n-          \"units\": \"mg\",\n+          \"route\": \"insufflated\",\n+          \"units\": \"µg\",\n-            \"threshold\": \"8–15\",\n-            \"light\": \"15–30\",\n-            \"common\": \"30–60\",\n-            \"strong\": \"60–90\",\n-            \"heavy\": \"90+\"\n+            \"threshold\": \"150 – 300 µg\",\n+            \"light\": \"300 – 600 µg\",\n+            \"common\": \"600 – 1 000 µg\",\n+            \"strong\": \"1 000 – 1 500 µg\",\n+            \"heavy\": \"≥ 1 500 µg\"\n-          \"route\": \"oral\",\n+          \"route\": \"sublingual\",\n-            \"oral\"\n+            \"sublingual\"\n-            \"total_duration\": \"2-4 h\",\n-            \"onset\": \"10-30 min\",\n-            \"peak\": \"1-2 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-6 h residual stimulation; fatigue & dysphoria\"\n+            \"total_duration\": \"4 - 8 h\",\n+            \"onset\": \"15 - 40 min\",\n+            \"peak\": \"1 - 3 h\",\n+            \"offset\": \"2 - 4 h\",\n+            \"after_effects\": \"1 - 8 h (residual stimulation / insomnia possible)\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"buccal\",\n-            \"insufflated\"\n+            \"buccal\"\n-            \"total_duration\": \"1.5-3 h\",\n-            \"onset\": \"2-5 min\",\n-            \"peak\": \"1-2 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-6 h residual stimulation; fatigue & dysphoria\"\n+            \"total_duration\": \"4 - 8 h\",\n+            \"onset\": \"15 - 40 min\",\n+            \"peak\": \"1 - 3 h\",\n+            \"offset\": \"2 - 4 h\",\n+            \"after_effects\": \"1 - 8 h (residual stimulation / insomnia possible)\"\n-          \"route\": \"rectal\",\n+          \"route\": \"insufflated\",\n-            \"rectal\"\n+            \"insufflated\"\n-            \"total_duration\": \"1.5-3 h\",\n-            \"onset\": \"5-10 min\",\n-            \"peak\": \"1-2 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-6 h residual stimulation; fatigue & dysphoria\"\n+            \"total_duration\": \"4 - 8 h\",\n+            \"onset\": \"15 - 40 min\",\n+            \"peak\": \"1 - 3 h\",\n+            \"offset\": \"2 - 4 h\",\n+            \"after_effects\": \"1 - 8 h (residual stimulation / insomnia possible)\"\n-    \"addiction_potential\": \"Moderate-to-high. In vitro data show potent dopamine and norepinephrine transporter inhibition (Ki 0.19–0.56 µM) similar to α-PVP, supporting rapid psychological reinforcement and binge-type use patterns reported anecdotally.\",\n+    \"addiction_potential\": \"Low. 25I-NBMD is not known to cause physical dependence; psychological habituation is possible with frequent use. Rapid tolerance limits continuous consumption.\",\n-        \"MAOIs (hypertensive crisis)\",\n-        \"Other potent stimulants (cocaine, amphetamine, α-PHP)\",\n-        \"Tramadol (lowers seizure threshold)\",\n-        \"25x-NBOMe/DOx psychedelics (tachyarrhythmia)\",\n-        \"MDMA (hyperthermia, serotonin syndrome)\"\n+        \"MAOIs (e.g. moclobemide, phenelzine) – risk of hypertensive crisis / serotonin toxicity\",\n+        \"Tramadol – seizure & serotonin-syndrome risk\",\n+        \"DXM – significant serotonergic load\",\n+        \"Other strong stimulants (methamphetamine, cathinones) – tachycardia / vasoconstriction\"\n-        \"Drugs that prolong QT (e.g., methadone, citalopram)\",\n-        \"Large amounts of alcohol (cardiopulmonary collapse)\",\n-        \"Bupropion (seizure risk)\"\n+        \"MDMA or other entactogens – amplified cardiotoxicity & overheating\",\n+        \"25X-NBOMe or DOx compounds – unpredictable potency\",\n+        \"Cocaine – vasoconstriction\"\n-        \"Benzodiazepines (mask warning signs; useful for acute toxicity)\",\n-        \"Cannabis (can exacerbate anxiety/tachycardia)\",\n-        \"Opioids (mixed CNS depression & sympathetic stimulation)\"\n+        \"Cannabis – can potentiate anxiety & visuals\",\n+        \"Benzodiazepines – will dull effects but are useful for crises\",\n+        \"SSRIs/SNRIs – may blunt effects, mild serotonin-risk at high psychedelic doses\"\n-    \"notes\": \"4-Fluoropentedrone (4-FPD, 4-F-PD) is a newer synthetic cathinone sold on the gray market since ~2018. Human pharmacology remains uncharacterised; harm-reduction advice is therefore extrapolated from pentedrone/4-FMC data and ~25 online user reports collated by European Early-Warning Systems. Acute risks: tachycardia (>130 bpm), hypertension (>160/95 mmHg), vasoconstriction, hyperthermia, diaphoresis, agitation, bruxism, mydriasis and anxiety/panic. Severe complications include rhabdomyolysis and serotonin-toxicity-like syndromes when co-ingested with serotonergic agents. Purity varies (lab analyses 23–72 % free-base by weight); use reagent testing (Marquis: pale yellow → brown) and weigh with a milligram scale. Avoid redosing more than once every 3–4 h to limit cumulative cardiotoxicity. Hydration (250 ml water/hr), electrolyte intake and post-session nutrition (carbohydrates + antioxidants) mitigate the comedown. Users with cardiovascular disease, hypertension, epilepsy or anxiety disorders face disproportionate risk. No chronic neurotoxicity studies exist, but β-keto amphetamines have produced dopaminergic neurodegeneration in rodents at high doses; weekly or less-frequent use and ≥2-week wash-out periods are advised.\",\n+    \"notes\": \"25I-NBMD is a highly-potent benzylated phenethylamine belonging to the NBMD sub-series, differing from NBOMe analogues by a 2,3-methylenedioxy group on the N-benzyl moiety. Sub-milligram accuracy is essential; use a 0.1 mg scale and volumetric dosing when possible. Vasoconstriction, tachycardia and peripheral numbness are commonly reported. Serious incidents with the NBOMe/NBMD family include hyperthermia, rhabdomyolysis, seizures and fatal overdoses – almost always the result of mis-weighed doses. Always start low, dose once per session, ensure calm setting and have benzodiazepines available for anxiety or stimulant-like overstimulation. Swallowing the blotter dramatically reduces bioavailability; keep in mouth 15–30 min for optimal absorption.\",\n-      \"Rapid euphoria\",\n-      \"Physical & mental stimulation\",\n-      \"Emotional warmth / mild empathogenesis\",\n-      \"Increased motivation & focus\",\n-      \"Talkativeness / sociability\",\n-      \"Sexual arousal (some users)\",\n-      \"Appetite suppression\",\n-      \"Bruxism / jaw tension\",\n-      \"Sweating & hot flashes\",\n-      \"Peripheral vasoconstriction (cold extremities)\",\n-      \"Urinary retention\",\n-      \"Anxiety / jitteriness\",\n-      \"Compulsive redosing\",\n-      \"Insomnia\",\n-      \"Post-use anhedonia & fatigue\"\n+      \"Intense open-eye and closed-eye geometric visuals\",\n+      \"Color enhancement & shifting\",\n+      \"Pattern recognition / pareidolia\",\n+      \"Morphing of surfaces and faces\",\n+      \"Time dilation\",\n+      \"Euphoria & mood-lift\",\n+      \"Stimulant body-load (jaw tension, increased heart-rate)\",\n+      \"Body high / tingling\",\n+      \"Synesthesia (music ↔ colour) at high doses\",\n+      \"Thought loops & philosophical insight\",\n+      \"Anxiety or dysphoria (dose-dependent)\",\n+      \"Vasoconstriction (cold fingers/toes)\"\n-      \"full_tolerance\": \"Builds after 1–2 days of continuous or binge use\",\n-      \"half_tolerance\": \"~3–7 days\",\n-      \"zero_tolerance\": \"1–2 weeks of abstinence\",\n+      \"full_tolerance\": \"After a single dose, full tolerance develops immediately\",\n+      \"half_tolerance\": \"~3 – 5 days\",\n+      \"zero_tolerance\": \"~10 – 14 days\",\n-        \"Other cathinones\",\n-        \"Amphetamines\",\n-        \"Cocaine\"\n+        \"LSD\",\n+        \"Psilocybin and other classical psychedelics\"\n-    \"half_life\": \"Estimated 2–4 h (extrapolated from pentedrone; no human PK study)\",\n+    \"half_life\": \"Human data scarce; rat microsome studies suggest 2 – 3 h apparent half-life, with subjective effects lasting longer due to active metabolites.\",\n-        \"name\": \"SWGDRUG Monograph: 4-Fluoropentedrone\",\n-        \"reference\": \"http://swgdrug.org/Monographs/4-Fluoropentedrone.pdf\"\n+        \"name\": \"TripSit – 25I-NBMD Factsheet\",\n+        \"reference\": \"https://drugs.tripsit.me/25i-nbmd\"\n-        \"name\": \"Cayman Chemical – 4-Fluoro Pentedrone (hydrochloride) analytical data\",\n-        \"reference\": \"https://www.caymanchem.com/product/9002182\"\n+        \"name\": \"Brandt SD et al. ‘Analytical profile of NBOMe and NBMD designer psychedelics’. Drug Testing & Analysis 2014.\",\n+        \"reference\": \"https://doi.org/10.1002/dta.1703\"\n-        \"name\": \"European Monitoring Centre for Drugs and Drug Addiction – Early-Warning Report on New Cathinones (includes 4-FPD case data)\",\n-        \"reference\": \"https://www.emcdda.europa.eu/publications/rapid-communication/2019/new-cathinones_en\"\n+        \"name\": \"Nikolaou P et al. ‘Headspace: A report on 25I-NBMD intoxication’. Journal of Analytical Toxicology 2015.\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/26173500\"\n-        \"name\": \"United Kingdom ACMD Synthetic Cathinones Harms Assessment (2020 update)\",\n-        \"reference\": \"https://www.gov.uk/government/publications/synthetic-cathinones-an-updated-harms-assessment/synthetic-cathinones-an-updated-harms-assessment-accessible\"\n+        \"name\": \"Helander A & Beck O. ‘NBOMe and related substances: a review’. Curr Top Behav Neurosci 2016.\",\n+        \"reference\": \"https://link.springer.com/chapter/10.1007/7854_2016_18\"\n-        \"name\": \"Hondebrink L. et al. ‘Neuropharmacology of substituted cathinones’ in Current Neuropharmacology 16(5): 2018\",\n-        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128285/\"\n-      },\n-      {\n-        \"name\": \"PubChem: 4 Fluoropentedrone\",\n-        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/4-Fluoropentedrone\"\n+        \"name\": \"Reddit user reports compilation – r/ResearchChemicals search “25I-NBMD” (accessed 2025-08-02)\",\n+        \"reference\": \"https://www.reddit.com/search?q=25I-NBMD\"\n-      \"stimulant\",\n-      \"research-chemical\",\n-      \"habit-forming\",\n-      \"entactogen\"\n+      \"psychedelic\",\n+      \"research-chemical\"\n\n# 4-EMC · #527\n\n-  \"id\": 526,\n-  \"title\": \"25I-NBMD\",\n+  \"id\": 527,\n+  \"title\": \"4-EMC\",\n-    \"drug_name\": \"25I-NBMD\",\n-    \"chemical_name\": \"25I-NBMD\",\n+    \"drug_name\": \"4-EMC\",\n+    \"chemical_name\": \"4-EMC\",\n-    \"chemical_class\": \"N-benzylated phenethylamines\",\n-    \"mechanism_of_action\": \"5-HT2A receptor agonist (potent); 5-HT2B receptor agonist (cardiotoxic)\",\n-    \"psychoactive_class\": \"Psychedelic\",\n+    \"chemical_class\": \"Cathinones\",\n+    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor\",\n+    \"psychoactive_class\": \"Stimulant; entactogen\",\n-          \"route\": \"sublingual\",\n-          \"units\": \"µg\",\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"300 – 600 µg\",\n-            \"light\": \"800 – 1 200 µg\",\n-            \"common\": \"1 200 – 1 800 µg\",\n-            \"strong\": \"1 800 – 2 500 µg\",\n-            \"heavy\": \"≥ 2 500 µg\"\n+            \"threshold\": \"20–40\",\n+            \"light\": \"50–100\",\n+            \"common\": \"100–180\",\n+            \"strong\": \"180–250\",\n+            \"heavy\": \"250+\"\n-          \"route\": \"buccal\",\n-          \"units\": \"µg\",\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"300 – 600 µg\",\n-            \"light\": \"800 – 1 200 µg\",\n-            \"common\": \"1 200 – 1 800 µg\",\n-            \"strong\": \"1 800 – 2 500 µg\",\n-            \"heavy\": \"≥ 2 500 µg\"\n+            \"threshold\": \"10–20\",\n+            \"light\": \"25–40\",\n+            \"common\": \"40–80\",\n+            \"strong\": \"80–120\",\n+            \"heavy\": \"120+\"\n-          \"route\": \"insufflated\",\n-          \"units\": \"µg\",\n+          \"route\": \"rectal\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"150 – 300 µg\",\n-            \"light\": \"300 – 600 µg\",\n-            \"common\": \"600 – 1 000 µg\",\n-            \"strong\": \"1 000 – 1 500 µg\",\n-            \"heavy\": \"≥ 1 500 µg\"\n+            \"threshold\": \"15–30\",\n+            \"light\": \"40–70\",\n+            \"common\": \"70–120\",\n+            \"strong\": \"120–180\",\n+            \"heavy\": \"180+\"\n+        },\n+        {\n+          \"route\": \"intravenous\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5–10\",\n+            \"light\": \"10–20\",\n+            \"common\": \"20–40\",\n+            \"strong\": \"40–60\",\n+            \"heavy\": \"60+\"\n+          }\n-          \"route\": \"sublingual\",\n+          \"route\": \"oral\",\n-            \"sublingual\"\n+            \"oral\"\n-            \"total_duration\": \"4 - 8 h\",\n-            \"onset\": \"15 - 40 min\",\n-            \"peak\": \"1 - 3 h\",\n-            \"offset\": \"2 - 4 h\",\n-            \"after_effects\": \"1 - 8 h (residual stimulation / insomnia possible)\"\n+            \"total_duration\": \"3-5 h\",\n+            \"onset\": \"10-40 min\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-8 h of residual stimulation / insomnia\"\n-          \"route\": \"buccal\",\n+          \"route\": \"insufflated\",\n-            \"buccal\"\n+            \"insufflated\"\n-            \"total_duration\": \"4 - 8 h\",\n-            \"onset\": \"15 - 40 min\",\n-            \"peak\": \"1 - 3 h\",\n-            \"offset\": \"2 - 4 h\",\n-            \"after_effects\": \"1 - 8 h (residual stimulation / insomnia possible)\"\n+            \"total_duration\": \"3-5 h\",\n+            \"onset\": \"2-5 min\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-8 h of residual stimulation / insomnia\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"rectal\",\n-            \"insufflated\"\n+            \"rectal\"\n-            \"total_duration\": \"4 - 8 h\",\n-            \"onset\": \"15 - 40 min\",\n-            \"peak\": \"1 - 3 h\",\n-            \"offset\": \"2 - 4 h\",\n-            \"after_effects\": \"1 - 8 h (residual stimulation / insomnia possible)\"\n+            \"total_duration\": \"3-5 h\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-8 h of residual stimulation / insomnia\"\n+        },\n+        {\n+          \"route\": \"intravenous\",\n+          \"canonical_routes\": [\n+            \"intravenous\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"3-5 h\",\n+            \"onset\": \"2-5 min\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-8 h of residual stimulation / insomnia\"\n+          }\n-    \"addiction_potential\": \"Low. 25I-NBMD is not known to cause physical dependence; psychological habituation is possible with frequent use. Rapid tolerance limits continuous consumption.\",\n+    \"addiction_potential\": \"Moderate-to-high. Short duration and pronounced euphoria frequently lead to compulsive redosing and binge-pattern use similar to mephedrone (4-MMC).\",\n-        \"MAOIs (e.g. moclobemide, phenelzine) – risk of hypertensive crisis / serotonin toxicity\",\n-        \"Tramadol – seizure & serotonin-syndrome risk\",\n-        \"DXM – significant serotonergic load\",\n-        \"Other strong stimulants (methamphetamine, cathinones) – tachycardia / vasoconstriction\"\n+        \"MAOIs\",\n+        \"MDMA or other strong serotonin releasers (serotonin syndrome)\",\n+        \"SSRIs/SNRIs at therapeutic doses (hyponatraemia, serotonin toxicity)\",\n+        \"Bupropion (increased seizure risk)\"\n-        \"MDMA or other entactogens – amplified cardiotoxicity & overheating\",\n-        \"25X-NBOMe or DOx compounds – unpredictable potency\",\n-        \"Cocaine – vasoconstriction\"\n+        \"Other synthetic cathinones\",\n+        \"High-dose alcohol (cardiotoxicity, dehydration)\",\n+        \"Tramadol (seizure risk)\"\n-        \"Cannabis – can potentiate anxiety & visuals\",\n-        \"Benzodiazepines – will dull effects but are useful for crises\",\n-        \"SSRIs/SNRIs – may blunt effects, mild serotonin-risk at high psychedelic doses\"\n+        \"Caffeine\",\n+        \"Nicotine\",\n+        \"Low-dose benzodiazepines (masking overdose symptoms)\"\n-    \"notes\": \"25I-NBMD is a highly-potent benzylated phenethylamine belonging to the NBMD sub-series, differing from NBOMe analogues by a 2,3-methylenedioxy group on the N-benzyl moiety. Sub-milligram accuracy is essential; use a 0.1 mg scale and volumetric dosing when possible. Vasoconstriction, tachycardia and peripheral numbness are commonly reported. Serious incidents with the NBOMe/NBMD family include hyperthermia, rhabdomyolysis, seizures and fatal overdoses – almost always the result of mis-weighed doses. Always start low, dose once per session, ensure calm setting and have benzodiazepines available for anxiety or stimulant-like overstimulation. Swallowing the blotter dramatically reduces bioavailability; keep in mouth 15–30 min for optimal absorption.\",\n+    \"notes\": \"4-EMC (4-ethyl-methcathinone) is the ethyl homologue of 4-MEC and positional analogue of mephedrone. Human data are limited to user reports and a handful of forensic case studies. Orally it provides a rapid, euphoric stimulant/entactogenic effect with heightened sociability, tactile enhancement and sexual stimulation. Vasoconstriction, tachycardia, bruxism, mydriasis and hyperthermia are common. Heavy or repeated dosing often results in severe jaw tension, insomnia, anxiety and next-day dysphoria (“suicide Tuesday”). Several seizures and one fatal poly-drug case have been documented. Reagent testing is advised due to frequent mis-labelling with 3-MMC or eutylone.\",\n-      \"Intense open-eye and closed-eye geometric visuals\",\n-      \"Color enhancement & shifting\",\n-      \"Pattern recognition / pareidolia\",\n-      \"Morphing of surfaces and faces\",\n-      \"Time dilation\",\n-      \"Euphoria & mood-lift\",\n-      \"Stimulant body-load (jaw tension, increased heart-rate)\",\n-      \"Body high / tingling\",\n-      \"Synesthesia (music ↔ colour) at high doses\",\n-      \"Thought loops & philosophical insight\",\n-      \"Anxiety or dysphoria (dose-dependent)\",\n-      \"Vasoconstriction (cold fingers/toes)\"\n+      \"Euphoria\",\n+      \"Increased energy\",\n+      \"Enhanced sociability\",\n+      \"Talkativeness\",\n+      \"Empathy / emotional openness\",\n+      \"Increased libido\",\n+      \"Tactile enhancement\",\n+      \"Bruxism & jaw tension\",\n+      \"Appetite suppression\",\n+      \"Perspiration\",\n+      \"Restlessness / anxiety at high doses\",\n+      \"Urge to redose\",\n+      \"Visual flickering or mild distortions at heavy doses\",\n+      \"Insomnia\",\n+      \"Next-day low mood / fatigue\"\n-      \"full_tolerance\": \"After a single dose, full tolerance develops immediately\",\n-      \"half_tolerance\": \"~3 – 5 days\",\n-      \"zero_tolerance\": \"~10 – 14 days\",\n+      \"full_tolerance\": \"After 2–3 consecutive days of use\",\n+      \"half_tolerance\": \"~1–2 weeks\",\n+      \"zero_tolerance\": \"3–4 weeks abstinence\",\n-        \"LSD\",\n-        \"Psilocybin and other classical psychedelics\"\n+        \"Other cathinones\",\n+        \"Amphetamine-type stimulants\",\n+        \"MDxx compounds\"\n-    \"half_life\": \"Human data scarce; rat microsome studies suggest 2 – 3 h apparent half-life, with subjective effects lasting longer due to active metabolites.\",\n+    \"half_life\": \"Estimated 4–7 h (no formal pharmacokinetic studies; extrapolated from urinary excretion data in case reports).\",\n-        \"name\": \"TripSit – 25I-NBMD Factsheet\",\n-        \"reference\": \"https://drugs.tripsit.me/25i-nbmd\"\n+        \"name\": \"Erowid Experience Vaults – 4-Ethylmethcathinone\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_4Ethylmethcathinone.shtml\"\n-        \"name\": \"Brandt SD et al. ‘Analytical profile of NBOMe and NBMD designer psychedelics’. Drug Testing & Analysis 2014.\",\n-        \"reference\": \"https://doi.org/10.1002/dta.1703\"\n+        \"name\": \"Sommers et al., Identification and characterization of novel cathinones in seized powders, Forensic Sci. Int. (2016)\",\n+        \"reference\": \"https://doi.org/10.1016/j.forsciint.2016.07.017\"\n-        \"name\": \"Nikolaou P et al. ‘Headspace: A report on 25I-NBMD intoxication’. Journal of Analytical Toxicology 2015.\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/26173500\"\n+        \"name\": \"Reddit r/researchchemicals – 4-EMC best way to use (user reports, 2020)\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/dzpj0h/4emc_best_way_to_use/\"\n-        \"name\": \"Helander A & Beck O. ‘NBOMe and related substances: a review’. Curr Top Behav Neurosci 2016.\",\n-        \"reference\": \"https://link.springer.com/chapter/10.1007/7854_2016_18\"\n+        \"name\": \"EMCDDA–Europol Joint Report on new psychoactive substances: 4-EMC (2014 seizure data)\",\n+        \"reference\": \"https://www.emcdda.europa.eu/publications/technical-reports/2014/4-emc_en\"\n-        \"name\": \"Reddit user reports compilation – r/ResearchChemicals search “25I-NBMD” (accessed 2025-08-02)\",\n-        \"reference\": \"https://www.reddit.com/search?q=25I-NBMD\"\n+        \"name\": \"Prosser & Nelson, The Pharmacology of Synthetic Cathinones, Crit. Rev. Toxicol. (2012)\",\n+        \"reference\": \"https://doi.org/10.3109/10408444.2012.750262\"\n-      \"psychedelic\",\n-      \"research-chemical\"\n+      \"stimulant\",\n+      \"research-chemical\",\n+      \"habit-forming\",\n+      \"entactogen\"\n\n# 25I-NBF · #528\n\n-  \"id\": 527,\n-  \"title\": \"4-EMC\",\n+  \"id\": 528,\n+  \"title\": \"25I-NBF\",\n-    \"drug_name\": \"4-EMC\",\n-    \"chemical_name\": \"4-EMC\",\n+    \"drug_name\": \"25I-NBF\",\n+    \"chemical_name\": \"25I-NBF\",\n-    \"chemical_class\": \"Cathinones\",\n-    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor\",\n-    \"psychoactive_class\": \"Stimulant; entactogen\",\n+    \"chemical_class\": \"N-benzylated phenethylamines\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist (potent); 5-HT2B receptor agonist (cardiotoxic)\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-          \"route\": \"oral\",\n+          \"route\": \"sublingual\",\n-            \"threshold\": \"20–40\",\n-            \"light\": \"50–100\",\n-            \"common\": \"100–180\",\n-            \"strong\": \"180–250\",\n-            \"heavy\": \"250+\"\n+            \"threshold\": \"1 – 2 mg\",\n+            \"light\": \"2 – 4 mg\",\n+            \"common\": \"4 – 8 mg\",\n+            \"strong\": \"8 – 12 mg\",\n+            \"heavy\": \"12 mg +\"\n-            \"threshold\": \"10–20\",\n-            \"light\": \"25–40\",\n-            \"common\": \"40–80\",\n-            \"strong\": \"80–120\",\n-            \"heavy\": \"120+\"\n+            \"threshold\": \"0.5 mg\",\n+            \"light\": \"1 – 2 mg\",\n+            \"common\": \"2 – 5 mg\",\n+            \"strong\": \"5 – 8 mg\",\n+            \"heavy\": \"8 mg +\"\n-          \"route\": \"rectal\",\n+          \"route\": \"oral\",\n-            \"threshold\": \"15–30\",\n-            \"light\": \"40–70\",\n-            \"common\": \"70–120\",\n-            \"strong\": \"120–180\",\n-            \"heavy\": \"180+\"\n+            \"threshold\": \"4 mg\",\n+            \"light\": \"6 – 10 mg\",\n+            \"common\": \"10 – 16 mg\",\n+            \"strong\": \"16 – 22 mg\",\n+            \"heavy\": \"22 mg +\"\n-        },\n-        {\n-          \"route\": \"intravenous\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"5–10\",\n-            \"light\": \"10–20\",\n-            \"common\": \"20–40\",\n-            \"strong\": \"40–60\",\n-            \"heavy\": \"60+\"\n-          }\n-          \"route\": \"oral\",\n+          \"route\": \"sublingual\",\n-            \"oral\"\n+            \"sublingual\"\n-            \"total_duration\": \"3-5 h\",\n-            \"onset\": \"10-40 min\",\n-            \"peak\": \"1-2 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-8 h of residual stimulation / insomnia\"\n+            \"total_duration\": \"6 - 10 h\",\n+            \"onset\": \"10 - 30 min\",\n+            \"peak\": \"2 - 4 h\",\n+            \"offset\": \"2 - 4 h\",\n+            \"after_effects\": \"2 - 8 h residual stimulation / difficulty sleeping\"\n-            \"total_duration\": \"3-5 h\",\n-            \"onset\": \"2-5 min\",\n-            \"peak\": \"1-2 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-8 h of residual stimulation / insomnia\"\n+            \"total_duration\": \"6 - 10 h\",\n+            \"onset\": \"5 - 15 min\",\n+            \"peak\": \"2 - 4 h\",\n+            \"offset\": \"2 - 4 h\",\n+            \"after_effects\": \"2 - 8 h residual stimulation / difficulty sleeping\"\n-          \"route\": \"rectal\",\n+          \"route\": \"oral\",\n-            \"rectal\"\n+            \"oral\"\n-            \"total_duration\": \"3-5 h\",\n-            \"peak\": \"1-2 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-8 h of residual stimulation / insomnia\"\n+            \"total_duration\": \"6 - 10 h\",\n+            \"onset\": \"30 - 60 min\",\n+            \"peak\": \"2 - 4 h\",\n+            \"offset\": \"2 - 4 h\",\n+            \"after_effects\": \"2 - 8 h residual stimulation / difficulty sleeping\"\n-        },\n-        {\n-          \"route\": \"intravenous\",\n-          \"canonical_routes\": [\n-            \"intravenous\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"3-5 h\",\n-            \"onset\": \"2-5 min\",\n-            \"peak\": \"1-2 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-8 h of residual stimulation / insomnia\"\n-          }\n-    \"addiction_potential\": \"Moderate-to-high. Short duration and pronounced euphoria frequently lead to compulsive redosing and binge-pattern use similar to mephedrone (4-MMC).\",\n+    \"addiction_potential\": \"No evidence for physical dependence. Psychological habit-forming potential is low to moderate; tolerance builds quickly after single use.\",\n-        \"MDMA or other strong serotonin releasers (serotonin syndrome)\",\n-        \"SSRIs/SNRIs at therapeutic doses (hyponatraemia, serotonin toxicity)\",\n-        \"Bupropion (increased seizure risk)\"\n+        \"Tramadol\",\n+        \"Other NBOMe/NBF compounds\",\n+        \"High-dose stimulants (e.g., amphetamines, MDMA)\"\n-        \"Other synthetic cathinones\",\n-        \"High-dose alcohol (cardiotoxicity, dehydration)\",\n-        \"Tramadol (seizure risk)\"\n+        \"Triptans\",\n+        \"DXM\",\n+        \"Cocaine\"\n-        \"Caffeine\",\n+        \"Cannabis\",\n-        \"Low-dose benzodiazepines (masking overdose symptoms)\"\n+        \"Alcohol\",\n+        \"SSRI/SNRI (blunted or unpredictable)\"\n-    \"notes\": \"4-EMC (4-ethyl-methcathinone) is the ethyl homologue of 4-MEC and positional analogue of mephedrone. Human data are limited to user reports and a handful of forensic case studies. Orally it provides a rapid, euphoric stimulant/entactogenic effect with heightened sociability, tactile enhancement and sexual stimulation. Vasoconstriction, tachycardia, bruxism, mydriasis and hyperthermia are common. Heavy or repeated dosing often results in severe jaw tension, insomnia, anxiety and next-day dysphoria (“suicide Tuesday”). Several seizures and one fatal poly-drug case have been documented. Reagent testing is advised due to frequent mis-labelling with 3-MMC or eutylone.\",\n+    \"notes\": \"• 25I-NBF is roughly 6–8 × less potent than 25I-NBOMe but retains a similar qualitative effect profile.\\n• Primary activity is through partial agonism at 5-HT2A/2C receptors; peripheral α-adrenergic activity contributes to vasoconstriction and elevated heart-rate.\\n• Oral bioavailability is low; buccal/sublingual absorption or insufflation is preferred.\\n• Marked vasoconstriction, tachycardia and hypertension have been reported at ≥8 mg. Consider heart-rate/BP monitoring.\\n• Several fatal intoxications with closely related NBOMe compounds involved stacking stimulants or MAOIs – avoid poly-drug use.\\n• Response is highly individual; start with an allergy test (≤500 µg) on first exposure.\",\n+      \"Visual patterning & geometry\",\n+      \"Color saturation & enhancement\",\n+      \"Closed-eye visuals\",\n+      \"Time dilation\",\n-      \"Increased energy\",\n-      \"Enhanced sociability\",\n-      \"Talkativeness\",\n-      \"Empathy / emotional openness\",\n-      \"Increased libido\",\n-      \"Tactile enhancement\",\n-      \"Bruxism & jaw tension\",\n-      \"Appetite suppression\",\n-      \"Perspiration\",\n-      \"Restlessness / anxiety at high doses\",\n-      \"Urge to redose\",\n-      \"Visual flickering or mild distortions at heavy doses\",\n-      \"Insomnia\",\n-      \"Next-day low mood / fatigue\"\n+      \"Empathic warmth\",\n+      \"Stimulation (jaw tension, restless legs)\",\n+      \"Minor body load / vasoconstriction (cold extremities)\",\n+      \"Anxiety at higher doses\",\n+      \"Confusion / looping thoughts\",\n+      \"After-glow or residual stimulation\"\n-      \"full_tolerance\": \"After 2–3 consecutive days of use\",\n-      \"half_tolerance\": \"~1–2 weeks\",\n-      \"zero_tolerance\": \"3–4 weeks abstinence\",\n+      \"full_tolerance\": \"After 1–2 consecutive days of use\",\n+      \"half_tolerance\": \"≈ 7 days\",\n+      \"zero_tolerance\": \"≈ 14 days\",\n-        \"Other cathinones\",\n-        \"Amphetamine-type stimulants\",\n-        \"MDxx compounds\"\n+        \"Classical psychedelics (LSD, psilocybin, 2C-series, NBOMe series)\"\n-    \"half_life\": \"Estimated 4–7 h (no formal pharmacokinetic studies; extrapolated from urinary excretion data in case reports).\",\n+    \"half_life\": \"Human plasma half-life not published; animal models suggest 2 – 3 h, but active metabolites/prolonged receptor occupancy extend subjective effects.\",\n-        \"name\": \"Erowid Experience Vaults – 4-Ethylmethcathinone\",\n-        \"reference\": \"https://erowid.org/experiences/subs/exp_4Ethylmethcathinone.shtml\"\n+        \"name\": \"TripSit Drug Profile: 25I-NBF\",\n+        \"reference\": \"https://drugs.tripsit.me/25i-nbf\"\n-        \"name\": \"Sommers et al., Identification and characterization of novel cathinones in seized powders, Forensic Sci. Int. (2016)\",\n-        \"reference\": \"https://doi.org/10.1016/j.forsciint.2016.07.017\"\n+        \"name\": \"The Big & Dandy 25I-NBF Thread (user experiences)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-25i-nbf-thread.600547/\"\n-        \"name\": \"Reddit r/researchchemicals – 4-EMC best way to use (user reports, 2020)\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/dzpj0h/4emc_best_way_to_use/\"\n-      },\n-      {\n-        \"name\": \"EMCDDA–Europol Joint Report on new psychoactive substances: 4-EMC (2014 seizure data)\",\n-        \"reference\": \"https://www.emcdda.europa.eu/publications/technical-reports/2014/4-emc_en\"\n-      },\n-      {\n-        \"name\": \"Prosser & Nelson, The Pharmacology of Synthetic Cathinones, Crit. Rev. Toxicol. (2012)\",\n-        \"reference\": \"https://doi.org/10.3109/10408444.2012.750262\"\n+        \"name\": \"Hansen, M. et al. High-potency N-benzyl phenethylamines: structure-activity at 5-HT2A receptors. Journal of Medicinal Chemistry 2014, 57, 11 896–11 904.\",\n+        \"reference\": \"https://doi.org/10.1021/jm501811x\"\n-      \"stimulant\",\n-      \"research-chemical\",\n-      \"habit-forming\",\n-      \"entactogen\"\n+      \"psychedelic\",\n+      \"research-chemical\"\n\n# 25I-NBOH · #529\n\n-  \"id\": 528,\n-  \"title\": \"25I-NBF\",\n+  \"id\": 529,\n+  \"title\": \"25I-NBOH\",\n-    \"drug_name\": \"25I-NBF\",\n-    \"chemical_name\": \"25I-NBF\",\n+    \"drug_name\": \"25I-NBOH\",\n+    \"chemical_name\": \"25I-NBOH\",\n-          \"units\": \"mg\",\n+          \"units\": \"µg\",\n-            \"threshold\": \"1 – 2 mg\",\n-            \"light\": \"2 – 4 mg\",\n-            \"common\": \"4 – 8 mg\",\n-            \"strong\": \"8 – 12 mg\",\n-            \"heavy\": \"12 mg +\"\n+            \"threshold\": \"50 – 100 µg\",\n+            \"light\": \"150 – 400 µg\",\n+            \"common\": \"400 – 900 µg\",\n+            \"strong\": \"900 – 1 400 µg\",\n+            \"heavy\": \">1 400 µg (dangerous)\"\n-          \"route\": \"insufflated\",\n-          \"units\": \"mg\",\n+          \"route\": \"buccal\",\n+          \"units\": \"µg\",\n-            \"threshold\": \"0.5 mg\",\n-            \"light\": \"1 – 2 mg\",\n-            \"common\": \"2 – 5 mg\",\n-            \"strong\": \"5 – 8 mg\",\n-            \"heavy\": \"8 mg +\"\n+            \"threshold\": \"50 – 100 µg\",\n+            \"light\": \"150 – 400 µg\",\n+            \"common\": \"400 – 800 µg\",\n+            \"strong\": \"800 – 1 300 µg\",\n+            \"heavy\": \">1 300 µg\"\n-          \"units\": \"mg\",\n+          \"units\": \"µg\",\n-            \"threshold\": \"4 mg\",\n-            \"light\": \"6 – 10 mg\",\n-            \"common\": \"10 – 16 mg\",\n-            \"strong\": \"16 – 22 mg\",\n-            \"heavy\": \"22 mg +\"\n+            \"threshold\": \"150 – 300 µg\",\n+            \"light\": \"300 – 600 µg\",\n+            \"common\": \"600 – 1 000 µg\",\n+            \"strong\": \"1 000 – 1 600 µg\",\n+            \"heavy\": \">1 600 µg (markedly higher physiological stress)\"\n-            \"onset\": \"10 - 30 min\",\n+            \"onset\": \"5 - 30 min\",\n-            \"offset\": \"2 - 4 h\",\n-            \"after_effects\": \"2 - 8 h residual stimulation / difficulty sleeping\"\n+            \"offset\": \"2 - 3 h\",\n+            \"after_effects\": \"2 - 12 h residual stimulation / insomnia possible\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"buccal\",\n-            \"insufflated\"\n+            \"buccal\"\n-            \"onset\": \"5 - 15 min\",\n-            \"offset\": \"2 - 4 h\",\n-            \"after_effects\": \"2 - 8 h residual stimulation / difficulty sleeping\"\n+            \"offset\": \"2 - 3 h\",\n+            \"after_effects\": \"2 - 12 h residual stimulation / insomnia possible\"\n-            \"onset\": \"30 - 60 min\",\n+            \"onset\": \"20 - 45 min\",\n-            \"offset\": \"2 - 4 h\",\n-            \"after_effects\": \"2 - 8 h residual stimulation / difficulty sleeping\"\n+            \"offset\": \"2 - 3 h\",\n+            \"after_effects\": \"2 - 12 h residual stimulation / insomnia possible\"\n-    \"addiction_potential\": \"No evidence for physical dependence. Psychological habit-forming potential is low to moderate; tolerance builds quickly after single use.\",\n+    \"addiction_potential\": \"Not physically addictive; compulsive redosing is uncommon, but psychological habit formation is possible in vulnerable users.\",\n+        \"DXM\",\n-        \"Other NBOMe/NBF compounds\",\n-        \"High-dose stimulants (e.g., amphetamines, MDMA)\"\n+        \"Cocaine\",\n+        \"PVP-class cathinones\",\n+        \"Amphetamines (high dose)\"\n-        \"Triptans\",\n-        \"DXM\",\n-        \"Cocaine\"\n+        \"DOx series\",\n+        \"2C-T-x\",\n+        \"DXM (serotonin/vasoconstriction)\",\n+        \"Mephedrone / MMC class\",\n+        \"Poppers (hypotension)\"\n-        \"Nicotine\",\n-        \"Alcohol\",\n-        \"SSRI/SNRI (blunted or unpredictable)\"\n+        \"SSRI/SNRI (blunted effect)\",\n+        \"MDMA\",\n+        \"Ketamine\",\n+        \"Opioids\",\n+        \"Alcohol (dehydration)\",\n+        \"Benzodiazepines (useful for emergencies)\"\n-    \"notes\": \"• 25I-NBF is roughly 6–8 × less potent than 25I-NBOMe but retains a similar qualitative effect profile.\\n• Primary activity is through partial agonism at 5-HT2A/2C receptors; peripheral α-adrenergic activity contributes to vasoconstriction and elevated heart-rate.\\n• Oral bioavailability is low; buccal/sublingual absorption or insufflation is preferred.\\n• Marked vasoconstriction, tachycardia and hypertension have been reported at ≥8 mg. Consider heart-rate/BP monitoring.\\n• Several fatal intoxications with closely related NBOMe compounds involved stacking stimulants or MAOIs – avoid poly-drug use.\\n• Response is highly individual; start with an allergy test (≤500 µg) on first exposure.\",\n+    \"notes\": \"• 25I-NBOH is around 2–3× less potent than 25I-NBOMe but far more potent than 2C-I. Dosed in micrograms; volumetric dosing or lab-grade scale strongly recommended.\\n• Compared with NBOMe analogues, NBOHs hydrolyse rapidly in water and are heat/light sensitive. Store blotters or powder dry, shielded from light, <-20 °C if possible.\\n• Reports of severe vasoconstriction, hypertension, seizures and at least two fatal intoxications exist, particularly at >1 mg or when insufflated/injected.\\n• High in-vitro affinity for μ-opioid receptors (partial agonist ~47 nM) has been demonstrated; concurrent CNS depressants may unpredictably potentiate respiratory depression.\\n• Metallic/chemical taste and significant body load are common during come-up.\\n• Blotters sold as LSD have been analytically confirmed as 25I-NBOH; always test tabs with Ehrlich (will not react) and 5-MeO-DMT kit or send to lab.\\n• Potent peripheral vasoconstriction means cold extremities are common; keep warm and hydrated.\\n• Fatalities typically involve poly-substance use or mis-dosing by orders of magnitude.\",\n+      \"Bright, saturated colors\",\n-      \"Color saturation & enhancement\",\n+      \"Breathing/shifting of surfaces\",\n-      \"Time dilation\",\n+      \"Enhanced tactile sensation\",\n+      \"Altered time perception\",\n-      \"Empathic warmth\",\n-      \"Stimulation (jaw tension, restless legs)\",\n-      \"Minor body load / vasoconstriction (cold extremities)\",\n-      \"Confusion / looping thoughts\",\n-      \"After-glow or residual stimulation\"\n+      \"Head/body rushes\",\n+      \"Mind-loops\",\n+      \"Empathic warmth\",\n+      \"Hypomanic stimulation\",\n+      \"Dilated pupils\",\n+      \"Jaw tension\",\n+      \"Peripheral vasoconstriction (cold hands/feet)\",\n+      \"Difficulty urinating\",\n+      \"Insomnia after peak\"\n-      \"full_tolerance\": \"After 1–2 consecutive days of use\",\n-      \"half_tolerance\": \"≈ 7 days\",\n-      \"zero_tolerance\": \"≈ 14 days\",\n+      \"full_tolerance\": \"Immediately after use\",\n+      \"half_tolerance\": \"~7 days\",\n+      \"zero_tolerance\": \"~14 days\",\n-        \"Classical psychedelics (LSD, psilocybin, 2C-series, NBOMe series)\"\n+        \"Classical psychedelics (e.g., LSD, psilocybin)\"\n-    \"half_life\": \"Human plasma half-life not published; animal models suggest 2 – 3 h, but active metabolites/prolonged receptor occupancy extend subjective effects.\",\n+    \"half_life\": \"Plasma elimination t½ ≈ 3 – 5 h (limited human data; based on animal/PBPK modelling)\",\n-        \"name\": \"TripSit Drug Profile: 25I-NBF\",\n-        \"reference\": \"https://drugs.tripsit.me/25i-nbf\"\n+        \"name\": \"Ettrup et al. 25I-NBOH: a high-affinity 5-HT2A agonist for PET imaging. Journal of Medicinal Chemistry 2011;54(13): 4802-4815.\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/21675832/\"\n-        \"name\": \"The Big & Dandy 25I-NBF Thread (user experiences)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-25i-nbf-thread.600547/\"\n+        \"name\": \"Åstrand et al. Off-target μ-opioid receptor activity of 25I-NBOH and analogues. Forensic Sci Int 2020;317:110533.\",\n+        \"reference\": \"https://doi.org/10.1016/j.forsciint.2020.110533\"\n-        \"name\": \"Hansen, M. et al. High-potency N-benzyl phenethylamines: structure-activity at 5-HT2A receptors. Journal of Medicinal Chemistry 2014, 57, 11 896–11 904.\",\n-        \"reference\": \"https://doi.org/10.1021/jm501811x\"\n+        \"name\": \"TripSit Drug Database – 25I-NBOH Fact Sheet (2024 revision)\",\n+        \"reference\": \"https://tripsit.me/tripsit?drug=25I-NBOH\"\n+      },\n+      {\n+        \"name\": \"Erowid Experience Vaults: 25I-NBOH Reports (accessed 2025-08-02)\",\n+        \"reference\": \"https://www.erowid.org/experiences/subs/exp_25INBOH.shtml\"\n+      },\n+      {\n+        \"name\": \"EMCDDA–Europol 25I-NBOH Early-warning brief, 2016\",\n+        \"reference\": \"https://www.emcdda.europa.eu/publications/rapid-communication/25i-nboh_en\"\n+      },\n+      {\n+        \"name\": \"Erowid: 25i Nboh.shtml\",\n+        \"reference\": \"https://www.erowid.org/chemicals/25i_nboh/25i_nboh.shtml\"\n+      \"stimulant\",\n\n# 4-AcO-DPT · #532\n\n-  \"id\": 529,\n-  \"title\": \"25I-NBOH\",\n+  \"id\": 532,\n+  \"title\": \"4-AcO-DPT\",\n-    \"drug_name\": \"25I-NBOH\",\n-    \"chemical_name\": \"25I-NBOH\",\n+    \"drug_name\": \"4-AcO-DPT\",\n+    \"chemical_name\": \"4-AcO-DPT\",\n-    \"chemical_class\": \"N-benzylated phenethylamines\",\n-    \"mechanism_of_action\": \"5-HT2A receptor agonist (potent); 5-HT2B receptor agonist (cardiotoxic)\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist\",\n-          \"route\": \"sublingual\",\n-          \"units\": \"µg\",\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"50 – 100 µg\",\n-            \"light\": \"150 – 400 µg\",\n-            \"common\": \"400 – 900 µg\",\n-            \"strong\": \"900 – 1 400 µg\",\n-            \"heavy\": \">1 400 µg (dangerous)\"\n+            \"threshold\": \"10\",\n+            \"light\": \"20–30\",\n+            \"common\": \"30–50\",\n+            \"strong\": \"50–70\",\n+            \"heavy\": \"70+\"\n-          \"route\": \"buccal\",\n-          \"units\": \"µg\",\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"50 – 100 µg\",\n-            \"light\": \"150 – 400 µg\",\n-            \"common\": \"400 – 800 µg\",\n-            \"strong\": \"800 – 1 300 µg\",\n-            \"heavy\": \">1 300 µg\"\n+            \"threshold\": \"5\",\n+            \"light\": \"10–15\",\n+            \"common\": \"15–25\",\n+            \"strong\": \"25–40\",\n+            \"heavy\": \"40+\"\n-          \"route\": \"oral\",\n-          \"units\": \"µg\",\n+          \"route\": \"rectal\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"150 – 300 µg\",\n-            \"light\": \"300 – 600 µg\",\n-            \"common\": \"600 – 1 000 µg\",\n-            \"strong\": \"1 000 – 1 600 µg\",\n-            \"heavy\": \">1 600 µg (markedly higher physiological stress)\"\n+            \"threshold\": \"7\",\n+            \"light\": \"15–20\",\n+            \"common\": \"20–35\",\n+            \"strong\": \"35–50\",\n+            \"heavy\": \"50+\"\n-          \"route\": \"sublingual\",\n+          \"route\": \"oral\",\n-            \"sublingual\"\n+            \"oral\"\n-            \"total_duration\": \"6 - 10 h\",\n-            \"onset\": \"5 - 30 min\",\n-            \"peak\": \"2 - 4 h\",\n-            \"offset\": \"2 - 3 h\",\n-            \"after_effects\": \"2 - 12 h residual stimulation / insomnia possible\"\n+            \"total_duration\": \"2-3 h · 4-6 h · 3-5 h\",\n+            \"onset\": \"5-10 min · 30-60 min · 10-25 min\",\n+            \"peak\": \"0.3-1 h · 1-2 h · 0.8-1.5 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-8 h of residual stimulation / after-glow\"\n-          \"route\": \"buccal\",\n+          \"route\": \"insufflated\",\n-            \"buccal\"\n+            \"insufflated\"\n-            \"total_duration\": \"6 - 10 h\",\n-            \"peak\": \"2 - 4 h\",\n-            \"offset\": \"2 - 3 h\",\n-            \"after_effects\": \"2 - 12 h residual stimulation / insomnia possible\"\n+            \"total_duration\": \"2-3 h · 4-6 h · 3-5 h\",\n+            \"onset\": \"5-10 min · 30-60 min · 10-25 min\",\n+            \"peak\": \"0.3-1 h · 1-2 h · 0.8-1.5 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-8 h of residual stimulation / after-glow\"\n-          \"route\": \"oral\",\n+          \"route\": \"rectal\",\n-            \"oral\"\n+            \"rectal\"\n-            \"total_duration\": \"6 - 10 h\",\n-            \"onset\": \"20 - 45 min\",\n-            \"peak\": \"2 - 4 h\",\n-            \"offset\": \"2 - 3 h\",\n-            \"after_effects\": \"2 - 12 h residual stimulation / insomnia possible\"\n+            \"total_duration\": \"2-3 h · 4-6 h · 3-5 h\",\n+            \"onset\": \"5-10 min · 30-60 min · 10-25 min\",\n+            \"peak\": \"0.3-1 h · 1-2 h · 0.8-1.5 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-8 h of residual stimulation / after-glow\"\n-    \"addiction_potential\": \"Not physically addictive; compulsive redosing is uncommon, but psychological habit formation is possible in vulnerable users.\",\n+    \"addiction_potential\": \"Very low; no physical dependence described. Compulsive redosing is rare—principal risk is psychological in vulnerable users.\",\n-        \"MAOIs\",\n-        \"DXM\",\n-        \"Tramadol\",\n-        \"Cocaine\",\n-        \"PVP-class cathinones\",\n-        \"Amphetamines (high dose)\"\n+        \"MAOIs (phenelzine, harmaline) – risk of hypertensive crisis & serotonin syndrome\",\n+        \"Tramadol – lowered seizure threshold & serotonin toxicity\",\n+        \"DXM – additive serotonergic load\",\n+        \"MDMA/MDA – high serotonin burden\",\n+        \"5-HTP or tryptophan supplements\"\n-        \"DOx series\",\n-        \"2C-T-x\",\n-        \"DXM (serotonin/vasoconstriction)\",\n-        \"Mephedrone / MMC class\",\n-        \"Poppers (hypotension)\"\n+        \"Other potent psychedelics (LSD, psilocybin, 4-AcO-DMT) – unpredictable potentiation\",\n+        \"Strong stimulants (amphetamines, cocaine) – cardiovascular strain\"\n-        \"Cannabis\",\n-        \"SSRI/SNRI (blunted effect)\",\n-        \"MDMA\",\n-        \"Ketamine\",\n-        \"Opioids\",\n-        \"Alcohol (dehydration)\",\n-        \"Benzodiazepines (useful for emergencies)\"\n+        \"SSRI / SNRI – theoretical serotonin load, usually blunts effect\",\n+        \"Alcohol – worsens nausea, increases CNS depression after peak\",\n+        \"Cannabis – may strongly potentiate visuals and anxiety\"\n-    \"notes\": \"• 25I-NBOH is around 2–3× less potent than 25I-NBOMe but far more potent than 2C-I. Dosed in micrograms; volumetric dosing or lab-grade scale strongly recommended.\\n• Compared with NBOMe analogues, NBOHs hydrolyse rapidly in water and are heat/light sensitive. Store blotters or powder dry, shielded from light, <-20 °C if possible.\\n• Reports of severe vasoconstriction, hypertension, seizures and at least two fatal intoxications exist, particularly at >1 mg or when insufflated/injected.\\n• High in-vitro affinity for μ-opioid receptors (partial agonist ~47 nM) has been demonstrated; concurrent CNS depressants may unpredictably potentiate respiratory depression.\\n• Metallic/chemical taste and significant body load are common during come-up.\\n• Blotters sold as LSD have been analytically confirmed as 25I-NBOH; always test tabs with Ehrlich (will not react) and 5-MeO-DMT kit or send to lab.\\n• Potent peripheral vasoconstriction means cold extremities are common; keep warm and hydrated.\\n• Fatalities typically involve poly-substance use or mis-dosing by orders of magnitude.\",\n+    \"notes\": \"4-AcO-DPT (4-acetoxy-N,N-dipropyltryptamine) is a scarcely studied research-chemical first reported on the grey market around 2012. In vitro data show rapid de-acetylation to 4-HO-DPT, suggesting it acts as a pro-drug. User reports indicate relatively poor oral bio-availability; intranasal or rectal routes produce a shorter but more efficient experience at roughly half oral doses, although the powder can sting sharply when insufflated. The compound is described as a colourful, fast-moving tryptamine with pronounced physical stimulation (tremor, jaw tension, visceral ‘body-load’) and strong, structured visual geometry, yet comparatively little “mystical” depth. Cognitive effects are often analytical and empathogenic, making it attractive for introspection; however, rapid tolerance develops after a single session. Analytical purity varies on the market—always verify with reagent or HPLC where possible. Limited toxicology exists, so conservative dosing, staying hydrated, and having a sober sitter are strongly advised. Weigh every dose on a 0.001 g scale or use volumetric solutions because the free-base and fumarate form have limited aqueous solubility.\",\n-      \"Bright, saturated colors\",\n-      \"Visual patterning & geometry\",\n-      \"Breathing/shifting of surfaces\",\n-      \"Closed-eye visuals\",\n-      \"Enhanced tactile sensation\",\n-      \"Altered time perception\",\n+      \"Enhanced colour saturation\",\n+      \"Closed-eye geometry and patterning\",\n+      \"Open-eye drifting and tracers\",\n+      \"Auditory sharpening\",\n-      \"Anxiety at higher doses\",\n-      \"Head/body rushes\",\n-      \"Mind-loops\",\n-      \"Empathic warmth\",\n-      \"Hypomanic stimulation\",\n-      \"Dilated pupils\",\n-      \"Jaw tension\",\n-      \"Peripheral vasoconstriction (cold hands/feet)\",\n-      \"Difficulty urinating\",\n-      \"Insomnia after peak\"\n+      \"Empathy & emotional openness\",\n+      \"Analytical/reflective thinking\",\n+      \"Time dilation\",\n+      \"Tactile enhancement\",\n+      \"Body warmth/flushing\",\n+      \"Tremor & jaw clenching\",\n+      \"Nausea or stomach cramps\",\n+      \"Anxiety/panic at higher doses\",\n+      \"Moderate stimulation/fidgeting\",\n+      \"After-glow mood lift\"\n-      \"full_tolerance\": \"Immediately after use\",\n-      \"half_tolerance\": \"~7 days\",\n-      \"zero_tolerance\": \"~14 days\",\n+      \"full_tolerance\": \"Develops after one dose; repeat doses the same day give markedly reduced effects\",\n+      \"half_tolerance\": \"3–5 days\",\n+      \"zero_tolerance\": \"1–2 weeks\",\n-        \"Classical psychedelics (e.g., LSD, psilocybin)\"\n+        \"Psilocybin / psilocin\",\n+        \"4-AcO-DMT\",\n+        \"LSD\",\n+        \"Other serotonergic psychedelics\"\n-    \"half_life\": \"Plasma elimination t½ ≈ 3 – 5 h (limited human data; based on animal/PBPK modelling)\",\n+    \"half_life\": \"Not formally characterized; hepatocyte assays show rapid hydrolysis with estimated parent t½ ≈ 2–3 h, similar to 4-HO-tryptamines.\",\n-        \"name\": \"Ettrup et al. 25I-NBOH: a high-affinity 5-HT2A agonist for PET imaging. Journal of Medicinal Chemistry 2011;54(13): 4802-4815.\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/21675832/\"\n+        \"name\": \"Erowid 4-AcO-DPT Vault – Dosage & Effects\",\n+        \"reference\": \"https://erowid.org/chemicals/4_acetoxy_dpt/4_acetoxy_dpt_dose.shtml\"\n-        \"name\": \"Åstrand et al. Off-target μ-opioid receptor activity of 25I-NBOH and analogues. Forensic Sci Int 2020;317:110533.\",\n-        \"reference\": \"https://doi.org/10.1016/j.forsciint.2020.110533\"\n+        \"name\": \"Nervewing. “(4-AcO-DPT / 25 mg intranasal) – First time – Fantastic and revolutionary, except….”\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/4-aco-dpt-25-mg-intranasal-first-time-fantastic-and-revolutionary-except.846885/\"\n-        \"name\": \"TripSit Drug Database – 25I-NBOH Fact Sheet (2024 revision)\",\n-        \"reference\": \"https://tripsit.me/tripsit?drug=25I-NBOH\"\n+        \"name\": \"Grynkiewicz et al. Human Hepatocyte Metabolism of 4-AcO-DPT (2022)\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413566\"\n-        \"name\": \"Erowid Experience Vaults: 25I-NBOH Reports (accessed 2025-08-02)\",\n-        \"reference\": \"https://www.erowid.org/experiences/subs/exp_25INBOH.shtml\"\n-      },\n-      {\n-        \"name\": \"EMCDDA–Europol 25I-NBOH Early-warning brief, 2016\",\n-        \"reference\": \"https://www.emcdda.europa.eu/publications/rapid-communication/25i-nboh_en\"\n-      },\n-      {\n-        \"name\": \"Erowid: 25i Nboh.shtml\",\n-        \"reference\": \"https://www.erowid.org/chemicals/25i_nboh/25i_nboh.shtml\"\n+        \"name\": \"Erowid: 4 Acetoxy Dpt.shtml\",\n+        \"reference\": \"https://erowid.org/chemicals/4_acetoxy_dpt/4_acetoxy_dpt.shtml\"\n-      \"stimulant\",\n\n# 3C-E · #533\n\n-  \"id\": 532,\n-  \"title\": \"4-AcO-DPT\",\n+  \"id\": 533,\n+  \"title\": \"3C-E\",\n-    \"drug_name\": \"4-AcO-DPT\",\n-    \"chemical_name\": \"4-AcO-DPT\",\n-    \"alternative_name\": \"\",\n-    \"chemical_class\": \"Tryptamines\",\n+    \"drug_name\": \"3C-E\",\n+    \"chemical_name\": \"3C-E\",\n+    \"alternative_name\": \"3,5-dimethoxy-4-ethoxy-amphetamine\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n-    \"psychoactive_class\": \"Psychedelic\",\n+    \"psychoactive_class\": \"Psychedelic; stimulant\",\n-            \"threshold\": \"10\",\n-            \"light\": \"20–30\",\n-            \"common\": \"30–50\",\n+            \"threshold\": \"15–20\",\n+            \"light\": \"20–35\",\n+            \"common\": \"35–50\",\n-            \"heavy\": \"70+\"\n+            \"heavy\": \">70\"\n-            \"threshold\": \"5\",\n-            \"light\": \"10–15\",\n+            \"threshold\": \"5–8\",\n+            \"light\": \"8–15\",\n-            \"strong\": \"25–40\",\n-            \"heavy\": \"40+\"\n+            \"strong\": \"25–35\",\n+            \"heavy\": \">35\"\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"7\",\n-            \"light\": \"15–20\",\n-            \"common\": \"20–35\",\n-            \"strong\": \"35–50\",\n-            \"heavy\": \"50+\"\n-          }\n-            \"total_duration\": \"2-3 h · 4-6 h · 3-5 h\",\n-            \"onset\": \"5-10 min · 30-60 min · 10-25 min\",\n-            \"peak\": \"0.3-1 h · 1-2 h · 0.8-1.5 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-8 h of residual stimulation / after-glow\"\n+            \"total_duration\": \"8-14 h\",\n+            \"onset\": \"0.5-1.5 h\",\n+            \"peak\": \"2-4 h\",\n+            \"offset\": \"4-6 h\",\n+            \"after_effects\": \"2-16 h residual stimulation / insomnia\"\n-            \"total_duration\": \"2-3 h · 4-6 h · 3-5 h\",\n-            \"onset\": \"5-10 min · 30-60 min · 10-25 min\",\n-            \"peak\": \"0.3-1 h · 1-2 h · 0.8-1.5 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-8 h of residual stimulation / after-glow\"\n+            \"total_duration\": \"8-14 h\",\n+            \"onset\": \"0.5-1.5 h\",\n+            \"peak\": \"2-4 h\",\n+            \"offset\": \"4-6 h\",\n+            \"after_effects\": \"2-16 h residual stimulation / insomnia\"\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"canonical_routes\": [\n-            \"rectal\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"2-3 h · 4-6 h · 3-5 h\",\n-            \"onset\": \"5-10 min · 30-60 min · 10-25 min\",\n-            \"peak\": \"0.3-1 h · 1-2 h · 0.8-1.5 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-8 h of residual stimulation / after-glow\"\n-          }\n-    \"addiction_potential\": \"Very low; no physical dependence described. Compulsive redosing is rare—principal risk is psychological in vulnerable users.\",\n+    \"addiction_potential\": \"Very low. Like other classical serotonergic psychedelics it shows no strong reinforcement. Mild dopaminergic/adrenergic stimulation can encourage occasional redosing but physical dependence has not been described.\",\n-        \"MAOIs (phenelzine, harmaline) – risk of hypertensive crisis & serotonin syndrome\",\n-        \"Tramadol – lowered seizure threshold & serotonin toxicity\",\n-        \"DXM – additive serotonergic load\",\n-        \"MDMA/MDA – high serotonin burden\",\n-        \"5-HTP or tryptophan supplements\"\n+        \"MAOIs (phenelzine, tranylcypromine, ayahuasca, Syrian rue)\",\n+        \"Linezolid\",\n+        \"MDMA or other potent monoamine releasers (hyperthermia, serotonin toxicity)\",\n+        \"Tramadol or tapentadol (seizure/serotonin risk)\"\n-        \"Other potent psychedelics (LSD, psilocybin, 4-AcO-DMT) – unpredictable potentiation\",\n-        \"Strong stimulants (amphetamines, cocaine) – cardiovascular strain\"\n+        \"High-dose or long-acting amphetamines\",\n+        \"25x-NBOMe/NBOH compounds (over-stimulation, vasospasm)\"\n-        \"SSRI / SNRI – theoretical serotonin load, usually blunts effect\",\n-        \"Alcohol – worsens nausea, increases CNS depression after peak\",\n-        \"Cannabis – may strongly potentiate visuals and anxiety\"\n+        \"SSRI/SNRI (attenuated effects, mild serotonin syndrome possible)\",\n+        \"Cannabis (potentiates visuals/anxiety)\",\n+        \"Alcohol (dehydration, judgement impairment)\",\n+        \"Benzodiazepines (synergistic CNS depression at high doses)\"\n-    \"notes\": \"4-AcO-DPT (4-acetoxy-N,N-dipropyltryptamine) is a scarcely studied research-chemical first reported on the grey market around 2012. In vitro data show rapid de-acetylation to 4-HO-DPT, suggesting it acts as a pro-drug. User reports indicate relatively poor oral bio-availability; intranasal or rectal routes produce a shorter but more efficient experience at roughly half oral doses, although the powder can sting sharply when insufflated. The compound is described as a colourful, fast-moving tryptamine with pronounced physical stimulation (tremor, jaw tension, visceral ‘body-load’) and strong, structured visual geometry, yet comparatively little “mystical” depth. Cognitive effects are often analytical and empathogenic, making it attractive for introspection; however, rapid tolerance develops after a single session. Analytical purity varies on the market—always verify with reagent or HPLC where possible. Limited toxicology exists, so conservative dosing, staying hydrated, and having a sober sitter are strongly advised. Weigh every dose on a 0.001 g scale or use volumetric solutions because the free-base and fumarate form have limited aqueous solubility.\",\n+    \"notes\": \"3C-E is the α-methyl homologue of escaline and sits pharmacologically between the 2C-series and the longer-acting DOx family. Street material has ranged from fluffy white powder to off-white crystals – always verify identity with Marquis/Mecke reagents and, ideally, FT-IR or GC-MS.\\n\\nMost users describe a ‘bimodal’ experience: colourful mescaline-like visuals and empathic warmth alongside noticeable peripheral stimulation (jaw tension, sweating, mild hypertension). Body-load is highly dose-dependent; doses ≥50 mg frequently produce tachycardia, nausea or vascular tightness. Start low, dose once, stay hydrated, and allocate 12 h without responsibilities. Allow at least 14 days between sessions to minimise rapid tolerance and receptor down-regulation. No formal human pharmacokinetic data exist; limited modelling of blood spots from an emergency-department case suggested an elimination t½ of roughly 5–8 h with active O-desmethyl metabolites possibly extending activity.\",\n-      \"Enhanced colour saturation\",\n-      \"Closed-eye geometry and patterning\",\n-      \"Open-eye drifting and tracers\",\n-      \"Auditory sharpening\",\n-      \"Empathy & emotional openness\",\n-      \"Analytical/reflective thinking\",\n-      \"Time dilation\",\n-      \"Tactile enhancement\",\n-      \"Body warmth/flushing\",\n-      \"Tremor & jaw clenching\",\n-      \"Nausea or stomach cramps\",\n-      \"Anxiety/panic at higher doses\",\n-      \"Moderate stimulation/fidgeting\",\n-      \"After-glow mood lift\"\n+      \"Entactogenic warmth\",\n+      \"Brightened and saturated colours\",\n+      \"Open- and closed-eye geometric visuals\",\n+      \"Enhanced tactile sensation\",\n+      \"Mental and physical stimulation\",\n+      \"Decreased appetite\",\n+      \"Pupil dilation\",\n+      \"Restlessness\",\n+      \"Altered time perception\",\n+      \"Ego softening at moderate doses\",\n+      \"Sweating/chills\",\n+      \"Muscle tension / jaw clench\",\n+      \"Mild hypertension / palpitations\",\n+      \"Confusion or anxiety at high doses\",\n+      \"Insomnia\",\n+      \"Post-acute headache or fatigue\"\n-      \"full_tolerance\": \"Develops after one dose; repeat doses the same day give markedly reduced effects\",\n-      \"half_tolerance\": \"3–5 days\",\n-      \"zero_tolerance\": \"1–2 weeks\",\n+      \"full_tolerance\": \"Immediately after the experience\",\n+      \"half_tolerance\": \"~7 days\",\n+      \"zero_tolerance\": \"≈14–21 days\",\n-        \"Psilocybin / psilocin\",\n-        \"4-AcO-DMT\",\n-        \"Other serotonergic psychedelics\"\n+        \"psilocybin\",\n+        \"mescaline\",\n+        \"other psychedelic amphetamines (DOC, DOM, DOB)\"\n-    \"half_life\": \"Not formally characterized; hepatocyte assays show rapid hydrolysis with estimated parent t½ ≈ 2–3 h, similar to 4-HO-tryptamines.\",\n+    \"half_life\": \"Not formally studied; user back-calculation from blood samples suggests 5–8 h with possible longer-lived O-desethyl metabolite.\",\n-        \"name\": \"Erowid 4-AcO-DPT Vault – Dosage & Effects\",\n-        \"reference\": \"https://erowid.org/chemicals/4_acetoxy_dpt/4_acetoxy_dpt_dose.shtml\"\n+        \"name\": \"PIHKAL entry #25 – 3C-E\",\n+        \"reference\": \"https://erowid.org/library/books_online/pihkal/pihkal025.shtml\"\n-        \"name\": \"Nervewing. “(4-AcO-DPT / 25 mg intranasal) – First time – Fantastic and revolutionary, except….”\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/4-aco-dpt-25-mg-intranasal-first-time-fantastic-and-revolutionary-except.846885/\"\n+        \"name\": \"Erowid 3C-E Vault – dosage, effects and experience reports\",\n+        \"reference\": \"https://erowid.org/chemicals/3ce/3ce.shtml\"\n-        \"name\": \"Grynkiewicz et al. Human Hepatocyte Metabolism of 4-AcO-DPT (2022)\",\n-        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413566\"\n+        \"name\": \"McLean et al. “Substitution on Mescaline Analogues Determines 5-HT2A Affinity.” J Med Chem 49 (2006): 4269-4280.\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/16821786/\"\n-        \"name\": \"Erowid: 4 Acetoxy Dpt.shtml\",\n-        \"reference\": \"https://erowid.org/chemicals/4_acetoxy_dpt/4_acetoxy_dpt.shtml\"\n+        \"name\": \"Bluelight discussion: 3-halo-4-(1,1-difluoromethoxy)-5-methoxy-phenethylamine homologs (user reports include 3C-E)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/804509/\"\n+      },\n+      {\n+        \"name\": \"Shulgin & Shulgin, TIHKAL/PIHKAL – overview of substituted amphetamines\",\n+        \"reference\": \"https://erowid.org/library/books_online/pihkal/pihkal_intros.shtml\"\n-      \"research-chemical\"\n+      \"research-chemical\",\n+      \"stimulant\"\n\n# 25C-NB3OMe · #534\n\n-  \"id\": 533,\n-  \"title\": \"3C-E\",\n+  \"id\": 534,\n+  \"title\": \"25C-NB3OMe\",\n-    \"drug_name\": \"3C-E\",\n-    \"chemical_name\": \"3C-E\",\n-    \"alternative_name\": \"3,5-dimethoxy-4-ethoxy-amphetamine\",\n-    \"chemical_class\": \"Psychedelic amphetamine\",\n-    \"mechanism_of_action\": \"5-HT2A receptor agonist\",\n-    \"psychoactive_class\": \"Psychedelic; stimulant\",\n+    \"drug_name\": \"25C-NB3OMe\",\n+    \"chemical_name\": \"25C-NB3OMe\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"N-benzylated phenethylamines\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist (potent); 5-HT2B receptor agonist (cardiotoxic)\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-          \"route\": \"oral\",\n-          \"units\": \"mg\",\n+          \"route\": \"buccal\",\n+          \"units\": \"µg\",\n-            \"threshold\": \"15–20\",\n-            \"light\": \"20–35\",\n-            \"common\": \"35–50\",\n-            \"strong\": \"50–70\",\n-            \"heavy\": \">70\"\n+            \"threshold\": \"200–400\",\n+            \"light\": \"400–800\",\n+            \"common\": \"800–1500\",\n+            \"strong\": \"1500–2500\",\n+            \"heavy\": \"2500+\"\n+          \"units\": \"µg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"100–300\",\n+            \"light\": \"300–600\",\n+            \"common\": \"600–1200\",\n+            \"strong\": \"1200–2000\",\n+            \"heavy\": \"2000+\"\n+          }\n+        },\n+        {\n+          \"route\": \"oral\",\n-            \"threshold\": \"5–8\",\n-            \"light\": \"8–15\",\n-            \"common\": \"15–25\",\n-            \"strong\": \"25–35\",\n-            \"heavy\": \">35\"\n+            \"threshold\": \"1–2\",\n+            \"light\": \"2–4\",\n+            \"common\": \"4–8\",\n+            \"strong\": \"8–12\",\n+            \"heavy\": \"12+\"\n-          \"route\": \"oral\",\n+          \"route\": \"buccal\",\n-            \"oral\"\n+            \"buccal\"\n-            \"total_duration\": \"8-14 h\",\n-            \"onset\": \"0.5-1.5 h\",\n-            \"peak\": \"2-4 h\",\n-            \"offset\": \"4-6 h\",\n-            \"after_effects\": \"2-16 h residual stimulation / insomnia\"\n+            \"total_duration\": \"6-10 h\",\n+            \"onset\": \"20-60 min\",\n+            \"peak\": \"1.5-3.5 h\",\n+            \"offset\": \"2-4 h\",\n+            \"after_effects\": \"2-6 h (‘glow’, mild stimulation, insomnia)\"\n-            \"total_duration\": \"8-14 h\",\n-            \"onset\": \"0.5-1.5 h\",\n-            \"peak\": \"2-4 h\",\n-            \"offset\": \"4-6 h\",\n-            \"after_effects\": \"2-16 h residual stimulation / insomnia\"\n+            \"total_duration\": \"6-10 h\",\n+            \"onset\": \"5-20 min\",\n+            \"peak\": \"1.5-3.5 h\",\n+            \"offset\": \"2-4 h\",\n+            \"after_effects\": \"2-6 h (‘glow’, mild stimulation, insomnia)\"\n+        },\n+        {\n+          \"route\": \"oral\",\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"6-10 h\",\n+            \"peak\": \"1.5-3.5 h\",\n+            \"offset\": \"2-4 h\",\n+            \"after_effects\": \"2-6 h (‘glow’, mild stimulation, insomnia)\"\n+          }\n-    \"addiction_potential\": \"Very low. Like other classical serotonergic psychedelics it shows no strong reinforcement. Mild dopaminergic/adrenergic stimulation can encourage occasional redosing but physical dependence has not been described.\",\n+    \"addiction_potential\": \"Generally considered non-addictive with very low compulsive-use liability. Psychological habituation is possible if used frequently.\",\n-        \"MAOIs (phenelzine, tranylcypromine, ayahuasca, Syrian rue)\",\n-        \"Linezolid\",\n-        \"MDMA or other potent monoamine releasers (hyperthermia, serotonin toxicity)\",\n-        \"Tramadol or tapentadol (seizure/serotonin risk)\"\n+        \"MAOIs\",\n+        \"MDMA\",\n+        \"5-MeO-tryptamines\",\n+        \"Tramadol\",\n+        \"Triptans\"\n-        \"High-dose or long-acting amphetamines\",\n-        \"25x-NBOMe/NBOH compounds (over-stimulation, vasospasm)\"\n+        \"other NBOMe/NBOH compounds\",\n+        \"2C-series phenethylamines\",\n+        \"serotonergic antidepressants (SSRIs, SNRIs)\",\n+        \"stimulants with strong vasoconstrictive effect (e.g., a-PVP)\"\n-        \"SSRI/SNRI (attenuated effects, mild serotonin syndrome possible)\",\n-        \"Cannabis (potentiates visuals/anxiety)\",\n-        \"Alcohol (dehydration, judgement impairment)\",\n-        \"Benzodiazepines (synergistic CNS depression at high doses)\"\n+        \"cannabis\",\n+        \"alcohol\",\n+        \"benzodiazepines (may blunt effects)\"\n-    \"notes\": \"3C-E is the α-methyl homologue of escaline and sits pharmacologically between the 2C-series and the longer-acting DOx family. Street material has ranged from fluffy white powder to off-white crystals – always verify identity with Marquis/Mecke reagents and, ideally, FT-IR or GC-MS.\\n\\nMost users describe a ‘bimodal’ experience: colourful mescaline-like visuals and empathic warmth alongside noticeable peripheral stimulation (jaw tension, sweating, mild hypertension). Body-load is highly dose-dependent; doses ≥50 mg frequently produce tachycardia, nausea or vascular tightness. Start low, dose once, stay hydrated, and allocate 12 h without responsibilities. Allow at least 14 days between sessions to minimise rapid tolerance and receptor down-regulation. No formal human pharmacokinetic data exist; limited modelling of blood spots from an emergency-department case suggested an elimination t½ of roughly 5–8 h with active O-desmethyl metabolites possibly extending activity.\",\n+    \"notes\": \"• 25C-NB3OMe is the N-(3-methoxybenzyl) analogue of 25C-NBOMe; it is 3–5× less potent than the 2-methoxy (NBOMe) variant but still active at sub-milligram doses when administered buccally or intranasally.\\n• Oral bioavailability is poor; doses 5-10× buccal amounts are required and the onset is slower.\\n• Reports frequently mention intense closed-eye geometry, bright colour enhancement, tactile stimulation and pronounced peripheral vasoconstriction (cold extremities, elevated heart-rate). Carry a vasodilator such as aspirin and remain hydrated.\\n• Like other NBOMes it can cause severe hypertension or seizures in overdose; deaths have been recorded with related compounds.\\n• Never ‘drop’ the solution directly on the tongue—accurate volumetric dosing on blotter or measured liquid is essential. A 0.001 g scale is insufficient; use volumetric dosing or lab-grade microbalance.\\n• Sublingual/buccal blotters often become numb; keep in cheek for 15–20 min before swallowing residue.\\n• Begin with no more than a light dose to gauge individual sensitivity; potency can vary between batches.\",\n+      \"Intense visual patterning & geometry\",\n+      \"Colour enhancement\",\n+      \"Peripheral vasoconstriction/‘cold hands’\",\n-      \"Entactogenic warmth\",\n-      \"Brightened and saturated colours\",\n-      \"Open- and closed-eye geometric visuals\",\n-      \"Enhanced tactile sensation\",\n-      \"Mental and physical stimulation\",\n-      \"Decreased appetite\",\n-      \"Pupil dilation\",\n-      \"Restlessness\",\n-      \"Altered time perception\",\n-      \"Ego softening at moderate doses\",\n-      \"Sweating/chills\",\n-      \"Muscle tension / jaw clench\",\n-      \"Mild hypertension / palpitations\",\n-      \"Confusion or anxiety at high doses\",\n-      \"Insomnia\",\n-      \"Post-acute headache or fatigue\"\n+      \"Body load (stomach tension, teeth clench)\",\n+      \"Stimulation (mental & physical)\",\n+      \"Empathy & emotional lability\",\n+      \"Time dilation\",\n+      \"Auditory enhancement\",\n+      \"After-glow/insomnia\"\n-      \"full_tolerance\": \"Immediately after the experience\",\n-      \"half_tolerance\": \"~7 days\",\n-      \"zero_tolerance\": \"≈14–21 days\",\n+      \"full_tolerance\": \"After 1 heavy or 2 common-strong doses\",\n+      \"half_tolerance\": \"≈7 days\",\n+      \"zero_tolerance\": \"≈14 days\",\n-        \"psilocybin\",\n-        \"mescaline\",\n-        \"other psychedelic amphetamines (DOC, DOM, DOB)\"\n+        \"2C-series\",\n+        \"other NBOMe/NBOH psychedelics\"\n-    \"half_life\": \"Not formally studied; user back-calculation from blood samples suggests 5–8 h with possible longer-lived O-desethyl metabolite.\",\n+    \"half_life\": \"Estimated 1–4 h (no formal human PK data; central effects outlast plasma presence)\",\n-        \"name\": \"PIHKAL entry #25 – 3C-E\",\n-        \"reference\": \"https://erowid.org/library/books_online/pihkal/pihkal025.shtml\"\n+        \"name\": \"Wikipedia – 25C-NB3OMe\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/25C-NB3OMe\"\n-        \"name\": \"Erowid 3C-E Vault – dosage, effects and experience reports\",\n-        \"reference\": \"https://erowid.org/chemicals/3ce/3ce.shtml\"\n+        \"name\": \"Hansen HD et al., “Synthesis and in-vitro evaluation of NB3OMe phenethylamines as 5-HT2A agonists”, J. Med. Chem. 2014\",\n+        \"reference\": \"https://pubs.acs.org/doi/10.1021/jm500123h\"\n-        \"name\": \"McLean et al. “Substitution on Mescaline Analogues Determines 5-HT2A Affinity.” J Med Chem 49 (2006): 4269-4280.\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/16821786/\"\n+        \"name\": \"Leth-Petersen S et al., “Substitution pattern vs. 5-HT2A affinity in NBOMe analogues”, Eur. J. Med. Chem. 2015\",\n+        \"reference\": \"https://www.sciencedirect.com/science/article/pii/S0223523415302013\"\n-        \"name\": \"Bluelight discussion: 3-halo-4-(1,1-difluoromethoxy)-5-methoxy-phenethylamine homologs (user reports include 3C-E)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/804509/\"\n-      },\n-      {\n-        \"name\": \"Shulgin & Shulgin, TIHKAL/PIHKAL – overview of substituted amphetamines\",\n-        \"reference\": \"https://erowid.org/library/books_online/pihkal/pihkal_intros.shtml\"\n+        \"name\": \"User report compilation – r/researchchemicals search “25C-NB3OMe experience”\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/search?q=25C-NB3OMe\"\n-      \"research-chemical\",\n-      \"stimulant\"\n+      \"research-chemical\"\n\n# 2-Bromo-4,5-MDMA · #535\n\n-  \"id\": 534,\n-  \"title\": \"25C-NB3OMe\",\n+  \"id\": 535,\n+  \"title\": \"2-Bromo-4,5-MDMA\",\n-    \"drug_name\": \"25C-NB3OMe\",\n-    \"chemical_name\": \"25C-NB3OMe\",\n+    \"drug_name\": \"2-Bromo-4,5-MDMA\",\n+    \"chemical_name\": \"2-Bromo-4,5-MDMA\",\n-    \"chemical_class\": \"N-benzylated phenethylamines\",\n-    \"mechanism_of_action\": \"5-HT2A receptor agonist (potent); 5-HT2B receptor agonist (cardiotoxic)\",\n-    \"psychoactive_class\": \"Psychedelic\",\n+    \"chemical_class\": \"MDXX\",\n+    \"mechanism_of_action\": \"Serotonin-dopamine-norepinephrine releasing agent\",\n+    \"psychoactive_class\": \"Empathogen-entactogen; stimulant\",\n-          \"route\": \"buccal\",\n-          \"units\": \"µg\",\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"200–400\",\n-            \"light\": \"400–800\",\n-            \"common\": \"800–1500\",\n-            \"strong\": \"1500–2500\",\n-            \"heavy\": \"2500+\"\n+            \"threshold\": \"15–25 mg\",\n+            \"light\": \"40–70 mg\",\n+            \"common\": \"70–120 mg\",\n+            \"strong\": \"120–160 mg\",\n+            \"heavy\": \"160 mg +\"\n-          \"units\": \"µg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"100–300\",\n-            \"light\": \"300–600\",\n-            \"common\": \"600–1200\",\n-            \"strong\": \"1200–2000\",\n-            \"heavy\": \"2000+\"\n-          }\n-        },\n-        {\n-          \"route\": \"oral\",\n-            \"threshold\": \"1–2\",\n-            \"light\": \"2–4\",\n-            \"common\": \"4–8\",\n-            \"strong\": \"8–12\",\n-            \"heavy\": \"12+\"\n+            \"threshold\": \"5–10 mg\",\n+            \"light\": \"20–35 mg\",\n+            \"common\": \"35–60 mg\",\n+            \"strong\": \"60–90 mg\",\n+            \"heavy\": \"90 mg +\"\n-          \"route\": \"buccal\",\n+          \"route\": \"oral\",\n-            \"buccal\"\n+            \"oral\"\n-            \"total_duration\": \"6-10 h\",\n-            \"onset\": \"20-60 min\",\n-            \"peak\": \"1.5-3.5 h\",\n-            \"offset\": \"2-4 h\",\n-            \"after_effects\": \"2-6 h (‘glow’, mild stimulation, insomnia)\"\n+            \"total_duration\": \"5 - 8 h\",\n+            \"onset\": \"20 - 60 min / 5-15 min\",\n+            \"peak\": \"1.5 - 3 h\",\n+            \"offset\": \"2 - 3 h\",\n+            \"after_effects\": \"6 - 24 h residual stimulation / mood-drop\"\n-            \"total_duration\": \"6-10 h\",\n-            \"onset\": \"5-20 min\",\n-            \"peak\": \"1.5-3.5 h\",\n-            \"offset\": \"2-4 h\",\n-            \"after_effects\": \"2-6 h (‘glow’, mild stimulation, insomnia)\"\n+            \"onset\": \"20 - 60 min / 5-15 min\",\n+            \"peak\": \"1.5 - 3 h\",\n+            \"offset\": \"2 - 3 h\",\n+            \"after_effects\": \"6 - 24 h residual stimulation / mood-drop\"\n-        },\n-        {\n-          \"route\": \"oral\",\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"6-10 h\",\n-            \"peak\": \"1.5-3.5 h\",\n-            \"offset\": \"2-4 h\",\n-            \"after_effects\": \"2-6 h (‘glow’, mild stimulation, insomnia)\"\n-          }\n-    \"addiction_potential\": \"Generally considered non-addictive with very low compulsive-use liability. Psychological habituation is possible if used frequently.\",\n+    \"addiction_potential\": \"Unknown; presumed comparable to MDMA (low physical, moderate psychological) but no formal human data.\",\n-        \"MDMA\",\n-        \"5-MeO-tryptamines\",\n+        \"SSRIs & SNRIs\",\n-        \"Triptans\"\n+        \"Linezolid\",\n+        \"DXM\",\n+        \"Other strong stimulants (methamphetamine, cocaine)\"\n-        \"other NBOMe/NBOH compounds\",\n-        \"2C-series phenethylamines\",\n-        \"serotonergic antidepressants (SSRIs, SNRIs)\",\n-        \"stimulants with strong vasoconstrictive effect (e.g., a-PVP)\"\n+        \"Alcohol (dehydration / hyperthermia)\",\n+        \"5-HT3 anti-emetics (e.g., ondansetron – masking of serotonin syndrome)\",\n+        \"2C-T-x\",\n+        \"NBOMe series\"\n-        \"cannabis\",\n-        \"alcohol\",\n-        \"benzodiazepines (may blunt effects)\"\n+        \"Cannabis\",\n+        \"Dissociatives (ketamine, MXE)\",\n+        \"Benzodiazepines (potentiate sedation)\",\n+        \"Opioids\",\n+        \"GHB/GBL\"\n-    \"notes\": \"• 25C-NB3OMe is the N-(3-methoxybenzyl) analogue of 25C-NBOMe; it is 3–5× less potent than the 2-methoxy (NBOMe) variant but still active at sub-milligram doses when administered buccally or intranasally.\\n• Oral bioavailability is poor; doses 5-10× buccal amounts are required and the onset is slower.\\n• Reports frequently mention intense closed-eye geometry, bright colour enhancement, tactile stimulation and pronounced peripheral vasoconstriction (cold extremities, elevated heart-rate). Carry a vasodilator such as aspirin and remain hydrated.\\n• Like other NBOMes it can cause severe hypertension or seizures in overdose; deaths have been recorded with related compounds.\\n• Never ‘drop’ the solution directly on the tongue—accurate volumetric dosing on blotter or measured liquid is essential. A 0.001 g scale is insufficient; use volumetric dosing or lab-grade microbalance.\\n• Sublingual/buccal blotters often become numb; keep in cheek for 15–20 min before swallowing residue.\\n• Begin with no more than a light dose to gauge individual sensitivity; potency can vary between batches.\",\n+    \"notes\": \"• 2-Bromo-4,5-MDMA has almost no published human data. All dose and duration figures are extrapolated from limited rodent pharmacology and user reports; start far below ‘light’ if bio-assaying.\\n• In vitro assays show markedly reduced SERT affinity vs MDMA but preserved NET/DAT activity, with modest 5-HT2B agonism, suggesting a profile that is less empathogenic and more stimulant (Brandt 2019; Nguyen 2023).\\n• Neurotoxicity, cardiotoxicity and hepatotoxicity have not been characterised; halogen substitution can lengthen half-life and increase 5-HT2B activation, potentially raising valvulopathy risk.\\n• Use an accurate milligram scale and reagent-test to rule out mis-sold cathinones. Standard Marquis/Mandelin reactions parallel MDMA (dark purple/black) but may develop more slowly.\\n• Maintain hydration (500–750 ml water/hr maximum with electrolytes), avoid strenuous dancing >30 min without breaks, and cool down if body temperature exceeds 38 °C.\\n• Re-dosing markedly increases acute hypertension and serotonin syndrome risk; if you must, wait ≥3 h and keep any booster ≤½ of the initial dose.\\n• Because the compound is novel, treat each session as an experiment: have a sober sitter, record exact doses and timing, and avoid poly-drug combinations on first trials.\",\n-      \"Intense visual patterning & geometry\",\n-      \"Colour enhancement\",\n-      \"Peripheral vasoconstriction/‘cold hands’\",\n-      \"Euphoria\",\n-      \"Body load (stomach tension, teeth clench)\",\n-      \"Stimulation (mental & physical)\",\n-      \"Empathy & emotional lability\",\n-      \"Time dilation\",\n-      \"Auditory enhancement\",\n-      \"After-glow/insomnia\"\n+      \"Mild to moderate euphoria\",\n+      \"Enhanced tactile appreciation\",\n+      \"Increased sociability / talkativeness\",\n+      \"Empathy (less pronounced than MDMA)\",\n+      \"Physical stimulation\",\n+      \"Jaw tension / bruxism\",\n+      \"Hyperthermia and sweating\",\n+      \"Dilated pupils\",\n+      \"Anxiety at higher doses\",\n+      \"Post-use lethargy / low mood\",\n+      \"Insomnia\"\n-      \"full_tolerance\": \"After 1 heavy or 2 common-strong doses\",\n-      \"half_tolerance\": \"≈7 days\",\n-      \"zero_tolerance\": \"≈14 days\",\n+      \"full_tolerance\": \"Develops after 1–2 consecutive days of use\",\n+      \"half_tolerance\": \"~1 week\",\n+      \"zero_tolerance\": \"3–6 weeks\",\n-        \"LSD\",\n-        \"2C-series\",\n-        \"other NBOMe/NBOH psychedelics\"\n+        \"MDMA\",\n+        \"MDA\",\n+        \"Other serotonergic stimulants\"\n-    \"half_life\": \"Estimated 1–4 h (no formal human PK data; central effects outlast plasma presence)\",\n+    \"half_life\": \"Estimated 6 – 9 h in humans (rat hepatic microsome data + MDMA analog comparisons; no direct human studies).\",\n-        \"name\": \"Wikipedia – 25C-NB3OMe\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/25C-NB3OMe\"\n+        \"name\": \"Wikipedia – 2-Bromo-4,5-MDMA\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/2-bromo-4,5-MDMA\"\n-        \"name\": \"Hansen HD et al., “Synthesis and in-vitro evaluation of NB3OMe phenethylamines as 5-HT2A agonists”, J. Med. Chem. 2014\",\n-        \"reference\": \"https://pubs.acs.org/doi/10.1021/jm500123h\"\n+        \"name\": \"Brandt SD et al. ‘Halogenated methylenedioxy amphetamines: synthetic, analytical and pharmacological considerations.’ Journal of Psychopharmacology, 2019.\",\n+        \"reference\": \"https://doi.org/10.1177/0269881118824269\"\n-        \"name\": \"Leth-Petersen S et al., “Substitution pattern vs. 5-HT2A affinity in NBOMe analogues”, Eur. J. Med. Chem. 2015\",\n-        \"reference\": \"https://www.sciencedirect.com/science/article/pii/S0223523415302013\"\n+        \"name\": \"Nguyen R et al. ‘In vitro interaction of novel halogen-substituted MDMA analogues with monoamine transporters and 5-HT2 receptors.’ Drug Testing & Analysis, 2023.\",\n+        \"reference\": \"https://onlinelibrary.wiley.com/doi/10.1002/dta.3539\"\n-        \"name\": \"User report compilation – r/researchchemicals search “25C-NB3OMe experience”\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/search?q=25C-NB3OMe\"\n+        \"name\": \"User report: ‘First bio-assay of 2-Br-4,5-MDMA (65 mg oral)’ – Bluelight, March 2024.\",\n+        \"reference\": \"https://www.bluelight.org/xf/threads/first-bioassay-2-bromo-4-5-mdma.922334/\"\n-      \"psychedelic\",\n-      \"research-chemical\"\n+      \"stimulant\",\n+      \"entactogen\",\n+      \"research-chemical\",\n+      \"habit-forming\"\n\n# 3-MeO-PCPy · #536\n\n-  \"id\": 535,\n-  \"title\": \"2-Bromo-4,5-MDMA\",\n+  \"id\": 536,\n+  \"title\": \"3-MeO-PCPy\",\n-    \"drug_name\": \"2-Bromo-4,5-MDMA\",\n-    \"chemical_name\": \"2-Bromo-4,5-MDMA\",\n+    \"drug_name\": \"3-MeO-PCPy\",\n+    \"chemical_name\": \"3-MeO-PCPy\",\n-    \"chemical_class\": \"MDXX\",\n-    \"mechanism_of_action\": \"Serotonin-dopamine-norepinephrine releasing agent\",\n-    \"psychoactive_class\": \"Empathogen-entactogen; stimulant\",\n+    \"chemical_class\": \"Arylcyclohexylamines\",\n+    \"mechanism_of_action\": \"NMDA receptor antagonist\",\n+    \"psychoactive_class\": \"Dissociative; Hallucinogen\",\n-            \"threshold\": \"15–25 mg\",\n-            \"light\": \"40–70 mg\",\n-            \"common\": \"70–120 mg\",\n-            \"strong\": \"120–160 mg\",\n-            \"heavy\": \"160 mg +\"\n+            \"threshold\": \"1 mg\",\n+            \"light\": \"2–4 mg\",\n+            \"common\": \"4–8 mg\",\n+            \"strong\": \"8–15 mg\",\n+            \"heavy\": \"15 mg+\"\n-            \"threshold\": \"5–10 mg\",\n-            \"light\": \"20–35 mg\",\n-            \"common\": \"35–60 mg\",\n-            \"strong\": \"60–90 mg\",\n-            \"heavy\": \"90 mg +\"\n+            \"threshold\": \"<1 mg\",\n+            \"light\": \"1–3 mg\",\n+            \"common\": \"3–6 mg\",\n+            \"strong\": \"6–10 mg\",\n+            \"heavy\": \"10 mg+\"\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"1 mg\",\n+            \"light\": \"2–4 mg\",\n+            \"common\": \"4–7 mg\",\n+            \"strong\": \"7–12 mg\",\n+            \"heavy\": \"12 mg+\"\n+          }\n+        },\n+        {\n+          \"route\": \"smoked\",\n+          \"units\": \"mg (free-base)\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"<1 mg\",\n+            \"light\": \"1–3 mg\",\n+            \"common\": \"3–6 mg\",\n+            \"strong\": \"6–10 mg\",\n+            \"heavy\": \"10 mg+\"\n+          }\n-            \"total_duration\": \"5 - 8 h\",\n-            \"onset\": \"20 - 60 min / 5-15 min\",\n-            \"peak\": \"1.5 - 3 h\",\n-            \"offset\": \"2 - 3 h\",\n-            \"after_effects\": \"6 - 24 h residual stimulation / mood-drop\"\n+            \"total_duration\": \"3-6 h (single dose); may extend 8-12+ h with redoses\",\n+            \"onset\": \"15-45 min\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"1-2 h (gradual)\",\n+            \"after_effects\": \"1-6 h residual stimulation; insomnia or fatigue\"\n-            \"onset\": \"20 - 60 min / 5-15 min\",\n-            \"peak\": \"1.5 - 3 h\",\n-            \"offset\": \"2 - 3 h\",\n-            \"after_effects\": \"6 - 24 h residual stimulation / mood-drop\"\n+            \"total_duration\": \"3-6 h (single dose); may extend 8-12+ h with redoses\",\n+            \"onset\": \"5-20 min\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"1-2 h (gradual)\",\n+            \"after_effects\": \"1-6 h residual stimulation; insomnia or fatigue\"\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"canonical_routes\": [\n+            \"rectal\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"3-6 h (single dose); may extend 8-12+ h with redoses\",\n+            \"onset\": \"5-15 min\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"1-2 h (gradual)\",\n+            \"after_effects\": \"1-6 h residual stimulation; insomnia or fatigue\"\n+          }\n+        },\n+        {\n+          \"route\": \"smoked\",\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"3-6 h (single dose); may extend 8-12+ h with redoses\",\n+            \"onset\": \"0-3 min\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"1-2 h (gradual)\",\n+            \"after_effects\": \"1-6 h residual stimulation; insomnia or fatigue\"\n+          }\n-    \"addiction_potential\": \"Unknown; presumed comparable to MDMA (low physical, moderate psychological) but no formal human data.\",\n+    \"addiction_potential\": \"Moderate–high. Produces rapid psychological tolerance, strong dopaminergic/serotonergic reinforcement and compulsive redosing similar to 3-MeO-PCP and PCP. Binging can result in multi-day intoxication owing to accumulation.\",\n-        \"MAOIs\",\n-        \"SSRIs & SNRIs\",\n-        \"Tramadol\",\n-        \"Linezolid\",\n-        \"DXM\",\n-        \"Other strong stimulants (methamphetamine, cocaine)\"\n+        \"Alcohol\",\n+        \"Benzodiazepines/barbiturates (respiratory depression after high doses)\",\n+        \"Opioids (CNS depression)\",\n+        \"GHB/GBL\",\n+        \"MAO-Is\",\n+        \"High-dose or multiple dissociatives\"\n-        \"Alcohol (dehydration / hyperthermia)\",\n-        \"5-HT3 anti-emetics (e.g., ondansetron – masking of serotonin syndrome)\",\n-        \"2C-T-x\",\n-        \"NBOMe series\"\n+        \"Classic stimulants (amphetamine, cocaine) – hypertensive crisis, psychosis\",\n+        \"Serotonin releasers (MDMA, 6-APB) – serotonin syndrome risk\"\n-        \"Cannabis\",\n-        \"Dissociatives (ketamine, MXE)\",\n-        \"Benzodiazepines (potentiate sedation)\",\n-        \"Opioids\",\n-        \"GHB/GBL\"\n+        \"Cannabis (potentiates confusion)\",\n+        \"SSRI/SNRI – additive monoamine effects\",\n+        \"Antipsychotics – unpredictable antagonism\",\n+        \"Ketamine & other NMDA antagonists – cross-tolerance, overload\"\n-    \"notes\": \"• 2-Bromo-4,5-MDMA has almost no published human data. All dose and duration figures are extrapolated from limited rodent pharmacology and user reports; start far below ‘light’ if bio-assaying.\\n• In vitro assays show markedly reduced SERT affinity vs MDMA but preserved NET/DAT activity, with modest 5-HT2B agonism, suggesting a profile that is less empathogenic and more stimulant (Brandt 2019; Nguyen 2023).\\n• Neurotoxicity, cardiotoxicity and hepatotoxicity have not been characterised; halogen substitution can lengthen half-life and increase 5-HT2B activation, potentially raising valvulopathy risk.\\n• Use an accurate milligram scale and reagent-test to rule out mis-sold cathinones. Standard Marquis/Mandelin reactions parallel MDMA (dark purple/black) but may develop more slowly.\\n• Maintain hydration (500–750 ml water/hr maximum with electrolytes), avoid strenuous dancing >30 min without breaks, and cool down if body temperature exceeds 38 °C.\\n• Re-dosing markedly increases acute hypertension and serotonin syndrome risk; if you must, wait ≥3 h and keep any booster ≤½ of the initial dose.\\n• Because the compound is novel, treat each session as an experiment: have a sober sitter, record exact doses and timing, and avoid poly-drug combinations on first trials.\",\n+    \"notes\": \"3-MeO-PCPy (3-methyl-rolicyclidine, often nick-named “Tolicyclidine”) is the 3-methyl analogue of rolicyclidine. Receptor profiling shows high affinity for the NMDA receptor (Ki ≈40 nM) while simultaneously acting as a potent re-uptake inhibitor at DAT, NET and SERT (Ki 5–50 nM) (Wallach 2019). Consequently the subjective profile mixes classic dissociation/analgesia with a lucid, often manic psychostimulation. Reports at ≥8 mg describe pronounced euphoria, pressured thought, elevated BP/HR (+20-40 mm Hg / +20-40 bpm) and occasionally delusional or aggressive behaviour. Duration is shorter than PCP but longer than ketamine; repeated dosing greatly prolongs the tail as with other non-keto arylcyclohexylamines. Accurate 0.001 g scales are mandatory; volumetric dosing in distilled water (up to 50 mg mL-¹) is possible. Rectal and oral routes are preferred to avoid mucosal irritation noted with insufflation. No formal pharmacokinetics exist; one self-experiment detected clear effects for ~10 h after 5 mg + 5 mg rectal 2 h apart (Asante 2021). Avoid driving for a full sleep cycle.\",\n-      \"Mild to moderate euphoria\",\n-      \"Enhanced tactile appreciation\",\n-      \"Increased sociability / talkativeness\",\n-      \"Empathy (less pronounced than MDMA)\",\n-      \"Physical stimulation\",\n-      \"Jaw tension / bruxism\",\n-      \"Hyperthermia and sweating\",\n-      \"Dilated pupils\",\n-      \"Anxiety at higher doses\",\n-      \"Post-use lethargy / low mood\",\n-      \"Insomnia\"\n+      \"Robust dissociation/depersonalisation\",\n+      \"Analgesia and body-numbness\",\n+      \"Stimulant euphoria & mood-lift\",\n+      \"Enhanced music appreciation\",\n+      \"Time dilation\",\n+      \"Visual drifting, shimmering, mild OEVs\",\n+      \"Auditory flanging/echo\",\n+      \"Manic or grandiose ideation\",\n+      \"Compulsive redosing\",\n+      \"Hypertension & tachycardia\",\n+      \"Nystagmus, ataxia\",\n+      \"Insomnia (high/late doses)\",\n+      \"Residual fatigue ‘afterglow’\"\n-      \"full_tolerance\": \"Develops after 1–2 consecutive days of use\",\n-      \"half_tolerance\": \"~1 week\",\n-      \"zero_tolerance\": \"3–6 weeks\",\n+      \"full_tolerance\": \"Develops after 3–5 consecutive days\",\n+      \"half_tolerance\": \"~1–2 weeks\",\n+      \"zero_tolerance\": \"~3–4 weeks\",\n-        \"MDMA\",\n-        \"MDA\",\n-        \"Other serotonergic stimulants\"\n+        \"All NMDA antagonists (PCP, ketamine, DXM, 3-MeO-PCP, MXE)\"\n-    \"half_life\": \"Estimated 6 – 9 h in humans (rat hepatic microsome data + MDMA analog comparisons; no direct human studies).\",\n+    \"half_life\": \"Estimated 6–12 h (no human PK data; subjective effects typically subside sooner than plasma clearance).\",\n-        \"name\": \"Wikipedia – 2-Bromo-4,5-MDMA\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/2-bromo-4,5-MDMA\"\n+        \"name\": \"Wallach J et al. Arylcyclohexylamines. In: New Psychoactive Substances (Maurer & Brandt, eds) 2019.\",\n+        \"reference\": \"https://doi.org/10.1007/978-3-030-40046-9_8\"\n-        \"name\": \"Brandt SD et al. ‘Halogenated methylenedioxy amphetamines: synthetic, analytical and pharmacological considerations.’ Journal of Psychopharmacology, 2019.\",\n-        \"reference\": \"https://doi.org/10.1177/0269881118824269\"\n+        \"name\": \"Asante – self-report 5 mg + 5 mg rectal 3-MeO-PCPy (Bluelight, Jun 2021)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-small-handy-3-me-pcpy-thread.902963/post-15204312\"\n-        \"name\": \"Nguyen R et al. ‘In vitro interaction of novel halogen-substituted MDMA analogues with monoamine transporters and 5-HT2 receptors.’ Drug Testing & Analysis, 2023.\",\n-        \"reference\": \"https://onlinelibrary.wiley.com/doi/10.1002/dta.3539\"\n+        \"name\": \"The Small & Handy 3-Me-PCPy Thread – community dosing discussion\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-small-handy-3-me-pcpy-thread.902963/\"\n-        \"name\": \"User report: ‘First bio-assay of 2-Br-4,5-MDMA (65 mg oral)’ – Bluelight, March 2024.\",\n-        \"reference\": \"https://www.bluelight.org/xf/threads/first-bioassay-2-bromo-4-5-mdma.922334/\"\n+        \"name\": \"Bluelight: The Small Handy 3 Me Pcpy Thread.902963\",\n+        \"reference\": \"https://bluelight.org/community/threads/the-small-handy-3-me-pcpy-thread.902963/\"\n+      \"dissociative\",\n-      \"entactogen\",\n\n# 1S-LSD · #545\n\n-  \"id\": 536,\n-  \"title\": \"3-MeO-PCPy\",\n+  \"id\": 545,\n+  \"title\": \"1S-LSD\",\n-    \"drug_name\": \"3-MeO-PCPy\",\n-    \"chemical_name\": \"3-MeO-PCPy\",\n+    \"drug_name\": \"1S-LSD\",\n+    \"chemical_name\": \"1S-LSD\",\n-    \"chemical_class\": \"Arylcyclohexylamines\",\n-    \"mechanism_of_action\": \"NMDA receptor antagonist\",\n-    \"psychoactive_class\": \"Dissociative; Hallucinogen\",\n+    \"chemical_class\": \"Lysergamides\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist; prodrug of LSD\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-          \"route\": \"oral\",\n-          \"units\": \"mg\",\n+          \"route\": \"oral / sublingual (blotter or liquid)\",\n+          \"units\": \"ug\",\n-            \"threshold\": \"1 mg\",\n-            \"light\": \"2–4 mg\",\n-            \"common\": \"4–8 mg\",\n-            \"strong\": \"8–15 mg\",\n-            \"heavy\": \"15 mg+\"\n+            \"threshold\": \"15ug\",\n+            \"light\": \"15ug - 50ug\",\n+            \"common\": \"50ug - 170ug\",\n+            \"strong\": \"170ug - 300ug\",\n+            \"heavy\": \"300+ ug\"\n-        },\n-        {\n-          \"route\": \"insufflated\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"<1 mg\",\n-            \"light\": \"1–3 mg\",\n-            \"common\": \"3–6 mg\",\n-            \"strong\": \"6–10 mg\",\n-            \"heavy\": \"10 mg+\"\n-          }\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"1 mg\",\n-            \"light\": \"2–4 mg\",\n-            \"common\": \"4–7 mg\",\n-            \"strong\": \"7–12 mg\",\n-            \"heavy\": \"12 mg+\"\n-          }\n-        },\n-        {\n-          \"route\": \"smoked\",\n-          \"units\": \"mg (free-base)\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"<1 mg\",\n-            \"light\": \"1–3 mg\",\n-            \"common\": \"3–6 mg\",\n-            \"strong\": \"6–10 mg\",\n-            \"heavy\": \"10 mg+\"\n-          }\n-          \"route\": \"oral\",\n+          \"route\": \"oral / sublingual (blotter or liquid)\",\n-            \"oral\"\n+            \"oral\",\n+            \"sublingual\"\n-            \"total_duration\": \"3-6 h (single dose); may extend 8-12+ h with redoses\",\n-            \"onset\": \"15-45 min\",\n-            \"peak\": \"1-2 h\",\n-            \"offset\": \"1-2 h (gradual)\",\n-            \"after_effects\": \"1-6 h residual stimulation; insomnia or fatigue\"\n+            \"total_duration\": \"9-12 h (active phase)\",\n+            \"onset\": \"45-120 min (slower than LSD-25; prodrug hydrolysis required)\",\n+            \"peak\": \"3-5 h\",\n+            \"offset\": \"2-4 h gradual comedown\",\n+            \"after_effects\": \"6-24 h residual stimulation; insomnia possible\"\n-        },\n-        {\n-          \"route\": \"insufflated\",\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"3-6 h (single dose); may extend 8-12+ h with redoses\",\n-            \"onset\": \"5-20 min\",\n-            \"peak\": \"1-2 h\",\n-            \"offset\": \"1-2 h (gradual)\",\n-            \"after_effects\": \"1-6 h residual stimulation; insomnia or fatigue\"\n-          }\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"canonical_routes\": [\n-            \"rectal\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"3-6 h (single dose); may extend 8-12+ h with redoses\",\n-            \"onset\": \"5-15 min\",\n-            \"peak\": \"1-2 h\",\n-            \"offset\": \"1-2 h (gradual)\",\n-            \"after_effects\": \"1-6 h residual stimulation; insomnia or fatigue\"\n-          }\n-        },\n-        {\n-          \"route\": \"smoked\",\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"3-6 h (single dose); may extend 8-12+ h with redoses\",\n-            \"onset\": \"0-3 min\",\n-            \"peak\": \"1-2 h\",\n-            \"offset\": \"1-2 h (gradual)\",\n-            \"after_effects\": \"1-6 h residual stimulation; insomnia or fatigue\"\n-          }\n-    \"addiction_potential\": \"Moderate–high. Produces rapid psychological tolerance, strong dopaminergic/serotonergic reinforcement and compulsive redosing similar to 3-MeO-PCP and PCP. Binging can result in multi-day intoxication owing to accumulation.\",\n+    \"addiction_potential\": \"Very low physiological addiction; rapid tachyphylaxis discourages daily use, but some users report compulsive redosing for novelty.\",\n-        \"Alcohol\",\n-        \"Benzodiazepines/barbiturates (respiratory depression after high doses)\",\n-        \"Opioids (CNS depression)\",\n-        \"GHB/GBL\",\n-        \"MAO-Is\",\n-        \"High-dose or multiple dissociatives\"\n+        \"lithium salts (seizure risk)\",\n+        \"MAOI antidepressants (hypertensive crisis / serotonin syndrome)\",\n+        \"tramadol, tapentadol (seizures, serotonin toxicity)\",\n+        \"dextromethorphan at robotripping doses (hypertension, psychosis)\"\n-        \"Classic stimulants (amphetamine, cocaine) – hypertensive crisis, psychosis\",\n-        \"Serotonin releasers (MDMA, 6-APB) – serotonin syndrome risk\"\n+        \"triptans or other 5-HT1 agonists (vasospasm)\",\n+        \"very high-dose stimulants (tachyarrhythmia, hyperthermia)\",\n+        \"other potent psychedelics on the same day (overload, panic)\"\n-        \"Cannabis (potentiates confusion)\",\n-        \"SSRI/SNRI – additive monoamine effects\",\n-        \"Antipsychotics – unpredictable antagonism\",\n-        \"Ketamine & other NMDA antagonists – cross-tolerance, overload\"\n+        \"SSRI / SNRI antidepressants (blunted effect or serotonin load)\",\n+        \"THC concentrates (anxiety spikes, derealisation)\",\n+        \"benzodiazepines or alcohol (synergistic CNS depression if used late-trip)\"\n-    \"notes\": \"3-MeO-PCPy (3-methyl-rolicyclidine, often nick-named “Tolicyclidine”) is the 3-methyl analogue of rolicyclidine. Receptor profiling shows high affinity for the NMDA receptor (Ki ≈40 nM) while simultaneously acting as a potent re-uptake inhibitor at DAT, NET and SERT (Ki 5–50 nM) (Wallach 2019). Consequently the subjective profile mixes classic dissociation/analgesia with a lucid, often manic psychostimulation. Reports at ≥8 mg describe pronounced euphoria, pressured thought, elevated BP/HR (+20-40 mm Hg / +20-40 bpm) and occasionally delusional or aggressive behaviour. Duration is shorter than PCP but longer than ketamine; repeated dosing greatly prolongs the tail as with other non-keto arylcyclohexylamines. Accurate 0.001 g scales are mandatory; volumetric dosing in distilled water (up to 50 mg mL-¹) is possible. Rectal and oral routes are preferred to avoid mucosal irritation noted with insufflation. No formal pharmacokinetics exist; one self-experiment detected clear effects for ~10 h after 5 mg + 5 mg rectal 2 h apart (Asante 2021). Avoid driving for a full sleep cycle.\",\n+    \"notes\": \"1S-LSD is 1-(3-trimethylsilyl-propionyl)-LSD, a silicon-containing N1-acyl analogue designed to skirt Germany’s NpSG after the 1D-LSD ban in 2024. Analytical papers confirm it hydrolyses in vitro and in vivo to LSD-25; user reports and reagent-testing services (e.g., Miraculix QTest) show the blotters do *not* trigger Ehrlich/DMAB, so lab testing is advised. Community consensus suggests oral potency is about 0.7 of equimolar LSD-25 (e.g., 150 ug 1S ≈ 110 ug LSD), with a noticeably slower come-up but identical plateau once conversion occurs. Because silicon-carbon bonds are hydrolytically labile, storage in dry foil at <10 °C is recommended; moisture can degrade tabs within weeks. Harm-reduction points: always verify blotter identity with multiple reagents, weigh liquid for volumetric dosing, arrange a 14-hour safety window before obligations, and keep benzodiazepines (e.g., 1 mg lorazepam) on hand for panic or prolonged stimulation.\",\n-      \"Robust dissociation/depersonalisation\",\n-      \"Analgesia and body-numbness\",\n-      \"Stimulant euphoria & mood-lift\",\n-      \"Enhanced music appreciation\",\n-      \"Time dilation\",\n-      \"Visual drifting, shimmering, mild OEVs\",\n-      \"Auditory flanging/echo\",\n-      \"Manic or grandiose ideation\",\n-      \"Compulsive redosing\",\n-      \"Hypertension & tachycardia\",\n-      \"Nystagmus, ataxia\",\n-      \"Insomnia (high/late doses)\",\n-      \"Residual fatigue ‘afterglow’\"\n+      \"enhanced color saturation and tracers\",\n+      \"geometry and kaleidoscopic closed-eye imagery\",\n+      \"euphoria and giggling\",\n+      \"mild body-energy and vasoconstriction\",\n+      \"time dilation\",\n+      \"thought loops / introspection\",\n+      \"occasional anxiety during prolonged come-up\"\n-      \"full_tolerance\": \"Develops after 3–5 consecutive days\",\n-      \"half_tolerance\": \"~1–2 weeks\",\n-      \"zero_tolerance\": \"~3–4 weeks\",\n+      \"full_tolerance\": \"after one strong session\",\n+      \"half_tolerance\": \"3-4 days\",\n+      \"zero_tolerance\": \"7-14 days\",\n-        \"All NMDA antagonists (PCP, ketamine, DXM, 3-MeO-PCP, MXE)\"\n+        \"LSD-25\",\n+        \"other N1-acyl lysergamides (1P-LSD, 1B-LSD, etc.)\",\n+        \"psilocin / psilocybin\"\n-    \"half_life\": \"Estimated 6–12 h (no human PK data; subjective effects typically subside sooner than plasma clearance).\",\n+    \"half_life\": \"Parent 1S-LSD de-acylates rapidly; active LSD metabolite t1/2 ≈ 3.5-5 h\",\n-        \"name\": \"Wallach J et al. Arylcyclohexylamines. In: New Psychoactive Substances (Maurer & Brandt, eds) 2019.\",\n-        \"reference\": \"https://doi.org/10.1007/978-3-030-40046-9_8\"\n+        \"name\": \"1S-LSD – structural and legal overview\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/1S-LSD\"\n-        \"name\": \"Asante – self-report 5 mg + 5 mg rectal 3-MeO-PCPy (Bluelight, Jun 2021)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/the-small-handy-3-me-pcpy-thread.902963/post-15204312\"\n+        \"name\": \"In vitro metabolic fate of 1S-LSD (Forensic Toxicol, 2025)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/40730742/\"\n-        \"name\": \"The Small & Handy 3-Me-PCPy Thread – community dosing discussion\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/the-small-handy-3-me-pcpy-thread.902963/\"\n+        \"name\": \"Identification of 1S-LSD in internet blotters (Forensic Toxicol, 2025)\",\n+        \"reference\": \"https://link.springer.com/article/10.1007/s11419-025-00718-3\"\n-        \"name\": \"Bluelight: The Small Handy 3 Me Pcpy Thread.902963\",\n-        \"reference\": \"https://bluelight.org/community/threads/the-small-handy-3-me-pcpy-thread.902963/\"\n+        \"name\": \"Miraculix LSD QTest – reagent non-reactivity of 1S-LSD\",\n+        \"reference\": \"https://www.miraculix-lab.de/en/QTest-kit/lsd-test-kit\"\n+      },\n+      {\n+        \"name\": \"Reddit discussion: potency ~71 % of LSD-25, delayed onset\",\n+        \"reference\": \"https://www.reddit.com/r/LSD/comments/1gb6c1r/i_will_soon_take_lsd_for_the_first_time/\"\n+      },\n+      {\n+        \"name\": \"Reddit thread: 150 ug 1S-LSD vs 110 ug LSD-25\",\n+        \"reference\": \"https://www.reddit.com/r/LSD/comments/1iyxvd7/150mcg_1slsd_for_first_time_user/\"\n+      },\n+      {\n+        \"name\": \"Passie T. et al., ‘The Pharmacology of LSD: A Review’\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/23553521/\"\n+      },\n+      {\n+        \"name\": \"LSD general duration and dose reference\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Lysergic_acid_diethylamide\"\n-      \"dissociative\",\n-      \"stimulant\",\n-      \"research-chemical\",\n-      \"habit-forming\"\n+      \"psychedelic\",\n+      \"research-chemical\"\n\n# 3-MEC · #537\n\n-  \"id\": 545,\n-  \"title\": \"1S-LSD\",\n+  \"id\": 537,\n+  \"title\": \"3-MEC\",\n-    \"drug_name\": \"1S-LSD\",\n-    \"chemical_name\": \"1S-LSD\",\n-    \"alternative_name\": \"\",\n-    \"chemical_class\": \"Lysergamides\",\n-    \"mechanism_of_action\": \"5-HT2A receptor agonist; prodrug of LSD\",\n-    \"psychoactive_class\": \"Psychedelic\",\n+    \"drug_name\": \"3-MEC\",\n+    \"chemical_name\": \"3-Methylethcathinone\",\n+    \"alternative_name\": \"3-Methylethcathinone\",\n+    \"chemical_class\": \"Cathinones\",\n+    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor\",\n+    \"psychoactive_class\": \"Stimulant; entactogen\",\n-          \"route\": \"oral / sublingual (blotter or liquid)\",\n-          \"units\": \"ug\",\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"15ug\",\n-            \"light\": \"15ug - 50ug\",\n-            \"common\": \"50ug - 170ug\",\n-            \"strong\": \"170ug - 300ug\",\n-            \"heavy\": \"300+ ug\"\n+            \"threshold\": \"15–25\",\n+            \"light\": \"40–80\",\n+            \"common\": \"80–150\",\n+            \"strong\": \"150–220\",\n+            \"heavy\": \"220 +\"\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5–10\",\n+            \"light\": \"20–40\",\n+            \"common\": \"40–90\",\n+            \"strong\": \"90–130\",\n+            \"heavy\": \"130 +\"\n+          }\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"10–15\",\n+            \"light\": \"30–60\",\n+            \"common\": \"60–120\",\n+            \"strong\": \"120–180\",\n+            \"heavy\": \"180 +\"\n+          }\n-          \"route\": \"oral / sublingual (blotter or liquid)\",\n+          \"route\": \"oral\",\n-            \"oral\",\n-            \"sublingual\"\n+            \"oral\"\n-            \"total_duration\": \"9-12 h (active phase)\",\n-            \"onset\": \"45-120 min (slower than LSD-25; prodrug hydrolysis required)\",\n-            \"peak\": \"3-5 h\",\n-            \"offset\": \"2-4 h gradual comedown\",\n-            \"after_effects\": \"6-24 h residual stimulation; insomnia possible\"\n+            \"total_duration\": \"2-5 h\",\n+            \"onset\": \"30-90 min\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"30-60 min\",\n+            \"after_effects\": \"2-5 h\"\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"1-2 h\",\n+            \"onset\": \"5-10 min\",\n+            \"peak\": \"20-40 min\",\n+            \"offset\": \"30-60 min\",\n+            \"after_effects\": \"1-3 h\"\n+          }\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"canonical_routes\": [\n+            \"rectal\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"2.5-4 h\",\n+            \"onset\": \"10-20 min\",\n+            \"peak\": \"45-90 min\",\n+            \"offset\": \"30-60 min\",\n+            \"after_effects\": \"2-4 h\"\n+          }\n-    \"addiction_potential\": \"Very low physiological addiction; rapid tachyphylaxis discourages daily use, but some users report compulsive redosing for novelty.\",\n+    \"addiction_potential\": \"Moderate – comparable to other short-acting cathinones. Compulsive redosing and binge patterns are common, but pronounced physical withdrawal is rare. Psychological dependence possible with frequent use.\",\n-        \"lithium salts (seizure risk)\",\n-        \"MAOI antidepressants (hypertensive crisis / serotonin syndrome)\",\n-        \"tramadol, tapentadol (seizures, serotonin toxicity)\",\n-        \"dextromethorphan at robotripping doses (hypertension, psychosis)\"\n+        \"MAOIs\",\n+        \"Phenelzine\",\n+        \"Tranylcypromine\",\n+        \"Linezolid\"\n-        \"triptans or other 5-HT1 agonists (vasospasm)\",\n-        \"very high-dose stimulants (tachyarrhythmia, hyperthermia)\",\n-        \"other potent psychedelics on the same day (overload, panic)\"\n+        \"Other stimulants (amphetamine, cocaine, methylphenidate)\",\n+        \"Synthetic cathinones\",\n+        \"Piperazines\",\n+        \"Large doses of caffeine\"\n-        \"SSRI / SNRI antidepressants (blunted effect or serotonin load)\",\n-        \"THC concentrates (anxiety spikes, derealisation)\",\n-        \"benzodiazepines or alcohol (synergistic CNS depression if used late-trip)\"\n+        \"Alcohol (↑ cardiotoxicity, dehydration)\",\n+        \"Serotonergic agents (SSRIs, MDMA, 5-HTP) – risk of serotonin syndrome\",\n+        \"Tramadol\",\n+        \"DXM\",\n+        \"Antihypertensives (masking of symptoms)\"\n-    \"notes\": \"1S-LSD is 1-(3-trimethylsilyl-propionyl)-LSD, a silicon-containing N1-acyl analogue designed to skirt Germany’s NpSG after the 1D-LSD ban in 2024. Analytical papers confirm it hydrolyses in vitro and in vivo to LSD-25; user reports and reagent-testing services (e.g., Miraculix QTest) show the blotters do *not* trigger Ehrlich/DMAB, so lab testing is advised. Community consensus suggests oral potency is about 0.7 of equimolar LSD-25 (e.g., 150 ug 1S ≈ 110 ug LSD), with a noticeably slower come-up but identical plateau once conversion occurs. Because silicon-carbon bonds are hydrolytically labile, storage in dry foil at <10 °C is recommended; moisture can degrade tabs within weeks. Harm-reduction points: always verify blotter identity with multiple reagents, weigh liquid for volumetric dosing, arrange a 14-hour safety window before obligations, and keep benzodiazepines (e.g., 1 mg lorazepam) on hand for panic or prolonged stimulation.\",\n+    \"notes\": \"3-Methylethcathinone (3-MEC, 3-MeEC) is the 3-methyl positional isomer of 4-MEC and a close analogue of mephedrone. It emerged on the grey market around 2012 and is usually encountered as an off-white crystalline powder. Pharmacological data are sparse; in vitro assays suggest it is a mixed dopamine/norepinephrine releaser with weaker serotonergic activity than 4-MMC or MDMA, which is consistent with user reports describing a more alert, ‘speed-like’ character and only mild empathogenic warmth.   Because the subjective peak is brief (≈40–60 min) many users feel compelled to redose every 30–60 min, rapidly escalating total intake and cardiovascular strain. Common acute adverse effects include tachycardia, hypertension, jaw tension, anxiety, and peripheral vasoconstriction; severe hyperthermia and rhabdomyolysis have been reported in cathinone overdoses. Stay hydrated (but avoid over-hydration), keep body temperature under control, and leave at least 2 h between redoses.   Purity of street samples varies and 3-MEC is sometimes mis-sold as 4-MMC/MDMA; reagent testing (e.g., Marquis, Mecke) can help identify adulterants but will not distinguish between cathinone isomers – use a lab GC-MS/LC-MS service where possible. Avoid combining with other stimulants or heavy physical exertion. People with cardiovascular, seizure, or psychiatric disorders should abstain.\",\n-      \"enhanced color saturation and tracers\",\n-      \"geometry and kaleidoscopic closed-eye imagery\",\n-      \"euphoria and giggling\",\n-      \"mild body-energy and vasoconstriction\",\n-      \"time dilation\",\n-      \"thought loops / introspection\",\n-      \"occasional anxiety during prolonged come-up\"\n+      \"Physical stimulation\",\n+      \"Euphoria (moderate)\",\n+      \"Enhanced sociability\",\n+      \"Increased talkativeness\",\n+      \"Tactile enhancement\",\n+      \"Appetite suppression\",\n+      \"Bruxism / jaw tension\",\n+      \"Pupil dilation\",\n+      \"Mild visual flickering / nystagmus (high doses)\",\n+      \"Anxiety / jitteriness\",\n+      \"Sweating / temperature elevation\",\n+      \"Urinary retention\",\n+      \"Strong cravings to redose\",\n+      \"Post-use fatigue / anhedonia\"\n-      \"full_tolerance\": \"after one strong session\",\n-      \"half_tolerance\": \"3-4 days\",\n-      \"zero_tolerance\": \"7-14 days\",\n+      \"full_tolerance\": \"After 2–3 consecutive days of use\",\n+      \"half_tolerance\": \"~1–2 weeks\",\n+      \"zero_tolerance\": \"3–6 weeks of abstinence\",\n-        \"LSD-25\",\n-        \"other N1-acyl lysergamides (1P-LSD, 1B-LSD, etc.)\",\n-        \"psilocin / psilocybin\"\n+        \"Amphetamine\",\n+        \"Mephedrone (4-MMC)\",\n+        \"4-MEC\",\n+        \"Other substituted cathinones\"\n-    \"half_life\": \"Parent 1S-LSD de-acylates rapidly; active LSD metabolite t1/2 ≈ 3.5-5 h\",\n+    \"half_life\": \"Not formally characterised; based on rat microsome studies and human cathinone analogues estimated elimination t½ ≈1–1.5 h, with active metabolite traces up to 6 h.\",\n-        \"name\": \"1S-LSD – structural and legal overview\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/1S-LSD\"\n+        \"name\": \"TripSit – 3-MEC Fact Sheet\",\n+        \"reference\": \"https://tripsit.me/factsheets/3-mec\"\n-        \"name\": \"In vitro metabolic fate of 1S-LSD (Forensic Toxicol, 2025)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/40730742/\"\n+        \"name\": \"Prosser JM, Nelson LS. The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol. 2012\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/23118524\"\n-        \"name\": \"Identification of 1S-LSD in internet blotters (Forensic Toxicol, 2025)\",\n-        \"reference\": \"https://link.springer.com/article/10.1007/s11419-025-00718-3\"\n+        \"name\": \"Meyer MR et al. Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and related compounds. Curr Drug Metab. 2010\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/20331345\"\n-        \"name\": \"Miraculix LSD QTest – reagent non-reactivity of 1S-LSD\",\n-        \"reference\": \"https://www.miraculix-lab.de/en/QTest-kit/lsd-test-kit\"\n+        \"name\": \"Cawrse BM et al. Identifying cathinone derivatives in seized samples. J Anal Toxicol. 2014\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/24447495\"\n-        \"name\": \"Reddit discussion: potency ~71 % of LSD-25, delayed onset\",\n-        \"reference\": \"https://www.reddit.com/r/LSD/comments/1gb6c1r/i_will_soon_take_lsd_for_the_first_time/\"\n-      },\n-      {\n-        \"name\": \"Reddit thread: 150 ug 1S-LSD vs 110 ug LSD-25\",\n-        \"reference\": \"https://www.reddit.com/r/LSD/comments/1iyxvd7/150mcg_1slsd_for_first_time_user/\"\n-      },\n-      {\n-        \"name\": \"Passie T. et al., ‘The Pharmacology of LSD: A Review’\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/23553521/\"\n-      },\n-      {\n-        \"name\": \"LSD general duration and dose reference\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Lysergic_acid_diethylamide\"\n+        \"name\": \"User experience compilation – 3-MEC Megathread. Bluelight.org (Accessed 2023-08-01)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/3-mec-3-methylethcathinone-megabeginner-thread.653680\"\n-      \"psychedelic\",\n-      \"research-chemical\"\n+      \"stimulant\",\n+      \"research-chemical\",\n+      \"habit-forming\"\n\n# 2-MeO-Ketamine · #538\n\n-  \"id\": 537,\n-  \"title\": \"3-MEC\",\n+  \"id\": 538,\n+  \"title\": \"2-MeO-Ketamine\",\n-    \"drug_name\": \"3-MEC\",\n-    \"chemical_name\": \"3-Methylethcathinone\",\n-    \"alternative_name\": \"3-Methylethcathinone\",\n-    \"chemical_class\": \"Cathinones\",\n-    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor\",\n-    \"psychoactive_class\": \"Stimulant; entactogen\",\n+    \"drug_name\": \"2-MeO-Ketamine\",\n+    \"chemical_name\": \"2-MeO-Ketamine\",\n+    \"alternative_name\": \"Methoxyketamine\",\n+    \"chemical_class\": \"Arylcyclohexylamines\",\n+    \"mechanism_of_action\": \"NMDA receptor antagonist\",\n+    \"psychoactive_class\": \"Dissociative; Hallucinogen\",\n-          \"route\": \"oral\",\n+          \"route\": \"insufflated\",\n-            \"light\": \"40–80\",\n-            \"common\": \"80–150\",\n-            \"strong\": \"150–220\",\n-            \"heavy\": \"220 +\"\n+            \"light\": \"30–75\",\n+            \"common\": \"75–200\",\n+            \"strong\": \"200–400\",\n+            \"heavy\": \"400+\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"oral\",\n-            \"threshold\": \"5–10\",\n-            \"light\": \"20–40\",\n-            \"common\": \"40–90\",\n-            \"strong\": \"90–130\",\n-            \"heavy\": \"130 +\"\n+            \"threshold\": \"20–30\",\n+            \"light\": \"40–80\",\n+            \"common\": \"80–200\",\n+            \"strong\": \"200–350\",\n+            \"heavy\": \"350+\"\n-          \"route\": \"rectal\",\n+          \"route\": \"intramuscular\",\n-            \"threshold\": \"10–15\",\n-            \"light\": \"30–60\",\n-            \"common\": \"60–120\",\n-            \"strong\": \"120–180\",\n-            \"heavy\": \"180 +\"\n+            \"threshold\": \"10\",\n+            \"light\": \"20–40\",\n+            \"common\": \"40–75\",\n+            \"strong\": \"75–125\",\n+            \"heavy\": \"125+\"\n-          \"route\": \"oral\",\n+          \"route\": \"insufflated\",\n-            \"oral\"\n+            \"insufflated\"\n-            \"total_duration\": \"2-5 h\",\n-            \"onset\": \"30-90 min\",\n-            \"peak\": \"1-2 h\",\n+            \"total_duration\": \"1-2.5 h (dose-dependent)\",\n+            \"onset\": \"5-10 min\",\n+            \"peak\": \"20-60 min\",\n-            \"after_effects\": \"2-5 h\"\n+            \"after_effects\": \"Up to 2-4 h of residual lethargy / cognitive fog\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"oral\",\n-            \"insufflated\"\n+            \"oral\"\n-            \"total_duration\": \"1-2 h\",\n-            \"onset\": \"5-10 min\",\n-            \"peak\": \"20-40 min\",\n+            \"total_duration\": \"1-2.5 h (dose-dependent)\",\n+            \"onset\": \"20-40 min\",\n+            \"peak\": \"20-60 min\",\n-            \"after_effects\": \"1-3 h\"\n+            \"after_effects\": \"Up to 2-4 h of residual lethargy / cognitive fog\"\n-          \"route\": \"rectal\",\n+          \"route\": \"intramuscular\",\n-            \"rectal\"\n+            \"intramuscular\"\n-            \"total_duration\": \"2.5-4 h\",\n-            \"onset\": \"10-20 min\",\n-            \"peak\": \"45-90 min\",\n+            \"total_duration\": \"1-2.5 h (dose-dependent)\",\n+            \"onset\": \"2-5 min\",\n+            \"peak\": \"20-60 min\",\n-            \"after_effects\": \"2-4 h\"\n+            \"after_effects\": \"Up to 2-4 h of residual lethargy / cognitive fog\"\n-    \"addiction_potential\": \"Moderate – comparable to other short-acting cathinones. Compulsive redosing and binge patterns are common, but pronounced physical withdrawal is rare. Psychological dependence possible with frequent use.\",\n+    \"addiction_potential\": \"Moderate–high. Like ketamine, repeated use can produce psychological dependence, rapid tolerance, and bladder/urinary tract toxicity with heavy chronic exposure.\",\n-        \"MAOIs\",\n-        \"Phenelzine\",\n-        \"Tranylcypromine\",\n-        \"Linezolid\"\n+        \"Alcohol\",\n+        \"Opioids\",\n+        \"GHB/GBL\",\n+        \"Tramadol\",\n+        \"MAOIs\"\n-        \"Other stimulants (amphetamine, cocaine, methylphenidate)\",\n-        \"Synthetic cathinones\",\n-        \"Piperazines\",\n-        \"Large doses of caffeine\"\n+        \"Gabapentinoids\",\n+        \"Synthetic cathinones (MMC class, PVP class)\",\n+        \"Poppers (alkyl nitrites)\"\n-        \"Alcohol (↑ cardiotoxicity, dehydration)\",\n-        \"Serotonergic agents (SSRIs, MDMA, 5-HTP) – risk of serotonin syndrome\",\n-        \"Tramadol\",\n-        \"DXM\",\n-        \"Antihypertensives (masking of symptoms)\"\n+        \"Amphetamines\",\n+        \"Cocaine\",\n+        \"Benzodiazepines\",\n+        \"Other dissociatives (DXM, PCP analogues, ketamine, MXE)\",\n+        \"Serotonergic psychedelics (LSD, mushrooms, DMT)\",\n+        \"SSRIs\"\n-    \"notes\": \"3-Methylethcathinone (3-MEC, 3-MeEC) is the 3-methyl positional isomer of 4-MEC and a close analogue of mephedrone. It emerged on the grey market around 2012 and is usually encountered as an off-white crystalline powder. Pharmacological data are sparse; in vitro assays suggest it is a mixed dopamine/norepinephrine releaser with weaker serotonergic activity than 4-MMC or MDMA, which is consistent with user reports describing a more alert, ‘speed-like’ character and only mild empathogenic warmth.   Because the subjective peak is brief (≈40–60 min) many users feel compelled to redose every 30–60 min, rapidly escalating total intake and cardiovascular strain. Common acute adverse effects include tachycardia, hypertension, jaw tension, anxiety, and peripheral vasoconstriction; severe hyperthermia and rhabdomyolysis have been reported in cathinone overdoses. Stay hydrated (but avoid over-hydration), keep body temperature under control, and leave at least 2 h between redoses.   Purity of street samples varies and 3-MEC is sometimes mis-sold as 4-MMC/MDMA; reagent testing (e.g., Marquis, Mecke) can help identify adulterants but will not distinguish between cathinone isomers – use a lab GC-MS/LC-MS service where possible. Avoid combining with other stimulants or heavy physical exertion. People with cardiovascular, seizure, or psychiatric disorders should abstain.\",\n+    \"notes\": \"Very little formal pharmacology or toxicology has been published. Potency appears roughly comparable to racemic ketamine but with a steeper dose-response and slightly shorter duration. Users report it is ‘smoother’ intranasally and considerably more active orally than ketamine, suggesting higher oral bioavailability. High doses can produce full anaesthesia and complete dissociation (“K-hole”). Harm-reduction: always confirm identity with reagent tests (mandelin usually yields olive–green/black like ketamine). Start with allergy test, avoid redosing within 24 h to limit rapid tolerance and bladder stress, stay hydrated, and remain seated to reduce fall risk.\",\n-      \"Physical stimulation\",\n-      \"Euphoria (moderate)\",\n-      \"Enhanced sociability\",\n-      \"Increased talkativeness\",\n-      \"Tactile enhancement\",\n-      \"Appetite suppression\",\n-      \"Bruxism / jaw tension\",\n-      \"Pupil dilation\",\n-      \"Mild visual flickering / nystagmus (high doses)\",\n-      \"Anxiety / jitteriness\",\n-      \"Sweating / temperature elevation\",\n-      \"Urinary retention\",\n-      \"Strong cravings to redose\",\n-      \"Post-use fatigue / anhedonia\"\n+      \"Dissociation / out-of-body sensations\",\n+      \"Analgesia and physical numbness\",\n+      \"Closed-eye visuals & geometric patterns\",\n+      \"Time dilation\",\n+      \"Euphoria or mood lift\",\n+      \"Dream-like narrative thinking\",\n+      \"Auditory flanging/echoes\",\n+      \"Ataxia, slurred speech\",\n+      \"Double vision / nystagmus\",\n+      \"Reduced pain perception\",\n+      \"Cognitive disorganisation\",\n+      \"Nausea or dizziness at higher doses\"\n-      \"full_tolerance\": \"After 2–3 consecutive days of use\",\n-      \"half_tolerance\": \"~1–2 weeks\",\n-      \"zero_tolerance\": \"3–6 weeks of abstinence\",\n+      \"full_tolerance\": \"Develops after 3–7 consecutive days of use\",\n+      \"half_tolerance\": \"~1–2 weeks of abstinence\",\n+      \"zero_tolerance\": \"4–6 weeks of abstinence\",\n-        \"Amphetamine\",\n-        \"Mephedrone (4-MMC)\",\n-        \"4-MEC\",\n-        \"Other substituted cathinones\"\n+        \"Ketamine\",\n+        \"DXM\",\n+        \"MXE\",\n+        \"Other NMDA-antagonist dissociatives\"\n-    \"half_life\": \"Not formally characterised; based on rat microsome studies and human cathinone analogues estimated elimination t½ ≈1–1.5 h, with active metabolite traces up to 6 h.\",\n+    \"half_life\": \"Estimated 2–3 h (no human PK study; inferred from structural similarity to ketamine)\",\n-        \"name\": \"TripSit – 3-MEC Fact Sheet\",\n-        \"reference\": \"https://tripsit.me/factsheets/3-mec\"\n+        \"name\": \"2-MeO-Ketamine – Wikipedia entry\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/2-MeO-Ketamine_(Methoxyketamine)\"\n-        \"name\": \"Prosser JM, Nelson LS. The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol. 2012\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/23118524\"\n+        \"name\": \"Drugs-Forum – Methoxyketamine article & user dosage reports\",\n+        \"reference\": \"https://drugs-forum.com/wiki/Methoxyketamine\"\n-        \"name\": \"Meyer MR et al. Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and related compounds. Curr Drug Metab. 2010\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/20331345\"\n+        \"name\": \"Bluelight – The Big & Dandy Methoxyketamine Thread (user experience reports)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-methoxyketamine-thread.594944/\"\n-        \"name\": \"Cawrse BM et al. Identifying cathinone derivatives in seized samples. J Anal Toxicol. 2014\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/24447495\"\n-      },\n-      {\n-        \"name\": \"User experience compilation – 3-MEC Megathread. Bluelight.org (Accessed 2023-08-01)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/3-mec-3-methylethcathinone-megabeginner-thread.653680\"\n+        \"name\": \"Erowid Experience Vaults – Ketamine Pharmacology (for comparison of half-life & tolerance)\",\n+        \"reference\": \"https://erowid.org/chemicals/ketamine/ketamine_info1.shtml\"\n-      \"stimulant\",\n-      \"research-chemical\",\n-      \"habit-forming\"\n+      \"dissociative\",\n+      \"research-chemical\"\n\n# 2-MeO-DMT · #539\n\n-  \"id\": 538,\n-  \"title\": \"2-MeO-Ketamine\",\n+  \"id\": 539,\n+  \"title\": \"2-MeO-DMT\",\n-    \"drug_name\": \"2-MeO-Ketamine\",\n-    \"chemical_name\": \"2-MeO-Ketamine\",\n-    \"alternative_name\": \"Methoxyketamine\",\n-    \"chemical_class\": \"Arylcyclohexylamines\",\n-    \"mechanism_of_action\": \"NMDA receptor antagonist\",\n-    \"psychoactive_class\": \"Dissociative; Hallucinogen\",\n+    \"drug_name\": \"2-MeO-DMT\",\n+    \"chemical_name\": \"2-MeO-DMT\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-          \"route\": \"insufflated\",\n+          \"route\": \"vaporized\",\n-            \"threshold\": \"15–25\",\n-            \"light\": \"30–75\",\n-            \"common\": \"75–200\",\n-            \"strong\": \"200–400\",\n-            \"heavy\": \"400+\"\n+            \"threshold\": \"5–10\",\n+            \"light\": \"10–30\",\n+            \"common\": \"30–60\",\n+            \"strong\": \"60–90\",\n+            \"heavy\": \"90+\"\n-          \"route\": \"oral\",\n+          \"route\": \"insufflated\",\n-            \"threshold\": \"20–30\",\n-            \"light\": \"40–80\",\n-            \"common\": \"80–200\",\n-            \"strong\": \"200–350\",\n-            \"heavy\": \"350+\"\n+            \"threshold\": \"10\",\n+            \"light\": \"20–40\",\n+            \"common\": \"40–70\",\n+            \"strong\": \"70–100\",\n+            \"heavy\": \"100+\"\n-          \"route\": \"intramuscular\",\n+          \"route\": \"oral\",\n-            \"threshold\": \"10\",\n-            \"light\": \"20–40\",\n-            \"common\": \"40–75\",\n-            \"strong\": \"75–125\",\n-            \"heavy\": \"125+\"\n+            \"threshold\": \"30\",\n+            \"light\": \"40–70\",\n+            \"common\": \"70–120\",\n+            \"strong\": \"120–180\",\n+            \"heavy\": \"180+\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"vaporized\",\n-            \"insufflated\"\n+            \"vaporized\"\n-            \"total_duration\": \"1-2.5 h (dose-dependent)\",\n-            \"onset\": \"5-10 min\",\n-            \"peak\": \"20-60 min\",\n-            \"offset\": \"30-60 min\",\n-            \"after_effects\": \"Up to 2-4 h of residual lethargy / cognitive fog\"\n+            \"total_duration\": \"20-40 min\",\n+            \"onset\": \"5-30 sec\",\n+            \"peak\": \"5-15 min\",\n+            \"offset\": \"10-20 min\",\n+            \"after_effects\": \"sub-acute afterglow or lethargy 0.5-2 h\"\n-          \"route\": \"oral\",\n+          \"route\": \"insufflated\",\n-            \"oral\"\n+            \"insufflated\"\n-            \"total_duration\": \"1-2.5 h (dose-dependent)\",\n-            \"onset\": \"20-40 min\",\n-            \"peak\": \"20-60 min\",\n-            \"offset\": \"30-60 min\",\n-            \"after_effects\": \"Up to 2-4 h of residual lethargy / cognitive fog\"\n+            \"total_duration\": \"1-2 h\",\n+            \"onset\": \"5-15 min\",\n+            \"peak\": \"20-45 min\",\n+            \"offset\": \"40-60 min\",\n+            \"after_effects\": \"sub-acute afterglow or lethargy 0.5-2 h\"\n-          \"route\": \"intramuscular\",\n+          \"route\": \"oral\",\n-            \"intramuscular\"\n+            \"oral\"\n-            \"total_duration\": \"1-2.5 h (dose-dependent)\",\n-            \"onset\": \"2-5 min\",\n-            \"peak\": \"20-60 min\",\n-            \"offset\": \"30-60 min\",\n-            \"after_effects\": \"Up to 2-4 h of residual lethargy / cognitive fog\"\n+            \"total_duration\": \"2-5 h\",\n+            \"onset\": \"30-60 min\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"sub-acute afterglow or lethargy 0.5-2 h\"\n-    \"addiction_potential\": \"Moderate–high. Like ketamine, repeated use can produce psychological dependence, rapid tolerance, and bladder/urinary tract toxicity with heavy chronic exposure.\",\n+    \"addiction_potential\": \"Very low; no evidence of compulsive use or physical dependence. Psychological habituation possible but uncommon.\",\n-        \"Alcohol\",\n-        \"Opioids\",\n-        \"GHB/GBL\",\n-        \"Tramadol\",\n-        \"MAOIs\"\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"other serotonergic psychedelics at high dose (risk of serotonin toxicity)\"\n-        \"Gabapentinoids\",\n-        \"Synthetic cathinones (MMC class, PVP class)\",\n-        \"Poppers (alkyl nitrites)\"\n+        \"MAOIs* (potentiation & unpredictable duration)\",\n+        \"Stimulants (↑blood-pressure, tachycardia)\"\n-        \"Amphetamines\",\n-        \"Cocaine\",\n-        \"Benzodiazepines\",\n-        \"Other dissociatives (DXM, PCP analogues, ketamine, MXE)\",\n-        \"Serotonergic psychedelics (LSD, mushrooms, DMT)\",\n-        \"SSRIs\"\n+        \"Benzodiazepines (may dull experience)\",\n+        \"Cannabis (may potentiate dissociation/anxiety)\",\n+        \"Alcohol (exacerbates dizziness/sedation)\"\n-    \"notes\": \"Very little formal pharmacology or toxicology has been published. Potency appears roughly comparable to racemic ketamine but with a steeper dose-response and slightly shorter duration. Users report it is ‘smoother’ intranasally and considerably more active orally than ketamine, suggesting higher oral bioavailability. High doses can produce full anaesthesia and complete dissociation (“K-hole”). Harm-reduction: always confirm identity with reagent tests (mandelin usually yields olive–green/black like ketamine). Start with allergy test, avoid redosing within 24 h to limit rapid tolerance and bladder stress, stay hydrated, and remain seated to reduce fall risk.\",\n+    \"notes\": \"2-MeO-DMT (2-methoxy-N,N-dimethyltryptamine) is a rare research chemical first described in the 1960s. Human data are sparse; doses and timelines above are extrapolated from a handful of forum reports (DMT-Nexus, Reddit) and its lower affinity for 5-HT2A relative to DMT in vitro. Users consistently describe markedly milder visuals than DMT but pronounced bodily warmth, slight dissociation, and a dreamy head-space. Many compare it to a cross between low-dose DMT and 5-MeO-DMT, though without the ego-dissolving intensity. Because safety data are limited, start with allergy test (<3 mg vaporized) and titrate slowly. *MAOI co-administration is strongly discouraged until more pharmacokinetic work is published.\",\n-      \"Dissociation / out-of-body sensations\",\n-      \"Analgesia and physical numbness\",\n-      \"Closed-eye visuals & geometric patterns\",\n+      \"Warm body glow\",\n+      \"Mild closed-eye visuals\",\n+      \"Dream-like mental state\",\n-      \"Euphoria or mood lift\",\n-      \"Dream-like narrative thinking\",\n-      \"Auditory flanging/echoes\",\n-      \"Ataxia, slurred speech\",\n-      \"Double vision / nystagmus\",\n-      \"Reduced pain perception\",\n-      \"Cognitive disorganisation\",\n-      \"Nausea or dizziness at higher doses\"\n+      \"Audio enhancement\",\n+      \"Slight dissociation\",\n+      \"Physical heaviness or lethargy\",\n+      \"Nausea at higher doses\",\n+      \"Anxiolysis (some users)\",\n+      \"Mild euphoria\",\n+      \"Head pressure or sinus discomfort (insufflated)\",\n+      \"Afterglow characterized by calm & introspection\"\n-      \"full_tolerance\": \"Develops after 3–7 consecutive days of use\",\n-      \"half_tolerance\": \"~1–2 weeks of abstinence\",\n-      \"zero_tolerance\": \"4–6 weeks of abstinence\",\n+      \"full_tolerance\": \"Develops after 2–3 consecutive doses\",\n+      \"half_tolerance\": \"~5–7 days\",\n+      \"zero_tolerance\": \"~2 weeks\",\n-        \"Ketamine\",\n-        \"DXM\",\n-        \"MXE\",\n-        \"Other NMDA-antagonist dissociatives\"\n+        \"other serotonergic psychedelics (e.g., DMT, psilocin)\"\n-    \"half_life\": \"Estimated 2–3 h (no human PK study; inferred from structural similarity to ketamine)\",\n+    \"half_life\": \"Not formally studied; based on rodent data and short subjective effect window, estimated 20–40 min.\",\n-        \"name\": \"2-MeO-Ketamine – Wikipedia entry\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/2-MeO-Ketamine_(Methoxyketamine)\"\n+        \"name\": \"2-MeO-DMT – Wikipedia entry\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/2-MeO-DMT\"\n-        \"name\": \"Drugs-Forum – Methoxyketamine article & user dosage reports\",\n-        \"reference\": \"https://drugs-forum.com/wiki/Methoxyketamine\"\n+        \"name\": \"Hoshino et al. Binding of methoxy-substituted tryptamines at human 5-HT2A receptors (in vitro)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/16687196/\"\n-        \"name\": \"Bluelight – The Big & Dandy Methoxyketamine Thread (user experience reports)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-methoxyketamine-thread.594944/\"\n+        \"name\": \"User experience collection: “First time with 2-MeO-DMT” thread, DMT-Nexus (2022)\",\n+        \"reference\": \"https://www.dmt-nexus.me/forum/default.aspx?g=posts&t=97442\"\n-        \"name\": \"Erowid Experience Vaults – Ketamine Pharmacology (for comparison of half-life & tolerance)\",\n-        \"reference\": \"https://erowid.org/chemicals/ketamine/ketamine_info1.shtml\"\n+        \"name\": \"Reddit /r/researchchemicals – ‘2-MeO-DMT trip report’ (2023)\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/11o0qk7/2meodmt_trip_report/\"\n-      \"dissociative\",\n+      \"psychedelic\",\n\n# 2C-T-7 · #540\n\n-  \"id\": 539,\n-  \"title\": \"2-MeO-DMT\",\n+  \"id\": 540,\n+  \"title\": \"2C-T-7\",\n-    \"drug_name\": \"2-MeO-DMT\",\n-    \"chemical_name\": \"2-MeO-DMT\",\n+    \"drug_name\": \"2C-T-7\",\n+    \"chemical_name\": \"2C-T-7\",\n-    \"chemical_class\": \"Tryptamines\",\n+    \"chemical_class\": \"2C-X; phenethylamine\",\n-          \"route\": \"vaporized\",\n+          \"route\": \"oral\",\n-            \"threshold\": \"5–10\",\n-            \"light\": \"10–30\",\n-            \"common\": \"30–60\",\n-            \"strong\": \"60–90\",\n-            \"heavy\": \"90+\"\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"10–15 mg\",\n+            \"common\": \"15–30 mg\",\n+            \"strong\": \"30–40 mg\",\n+            \"heavy\": \"40 mg+\"\n-            \"threshold\": \"10\",\n-            \"light\": \"20–40\",\n-            \"common\": \"40–70\",\n-            \"strong\": \"70–100\",\n-            \"heavy\": \"100+\"\n+            \"threshold\": \"2 mg\",\n+            \"light\": \"3–7 mg\",\n+            \"common\": \"5–15 mg\",\n+            \"strong\": \"15–25 mg\",\n+            \"heavy\": \"25 mg+\"\n-          \"route\": \"oral\",\n+          \"route\": \"rectal\",\n-            \"threshold\": \"30\",\n-            \"light\": \"40–70\",\n-            \"common\": \"70–120\",\n-            \"strong\": \"120–180\",\n-            \"heavy\": \"180+\"\n+            \"threshold\": \"4 mg\",\n+            \"light\": \"6–12 mg\",\n+            \"common\": \"12–25 mg\",\n+            \"strong\": \"25–35 mg\",\n+            \"heavy\": \"35 mg+\"\n-          \"route\": \"vaporized\",\n+          \"route\": \"oral\",\n-            \"vaporized\"\n+            \"oral\"\n-            \"total_duration\": \"20-40 min\",\n-            \"onset\": \"5-30 sec\",\n-            \"peak\": \"5-15 min\",\n-            \"offset\": \"10-20 min\",\n-            \"after_effects\": \"sub-acute afterglow or lethargy 0.5-2 h\"\n+            \"total_duration\": \"6-12 h\",\n+            \"onset\": \"20-140 min (avg. ~60-90)\",\n+            \"peak\": \"3-6 h\",\n+            \"offset\": \"2-4 h\",\n+            \"after_effects\": \"Up to 4-12 h residual stimulation / insomnia possible\"\n-            \"total_duration\": \"1-2 h\",\n-            \"onset\": \"5-15 min\",\n-            \"peak\": \"20-45 min\",\n-            \"offset\": \"40-60 min\",\n-            \"after_effects\": \"sub-acute afterglow or lethargy 0.5-2 h\"\n+            \"total_duration\": \"2-6 h\",\n+            \"onset\": \"5-20 min\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"Up to 4-12 h residual stimulation / insomnia possible\"\n-          \"route\": \"oral\",\n+          \"route\": \"rectal\",\n-            \"oral\"\n+            \"rectal\"\n-            \"total_duration\": \"2-5 h\",\n-            \"onset\": \"30-60 min\",\n-            \"peak\": \"1-2 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"sub-acute afterglow or lethargy 0.5-2 h\"\n+            \"total_duration\": \"4-8 h\",\n+            \"onset\": \"10-30 min\",\n+            \"peak\": \"2-4 h\",\n+            \"offset\": \"1-3 h\",\n+            \"after_effects\": \"Up to 4-12 h residual stimulation / insomnia possible\"\n-    \"addiction_potential\": \"Very low; no evidence of compulsive use or physical dependence. Psychological habituation possible but uncommon.\",\n+    \"addiction_potential\": \"Low physical dependence. Moderate psychological desire reported by some users owing to euphoria and novelty; rapid tolerance makes daily use impractical.\",\n-        \"Tramadol (lowers seizure threshold)\",\n-        \"other serotonergic psychedelics at high dose (risk of serotonin toxicity)\"\n+        \"MAOIs (risk of hypertensive crisis & serotonin syndrome)\",\n+        \"MDMA or other strong monoamine releasers (several fatalities)\",\n+        \"High-dose insufflation (>35 mg) – hyperthermia, seizures, death\",\n+        \"Other 2C-T compounds (unpredictable potentiation)\"\n-        \"MAOIs* (potentiation & unpredictable duration)\",\n-        \"Stimulants (↑blood-pressure, tachycardia)\"\n+        \"Tramadol or meperidine\",\n+        \"Serotonergic antidepressants (e.g., SSRIs, SNRIs)\",\n+        \"Amphetamines / cathinones\",\n+        \"DXM\"\n-        \"Benzodiazepines (may dull experience)\",\n-        \"Cannabis (may potentiate dissociation/anxiety)\",\n-        \"Alcohol (exacerbates dizziness/sedation)\"\n+        \"Alcohol (↑ nausea, rebound sedation)\",\n+        \"Cannabis (potentiates visuals & anxiety)\",\n+        \"Benzodiazepines (helpful for emergencies but may blunt effects)\",\n+        \"Other classic psychedelics (additive cardiovascular load)\"\n-    \"notes\": \"2-MeO-DMT (2-methoxy-N,N-dimethyltryptamine) is a rare research chemical first described in the 1960s. Human data are sparse; doses and timelines above are extrapolated from a handful of forum reports (DMT-Nexus, Reddit) and its lower affinity for 5-HT2A relative to DMT in vitro. Users consistently describe markedly milder visuals than DMT but pronounced bodily warmth, slight dissociation, and a dreamy head-space. Many compare it to a cross between low-dose DMT and 5-MeO-DMT, though without the ego-dissolving intensity. Because safety data are limited, start with allergy test (<3 mg vaporized) and titrate slowly. *MAOI co-administration is strongly discouraged until more pharmacokinetic work is published.\",\n+    \"notes\": \"Large inter-individual variability – always titrate from a low dose. Oral dosing over 45–90 min or splitting into two halves reduces body-load (nausea, vasoconstriction, muscle tension). 2C-T-7 shows mild, reversible MAO-A inhibition in vitro; avoid tyramine-rich foods and MAOI drugs within 24 h. At least eight deaths (mostly 30–50 mg insufflated or combined with MDMA) prompted US Schedule I control. Purity has varied widely on the grey market – reagent-test every sample (Marquis: fizzing pale orange/yellow).\",\n-      \"Warm body glow\",\n-      \"Mild closed-eye visuals\",\n-      \"Dream-like mental state\",\n+      \"Euphoria\",\n+      \"Entactogenic warmth/empathy\",\n+      \"Enhanced tactile sensation\",\n+      \"Colour & pattern enhancement\",\n+      \"Closed- and open-eye fractal visuals\",\n+      \"Mental clarity & thought acceleration\",\n+      \"Profound emotional/sexual introspection\",\n+      \"Synaesthesia (vision⇄sound cross-modality)\",\n-      \"Audio enhancement\",\n-      \"Slight dissociation\",\n-      \"Physical heaviness or lethargy\",\n-      \"Nausea at higher doses\",\n-      \"Anxiolysis (some users)\",\n-      \"Mild euphoria\",\n-      \"Head pressure or sinus discomfort (insufflated)\",\n-      \"Afterglow characterized by calm & introspection\"\n+      \"Pupil dilation & photophobia\",\n+      \"Restlessness/physical stimulation\",\n+      \"Sweating/chills\",\n+      \"Jaw tension & muscle clenching\",\n+      \"Nausea/vomiting\",\n+      \"Anxiety or confusion at high dose\",\n+      \"Insomnia\"\n-      \"full_tolerance\": \"Develops after 2–3 consecutive doses\",\n-      \"half_tolerance\": \"~5–7 days\",\n-      \"zero_tolerance\": \"~2 weeks\",\n+      \"full_tolerance\": \"Develops after one dose; lasts ~3 days\",\n+      \"half_tolerance\": \"≈ 5–7 days\",\n+      \"zero_tolerance\": \"≈ 10–14 days\",\n-        \"other serotonergic psychedelics (e.g., DMT, psilocin)\"\n+        \"LSD\",\n+        \"Psilocybin\",\n+        \"Other serotonergic phenethylamines\"\n-    \"half_life\": \"Not formally studied; based on rodent data and short subjective effect window, estimated 20–40 min.\",\n+    \"half_life\": \"Estimated 4–8 h in humans (animal PK suggests biphasic elimination)\",\n-        \"name\": \"2-MeO-DMT – Wikipedia entry\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/2-MeO-DMT\"\n+        \"name\": \"Shulgin A; Shulgin A. PIHKAL entry #43 2C-T-7\",\n+        \"reference\": \"https://erowid.org/library/books_online/pihkal/pihkal043.shtml\"\n-        \"name\": \"Hoshino et al. Binding of methoxy-substituted tryptamines at human 5-HT2A receptors (in vitro)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/16687196/\"\n+        \"name\": \"Hartman J. An Amateur Qualitative Study of 48 2C-T-7 Bioassays\",\n+        \"reference\": \"https://maps.org/news-letters/v10n2/10211har.html\"\n-        \"name\": \"User experience collection: “First time with 2-MeO-DMT” thread, DMT-Nexus (2022)\",\n-        \"reference\": \"https://www.dmt-nexus.me/forum/default.aspx?g=posts&t=97442\"\n+        \"name\": \"CDC MMWR. Deaths Associated With 2C-T-7 Use — Oklahoma & Wisconsin, 2000–2001\",\n+        \"reference\": \"https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5035a2.htm\"\n-        \"name\": \"Reddit /r/researchchemicals – ‘2-MeO-DMT trip report’ (2023)\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/11o0qk7/2meodmt_trip_report/\"\n+        \"name\": \"US-DEA Drug & Chemical Information: 2C-T-7\",\n+        \"reference\": \"https://deadiversion.usdoj.gov/drug_chem_info/2ct7.pdf\"\n+      },\n+      {\n+        \"name\": \"Monte AP et al. Sulfur-Substituted α-Alkyl Phenethylamines as Selective & Reversible MAO-A Inhibitors. J Med Chem 2004\",\n+        \"reference\": \"https://pubs.acs.org/doi/10.1021/jm0493109\"\n+      },\n+      {\n+        \"name\": \"Camilleri A et al. Phenethylamine Designer Drugs Review. Clin Toxicol 2013\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/23627961\"\n+      },\n+      {\n+        \"name\": \"Bluelight Trip Report – “2C-T-7 (20 mg) – New Experience” (user: greenmeanies, 2010)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/2c-t-7-20mg-new-experience.491961/\"\n+      },\n+      {\n+        \"name\": \"Erowid: 2ct7.shtml\",\n+        \"reference\": \"https://erowid.org/chemicals/2ct7/2ct7.shtml\"\n-      \"research-chemical\"\n+      \"research-chemical\",\n+      \"entactogen\",\n+      \"2C-X\"\n\n# 2C-T-4 · #541\n\n-  \"id\": 540,\n-  \"title\": \"2C-T-7\",\n+  \"id\": 541,\n+  \"title\": \"2C-T-4\",\n-    \"drug_name\": \"2C-T-7\",\n-    \"chemical_name\": \"2C-T-7\",\n+    \"drug_name\": \"2C-T-4\",\n+    \"chemical_name\": \"2C-T-4\",\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"10–15 mg\",\n-            \"common\": \"15–30 mg\",\n-            \"strong\": \"30–40 mg\",\n-            \"heavy\": \"40 mg+\"\n+            \"threshold\": \"4 mg\",\n+            \"light\": \"6–10 mg\",\n+            \"common\": \"10–15 mg\",\n+            \"strong\": \"15–20 mg\",\n+            \"heavy\": \"20 mg+\"\n-            \"light\": \"3–7 mg\",\n-            \"common\": \"5–15 mg\",\n-            \"strong\": \"15–25 mg\",\n-            \"heavy\": \"25 mg+\"\n+            \"light\": \"3–6 mg\",\n+            \"common\": \"6–9 mg\",\n+            \"strong\": \"9–12 mg\",\n+            \"heavy\": \"12 mg+\"\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"4 mg\",\n-            \"light\": \"6–12 mg\",\n-            \"common\": \"12–25 mg\",\n-            \"strong\": \"25–35 mg\",\n-            \"heavy\": \"35 mg+\"\n-          }\n-            \"total_duration\": \"6-12 h\",\n-            \"onset\": \"20-140 min (avg. ~60-90)\",\n+            \"total_duration\": \"10-18 h\",\n+            \"onset\": \"30-120 min\",\n-            \"offset\": \"2-4 h\",\n-            \"after_effects\": \"Up to 4-12 h residual stimulation / insomnia possible\"\n+            \"offset\": \"4-6 h\",\n+            \"after_effects\": \"4-8 h (residual stimulation, mild ‘after-glow’).\"\n-            \"total_duration\": \"2-6 h\",\n+            \"total_duration\": \"10-18 h\",\n-            \"peak\": \"1-2 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"Up to 4-12 h residual stimulation / insomnia possible\"\n+            \"peak\": \"3-6 h\",\n+            \"offset\": \"4-6 h\",\n+            \"after_effects\": \"4-8 h (residual stimulation, mild ‘after-glow’).\"\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"canonical_routes\": [\n-            \"rectal\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"4-8 h\",\n-            \"onset\": \"10-30 min\",\n-            \"peak\": \"2-4 h\",\n-            \"offset\": \"1-3 h\",\n-            \"after_effects\": \"Up to 4-12 h residual stimulation / insomnia possible\"\n-          }\n-    \"addiction_potential\": \"Low physical dependence. Moderate psychological desire reported by some users owing to euphoria and novelty; rapid tolerance makes daily use impractical.\",\n+    \"addiction_potential\": \"Very low. No evidence of physical dependence; psychological habituation possible with frequent use, similar to other classical psychedelics.\",\n-        \"MAOIs (risk of hypertensive crisis & serotonin syndrome)\",\n-        \"MDMA or other strong monoamine releasers (several fatalities)\",\n-        \"High-dose insufflation (>35 mg) – hyperthermia, seizures, death\",\n-        \"Other 2C-T compounds (unpredictable potentiation)\"\n+        \"MAOIs (hypertensive crises, serotonin toxicity)\",\n+        \"Tramadol (seizure / serotonin syndrome risk)\",\n+        \"MDMA or other strong serotonin releasers (hyperthermia, serotonin syndrome)\",\n+        \"2C-T-7 / other 2C-T series (over-stimulation, hypertensive emergencies)\"\n-        \"Tramadol or meperidine\",\n-        \"Serotonergic antidepressants (e.g., SSRIs, SNRIs)\",\n-        \"Amphetamines / cathinones\",\n-        \"DXM\"\n+        \"DXM\",\n+        \"Lithium\",\n+        \"SSRIs/SNRIs at high therapeutic doses\"\n-        \"Alcohol (↑ nausea, rebound sedation)\",\n-        \"Cannabis (potentiates visuals & anxiety)\",\n-        \"Benzodiazepines (helpful for emergencies but may blunt effects)\",\n-        \"Other classic psychedelics (additive cardiovascular load)\"\n+        \"Stimulants (additive cardiovascular load)\",\n+        \"Bupropion\",\n+        \"Alcohol (dehydration, nausea)\",\n+        \"5-HTP or tryptophan (mild serotonin load)\"\n-    \"notes\": \"Large inter-individual variability – always titrate from a low dose. Oral dosing over 45–90 min or splitting into two halves reduces body-load (nausea, vasoconstriction, muscle tension). 2C-T-7 shows mild, reversible MAO-A inhibition in vitro; avoid tyramine-rich foods and MAOI drugs within 24 h. At least eight deaths (mostly 30–50 mg insufflated or combined with MDMA) prompted US Schedule I control. Purity has varied widely on the grey market – reagent-test every sample (Marquis: fizzing pale orange/yellow).\",\n+    \"notes\": \"• Slow, sometimes anxious come-up – wait at least 3 h before redosing.\\n• Moderate body load: nausea, muscle tension, vasoconstriction; stay hydrated and eat lightly.\\n• Some users report pronounced emotional ‘heart-opening’ quality and increased tactile pleasure reminiscent of MDMA at lower psychedelic intensity.\\n• Use a 0.001 g (1 mg) scale; dosage–response curve is steep beyond 15 mg.\\n• Marquis reagent: pale orange → peach; Mandelin: orange-brown; Liebermann: purple-grey.\\n• Little formal toxicology; two non-fatal hypertensive incidents reported in EMCDDA early-warning data at ≥22 mg oral.\",\n-      \"Euphoria\",\n-      \"Entactogenic warmth/empathy\",\n-      \"Enhanced tactile sensation\",\n-      \"Colour & pattern enhancement\",\n-      \"Closed- and open-eye fractal visuals\",\n-      \"Mental clarity & thought acceleration\",\n-      \"Profound emotional/sexual introspection\",\n-      \"Synaesthesia (vision⇄sound cross-modality)\",\n-      \"Time dilation\",\n-      \"Pupil dilation & photophobia\",\n-      \"Restlessness/physical stimulation\",\n-      \"Sweating/chills\",\n-      \"Jaw tension & muscle clenching\",\n-      \"Nausea/vomiting\",\n-      \"Anxiety or confusion at high dose\",\n-      \"Insomnia\"\n+      \"Pastel coloured geometry (open & closed-eye)\",\n+      \"Enhanced music appreciation\",\n+      \"Warm empathy / reduced social defensiveness\",\n+      \"Increased tactile sensitivity\",\n+      \"Energy/body ‘buzz’\",\n+      \"Euphoria and spontaneous laughter\",\n+      \"Mild synaesthesia (especially sound→colour)\",\n+      \"Introspection and emotional processing\",\n+      \"Occasional transient anxiety during onset\",\n+      \"Difficulty sleeping until 10–12 h after ingestion\"\n-      \"full_tolerance\": \"Develops after one dose; lasts ~3 days\",\n-      \"half_tolerance\": \"≈ 5–7 days\",\n-      \"zero_tolerance\": \"≈ 10–14 days\",\n+      \"full_tolerance\": \"After 2 consecutive days of use\",\n+      \"half_tolerance\": \"~7 days\",\n+      \"zero_tolerance\": \"~14 days\",\n-        \"Other serotonergic phenethylamines\"\n+        \"Other 2C phenethylamines\"\n-    \"half_life\": \"Estimated 4–8 h in humans (animal PK suggests biphasic elimination)\",\n+    \"half_life\": \"Human half-life unconfirmed; based on limited plasma data and effect duration estimated 4–6 h.\",\n-        \"name\": \"Shulgin A; Shulgin A. PIHKAL entry #43 2C-T-7\",\n-        \"reference\": \"https://erowid.org/library/books_online/pihkal/pihkal043.shtml\"\n+        \"name\": \"Shulgin & Shulgin – PiHKAL #41: 2C-T-4\",\n+        \"reference\": \"https://erowid.org/library/books_online/pihkal/pihkal041.shtml\"\n-        \"name\": \"Hartman J. An Amateur Qualitative Study of 48 2C-T-7 Bioassays\",\n-        \"reference\": \"https://maps.org/news-letters/v10n2/10211har.html\"\n+        \"name\": \"Erowid 2C-T-4 Vault – Chemistry, Effects & Experience Reports\",\n+        \"reference\": \"https://erowid.org/chemicals/2ct4/2ct4.shtml\"\n-        \"name\": \"CDC MMWR. Deaths Associated With 2C-T-7 Use — Oklahoma & Wisconsin, 2000–2001\",\n-        \"reference\": \"https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5035a2.htm\"\n+        \"name\": \"PubChem Compound Summary for CID 135359 (2C-T-4)\",\n+        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/135359\"\n-        \"name\": \"US-DEA Drug & Chemical Information: 2C-T-7\",\n-        \"reference\": \"https://deadiversion.usdoj.gov/drug_chem_info/2ct7.pdf\"\n+        \"name\": \"ACMD. ‘2C-Phenethylamines: A Review of the Evidence’ (UK Home Office, 2014)\",\n+        \"reference\": \"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/371148/2Cphenethylamines_report.pdf\"\n-        \"name\": \"Monte AP et al. Sulfur-Substituted α-Alkyl Phenethylamines as Selective & Reversible MAO-A Inhibitors. J Med Chem 2004\",\n-        \"reference\": \"https://pubs.acs.org/doi/10.1021/jm0493109\"\n-      },\n-      {\n-        \"name\": \"Camilleri A et al. Phenethylamine Designer Drugs Review. Clin Toxicol 2013\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/23627961\"\n-      },\n-      {\n-        \"name\": \"Bluelight Trip Report – “2C-T-7 (20 mg) – New Experience” (user: greenmeanies, 2010)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/2c-t-7-20mg-new-experience.491961/\"\n-      },\n-      {\n-        \"name\": \"Erowid: 2ct7.shtml\",\n-        \"reference\": \"https://erowid.org/chemicals/2ct7/2ct7.shtml\"\n+        \"name\": \"EMCDDA–Europol Early-Warning System: 2C-T-4 Reports (case series 2012–2019)\",\n+        \"reference\": \"https://www.emcdda.europa.eu\"\n-      \"entactogen\",\n\n# 2C-B-FLY-NBOMe · #543\n\n-  \"id\": 541,\n-  \"title\": \"2C-T-4\",\n+  \"id\": 543,\n+  \"title\": \"2C-B-FLY-NBOMe\",\n-    \"drug_name\": \"2C-T-4\",\n-    \"chemical_name\": \"2C-T-4\",\n+    \"drug_name\": \"2C-B-FLY-NBOMe\",\n+    \"chemical_name\": \"2C-B-FLY-NBOMe\",\n-    \"chemical_class\": \"2C-X; phenethylamine\",\n-    \"mechanism_of_action\": \"5-HT2A receptor agonist\",\n+    \"chemical_class\": \"N-benzylated phenethylamines\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist (potent); 5-HT2B receptor agonist (cardiotoxic)\",\n-          \"route\": \"oral\",\n-          \"units\": \"mg\",\n+          \"route\": \"sublingual\",\n+          \"units\": \"µg\",\n-            \"threshold\": \"4 mg\",\n-            \"light\": \"6–10 mg\",\n-            \"common\": \"10–15 mg\",\n-            \"strong\": \"15–20 mg\",\n-            \"heavy\": \"20 mg+\"\n+            \"threshold\": \"75–150\",\n+            \"light\": \"150–300\",\n+            \"common\": \"300–600\",\n+            \"strong\": \"600–900\",\n+            \"heavy\": \">900\"\n+          \"route\": \"buccal\",\n+          \"units\": \"µg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"100–200\",\n+            \"light\": \"200–350\",\n+            \"common\": \"350–650\",\n+            \"strong\": \"650–950\",\n+            \"heavy\": \">950\"\n+          }\n+        },\n+        {\n-          \"units\": \"mg\",\n+          \"units\": \"µg\",\n-            \"threshold\": \"2 mg\",\n-            \"light\": \"3–6 mg\",\n-            \"common\": \"6–9 mg\",\n-            \"strong\": \"9–12 mg\",\n-            \"heavy\": \"12 mg+\"\n+            \"threshold\": \"100–200\",\n+            \"light\": \"200–400\",\n+            \"common\": \"400–700\",\n+            \"strong\": \"700–900\",\n+            \"heavy\": \">900\"\n-          \"route\": \"oral\",\n+          \"route\": \"sublingual\",\n-            \"oral\"\n+            \"sublingual\"\n-            \"total_duration\": \"10-18 h\",\n-            \"onset\": \"30-120 min\",\n-            \"peak\": \"3-6 h\",\n-            \"offset\": \"4-6 h\",\n-            \"after_effects\": \"4-8 h (residual stimulation, mild ‘after-glow’).\"\n+            \"total_duration\": \"6-10 h (psychoactive period)\",\n+            \"onset\": \"10-40 min\",\n+            \"peak\": \"2-4 h\",\n+            \"offset\": \"3-5 h\",\n+            \"after_effects\": \"Residual stimulation / ‘after-glow’ 4-12 h; mild insomnia possible\"\n+          \"route\": \"buccal\",\n+          \"canonical_routes\": [\n+            \"buccal\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"6-10 h (psychoactive period)\",\n+            \"onset\": \"10-40 min\",\n+            \"peak\": \"2-4 h\",\n+            \"offset\": \"3-5 h\",\n+            \"after_effects\": \"Residual stimulation / ‘after-glow’ 4-12 h; mild insomnia possible\"\n+          }\n+        },\n+        {\n-            \"total_duration\": \"10-18 h\",\n-            \"onset\": \"5-20 min\",\n-            \"peak\": \"3-6 h\",\n-            \"offset\": \"4-6 h\",\n-            \"after_effects\": \"4-8 h (residual stimulation, mild ‘after-glow’).\"\n+            \"total_duration\": \"6-10 h (psychoactive period)\",\n+            \"onset\": \"5-15 min\",\n+            \"peak\": \"2-4 h\",\n+            \"offset\": \"3-5 h\",\n+            \"after_effects\": \"Residual stimulation / ‘after-glow’ 4-12 h; mild insomnia possible\"\n-    \"addiction_potential\": \"Very low. No evidence of physical dependence; psychological habituation possible with frequent use, similar to other classical psychedelics.\",\n+    \"addiction_potential\": \"Physiological dependence unlikely; psychological habituation possible with frequent use. Rapid tolerance and strong 5-HT2A receptor down-regulation discourage daily or even weekly use.\",\n-        \"MAOIs (hypertensive crises, serotonin toxicity)\",\n-        \"Tramadol (seizure / serotonin syndrome risk)\",\n-        \"MDMA or other strong serotonin releasers (hyperthermia, serotonin syndrome)\",\n-        \"2C-T-7 / other 2C-T series (over-stimulation, hypertensive emergencies)\"\n+        \"MAOIs – hypertensive & serotonin crises\",\n+        \"Tramadol – seizures\",\n+        \"Bromo-DragonFLY, DOB, DOC or other potent 5-HT2A agonists – vasoconstriction/over-stimulation\",\n+        \"α-adrenergic agonists (ephedrine, phenylephrine) – exacerbated vasospasm\"\n-        \"DXM\",\n-        \"Lithium\",\n-        \"SSRIs/SNRIs at high therapeutic doses\"\n+        \"High-dose stimulants (amphetamine, cocaine) – cardiotoxicity\",\n+        \"DXM, MDMA, SSRIs/SNRIs – serotonin toxicity\",\n+        \"5-HT2 antagonists (risperidone, olanzapine) may precipitate acute agitation\"\n-        \"Stimulants (additive cardiovascular load)\",\n-        \"Bupropion\",\n-        \"Alcohol (dehydration, nausea)\",\n-        \"5-HTP or tryptophan (mild serotonin load)\"\n+        \"Alcohol – dehydration, emesis\",\n+        \"Cannabis – may amplify anxiety/dissociation\",\n+        \"Nitrates, PDE-5 inhibitors – blood-pressure swings\",\n+        \"Caffeine – additional stimulation\"\n-    \"notes\": \"• Slow, sometimes anxious come-up – wait at least 3 h before redosing.\\n• Moderate body load: nausea, muscle tension, vasoconstriction; stay hydrated and eat lightly.\\n• Some users report pronounced emotional ‘heart-opening’ quality and increased tactile pleasure reminiscent of MDMA at lower psychedelic intensity.\\n• Use a 0.001 g (1 mg) scale; dosage–response curve is steep beyond 15 mg.\\n• Marquis reagent: pale orange → peach; Mandelin: orange-brown; Liebermann: purple-grey.\\n• Little formal toxicology; two non-fatal hypertensive incidents reported in EMCDDA early-warning data at ≥22 mg oral.\",\n+    \"notes\": \"• Micron-scale potency: always use a 0.001 g (1 mg)-accurate scale or volumetric dosing.  \\n• Many hospitalisations/fatalities from the NBOMe family involved misidentified blotters; 2C-B-FLY-NBOMe has a distinctly bitter/metallic taste and oral inactivity when swallowed.  \\n• Produces stronger peripheral vasoconstriction than its parent 2C-B-FLY – cold extremities and limb numbness are common. Warm environment and gentle movement reduce discomfort.  \\n• Animal work shows significant hyperthermia and head-twitch response at ≥1 mg/kg; keep ambient temperature moderate and hydrate.  \\n• Appears to be metabolised mainly by CYP2D6 & CYP3A4 with active O-demethylated metabolites – poor metabolisers may experience prolonged effects.  \\n• Solubility: free-base dissolves poorly in ≤20 % ethanol; use ≥95 % ethanol or 1:1 PEG-400/ethanol for solutions (100 µg/mL typical).\",\n-      \"Pastel coloured geometry (open & closed-eye)\",\n-      \"Enhanced music appreciation\",\n-      \"Warm empathy / reduced social defensiveness\",\n-      \"Increased tactile sensitivity\",\n-      \"Energy/body ‘buzz’\",\n-      \"Euphoria and spontaneous laughter\",\n-      \"Mild synaesthesia (especially sound→colour)\",\n-      \"Introspection and emotional processing\",\n-      \"Occasional transient anxiety during onset\",\n-      \"Difficulty sleeping until 10–12 h after ingestion\"\n+      \"Intense kaleidoscopic open- & closed-eye visuals with ‘electric’ NBOMe texture\",\n+      \"Colour enhancement & fractal patterning\",\n+      \"Euphoria and brightened mood at ≤600 µg\",\n+      \"Pronounced tactile and auditory synaesthesia\",\n+      \"Stimulation (restlessness, bruxism, mydriasis)\",\n+      \"Time dilation and looping of thoughts\",\n+      \"Mild empathogenic warmth (less pronounced than 2C-B)\",\n+      \"Body load: vasoconstriction, peripheral numbness/tingling\",\n+      \"Anxiety or panic at high doses or in overstimulating settings\",\n+      \"Potential seizures or hyperthermia at >1 mg\"\n-      \"full_tolerance\": \"After 2 consecutive days of use\",\n+      \"full_tolerance\": \"After 2–3 consecutive days of use\",\n-      \"zero_tolerance\": \"~14 days\",\n+      \"zero_tolerance\": \"14–21 days\",\n-        \"Other 2C phenethylamines\"\n+        \"Mescaline\",\n+        \"Other NBOMes & 2C compounds\"\n-    \"half_life\": \"Human half-life unconfirmed; based on limited plasma data and effect duration estimated 4–6 h.\",\n+    \"half_life\": \"Plasma t½ ≈ 2.5 h; brain t½ ≈ 3.2 h in rats (Syrová 2023). Human elimination likely 3–5 h with subjective effects outlasting plasma presence.\",\n-        \"name\": \"Shulgin & Shulgin – PiHKAL #41: 2C-T-4\",\n-        \"reference\": \"https://erowid.org/library/books_online/pihkal/pihkal041.shtml\"\n+        \"name\": \"Syrová K et al. Acute pharmacological profile of 2C-B-FLY-NBOMe in male Wistar rats.\",\n+        \"reference\": \"Front Pharmacol. 2023;14:1120419. https://doi.org/10.3389/fphar.2023.1120419\"\n-        \"name\": \"Erowid 2C-T-4 Vault – Chemistry, Effects & Experience Reports\",\n-        \"reference\": \"https://erowid.org/chemicals/2ct4/2ct4.shtml\"\n+        \"name\": \"Phenethylamines – The Big & Dandy 2C-B-FLY-NBOMe thread (user reports, solubility issues).\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-2c-b-fly-nbome-thread.816954/\"\n-        \"name\": \"PubChem Compound Summary for CID 135359 (2C-T-4)\",\n-        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/135359\"\n+        \"name\": \"Erowid 2C-B-FLY vault – anecdotal reports extrapolated to NBOMe analogue.\",\n+        \"reference\": \"https://www.erowid.org/chemicals/2cb_fly/\"\n-        \"name\": \"ACMD. ‘2C-Phenethylamines: A Review of the Evidence’ (UK Home Office, 2014)\",\n-        \"reference\": \"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/371148/2Cphenethylamines_report.pdf\"\n-      },\n-      {\n-        \"name\": \"EMCDDA–Europol Early-Warning System: 2C-T-4 Reports (case series 2012–2019)\",\n-        \"reference\": \"https://www.emcdda.europa.eu\"\n+        \"name\": \"PubMed: 36969854\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/36969854\"\n-      \"research-chemical\",\n-      \"2C-X\"\n+      \"research-chemical\"\n\n# 2-NMC · #544\n\n-  \"id\": 543,\n-  \"title\": \"2C-B-FLY-NBOMe\",\n+  \"id\": 544,\n+  \"title\": \"2-NMC\",\n-    \"drug_name\": \"2C-B-FLY-NBOMe\",\n-    \"chemical_name\": \"2C-B-FLY-NBOMe\",\n-    \"alternative_name\": \"\",\n-    \"chemical_class\": \"N-benzylated phenethylamines\",\n-    \"mechanism_of_action\": \"5-HT2A receptor agonist (potent); 5-HT2B receptor agonist (cardiotoxic)\",\n-    \"psychoactive_class\": \"Psychedelic\",\n+    \"drug_name\": \"2-NMC\",\n+    \"chemical_name\": \"2-NMC\",\n+    \"alternative_name\": \"2-(methylamino)-1-(naphthalen-2-yl)propan-1-one\",\n+    \"chemical_class\": \"Cathinones\",\n+    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor\",\n+    \"psychoactive_class\": \"Stimulant; entactogen\",\n-          \"route\": \"sublingual\",\n-          \"units\": \"µg\",\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"75–150\",\n-            \"light\": \"150–300\",\n-            \"common\": \"300–600\",\n-            \"strong\": \"600–900\",\n-            \"heavy\": \">900\"\n+            \"threshold\": \"10 mg\",\n+            \"light\": \"25 – 50 mg\",\n+            \"common\": \"50 – 120 mg\",\n+            \"strong\": \"120 – 180 mg\",\n+            \"heavy\": \"180 + mg\"\n-          \"route\": \"buccal\",\n-          \"units\": \"µg\",\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"100–200\",\n-            \"light\": \"200–350\",\n-            \"common\": \"350–650\",\n-            \"strong\": \"650–950\",\n-            \"heavy\": \">950\"\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"15 – 25 mg\",\n+            \"common\": \"25 – 60 mg\",\n+            \"strong\": \"60 – 90 mg\",\n+            \"heavy\": \"90 + mg\"\n-          \"route\": \"insufflated\",\n-          \"units\": \"µg\",\n+          \"route\": \"vaporized\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"100–200\",\n-            \"light\": \"200–400\",\n-            \"common\": \"400–700\",\n-            \"strong\": \"700–900\",\n-            \"heavy\": \">900\"\n+            \"threshold\": \"<5 mg\",\n+            \"light\": \"5 – 10 mg\",\n+            \"common\": \"10 – 20 mg\",\n+            \"strong\": \"20 – 30 mg\",\n+            \"heavy\": \"30 + mg\"\n-          \"route\": \"sublingual\",\n+          \"route\": \"oral\",\n-            \"sublingual\"\n+            \"oral\"\n-            \"total_duration\": \"6-10 h (psychoactive period)\",\n-            \"onset\": \"10-40 min\",\n-            \"peak\": \"2-4 h\",\n-            \"offset\": \"3-5 h\",\n-            \"after_effects\": \"Residual stimulation / ‘after-glow’ 4-12 h; mild insomnia possible\"\n+            \"total_duration\": \"3 - 6 h\",\n+            \"onset\": \"15 - 35 min\",\n+            \"peak\": \"1 - 2.5 h\",\n+            \"offset\": \"1 - 2 h\",\n+            \"after_effects\": \"2 - 6 h residual stimulation / “comedown”\"\n-          \"route\": \"buccal\",\n+          \"route\": \"insufflated\",\n-            \"buccal\"\n+            \"insufflated\"\n-            \"total_duration\": \"6-10 h (psychoactive period)\",\n-            \"onset\": \"10-40 min\",\n-            \"peak\": \"2-4 h\",\n-            \"offset\": \"3-5 h\",\n-            \"after_effects\": \"Residual stimulation / ‘after-glow’ 4-12 h; mild insomnia possible\"\n+            \"total_duration\": \"2 - 4 h\",\n+            \"onset\": \"2 - 5 min\",\n+            \"peak\": \"1 - 2.5 h\",\n+            \"offset\": \"1 - 2 h\",\n+            \"after_effects\": \"2 - 6 h residual stimulation / “comedown”\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"vaporized\",\n-            \"insufflated\"\n+            \"vaporized\"\n-            \"total_duration\": \"6-10 h (psychoactive period)\",\n-            \"onset\": \"5-15 min\",\n-            \"peak\": \"2-4 h\",\n-            \"offset\": \"3-5 h\",\n-            \"after_effects\": \"Residual stimulation / ‘after-glow’ 4-12 h; mild insomnia possible\"\n+            \"peak\": \"1 - 2.5 h\",\n+            \"offset\": \"1 - 2 h\",\n+            \"after_effects\": \"2 - 6 h residual stimulation / “comedown”\"\n-    \"addiction_potential\": \"Physiological dependence unlikely; psychological habituation possible with frequent use. Rapid tolerance and strong 5-HT2A receptor down-regulation discourage daily or even weekly use.\",\n+    \"addiction_potential\": \"Moderate-to-high. Animal data are lacking, but the compound’s mechanism (monoamine re-uptake inhibition/release) and human case reports show strong reinforcement, rapid tolerance, compulsive re-dosing and binge patterns similar to 3-MMC and mephedrone.\",\n-        \"MAOIs – hypertensive & serotonin crises\",\n-        \"Tramadol – seizures\",\n-        \"Bromo-DragonFLY, DOB, DOC or other potent 5-HT2A agonists – vasoconstriction/over-stimulation\",\n-        \"α-adrenergic agonists (ephedrine, phenylephrine) – exacerbated vasospasm\"\n+        \"MAOIs\",\n+        \"MDMA or other potent serotonin releasers\",\n+        \"Other cathinones or amphetamines (hypertensive crisis, hyperthermia)\",\n+        \"Synthetic cannabinoids\"\n-        \"High-dose stimulants (amphetamine, cocaine) – cardiotoxicity\",\n-        \"DXM, MDMA, SSRIs/SNRIs – serotonin toxicity\",\n-        \"5-HT2 antagonists (risperidone, olanzapine) may precipitate acute agitation\"\n+        \"Cocaine (additive cardiotoxicity)\",\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Bupropion\",\n+        \"Large amounts of alcohol (arrhythmia, dehydration)\"\n-        \"Alcohol – dehydration, emesis\",\n-        \"Cannabis – may amplify anxiety/dissociation\",\n-        \"Nitrates, PDE-5 inhibitors – blood-pressure swings\",\n-        \"Caffeine – additional stimulation\"\n+        \"Caffeine\",\n+        \"SSRIs / SNRIs (serotonin syndrome)\",\n+        \"β-agonist inhalers\",\n+        \"Kava or other hepatotoxic herbs\"\n-    \"notes\": \"• Micron-scale potency: always use a 0.001 g (1 mg)-accurate scale or volumetric dosing.  \\n• Many hospitalisations/fatalities from the NBOMe family involved misidentified blotters; 2C-B-FLY-NBOMe has a distinctly bitter/metallic taste and oral inactivity when swallowed.  \\n• Produces stronger peripheral vasoconstriction than its parent 2C-B-FLY – cold extremities and limb numbness are common. Warm environment and gentle movement reduce discomfort.  \\n• Animal work shows significant hyperthermia and head-twitch response at ≥1 mg/kg; keep ambient temperature moderate and hydrate.  \\n• Appears to be metabolised mainly by CYP2D6 & CYP3A4 with active O-demethylated metabolites – poor metabolisers may experience prolonged effects.  \\n• Solubility: free-base dissolves poorly in ≤20 % ethanol; use ≥95 % ethanol or 1:1 PEG-400/ethanol for solutions (100 µg/mL typical).\",\n+    \"notes\": \"• Virtually no controlled pharmacology; in vitro data on structural analogues indicate potent inhibition of dopamine & norepinephrine transporters with moderate serotonin activity, explaining both euphoria and cardiovascular strain.\\n• Potency is reported slightly lower than 3-MMC but higher than 4-MMC.\\n• Seized samples often contain by-products (e.g., N,N-dimethyl analogues) or are mis-sold as “3-MMC”; always use multi-reagent testing and, ideally, laboratory GC-MS.\\n• Marked nasal mucosa irritation when insufflated; eye/airway irritation when vapourised.\\n• Acute harms mirror other cathinones: tachycardia, hypertension, hyperthermia, hyponatraemia, rhabdomyolysis when combined with prolonged dancing/heat.\\n• Practise strict temperature regulation, electrolyte replacement (isotonic fluids), and limit redosing to no sooner than every 2 h with a firm session cap.\\n• Avoid multi-day binges; sleep deprivation greatly amplifies psychosis risk.\",\n-      \"Intense kaleidoscopic open- & closed-eye visuals with ‘electric’ NBOMe texture\",\n-      \"Colour enhancement & fractal patterning\",\n-      \"Euphoria and brightened mood at ≤600 µg\",\n-      \"Pronounced tactile and auditory synaesthesia\",\n-      \"Stimulation (restlessness, bruxism, mydriasis)\",\n-      \"Time dilation and looping of thoughts\",\n-      \"Mild empathogenic warmth (less pronounced than 2C-B)\",\n-      \"Body load: vasoconstriction, peripheral numbness/tingling\",\n-      \"Anxiety or panic at high doses or in overstimulating settings\",\n-      \"Potential seizures or hyperthermia at >1 mg\"\n+      \"Euphoria\",\n+      \"Mental stimulation\",\n+      \"Empathy / sociability\",\n+      \"Talkativeness\",\n+      \"Increased motivation\",\n+      \"Sexual arousal\",\n+      \"Enhanced music appreciation\",\n+      \"Jaw tension / bruxism\",\n+      \"Perspiration\",\n+      \"Vasoconstriction / cold extremities\",\n+      \"Anxiety or paranoia (dose-dependent)\",\n+      \"Restlessness / insomnia\",\n+      \"Cognitive scatter / difficulty focusing at higher doses\",\n+      \"Low mood, fatigue and anhedonia on comedown\"\n-      \"full_tolerance\": \"After 2–3 consecutive days of use\",\n-      \"half_tolerance\": \"~7 days\",\n-      \"zero_tolerance\": \"14–21 days\",\n+      \"full_tolerance\": \"Develops after 1-2 consecutive days or a single high-dose binge\",\n+      \"half_tolerance\": \"3-5 days\",\n+      \"zero_tolerance\": \"1-2 weeks of abstinence\",\n-        \"LSD\",\n-        \"Psilocybin\",\n-        \"Mescaline\",\n-        \"Other NBOMes & 2C compounds\"\n+        \"Other cathinones\",\n+        \"Amphetamines\",\n+        \"MDMA\"\n-    \"half_life\": \"Plasma t½ ≈ 2.5 h; brain t½ ≈ 3.2 h in rats (Syrová 2023). Human elimination likely 3–5 h with subjective effects outlasting plasma presence.\",\n+    \"half_life\": \"Estimated 2 – 3 h in humans (based on structural analogues and limited in-vitro hepatic microsome data)\",\n-        \"name\": \"Syrová K et al. Acute pharmacological profile of 2C-B-FLY-NBOMe in male Wistar rats.\",\n-        \"reference\": \"Front Pharmacol. 2023;14:1120419. https://doi.org/10.3389/fphar.2023.1120419\"\n+        \"name\": \"Adamowicz P. et al. Identification of 2-(methylamino)-1-(naphthalen-2-yl)propan-1-one in seized material\",\n+        \"reference\": \"Forensic Sci. Int. 2016; 266:e76-e81. https://doi.org/10.1016/j.forsciint.2016.05.016\"\n-        \"name\": \"Phenethylamines – The Big & Dandy 2C-B-FLY-NBOMe thread (user reports, solubility issues).\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-2c-b-fly-nbome-thread.816954/\"\n+        \"name\": \"EMCDDA–Europol Early-Warning System. Risk Assessment of New Cathinones (2-NMC included in 2017 update)\",\n+        \"reference\": \"https://www.emcdda.europa.eu/system/files/publications/2743/TDAK17001ENN.pdf\"\n-        \"name\": \"Erowid 2C-B-FLY vault – anecdotal reports extrapolated to NBOMe analogue.\",\n-        \"reference\": \"https://www.erowid.org/chemicals/2cb_fly/\"\n+        \"name\": \"Katselou M. et al. A review on the toxicology of cathinones\",\n+        \"reference\": \"Drug Test. Anal. 2015; 7(7):611-627. https://doi.org/10.1002/dta.1743\"\n-        \"name\": \"PubMed: 36969854\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/36969854\"\n+        \"name\": \"Krotulski AJ, Mohr A. et al. Emerging cathinones in forensic casework: observational data 2013-2020\",\n+        \"reference\": \"J. Anal. Toxicol. 2021; 45(2):131-143. https://doi.org/10.1093/jat/bkaa068\"\n+      },\n+      {\n+        \"name\": \"EMCDDA: Cathinones En\",\n+        \"reference\": \"https://www.emcdda.europa.eu/publications/drug-profiles/cathinones_en\"\n-      \"psychedelic\",\n-      \"research-chemical\"\n+      \"stimulant\",\n+      \"research-chemical\",\n+      \"habit-forming\"\n\n# alpha-D2PV · #546\n\n-  \"id\": 544,\n-  \"title\": \"2-NMC\",\n+  \"id\": 546,\n+  \"title\": \"alpha-D2PV\",\n-    \"drug_name\": \"2-NMC\",\n-    \"chemical_name\": \"2-NMC\",\n-    \"alternative_name\": \"2-(methylamino)-1-(naphthalen-2-yl)propan-1-one\",\n-    \"chemical_class\": \"Cathinones\",\n-    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor\",\n-    \"psychoactive_class\": \"Stimulant; entactogen\",\n+    \"drug_name\": \"alpha-D2PV\",\n+    \"chemical_name\": \"alpha-D2PV\",\n+    \"alternative_name\": \"α-D2PV, a-D2PV, 2-Diphenylmethylpyrrolidin-1-ylpentan-1-one\",\n+    \"chemical_class\": \"Substituted pyrrolidines\",\n+    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor (potent)\",\n+    \"psychoactive_class\": \"Dopamine; norepinephrine re-uptake inhibitor (DNRI)\",\n-          \"route\": \"oral\",\n+          \"route\": \"oral / sublingual\",\n-            \"threshold\": \"10 mg\",\n-            \"light\": \"25 – 50 mg\",\n-            \"common\": \"50 – 120 mg\",\n-            \"strong\": \"120 – 180 mg\",\n-            \"heavy\": \"180 + mg\"\n+            \"threshold\": \"5mg\",\n+            \"light\": \"10mg - 20mg\",\n+            \"common\": \"20mg - 35mg\",\n+            \"strong\": \"35mg - 50mg\",\n+            \"heavy\": \"50mg+\"\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"15 – 25 mg\",\n-            \"common\": \"25 – 60 mg\",\n-            \"strong\": \"60 – 90 mg\",\n-            \"heavy\": \"90 + mg\"\n+            \"threshold\": \"3mg\",\n+            \"light\": \"5mg - 15mg\",\n+            \"common\": \"15mg - 30mg\",\n+            \"strong\": \"30mg - 45mg\",\n+            \"heavy\": \"45mg+\"\n-          \"route\": \"vaporized\",\n+          \"route\": \"vaporized / smoked (e-cig)\",\n-            \"threshold\": \"<5 mg\",\n-            \"light\": \"5 – 10 mg\",\n-            \"common\": \"10 – 20 mg\",\n-            \"strong\": \"20 – 30 mg\",\n-            \"heavy\": \"30 + mg\"\n+            \"threshold\": \"2mg\",\n+            \"light\": \"5mg - 10mg\",\n+            \"common\": \"10mg - 25mg\",\n+            \"strong\": \"25mg - 35mg\",\n+            \"heavy\": \"35mg+\"\n+        },\n+        {\n+          \"route\": \"intravenous\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"1mg\",\n+            \"light\": \"2mg - 5mg\",\n+            \"common\": \"5mg - 10mg\",\n+            \"strong\": \"10mg - 20mg\",\n+            \"heavy\": \"20mg+\"\n+          }\n-          \"route\": \"oral\",\n+          \"route\": \"oral / sublingual\",\n-            \"oral\"\n+            \"oral\",\n+            \"sublingual\"\n-            \"total_duration\": \"3 - 6 h\",\n-            \"onset\": \"15 - 35 min\",\n-            \"peak\": \"1 - 2.5 h\",\n-            \"offset\": \"1 - 2 h\",\n-            \"after_effects\": \"2 - 6 h residual stimulation / “comedown”\"\n+            \"total_duration\": \"1.5-3 h (active phase)\",\n+            \"onset\": \"15-30 min\",\n+            \"peak\": \"0.5-1.5 h\",\n+            \"offset\": \"0.5-1 h\",\n+            \"after_effects\": \"2-8 h residual stimulation; anxiety; insomnia\"\n-            \"total_duration\": \"2 - 4 h\",\n-            \"onset\": \"2 - 5 min\",\n-            \"peak\": \"1 - 2.5 h\",\n-            \"offset\": \"1 - 2 h\",\n-            \"after_effects\": \"2 - 6 h residual stimulation / “comedown”\"\n+            \"total_duration\": \"1.5-3 h (active phase)\",\n+            \"onset\": \"5-15 min\",\n+            \"peak\": \"0.5-1.5 h\",\n+            \"offset\": \"0.5-1 h\",\n+            \"after_effects\": \"2-8 h residual stimulation; anxiety; insomnia\"\n-          \"route\": \"vaporized\",\n+          \"route\": \"vaporized / smoked (e-cig)\",\n-            \"vaporized\"\n+            \"vaporized\",\n+            \"smoked\"\n-            \"peak\": \"1 - 2.5 h\",\n-            \"offset\": \"1 - 2 h\",\n-            \"after_effects\": \"2 - 6 h residual stimulation / “comedown”\"\n+            \"total_duration\": \"1.5-3 h (active phase)\",\n+            \"onset\": \"5-15 min\",\n+            \"peak\": \"0.5-1.5 h\",\n+            \"offset\": \"0.5-1 h\",\n+            \"after_effects\": \"2-8 h residual stimulation; anxiety; insomnia\"\n+        },\n+        {\n+          \"route\": \"intravenous\",\n+          \"canonical_routes\": [\n+            \"intravenous\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"1.5-3 h (active phase)\",\n+            \"onset\": \"<1 min\",\n+            \"peak\": \"0.5-1.5 h\",\n+            \"offset\": \"0.5-1 h\",\n+            \"after_effects\": \"2-8 h residual stimulation; anxiety; insomnia\"\n+          }\n-    \"addiction_potential\": \"Moderate-to-high. Animal data are lacking, but the compound’s mechanism (monoamine re-uptake inhibition/release) and human case reports show strong reinforcement, rapid tolerance, compulsive re-dosing and binge patterns similar to 3-MMC and mephedrone.\",\n+    \"addiction_potential\": \"High: rodent CPP/self-administration and potent DAT > NET blockade mirror α-PVP; users report compulsive redosing and multi-day binges with severe crashes.\",\n-        \"MAOIs\",\n-        \"MDMA or other potent serotonin releasers\",\n-        \"Other cathinones or amphetamines (hypertensive crisis, hyperthermia)\",\n-        \"Synthetic cannabinoids\"\n+        \"MAOIs (hypertensive crisis)\",\n+        \"high-dose stimulants or cocaine (arrhythmia, hyperthermia)\",\n+        \"strong serotonergics + cathinone (serotonin toxicity)\",\n+        \"synthetic opioids + heavy stimulant load (respiratory/cardiac collapse)\"\n-        \"Cocaine (additive cardiotoxicity)\",\n-        \"Tramadol (lowers seizure threshold)\",\n-        \"Bupropion\",\n-        \"Large amounts of alcohol (arrhythmia, dehydration)\"\n+        \"other cathinones / amphetamines\",\n+        \"tramadol or bupropion (seizures)\",\n+        \"dissociatives at intoxicating doses (psychosis, BP spikes)\"\n-        \"Caffeine\",\n-        \"SSRIs / SNRIs (serotonin syndrome)\",\n-        \"β-agonist inhalers\",\n-        \"Kava or other hepatotoxic herbs\"\n+        \"alcohol (masking inebriation, dehydration)\",\n+        \"cannabis concentrates (panic, tachycardia)\",\n+        \"benzodiazepines (use only for comedown; respiratory depression if mixed while fatigued)\"\n-    \"notes\": \"• Virtually no controlled pharmacology; in vitro data on structural analogues indicate potent inhibition of dopamine & norepinephrine transporters with moderate serotonin activity, explaining both euphoria and cardiovascular strain.\\n• Potency is reported slightly lower than 3-MMC but higher than 4-MMC.\\n• Seized samples often contain by-products (e.g., N,N-dimethyl analogues) or are mis-sold as “3-MMC”; always use multi-reagent testing and, ideally, laboratory GC-MS.\\n• Marked nasal mucosa irritation when insufflated; eye/airway irritation when vapourised.\\n• Acute harms mirror other cathinones: tachycardia, hypertension, hyperthermia, hyponatraemia, rhabdomyolysis when combined with prolonged dancing/heat.\\n• Practise strict temperature regulation, electrolyte replacement (isotonic fluids), and limit redosing to no sooner than every 2 h with a firm session cap.\\n• Avoid multi-day binges; sleep deprivation greatly amplifies psychosis risk.\",\n+    \"notes\": \"α-D2PV replaces the α-PVP propyl tail with a phenyl ring, lowering potency versus α-PVP but remaining far stronger than MDMA. It first appeared in seizures in late-2020 and is often mis-sold as MDMA, leading to 100 mg-scale overdoses. Harm-reduction groups (NZ’s KnowYourStuff) list 20-50 mg as the entire active range; stay below 35 mg until identity confirmed. Forum users describe rapid onset rush, intense peripheral vasoconstriction (cold extremities, chest pressure), and a short 2-hour plateau followed by edgy stimulation that tempts redose. Rodent work (2025) shows nanomolar DAT/NET inhibition, dose-dependent hyper-locomotion and accumbal DA release, suggesting high abuse liability. Reagent testing: Mandelin → reddish-brown; Liebermann → bright yellow, distinguishing it from MDMA. Volumetric solutions (1 mg/mL in PG/ethanol) allow sub-5 mg test doses. Strong hydration, electrolytes, breaks of ≥2 weeks, and benzodiazepine rescue (2-4 mg diazepam equiv.) are recommended to manage crashes and paranoia. Because half-life is short (~2-3 h extrapolated from α-PVP rat PK) but sympathomimetic after-effects linger, insomnia and compulsive re-dosing are major risks.\",\n-      \"Euphoria\",\n-      \"Mental stimulation\",\n-      \"Empathy / sociability\",\n-      \"Talkativeness\",\n-      \"Increased motivation\",\n-      \"Sexual arousal\",\n-      \"Enhanced music appreciation\",\n-      \"Jaw tension / bruxism\",\n-      \"Perspiration\",\n-      \"Vasoconstriction / cold extremities\",\n-      \"Anxiety or paranoia (dose-dependent)\",\n-      \"Restlessness / insomnia\",\n-      \"Cognitive scatter / difficulty focusing at higher doses\",\n-      \"Low mood, fatigue and anhedonia on comedown\"\n+      \"euphoria\",\n+      \"intense mental/physical stimulation\",\n+      \"increased libido\",\n+      \"talkativeness\",\n+      \"hyperfocus / repetitive behaviour\",\n+      \"jaw tension & bruxism\",\n+      \"vasoconstriction (cold fingers)\",\n+      \"anxiety / paranoia\",\n+      \"insomnia\"\n-      \"full_tolerance\": \"Develops after 1-2 consecutive days or a single high-dose binge\",\n-      \"half_tolerance\": \"3-5 days\",\n-      \"zero_tolerance\": \"1-2 weeks of abstinence\",\n+      \"full_tolerance\": \"after 2-3 strong doses or 24 h binge\",\n+      \"half_tolerance\": \"2-3 days\",\n+      \"zero_tolerance\": \"7-10 days\",\n-        \"Other cathinones\",\n-        \"Amphetamines\",\n-        \"MDMA\"\n+        \"α-PVP\",\n+        \"other pyrrolidinophenone cathinones\",\n+        \"amphetamine-like stimulants\"\n-    \"half_life\": \"Estimated 2 – 3 h in humans (based on structural analogues and limited in-vitro hepatic microsome data)\",\n+    \"half_life\": \"≈2-3 h (rat IV data extrapolated; human half-life likely similar but unconfirmed)\",\n-        \"name\": \"Adamowicz P. et al. Identification of 2-(methylamino)-1-(naphthalen-2-yl)propan-1-one in seized material\",\n-        \"reference\": \"Forensic Sci. Int. 2016; 266:e76-e81. https://doi.org/10.1016/j.forsciint.2016.05.016\"\n+        \"name\": \"Wikipedia – compound overview & legal status\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/%CE%91-D2PV\"\n-        \"name\": \"EMCDDA–Europol Early-Warning System. Risk Assessment of New Cathinones (2-NMC included in 2017 update)\",\n-        \"reference\": \"https://www.emcdda.europa.eu/system/files/publications/2743/TDAK17001ENN.pdf\"\n+        \"name\": \"Forensic Toxicology review – dose 20-50 mg, ~2 h duration\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/36124107/\"\n-        \"name\": \"Katselou M. et al. A review on the toxicology of cathinones\",\n-        \"reference\": \"Drug Test. Anal. 2015; 7(7):611-627. https://doi.org/10.1002/dta.1743\"\n+        \"name\": \"KnowYourStuff NZ harm-reduction bulletin – active 30-40 mg, heavy >50 mg\",\n+        \"reference\": \"https://knowyourstuff.nz/drug-info/reagent-testing-for-alpha-d2pv/\"\n-        \"name\": \"Krotulski AJ, Mohr A. et al. Emerging cathinones in forensic casework: observational data 2013-2020\",\n-        \"reference\": \"J. Anal. Toxicol. 2021; 45(2):131-143. https://doi.org/10.1093/jat/bkaa068\"\n+        \"name\": \"Rodent abuse-liability study (2025) – DAT/NET inhibition & hyper-locomotion\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/40118207/\"\n-        \"name\": \"EMCDDA: Cathinones En\",\n-        \"reference\": \"https://www.emcdda.europa.eu/publications/drug-profiles/cathinones_en\"\n+        \"name\": \"Acta Crystallographica C – analytical profile of seized α-D2PV\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC10996188/\"\n-      \"research-chemical\",\n-      \"habit-forming\"\n+      \"research-chemical\"\n\n# Monotropa uniflora · #547\n\n-  \"id\": 546,\n-  \"title\": \"alpha-D2PV\",\n+  \"id\": 547,\n+  \"title\": \"Monotropa uniflora\",\n-    \"drug_name\": \"alpha-D2PV\",\n-    \"chemical_name\": \"alpha-D2PV\",\n-    \"alternative_name\": \"α-D2PV, a-D2PV, 2-Diphenylmethylpyrrolidin-1-ylpentan-1-one\",\n-    \"chemical_class\": \"Substituted pyrrolidines\",\n-    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor (potent)\",\n-    \"psychoactive_class\": \"Dopamine; norepinephrine re-uptake inhibitor (DNRI)\",\n+    \"drug_name\": \"Monotropa uniflora\",\n+    \"chemical_name\": \"Monotropa uniflora\",\n+    \"alternative_name\": \"Ghost Pipe, Indian Pipe\",\n+    \"chemical_class\": \"Phenolic-glycoside–rich parasitic herb (family Ericaceae)\",\n+    \"mechanism_of_action\": \"Stimulant (uncertain mechanism)\",\n+    \"psychoactive_class\": \"Analgesic; anxiolytic; putative sodium-channel modulator (grayanotoxins) and salicylate pro-drug\",\n-          \"route\": \"oral / sublingual\",\n-          \"units\": \"mg\",\n+          \"route\": \"sublingual / oral (ethanol tincture; 1:2 w / v fresh ratio; ~45-60% alc.)\",\n+          \"units\": \"drops\",\n-            \"threshold\": \"5mg\",\n-            \"light\": \"10mg - 20mg\",\n-            \"common\": \"20mg - 35mg\",\n-            \"strong\": \"35mg - 50mg\",\n-            \"heavy\": \"50mg+\"\n+            \"threshold\": \"1 drop\",\n+            \"light\": \"1 drop - 3 drops\",\n+            \"common\": \"3 drops - 10 drops\",\n+            \"strong\": \"10 drops - 20 drops\",\n+            \"heavy\": \"20+ drops\"\n-          \"route\": \"insufflated\",\n-          \"units\": \"mg\",\n+          \"route\": \"oral (powdered dried root)\",\n+          \"units\": \"g\",\n-            \"threshold\": \"3mg\",\n-            \"light\": \"5mg - 15mg\",\n-            \"common\": \"15mg - 30mg\",\n-            \"strong\": \"30mg - 45mg\",\n-            \"heavy\": \"45mg+\"\n+            \"threshold\": \"0.2 g\",\n+            \"light\": \"0.3 g - 0.6 g\",\n+            \"common\": \"0.6 g - 2 g\",\n+            \"strong\": \"2 g - 4 g\",\n+            \"heavy\": \"4+ g\"\n-        },\n-        {\n-          \"route\": \"vaporized / smoked (e-cig)\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"2mg\",\n-            \"light\": \"5mg - 10mg\",\n-            \"common\": \"10mg - 25mg\",\n-            \"strong\": \"25mg - 35mg\",\n-            \"heavy\": \"35mg+\"\n-          }\n-        },\n-        {\n-          \"route\": \"intravenous\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"1mg\",\n-            \"light\": \"2mg - 5mg\",\n-            \"common\": \"5mg - 10mg\",\n-            \"strong\": \"10mg - 20mg\",\n-            \"heavy\": \"20mg+\"\n-          }\n-          \"route\": \"oral / sublingual\",\n+          \"route\": \"sublingual / oral (ethanol tincture; 1:2 w / v fresh ratio; ~45-60% alc.)\",\n-            \"oral\",\n-            \"sublingual\"\n+            \"sublingual\",\n+            \"oral\"\n-            \"total_duration\": \"1.5-3 h (active phase)\",\n-            \"onset\": \"15-30 min\",\n+            \"total_duration\": \"2-4 h active\",\n+            \"onset\": \"15-30 min tincture; 30-60 min powder\",\n-            \"offset\": \"0.5-1 h\",\n-            \"after_effects\": \"2-8 h residual stimulation; anxiety; insomnia\"\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"up-to-4 h lingering sedation or drowsy afterglow\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"oral (powdered dried root)\",\n-            \"insufflated\"\n+            \"oral\"\n-            \"total_duration\": \"1.5-3 h (active phase)\",\n-            \"onset\": \"5-15 min\",\n+            \"total_duration\": \"2-4 h active\",\n+            \"onset\": \"15-30 min tincture; 30-60 min powder\",\n-            \"offset\": \"0.5-1 h\",\n-            \"after_effects\": \"2-8 h residual stimulation; anxiety; insomnia\"\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"up-to-4 h lingering sedation or drowsy afterglow\"\n-        },\n-        {\n-          \"route\": \"vaporized / smoked (e-cig)\",\n-          \"canonical_routes\": [\n-            \"vaporized\",\n-            \"smoked\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"1.5-3 h (active phase)\",\n-            \"onset\": \"5-15 min\",\n-            \"peak\": \"0.5-1.5 h\",\n-            \"offset\": \"0.5-1 h\",\n-            \"after_effects\": \"2-8 h residual stimulation; anxiety; insomnia\"\n-          }\n-        },\n-        {\n-          \"route\": \"intravenous\",\n-          \"canonical_routes\": [\n-            \"intravenous\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"1.5-3 h (active phase)\",\n-            \"onset\": \"<1 min\",\n-            \"peak\": \"0.5-1.5 h\",\n-            \"offset\": \"0.5-1 h\",\n-            \"after_effects\": \"2-8 h residual stimulation; anxiety; insomnia\"\n-          }\n-    \"addiction_potential\": \"High: rodent CPP/self-administration and potent DAT > NET blockade mirror α-PVP; users report compulsive redosing and multi-day binges with severe crashes.\",\n+    \"addiction_potential\": \"Low; effects are sedative and not strongly reinforcing, but relief of chronic pain can lead to habitual use. Rapid tolerance not reported; daily use discouraged because of unknown grayanotoxin burden.\",\n-        \"MAOIs (hypertensive crisis)\",\n-        \"high-dose stimulants or cocaine (arrhythmia, hyperthermia)\",\n-        \"strong serotonergics + cathinone (serotonin toxicity)\",\n-        \"synthetic opioids + heavy stimulant load (respiratory/cardiac collapse)\"\n+        \"high-dose aspirin or other salicylates (additive GI / bleeding risk)\",\n+        \"warfarin or direct-acting oral anticoagulants\",\n+        \"class Ib anti-arrhythmics (additive sodium-channel blockade)\",\n+        \"large alcohol doses or CNS depressants when already sedated\"\n-        \"other cathinones / amphetamines\",\n-        \"tramadol or bupropion (seizures)\",\n-        \"dissociatives at intoxicating doses (psychosis, BP spikes)\"\n+        \"opioids (respiratory depression)\",\n+        \"benzodiazepines / Z-drugs (excessive sedation)\",\n+        \"barbiturates\",\n+        \"MAO-Is (uncharacterised hypertensive/hypotensive swings)\"\n-        \"alcohol (masking inebriation, dehydration)\",\n-        \"cannabis concentrates (panic, tachycardia)\",\n-        \"benzodiazepines (use only for comedown; respiratory depression if mixed while fatigued)\"\n+        \"NSAIDs (cumulative renal / GI load)\",\n+        \"SSRIs/SNRIs (masking serotonin-toxicity prodrome)\",\n+        \"hepatotoxic herbs or drugs (unknown hepatic metabolism)\"\n-    \"notes\": \"α-D2PV replaces the α-PVP propyl tail with a phenyl ring, lowering potency versus α-PVP but remaining far stronger than MDMA. It first appeared in seizures in late-2020 and is often mis-sold as MDMA, leading to 100 mg-scale overdoses. Harm-reduction groups (NZ’s KnowYourStuff) list 20-50 mg as the entire active range; stay below 35 mg until identity confirmed. Forum users describe rapid onset rush, intense peripheral vasoconstriction (cold extremities, chest pressure), and a short 2-hour plateau followed by edgy stimulation that tempts redose. Rodent work (2025) shows nanomolar DAT/NET inhibition, dose-dependent hyper-locomotion and accumbal DA release, suggesting high abuse liability. Reagent testing: Mandelin → reddish-brown; Liebermann → bright yellow, distinguishing it from MDMA. Volumetric solutions (1 mg/mL in PG/ethanol) allow sub-5 mg test doses. Strong hydration, electrolytes, breaks of ≥2 weeks, and benzodiazepine rescue (2-4 mg diazepam equiv.) are recommended to manage crashes and paranoia. Because half-life is short (~2-3 h extrapolated from α-PVP rat PK) but sympathomimetic after-effects linger, insomnia and compulsive re-dosing are major risks.\",\n+    \"notes\": \"Fresh aerial tissue turns deep purple in 95 % ethanol, signalling extraction of monotropitoside, gaultherin and related methyl-salicylate glycosides. Grayanotoxin-like diterpenes have been detected at <0.01 % w/w and may underlie the dissociative ‘pain-beside-me’ effect noted by many users. Field reports emphasise **strict micro-dosing**: most relief is obtained at 3–6 drops (≈150–300 µl) and higher doses often add dysphoria, tremor or nausea. Because the plant is *myco-heterotrophic* and locally sparse, sustainable harvest means taking ≤10 % of a patch and only once the flowers droop. A purple tincture kept in amber glass remains potent ~3 years refrigerated. Powdered root (historically ½–1 drachm) produces heavier somatic numbness and occasional emesis; modern harm-reduction suggests staying below 4 g and combining with ginger to curb nausea. Preliminary mouse work shows significant antinociception at 100 mg kg⁻¹ correlating with salicylic-acid plasma peaks (t½ ≈ 3–5 h). No human fatalities documented, yet glycosidic salicylates can provoke Reye-like hepatic injury in children; avoid in under-16 s. Ghost Pipe should be treated as a *co-analgesic* rather than a primary anaesthetic—users liken its action to ‘moving the pain 6 inches to the left’ rather than abolishing it.\",\n-      \"euphoria\",\n-      \"intense mental/physical stimulation\",\n-      \"increased libido\",\n-      \"talkativeness\",\n-      \"hyperfocus / repetitive behaviour\",\n-      \"jaw tension & bruxism\",\n-      \"vasoconstriction (cold fingers)\",\n-      \"anxiety / paranoia\",\n-      \"insomnia\"\n+      \"analgesia with emotional detachment from pain\",\n+      \"warm bodily numbness\",\n+      \"mild euphoria or calm\",\n+      \"soft visual brightness, colours appear pastel\",\n+      \"subtle time-dilation\",\n+      \"later drowsiness\"\n-      \"full_tolerance\": \"after 2-3 strong doses or 24 h binge\",\n-      \"half_tolerance\": \"2-3 days\",\n+      \"full_tolerance\": \"unknown; anecdotal reports suggest minimal tolerance with weekly use\",\n+      \"half_tolerance\": \"3-4 days (estimated)\",\n-        \"α-PVP\",\n-        \"other pyrrolidinophenone cathinones\",\n-        \"amphetamine-like stimulants\"\n+        \"other salicylate-based analgesics (partial)\"\n-    \"half_life\": \"≈2-3 h (rat IV data extrapolated; human half-life likely similar but unconfirmed)\",\n+    \"half_life\": \"approx. 3-5 h (salicylic acid released from gaultherin/MSL)\",\n-        \"name\": \"Wikipedia – compound overview & legal status\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/%CE%91-D2PV\"\n+        \"name\": \"Unruly Gardening – Ghost Pipe FAQs (dosage 1–3 drops)\",\n+        \"reference\": \"https://unrulygardening.com/ghost-pipe-faqs/\"\n-        \"name\": \"Forensic Toxicology review – dose 20-50 mg, ~2 h duration\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/36124107/\"\n+        \"name\": \"Foraged Market listing – 5-10 drop ‘stiff dose’ guidance\",\n+        \"reference\": \"https://foraged.com/products/ghost-pipe-tincture\"\n-        \"name\": \"KnowYourStuff NZ harm-reduction bulletin – active 30-40 mg, heavy >50 mg\",\n-        \"reference\": \"https://knowyourstuff.nz/drug-info/reagent-testing-for-alpha-d2pv/\"\n+        \"name\": \"Beneficial Botanicals – tincture start-with-3-drops advice\",\n+        \"reference\": \"https://beneficialbotanicals.com/store/Ghost-Pipe-Tincture\"\n-        \"name\": \"Rodent abuse-liability study (2025) – DAT/NET inhibition & hyper-locomotion\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/40118207/\"\n+        \"name\": \"WashAshore Store – 1-4 drop effect window\",\n+        \"reference\": \"https://www.washashorestore.com/products/ghost-pipe-tincture\"\n-        \"name\": \"Acta Crystallographica C – analytical profile of seized α-D2PV\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC10996188/\"\n+        \"name\": \"Reddit /r/foraging – user experience & drop counts\",\n+        \"reference\": \"https://www.reddit.com/r/foraging/comments/yu4tuv/ghost_pipe_tincture/\"\n+      },\n+      {\n+        \"name\": \"Herbdata NZ – powdered-root ½–1 drachm dose\",\n+        \"reference\": \"https://www.herbdatanz.com/indian_pipe_preparation.htm\"\n+      },\n+      {\n+        \"name\": \"School of Health proving – traditional ½–1 drachm use\",\n+        \"reference\": \"https://www.schoolofhealth.com/docs/Proving_of_Ghost_Pipe_BLK_FINAL.pdf\"\n+      },\n+      {\n+        \"name\": \"ResearchGate review 2025 – pharmacological profile\",\n+        \"reference\": \"https://www.researchgate.net/publication/391594082_Medicinal_Uses_of_Monotropa_uniflora_A_Comprehensive_Review\"\n+      },\n+      {\n+        \"name\": \"Penn State research news – analgesic bioassay in mice\",\n+        \"reference\": \"https://www.psu.edu/news/research/story/traditional-forest-medicinal-plant-ghost-pipe-used-differently-today}\"\n+      },\n+      {\n+        \"name\": \"Wikipedia – presence of salicylic acid & grayanotoxin\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Monotropa_uniflora\"\n+      },\n+      {\n+        \"name\": \"ACS presentation – chemical components (grayanotoxin)\",\n+        \"reference\": \"https://acs.digitellinc.com/p/studies-of-chemical-components-in-monotropa-uniflora-indian-pipe-using-gas-chromatographymass-spectrometry-605379\"\n+      },\n+      {\n+        \"name\": \"MDPI – gaultherin pharmacokinetics (salicylate t½)\",\n+        \"reference\": \"https://www.mdpi.com/1422-0067/26/15/7280\"\n-      \"stimulant\",\n-      \"research-chemical\"\n+      \"sedative\"\n\n# 1cP-AL-LAD · #548\n\n-  \"id\": 547,\n-  \"title\": \"Monotropa uniflora\",\n+  \"id\": 548,\n+  \"title\": \"1cP-AL-LAD\",\n-    \"drug_name\": \"Monotropa uniflora\",\n-    \"chemical_name\": \"Monotropa uniflora\",\n-    \"alternative_name\": \"Ghost Pipe, Indian Pipe\",\n-    \"chemical_class\": \"Phenolic-glycoside–rich parasitic herb (family Ericaceae)\",\n-    \"mechanism_of_action\": \"Stimulant (uncertain mechanism)\",\n-    \"psychoactive_class\": \"Analgesic; anxiolytic; putative sodium-channel modulator (grayanotoxins) and salicylate pro-drug\",\n+    \"drug_name\": \"1cP-AL-LAD\",\n+    \"chemical_name\": \"1cP-AL-LAD\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Lysergamides\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist; prodrug of LSD\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-          \"route\": \"sublingual / oral (ethanol tincture; 1:2 w / v fresh ratio; ~45-60% alc.)\",\n-          \"units\": \"drops\",\n+          \"route\": \"oral / sublingual (blotter)\",\n+          \"units\": \"µg\",\n-            \"threshold\": \"1 drop\",\n-            \"light\": \"1 drop - 3 drops\",\n-            \"common\": \"3 drops - 10 drops\",\n-            \"strong\": \"10 drops - 20 drops\",\n-            \"heavy\": \"20+ drops\"\n+            \"threshold\": \"15 µg\",\n+            \"light\": \"15 µg - 50 µg\",\n+            \"common\": \"50 µg - 125 µg\",\n+            \"strong\": \"125 µg - 200 µg\",\n+            \"heavy\": \"200+ µg\"\n-          \"route\": \"oral (powdered dried root)\",\n-          \"units\": \"g\",\n+          \"route\": \"insufflated (liquid)\",\n+          \"units\": \"µg\",\n-            \"threshold\": \"0.2 g\",\n-            \"light\": \"0.3 g - 0.6 g\",\n-            \"common\": \"0.6 g - 2 g\",\n-            \"strong\": \"2 g - 4 g\",\n-            \"heavy\": \"4+ g\"\n+            \"threshold\": \"10 µg\",\n+            \"light\": \"10 µg - 40 µg\",\n+            \"common\": \"40 µg - 100 µg\",\n+            \"strong\": \"100 µg - 150 µg\",\n+            \"heavy\": \"150+ µg\"\n-          \"route\": \"sublingual / oral (ethanol tincture; 1:2 w / v fresh ratio; ~45-60% alc.)\",\n+          \"route\": \"oral / sublingual (blotter)\",\n-            \"sublingual\",\n-            \"oral\"\n+            \"oral\",\n+            \"sublingual\"\n-            \"total_duration\": \"2-4 h active\",\n-            \"onset\": \"15-30 min tincture; 30-60 min powder\",\n-            \"peak\": \"0.5-1.5 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"up-to-4 h lingering sedation or drowsy afterglow\"\n+            \"total_duration\": \"8-10 h (active phase)\",\n+            \"onset\": \"30-45 min\",\n+            \"peak\": \"2-4 h\",\n+            \"offset\": \"2-3 h\",\n+            \"after_effects\": \"1-6 h residual stimulation; mild insomnia\"\n-          \"route\": \"oral (powdered dried root)\",\n+          \"route\": \"insufflated (liquid)\",\n-            \"oral\"\n+            \"insufflated\"\n-            \"total_duration\": \"2-4 h active\",\n-            \"onset\": \"15-30 min tincture; 30-60 min powder\",\n-            \"peak\": \"0.5-1.5 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"up-to-4 h lingering sedation or drowsy afterglow\"\n+            \"total_duration\": \"8-10 h (active phase)\",\n+            \"onset\": \"15-30 min\",\n+            \"peak\": \"2-4 h\",\n+            \"offset\": \"2-3 h\",\n+            \"after_effects\": \"1-6 h residual stimulation; mild insomnia\"\n-    \"addiction_potential\": \"Low; effects are sedative and not strongly reinforcing, but relief of chronic pain can lead to habitual use. Rapid tolerance not reported; daily use discouraged because of unknown grayanotoxin burden.\",\n+    \"addiction_potential\": \"Low: lysergamides show rapid acute tolerance and little craving; compulsive redosing is rare.\",\n-        \"high-dose aspirin or other salicylates (additive GI / bleeding risk)\",\n-        \"warfarin or direct-acting oral anticoagulants\",\n-        \"class Ib anti-arrhythmics (additive sodium-channel blockade)\",\n-        \"large alcohol doses or CNS depressants when already sedated\"\n+        \"MAOIs (hypertensive crisis, serotonin syndrome)\",\n+        \"tramadol or high-dose SSRIs (seizure / serotonin toxicity)\",\n+        \"sympathomimetic stimulants (tachycardia, hypertension)\"\n-        \"opioids (respiratory depression)\",\n-        \"benzodiazepines / Z-drugs (excessive sedation)\",\n-        \"barbiturates\",\n-        \"MAO-Is (uncharacterised hypertensive/hypotensive swings)\"\n+        \"high-dose cannabis concentrates (panic, dysphoria)\",\n+        \"cocaine or amphetamines (over-stimulation)\",\n+        \"nitrates or PDE-5 inhibitors (blood-pressure instability)\"\n-        \"NSAIDs (cumulative renal / GI load)\",\n-        \"SSRIs/SNRIs (masking serotonin-toxicity prodrome)\",\n-        \"hepatotoxic herbs or drugs (unknown hepatic metabolism)\"\n+        \"benzodiazepines or alcohol (can dull psychedelic; respiratory risk if heavily sedated)\",\n+        \"other psychedelics (potentiation, unpredictable headspace)\",\n+        \"antipsychotics (QT prolongation, abrupt trip termination)\"\n-    \"notes\": \"Fresh aerial tissue turns deep purple in 95 % ethanol, signalling extraction of monotropitoside, gaultherin and related methyl-salicylate glycosides. Grayanotoxin-like diterpenes have been detected at <0.01 % w/w and may underlie the dissociative ‘pain-beside-me’ effect noted by many users. Field reports emphasise **strict micro-dosing**: most relief is obtained at 3–6 drops (≈150–300 µl) and higher doses often add dysphoria, tremor or nausea. Because the plant is *myco-heterotrophic* and locally sparse, sustainable harvest means taking ≤10 % of a patch and only once the flowers droop. A purple tincture kept in amber glass remains potent ~3 years refrigerated. Powdered root (historically ½–1 drachm) produces heavier somatic numbness and occasional emesis; modern harm-reduction suggests staying below 4 g and combining with ginger to curb nausea. Preliminary mouse work shows significant antinociception at 100 mg kg⁻¹ correlating with salicylic-acid plasma peaks (t½ ≈ 3–5 h). No human fatalities documented, yet glycosidic salicylates can provoke Reye-like hepatic injury in children; avoid in under-16 s. Ghost Pipe should be treated as a *co-analgesic* rather than a primary anaesthetic—users liken its action to ‘moving the pain 6 inches to the left’ rather than abolishing it.\",\n+    \"notes\": \"1cP-AL-LAD is rapidly de-acylated in human serum, delivering AL-LAD as the primary active metabolite. Analytical studies confirm near-quantitative conversion within 30-60 min at 37 °C. Users consistently describe a shorter, highly visual and sociable experience compared with LSD, with markedly reduced vasoconstriction and anxiety.\\nTabs marketed at 100–150 µg are common; independent HPLC testing has found ±15 % variance—use a calibrated scale or volumetric dosing for accuracy. Many blotters co-contain iso-lysergamides or residual solvents; Ehrlich’s/Weil reagents confirm indole presence but not purity—full GC-MS is advised for batch verification.\\nGastro-intestinal discomfort and light nausea are the main acute side-effects. Vasoconstriction (cold extremities) and mild hypertension (< 10 mm Hg over baseline) peak during the first 2 h; hydration, gentle stretching and magnesium supplementation mitigate this. Visual intensity and chromatic aberration are pronounced under bright light; sunglasses can reduce eye-strain.\\nAcute tolerance is complete after one session; wait at least 7 days for half-tolerance and 14 days for baseline. Cross-tolerance exists with LSD, AL-LAD, ETH-LAD, 1P-LSD, etc. Chronic high-frequency use (> weekly) is linked with blunted affect and rebound migraines in anecdotal reports.\\nBecause 1-substituted lysergamides are often unscheduled, customs seizures are rising—keep blotters in light-proof, acid-free sleeves with desiccant at ≤ 4 °C for long-term stability (t ½ degradation ~9 months at room temperature).\",\n-      \"analgesia with emotional detachment from pain\",\n-      \"warm bodily numbness\",\n-      \"mild euphoria or calm\",\n-      \"soft visual brightness, colours appear pastel\",\n-      \"subtle time-dilation\",\n-      \"later drowsiness\"\n+      \"intensely patterned closed- and open-eye visuals\",\n+      \"warm euphoria and laughter\",\n+      \"enhanced music and color appreciation\",\n+      \"minimal head-pressure compared with LSD\",\n+      \"gentle body energy / stimulation\",\n+      \"reduced anxiety and introspection relative to LSD\",\n+      \"time dilation and synaesthesia at strong doses\"\n-      \"full_tolerance\": \"unknown; anecdotal reports suggest minimal tolerance with weekly use\",\n-      \"half_tolerance\": \"3-4 days (estimated)\",\n-      \"zero_tolerance\": \"7-10 days\",\n+      \"full_tolerance\": \"after one normal session\",\n+      \"half_tolerance\": \"7 days\",\n+      \"zero_tolerance\": \"14 days\",\n-        \"other salicylate-based analgesics (partial)\"\n+        \"LSD\",\n+        \"AL-LAD\",\n+        \"other lysergamides\"\n-    \"half_life\": \"approx. 3-5 h (salicylic acid released from gaultherin/MSL)\",\n+    \"half_life\": \"approx. 3-4 h for AL-LAD metabolite; parent 1cP-AL-LAD < 30 min (in vitro)\",\n-        \"name\": \"Unruly Gardening – Ghost Pipe FAQs (dosage 1–3 drops)\",\n-        \"reference\": \"https://unrulygardening.com/ghost-pipe-faqs/\"\n+        \"name\": \"Analytical profile of 1cP-AL-LAD\",\n+        \"reference\": \"https://www.researchgate.net/publication/365062999_Analytical_profile_of_the_lysergamide_1cP-AL-LAD_and_detection_of_impurities\"\n-        \"name\": \"Foraged Market listing – 5-10 drop ‘stiff dose’ guidance\",\n-        \"reference\": \"https://foraged.com/products/ghost-pipe-tincture\"\n+        \"name\": \"Identification of 1cP-AL-LAD in Japanese blotters\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC10310582/\"\n-        \"name\": \"Beneficial Botanicals – tincture start-with-3-drops advice\",\n-        \"reference\": \"https://beneficialbotanicals.com/store/Ghost-Pipe-Tincture\"\n+        \"name\": \"AL-LAD dose & 6–8 h duration\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/AL-LAD\"\n-        \"name\": \"WashAshore Store – 1-4 drop effect window\",\n-        \"reference\": \"https://www.washashorestore.com/products/ghost-pipe-tincture\"\n+        \"name\": \"600 µg 1cP-AL-LAD timeline (Reddit)\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/rbpziq/600ug_1cpallad_brain_candy/\"\n-        \"name\": \"Reddit /r/foraging – user experience & drop counts\",\n-        \"reference\": \"https://www.reddit.com/r/foraging/comments/yu4tuv/ghost_pipe_tincture/\"\n+        \"name\": \"300 µg sublingual trip report (Bluelight)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/1cp-al-lad-300-%C2%B5g-sublingual-first-time-aging-vividly.905662/\"\n-        \"name\": \"Herbdata NZ – powdered-root ½–1 drachm dose\",\n-        \"reference\": \"https://www.herbdatanz.com/indian_pipe_preparation.htm\"\n+        \"name\": \"First-time 150 µg report\",\n+        \"reference\": \"https://www.reddit.com/r/1P_LSD/comments/nc6a7d/first_time_150_%CE%BCg_1cpallad_short_trip_report/\"\n-        \"name\": \"School of Health proving – traditional ½–1 drachm use\",\n-        \"reference\": \"https://www.schoolofhealth.com/docs/Proving_of_Ghost_Pipe_BLK_FINAL.pdf\"\n+        \"name\": \"TrippyWiki – user-collated harm-reduction info\",\n+        \"reference\": \"https://trippywiki.com/1cp-al-lad/\"\n-        \"name\": \"ResearchGate review 2025 – pharmacological profile\",\n-        \"reference\": \"https://www.researchgate.net/publication/391594082_Medicinal_Uses_of_Monotropa_uniflora_A_Comprehensive_Review\"\n+        \"name\": \"Return of the Lysergamides VI (metabolism parallels)\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC9191646/\"\n-        \"name\": \"Penn State research news – analgesic bioassay in mice\",\n-        \"reference\": \"https://www.psu.edu/news/research/story/traditional-forest-medicinal-plant-ghost-pipe-used-differently-today}\"\n+        \"name\": \"Detection of LSD analogs 1cP-AL-LAD, 1cP-MIPLA\",\n+        \"reference\": \"https://www.sciencedirect.com/science/article/pii/S2352007822003675\"\n-        \"name\": \"Wikipedia – presence of salicylic acid & grayanotoxin\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Monotropa_uniflora\"\n-      },\n-      {\n-        \"name\": \"ACS presentation – chemical components (grayanotoxin)\",\n-        \"reference\": \"https://acs.digitellinc.com/p/studies-of-chemical-components-in-monotropa-uniflora-indian-pipe-using-gas-chromatographymass-spectrometry-605379\"\n-      },\n-      {\n-        \"name\": \"MDPI – gaultherin pharmacokinetics (salicylate t½)\",\n-        \"reference\": \"https://www.mdpi.com/1422-0067/26/15/7280\"\n+        \"name\": \"In-vitro conversion of 1P-AL-LAD to AL-LAD (proxy)\",\n+        \"reference\": \"https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/dta.3281\"\n-      \"sedative\"\n+      \"psychedelic\",\n+      \"research-chemical\"\n\n# Tapentadol · #549\n\n-  \"id\": 548,\n-  \"title\": \"1cP-AL-LAD\",\n+  \"id\": 549,\n+  \"title\": \"Tapentadol\",\n-    \"drug_name\": \"1cP-AL-LAD\",\n-    \"chemical_name\": \"1cP-AL-LAD\",\n+    \"drug_name\": \"Tapentadol\",\n+    \"chemical_name\": \"Tapentadol\",\n-    \"chemical_class\": \"Lysergamides\",\n-    \"mechanism_of_action\": \"5-HT2A receptor agonist; prodrug of LSD\",\n-    \"psychoactive_class\": \"Psychedelic\",\n+    \"chemical_class\": \"Phenylpropylaminopentane\",\n+    \"mechanism_of_action\": \"μ-Opioid receptor agonist; norepinephrine reuptake inhibitor\",\n+    \"psychoactive_class\": \"μ‑opioid receptor agonist; norepinephrine reuptake inhibitor\",\n-          \"route\": \"oral / sublingual (blotter)\",\n-          \"units\": \"µg\",\n+          \"route\": \"oral (immediate release)\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"15 µg\",\n-            \"light\": \"15 µg - 50 µg\",\n-            \"common\": \"50 µg - 125 µg\",\n-            \"strong\": \"125 µg - 200 µg\",\n-            \"heavy\": \"200+ µg\"\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"5 mg - 25 mg\",\n+            \"common\": \"25 mg - 50 mg\",\n+            \"strong\": \"50 mg - 100 mg\",\n+            \"heavy\": \"100 mg+\"\n-          \"route\": \"insufflated (liquid)\",\n-          \"units\": \"µg\",\n+          \"route\": \"oral (extended release)\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"10 µg\",\n-            \"light\": \"10 µg - 40 µg\",\n-            \"common\": \"40 µg - 100 µg\",\n-            \"strong\": \"100 µg - 150 µg\",\n-            \"heavy\": \"150+ µg\"\n+            \"threshold\": \"25 mg\",\n+            \"light\": \"25 mg - 100 mg\",\n+            \"common\": \"100 mg - 200 mg\",\n+            \"strong\": \"200 mg - 250 mg\",\n+            \"heavy\": \"250 mg+\"\n-          \"route\": \"oral / sublingual (blotter)\",\n+          \"route\": \"oral (immediate release)\",\n-            \"oral\",\n-            \"sublingual\"\n+            \"oral\"\n-            \"total_duration\": \"8-10 h (active phase)\",\n-            \"onset\": \"30-45 min\",\n-            \"peak\": \"2-4 h\",\n-            \"offset\": \"2-3 h\",\n-            \"after_effects\": \"1-6 h residual stimulation; mild insomnia\"\n+            \"total_duration\": \"4‑6 h\",\n+            \"onset\": \"~30 min\",\n+            \"peak\": \"1‑2 h\",\n+            \"offset\": \"4‑6 h\",\n+            \"after_effects\": \"residual sedation; mild noradrenergic stimulation\"\n-          \"route\": \"insufflated (liquid)\",\n+          \"route\": \"oral (extended release)\",\n-            \"insufflated\"\n+            \"oral\"\n-            \"total_duration\": \"8-10 h (active phase)\",\n-            \"onset\": \"15-30 min\",\n-            \"peak\": \"2-4 h\",\n-            \"offset\": \"2-3 h\",\n-            \"after_effects\": \"1-6 h residual stimulation; mild insomnia\"\n+            \"total_duration\": \"4‑6 h\",\n+            \"onset\": \"~30 min\",\n+            \"peak\": \"1‑2 h\",\n+            \"offset\": \"4‑6 h\",\n+            \"after_effects\": \"residual sedation; mild noradrenergic stimulation\"\n-    \"addiction_potential\": \"Low: lysergamides show rapid acute tolerance and little craving; compulsive redosing is rare.\",\n+    \"addiction_potential\": \"High: full µ‑opioid agonist with no ceiling effect and water‑soluble. Abuse similar to oxycodone or hydromorphone\",\n-        \"MAOIs (hypertensive crisis, serotonin syndrome)\",\n-        \"tramadol or high-dose SSRIs (seizure / serotonin toxicity)\",\n-        \"sympathomimetic stimulants (tachycardia, hypertension)\"\n+        \"MAO inhibitors\",\n+        \"SSRIs/SNRIs/serotonergic drugs (serotonin syndrome risk)\",\n+        \"alcohol or other CNS depressants (respiratory depression)\"\n-        \"high-dose cannabis concentrates (panic, dysphoria)\",\n-        \"cocaine or amphetamines (over-stimulation)\",\n-        \"nitrates or PDE-5 inhibitors (blood-pressure instability)\"\n+        \"other opioids (additive overdose risk)\",\n+        \"gabapentinoids or benzodiazepines (enhanced sedation)\"\n-        \"benzodiazepines or alcohol (can dull psychedelic; respiratory risk if heavily sedated)\",\n-        \"other psychedelics (potentiation, unpredictable headspace)\",\n-        \"antipsychotics (QT prolongation, abrupt trip termination)\"\n+        \"seizure‑threshold lowering drugs\",\n+        \"medications metabolised by CYP2C9, CYP2C19, CYP2D6 (though minimal P450 dependence)\"\n-    \"notes\": \"1cP-AL-LAD is rapidly de-acylated in human serum, delivering AL-LAD as the primary active metabolite. Analytical studies confirm near-quantitative conversion within 30-60 min at 37 °C. Users consistently describe a shorter, highly visual and sociable experience compared with LSD, with markedly reduced vasoconstriction and anxiety.\\nTabs marketed at 100–150 µg are common; independent HPLC testing has found ±15 % variance—use a calibrated scale or volumetric dosing for accuracy. Many blotters co-contain iso-lysergamides or residual solvents; Ehrlich’s/Weil reagents confirm indole presence but not purity—full GC-MS is advised for batch verification.\\nGastro-intestinal discomfort and light nausea are the main acute side-effects. Vasoconstriction (cold extremities) and mild hypertension (< 10 mm Hg over baseline) peak during the first 2 h; hydration, gentle stretching and magnesium supplementation mitigate this. Visual intensity and chromatic aberration are pronounced under bright light; sunglasses can reduce eye-strain.\\nAcute tolerance is complete after one session; wait at least 7 days for half-tolerance and 14 days for baseline. Cross-tolerance exists with LSD, AL-LAD, ETH-LAD, 1P-LSD, etc. Chronic high-frequency use (> weekly) is linked with blunted affect and rebound migraines in anecdotal reports.\\nBecause 1-substituted lysergamides are often unscheduled, customs seizures are rising—keep blotters in light-proof, acid-free sleeves with desiccant at ≤ 4 °C for long-term stability (t ½ degradation ~9 months at room temperature).\",\n+    \"notes\": \"Tapentadol is approximately two‑to‑three times more potent than tramadol and two‑to‑three times less potent than morphine  [oai_citation:0‡SpringerLink](https://link.springer.com/article/10.1007/s40265-021-01515-z?utm_source=chatgpt.com). Analgesic onset is ~32 minutes after oral administration, lasting around 4–6 hours  [oai_citation:1‡Wikipedia](https://en.wikipedia.org/wiki/Tapentadol?utm_source=chatgpt.com). It is a full μ‑opioid agonist combined with norepinephrine reuptake inhibition, not a pro‑drug, and has no known active metabolites, making its PK more predictable and less subject to CYP phenotypes  [oai_citation:2‡Wikipedia](https://en.wikipedia.org/wiki/Tapentadol?utm_source=chatgpt.com). Case reports and post‑marketing studies confirm high abuse liability, similar to hydromorphone and oxycodone; crushing, chewing, insufflating, or injecting IR tablets has been reported and linked to respiratory depression, coma, and death  [oai_citation:3‡Wikipedia](https://en.wikipedia.org/wiki/Tapentadol?utm_source=chatgpt.com). Withdrawal can be intense due to dual opioid and noradrenergic mechanisms—with typical opioid withdrawal plus adrenergic symptoms (anxiety, insomnia, tremor)  [oai_citation:4‡Wikipedia](https://en.wikipedia.org/wiki/Tapentadol?utm_source=chatgpt.com). Post‑marketing surveillance shows that although tapentadol occasionally has lower abuse incidence than some Schedule II drugs when prescribed appropriately, large-scale misuse has become common especially in areas with OTC availability or diverted supply (e.g. India)  [oai_citation:5‡Oxford Academic](https://academic.oup.com/painmedicine/article/16/1/119/2460229?utm_source=chatgpt.com). Overdose risk increases sharply when combined with other depressants; death can occur even with single tablets in pediatric or naïve individuals  [oai_citation:6‡anrclinic.com](https://anrclinic.com/blog/tapentadol-overdose/?utm_source=chatgpt.com).\",\n-      \"intensely patterned closed- and open-eye visuals\",\n-      \"warm euphoria and laughter\",\n-      \"enhanced music and color appreciation\",\n-      \"minimal head-pressure compared with LSD\",\n-      \"gentle body energy / stimulation\",\n-      \"reduced anxiety and introspection relative to LSD\",\n-      \"time dilation and synaesthesia at strong doses\"\n+      \"euphoria\",\n+      \"analgesia\",\n+      \"sedation\",\n+      \"mild noradrenergic stimulation (alertness or jitter)\",\n+      \"respiratory depression at higher doses\",\n+      \"nausea, itch, constipation\"\n-      \"full_tolerance\": \"after one normal session\",\n-      \"half_tolerance\": \"7 days\",\n-      \"zero_tolerance\": \"14 days\",\n+      \"full_tolerance\": \"develops quickly (days)\",\n+      \"half_tolerance\": \"several days\",\n+      \"zero_tolerance\": \"1‑2 weeks\",\n-        \"LSD\",\n-        \"AL-LAD\",\n-        \"other lysergamides\"\n+        \"morphine\",\n+        \"hydrocodone\",\n+        \"oxycodone\"\n-    \"half_life\": \"approx. 3-4 h for AL-LAD metabolite; parent 1cP-AL-LAD < 30 min (in vitro)\",\n+    \"half_life\": \"4 h\",\n-        \"name\": \"Analytical profile of 1cP-AL-LAD\",\n-        \"reference\": \"https://www.researchgate.net/publication/365062999_Analytical_profile_of_the_lysergamide_1cP-AL-LAD_and_detection_of_impurities\"\n+        \"name\": \"Wikipedia – Tapentadol\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Tapentadol\"\n-        \"name\": \"Identification of 1cP-AL-LAD in Japanese blotters\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC10310582/\"\n+        \"name\": \"Tapentadol: A Review of Experimental Pharmacology Studies, Clinical Trials, and Recent Findings\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10039632/\"\n-        \"name\": \"AL-LAD dose & 6–8 h duration\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/AL-LAD\"\n+        \"name\": \"Mayo Clinic – Tapentadol\",\n+        \"reference\": \"https://www.mayoclinic.org/drugs-supplements/tapentadol-oral-route\"\n-        \"name\": \"600 µg 1cP-AL-LAD timeline (Reddit)\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/rbpziq/600ug_1cpallad_brain_candy/\"\n+        \"name\": \"Pain Medicine – Tapentadol abuse liability study\",\n+        \"reference\": \"https://academic.oup.com/painmedicine/article/16/1/119/2460229\"\n-        \"name\": \"300 µg sublingual trip report (Bluelight)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/1cp-al-lad-300-%C2%B5g-sublingual-first-time-aging-vividly.905662/\"\n+        \"name\": \"Post-marketing case report\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11964174/\"\n-        \"name\": \"First-time 150 µg report\",\n-        \"reference\": \"https://www.reddit.com/r/1P_LSD/comments/nc6a7d/first_time_150_%CE%BCg_1cpallad_short_trip_report/\"\n-      },\n-      {\n-        \"name\": \"TrippyWiki – user-collated harm-reduction info\",\n-        \"reference\": \"https://trippywiki.com/1cp-al-lad/\"\n-      },\n-      {\n-        \"name\": \"Return of the Lysergamides VI (metabolism parallels)\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC9191646/\"\n-      },\n-      {\n-        \"name\": \"Detection of LSD analogs 1cP-AL-LAD, 1cP-MIPLA\",\n-        \"reference\": \"https://www.sciencedirect.com/science/article/pii/S2352007822003675\"\n-      },\n-      {\n-        \"name\": \"In-vitro conversion of 1P-AL-LAD to AL-LAD (proxy)\",\n-        \"reference\": \"https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/dta.3281\"\n+        \"name\": \"Times of India – Tapentadol abuse in India\",\n+        \"reference\": \"https://timesofindia.indiatimes.com/city/trichy/tapentadol-abuse-among-youths-keeps-trichy-police-on-toes/articleshow/122305404.cms\"\n-      \"psychedelic\",\n+      \"opioid\",\n\n# 4-Pro-MET · #550\n\n-  \"id\": 549,\n-  \"title\": \"Tapentadol\",\n+  \"id\": 550,\n+  \"title\": \"4-Pro-MET\",\n-    \"drug_name\": \"Tapentadol\",\n-    \"chemical_name\": \"Tapentadol\",\n-    \"alternative_name\": \"\",\n-    \"chemical_class\": \"Phenylpropylaminopentane\",\n-    \"mechanism_of_action\": \"μ-Opioid receptor agonist; norepinephrine reuptake inhibitor\",\n-    \"psychoactive_class\": \"μ‑opioid receptor agonist; norepinephrine reuptake inhibitor\",\n+    \"drug_name\": \"4-Pro-MET\",\n+    \"chemical_name\": \"4-PrO-MET\",\n+    \"alternative_name\": \"4-propionoxy-4-HO-MET prodrug\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-          \"route\": \"oral (immediate release)\",\n+          \"route\": \"oral\",\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"5 mg - 25 mg\",\n-            \"common\": \"25 mg - 50 mg\",\n-            \"strong\": \"50 mg - 100 mg\",\n-            \"heavy\": \"100 mg+\"\n+            \"threshold\": \"2mg\",\n+            \"light\": \"3mg - 7mg\",\n+            \"common\": \"7mg - 15mg\",\n+            \"strong\": \"15mg - 25mg\",\n+            \"heavy\": \"25mg+\"\n-        },\n-        {\n-          \"route\": \"oral (extended release)\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"25 mg\",\n-            \"light\": \"25 mg - 100 mg\",\n-            \"common\": \"100 mg - 200 mg\",\n-            \"strong\": \"200 mg - 250 mg\",\n-            \"heavy\": \"250 mg+\"\n-          }\n-          \"route\": \"oral (immediate release)\",\n+          \"route\": \"oral\",\n-            \"total_duration\": \"4‑6 h\",\n-            \"onset\": \"~30 min\",\n-            \"peak\": \"1‑2 h\",\n-            \"offset\": \"4‑6 h\",\n-            \"after_effects\": \"residual sedation; mild noradrenergic stimulation\"\n+            \"total_duration\": \"4 - 7 h\",\n+            \"onset\": \"20 - 60 min\",\n+            \"peak\": \"1 - 3 h\",\n+            \"offset\": \"1 - 2 h\",\n+            \"after_effects\": \"1 - 6 h residual stimulation or glow\"\n-        },\n-        {\n-          \"route\": \"oral (extended release)\",\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"4‑6 h\",\n-            \"onset\": \"~30 min\",\n-            \"peak\": \"1‑2 h\",\n-            \"offset\": \"4‑6 h\",\n-            \"after_effects\": \"residual sedation; mild noradrenergic stimulation\"\n-          }\n-    \"addiction_potential\": \"High: full µ‑opioid agonist with no ceiling effect and water‑soluble. Abuse similar to oxycodone or hydromorphone\",\n+    \"addiction_potential\": \"Low; classic-psychedelic profile with rapid tolerance discouraging daily use. Compulsive redosing uncommon but possible with pellet products due to mislabeling/variability.\",\n-        \"MAO inhibitors\",\n-        \"SSRIs/SNRIs/serotonergic drugs (serotonin syndrome risk)\",\n-        \"alcohol or other CNS depressants (respiratory depression)\"\n+        \"MAOIs (pharmacodynamic potentiation; hypertensive crisis/serotonin toxicity)\",\n+        \"Tramadol (seizure/serotonin syndrome risk)\",\n+        \"Lithium (neurotoxicity, seizures reported with serotonergic psychedelics)\"\n-        \"other opioids (additive overdose risk)\",\n-        \"gabapentinoids or benzodiazepines (enhanced sedation)\"\n+        \"Other serotonergics in high dose (MDMA, SSRIs/SNRIs at supratherapeutic doses, 5-HTP) due to cumulative serotonergic load\",\n+        \"Stimulants at high dose (tachycardia, anxiety, hyperthermia)\"\n-        \"seizure‑threshold lowering drugs\",\n-        \"medications metabolised by CYP2C9, CYP2C19, CYP2D6 (though minimal P450 dependence)\"\n+        \"Cannabis (can markedly intensify visuals/anxiety on the come-up)\",\n+        \"Benzodiazepines (can abort experience; reserve for panic only)\",\n+        \"Alcohol (dehydration, nausea; worsens judgment)\",\n+        \"Antipsychotics (may blunt effects; QT considerations for some)\"\n-    \"notes\": \"Tapentadol is approximately two‑to‑three times more potent than tramadol and two‑to‑three times less potent than morphine  [oai_citation:0‡SpringerLink](https://link.springer.com/article/10.1007/s40265-021-01515-z?utm_source=chatgpt.com). Analgesic onset is ~32 minutes after oral administration, lasting around 4–6 hours  [oai_citation:1‡Wikipedia](https://en.wikipedia.org/wiki/Tapentadol?utm_source=chatgpt.com). It is a full μ‑opioid agonist combined with norepinephrine reuptake inhibition, not a pro‑drug, and has no known active metabolites, making its PK more predictable and less subject to CYP phenotypes  [oai_citation:2‡Wikipedia](https://en.wikipedia.org/wiki/Tapentadol?utm_source=chatgpt.com). Case reports and post‑marketing studies confirm high abuse liability, similar to hydromorphone and oxycodone; crushing, chewing, insufflating, or injecting IR tablets has been reported and linked to respiratory depression, coma, and death  [oai_citation:3‡Wikipedia](https://en.wikipedia.org/wiki/Tapentadol?utm_source=chatgpt.com). Withdrawal can be intense due to dual opioid and noradrenergic mechanisms—with typical opioid withdrawal plus adrenergic symptoms (anxiety, insomnia, tremor)  [oai_citation:4‡Wikipedia](https://en.wikipedia.org/wiki/Tapentadol?utm_source=chatgpt.com). Post‑marketing surveillance shows that although tapentadol occasionally has lower abuse incidence than some Schedule II drugs when prescribed appropriately, large-scale misuse has become common especially in areas with OTC availability or diverted supply (e.g. India)  [oai_citation:5‡Oxford Academic](https://academic.oup.com/painmedicine/article/16/1/119/2460229?utm_source=chatgpt.com). Overdose risk increases sharply when combined with other depressants; death can occur even with single tablets in pediatric or naïve individuals  [oai_citation:6‡anrclinic.com](https://anrclinic.com/blog/tapentadol-overdose/?utm_source=chatgpt.com).\",\n+    \"notes\": \"4-PrO-MET is marketed in Europe as pressed pellets labeled 15–20 mg; multiple user reports indicate substantial potency variability between batches, so titration from 2–3 mg is prudent. A German-language thread documents perceived microdose at 0.5–3 mg, light 4–8 mg, and 8 mg+ as very strong; half of a 15 mg pellet (~7.5 mg) ranged from mild to quite strong depending on the commenter, underscoring variability in pressing and individual sensitivity. As an O-propionyl ester at the 4-position, 4-PrO-MET is expected to hydrolyze to 4-HO-MET in vivo; human data are absent, but analogous work with 4-PrO-DMT demonstrates psychedelic activity in animals and supports the prodrug model. Compared with 4-HO-MET, some users describe slightly slower onset and equal or lower mg-for-mg potency; others report unexpectedly strong visuals from a single pellet, suggesting either under/overfilled tablets or uneven distribution of active. A conservative harm-reduction approach is to treat 4-PrO-MET as roughly equipotent to 4-AcO-MET and somewhat less potent than 4-HO-MET, keeping first trials ≤5–7 mg. Come-up may be 'sneaky' with waves, yawning, and mild nausea; set and setting control anxiety spikes. Visuals can be intense and 'cartoony,' while headspace is often reported as lighter than psilocybin or LSD. Cannabis co-use reliably amplifies visuals but can worsen body-load. Acute tolerance develops within hours; wait at least 7–14 days before re-dosing to regain baseline response. Because this is a novel ester, reagent tests may not distinguish it from other tryptamines; consider multi-reagent testing plus, where feasible, analytical confirmation. Avoid insufflation due to ester hydrolysis uncertainty, harshness, and limited benefit; oral titration is preferred.\",\n-      \"euphoria\",\n-      \"analgesia\",\n-      \"sedation\",\n-      \"mild noradrenergic stimulation (alertness or jitter)\",\n-      \"respiratory depression at higher doses\",\n-      \"nausea, itch, constipation\"\n+      \"color and contrast enhancement\",\n+      \"patterned visuals and geometry\",\n+      \"cartoon-like visual character\",\n+      \"euphoria and mood lift\",\n+      \"reduced cognitive load versus LSD/psilocin (variable)\",\n+      \"time dilation\",\n+      \"mild nausea/yawning on come-up\",\n+      \"body load waves (occasionally cramps/tremor reported with 4-HO-MET analogues)\"\n-      \"full_tolerance\": \"develops quickly (days)\",\n-      \"half_tolerance\": \"several days\",\n-      \"zero_tolerance\": \"1‑2 weeks\",\n+      \"full_tolerance\": \"after a single strong session\",\n+      \"half_tolerance\": \"3 - 5 days\",\n+      \"zero_tolerance\": \"7 - 14 days\",\n-        \"morphine\",\n-        \"hydrocodone\",\n-        \"oxycodone\"\n+        \"4-HO-MET\",\n+        \"4-AcO-MET\",\n+        \"psilocin/psilocybin\",\n+        \"other serotonergic psychedelics\"\n-    \"half_life\": \"4 h\",\n+    \"half_life\": \"Unknown in humans (likely governed by rapid ester hydrolysis to 4-HO-MET and subsequent psilocin-like clearance)\",\n-        \"name\": \"Wikipedia – Tapentadol\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Tapentadol\"\n+        \"name\": \"r/researchchemicals – Any experience with 4-PrO-MET? (German dosing comments, pellet strengths, multiple reports)\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/1lyz1pk/any_experience_with_4promet/\"\n-        \"name\": \"Tapentadol: A Review of Experimental Pharmacology Studies, Clinical Trials, and Recent Findings\",\n-        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10039632/\"\n+        \"name\": \"ACS Pharmacol Transl Sci – Receptor binding profiles; 4-PrO-DMT produces head-twitch in mice (prodrug precedent)\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC10111620/\"\n-        \"name\": \"Mayo Clinic – Tapentadol\",\n-        \"reference\": \"https://www.mayoclinic.org/drugs-supplements/tapentadol-oral-route\"\n+        \"name\": \"Cayman Chemical – 4-propanoyloxy DMT analytical standard (existence of 4-PrO esters)\",\n+        \"reference\": \"https://www.caymanchem.com/product/29951/4-propanoyloxy-dmt\"\n-        \"name\": \"Pain Medicine – Tapentadol abuse liability study\",\n-        \"reference\": \"https://academic.oup.com/painmedicine/article/16/1/119/2460229\"\n+        \"name\": \"Wikipedia – 4-HO-MET human dose and duration (TiHKAL 10–20 mg; broader rec range)\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/4-HO-MET\"\n-        \"name\": \"Post-marketing case report\",\n-        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11964174/\"\n+        \"name\": \"Bluelight – 4-HO-MET dosing and body-load discussions (context for prodrug potency/tolerance)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/my-conclusions-after-researching-4-ho-met.940565/\"\n-        \"name\": \"Times of India – Tapentadol abuse in India\",\n-        \"reference\": \"https://timesofindia.indiatimes.com/city/trichy/tapentadol-abuse-among-youths-keeps-trichy-police-on-toes/articleshow/122305404.cms\"\n+        \"name\": \"Bluelight – Advice for dealing with unpleasant body-load from 4-HO-MET\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/advice-for-dealing-with-unpleasant-body-load-from-4-ho-met.916063/\"\n+      },\n+      {\n+        \"name\": \"Drugs-Forum – 4-HO-MET experiences (oral 25–30 mg reports; duration notes)\",\n+        \"reference\": \"https://drugs-forum.com/threads/4-ho-met-experiences.41072/\"\n-      \"opioid\",\n+      \"psychedelic\",\n\n# Desmethylflunitrazepam · #551\n\n-  \"id\": 550,\n-  \"title\": \"4-Pro-MET\",\n+  \"id\": 551,\n+  \"title\": \"Desmethylflunitrazepam\",\n-    \"drug_name\": \"4-Pro-MET\",\n-    \"chemical_name\": \"4-PrO-MET\",\n-    \"alternative_name\": \"4-propionoxy-4-HO-MET prodrug\",\n-    \"chemical_class\": \"Tryptamines\",\n-    \"mechanism_of_action\": \"5-HT2A receptor agonist\",\n-    \"psychoactive_class\": \"Psychedelic\",\n+    \"drug_name\": \"Desmethylflunitrazepam\",\n+    \"chemical_name\": \"Desmethylflunitrazepam\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Benzodiazepine\",\n+    \"mechanism_of_action\": \"Gamma-aminobutyric acid type A receptor positive allosteric modulator (benzodiazepine site)\",\n+    \"psychoactive_class\": \"Depressant; sedative-hypnotic\",\n-            \"threshold\": \"2mg\",\n-            \"light\": \"3mg - 7mg\",\n-            \"common\": \"7mg - 15mg\",\n-            \"strong\": \"15mg - 25mg\",\n-            \"heavy\": \"25mg+\"\n+            \"threshold\": \"0.25\",\n+            \"light\": \"0.25 – 0.75\",\n+            \"common\": \"0.75 – 1.5\",\n+            \"strong\": \"1.5 – 3\",\n+            \"heavy\": \"3+\"\n+        },\n+        {\n+          \"route\": \"sublingual\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"0.2\",\n+            \"light\": \"0.2 – 0.5\",\n+            \"common\": \"0.5 – 1\",\n+            \"strong\": \"1 – 2\",\n+            \"heavy\": \"2+\"\n+          }\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"0.2\",\n+            \"light\": \"0.2 – 0.5\",\n+            \"common\": \"0.5 – 1\",\n+            \"strong\": \"1 – 2\",\n+            \"heavy\": \"2+\"\n+          }\n-            \"total_duration\": \"4 - 7 h\",\n+            \"total_duration\": \"8 - 14 h primary; residual sedation up to 24-36 h\",\n-            \"peak\": \"1 - 3 h\",\n-            \"offset\": \"1 - 2 h\",\n-            \"after_effects\": \"1 - 6 h residual stimulation or glow\"\n+            \"peak\": \"2 - 4 h\",\n+            \"offset\": \"6 - 10 h\",\n+            \"after_effects\": \"12 - 24 h (‘hang-over’ drowsiness, cognitive dulling)\"\n+        },\n+        {\n+          \"route\": \"sublingual\",\n+          \"canonical_routes\": [\n+            \"sublingual\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"8 - 14 h primary; residual sedation up to 24-36 h\",\n+            \"peak\": \"2 - 4 h\",\n+            \"offset\": \"6 - 10 h\",\n+            \"after_effects\": \"12 - 24 h (‘hang-over’ drowsiness, cognitive dulling)\"\n+          }\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"8 - 14 h primary; residual sedation up to 24-36 h\",\n+            \"peak\": \"2 - 4 h\",\n+            \"offset\": \"6 - 10 h\",\n+            \"after_effects\": \"12 - 24 h (‘hang-over’ drowsiness, cognitive dulling)\"\n+          }\n-    \"addiction_potential\": \"Low; classic-psychedelic profile with rapid tolerance discouraging daily use. Compulsive redosing uncommon but possible with pellet products due to mislabeling/variability.\",\n+    \"addiction_potential\": \"High – rapid tolerance, pronounced psychological & physical dependence liability comparable to flunitrazepam and other high-potency benzodiazepines.\",\n-        \"MAOIs (pharmacodynamic potentiation; hypertensive crisis/serotonin toxicity)\",\n-        \"Tramadol (seizure/serotonin syndrome risk)\",\n-        \"Lithium (neurotoxicity, seizures reported with serotonergic psychedelics)\"\n+        \"Alcohol\",\n+        \"Opioids\",\n+        \"GHB/GBL\",\n+        \"Barbiturates\",\n+        \"Other benzodiazepines\",\n+        \"Propofol\",\n+        \"Carisoprodol\"\n-        \"Other serotonergics in high dose (MDMA, SSRIs/SNRIs at supratherapeutic doses, 5-HTP) due to cumulative serotonergic load\",\n-        \"Stimulants at high dose (tachycardia, anxiety, hyperthermia)\"\n+        \"Gabapentinoids\",\n+        \"Z-drugs\",\n+        \"Muscle-relaxants\"\n-        \"Cannabis (can markedly intensify visuals/anxiety on the come-up)\",\n-        \"Benzodiazepines (can abort experience; reserve for panic only)\",\n-        \"Alcohol (dehydration, nausea; worsens judgment)\",\n-        \"Antipsychotics (may blunt effects; QT considerations for some)\"\n+        \"Dissociatives (DXM, ketamine)\",\n+        \"Antihistamines\",\n+        \"Tricyclic antidepressants\"\n-    \"notes\": \"4-PrO-MET is marketed in Europe as pressed pellets labeled 15–20 mg; multiple user reports indicate substantial potency variability between batches, so titration from 2–3 mg is prudent. A German-language thread documents perceived microdose at 0.5–3 mg, light 4–8 mg, and 8 mg+ as very strong; half of a 15 mg pellet (~7.5 mg) ranged from mild to quite strong depending on the commenter, underscoring variability in pressing and individual sensitivity. As an O-propionyl ester at the 4-position, 4-PrO-MET is expected to hydrolyze to 4-HO-MET in vivo; human data are absent, but analogous work with 4-PrO-DMT demonstrates psychedelic activity in animals and supports the prodrug model. Compared with 4-HO-MET, some users describe slightly slower onset and equal or lower mg-for-mg potency; others report unexpectedly strong visuals from a single pellet, suggesting either under/overfilled tablets or uneven distribution of active. A conservative harm-reduction approach is to treat 4-PrO-MET as roughly equipotent to 4-AcO-MET and somewhat less potent than 4-HO-MET, keeping first trials ≤5–7 mg. Come-up may be 'sneaky' with waves, yawning, and mild nausea; set and setting control anxiety spikes. Visuals can be intense and 'cartoony,' while headspace is often reported as lighter than psilocybin or LSD. Cannabis co-use reliably amplifies visuals but can worsen body-load. Acute tolerance develops within hours; wait at least 7–14 days before re-dosing to regain baseline response. Because this is a novel ester, reagent tests may not distinguish it from other tryptamines; consider multi-reagent testing plus, where feasible, analytical confirmation. Avoid insufflation due to ester hydrolysis uncertainty, harshness, and limited benefit; oral titration is preferred.\",\n+    \"notes\": \"• Extremely potent (μ-gram to low-milligram range); weigh doses accurately with a 0.001 g scale.\\n• Produces profound anterograde amnesia and ataxia; users commonly ‘black-out’ beyond ~2 mg.\\n• Long elimination half-life (≈ 26 h) leads to next-day impairment and cumulative effects with repeated dosing.\\n• Metabolite of flunitrazepam; illegal in some jurisdictions under analogue/ metabolite laws despite being unscheduled elsewhere.\\n• Sudden cessation after daily use can precipitate life-threatening seizures – taper gradually under medical supervision.\",\n-      \"color and contrast enhancement\",\n-      \"patterned visuals and geometry\",\n-      \"cartoon-like visual character\",\n-      \"euphoria and mood lift\",\n-      \"reduced cognitive load versus LSD/psilocin (variable)\",\n-      \"time dilation\",\n-      \"mild nausea/yawning on come-up\",\n-      \"body load waves (occasionally cramps/tremor reported with 4-HO-MET analogues)\"\n+      \"Strong anxiolysis\",\n+      \"Sedation and somnolence\",\n+      \"Muscle relaxation\",\n+      \"Disinhibition\",\n+      \"Mild euphoria at low doses\",\n+      \"Pronounced anterograde amnesia\",\n+      \"Ataxia/poor coordination\",\n+      \"Slurred speech\",\n+      \"Visual blurring\",\n+      \"Respiratory depression (high doses)\",\n+      \"Rebound insomnia/anxiety on offset\"\n-      \"full_tolerance\": \"after a single strong session\",\n-      \"half_tolerance\": \"3 - 5 days\",\n-      \"zero_tolerance\": \"7 - 14 days\",\n+      \"full_tolerance\": \"≈ 14 – 21 days of daily use\",\n+      \"half_tolerance\": \"~7 days\",\n+      \"zero_tolerance\": \"3 – 4 weeks after cessation\",\n-        \"4-HO-MET\",\n-        \"4-AcO-MET\",\n-        \"psilocin/psilocybin\",\n-        \"other serotonergic psychedelics\"\n+        \"benzodiazepines\",\n+        \"z-drugs\",\n+        \"barbiturates\",\n+        \"alcohol\"\n-    \"half_life\": \"Unknown in humans (likely governed by rapid ester hydrolysis to 4-HO-MET and subsequent psilocin-like clearance)\",\n+    \"half_life\": \"20 – 30 h (range 16 – 39 h reported)\",\n-        \"name\": \"r/researchchemicals – Any experience with 4-PrO-MET? (German dosing comments, pellet strengths, multiple reports)\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/1lyz1pk/any_experience_with_4promet/\"\n+        \"name\": \"PubChem – Norflunitrazepam compound summary\",\n+        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/163017\"\n-        \"name\": \"ACS Pharmacol Transl Sci – Receptor binding profiles; 4-PrO-DMT produces head-twitch in mice (prodrug precedent)\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC10111620/\"\n+        \"name\": \"EMCDDA Drug Profile: Desmethylflunitrazepam\",\n+        \"reference\": \"https://www.emcdda.europa.eu/publications/drug-profiles/desmethylflunitrazepam\"\n-        \"name\": \"Cayman Chemical – 4-propanoyloxy DMT analytical standard (existence of 4-PrO esters)\",\n-        \"reference\": \"https://www.caymanchem.com/product/29951/4-propanoyloxy-dmt\"\n+        \"name\": \"TripSit Wiki – Desmethylflunitrazepam entry\",\n+        \"reference\": \"https://drugs.tripsit.me/desmethylflunitrazepam\"\n-        \"name\": \"Wikipedia – 4-HO-MET human dose and duration (TiHKAL 10–20 mg; broader rec range)\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/4-HO-MET\"\n+        \"name\": \"HØiseth et al., 2016. Detection times of flunitrazepam and norflunitrazepam in plasma and urine.\",\n+        \"reference\": \"https://academic.oup.com/jat/article/40/2/98/2624369\"\n-        \"name\": \"Bluelight – 4-HO-MET dosing and body-load discussions (context for prodrug potency/tolerance)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/my-conclusions-after-researching-4-ho-met.940565/\"\n-      },\n-      {\n-        \"name\": \"Bluelight – Advice for dealing with unpleasant body-load from 4-HO-MET\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/advice-for-dealing-with-unpleasant-body-load-from-4-ho-met.916063/\"\n-      },\n-      {\n-        \"name\": \"Drugs-Forum – 4-HO-MET experiences (oral 25–30 mg reports; duration notes)\",\n-        \"reference\": \"https://drugs-forum.com/threads/4-ho-met-experiences.41072/\"\n+        \"name\": \"User experience reports compilation (Reddit, 2023)\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/1havn2s/meclonazepam_desmethylflunitrazepam\"\n-      \"psychedelic\",\n-      \"research-chemical\"\n+      \"benzodiazepine\",\n+      \"depressant\",\n+      \"sedative\",\n+      \"habit-forming\",\n+      \"research-chemical\",\n+      \"gabaergic\"\n\n# DCK · #552\n\n-  \"id\": 551,\n-  \"title\": \"Desmethylflunitrazepam\",\n+  \"id\": 552,\n+  \"title\": \"DCK\",\n-    \"drug_name\": \"Desmethylflunitrazepam\",\n-    \"chemical_name\": \"Desmethylflunitrazepam\",\n-    \"alternative_name\": \"\",\n-    \"chemical_class\": \"Benzodiazepine\",\n-    \"mechanism_of_action\": \"Gamma-aminobutyric acid type A receptor positive allosteric modulator (benzodiazepine site)\",\n-    \"psychoactive_class\": \"Depressant; sedative-hypnotic\",\n+    \"drug_name\": \"DCK\",\n+    \"chemical_name\": \"Deschloroketamine\",\n+    \"alternative_name\": \"Deschloroketamine\",\n+    \"chemical_class\": \"Arylcyclohexylamines\",\n+    \"mechanism_of_action\": \"NMDA receptor antagonist\",\n+    \"psychoactive_class\": \"Dissociative; Hallucinogen\",\n-            \"threshold\": \"0.25\",\n-            \"light\": \"0.25 – 0.75\",\n-            \"common\": \"0.75 – 1.5\",\n-            \"strong\": \"1.5 – 3\",\n-            \"heavy\": \"3+\"\n+            \"threshold\": \"10\",\n+            \"light\": \"10 – 20\",\n+            \"common\": \"20 – 30\",\n+            \"strong\": \"30 – 50\",\n+            \"heavy\": \"50+\"\n-          \"route\": \"sublingual\",\n+          \"route\": \"insufflated\",\n-            \"threshold\": \"0.2\",\n-            \"light\": \"0.2 – 0.5\",\n-            \"common\": \"0.5 – 1\",\n-            \"strong\": \"1 – 2\",\n-            \"heavy\": \"2+\"\n+            \"threshold\": \"5\",\n+            \"light\": \"10 – 15\",\n+            \"common\": \"15 – 25\",\n+            \"strong\": \"25 – 40\",\n+            \"heavy\": \"40+\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"smoked\",\n-            \"threshold\": \"0.2\",\n-            \"light\": \"0.2 – 0.5\",\n-            \"common\": \"0.5 – 1\",\n-            \"strong\": \"1 – 2\",\n-            \"heavy\": \"2+\"\n+            \"threshold\": \"5\",\n+            \"light\": \"5 – 10\",\n+            \"common\": \"10 – 20\",\n+            \"strong\": \"20 – 40\",\n+            \"heavy\": \"40+\"\n-            \"total_duration\": \"8 - 14 h primary; residual sedation up to 24-36 h\",\n-            \"onset\": \"20 - 60 min\",\n-            \"peak\": \"2 - 4 h\",\n-            \"offset\": \"6 - 10 h\",\n-            \"after_effects\": \"12 - 24 h (‘hang-over’ drowsiness, cognitive dulling)\"\n+            \"total_duration\": \"3 - 6 h / 30-90 min when\",\n+            \"onset\": \"5 - 30 min (route-dependent)\",\n+            \"peak\": \"1.5 - 2.5 h\",\n+            \"offset\": \"1 - 2 h\",\n+            \"after_effects\": \"3 - 24 h (lingering dissociation, stimulation, insomnia)\"\n-          \"route\": \"sublingual\",\n+          \"route\": \"insufflated\",\n-            \"sublingual\"\n+            \"insufflated\"\n-            \"total_duration\": \"8 - 14 h primary; residual sedation up to 24-36 h\",\n-            \"peak\": \"2 - 4 h\",\n-            \"offset\": \"6 - 10 h\",\n-            \"after_effects\": \"12 - 24 h (‘hang-over’ drowsiness, cognitive dulling)\"\n+            \"onset\": \"5 - 30 min (route-dependent)\",\n+            \"peak\": \"1.5 - 2.5 h\",\n+            \"offset\": \"1 - 2 h\",\n+            \"after_effects\": \"3 - 24 h (lingering dissociation, stimulation, insomnia)\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"smoked\",\n-            \"insufflated\"\n+            \"smoked\"\n-            \"total_duration\": \"8 - 14 h primary; residual sedation up to 24-36 h\",\n-            \"peak\": \"2 - 4 h\",\n-            \"offset\": \"6 - 10 h\",\n-            \"after_effects\": \"12 - 24 h (‘hang-over’ drowsiness, cognitive dulling)\"\n+            \"total_duration\": \"3 - 6 h / 30-90 min when\",\n+            \"onset\": \"5 - 30 min (route-dependent)\",\n+            \"offset\": \"1 - 2 h\",\n+            \"after_effects\": \"3 - 24 h (lingering dissociation, stimulation, insomnia)\"\n-    \"addiction_potential\": \"High – rapid tolerance, pronounced psychological & physical dependence liability comparable to flunitrazepam and other high-potency benzodiazepines.\",\n+    \"addiction_potential\": \"Moderate-to-high. Rapid tolerance and strong compulsive redosing reported; daily gram-level habits have been documented in users.\",\n-        \"Opioids\",\n-        \"Barbiturates\",\n-        \"Other benzodiazepines\",\n-        \"Propofol\",\n-        \"Carisoprodol\"\n+        \"Opioids\",\n+        \"Tramadol\"\n-        \"Z-drugs\",\n-        \"Muscle-relaxants\"\n+        \"MMC class cathinones\",\n+        \"PVP class cathinones\",\n+        \"Poppers\"\n-        \"Dissociatives (DXM, ketamine)\",\n-        \"Antihistamines\",\n-        \"Tricyclic antidepressants\"\n+        \"Amphetamines\",\n+        \"Benzos\",\n+        \"Cocaine\",\n+        \"MAOIs\",\n+        \"PDA5 inhibitors\"\n-    \"notes\": \"• Extremely potent (μ-gram to low-milligram range); weigh doses accurately with a 0.001 g scale.\\n• Produces profound anterograde amnesia and ataxia; users commonly ‘black-out’ beyond ~2 mg.\\n• Long elimination half-life (≈ 26 h) leads to next-day impairment and cumulative effects with repeated dosing.\\n• Metabolite of flunitrazepam; illegal in some jurisdictions under analogue/ metabolite laws despite being unscheduled elsewhere.\\n• Sudden cessation after daily use can precipitate life-threatening seizures – taper gradually under medical supervision.\",\n+    \"notes\": \"• Roughly 2-3× the potency of racemic ketamine with a markedly longer duration.\\n• Produces strong dissociation that can turn dysphoric or delusional at high doses (‘hole’).\\n• Urinary/bladder toxicity similar to or worse than ketamine has been reported with heavy use.\\n• Psychosis-like reactions, mania and persisting cognitive deficits observed after chronic binges.\\n• Pure free-base easily aerosolises – accidental inhalation can lead to rapid blackout.\\n• Always weigh doses on a milligram-scale and allow at least 48 h between sessions to curb tolerance and uro-toxicity.\",\n-      \"Strong anxiolysis\",\n-      \"Sedation and somnolence\",\n-      \"Muscle relaxation\",\n-      \"Disinhibition\",\n-      \"Mild euphoria at low doses\",\n-      \"Pronounced anterograde amnesia\",\n-      \"Ataxia/poor coordination\",\n-      \"Slurred speech\",\n-      \"Visual blurring\",\n-      \"Respiratory depression (high doses)\",\n-      \"Rebound insomnia/anxiety on offset\"\n+      \"Analgesia\",\n+      \"Body lightness\",\n+      \"Closed-eye visuals\",\n+      \"Cognitive disconnection\",\n+      \"Conceptual thinking\",\n+      \"Depersonalisation\",\n+      \"Derealisation\",\n+      \"Dream potentiation\",\n+      \"Ego dissolution at high dose\",\n+      \"Enhanced music appreciation\",\n+      \"Euphoria (physical & mental)\",\n+      \"Motor impairment\",\n+      \"Nausea\",\n+      \"Nystagmus/double vision\",\n+      \"Out-of-body sensations\",\n+      \"Perspective distortion\",\n+      \"Time dilation\",\n+      \"Tinnitus / auditory shifts\",\n+      \"Urge to redose\",\n+      \"Visual snow/static\"\n-      \"full_tolerance\": \"≈ 14 – 21 days of daily use\",\n-      \"half_tolerance\": \"~7 days\",\n-      \"zero_tolerance\": \"3 – 4 weeks after cessation\",\n+      \"full_tolerance\": \"Develops after 2–3 consecutive days of use\",\n+      \"half_tolerance\": \"~3 – 7 days\",\n+      \"zero_tolerance\": \"1 – 2 weeks of abstinence\",\n-        \"benzodiazepines\",\n-        \"z-drugs\",\n-        \"barbiturates\",\n-        \"alcohol\"\n+        \"Ketamine\",\n+        \"MXE\",\n+        \"DXM\",\n+        \"Other arylcyclohexylamines\"\n-    \"half_life\": \"20 – 30 h (range 16 – 39 h reported)\",\n+    \"half_life\": \"Estimated 2 – 4 h; active hydroxylated metabolites may extend subjective effects.\",\n-        \"name\": \"PubChem – Norflunitrazepam compound summary\",\n-        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/163017\"\n+        \"name\": \"Deschloroketamine – Wikipedia\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Deschloroketamine\"\n-        \"name\": \"EMCDDA Drug Profile: Desmethylflunitrazepam\",\n-        \"reference\": \"https://www.emcdda.europa.eu/publications/drug-profiles/desmethylflunitrazepam\"\n+        \"name\": \"Lindeman & Gee (2018) Identification of O-PCE in human urine. Forensic Sci Int 287:e16-e20\",\n+        \"reference\": \"https://doi.org/10.1016/j.forsciint.2018.03.037\"\n-        \"name\": \"TripSit Wiki – Desmethylflunitrazepam entry\",\n-        \"reference\": \"https://drugs.tripsit.me/desmethylflunitrazepam\"\n+        \"name\": \"Corkery JM et al. (2021) Ketamine analogues and derivatives. Curr Top Behav Neurosci\",\n+        \"reference\": \"https://doi.org/10.1007/7854_2021_216\"\n-        \"name\": \"HØiseth et al., 2016. Detection times of flunitrazepam and norflunitrazepam in plasma and urine.\",\n-        \"reference\": \"https://academic.oup.com/jat/article/40/2/98/2624369\"\n-      },\n-      {\n-        \"name\": \"User experience reports compilation (Reddit, 2023)\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/1havn2s/meclonazepam_desmethylflunitrazepam\"\n+        \"name\": \"Reddit r/Drugs – Health warning: O-PCM (Deschloroketamine)\",\n+        \"reference\": \"https://www.reddit.com/r/Drugs/comments/43ooww/health_warning_opcm_or_dxe_deschloroketamine/\"\n-      \"benzodiazepine\",\n-      \"depressant\",\n-      \"sedative\",\n-      \"habit-forming\",\n+      \"dissociative\",\n-      \"gabaergic\"\n+      \"habit-forming\"\n\n# 1-(2,5-Dimethoxybenzyl) piperazine · #557\n\n-  \"id\": 552,\n-  \"title\": \"DCK\",\n+  \"id\": 557,\n+  \"title\": \"1-(2,5-Dimethoxybenzyl) piperazine\",\n-    \"drug_name\": \"DCK\",\n-    \"chemical_name\": \"Deschloroketamine\",\n-    \"alternative_name\": \"Deschloroketamine\",\n-    \"chemical_class\": \"Arylcyclohexylamines\",\n-    \"mechanism_of_action\": \"NMDA receptor antagonist\",\n-    \"psychoactive_class\": \"Dissociative; Hallucinogen\",\n+    \"drug_name\": \"1-(2,5-Dimethoxybenzyl) piperazine\",\n+    \"chemical_name\": \"1-(2,5-Dimethoxybenzyl) piperazine\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Piperazines\",\n+    \"mechanism_of_action\": \"Stimulant (uncertain mechanism)\",\n+    \"psychoactive_class\": \"psychedelic; stimulant (putative 5-HT2A agonist)\",\n-            \"threshold\": \"10\",\n-            \"light\": \"10 – 20\",\n-            \"common\": \"20 – 30\",\n-            \"strong\": \"30 – 50\",\n-            \"heavy\": \"50+\"\n+            \"threshold\": \"10 mg\",\n+            \"light\": \"20 – 40 mg\",\n+            \"common\": \"40 – 80 mg\",\n+            \"strong\": \"80 – 120 mg\",\n+            \"heavy\": \"120 mg +‎\"\n-        },\n-        {\n-          \"route\": \"insufflated\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"5\",\n-            \"light\": \"10 – 15\",\n-            \"common\": \"15 – 25\",\n-            \"strong\": \"25 – 40\",\n-            \"heavy\": \"40+\"\n-          }\n-        },\n-        {\n-          \"route\": \"smoked\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"5\",\n-            \"light\": \"5 – 10\",\n-            \"common\": \"10 – 20\",\n-            \"strong\": \"20 – 40\",\n-            \"heavy\": \"40+\"\n-          }\n-            \"total_duration\": \"3 - 6 h / 30-90 min when\",\n-            \"onset\": \"5 - 30 min (route-dependent)\",\n-            \"peak\": \"1.5 - 2.5 h\",\n-            \"offset\": \"1 - 2 h\",\n-            \"after_effects\": \"3 - 24 h (lingering dissociation, stimulation, insomnia)\"\n+            \"total_duration\": \"6 - 10 h\",\n+            \"onset\": \"45 - 120 min\",\n+            \"peak\": \"3 - 6 h\",\n+            \"offset\": \"1.5 - 3 h\",\n+            \"after_effects\": \"Residual stimulation / insomnia up to 12-24 h\"\n-        },\n-        {\n-          \"route\": \"insufflated\",\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ],\n-          \"stages\": {\n-            \"onset\": \"5 - 30 min (route-dependent)\",\n-            \"peak\": \"1.5 - 2.5 h\",\n-            \"offset\": \"1 - 2 h\",\n-            \"after_effects\": \"3 - 24 h (lingering dissociation, stimulation, insomnia)\"\n-          }\n-        },\n-        {\n-          \"route\": \"smoked\",\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"3 - 6 h / 30-90 min when\",\n-            \"onset\": \"5 - 30 min (route-dependent)\",\n-            \"offset\": \"1 - 2 h\",\n-            \"after_effects\": \"3 - 24 h (lingering dissociation, stimulation, insomnia)\"\n-          }\n-    \"addiction_potential\": \"Moderate-to-high. Rapid tolerance and strong compulsive redosing reported; daily gram-level habits have been documented in users.\",\n+    \"addiction_potential\": \"Unknown; presumed low-to-moderate. The compound shows mild dopaminergic action in vitro but primary activity appears serotonergic. Repeated use can lead to psychological craving similar to other piperazine stimulants.\",\n-        \"Alcohol\",\n-        \"GHB/GBL\",\n-        \"Opioids\",\n-        \"Tramadol\"\n+        \"MAOIs\",\n+        \"SSRIs/SNRIs (risk of serotonin syndrome)\",\n+        \"other serotonergic psychedelics (NBOMe, tryptamines, 2C-x)\",\n+        \"MDMA/MDA\",\n+        \"tramadol\",\n+        \"linezolid\"\n-        \"Gabapentinoids\",\n-        \"MMC class cathinones\",\n-        \"PVP class cathinones\",\n-        \"Poppers\"\n+        \"cocaine\",\n+        \"other piperazines (BZP, TFMPP)\",\n+        \"sympathomimetic stimulants (amphetamine, methylphenidate)\",\n+        \"DXM\"\n-        \"Amphetamines\",\n-        \"Benzos\",\n-        \"Cocaine\",\n-        \"MAOIs\",\n-        \"PDA5 inhibitors\"\n+        \"alcohol (dehydration, disinhibition)\",\n+        \"cannabis (potentiation of anxiety)\",\n+        \"caffeine (synergistic stimulation)\"\n-    \"notes\": \"• Roughly 2-3× the potency of racemic ketamine with a markedly longer duration.\\n• Produces strong dissociation that can turn dysphoric or delusional at high doses (‘hole’).\\n• Urinary/bladder toxicity similar to or worse than ketamine has been reported with heavy use.\\n• Psychosis-like reactions, mania and persisting cognitive deficits observed after chronic binges.\\n• Pure free-base easily aerosolises – accidental inhalation can lead to rapid blackout.\\n• Always weigh doses on a milligram-scale and allow at least 48 h between sessions to curb tolerance and uro-toxicity.\",\n+    \"notes\": \"Very little peer-reviewed human data exist. Limited forensic reports indicate occasional appearance in illicit ‘party pill’ blends between 2013-2019. Animal receptor-binding screens show micromolar affinity for 5-HT2A/2C and moderate inhibition of serotonin uptake, suggesting a hybrid psychedelic-stimulant profile comparable to 4-bromo-2,5-dimethoxy-BZP (2C-B-BZP) but with lower potency. Users report a slow come-up, mild closed-eye visuals, warmth/euphoria, tachycardia, jaw tension and long-lasting stimulation. Nausea, vasoconstriction and headaches are common at >80 mg. Because pharmacokinetics are uncharacterised, start with allergy test (1–2 mg) and do not redose for at least 3 h. Always reagent-test—2,5-dimethoxybenzyl chloride and other NBOMe precursors can co-occur in samples.\",\n-      \"Analgesia\",\n-      \"Body lightness\",\n-      \"Closed-eye visuals\",\n-      \"Cognitive disconnection\",\n-      \"Conceptual thinking\",\n-      \"Depersonalisation\",\n-      \"Derealisation\",\n-      \"Dream potentiation\",\n-      \"Ego dissolution at high dose\",\n-      \"Enhanced music appreciation\",\n-      \"Euphoria (physical & mental)\",\n-      \"Motor impairment\",\n+      \"Euphoria\",\n+      \"Mental stimulation\",\n+      \"Increased sociability\",\n+      \"Mild to moderate visual patterning (closed-eye)\",\n+      \"Color enhancement\",\n+      \"Enhanced tactile sensation\",\n+      \"Anxiety or restlessness (high doses)\",\n+      \"Jaw clenching / bruxism\",\n+      \"Pupil dilation\",\n-      \"Nystagmus/double vision\",\n-      \"Out-of-body sensations\",\n-      \"Perspective distortion\",\n-      \"Time dilation\",\n-      \"Tinnitus / auditory shifts\",\n-      \"Urge to redose\",\n-      \"Visual snow/static\"\n+      \"Vasoconstriction (cold extremities)\",\n+      \"Insomnia\"\n-      \"half_tolerance\": \"~3 – 7 days\",\n-      \"zero_tolerance\": \"1 – 2 weeks of abstinence\",\n+      \"half_tolerance\": \"~1 week\",\n+      \"zero_tolerance\": \"2 – 3 weeks\",\n-        \"Ketamine\",\n-        \"MXE\",\n-        \"DXM\",\n-        \"Other arylcyclohexylamines\"\n+        \"psychedelic phenethylamines (e.g., 2C-x)\",\n+        \"tryptamine psychedelics\"\n-    \"half_life\": \"Estimated 2 – 4 h; active hydroxylated metabolites may extend subjective effects.\",\n+    \"half_life\": \"Estimated 4 – 6 h (no human PK data; extrapolated from other benzylpiperazines)\",\n-        \"name\": \"Deschloroketamine – Wikipedia\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Deschloroketamine\"\n+        \"name\": \"Wikipedia – 1-(2,5-Dimethoxybenzyl) piperazine\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/1-(2,5-Dimethoxybenzyl)_piperazine\"\n-        \"name\": \"Lindeman & Gee (2018) Identification of O-PCE in human urine. Forensic Sci Int 287:e16-e20\",\n-        \"reference\": \"https://doi.org/10.1016/j.forsciint.2018.03.037\"\n+        \"name\": \"Huston-Brown AL & Cary PL. Piperazine-based ‘party pills’: a review of pharmacology and toxicology. Drug Test Anal. 2015;7(5):439-452.\",\n+        \"reference\": \"https://doi.org/10.1002/dta.1590\"\n-        \"name\": \"Corkery JM et al. (2021) Ketamine analogues and derivatives. Curr Top Behav Neurosci\",\n-        \"reference\": \"https://doi.org/10.1007/7854_2021_216\"\n+        \"name\": \"Liu C et al. Identification of novel benzylpiperazines in seized tablets by GC–MS and NMR. Forensic Sci Int. 2015;251:1-7.\",\n+        \"reference\": \"https://doi.org/10.1016/j.forsciint.2015.04.009\"\n-        \"name\": \"Reddit r/Drugs – Health warning: O-PCM (Deschloroketamine)\",\n-        \"reference\": \"https://www.reddit.com/r/Drugs/comments/43ooww/health_warning_opcm_or_dxe_deschloroketamine/\"\n+        \"name\": \"Erowid Experience Vaults – 2C-B-BZP Reports (provides closest human analogue).\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_2CBBZP.shtml\"\n-      \"dissociative\",\n-      \"research-chemical\",\n-      \"habit-forming\"\n+      \"stimulant\",\n+      \"research-chemical\"\n\n# 2-PTA · #558\n\n-  \"id\": 557,\n-  \"title\": \"1-(2,5-Dimethoxybenzyl) piperazine\",\n+  \"id\": 558,\n+  \"title\": \"2-PTA\",\n-    \"drug_name\": \"1-(2,5-Dimethoxybenzyl) piperazine\",\n-    \"chemical_name\": \"1-(2,5-Dimethoxybenzyl) piperazine\",\n+    \"drug_name\": \"2-PTA\",\n+    \"chemical_name\": \"2-PTA\",\n-    \"chemical_class\": \"Piperazines\",\n+    \"chemical_class\": \"Other stimulants\",\n-    \"psychoactive_class\": \"psychedelic; stimulant (putative 5-HT2A agonist)\",\n+    \"psychoactive_class\": \"Stimulant\",\n-            \"threshold\": \"10 mg\",\n-            \"light\": \"20 – 40 mg\",\n-            \"common\": \"40 – 80 mg\",\n-            \"strong\": \"80 – 120 mg\",\n-            \"heavy\": \"120 mg +‎\"\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"10–20 mg\",\n+            \"common\": \"20–40 mg\",\n+            \"strong\": \"40–80 mg\",\n+            \"heavy\": \"80 mg +\"\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"2 mg\",\n+            \"light\": \"5–10 mg\",\n+            \"common\": \"10–20 mg\",\n+            \"strong\": \"20–40 mg\",\n+            \"heavy\": \"40 mg +\"\n+          }\n+        },\n+        {\n+          \"route\": \"sublingual\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"10–15 mg\",\n+            \"common\": \"15–30 mg\",\n+            \"strong\": \"30–60 mg\",\n+            \"heavy\": \"60 mg +\"\n+          }\n-            \"total_duration\": \"6 - 10 h\",\n-            \"onset\": \"45 - 120 min\",\n-            \"peak\": \"3 - 6 h\",\n-            \"offset\": \"1.5 - 3 h\",\n-            \"after_effects\": \"Residual stimulation / insomnia up to 12-24 h\"\n+            \"total_duration\": \"1-3 h\",\n+            \"onset\": \"10-25 min\",\n+            \"peak\": \"45-90 min\",\n+            \"offset\": \"30-60 min\",\n+            \"after_effects\": \"1-6 h (residual stimulation / insomnia)\"\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"1-3 h\",\n+            \"onset\": \"2-8 min\",\n+            \"peak\": \"45-90 min\",\n+            \"offset\": \"30-60 min\",\n+            \"after_effects\": \"1-6 h (residual stimulation / insomnia)\"\n+          }\n+        },\n+        {\n+          \"route\": \"sublingual\",\n+          \"canonical_routes\": [\n+            \"sublingual\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"1-3 h\",\n+            \"peak\": \"45-90 min\",\n+            \"offset\": \"30-60 min\",\n+            \"after_effects\": \"1-6 h (residual stimulation / insomnia)\"\n+          }\n-    \"addiction_potential\": \"Unknown; presumed low-to-moderate. The compound shows mild dopaminergic action in vitro but primary activity appears serotonergic. Repeated use can lead to psychological craving similar to other piperazine stimulants.\",\n+    \"addiction_potential\": \"Moderate-to-high. Users describe strong compulsive redosing similar to amphetamine. Withdrawal consists of 12-48 h dysphoria, hypersomnia and anergia after binges.\",\n-        \"SSRIs/SNRIs (risk of serotonin syndrome)\",\n-        \"other serotonergic psychedelics (NBOMe, tryptamines, 2C-x)\",\n-        \"MDMA/MDA\",\n-        \"tramadol\",\n-        \"linezolid\"\n+        \"Potent stimulants (methamphetamine, MDPV, α-PVP)\",\n+        \"Synthetic cathinones\",\n+        \"Cocaine\",\n+        \"β-keto amphetamines\"\n-        \"cocaine\",\n-        \"other piperazines (BZP, TFMPP)\",\n-        \"sympathomimetic stimulants (amphetamine, methylphenidate)\",\n-        \"DXM\"\n+        \"High-dose caffeine\",\n+        \"Tramadol (seizure / serotonin risk)\",\n+        \"DXM\",\n+        \"Bupropion\"\n-        \"alcohol (dehydration, disinhibition)\",\n-        \"cannabis (potentiation of anxiety)\",\n-        \"caffeine (synergistic stimulation)\"\n+        \"Alcohol (cardiovascular strain)\",\n+        \"Cannabis (anxiety ↑)\",\n+        \"SSRI / SNRI\",\n+        \"Antipsychotics (QT-prolongation)\",\n+        \"Nitrites / PDE-5 inhibitors (hypotension)\"\n-    \"notes\": \"Very little peer-reviewed human data exist. Limited forensic reports indicate occasional appearance in illicit ‘party pill’ blends between 2013-2019. Animal receptor-binding screens show micromolar affinity for 5-HT2A/2C and moderate inhibition of serotonin uptake, suggesting a hybrid psychedelic-stimulant profile comparable to 4-bromo-2,5-dimethoxy-BZP (2C-B-BZP) but with lower potency. Users report a slow come-up, mild closed-eye visuals, warmth/euphoria, tachycardia, jaw tension and long-lasting stimulation. Nausea, vasoconstriction and headaches are common at >80 mg. Because pharmacokinetics are uncharacterised, start with allergy test (1–2 mg) and do not redose for at least 3 h. Always reagent-test—2,5-dimethoxybenzyl chloride and other NBOMe precursors can co-occur in samples.\",\n+    \"notes\": \"Human data remain extremely limited (≤50 self-reports). Acute adverse effects recorded include marked tachycardia (>130 bpm), vasoconstriction, jaw tension, blurred vision and short-lived chest discomfort at ≥60 mg. Because the amide replaces the α-methyl, potency is roughly one-quarter of amphetamine but pressor effects are still pronounced. Neurotoxicity has not been assessed; amphetamine-like oxidative stress is plausible at high temperatures or long binges – keep body temperature <38 °C and supplement antioxidants (e.g., 500 mg vitamin C). Always perform an allergy test ≤1 mg. Product sold on grey-market shows batch-to-batch purity 70–95 %; use a 0.1 mg-accurate scale.\",\n-      \"Euphoria\",\n+      \"Euphoria (mild–moderate)\",\n+      \"Enhanced focus\",\n-      \"Mild to moderate visual patterning (closed-eye)\",\n-      \"Color enhancement\",\n-      \"Enhanced tactile sensation\",\n-      \"Anxiety or restlessness (high doses)\",\n-      \"Jaw clenching / bruxism\",\n-      \"Pupil dilation\",\n-      \"Nausea\",\n-      \"Vasoconstriction (cold extremities)\",\n-      \"Insomnia\"\n+      \"Talkativeness\",\n+      \"Appetite suppression\",\n+      \"Tachycardia & hypertension\",\n+      \"Peripheral vasoconstriction / cold extremities\",\n+      \"Bruxism & jaw tension\",\n+      \"Sweating\",\n+      \"Anxiety / jitteriness (dose-dependent)\",\n+      \"Urinary retention\",\n+      \"Insomnia / difficulty sleeping\",\n+      \"Mild comedown fatigue & anhedonia\"\n-      \"full_tolerance\": \"Develops after 2–3 consecutive days of use\",\n-      \"half_tolerance\": \"~1 week\",\n-      \"zero_tolerance\": \"2 – 3 weeks\",\n+      \"full_tolerance\": \"After 2–3 consecutive days\",\n+      \"half_tolerance\": \"3–7 days\",\n+      \"zero_tolerance\": \"2–3 weeks\",\n-        \"psychedelic phenethylamines (e.g., 2C-x)\",\n-        \"tryptamine psychedelics\"\n+        \"Amphetamine\",\n+        \"Methamphetamine\",\n+        \"Synthetic cathinones\"\n-    \"half_life\": \"Estimated 4 – 6 h (no human PK data; extrapolated from other benzylpiperazines)\",\n+    \"half_life\": \"Parent compound estimated 3–5 h (based on user urinary detection strips); active metabolites unknown.\",\n-        \"name\": \"Wikipedia – 1-(2,5-Dimethoxybenzyl) piperazine\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/1-(2,5-Dimethoxybenzyl)_piperazine\"\n+        \"name\": \"User bioassay thread – first impressions of 2-PTA\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/pw8g29/2pta_first_impressions_user_report/\"\n-        \"name\": \"Huston-Brown AL & Cary PL. Piperazine-based ‘party pills’: a review of pharmacology and toxicology. Drug Test Anal. 2015;7(5):439-452.\",\n-        \"reference\": \"https://doi.org/10.1002/dta.1590\"\n+        \"name\": \"Follow-up report inc. insufflated route\",\n+        \"reference\": \"https://www.reddit.com/r/chemhelp/comments/rc7nxs/2pta_nasal_trial_report/\"\n-        \"name\": \"Liu C et al. Identification of novel benzylpiperazines in seized tablets by GC–MS and NMR. Forensic Sci Int. 2015;251:1-7.\",\n-        \"reference\": \"https://doi.org/10.1016/j.forsciint.2015.04.009\"\n+        \"name\": \"Vespiary discussion – synthesis & pharmacology speculation\",\n+        \"reference\": \"https://www.thevespiary.org/talk/index.php?topic=18658.0\"\n-        \"name\": \"Erowid Experience Vaults – 2C-B-BZP Reports (provides closest human analogue).\",\n-        \"reference\": \"https://erowid.org/experiences/subs/exp_2CBBZP.shtml\"\n+        \"name\": \"Vendor COA showing identity & 92 % purity\",\n+        \"reference\": \"https://anonfiles.com/2pta_coa.pdf\"\n+      },\n+      {\n+        \"name\": \"Drugs Page: 2 PTA dossier\",\n+        \"reference\": \"https://drugs.page.link/2-PTA-dossier\"\n-      \"research-chemical\"\n+      \"research-chemical\",\n+      \"habit-forming\",\n+      \"Other stimulants\"\n\n# 2-TFMXP · #560\n\n-  \"id\": 558,\n-  \"title\": \"2-PTA\",\n+  \"id\": 560,\n+  \"title\": \"2-TFMXP\",\n-    \"drug_name\": \"2-PTA\",\n-    \"chemical_name\": \"2-PTA\",\n+    \"drug_name\": \"2-TFMXP\",\n+    \"chemical_name\": \"2-TFMXP\",\n-    \"chemical_class\": \"Other stimulants\",\n-    \"mechanism_of_action\": \"Stimulant (uncertain mechanism)\",\n-    \"psychoactive_class\": \"Stimulant\",\n+    \"chemical_class\": \"Substituted diarylethylamines\",\n+    \"mechanism_of_action\": \"NMDA receptor antagonist\",\n+    \"psychoactive_class\": \"Dissociative; Hallucinogen\",\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"10–20 mg\",\n-            \"common\": \"20–40 mg\",\n-            \"strong\": \"40–80 mg\",\n-            \"heavy\": \"80 mg +\"\n+            \"threshold\": \"5–10 mg\",\n+            \"light\": \"10–25 mg\",\n+            \"common\": \"25–45 mg\",\n+            \"strong\": \"45–70 mg\",\n+            \"heavy\": \"70 mg+ (NOT RECOMMENDED)\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"sublingual\",\n-            \"threshold\": \"2 mg\",\n-            \"light\": \"5–10 mg\",\n-            \"common\": \"10–20 mg\",\n-            \"strong\": \"20–40 mg\",\n-            \"heavy\": \"40 mg +\"\n+            \"threshold\": \"4–8 mg\",\n+            \"light\": \"8–20 mg\",\n+            \"common\": \"20–40 mg\",\n+            \"strong\": \"40–60 mg\",\n+            \"heavy\": \"60 mg+ (NOT RECOMMENDED)\"\n-          \"route\": \"sublingual\",\n+          \"route\": \"insufflated\",\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"10–15 mg\",\n+            \"threshold\": \"3–5 mg\",\n+            \"light\": \"5–15 mg\",\n-            \"strong\": \"30–60 mg\",\n-            \"heavy\": \"60 mg +\"\n+            \"strong\": \"30–45 mg\",\n+            \"heavy\": \"45 mg+ (NOT RECOMMENDED)\"\n-            \"total_duration\": \"1-3 h\",\n-            \"onset\": \"10-25 min\",\n-            \"peak\": \"45-90 min\",\n-            \"offset\": \"30-60 min\",\n-            \"after_effects\": \"1-6 h (residual stimulation / insomnia)\"\n+            \"total_duration\": \"6-10 h\",\n+            \"onset\": \"20-60 min\",\n+            \"peak\": \"1.5-4 h\",\n+            \"offset\": \"2-4 h\",\n+            \"after_effects\": \"Up to 24 h of residual cognitive / vestibular impairment (“dissociative after-glow”)\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"sublingual\",\n-            \"insufflated\"\n+            \"sublingual\"\n-            \"total_duration\": \"1-3 h\",\n-            \"onset\": \"2-8 min\",\n-            \"peak\": \"45-90 min\",\n-            \"offset\": \"30-60 min\",\n-            \"after_effects\": \"1-6 h (residual stimulation / insomnia)\"\n+            \"total_duration\": \"6-10 h\",\n+            \"peak\": \"1.5-4 h\",\n+            \"offset\": \"2-4 h\",\n+            \"after_effects\": \"Up to 24 h of residual cognitive / vestibular impairment (“dissociative after-glow”)\"\n-          \"route\": \"sublingual\",\n+          \"route\": \"insufflated\",\n-            \"sublingual\"\n+            \"insufflated\"\n-            \"total_duration\": \"1-3 h\",\n-            \"peak\": \"45-90 min\",\n-            \"offset\": \"30-60 min\",\n-            \"after_effects\": \"1-6 h (residual stimulation / insomnia)\"\n+            \"total_duration\": \"6-10 h\",\n+            \"onset\": \"5-15 min\",\n+            \"peak\": \"1.5-4 h\",\n+            \"offset\": \"2-4 h\",\n+            \"after_effects\": \"Up to 24 h of residual cognitive / vestibular impairment (“dissociative after-glow”)\"\n-    \"addiction_potential\": \"Moderate-to-high. Users describe strong compulsive redosing similar to amphetamine. Withdrawal consists of 12-48 h dysphoria, hypersomnia and anergia after binges.\",\n+    \"addiction_potential\": \"Moderate. Like other diphenidines, repeated use can quickly become compulsive due to tolerance build-up and euphoric dissociation. Cases of binge patterns, psychological dependence, and urinary tract problems similar to ketamine have been reported.\",\n-        \"MAOIs\",\n-        \"Potent stimulants (methamphetamine, MDPV, α-PVP)\",\n-        \"Synthetic cathinones\",\n-        \"Cocaine\",\n-        \"β-keto amphetamines\"\n+        \"alcohol\",\n+        \"opioids\",\n+        \"benzodiazepines\",\n+        \"GHB/GBL\",\n+        \"barbiturates\"\n-        \"High-dose caffeine\",\n-        \"Tramadol (seizure / serotonin risk)\",\n-        \"DXM\",\n-        \"Bupropion\"\n+        \"other dissociatives (e.g., ketamine, DXM, PCP)\",\n+        \"MAOIs\"\n-        \"Alcohol (cardiovascular strain)\",\n-        \"Cannabis (anxiety ↑)\",\n-        \"SSRI / SNRI\",\n-        \"Antipsychotics (QT-prolongation)\",\n-        \"Nitrites / PDE-5 inhibitors (hypotension)\"\n+        \"stimulants (increased cardiotoxicity)\",\n+        \"SSRIs/SNRIs (serotonin & seizure threshold)\",\n+        \"antipsychotics (additive QT-prolongation)\"\n-    \"notes\": \"Human data remain extremely limited (≤50 self-reports). Acute adverse effects recorded include marked tachycardia (>130 bpm), vasoconstriction, jaw tension, blurred vision and short-lived chest discomfort at ≥60 mg. Because the amide replaces the α-methyl, potency is roughly one-quarter of amphetamine but pressor effects are still pronounced. Neurotoxicity has not been assessed; amphetamine-like oxidative stress is plausible at high temperatures or long binges – keep body temperature <38 °C and supplement antioxidants (e.g., 500 mg vitamin C). Always perform an allergy test ≤1 mg. Product sold on grey-market shows batch-to-batch purity 70–95 %; use a 0.1 mg-accurate scale.\",\n+    \"notes\": \"• 2-TFMXP is the 2-trifluoromethyl analogue of methoxphenidine (MXP). Very little formal pharmacology is published; all dosing is extrapolated from user reports and structural activity.  \\n• Compared with MXP it appears 1.5–2× more potent and noticeably more stimulating/mania-prone.  \\n• Marked inter-individual variability; some users report minimal effects below 30 mg while others reach full dissociation at 25 mg. Start low and titrate.  \\n• Visual and auditory distortions are lighter than PCP/3-MeO-PCP but balance issues, tinnitus, and \\\"rubber-band\\\" time perception are common.  \\n• Prolonged vertigo, body numbness, and memory holes (>12 h) have been described after heavy redosing.  \\n• No validated reagent test; will typically show weak to no colour reaction with Marquis/Mecke. Send to laboratory for confirmation.  \\n• Avoid driving for at least 12 h after last dose.  \\n• Harm-reduction: weigh to 1 mg accuracy, dose no more than once every 3–4 days to control tolerance and bladder risk.\",\n-      \"Mental stimulation\",\n-      \"Euphoria (mild–moderate)\",\n-      \"Enhanced focus\",\n-      \"Increased sociability\",\n-      \"Talkativeness\",\n-      \"Appetite suppression\",\n-      \"Tachycardia & hypertension\",\n-      \"Peripheral vasoconstriction / cold extremities\",\n-      \"Bruxism & jaw tension\",\n-      \"Sweating\",\n-      \"Anxiety / jitteriness (dose-dependent)\",\n-      \"Urinary retention\",\n-      \"Insomnia / difficulty sleeping\",\n-      \"Mild comedown fatigue & anhedonia\"\n+      \"Floating/body-lightness\",\n+      \"Analgesia\",\n+      \"Numbing of extremities\",\n+      \"Closed-eye imagery\",\n+      \"Mild open-eye visuals (patterning, warping)\",\n+      \"Time dilation\",\n+      \"Cognitive disconnection/\\\"hole\\\" states\",\n+      \"Euphoria or manic stimulation\",\n+      \"Ataxia/poor motor control\",\n+      \"Short-term memory impairment\",\n+      \"After-glow dysphoria or brain-fog\"\n-      \"full_tolerance\": \"After 2–3 consecutive days\",\n-      \"half_tolerance\": \"3–7 days\",\n-      \"zero_tolerance\": \"2–3 weeks\",\n+      \"full_tolerance\": \"After 3–5 consecutive days of use\",\n+      \"half_tolerance\": \"~1–2 weeks\",\n+      \"zero_tolerance\": \"4–6 weeks of abstinence\",\n-        \"Amphetamine\",\n-        \"Methamphetamine\",\n-        \"Synthetic cathinones\"\n+        \"Ketamine\",\n+        \"MXE\",\n+        \"MXP\",\n+        \"3-MeO-PCP\",\n+        \"DXM\"\n-    \"half_life\": \"Parent compound estimated 3–5 h (based on user urinary detection strips); active metabolites unknown.\",\n+    \"half_life\": \"Estimated 4–8 h (no formal data; based on user urine detection windows and structural similarity to MXP)\",\n-        \"name\": \"User bioassay thread – first impressions of 2-PTA\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/pw8g29/2pta_first_impressions_user_report/\"\n+        \"name\": \"2-TFMXP – Wikipedia\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/2-TFMXP\"\n-        \"name\": \"Follow-up report inc. insufflated route\",\n-        \"reference\": \"https://www.reddit.com/r/chemhelp/comments/rc7nxs/2pta_nasal_trial_report/\"\n+        \"name\": \"Forensic identification of new arylcyclohexylamines including 2-TFMXP\",\n+        \"reference\": \"https://doi.org/10.1016/j.forsciint.2023.111426\"\n-        \"name\": \"Vespiary discussion – synthesis & pharmacology speculation\",\n-        \"reference\": \"https://www.thevespiary.org/talk/index.php?topic=18658.0\"\n-      },\n-      {\n-        \"name\": \"Vendor COA showing identity & 92 % purity\",\n-        \"reference\": \"https://anonfiles.com/2pta_coa.pdf\"\n-      },\n-      {\n-        \"name\": \"Drugs Page: 2 PTA dossier\",\n-        \"reference\": \"https://drugs.page.link/2-PTA-dossier\"\n+        \"name\": \"u/TrainwreckTurtle – 2-TFMXP First-time report, r/researchchemicals (2022)\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/yeh7yh/2tfmxp_first_impressions/\"\n-      \"stimulant\",\n-      \"research-chemical\",\n-      \"habit-forming\",\n-      \"Other stimulants\"\n+      \"dissociative\",\n+      \"research-chemical\"\n\n# 4-EPD · #562\n\n-  \"id\": 560,\n-  \"title\": \"2-TFMXP\",\n+  \"id\": 562,\n+  \"title\": \"4-EPD\",\n-    \"drug_name\": \"2-TFMXP\",\n-    \"chemical_name\": \"2-TFMXP\",\n-    \"alternative_name\": \"\",\n-    \"chemical_class\": \"Substituted diarylethylamines\",\n-    \"mechanism_of_action\": \"NMDA receptor antagonist\",\n-    \"psychoactive_class\": \"Dissociative; Hallucinogen\",\n+    \"drug_name\": \"4-EPD\",\n+    \"chemical_name\": \"4-Ethylpentedrone\",\n+    \"alternative_name\": \"4-Ethylpentedrone\",\n+    \"chemical_class\": \"Cathinones\",\n+    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor\",\n+    \"psychoactive_class\": \"Stimulant\",\n-            \"threshold\": \"5–10 mg\",\n-            \"light\": \"10–25 mg\",\n-            \"common\": \"25–45 mg\",\n-            \"strong\": \"45–70 mg\",\n-            \"heavy\": \"70 mg+ (NOT RECOMMENDED)\"\n+            \"threshold\": \"10 mg\",\n+            \"light\": \"15–30 mg\",\n+            \"common\": \"30–60 mg\",\n+            \"strong\": \"60–90 mg\",\n+            \"heavy\": \"90 mg +\"\n-          \"route\": \"sublingual\",\n+          \"route\": \"insufflated\",\n-            \"threshold\": \"4–8 mg\",\n-            \"light\": \"8–20 mg\",\n-            \"common\": \"20–40 mg\",\n-            \"strong\": \"40–60 mg\",\n-            \"heavy\": \"60 mg+ (NOT RECOMMENDED)\"\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"10–20 mg\",\n+            \"common\": \"20–35 mg\",\n+            \"strong\": \"35–50 mg\",\n+            \"heavy\": \"50 mg +\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"rectal\",\n-            \"threshold\": \"3–5 mg\",\n-            \"light\": \"5–15 mg\",\n-            \"common\": \"15–30 mg\",\n-            \"strong\": \"30–45 mg\",\n-            \"heavy\": \"45 mg+ (NOT RECOMMENDED)\"\n+            \"threshold\": \"8 mg\",\n+            \"light\": \"12–25 mg\",\n+            \"common\": \"25–45 mg\",\n+            \"strong\": \"45–70 mg\",\n+            \"heavy\": \"70 mg +\"\n-            \"total_duration\": \"6-10 h\",\n-            \"onset\": \"20-60 min\",\n-            \"peak\": \"1.5-4 h\",\n-            \"offset\": \"2-4 h\",\n-            \"after_effects\": \"Up to 24 h of residual cognitive / vestibular impairment (“dissociative after-glow”)\"\n+            \"total_duration\": \"2-4 h (primary); 4-12 h including after-effects\",\n+            \"onset\": \"20-45 min\",\n+            \"peak\": \"0.5-1.5 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-8 h residual stimulation / mood drop\"\n-          \"route\": \"sublingual\",\n+          \"route\": \"insufflated\",\n-            \"sublingual\"\n+            \"insufflated\"\n-            \"total_duration\": \"6-10 h\",\n-            \"peak\": \"1.5-4 h\",\n-            \"offset\": \"2-4 h\",\n-            \"after_effects\": \"Up to 24 h of residual cognitive / vestibular impairment (“dissociative after-glow”)\"\n+            \"total_duration\": \"2-4 h (primary); 4-12 h including after-effects\",\n+            \"onset\": \"5-30 min\",\n+            \"peak\": \"0.5-1.5 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-8 h residual stimulation / mood drop\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"rectal\",\n-            \"insufflated\"\n+            \"rectal\"\n-            \"total_duration\": \"6-10 h\",\n+            \"total_duration\": \"2-4 h (primary); 4-12 h including after-effects\",\n-            \"peak\": \"1.5-4 h\",\n-            \"offset\": \"2-4 h\",\n-            \"after_effects\": \"Up to 24 h of residual cognitive / vestibular impairment (“dissociative after-glow”)\"\n+            \"peak\": \"0.5-1.5 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-8 h residual stimulation / mood drop\"\n-    \"addiction_potential\": \"Moderate. Like other diphenidines, repeated use can quickly become compulsive due to tolerance build-up and euphoric dissociation. Cases of binge patterns, psychological dependence, and urinary tract problems similar to ketamine have been reported.\",\n+    \"addiction_potential\": \"Moderate to high. Rapid onset, short duration and pronounced euphoria promote compulsive redosing. Daily or binge use over several days has produced severe insomnia, agitation, and depressive crash on cessation in case reports.\",\n-        \"alcohol\",\n-        \"opioids\",\n-        \"benzodiazepines\",\n-        \"GHB/GBL\",\n-        \"barbiturates\"\n+        \"MAOIs\",\n+        \"Other powerful stimulants (methamphetamine, α-PVP, cocaine)\",\n+        \"Synthetic cannabinoids with strong CB1 agonism\",\n+        \"Strong serotonergics at recreational doses (NBOMe series, 2C-T compounds)\"\n-        \"other dissociatives (e.g., ketamine, DXM, PCP)\",\n-        \"MAOIs\"\n+        \"Large amounts of alcohol (cardiotoxic synergy)\",\n+        \"Tricyclic antidepressants\",\n+        \"Bupropion\",\n+        \"High-dose DXM\"\n-        \"stimulants (increased cardiotoxicity)\",\n-        \"SSRIs/SNRIs (serotonin & seizure threshold)\",\n-        \"antipsychotics (additive QT-prolongation)\"\n+        \"SSRI/SNRI antidepressants\",\n+        \"Opioids (respiratory depression risk if used to sedate the comedown)\",\n+        \"Cannabis (tachycardia/anxiety)\",\n+        \"Benzodiazepines (safe for acute agitation but respiratory depression possible if combined with alcohol)\"\n-    \"notes\": \"• 2-TFMXP is the 2-trifluoromethyl analogue of methoxphenidine (MXP). Very little formal pharmacology is published; all dosing is extrapolated from user reports and structural activity.  \\n• Compared with MXP it appears 1.5–2× more potent and noticeably more stimulating/mania-prone.  \\n• Marked inter-individual variability; some users report minimal effects below 30 mg while others reach full dissociation at 25 mg. Start low and titrate.  \\n• Visual and auditory distortions are lighter than PCP/3-MeO-PCP but balance issues, tinnitus, and \\\"rubber-band\\\" time perception are common.  \\n• Prolonged vertigo, body numbness, and memory holes (>12 h) have been described after heavy redosing.  \\n• No validated reagent test; will typically show weak to no colour reaction with Marquis/Mecke. Send to laboratory for confirmation.  \\n• Avoid driving for at least 12 h after last dose.  \\n• Harm-reduction: weigh to 1 mg accuracy, dose no more than once every 3–4 days to control tolerance and bladder risk.\",\n+    \"notes\": \"4-EPD is a ring-ethyl analogue of pentedrone first detected in European drug-checking samples in 2018. Toxicological information is sparse; a handful of fatal intoxications have been documented, usually with poly-drug use. Acute risks mirror those of other potent cathinones: tachycardia, hypertension, hyperthermia, rhabdomyolysis, hyponatraemia from excessive water intake, acute psychosis, and serotonin syndrome when mixed with serotonergics. Weigh doses on a 0.001 g scale and perform an allergy test (<2 mg). Redosing markedly prolongs stimulation and increases vasoconstriction—limit to one re-dose if at all. Maintain electrolytes (sports drink), keep body temperature in check, and eat a balanced meal beforehand. Allow at least 4–6 weeks between sessions to reduce neuroadaptation and mood disturbances.\",\n-      \"Floating/body-lightness\",\n-      \"Analgesia\",\n-      \"Numbing of extremities\",\n-      \"Closed-eye imagery\",\n-      \"Mild open-eye visuals (patterning, warping)\",\n-      \"Time dilation\",\n-      \"Cognitive disconnection/\\\"hole\\\" states\",\n-      \"Euphoria or manic stimulation\",\n-      \"Ataxia/poor motor control\",\n-      \"Short-term memory impairment\",\n-      \"After-glow dysphoria or brain-fog\"\n+      \"Euphoria\",\n+      \"Mental & physical stimulation\",\n+      \"Motivation enhancement\",\n+      \"Increased sociability\",\n+      \"Talkativeness\",\n+      \"Empathy enhancement (mild)\",\n+      \"Anxiolysis (low doses) → Anxiety/paranoia (high doses)\",\n+      \"Increased heart rate\",\n+      \"Elevated blood pressure\",\n+      \"Jaw clenching/bruxism\",\n+      \"Sweating\",\n+      \"Vasoconstriction/cold extremities\",\n+      \"Decreased appetite\",\n+      \"Urinary retention\",\n+      \"Insomnia\",\n+      \"Compulsive redosing urge\",\n+      \"Comedown dysphoria/irritability\"\n-      \"full_tolerance\": \"After 3–5 consecutive days of use\",\n-      \"half_tolerance\": \"~1–2 weeks\",\n+      \"full_tolerance\": \"Develops after 2–5 consecutive days of use\",\n+      \"half_tolerance\": \"≈1–2 weeks\",\n-        \"Ketamine\",\n-        \"MXE\",\n-        \"MXP\",\n-        \"3-MeO-PCP\",\n-        \"DXM\"\n+        \"Other cathinones\",\n+        \"Amphetamines\"\n-    \"half_life\": \"Estimated 4–8 h (no formal data; based on user urine detection windows and structural similarity to MXP)\",\n+    \"half_life\": \"Estimated 1.5–3 h (human data lacking; value derived from structural analogues and limited case data)\",\n-        \"name\": \"2-TFMXP – Wikipedia\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/2-TFMXP\"\n+        \"name\": \"Bäckberg, Helander et al. Identification of 4-ethylpentedrone in acute intoxications, Sweden 2018-2020\",\n+        \"reference\": \"https://doi.org/10.1007/s11419-021-00583-5\"\n-        \"name\": \"Forensic identification of new arylcyclohexylamines including 2-TFMXP\",\n-        \"reference\": \"https://doi.org/10.1016/j.forsciint.2023.111426\"\n+        \"name\": \"EMCDDA Early-Warning System report: 4-Ethylpentedrone (4-EPD) 2021\",\n+        \"reference\": \"https://www.emcdda.europa.eu/system/files/publications/13777/4-ethylpentedrone_EWS-report.pdf\"\n-        \"name\": \"u/TrainwreckTurtle – 2-TFMXP First-time report, r/researchchemicals (2022)\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/yeh7yh/2tfmxp_first_impressions/\"\n+        \"name\": \"Trost et al. Fatal intoxication involving 4-ethylpentedrone documented by high-resolution mass spectrometry (Forensic Sci Int, 2022)\",\n+        \"reference\": \"https://doi.org/10.1016/j.forsciint.2022.111418\"\n+      },\n+      {\n+        \"name\": \"Reddit r/researchchemicals – User experience compilation on 4-EPD (accessed 2025-03-29)\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/g0n4uu/4ethylpentedrone_megathread/\"\n+      },\n+      {\n+        \"name\": \"Global Drug Survey 2023 – Cathinone section (self-reported effects & harms)\",\n+        \"reference\": \"https://www.globaldrugsurvey.com/gds-2023-key-findings/\"\n+      },\n+      {\n+        \"name\": \"PubChem: 163193057\",\n+        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/163193057\"\n-      \"dissociative\",\n+      \"stimulant\",\n+      \"habit-forming\",\n\n# CBC · #563\n\n-  \"id\": 562,\n-  \"title\": \"4-EPD\",\n+  \"id\": 563,\n+  \"title\": \"CBC\",\n-    \"drug_name\": \"4-EPD\",\n-    \"chemical_name\": \"4-Ethylpentedrone\",\n-    \"alternative_name\": \"4-Ethylpentedrone\",\n-    \"chemical_class\": \"Cathinones\",\n-    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor\",\n-    \"psychoactive_class\": \"Stimulant\",\n+    \"drug_name\": \"CBC\",\n+    \"chemical_name\": \"Cannabichromene\",\n+    \"alternative_name\": \"Cannabichromene\",\n+    \"chemical_class\": \"Cannabinoids\",\n+    \"mechanism_of_action\": \"Multi-target modulator\",\n+    \"psychoactive_class\": \"cannabinoid; hallucinogen\",\n-            \"threshold\": \"10 mg\",\n-            \"light\": \"15–30 mg\",\n-            \"common\": \"30–60 mg\",\n-            \"strong\": \"60–90 mg\",\n-            \"heavy\": \"90 mg +\"\n-          }\n-        },\n-        {\n-          \"route\": \"insufflated\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"light\": \"10–20 mg\",\n-            \"common\": \"20–35 mg\",\n-            \"strong\": \"35–50 mg\",\n-            \"heavy\": \"50 mg +\"\n+            \"light\": \"10 – 30 mg\",\n+            \"common\": \"30 – 70 mg\",\n+            \"strong\": \"70 – 150 mg\",\n+            \"heavy\": \"150 mg +‎\"\n-          \"route\": \"rectal\",\n+          \"route\": \"vaporized\",\n-            \"threshold\": \"8 mg\",\n-            \"light\": \"12–25 mg\",\n-            \"common\": \"25–45 mg\",\n-            \"strong\": \"45–70 mg\",\n-            \"heavy\": \"70 mg +\"\n+            \"threshold\": \"1 mg\",\n+            \"light\": \"1 – 5 mg\",\n+            \"common\": \"5 – 20 mg\",\n+            \"strong\": \"20 – 50 mg\",\n+            \"heavy\": \"50 mg +‎\"\n-            \"total_duration\": \"2-4 h (primary); 4-12 h including after-effects\",\n-            \"onset\": \"20-45 min\",\n-            \"peak\": \"0.5-1.5 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-8 h residual stimulation / mood drop\"\n+            \"total_duration\": \"4 - 8 h\",\n+            \"onset\": \"30 - 90 min\",\n+            \"peak\": \"1 - 3 h\",\n+            \"offset\": \"2 - 4 h\",\n+            \"after_effects\": \"especially with higher doses\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"vaporized\",\n-            \"insufflated\"\n+            \"vaporized\"\n-            \"total_duration\": \"2-4 h (primary); 4-12 h including after-effects\",\n-            \"onset\": \"5-30 min\",\n-            \"peak\": \"0.5-1.5 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-8 h residual stimulation / mood drop\"\n+            \"total_duration\": \"1 - 3 h\",\n+            \"onset\": \"0 - 5 min\",\n+            \"peak\": \"10 - 30 min\",\n+            \"offset\": \"0.5 - 1 h\",\n+            \"after_effects\": \"Mild relaxation 2 - 12 h\"\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"canonical_routes\": [\n-            \"rectal\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"2-4 h (primary); 4-12 h including after-effects\",\n-            \"onset\": \"5-15 min\",\n-            \"peak\": \"0.5-1.5 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-8 h residual stimulation / mood drop\"\n-          }\n-    \"addiction_potential\": \"Moderate to high. Rapid onset, short duration and pronounced euphoria promote compulsive redosing. Daily or binge use over several days has produced severe insomnia, agitation, and depressive crash on cessation in case reports.\",\n+    \"addiction_potential\": \"Very low. No reinforcing effects observed in animal models and no human case reports of dependence. Comparable to CBD rather than THC.\",\n-      \"dangerous\": [\n-        \"MAOIs\",\n-        \"Other powerful stimulants (methamphetamine, α-PVP, cocaine)\",\n-        \"Synthetic cannabinoids with strong CB1 agonism\",\n-        \"Strong serotonergics at recreational doses (NBOMe series, 2C-T compounds)\"\n-      ],\n+      \"dangerous\": [],\n-        \"Large amounts of alcohol (cardiotoxic synergy)\",\n-        \"Tricyclic antidepressants\",\n-        \"Bupropion\",\n-        \"High-dose DXM\"\n+        \"Warfarin & other narrow-therapeutic-index CYP2C9 substrates (possible metabolic inhibition)\"\n-        \"SSRI/SNRI antidepressants\",\n-        \"Opioids (respiratory depression risk if used to sedate the comedown)\",\n-        \"Cannabis (tachycardia/anxiety)\",\n-        \"Benzodiazepines (safe for acute agitation but respiratory depression possible if combined with alcohol)\"\n+        \"Alcohol\",\n+        \"Benzodiazepines\",\n+        \"Opioids\",\n+        \"Other cannabinoids (THC, CBD)\",\n+        \"Sedating antihistamines\",\n+        \"SSRIs/SNRIs (mild CYP interactions)\"\n-    \"notes\": \"4-EPD is a ring-ethyl analogue of pentedrone first detected in European drug-checking samples in 2018. Toxicological information is sparse; a handful of fatal intoxications have been documented, usually with poly-drug use. Acute risks mirror those of other potent cathinones: tachycardia, hypertension, hyperthermia, rhabdomyolysis, hyponatraemia from excessive water intake, acute psychosis, and serotonin syndrome when mixed with serotonergics. Weigh doses on a 0.001 g scale and perform an allergy test (<2 mg). Redosing markedly prolongs stimulation and increases vasoconstriction—limit to one re-dose if at all. Maintain electrolytes (sports drink), keep body temperature in check, and eat a balanced meal beforehand. Allow at least 4–6 weeks between sessions to reduce neuroadaptation and mood disturbances.\",\n+    \"notes\": \"CBC is a rare, non-intoxicating cannabinoid found in small amounts in Cannabis sativa. It shows affinity for CB2, TRPA1, TRPV1, and other receptors and has demonstrated anti-inflammatory, analgesic, antidepressant-like, and neurogenic properties in pre-clinical work. Human data are sparse; most information comes from animal studies and anecdotal reports with commercially available CBC isolates (tinctures, vape cartridges). The numbers above are extrapolated from product labeling (5–50 mg/serving) and user reports. Avoid high doses in combination with other CNS depressants until individual response is known. Because CBC may inhibit several CYP450 isoenzymes, monitor medications metabolised by CYP2C9, 2C19 and 3A4.\",\n-      \"Euphoria\",\n-      \"Mental & physical stimulation\",\n-      \"Motivation enhancement\",\n-      \"Increased sociability\",\n-      \"Talkativeness\",\n-      \"Empathy enhancement (mild)\",\n-      \"Anxiolysis (low doses) → Anxiety/paranoia (high doses)\",\n-      \"Increased heart rate\",\n-      \"Elevated blood pressure\",\n-      \"Jaw clenching/bruxism\",\n-      \"Sweating\",\n-      \"Vasoconstriction/cold extremities\",\n-      \"Decreased appetite\",\n-      \"Urinary retention\",\n-      \"Insomnia\",\n-      \"Compulsive redosing urge\",\n-      \"Comedown dysphoria/irritability\"\n+      \"Subtle mood lift\",\n+      \"Anxiolysis\",\n+      \"Analgesia (especially inflammatory pain)\",\n+      \"Body relaxation\",\n+      \"Minor muscular sedation\",\n+      \"Clear-headed focus\",\n+      \"Anti-inflammatory relief (subjective)\",\n+      \"Absence of strong euphoria or cognitive impairment at normal doses\"\n-      \"full_tolerance\": \"Develops after 2–5 consecutive days of use\",\n-      \"half_tolerance\": \"≈1–2 weeks\",\n-      \"zero_tolerance\": \"4–6 weeks of abstinence\",\n+      \"full_tolerance\": \"Data lacking; likely slow development with chronic daily use (weeks)\",\n+      \"half_tolerance\": \"~1–2 weeks of abstinence (extrapolated)\",\n+      \"zero_tolerance\": \"~4 weeks\",\n-        \"Other cathinones\",\n-        \"Amphetamines\"\n+        \"Other cannabinoids (partial)\"\n-    \"half_life\": \"Estimated 1.5–3 h (human data lacking; value derived from structural analogues and limited case data)\",\n+    \"half_life\": \"Animal data: 1–4 h; human half-life not formally characterised – expected to be in the low-hour range with lipophilic tissue retention similar to other phytocannabinoids.\",\n-        \"name\": \"Bäckberg, Helander et al. Identification of 4-ethylpentedrone in acute intoxications, Sweden 2018-2020\",\n-        \"reference\": \"https://doi.org/10.1007/s11419-021-00583-5\"\n+        \"name\": \"Cannabichromene – Wikipedia\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Cannabichromene\"\n-        \"name\": \"EMCDDA Early-Warning System report: 4-Ethylpentedrone (4-EPD) 2021\",\n-        \"reference\": \"https://www.emcdda.europa.eu/system/files/publications/13777/4-ethylpentedrone_EWS-report.pdf\"\n+        \"name\": \"Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011.\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165946/\"\n-        \"name\": \"Trost et al. Fatal intoxication involving 4-ethylpentedrone documented by high-resolution mass spectrometry (Forensic Sci Int, 2022)\",\n-        \"reference\": \"https://doi.org/10.1016/j.forsciint.2022.111418\"\n+        \"name\": \"DeLong GT et al. Quantification and pharmacokinetics of cannabinoids in oral cannabis extract in rats. Cannabis Cannabinoid Res. 2017.\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523269/\"\n-        \"name\": \"Reddit r/researchchemicals – User experience compilation on 4-EPD (accessed 2025-03-29)\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/g0n4uu/4ethylpentedrone_megathread/\"\n+        \"name\": \"Martín-Montañez A et al. Cannabichromene exerts antinociceptive and anti-inflammatory effects in murine models. Front Pharmacol. 2020.\",\n+        \"reference\": \"https://www.frontiersin.org/articles/10.3389/fphar.2020.00309\"\n-        \"name\": \"Global Drug Survey 2023 – Cathinone section (self-reported effects & harms)\",\n-        \"reference\": \"https://www.globaldrugsurvey.com/gds-2023-key-findings/\"\n-      },\n-      {\n-        \"name\": \"PubChem: 163193057\",\n-        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/163193057\"\n+        \"name\": \"Krishnan S et al. Comparative metabolism of cannabichromene and other phytocannabinoids via human cytochrome P450 enzymes. Drug Metab Dispos. 2022.\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/35704277/\"\n-      \"stimulant\",\n-      \"habit-forming\",\n-      \"research-chemical\"\n+      \"cannabinoid\",\n+      \"depressant\",\n+      \"nootropic\"\n\n# CBG · #566\n\n-  \"id\": 563,\n-  \"title\": \"CBC\",\n+  \"id\": 566,\n+  \"title\": \"CBG\",\n-    \"drug_name\": \"CBC\",\n-    \"chemical_name\": \"Cannabichromene\",\n-    \"alternative_name\": \"Cannabichromene\",\n+    \"drug_name\": \"CBG\",\n+    \"chemical_name\": \"Cannabigerol\",\n+    \"alternative_name\": \"Cannabigerol\",\n-            \"light\": \"10 – 30 mg\",\n-            \"common\": \"30 – 70 mg\",\n-            \"strong\": \"70 – 150 mg\",\n-            \"heavy\": \"150 mg +‎\"\n+            \"light\": \"5 – 15 mg\",\n+            \"common\": \"15 – 40 mg\",\n+            \"strong\": \"40 – 80 mg\",\n+            \"heavy\": \"80 mg +\"\n+          \"route\": \"sublingual\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"3 mg\",\n+            \"light\": \"3 – 10 mg\",\n+            \"common\": \"10 – 30 mg\",\n+            \"strong\": \"30 – 60 mg\",\n+            \"heavy\": \"60 mg +\"\n+          }\n+        },\n+        {\n-            \"common\": \"5 – 20 mg\",\n-            \"strong\": \"20 – 50 mg\",\n-            \"heavy\": \"50 mg +‎\"\n+            \"common\": \"5 – 15 mg\",\n+            \"strong\": \"15 – 30 mg\",\n+            \"heavy\": \"30 mg +\"\n-            \"total_duration\": \"4 - 8 h\",\n-            \"onset\": \"30 - 90 min\",\n-            \"peak\": \"1 - 3 h\",\n-            \"offset\": \"2 - 4 h\",\n-            \"after_effects\": \"especially with higher doses\"\n+            \"total_duration\": \"4 - 6 h 1 - 3 h\",\n+            \"onset\": \"30 - 90 min 1 - 5 min\",\n+            \"peak\": \"1 - 2 h 15 - 30 min\",\n+            \"offset\": \"2 - 4 h 30 - 90 min\",\n+            \"after_effects\": \"Up-to 4 h residual calm / relief\"\n+          \"route\": \"sublingual\",\n+          \"canonical_routes\": [\n+            \"sublingual\"\n+          ],\n+          \"stages\": {\n+            \"after_effects\": \"Up-to 4 h residual calm / relief\"\n+          }\n+        },\n+        {\n-            \"total_duration\": \"1 - 3 h\",\n-            \"onset\": \"0 - 5 min\",\n-            \"peak\": \"10 - 30 min\",\n-            \"offset\": \"0.5 - 1 h\",\n-            \"after_effects\": \"Mild relaxation 2 - 12 h\"\n+            \"total_duration\": \"4 - 6 h 1 - 3 h\",\n+            \"onset\": \"30 - 90 min 1 - 5 min\",\n+            \"peak\": \"1 - 2 h 15 - 30 min\",\n+            \"offset\": \"2 - 4 h 30 - 90 min\",\n+            \"after_effects\": \"Up-to 4 h residual calm / relief\"\n-    \"addiction_potential\": \"Very low. No reinforcing effects observed in animal models and no human case reports of dependence. Comparable to CBD rather than THC.\",\n+    \"addiction_potential\": \"Very low; no evidence of compulsive use or withdrawal. Dependence has not been documented in humans.\",\n-      \"dangerous\": [],\n-      \"unsafe\": [\n-        \"Warfarin & other narrow-therapeutic-index CYP2C9 substrates (possible metabolic inhibition)\"\n+      \"dangerous\": [\n+        \"Poppers (alkyl nitrites)\",\n+        \"Gabapentinoids (pregabalin, gabapentin)\"\n-      \"caution\": [\n+      \"unsafe\": [\n-        \"Other cannabinoids (THC, CBD)\",\n-        \"Sedating antihistamines\",\n-        \"SSRIs/SNRIs (mild CYP interactions)\"\n+        \"GHB/GBL\"\n+      ],\n+      \"caution\": [\n+        \"Amphetamines\",\n+        \"Cocaine\",\n+        \"MAOIs\",\n+        \"Tramadol\",\n+        \"DXM\",\n+        \"Ketamine\",\n+        \"Nitrous\",\n+        \"LSD\",\n+        \"Psilocybin/Mushrooms\",\n+        \"DMT\",\n+        \"Mescaline\",\n+        \"DOx\",\n+        \"2C-x\",\n+        \"NBOMe series\",\n+        \"MDMA\",\n+        \"MXE\",\n+        \"2C-T-x\",\n+        \"PVP class\",\n+        \"MMC class\",\n+        \"SSRIs\",\n+        \"Caffeine\"\n-    \"notes\": \"CBC is a rare, non-intoxicating cannabinoid found in small amounts in Cannabis sativa. It shows affinity for CB2, TRPA1, TRPV1, and other receptors and has demonstrated anti-inflammatory, analgesic, antidepressant-like, and neurogenic properties in pre-clinical work. Human data are sparse; most information comes from animal studies and anecdotal reports with commercially available CBC isolates (tinctures, vape cartridges). The numbers above are extrapolated from product labeling (5–50 mg/serving) and user reports. Avoid high doses in combination with other CNS depressants until individual response is known. Because CBC may inhibit several CYP450 isoenzymes, monitor medications metabolised by CYP2C9, 2C19 and 3A4.\",\n+    \"notes\": \"• CBG is the biosynthetic precursor of THC and CBD but itself produces no appreciable intoxication or euphoria.\\n• Acts as a partial agonist at CB1/CB2 with low affinity; also an α2-adrenergic agonist and 5-HT1A antagonist, which may underlie its alert-yet-calm profile.\\n• Pre-clinical work shows anti-inflammatory, neuroprotective, antibacterial (incl. MRSA) and intra-ocular-pressure-lowering effects.\\n• Human pilot study (20 mg oral) reported significant anxiety reduction without cognitive impairment.\\n• May mildly lower blood pressure and heart-rate; start low in people with cardiovascular issues.\\n• Metabolised mainly by CYP2C9, 2C19 and 3A4—potential drug-interaction pathway.\\n• Commercial products vary widely in purity; request COA≥98 % CBG and verify THC < 0.3 % to avoid unexpected intoxication.\\n• Because it is non-scheduled in most jurisdictions, isolates are often marketed as supplements; quality control is inconsistent.\",\n-      \"Subtle mood lift\",\n-      \"Analgesia (especially inflammatory pain)\",\n-      \"Body relaxation\",\n-      \"Minor muscular sedation\",\n+      \"Mood brightening\",\n-      \"Anti-inflammatory relief (subjective)\",\n-      \"Absence of strong euphoria or cognitive impairment at normal doses\"\n+      \"Mild physical stimulation/energy\",\n+      \"Analgesia (especially visceral/neuropathic)\",\n+      \"Anti-inflammatory body relief\",\n+      \"Reduced intra-ocular pressure\",\n+      \"Appetite modulation (slight increase or normalization)\",\n+      \"Dry mouth\",\n+      \"Eye dryness\",\n+      \"Lowered blood pressure/heart rate\",\n+      \"Sedation at very high doses\",\n+      \"Reduction of cannabis \\\"munchies\\\" when co-used with THC\"\n-      \"full_tolerance\": \"Data lacking; likely slow development with chronic daily use (weeks)\",\n-      \"half_tolerance\": \"~1–2 weeks of abstinence (extrapolated)\",\n-      \"zero_tolerance\": \"~4 weeks\",\n+      \"full_tolerance\": \"May develop after 10-14 days of heavy daily use\",\n+      \"half_tolerance\": \"3-5 days abstinence\",\n+      \"zero_tolerance\": \"1-2 weeks abstinence\",\n-        \"Other cannabinoids (partial)\"\n+        \"Other phytocannabinoids (CBD, THC, CBN)\"\n-    \"half_life\": \"Animal data: 1–4 h; human half-life not formally characterised – expected to be in the low-hour range with lipophilic tissue retention similar to other phytocannabinoids.\",\n+    \"half_life\": \"~4 – 6 h (human plasma, oral); slightly shorter when inhaled\",\n-        \"name\": \"Cannabichromene – Wikipedia\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Cannabichromene\"\n+        \"name\": \"Cascio MG et al. (2010) CBG is a potent α2-adrenoceptor agonist and 5-HT1A antagonist\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/20590562/\"\n-        \"name\": \"Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011.\",\n-        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165946/\"\n+        \"name\": \"De Ian Tomaso C et al. (2022) Pharmacokinetics of cannabigerol in rodents\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/35594464/\"\n-        \"name\": \"DeLong GT et al. Quantification and pharmacokinetics of cannabinoids in oral cannabis extract in rats. Cannabis Cannabinoid Res. 2017.\",\n-        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523269/\"\n+        \"name\": \"Brierley DI et al. (2016) CBG exerts neuroprotective effects in Huntington’s disease models\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/27663311/\"\n-        \"name\": \"Martín-Montañez A et al. Cannabichromene exerts antinociceptive and anti-inflammatory effects in murine models. Front Pharmacol. 2020.\",\n-        \"reference\": \"https://www.frontiersin.org/articles/10.3389/fphar.2020.00309\"\n+        \"name\": \"Farha MA et al. (2020) CBG targets the cell membrane of drug-resistant MRSA\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/32094925/\"\n-        \"name\": \"Krishnan S et al. Comparative metabolism of cannabichromene and other phytocannabinoids via human cytochrome P450 enzymes. Drug Metab Dispos. 2022.\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/35704277/\"\n+        \"name\": \"Kohut SJ & Fichna J (2021) CBG for inflammatory bowel disease—pre-clinical evidence\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/34537453/\"\n+      },\n+      {\n+        \"name\": \"Henson JD et al. (2023) Single-dose 20 mg oral CBG reduces state anxiety in healthy adults (pilot RCT)\",\n+        \"reference\": \"https://clinicaltrials.gov/ct2/show/NCT05627450\"\n+      },\n+      {\n+        \"name\": \"Wikipedia – Cannabigerol\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Cannabigerol\"\n-      \"depressant\",\n-      \"nootropic\"\n+      \"nootropic\",\n+      \"supplement\"\n\n# 3,4-Trimethylenepentedrone · #567\n\n-  \"id\": 566,\n-  \"title\": \"CBG\",\n+  \"id\": 567,\n+  \"title\": \"3,4-Trimethylenepentedrone\",\n-    \"drug_name\": \"CBG\",\n-    \"chemical_name\": \"Cannabigerol\",\n-    \"alternative_name\": \"Cannabigerol\",\n-    \"chemical_class\": \"Cannabinoids\",\n-    \"mechanism_of_action\": \"Multi-target modulator\",\n-    \"psychoactive_class\": \"cannabinoid; hallucinogen\",\n+    \"drug_name\": \"3,4-Trimethylenepentedrone\",\n+    \"chemical_name\": \"3,4-Trimethylenepentedrone\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Cathinones\",\n+    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor\",\n+    \"psychoactive_class\": \"Stimulant; entactogen\",\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"5 – 15 mg\",\n-            \"common\": \"15 – 40 mg\",\n-            \"strong\": \"40 – 80 mg\",\n-            \"heavy\": \"80 mg +\"\n+            \"threshold\": \"10–15\",\n+            \"light\": \"15–30\",\n+            \"common\": \"30–60\",\n+            \"strong\": \"60–90\",\n+            \"heavy\": \"90+\"\n-          \"route\": \"sublingual\",\n+          \"route\": \"insufflated\",\n-            \"threshold\": \"3 mg\",\n-            \"light\": \"3 – 10 mg\",\n-            \"common\": \"10 – 30 mg\",\n-            \"strong\": \"30 – 60 mg\",\n-            \"heavy\": \"60 mg +\"\n+            \"threshold\": \"5–10\",\n+            \"light\": \"10–20\",\n+            \"common\": \"20–40\",\n+            \"strong\": \"40–60\",\n+            \"heavy\": \"60+\"\n-          \"route\": \"vaporized\",\n+          \"route\": \"rectal\",\n-            \"threshold\": \"1 mg\",\n-            \"light\": \"1 – 5 mg\",\n-            \"common\": \"5 – 15 mg\",\n-            \"strong\": \"15 – 30 mg\",\n-            \"heavy\": \"30 mg +\"\n+            \"threshold\": \"7–12\",\n+            \"light\": \"12–25\",\n+            \"common\": \"25–45\",\n+            \"strong\": \"45–70\",\n+            \"heavy\": \"70+\"\n-            \"total_duration\": \"4 - 6 h 1 - 3 h\",\n-            \"onset\": \"30 - 90 min 1 - 5 min\",\n-            \"peak\": \"1 - 2 h 15 - 30 min\",\n-            \"offset\": \"2 - 4 h 30 - 90 min\",\n-            \"after_effects\": \"Up-to 4 h residual calm / relief\"\n+            \"total_duration\": \"3-6 h\",\n+            \"peak\": \"1-2.5 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"1-3 h residual stimulation / fatigue (‘comedown’)\"\n-          \"route\": \"sublingual\",\n+          \"route\": \"insufflated\",\n-            \"sublingual\"\n+            \"insufflated\"\n-            \"after_effects\": \"Up-to 4 h residual calm / relief\"\n+            \"total_duration\": \"3-6 h\",\n+            \"onset\": \"0:05-0:30 h\",\n+            \"peak\": \"1-2.5 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"1-3 h residual stimulation / fatigue (‘comedown’)\"\n-          \"route\": \"vaporized\",\n+          \"route\": \"rectal\",\n-            \"vaporized\"\n+            \"rectal\"\n-            \"total_duration\": \"4 - 6 h 1 - 3 h\",\n-            \"onset\": \"30 - 90 min 1 - 5 min\",\n-            \"peak\": \"1 - 2 h 15 - 30 min\",\n-            \"offset\": \"2 - 4 h 30 - 90 min\",\n-            \"after_effects\": \"Up-to 4 h residual calm / relief\"\n+            \"total_duration\": \"3-6 h\",\n+            \"peak\": \"1-2.5 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"1-3 h residual stimulation / fatigue (‘comedown’)\"\n-    \"addiction_potential\": \"Very low; no evidence of compulsive use or withdrawal. Dependence has not been documented in humans.\",\n+    \"addiction_potential\": \"Moderate to high – like other monoamine-releasing cathinones, repeated redosing is common and binge patterns can develop. Psychological dependence and compulsive use have been reported anecdotally.\",\n-        \"Poppers (alkyl nitrites)\",\n-        \"Gabapentinoids (pregabalin, gabapentin)\"\n+        \"MAOIs\",\n+        \"Tramadol\",\n+        \"2C-T-x\",\n+        \"5-MeO-x tryptamines\",\n+        \"Cocaine\",\n+        \"Amphetamines\",\n+        \"Other cathinones (MMC class)\"\n-        \"Alcohol\",\n-        \"Benzodiazepines\",\n+        \"DXM\",\n+        \"DOx\",\n+        \"Ketamine\",\n+        \"GHB/GBL\",\n-        \"GHB/GBL\"\n+        \"NBOMe series\"\n-        \"Amphetamines\",\n-        \"Cocaine\",\n-        \"MAOIs\",\n-        \"Tramadol\",\n-        \"DXM\",\n-        \"Ketamine\",\n-        \"Nitrous\",\n-        \"LSD\",\n-        \"Psilocybin/Mushrooms\",\n-        \"DMT\",\n-        \"Mescaline\",\n-        \"DOx\",\n-        \"2C-x\",\n-        \"NBOMe series\",\n+        \"Alcohol\",\n+        \"Cannabis\",\n+        \"Caffeine\",\n-        \"MXE\",\n-        \"2C-T-x\",\n-        \"PVP class\",\n-        \"MMC class\",\n-        \"SSRIs\",\n-        \"Caffeine\"\n+        \"SSRIs (reduced effect)\",\n+        \"Benzodiazepines (respiratory depression when combined in heavy doses)\"\n-    \"notes\": \"• CBG is the biosynthetic precursor of THC and CBD but itself produces no appreciable intoxication or euphoria.\\n• Acts as a partial agonist at CB1/CB2 with low affinity; also an α2-adrenergic agonist and 5-HT1A antagonist, which may underlie its alert-yet-calm profile.\\n• Pre-clinical work shows anti-inflammatory, neuroprotective, antibacterial (incl. MRSA) and intra-ocular-pressure-lowering effects.\\n• Human pilot study (20 mg oral) reported significant anxiety reduction without cognitive impairment.\\n• May mildly lower blood pressure and heart-rate; start low in people with cardiovascular issues.\\n• Metabolised mainly by CYP2C9, 2C19 and 3A4—potential drug-interaction pathway.\\n• Commercial products vary widely in purity; request COA≥98 % CBG and verify THC < 0.3 % to avoid unexpected intoxication.\\n• Because it is non-scheduled in most jurisdictions, isolates are often marketed as supplements; quality control is inconsistent.\",\n+    \"notes\": \"Very little human data exist – all dosage estimates are extrapolated from closely related cathinones such as pentedrone & pentylone, a handful of Reddit/Bluelight reports, and forensic potency modelling. Users describe a rapid, clean stimulation with mild empathogenic warmth, stronger on dopamine/norepinephrine than serotonin. Significant cardiovascular strain (tachycardia, vasoconstriction) and a harsh comedown have been reported above ~60 mg oral. Because metabolic/toxicological profiles are unknown, start with allergy tests (≤5 mg) and avoid frequent redosing (>3 doses / session). No published human toxicity cases, but animal hepatotoxicity data on structural analogues suggest possible liver stress at high doses. Always employ harm-reduction practices: stay hydrated, keep body-temperature down, do not drive during or after use.\",\n-      \"Anxiolysis\",\n-      \"Mood brightening\",\n-      \"Clear-headed focus\",\n-      \"Mild physical stimulation/energy\",\n-      \"Analgesia (especially visceral/neuropathic)\",\n-      \"Anti-inflammatory body relief\",\n-      \"Reduced intra-ocular pressure\",\n-      \"Appetite modulation (slight increase or normalization)\",\n-      \"Dry mouth\",\n-      \"Eye dryness\",\n-      \"Lowered blood pressure/heart rate\",\n-      \"Sedation at very high doses\",\n-      \"Reduction of cannabis \\\"munchies\\\" when co-used with THC\"\n+      \"Euphoric stimulation\",\n+      \"Enhanced sociability\",\n+      \"Increased motivation\",\n+      \"Mild tactile enhancement\",\n+      \"Anxiety at higher doses\",\n+      \"Bruxism and muscle tension\",\n+      \"Sweating and vasoconstriction\",\n+      \"Insomnia (especially with late dosing)\",\n+      \"Appetite suppression\",\n+      \"Crash/low mood next day\"\n-      \"full_tolerance\": \"May develop after 10-14 days of heavy daily use\",\n-      \"half_tolerance\": \"3-5 days abstinence\",\n-      \"zero_tolerance\": \"1-2 weeks abstinence\",\n+      \"full_tolerance\": \"Develops after 2–3 consecutive days of use\",\n+      \"half_tolerance\": \"1–2 weeks\",\n+      \"zero_tolerance\": \"4–8 weeks of abstinence\",\n-        \"Other phytocannabinoids (CBD, THC, CBN)\"\n+        \"Other substituted cathinones\",\n+        \"Classical stimulants (e.g., amphetamine, cocaine)\"\n-    \"half_life\": \"~4 – 6 h (human plasma, oral); slightly shorter when inhaled\",\n+    \"half_life\": \"Estimated 3–5 h (no human PK data; based on in-vitro microsome study and structural analogues)\",\n-        \"name\": \"Cascio MG et al. (2010) CBG is a potent α2-adrenoceptor agonist and 5-HT1A antagonist\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/20590562/\"\n+        \"name\": \"EMCDDA – New psychoactive substances: global update 2021 (first European seizure of 3,4-TMPD)\",\n+        \"reference\": \"https://www.emcdda.europa.eu/system/files/publications/13939/20212930_TD0521602ENN_PDF.pdf\"\n-        \"name\": \"De Ian Tomaso C et al. (2022) Pharmacokinetics of cannabigerol in rodents\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/35594464/\"\n+        \"name\": \"Adamowicz, P. et al. First identification of 3,4-trimethylenepentedrone in seized material\",\n+        \"reference\": \"https://doi.org/10.1016/j.forsciint.2021.110948\"\n-        \"name\": \"Brierley DI et al. (2016) CBG exerts neuroprotective effects in Huntington’s disease models\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/27663311/\"\n+        \"name\": \"PubChem – 3,4-Trimethylenepentedrone compound summary\",\n+        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/164416210\"\n-        \"name\": \"Farha MA et al. (2020) CBG targets the cell membrane of drug-resistant MRSA\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/32094925/\"\n+        \"name\": \"User experience compilation thread – r/researchchemicals (2023)\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/13xwtcn/34_trimethylenepentedrone_megathread/\"\n-        \"name\": \"Kohut SJ & Fichna J (2021) CBG for inflammatory bowel disease—pre-clinical evidence\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/34537453/\"\n-      },\n-      {\n-        \"name\": \"Henson JD et al. (2023) Single-dose 20 mg oral CBG reduces state anxiety in healthy adults (pilot RCT)\",\n-        \"reference\": \"https://clinicaltrials.gov/ct2/show/NCT05627450\"\n-      },\n-      {\n-        \"name\": \"Wikipedia – Cannabigerol\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Cannabigerol\"\n+        \"name\": \"Wikipedia: 3,4 Trimethylenepentedrone\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/3,4-Trimethylenepentedrone\"\n-      \"cannabinoid\",\n-      \"nootropic\",\n-      \"supplement\"\n+      \"stimulant\",\n+      \"research-chemical\",\n+      \"habit-forming\"\n\n# 4Cl-iBF · #568\n\n-  \"id\": 567,\n-  \"title\": \"3,4-Trimethylenepentedrone\",\n+  \"id\": 568,\n+  \"title\": \"4Cl-iBF\",\n-    \"drug_name\": \"3,4-Trimethylenepentedrone\",\n-    \"chemical_name\": \"3,4-Trimethylenepentedrone\",\n-    \"alternative_name\": \"\",\n-    \"chemical_class\": \"Cathinones\",\n-    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor\",\n-    \"psychoactive_class\": \"Stimulant; entactogen\",\n+    \"drug_name\": \"4Cl-iBF\",\n+    \"chemical_name\": \"4Cl-iBF\",\n+    \"alternative_name\": \"p-Chloro-isobutyrylfentanyl\",\n+    \"chemical_class\": \"Anilinopiperidines\",\n+    \"mechanism_of_action\": \"μ-Opioid receptor agonist (full)\",\n+    \"psychoactive_class\": \"Opioid (µ-opioid receptor agonist)\",\n-          \"route\": \"oral\",\n-          \"units\": \"mg\",\n+          \"route\": \"insufflated\",\n+          \"units\": \"µg\",\n-            \"threshold\": \"10–15\",\n-            \"light\": \"15–30\",\n-            \"common\": \"30–60\",\n-            \"strong\": \"60–90\",\n-            \"heavy\": \"90+\"\n+            \"threshold\": \"10–20 µg\",\n+            \"light\": \"20–40 µg\",\n+            \"common\": \"40–80 µg\",\n+            \"strong\": \"80–150 µg\",\n+            \"heavy\": \">150 µg\"\n-          \"route\": \"insufflated\",\n-          \"units\": \"mg\",\n+          \"route\": \"sublingual\",\n+          \"units\": \"µg\",\n-            \"threshold\": \"5–10\",\n-            \"light\": \"10–20\",\n-            \"common\": \"20–40\",\n-            \"strong\": \"40–60\",\n-            \"heavy\": \"60+\"\n+            \"threshold\": \"15–30 µg\",\n+            \"light\": \"30–60 µg\",\n+            \"common\": \"60–120 µg\",\n+            \"strong\": \"120–200 µg\",\n+            \"heavy\": \">200 µg\"\n-          \"route\": \"rectal\",\n-          \"units\": \"mg\",\n+          \"route\": \"intravenous\",\n+          \"units\": \"µg\",\n-            \"threshold\": \"7–12\",\n-            \"light\": \"12–25\",\n-            \"common\": \"25–45\",\n-            \"strong\": \"45–70\",\n-            \"heavy\": \"70+\"\n+            \"threshold\": \"5–10 µg\",\n+            \"light\": \"10–25 µg\",\n+            \"common\": \"25–50 µg\",\n+            \"strong\": \"50–100 µg\",\n+            \"heavy\": \">100 µg\"\n-          \"route\": \"oral\",\n+          \"route\": \"insufflated\",\n-            \"oral\"\n+            \"insufflated\"\n-            \"total_duration\": \"3-6 h\",\n-            \"peak\": \"1-2.5 h\",\n+            \"total_duration\": \"1.5 - 4 h (route-dependent)\",\n+            \"onset\": \"Seconds / 2-5 min / 5-15 min\",\n+            \"peak\": \"15-45 min\",\n-            \"after_effects\": \"1-3 h residual stimulation / fatigue (‘comedown’)\"\n+            \"after_effects\": \"Residual sedation & lethargy 2-6 h; possible next-day fatigue\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"sublingual\",\n-            \"insufflated\"\n+            \"sublingual\"\n-            \"total_duration\": \"3-6 h\",\n-            \"onset\": \"0:05-0:30 h\",\n-            \"peak\": \"1-2.5 h\",\n+            \"total_duration\": \"1.5 - 4 h (route-dependent)\",\n+            \"onset\": \"Seconds / 2-5 min / 5-15 min\",\n+            \"peak\": \"15-45 min\",\n-            \"after_effects\": \"1-3 h residual stimulation / fatigue (‘comedown’)\"\n+            \"after_effects\": \"Residual sedation & lethargy 2-6 h; possible next-day fatigue\"\n-          \"route\": \"rectal\",\n+          \"route\": \"intravenous\",\n-            \"rectal\"\n+            \"intravenous\"\n-            \"total_duration\": \"3-6 h\",\n-            \"peak\": \"1-2.5 h\",\n+            \"total_duration\": \"1.5 - 4 h (route-dependent)\",\n+            \"onset\": \"Seconds / 2-5 min / 5-15 min\",\n+            \"peak\": \"15-45 min\",\n-            \"after_effects\": \"1-3 h residual stimulation / fatigue (‘comedown’)\"\n+            \"after_effects\": \"Residual sedation & lethargy 2-6 h; possible next-day fatigue\"\n-    \"addiction_potential\": \"Moderate to high – like other monoamine-releasing cathinones, repeated redosing is common and binge patterns can develop. Psychological dependence and compulsive use have been reported anecdotally.\",\n+    \"addiction_potential\": \"Very high – comparable to other fentanyl analogues. Rapid tolerance, strong psychological reinforcement and severe physical dependence are reported in case studies.\",\n-        \"MAOIs\",\n+        \"Alcohol\",\n+        \"Benzodiazepines\",\n+        \"Barbiturates\",\n+        \"GHB/GBL\",\n+        \"Gabapentinoids\",\n+        \"Other opioids\",\n+        \"DXM\",\n+        \"Ketamine\",\n-        \"2C-T-x\",\n-        \"5-MeO-x tryptamines\",\n-        \"Cocaine\",\n-        \"Amphetamines\",\n-        \"Other cathinones (MMC class)\"\n+        \"MAOIs (risk of serotonin syndrome & respiratory depression)\"\n-        \"DXM\",\n-        \"DOx\",\n-        \"Ketamine\",\n-        \"GHB/GBL\",\n-        \"Opioids\",\n-        \"NBOMe series\"\n+        \"Sympathomimetic cathinones (\\\"MMC class\\\")\",\n+        \"Stimulant pyrrolidines (\\\"PVP class\\\")\",\n+        \"Poppers (severe hypotension)\"\n-        \"Alcohol\",\n+        \"Amphetamines\",\n-        \"Caffeine\",\n-        \"MDMA\",\n-        \"SSRIs (reduced effect)\",\n-        \"Benzodiazepines (respiratory depression when combined in heavy doses)\"\n+        \"Nitrous oxide\",\n+        \"SSRIs/SNRIs (serotonin, respiratory)\"\n-    \"notes\": \"Very little human data exist – all dosage estimates are extrapolated from closely related cathinones such as pentedrone & pentylone, a handful of Reddit/Bluelight reports, and forensic potency modelling. Users describe a rapid, clean stimulation with mild empathogenic warmth, stronger on dopamine/norepinephrine than serotonin. Significant cardiovascular strain (tachycardia, vasoconstriction) and a harsh comedown have been reported above ~60 mg oral. Because metabolic/toxicological profiles are unknown, start with allergy tests (≤5 mg) and avoid frequent redosing (>3 doses / session). No published human toxicity cases, but animal hepatotoxicity data on structural analogues suggest possible liver stress at high doses. Always employ harm-reduction practices: stay hydrated, keep body-temperature down, do not drive during or after use.\",\n+    \"notes\": \"• Potency of 4Cl-iBF is not precisely established, but in vitro binding (Ki ≈ 25–35 nM) suggests it is weaker than fentanyl yet far more potent than morphine – DO NOT eyeball powder; use a calibrated 0.1 mg (100 µg) scale or volumetric solution.\\n• Numerous post-mortem and seized-sample reports confirm involvement in fatal overdoses; naloxone reverses toxicity but may require repeated dosing because of longer half-life than naloxone.\\n• Strong histamine release and chest-wall rigidity have been described with analogous compounds; administer slowly if IV.\\n• Oral bioavailability is low (<30 %), hence higher sublingual/PO doses than parenteral but still microgram-level.\\n• Always employ test-dose strategy and never use alone – respiratory depression can appear abruptly during or immediately after peak.\\n• Fentanyl testing strips are unlikely to detect 4Cl-iBF reliably.\",\n-      \"Euphoric stimulation\",\n-      \"Enhanced sociability\",\n-      \"Increased motivation\",\n-      \"Mild tactile enhancement\",\n-      \"Anxiety at higher doses\",\n-      \"Bruxism and muscle tension\",\n-      \"Sweating and vasoconstriction\",\n-      \"Insomnia (especially with late dosing)\",\n-      \"Appetite suppression\",\n-      \"Crash/low mood next day\"\n+      \"Warm euphoria\",\n+      \"Analgesia\",\n+      \"Sedation / \\\"nodding\\\"\",\n+      \"Anxiolysis\",\n+      \"Itching & flushing\",\n+      \"Miosis\",\n+      \"Constipation\",\n+      \"Nausea\",\n+      \"Respiratory depression\",\n+      \"Chest tightness at high doses\",\n+      \"Severe pruritus\",\n+      \"Dizziness / disequilibrium\"\n-      \"full_tolerance\": \"Develops after 2–3 consecutive days of use\",\n-      \"half_tolerance\": \"1–2 weeks\",\n-      \"zero_tolerance\": \"4–8 weeks of abstinence\",\n+      \"full_tolerance\": \"Develops after 3–7 days of daily use\",\n+      \"half_tolerance\": \"1–2 weeks abstinence\",\n+      \"zero_tolerance\": \"3–4 weeks abstinence\",\n-        \"Other substituted cathinones\",\n-        \"Classical stimulants (e.g., amphetamine, cocaine)\"\n+        \"All µ-opioid agonists (morphine, oxycodone, heroin, fentanyl family)\"\n-    \"half_life\": \"Estimated 3–5 h (no human PK data; based on in-vitro microsome study and structural analogues)\",\n+    \"half_life\": \"Elimination t½ estimated 3 – 6 h (based on case-work plasma data; longer in chronic users)\",\n-        \"name\": \"EMCDDA – New psychoactive substances: global update 2021 (first European seizure of 3,4-TMPD)\",\n-        \"reference\": \"https://www.emcdda.europa.eu/system/files/publications/13939/20212930_TD0521602ENN_PDF.pdf\"\n+        \"name\": \"Wikipedia – 4Cl-iBF\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/4Cl-iBF_(p-Chloro-isobutyrylfentanyl)\"\n-        \"name\": \"Adamowicz, P. et al. First identification of 3,4-trimethylenepentedrone in seized material\",\n-        \"reference\": \"https://doi.org/10.1016/j.forsciint.2021.110948\"\n+        \"name\": \"Arillotta D. et al. Novel opioids: systematic web-crawling within the e-psychonauts’ scenario. Front Neurosci (2020)\",\n+        \"reference\": \"https://www.frontiersin.org/articles/10.3389/fnins.2020.00149/full\"\n-        \"name\": \"PubChem – 3,4-Trimethylenepentedrone compound summary\",\n-        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/164416210\"\n+        \"name\": \"Krotulski AJ et al. A regional initiative to characterize novel synthetic opioid exposures in the United States. J Anal Toxicol (2022)\",\n+        \"reference\": \"https://doi.org/10.1093/jat/bkab146\"\n-        \"name\": \"User experience compilation thread – r/researchchemicals (2023)\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/13xwtcn/34_trimethylenepentedrone_megathread/\"\n-      },\n-      {\n-        \"name\": \"Wikipedia: 3,4 Trimethylenepentedrone\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/3,4-Trimethylenepentedrone\"\n+        \"name\": \"Helander A. & Bäckberg M. New synthetic opioids in Sweden — intoxications involving fentanyl analogs 2015-2016. Drug Test Anal (2017)\",\n+        \"reference\": \"https://doi.org/10.1002/dta.2144\"\n-      \"stimulant\",\n+      \"opioid\",\n-      \"habit-forming\"\n+      \"habit-forming\",\n+      \"depressant\"\n\n# 4F-MABP · #569\n\n-  \"id\": 568,\n-  \"title\": \"4Cl-iBF\",\n+  \"id\": 569,\n+  \"title\": \"4F-MABP\",\n-    \"drug_name\": \"4Cl-iBF\",\n-    \"chemical_name\": \"4Cl-iBF\",\n-    \"alternative_name\": \"p-Chloro-isobutyrylfentanyl\",\n-    \"chemical_class\": \"Anilinopiperidines\",\n-    \"mechanism_of_action\": \"μ-Opioid receptor agonist (full)\",\n-    \"psychoactive_class\": \"Opioid (µ-opioid receptor agonist)\",\n+    \"drug_name\": \"4F-MABP\",\n+    \"chemical_name\": \"4F-MABP\",\n+    \"alternative_name\": \"4-fluorobuphedrone\",\n+    \"chemical_class\": \"Cathinones\",\n+    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor\",\n+    \"psychoactive_class\": \"stimulant\",\n-          \"route\": \"insufflated\",\n-          \"units\": \"µg\",\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"10–20 µg\",\n-            \"light\": \"20–40 µg\",\n-            \"common\": \"40–80 µg\",\n-            \"strong\": \"80–150 µg\",\n-            \"heavy\": \">150 µg\"\n+            \"threshold\": \"20 mg\",\n+            \"light\": \"30 – 60 mg\",\n+            \"common\": \"60 – 120 mg\",\n+            \"strong\": \"120 – 180 mg\",\n+            \"heavy\": \"180 mg +​\"\n-          \"route\": \"sublingual\",\n-          \"units\": \"µg\",\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"15–30 µg\",\n-            \"light\": \"30–60 µg\",\n-            \"common\": \"60–120 µg\",\n-            \"strong\": \"120–200 µg\",\n-            \"heavy\": \">200 µg\"\n+            \"threshold\": \"10 mg\",\n+            \"light\": \"15 – 30 mg\",\n+            \"common\": \"30 – 70 mg\",\n+            \"strong\": \"70 – 120 mg\",\n+            \"heavy\": \"120 mg +​\"\n-        },\n-        {\n-          \"route\": \"intravenous\",\n-          \"units\": \"µg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"5–10 µg\",\n-            \"light\": \"10–25 µg\",\n-            \"common\": \"25–50 µg\",\n-            \"strong\": \"50–100 µg\",\n-            \"heavy\": \">100 µg\"\n-          }\n-          \"route\": \"insufflated\",\n+          \"route\": \"oral\",\n-            \"insufflated\"\n+            \"oral\"\n-            \"total_duration\": \"1.5 - 4 h (route-dependent)\",\n-            \"onset\": \"Seconds / 2-5 min / 5-15 min\",\n-            \"peak\": \"15-45 min\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"Residual sedation & lethargy 2-6 h; possible next-day fatigue\"\n+            \"total_duration\": \"3 - 5 h\",\n+            \"onset\": \"15 - 30 min\",\n+            \"peak\": \"1 - 2 h\",\n+            \"offset\": \"1 - 2 h\",\n+            \"after_effects\": \"Residual stimulation / ‘comedown’ 2 - 6 h\"\n-          \"route\": \"sublingual\",\n+          \"route\": \"insufflated\",\n-            \"sublingual\"\n+            \"insufflated\"\n-            \"total_duration\": \"1.5 - 4 h (route-dependent)\",\n-            \"onset\": \"Seconds / 2-5 min / 5-15 min\",\n-            \"peak\": \"15-45 min\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"Residual sedation & lethargy 2-6 h; possible next-day fatigue\"\n+            \"total_duration\": \"2 - 4 h\",\n+            \"onset\": \"2 - 5 min\",\n+            \"peak\": \"0.5 - 1.5 h\",\n+            \"offset\": \"0.5 - 1 h\",\n+            \"after_effects\": \"Residual stimulation / ‘comedown’ 2 - 6 h\"\n-        },\n-        {\n-          \"route\": \"intravenous\",\n-          \"canonical_routes\": [\n-            \"intravenous\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"1.5 - 4 h (route-dependent)\",\n-            \"onset\": \"Seconds / 2-5 min / 5-15 min\",\n-            \"peak\": \"15-45 min\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"Residual sedation & lethargy 2-6 h; possible next-day fatigue\"\n-          }\n-    \"addiction_potential\": \"Very high – comparable to other fentanyl analogues. Rapid tolerance, strong psychological reinforcement and severe physical dependence are reported in case studies.\",\n+    \"addiction_potential\": \"Moderate–high. Like other dopaminergic cathinones it produces strong reinforcement and compulsive redosing; repeated binges have led to dependence in case reports.\",\n-        \"Alcohol\",\n-        \"Benzodiazepines\",\n-        \"Barbiturates\",\n-        \"GHB/GBL\",\n-        \"Gabapentinoids\",\n-        \"Other opioids\",\n-        \"DXM\",\n-        \"Ketamine\",\n-        \"Tramadol\",\n-        \"MAOIs (risk of serotonin syndrome & respiratory depression)\"\n+        \"MAOIs\",\n+        \"other potent stimulants (methamphetamine, cocaine)\",\n+        \"25x-NBOMe series\"\n-        \"Sympathomimetic cathinones (\\\"MMC class\\\")\",\n-        \"Stimulant pyrrolidines (\\\"PVP class\\\")\",\n-        \"Poppers (severe hypotension)\"\n+        \"SSRIs/SNRIs (risk of serotonin syndrome)\",\n+        \"MDMA\",\n+        \"tramadol (seizure risk)\",\n+        \"large amounts of alcohol\"\n-        \"Amphetamines\",\n-        \"Cannabis\",\n-        \"Nitrous oxide\",\n-        \"SSRIs/SNRIs (serotonin, respiratory)\"\n+        \"cannabis\",\n+        \"dissociatives\",\n+        \"caffeine\",\n+        \"bupropion\"\n-    \"notes\": \"• Potency of 4Cl-iBF is not precisely established, but in vitro binding (Ki ≈ 25–35 nM) suggests it is weaker than fentanyl yet far more potent than morphine – DO NOT eyeball powder; use a calibrated 0.1 mg (100 µg) scale or volumetric solution.\\n• Numerous post-mortem and seized-sample reports confirm involvement in fatal overdoses; naloxone reverses toxicity but may require repeated dosing because of longer half-life than naloxone.\\n• Strong histamine release and chest-wall rigidity have been described with analogous compounds; administer slowly if IV.\\n• Oral bioavailability is low (<30 %), hence higher sublingual/PO doses than parenteral but still microgram-level.\\n• Always employ test-dose strategy and never use alone – respiratory depression can appear abruptly during or immediately after peak.\\n• Fentanyl testing strips are unlikely to detect 4Cl-iBF reliably.\",\n+    \"notes\": \"4F-MABP is a little-studied fluorinated analogue of buphedrone first identified on the European NPS market in 2014. Animal data and seizure analyses show it acts as a dopamine and norepinephrine reuptake inhibitor comparable in potency to flephedrone. Human reports are scarce; effects resemble other short-acting cathinones—rapid onset euphoria, strong urge to redose, and an uncomfortable crash. Because no pharmacological or toxicological studies in humans exist, dosing should start low. Users have reported pronounced peripheral vasoconstriction and tachycardia; people with cardiovascular, psychiatric or seizure disorders should avoid use. Always measure doses with a milligram scale, stay hydrated and keep ambient temperature cool.\",\n-      \"Warm euphoria\",\n-      \"Analgesia\",\n-      \"Sedation / \\\"nodding\\\"\",\n-      \"Anxiolysis\",\n-      \"Itching & flushing\",\n-      \"Miosis\",\n-      \"Constipation\",\n-      \"Nausea\",\n-      \"Respiratory depression\",\n-      \"Chest tightness at high doses\",\n-      \"Severe pruritus\",\n-      \"Dizziness / disequilibrium\"\n+      \"Euphoria\",\n+      \"Stimulation\",\n+      \"Talkativeness\",\n+      \"Increased sociability\",\n+      \"Empathy (mild)\",\n+      \"Enhanced music appreciation\",\n+      \"Sexual arousal\",\n+      \"Bruxism/teeth grinding\",\n+      \"Sweating\",\n+      \"Vasoconstriction (cold extremities)\",\n+      \"Anxiety/jitters\",\n+      \"Elevated heart rate & blood pressure\",\n+      \"Insomnia\",\n+      \"Compulsive redosing\",\n+      \"Depressive ‘crash’ / fatigue\"\n-      \"full_tolerance\": \"Develops after 3–7 days of daily use\",\n-      \"half_tolerance\": \"1–2 weeks abstinence\",\n-      \"zero_tolerance\": \"3–4 weeks abstinence\",\n+      \"full_tolerance\": \"Develops after 2–3 consecutive days or a single binge session\",\n+      \"half_tolerance\": \"3–7 days\",\n+      \"zero_tolerance\": \"1–2 weeks\",\n-        \"All µ-opioid agonists (morphine, oxycodone, heroin, fentanyl family)\"\n+        \"other cathinones (mephedrone, flephedrone, buphedrone)\",\n+        \"amphetamine-type stimulants\"\n-    \"half_life\": \"Elimination t½ estimated 3 – 6 h (based on case-work plasma data; longer in chronic users)\",\n+    \"half_life\": \"Estimated 2 – 4 h (no human PK data; inferred from structural analogues)\",\n-        \"name\": \"Wikipedia – 4Cl-iBF\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/4Cl-iBF_(p-Chloro-isobutyrylfentanyl)\"\n+        \"name\": \"4F-MABP (4-fluorobuphedrone) – Wikipedia\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/4F-MABP_(4-fluorobuphedrone)\"\n-        \"name\": \"Arillotta D. et al. Novel opioids: systematic web-crawling within the e-psychonauts’ scenario. Front Neurosci (2020)\",\n-        \"reference\": \"https://www.frontiersin.org/articles/10.3389/fnins.2020.00149/full\"\n+        \"name\": \"EMCDDA–Europol 2015 Annual Report on new psychoactive substances\",\n+        \"reference\": \"https://www.emcdda.europa.eu/publications/implementation-reports/2015_en\"\n-        \"name\": \"Krotulski AJ et al. A regional initiative to characterize novel synthetic opioid exposures in the United States. J Anal Toxicol (2022)\",\n-        \"reference\": \"https://doi.org/10.1093/jat/bkab146\"\n+        \"name\": \"Štefková K et al. ‘Identification of 4-fluorobuphedrone in seized samples by UPLC-HRMS.’ Forensic Sci Int 2020; 308:110177.\",\n+        \"reference\": \"https://doi.org/10.1016/j.forsciint.2020.110177\"\n-        \"name\": \"Helander A. & Bäckberg M. New synthetic opioids in Sweden — intoxications involving fentanyl analogs 2015-2016. Drug Test Anal (2017)\",\n-        \"reference\": \"https://doi.org/10.1002/dta.2144\"\n+        \"name\": \"Páleníček T et al. ‘Behavioral and neurochemical effects of novel synthetic cathinones in rats.’ Psychopharmacology 2016;233(10):1901-1915.\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/26820778/\"\n-      \"opioid\",\n-      \"research-chemical\",\n-      \"habit-forming\",\n-      \"depressant\"\n+      \"stimulant\",\n+      \"research-chemical\"\n\n# 4F-MDMB-BINACA · #570\n\n-  \"id\": 569,\n-  \"title\": \"4F-MABP\",\n+  \"id\": 570,\n+  \"title\": \"4F-MDMB-BINACA\",\n-    \"drug_name\": \"4F-MABP\",\n-    \"chemical_name\": \"4F-MABP\",\n-    \"alternative_name\": \"4-fluorobuphedrone\",\n-    \"chemical_class\": \"Cathinones\",\n-    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor\",\n-    \"psychoactive_class\": \"stimulant\",\n+    \"drug_name\": \"4F-MDMB-BINACA\",\n+    \"chemical_name\": \"4F-MDMB-BINACA\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Synthetic cannabinoids\",\n+    \"mechanism_of_action\": \"CB1 and CB2 receptor full agonist\",\n+    \"psychoactive_class\": \"cannabinoid; hallucinogen\",\n-          \"route\": \"oral\",\n-          \"units\": \"mg\",\n+          \"route\": \"smoked\",\n+          \"units\": \"mg (weighed) or µg (weighed)\",\n-            \"threshold\": \"20 mg\",\n-            \"light\": \"30 – 60 mg\",\n-            \"common\": \"60 – 120 mg\",\n-            \"strong\": \"120 – 180 mg\",\n-            \"heavy\": \"180 mg +​\"\n+            \"threshold\": \"<0.1 mg (≈100 µg)\",\n+            \"light\": \"0.1 – 0.3 mg\",\n+            \"common\": \"0.3 – 0.8 mg\",\n+            \"strong\": \"0.8 – 1.5 mg\",\n+            \"heavy\": \"≥1.5 mg\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"oral\",\n-            \"threshold\": \"10 mg\",\n-            \"light\": \"15 – 30 mg\",\n-            \"common\": \"30 – 70 mg\",\n-            \"strong\": \"70 – 120 mg\",\n-            \"heavy\": \"120 mg +​\"\n+            \"threshold\": \"0.05 mg\",\n+            \"light\": \"0.05 – 0.15 mg\",\n+            \"common\": \"0.15 – 0.4 mg\",\n+            \"strong\": \"0.4 – 0.8 mg\",\n+            \"heavy\": \"≥0.8 mg\"\n-          \"route\": \"oral\",\n+          \"route\": \"smoked\",\n-            \"oral\"\n+            \"smoked\"\n-            \"total_duration\": \"3 - 5 h\",\n-            \"onset\": \"15 - 30 min\",\n-            \"peak\": \"1 - 2 h\",\n-            \"offset\": \"1 - 2 h\",\n-            \"after_effects\": \"Residual stimulation / ‘comedown’ 2 - 6 h\"\n+            \"total_duration\": \"≈ 1 - 2 h ( 2 - 4 h)\",\n+            \"onset\": \"15-60 sec ( 15-40 min)\",\n+            \"peak\": \"5 - 20 min ( 45-90 min)\",\n+            \"offset\": \"30-60 min ( 1-2 h)\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"oral\",\n-            \"insufflated\"\n+            \"oral\"\n-            \"total_duration\": \"2 - 4 h\",\n-            \"onset\": \"2 - 5 min\",\n-            \"peak\": \"0.5 - 1.5 h\",\n-            \"offset\": \"0.5 - 1 h\",\n-            \"after_effects\": \"Residual stimulation / ‘comedown’ 2 - 6 h\"\n+            \"total_duration\": \"≈ 1 - 2 h ( 2 - 4 h)\",\n+            \"onset\": \"15-60 sec ( 15-40 min)\",\n+            \"peak\": \"5 - 20 min ( 45-90 min)\",\n+            \"offset\": \"30-60 min ( 1-2 h)\",\n+            \"after_effects\": \"Residual lethargy / anxiety 1-3 h\"\n-    \"addiction_potential\": \"Moderate–high. Like other dopaminergic cathinones it produces strong reinforcement and compulsive redosing; repeated binges have led to dependence in case reports.\",\n+    \"addiction_potential\": \"High. Daily or binge use commonly results in compulsive redosing, marked withdrawal (insomnia, sweats, irritability, nausea) and rapid tolerance. Dependence syndromes comparable to or worse than high-potency commercial ‘spice’ blends are well documented.\",\n+        \"Other synthetic cannabinoids\",\n-        \"other potent stimulants (methamphetamine, cocaine)\",\n-        \"25x-NBOMe series\"\n+        \"Strong stimulants (cocaine, methamphetamine)\",\n+        \"β-agonist inhalers\"\n-        \"SSRIs/SNRIs (risk of serotonin syndrome)\",\n-        \"MDMA\",\n-        \"tramadol (seizure risk)\",\n-        \"large amounts of alcohol\"\n+        \"Gabapentinoids\",\n+        \"Poppers (amyl nitrite)\",\n+        \"Strong opioids\"\n-        \"cannabis\",\n-        \"dissociatives\",\n-        \"caffeine\",\n-        \"bupropion\"\n+        \"Alcohol\",\n+        \"Benzodiazepines\",\n+        \"Dissociatives (ketamine, DXM)\",\n+        \"Classical psychedelics (LSD, psilocybin)\",\n+        \"SSRIs\"\n-    \"notes\": \"4F-MABP is a little-studied fluorinated analogue of buphedrone first identified on the European NPS market in 2014. Animal data and seizure analyses show it acts as a dopamine and norepinephrine reuptake inhibitor comparable in potency to flephedrone. Human reports are scarce; effects resemble other short-acting cathinones—rapid onset euphoria, strong urge to redose, and an uncomfortable crash. Because no pharmacological or toxicological studies in humans exist, dosing should start low. Users have reported pronounced peripheral vasoconstriction and tachycardia; people with cardiovascular, psychiatric or seizure disorders should avoid use. Always measure doses with a milligram scale, stay hydrated and keep ambient temperature cool.\",\n+    \"notes\": \"4F-MDMB-BINACA is one of the most potent synthetic cannabinoids currently encountered (EC50 ≈ 6 nM at CB1). A single match-head sized crystal can exceed a strong dose; always use a milligram-scale and dissolve for volumetric dosing if possible. Do NOT eye-ball. Numerous severe poisonings and several fatalities have been linked to amounts <2 mg, particularly when sprayed unevenly onto herbal material or mixed into counterfeit cannabis flower. Acute toxicity can involve severe tachycardia, hypertension or hypotension, seizures, loss of consciousness, acute psychosis and respiratory depression. Because the parent drug and active metabolites are lipophilic, impairment can outlast the subjective high. Emergency management is supportive (benzodiazepines for agitation/seizure control, anti-emetics, IV fluids, cardiac monitoring). Naloxone is NOT effective. Users should have company, start with tiny allergy test puffs and wait at least 15 min before redosing.\",\n-      \"Euphoria\",\n-      \"Stimulation\",\n-      \"Talkativeness\",\n-      \"Increased sociability\",\n-      \"Empathy (mild)\",\n-      \"Enhanced music appreciation\",\n-      \"Sexual arousal\",\n-      \"Bruxism/teeth grinding\",\n-      \"Sweating\",\n-      \"Vasoconstriction (cold extremities)\",\n-      \"Anxiety/jitters\",\n-      \"Elevated heart rate & blood pressure\",\n-      \"Insomnia\",\n-      \"Compulsive redosing\",\n-      \"Depressive ‘crash’ / fatigue\"\n+      \"Rapid, intense cannabis-like intoxication\",\n+      \"Euphoria or dysphoria switching rapidly\",\n+      \"Closed-eye imagery\",\n+      \"Time distortion\",\n+      \"Short-term memory suppression\",\n+      \"Body heaviness\",\n+      \"Motor incoordination\",\n+      \"Anxiety/panic\",\n+      \"Paranoia\",\n+      \"Profound dry mouth\",\n+      \"Visual snow/blurred vision\",\n+      \"Auditory distortions\",\n+      \"Tachycardia & palpitations\",\n+      \"Nausea/vomiting\",\n+      \"Sweating & chills\",\n+      \"Afterglow fatigue or headache\"\n-      \"full_tolerance\": \"Develops after 2–3 consecutive days or a single binge session\",\n-      \"half_tolerance\": \"3–7 days\",\n-      \"zero_tolerance\": \"1–2 weeks\",\n+      \"full_tolerance\": \"Develops within 2-5 consecutive days of heavy use\",\n+      \"half_tolerance\": \"1-2 weeks\",\n+      \"zero_tolerance\": \"4-6 weeks of abstinence\",\n-        \"other cathinones (mephedrone, flephedrone, buphedrone)\",\n-        \"amphetamine-type stimulants\"\n+        \"Cannabis (THC)\",\n+        \"Other synthetic cannabinoids\"\n-    \"half_life\": \"Estimated 2 – 4 h (no human PK data; inferred from structural analogues)\",\n+    \"half_life\": \"Estimated 1 – 2 h for parent compound; psychoactive metabolites may extend effective half-life to 3 – 6 h (human data limited).\",\n-        \"name\": \"4F-MABP (4-fluorobuphedrone) – Wikipedia\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/4F-MABP_(4-fluorobuphedrone)\"\n+        \"name\": \"4F-MDMB-BINACA – Drug profile\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/4F-MDMB-BINACA\"\n-        \"name\": \"EMCDDA–Europol 2015 Annual Report on new psychoactive substances\",\n-        \"reference\": \"https://www.emcdda.europa.eu/publications/implementation-reports/2015_en\"\n+        \"name\": \"EMCDDA Europol Early-Warning Report on 4F-MDMB-BINACA (2018)\",\n+        \"reference\": \"https://www.emcdda.europa.eu/system/files/publications/10238/20181213_TDAS18001ENN_PDF.pdf\"\n-        \"name\": \"Štefková K et al. ‘Identification of 4-fluorobuphedrone in seized samples by UPLC-HRMS.’ Forensic Sci Int 2020; 308:110177.\",\n-        \"reference\": \"https://doi.org/10.1016/j.forsciint.2020.110177\"\n+        \"name\": \"Fatla S et al. Fatal intoxication with synthetic cannabinoids 5F-MDMB-PICA and 4F-MDMB-BINACA. Forensic Sci Int. 2022;336:111368.\",\n+        \"reference\": \"https://doi.org/10.1016/j.forsciint.2022.111368\"\n-        \"name\": \"Páleníček T et al. ‘Behavioral and neurochemical effects of novel synthetic cathinones in rats.’ Psychopharmacology 2016;233(10):1901-1915.\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/26820778/\"\n+        \"name\": \"DrugsData sample #7708: 4F-MDMB-BINACA in counterfeit cannabis bud (2019)\",\n+        \"reference\": \"https://www.drugsdata.org/view.php?id=7708\"\n+      },\n+      {\n+        \"name\": \"Austrian CheckIt! alert – 4F-MDMB-BINACA found in Innsbruck herbal sample (2019)\",\n+        \"reference\": \"https://checkit.wien/wp-content/uploads/2019/08/4F-MDMB-BINACA_warning.pdf\"\n-      \"stimulant\",\n-      \"research-chemical\"\n+      \"cannabinoid\",\n+      \"research-chemical\",\n+      \"habit-forming\"\n\n# Benzedrone · #575\n\n-  \"id\": 570,\n-  \"title\": \"4F-MDMB-BINACA\",\n+  \"id\": 575,\n+  \"title\": \"Benzedrone\",\n-    \"drug_name\": \"4F-MDMB-BINACA\",\n-    \"chemical_name\": \"4F-MDMB-BINACA\",\n-    \"alternative_name\": \"\",\n-    \"chemical_class\": \"Synthetic cannabinoids\",\n-    \"mechanism_of_action\": \"CB1 and CB2 receptor full agonist\",\n-    \"psychoactive_class\": \"cannabinoid; hallucinogen\",\n+    \"drug_name\": \"Benzedrone\",\n+    \"chemical_name\": \"4-MBC\",\n+    \"alternative_name\": \"4-MBC\",\n+    \"chemical_class\": \"Cathinones\",\n+    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor\",\n+    \"psychoactive_class\": \"stimulant; mild empathogen\",\n-          \"route\": \"smoked\",\n-          \"units\": \"mg (weighed) or µg (weighed)\",\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"<0.1 mg (≈100 µg)\",\n-            \"light\": \"0.1 – 0.3 mg\",\n-            \"common\": \"0.3 – 0.8 mg\",\n-            \"strong\": \"0.8 – 1.5 mg\",\n-            \"heavy\": \"≥1.5 mg\"\n+            \"threshold\": \"30 – 50 mg\",\n+            \"light\": \"100 – 200 mg\",\n+            \"common\": \"200 – 350 mg\",\n+            \"strong\": \"350 – 500 mg\",\n+            \"heavy\": \"500 mg + (not advised)\"\n-          \"route\": \"oral\",\n+          \"route\": \"insufflated\",\n-            \"threshold\": \"0.05 mg\",\n-            \"light\": \"0.05 – 0.15 mg\",\n-            \"common\": \"0.15 – 0.4 mg\",\n-            \"strong\": \"0.4 – 0.8 mg\",\n-            \"heavy\": \"≥0.8 mg\"\n+            \"threshold\": \"10 – 20 mg\",\n+            \"light\": \"25 – 60 mg\",\n+            \"common\": \"60 – 120 mg\",\n+            \"strong\": \"120 – 200 mg\",\n+            \"heavy\": \"200 mg + (not advised)\"\n-          \"route\": \"smoked\",\n+          \"route\": \"oral\",\n-            \"smoked\"\n+            \"oral\"\n-            \"total_duration\": \"≈ 1 - 2 h ( 2 - 4 h)\",\n-            \"onset\": \"15-60 sec ( 15-40 min)\",\n-            \"peak\": \"5 - 20 min ( 45-90 min)\",\n-            \"offset\": \"30-60 min ( 1-2 h)\"\n+            \"total_duration\": \"4 - 6 h\",\n+            \"onset\": \"30 - 60 min\",\n+            \"peak\": \"1.5 - 2.5 h\",\n+            \"offset\": \"1 - 2 h gradual comedown\",\n+            \"after_effects\": \"2 - 6 h residual stimulation / insomnia\"\n-          \"route\": \"oral\",\n+          \"route\": \"insufflated\",\n-            \"oral\"\n+            \"insufflated\"\n-            \"total_duration\": \"≈ 1 - 2 h ( 2 - 4 h)\",\n-            \"onset\": \"15-60 sec ( 15-40 min)\",\n-            \"peak\": \"5 - 20 min ( 45-90 min)\",\n-            \"offset\": \"30-60 min ( 1-2 h)\",\n-            \"after_effects\": \"Residual lethargy / anxiety 1-3 h\"\n+            \"total_duration\": \"2 - 4 h\",\n+            \"onset\": \"5 - 10 min\",\n+            \"peak\": \"1.5 - 2.5 h\",\n+            \"offset\": \"1 - 2 h gradual comedown\",\n+            \"after_effects\": \"2 - 6 h residual stimulation / insomnia\"\n-    \"addiction_potential\": \"High. Daily or binge use commonly results in compulsive redosing, marked withdrawal (insomnia, sweats, irritability, nausea) and rapid tolerance. Dependence syndromes comparable to or worse than high-potency commercial ‘spice’ blends are well documented.\",\n+    \"addiction_potential\": \"Moderate. Reports of compulsive redosing similar to other short-acting cathinones, but overall craving described as lower than mephedrone. Psychological dependence possible; physical withdrawal is mild (fatigue, low mood).\",\n-        \"Other synthetic cannabinoids\",\n-        \"Strong stimulants (cocaine, methamphetamine)\",\n-        \"β-agonist inhalers\"\n+        \"MDMA\",\n+        \"MDAI\",\n+        \"MAO-B inhibitors\",\n+        \"4-FA\"\n-        \"Gabapentinoids\",\n-        \"Poppers (amyl nitrite)\",\n-        \"Strong opioids\"\n+        \"other stimulants (amphetamine, cocaine, methylphenidate)\",\n+        \"synthetic cathinones\",\n+        \"bupropion\"\n-        \"Alcohol\",\n-        \"Benzodiazepines\",\n-        \"Dissociatives (ketamine, DXM)\",\n-        \"Classical psychedelics (LSD, psilocybin)\",\n-        \"SSRIs\"\n+        \"SSRIs/SNRIs (serotonin load)\",\n+        \"alcohol (dehydration, cardiotoxicity)\",\n+        \"caffeine (synergistic tachycardia)\",\n+        \"beta-keto hallucinogens (e.g., 2-CB-Fly)\"\n-    \"notes\": \"4F-MDMB-BINACA is one of the most potent synthetic cannabinoids currently encountered (EC50 ≈ 6 nM at CB1). A single match-head sized crystal can exceed a strong dose; always use a milligram-scale and dissolve for volumetric dosing if possible. Do NOT eye-ball. Numerous severe poisonings and several fatalities have been linked to amounts <2 mg, particularly when sprayed unevenly onto herbal material or mixed into counterfeit cannabis flower. Acute toxicity can involve severe tachycardia, hypertension or hypotension, seizures, loss of consciousness, acute psychosis and respiratory depression. Because the parent drug and active metabolites are lipophilic, impairment can outlast the subjective high. Emergency management is supportive (benzodiazepines for agitation/seizure control, anti-emetics, IV fluids, cardiac monitoring). Naloxone is NOT effective. Users should have company, start with tiny allergy test puffs and wait at least 15 min before redosing.\",\n+    \"notes\": \"• Limited human data – treat as an experimental drug.\\n• Appears to act as a pro-drug to mephedrone in vivo via N-debenzylation, but with markedly lower potency and euphoria.\\n• Prominent peripheral stimulation (tachycardia, vasoconstriction) with comparatively subtle empathogenic qualities.\\n• Nasal administration burns sharply and may cause epistaxis; oral ‘bombing’ or capsule is preferred for harm reduction.\\n• Hydration, electrolyte balance and cooling are important during extended sessions.\\n• Avoid redosing more than once per 3 h; cumulative vasoconstriction and hypertension have been reported at binge doses (>1 g/day).\\n• No controlled toxicology; rodent data suggest hepatotoxic metabolites – consider liver function prudence.\",\n-      \"Rapid, intense cannabis-like intoxication\",\n-      \"Euphoria or dysphoria switching rapidly\",\n-      \"Closed-eye imagery\",\n-      \"Time distortion\",\n-      \"Short-term memory suppression\",\n-      \"Body heaviness\",\n-      \"Motor incoordination\",\n-      \"Anxiety/panic\",\n-      \"Paranoia\",\n-      \"Profound dry mouth\",\n-      \"Visual snow/blurred vision\",\n-      \"Auditory distortions\",\n-      \"Tachycardia & palpitations\",\n-      \"Nausea/vomiting\",\n-      \"Sweating & chills\",\n-      \"Afterglow fatigue or headache\"\n+      \"alertness\",\n+      \"physical energy\",\n+      \"mild euphoria\",\n+      \"increased sociability/talkativeness\",\n+      \"focus/drive enhancement\",\n+      \"appetite suppression\",\n+      \"bruxism/jaw tension\",\n+      \"vasoconstriction (cold extremities)\",\n+      \"mild visual brightness enhancement\",\n+      \"anxiety/jitteriness at high doses\",\n+      \"insomnia during comedown\"\n-      \"full_tolerance\": \"Develops within 2-5 consecutive days of heavy use\",\n-      \"half_tolerance\": \"1-2 weeks\",\n-      \"zero_tolerance\": \"4-6 weeks of abstinence\",\n+      \"full_tolerance\": \"after 2–3 consecutive days of use\",\n+      \"half_tolerance\": \"≈ 3–7 days\",\n+      \"zero_tolerance\": \"≈ 2–3 weeks\",\n-        \"Cannabis (THC)\",\n-        \"Other synthetic cannabinoids\"\n+        \"other substituted cathinones\",\n+        \"amphetamine-type stimulants\"\n-    \"half_life\": \"Estimated 1 – 2 h for parent compound; psychoactive metabolites may extend effective half-life to 3 – 6 h (human data limited).\",\n+    \"half_life\": \"Estimated 3 – 5 h (no formal pharmacokinetic studies)\",\n-        \"name\": \"4F-MDMB-BINACA – Drug profile\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/4F-MDMB-BINACA\"\n+        \"name\": \"Wikipedia – 4-MBC (Benzedrone)\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/4-MBC_(Benzedrone)\"\n-        \"name\": \"EMCDDA Europol Early-Warning Report on 4F-MDMB-BINACA (2018)\",\n-        \"reference\": \"https://www.emcdda.europa.eu/system/files/publications/10238/20181213_TDAS18001ENN_PDF.pdf\"\n+        \"name\": \"Bluelight thread: Benzedrone (4-MBC) Personal Experiences\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/benzedrone-4-mbc-personal-experiences.629950/\"\n-        \"name\": \"Fatla S et al. Fatal intoxication with synthetic cannabinoids 5F-MDMB-PICA and 4F-MDMB-BINACA. Forensic Sci Int. 2022;336:111368.\",\n-        \"reference\": \"https://doi.org/10.1016/j.forsciint.2022.111368\"\n+        \"name\": \"Reddit r/Drugs – Any 1st-hand info on Benzedrone?\",\n+        \"reference\": \"https://www.reddit.com/r/Drugs/comments/ved4x/any_1sthand_info_on_benzedrone_4mbc/\"\n-        \"name\": \"DrugsData sample #7708: 4F-MDMB-BINACA in counterfeit cannabis bud (2019)\",\n-        \"reference\": \"https://www.drugsdata.org/view.php?id=7708\"\n-      },\n-      {\n-        \"name\": \"Austrian CheckIt! alert – 4F-MDMB-BINACA found in Innsbruck herbal sample (2019)\",\n-        \"reference\": \"https://checkit.wien/wp-content/uploads/2019/08/4F-MDMB-BINACA_warning.pdf\"\n+        \"name\": \"Westphal F. et al., \\\"Characterization of the designer drug 4-methylbenzylcathinone (benzedrone)\\\", Forensic Science International, 2012\",\n+        \"reference\": \"https://doi.org/10.1016/j.forsciint.2011.10.021\"\n-      \"cannabinoid\",\n-      \"research-chemical\",\n-      \"habit-forming\"\n+      \"stimulant\",\n+      \"research-chemical\"\n\n# ADB-INACA · #572\n\n-  \"id\": 575,\n-  \"title\": \"Benzedrone\",\n+  \"id\": 572,\n+  \"title\": \"ADB-INACA\",\n-    \"drug_name\": \"Benzedrone\",\n-    \"chemical_name\": \"4-MBC\",\n-    \"alternative_name\": \"4-MBC\",\n-    \"chemical_class\": \"Cathinones\",\n-    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor\",\n-    \"psychoactive_class\": \"stimulant; mild empathogen\",\n+    \"drug_name\": \"ADB-INACA\",\n+    \"chemical_name\": \"ADB-INACA\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Synthetic cannabinoids\",\n+    \"mechanism_of_action\": \"CB1 and CB2 receptor full agonist\",\n+    \"psychoactive_class\": \"cannabinoid; hallucinogen\",\n-            \"threshold\": \"30 – 50 mg\",\n-            \"light\": \"100 – 200 mg\",\n-            \"common\": \"200 – 350 mg\",\n-            \"strong\": \"350 – 500 mg\",\n-            \"heavy\": \"500 mg + (not advised)\"\n+            \"threshold\": \"1 mg\",\n+            \"light\": \"1-3 mg\",\n+            \"common\": \"3-6 mg\",\n+            \"strong\": \"6-10 mg\",\n+            \"heavy\": \">10 mg\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"smoked\",\n-            \"threshold\": \"10 – 20 mg\",\n-            \"light\": \"25 – 60 mg\",\n-            \"common\": \"60 – 120 mg\",\n-            \"strong\": \"120 – 200 mg\",\n-            \"heavy\": \"200 mg + (not advised)\"\n+            \"threshold\": \"0.5 mg\",\n+            \"light\": \"0.5-1 mg\",\n+            \"common\": \"1-3 mg\",\n+            \"strong\": \"3-5 mg\",\n+            \"heavy\": \">5 mg\"\n-            \"total_duration\": \"4 - 6 h\",\n-            \"onset\": \"30 - 60 min\",\n-            \"peak\": \"1.5 - 2.5 h\",\n-            \"offset\": \"1 - 2 h gradual comedown\",\n-            \"after_effects\": \"2 - 6 h residual stimulation / insomnia\"\n+            \"total_duration\": \"2-6 hours\",\n+            \"onset\": \"Minutes\",\n+            \"peak\": \"30-60 minutes\",\n+            \"offset\": \"Varies\",\n+            \"after_effects\": \"1-3 hours\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"smoked\",\n-            \"insufflated\"\n+            \"smoked\"\n-            \"total_duration\": \"2 - 4 h\",\n-            \"onset\": \"5 - 10 min\",\n-            \"peak\": \"1.5 - 2.5 h\",\n-            \"offset\": \"1 - 2 h gradual comedown\",\n-            \"after_effects\": \"2 - 6 h residual stimulation / insomnia\"\n+            \"total_duration\": \"2-6 hours\",\n+            \"onset\": \"Minutes\",\n+            \"peak\": \"30-60 minutes\",\n+            \"offset\": \"Varies\",\n+            \"after_effects\": \"1-3 hours\"\n-    \"addiction_potential\": \"Moderate. Reports of compulsive redosing similar to other short-acting cathinones, but overall craving described as lower than mephedrone. Psychological dependence possible; physical withdrawal is mild (fatigue, low mood).\",\n+    \"addiction_potential\": \"High potential for dependency due to its action as a potent cannabinoid receptor agonist.\",\n-        \"MAOIs\",\n-        \"MDMA\",\n-        \"MDAI\",\n-        \"MAO-B inhibitors\",\n-        \"4-FA\"\n+        \"Alcohol\",\n+        \"Opioids\",\n+        \"Other synthetic cannabinoids in the same session\",\n+        \"Unknown herbal blends or sprayed papers containing mixed SCRAs\",\n+        \"Tramadol\"\n-        \"other stimulants (amphetamine, cocaine, methylphenidate)\",\n-        \"synthetic cathinones\",\n-        \"bupropion\"\n+        \"Benzodiazepines\",\n+        \"Sedating antihistamines (e.g., diphenhydramine, doxylamine)\",\n+        \"Gabapentinoids at high doses\",\n+        \"Kratom at high doses\"\n-        \"SSRIs/SNRIs (serotonin load)\",\n-        \"alcohol (dehydration, cardiotoxicity)\",\n-        \"caffeine (synergistic tachycardia)\",\n-        \"beta-keto hallucinogens (e.g., 2-CB-Fly)\"\n+        \"Stimulants\",\n+        \"CYP3A4/CYP2C19 inhibitors or inducers\",\n+        \"Antipsychotics and other QT-prolonging drugs\",\n+        \"THC or high-potency cannabis concentrates\"\n-    \"notes\": \"• Limited human data – treat as an experimental drug.\\n• Appears to act as a pro-drug to mephedrone in vivo via N-debenzylation, but with markedly lower potency and euphoria.\\n• Prominent peripheral stimulation (tachycardia, vasoconstriction) with comparatively subtle empathogenic qualities.\\n• Nasal administration burns sharply and may cause epistaxis; oral ‘bombing’ or capsule is preferred for harm reduction.\\n• Hydration, electrolyte balance and cooling are important during extended sessions.\\n• Avoid redosing more than once per 3 h; cumulative vasoconstriction and hypertension have been reported at binge doses (>1 g/day).\\n• No controlled toxicology; rodent data suggest hepatotoxic metabolites – consider liver function prudence.\",\n+    \"notes\": \"ADB-INACA is an indazole-3-carboxamide frequently detected as a precursor or minor component alongside potent tailed SCRAs (e.g., ADB-BUTINACA, MDMB-4en-PINACA) in seized products; real-world harms often reflect co-formulation rather than pure ADB-INACA. Treat unknown powders and sprayed plant matter as if they contain a nanomolar CB1 agonist; avoid eyeballing and use a milligram scale or volumetric solutions, start at sub-milligram smoked or low-milligram oral doses, and wait through the full peak before redosing. Plant matter and papers can have uneven application (“hot spots”), so thorough homogenization and very dilute solutions reduce per-puff variability and overdose risk. Acute risks for the SCRA class include tachycardia, anxiety or panic, severe agitation, nausea/vomiting, confusion, transient psychosis, seizures, and rare hyperthermia, rhabdomyolysis, renal injury, and serious cardiotoxicity; risk increases with alcohol or polydrug use. If serious agitation occurs, emergency departments typically manage with benzodiazepines; this clinical use is distinct from recreational co-use, which adds respiratory and injury risks. Color reagents cannot reliably identify specific SCRAs; only GC/MS or LC/MS can confirm identity and distinguish precursors from active analogs. Legal exposure may arise via analogue laws even if ADB-INACA itself is unscheduled; several forensic programs monitor it due to its role in clandestine synthesis pipelines. Plan conservative set and setting, avoid driving for the whole active window plus after-effects, hydrate, and set firm session caps to prevent compulsive redosing.\",\n-      \"alertness\",\n-      \"physical energy\",\n-      \"mild euphoria\",\n-      \"increased sociability/talkativeness\",\n-      \"focus/drive enhancement\",\n-      \"appetite suppression\",\n-      \"bruxism/jaw tension\",\n-      \"vasoconstriction (cold extremities)\",\n-      \"mild visual brightness enhancement\",\n-      \"anxiety/jitteriness at high doses\",\n-      \"insomnia during comedown\"\n+      \"Euphoria\",\n+      \"Altered perception\",\n+      \"Anxiety\",\n+      \"Paranoia\",\n+      \"Sedation\",\n+      \"Hallucinations\",\n+      \"Time distortion\",\n+      \"Dry mouth\",\n+      \"Tachycardia awareness\",\n+      \"Nausea\",\n+      \"Confusion or derealization\",\n+      \"Head pressure\"\n-      \"full_tolerance\": \"after 2–3 consecutive days of use\",\n-      \"half_tolerance\": \"≈ 3–7 days\",\n-      \"zero_tolerance\": \"≈ 2–3 weeks\",\n+      \"full_tolerance\": \"Develops rapidly with repeated use\",\n+      \"half_tolerance\": \"1-2 weeks\",\n+      \"zero_tolerance\": \"4 weeks\",\n-        \"other substituted cathinones\",\n-        \"amphetamine-type stimulants\"\n+        \"Cannabinoids\",\n+        \"Synthetic cannabinoids\"\n-    \"half_life\": \"Estimated 3 – 5 h (no formal pharmacokinetic studies)\",\n+    \"half_life\": \"Unknown\",\n-        \"name\": \"Wikipedia – 4-MBC (Benzedrone)\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/4-MBC_(Benzedrone)\"\n+        \"name\": \"PubChem Compound Summary for CID 155928944, ADB-INACA\",\n+        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/ADB-INACA\"\n-        \"name\": \"Bluelight thread: Benzedrone (4-MBC) Personal Experiences\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/benzedrone-4-mbc-personal-experiences.629950/\"\n+        \"name\": \"CFSRE NPS Discovery Monograph: ADB-INACA (2022-12-14)\",\n+        \"reference\": \"https://www.cfsre.org/nps-discovery/monographs/adb-inaca\"\n-        \"name\": \"Reddit r/Drugs – Any 1st-hand info on Benzedrone?\",\n-        \"reference\": \"https://www.reddit.com/r/Drugs/comments/ved4x/any_1sthand_info_on_benzedrone_4mbc/\"\n+        \"name\": \"CFSRE ADB-INACA Analytical Report (PDF)\",\n+        \"reference\": \"https://www.cfsre.org/images/monographs/ADB-INACA-121422-NMSLabs-Report.pdf\"\n-        \"name\": \"Westphal F. et al., \\\"Characterization of the designer drug 4-methylbenzylcathinone (benzedrone)\\\", Forensic Science International, 2012\",\n-        \"reference\": \"https://doi.org/10.1016/j.forsciint.2011.10.021\"\n+        \"name\": \"Cayman Chemical – ADB-INACA analytical standard\",\n+        \"reference\": \"https://www.caymanchem.com/product/37729/adb-inaca\"\n+      },\n+      {\n+        \"name\": \"Inxight/GSRS – ADB-INACA S-isomer (UNII JSR4Z7QBW9)\",\n+        \"reference\": \"https://drugs.ncats.io/substance/JSR4Z7QBW9\"\n+      },\n+      {\n+        \"name\": \"Systematic review – Toxicity of synthetic cannabinoids (2023)\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC10377539/\"\n-      \"stimulant\",\n-      \"research-chemical\"\n+      \"cannabinoid\",\n+      \"habit-forming\"\n\n# 4-CBC · #573\n\n-  \"id\": 572,\n-  \"title\": \"ADB-INACA\",\n+  \"id\": 573,\n+  \"title\": \"4-CBC\",\n-    \"drug_name\": \"ADB-INACA\",\n-    \"chemical_name\": \"ADB-INACA\",\n-    \"alternative_name\": \"\",\n-    \"chemical_class\": \"Synthetic cannabinoids\",\n-    \"mechanism_of_action\": \"CB1 and CB2 receptor full agonist\",\n-    \"psychoactive_class\": \"cannabinoid; hallucinogen\",\n+    \"drug_name\": \"4-CBC\",\n+    \"chemical_name\": \"4-Chlorobuphedrone\",\n+    \"alternative_name\": \"4-Chlorobuphedrone\",\n+    \"chemical_class\": \"Cathinones\",\n+    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor\",\n+    \"psychoactive_class\": \"Stimulant; Empathogen; Entactogen\",\n-            \"threshold\": \"1 mg\",\n-            \"light\": \"1-3 mg\",\n-            \"common\": \"3-6 mg\",\n-            \"strong\": \"6-10 mg\",\n-            \"heavy\": \">10 mg\"\n+            \"threshold\": \"15–20\",\n+            \"light\": \"40–70\",\n+            \"common\": \"70–110\",\n+            \"strong\": \"110–140\",\n+            \"heavy\": \"140+\"\n-          \"route\": \"smoked\",\n+          \"route\": \"insufflated\",\n-            \"threshold\": \"0.5 mg\",\n-            \"light\": \"0.5-1 mg\",\n-            \"common\": \"1-3 mg\",\n-            \"strong\": \"3-5 mg\",\n-            \"heavy\": \">5 mg\"\n+            \"threshold\": \"5–10\",\n+            \"light\": \"30–50\",\n+            \"common\": \"50–80\",\n+            \"strong\": \"80–110\",\n+            \"heavy\": \"110+\"\n-            \"total_duration\": \"2-6 hours\",\n-            \"onset\": \"Minutes\",\n-            \"peak\": \"30-60 minutes\",\n-            \"offset\": \"Varies\",\n-            \"after_effects\": \"1-3 hours\"\n+            \"total_duration\": \"2-4 h\",\n+            \"onset\": \"20-60 min\",\n+            \"peak\": \"0.5-1.5 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-8 h residual stimulation / mood-drop\"\n-          \"route\": \"smoked\",\n+          \"route\": \"insufflated\",\n-            \"smoked\"\n+            \"insufflated\"\n-            \"total_duration\": \"2-6 hours\",\n-            \"onset\": \"Minutes\",\n-            \"peak\": \"30-60 minutes\",\n-            \"offset\": \"Varies\",\n-            \"after_effects\": \"1-3 hours\"\n+            \"total_duration\": \"1-3 h\",\n+            \"onset\": \"5-20 min\",\n+            \"peak\": \"0.5-1.5 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-8 h residual stimulation / mood-drop\"\n-    \"addiction_potential\": \"High potential for dependency due to its action as a potent cannabinoid receptor agonist.\",\n+    \"addiction_potential\": \"Moderate–high. Short duration and dopaminergic action promote compulsive redosing; binge patterns and tolerance comparable to mephedrone and 4-CMC.\",\n-        \"Alcohol\",\n-        \"Opioids\",\n-        \"Other synthetic cannabinoids in the same session\",\n-        \"Unknown herbal blends or sprayed papers containing mixed SCRAs\",\n-        \"Tramadol\"\n+        \"MAOIs\",\n+        \"Other potent stimulants (cocaine, methylphenidate, amphetamines, other cathinones)\",\n+        \"High-dose DXM (serotonin & BP spikes)\"\n-        \"Benzodiazepines\",\n-        \"Sedating antihistamines (e.g., diphenhydramine, doxylamine)\",\n-        \"Gabapentinoids at high doses\",\n-        \"Kratom at high doses\"\n+        \"Large amounts of alcohol (↑ cardiotoxicity & dehydration)\",\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Synthetic cannabinoids\"\n-        \"Stimulants\",\n-        \"CYP3A4/CYP2C19 inhibitors or inducers\",\n-        \"Antipsychotics and other QT-prolonging drugs\",\n-        \"THC or high-potency cannabis concentrates\"\n+        \"SSRIs/SNRIs (serotonin load)\",\n+        \"Caffeine (>300 mg)\",\n+        \"Bupropion\",\n+        \"Cannabis (may worsen anxiety)\"\n-    \"notes\": \"ADB-INACA is an indazole-3-carboxamide frequently detected as a precursor or minor component alongside potent tailed SCRAs (e.g., ADB-BUTINACA, MDMB-4en-PINACA) in seized products; real-world harms often reflect co-formulation rather than pure ADB-INACA. Treat unknown powders and sprayed plant matter as if they contain a nanomolar CB1 agonist; avoid eyeballing and use a milligram scale or volumetric solutions, start at sub-milligram smoked or low-milligram oral doses, and wait through the full peak before redosing. Plant matter and papers can have uneven application (“hot spots”), so thorough homogenization and very dilute solutions reduce per-puff variability and overdose risk. Acute risks for the SCRA class include tachycardia, anxiety or panic, severe agitation, nausea/vomiting, confusion, transient psychosis, seizures, and rare hyperthermia, rhabdomyolysis, renal injury, and serious cardiotoxicity; risk increases with alcohol or polydrug use. If serious agitation occurs, emergency departments typically manage with benzodiazepines; this clinical use is distinct from recreational co-use, which adds respiratory and injury risks. Color reagents cannot reliably identify specific SCRAs; only GC/MS or LC/MS can confirm identity and distinguish precursors from active analogs. Legal exposure may arise via analogue laws even if ADB-INACA itself is unscheduled; several forensic programs monitor it due to its role in clandestine synthesis pipelines. Plan conservative set and setting, avoid driving for the whole active window plus after-effects, hydrate, and set firm session caps to prevent compulsive redosing.\",\n+    \"notes\": \"• Pharmacology: In vitro uptake assays show 4-CBC is a monoamine transporter substrate (DA ≈ NE > 5-HT) with EC50 values similar to 4-CMC, indicating strong dopaminergic stimulation and moderate serotonergic release.\\n• Toxicology: Halogenated cathinones produce oxidative stress in cardiomyocytes; rat hepatocyte studies indicate mitochondrial dysfunction at ≥100 µM.\\n• Physiological risks (reported by users & clinicians): tachycardia (120–160 bpm), hypertension, mydriasis, bruxism, thermoregulatory dysregulation, chest tightness. Seizures have been documented in at least two ED admissions in Poland (2019).\\n• Harm-reduction guidelines: 1) Use a 0.001 g (1 mg)-resolution scale; 2) Start with ≤½ common dose to gauge sensitivity; 3) Redose no sooner than every 3 h and limit total session to ≤250 mg; 4) Sip 250 ml water or isotonic drink per hour; 5) Supplement 200–400 mg magnesium to reduce jaw tension; 6) Avoid consecutive-day use—take minimum 2 weeks between sessions.\\n• Drug checking: Reagent tests give bright yellow (Marquis) similar to 4-CMC; confirm identity by GC-MS/HPLC where possible.\",\n-      \"Euphoria\",\n-      \"Altered perception\",\n-      \"Anxiety\",\n-      \"Paranoia\",\n-      \"Sedation\",\n-      \"Hallucinations\",\n-      \"Time distortion\",\n-      \"Dry mouth\",\n-      \"Tachycardia awareness\",\n-      \"Nausea\",\n-      \"Confusion or derealization\",\n-      \"Head pressure\"\n+      \"Rush of euphoria\",\n+      \"Increased sociability & talkativeness\",\n+      \"Moderate entactogenic warmth/empathy (weaker than MDMA)\",\n+      \"Enhanced tactile & musical appreciation\",\n+      \"Mental stimulation / focus\",\n+      \"Increased libido\",\n+      \"Mild peripheral visuals (color saturation, trailing) at high doses\",\n+      \"Jaw clenching, muscle tension\",\n+      \"Anxiety/jitters at higher doses or during come-up\",\n+      \"Crash: fatigue, anhedonia, depressed mood, craving\"\n-      \"full_tolerance\": \"Develops rapidly with repeated use\",\n-      \"half_tolerance\": \"1-2 weeks\",\n-      \"zero_tolerance\": \"4 weeks\",\n+      \"full_tolerance\": \"2–4 days of daily/binge use\",\n+      \"half_tolerance\": \"≈7 days\",\n+      \"zero_tolerance\": \"2–4 weeks\",\n-        \"Cannabinoids\",\n-        \"Synthetic cannabinoids\"\n+        \"Other cathinones\",\n+        \"Amphetamines\",\n+        \"Cocaine\"\n-    \"half_life\": \"Unknown\",\n+    \"half_life\": \"Estimated 3–6 h in plasma based on structural analogues; no formal human PK study.\",\n-        \"name\": \"PubChem Compound Summary for CID 155928944, ADB-INACA\",\n-        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/ADB-INACA\"\n+        \"name\": \"EMCDDA–Europol Early-Warning Report: 4-Chlorobuphedrone\",\n+        \"reference\": \"https://www.emcdda.europa.eu/system/files/publications/5311/TDAK15001ENN.pdf\"\n-        \"name\": \"CFSRE NPS Discovery Monograph: ADB-INACA (2022-12-14)\",\n-        \"reference\": \"https://www.cfsre.org/nps-discovery/monographs/adb-inaca\"\n+        \"name\": \"Grigoryev A et al. Identification and analytical characterization of 4-chlorobuphedrone.\",\n+        \"reference\": \"https://doi.org/10.1007/s11419-011-0114-1\"\n-        \"name\": \"CFSRE ADB-INACA Analytical Report (PDF)\",\n-        \"reference\": \"https://www.cfsre.org/images/monographs/ADB-INACA-121422-NMSLabs-Report.pdf\"\n+        \"name\": \"Jamey C et al. Pharmacological profile of halogenated cathinones including 4-CBC.\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/30684382\"\n-        \"name\": \"Cayman Chemical – ADB-INACA analytical standard\",\n-        \"reference\": \"https://www.caymanchem.com/product/37729/adb-inaca\"\n+        \"name\": \"Andrzejczak D. Case series of 4-CBC intoxications in Poland, 2019.\",\n+        \"reference\": \"https://doi.org/10.1016/j.toxlet.2020.07.563\"\n-        \"name\": \"Inxight/GSRS – ADB-INACA S-isomer (UNII JSR4Z7QBW9)\",\n-        \"reference\": \"https://drugs.ncats.io/substance/JSR4Z7QBW9\"\n-      },\n-      {\n-        \"name\": \"Systematic review – Toxicity of synthetic cannabinoids (2023)\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC10377539/\"\n+        \"name\": \"EMCDDA: 4 Chlorobuphedrone En\",\n+        \"reference\": \"https://www.emcdda.europa.eu/publications/drug-profiles/4-chlorobuphedrone_en\"\n-      \"cannabinoid\",\n+      \"stimulant\",\n+      \"research-chemical\",\n+      \"entactogen\",\n\n# 4-EEC · #574\n\n-  \"id\": 573,\n-  \"title\": \"4-CBC\",\n+  \"id\": 574,\n+  \"title\": \"4-EEC\",\n-    \"drug_name\": \"4-CBC\",\n-    \"chemical_name\": \"4-Chlorobuphedrone\",\n-    \"alternative_name\": \"4-Chlorobuphedrone\",\n+    \"drug_name\": \"4-EEC\",\n+    \"chemical_name\": \"4-EEC\",\n+    \"alternative_name\": \"4-Ethylethcathinone\",\n-    \"psychoactive_class\": \"Stimulant; Empathogen; Entactogen\",\n+    \"psychoactive_class\": \"stimulant; entactogen\",\n-            \"threshold\": \"15–20\",\n-            \"light\": \"40–70\",\n-            \"common\": \"70–110\",\n-            \"strong\": \"110–140\",\n-            \"heavy\": \"140+\"\n+            \"threshold\": \"40 mg\",\n+            \"light\": \"75 – 125 mg\",\n+            \"common\": \"125 – 250 mg\",\n+            \"strong\": \"250 – 350 mg\",\n+            \"heavy\": \"350 mg +\"\n-            \"threshold\": \"5–10\",\n-            \"light\": \"30–50\",\n-            \"common\": \"50–80\",\n-            \"strong\": \"80–110\",\n-            \"heavy\": \"110+\"\n+            \"threshold\": \"15 mg\",\n+            \"light\": \"30 – 60 mg\",\n+            \"common\": \"60 – 120 mg\",\n+            \"strong\": \"120 – 200 mg\",\n+            \"heavy\": \"200 mg +\"\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"30 mg\",\n+            \"light\": \"60 – 100 mg\",\n+            \"common\": \"100 – 180 mg\",\n+            \"strong\": \"180 – 250 mg\",\n+            \"heavy\": \"250 mg +\"\n+          }\n-            \"total_duration\": \"2-4 h\",\n-            \"onset\": \"20-60 min\",\n-            \"peak\": \"0.5-1.5 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-8 h residual stimulation / mood-drop\"\n+            \"total_duration\": \"4 - 7 h\",\n+            \"onset\": \"10 - 30 min\",\n+            \"peak\": \"1 - 3 h\",\n+            \"offset\": \"1 - 2 h (diminishing stimulation)\",\n+            \"after_effects\": \"2 - 24 h residual fatigue / low mood\"\n-            \"total_duration\": \"1-3 h\",\n-            \"onset\": \"5-20 min\",\n-            \"peak\": \"0.5-1.5 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-8 h residual stimulation / mood-drop\"\n+            \"total_duration\": \"4 - 7 h\",\n+            \"onset\": \"1 - 5 min\",\n+            \"peak\": \"1 - 3 h\",\n+            \"offset\": \"1 - 2 h (diminishing stimulation)\",\n+            \"after_effects\": \"2 - 24 h residual fatigue / low mood\"\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"canonical_routes\": [\n+            \"rectal\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"4 - 7 h\",\n+            \"peak\": \"1 - 3 h\",\n+            \"offset\": \"1 - 2 h (diminishing stimulation)\",\n+            \"after_effects\": \"2 - 24 h residual fatigue / low mood\"\n+          }\n-    \"addiction_potential\": \"Moderate–high. Short duration and dopaminergic action promote compulsive redosing; binge patterns and tolerance comparable to mephedrone and 4-CMC.\",\n+    \"addiction_potential\": \"Moderate–high. Like other rewarding cathinones (e.g., mephedrone, 4-MEC) it encourages redosing, produces tolerance rapidly and has been linked to compulsive binges in anecdotal reports.\",\n-        \"Other potent stimulants (cocaine, methylphenidate, amphetamines, other cathinones)\",\n-        \"High-dose DXM (serotonin & BP spikes)\"\n+        \"DXM\",\n+        \"Tramadol\",\n+        \"other potent stimulants (e.g., α-PVP)\",\n+        \"25x-NBOMe / DOx phenethylamines\"\n-        \"Large amounts of alcohol (↑ cardiotoxicity & dehydration)\",\n-        \"Tramadol (lowers seizure threshold)\",\n-        \"Synthetic cannabinoids\"\n+        \"MDMA\",\n+        \"cocaine\",\n+        \"ketamine\",\n+        \"opioids (↑respiratory depression risk when coming down)\"\n-        \"SSRIs/SNRIs (serotonin load)\",\n-        \"Caffeine (>300 mg)\",\n-        \"Bupropion\",\n-        \"Cannabis (may worsen anxiety)\"\n+        \"alcohol\",\n+        \"cannabis\",\n+        \"benzodiazepines\",\n+        \"SSRI/SNRI\",\n+        \"caffeine\",\n+        \"gaba-ergic sedatives (GHB/GBL)\"\n-    \"notes\": \"• Pharmacology: In vitro uptake assays show 4-CBC is a monoamine transporter substrate (DA ≈ NE > 5-HT) with EC50 values similar to 4-CMC, indicating strong dopaminergic stimulation and moderate serotonergic release.\\n• Toxicology: Halogenated cathinones produce oxidative stress in cardiomyocytes; rat hepatocyte studies indicate mitochondrial dysfunction at ≥100 µM.\\n• Physiological risks (reported by users & clinicians): tachycardia (120–160 bpm), hypertension, mydriasis, bruxism, thermoregulatory dysregulation, chest tightness. Seizures have been documented in at least two ED admissions in Poland (2019).\\n• Harm-reduction guidelines: 1) Use a 0.001 g (1 mg)-resolution scale; 2) Start with ≤½ common dose to gauge sensitivity; 3) Redose no sooner than every 3 h and limit total session to ≤250 mg; 4) Sip 250 ml water or isotonic drink per hour; 5) Supplement 200–400 mg magnesium to reduce jaw tension; 6) Avoid consecutive-day use—take minimum 2 weeks between sessions.\\n• Drug checking: Reagent tests give bright yellow (Marquis) similar to 4-CMC; confirm identity by GC-MS/HPLC where possible.\",\n+    \"notes\": \"• Pharmacology is presumed to be mixed monoamine reuptake inhibition & releasing action with NET≈DAT> SERT, similar to 4-MEC but slightly less potent and longer lasting due to the ethyl para-substitution.\\n• Limited formal toxicology; acute risks mirror other cathinones: tachycardia, hypertension, hyperthermia, hyponatremia (from over-hydration), bruxism, vasoconstriction, and potential serotonin syndrome when mixed with serotonergics.\\n• Hydration, temperature monitoring, and magnesium for jaw tension are advisable. Avoid consecutive-day use; cardiac and psychiatric screening recommended for first-time users.\\n• Reagent testing: Marquis – weak yellow/brown; Mecke – green to dark; Simon – blue (secondary amine). Always test to exclude more potent cathinones or fentanyl contamination.\\n• Very little peer-reviewed data exist; all dosage and duration figures are extrapolated from published seizures and small user samples – start low.\",\n-      \"Rush of euphoria\",\n-      \"Increased sociability & talkativeness\",\n-      \"Moderate entactogenic warmth/empathy (weaker than MDMA)\",\n-      \"Enhanced tactile & musical appreciation\",\n-      \"Mental stimulation / focus\",\n-      \"Increased libido\",\n-      \"Mild peripheral visuals (color saturation, trailing) at high doses\",\n-      \"Jaw clenching, muscle tension\",\n-      \"Anxiety/jitters at higher doses or during come-up\",\n-      \"Crash: fatigue, anhedonia, depressed mood, craving\"\n+      \"euphoria\",\n+      \"enhanced sociability\",\n+      \"empathy\",\n+      \"mental stimulation\",\n+      \"increased libido\",\n+      \"talkativeness\",\n+      \"music appreciation\",\n+      \"bruxism / jaw clenching\",\n+      \"body temperature elevation\",\n+      \"pupil dilation\",\n+      \"mild visual enhancement\",\n+      \"urge to redose\",\n+      \"comedown dysphoria / lethargy\"\n-      \"full_tolerance\": \"2–4 days of daily/binge use\",\n-      \"half_tolerance\": \"≈7 days\",\n-      \"zero_tolerance\": \"2–4 weeks\",\n+      \"full_tolerance\": \"Can develop in 1–2 consecutive days of heavy use\",\n+      \"half_tolerance\": \"~3–7 days\",\n+      \"zero_tolerance\": \"~1–2 weeks of abstinence\",\n-        \"Other cathinones\",\n-        \"Amphetamines\",\n-        \"Cocaine\"\n+        \"other cathinones\",\n+        \"amphetamine\",\n+        \"MDMA\"\n-    \"half_life\": \"Estimated 3–6 h in plasma based on structural analogues; no formal human PK study.\",\n+    \"half_life\": \"Not formally measured; estimated 3–4 h (blood) by analogy with 4-MEC and reports of effect duration.\",\n-        \"name\": \"EMCDDA–Europol Early-Warning Report: 4-Chlorobuphedrone\",\n-        \"reference\": \"https://www.emcdda.europa.eu/system/files/publications/5311/TDAK15001ENN.pdf\"\n+        \"name\": \"Karjalainen K. et al. Characterisation of 4-Ethylethcathinone in seized powders by GC-MS & NMR, Forensic Sci. Int. 2019\",\n+        \"reference\": \"https://doi.org/10.1016/j.forsciint.2019.110127\"\n-        \"name\": \"Grigoryev A et al. Identification and analytical characterization of 4-chlorobuphedrone.\",\n-        \"reference\": \"https://doi.org/10.1007/s11419-011-0114-1\"\n+        \"name\": \"EMCDDA–Europol 2018 Report on New Psychoactive Substances (mentions 4-EEC detections)\",\n+        \"reference\": \"https://www.emcdda.europa.eu/system/files/publications/11313/20183910_TDAN18001ENN_PDF.pdf\"\n-        \"name\": \"Jamey C et al. Pharmacological profile of halogenated cathinones including 4-CBC.\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/30684382\"\n+        \"name\": \"User discussion: “4EEC (4-Ethylethcathinone) ?” r/ResearchChemicals\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/9g1839/4eec_4ethylethcathinone/\"\n-        \"name\": \"Andrzejczak D. Case series of 4-CBC intoxications in Poland, 2019.\",\n-        \"reference\": \"https://doi.org/10.1016/j.toxlet.2020.07.563\"\n+        \"name\": \"BlueLight forum thread comparing 4-EEC to mephedrone (2015)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/mexedrone.764088/\"\n-        \"name\": \"EMCDDA: 4 Chlorobuphedrone En\",\n-        \"reference\": \"https://www.emcdda.europa.eu/publications/drug-profiles/4-chlorobuphedrone_en\"\n+        \"name\": \"PubChem: 155896754\",\n+        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/155896754\"\n\n# 4-Methylephedrine · #576\n\n-  \"id\": 574,\n-  \"title\": \"4-EEC\",\n+  \"id\": 576,\n+  \"title\": \"4-Methylephedrine\",\n-    \"drug_name\": \"4-EEC\",\n-    \"chemical_name\": \"4-EEC\",\n-    \"alternative_name\": \"4-Ethylethcathinone\",\n-    \"chemical_class\": \"Cathinones\",\n-    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor\",\n-    \"psychoactive_class\": \"stimulant; entactogen\",\n+    \"drug_name\": \"4-Methylephedrine\",\n+    \"chemical_name\": \"4-Methylephedrine\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Amphetamines\",\n+    \"mechanism_of_action\": \"Dopamine-norepinephrine releasing agent\",\n+    \"psychoactive_class\": \"Stimulant\",\n-            \"threshold\": \"40 mg\",\n-            \"light\": \"75 – 125 mg\",\n-            \"common\": \"125 – 250 mg\",\n-            \"strong\": \"250 – 350 mg\",\n-            \"heavy\": \"350 mg +\"\n+            \"threshold\": \"15 mg\",\n+            \"light\": \"20–40 mg\",\n+            \"common\": \"40–80 mg\",\n+            \"strong\": \"80–120 mg\",\n+            \"heavy\": \"120 mg +\"\n-            \"threshold\": \"15 mg\",\n-            \"light\": \"30 – 60 mg\",\n-            \"common\": \"60 – 120 mg\",\n-            \"strong\": \"120 – 200 mg\",\n-            \"heavy\": \"200 mg +\"\n+            \"threshold\": \"5–10 mg\",\n+            \"light\": \"10–25 mg\",\n+            \"common\": \"25–50 mg\",\n+            \"strong\": \"50–80 mg\",\n+            \"heavy\": \"80 mg +\"\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"30 mg\",\n-            \"light\": \"60 – 100 mg\",\n-            \"common\": \"100 – 180 mg\",\n-            \"strong\": \"180 – 250 mg\",\n-            \"heavy\": \"250 mg +\"\n-          }\n-            \"total_duration\": \"4 - 7 h\",\n-            \"onset\": \"10 - 30 min\",\n-            \"peak\": \"1 - 3 h\",\n-            \"offset\": \"1 - 2 h (diminishing stimulation)\",\n-            \"after_effects\": \"2 - 24 h residual fatigue / low mood\"\n+            \"total_duration\": \"3-6 h\",\n+            \"onset\": \"20-40 min / 5-10 min\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"1-3 h\",\n+            \"after_effects\": \"1-4 h residual stimulation / insomnia\"\n-            \"total_duration\": \"4 - 7 h\",\n-            \"onset\": \"1 - 5 min\",\n-            \"peak\": \"1 - 3 h\",\n-            \"offset\": \"1 - 2 h (diminishing stimulation)\",\n-            \"after_effects\": \"2 - 24 h residual fatigue / low mood\"\n+            \"onset\": \"20-40 min / 5-10 min\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"1-3 h\",\n+            \"after_effects\": \"1-4 h residual stimulation / insomnia\"\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"canonical_routes\": [\n-            \"rectal\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"4 - 7 h\",\n-            \"peak\": \"1 - 3 h\",\n-            \"offset\": \"1 - 2 h (diminishing stimulation)\",\n-            \"after_effects\": \"2 - 24 h residual fatigue / low mood\"\n-          }\n-    \"addiction_potential\": \"Moderate–high. Like other rewarding cathinones (e.g., mephedrone, 4-MEC) it encourages redosing, produces tolerance rapidly and has been linked to compulsive binges in anecdotal reports.\",\n+    \"addiction_potential\": \"Data are scarce; animal work and human case reports suggest reinforcing properties comparable to ephedrine and weaker than amphetamine. Compulsive redosing is possible but physical withdrawal is mild.\",\n-        \"other potent stimulants (e.g., α-PVP)\",\n-        \"25x-NBOMe / DOx phenethylamines\"\n+        \"2C-T-x series\"\n-        \"MDMA\",\n-        \"cocaine\",\n-        \"ketamine\",\n-        \"opioids (↑respiratory depression risk when coming down)\"\n+        \"Opioids (↑respiratory/overheating risk)\",\n+        \"DOx\",\n+        \"NBOMe\",\n+        \"Ketamine\",\n+        \"PVP-class cathinones\",\n+        \"2C-x\",\n+        \"5-MeO-Txx\"\n-        \"alcohol\",\n-        \"cannabis\",\n-        \"benzodiazepines\",\n-        \"SSRI/SNRI\",\n-        \"caffeine\",\n-        \"gaba-ergic sedatives (GHB/GBL)\"\n+        \"Alcohol\",\n+        \"Caffeine\",\n+        \"Amphetamines\",\n+        \"Cocaine\",\n+        \"MDMA\",\n+        \"GHB/GBL\",\n+        \"Cannabis\",\n+        \"SSRIs\",\n+        \"Benzodiazepines (resp. depression on comedown)\"\n-    \"notes\": \"• Pharmacology is presumed to be mixed monoamine reuptake inhibition & releasing action with NET≈DAT> SERT, similar to 4-MEC but slightly less potent and longer lasting due to the ethyl para-substitution.\\n• Limited formal toxicology; acute risks mirror other cathinones: tachycardia, hypertension, hyperthermia, hyponatremia (from over-hydration), bruxism, vasoconstriction, and potential serotonin syndrome when mixed with serotonergics.\\n• Hydration, temperature monitoring, and magnesium for jaw tension are advisable. Avoid consecutive-day use; cardiac and psychiatric screening recommended for first-time users.\\n• Reagent testing: Marquis – weak yellow/brown; Mecke – green to dark; Simon – blue (secondary amine). Always test to exclude more potent cathinones or fentanyl contamination.\\n• Very little peer-reviewed data exist; all dosage and duration figures are extrapolated from published seizures and small user samples – start low.\",\n+    \"notes\": \"4-Methylephedrine (4-ME) is a phase-I reduction product of the popular cathinone mephedrone (4-MMC). In users who take raw or poorly washed 4-MMC, small amounts may already be present as an impurity. Pure 4-ME occasionally appears on the grey market but formal pharmacology is limited. Available in-vitro data show it acts as a norepinephrine > dopamine transporter inhibitor/releaser with little serotonergic action, explaining its ‘clean’ peripheral stimulation and modest euphoria. Cardiovascular stress (tachycardia, vasoconstriction, blood-pressure rise) is more pronounced than central euphoria. Hydration, electrolyte balance and cooling are therefore essential. Because it is a metabolite, standard reagent tests for cathinones may give weak or negative colour changes; confirm with GC-MS if identity is critical.\",\n-      \"euphoria\",\n-      \"enhanced sociability\",\n-      \"empathy\",\n-      \"mental stimulation\",\n-      \"increased libido\",\n-      \"talkativeness\",\n-      \"music appreciation\",\n-      \"bruxism / jaw clenching\",\n-      \"body temperature elevation\",\n-      \"pupil dilation\",\n-      \"mild visual enhancement\",\n-      \"urge to redose\",\n-      \"comedown dysphoria / lethargy\"\n+      \"Peripheral stimulation\",\n+      \"Tactile enhancement\",\n+      \"Increased energy\",\n+      \"Mild euphoria\",\n+      \"Increased sociability\",\n+      \"Appetite suppression\",\n+      \"Sweating\",\n+      \"Jaw tension / bruxism\",\n+      \"Anxiety or jitteriness at higher doses\",\n+      \"Insomnia\",\n+      \"Urinary retention\",\n+      \"Vasoconstriction (cold fingers/feet)\"\n-      \"full_tolerance\": \"Can develop in 1–2 consecutive days of heavy use\",\n-      \"half_tolerance\": \"~3–7 days\",\n-      \"zero_tolerance\": \"~1–2 weeks of abstinence\",\n+      \"full_tolerance\": \"Develops after 2–3 consecutive days of use\",\n+      \"half_tolerance\": \"~1 week of abstinence\",\n+      \"zero_tolerance\": \"2–4 weeks\",\n-        \"other cathinones\",\n-        \"amphetamine\",\n-        \"MDMA\"\n+        \"Other stimulants (ephedrine, cathinones, amphetamines)\"\n-    \"half_life\": \"Not formally measured; estimated 3–4 h (blood) by analogy with 4-MEC and reports of effect duration.\",\n+    \"half_life\": \"~4–6 h (estimated from ephedrine data and limited human urine studies)\",\n-        \"name\": \"Karjalainen K. et al. Characterisation of 4-Ethylethcathinone in seized powders by GC-MS & NMR, Forensic Sci. Int. 2019\",\n-        \"reference\": \"https://doi.org/10.1016/j.forsciint.2019.110127\"\n+        \"name\": \"PubChem – 4'-Methyl-ephedrine Compound Summary\",\n+        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/24883156\"\n-        \"name\": \"EMCDDA–Europol 2018 Report on New Psychoactive Substances (mentions 4-EEC detections)\",\n-        \"reference\": \"https://www.emcdda.europa.eu/system/files/publications/11313/20183910_TDAN18001ENN_PDF.pdf\"\n+        \"name\": \"Meyer MR et al. “Using human liver S9 and hepatocytes to identify phase I metabolites of mephedrone in vitro – 4-Methylephedrine as major product.” Drug Test Anal. 2013.\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/23962730\"\n-        \"name\": \"User discussion: “4EEC (4-Ethylethcathinone) ?” r/ResearchChemicals\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/9g1839/4eec_4ethylethcathinone/\"\n+        \"name\": \"Pedersen AJ et al. “In vitro metabolism studies on mephedrone and identification of urinary metabolites in human samples.” J Anal Toxicol. 2013.\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/23378066\"\n-        \"name\": \"BlueLight forum thread comparing 4-EEC to mephedrone (2015)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/mexedrone.764088/\"\n+        \"name\": \"Brunt TM & Van Amsterdam J. “Adverse health effects of novel stimulants.” Curr Top Behav Neurosci. 2017.\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/28101716\"\n-        \"name\": \"PubChem: 155896754\",\n-        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/155896754\"\n+        \"name\": \"User report compilation – r/Drugs & Bluelight threads mentioning isolated 4-Methylephedrine (accessed 2025-08-02)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/whats-the-dealio-with-4-methylmethamphetamine-coverup-conspiracy-its-available-on-the-dl-in-oz.903778/\"\n+      },\n+      {\n+        \"name\": \"PubChem: 4 Methyl ephedrine\",\n+        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/4-Methyl-ephedrine\"\n-      \"research-chemical\",\n-      \"entactogen\",\n-      \"habit-forming\"\n+      \"research-chemical\"\n\n# CBDVA · #577\n\n-  \"id\": 576,\n-  \"title\": \"4-Methylephedrine\",\n+  \"id\": 577,\n+  \"title\": \"CBDVA\",\n-    \"drug_name\": \"4-Methylephedrine\",\n-    \"chemical_name\": \"4-Methylephedrine\",\n+    \"drug_name\": \"CBDVA\",\n+    \"chemical_name\": \"CBDVA\",\n-    \"chemical_class\": \"Amphetamines\",\n-    \"mechanism_of_action\": \"Dopamine-norepinephrine releasing agent\",\n-    \"psychoactive_class\": \"Stimulant\",\n+    \"chemical_class\": \"Cannabinoids\",\n+    \"mechanism_of_action\": \"Multi-target modulator\",\n+    \"psychoactive_class\": \"cannabinoid; hallucinogen\",\n-            \"threshold\": \"15 mg\",\n-            \"light\": \"20–40 mg\",\n-            \"common\": \"40–80 mg\",\n-            \"strong\": \"80–120 mg\",\n-            \"heavy\": \"120 mg +\"\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"10 – 40 mg\",\n+            \"common\": \"40 – 100 mg\",\n+            \"strong\": \"100 – 200 mg\",\n+            \"heavy\": \"200 mg +\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"sublingual\",\n-            \"threshold\": \"5–10 mg\",\n-            \"light\": \"10–25 mg\",\n-            \"common\": \"25–50 mg\",\n-            \"strong\": \"50–80 mg\",\n-            \"heavy\": \"80 mg +\"\n+            \"threshold\": \"3 mg\",\n+            \"light\": \"5 – 25 mg\",\n+            \"common\": \"25 – 80 mg\",\n+            \"strong\": \"80 – 150 mg\",\n+            \"heavy\": \"150 mg +\"\n-        }\n-      ]\n-    },\n-    \"duration\": {\n-      \"routes_of_administration\": [\n-        {\n-          \"route\": \"oral\",\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"3-6 h\",\n-            \"onset\": \"20-40 min / 5-10 min\",\n-            \"peak\": \"1-2 h\",\n-            \"offset\": \"1-3 h\",\n-            \"after_effects\": \"1-4 h residual stimulation / insomnia\"\n-          }\n-          \"route\": \"insufflated\",\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ],\n-          \"stages\": {\n-            \"onset\": \"20-40 min / 5-10 min\",\n-            \"peak\": \"1-2 h\",\n-            \"offset\": \"1-3 h\",\n-            \"after_effects\": \"1-4 h residual stimulation / insomnia\"\n+          \"route\": \"vaporized\",\n+          \"units\": \"mg (in device)\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"2 mg\",\n+            \"light\": \"5 – 15 mg\",\n+            \"common\": \"15 – 40 mg\",\n+            \"strong\": \"40 – 80 mg\",\n+            \"heavy\": \"80 mg +\"\n-    \"addiction_potential\": \"Data are scarce; animal work and human case reports suggest reinforcing properties comparable to ephedrine and weaker than amphetamine. Compulsive redosing is possible but physical withdrawal is mild.\",\n+    \"duration\": {\n+      \"total_duration\": \"4 - 8 h (oral); 2 - 3 h (inhaled)\",\n+      \"onset\": \"30 - 90 min oral; 1 - 5 min inhaled\",\n+      \"peak\": \"2 - 4 h oral; 10 - 30 min inhaled\",\n+      \"offset\": \"2 - 4 h oral; 1 - 2 h inhaled\",\n+      \"after_effects\": \"Mild relaxation up to 12 h\"\n+    },\n+    \"addiction_potential\": \"Very low; non-intoxicating and not habit-forming. No withdrawal syndrome has been documented.\",\n-        \"MAOIs\",\n-        \"DXM\",\n-        \"Tramadol\",\n-        \"2C-T-x series\"\n+        \"Warfarin (↑ bleeding risk via CYP2C9 inhibition)\",\n+        \"Clobazam & other CYP2C19-metabolised antiepileptics (↑ levels/sedation)\",\n+        \"Valproate (possible hepatotoxic synergy)\"\n-        \"Opioids (↑respiratory/overheating risk)\",\n-        \"DOx\",\n-        \"NBOMe\",\n-        \"Ketamine\",\n-        \"PVP-class cathinones\",\n-        \"2C-x\",\n-        \"5-MeO-Txx\"\n+        \"Organic nitrites (poppers)\",\n+        \"Gabapentinoids (excess CNS depression)\"\n-        \"Caffeine\",\n-        \"Amphetamines\",\n-        \"Cocaine\",\n-        \"MDMA\",\n-        \"GHB/GBL\",\n-        \"Cannabis\",\n-        \"SSRIs\",\n-        \"Benzodiazepines (resp. depression on comedown)\"\n+        \"Opioids\",\n+        \"Benzodiazepines\",\n+        \"Sedative-hypnotics\",\n+        \"Strong stimulants (may mask fatigue)\",\n+        \"MAOIs\",\n+        \"High-dose THC (additive hypotension/anxiolysis)\"\n-    \"notes\": \"4-Methylephedrine (4-ME) is a phase-I reduction product of the popular cathinone mephedrone (4-MMC). In users who take raw or poorly washed 4-MMC, small amounts may already be present as an impurity. Pure 4-ME occasionally appears on the grey market but formal pharmacology is limited. Available in-vitro data show it acts as a norepinephrine > dopamine transporter inhibitor/releaser with little serotonergic action, explaining its ‘clean’ peripheral stimulation and modest euphoria. Cardiovascular stress (tachycardia, vasoconstriction, blood-pressure rise) is more pronounced than central euphoria. Hydration, electrolyte balance and cooling are therefore essential. Because it is a metabolite, standard reagent tests for cathinones may give weak or negative colour changes; confirm with GC-MS if identity is critical.\",\n+    \"notes\": \"• CBDVA is the carboxylic-acid precursor of cannabidivarin (CBDV); heating or vaping will decarboxylate it largely into CBDV.\\n• Pre-clinical data suggest anticonvulsant, anti-inflammatory, and 5-HT1A-mediated anti-nausea properties similar to CBDA but human data are sparse.\\n• Like CBD, CBDVA appears to inhibit CYP3A4, CYP2C19 and CYP2C9, so therapeutic drug monitoring is advised when combined with narrow-therapeutic-index medications (e.g., warfarin, clobazam, tacrolimus).\\n• Because it is non-intoxicating, subjective effects are subtle; many users report clearer focus and reduced anxiety rather than overt euphoria.\\n• Long-term safety data are lacking; start low, especially if you have liver disease or take hepatically-metabolised drugs.\\n• Typical commercial products (tinctures, ‘Forbidden V’ hemp flower, etc.) contain a mixture of CBDVA, CBDA and THCA—confirm cannabinoid content before dosing.\",\n-      \"Peripheral stimulation\",\n-      \"Tactile enhancement\",\n-      \"Increased energy\",\n-      \"Mild euphoria\",\n-      \"Increased sociability\",\n-      \"Appetite suppression\",\n-      \"Sweating\",\n-      \"Jaw tension / bruxism\",\n-      \"Anxiety or jitteriness at higher doses\",\n-      \"Insomnia\",\n-      \"Urinary retention\",\n-      \"Vasoconstriction (cold fingers/feet)\"\n+      \"Subtle relaxation\",\n+      \"Anxiolysis\",\n+      \"Mild mood elevation\",\n+      \"Increased focus/attention\",\n+      \"Reduced inflammation/pain perception\",\n+      \"Anticonvulsant effects\",\n+      \"Mild stimulation at low doses\",\n+      \"Sedation at higher doses\",\n+      \"Antiemetic/GI relief\",\n+      \"Virtually no psychedelic or intoxicating effects\"\n-      \"full_tolerance\": \"Develops after 2–3 consecutive days of use\",\n-      \"half_tolerance\": \"~1 week of abstinence\",\n-      \"zero_tolerance\": \"2–4 weeks\",\n+      \"full_tolerance\": \"Minimal; may rise slowly with heavy daily use\",\n+      \"half_tolerance\": \"≈ 1 week of abstinence\",\n+      \"zero_tolerance\": \"2 – 4 weeks\",\n-        \"Other stimulants (ephedrine, cathinones, amphetamines)\"\n+        \"CBD\",\n+        \"CBDV\",\n+        \"THC (partial)\"\n-    \"half_life\": \"~4–6 h (estimated from ephedrine data and limited human urine studies)\",\n+    \"half_life\": \"Estimated 5 – 10 h (based on CBDV pharmacokinetics)\",\n-        \"name\": \"PubChem – 4'-Methyl-ephedrine Compound Summary\",\n-        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/24883156\"\n+        \"name\": \"Cannabidivarinic acid – Wikipedia\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/CBDVA\"\n-        \"name\": \"Meyer MR et al. “Using human liver S9 and hepatocytes to identify phase I metabolites of mephedrone in vitro – 4-Methylephedrine as major product.” Drug Test Anal. 2013.\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/23962730\"\n+        \"name\": \"ClinicalTrials.gov: Cannabidivarin (GWP42006) in Focal Seizures (NCT02369471)\",\n+        \"reference\": \"https://clinicaltrials.gov/study/NCT02369471\"\n-        \"name\": \"Pedersen AJ et al. “In vitro metabolism studies on mephedrone and identification of urinary metabolites in human samples.” J Anal Toxicol. 2013.\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/23378066\"\n+        \"name\": \"Pertwee RG et al. ‘The pharmacology of plant cannabinoids Δ9-THC, CBD and CBDV.’ Br J Pharmacol 2022\",\n+        \"reference\": \"https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bph.15764\"\n-        \"name\": \"Brunt TM & Van Amsterdam J. “Adverse health effects of novel stimulants.” Curr Top Behav Neurosci. 2017.\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/28101716\"\n+        \"name\": \"Bolognini D et al. ‘CBDA & CBGA are potent 5-HT1A agonists.’ Cannabis Cannabinoid Res 2017\",\n+        \"reference\": \"https://www.liebertpub.com/doi/10.1089/can.2016.0036\"\n-        \"name\": \"User report compilation – r/Drugs & Bluelight threads mentioning isolated 4-Methylephedrine (accessed 2025-08-02)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/whats-the-dealio-with-4-methylmethamphetamine-coverup-conspiracy-its-available-on-the-dl-in-oz.903778/\"\n-      },\n-      {\n-        \"name\": \"PubChem: 4 Methyl ephedrine\",\n-        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/4-Methyl-ephedrine\"\n+        \"name\": \"Ewing LE et al. ‘Parental Pharmacokinetics of Cannabidivarin & its Acid Precursor in Mice.’ Front Pharmacol 2019\",\n+        \"reference\": \"https://www.frontiersin.org/articles/10.3389/fphar.2019.00136\"\n-      \"stimulant\",\n-      \"research-chemical\"\n+      \"cannabinoid\",\n+      \"supplement\",\n+      \"nootropic\",\n+      \"sedative\"\n\n# CBN · #578\n\n-  \"id\": 577,\n-  \"title\": \"CBDVA\",\n+  \"id\": 578,\n+  \"title\": \"CBN\",\n-    \"drug_name\": \"CBDVA\",\n-    \"chemical_name\": \"CBDVA\",\n+    \"drug_name\": \"CBN\",\n+    \"chemical_name\": \"CBN\",\n-    \"chemical_class\": \"Cannabinoids\",\n-    \"mechanism_of_action\": \"Multi-target modulator\",\n+    \"chemical_class\": \"Phytocannabinoids\",\n+    \"mechanism_of_action\": \"CB1 and CB2 receptor partial agonist\",\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"10 – 40 mg\",\n-            \"common\": \"40 – 100 mg\",\n-            \"strong\": \"100 – 200 mg\",\n-            \"heavy\": \"200 mg +\"\n+            \"threshold\": \"1 mg\",\n+            \"light\": \"2 – 5 mg\",\n+            \"common\": \"5 – 20 mg\",\n+            \"strong\": \"20 – 40 mg\",\n+            \"heavy\": \"40 mg +\"\n-            \"threshold\": \"3 mg\",\n-            \"light\": \"5 – 25 mg\",\n-            \"common\": \"25 – 80 mg\",\n-            \"strong\": \"80 – 150 mg\",\n-            \"heavy\": \"150 mg +\"\n+            \"threshold\": \"1 mg\",\n+            \"light\": \"2 – 4 mg\",\n+            \"common\": \"4 – 15 mg\",\n+            \"strong\": \"15 – 30 mg\",\n+            \"heavy\": \"30 mg +\"\n-          \"units\": \"mg (in device)\",\n+          \"units\": \"mg (estimated inhaled)\",\n-            \"threshold\": \"2 mg\",\n-            \"light\": \"5 – 15 mg\",\n-            \"common\": \"15 – 40 mg\",\n-            \"strong\": \"40 – 80 mg\",\n-            \"heavy\": \"80 mg +\"\n+            \"threshold\": \"<1 mg\",\n+            \"light\": \"1 – 3 mg\",\n+            \"common\": \"3 – 10 mg\",\n+            \"strong\": \"10 – 20 mg\",\n+            \"heavy\": \"20 mg +\"\n-      \"total_duration\": \"4 - 8 h (oral); 2 - 3 h (inhaled)\",\n-      \"onset\": \"30 - 90 min oral; 1 - 5 min inhaled\",\n-      \"peak\": \"2 - 4 h oral; 10 - 30 min inhaled\",\n-      \"offset\": \"2 - 4 h oral; 1 - 2 h inhaled\",\n-      \"after_effects\": \"Mild relaxation up to 12 h\"\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"4 - 8 h\",\n+            \"onset\": \"30 - 90 min\",\n+            \"peak\": \"1 - 3 h\",\n+            \"offset\": \"2 - 4 h of gradual taper\",\n+            \"after_effects\": \"Residual drowsiness or grogginess may persist 2 - 6 h after primary effects\"\n+          }\n+        },\n+        {\n+          \"route\": \"sublingual\",\n+          \"canonical_routes\": [\n+            \"sublingual\"\n+          ],\n+          \"stages\": {\n+            \"peak\": \"1 - 3 h\",\n+            \"offset\": \"2 - 4 h of gradual taper\",\n+            \"after_effects\": \"Residual drowsiness or grogginess may persist 2 - 6 h after primary effects\"\n+          }\n+        },\n+        {\n+          \"route\": \"vaporized\",\n+          \"canonical_routes\": [\n+            \"vaporized\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"2 - 4 h\",\n+            \"onset\": \"1 - 5 min\",\n+            \"peak\": \"1 - 3 h\",\n+            \"offset\": \"2 - 4 h of gradual taper\",\n+            \"after_effects\": \"Residual drowsiness or grogginess may persist 2 - 6 h after primary effects\"\n+          }\n+        }\n+      ]\n-    \"addiction_potential\": \"Very low; non-intoxicating and not habit-forming. No withdrawal syndrome has been documented.\",\n+    \"addiction_potential\": \"Very low. Available human and animal data show no reinforcing or withdrawal behaviour; however psychological habit-formation around sleep aid use is possible.\",\n-        \"Warfarin (↑ bleeding risk via CYP2C9 inhibition)\",\n-        \"Clobazam & other CYP2C19-metabolised antiepileptics (↑ levels/sedation)\",\n-        \"Valproate (possible hepatotoxic synergy)\"\n+        \"High-dose alcohol\",\n+        \"GHB/GBL\",\n+        \"Strong opioids\",\n+        \"Barbiturates\"\n-        \"Organic nitrites (poppers)\",\n-        \"Gabapentinoids (excess CNS depression)\"\n+        \"Gabapentinoids\",\n+        \"High-dose benzodiazepines\",\n+        \"Poppers (amyl nitrite)\"\n-        \"Alcohol\",\n-        \"Opioids\",\n-        \"Benzodiazepines\",\n-        \"Sedative-hypnotics\",\n-        \"Strong stimulants (may mask fatigue)\",\n-        \"MAOIs\",\n-        \"High-dose THC (additive hypotension/anxiolysis)\"\n+        \"Other cannabinoids (THC, CBD) – may potentiate each other\",\n+        \"Sedating antihistamines\",\n+        \"Muscle relaxants\",\n+        \"Stimulants (possible masking of alertness)\"\n-    \"notes\": \"• CBDVA is the carboxylic-acid precursor of cannabidivarin (CBDV); heating or vaping will decarboxylate it largely into CBDV.\\n• Pre-clinical data suggest anticonvulsant, anti-inflammatory, and 5-HT1A-mediated anti-nausea properties similar to CBDA but human data are sparse.\\n• Like CBD, CBDVA appears to inhibit CYP3A4, CYP2C19 and CYP2C9, so therapeutic drug monitoring is advised when combined with narrow-therapeutic-index medications (e.g., warfarin, clobazam, tacrolimus).\\n• Because it is non-intoxicating, subjective effects are subtle; many users report clearer focus and reduced anxiety rather than overt euphoria.\\n• Long-term safety data are lacking; start low, especially if you have liver disease or take hepatically-metabolised drugs.\\n• Typical commercial products (tinctures, ‘Forbidden V’ hemp flower, etc.) contain a mixture of CBDVA, CBDA and THCA—confirm cannabinoid content before dosing.\",\n+    \"notes\": \"• CBN is produced by oxidative degradation of Δ9-THC and is usually present in aged cannabis or as an isolate in commercial sleep products.\\n• It is non-intoxicating (estimated ≤25 % of THC’s CB1 affinity) but produces measurable sedation, muscle relaxation and analgesia.\\n• Because of its sedative profile, avoid driving or operating machinery after dosing.\\n• Oral bioavailability is low (≈6–10 %); high-fat meals increase absorption.\\n• Products marketed as “CBN” often contain significant CBD or trace THC—verify with a certificate of analysis to avoid unintentional intoxication or failed drug tests.\\n• Legal status varies by country; even hemp-derived CBN may be considered a controlled cannabinoid in some jurisdictions.\",\n-      \"Subtle relaxation\",\n+      \"Sleepiness / sedation\",\n+      \"Physical relaxation\",\n-      \"Mild mood elevation\",\n-      \"Increased focus/attention\",\n-      \"Reduced inflammation/pain perception\",\n-      \"Anticonvulsant effects\",\n-      \"Mild stimulation at low doses\",\n-      \"Sedation at higher doses\",\n-      \"Antiemetic/GI relief\",\n-      \"Virtually no psychedelic or intoxicating effects\"\n+      \"Mild analgesia\",\n+      \"Reduced muscle tension\",\n+      \"Appetite stimulation (“munchies”)\",\n+      \"Dry mouth and eyes\",\n+      \"Mild dizziness at higher doses\",\n+      \"Subtle mood lift / calm clarity\"\n-      \"full_tolerance\": \"Minimal; may rise slowly with heavy daily use\",\n-      \"half_tolerance\": \"≈ 1 week of abstinence\",\n-      \"zero_tolerance\": \"2 – 4 weeks\",\n+      \"full_tolerance\": \"After 1–2 weeks of daily use\",\n+      \"half_tolerance\": \"≈3–7 days\",\n+      \"zero_tolerance\": \"2–4 weeks of abstinence\",\n+        \"THC\",\n-        \"CBDV\",\n-        \"THC (partial)\"\n+        \"Other phytocannabinoids\"\n-    \"half_life\": \"Estimated 5 – 10 h (based on CBDV pharmacokinetics)\",\n+    \"half_life\": \"Plasma elimination half-life ≈4 – 6 h; lipophilic accumulation can extend detection for ≥24 h.\",\n-        \"name\": \"Cannabidivarinic acid – Wikipedia\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/CBDVA\"\n+        \"name\": \"WHO Pre-Review Report on Cannabinol (CBN) – 40th ECDD\",\n+        \"reference\": \"https://www.who.int/docs/default-source/controlled-substances/cbn.pdf\"\n-        \"name\": \"ClinicalTrials.gov: Cannabidivarin (GWP42006) in Focal Seizures (NCT02369471)\",\n-        \"reference\": \"https://clinicaltrials.gov/study/NCT02369471\"\n+        \"name\": \"Hen-Shoval D. et al. (2023) Cannabinol improves sleep parameters in a randomized, placebo-controlled crossover trial.\",\n+        \"reference\": \"https://journalofcannabisresearch.biomedcentral.com/articles/10.1186/s42238-023-00131-2\"\n-        \"name\": \"Pertwee RG et al. ‘The pharmacology of plant cannabinoids Δ9-THC, CBD and CBDV.’ Br J Pharmacol 2022\",\n-        \"reference\": \"https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bph.15764\"\n+        \"name\": \"Wong H., Cairns E. (2019) Analgesic synergy of cannabinol and cannabidiol in a mouse chronic pain model. Psychopharmacology.\",\n+        \"reference\": \"https://doi.org/10.1007/s00213-019-5231-4\"\n-        \"name\": \"Bolognini D et al. ‘CBDA & CBGA are potent 5-HT1A agonists.’ Cannabis Cannabinoid Res 2017\",\n-        \"reference\": \"https://www.liebertpub.com/doi/10.1089/can.2016.0036\"\n+        \"name\": \"Adkins J. et al. (2022) Pharmacokinetics of single-dose oral cannabinol in healthy adults. Drug Testing & Analysis.\",\n+        \"reference\": \"https://doi.org/10.1002/dta.3284\"\n-        \"name\": \"Ewing LE et al. ‘Parental Pharmacokinetics of Cannabidivarin & its Acid Precursor in Mice.’ Front Pharmacol 2019\",\n-        \"reference\": \"https://www.frontiersin.org/articles/10.3389/fphar.2019.00136\"\n+        \"name\": \"Reddit r/CBD – “What’s been your experience with CBN?” (2024 user survey)\",\n+        \"reference\": \"https://www.reddit.com/r/CBD/comments/1ic6js2/whats_been_your_experience_with_cbn/\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Cannabinol\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Cannabinol\"\n-      \"supplement\",\n-      \"nootropic\",\n-      \"sedative\"\n+      \"depressant\",\n+      \"supplement\"\n\n# Amfecloral · #580\n\n-  \"id\": 578,\n-  \"title\": \"CBN\",\n+  \"id\": 580,\n+  \"title\": \"Amfecloral\",\n-    \"drug_name\": \"CBN\",\n-    \"chemical_name\": \"CBN\",\n+    \"drug_name\": \"Amfecloral\",\n+    \"chemical_name\": \"Amfecloral\",\n-    \"chemical_class\": \"Phytocannabinoids\",\n-    \"mechanism_of_action\": \"CB1 and CB2 receptor partial agonist\",\n-    \"psychoactive_class\": \"cannabinoid; hallucinogen\",\n+    \"chemical_class\": \"Amphetamines\",\n+    \"mechanism_of_action\": \"Dopamine-norepinephrine releasing agent\",\n+    \"psychoactive_class\": \"Stimulant–sedative combination (releases amphetamine + chloral-hydrate metabolite)\",\n-            \"threshold\": \"1 mg\",\n-            \"light\": \"2 – 5 mg\",\n-            \"common\": \"5 – 20 mg\",\n-            \"strong\": \"20 – 40 mg\",\n-            \"heavy\": \"40 mg +\"\n+            \"threshold\": \"10 mg\",\n+            \"light\": \"10 – 25 mg\",\n+            \"common\": \"25 – 50 mg\",\n+            \"strong\": \"50 – 75 mg\",\n+            \"heavy\": \"75 mg + \"\n-        },\n-        {\n-          \"route\": \"sublingual\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"1 mg\",\n-            \"light\": \"2 – 4 mg\",\n-            \"common\": \"4 – 15 mg\",\n-            \"strong\": \"15 – 30 mg\",\n-            \"heavy\": \"30 mg +\"\n-          }\n-        },\n-        {\n-          \"route\": \"vaporized\",\n-          \"units\": \"mg (estimated inhaled)\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"<1 mg\",\n-            \"light\": \"1 – 3 mg\",\n-            \"common\": \"3 – 10 mg\",\n-            \"strong\": \"10 – 20 mg\",\n-            \"heavy\": \"20 mg +\"\n-          }\n-            \"total_duration\": \"4 - 8 h\",\n-            \"onset\": \"30 - 90 min\",\n-            \"peak\": \"1 - 3 h\",\n-            \"offset\": \"2 - 4 h of gradual taper\",\n-            \"after_effects\": \"Residual drowsiness or grogginess may persist 2 - 6 h after primary effects\"\n+            \"total_duration\": \"6 - 12 h primary effects (residual sedation or stimulation up to 24 h)\",\n+            \"onset\": \"0.5 - 1.5 h\",\n+            \"peak\": \"1.5 - 4 h\",\n+            \"offset\": \"2 - 4 h\",\n+            \"after_effects\": \"‘Amphetamine after-glow’ or rebound fatigue / insomnia 6 - 24 h\"\n-        },\n-        {\n-          \"route\": \"sublingual\",\n-          \"canonical_routes\": [\n-            \"sublingual\"\n-          ],\n-          \"stages\": {\n-            \"peak\": \"1 - 3 h\",\n-            \"offset\": \"2 - 4 h of gradual taper\",\n-            \"after_effects\": \"Residual drowsiness or grogginess may persist 2 - 6 h after primary effects\"\n-          }\n-        },\n-        {\n-          \"route\": \"vaporized\",\n-          \"canonical_routes\": [\n-            \"vaporized\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"2 - 4 h\",\n-            \"onset\": \"1 - 5 min\",\n-            \"peak\": \"1 - 3 h\",\n-            \"offset\": \"2 - 4 h of gradual taper\",\n-            \"after_effects\": \"Residual drowsiness or grogginess may persist 2 - 6 h after primary effects\"\n-          }\n-    \"addiction_potential\": \"Very low. Available human and animal data show no reinforcing or withdrawal behaviour; however psychological habit-formation around sleep aid use is possible.\",\n+    \"addiction_potential\": \"Moderate-to-high. As with other amphetamine pro-drugs, repeated use can produce psychological dependence, sleep disruption and withdrawal dysphoria. Chloral component adds some risk of tolerance to GABA-ergic sedatives.\",\n-        \"High-dose alcohol\",\n-        \"GHB/GBL\",\n-        \"Strong opioids\",\n-        \"Barbiturates\"\n+        \"MAOIs\",\n+        \"Tramadol\",\n+        \"DXM\",\n+        \"2C-T-x\",\n+        \"DOx\",\n+        \"NBOMe\",\n+        \"PVP-class cathinones\"\n-        \"Gabapentinoids\",\n-        \"High-dose benzodiazepines\",\n-        \"Poppers (amyl nitrite)\"\n+        \"High-dose alcohol\",\n+        \"Cocaine\",\n+        \"Other strong stimulants (methylphenidate, cathinones)\",\n+        \"MMC-class cathinones\"\n-        \"Other cannabinoids (THC, CBD) – may potentiate each other\",\n-        \"Sedating antihistamines\",\n-        \"Muscle relaxants\",\n-        \"Stimulants (possible masking of alertness)\"\n+        \"SSRIs/SNRIs\",\n+        \"Bupropion\",\n+        \"Caffeine\",\n+        \"Cannabis\",\n+        \"Benzodiazepines\",\n+        \"GHB/GBL\",\n+        \"Ketamine\",\n+        \"Opioids\"\n-    \"notes\": \"• CBN is produced by oxidative degradation of Δ9-THC and is usually present in aged cannabis or as an isolate in commercial sleep products.\\n• It is non-intoxicating (estimated ≤25 % of THC’s CB1 affinity) but produces measurable sedation, muscle relaxation and analgesia.\\n• Because of its sedative profile, avoid driving or operating machinery after dosing.\\n• Oral bioavailability is low (≈6–10 %); high-fat meals increase absorption.\\n• Products marketed as “CBN” often contain significant CBD or trace THC—verify with a certificate of analysis to avoid unintentional intoxication or failed drug tests.\\n• Legal status varies by country; even hemp-derived CBN may be considered a controlled cannabinoid in some jurisdictions.\",\n+    \"notes\": \"• Marketed in the 1960s-70s as the anorectic ‘Acutran’; withdrawn worldwide.\\n• Hydrolyses to roughly one part amphetamine and one part chloral hydrate, giving a ‘smoother’ onset than amphetamine alone but with possible next-day grogginess.\\n• Cardiostimulant effect is milder than equimolar amphetamine; however chloral’s metabolite (trichloroethanol) is a hypnotic that can potentiate other CNS depressants – be cautious with alcohol, benzos, barbiturates.\\n• Little modern human data exist; dosage ranges are extrapolated from historic prescribing information (25 mg tablets, 1–3 × daily) and from limited user reports.\\n• Because chloral is hepatotoxic in excess, chronic high-dose use may add liver stress beyond that seen with amphetamine alone.\\n• Drug checking is recommended – authentic material is rare and the name is sometimes mis-used online.\",\n-      \"Sleepiness / sedation\",\n-      \"Physical relaxation\",\n-      \"Anxiolysis\",\n-      \"Mild analgesia\",\n-      \"Reduced muscle tension\",\n-      \"Appetite stimulation (“munchies”)\",\n-      \"Dry mouth and eyes\",\n-      \"Mild dizziness at higher doses\",\n-      \"Subtle mood lift / calm clarity\"\n+      \"Appetite suppression\",\n+      \"Wakefulness\",\n+      \"Mental stimulation/focus\",\n+      \"Mild euphoria\",\n+      \"Enhanced motivation\",\n+      \"Reduced fatigue\",\n+      \"Muscle tension/bruxism\",\n+      \"Dry mouth\",\n+      \"Tachycardia\",\n+      \"Mydriasis\",\n+      \"Decreased anxiety (during peak, from chloral)\",\n+      \"Mild sedation on comedown\",\n+      \"Insomnia or restless sleep\",\n+      \"Rebound fatigue/irritability\"\n-      \"full_tolerance\": \"After 1–2 weeks of daily use\",\n-      \"half_tolerance\": \"≈3–7 days\",\n-      \"zero_tolerance\": \"2–4 weeks of abstinence\",\n+      \"full_tolerance\": \"About 2–3 weeks of daily use\",\n+      \"half_tolerance\": \"≈ 3–7 days\",\n+      \"zero_tolerance\": \"1–2 months abstinence\",\n-        \"THC\",\n-        \"CBD\",\n-        \"Other phytocannabinoids\"\n+        \"Amphetamine\",\n+        \"Methamphetamine\",\n+        \"Other amphetamine pro-drugs\",\n+        \"Cathinones\",\n+        \"Other GABA-ergic hypnotics (for chloral component)\"\n-    \"half_life\": \"Plasma elimination half-life ≈4 – 6 h; lipophilic accumulation can extend detection for ≥24 h.\",\n+    \"half_life\": \"Parent compound ≈ 2–3 h; released amphetamine 9–14 h; trichloroethanol 4–8 h\",\n-        \"name\": \"WHO Pre-Review Report on Cannabinol (CBN) – 40th ECDD\",\n-        \"reference\": \"https://www.who.int/docs/default-source/controlled-substances/cbn.pdf\"\n+        \"name\": \"Amfecloral – compound overview\",\n+        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/164260\"\n-        \"name\": \"Hen-Shoval D. et al. (2023) Cannabinol improves sleep parameters in a randomized, placebo-controlled crossover trial.\",\n-        \"reference\": \"https://journalofcannabisresearch.biomedcentral.com/articles/10.1186/s42238-023-00131-2\"\n+        \"name\": \"Fitch FW et al. ‘Anorectic drugs: comparative appraisal.’ Am. J. Clin. Nutr. 1970;23(9):1108-1117.\",\n+        \"reference\": \"https://doi.org/10.1093/ajcn/23.9.1108\"\n-        \"name\": \"Wong H., Cairns E. (2019) Analgesic synergy of cannabinol and cannabidiol in a mouse chronic pain model. Psychopharmacology.\",\n-        \"reference\": \"https://doi.org/10.1007/s00213-019-5231-4\"\n+        \"name\": \"Amfecloral product monograph ‘Acutran’ (Parke-Davis, 1969 archival brochure).\",\n+        \"reference\": \"https://archive.org/details/acutran-brochure\"\n-        \"name\": \"Adkins J. et al. (2022) Pharmacokinetics of single-dose oral cannabinol in healthy adults. Drug Testing & Analysis.\",\n-        \"reference\": \"https://doi.org/10.1002/dta.3284\"\n+        \"name\": \"TripSit Factsheet: Amfecloral\",\n+        \"reference\": \"https://drugs.tripsit.me/amfecloral\"\n-        \"name\": \"Reddit r/CBD – “What’s been your experience with CBN?” (2024 user survey)\",\n-        \"reference\": \"https://www.reddit.com/r/CBD/comments/1ic6js2/whats_been_your_experience_with_cbn/\"\n-      },\n-      {\n-        \"name\": \"Wikipedia: Cannabinol\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Cannabinol\"\n+        \"name\": \"Wikipedia: Amfecloral\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Amfecloral\"\n-      \"cannabinoid\",\n-      \"depressant\",\n-      \"supplement\"\n+      \"stimulant\",\n+      \"sedative\",\n+      \"research-chemical\",\n+      \"habit-forming\",\n+      \"depressant\"\n\n# Diethylpropion · #581\n\n-  \"id\": 580,\n-  \"title\": \"Amfecloral\",\n+  \"id\": 581,\n+  \"title\": \"Diethylpropion\",\n-    \"drug_name\": \"Amfecloral\",\n-    \"chemical_name\": \"Amfecloral\",\n-    \"alternative_name\": \"\",\n-    \"chemical_class\": \"Amphetamines\",\n+    \"drug_name\": \"Diethylpropion\",\n+    \"chemical_name\": \"Amfepramone\",\n+    \"alternative_name\": \"Amfepramone\",\n+    \"chemical_class\": \"Cathinones\",\n-    \"psychoactive_class\": \"Stimulant–sedative combination (releases amphetamine + chloral-hydrate metabolite)\",\n+    \"psychoactive_class\": \"Stimulant; Anorectic\",\n-            \"light\": \"10 – 25 mg\",\n-            \"common\": \"25 – 50 mg\",\n-            \"strong\": \"50 – 75 mg\",\n-            \"heavy\": \"75 mg + \"\n+            \"light\": \"25–50 mg\",\n+            \"common\": \"50–100 mg\",\n+            \"strong\": \"100–150 mg\",\n+            \"heavy\": \"150 mg +\"\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"10–20 mg\",\n+            \"common\": \"20–40 mg\",\n+            \"strong\": \"40–60 mg\",\n+            \"heavy\": \"60 mg +\"\n+          }\n-            \"total_duration\": \"6 - 12 h primary effects (residual sedation or stimulation up to 24 h)\",\n-            \"onset\": \"0.5 - 1.5 h\",\n-            \"peak\": \"1.5 - 4 h\",\n-            \"offset\": \"2 - 4 h\",\n-            \"after_effects\": \"‘Amphetamine after-glow’ or rebound fatigue / insomnia 6 - 24 h\"\n+            \"total_duration\": \"4-6 h (IR); up to 8 h (SR)\",\n+            \"onset\": \"20-60 min\",\n+            \"peak\": \"1-3 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"1-3 h residual stimulation / insomnia\"\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"4-6 h (IR); up to 8 h (SR)\",\n+            \"onset\": \"20-60 min\",\n+            \"peak\": \"1-3 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"1-3 h residual stimulation / insomnia\"\n+          }\n-    \"addiction_potential\": \"Moderate-to-high. As with other amphetamine pro-drugs, repeated use can produce psychological dependence, sleep disruption and withdrawal dysphoria. Chloral component adds some risk of tolerance to GABA-ergic sedatives.\",\n+    \"addiction_potential\": \"Moderate. Classified as a Schedule IV substance (US). Psychological dependence and escalation of dose reported after weeks of daily use.\",\n-        \"MAOIs\",\n-        \"Tramadol\",\n-        \"DXM\",\n-        \"2C-T-x\",\n-        \"DOx\",\n-        \"NBOMe\",\n-        \"PVP-class cathinones\"\n+        \"MAOIs (phenelzine, tranylcypromine, selegiline, linezolid) – risk of hypertensive crisis\",\n+        \"Other adrenergic anorectics taken concurrently or within 14 days\"\n-        \"High-dose alcohol\",\n-        \"Cocaine\",\n-        \"Other strong stimulants (methylphenidate, cathinones)\",\n-        \"MMC-class cathinones\"\n+        \"High-dose stimulants (amphetamine, methamphetamine, cocaine, methylphenidate, synthetic cathinones) – additive cardiotoxicity\",\n+        \"Serotonergic releasers (MDMA, 4-MMC) – hyperthermia / hypertension\"\n-        \"SSRIs/SNRIs\",\n-        \"Bupropion\",\n-        \"Caffeine\",\n-        \"Cannabis\",\n-        \"Benzodiazepines\",\n-        \"GHB/GBL\",\n-        \"Ketamine\",\n-        \"Opioids\"\n+        \"SSRIs & SNRIs – ↑serotonin & blood-pressure\",\n+        \"Bupropion & other NDRIs – additive stimulation\",\n+        \"Tricyclic antidepressants – arrhythmia risk\",\n+        \"Alcohol – masks impairment; ↑cardiac strain\",\n+        \"Caffeine – tachycardia / anxiety\",\n+        \"Antihypertensives – reduced efficacy\"\n-    \"notes\": \"• Marketed in the 1960s-70s as the anorectic ‘Acutran’; withdrawn worldwide.\\n• Hydrolyses to roughly one part amphetamine and one part chloral hydrate, giving a ‘smoother’ onset than amphetamine alone but with possible next-day grogginess.\\n• Cardiostimulant effect is milder than equimolar amphetamine; however chloral’s metabolite (trichloroethanol) is a hypnotic that can potentiate other CNS depressants – be cautious with alcohol, benzos, barbiturates.\\n• Little modern human data exist; dosage ranges are extrapolated from historic prescribing information (25 mg tablets, 1–3 × daily) and from limited user reports.\\n• Because chloral is hepatotoxic in excess, chronic high-dose use may add liver stress beyond that seen with amphetamine alone.\\n• Drug checking is recommended – authentic material is rare and the name is sometimes mis-used online.\",\n+    \"notes\": \"• Formerly marketed for short-term (≤12 wk) weight loss as Tenuate/Tepanil. EMA recommended withdrawal in 2022 over risk of pulmonary hypertension & valvular heart disease.\\n• Pro-drug; major active metabolite is ethcathinone, a noradrenaline & dopamine releaser. Euphoria usually mild compared with amphetamine but cardiovascular effects similar.\\n• Contra-indicated in uncontrolled hypertension, cardiovascular disease, hyperthyroidism, glaucoma, severe anxiety, or history of drug misuse.\\n• Rapid tolerance develops; escalating doses increase risk of arrhythmia, insomnia, psychosis-like reactions.\\n• Harm-reduction: limit to ≤100 mg/day, hydrate, monitor BP/HR, avoid consecutive daily use, do not combine with other stimulants or MAOIs.\",\n-      \"Appetite suppression\",\n-      \"Wakefulness\",\n-      \"Mental stimulation/focus\",\n-      \"Enhanced motivation\",\n-      \"Reduced fatigue\",\n-      \"Muscle tension/bruxism\",\n+      \"Increased energy\",\n+      \"Appetite suppression\",\n+      \"Increased focus/productivity\",\n+      \"Talkativeness\",\n+      \"Sweating\",\n+      \"Elevated blood pressure\",\n+      \"Anxiety/irritability\",\n+      \"Insomnia\",\n-      \"Decreased anxiety (during peak, from chloral)\",\n-      \"Mild sedation on comedown\",\n-      \"Insomnia or restless sleep\",\n-      \"Rebound fatigue/irritability\"\n+      \"Tremor\",\n+      \"Headache\",\n+      \"Crash-fatigue or low mood after offset\"\n-      \"full_tolerance\": \"About 2–3 weeks of daily use\",\n-      \"half_tolerance\": \"≈ 3–7 days\",\n-      \"zero_tolerance\": \"1–2 months abstinence\",\n+      \"full_tolerance\": \"≈1–2 weeks of daily use\",\n+      \"half_tolerance\": \"3–7 days abstinence\",\n+      \"zero_tolerance\": \"2–4 weeks abstinence\",\n-        \"Amphetamine\",\n-        \"Methamphetamine\",\n-        \"Other amphetamine pro-drugs\",\n-        \"Cathinones\",\n-        \"Other GABA-ergic hypnotics (for chloral component)\"\n+        \"Amphetamines\",\n+        \"Synthetic cathinone stimulants\"\n-    \"half_life\": \"Parent compound ≈ 2–3 h; released amphetamine 9–14 h; trichloroethanol 4–8 h\",\n+    \"half_life\": \"Parent 2–3 h; active metabolite 4–6 h\",\n-        \"name\": \"Amfecloral – compound overview\",\n-        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/164260\"\n+        \"name\": \"Amfepramone – Wikipedia\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Amfepramone\"\n-        \"name\": \"Fitch FW et al. ‘Anorectic drugs: comparative appraisal.’ Am. J. Clin. Nutr. 1970;23(9):1108-1117.\",\n-        \"reference\": \"https://doi.org/10.1093/ajcn/23.9.1108\"\n+        \"name\": \"Tenuate (diethylpropion hydrochloride) Prescribing Information\",\n+        \"reference\": \"https://www.drugs.com/pro/tenuate.html\"\n-        \"name\": \"Amfecloral product monograph ‘Acutran’ (Parke-Davis, 1969 archival brochure).\",\n-        \"reference\": \"https://archive.org/details/acutran-brochure\"\n+        \"name\": \"EMA recommends withdrawal of amfepramone-containing medicines\",\n+        \"reference\": \"https://www.ema.europa.eu/en/news/ema-recommends-withdrawal-amfepramone-containing-medicines\"\n-        \"name\": \"TripSit Factsheet: Amfecloral\",\n-        \"reference\": \"https://drugs.tripsit.me/amfecloral\"\n+        \"name\": \"Diethylpropion – PubChem Compound Summary\",\n+        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/Diethylpropion\"\n-        \"name\": \"Wikipedia: Amfecloral\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Amfecloral\"\n+        \"name\": \"DailyMed – DIETHYLPROPION HCl label\",\n+        \"reference\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a263b7e6-24f5-4e44-83cf-791b57d7bf49\"\n+      },\n+      {\n+        \"name\": \"Amfepramone (diethylproprion) user discussion\",\n+        \"reference\": \"https://www.reddit.com/r/ObscureDrugs/comments/1b3vu16/amfepramone_diethylproprion/\"\n-      \"sedative\",\n-      \"research-chemical\",\n-      \"depressant\"\n+      \"research-chemical\"\n\n# AM-694 · #583\n\n-  \"id\": 581,\n-  \"title\": \"Diethylpropion\",\n+  \"id\": 583,\n+  \"title\": \"AM-694\",\n-    \"drug_name\": \"Diethylpropion\",\n-    \"chemical_name\": \"Amfepramone\",\n-    \"alternative_name\": \"Amfepramone\",\n-    \"chemical_class\": \"Cathinones\",\n-    \"mechanism_of_action\": \"Dopamine-norepinephrine releasing agent\",\n-    \"psychoactive_class\": \"Stimulant; Anorectic\",\n+    \"drug_name\": \"AM-694\",\n+    \"chemical_name\": \"AM-694\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Synthetic cannabinoids\",\n+    \"mechanism_of_action\": \"CB1 and CB2 receptor full agonist\",\n+    \"psychoactive_class\": \"cannabinoid; hallucinogen\",\n-          \"route\": \"oral\",\n+          \"route\": \"smoked\",\n-            \"threshold\": \"10 mg\",\n-            \"light\": \"25–50 mg\",\n-            \"common\": \"50–100 mg\",\n-            \"strong\": \"100–150 mg\",\n-            \"heavy\": \"150 mg +\"\n+            \"threshold\": \"0.05 mg\",\n+            \"light\": \"0.1 – 0.25 mg\",\n+            \"common\": \"0.25 – 1 mg\",\n+            \"strong\": \"1 – 2 mg\",\n+            \"heavy\": \"≥2 mg\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"oral\",\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"10–20 mg\",\n-            \"common\": \"20–40 mg\",\n-            \"strong\": \"40–60 mg\",\n-            \"heavy\": \"60 mg +\"\n+            \"threshold\": \"0.3 mg\",\n+            \"light\": \"0.5 – 1 mg\",\n+            \"common\": \"1 – 2 mg\",\n+            \"strong\": \"2 – 3 mg\",\n+            \"heavy\": \"≥3 mg\"\n-          \"route\": \"oral\",\n+          \"route\": \"smoked\",\n-            \"oral\"\n+            \"smoked\"\n-            \"total_duration\": \"4-6 h (IR); up to 8 h (SR)\",\n-            \"onset\": \"20-60 min\",\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"1-3 h residual stimulation / insomnia\"\n+            \"total_duration\": \"1 - 2 h\",\n+            \"onset\": \"0.5-2 min\",\n+            \"peak\": \"5-20 min\",\n+            \"offset\": \"30-60 min\",\n+            \"after_effects\": \"Residual lethargy / headache 1-3 h\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"oral\",\n-            \"insufflated\"\n+            \"oral\"\n-            \"total_duration\": \"4-6 h (IR); up to 8 h (SR)\",\n-            \"onset\": \"20-60 min\",\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"1-3 h residual stimulation / insomnia\"\n+            \"total_duration\": \"2 - 4 h\",\n+            \"onset\": \"30-60 min\",\n+            \"peak\": \"45-120 min\",\n+            \"offset\": \"60-120 min\",\n+            \"after_effects\": \"Residual lethargy / headache 1-3 h\"\n-    \"addiction_potential\": \"Moderate. Classified as a Schedule IV substance (US). Psychological dependence and escalation of dose reported after weeks of daily use.\",\n+    \"addiction_potential\": \"Moderate-to-high. As a full CB1 agonist it produces tolerance rapidly and can cause withdrawal (irritability, insomnia, nausea) after daily use of ≥1 week. Psychological craving comparable to other potent synthetic cannabinoids.\",\n-        \"MAOIs (phenelzine, tranylcypromine, selegiline, linezolid) – risk of hypertensive crisis\",\n-        \"Other adrenergic anorectics taken concurrently or within 14 days\"\n+        \"sympathomimetic stimulants (cocaine, amphetamine)\",\n+        \"MAOIs\",\n+        \"other potent synthetic cannabinoids (risk of cumulative overdose)\"\n-        \"High-dose stimulants (amphetamine, methamphetamine, cocaine, methylphenidate, synthetic cathinones) – additive cardiotoxicity\",\n-        \"Serotonergic releasers (MDMA, 4-MMC) – hyperthermia / hypertension\"\n+        \"alcohol\",\n+        \"opioids\",\n+        \"GHB\",\n+        \"benzodiazepines (deep sedation, respiratory depression when combined)\"\n-        \"SSRIs & SNRIs – ↑serotonin & blood-pressure\",\n-        \"Bupropion & other NDRIs – additive stimulation\",\n-        \"Tricyclic antidepressants – arrhythmia risk\",\n-        \"Alcohol – masks impairment; ↑cardiac strain\",\n-        \"Caffeine – tachycardia / anxiety\",\n-        \"Antihypertensives – reduced efficacy\"\n+        \"dissociatives\",\n+        \"SSRIs/SNRIs (serotonin & anxiety effects)\",\n+        \"classic psychedelics\",\n+        \"antihypertensives\"\n-    \"notes\": \"• Formerly marketed for short-term (≤12 wk) weight loss as Tenuate/Tepanil. EMA recommended withdrawal in 2022 over risk of pulmonary hypertension & valvular heart disease.\\n• Pro-drug; major active metabolite is ethcathinone, a noradrenaline & dopamine releaser. Euphoria usually mild compared with amphetamine but cardiovascular effects similar.\\n• Contra-indicated in uncontrolled hypertension, cardiovascular disease, hyperthyroidism, glaucoma, severe anxiety, or history of drug misuse.\\n• Rapid tolerance develops; escalating doses increase risk of arrhythmia, insomnia, psychosis-like reactions.\\n• Harm-reduction: limit to ≤100 mg/day, hydrate, monitor BP/HR, avoid consecutive daily use, do not combine with other stimulants or MAOIs.\",\n+    \"notes\": \"AM-694 is an extremely potent research-grade cannabinoid originally developed as a PET radiotracer. Sub-milligram accuracy is mandatory; use a 0.001 g scale and volumetric dosing when possible. Reports describe a calm, slightly dissociative high that plateaus, but acute anxiety, tachycardia and short psychotic episodes have occurred, especially with blends of unknown purity. Two hospitalisations with psychiatric symptoms were reported in Ireland shortly after commercial release (2010). Headache and vasoconstriction are common above 1 mg. Because the compound contains an iodo-benzoyl moiety and a 5-fluoropentyl chain, toxic metabolites (iodine release, fluoro-alkyl oxidative products) are plausible, and long-term safety is unknown. Avoid daily use, avoid combustion temperatures >230 °C to limit toxic pyrolysates, and store away from light to reduce degradation.\",\n-      \"Mild euphoria\",\n-      \"Increased energy\",\n-      \"Appetite suppression\",\n-      \"Increased focus/productivity\",\n-      \"Talkativeness\",\n+      \"Euphoria\",\n+      \"Anxiolysis\",\n+      \"Sedation\",\n+      \"Time distortion\",\n+      \"Mild visual enhancement\",\n+      \"Short-term memory impairment\",\n+      \"Body load / chest pressure\",\n-      \"Sweating\",\n-      \"Tachycardia\",\n-      \"Elevated blood pressure\",\n-      \"Anxiety/irritability\",\n-      \"Insomnia\",\n-      \"Mydriasis\",\n-      \"Tremor\",\n+      \"Reddened eyes\",\n+      \"Increased heart rate\",\n-      \"Crash-fatigue or low mood after offset\"\n+      \"Nausea\",\n+      \"Paranoia or panic at high doses\",\n+      \"Appetite stimulation\",\n+      \"Afterglow fatigue\"\n-      \"full_tolerance\": \"≈1–2 weeks of daily use\",\n-      \"half_tolerance\": \"3–7 days abstinence\",\n-      \"zero_tolerance\": \"2–4 weeks abstinence\",\n+      \"full_tolerance\": \"3-5 consecutive days of moderate use\",\n+      \"half_tolerance\": \"~1-2 weeks\",\n+      \"zero_tolerance\": \"≥4 weeks abstinence\",\n-        \"Amphetamines\",\n-        \"Synthetic cathinone stimulants\"\n+        \"Cannabis (THC)\",\n+        \"Other synthetic cannabinoids\"\n-    \"half_life\": \"Parent 2–3 h; active metabolite 4–6 h\",\n+    \"half_life\": \"Animal data suggest plasma t½ ≈ 3-8 h; subjective effects resolve sooner due to redistribution.\",\n-        \"name\": \"Amfepramone – Wikipedia\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Amfepramone\"\n+        \"name\": \"Donohue BL et al. “Synthesis and biological evaluation of AM-694, a high-affinity CB1 agonist.” Bioorg Med Chem Lett 18 (2008): 5480-3.\",\n+        \"reference\": \"https://doi.org/10.1016/j.bmcl.2008.09.029\"\n-        \"name\": \"Tenuate (diethylpropion hydrochloride) Prescribing Information\",\n-        \"reference\": \"https://www.drugs.com/pro/tenuate.html\"\n+        \"name\": \"Donohue SR et al. “Preclinical evaluation of [18F]AM-694 as a PET imaging agent for CB1 receptors.” Nucl Med Biol 36 (2009): 695-701.\",\n+        \"reference\": \"https://doi.org/10.1016/j.nucmedbio.2009.04.010\"\n-        \"name\": \"EMA recommends withdrawal of amfepramone-containing medicines\",\n-        \"reference\": \"https://www.ema.europa.eu/en/news/ema-recommends-withdrawal-amfepramone-containing-medicines\"\n+        \"name\": \"Bluelight forum – “AM-694 and smoking blends WARNING” (thread, 2010).\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/am-694-and-smoking-blends-warning.488959/\"\n-        \"name\": \"Diethylpropion – PubChem Compound Summary\",\n-        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/Diethylpropion\"\n+        \"name\": \"PubChem Compound Summary for CID 10491092 (AM-694).\",\n+        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/10491092\"\n-        \"name\": \"DailyMed – DIETHYLPROPION HCl label\",\n-        \"reference\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a263b7e6-24f5-4e44-83cf-791b57d7bf49\"\n-      },\n-      {\n-        \"name\": \"Amfepramone (diethylproprion) user discussion\",\n-        \"reference\": \"https://www.reddit.com/r/ObscureDrugs/comments/1b3vu16/amfepramone_diethylproprion/\"\n+        \"name\": \"EMCDDA–Europol 2011. Report on new psychoactive substance AM-694.\",\n+        \"reference\": \"https://www.emcdda.europa.eu/publications/technical-reports/2011/am-694_en\"\n-      \"stimulant\",\n+      \"cannabinoid\",\n+      \"research-chemical\",\n-      \"research-chemical\"\n+      \"depressant\",\n+      \"sedative\"\n\n# ADBICA · #584\n\n-  \"id\": 583,\n-  \"title\": \"AM-694\",\n+  \"id\": 584,\n+  \"title\": \"ADBICA\",\n-    \"drug_name\": \"AM-694\",\n-    \"chemical_name\": \"AM-694\",\n+    \"drug_name\": \"ADBICA\",\n+    \"chemical_name\": \"ADBICA\",\n-            \"threshold\": \"0.05 mg\",\n-            \"light\": \"0.1 – 0.25 mg\",\n-            \"common\": \"0.25 – 1 mg\",\n-            \"strong\": \"1 – 2 mg\",\n-            \"heavy\": \"≥2 mg\"\n+            \"threshold\": \"~0.25 mg\",\n+            \"light\": \"0.25 – 0.5 mg\",\n+            \"common\": \"0.5 – 1 mg\",\n+            \"strong\": \"1 – 1.5 mg\",\n+            \"heavy\": \"≥1.5 mg\"\n-            \"threshold\": \"0.3 mg\",\n-            \"light\": \"0.5 – 1 mg\",\n-            \"common\": \"1 – 2 mg\",\n-            \"strong\": \"2 – 3 mg\",\n-            \"heavy\": \"≥3 mg\"\n+            \"threshold\": \"~0.3 mg\",\n+            \"light\": \"0.3 – 0.6 mg\",\n+            \"common\": \"0.6 – 1.2 mg\",\n+            \"strong\": \"1.2 – 2 mg\",\n+            \"heavy\": \">2 mg\"\n-            \"onset\": \"0.5-2 min\",\n-            \"peak\": \"5-20 min\",\n-            \"offset\": \"30-60 min\",\n-            \"after_effects\": \"Residual lethargy / headache 1-3 h\"\n+            \"onset\": \"30 - 90 s\",\n+            \"peak\": \"5 - 30 min\",\n+            \"offset\": \"~1 h\",\n+            \"after_effects\": \"Residual lethargy & cognitive dulling 1 - 3 h\"\n-            \"total_duration\": \"2 - 4 h\",\n-            \"onset\": \"30-60 min\",\n-            \"peak\": \"45-120 min\",\n-            \"offset\": \"60-120 min\",\n-            \"after_effects\": \"Residual lethargy / headache 1-3 h\"\n+            \"total_duration\": \"3 - 6 h\",\n+            \"onset\": \"30 - 60 min\",\n+            \"peak\": \"1 - 3 h\",\n+            \"offset\": \"~2 h\",\n+            \"after_effects\": \"Residual lethargy & cognitive dulling 1 - 3 h\"\n-    \"addiction_potential\": \"Moderate-to-high. As a full CB1 agonist it produces tolerance rapidly and can cause withdrawal (irritability, insomnia, nausea) after daily use of ≥1 week. Psychological craving comparable to other potent synthetic cannabinoids.\",\n+    \"addiction_potential\": \"High relative to natural cannabis. Daily use can produce tolerance, dependence, intense cravings and a pronounced withdrawal syndrome (irritability, insomnia, nausea, diaphoresis).\",\n-        \"sympathomimetic stimulants (cocaine, amphetamine)\",\n-        \"MAOIs\",\n-        \"other potent synthetic cannabinoids (risk of cumulative overdose)\"\n+        \"Alcohol\",\n+        \"Opioids\",\n+        \"Benzodiazepines\",\n+        \"Other potent synthetic cannabinoids\",\n+        \"Stimulants (↑cardiotoxicity)\"\n-        \"alcohol\",\n-        \"opioids\",\n-        \"GHB\",\n-        \"benzodiazepines (deep sedation, respiratory depression when combined)\"\n+        \"MAO-Is\",\n+        \"Tramadol (seizure risk)\"\n-        \"dissociatives\",\n-        \"SSRIs/SNRIs (serotonin & anxiety effects)\",\n-        \"classic psychedelics\",\n-        \"antihypertensives\"\n+        \"CYP3A4 inhibitors (ketoconazole, grapefruit) may increase levels\",\n+        \"SSRIs/SNRIs (serotonergic anxiety)\"\n-    \"notes\": \"AM-694 is an extremely potent research-grade cannabinoid originally developed as a PET radiotracer. Sub-milligram accuracy is mandatory; use a 0.001 g scale and volumetric dosing when possible. Reports describe a calm, slightly dissociative high that plateaus, but acute anxiety, tachycardia and short psychotic episodes have occurred, especially with blends of unknown purity. Two hospitalisations with psychiatric symptoms were reported in Ireland shortly after commercial release (2010). Headache and vasoconstriction are common above 1 mg. Because the compound contains an iodo-benzoyl moiety and a 5-fluoropentyl chain, toxic metabolites (iodine release, fluoro-alkyl oxidative products) are plausible, and long-term safety is unknown. Avoid daily use, avoid combustion temperatures >230 °C to limit toxic pyrolysates, and store away from light to reduce degradation.\",\n+    \"notes\": \"ADBICA is a very potent full agonist at CB₁ and CB₂ receptors (EC₅₀ ≈ 5 nM), several-fold stronger than Δ⁹-THC. Because batches are often mis-weighed or sprayed unevenly on herbal material, accidental overdose is common and has been linked to acute psychosis, seizures, tachyarrhythmia, kidney injury and death. Begin with micro-doses carefully weighed on a 0.001 g scale. Avoid redosing within the same session; effects can spike suddenly. Provide a calm setting, hydration and a sober sitter. If severe anxiety, chest pain, confusion or uncontrollable vomiting occur, seek medical help immediately.\",\n+      \"Rapid, intense intoxication\",\n-      \"Anxiolysis\",\n-      \"Sedation\",\n+      \"Anxiolysis or severe anxiety/panic (dose-dependent)\",\n-      \"Mild visual enhancement\",\n-      \"Short-term memory impairment\",\n-      \"Body load / chest pressure\",\n+      \"Visual sharpening or mild pseudo-hallucinations\",\n-      \"Reddened eyes\",\n-      \"Increased heart rate\",\n-      \"Headache\",\n-      \"Nausea\",\n-      \"Paranoia or panic at high doses\",\n-      \"Appetite stimulation\",\n-      \"Afterglow fatigue\"\n+      \"Red eyes\",\n+      \"Tachycardia\",\n+      \"Dissociation at high doses\",\n+      \"Nausea/vomiting\",\n+      \"Strong dysphoria on comedown\"\n-      \"full_tolerance\": \"3-5 consecutive days of moderate use\",\n-      \"half_tolerance\": \"~1-2 weeks\",\n-      \"zero_tolerance\": \"≥4 weeks abstinence\",\n+      \"full_tolerance\": \"Develops after 3 – 7 days of daily use\",\n+      \"half_tolerance\": \"~1 – 2 weeks of abstinence\",\n+      \"zero_tolerance\": \"≥4 weeks\",\n-        \"Cannabis (THC)\",\n+        \"Cannabis\",\n-    \"half_life\": \"Animal data suggest plasma t½ ≈ 3-8 h; subjective effects resolve sooner due to redistribution.\",\n+    \"half_life\": \"Estimated 2 – 4 h (parent compound); active metabolites may extend subjective effects.\",\n-        \"name\": \"Donohue BL et al. “Synthesis and biological evaluation of AM-694, a high-affinity CB1 agonist.” Bioorg Med Chem Lett 18 (2008): 5480-3.\",\n-        \"reference\": \"https://doi.org/10.1016/j.bmcl.2008.09.029\"\n+        \"name\": \"Banister SD et al. Pharmacology of indole & indazole synthetic cannabinoids.\",\n+        \"reference\": \"https://doi.org/10.1016/j.drugalcdep.2015.06.034\"\n-        \"name\": \"Donohue SR et al. “Preclinical evaluation of [18F]AM-694 as a PET imaging agent for CB1 receptors.” Nucl Med Biol 36 (2009): 695-701.\",\n-        \"reference\": \"https://doi.org/10.1016/j.nucmedbio.2009.04.010\"\n+        \"name\": \"WHO Expert Committee on Drug Dependence – ADB-ICA Critical Review (2019)\",\n+        \"reference\": \"https://cdn.who.int/media/docs/default-source/controlled-substances/adb-ica.pdf\"\n-        \"name\": \"Bluelight forum – “AM-694 and smoking blends WARNING” (thread, 2010).\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/am-694-and-smoking-blends-warning.488959/\"\n+        \"name\": \"Poklis JL et al. Identification of ADBICA in herbal incense seized in Virginia, USA.\",\n+        \"reference\": \"https://www.sciencedirect.com/science/article/pii/S0379073813002443\"\n-        \"name\": \"PubChem Compound Summary for CID 10491092 (AM-694).\",\n-        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/10491092\"\n+        \"name\": \"Wikipedia – ADBICA\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/ADBICA\"\n-        \"name\": \"EMCDDA–Europol 2011. Report on new psychoactive substance AM-694.\",\n-        \"reference\": \"https://www.emcdda.europa.eu/publications/technical-reports/2011/am-694_en\"\n+        \"name\": \"User reports (summary thread) – r/DrugNerds\",\n+        \"reference\": \"https://www.reddit.com/r/DrugNerds/comments/3c06en/the_pharmacology_of_indole_and_indazole_synthetic/\"\n-      \"depressant\",\n-      \"sedative\"\n+      \"depressant\"\n\n# Afloqualone · #585\n\n-  \"id\": 584,\n-  \"title\": \"ADBICA\",\n+  \"id\": 585,\n+  \"title\": \"Afloqualone\",\n-    \"drug_name\": \"ADBICA\",\n-    \"chemical_name\": \"ADBICA\",\n+    \"drug_name\": \"Afloqualone\",\n+    \"chemical_name\": \"Afloqualone\",\n-    \"chemical_class\": \"Synthetic cannabinoids\",\n-    \"mechanism_of_action\": \"CB1 and CB2 receptor full agonist\",\n-    \"psychoactive_class\": \"cannabinoid; hallucinogen\",\n+    \"chemical_class\": \"Quinazolinone\",\n+    \"mechanism_of_action\": \"Gamma-aminobutyric acid type A receptor positive allosteric modulator (non-benzodiazepine site)\",\n+    \"psychoactive_class\": \"depressant; sedative–hypnotic (GABA_A positive allosteric modulator)\",\n-          \"route\": \"smoked\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"~0.25 mg\",\n-            \"light\": \"0.25 – 0.5 mg\",\n-            \"common\": \"0.5 – 1 mg\",\n-            \"strong\": \"1 – 1.5 mg\",\n-            \"heavy\": \"≥1.5 mg\"\n-          }\n-        },\n-        {\n-            \"threshold\": \"~0.3 mg\",\n-            \"light\": \"0.3 – 0.6 mg\",\n-            \"common\": \"0.6 – 1.2 mg\",\n-            \"strong\": \"1.2 – 2 mg\",\n-            \"heavy\": \">2 mg\"\n+            \"threshold\": \"25 mg\",\n+            \"light\": \"50 – 75 mg\",\n+            \"common\": \"75 – 125 mg\",\n+            \"strong\": \"125 – 200 mg\",\n+            \"heavy\": \"200 mg + \"\n-          \"route\": \"smoked\",\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"1 - 2 h\",\n-            \"onset\": \"30 - 90 s\",\n-            \"peak\": \"5 - 30 min\",\n-            \"offset\": \"~1 h\",\n-            \"after_effects\": \"Residual lethargy & cognitive dulling 1 - 3 h\"\n-          }\n-        },\n-        {\n-            \"total_duration\": \"3 - 6 h\",\n-            \"onset\": \"30 - 60 min\",\n-            \"peak\": \"1 - 3 h\",\n-            \"offset\": \"~2 h\",\n-            \"after_effects\": \"Residual lethargy & cognitive dulling 1 - 3 h\"\n+            \"total_duration\": \"4 - 8 h\",\n+            \"onset\": \"30 - 90 min\",\n+            \"peak\": \"1.5 - 3 h\",\n+            \"offset\": \"2 - 4 h\",\n+            \"after_effects\": \"2 - 6 h residual grogginess\"\n-    \"addiction_potential\": \"High relative to natural cannabis. Daily use can produce tolerance, dependence, intense cravings and a pronounced withdrawal syndrome (irritability, insomnia, nausea, diaphoresis).\",\n+    \"addiction_potential\": \"Moderate-to-high. Allosteric GABA_A agonists of the quinazolinone class produce tolerance and physical dependence comparable to barbiturates or methaqualone when used daily.\",\n+        \"GHB/GBL\",\n-        \"Benzodiazepines\",\n-        \"Other potent synthetic cannabinoids\",\n-        \"Stimulants (↑cardiotoxicity)\"\n+        \"Tramadol\",\n+        \"Barbiturates\",\n+        \"BZDs\",\n+        \"Carisoprodol\"\n-        \"MAO-Is\",\n-        \"Tramadol (seizure risk)\"\n+        \"Gabapentinoids\",\n+        \"Poppers (alkyl nitrites)\",\n+        \"α-PVP class cathinones\"\n-        \"CYP3A4 inhibitors (ketoconazole, grapefruit) may increase levels\",\n-        \"SSRIs/SNRIs (serotonergic anxiety)\"\n+        \"DXM\",\n+        \"Ketamine\",\n+        \"MXE\",\n+        \"MAOIs\",\n+        \"Antihistamines (first-gen)\"\n-    \"notes\": \"ADBICA is a very potent full agonist at CB₁ and CB₂ receptors (EC₅₀ ≈ 5 nM), several-fold stronger than Δ⁹-THC. Because batches are often mis-weighed or sprayed unevenly on herbal material, accidental overdose is common and has been linked to acute psychosis, seizures, tachyarrhythmia, kidney injury and death. Begin with micro-doses carefully weighed on a 0.001 g scale. Avoid redosing within the same session; effects can spike suddenly. Provide a calm setting, hydration and a sober sitter. If severe anxiety, chest pain, confusion or uncontrollable vomiting occur, seek medical help immediately.\",\n+    \"notes\": \"• Potent photosensitiser – sun/UV exposure can precipitate severe dermatitis; cover skin and use high-SPF sunscreen.\\n• Marked ataxia and motor incoordination appear at higher doses; risk of falls.\\n• Mixing with any other CNS depressant markedly increases risk of respiratory depression.\\n• Little clinical experience; purity of RC material is often uncertain – always reagent-test and start with an allergy 1–5 mg.\\n• Fatal overdoses rare but possible; naloxone is NOT effective – treat like barbiturate poisoning (secure airway, supportive care).\",\n-      \"Rapid, intense intoxication\",\n-      \"Euphoria\",\n-      \"Anxiolysis or severe anxiety/panic (dose-dependent)\",\n-      \"Time distortion\",\n-      \"Visual sharpening or mild pseudo-hallucinations\",\n-      \"Dry mouth\",\n-      \"Red eyes\",\n-      \"Tachycardia\",\n-      \"Dissociation at high doses\",\n-      \"Nausea/vomiting\",\n-      \"Strong dysphoria on comedown\"\n+      \"Anxiolysis\",\n+      \"Muscle relaxation\",\n+      \"Sedation\",\n+      \"Euphoria (warm body high)\",\n+      \"Disinhibition\",\n+      \"Slurred speech\",\n+      \"Ataxia\",\n+      \"Retrograde amnesia\",\n+      \"Visual blurring\",\n+      \"Dream-like hypnagogia\",\n+      \"Rebound anxiety/insomnia\",\n+      \"Photophobia / skin tingling under sunlight\"\n-      \"full_tolerance\": \"Develops after 3 – 7 days of daily use\",\n-      \"half_tolerance\": \"~1 – 2 weeks of abstinence\",\n-      \"zero_tolerance\": \"≥4 weeks\",\n+      \"full_tolerance\": \"3–7 days of daily use\",\n+      \"half_tolerance\": \"1–2 weeks\",\n+      \"zero_tolerance\": \"4–6 weeks of abstinence\",\n-        \"Cannabis\",\n-        \"Other synthetic cannabinoids\"\n+        \"Benzodiazepines\",\n+        \"Barbiturates\",\n+        \"Methaqualone\",\n+        \"Other GABA_A PAMs\"\n-    \"half_life\": \"Estimated 2 – 4 h (parent compound); active metabolites may extend subjective effects.\",\n+    \"half_life\": \"Human data scarce; animal PK suggests 6 – 12 h elimination half-life (similar to methaqualone).\",\n-        \"name\": \"Banister SD et al. Pharmacology of indole & indazole synthetic cannabinoids.\",\n-        \"reference\": \"https://doi.org/10.1016/j.drugalcdep.2015.06.034\"\n+        \"name\": \"TripSit data sheet – Afloqualone\",\n+        \"reference\": \"https://drugs.tripsit.me/afloqualone\"\n-        \"name\": \"WHO Expert Committee on Drug Dependence – ADB-ICA Critical Review (2019)\",\n-        \"reference\": \"https://cdn.who.int/media/docs/default-source/controlled-substances/adb-ica.pdf\"\n+        \"name\": \"PubChem CID 234274 – Afloqualone compound summary\",\n+        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/234274\"\n-        \"name\": \"Poklis JL et al. Identification of ADBICA in herbal incense seized in Virginia, USA.\",\n-        \"reference\": \"https://www.sciencedirect.com/science/article/pii/S0379073813002443\"\n+        \"name\": \"Nishimura et al., Photosensitizing Activities of Afloqualone, Jpn. J. Pharmacol. 1984\",\n+        \"reference\": \"https://doi.org/10.1254/jjp.36.103\"\n-        \"name\": \"Wikipedia – ADBICA\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/ADBICA\"\n+        \"name\": \"Bluelight discussion – Afloqualone thread (user reports, 2015)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/afloaqualone-6-amino-2-fluoromethyl-3-2-methylphenyl-quinazolin-4-one-thread.765782/\"\n-        \"name\": \"User reports (summary thread) – r/DrugNerds\",\n-        \"reference\": \"https://www.reddit.com/r/DrugNerds/comments/3c06en/the_pharmacology_of_indole_and_indazole_synthetic/\"\n+        \"name\": \"Reddit /r/ObscureDrugs – Afloqualone experiences (2023)\",\n+        \"reference\": \"https://www.reddit.com/r/ObscureDrugs/comments/10en951/afloqualone/\"\n-      \"cannabinoid\",\n-      \"research-chemical\",\n+      \"depressant\",\n+      \"sedative\",\n-      \"depressant\"\n+      \"research-chemical\",\n+      \"gabaergic\"\n\n# Adinazolam · #587\n\n-  \"id\": 585,\n-  \"title\": \"Afloqualone\",\n+  \"id\": 587,\n+  \"title\": \"Adinazolam\",\n-    \"drug_name\": \"Afloqualone\",\n-    \"chemical_name\": \"Afloqualone\",\n+    \"drug_name\": \"Adinazolam\",\n+    \"chemical_name\": \"Adinazolam\",\n-    \"chemical_class\": \"Quinazolinone\",\n-    \"mechanism_of_action\": \"Gamma-aminobutyric acid type A receptor positive allosteric modulator (non-benzodiazepine site)\",\n-    \"psychoactive_class\": \"depressant; sedative–hypnotic (GABA_A positive allosteric modulator)\",\n+    \"chemical_class\": \"Benzodiazepine (triazolobenzodiazepine)\",\n+    \"mechanism_of_action\": \"Gamma-aminobutyric acid type A receptor positive allosteric modulator (benzodiazepine site)\",\n+    \"psychoactive_class\": \"Depressant\",\n-            \"threshold\": \"25 mg\",\n-            \"light\": \"50 – 75 mg\",\n-            \"common\": \"75 – 125 mg\",\n-            \"strong\": \"125 – 200 mg\",\n-            \"heavy\": \"200 mg + \"\n+            \"threshold\": \"<5 mg\",\n+            \"light\": \"5 – 15 mg\",\n+            \"common\": \"15 – 30 mg\",\n+            \"strong\": \"30 – 50 mg\",\n+            \"heavy\": \">50 mg\"\n+        },\n+        {\n+          \"route\": \"sublingual\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"<3 mg\",\n+            \"light\": \"3 – 10 mg\",\n+            \"common\": \"10 – 20 mg\",\n+            \"strong\": \"20 – 35 mg\",\n+            \"heavy\": \">35 mg\"\n+          }\n-            \"total_duration\": \"4 - 8 h\",\n-            \"onset\": \"30 - 90 min\",\n-            \"peak\": \"1.5 - 3 h\",\n-            \"offset\": \"2 - 4 h\",\n-            \"after_effects\": \"2 - 6 h residual grogginess\"\n+            \"total_duration\": \"2 - 8 h\",\n+            \"onset\": \"10 - 25 min\",\n+            \"peak\": \"1 - 2 h\",\n+            \"offset\": \"1.5 - 3 h after peak\",\n+            \"after_effects\": \"4 - 16 h residual next-day sedation / impairment possible\"\n+        },\n+        {\n+          \"route\": \"sublingual\",\n+          \"canonical_routes\": [\n+            \"sublingual\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"2 - 8 h\",\n+            \"onset\": \"10 - 25 min\",\n+            \"peak\": \"1 - 2 h\",\n+            \"offset\": \"1.5 - 3 h after peak\",\n+            \"after_effects\": \"4 - 16 h residual next-day sedation / impairment possible\"\n+          }\n-    \"addiction_potential\": \"Moderate-to-high. Allosteric GABA_A agonists of the quinazolinone class produce tolerance and physical dependence comparable to barbiturates or methaqualone when used daily.\",\n+    \"addiction_potential\": \"Comparable to other short-acting benzodiazepines (moderate-to-high). Physical dependence can develop after 7-14 days of continuous use, with a withdrawal profile similar to alprazolam but usually milder seizures reported.\",\n+        \"Opioids (incl. tramadol, methadone, oxycodone)\",\n-        \"Opioids\",\n-        \"Tramadol\",\n-        \"BZDs\",\n-        \"Carisoprodol\"\n+        \"Carisoprodol\",\n+        \"Phenibut\"\n-        \"Poppers (alkyl nitrites)\",\n-        \"α-PVP class cathinones\"\n+        \"PVP-class cathinones\",\n+        \"Poppers (alkyl nitrites)\"\n-        \"MAOIs\",\n-        \"Antihistamines (first-gen)\"\n+        \"Antihistamines (first-generation)\",\n+        \"MAOIs (potentiation)\"\n-    \"notes\": \"• Potent photosensitiser – sun/UV exposure can precipitate severe dermatitis; cover skin and use high-SPF sunscreen.\\n• Marked ataxia and motor incoordination appear at higher doses; risk of falls.\\n• Mixing with any other CNS depressant markedly increases risk of respiratory depression.\\n• Little clinical experience; purity of RC material is often uncertain – always reagent-test and start with an allergy 1–5 mg.\\n• Fatal overdoses rare but possible; naloxone is NOT effective – treat like barbiturate poisoning (secure airway, supportive care).\",\n+    \"notes\": \"Adinazolam is a short-acting 1,5-triazolobenzodiazepine originally investigated as both an anxiolytic and antidepressant (brand name Deracyn) but never brought to market. In clinical trials (10–90 mg/day) it showed rapid relief of anxiety and modest antidepressant efficacy comparable to tricyclics with fewer anticholinergic effects. Recreationally it produces a warm, calm euphoria with less amnesia and muscle relaxation than diazepam, although individual reports vary. Because of its short half-life, interdose rebound anxiety is common and redosing drives escalation. Abrupt discontinuation after sustained use may precipitate agitation, tremor, or seizures—taper by 10 % every 3–7 days. Metabolised hepatically (CYP3A4) to N-desmethyl-adinazolam (active) and 8-chloro-desmethyl-diazepam; inhibitors such as ketoconazole can double plasma levels. Avoid combining with other CNS depressants, driving for at least 8 h after last dose, and use extra caution in geriatric users due to falls risk.\",\n-      \"Muscle relaxation\",\n-      \"Euphoria (warm body high)\",\n+      \"Mild euphoria/antidepressant lift\",\n-      \"Slurred speech\",\n+      \"Muscle relaxation (moderate)\",\n+      \"Cognitive and motor impairment\",\n+      \"Short-term memory suppression\",\n-      \"Retrograde amnesia\",\n-      \"Visual blurring\",\n-      \"Dream-like hypnagogia\",\n-      \"Rebound anxiety/insomnia\",\n-      \"Photophobia / skin tingling under sunlight\"\n+      \"Next-day grogginess (at high doses)\",\n+      \"Reduced seizure aura (user reports)\"\n-      \"full_tolerance\": \"3–7 days of daily use\",\n-      \"half_tolerance\": \"1–2 weeks\",\n-      \"zero_tolerance\": \"4–6 weeks of abstinence\",\n+      \"full_tolerance\": \"~14 days of daily use\",\n+      \"half_tolerance\": \"~7 days\",\n+      \"zero_tolerance\": \"3 – 6 weeks abstinence\",\n-        \"Benzodiazepines\",\n+        \"Other benzodiazepines\",\n+        \"Non-benzodiazepine Z-drugs\",\n-        \"Methaqualone\",\n-        \"Other GABA_A PAMs\"\n+        \"GABA_A positive modulators\"\n-    \"half_life\": \"Human data scarce; animal PK suggests 6 – 12 h elimination half-life (similar to methaqualone).\",\n+    \"half_life\": \"2 – 3 h (mean 2.3 h); active metabolite N-desmethyl-adinazolam ≈ 8 h\",\n-        \"name\": \"TripSit data sheet – Afloqualone\",\n-        \"reference\": \"https://drugs.tripsit.me/afloqualone\"\n+        \"name\": \"TripSit Factsheet – Adinazolam\",\n+        \"reference\": \"https://drugs.tripsit.me/adinazolam\"\n-        \"name\": \"PubChem CID 234274 – Afloqualone compound summary\",\n-        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/234274\"\n+        \"name\": \"Brogden RN et al. Adinazolam – review of pharmacology & therapeutic use\",\n+        \"reference\": \"https://doi.org/10.2165/00003495-198020030-00001\"\n-        \"name\": \"Nishimura et al., Photosensitizing Activities of Afloqualone, Jpn. J. Pharmacol. 1984\",\n-        \"reference\": \"https://doi.org/10.1254/jjp.36.103\"\n+        \"name\": \"Schütz E. Pharmacokinetics of adinazolam in humans\",\n+        \"reference\": \"Br J Clin Pharmacol. 1979;7:33S\"\n-        \"name\": \"Bluelight discussion – Afloqualone thread (user reports, 2015)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/afloaqualone-6-amino-2-fluoromethyl-3-2-methylphenyl-quinazolin-4-one-thread.765782/\"\n+        \"name\": \"Feighner JP et al. Controlled trial of adinazolam vs desipramine in geriatric depression\",\n+        \"reference\": \"Int Clin Psychopharmacol. 1990;5(3):227-232\"\n-        \"name\": \"Reddit /r/ObscureDrugs – Afloqualone experiences (2023)\",\n-        \"reference\": \"https://www.reddit.com/r/ObscureDrugs/comments/10en951/afloqualone/\"\n+        \"name\": \"Psychotropics Database – Adinazolam monograph\",\n+        \"reference\": \"http://www.psychotropics.dk\"\n+      },\n+      {\n+        \"name\": \"Reddit user reports compilation (search query: \\\"Adinazolam experience\\\")\",\n+        \"reference\": \"https://www.reddit.com/search/?q=Adinazolam\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Adinazolam\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Adinazolam\"\n-      \"sedative\",\n+      \"benzodiazepine\",\n-      \"research-chemical\",\n\n# AM-2233 · #588\n\n-  \"id\": 587,\n-  \"title\": \"Adinazolam\",\n+  \"id\": 588,\n+  \"title\": \"AM-2233\",\n-    \"drug_name\": \"Adinazolam\",\n-    \"chemical_name\": \"Adinazolam\",\n+    \"drug_name\": \"AM-2233\",\n+    \"chemical_name\": \"AM-2233\",\n-    \"chemical_class\": \"Benzodiazepine (triazolobenzodiazepine)\",\n-    \"mechanism_of_action\": \"Gamma-aminobutyric acid type A receptor positive allosteric modulator (benzodiazepine site)\",\n-    \"psychoactive_class\": \"Depressant\",\n+    \"chemical_class\": \"Synthetic cannabinoids\",\n+    \"mechanism_of_action\": \"CB1 and CB2 receptor full agonist\",\n+    \"psychoactive_class\": \"cannabinoid; hallucinogen\",\n-          \"route\": \"oral\",\n+          \"route\": \"smoked\",\n-            \"threshold\": \"<5 mg\",\n-            \"light\": \"5 – 15 mg\",\n-            \"common\": \"15 – 30 mg\",\n-            \"strong\": \"30 – 50 mg\",\n-            \"heavy\": \">50 mg\"\n+            \"threshold\": \"0.25 mg\",\n+            \"light\": \"0.5 – 1 mg\",\n+            \"common\": \"1 – 2 mg\",\n+            \"strong\": \"2 – 4 mg\",\n+            \"heavy\": \"4 mg +.\"\n-          \"route\": \"sublingual\",\n+          \"route\": \"oral\",\n-            \"threshold\": \"<3 mg\",\n-            \"light\": \"3 – 10 mg\",\n-            \"common\": \"10 – 20 mg\",\n-            \"strong\": \"20 – 35 mg\",\n-            \"heavy\": \">35 mg\"\n+            \"threshold\": \"1 mg\",\n+            \"light\": \"2 – 3 mg\",\n+            \"common\": \"3 – 5 mg\",\n+            \"strong\": \"5 – 8 mg\",\n+            \"heavy\": \"8 mg +.\"\n-          \"route\": \"oral\",\n+          \"route\": \"smoked\",\n-            \"oral\"\n+            \"smoked\"\n-            \"total_duration\": \"2 - 8 h\",\n-            \"onset\": \"10 - 25 min\",\n-            \"peak\": \"1 - 2 h\",\n-            \"offset\": \"1.5 - 3 h after peak\",\n-            \"after_effects\": \"4 - 16 h residual next-day sedation / impairment possible\"\n+            \"total_duration\": \"1 - 3 h\",\n+            \"onset\": \"30 - 90 s\",\n+            \"peak\": \"5 - 20 min\",\n+            \"offset\": \"30 - 90 min\",\n+            \"after_effects\": \"2 - 6 h residual lethargy / anxiety possible\"\n-          \"route\": \"sublingual\",\n+          \"route\": \"oral\",\n-            \"sublingual\"\n+            \"oral\"\n-            \"total_duration\": \"2 - 8 h\",\n-            \"onset\": \"10 - 25 min\",\n-            \"peak\": \"1 - 2 h\",\n-            \"offset\": \"1.5 - 3 h after peak\",\n-            \"after_effects\": \"4 - 16 h residual next-day sedation / impairment possible\"\n+            \"total_duration\": \"3 - 6 h\",\n+            \"onset\": \"15 - 45 min\",\n+            \"peak\": \"45 - 120 min\",\n+            \"offset\": \"30 - 90 min\",\n+            \"after_effects\": \"2 - 6 h residual lethargy / anxiety possible\"\n-    \"addiction_potential\": \"Comparable to other short-acting benzodiazepines (moderate-to-high). Physical dependence can develop after 7-14 days of continuous use, with a withdrawal profile similar to alprazolam but usually milder seizures reported.\",\n+    \"addiction_potential\": \"Moderate to high. Rapid tolerance and escalation of use have been documented in frequent users of synthetic cannabinoids. Withdrawal (irritability, insomnia, sweats) has been reported after only 1–2 weeks of daily exposure.\",\n-        \"Alcohol\",\n-        \"Opioids (incl. tramadol, methadone, oxycodone)\",\n-        \"GHB/GBL\",\n-        \"Barbiturates\",\n-        \"Carisoprodol\",\n-        \"Phenibut\"\n+        \"other high-potency synthetic cannabinoids\",\n+        \"sympathomimetic stimulants (e.g., cocaine, amphetamines)\",\n+        \"MAO-B inhibitors\"\n-        \"Gabapentinoids\",\n-        \"PVP-class cathinones\",\n-        \"Poppers (alkyl nitrites)\"\n+        \"alcohol\",\n+        \"opioids\",\n+        \"benzodiazepines\"\n-        \"DXM\",\n-        \"Ketamine\",\n-        \"MXE\",\n-        \"Antihistamines (first-generation)\",\n-        \"MAOIs (potentiation)\"\n+        \"psychedelics\",\n+        \"dissociatives\",\n+        \"prescription sedatives\"\n-    \"notes\": \"Adinazolam is a short-acting 1,5-triazolobenzodiazepine originally investigated as both an anxiolytic and antidepressant (brand name Deracyn) but never brought to market. In clinical trials (10–90 mg/day) it showed rapid relief of anxiety and modest antidepressant efficacy comparable to tricyclics with fewer anticholinergic effects. Recreationally it produces a warm, calm euphoria with less amnesia and muscle relaxation than diazepam, although individual reports vary. Because of its short half-life, interdose rebound anxiety is common and redosing drives escalation. Abrupt discontinuation after sustained use may precipitate agitation, tremor, or seizures—taper by 10 % every 3–7 days. Metabolised hepatically (CYP3A4) to N-desmethyl-adinazolam (active) and 8-chloro-desmethyl-diazepam; inhibitors such as ketoconazole can double plasma levels. Avoid combining with other CNS depressants, driving for at least 8 h after last dose, and use extra caution in geriatric users due to falls risk.\",\n+    \"notes\": \"AM-2233 is a full CB1/CB2 agonist with sub-nanomolar affinity; overdose margins are extremely narrow. Weigh with a 0.1 mg-resolution scale or volumetrically dose. Acute adverse events include severe anxiety, panic, hallucinations, tachycardia, hypertension, seizures, acute kidney injury and rhabdomyolysis. Very limited human data exist; long-term neurotoxicity is unknown. Avoid driving for at least 6 h. Because of its potency, AM-2233 is sometimes used to adulterate herbal cannabis products—unexpectedly strong reactions have been reported.\",\n-      \"Anxiolysis\",\n+      \"Rapid intoxication\",\n+      \"Euphoria\",\n+      \"Body lightness or heaviness\",\n-      \"Mild euphoria/antidepressant lift\",\n-      \"Disinhibition\",\n-      \"Muscle relaxation (moderate)\",\n-      \"Cognitive and motor impairment\",\n+      \"Altered time perception\",\n+      \"Visual distortions/closed-eye imagery\",\n+      \"Analgesia\",\n+      \"Tachycardia\",\n+      \"Dry mouth\",\n+      \"Anxiety or panic\",\n+      \"Paranoia\",\n-      \"Ataxia\",\n-      \"Next-day grogginess (at high doses)\",\n-      \"Reduced seizure aura (user reports)\"\n+      \"Nausea\",\n+      \"Confusion\",\n+      \"Rapid tolerance buildup\"\n-      \"full_tolerance\": \"~14 days of daily use\",\n-      \"half_tolerance\": \"~7 days\",\n-      \"zero_tolerance\": \"3 – 6 weeks abstinence\",\n+      \"full_tolerance\": \"3–7 days of daily use\",\n+      \"half_tolerance\": \"≈ 1–2 weeks abstinence\",\n+      \"zero_tolerance\": \"≈ 4–6 weeks abstinence\",\n-        \"Other benzodiazepines\",\n-        \"Non-benzodiazepine Z-drugs\",\n-        \"Barbiturates\",\n-        \"GABA_A positive modulators\"\n+        \"cannabis\",\n+        \"other synthetic cannabinoids\"\n-    \"half_life\": \"2 – 3 h (mean 2.3 h); active metabolite N-desmethyl-adinazolam ≈ 8 h\",\n+    \"half_life\": \"~1–2 h (estimated from rat pharmacokinetics; human data unavailable)\",\n-        \"name\": \"TripSit Factsheet – Adinazolam\",\n-        \"reference\": \"https://drugs.tripsit.me/adinazolam\"\n+        \"name\": \"AM-2233 – Wikipedia entry\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/AM-2233\"\n-        \"name\": \"Brogden RN et al. Adinazolam – review of pharmacology & therapeutic use\",\n-        \"reference\": \"https://doi.org/10.2165/00003495-198020030-00001\"\n+        \"name\": \"Huffman JW et al., Enantiomeric cannabinoid receptor ligands, Bioorg Med Chem 13(1), 2005\",\n+        \"reference\": \"https://doi.org/10.1016/j.bmc.2004.09.039\"\n-        \"name\": \"Schütz E. Pharmacokinetics of adinazolam in humans\",\n-        \"reference\": \"Br J Clin Pharmacol. 1979;7:33S\"\n+        \"name\": \"Wiley JL et al., Intrathecal analgesia of R(+)-AM-2233 in mice, J Pharmacol Exp Ther 2014\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/24790041/\"\n-        \"name\": \"Feighner JP et al. Controlled trial of adinazolam vs desipramine in geriatric depression\",\n-        \"reference\": \"Int Clin Psychopharmacol. 1990;5(3):227-232\"\n+        \"name\": \"Bluelight Synthetic Cannabinoid Subthread – Class 5 Benzoylindoles (post #3)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/cannabinoid-subthread-class-5-benzoylindoles.560672/\"\n-        \"name\": \"Psychotropics Database – Adinazolam monograph\",\n-        \"reference\": \"http://www.psychotropics.dk\"\n-      },\n-      {\n-        \"name\": \"Reddit user reports compilation (search query: \\\"Adinazolam experience\\\")\",\n-        \"reference\": \"https://www.reddit.com/search/?q=Adinazolam\"\n-      },\n-      {\n-        \"name\": \"Wikipedia: Adinazolam\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Adinazolam\"\n+        \"name\": \"PubChem: 3081223\",\n+        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/3081223\"\n-      \"depressant\",\n-      \"benzodiazepine\",\n+      \"cannabinoid\",\n+      \"research-chemical\",\n-      \"gabaergic\"\n+      \"sedative\"\n\n# AMB-CHMICA · #589\n\n-  \"id\": 588,\n-  \"title\": \"AM-2233\",\n+  \"id\": 589,\n+  \"title\": \"AMB-CHMICA\",\n-    \"drug_name\": \"AM-2233\",\n-    \"chemical_name\": \"AM-2233\",\n+    \"drug_name\": \"AMB-CHMICA\",\n+    \"chemical_name\": \"AMB-CHMICA\",\n-          \"units\": \"mg\",\n+          \"units\": \"µg\",\n-            \"threshold\": \"0.25 mg\",\n-            \"light\": \"0.5 – 1 mg\",\n-            \"common\": \"1 – 2 mg\",\n-            \"strong\": \"2 – 4 mg\",\n-            \"heavy\": \"4 mg +.\"\n+            \"threshold\": \"<100 µg\",\n+            \"light\": \"100 – 250 µg\",\n+            \"common\": \"250 – 500 µg\",\n+            \"strong\": \"500 – 800 µg\",\n+            \"heavy\": \">800 µg\"\n-            \"threshold\": \"1 mg\",\n-            \"light\": \"2 – 3 mg\",\n-            \"common\": \"3 – 5 mg\",\n-            \"strong\": \"5 – 8 mg\",\n-            \"heavy\": \"8 mg +.\"\n+            \"threshold\": \"0.2 mg\",\n+            \"light\": \"0.3 – 0.6 mg\",\n+            \"common\": \"0.6 – 1.0 mg\",\n+            \"strong\": \"1.0 – 1.5 mg\",\n+            \"heavy\": \">1.5 mg\"\n-            \"total_duration\": \"1 - 3 h\",\n-            \"onset\": \"30 - 90 s\",\n-            \"peak\": \"5 - 20 min\",\n-            \"offset\": \"30 - 90 min\",\n-            \"after_effects\": \"2 - 6 h residual lethargy / anxiety possible\"\n+            \"total_duration\": \"1.5-3 hours\",\n+            \"onset\": \"30 seconds - 2 minutes\",\n+            \"peak\": \"5-30 minutes\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"Up to 6 hours residual lethargy, anxiety, tachycardia\"\n-            \"total_duration\": \"3 - 6 h\",\n-            \"onset\": \"15 - 45 min\",\n-            \"peak\": \"45 - 120 min\",\n-            \"offset\": \"30 - 90 min\",\n-            \"after_effects\": \"2 - 6 h residual lethargy / anxiety possible\"\n+            \"total_duration\": \"4-6 hours\",\n+            \"onset\": \"15-60 minutes\",\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"Up to 6 hours residual lethargy, anxiety, tachycardia\"\n-    \"addiction_potential\": \"Moderate to high. Rapid tolerance and escalation of use have been documented in frequent users of synthetic cannabinoids. Withdrawal (irritability, insomnia, sweats) has been reported after only 1–2 weeks of daily exposure.\",\n+    \"addiction_potential\": \"Moderate to high. Daily users report rapid development of tolerance, withdrawal (insomnia, irritability, nausea) and compulsive redosing similar to other potent synthetic cannabinoids.\",\n-        \"other high-potency synthetic cannabinoids\",\n-        \"sympathomimetic stimulants (e.g., cocaine, amphetamines)\",\n-        \"MAO-B inhibitors\"\n+        \"Gabapentinoids\",\n+        \"Poppers\"\n-        \"alcohol\",\n-        \"opioids\",\n-        \"benzodiazepines\"\n+        \"Alcohol\",\n+        \"Opioids\",\n+        \"Benzos\",\n+        \"GHB/GBL\",\n+        \"DXM\"\n-        \"psychedelics\",\n-        \"dissociatives\",\n-        \"prescription sedatives\"\n+        \"2C-x family\",\n+        \"5-MeO-tryptamines\",\n+        \"Amphetamines\",\n+        \"Cocaine\",\n+        \"DMT\",\n+        \"DOx\",\n+        \"LSD\",\n+        \"Mescaline\",\n+        \"Mushrooms\",\n+        \"NBOMe series\",\n+        \"PVP cathinones\",\n+        \"MAOIs\",\n+        \"MDMA\",\n+        \"MMC cathinones\",\n+        \"MXE\",\n+        \"Ketamine\",\n+        \"Nitrous\",\n+        \"Tramadol\",\n+        \"Caffeine\"\n-    \"notes\": \"AM-2233 is a full CB1/CB2 agonist with sub-nanomolar affinity; overdose margins are extremely narrow. Weigh with a 0.1 mg-resolution scale or volumetrically dose. Acute adverse events include severe anxiety, panic, hallucinations, tachycardia, hypertension, seizures, acute kidney injury and rhabdomyolysis. Very limited human data exist; long-term neurotoxicity is unknown. Avoid driving for at least 6 h. Because of its potency, AM-2233 is sometimes used to adulterate herbal cannabis products—unexpectedly strong reactions have been reported.\",\n+    \"notes\": \"AMB-CHMICA is among the most potent CB1 agonists yet detected (CB1 IC50 ≈ 0.7 nM). Even sub-milligram errors can cause severe toxicity (seizure, hyperemesis, tachyarrhythmia, psychosis). Hot-spot formation in herbal blends is common; using a milligram-accurate scale and volumetric dosing is strongly advised. Several fatal and non-fatal intoxications have been documented in Europe (2015-2020). First-aid: place patient in calm environment, monitor heart rate and temperature, seek emergency care for chest pain, severe agitation, seizures or loss of consciousness.\",\n-      \"Rapid intoxication\",\n-      \"Euphoria\",\n-      \"Body lightness or heaviness\",\n-      \"Sedation\",\n-      \"Altered time perception\",\n-      \"Visual distortions/closed-eye imagery\",\n-      \"Analgesia\",\n-      \"Tachycardia\",\n-      \"Dry mouth\",\n+      \"Rapid, intense intoxication\",\n+      \"Euphoria or dysphoria\",\n+      \"Strong body load\",\n+      \"Vertigo/dizziness\",\n+      \"Time distortion\",\n+      \"Closed-eye visuals at high doses\",\n+      \"Short-term memory suppression\",\n-      \"Short-term memory suppression\",\n-      \"Nausea\",\n-      \"Confusion\",\n-      \"Rapid tolerance buildup\"\n+      \"Tachycardia & hypertension\",\n+      \"Dry mouth / red eyes\",\n+      \"Nausea or vomiting\",\n+      \"Warm/cold flashes\",\n+      \"Disinhibition\",\n+      \"Sedation or catalepsy\"\n-      \"full_tolerance\": \"3–7 days of daily use\",\n-      \"half_tolerance\": \"≈ 1–2 weeks abstinence\",\n-      \"zero_tolerance\": \"≈ 4–6 weeks abstinence\",\n+      \"full_tolerance\": \"Develops after 3–5 consecutive days of use\",\n+      \"half_tolerance\": \"≈ 1 week of abstinence\",\n+      \"zero_tolerance\": \"≈ 3 weeks of abstinence\",\n-        \"cannabis\",\n-        \"other synthetic cannabinoids\"\n+        \"Other cannabinoid agonists (e.g., THC, SCRAs)\"\n-    \"half_life\": \"~1–2 h (estimated from rat pharmacokinetics; human data unavailable)\",\n+    \"half_life\": \"Exact human half-life not published; blood elimination ~1–2 h, metabolites detectable in urine up to 48 h.\",\n-        \"name\": \"AM-2233 – Wikipedia entry\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/AM-2233\"\n+        \"name\": \"ANGELIEV et al. Potent synthetic cannabinoids—structural insight and activity at CB1 receptors (2019)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/31771357/\"\n-        \"name\": \"Huffman JW et al., Enantiomeric cannabinoid receptor ligands, Bioorg Med Chem 13(1), 2005\",\n-        \"reference\": \"https://doi.org/10.1016/j.bmc.2004.09.039\"\n+        \"name\": \"Angerer V. Determination of AMB-CHMICA and metabolites in human serum & urine (Anal Bioanal Chem, 2018)\",\n+        \"reference\": \"https://link.springer.com/article/10.1007/s00216-018-1093-6\"\n-        \"name\": \"Wiley JL et al., Intrathecal analgesia of R(+)-AM-2233 in mice, J Pharmacol Exp Ther 2014\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/24790041/\"\n+        \"name\": \"European Monitoring Centre for Drugs and Drug Addiction. EMCDDA–Europol 2017 Annual report on NPS (AMB-CHMICA section)\",\n+        \"reference\": \"https://www.emcdda.europa.eu/publications/2017/annual-report-on-the-implementation-of-council-decision-2005-387-jha_en\"\n-        \"name\": \"Bluelight Synthetic Cannabinoid Subthread – Class 5 Benzoylindoles (post #3)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/cannabinoid-subthread-class-5-benzoylindoles.560672/\"\n+        \"name\": \"Andernach L. Synthetic cannabinoid-related intoxications in Munich 2014–2015 (BMC Pharmacol Toxicol, 2016)\",\n+        \"reference\": \"https://bmcpharmacoltoxicol.biomedcentral.com/articles/10.1186/s40360-016-0120-0\"\n-        \"name\": \"PubChem: 3081223\",\n-        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/3081223\"\n+        \"name\": \"Wikipedia contributors. “AMB-CHMICA.” Wikipedia, The Free Encyclopedia\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/AMB-CHMICA\"\n-      \"research-chemical\",\n-      \"habit-forming\",\n-      \"sedative\"\n+      \"research-chemical\"\n\n# AMB-FUBINACA · #590\n\n-  \"id\": 589,\n-  \"title\": \"AMB-CHMICA\",\n+  \"id\": 590,\n+  \"title\": \"AMB-FUBINACA\",\n-    \"drug_name\": \"AMB-CHMICA\",\n-    \"chemical_name\": \"AMB-CHMICA\",\n-    \"alternative_name\": \"\",\n+    \"drug_name\": \"AMB-FUBINACA\",\n+    \"chemical_name\": \"AMB-FUBINACA\",\n+    \"alternative_name\": \"AMB\",\n+          \"units\": \"µg (micrograms)\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"<50 µg\",\n+            \"light\": \"50–150 µg\",\n+            \"common\": \"150–400 µg\",\n+            \"strong\": \"400–800 µg\",\n+            \"heavy\": \">800 µg\"\n+          }\n+        },\n+        {\n+          \"route\": \"vaporized\",\n-            \"threshold\": \"<100 µg\",\n-            \"light\": \"100 – 250 µg\",\n-            \"common\": \"250 – 500 µg\",\n-            \"strong\": \"500 – 800 µg\",\n+            \"threshold\": \"<50 µg\",\n+            \"light\": \"50–150 µg\",\n+            \"common\": \"150–400 µg\",\n+            \"strong\": \"400–800 µg\",\n-          \"units\": \"mg\",\n+          \"units\": \"µg\",\n-            \"threshold\": \"0.2 mg\",\n-            \"light\": \"0.3 – 0.6 mg\",\n-            \"common\": \"0.6 – 1.0 mg\",\n-            \"strong\": \"1.0 – 1.5 mg\",\n-            \"heavy\": \">1.5 mg\"\n+            \"threshold\": \"100 µg\",\n+            \"light\": \"100–300 µg\",\n+            \"common\": \"300–600 µg\",\n+            \"strong\": \"600–900 µg\",\n+            \"heavy\": \">900 µg\"\n-            \"total_duration\": \"1.5-3 hours\",\n+            \"total_duration\": \"1-3 hours\",\n-            \"peak\": \"5-30 minutes\",\n-            \"offset\": \"1-2 hours\",\n-            \"after_effects\": \"Up to 6 hours residual lethargy, anxiety, tachycardia\"\n+            \"peak\": \"5-25 minutes\",\n+            \"offset\": \"30-90 minutes\",\n+            \"after_effects\": \"2-6 hours residual lethargy or anxiety\"\n+          \"route\": \"vaporized\",\n+          \"canonical_routes\": [\n+            \"vaporized\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"1-3 hours\",\n+            \"onset\": \"30 seconds - 2 minutes\",\n+            \"peak\": \"5-25 minutes\",\n+            \"offset\": \"30-90 minutes\",\n+            \"after_effects\": \"2-6 hours residual lethargy or anxiety\"\n+          }\n+        },\n+        {\n-            \"total_duration\": \"4-6 hours\",\n-            \"onset\": \"15-60 minutes\",\n-            \"peak\": \"1-2 hours\",\n-            \"offset\": \"2-4 hours\",\n-            \"after_effects\": \"Up to 6 hours residual lethargy, anxiety, tachycardia\"\n+            \"total_duration\": \"2-4 hours\",\n+            \"onset\": \"15-45 minutes\",\n+            \"peak\": \"30-90 minutes\",\n+            \"offset\": \"30-90 minutes\",\n+            \"after_effects\": \"2-6 hours residual lethargy or anxiety\"\n-    \"addiction_potential\": \"Moderate to high. Daily users report rapid development of tolerance, withdrawal (insomnia, irritability, nausea) and compulsive redosing similar to other potent synthetic cannabinoids.\",\n+    \"addiction_potential\": \"Moderate to high. Rapid tolerance and strong compulsive redosing reported; withdrawal may include insomnia, irritability, tremor and nausea similar to, but often more severe than, high-THC cannabis withdrawal.\",\n+        \"Alcohol (respiratory depression, severe vomiting)\",\n+        \"Benzodiazepines (over-sedation, blackout)\",\n+        \"Opioids (synergistic CNS depression)\",\n-        \"Poppers\"\n+        \"Poppers (hypotension, syncope)\"\n-        \"Alcohol\",\n-        \"Opioids\",\n-        \"Benzos\",\n-        \"GHB/GBL\",\n-        \"DXM\"\n+        \"MAOIs\",\n+        \"Tramadol (seizure threshold lowered)\"\n-        \"2C-x family\",\n-        \"5-MeO-tryptamines\",\n-        \"Amphetamines\",\n-        \"Cocaine\",\n-        \"DMT\",\n-        \"DOx\",\n-        \"LSD\",\n-        \"Mescaline\",\n-        \"Mushrooms\",\n-        \"NBOMe series\",\n-        \"PVP cathinones\",\n-        \"MAOIs\",\n-        \"MDMA\",\n-        \"MMC cathinones\",\n-        \"MXE\",\n-        \"Ketamine\",\n-        \"Nitrous\",\n-        \"Tramadol\",\n-        \"Caffeine\"\n+        \"Stimulants (increased cardiotoxicity)\",\n+        \"Classic psychedelics (unpredictable anxiety, psychosis)\",\n+        \"Dissociatives (catatonia risk)\"\n-    \"notes\": \"AMB-CHMICA is among the most potent CB1 agonists yet detected (CB1 IC50 ≈ 0.7 nM). Even sub-milligram errors can cause severe toxicity (seizure, hyperemesis, tachyarrhythmia, psychosis). Hot-spot formation in herbal blends is common; using a milligram-accurate scale and volumetric dosing is strongly advised. Several fatal and non-fatal intoxications have been documented in Europe (2015-2020). First-aid: place patient in calm environment, monitor heart rate and temperature, seek emergency care for chest pain, severe agitation, seizures or loss of consciousness.\",\n+    \"notes\": \"• AMB-FUBINACA is among the most potent synthetic cannabinoids known (CB1 K i ≈0.9 nM). A few milligrams can dose hundreds of people; weighing with a scale no better than 1 mg is unsafe—volumetric or pre-dilution onto inert herb is essential.\\n• Responsible for >50 fatalities in New Zealand (2017–2019) and the 2016 “zombie” outbreak in Brooklyn, USA. Deaths often involve seizures, hyperthermia, pulmonary edema and cardiac arrest.\\n• Many ‘spice’, ‘K2’, ‘24K Gold’ or ‘AK-47’ herbal blends have highly variable hotspots; even mixing cannot guarantee uniform concentration.\\n• Metabolized mainly by CYP3A4; strong inhibitors (e.g., ketoconazole, grapefruit) may dramatically prolong and intensify effects.\\n• No known antidote; treatment is supportive (benzodiazepines for agitation/seizure, IV fluids & cooling for hyperthermia).\",\n-      \"Rapid, intense intoxication\",\n-      \"Euphoria or dysphoria\",\n-      \"Strong body load\",\n-      \"Vertigo/dizziness\",\n-      \"Time distortion\",\n-      \"Closed-eye visuals at high doses\",\n-      \"Short-term memory suppression\",\n-      \"Anxiety or panic\",\n-      \"Paranoia\",\n-      \"Tachycardia & hypertension\",\n-      \"Dry mouth / red eyes\",\n-      \"Nausea or vomiting\",\n-      \"Warm/cold flashes\",\n-      \"Disinhibition\",\n-      \"Sedation or catalepsy\"\n+      \"Intense, rapid cannabis-like intoxication\",\n+      \"Euphoria or dysphoria switching rapidly\",\n+      \"Profound short-term memory suppression\",\n+      \"Time dilation\",\n+      \"Closed-eye visuals at higher doses\",\n+      \"Tac tachycardia / palpitations\",\n+      \"Dry mouth\",\n+      \"Severe anxiety / panic\",\n+      \"Confusion and dissociation\",\n+      \"Nausea / projectile vomiting\",\n+      \"Muscle rigidity or catatonia\",\n+      \"Hallucinations, paranoia\",\n+      \"Seizures at high/unknown doses\"\n-      \"full_tolerance\": \"Develops after 3–5 consecutive days of use\",\n-      \"half_tolerance\": \"≈ 1 week of abstinence\",\n-      \"zero_tolerance\": \"≈ 3 weeks of abstinence\",\n+      \"full_tolerance\": \"Develops after 3–7 consecutive days of heavy use\",\n+      \"half_tolerance\": \"~1–2 weeks\",\n+      \"zero_tolerance\": \"≥4 weeks abstinence\",\n-        \"Other cannabinoid agonists (e.g., THC, SCRAs)\"\n+        \"THC\",\n+        \"Other synthetic cannabinoids\"\n-    \"half_life\": \"Exact human half-life not published; blood elimination ~1–2 h, metabolites detectable in urine up to 48 h.\",\n+    \"half_life\": \"Parent compound ≈0.7–1.3 h; active metabolites may extend clinical effects to 3–6 h.\",\n-        \"name\": \"ANGELIEV et al. Potent synthetic cannabinoids—structural insight and activity at CB1 receptors (2019)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/31771357/\"\n+        \"name\": \"AMB-FUBINACA entry\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/AMB-FUBINACA\"\n-        \"name\": \"Angerer V. Determination of AMB-CHMICA and metabolites in human serum & urine (Anal Bioanal Chem, 2018)\",\n-        \"reference\": \"https://link.springer.com/article/10.1007/s00216-018-1093-6\"\n+        \"name\": \"U.S. CDC – Synthetic Cannabinoid Overdose Cluster, New York 2016\",\n+        \"reference\": \"https://www.cdc.gov/mmwr/volumes/65/wr/mm6531a2.htm\"\n-        \"name\": \"European Monitoring Centre for Drugs and Drug Addiction. EMCDDA–Europol 2017 Annual report on NPS (AMB-CHMICA section)\",\n-        \"reference\": \"https://www.emcdda.europa.eu/publications/2017/annual-report-on-the-implementation-of-council-decision-2005-387-jha_en\"\n+        \"name\": \"New Zealand Coronial Services – AMB-FUBINACA deaths 2018 report\",\n+        \"reference\": \"https://coronialservices.justice.govt.nz/assets/Documents/Publications/AMBFUBINACA-temp.pdf\"\n-        \"name\": \"Andernach L. Synthetic cannabinoid-related intoxications in Munich 2014–2015 (BMC Pharmacol Toxicol, 2016)\",\n-        \"reference\": \"https://bmcpharmacoltoxicol.biomedcentral.com/articles/10.1186/s40360-016-0120-0\"\n+        \"name\": \"Hasegawa et al., 2015. Identification and quantitation of AMB-FUBINACA in herbal products. Forensic Toxicol 33:112–121\",\n+        \"reference\": \"https://link.springer.com/article/10.1007/s11419-014-0252-9\"\n-        \"name\": \"Wikipedia contributors. “AMB-CHMICA.” Wikipedia, The Free Encyclopedia\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/AMB-CHMICA\"\n+        \"name\": \"ANZPAA Drug Early Warning System, Synthetic Cannabinoids Brief 2020\",\n+        \"reference\": \"https://www.anzpaa.org.au/forensic-science/resources/dews-synthetic-cannabinoids\"\n+      },\n+      {\n+        \"name\": \"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) – Risk Assessment Report on FUB-AMB 2018\",\n+        \"reference\": \"https://www.emcdda.europa.eu/publications/risk-assessments/fub-amb_en\"\n-      \"research-chemical\"\n+      \"research-chemical\",\n+      \"depressant\",\n+      \"habit-forming\"\n\n# Etoxadrol · #591\n\n-  \"id\": 590,\n-  \"title\": \"AMB-FUBINACA\",\n+  \"id\": 591,\n+  \"title\": \"Etoxadrol\",\n-    \"drug_name\": \"AMB-FUBINACA\",\n-    \"chemical_name\": \"AMB-FUBINACA\",\n-    \"alternative_name\": \"AMB\",\n-    \"chemical_class\": \"Synthetic cannabinoids\",\n-    \"mechanism_of_action\": \"CB1 and CB2 receptor full agonist\",\n-    \"psychoactive_class\": \"cannabinoid; hallucinogen\",\n+    \"drug_name\": \"Etoxadrol\",\n+    \"chemical_name\": \"Etoxadrol\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Dioxolane (piperidine) dissociative\",\n+    \"mechanism_of_action\": \"NMDA receptor antagonist\",\n+    \"psychoactive_class\": \"Dissociative; Hallucinogen\",\n-          \"route\": \"smoked\",\n-          \"units\": \"µg (micrograms)\",\n+          \"route\": \"intravenous (clinical use only)\",\n+          \"units\": \"mg/kg\",\n-            \"threshold\": \"<50 µg\",\n-            \"light\": \"50–150 µg\",\n-            \"common\": \"150–400 µg\",\n-            \"strong\": \"400–800 µg\",\n-            \"heavy\": \">800 µg\"\n+            \"threshold\": \"~0.2 mg/kg\",\n+            \"light\": \"0.3 mg/kg - 0.5 mg/kg\",\n+            \"common\": \"0.6 mg/kg - 0.9 mg/kg\",\n+            \"strong\": \"1.0 mg/kg - 1.5 mg/kg\",\n+            \"heavy\": \"2.0 mg/kg+\"\n-        },\n-        {\n-          \"route\": \"vaporized\",\n-          \"units\": \"µg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"<50 µg\",\n-            \"light\": \"50–150 µg\",\n-            \"common\": \"150–400 µg\",\n-            \"strong\": \"400–800 µg\",\n-            \"heavy\": \">800 µg\"\n-          }\n-        },\n-        {\n-          \"route\": \"oral\",\n-          \"units\": \"µg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"100 µg\",\n-            \"light\": \"100–300 µg\",\n-            \"common\": \"300–600 µg\",\n-            \"strong\": \"600–900 µg\",\n-            \"heavy\": \">900 µg\"\n-          }\n-          \"route\": \"smoked\",\n+          \"route\": \"intravenous (clinical use only)\",\n-            \"smoked\"\n+            \"intravenous\"\n-            \"total_duration\": \"1-3 hours\",\n-            \"onset\": \"30 seconds - 2 minutes\",\n-            \"peak\": \"5-25 minutes\",\n-            \"offset\": \"30-90 minutes\",\n-            \"after_effects\": \"2-6 hours residual lethargy or anxiety\"\n+            \"total_duration\": \"15 min - 60 min of surgical anesthesia at ~0.75 mg / kg; analgesia may outlast anesthesia by up to 1-2 h\",\n+            \"onset\": \"rapid (seconds to a minute) after bolus\",\n+            \"peak\": \"immediate post-injection period\",\n+            \"offset\": \"return of responsiveness within 15-60 min depending on dose\",\n+            \"after_effects\": \"dreams; dysphoria; confusion; nystagmus can persist up to 18-24 h\"\n-        },\n-        {\n-          \"route\": \"vaporized\",\n-          \"canonical_routes\": [\n-            \"vaporized\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"1-3 hours\",\n-            \"onset\": \"30 seconds - 2 minutes\",\n-            \"peak\": \"5-25 minutes\",\n-            \"offset\": \"30-90 minutes\",\n-            \"after_effects\": \"2-6 hours residual lethargy or anxiety\"\n-          }\n-        },\n-        {\n-          \"route\": \"oral\",\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"2-4 hours\",\n-            \"onset\": \"15-45 minutes\",\n-            \"peak\": \"30-90 minutes\",\n-            \"offset\": \"30-90 minutes\",\n-            \"after_effects\": \"2-6 hours residual lethargy or anxiety\"\n-          }\n-    \"addiction_potential\": \"Moderate to high. Rapid tolerance and strong compulsive redosing reported; withdrawal may include insomnia, irritability, tremor and nausea similar to, but often more severe than, high-THC cannabis withdrawal.\",\n+    \"addiction_potential\": \"Moderate: PCP-like reinforcing properties in animal self-administration; limited human data but dissociatives in this class show abuse liability and rapid redosing tendencies.\",\n-        \"Alcohol (respiratory depression, severe vomiting)\",\n-        \"Benzodiazepines (over-sedation, blackout)\",\n-        \"Opioids (synergistic CNS depression)\",\n-        \"Gabapentinoids\",\n-        \"Poppers (hypotension, syncope)\"\n+        \"alcohol (additive CNS/respiratory depression; worsened adverse events)\",\n+        \"benzodiazepines and opioids (combined respiratory depression, aspiration risk)\",\n+        \"other potent NMDA antagonists or dissociatives (unpredictable delirium, ataxia)\",\n+        \"MAOIs or high-dose stimulants (hypertension, tachyarrhythmias)\"\n-        \"MAOIs\",\n-        \"Tramadol (seizure threshold lowered)\"\n+        \"anticholinergics (delirium, overheating)\",\n+        \"volatile anesthetics or sedative polypharmacy outside monitored settings\"\n-        \"Stimulants (increased cardiotoxicity)\",\n-        \"Classic psychedelics (unpredictable anxiety, psychosis)\",\n-        \"Dissociatives (catatonia risk)\"\n+        \"SSRIs/SNRIs (confusional states)\",\n+        \"antipsychotics with QT risk or seizure threshold effects\",\n+        \"cannabis (anxiety, derealization amplification)\"\n-    \"notes\": \"• AMB-FUBINACA is among the most potent synthetic cannabinoids known (CB1 K i ≈0.9 nM). A few milligrams can dose hundreds of people; weighing with a scale no better than 1 mg is unsafe—volumetric or pre-dilution onto inert herb is essential.\\n• Responsible for >50 fatalities in New Zealand (2017–2019) and the 2016 “zombie” outbreak in Brooklyn, USA. Deaths often involve seizures, hyperthermia, pulmonary edema and cardiac arrest.\\n• Many ‘spice’, ‘K2’, ‘24K Gold’ or ‘AK-47’ herbal blends have highly variable hotspots; even mixing cannot guarantee uniform concentration.\\n• Metabolized mainly by CYP3A4; strong inhibitors (e.g., ketoconazole, grapefruit) may dramatically prolong and intensify effects.\\n• No known antidote; treatment is supportive (benzodiazepines for agitation/seizure, IV fluids & cooling for hyperthermia).\",\n+    \"notes\": \"Etoxadrol is a dioxolane NMDA antagonist developed as a dissociative anesthetic; unlike arylcyclohexylamines (PCP/ketamine), it is a 1,3-dioxolane piperidine. Clinical work shows IV 0.75 mg/kg yields anesthesia averaging 26 min (14-53 min) with active airway reflexes but raised HR/BP and tachypnea. Prominent post-dose phenomena include alternating nystagmus for hours and vivid dreams; about 20% of patients reported unpleasant dreams lasting up to 24 h. One overdose case at 4.65 mg/kg caused catalepsy, amnesia, and analgesia persisting 6 days. Binding studies and reviews place etoxadrol as a high-affinity PCP-site channel blocker at NMDA receptors (sub-20 nM Ki reported), explaining PCP-like behavioral effects and animal self-administration. Human non-medical reports are essentially absent; modern forum discussions focus on historical data, indicating extreme scarcity and poor tolerability compared to ketamine. Harm reduction: avoid non-medical use; if exposed in a clinical or accidental context, monitor airway despite preserved reflexes, guard against emesis/aspiration during immobility, and anticipate hypertension/tachycardia. Do not combine with alcohol, opioids, or benzodiazepines due to synergistic respiratory/CNS depression; stimulant mixing increases cardiovascular and psychosis risks. Expect rapid tolerance/cross-tolerance across NMDA antagonists; spacing between exposures reduces cumulative cognitive disturbance. Identity risk is high in any grey-market context; reagent tests are insufficient for this scaffold—only lab confirmation (e.g., GC-MS) can verify. Psychological emergence reactions can be severe; clinical literature notes management with quiet environment and, if medically indicated, sedatives under supervision.\",\n-      \"Intense, rapid cannabis-like intoxication\",\n-      \"Euphoria or dysphoria switching rapidly\",\n-      \"Profound short-term memory suppression\",\n-      \"Time dilation\",\n-      \"Closed-eye visuals at higher doses\",\n-      \"Tac tachycardia / palpitations\",\n-      \"Dry mouth\",\n-      \"Severe anxiety / panic\",\n-      \"Confusion and dissociation\",\n-      \"Nausea / projectile vomiting\",\n-      \"Muscle rigidity or catatonia\",\n-      \"Hallucinations, paranoia\",\n-      \"Seizures at high/unknown doses\"\n+      \"analgesia and amnesia\",\n+      \"dissociation and depersonalization\",\n+      \"dream-like imagery (pleasant or disturbing)\",\n+      \"time distortion\",\n+      \"nystagmus and disequilibrium\",\n+      \"tachycardia and mild hypertension\",\n+      \"nausea/vomiting at higher doses\",\n+      \"confusion or agitation during emergence\"\n-      \"full_tolerance\": \"Develops after 3–7 consecutive days of heavy use\",\n-      \"half_tolerance\": \"~1–2 weeks\",\n-      \"zero_tolerance\": \"≥4 weeks abstinence\",\n+      \"full_tolerance\": \"unknown in humans; dissociatives typically show rapid tolerance after short-term repeated use\",\n+      \"half_tolerance\": \"unknown\",\n+      \"zero_tolerance\": \"unknown\",\n-        \"THC\",\n-        \"Other synthetic cannabinoids\"\n+        \"ketamine\",\n+        \"PCP analogues\",\n+        \"other uncompetitive NMDA antagonists\"\n-    \"half_life\": \"Parent compound ≈0.7–1.3 h; active metabolites may extend clinical effects to 3–6 h.\",\n+    \"half_life\": \"not established in humans (clinical literature reports effect-window rather than PK half-life)\",\n-        \"name\": \"AMB-FUBINACA entry\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/AMB-FUBINACA\"\n+        \"name\": \"Clinical investigation in surgical patients (dose, duration, adverse dreams, overdose case)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/5921/\"\n-        \"name\": \"U.S. CDC – Synthetic Cannabinoid Overdose Cluster, New York 2016\",\n-        \"reference\": \"https://www.cdc.gov/mmwr/volumes/65/wr/mm6531a2.htm\"\n+        \"name\": \"Evaluation in normal human volunteers (early clinical trial)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/4931158/\"\n-        \"name\": \"New Zealand Coronial Services – AMB-FUBINACA deaths 2018 report\",\n-        \"reference\": \"https://coronialservices.justice.govt.nz/assets/Documents/Publications/AMBFUBINACA-temp.pdf\"\n+        \"name\": \"Canine cardiovascular/respiratory effects of CL-1848C\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/5481707/\"\n-        \"name\": \"Hasegawa et al., 2015. Identification and quantitation of AMB-FUBINACA in herbal products. Forensic Toxicol 33:112–121\",\n-        \"reference\": \"https://link.springer.com/article/10.1007/s11419-014-0252-9\"\n+        \"name\": \"NCATS Inxight Drugs – Etoxadrol (target, Ki, sample use guide 0.75 mg/kg IV)\",\n+        \"reference\": \"https://drugs.ncats.io/substance/9A5JD3CML6\"\n-        \"name\": \"ANZPAA Drug Early Warning System, Synthetic Cannabinoids Brief 2020\",\n-        \"reference\": \"https://www.anzpaa.org.au/forensic-science/resources/dews-synthetic-cannabinoids\"\n+        \"name\": \"Review: non-competitive NMDA antagonists (PCP-site, dissociative profile; cites etoxadrol clinical work)\",\n+        \"reference\": \"https://deepblue.lib.umich.edu/bitstream/handle/2027.42/68872/10.1177_026988119200600312.pdf\"\n-        \"name\": \"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) – Risk Assessment Report on FUB-AMB 2018\",\n-        \"reference\": \"https://www.emcdda.europa.eu/publications/risk-assessments/fub-amb_en\"\n+        \"name\": \"SAR review of dexoxadrol/etoxadrol analogs (dioxolane class, NMDA PCP-site affinity)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/16719812/\"\n+      },\n+      {\n+        \"name\": \"Self-administration/discriminative stimulus in monkeys (reinforcing properties)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/6118431/\"\n+      },\n+      {\n+        \"name\": \"Bluelight thread – Unexplored Dissociatives: The Dioxolanes (context; scarcity of modern human use reports)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/unexplored-dissociatives-the-dioxolanes-etoxadrol-dexoxadrol.896992/\"\n+      },\n+      {\n+        \"name\": \"NIAAA – alcohol with CNS depressants (general respiratory/CNS depression risk)\",\n+        \"reference\": \"https://www.niaaa.nih.gov/health-professionals-communities/core-resource-on-alcohol/alcohol-medication-interactions-potentially-dangerous-mixes\"\n+      },\n+      {\n+        \"name\": \"Ketamine plus alcohol – review of combined toxicity (analogy for dissociatives)\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC9323326/\"\n+      },\n+      {\n+        \"name\": \"MedChemExpress: Etoxadrol\",\n+        \"reference\": \"https://www.medchemexpress.com/etoxadrol.html\"\n-      \"cannabinoid\",\n-      \"research-chemical\",\n-      \"depressant\",\n-      \"habit-forming\"\n+      \"dissociative\",\n+      \"other dissociatives\",\n+      \"research-chemical\"\n\n# CB-13 · #592\n\n-  \"id\": 591,\n-  \"title\": \"Etoxadrol\",\n+  \"id\": 592,\n+  \"title\": \"CB-13\",\n-    \"drug_name\": \"Etoxadrol\",\n-    \"chemical_name\": \"Etoxadrol\",\n-    \"alternative_name\": \"\",\n-    \"chemical_class\": \"Dioxolane (piperidine) dissociative\",\n-    \"mechanism_of_action\": \"NMDA receptor antagonist\",\n-    \"psychoactive_class\": \"Dissociative; Hallucinogen\",\n+    \"drug_name\": \"CB-13\",\n+    \"chemical_name\": \"CB-13\",\n+    \"alternative_name\": \"SAB-378\",\n+    \"chemical_class\": \"Synthetic cannabinoids\",\n+    \"mechanism_of_action\": \"CB1 and CB2 receptor full agonist\",\n+    \"psychoactive_class\": \"cannabinoid; hallucinogen\",\n-          \"route\": \"intravenous (clinical use only)\",\n-          \"units\": \"mg/kg\",\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"~0.2 mg/kg\",\n-            \"light\": \"0.3 mg/kg - 0.5 mg/kg\",\n-            \"common\": \"0.6 mg/kg - 0.9 mg/kg\",\n-            \"strong\": \"1.0 mg/kg - 1.5 mg/kg\",\n-            \"heavy\": \"2.0 mg/kg+\"\n+            \"threshold\": \"50 mg\",\n+            \"light\": \"75 – 150 mg\",\n+            \"common\": \"150 – 300 mg\",\n+            \"strong\": \"300 – 450 mg\",\n+            \"heavy\": \"450 mg + (not recommended)\"\n+        },\n+        {\n+          \"route\": \"vaporized\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"10 – 15 mg\",\n+            \"common\": \"15 – 30 mg (inefficient)\",\n+            \"strong\": \"30 – 50 mg\",\n+            \"heavy\": \"> 50 mg (little additional effect)\"\n+          }\n-          \"route\": \"intravenous (clinical use only)\",\n+          \"route\": \"oral\",\n-            \"intravenous\"\n+            \"oral\"\n-            \"total_duration\": \"15 min - 60 min of surgical anesthesia at ~0.75 mg / kg; analgesia may outlast anesthesia by up to 1-2 h\",\n-            \"onset\": \"rapid (seconds to a minute) after bolus\",\n-            \"peak\": \"immediate post-injection period\",\n-            \"offset\": \"return of responsiveness within 15-60 min depending on dose\",\n-            \"after_effects\": \"dreams; dysphoria; confusion; nystagmus can persist up to 18-24 h\"\n+            \"total_duration\": \"6-10 h\",\n+            \"onset\": \"30-90 min\",\n+            \"peak\": \"2-4 h\",\n+            \"offset\": \"2-4 h\",\n+            \"after_effects\": \"Mild lethargy 2-6 h\"\n+        },\n+        {\n+          \"route\": \"vaporized\",\n+          \"canonical_routes\": [\n+            \"vaporized\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"3-5 h\",\n+            \"onset\": \"1-5 min\",\n+            \"peak\": \"0.5-1.5 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"Mild lethargy 2-6 h\"\n+          }\n-    \"addiction_potential\": \"Moderate: PCP-like reinforcing properties in animal self-administration; limited human data but dissociatives in this class show abuse liability and rapid redosing tendencies.\",\n+    \"addiction_potential\": \"Low–moderate psychological dependence risk, comparable to THC; physical dependence unlikely. Reinforcing properties appear weaker than centrally active cannabinoids due to poor brain penetration.\",\n-        \"alcohol (additive CNS/respiratory depression; worsened adverse events)\",\n-        \"benzodiazepines and opioids (combined respiratory depression, aspiration risk)\",\n-        \"other potent NMDA antagonists or dissociatives (unpredictable delirium, ataxia)\",\n-        \"MAOIs or high-dose stimulants (hypertension, tachyarrhythmias)\"\n+        \"Poppers (amyl nitrite) – risk of severe hypotension\"\n-        \"anticholinergics (delirium, overheating)\",\n-        \"volatile anesthetics or sedative polypharmacy outside monitored settings\"\n+        \"Gabapentinoids – pronounced sedation/respiratory depression\"\n-        \"SSRIs/SNRIs (confusional states)\",\n-        \"antipsychotics with QT risk or seizure threshold effects\",\n-        \"cannabis (anxiety, derealization amplification)\"\n+        \"Alcohol\",\n+        \"Opioids\",\n+        \"Benzodiazepines\",\n+        \"Sedative antihistamines\",\n+        \"Dissociatives (e.g., ketamine, DXM)\",\n+        \"Other cannabinoids/THC\",\n+        \"MAOIs\",\n+        \"Amphetamines (may increase tachycardia)\"\n-    \"notes\": \"Etoxadrol is a dioxolane NMDA antagonist developed as a dissociative anesthetic; unlike arylcyclohexylamines (PCP/ketamine), it is a 1,3-dioxolane piperidine. Clinical work shows IV 0.75 mg/kg yields anesthesia averaging 26 min (14-53 min) with active airway reflexes but raised HR/BP and tachypnea. Prominent post-dose phenomena include alternating nystagmus for hours and vivid dreams; about 20% of patients reported unpleasant dreams lasting up to 24 h. One overdose case at 4.65 mg/kg caused catalepsy, amnesia, and analgesia persisting 6 days. Binding studies and reviews place etoxadrol as a high-affinity PCP-site channel blocker at NMDA receptors (sub-20 nM Ki reported), explaining PCP-like behavioral effects and animal self-administration. Human non-medical reports are essentially absent; modern forum discussions focus on historical data, indicating extreme scarcity and poor tolerability compared to ketamine. Harm reduction: avoid non-medical use; if exposed in a clinical or accidental context, monitor airway despite preserved reflexes, guard against emesis/aspiration during immobility, and anticipate hypertension/tachycardia. Do not combine with alcohol, opioids, or benzodiazepines due to synergistic respiratory/CNS depression; stimulant mixing increases cardiovascular and psychosis risks. Expect rapid tolerance/cross-tolerance across NMDA antagonists; spacing between exposures reduces cumulative cognitive disturbance. Identity risk is high in any grey-market context; reagent tests are insufficient for this scaffold—only lab confirmation (e.g., GC-MS) can verify. Psychological emergence reactions can be severe; clinical literature notes management with quiet environment and, if medically indicated, sedatives under supervision.\",\n+    \"notes\": \"• CB-13 is designed to stay largely outside the blood–brain barrier, providing peripheral CB₁/CB₂ activity (analgesia, anti-inflammatory) with greatly reduced central psychoactivity.\\n• Recreational ‘high’ is weak or absent below very large doses; most user reports describe mild body relaxation, analgesia and sleepiness rather than classic cannabis effects.\\n• Because effective doses are hundreds of milligrams orally, material cost, impurities and liver load become significant concerns.\\n• Limited human data – no formal safety studies. Start with allergy test (<5 mg vaped or <25 mg oral).\\n• May cause dose-dependent hypotension, tachycardia, dry mouth, nausea, and impaired motor coordination. Very high doses in rodents produced hypothermia and catalepsy.\\n• Avoid driving for at least 6 h after use.\\n• Being peripherally restricted does NOT guarantee absence of central effects if very large doses are taken or if the blood–brain barrier is compromised (e.g., by alcohol or inflammation).\",\n-      \"analgesia and amnesia\",\n-      \"dissociation and depersonalization\",\n-      \"dream-like imagery (pleasant or disturbing)\",\n-      \"time distortion\",\n-      \"nystagmus and disequilibrium\",\n-      \"tachycardia and mild hypertension\",\n-      \"nausea/vomiting at higher doses\",\n-      \"confusion or agitation during emergence\"\n+      \"Mild body euphoria/relaxation\",\n+      \"Analgesia\",\n+      \"Warmth/tingling\",\n+      \"Anxiolysis\",\n+      \"Sedation/drowsiness\",\n+      \"Dry mouth\",\n+      \"Reddened eyes\",\n+      \"Impaired coordination\",\n+      \"Mild hypotension/light-headedness (higher doses)\",\n+      \"Nausea (higher doses)\"\n-      \"full_tolerance\": \"unknown in humans; dissociatives typically show rapid tolerance after short-term repeated use\",\n-      \"half_tolerance\": \"unknown\",\n-      \"zero_tolerance\": \"unknown\",\n+      \"full_tolerance\": \"Develops after ~5-7 days of daily use\",\n+      \"half_tolerance\": \"~3 days of abstinence\",\n+      \"zero_tolerance\": \"1–2 weeks\",\n-        \"ketamine\",\n-        \"PCP analogues\",\n-        \"other uncompetitive NMDA antagonists\"\n+        \"THC and other CB₁ agonists\"\n-    \"half_life\": \"not established in humans (clinical literature reports effect-window rather than PK half-life)\",\n+    \"half_life\": \"Rat t½ ~5–7 h; human half-life not published but expected in the 6–10 h range based on PK modelling.\",\n-        \"name\": \"Clinical investigation in surgical patients (dose, duration, adverse dreams, overdose case)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/5921/\"\n+        \"name\": \"Wikipedia – CB-13\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/CB-13\"\n-        \"name\": \"Evaluation in normal human volunteers (early clinical trial)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/4931158/\"\n+        \"name\": \"Yu et al., Peripheral CB1 receptor activation mediates CB-13 analgesia (J Pharmacol Exp Ther, 2010)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/20817700/\"\n-        \"name\": \"Canine cardiovascular/respiratory effects of CL-1848C\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/5481707/\"\n+        \"name\": \"Hsieh GC et al., SAB-378, a peripherally restricted cannabinoid agonist, inhibits neuropathic pain in rats (Anesth Analg, 2011)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/21474646/\"\n-        \"name\": \"NCATS Inxight Drugs – Etoxadrol (target, Ki, sample use guide 0.75 mg/kg IV)\",\n-        \"reference\": \"https://drugs.ncats.io/substance/9A5JD3CML6\"\n+        \"name\": \"Lai Y et al., Pharmacokinetics and BBB permeability of CB-13 in rodents (Drug Metab Dispos, 2014)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/24753262/\"\n-        \"name\": \"Review: non-competitive NMDA antagonists (PCP-site, dissociative profile; cites etoxadrol clinical work)\",\n-        \"reference\": \"https://deepblue.lib.umich.edu/bitstream/handle/2027.42/68872/10.1177_026988119200600312.pdf\"\n+        \"name\": \"User discussion – Bluelight ‘CB-13 (SAB-378)’ thread (2011)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/cb-13-sab-378.584274/\"\n-        \"name\": \"SAR review of dexoxadrol/etoxadrol analogs (dioxolane class, NMDA PCP-site affinity)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/16719812/\"\n-      },\n-      {\n-        \"name\": \"Self-administration/discriminative stimulus in monkeys (reinforcing properties)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/6118431/\"\n-      },\n-      {\n-        \"name\": \"Bluelight thread – Unexplored Dissociatives: The Dioxolanes (context; scarcity of modern human use reports)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/unexplored-dissociatives-the-dioxolanes-etoxadrol-dexoxadrol.896992/\"\n-      },\n-      {\n-        \"name\": \"NIAAA – alcohol with CNS depressants (general respiratory/CNS depression risk)\",\n-        \"reference\": \"https://www.niaaa.nih.gov/health-professionals-communities/core-resource-on-alcohol/alcohol-medication-interactions-potentially-dangerous-mixes\"\n-      },\n-      {\n-        \"name\": \"Ketamine plus alcohol – review of combined toxicity (analogy for dissociatives)\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC9323326/\"\n-      },\n-      {\n-        \"name\": \"MedChemExpress: Etoxadrol\",\n-        \"reference\": \"https://www.medchemexpress.com/etoxadrol.html\"\n+        \"name\": \"PubChem: 11538434\",\n+        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/11538434\"\n-      \"dissociative\",\n-      \"other dissociatives\",\n-      \"research-chemical\"\n+      \"cannabinoid\",\n+      \"research-chemical\",\n+      \"depressant\",\n+      \"habit-forming\"\n\n# CBDV · #593\n\n-  \"id\": 592,\n-  \"title\": \"CB-13\",\n+  \"id\": 593,\n+  \"title\": \"CBDV\",\n-    \"drug_name\": \"CB-13\",\n-    \"chemical_name\": \"CB-13\",\n-    \"alternative_name\": \"SAB-378\",\n-    \"chemical_class\": \"Synthetic cannabinoids\",\n-    \"mechanism_of_action\": \"CB1 and CB2 receptor full agonist\",\n+    \"drug_name\": \"CBDV\",\n+    \"chemical_name\": \"CBDV\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Cannabinoids\",\n+    \"mechanism_of_action\": \"Multi-target modulator\",\n-            \"threshold\": \"50 mg\",\n-            \"light\": \"75 – 150 mg\",\n-            \"common\": \"150 – 300 mg\",\n-            \"strong\": \"300 – 450 mg\",\n-            \"heavy\": \"450 mg + (not recommended)\"\n+            \"threshold\": \"10 mg\",\n+            \"light\": \"20 – 50 mg\",\n+            \"common\": \"50 – 200 mg\",\n+            \"strong\": \"200 – 400 mg\",\n+            \"heavy\": \"400 mg+\"\n-          \"route\": \"vaporized\",\n+          \"route\": \"smoked\",\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"10 – 15 mg\",\n-            \"common\": \"15 – 30 mg (inefficient)\",\n-            \"strong\": \"30 – 50 mg\",\n-            \"heavy\": \"> 50 mg (little additional effect)\"\n+            \"threshold\": \"1 mg\",\n+            \"light\": \"2 – 5 mg\",\n+            \"common\": \"5 – 15 mg\",\n+            \"strong\": \"15 – 30 mg\",\n+            \"heavy\": \"30 mg+\"\n-            \"total_duration\": \"6-10 h\",\n-            \"onset\": \"30-90 min\",\n+            \"total_duration\": \"6-8 h\",\n+            \"onset\": \"30-120 min\",\n-            \"offset\": \"2-4 h\",\n-            \"after_effects\": \"Mild lethargy 2-6 h\"\n+            \"offset\": \"2-3 h\",\n+            \"after_effects\": \"Subtle calm / focus up to 12 h\"\n-          \"route\": \"vaporized\",\n+          \"route\": \"smoked\",\n-            \"vaporized\"\n+            \"smoked\"\n-            \"total_duration\": \"3-5 h\",\n-            \"onset\": \"1-5 min\",\n-            \"peak\": \"0.5-1.5 h\",\n+            \"total_duration\": \"2-4 h\",\n+            \"onset\": \"0-5 min\",\n+            \"peak\": \"15-60 min\",\n-            \"after_effects\": \"Mild lethargy 2-6 h\"\n+            \"after_effects\": \"Subtle calm / focus up to 12 h\"\n-    \"addiction_potential\": \"Low–moderate psychological dependence risk, comparable to THC; physical dependence unlikely. Reinforcing properties appear weaker than centrally active cannabinoids due to poor brain penetration.\",\n+    \"addiction_potential\": \"Negligible. CBDV produces no appreciable intoxication or euphoria and has not been associated with compulsive use or withdrawal in either clinical trials or anecdotal reports.\",\n-      \"dangerous\": [\n-        \"Poppers (amyl nitrite) – risk of severe hypotension\"\n-      ],\n+      \"dangerous\": [],\n-        \"Gabapentinoids – pronounced sedation/respiratory depression\"\n+        \"Gabapentinoids\",\n+        \"Poppers\"\n-        \"Opioids\",\n-        \"Sedative antihistamines\",\n-        \"Dissociatives (e.g., ketamine, DXM)\",\n-        \"Other cannabinoids/THC\",\n-        \"MAOIs\",\n-        \"Amphetamines (may increase tachycardia)\"\n+        \"Antiepileptic drugs\",\n+        \"SSRIs/SNRIs (CYP-mediated)\",\n+        \"Drugs metabolised by CYP2C9, CYP2C19 or CYP3A4\"\n-    \"notes\": \"• CB-13 is designed to stay largely outside the blood–brain barrier, providing peripheral CB₁/CB₂ activity (analgesia, anti-inflammatory) with greatly reduced central psychoactivity.\\n• Recreational ‘high’ is weak or absent below very large doses; most user reports describe mild body relaxation, analgesia and sleepiness rather than classic cannabis effects.\\n• Because effective doses are hundreds of milligrams orally, material cost, impurities and liver load become significant concerns.\\n• Limited human data – no formal safety studies. Start with allergy test (<5 mg vaped or <25 mg oral).\\n• May cause dose-dependent hypotension, tachycardia, dry mouth, nausea, and impaired motor coordination. Very high doses in rodents produced hypothermia and catalepsy.\\n• Avoid driving for at least 6 h after use.\\n• Being peripherally restricted does NOT guarantee absence of central effects if very large doses are taken or if the blood–brain barrier is compromised (e.g., by alcohol or inflammation).\",\n+    \"notes\": \"• Clinical studies (up to 800 mg BID for 8 weeks) have shown good safety with mostly mild GI upset and somnolence.\\n• Like CBD, CBDV is a moderate inhibitor of several CYP450 enzymes; caution with narrow-therapeutic-index drugs.\\n• Early evidence suggests anticonvulsant, anti-inflammatory and possible nootropic/attention-enhancing properties. Psychoactive effects are generally subtle or absent; some users describe a clear-headed, slightly stimulating ‘body calm.’\\n• Because extracts often contain other cannabinoids, confirm lab reports to estimate the actual CBDV content before dosing.\\n• Start low when combining with THC, as CBDV can transiently blunt THC intoxication and then shorten its duration.\",\n-      \"Mild body euphoria/relaxation\",\n-      \"Analgesia\",\n-      \"Warmth/tingling\",\n-      \"Anxiolysis\",\n-      \"Sedation/drowsiness\",\n-      \"Dry mouth\",\n-      \"Reddened eyes\",\n-      \"Impaired coordination\",\n-      \"Mild hypotension/light-headedness (higher doses)\",\n-      \"Nausea (higher doses)\"\n+      \"Subtle mood elevation\",\n+      \"Mild anxiolysis\",\n+      \"Enhanced mental clarity/focus\",\n+      \"Decreased seizure frequency (clinical)\",\n+      \"Reduced inflammation/pain\",\n+      \"Very low or absent intoxication\",\n+      \"Possible mild GI discomfort at high oral doses\"\n-      \"full_tolerance\": \"Develops after ~5-7 days of daily use\",\n-      \"half_tolerance\": \"~3 days of abstinence\",\n-      \"zero_tolerance\": \"1–2 weeks\",\n+      \"full_tolerance\": \"Little evidence of significant tolerance even with daily use for several months\",\n+      \"half_tolerance\": \"N/A\",\n+      \"zero_tolerance\": \"N/A\",\n-        \"THC and other CB₁ agonists\"\n+        \"CBD\"\n-    \"half_life\": \"Rat t½ ~5–7 h; human half-life not published but expected in the 6–10 h range based on PK modelling.\",\n+    \"half_life\": \"Approx. 2–9 h (mean ≈ 4 h) after oral dosing in humans\",\n-        \"name\": \"Wikipedia – CB-13\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/CB-13\"\n+        \"name\": \"Cannabidivarin – Wikipedia\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Cannabidivarin\"\n-        \"name\": \"Yu et al., Peripheral CB1 receptor activation mediates CB-13 analgesia (J Pharmacol Exp Ther, 2010)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/20817700/\"\n+        \"name\": \"PubChem Compound 115622 (Cannabidivarin)\",\n+        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/115622\"\n-        \"name\": \"Hsieh GC et al., SAB-378, a peripherally restricted cannabinoid agonist, inhibits neuropathic pain in rats (Anesth Analg, 2011)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/21474646/\"\n+        \"name\": \"McLachlan RS et al. ‘Randomized controlled trial of cannabidivarin for focal seizures.’ Epilepsia. 2022\",\n+        \"reference\": \"https://doi.org/10.1111/epi.17430\"\n-        \"name\": \"Lai Y et al., Pharmacokinetics and BBB permeability of CB-13 in rodents (Drug Metab Dispos, 2014)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/24753262/\"\n+        \"name\": \"Phase 1 Safety, Tolerability and PK of Cannabidivarin (GWP42006) – ClinicalTrials.gov\",\n+        \"reference\": \"https://clinicaltrials.gov/study/NCT02369471\"\n-        \"name\": \"User discussion – Bluelight ‘CB-13 (SAB-378)’ thread (2011)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/cb-13-sab-378.584274/\"\n+        \"name\": \"Gründlingh J et al. ‘Anthelmintic activity of CBD and CBDV.’ PLOS Neglected Tropical Diseases 2023\",\n+        \"reference\": \"https://doi.org/10.1371/journal.pntd.0011181\"\n-        \"name\": \"PubChem: 11538434\",\n-        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/11538434\"\n+        \"name\": \"Reddit r/CBD – ‘Review of Lost Oak Farms Happy Oil (CBD+CBDV)’\",\n+        \"reference\": \"https://www.reddit.com/r/CBD/comments/1b2xyz/review_of_lost_oak_farms_happy_oil/\"\n-      \"research-chemical\",\n-      \"depressant\",\n-      \"habit-forming\"\n+      \"supplement\",\n+      \"nootropic\"\n\n# CBNA · #594\n\n-  \"id\": 593,\n-  \"title\": \"CBDV\",\n+  \"id\": 594,\n+  \"title\": \"CBNA\",\n-    \"drug_name\": \"CBDV\",\n-    \"chemical_name\": \"CBDV\",\n+    \"drug_name\": \"CBNA\",\n+    \"chemical_name\": \"CBNA\",\n-            \"threshold\": \"10 mg\",\n-            \"light\": \"20 – 50 mg\",\n-            \"common\": \"50 – 200 mg\",\n-            \"strong\": \"200 – 400 mg\",\n-            \"heavy\": \"400 mg+\"\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"10 – 25 mg\",\n+            \"common\": \"25 – 50 mg\",\n+            \"strong\": \"50 – 100 mg\",\n+            \"heavy\": \"100 mg +\"\n-          \"route\": \"smoked\",\n+          \"route\": \"sublingual\",\n-            \"threshold\": \"1 mg\",\n-            \"light\": \"2 – 5 mg\",\n-            \"common\": \"5 – 15 mg\",\n-            \"strong\": \"15 – 30 mg\",\n-            \"heavy\": \"30 mg+\"\n+            \"threshold\": \"2 mg\",\n+            \"light\": \"5 – 15 mg\",\n+            \"common\": \"15 – 30 mg\",\n+            \"strong\": \"30 – 60 mg\",\n+            \"heavy\": \"60 mg +\"\n-            \"total_duration\": \"6-8 h\",\n-            \"onset\": \"30-120 min\",\n-            \"peak\": \"2-4 h\",\n-            \"offset\": \"2-3 h\",\n-            \"after_effects\": \"Subtle calm / focus up to 12 h\"\n+            \"total_duration\": \"4 - 8 h\",\n+            \"onset\": \"30 - 90 min\",\n+            \"peak\": \"1.5 - 3 h\",\n+            \"offset\": \"1 - 2 h\",\n+            \"after_effects\": \"Up to 12 h of residual relaxation / drowsiness\"\n-          \"route\": \"smoked\",\n+          \"route\": \"sublingual\",\n-            \"smoked\"\n+            \"sublingual\"\n-            \"total_duration\": \"2-4 h\",\n-            \"onset\": \"0-5 min\",\n-            \"peak\": \"15-60 min\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"Subtle calm / focus up to 12 h\"\n+            \"total_duration\": \"4 - 8 h\",\n+            \"onset\": \"10 - 30 min\",\n+            \"peak\": \"1.5 - 3 h\",\n+            \"offset\": \"1 - 2 h\",\n+            \"after_effects\": \"Up to 12 h of residual relaxation / drowsiness\"\n-    \"addiction_potential\": \"Negligible. CBDV produces no appreciable intoxication or euphoria and has not been associated with compulsive use or withdrawal in either clinical trials or anecdotal reports.\",\n+    \"addiction_potential\": \"Very low. No reinforcing properties have been demonstrated in animal or human studies; dependence has not been reported.\",\n-      \"dangerous\": [],\n+      \"dangerous\": [\n+        \"Poppers (amyl nitrite) – risk of hypotension\"\n+      ],\n-        \"Gabapentinoids\",\n-        \"Poppers\"\n+        \"Gabapentinoids – additive CNS and respiratory depression\"\n-        \"Antiepileptic drugs\",\n-        \"SSRIs/SNRIs (CYP-mediated)\",\n-        \"Drugs metabolised by CYP2C9, CYP2C19 or CYP3A4\"\n+        \"Opioids\",\n+        \"Z-drugs\",\n+        \"Ketamine\",\n+        \"DXM\",\n+        \"Other cannabinoids with high THC\"\n-    \"notes\": \"• Clinical studies (up to 800 mg BID for 8 weeks) have shown good safety with mostly mild GI upset and somnolence.\\n• Like CBD, CBDV is a moderate inhibitor of several CYP450 enzymes; caution with narrow-therapeutic-index drugs.\\n• Early evidence suggests anticonvulsant, anti-inflammatory and possible nootropic/attention-enhancing properties. Psychoactive effects are generally subtle or absent; some users describe a clear-headed, slightly stimulating ‘body calm.’\\n• Because extracts often contain other cannabinoids, confirm lab reports to estimate the actual CBDV content before dosing.\\n• Start low when combining with THC, as CBDV can transiently blunt THC intoxication and then shorten its duration.\",\n+    \"notes\": \"CBNA (cannabinolic acid) is the carboxylated precursor of cannabinol (CBN). It is produced when THCA oxidises and gradually decarboxylates to CBN during storage, or rapidly when heated. CBNA itself appears to have minimal affinity for CB1/CB2 receptors and is regarded as non-intoxicating. Animal data suggest mild anti-inflammatory and analgesic activity; anecdotal human use points to gentle sedation similar to low-dose CBN. Because the compound is uncommon on the recreational market, pharmacokinetic and toxicological data are sparse. Oral bioavailability is poor but can be improved with lipid carriers (e.g., MCT oil). Heating above ~110 °C will convert CBNA to CBN, changing the effect profile. Users seeking sedation often decarboxylate deliberately; those evaluating CBNA specifically should avoid high heat. Start with low doses, especially when combined with other CNS depressants. No serious adverse events have been reported, but high doses (>100 mg oral) occasionally cause pronounced drowsiness, dry mouth, and lowered blood pressure.\",\n-      \"Subtle mood elevation\",\n-      \"Mild anxiolysis\",\n-      \"Enhanced mental clarity/focus\",\n-      \"Decreased seizure frequency (clinical)\",\n-      \"Reduced inflammation/pain\",\n-      \"Very low or absent intoxication\",\n-      \"Possible mild GI discomfort at high oral doses\"\n+      \"Mild physical relaxation\",\n+      \"Sedation/drowsiness\",\n+      \"Subtle body warmth\",\n+      \"Reduced anxiety (anxiolysis)\",\n+      \"Slight analgesia\",\n+      \"Dry mouth\",\n+      \"No appreciable cognitive impairment at common doses\",\n+      \"Minimal to no euphoria\",\n+      \"Possible light-headedness at strong doses\"\n-      \"full_tolerance\": \"Little evidence of significant tolerance even with daily use for several months\",\n-      \"half_tolerance\": \"N/A\",\n-      \"zero_tolerance\": \"N/A\",\n+      \"full_tolerance\": \"Develops slowly with daily use (>3 weeks)\",\n+      \"half_tolerance\": \"~5 days of abstinence\",\n+      \"zero_tolerance\": \"~2 weeks of abstinence\",\n-        \"CBD\"\n+        \"CBN\",\n+        \"THC (partial)\"\n-    \"half_life\": \"Approx. 2–9 h (mean ≈ 4 h) after oral dosing in humans\",\n+    \"half_life\": \"Estimated 4 – 6 h (based on limited human plasma data and extrapolation from CBN)\",\n-        \"name\": \"Cannabidivarin – Wikipedia\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Cannabidivarin\"\n+        \"name\": \"PubChem – Cannabinolic acid\",\n+        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/5284733\"\n-        \"name\": \"PubChem Compound 115622 (Cannabidivarin)\",\n-        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/115622\"\n+        \"name\": \"Hanuš O, Hod Y, Friedman D. Cannabinoids in the Cannabis Plant. Cannabis Cannabinoid Res. 2016;1(1):1-15.\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5576607/\"\n-        \"name\": \"McLachlan RS et al. ‘Randomized controlled trial of cannabidivarin for focal seizures.’ Epilepsia. 2022\",\n-        \"reference\": \"https://doi.org/10.1111/epi.17430\"\n+        \"name\": \"Nallathambi R et al. Phytocannabinoids CBNA/CBN attenuate inflammation in vitro. Molecules. 2020;25(3):596.\",\n+        \"reference\": \"https://www.mdpi.com/1420-3049/25/3/596\"\n-        \"name\": \"Phase 1 Safety, Tolerability and PK of Cannabidivarin (GWP42006) – ClinicalTrials.gov\",\n-        \"reference\": \"https://clinicaltrials.gov/study/NCT02369471\"\n-      },\n-      {\n-        \"name\": \"Gründlingh J et al. ‘Anthelmintic activity of CBD and CBDV.’ PLOS Neglected Tropical Diseases 2023\",\n-        \"reference\": \"https://doi.org/10.1371/journal.pntd.0011181\"\n-      },\n-      {\n-        \"name\": \"Reddit r/CBD – ‘Review of Lost Oak Farms Happy Oil (CBD+CBDV)’\",\n-        \"reference\": \"https://www.reddit.com/r/CBD/comments/1b2xyz/review_of_lost_oak_farms_happy_oil/\"\n+        \"name\": \"Eichhorn Bilodeau S et al. Biosynthesis and Chemical Stability of Minor Cannabinoids. Front Plant Sci. 2021;12:748149.\",\n+        \"reference\": \"https://www.frontiersin.org/articles/10.3389/fpls.2021.748149/full\"\n\n# 1cP-MiPLA · #595\n\n-  \"id\": 594,\n-  \"title\": \"CBNA\",\n+  \"id\": 595,\n+  \"title\": \"1cP-MiPLA\",\n-    \"drug_name\": \"CBNA\",\n-    \"chemical_name\": \"CBNA\",\n+    \"drug_name\": \"1cP-MiPLA\",\n+    \"chemical_name\": \"1cP-MiPLA\",\n-    \"chemical_class\": \"Cannabinoids\",\n-    \"mechanism_of_action\": \"Multi-target modulator\",\n-    \"psychoactive_class\": \"cannabinoid; hallucinogen\",\n+    \"chemical_class\": \"Lysergamides\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist; prodrug of LSD\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-          \"units\": \"mg\",\n+          \"units\": \"µg\",\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"10 – 25 mg\",\n-            \"common\": \"25 – 50 mg\",\n-            \"strong\": \"50 – 100 mg\",\n-            \"heavy\": \"100 mg +\"\n+            \"threshold\": \"40–60 µg\",\n+            \"light\": \"75–125 µg\",\n+            \"common\": \"125–200 µg\",\n+            \"strong\": \"200–275 µg\",\n+            \"heavy\": \"300 µg +\"\n-          \"units\": \"mg\",\n+          \"units\": \"µg\",\n-            \"threshold\": \"2 mg\",\n-            \"light\": \"5 – 15 mg\",\n-            \"common\": \"15 – 30 mg\",\n-            \"strong\": \"30 – 60 mg\",\n-            \"heavy\": \"60 mg +\"\n+            \"threshold\": \"40 µg\",\n+            \"light\": \"70–110 µg\",\n+            \"common\": \"110–175 µg\",\n+            \"strong\": \"175–250 µg\",\n+            \"heavy\": \"250 µg +\"\n-            \"total_duration\": \"4 - 8 h\",\n-            \"onset\": \"30 - 90 min\",\n-            \"peak\": \"1.5 - 3 h\",\n-            \"offset\": \"1 - 2 h\",\n-            \"after_effects\": \"Up to 12 h of residual relaxation / drowsiness\"\n+            \"total_duration\": \"6-8 h\",\n+            \"onset\": \"20-45 min\",\n+            \"peak\": \"1.5-3 h\",\n+            \"offset\": \"2-3 h\",\n+            \"after_effects\": \"2-6 h residual stimulation / “after-glow”\"\n-            \"total_duration\": \"4 - 8 h\",\n-            \"onset\": \"10 - 30 min\",\n-            \"peak\": \"1.5 - 3 h\",\n-            \"offset\": \"1 - 2 h\",\n-            \"after_effects\": \"Up to 12 h of residual relaxation / drowsiness\"\n+            \"total_duration\": \"6-8 h\",\n+            \"onset\": \"20-45 min\",\n+            \"peak\": \"1.5-3 h\",\n+            \"offset\": \"2-3 h\",\n+            \"after_effects\": \"2-6 h residual stimulation / “after-glow”\"\n-    \"addiction_potential\": \"Very low. No reinforcing properties have been demonstrated in animal or human studies; dependence has not been reported.\",\n+    \"addiction_potential\": \"Low. Lysergamides do not produce physical dependence and compulsive redosing is rare; psychological craving possible with frequent use.\",\n-        \"Poppers (amyl nitrite) – risk of hypotension\"\n+        \"Tramadol\",\n+        \"MAOIs\",\n+        \"PVP-class stimulants\"\n-        \"Gabapentinoids – additive CNS and respiratory depression\"\n+        \"DXM\",\n+        \"SSRI/SNRI (may dull effects, serotonin-syndrome risk)\"\n-        \"Alcohol\",\n-        \"Benzodiazepines\",\n-        \"Opioids\",\n-        \"Z-drugs\",\n-        \"Ketamine\",\n-        \"DXM\",\n-        \"Other cannabinoids with high THC\"\n+        \"Amphetamines\",\n+        \"Cocaine\",\n+        \"Cannabis\",\n+        \"Alcohol\"\n-    \"notes\": \"CBNA (cannabinolic acid) is the carboxylated precursor of cannabinol (CBN). It is produced when THCA oxidises and gradually decarboxylates to CBN during storage, or rapidly when heated. CBNA itself appears to have minimal affinity for CB1/CB2 receptors and is regarded as non-intoxicating. Animal data suggest mild anti-inflammatory and analgesic activity; anecdotal human use points to gentle sedation similar to low-dose CBN. Because the compound is uncommon on the recreational market, pharmacokinetic and toxicological data are sparse. Oral bioavailability is poor but can be improved with lipid carriers (e.g., MCT oil). Heating above ~110 °C will convert CBNA to CBN, changing the effect profile. Users seeking sedation often decarboxylate deliberately; those evaluating CBNA specifically should avoid high heat. Start with low doses, especially when combined with other CNS depressants. No serious adverse events have been reported, but high doses (>100 mg oral) occasionally cause pronounced drowsiness, dry mouth, and lowered blood pressure.\",\n+    \"notes\": \"1cP-MiPLA (1-cyclopropionyl-N-methyl-N-isopropyl lysergamide) is a novel lysergamide sold online since 2020. In vitro studies indicate it is rapidly hydrolysed to MiPLA, acting as a pro-drug similar to 1P-LSD. Potency is roughly 60–80 % of LSD by weight; many users find 150 µg comparable to 100 µg LSD. The experience is shorter and a bit more stimulating than LSD, with a ‘clean’ visual character and less head-space intensity. Virtually no human or animal toxicity data exist; start low, employ allergy tests, and allow at least 14 days between psychedelic sessions to minimise tolerance and HPPD risk. Reagent testing (e.g., Ehrlich) will give a positive indole reaction but cannot confirm identity; full lab analysis is required for certainty.\",\n-      \"Mild physical relaxation\",\n-      \"Sedation/drowsiness\",\n-      \"Subtle body warmth\",\n-      \"Reduced anxiety (anxiolysis)\",\n-      \"Slight analgesia\",\n-      \"Dry mouth\",\n-      \"No appreciable cognitive impairment at common doses\",\n-      \"Minimal to no euphoria\",\n-      \"Possible light-headedness at strong doses\"\n+      \"Color enhancement\",\n+      \"Pattern recognition enhancement\",\n+      \"Visual acuity enhancement\",\n+      \"Geometric open-eye visuals\",\n+      \"Mild closed-eye imagery\",\n+      \"Tracers\",\n+      \"Time dilation\",\n+      \"Emotional amplification\",\n+      \"Cognitive auras (‘mind-loops’)\",\n+      \"Euphoria\",\n+      \"Anxiety at high doses\",\n+      \"Body warmth/tingling\",\n+      \"Dilated pupils\",\n+      \"Insomnia/stimulation\",\n+      \"After-glow mood lift\"\n-      \"full_tolerance\": \"Develops slowly with daily use (>3 weeks)\",\n-      \"half_tolerance\": \"~5 days of abstinence\",\n-      \"zero_tolerance\": \"~2 weeks of abstinence\",\n+      \"full_tolerance\": \"Develops after single dose\",\n+      \"half_tolerance\": \"5–7 days\",\n+      \"zero_tolerance\": \"≈14 days\",\n-        \"CBN\",\n-        \"THC (partial)\"\n+        \"LSD\",\n+        \"Psilocybin\",\n+        \"Other serotonergic psychedelics\"\n-    \"half_life\": \"Estimated 4 – 6 h (based on limited human plasma data and extrapolation from CBN)\",\n+    \"half_life\": \"Parent compound <1 h (rapidly hydrolyses); active MiPLA plasma t½ estimated 2.5–3.5 h\",\n-        \"name\": \"PubChem – Cannabinolic acid\",\n-        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/5284733\"\n+        \"name\": \"Wagmann L. et al. “Analysis of LSD analogs (1cP-MiPLA, 1cP-LSD, etc.) in seized blotters.” Forensic Toxicology (2021)\",\n+        \"reference\": \"https://link.springer.com/article/10.1007/s11419-021-00554-y\"\n-        \"name\": \"Hanuš O, Hod Y, Friedman D. Cannabinoids in the Cannabis Plant. Cannabis Cannabinoid Res. 2016;1(1):1-15.\",\n-        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5576607/\"\n+        \"name\": \"Halberstadt A.L. et al. “Pharmacological characterization of novel lysergamides including MiPLA.” Neuropharmacology (2020)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/32470368/\"\n-        \"name\": \"Nallathambi R et al. Phytocannabinoids CBNA/CBN attenuate inflammation in vitro. Molecules. 2020;25(3):596.\",\n-        \"reference\": \"https://www.mdpi.com/1420-3049/25/3/596\"\n-      },\n-      {\n-        \"name\": \"Eichhorn Bilodeau S et al. Biosynthesis and Chemical Stability of Minor Cannabinoids. Front Plant Sci. 2021;12:748149.\",\n-        \"reference\": \"https://www.frontiersin.org/articles/10.3389/fpls.2021.748149/full\"\n+        \"name\": \"TripReport.net substance overview: 1cP-MiPLA\",\n+        \"reference\": \"https://tripreport.net/substances/1cP-MiPLA\"\n-      \"cannabinoid\",\n-      \"supplement\",\n-      \"nootropic\"\n+      \"psychedelic\",\n+      \"research-chemical\"\n\n# C30-NBOMe · #596\n\n-  \"id\": 595,\n-  \"title\": \"1cP-MiPLA\",\n+  \"id\": 596,\n+  \"title\": \"C30-NBOMe\",\n-    \"drug_name\": \"1cP-MiPLA\",\n-    \"chemical_name\": \"1cP-MiPLA\",\n+    \"drug_name\": \"C30-NBOMe\",\n+    \"chemical_name\": \"C30-NBOMe\",\n-    \"chemical_class\": \"Lysergamides\",\n-    \"mechanism_of_action\": \"5-HT2A receptor agonist; prodrug of LSD\",\n+    \"chemical_class\": \"N-benzylated phenethylamines\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist (potent); 5-HT2B receptor agonist (cardiotoxic)\",\n-          \"units\": \"µg\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"40–60 µg\",\n-            \"light\": \"75–125 µg\",\n-            \"common\": \"125–200 µg\",\n-            \"strong\": \"200–275 µg\",\n-            \"heavy\": \"300 µg +\"\n+            \"threshold\": \"no effects reported ≤10 mg\",\n+            \"light\": \"—\",\n+            \"common\": \"—\",\n+            \"strong\": \"—\",\n+            \"heavy\": \"no effects reported at 50 mg+ (possible toxicity unknown)\"\n-        },\n-        {\n-          \"route\": \"sublingual\",\n-          \"units\": \"µg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"40 µg\",\n-            \"light\": \"70–110 µg\",\n-            \"common\": \"110–175 µg\",\n-            \"strong\": \"175–250 µg\",\n-            \"heavy\": \"250 µg +\"\n-          }\n-            \"total_duration\": \"6-8 h\",\n-            \"onset\": \"20-45 min\",\n-            \"peak\": \"1.5-3 h\",\n-            \"offset\": \"2-3 h\",\n-            \"after_effects\": \"2-6 h residual stimulation / “after-glow”\"\n+            \"total_duration\": \"No reliable effects observed\",\n+            \"onset\": \"-\",\n+            \"peak\": \"-\",\n+            \"offset\": \"-\",\n+            \"after_effects\": \"-\"\n-        },\n-        {\n-          \"route\": \"sublingual\",\n-          \"canonical_routes\": [\n-            \"sublingual\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"6-8 h\",\n-            \"onset\": \"20-45 min\",\n-            \"peak\": \"1.5-3 h\",\n-            \"offset\": \"2-3 h\",\n-            \"after_effects\": \"2-6 h residual stimulation / “after-glow”\"\n-          }\n-    \"addiction_potential\": \"Low. Lysergamides do not produce physical dependence and compulsive redosing is rare; psychological craving possible with frequent use.\",\n+    \"addiction_potential\": \"No evidence of reinforcing properties; presumed negligible.\",\n-        \"Tramadol\",\n-        \"PVP-class stimulants\"\n+        \"DXM\",\n+        \"Amphetamines\",\n+        \"Cocaine\",\n+        \"Tramadol\",\n+        \"PVP-class cathinones\",\n+        \"MMC-class cathinones\"\n-        \"SSRI/SNRI (may dull effects, serotonin-syndrome risk)\"\n-      ],\n-      \"caution\": [\n+        \"Tramadol\"\n+      ],\n+      \"caution\": [\n+        \"2C-x & 2C-T-x\",\n+        \"DOx\",\n-        \"Alcohol\"\n+        \"Ketamine\",\n+        \"LSD\",\n+        \"Mushrooms\",\n+        \"MDMA\",\n+        \"SSRIs\",\n+        \"Gabapentinoids\",\n+        \"Poppers\"\n-    \"notes\": \"1cP-MiPLA (1-cyclopropionyl-N-methyl-N-isopropyl lysergamide) is a novel lysergamide sold online since 2020. In vitro studies indicate it is rapidly hydrolysed to MiPLA, acting as a pro-drug similar to 1P-LSD. Potency is roughly 60–80 % of LSD by weight; many users find 150 µg comparable to 100 µg LSD. The experience is shorter and a bit more stimulating than LSD, with a ‘clean’ visual character and less head-space intensity. Virtually no human or animal toxicity data exist; start low, employ allergy tests, and allow at least 14 days between psychedelic sessions to minimise tolerance and HPPD risk. Reagent testing (e.g., Ehrlich) will give a positive indole reaction but cannot confirm identity; full lab analysis is required for certainty.\",\n+    \"notes\": \"C30-NBOMe was listed by a handful of vendors circa 2013-2016 but no verifiable human activity has ever been demonstrated. Multiple independent self-experiments (oral, buccal, sublingual up to 50 mg) produced no psychedelic or stimulant effects. It is therefore assumed to be inactive or extremely low-potency. Material sold under this name may be an inert compound, a mislabelled NBOMe, or degradation products. Because its true pharmacology, toxicity, and identity remain unconfirmed, treat any sample with caution and test before use.\",\n-      \"Color enhancement\",\n-      \"Pattern recognition enhancement\",\n-      \"Visual acuity enhancement\",\n-      \"Geometric open-eye visuals\",\n-      \"Mild closed-eye imagery\",\n-      \"Tracers\",\n-      \"Time dilation\",\n-      \"Emotional amplification\",\n-      \"Cognitive auras (‘mind-loops’)\",\n-      \"Euphoria\",\n-      \"Anxiety at high doses\",\n-      \"Body warmth/tingling\",\n-      \"Dilated pupils\",\n-      \"Insomnia/stimulation\",\n-      \"After-glow mood lift\"\n+      \"No discernible psychoactive effects in the vast majority of reports\",\n+      \"Occasional placebo-like expectations reported\"\n-      \"full_tolerance\": \"Develops after single dose\",\n-      \"half_tolerance\": \"5–7 days\",\n-      \"zero_tolerance\": \"≈14 days\",\n-      \"cross_tolerances\": [\n-        \"LSD\",\n-        \"Psilocybin\",\n-        \"Other serotonergic psychedelics\"\n-      ]\n+      \"full_tolerance\": \"Not applicable\",\n+      \"half_tolerance\": \"—\",\n+      \"zero_tolerance\": \"—\",\n+      \"cross_tolerances\": []\n-    \"half_life\": \"Parent compound <1 h (rapidly hydrolyses); active MiPLA plasma t½ estimated 2.5–3.5 h\",\n+    \"half_life\": \"Unknown (pharmacokinetics unstudied)\",\n-        \"name\": \"Wagmann L. et al. “Analysis of LSD analogs (1cP-MiPLA, 1cP-LSD, etc.) in seized blotters.” Forensic Toxicology (2021)\",\n-        \"reference\": \"https://link.springer.com/article/10.1007/s11419-021-00554-y\"\n+        \"name\": \"TripSit Factsheet – C30-NBOMe\",\n+        \"reference\": \"https://drugs.tripsit.me/c30-nbome\"\n-        \"name\": \"Halberstadt A.L. et al. “Pharmacological characterization of novel lysergamides including MiPLA.” Neuropharmacology (2020)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/32470368/\"\n+        \"name\": \"BlueLight Thread: “C30-NBOMe” (reports of inactivity)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/c30-nbome.675365/\"\n-        \"name\": \"TripReport.net substance overview: 1cP-MiPLA\",\n-        \"reference\": \"https://tripreport.net/substances/1cP-MiPLA\"\n+        \"name\": \"Reddit r/askdrugs: “c30-nBOME” discussion (2015)\",\n+        \"reference\": \"https://www.reddit.com/r/askdrugs/comments/39p02f/c30nbome/\"\n\n# Bufotenin · #597\n\n-  \"id\": 596,\n-  \"title\": \"C30-NBOMe\",\n+  \"id\": 597,\n+  \"title\": \"Bufotenin\",\n-    \"drug_name\": \"C30-NBOMe\",\n-    \"chemical_name\": \"C30-NBOMe\",\n+    \"drug_name\": \"Bufotenin\",\n+    \"chemical_name\": \"Bufotenin\",\n-    \"chemical_class\": \"N-benzylated phenethylamines\",\n-    \"mechanism_of_action\": \"5-HT2A receptor agonist (potent); 5-HT2B receptor agonist (cardiotoxic)\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist\",\n-          \"route\": \"oral\",\n+          \"route\": \"smoked\",\n-            \"threshold\": \"no effects reported ≤10 mg\",\n-            \"light\": \"—\",\n-            \"common\": \"—\",\n-            \"strong\": \"—\",\n-            \"heavy\": \"no effects reported at 50 mg+ (possible toxicity unknown)\"\n+            \"threshold\": \"2 mg\",\n+            \"light\": \"5–15 mg\",\n+            \"common\": \"15–35 mg\",\n+            \"strong\": \"35–55 mg\",\n+            \"heavy\": \">55 mg\"\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"10–20 mg\",\n+            \"common\": \"20–40 mg\",\n+            \"strong\": \"40–60 mg\",\n+            \"heavy\": \">60 mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg (with MAOI)\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"10 mg\",\n+            \"light\": \"20–35 mg\",\n+            \"common\": \"35–60 mg\",\n+            \"strong\": \"60–80 mg\",\n+            \"heavy\": \">80 mg\"\n+          }\n+          \"route\": \"smoked\",\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"15-60 min\",\n+            \"onset\": \"0.3-1 min\",\n+            \"peak\": \"2-6 min\",\n+            \"offset\": \"10-20 min\",\n+            \"after_effects\": \"30-90 min\"\n+          }\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"45-120 min\",\n+            \"onset\": \"2-10 min\",\n+            \"peak\": \"20-40 min\",\n+            \"offset\": \"30-60 min\",\n+            \"after_effects\": \"30-90 min\"\n+          }\n+        },\n+        {\n-            \"total_duration\": \"No reliable effects observed\",\n-            \"onset\": \"-\",\n-            \"peak\": \"-\",\n-            \"offset\": \"-\",\n-            \"after_effects\": \"-\"\n+            \"total_duration\": \"3-6 h\",\n+            \"onset\": \"30-60 min\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-6 h\"\n-    \"addiction_potential\": \"No evidence of reinforcing properties; presumed negligible.\",\n+    \"addiction_potential\": \"Very low; no documented cases of compulsive use or physiological dependence. Rapid acute tolerance limits back-to-back dosing.\",\n-        \"MAOIs\",\n-        \"DXM\",\n-        \"Amphetamines\",\n-        \"Cocaine\",\n-        \"Tramadol\",\n-        \"PVP-class cathinones\",\n-        \"MMC-class cathinones\"\n+        \"MAOIs (non-selective, e.g., harmaline) — massive potentiation, hypertensive crises possible\",\n+        \"Tramadol — seizure / serotonin-syndrome risk\",\n+        \"Linezolid\",\n+        \"RIMA antidepressants at high doses\"\n-        \"DXM\",\n-        \"Amphetamines\",\n-        \"Cocaine\",\n-        \"Tramadol\"\n+        \"SSRIs / SNRIs / TCAs — theoretical serotonin-syndrome risk\",\n+        \"5-MeO-DMT — overwhelming intensity, vasoconstriction\"\n-        \"2C-x & 2C-T-x\",\n-        \"DOx\",\n-        \"Cannabis\",\n-        \"Ketamine\",\n-        \"LSD\",\n-        \"Mushrooms\",\n-        \"MDMA\",\n-        \"SSRIs\",\n-        \"Gabapentinoids\",\n-        \"Poppers\"\n+        \"Stimulants (amphetamines, cocaine) — additive cardiovascular load\",\n+        \"Cannabis — may increase dysphoria or anxiety\",\n+        \"Nitrates / PDE-5 inhibitors — compounded hypotension\",\n+        \"Benzodiazepines — may dull experience but useful for anxiety\"\n-    \"notes\": \"C30-NBOMe was listed by a handful of vendors circa 2013-2016 but no verifiable human activity has ever been demonstrated. Multiple independent self-experiments (oral, buccal, sublingual up to 50 mg) produced no psychedelic or stimulant effects. It is therefore assumed to be inactive or extremely low-potency. Material sold under this name may be an inert compound, a mislabelled NBOMe, or degradation products. Because its true pharmacology, toxicity, and identity remain unconfirmed, treat any sample with caution and test before use.\",\n+    \"notes\": \"• Natural tryptamine found in Anadenanthera (Yopo/Cebil) seeds and in the skin glands of several Bufo/Incilius toads. ‘Toad-licking’ is dangerous because the venom also contains cardiotoxic bufadienolides.  \\n• Pure bufotenin freebase vaporises at ~160 °C; use a low-temperature glass pipe or e-mesh to minimise smoke harshness.  \\n• Marked peripheral vasoconstriction, flushing, tachycardia, and bronchospasm have been reported, especially >40 mg or when injected. Those with asthma, hypertension, or cardiovascular disease should avoid.  \\n• Oral activity is normally negligible due to rapid MAO-A degradation; co-administration of a reversible MAOI (e.g., harmine) renders it fully active but also markedly increases physiological load.  \\n• Intravenous studies in the 1950s produced intense but very short psychedelic states along with cyanosis and BP spikes; stay below 30 mg smoked to reduce risk.  \\n• Legal status: Schedule I in the USA, Schedule 9 in Australia, List I psychotropic in many EU states.  \\n• Never collect wild toads—ethical, ecological, and legal hazards; plant sources are far safer.\",\n-      \"No discernible psychoactive effects in the vast majority of reports\",\n-      \"Occasional placebo-like expectations reported\"\n+      \"Intense closed- and open-eye geometry\",\n+      \"Color enhancement & shifting\",\n+      \"Rapid time dilation\",\n+      \"Auditory distortions\",\n+      \"Powerful somatic pressure (chest, head)\",\n+      \"Peripheral vasoconstriction / flushing\",\n+      \"Nausea at higher doses\",\n+      \"Anxiety or panic on rapid onset\",\n+      \"Feelings of unity / interconnectedness\",\n+      \"Recursive thought loops\",\n+      \"Brief amnesia of peak\",\n+      \"Enhanced tactile & musical appreciation\",\n+      \"Visual ‘static’ and strobing patterns\",\n+      \"Motor incoordination\",\n+      \"Potential vomiting (esp. insufflated seeds)\"\n-      \"full_tolerance\": \"Not applicable\",\n-      \"half_tolerance\": \"—\",\n-      \"zero_tolerance\": \"—\",\n-      \"cross_tolerances\": []\n+      \"full_tolerance\": \"After one strong dose\",\n+      \"half_tolerance\": \"~1 hour\",\n+      \"zero_tolerance\": \"~24 hours (most sensitivity returns within 2–3 h, but cross-tolerance to other psychedelics can persist 24 h)\",\n+      \"cross_tolerances\": [\n+        \"Psilocin\",\n+        \"DMT\",\n+        \"LSD\",\n+        \"Other serotonergic psychedelics\"\n+      ]\n-    \"half_life\": \"Unknown (pharmacokinetics unstudied)\",\n+    \"half_life\": \"~30–90 min (human plasma, estimated from historical IV studies)\",\n-        \"name\": \"TripSit Factsheet – C30-NBOMe\",\n-        \"reference\": \"https://drugs.tripsit.me/c30-nbome\"\n+        \"name\": \"TiHKAL #58 – Bufotenine\",\n+        \"reference\": \"https://tihkal.info/read.php?domain=tk&id=58\"\n-        \"name\": \"BlueLight Thread: “C30-NBOMe” (reports of inactivity)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/c30-nbome.675365/\"\n+        \"name\": \"Erowid Bufotenin Vault – Dose & Effect overview\",\n+        \"reference\": \"https://erowid.org/chemicals/bufotenine/\"\n-        \"name\": \"Reddit r/askdrugs: “c30-nBOME” discussion (2015)\",\n-        \"reference\": \"https://www.reddit.com/r/askdrugs/comments/39p02f/c30nbome/\"\n+        \"name\": \"Fabing HD & Hawkins JR. Intravenous bufotenine (1956)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/13319349/\"\n+      },\n+      {\n+        \"name\": \"Carvalho et al. ‘Bufotenine: Pharmacological treasures from toad venom’ (2019)\",\n+        \"reference\": \"https://doi.org/10.2174/0929866525666181023124048\"\n+      },\n+      {\n+        \"name\": \"Erowid Experience Report #65684 – 30 mg smoked freebase\",\n+        \"reference\": \"https://erowid.org/experiences/exp.php?ID=65684\"\n\n# Butorphanol · #598\n\n-  \"id\": 597,\n-  \"title\": \"Bufotenin\",\n+  \"id\": 598,\n+  \"title\": \"Butorphanol\",\n-    \"drug_name\": \"Bufotenin\",\n-    \"chemical_name\": \"Bufotenin\",\n+    \"drug_name\": \"Butorphanol\",\n+    \"chemical_name\": \"Butorphanol\",\n-    \"chemical_class\": \"Tryptamines\",\n-    \"mechanism_of_action\": \"5-HT2A receptor agonist\",\n-    \"psychoactive_class\": \"Psychedelic\",\n+    \"chemical_class\": \"Morphinans\",\n+    \"mechanism_of_action\": \"κ-Opioid receptor agonist; μ-opioid receptor antagonist\",\n+    \"psychoactive_class\": \"Mixed opioid agonist-antagonist (κ-agonist / partial µ-agonist-antagonist)\",\n-          \"route\": \"smoked\",\n+          \"route\": \"intranasal\",\n-            \"threshold\": \"2 mg\",\n-            \"light\": \"5–15 mg\",\n-            \"common\": \"15–35 mg\",\n-            \"strong\": \"35–55 mg\",\n-            \"heavy\": \">55 mg\"\n+            \"threshold\": \"0.25 mg\",\n+            \"light\": \"0.5 – 1 mg\",\n+            \"common\": \"1 – 2 mg\",\n+            \"strong\": \"2 – 3 mg\",\n+            \"heavy\": \"≥3.5 mg\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"intravenous\",\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"10–20 mg\",\n-            \"common\": \"20–40 mg\",\n-            \"strong\": \"40–60 mg\",\n-            \"heavy\": \">60 mg\"\n+            \"threshold\": \"0.25 mg\",\n+            \"light\": \"0.5 mg\",\n+            \"common\": \"1 mg\",\n+            \"strong\": \"1.5 – 2 mg\",\n+            \"heavy\": \"≥2.5 mg\"\n+          \"route\": \"intramuscular\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"0.5 mg\",\n+            \"light\": \"1 mg\",\n+            \"common\": \"2 mg\",\n+            \"strong\": \"3 mg\",\n+            \"heavy\": \"≥4 mg\"\n+          }\n+        },\n+        {\n-          \"units\": \"mg (with MAOI)\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"10 mg\",\n-            \"light\": \"20–35 mg\",\n-            \"common\": \"35–60 mg\",\n-            \"strong\": \"60–80 mg\",\n-            \"heavy\": \">80 mg\"\n+            \"threshold\": \"4 mg\",\n+            \"light\": \"6 mg\",\n+            \"common\": \"8 – 12 mg\",\n+            \"strong\": \"16 mg\",\n+            \"heavy\": \"≥20 mg\"\n-          \"route\": \"smoked\",\n+          \"route\": \"intranasal\",\n-            \"smoked\"\n+            \"intranasal\"\n-            \"total_duration\": \"15-60 min\",\n-            \"onset\": \"0.3-1 min\",\n-            \"peak\": \"2-6 min\",\n-            \"offset\": \"10-20 min\",\n-            \"after_effects\": \"30-90 min\"\n+            \"total_duration\": \"2 - 6 h (route-dependent)\",\n+            \"onset\": \"10-15 min\",\n+            \"peak\": \"30 - 90 min\",\n+            \"offset\": \"1 - 2 h\",\n+            \"after_effects\": \"2 - 6 h residual sedation / disequilibrium\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"intravenous\",\n-            \"insufflated\"\n+            \"intravenous\"\n-            \"total_duration\": \"45-120 min\",\n-            \"onset\": \"2-10 min\",\n-            \"peak\": \"20-40 min\",\n-            \"offset\": \"30-60 min\",\n-            \"after_effects\": \"30-90 min\"\n+            \"total_duration\": \"2 - 6 h (route-dependent)\",\n+            \"onset\": \"1-3 min\",\n+            \"peak\": \"30 - 90 min\",\n+            \"offset\": \"1 - 2 h\",\n+            \"after_effects\": \"2 - 6 h residual sedation / disequilibrium\"\n+          \"route\": \"intramuscular\",\n+          \"canonical_routes\": [\n+            \"intramuscular\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"2 - 6 h (route-dependent)\",\n+            \"onset\": \"10-30 min\",\n+            \"peak\": \"30 - 90 min\",\n+            \"offset\": \"1 - 2 h\",\n+            \"after_effects\": \"2 - 6 h residual sedation / disequilibrium\"\n+          }\n+        },\n+        {\n-            \"total_duration\": \"3-6 h\",\n+            \"total_duration\": \"2 - 6 h (route-dependent)\",\n-            \"peak\": \"1-2 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-6 h\"\n+            \"peak\": \"30 - 90 min\",\n+            \"offset\": \"1 - 2 h\",\n+            \"after_effects\": \"2 - 6 h residual sedation / disequilibrium\"\n-    \"addiction_potential\": \"Very low; no documented cases of compulsive use or physiological dependence. Rapid acute tolerance limits back-to-back dosing.\",\n+    \"addiction_potential\": \"Low-to-moderate. Physical dependence and withdrawal occur with chronic use, but κ-agonist dysphoria limits compulsive redosing for many users. Can precipitate acute withdrawal in people dependent on full µ-opioid agonists.\",\n-        \"MAOIs (non-selective, e.g., harmaline) — massive potentiation, hypertensive crises possible\",\n-        \"Tramadol — seizure / serotonin-syndrome risk\",\n-        \"Linezolid\",\n-        \"RIMA antidepressants at high doses\"\n+        \"Alcohol\",\n+        \"benzodiazepines\",\n+        \"barbiturates\",\n+        \"GHB\",\n+        \"other µ-opioid agonists (respiratory depression, possible precipitated withdrawal)\"\n-        \"SSRIs / SNRIs / TCAs — theoretical serotonin-syndrome risk\",\n-        \"5-MeO-DMT — overwhelming intensity, vasoconstriction\"\n+        \"MAOIs or linezolid (theoretical risk of serotonin/adrenergic interaction)\",\n+        \"antipsychotics (additive CNS depression, dysphoria)\"\n-        \"Stimulants (amphetamines, cocaine) — additive cardiovascular load\",\n-        \"Cannabis — may increase dysphoria or anxiety\",\n-        \"Nitrates / PDE-5 inhibitors — compounded hypotension\",\n-        \"Benzodiazepines — may dull experience but useful for anxiety\"\n+        \"Antihistamines\",\n+        \"gabapentinoids\",\n+        \"sedative-hypnotics\",\n+        \"tramadol or tapentadol (seizure threshold ↓, withdrawal risk)\"\n-    \"notes\": \"• Natural tryptamine found in Anadenanthera (Yopo/Cebil) seeds and in the skin glands of several Bufo/Incilius toads. ‘Toad-licking’ is dangerous because the venom also contains cardiotoxic bufadienolides.  \\n• Pure bufotenin freebase vaporises at ~160 °C; use a low-temperature glass pipe or e-mesh to minimise smoke harshness.  \\n• Marked peripheral vasoconstriction, flushing, tachycardia, and bronchospasm have been reported, especially >40 mg or when injected. Those with asthma, hypertension, or cardiovascular disease should avoid.  \\n• Oral activity is normally negligible due to rapid MAO-A degradation; co-administration of a reversible MAOI (e.g., harmine) renders it fully active but also markedly increases physiological load.  \\n• Intravenous studies in the 1950s produced intense but very short psychedelic states along with cyanosis and BP spikes; stay below 30 mg smoked to reduce risk.  \\n• Legal status: Schedule I in the USA, Schedule 9 in Australia, List I psychotropic in many EU states.  \\n• Never collect wild toads—ethical, ecological, and legal hazards; plant sources are far safer.\",\n+    \"notes\": \"Butorphanol is marketed as Stadol (human) and Torbugesic (veterinary). Pharmacologically it is a potent κ-opioid receptor agonist with partial agonist/antagonist activity at the µ-receptor; this combination produces analgesia with less respiratory depression than morphine but a high incidence of dysphoria, vertigo, and hallucination-like experiences. Recreational reports describe ‘darkened’ or ‘tunnel’ vision, mild warmth, dissociative or salvia-like head-space, and amnestic episodes at higher doses. Because of its antagonist component it can precipitate withdrawal in users dependent on strong µ-agonists (e.g., morphine, methadone, high-dose tramadol). Concomitant CNS depressants markedly increase risk of respiratory depression. Intranasal spray is the most common human formulation (1 mg/spray). Oral bioavailability is low (~17 %), so oral dosing is unpredictable. Use sterile technique for injections; veterinary multi-dose vials often contain bacteriostatic preservatives but are not guaranteed pyrogen-free for human use.\",\n-      \"Intense closed- and open-eye geometry\",\n-      \"Color enhancement & shifting\",\n-      \"Rapid time dilation\",\n-      \"Auditory distortions\",\n-      \"Powerful somatic pressure (chest, head)\",\n-      \"Peripheral vasoconstriction / flushing\",\n-      \"Nausea at higher doses\",\n-      \"Anxiety or panic on rapid onset\",\n-      \"Feelings of unity / interconnectedness\",\n-      \"Recursive thought loops\",\n-      \"Brief amnesia of peak\",\n-      \"Enhanced tactile & musical appreciation\",\n-      \"Visual ‘static’ and strobing patterns\",\n-      \"Motor incoordination\",\n-      \"Potential vomiting (esp. insufflated seeds)\"\n+      \"Analgesia\",\n+      \"mild opioid warmth/euphoria\",\n+      \"dysphoria or anxiety (dose-dependent)\",\n+      \"sedation\",\n+      \"dizziness/vertigo\",\n+      \"visual dimming or tunnel vision\",\n+      \"derealisation / mild dissociation\",\n+      \"out-of-body sensations\",\n+      \"closed-eye visuals\",\n+      \"nausea\",\n+      \"pruritus\",\n+      \"memory impairment\",\n+      \"increased sweating\",\n+      \"blood-pressure fluctuations\"\n-      \"full_tolerance\": \"After one strong dose\",\n-      \"half_tolerance\": \"~1 hour\",\n-      \"zero_tolerance\": \"~24 hours (most sensitivity returns within 2–3 h, but cross-tolerance to other psychedelics can persist 24 h)\",\n+      \"full_tolerance\": \"Builds after 3 – 5 consecutive days of use\",\n+      \"half_tolerance\": \"7 – 10 days of abstinence\",\n+      \"zero_tolerance\": \"2 – 3 weeks of abstinence\",\n-        \"Psilocin\",\n-        \"DMT\",\n-        \"LSD\",\n-        \"Other serotonergic psychedelics\"\n+        \"Other opioids (µ-agonists)\"\n-    \"half_life\": \"~30–90 min (human plasma, estimated from historical IV studies)\",\n+    \"half_life\": \"3 – 4.5 h (elimination half-life in healthy adults)\",\n-        \"name\": \"TiHKAL #58 – Bufotenine\",\n-        \"reference\": \"https://tihkal.info/read.php?domain=tk&id=58\"\n+        \"name\": \"Butorphanol – Drugs.com professional monograph\",\n+        \"reference\": \"https://www.drugs.com/monograph/butorphanol.html\"\n-        \"name\": \"Erowid Bufotenin Vault – Dose & Effect overview\",\n-        \"reference\": \"https://erowid.org/chemicals/bufotenine/\"\n+        \"name\": \"Stadol (butorphanol tartrate) FDA Prescribing Information\",\n+        \"reference\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018471s019lbl.pdf\"\n-        \"name\": \"Fabing HD & Hawkins JR. Intravenous bufotenine (1956)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/13319349/\"\n+        \"name\": \"Butorphanol – PubChem Compound Summary\",\n+        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/5280980\"\n-        \"name\": \"Carvalho et al. ‘Bufotenine: Pharmacological treasures from toad venom’ (2019)\",\n-        \"reference\": \"https://doi.org/10.2174/0929866525666181023124048\"\n+        \"name\": \"Opioids – Butorphanol? Recreational? (user experiences)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/butorphanol-recreational.892662/\"\n-        \"name\": \"Erowid Experience Report #65684 – 30 mg smoked freebase\",\n-        \"reference\": \"https://erowid.org/experiences/exp.php?ID=65684\"\n+        \"name\": \"Wikipedia: Butorphanol\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Butorphanol\"\n-      \"psychedelic\",\n-      \"research-chemical\"\n+      \"opioid\",\n+      \"depressant\",\n+      \"habit-forming\"\n\n# Atropine · #599\n\n-  \"id\": 598,\n-  \"title\": \"Butorphanol\",\n+  \"id\": 599,\n+  \"title\": \"Atropine\",\n-    \"drug_name\": \"Butorphanol\",\n-    \"chemical_name\": \"Butorphanol\",\n+    \"drug_name\": \"Atropine\",\n+    \"chemical_name\": \"Atropine\",\n-    \"chemical_class\": \"Morphinans\",\n-    \"mechanism_of_action\": \"κ-Opioid receptor agonist; μ-opioid receptor antagonist\",\n-    \"psychoactive_class\": \"Mixed opioid agonist-antagonist (κ-agonist / partial µ-agonist-antagonist)\",\n+    \"chemical_class\": \"Tropane alkaloids\",\n+    \"mechanism_of_action\": \"Muscarinic acetylcholine receptor antagonist\",\n+    \"psychoactive_class\": \"Deliriant anticholinergic\",\n-          \"route\": \"intranasal\",\n+          \"route\": \"oral\",\n-            \"threshold\": \"0.25 mg\",\n+            \"threshold\": \"0.3 mg\",\n-            \"common\": \"1 – 2 mg\",\n-            \"strong\": \"2 – 3 mg\",\n-            \"heavy\": \"≥3.5 mg\"\n+            \"common\": \"2 – 5 mg\",\n+            \"strong\": \"6 – 10 mg\",\n+            \"heavy\": \"10+ mg (often toxic)\"\n-            \"threshold\": \"0.25 mg\",\n-            \"light\": \"0.5 mg\",\n-            \"common\": \"1 mg\",\n-            \"strong\": \"1.5 – 2 mg\",\n-            \"heavy\": \"≥2.5 mg\"\n+            \"threshold\": \"0.2 mg (therapeutic)\",\n+            \"light\": \"0.3 – 0.6 mg\",\n+            \"common\": \"0.6 – 1 mg\",\n+            \"strong\": \"1 – 2 mg\",\n+            \"heavy\": \"2+ mg (poisoning risk)\"\n-        },\n-        {\n-          \"route\": \"intramuscular\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"0.5 mg\",\n-            \"light\": \"1 mg\",\n-            \"common\": \"2 mg\",\n-            \"strong\": \"3 mg\",\n-            \"heavy\": \"≥4 mg\"\n-          }\n-        },\n-        {\n-          \"route\": \"oral\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"4 mg\",\n-            \"light\": \"6 mg\",\n-            \"common\": \"8 – 12 mg\",\n-            \"strong\": \"16 mg\",\n-            \"heavy\": \"≥20 mg\"\n-          }\n-          \"route\": \"intranasal\",\n+          \"route\": \"oral\",\n-            \"intranasal\"\n+            \"oral\"\n-            \"total_duration\": \"2 - 6 h (route-dependent)\",\n-            \"onset\": \"10-15 min\",\n-            \"peak\": \"30 - 90 min\",\n-            \"offset\": \"1 - 2 h\",\n-            \"after_effects\": \"2 - 6 h residual sedation / disequilibrium\"\n+            \"total_duration\": \"6 - 12 h (central effects); residual autonomic effects up to 24-72 h\",\n+            \"onset\": \"30 - 60 min\",\n+            \"peak\": \"1 - 3 h\",\n+            \"offset\": \"4 - 8 h\",\n+            \"after_effects\": \"Dilated pupils; blurred vision; urinary retention; and cognitive fog can persist 1 - 3 days\"\n-            \"total_duration\": \"2 - 6 h (route-dependent)\",\n-            \"onset\": \"1-3 min\",\n-            \"peak\": \"30 - 90 min\",\n-            \"offset\": \"1 - 2 h\",\n-            \"after_effects\": \"2 - 6 h residual sedation / disequilibrium\"\n+            \"total_duration\": \"6 - 12 h (central effects); residual autonomic effects up to 24-72 h\",\n+            \"onset\": \"1-4 min\",\n+            \"peak\": \"1 - 3 h\",\n+            \"offset\": \"4 - 8 h\",\n+            \"after_effects\": \"Dilated pupils; blurred vision; urinary retention; and cognitive fog can persist 1 - 3 days\"\n-        },\n-        {\n-          \"route\": \"intramuscular\",\n-          \"canonical_routes\": [\n-            \"intramuscular\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"2 - 6 h (route-dependent)\",\n-            \"onset\": \"10-30 min\",\n-            \"peak\": \"30 - 90 min\",\n-            \"offset\": \"1 - 2 h\",\n-            \"after_effects\": \"2 - 6 h residual sedation / disequilibrium\"\n-          }\n-        },\n-        {\n-          \"route\": \"oral\",\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"2 - 6 h (route-dependent)\",\n-            \"onset\": \"30-60 min\",\n-            \"peak\": \"30 - 90 min\",\n-            \"offset\": \"1 - 2 h\",\n-            \"after_effects\": \"2 - 6 h residual sedation / disequilibrium\"\n-          }\n-    \"addiction_potential\": \"Low-to-moderate. Physical dependence and withdrawal occur with chronic use, but κ-agonist dysphoria limits compulsive redosing for many users. Can precipitate acute withdrawal in people dependent on full µ-opioid agonists.\",\n+    \"addiction_potential\": \"Very low. Experiences are usually dysphoric and self-limiting; compulsive use is extremely rare.\",\n-        \"Alcohol\",\n-        \"benzodiazepines\",\n-        \"barbiturates\",\n-        \"GHB\",\n-        \"other µ-opioid agonists (respiratory depression, possible precipitated withdrawal)\"\n+        \"Other anticholinergics (diphenhydramine, scopolamine, datura, first-generation antihistamines)\",\n+        \"Tricyclic antidepressants (amitriptyline, clomipramine)\",\n+        \"Phenothiazine antipsychotics (chlorpromazine)\",\n+        \"Organophosphate antidote co-administration errors\",\n+        \"Strong stimulants (cocaine, amphetamines)\"\n-        \"MAOIs or linezolid (theoretical risk of serotonin/adrenergic interaction)\",\n-        \"antipsychotics (additive CNS depression, dysphoria)\"\n+        \"Alcohol or sedatives (exacerbated confusion/accidents)\",\n+        \"Opioids (additive constipation & urinary retention)\"\n-        \"Antihistamines\",\n-        \"gabapentinoids\",\n-        \"sedative-hypnotics\",\n-        \"tramadol or tapentadol (seizure threshold ↓, withdrawal risk)\"\n+        \"Cannabis (may potentiate tachycardia & confusion)\",\n+        \"SSRIs (additive dry mouth)\",\n+        \"Nitrates or PDE-5 inhibitors (hypotension risk when dehydrated)\"\n-    \"notes\": \"Butorphanol is marketed as Stadol (human) and Torbugesic (veterinary). Pharmacologically it is a potent κ-opioid receptor agonist with partial agonist/antagonist activity at the µ-receptor; this combination produces analgesia with less respiratory depression than morphine but a high incidence of dysphoria, vertigo, and hallucination-like experiences. Recreational reports describe ‘darkened’ or ‘tunnel’ vision, mild warmth, dissociative or salvia-like head-space, and amnestic episodes at higher doses. Because of its antagonist component it can precipitate withdrawal in users dependent on strong µ-agonists (e.g., morphine, methadone, high-dose tramadol). Concomitant CNS depressants markedly increase risk of respiratory depression. Intranasal spray is the most common human formulation (1 mg/spray). Oral bioavailability is low (~17 %), so oral dosing is unpredictable. Use sterile technique for injections; veterinary multi-dose vials often contain bacteriostatic preservatives but are not guaranteed pyrogen-free for human use.\",\n+    \"notes\": \"Atropine is a naturally occurring tropane alkaloid found in Atropa belladonna and related nightshades. Medically it is employed to treat bradycardia, organophosphate poisoning, and to induce mydriasis. Recreational use is strongly discouraged: its psychoactive profile is characterised by true delirium, intense peripheral anticholinergic burden, and profound amnesia. The effective dose range for central effects lies dangerously close to the toxic and potentially lethal range; fatalities have occurred at doses only modestly above those that cause hallucinations. Individual sensitivity varies widely and children are especially vulnerable. Severe complications include tachyarrhythmia, hyperthermia, urinary retention, seizures, respiratory failure, and coma. Physostigmine is the antidote but must be administered in hospital. Even low-concentration ophthalmic solutions can cause systemic poisoning if ingested. Pursue immediate emergency care if severe agitation, confusion, or visual disturbances follow exposure.\",\n-      \"Analgesia\",\n-      \"mild opioid warmth/euphoria\",\n-      \"dysphoria or anxiety (dose-dependent)\",\n-      \"sedation\",\n-      \"dizziness/vertigo\",\n-      \"visual dimming or tunnel vision\",\n-      \"derealisation / mild dissociation\",\n-      \"out-of-body sensations\",\n-      \"closed-eye visuals\",\n-      \"nausea\",\n-      \"pruritus\",\n-      \"memory impairment\",\n-      \"increased sweating\",\n-      \"blood-pressure fluctuations\"\n+      \"Extreme dry mouth and skin\",\n+      \"Dilated pupils (mydriasis) and blurred vision\",\n+      \"Tachycardia and palpitations\",\n+      \"Flushing and hyperthermia\",\n+      \"Urinary retention and constipation\",\n+      \"Profound confusion and disorientation\",\n+      \"Auditory & visual hallucinations indistinguishable from reality\",\n+      \"Restlessness alternating with sedation\",\n+      \"Slurred or nonsensical speech\",\n+      \"Retrograde and anterograde amnesia\",\n+      \"Paranoia or aggressive behaviour\",\n+      \"Inability to focus eyes or read\"\n-      \"full_tolerance\": \"Builds after 3 – 5 consecutive days of use\",\n-      \"half_tolerance\": \"7 – 10 days of abstinence\",\n-      \"zero_tolerance\": \"2 – 3 weeks of abstinence\",\n+      \"full_tolerance\": \"Develops rapidly with repeated daily dosing (≈2–3 days)\",\n+      \"half_tolerance\": \"3–7 days\",\n+      \"zero_tolerance\": \"1–2 weeks\",\n-        \"Other opioids (µ-agonists)\"\n+        \"Scopolamine\",\n+        \"Hyoscyamine\",\n+        \"Diphenhydramine\",\n+        \"Other muscarinic antagonists\"\n-    \"half_life\": \"3 – 4.5 h (elimination half-life in healthy adults)\",\n+    \"half_life\": \"≈2 – 4 h (plasma); central effects may persist considerably longer due to tissue binding\",\n-        \"name\": \"Butorphanol – Drugs.com professional monograph\",\n-        \"reference\": \"https://www.drugs.com/monograph/butorphanol.html\"\n+        \"name\": \"Atropine – Wikipedia\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Atropine\"\n-        \"name\": \"Stadol (butorphanol tartrate) FDA Prescribing Information\",\n-        \"reference\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018471s019lbl.pdf\"\n+        \"name\": \"PubChem Compound Summary: Atropine (CID 174174)\",\n+        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/174174\"\n-        \"name\": \"Butorphanol – PubChem Compound Summary\",\n-        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/5280980\"\n+        \"name\": \"StatPearls: Atropine\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/books/NBK557526/\"\n-        \"name\": \"Opioids – Butorphanol? Recreational? (user experiences)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/butorphanol-recreational.892662/\"\n+        \"name\": \"Drugs.com Monograph – Atropine Sulfate\",\n+        \"reference\": \"https://www.drugs.com/monograph/atropine-sulfate.html\"\n-        \"name\": \"Wikipedia: Butorphanol\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Butorphanol\"\n+        \"name\": \"RxList – Atropine\",\n+        \"reference\": \"https://www.rxlist.com/atropine-drug.htm\"\n+      },\n+      {\n+        \"name\": \"WHO Model Formulary 2008 – Atropine\",\n+        \"reference\": \"https://apps.who.int/iris/handle/10665/70004\"\n+      },\n+      {\n+        \"name\": \"UpToDate: Anticholinergic poisoning\",\n+        \"reference\": \"https://www.uptodate.com/contents/anticholinergic-poisoning\"\n+      },\n+      {\n+        \"name\": \"Bluelight discussion on Atropine misuse (2011)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/atropine.587812/\"\n+      },\n+      {\n+        \"name\": \"Reddit r/myopia – Atropine eye drops and blurry vision\",\n+        \"reference\": \"https://www.reddit.com/r/myopia/comments/1yzcaa/atropine_eye_drops/\"\n+      },\n+      {\n+        \"name\": \"Hendrickson RG, Shannon M. Anticholinergic Poisoning. 9th ed.\",\n+        \"reference\": \"https://doi.org/10.1016/B978-0-323-28502-7.00024-8\"\n-      \"opioid\",\n-      \"depressant\",\n-      \"habit-forming\"\n+      \"deliriant\"\n\n# AM-1248 · #600\n\n-  \"id\": 599,\n-  \"title\": \"Atropine\",\n+  \"id\": 600,\n+  \"title\": \"AM-1248\",\n-    \"drug_name\": \"Atropine\",\n-    \"chemical_name\": \"Atropine\",\n+    \"drug_name\": \"AM-1248\",\n+    \"chemical_name\": \"AM-1248\",\n-    \"chemical_class\": \"Tropane alkaloids\",\n-    \"mechanism_of_action\": \"Muscarinic acetylcholine receptor antagonist\",\n-    \"psychoactive_class\": \"Deliriant anticholinergic\",\n+    \"chemical_class\": \"Synthetic cannabinoids\",\n+    \"mechanism_of_action\": \"CB1 and CB2 receptor full agonist\",\n+    \"psychoactive_class\": \"cannabinoid; hallucinogen\",\n-          \"route\": \"oral\",\n-          \"units\": \"mg\",\n+          \"route\": \"vaporized\",\n+          \"units\": \"mg (measured as pure powder on material)\",\n-            \"threshold\": \"0.3 mg\",\n-            \"light\": \"0.5 – 1 mg\",\n-            \"common\": \"2 – 5 mg\",\n-            \"strong\": \"6 – 10 mg\",\n-            \"heavy\": \"10+ mg (often toxic)\"\n+            \"threshold\": \"<0.3 mg\",\n+            \"light\": \"0.3 – 1 mg\",\n+            \"common\": \"1 – 3 mg\",\n+            \"strong\": \"3 – 5 mg\",\n+            \"heavy\": \">5 mg\"\n-          \"route\": \"intravenous\",\n+          \"route\": \"oral\",\n-            \"threshold\": \"0.2 mg (therapeutic)\",\n-            \"light\": \"0.3 – 0.6 mg\",\n-            \"common\": \"0.6 – 1 mg\",\n-            \"strong\": \"1 – 2 mg\",\n-            \"heavy\": \"2+ mg (poisoning risk)\"\n+            \"threshold\": \"1 mg\",\n+            \"light\": \"1 – 3 mg\",\n+            \"common\": \"3 – 6 mg\",\n+            \"strong\": \"6 – 10 mg\",\n+            \"heavy\": \">10 mg\"\n-          \"route\": \"oral\",\n+          \"route\": \"vaporized\",\n-            \"oral\"\n+            \"vaporized\"\n-            \"total_duration\": \"6 - 12 h (central effects); residual autonomic effects up to 24-72 h\",\n-            \"onset\": \"30 - 60 min\",\n-            \"peak\": \"1 - 3 h\",\n-            \"offset\": \"4 - 8 h\",\n-            \"after_effects\": \"Dilated pupils; blurred vision; urinary retention; and cognitive fog can persist 1 - 3 days\"\n+            \"total_duration\": \"1 - 2 h │ : 3 - 6 h\",\n+            \"onset\": \"30 s - 2 min │ : 30 - 90 min\",\n+            \"peak\": \"5 - 30 min │ : 1 - 3 h\",\n+            \"offset\": \"30 - 60 min\",\n+            \"after_effects\": \"Mild lethargy / cognitive dulling for 2-6 h\"\n-          \"route\": \"intravenous\",\n+          \"route\": \"oral\",\n-            \"intravenous\"\n+            \"oral\"\n-            \"total_duration\": \"6 - 12 h (central effects); residual autonomic effects up to 24-72 h\",\n-            \"onset\": \"1-4 min\",\n-            \"peak\": \"1 - 3 h\",\n-            \"offset\": \"4 - 8 h\",\n-            \"after_effects\": \"Dilated pupils; blurred vision; urinary retention; and cognitive fog can persist 1 - 3 days\"\n+            \"total_duration\": \"1 - 2 h │ : 3 - 6 h\",\n+            \"onset\": \"30 s - 2 min │ : 30 - 90 min\",\n+            \"peak\": \"5 - 30 min │ : 1 - 3 h\",\n+            \"offset\": \"30 - 60 min\",\n+            \"after_effects\": \"Mild lethargy / cognitive dulling for 2-6 h\"\n-    \"addiction_potential\": \"Very low. Experiences are usually dysphoric and self-limiting; compulsive use is extremely rare.\",\n+    \"addiction_potential\": \"Moderate to high. Daily use produces rapid tolerance and a withdrawal syndrome (irritability, insomnia, nausea) similar to other high-potency synthetic cannabinoids.\",\n-        \"Other anticholinergics (diphenhydramine, scopolamine, datura, first-generation antihistamines)\",\n-        \"Tricyclic antidepressants (amitriptyline, clomipramine)\",\n-        \"Phenothiazine antipsychotics (chlorpromazine)\",\n-        \"Organophosphate antidote co-administration errors\",\n-        \"Strong stimulants (cocaine, amphetamines)\"\n+        \"MAOIs\",\n+        \"disulfiram\",\n+        \"other potent synthetic cannabinoids (e.g., AM-2201, 5F-ADB)\",\n+        \"sympathomimetic cathinones\",\n+        \"strong CNS depressants at high doses (risk of loss of consciousness, aspiration)\"\n-        \"Alcohol or sedatives (exacerbated confusion/accidents)\",\n-        \"Opioids (additive constipation & urinary retention)\"\n+        \"Alcohol (enhanced emesis, blackout)\",\n+        \"benzodiazepines (may cause profound sedation)\",\n+        \"opioids (respiratory depression)\"\n-        \"Cannabis (may potentiate tachycardia & confusion)\",\n-        \"SSRIs (additive dry mouth)\",\n-        \"Nitrates or PDE-5 inhibitors (hypotension risk when dehydrated)\"\n+        \"Classical psychedelics (may intensify anxiety)\",\n+        \"stimulants (tachycardia, hypertension)\",\n+        \"anticholinergics\"\n-    \"notes\": \"Atropine is a naturally occurring tropane alkaloid found in Atropa belladonna and related nightshades. Medically it is employed to treat bradycardia, organophosphate poisoning, and to induce mydriasis. Recreational use is strongly discouraged: its psychoactive profile is characterised by true delirium, intense peripheral anticholinergic burden, and profound amnesia. The effective dose range for central effects lies dangerously close to the toxic and potentially lethal range; fatalities have occurred at doses only modestly above those that cause hallucinations. Individual sensitivity varies widely and children are especially vulnerable. Severe complications include tachyarrhythmia, hyperthermia, urinary retention, seizures, respiratory failure, and coma. Physostigmine is the antidote but must be administered in hospital. Even low-concentration ophthalmic solutions can cause systemic poisoning if ingested. Pursue immediate emergency care if severe agitation, confusion, or visual disturbances follow exposure.\",\n+    \"notes\": \"AM-1248 is an extremely potent full agonist at CB1 and CB2 (Ki ≈ 1.0 nM and 0.5 nM respectively). Effects are qualitatively similar to very strong cannabis concentrates but arrive faster and without the self-titration possible when smoking plant material. Users report a steep dose-response curve; accidentally doubling a planned dose can turn a mild high into overwhelming dysphoria, panic, or unconsciousness. Because powder is usually applied to herbal carrier, uneven distribution (‘hot spots’) is common. Always dissolve accurately weighed material in high-proof ethanol or acetone, apply evenly to a pre-weighed herbal substrate, allow to dry, and remix thoroughly. A 1 mg test-dose (inhaled) is considered prudent for first-time users. Emergency presentations involving AM-1248 have included severe agitation, seizures, and acute kidney injury; supportive care is recommended as there are no specific antagonists. Possession is controlled in many jurisdictions under generic cannabinoid bans.\",\n-      \"Extreme dry mouth and skin\",\n-      \"Dilated pupils (mydriasis) and blurred vision\",\n+      \"Rapid rush/‘head-rush’\",\n+      \"Intense bodily warmth\",\n+      \"Euphoria or dysphoria (dose-dependent)\",\n+      \"Anxiolysis → severe anxiety/panic (high doses)\",\n+      \"Time dilation\",\n+      \"Visual snow / peripheral distortions\",\n+      \"Strong dry-mouth\",\n-      \"Flushing and hyperthermia\",\n-      \"Urinary retention and constipation\",\n-      \"Profound confusion and disorientation\",\n-      \"Auditory & visual hallucinations indistinguishable from reality\",\n-      \"Restlessness alternating with sedation\",\n-      \"Slurred or nonsensical speech\",\n-      \"Retrograde and anterograde amnesia\",\n-      \"Paranoia or aggressive behaviour\",\n-      \"Inability to focus eyes or read\"\n+      \"Nausea / vomiting at high dose\",\n+      \"Short-term memory suppression\",\n+      \"Afterglow lethargy\"\n-      \"full_tolerance\": \"Develops rapidly with repeated daily dosing (≈2–3 days)\",\n-      \"half_tolerance\": \"3–7 days\",\n-      \"zero_tolerance\": \"1–2 weeks\",\n+      \"full_tolerance\": \"Within 3–7 days of daily use\",\n+      \"half_tolerance\": \"~1–2 weeks of abstinence\",\n+      \"zero_tolerance\": \"~4 weeks\",\n-        \"Scopolamine\",\n-        \"Hyoscyamine\",\n-        \"Diphenhydramine\",\n-        \"Other muscarinic antagonists\"\n+        \"Cannabis (THC)\",\n+        \"Other synthetic cannabinoids\"\n-    \"half_life\": \"≈2 – 4 h (plasma); central effects may persist considerably longer due to tissue binding\",\n+    \"half_life\": \"Estimated 1–2 h (plasma, rat data); active metabolites may prolong subjective effects\",\n-        \"name\": \"Atropine – Wikipedia\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Atropine\"\n+        \"name\": \"Wiley et al., Cannabinoid receptor agonists and rapid tolerance, JPET 2013\",\n+        \"reference\": \"https://jpet.aspetjournals.org/content/347/3/634\"\n-        \"name\": \"PubChem Compound Summary: Atropine (CID 174174)\",\n-        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/174174\"\n+        \"name\": \"Banister & Connor, Synthetic cannabinoid receptor agonists: pharmacology and toxicology, Adv Pharmacol 2018\",\n+        \"reference\": \"https://www.sciencedirect.com/science/article/pii/S1054358917301182\"\n-        \"name\": \"StatPearls: Atropine\",\n-        \"reference\": \"https://www.ncbi.nlm.nih.gov/books/NBK557526/\"\n+        \"name\": \"Wikipedia – AM-1248\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/AM-1248\"\n-        \"name\": \"Drugs.com Monograph – Atropine Sulfate\",\n-        \"reference\": \"https://www.drugs.com/monograph/atropine-sulfate.html\"\n-      },\n-      {\n-        \"name\": \"RxList – Atropine\",\n-        \"reference\": \"https://www.rxlist.com/atropine-drug.htm\"\n-      },\n-      {\n-        \"name\": \"WHO Model Formulary 2008 – Atropine\",\n-        \"reference\": \"https://apps.who.int/iris/handle/10665/70004\"\n-      },\n-      {\n-        \"name\": \"UpToDate: Anticholinergic poisoning\",\n-        \"reference\": \"https://www.uptodate.com/contents/anticholinergic-poisoning\"\n-      },\n-      {\n-        \"name\": \"Bluelight discussion on Atropine misuse (2011)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/atropine.587812/\"\n-      },\n-      {\n-        \"name\": \"Reddit r/myopia – Atropine eye drops and blurry vision\",\n-        \"reference\": \"https://www.reddit.com/r/myopia/comments/1yzcaa/atropine_eye_drops/\"\n-      },\n-      {\n-        \"name\": \"Hendrickson RG, Shannon M. Anticholinergic Poisoning. 9th ed.\",\n-        \"reference\": \"https://doi.org/10.1016/B978-0-323-28502-7.00024-8\"\n+        \"name\": \"User reports – Synthetic cannabinoids megathread (includes AM-1248), Bluelight 2006-2015\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-synthetic-cannabinoids-thread.279987/\"\n-      \"deliriant\"\n+      \"cannabinoid\",\n+      \"research-chemical\"\n\n# Aniracetam · #601\n\n-  \"id\": 600,\n-  \"title\": \"AM-1248\",\n+  \"id\": 601,\n+  \"title\": \"Aniracetam\",\n-    \"drug_name\": \"AM-1248\",\n-    \"chemical_name\": \"AM-1248\",\n+    \"drug_name\": \"Aniracetam\",\n+    \"chemical_name\": \"Aniracetam\",\n-    \"chemical_class\": \"Synthetic cannabinoids\",\n-    \"mechanism_of_action\": \"CB1 and CB2 receptor full agonist\",\n-    \"psychoactive_class\": \"cannabinoid; hallucinogen\",\n+    \"chemical_class\": \"Racetams\",\n+    \"mechanism_of_action\": \"AMPA receptor positive allosteric modulator\",\n+    \"psychoactive_class\": \"Nootropic (AMPA-receptor positive allosteric modulator; anxiolytic)\",\n-          \"route\": \"vaporized\",\n-          \"units\": \"mg (measured as pure powder on material)\",\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"<0.3 mg\",\n-            \"light\": \"0.3 – 1 mg\",\n-            \"common\": \"1 – 3 mg\",\n-            \"strong\": \"3 – 5 mg\",\n-            \"heavy\": \">5 mg\"\n+            \"threshold\": \"200 mg\",\n+            \"light\": \"400 – 750 mg\",\n+            \"common\": \"750 – 1 500 mg\",\n+            \"strong\": \"1 500 – 2 500 mg\",\n+            \"heavy\": \"2 500 mg +\"\n-          \"route\": \"oral\",\n+          \"route\": \"sublingual\",\n-            \"threshold\": \"1 mg\",\n-            \"light\": \"1 – 3 mg\",\n-            \"common\": \"3 – 6 mg\",\n-            \"strong\": \"6 – 10 mg\",\n-            \"heavy\": \">10 mg\"\n+            \"threshold\": \"150 mg\",\n+            \"light\": \"300 – 600 mg\",\n+            \"common\": \"600 – 1 200 mg\",\n+            \"strong\": \"1 200 – 1 800 mg\",\n+            \"heavy\": \"1 800 mg +\"\n-          \"route\": \"vaporized\",\n+          \"route\": \"oral\",\n-            \"vaporized\"\n+            \"oral\"\n-            \"total_duration\": \"1 - 2 h │ : 3 - 6 h\",\n-            \"onset\": \"30 s - 2 min │ : 30 - 90 min\",\n-            \"peak\": \"5 - 30 min │ : 1 - 3 h\",\n-            \"offset\": \"30 - 60 min\",\n-            \"after_effects\": \"Mild lethargy / cognitive dulling for 2-6 h\"\n+            \"total_duration\": \"2 - 5 h\",\n+            \"onset\": \"20 - 60 min / 5 - 20 min\",\n+            \"peak\": \"1 - 2 h\",\n+            \"offset\": \"1 - 2 h\",\n+            \"after_effects\": \"1 - 4 h (subtle ‘after-glow’ and mild fatigue possible)\"\n-          \"route\": \"oral\",\n+          \"route\": \"sublingual\",\n-            \"oral\"\n+            \"sublingual\"\n-            \"total_duration\": \"1 - 2 h │ : 3 - 6 h\",\n-            \"onset\": \"30 s - 2 min │ : 30 - 90 min\",\n-            \"peak\": \"5 - 30 min │ : 1 - 3 h\",\n-            \"offset\": \"30 - 60 min\",\n-            \"after_effects\": \"Mild lethargy / cognitive dulling for 2-6 h\"\n+            \"total_duration\": \"2 - 5 h\",\n+            \"onset\": \"20 - 60 min / 5 - 20 min\",\n+            \"peak\": \"1 - 2 h\",\n+            \"offset\": \"1 - 2 h\",\n+            \"after_effects\": \"1 - 4 h (subtle ‘after-glow’ and mild fatigue possible)\"\n-    \"addiction_potential\": \"Moderate to high. Daily use produces rapid tolerance and a withdrawal syndrome (irritability, insomnia, nausea) similar to other high-potency synthetic cannabinoids.\",\n+    \"addiction_potential\": \"Considered non-addictive; produces no classic euphoria or compulsive redosing. Mild pharmacodynamic tolerance can appear with daily use but physical dependence has not been documented.\",\n-        \"MAOIs\",\n-        \"disulfiram\",\n-        \"other potent synthetic cannabinoids (e.g., AM-2201, 5F-ADB)\",\n-        \"sympathomimetic cathinones\",\n-        \"strong CNS depressants at high doses (risk of loss of consciousness, aspiration)\"\n+        \"High-dose alcohol (added CNS depression & liver load)\",\n+        \"Ketamine / MXE (additive glutamatergic excitation—seizure risk)\",\n+        \"Other high-impact AMPAkines (e.g., sunifiram, unifiram)\"\n-        \"Alcohol (enhanced emesis, blackout)\",\n-        \"benzodiazepines (may cause profound sedation)\",\n-        \"opioids (respiratory depression)\"\n+        \"Benzodiazepines (may unexpectedly potentiate sedation)\",\n+        \"Stimulants at high doses (over-stimulation, anxiety)\"\n-        \"Classical psychedelics (may intensify anxiety)\",\n-        \"stimulants (tachycardia, hypertension)\",\n-        \"anticholinergics\"\n+        \"Cholinergic agonists or choline donors (can cause headaches if acetylcholine is pushed too high)\",\n+        \"SSRIs / tricyclics (limited data, but theoretical serotonergic modulation)\",\n+        \"Anticoagulants (anecdotal reports of easier bruising)\"\n-    \"notes\": \"AM-1248 is an extremely potent full agonist at CB1 and CB2 (Ki ≈ 1.0 nM and 0.5 nM respectively). Effects are qualitatively similar to very strong cannabis concentrates but arrive faster and without the self-titration possible when smoking plant material. Users report a steep dose-response curve; accidentally doubling a planned dose can turn a mild high into overwhelming dysphoria, panic, or unconsciousness. Because powder is usually applied to herbal carrier, uneven distribution (‘hot spots’) is common. Always dissolve accurately weighed material in high-proof ethanol or acetone, apply evenly to a pre-weighed herbal substrate, allow to dry, and remix thoroughly. A 1 mg test-dose (inhaled) is considered prudent for first-time users. Emergency presentations involving AM-1248 have included severe agitation, seizures, and acute kidney injury; supportive care is recommended as there are no specific antagonists. Possession is controlled in many jurisdictions under generic cannabinoid bans.\",\n+    \"notes\": \"• Fat-soluble – absorption improves when taken with a meal containing dietary fat or a teaspoon of oil.\\n• Oral bioavailability of the parent drug is very low (~10%); most central activity is believed to come from active metabolites (notably N-anisoyl-GABA and 2-pyrrolidinone).\\n• Users often stack it with a choline source (CDP-choline, alpha-GPC) to reduce racetam-type ‘headaches,’ though clinical necessity is unproven.\\n• Produces mild anxiolysis in some users, sometimes described as ‘benzodiazepine-lite’ without cognitive dulling.\\n• Not approved by the U.S. FDA; in parts of Europe/Asia it has been prescribed (750–1 500 mg/day) for post-stroke cognitive impairment and Alzheimer’s disease.\\n• Because of rapid metabolism, split dosing (e.g., 750 mg every 3–4 h) is favoured for sustained effect.\\n• Rare adverse effects: headache, gastrointestinal upset, irritability, skin flushing. Discontinue if visual disturbances, agitation or severe nausea occur.\",\n-      \"Rapid rush/‘head-rush’\",\n-      \"Intense bodily warmth\",\n-      \"Euphoria or dysphoria (dose-dependent)\",\n-      \"Anxiolysis → severe anxiety/panic (high doses)\",\n-      \"Time dilation\",\n-      \"Visual snow / peripheral distortions\",\n-      \"Strong dry-mouth\",\n-      \"Tachycardia and palpitations\",\n-      \"Nausea / vomiting at high dose\",\n-      \"Short-term memory suppression\",\n-      \"Afterglow lethargy\"\n+      \"Anxiety suppression\",\n+      \"Focus enhancement\",\n+      \"Memory consolidation & recall facilitation\",\n+      \"Creativity enhancement\",\n+      \"Motivation enhancement\",\n+      \"Mild central stimulation / wakefulness\",\n+      \"Thought connectivity\",\n+      \"Mood lift\",\n+      \"Color & visual-acuity enhancement\",\n+      \"Auditory clarity\",\n+      \"Dream vividness / recall\"\n-      \"full_tolerance\": \"Within 3–7 days of daily use\",\n-      \"half_tolerance\": \"~1–2 weeks of abstinence\",\n-      \"zero_tolerance\": \"~4 weeks\",\n+      \"full_tolerance\": \"2 – 3 weeks of continuous daily use\",\n+      \"half_tolerance\": \"3 – 7 days\",\n+      \"zero_tolerance\": \"1 – 2 weeks of abstinence\",\n-        \"Cannabis (THC)\",\n-        \"Other synthetic cannabinoids\"\n+        \"Other racetams (piracetam, oxiracetam, phenylpiracetam)\"\n-    \"half_life\": \"Estimated 1–2 h (plasma, rat data); active metabolites may prolong subjective effects\",\n+    \"half_life\": \"Parent compound ≈ 1–2.5 h; primary metabolites 2–8 h\",\n-        \"name\": \"Wiley et al., Cannabinoid receptor agonists and rapid tolerance, JPET 2013\",\n-        \"reference\": \"https://jpet.aspetjournals.org/content/347/3/634\"\n+        \"name\": \"Examine.com – Aniracetam overview\",\n+        \"reference\": \"https://examine.com/supplements/aniracetam/\"\n-        \"name\": \"Banister & Connor, Synthetic cannabinoid receptor agonists: pharmacology and toxicology, Adv Pharmacol 2018\",\n-        \"reference\": \"https://www.sciencedirect.com/science/article/pii/S1054358917301182\"\n+        \"name\": \"Nakamura T et al. Pharmacokinetics of aniracetam in healthy volunteers (Eur J Drug Metab Pharmacokinet, 2000)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/11213134/\"\n-        \"name\": \"Wikipedia – AM-1248\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/AM-1248\"\n+        \"name\": \"DrugBank – Aniracetam (DB03913)\",\n+        \"reference\": \"https://go.drugbank.com/drugs/DB03913\"\n-        \"name\": \"User reports – Synthetic cannabinoids megathread (includes AM-1248), Bluelight 2006-2015\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-synthetic-cannabinoids-thread.279987/\"\n+        \"name\": \"Paterniti I et al. Aniracetam as an anxiolytic AMPAkine (CNS Drug Rev, 2010)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/20822598/\"\n+      },\n+      {\n+        \"name\": \"PubChem: 2159\",\n+        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/2159\"\n-      \"cannabinoid\",\n+      \"nootropic\",\n\n# Armodafinil · #602\n\n-  \"id\": 601,\n-  \"title\": \"Aniracetam\",\n+  \"id\": 602,\n+  \"title\": \"Armodafinil\",\n-    \"drug_name\": \"Aniracetam\",\n-    \"chemical_name\": \"Aniracetam\",\n+    \"drug_name\": \"Armodafinil\",\n+    \"chemical_name\": \"Armodafinil\",\n-    \"chemical_class\": \"Racetams\",\n-    \"mechanism_of_action\": \"AMPA receptor positive allosteric modulator\",\n-    \"psychoactive_class\": \"Nootropic (AMPA-receptor positive allosteric modulator; anxiolytic)\",\n+    \"chemical_class\": \"Diphenylmethylsulfinylacetamides (modafinil analogues)\",\n+    \"mechanism_of_action\": \"Atypical dopamine reuptake inhibitor\",\n+    \"psychoactive_class\": \"Eugeroic; wakefulness-promoting stimulant\",\n-            \"threshold\": \"200 mg\",\n-            \"light\": \"400 – 750 mg\",\n-            \"common\": \"750 – 1 500 mg\",\n-            \"strong\": \"1 500 – 2 500 mg\",\n-            \"heavy\": \"2 500 mg +\"\n+            \"threshold\": \"20-30\",\n+            \"light\": \"50-100\",\n+            \"common\": \"100-200\",\n+            \"strong\": \"200-300\",\n+            \"heavy\": \"300+\"\n-        },\n-        {\n-          \"route\": \"sublingual\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"150 mg\",\n-            \"light\": \"300 – 600 mg\",\n-            \"common\": \"600 – 1 200 mg\",\n-            \"strong\": \"1 200 – 1 800 mg\",\n-            \"heavy\": \"1 800 mg +\"\n-          }\n-            \"total_duration\": \"2 - 5 h\",\n-            \"onset\": \"20 - 60 min / 5 - 20 min\",\n-            \"peak\": \"1 - 2 h\",\n-            \"offset\": \"1 - 2 h\",\n-            \"after_effects\": \"1 - 4 h (subtle ‘after-glow’ and mild fatigue possible)\"\n+            \"total_duration\": \"8-15 h\",\n+            \"onset\": \"0.3-1 h\",\n+            \"peak\": \"4-7 h\",\n+            \"offset\": \"2-5 h\",\n+            \"after_effects\": \"2-12 h\"\n-        },\n-        {\n-          \"route\": \"sublingual\",\n-          \"canonical_routes\": [\n-            \"sublingual\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"2 - 5 h\",\n-            \"onset\": \"20 - 60 min / 5 - 20 min\",\n-            \"peak\": \"1 - 2 h\",\n-            \"offset\": \"1 - 2 h\",\n-            \"after_effects\": \"1 - 4 h (subtle ‘after-glow’ and mild fatigue possible)\"\n-          }\n-    \"addiction_potential\": \"Considered non-addictive; produces no classic euphoria or compulsive redosing. Mild pharmacodynamic tolerance can appear with daily use but physical dependence has not been documented.\",\n+    \"addiction_potential\": \"Low to moderate. Psychological habit-formation is possible with daily use, but physical dependence and classic withdrawal syndrome are uncommon.\",\n-        \"High-dose alcohol (added CNS depression & liver load)\",\n-        \"Ketamine / MXE (additive glutamatergic excitation—seizure risk)\",\n-        \"Other high-impact AMPAkines (e.g., sunifiram, unifiram)\"\n+        \"MAOIs\",\n+        \"High-dose amphetamines or cocaine (cardiovascular strain)\",\n+        \"Tramadol (seizure risk)\"\n-        \"Benzodiazepines (may unexpectedly potentiate sedation)\",\n-        \"Stimulants at high doses (over-stimulation, anxiety)\"\n+        \"Alcohol (unpredictable sedation-stimulation mix)\",\n+        \"Bupropion\",\n+        \"Tricyclic antidepressants\",\n+        \"Strong CYP3A4 modulators such as ketoconazole or rifampin\"\n-        \"Cholinergic agonists or choline donors (can cause headaches if acetylcholine is pushed too high)\",\n-        \"SSRIs / tricyclics (limited data, but theoretical serotonergic modulation)\",\n-        \"Anticoagulants (anecdotal reports of easier bruising)\"\n+        \"Caffeine (synergistic overstimulation)\",\n+        \"SSRI/SNRI antidepressants (anxiety, serotonin syndrome theoretical)\",\n+        \"Nicotine\",\n+        \"Hormonal contraceptives (reduced efficacy for up to 1 mo after last dose)\",\n+        \"Other eugeroics or stimulants\"\n-    \"notes\": \"• Fat-soluble – absorption improves when taken with a meal containing dietary fat or a teaspoon of oil.\\n• Oral bioavailability of the parent drug is very low (~10%); most central activity is believed to come from active metabolites (notably N-anisoyl-GABA and 2-pyrrolidinone).\\n• Users often stack it with a choline source (CDP-choline, alpha-GPC) to reduce racetam-type ‘headaches,’ though clinical necessity is unproven.\\n• Produces mild anxiolysis in some users, sometimes described as ‘benzodiazepine-lite’ without cognitive dulling.\\n• Not approved by the U.S. FDA; in parts of Europe/Asia it has been prescribed (750–1 500 mg/day) for post-stroke cognitive impairment and Alzheimer’s disease.\\n• Because of rapid metabolism, split dosing (e.g., 750 mg every 3–4 h) is favoured for sustained effect.\\n• Rare adverse effects: headache, gastrointestinal upset, irritability, skin flushing. Discontinue if visual disturbances, agitation or severe nausea occur.\",\n+    \"notes\": \"• Armodafinil is the pharmacologically active R-enantiomer of modafinil; it reaches higher plasma levels and lasts several hours longer than equal doses of racemic modafinil.\\n• Best taken early in the day with water and food to minimise gastrointestinal upset; late-day dosing often delays sleep onset.\\n• Hydration, dietary electrolytes and periodic blood-pressure checks reduce common side-effects (headache, mild hypertension, anxiety).\\n• Because the drug induces CYP3A4 and inhibits CYP2C19, it can lower plasma levels of hormonal contraceptives and many antiepileptics while raising levels of drugs such as diazepam or phenytoin.\\n• Discontinue immediately and seek care if rash, chest pain, severe anxiety, or psychosis appears – rare but documented idiosyncratic reactions.\\n• A 2-day on / 1-day off or weekend-off schedule helps slow tolerance development.\",\n-      \"Anxiety suppression\",\n-      \"Focus enhancement\",\n-      \"Memory consolidation & recall facilitation\",\n-      \"Creativity enhancement\",\n+      \"Wakefulness\",\n+      \"Focus intensification\",\n-      \"Mild central stimulation / wakefulness\",\n-      \"Thought connectivity\",\n-      \"Mood lift\",\n-      \"Color & visual-acuity enhancement\",\n-      \"Auditory clarity\",\n-      \"Dream vividness / recall\"\n+      \"Memory enhancement\",\n+      \"Thought acceleration\",\n+      \"Emotion suppression\",\n+      \"Appetite suppression\",\n+      \"Anxiety (or anxiety reduction in some users)\",\n+      \"Headache\",\n+      \"Nausea\",\n+      \"Photophobia\",\n+      \"Vasoconstriction / cold extremities\",\n+      \"Increased heart rate\",\n+      \"Slight blood-pressure rise\",\n+      \"Sweating / body-odor change\",\n+      \"Increased libido\",\n+      \"Time dilation or contraction\"\n-      \"full_tolerance\": \"2 – 3 weeks of continuous daily use\",\n-      \"half_tolerance\": \"3 – 7 days\",\n-      \"zero_tolerance\": \"1 – 2 weeks of abstinence\",\n+      \"full_tolerance\": \"Several weeks of continuous daily use\",\n+      \"half_tolerance\": \"3-7 days of abstinence\",\n+      \"zero_tolerance\": \"1-2 weeks abstinence\",\n-        \"Other racetams (piracetam, oxiracetam, phenylpiracetam)\"\n+        \"Modafinil\",\n+        \"Flmodafinil\",\n+        \"Other eugeroic stimulants\"\n-    \"half_life\": \"Parent compound ≈ 1–2.5 h; primary metabolites 2–8 h\",\n+    \"half_life\": \"Mean 12-15 h (range 7-21 h, prolonged in hepatic impairment)\",\n-        \"name\": \"Examine.com – Aniracetam overview\",\n-        \"reference\": \"https://examine.com/supplements/aniracetam/\"\n+        \"name\": \"Nuvigil (armodafinil) US Prescribing Information\",\n+        \"reference\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021875s025lbl.pdf\"\n-        \"name\": \"Nakamura T et al. Pharmacokinetics of aniracetam in healthy volunteers (Eur J Drug Metab Pharmacokinet, 2000)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/11213134/\"\n+        \"name\": \"DrugBank – Armodafinil (DB06208)\",\n+        \"reference\": \"https://go.drugbank.com/drugs/DB06208\"\n-        \"name\": \"DrugBank – Aniracetam (DB03913)\",\n-        \"reference\": \"https://go.drugbank.com/drugs/DB03913\"\n+        \"name\": \"Darwish et al., Clinical Pharmacokinetics of Armodafinil, Clin Pharmacokinet 2009\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/19271791/\"\n-        \"name\": \"Paterniti I et al. Aniracetam as an anxiolytic AMPAkine (CNS Drug Rev, 2010)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/20822598/\"\n+        \"name\": \"Erowid Armodafinil Experience Vault\",\n+        \"reference\": \"https://www.erowid.org/experiences/subs/exp_Armodafinil.shtml\"\n-        \"name\": \"PubChem: 2159\",\n-        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/2159\"\n+        \"name\": \"Bluelight Discussion – Is it possible to abuse armodafinil?\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/armodafinil.881471/\"\n+      },\n+      {\n+        \"name\": \"Drugs.com – Armodafinil Monograph\",\n+        \"reference\": \"https://www.drugs.com/armodafinil.html\"\n-      \"nootropic\",\n-      \"research-chemical\"\n+      \"stimulant\",\n+      \"nootropic\"\n\n# Acetyldihydrocodeine · #603\n\n-  \"id\": 602,\n-  \"title\": \"Armodafinil\",\n+  \"id\": 603,\n+  \"title\": \"Acetyldihydrocodeine\",\n-    \"drug_name\": \"Armodafinil\",\n-    \"chemical_name\": \"Armodafinil\",\n+    \"drug_name\": \"Acetyldihydrocodeine\",\n+    \"chemical_name\": \"Acetyldihydrocodeine\",\n-    \"chemical_class\": \"Diphenylmethylsulfinylacetamides (modafinil analogues)\",\n-    \"mechanism_of_action\": \"Atypical dopamine reuptake inhibitor\",\n-    \"psychoactive_class\": \"Eugeroic; wakefulness-promoting stimulant\",\n+    \"chemical_class\": \"Morphinans\",\n+    \"mechanism_of_action\": \"μ-Opioid receptor agonist; prodrug of dihydromorphine\",\n+    \"psychoactive_class\": \"opioid analgesic/antitussive\",\n-            \"threshold\": \"20-30\",\n-            \"light\": \"50-100\",\n-            \"common\": \"100-200\",\n-            \"strong\": \"200-300\",\n-            \"heavy\": \"300+\"\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"10 – 30 mg\",\n+            \"common\": \"30 – 60 mg\",\n+            \"strong\": \"60 – 120 mg\",\n+            \"heavy\": \"120 + mg\"\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"15 – 40 mg\",\n+            \"common\": \"40 – 70 mg\",\n+            \"strong\": \"70 – 130 mg\",\n+            \"heavy\": \"130 + mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"10 – 20 mg\",\n+            \"common\": \"20 – 40 mg\",\n+            \"strong\": \"40 – 80 mg\",\n+            \"heavy\": \"80 + mg\"\n+          }\n-            \"total_duration\": \"8-15 h\",\n-            \"onset\": \"0.3-1 h\",\n-            \"peak\": \"4-7 h\",\n-            \"offset\": \"2-5 h\",\n-            \"after_effects\": \"2-12 h\"\n+            \"total_duration\": \"4 - 7 h\",\n+            \"onset\": \"20 - 60 min\",\n+            \"peak\": \"1 - 2 h\",\n+            \"offset\": \"2 - 3 h\",\n+            \"after_effects\": \"1 - 3 h residual sedation\"\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"canonical_routes\": [\n+            \"rectal\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"4 - 7 h\",\n+            \"peak\": \"1 - 2 h\",\n+            \"offset\": \"2 - 3 h\",\n+            \"after_effects\": \"1 - 3 h residual sedation\"\n+          }\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"4 - 7 h\",\n+            \"peak\": \"1 - 2 h\",\n+            \"offset\": \"2 - 3 h\",\n+            \"after_effects\": \"1 - 3 h residual sedation\"\n+          }\n-    \"addiction_potential\": \"Low to moderate. Psychological habit-formation is possible with daily use, but physical dependence and classic withdrawal syndrome are uncommon.\",\n+    \"addiction_potential\": \"Moderate. Produces classical opioid reinforcement; dependence and withdrawal profile comparable to dihydrocodeine but somewhat stronger because of higher lipophilicity and faster CNS penetration.\",\n-        \"MAOIs\",\n-        \"High-dose amphetamines or cocaine (cardiovascular strain)\",\n-        \"Tramadol (seizure risk)\"\n+        \"alcohol\",\n+        \"benzodiazepines\",\n+        \"barbiturates\",\n+        \"other opioids\",\n+        \"GHB\",\n+        \"carisoprodol\"\n-        \"Alcohol (unpredictable sedation-stimulation mix)\",\n-        \"Bupropion\",\n-        \"Tricyclic antidepressants\",\n-        \"Strong CYP3A4 modulators such as ketoconazole or rifampin\"\n+        \"MAOIs (e.g., phenelzine)\",\n+        \"linezolid\",\n+        \"propoxyphene\"\n-        \"Caffeine (synergistic overstimulation)\",\n-        \"SSRI/SNRI antidepressants (anxiety, serotonin syndrome theoretical)\",\n-        \"Nicotine\",\n-        \"Hormonal contraceptives (reduced efficacy for up to 1 mo after last dose)\",\n-        \"Other eugeroics or stimulants\"\n+        \"CYP2D6 inhibitors (fluoxetine, paroxetine)\",\n+        \"CYP3A4 inhibitors (ketoconazole, grapefruit)\",\n+        \"antihistamines\",\n+        \"gabapentinoids\",\n+        \"serotonergic antidepressants (risk of serotonin syndrome in ultrarapid CYP2D6 metabolisers)\"\n-    \"notes\": \"• Armodafinil is the pharmacologically active R-enantiomer of modafinil; it reaches higher plasma levels and lasts several hours longer than equal doses of racemic modafinil.\\n• Best taken early in the day with water and food to minimise gastrointestinal upset; late-day dosing often delays sleep onset.\\n• Hydration, dietary electrolytes and periodic blood-pressure checks reduce common side-effects (headache, mild hypertension, anxiety).\\n• Because the drug induces CYP3A4 and inhibits CYP2C19, it can lower plasma levels of hormonal contraceptives and many antiepileptics while raising levels of drugs such as diazepam or phenytoin.\\n• Discontinue immediately and seek care if rash, chest pain, severe anxiety, or psychosis appears – rare but documented idiosyncratic reactions.\\n• A 2-day on / 1-day off or weekend-off schedule helps slow tolerance development.\",\n+    \"notes\": \"• 6-acetyl ester of dihydrocodeine; acts primarily as a pro-drug that is rapidly de-acetylated to dihydrocodeine and subsequently O-demethylated (CYP2D6) to the more potent dihydromorphine.\\n• First marketed in Europe in the 1930s as an analgesic and cough suppressant; now rarely prescribed but remains under international control (Single Convention Schedule I & III).\\n• Potency is roughly 1.2-1.5× dihydrocodeine by weight; start at the low end if you have no opioid tolerance.\\n• Poorly water-soluble; IV use is strongly discouraged due to insoluble esters and high risk of pulmonary embolism.\\n• Histamine release and pruritus are common; an antihistamine (non-sedating) can reduce itch but increases CNS depression in sedating varieties.\\n• Genetic non-responders: CYP2D6 poor metabolisers may experience little effect, whereas ultrarapid metabolisers face greater overdose risk.\",\n-      \"Wakefulness\",\n-      \"Focus intensification\",\n-      \"Motivation enhancement\",\n-      \"Memory enhancement\",\n-      \"Thought acceleration\",\n-      \"Emotion suppression\",\n-      \"Appetite suppression\",\n-      \"Anxiety (or anxiety reduction in some users)\",\n-      \"Headache\",\n-      \"Nausea\",\n-      \"Photophobia\",\n-      \"Vasoconstriction / cold extremities\",\n-      \"Increased heart rate\",\n-      \"Slight blood-pressure rise\",\n-      \"Sweating / body-odor change\",\n-      \"Increased libido\",\n-      \"Time dilation or contraction\"\n+      \"analgesia\",\n+      \"warm euphoria\",\n+      \"anxiolysis\",\n+      \"sedation\",\n+      \"itching/pruritus\",\n+      \"constipation\",\n+      \"miosis\",\n+      \"respiratory depression at high doses\",\n+      \"cough suppression\",\n+      \"dream-like introspection\"\n-      \"full_tolerance\": \"Several weeks of continuous daily use\",\n-      \"half_tolerance\": \"3-7 days of abstinence\",\n-      \"zero_tolerance\": \"1-2 weeks abstinence\",\n+      \"full_tolerance\": \"Develops after 3 – 7 consecutive days of high-dose use\",\n+      \"half_tolerance\": \"~1 – 2 weeks of abstinence\",\n+      \"zero_tolerance\": \"4 – 8 weeks of abstinence\",\n-        \"Modafinil\",\n-        \"Flmodafinil\",\n-        \"Other eugeroic stimulants\"\n+        \"all μ-opioid agonists (e.g., morphine, oxycodone, heroin)\"\n-    \"half_life\": \"Mean 12-15 h (range 7-21 h, prolonged in hepatic impairment)\",\n+    \"half_life\": \"Parent compound ≈ 1 h; active metabolites (dihydrocodeine & dihydromorphine) 3 – 4 h combined\",\n-        \"name\": \"Nuvigil (armodafinil) US Prescribing Information\",\n-        \"reference\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021875s025lbl.pdf\"\n+        \"name\": \"Acetyldihydrocodeine – PubChem Compound Summary\",\n+        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/Acetyldihydrocodeine\"\n-        \"name\": \"DrugBank – Armodafinil (DB06208)\",\n-        \"reference\": \"https://go.drugbank.com/drugs/DB06208\"\n+        \"name\": \"World Health Organization – 22nd Report, Expert Committee on Drug Dependence (1971)\",\n+        \"reference\": \"https://apps.who.int/iris/handle/10665/40936\"\n-        \"name\": \"Darwish et al., Clinical Pharmacokinetics of Armodafinil, Clin Pharmacokinet 2009\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/19271791/\"\n+        \"name\": \"UN INCB Yellow List (58th ed., 2023)\",\n+        \"reference\": \"https://www.incb.org/documents/Narcotic-Drugs/Yellow-List/narcosched/Yellow_List_58th_edition_EN.pdf\"\n-        \"name\": \"Erowid Armodafinil Experience Vault\",\n-        \"reference\": \"https://www.erowid.org/experiences/subs/exp_Armodafinil.shtml\"\n+        \"name\": \"Acethyl-dihydro-codeine – Wikipedia\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Acethyl-dihydro-codeine\"\n-        \"name\": \"Bluelight Discussion – Is it possible to abuse armodafinil?\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/armodafinil.881471/\"\n+        \"name\": \"Hoffmann, F. & Schüller, J. \\\"Pharmacological comparison of dihydrocodeine and its 6-acetate.\\\" Arzneimittelforschung. 1962;12:1082–1085.\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/13984733\"\n-        \"name\": \"Drugs.com – Armodafinil Monograph\",\n-        \"reference\": \"https://www.drugs.com/armodafinil.html\"\n+        \"name\": \"Karch, S. \\\"Opioids—Clinical Pharmacology & Abuse.\\\" In: Karch’s Pathology of Drug Abuse, 6th ed., CRC Press 2019.\",\n+        \"reference\": \"https://doi.org/10.1201/9780429470373\"\n-      \"stimulant\",\n-      \"nootropic\"\n+      \"opioid\",\n+      \"depressant\",\n+      \"habit-forming\",\n+      \"research-chemical\"\n\n# Acetildenafil · #604\n\n-  \"id\": 603,\n-  \"title\": \"Acetyldihydrocodeine\",\n+  \"id\": 604,\n+  \"title\": \"Acetildenafil\",\n-    \"drug_name\": \"Acetyldihydrocodeine\",\n-    \"chemical_name\": \"Acetyldihydrocodeine\",\n+    \"drug_name\": \"Acetildenafil\",\n+    \"chemical_name\": \"Acetildenafil\",\n-    \"chemical_class\": \"Morphinans\",\n-    \"mechanism_of_action\": \"μ-Opioid receptor agonist; prodrug of dihydromorphine\",\n-    \"psychoactive_class\": \"opioid analgesic/antitussive\",\n+    \"chemical_class\": \"Pyrazolopyrimidinone phosphodiesterase-5 inhibitor (sildenafil analogue)\",\n+    \"mechanism_of_action\": \"Uncertain mechanism\",\n+    \"psychoactive_class\": \"Peripheral vasodilator; aphrodisiac\",\n-            \"light\": \"10 – 30 mg\",\n-            \"common\": \"30 – 60 mg\",\n-            \"strong\": \"60 – 120 mg\",\n-            \"heavy\": \"120 + mg\"\n+            \"light\": \"5 – 15 mg\",\n+            \"common\": \"15 – 40 mg\",\n+            \"strong\": \"40 – 60 mg\",\n+            \"heavy\": \"60 mg +\"\n-          \"route\": \"rectal\",\n+          \"route\": \"sublingual\",\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"15 – 40 mg\",\n-            \"common\": \"40 – 70 mg\",\n-            \"strong\": \"70 – 130 mg\",\n-            \"heavy\": \"130 + mg\"\n+            \"threshold\": \"2 mg\",\n+            \"light\": \"3 – 10 mg\",\n+            \"common\": \"10 – 25 mg\",\n+            \"strong\": \"25 – 40 mg\",\n+            \"heavy\": \"40 mg +\"\n-        },\n-        {\n-          \"route\": \"insufflated\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"10 – 20 mg\",\n-            \"common\": \"20 – 40 mg\",\n-            \"strong\": \"40 – 80 mg\",\n-            \"heavy\": \"80 + mg\"\n-          }\n-            \"total_duration\": \"4 - 7 h\",\n-            \"onset\": \"20 - 60 min\",\n+            \"total_duration\": \"4 - 8 h (erectogenic window may persist up to 12 h)\",\n-            \"offset\": \"2 - 3 h\",\n-            \"after_effects\": \"1 - 3 h residual sedation\"\n+            \"offset\": \"3 - 5 h after peak\",\n+            \"after_effects\": \"Diminishing responsiveness 6 - 24 h (occasional nasal stuffiness / facial flushing)\"\n-          \"route\": \"rectal\",\n+          \"route\": \"sublingual\",\n-            \"rectal\"\n+            \"sublingual\"\n-            \"total_duration\": \"4 - 7 h\",\n+            \"total_duration\": \"4 - 8 h (erectogenic window may persist up to 12 h)\",\n+            \"onset\": \"10 - 45 min\",\n-            \"offset\": \"2 - 3 h\",\n-            \"after_effects\": \"1 - 3 h residual sedation\"\n+            \"offset\": \"3 - 5 h after peak\",\n+            \"after_effects\": \"Diminishing responsiveness 6 - 24 h (occasional nasal stuffiness / facial flushing)\"\n-        },\n-        {\n-          \"route\": \"insufflated\",\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"4 - 7 h\",\n-            \"peak\": \"1 - 2 h\",\n-            \"offset\": \"2 - 3 h\",\n-            \"after_effects\": \"1 - 3 h residual sedation\"\n-          }\n-    \"addiction_potential\": \"Moderate. Produces classical opioid reinforcement; dependence and withdrawal profile comparable to dihydrocodeine but somewhat stronger because of higher lipophilicity and faster CNS penetration.\",\n+    \"addiction_potential\": \"Very low – no appreciable reinforcing properties have been documented; psychological dependence is rare and limited to situational use.\",\n-        \"alcohol\",\n-        \"benzodiazepines\",\n-        \"barbiturates\",\n-        \"other opioids\",\n-        \"GHB\",\n-        \"carisoprodol\"\n+        \"Organic nitrates/nitrites (e.g. nitroglycerin, isosorbide dinitrate, amyl nitrite) – risk of life-threatening hypotension\",\n+        \"Riociguat (Adempas)\"\n-        \"MAOIs (e.g., phenelzine)\",\n-        \"linezolid\",\n-        \"propoxyphene\"\n+        \"Other PDE-5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) – additive hypotension\",\n+        \"Potent CYP3A4 inhibitors (ketoconazole, ritonavir) – ↑ plasma levels & adverse effects\"\n-        \"CYP2D6 inhibitors (fluoxetine, paroxetine)\",\n-        \"CYP3A4 inhibitors (ketoconazole, grapefruit)\",\n-        \"antihistamines\",\n-        \"gabapentinoids\",\n-        \"serotonergic antidepressants (risk of serotonin syndrome in ultrarapid CYP2D6 metabolisers)\"\n+        \"Alpha-blockers (tamsulosin, doxazosin) – orthostatic hypotension\",\n+        \"Large alcohol doses – enhanced vasodilation & dizziness\",\n+        \"Stimulants (cocaine, high-dose amphetamines) – increased cardiovascular strain\"\n-    \"notes\": \"• 6-acetyl ester of dihydrocodeine; acts primarily as a pro-drug that is rapidly de-acetylated to dihydrocodeine and subsequently O-demethylated (CYP2D6) to the more potent dihydromorphine.\\n• First marketed in Europe in the 1930s as an analgesic and cough suppressant; now rarely prescribed but remains under international control (Single Convention Schedule I & III).\\n• Potency is roughly 1.2-1.5× dihydrocodeine by weight; start at the low end if you have no opioid tolerance.\\n• Poorly water-soluble; IV use is strongly discouraged due to insoluble esters and high risk of pulmonary embolism.\\n• Histamine release and pruritus are common; an antihistamine (non-sedating) can reduce itch but increases CNS depression in sedating varieties.\\n• Genetic non-responders: CYP2D6 poor metabolisers may experience little effect, whereas ultrarapid metabolisers face greater overdose risk.\",\n+    \"notes\": \"Acetildenafil (a.k.a. Hongdenafil) is an unapproved research chemical often detected as an undeclared adulterant in “herbal” sexual-enhancement supplements. Pharmacologically it shows sub-micromolar PDE-5 inhibition comparable to sildenafil, with a slightly longer half-life (≈ 3–5 h) and anecdotal reports of milder facial flushing. Because it is metabolised mainly via CYP3A4, potent inhibitors can greatly increase its plasma concentration. Users report effective erectile support at 10–40 mg; however, some counterfeit tablets contain 80–120 mg, raising the risk of priapism, headache, and hypotension. Medical consultation is advised for anyone with cardiovascular disease. Never combine with nitrate medications or poppers.\",\n-      \"analgesia\",\n-      \"warm euphoria\",\n-      \"anxiolysis\",\n-      \"sedation\",\n-      \"itching/pruritus\",\n-      \"constipation\",\n-      \"miosis\",\n-      \"respiratory depression at high doses\",\n-      \"cough suppression\",\n-      \"dream-like introspection\"\n+      \"Improved ability to achieve/maintain erection\",\n+      \"Increased penile firmness\",\n+      \"Facial/upper-body flushing\",\n+      \"Warmth in extremities\",\n+      \"Mild nasal congestion\",\n+      \"Headache/pressure behind eyes\",\n+      \"Occasional visual tint or increased light sensitivity\",\n+      \"Dyspepsia\",\n+      \"Rare prolonged erection (priapism)\"\n-      \"full_tolerance\": \"Develops after 3 – 7 consecutive days of high-dose use\",\n-      \"half_tolerance\": \"~1 – 2 weeks of abstinence\",\n-      \"zero_tolerance\": \"4 – 8 weeks of abstinence\",\n+      \"full_tolerance\": \"Minimal; clinically relevant tolerance not observed with intermittent use\",\n+      \"half_tolerance\": \"N/A\",\n+      \"zero_tolerance\": \"N/A\",\n-        \"all μ-opioid agonists (e.g., morphine, oxycodone, heroin)\"\n+        \"Other PDE-5 inhibitors (partial cross-tolerance possible)\"\n-    \"half_life\": \"Parent compound ≈ 1 h; active metabolites (dihydrocodeine & dihydromorphine) 3 – 4 h combined\",\n+    \"half_life\": \"Approximately 3 – 5 hours\",\n-        \"name\": \"Acetyldihydrocodeine – PubChem Compound Summary\",\n-        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/Acetyldihydrocodeine\"\n+        \"name\": \"TripSit Acetildenafil Factsheet\",\n+        \"reference\": \"https://drugs.tripsit.me/acetildenafil\"\n-        \"name\": \"World Health Organization – 22nd Report, Expert Committee on Drug Dependence (1971)\",\n-        \"reference\": \"https://apps.who.int/iris/handle/10665/40936\"\n+        \"name\": \"Kimera Chems – A Complete Guide for Acetildenafil (Reddit post)\",\n+        \"reference\": \"https://www.reddit.com/r/Kimerachems/comments/1g8ge0t/a_complete_guide_for_acetildenafil_from_kimera/\"\n-        \"name\": \"UN INCB Yellow List (58th ed., 2023)\",\n-        \"reference\": \"https://www.incb.org/documents/Narcotic-Drugs/Yellow-List/narcosched/Yellow_List_58th_edition_EN.pdf\"\n+        \"name\": \"Bluelight: Acetildenafil (Hongdenafil) discussion thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/acetildenafil-hongdenafil.557904/\"\n-        \"name\": \"Acethyl-dihydro-codeine – Wikipedia\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Acethyl-dihydro-codeine\"\n+        \"name\": \"Venhuis BJ & de Kaste D. Sildenafil analogues as adulterants in herbal aphrodisiacs. Forensic Sci Int. 2012\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/22366324/\"\n-        \"name\": \"Hoffmann, F. & Schüller, J. \\\"Pharmacological comparison of dihydrocodeine and its 6-acetate.\\\" Arzneimittelforschung. 1962;12:1082–1085.\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/13984733\"\n-      },\n-      {\n-        \"name\": \"Karch, S. \\\"Opioids—Clinical Pharmacology & Abuse.\\\" In: Karch’s Pathology of Drug Abuse, 6th ed., CRC Press 2019.\",\n-        \"reference\": \"https://doi.org/10.1201/9780429470373\"\n+        \"name\": \"Hefnawy M et al. Determination of acetildenafil in dietary supplements by LC–MS/MS. J Pharm Biomed Anal. 2019\",\n+        \"reference\": \"https://doi.org/10.1016/j.jpba.2019.03.004\"\n-      \"opioid\",\n-      \"depressant\",\n-      \"habit-forming\",\n-      \"research-chemical\"\n+      \"research-chemical\",\n+      \"supplement\"\n\n# 25T-NBOMe · #605\n\n-  \"id\": 604,\n-  \"title\": \"Acetildenafil\",\n+  \"id\": 605,\n+  \"title\": \"25T-NBOMe\",\n-    \"drug_name\": \"Acetildenafil\",\n-    \"chemical_name\": \"Acetildenafil\",\n+    \"drug_name\": \"25T-NBOMe\",\n+    \"chemical_name\": \"25T-NBOMe\",\n-    \"chemical_class\": \"Pyrazolopyrimidinone phosphodiesterase-5 inhibitor (sildenafil analogue)\",\n-    \"mechanism_of_action\": \"Uncertain mechanism\",\n-    \"psychoactive_class\": \"Peripheral vasodilator; aphrodisiac\",\n+    \"chemical_class\": \"N-benzylated phenethylamines\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist (potent); 5-HT2B receptor agonist (cardiotoxic)\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-          \"route\": \"oral\",\n-          \"units\": \"mg\",\n+          \"route\": \"sublingual\",\n+          \"units\": \"µg\",\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"5 – 15 mg\",\n-            \"common\": \"15 – 40 mg\",\n-            \"strong\": \"40 – 60 mg\",\n-            \"heavy\": \"60 mg +\"\n+            \"threshold\": \"200–300\",\n+            \"light\": \"300–600\",\n+            \"common\": \"600–1200\",\n+            \"strong\": \"1200–2000\",\n+            \"heavy\": \"2000+\"\n-          \"route\": \"sublingual\",\n-          \"units\": \"mg\",\n+          \"route\": \"buccal\",\n+          \"units\": \"µg\",\n-            \"threshold\": \"2 mg\",\n-            \"light\": \"3 – 10 mg\",\n-            \"common\": \"10 – 25 mg\",\n-            \"strong\": \"25 – 40 mg\",\n-            \"heavy\": \"40 mg +\"\n+            \"threshold\": \"250–400\",\n+            \"light\": \"400–700\",\n+            \"common\": \"700–1400\",\n+            \"strong\": \"1400–2200\",\n+            \"heavy\": \"2200+\"\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"µg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"100–200\",\n+            \"light\": \"200–400\",\n+            \"common\": \"400–700\",\n+            \"strong\": \"700–1000\",\n+            \"heavy\": \"1000+\"\n+          }\n-          \"route\": \"oral\",\n+          \"route\": \"sublingual\",\n-            \"oral\"\n+            \"sublingual\"\n-            \"total_duration\": \"4 - 8 h (erectogenic window may persist up to 12 h)\",\n-            \"peak\": \"1 - 2 h\",\n-            \"offset\": \"3 - 5 h after peak\",\n-            \"after_effects\": \"Diminishing responsiveness 6 - 24 h (occasional nasal stuffiness / facial flushing)\"\n+            \"total_duration\": \"6-10 h\",\n+            \"onset\": \"15-45 min\",\n+            \"peak\": \"2-4 h\",\n+            \"offset\": \"2-3 h\",\n+            \"after_effects\": \"2-6 h residual stimulation / insomnia\"\n-          \"route\": \"sublingual\",\n+          \"route\": \"buccal\",\n-            \"sublingual\"\n+            \"buccal\"\n-            \"total_duration\": \"4 - 8 h (erectogenic window may persist up to 12 h)\",\n-            \"onset\": \"10 - 45 min\",\n-            \"peak\": \"1 - 2 h\",\n-            \"offset\": \"3 - 5 h after peak\",\n-            \"after_effects\": \"Diminishing responsiveness 6 - 24 h (occasional nasal stuffiness / facial flushing)\"\n+            \"total_duration\": \"6-10 h\",\n+            \"onset\": \"15-45 min\",\n+            \"peak\": \"2-4 h\",\n+            \"offset\": \"2-3 h\",\n+            \"after_effects\": \"2-6 h residual stimulation / insomnia\"\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"6-10 h\",\n+            \"onset\": \"5-15 min\",\n+            \"peak\": \"2-4 h\",\n+            \"offset\": \"2-3 h\",\n+            \"after_effects\": \"2-6 h residual stimulation / insomnia\"\n+          }\n-    \"addiction_potential\": \"Very low – no appreciable reinforcing properties have been documented; psychological dependence is rare and limited to situational use.\",\n+    \"addiction_potential\": \"Low. Classic serotonergic psychedelics seldom produce compulsive redosing; however sympathetic over-activation and uncomfortable body load may encourage sedative co-use.\",\n-        \"Organic nitrates/nitrites (e.g. nitroglycerin, isosorbide dinitrate, amyl nitrite) – risk of life-threatening hypotension\",\n-        \"Riociguat (Adempas)\"\n+        \"Tramadol\",\n+        \"Cocaine\",\n+        \"Amphetamines\",\n+        \"DXM\",\n+        \"PVP class\",\n+        \"MMC class\",\n+        \"MAOIs\"\n-        \"Other PDE-5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) – additive hypotension\",\n-        \"Potent CYP3A4 inhibitors (ketoconazole, ritonavir) – ↑ plasma levels & adverse effects\"\n+        \"DOx\",\n+        \"2C-x\",\n+        \"2C-T-x\",\n+        \"5-MeO-xxT\",\n+        \"Ketamine (high doses)\",\n+        \"MXE\"\n-        \"Alpha-blockers (tamsulosin, doxazosin) – orthostatic hypotension\",\n-        \"Large alcohol doses – enhanced vasodilation & dizziness\",\n-        \"Stimulants (cocaine, high-dose amphetamines) – increased cardiovascular strain\"\n+        \"Cannabis\",\n+        \"Alcohol\",\n+        \"Caffeine\",\n+        \"SSRI\",\n+        \"Benzos\",\n+        \"GHB/GBL\",\n+        \"Nitrous\",\n+        \"Opioids\",\n+        \"MDMA\",\n+        \"DMT\",\n+        \"LSD\",\n+        \"Mushrooms\"\n-    \"notes\": \"Acetildenafil (a.k.a. Hongdenafil) is an unapproved research chemical often detected as an undeclared adulterant in “herbal” sexual-enhancement supplements. Pharmacologically it shows sub-micromolar PDE-5 inhibition comparable to sildenafil, with a slightly longer half-life (≈ 3–5 h) and anecdotal reports of milder facial flushing. Because it is metabolised mainly via CYP3A4, potent inhibitors can greatly increase its plasma concentration. Users report effective erectile support at 10–40 mg; however, some counterfeit tablets contain 80–120 mg, raising the risk of priapism, headache, and hypotension. Medical consultation is advised for anyone with cardiovascular disease. Never combine with nitrate medications or poppers.\",\n+    \"notes\": \"25T-NBOMe (NBOMe-2C-T) is a potent, little-studied analogue of 2C-T in which an N-2-methoxybenzyl group confers sub-milligram activity. Laboratory binding data show high affinity for the 5-HT2A receptor (Ki ≈ 0.37 nM), but field reports suggest it is somewhat less potent than the halogenated 25I/25C compounds, with typical active doses in the mid-hundreds of micrograms. Oral bioavailability is poor; blotter, ethanol solution, or micro-weighted powder is usually held sublingually/buccally for 15–30 min.\\n\\nPhysiological risks mirror those of other NBOMes: vasoconstriction, tachycardia, hypertension, hyperthermia, nausea and acute anxiety. Severe toxicity (seizure, rhabdomyolysis, cardiac arrest) has occurred with related NBOMes at high doses or when combined with stimulants. Because active doses are so small, volumetric or liquid dosing and an allergy test (<50 µg) are strongly recommended. Redosing is ineffective due to rapid tolerance but increases cardiovascular strain. Individuals with cardiovascular, hepatic, or psychiatric conditions should avoid use. Very limited pharmacokinetic/human safety data exist—treat the compound as highly experimental.\",\n-      \"Improved ability to achieve/maintain erection\",\n-      \"Increased penile firmness\",\n-      \"Facial/upper-body flushing\",\n-      \"Warmth in extremities\",\n-      \"Mild nasal congestion\",\n-      \"Headache/pressure behind eyes\",\n-      \"Occasional visual tint or increased light sensitivity\",\n-      \"Dyspepsia\",\n-      \"Rare prolonged erection (priapism)\"\n+      \"Closed-eye visuals\",\n+      \"Open-eye geometric patterning\",\n+      \"Color enhancement\",\n+      \"Visual drifting/warping\",\n+      \"Synesthesia (high dose)\",\n+      \"Euphoria\",\n+      \"Empathy enhancement\",\n+      \"Mental stimulation\",\n+      \"Time distortion\",\n+      \"Spiritual or introspective thinking\",\n+      \"Vasoconstrictive body load (cold extremities)\",\n+      \"Nausea\",\n+      \"Anxiety or paranoia at high dose\"\n-      \"full_tolerance\": \"Minimal; clinically relevant tolerance not observed with intermittent use\",\n-      \"half_tolerance\": \"N/A\",\n-      \"zero_tolerance\": \"N/A\",\n+      \"full_tolerance\": \"After 1–2 days of repeated use\",\n+      \"half_tolerance\": \"≈ 3–5 days\",\n+      \"zero_tolerance\": \"10–14 days\",\n-        \"Other PDE-5 inhibitors (partial cross-tolerance possible)\"\n+        \"LSD\",\n+        \"Psilocin/psilocybin\",\n+        \"Other NBOMe compounds\",\n+        \"2C-x series\"\n-    \"half_life\": \"Approximately 3 – 5 hours\",\n+    \"half_life\": \"Estimated 2–4 h (extrapolated from animal data on 25I-NBOMe; no human PK studies)\",\n-        \"name\": \"TripSit Acetildenafil Factsheet\",\n-        \"reference\": \"https://drugs.tripsit.me/acetildenafil\"\n+        \"name\": \"25T-NBOMe – Wikipedia\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/25T-NBOMe\"\n-        \"name\": \"Kimera Chems – A Complete Guide for Acetildenafil (Reddit post)\",\n-        \"reference\": \"https://www.reddit.com/r/Kimerachems/comments/1g8ge0t/a_complete_guide_for_acetildenafil_from_kimera/\"\n+        \"name\": \"Hansen et al. N-Benzyl phenethylamines: potent 5-HT2A agonists (2010)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/20171316/\"\n-        \"name\": \"Bluelight: Acetildenafil (Hongdenafil) discussion thread\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/acetildenafil-hongdenafil.557904/\"\n+        \"name\": \"Helander et al. Emerging NBOMe psychedelics: clinical toxicology trends (2018)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/29953842/\"\n-        \"name\": \"Venhuis BJ & de Kaste D. Sildenafil analogues as adulterants in herbal aphrodisiacs. Forensic Sci Int. 2012\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/22366324/\"\n-      },\n-      {\n-        \"name\": \"Hefnawy M et al. Determination of acetildenafil in dietary supplements by LC–MS/MS. J Pharm Biomed Anal. 2019\",\n-        \"reference\": \"https://doi.org/10.1016/j.jpba.2019.03.004\"\n+        \"name\": \"User discussion: “25xNBTMe?” r/researchchemicals (2018)\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/9xr0pi/25xnbtme/\"\n-      \"research-chemical\",\n-      \"supplement\"\n+      \"psychedelic\",\n+      \"research-chemical\"\n\n# 5-MAPDB · #606\n\n-  \"id\": 605,\n-  \"title\": \"25T-NBOMe\",\n+  \"id\": 606,\n+  \"title\": \"5-MAPDB\",\n-    \"drug_name\": \"25T-NBOMe\",\n-    \"chemical_name\": \"25T-NBOMe\",\n+    \"drug_name\": \"5-MAPDB\",\n+    \"chemical_name\": \"5-MAPDB\",\n-    \"chemical_class\": \"N-benzylated phenethylamines\",\n-    \"mechanism_of_action\": \"5-HT2A receptor agonist (potent); 5-HT2B receptor agonist (cardiotoxic)\",\n-    \"psychoactive_class\": \"Psychedelic\",\n+    \"chemical_class\": \"Benzofurans\",\n+    \"mechanism_of_action\": \"Serotonin-dopamine-norepinephrine releasing agent\",\n+    \"psychoactive_class\": \"Entactogen; stimulant; serotonergic psychedelic\",\n-          \"route\": \"sublingual\",\n-          \"units\": \"µg\",\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"200–300\",\n-            \"light\": \"300–600\",\n-            \"common\": \"600–1200\",\n-            \"strong\": \"1200–2000\",\n-            \"heavy\": \"2000+\"\n+            \"threshold\": \"20 mg\",\n+            \"light\": \"40–70 mg\",\n+            \"common\": \"70–110 mg\",\n+            \"strong\": \"110–140 mg\",\n+            \"heavy\": \"140 mg+\"\n-          \"route\": \"buccal\",\n-          \"units\": \"µg\",\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"250–400\",\n-            \"light\": \"400–700\",\n-            \"common\": \"700–1400\",\n-            \"strong\": \"1400–2200\",\n-            \"heavy\": \"2200+\"\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"15–25 mg\",\n+            \"common\": \"25–40 mg\",\n+            \"strong\": \"40–60 mg\",\n+            \"heavy\": \"60 mg+\"\n-          \"route\": \"insufflated\",\n-          \"units\": \"µg\",\n+          \"route\": \"rectal\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"100–200\",\n-            \"light\": \"200–400\",\n-            \"common\": \"400–700\",\n-            \"strong\": \"700–1000\",\n-            \"heavy\": \"1000+\"\n+            \"threshold\": \"15 mg\",\n+            \"light\": \"35–60 mg\",\n+            \"common\": \"60–90 mg\",\n+            \"strong\": \"90–120 mg\",\n+            \"heavy\": \"120 mg+\"\n-          \"route\": \"sublingual\",\n+          \"route\": \"oral\",\n-            \"sublingual\"\n+            \"oral\"\n-            \"total_duration\": \"6-10 h\",\n-            \"onset\": \"15-45 min\",\n+            \"total_duration\": \"5-8 h (up to 12 h including after-effects)\",\n+            \"onset\": \"45-70 min\",\n-            \"offset\": \"2-3 h\",\n-            \"after_effects\": \"2-6 h residual stimulation / insomnia\"\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-4 h residual stimulation / sleeplessness\"\n-          \"route\": \"buccal\",\n+          \"route\": \"insufflated\",\n-            \"buccal\"\n+            \"insufflated\"\n-            \"total_duration\": \"6-10 h\",\n-            \"onset\": \"15-45 min\",\n+            \"total_duration\": \"5-8 h (up to 12 h including after-effects)\",\n+            \"onset\": \"5-15 min\",\n-            \"offset\": \"2-3 h\",\n-            \"after_effects\": \"2-6 h residual stimulation / insomnia\"\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-4 h residual stimulation / sleeplessness\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"rectal\",\n-            \"insufflated\"\n+            \"rectal\"\n-            \"total_duration\": \"6-10 h\",\n+            \"total_duration\": \"5-8 h (up to 12 h including after-effects)\",\n-            \"offset\": \"2-3 h\",\n-            \"after_effects\": \"2-6 h residual stimulation / insomnia\"\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-4 h residual stimulation / sleeplessness\"\n-    \"addiction_potential\": \"Low. Classic serotonergic psychedelics seldom produce compulsive redosing; however sympathetic over-activation and uncomfortable body load may encourage sedative co-use.\",\n+    \"addiction_potential\": \"Low-to-moderate. Compulsive redosing is limited by rapid tachyphylaxis and serotonergic depletion, but some users report psychological craving for its euphoric, empathetic peak.\",\n-        \"Tramadol\",\n-        \"Cocaine\",\n-        \"Amphetamines\",\n+        \"MAOIs (phenelzine, tranylcypromine)\",\n+        \"Linezolid\",\n+        \"Other strong 5-HT releasers (MDMA, 5-MAPB, 6-APB, MDA)\",\n+        \"Tramadol / Tapentadol\",\n+        \"Meperidine\",\n-        \"PVP class\",\n-        \"MMC class\",\n-        \"MAOIs\"\n+        \"Lorcaserin\"\n-        \"DOx\",\n-        \"2C-x\",\n-        \"2C-T-x\",\n-        \"5-MeO-xxT\",\n-        \"Ketamine (high doses)\",\n-        \"MXE\"\n+        \"SSRIs or SNRIs (serotonin syndrome at high doses, otherwise blunt effects)\",\n+        \"Bupropion\",\n+        \"Cocaine\",\n+        \"α-PVP and potent cathinones\",\n+        \"Amphetamines\"\n-        \"Cannabis\",\n-        \"Alcohol\",\n-        \"Caffeine\",\n-        \"SSRI\",\n-        \"Benzos\",\n-        \"GHB/GBL\",\n-        \"Nitrous\",\n-        \"Opioids\",\n-        \"MDMA\",\n-        \"DMT\",\n-        \"LSD\",\n-        \"Mushrooms\"\n+        \"Alcohol (dehydration, hyperthermia)\",\n+        \"Cannabis (anxiety / perceptual distortion)\",\n+        \"Benzodiazepines (may mask early overdose signs)\",\n+        \"5-HTP or other serotonin precursors\",\n+        \"St. John’s wort\"\n-    \"notes\": \"25T-NBOMe (NBOMe-2C-T) is a potent, little-studied analogue of 2C-T in which an N-2-methoxybenzyl group confers sub-milligram activity. Laboratory binding data show high affinity for the 5-HT2A receptor (Ki ≈ 0.37 nM), but field reports suggest it is somewhat less potent than the halogenated 25I/25C compounds, with typical active doses in the mid-hundreds of micrograms. Oral bioavailability is poor; blotter, ethanol solution, or micro-weighted powder is usually held sublingually/buccally for 15–30 min.\\n\\nPhysiological risks mirror those of other NBOMes: vasoconstriction, tachycardia, hypertension, hyperthermia, nausea and acute anxiety. Severe toxicity (seizure, rhabdomyolysis, cardiac arrest) has occurred with related NBOMes at high doses or when combined with stimulants. Because active doses are so small, volumetric or liquid dosing and an allergy test (<50 µg) are strongly recommended. Redosing is ineffective due to rapid tolerance but increases cardiovascular strain. Individuals with cardiovascular, hepatic, or psychiatric conditions should avoid use. Very limited pharmacokinetic/human safety data exist—treat the compound as highly experimental.\",\n+    \"notes\": \"• 5-MAPDB is a second-generation benzofuran entactogen first described by Monte et al. (2013) and pharmacologically characterised by Simmler & Rickli (2015).  In vitro it is a potent serotonin releasing agent (EC50≈30 nM) with weaker activity at DAT and NET, and a partial agonist at 5-HT2A/2B receptors (Rickli 2015).  \\n• Human data are limited to a few dozen anecdotal reports. Potency and identity in the grey market are inconsistent—ALWAYS reagent-test and start with an allergy dose (~1 mg).  \\n• Acute risks resemble those of MDMA: hyperthermia, dehydration, hyponatraemia, bruxism, mydriasis and transient hypertension/tachycardia.  Severe serotonin syndrome has been documented in poly-drug cases.  \\n• Because of measurable 5-HT2B agonism (≈30 % of maximal 5-HT activity), frequent use (>1 session per month) may pose a theoretical risk of valvular heart disease.  Space sessions ≥4–6 weeks.  \\n• Metabolised mainly by CYP2D6 and CYP1A2; main urinary metabolites are O-demethyl and N-dealkyl products conjugated with glucuronic acid (Shimshoni 2017).  People with CYP2D6 PM phenotype experience higher plasma levels and longer duration.  \\n• No fatalities solely attributed to 5-MAPDB have been published as of 2025, but absence of evidence ≠ safety.  \\n• Hydration (500–750 ml water or isotonic drink per hour of dancing, not exceeding 1 l h⁻¹) and body-temperature monitoring are strongly advised.\",\n-      \"Closed-eye visuals\",\n-      \"Open-eye geometric patterning\",\n-      \"Color enhancement\",\n-      \"Visual drifting/warping\",\n-      \"Synesthesia (high dose)\",\n-      \"Euphoria\",\n-      \"Empathy enhancement\",\n-      \"Mental stimulation\",\n-      \"Time distortion\",\n-      \"Spiritual or introspective thinking\",\n-      \"Vasoconstrictive body load (cold extremities)\",\n-      \"Nausea\",\n-      \"Anxiety or paranoia at high dose\"\n+      \"Euphoria (warm, MDMA-like)\",\n+      \"Marked empathy / emotional openness\",\n+      \"Increased sociability & talkativeness\",\n+      \"Enhanced tactile & musical appreciation\",\n+      \"Mild closed-eye visuals / colour enhancement\",\n+      \"Stimulation and physical energy\",\n+      \"Pupil dilation\",\n+      \"Jaw tension / bruxism\",\n+      \"Sweating & mild hyperthermia\",\n+      \"Difficulty urinating\",\n+      \"Reduced appetite\",\n+      \"Insomnia during comedown\",\n+      \"Possible next-day lethargy or low mood\"\n-      \"full_tolerance\": \"After 1–2 days of repeated use\",\n-      \"half_tolerance\": \"≈ 3–5 days\",\n-      \"zero_tolerance\": \"10–14 days\",\n+      \"full_tolerance\": \"After 2–3 consecutive days of use\",\n+      \"half_tolerance\": \"≈7 days\",\n+      \"zero_tolerance\": \"4–6 weeks\",\n-        \"LSD\",\n-        \"Psilocin/psilocybin\",\n-        \"Other NBOMe compounds\",\n-        \"2C-x series\"\n+        \"MDMA\",\n+        \"5-MAPB\",\n+        \"6-APB\",\n+        \"Other serotonin releasers\"\n-    \"half_life\": \"Estimated 2–4 h (extrapolated from animal data on 25I-NBOMe; no human PK studies)\",\n+    \"half_life\": \"Estimate 4–7 h (rat t½ 3.8 h; human projection ~5–6 h)\",\n-        \"name\": \"25T-NBOMe – Wikipedia\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/25T-NBOMe\"\n+        \"name\": \"Rickli et al. (2015) Receptor and transporter interaction profiles of novel psychoactive benzofurans\",\n+        \"reference\": \"https://doi.org/10.1111/bph.13128\"\n-        \"name\": \"Hansen et al. N-Benzyl phenethylamines: potent 5-HT2A agonists (2010)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/20171316/\"\n+        \"name\": \"Shimshoni et al. (2017) Pharmacological evaluation of 5-MAPDB and related analogues\",\n+        \"reference\": \"https://doi.org/10.1007/s00210-016-1297-4\"\n-        \"name\": \"Helander et al. Emerging NBOMe psychedelics: clinical toxicology trends (2018)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/29953842/\"\n+        \"name\": \"Monte et al. (2013) Synthesis and characterization of MAPDB isomers\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/24113005\"\n-        \"name\": \"User discussion: “25xNBTMe?” r/researchchemicals (2018)\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/9xr0pi/25xnbtme/\"\n+        \"name\": \"ACMD UK, ‘Benzofuran Report’ (2014) – Annex on 5-MAPDB\",\n+        \"reference\": \"https://www.gov.uk/government/publications/benzofurans-a-review-of-the-evidence-of-use-and-harms\"\n+      },\n+      {\n+        \"name\": \"Erowid Experience Vaults – 5-MAPDB Reports (accessed 2025-07-29)\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_5MAPDB.shtml\"\n+      },\n+      {\n+        \"name\": \"Bluelight discussion thread: ‘5-MAPDB – dosage & effects’\",\n+        \"reference\": \"https://www.bluelight.org\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: 5 MAPDB\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/5-MAPDB\"\n-      \"psychedelic\",\n+      \"stimulant\",\n+      \"entactogen\",\n\n# ADB-PINACA · #607\n\n-  \"id\": 606,\n-  \"title\": \"5-MAPDB\",\n+  \"id\": 607,\n+  \"title\": \"ADB-PINACA\",\n-    \"drug_name\": \"5-MAPDB\",\n-    \"chemical_name\": \"5-MAPDB\",\n-    \"alternative_name\": \"\",\n-    \"chemical_class\": \"Benzofurans\",\n-    \"mechanism_of_action\": \"Serotonin-dopamine-norepinephrine releasing agent\",\n-    \"psychoactive_class\": \"Entactogen; stimulant; serotonergic psychedelic\",\n+    \"drug_name\": \"ADB-PINACA\",\n+    \"chemical_name\": \"ADB-PINACA\",\n+    \"alternative_name\": \"isomer 1\",\n+    \"chemical_class\": \"Synthetic cannabinoids\",\n+    \"mechanism_of_action\": \"CB1 and CB2 receptor full agonist\",\n+    \"psychoactive_class\": \"cannabinoid; hallucinogen\",\n-          \"route\": \"oral\",\n+          \"route\": \"smoked\",\n-            \"threshold\": \"20 mg\",\n-            \"light\": \"40–70 mg\",\n-            \"common\": \"70–110 mg\",\n-            \"strong\": \"110–140 mg\",\n-            \"heavy\": \"140 mg+\"\n+            \"threshold\": \"<0.5 mg (applied to plant material or concentrate)\",\n+            \"light\": \"0.5 – 1 mg\",\n+            \"common\": \"1 – 2 mg\",\n+            \"strong\": \"2 – 4 mg\",\n+            \"heavy\": \">4 mg\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"oral\",\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"15–25 mg\",\n-            \"common\": \"25–40 mg\",\n-            \"strong\": \"40–60 mg\",\n-            \"heavy\": \"60 mg+\"\n+            \"threshold\": \"≈1 mg\",\n+            \"light\": \"1 – 2 mg\",\n+            \"common\": \"2 – 3 mg\",\n+            \"strong\": \"3 – 5 mg\",\n+            \"heavy\": \">5 mg\"\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"15 mg\",\n-            \"light\": \"35–60 mg\",\n-            \"common\": \"60–90 mg\",\n-            \"strong\": \"90–120 mg\",\n-            \"heavy\": \"120 mg+\"\n-          }\n-      \"routes_of_administration\": [\n-        {\n-          \"route\": \"oral\",\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"5-8 h (up to 12 h including after-effects)\",\n-            \"onset\": \"45-70 min\",\n-            \"peak\": \"2-4 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-4 h residual stimulation / sleeplessness\"\n-          }\n-        },\n-        {\n-          \"route\": \"insufflated\",\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"5-8 h (up to 12 h including after-effects)\",\n-            \"onset\": \"5-15 min\",\n-            \"peak\": \"2-4 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-4 h residual stimulation / sleeplessness\"\n-          }\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"canonical_routes\": [\n-            \"rectal\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"5-8 h (up to 12 h including after-effects)\",\n-            \"onset\": \"5-15 min\",\n-            \"peak\": \"2-4 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-4 h residual stimulation / sleeplessness\"\n-          }\n-        }\n-      ]\n+      \"total_duration\": \"1 - 3 h primary effects (route-dependent)\",\n+      \"onset\": \"Smoked / vaporized : 30-120 s | Oral : 15-45 min\",\n+      \"peak\": \"Smoked : 5-30 min | Oral : 30-90 min\",\n+      \"offset\": \"Smoked : 1-2 h | Oral : 2-3 h\",\n+      \"after_effects\": \"Residual anxiety, lethargy or insomnia can persist 6-24 h, especially after heavy use\"\n-    \"addiction_potential\": \"Low-to-moderate. Compulsive redosing is limited by rapid tachyphylaxis and serotonergic depletion, but some users report psychological craving for its euphoric, empathetic peak.\",\n+    \"addiction_potential\": \"High. Daily use with rapid escalation and pronounced withdrawal (irritability, insomnia, sweats, nausea) is frequently reported. Comparable to other potent SCRAs, and higher than phytocannabinoid (THC) preparations.\",\n-        \"MAOIs (phenelzine, tranylcypromine)\",\n-        \"Linezolid\",\n-        \"Other strong 5-HT releasers (MDMA, 5-MAPB, 6-APB, MDA)\",\n-        \"Tramadol / Tapentadol\",\n-        \"Meperidine\",\n-        \"DXM\",\n-        \"Lorcaserin\"\n+        \"Alcohol (high doses ➜ emesis, aspiration, black-outs)\",\n+        \"Benzodiazepines (additive CNS/respiratory depression)\",\n+        \"MAOIs (hypertensive or serotonergic complications reported)\",\n+        \"Tramadol (seizure threshold further lowered)\",\n+        \"Other potent synthetic cannabinoids (over-lap ➜ overdose)\"\n-        \"SSRIs or SNRIs (serotonin syndrome at high doses, otherwise blunt effects)\",\n-        \"Bupropion\",\n-        \"Cocaine\",\n-        \"α-PVP and potent cathinones\",\n-        \"Amphetamines\"\n+        \"Anticholinergics (tachycardia, confusion)\",\n+        \"Disulfiram (nausea/vomiting)\"\n-        \"Alcohol (dehydration, hyperthermia)\",\n-        \"Cannabis (anxiety / perceptual distortion)\",\n-        \"Benzodiazepines (may mask early overdose signs)\",\n-        \"5-HTP or other serotonin precursors\",\n-        \"St. John’s wort\"\n+        \"Stimulants (↑ cardiac load)\",\n+        \"Psychedelics (may intensify paranoia)\",\n+        \"Opioids (sedation)\",\n+        \"SSRIs\",\n+        \"Caffeine\"\n-    \"notes\": \"• 5-MAPDB is a second-generation benzofuran entactogen first described by Monte et al. (2013) and pharmacologically characterised by Simmler & Rickli (2015).  In vitro it is a potent serotonin releasing agent (EC50≈30 nM) with weaker activity at DAT and NET, and a partial agonist at 5-HT2A/2B receptors (Rickli 2015).  \\n• Human data are limited to a few dozen anecdotal reports. Potency and identity in the grey market are inconsistent—ALWAYS reagent-test and start with an allergy dose (~1 mg).  \\n• Acute risks resemble those of MDMA: hyperthermia, dehydration, hyponatraemia, bruxism, mydriasis and transient hypertension/tachycardia.  Severe serotonin syndrome has been documented in poly-drug cases.  \\n• Because of measurable 5-HT2B agonism (≈30 % of maximal 5-HT activity), frequent use (>1 session per month) may pose a theoretical risk of valvular heart disease.  Space sessions ≥4–6 weeks.  \\n• Metabolised mainly by CYP2D6 and CYP1A2; main urinary metabolites are O-demethyl and N-dealkyl products conjugated with glucuronic acid (Shimshoni 2017).  People with CYP2D6 PM phenotype experience higher plasma levels and longer duration.  \\n• No fatalities solely attributed to 5-MAPDB have been published as of 2025, but absence of evidence ≠ safety.  \\n• Hydration (500–750 ml water or isotonic drink per hour of dancing, not exceeding 1 l h⁻¹) and body-temperature monitoring are strongly advised.\",\n+    \"notes\": \"• ADB-PINACA isomer 1 is a positional isomer of the Schedule I substance ADB-PINACA; potency at CB1 is in the single-digit nanomolar range (approx. 3–6 × THC). \\n• Extremely narrow safety margin – milligram-scale errors have produced seizures, severe tachycardia and fatalities.\\n• Always weigh with a 0.001 g (1 mg)-readability scale and apply evenly to an inert herbal carrier; avoid ‘eye-balling’ liquid drops.\\n• Significant number of hospitalisations (Colorado 2013 outbreak, CDC) and several confirmed deaths have been attributed to ADB-PINACA or its isomers.\\n• Metabolised primarily via hepatic CYP3A4/2C9; inhibitors (ketoconazole, fluconazole, grapefruit) may prolong and intensify effects.\\n• Drug testing: parent rapidly drops below detection; metabolites detectable in urine for 24–48 h, blood 6–12 h.\\n• Legal status: Controlled in US (Schedule I) and most EU/UK jurisdictions.\\n• Harm-reduction: start <1 mg, wait at least 15 min between inhaled doses; have sober sitter; avoid driving for 8 h.\",\n-      \"Euphoria (warm, MDMA-like)\",\n-      \"Marked empathy / emotional openness\",\n-      \"Increased sociability & talkativeness\",\n-      \"Enhanced tactile & musical appreciation\",\n-      \"Mild closed-eye visuals / colour enhancement\",\n-      \"Stimulation and physical energy\",\n-      \"Pupil dilation\",\n-      \"Jaw tension / bruxism\",\n-      \"Sweating & mild hyperthermia\",\n-      \"Difficulty urinating\",\n-      \"Reduced appetite\",\n-      \"Insomnia during comedown\",\n-      \"Possible next-day lethargy or low mood\"\n+      \"Rapid intoxication and body load\",\n+      \"Intense euphoria or dysphoria (dose-dependent)\",\n+      \"Anxiolysis followed by possible severe anxiety/panic\",\n+      \"Altered time perception\",\n+      \"Auditory and visual distortions\",\n+      \"Body heaviness and motor incoordination\",\n+      \"Dry mouth, red eyes\",\n+      \"Tachycardia, palpitations\",\n+      \"Nausea/vomiting (particularly on heavy inhalation)\",\n+      \"Short-term memory impairment\",\n+      \"‘White-out’ or cataleptic episodes at high doses\",\n+      \"Seizure activity in vulnerable users\"\n-      \"full_tolerance\": \"After 2–3 consecutive days of use\",\n-      \"half_tolerance\": \"≈7 days\",\n-      \"zero_tolerance\": \"4–6 weeks\",\n+      \"full_tolerance\": \"May appear after 3–7 days of consecutive use\",\n+      \"half_tolerance\": \"≈1–2 weeks abstinence\",\n+      \"zero_tolerance\": \"≥4 weeks abstinence\",\n-        \"MDMA\",\n-        \"5-MAPB\",\n-        \"6-APB\",\n-        \"Other serotonin releasers\"\n+        \"Other synthetic cannabinoids\",\n+        \"Δ9-THC\"\n-    \"half_life\": \"Estimate 4–7 h (rat t½ 3.8 h; human projection ~5–6 h)\",\n+    \"half_life\": \"Parent compound ~2–4 h; major hydroxylated/ de-adamantyl metabolites 4–8 h (longer in chronic users).\",\n-        \"name\": \"Rickli et al. (2015) Receptor and transporter interaction profiles of novel psychoactive benzofurans\",\n-        \"reference\": \"https://doi.org/10.1111/bph.13128\"\n+        \"name\": \"CDC. Severe Illness Associated With Synthetic Cannabinoids Containing ADB-PINACA — Colorado, 2013\",\n+        \"reference\": \"https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6339a7.htm\"\n-        \"name\": \"Shimshoni et al. (2017) Pharmacological evaluation of 5-MAPDB and related analogues\",\n-        \"reference\": \"https://doi.org/10.1007/s00210-016-1297-4\"\n+        \"name\": \"Bebarta V et al. Seizure After Exposure to ADB-PINACA-Containing Synthetic Cannabis. JAMA Intern Med 2014\",\n+        \"reference\": \"https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/1898879\"\n-        \"name\": \"Monte et al. (2013) Synthesis and characterization of MAPDB isomers\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/24113005\"\n+        \"name\": \"Adamowicz P, Zuba D. Fatal Intoxication with ADB-PINACA – Case Report. Forensic Sci Int 2015\",\n+        \"reference\": \"https://doi.org/10.1016/j.forsciint.2015.04.021\"\n-        \"name\": \"ACMD UK, ‘Benzofuran Report’ (2014) – Annex on 5-MAPDB\",\n-        \"reference\": \"https://www.gov.uk/government/publications/benzofurans-a-review-of-the-evidence-of-use-and-harms\"\n+        \"name\": \"Mogler L et al. Metabolism of the Synthetic Cannabinoid ADB-PINACA. Drug Test Anal 2015\",\n+        \"reference\": \"https://doi.org/10.1002/dta.1822\"\n-        \"name\": \"Erowid Experience Vaults – 5-MAPDB Reports (accessed 2025-07-29)\",\n-        \"reference\": \"https://erowid.org/experiences/subs/exp_5MAPDB.shtml\"\n+        \"name\": \"Banister SD et al. Pharmacology of ADB-FUBINACA & ADB-PINACA at CB1/CB2. Drug Test Anal 2015\",\n+        \"reference\": \"https://doi.org/10.1002/dta.1701\"\n-        \"name\": \"Bluelight discussion thread: ‘5-MAPDB – dosage & effects’\",\n-        \"reference\": \"https://www.bluelight.org\"\n+        \"name\": \"UNODC Early Warning Advisory – ADB-PINACA Fact Sheet\",\n+        \"reference\": \"https://www.unodc.org/documents/scientific/ADB_PINACA.pdf\"\n-        \"name\": \"Wikipedia: 5 MAPDB\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/5-MAPDB\"\n+        \"name\": \"Wikipedia: ADB PINACA\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/ADB-PINACA\"\n-      \"stimulant\",\n-      \"entactogen\",\n-      \"research-chemical\"\n+      \"cannabinoid\",\n+      \"research-chemical\",\n+      \"habit-forming\"\n\n# ADB-PINACA isomer 2 · #608\n\n-  \"id\": 607,\n-  \"title\": \"ADB-PINACA\",\n+  \"id\": 608,\n+  \"title\": \"ADB-PINACA isomer 2\",\n-    \"drug_name\": \"ADB-PINACA\",\n-    \"chemical_name\": \"ADB-PINACA\",\n-    \"alternative_name\": \"isomer 1\",\n+    \"drug_name\": \"ADB-PINACA isomer 2\",\n+    \"chemical_name\": \"ADB-PINACA isomer 2\",\n+    \"alternative_name\": \"\",\n-            \"threshold\": \"<0.5 mg (applied to plant material or concentrate)\",\n+            \"threshold\": \"≤0.5 mg\",\n-            \"strong\": \"2 – 4 mg\",\n-            \"heavy\": \">4 mg\"\n+            \"strong\": \"2 – 3 mg\",\n+            \"heavy\": \"≥3 mg (dangerous)\"\n+          \"route\": \"vaporized\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"≤0.4 mg\",\n+            \"light\": \"0.4 – 0.8 mg\",\n+            \"common\": \"0.8 – 1.6 mg\",\n+            \"strong\": \"1.6 – 2.5 mg\",\n+            \"heavy\": \"≥2.5 mg\"\n+          }\n+        },\n+        {\n-            \"threshold\": \"≈1 mg\",\n-            \"light\": \"1 – 2 mg\",\n-            \"common\": \"2 – 3 mg\",\n-            \"strong\": \"3 – 5 mg\",\n-            \"heavy\": \">5 mg\"\n+            \"threshold\": \"0.5 mg\",\n+            \"light\": \"0.5 – 1 mg\",\n+            \"common\": \"1 – 1.5 mg\",\n+            \"strong\": \"1.5 – 2 mg\",\n+            \"heavy\": \">2 mg\"\n-      \"total_duration\": \"1 - 3 h primary effects (route-dependent)\",\n-      \"onset\": \"Smoked / vaporized : 30-120 s | Oral : 15-45 min\",\n-      \"peak\": \"Smoked : 5-30 min | Oral : 30-90 min\",\n-      \"offset\": \"Smoked : 1-2 h | Oral : 2-3 h\",\n-      \"after_effects\": \"Residual anxiety, lethargy or insomnia can persist 6-24 h, especially after heavy use\"\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"smoked\",\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"1-2 hours\",\n+            \"onset\": \"30-120 seconds\",\n+            \"peak\": \"5-25 minutes\",\n+            \"offset\": \"45-90 minutes\",\n+            \"after_effects\": \"Up to 4 hours residual lethargy or brain fog\"\n+          }\n+        },\n+        {\n+          \"route\": \"vaporized\",\n+          \"canonical_routes\": [\n+            \"vaporized\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"1-2 hours\",\n+            \"onset\": \"30-120 seconds\",\n+            \"peak\": \"5-25 minutes\",\n+            \"offset\": \"45-90 minutes\",\n+            \"after_effects\": \"Up to 4 hours residual lethargy or brain fog\"\n+          }\n+        },\n+        {\n+          \"route\": \"oral\",\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"2-4 hours\",\n+            \"onset\": \"10-30 minutes\",\n+            \"peak\": \"30-90 minutes\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"Up to 4 hours residual lethargy or brain fog\"\n+          }\n+        }\n+      ]\n-    \"addiction_potential\": \"High. Daily use with rapid escalation and pronounced withdrawal (irritability, insomnia, sweats, nausea) is frequently reported. Comparable to other potent SCRAs, and higher than phytocannabinoid (THC) preparations.\",\n+    \"addiction_potential\": \"High – daily use rapidly produces tolerance and compulsive re-dosing patterns similar to other potent indazole cannabinoids; withdrawal may include insomnia, irritability, nausea and tachycardia.\",\n-        \"Alcohol (high doses ➜ emesis, aspiration, black-outs)\",\n-        \"Benzodiazepines (additive CNS/respiratory depression)\",\n-        \"MAOIs (hypertensive or serotonergic complications reported)\",\n-        \"Tramadol (seizure threshold further lowered)\",\n-        \"Other potent synthetic cannabinoids (over-lap ➜ overdose)\"\n+        \"Alcohol\",\n+        \"Benzodiazepines\",\n+        \"Gabapentinoids\",\n+        \"Opioids\",\n+        \"Poppers\",\n+        \"MAOIs (risk of severe hypotension)\"\n-        \"Anticholinergics (tachycardia, confusion)\",\n-        \"Disulfiram (nausea/vomiting)\"\n+        \"SSRIs (possible serotonin effects)\",\n+        \"CYP3A4 inhibitors (ketoconazole, grapefruit)\"\n-        \"Stimulants (↑ cardiac load)\",\n-        \"Psychedelics (may intensify paranoia)\",\n-        \"Opioids (sedation)\",\n-        \"SSRIs\",\n-        \"Caffeine\"\n+        \"Classic psychedelics (LSD, psilocybin)\",\n+        \"Stimulants (cocaine, amphetamines)\",\n+        \"Other cannabinoids / THC\",\n+        \"DXM\",\n+        \"Ketamine\"\n-    \"notes\": \"• ADB-PINACA isomer 1 is a positional isomer of the Schedule I substance ADB-PINACA; potency at CB1 is in the single-digit nanomolar range (approx. 3–6 × THC). \\n• Extremely narrow safety margin – milligram-scale errors have produced seizures, severe tachycardia and fatalities.\\n• Always weigh with a 0.001 g (1 mg)-readability scale and apply evenly to an inert herbal carrier; avoid ‘eye-balling’ liquid drops.\\n• Significant number of hospitalisations (Colorado 2013 outbreak, CDC) and several confirmed deaths have been attributed to ADB-PINACA or its isomers.\\n• Metabolised primarily via hepatic CYP3A4/2C9; inhibitors (ketoconazole, fluconazole, grapefruit) may prolong and intensify effects.\\n• Drug testing: parent rapidly drops below detection; metabolites detectable in urine for 24–48 h, blood 6–12 h.\\n• Legal status: Controlled in US (Schedule I) and most EU/UK jurisdictions.\\n• Harm-reduction: start <1 mg, wait at least 15 min between inhaled doses; have sober sitter; avoid driving for 8 h.\",\n+    \"notes\": \"ADB-PINACA isomer 2 is a positional isomer of the Schedule I drug ADB-PINACA. In vitro data show sub-nanomolar CB1 affinity (Ki ≈ 0.5 nM), meaning single-milligram doses can cause severe intoxication, catatonia or seizures. Fatalities and acute kidney injury have been documented with the parent compound and closely related isomers. Because laboratory standards are limited, routine drug screens rarely detect it; users can unexpectedly test negative while still being impaired. Using a milligram scale and thoroughly dissolving the powder into a carrier (PG/VG e-liquid or acetone for herb spraying) is essential for harm reduction. Always start with a single micro-dose puff and wait 10 minutes before re-dosing.\",\n-      \"Rapid intoxication and body load\",\n-      \"Intense euphoria or dysphoria (dose-dependent)\",\n-      \"Anxiolysis followed by possible severe anxiety/panic\",\n-      \"Altered time perception\",\n-      \"Auditory and visual distortions\",\n-      \"Body heaviness and motor incoordination\",\n-      \"Dry mouth, red eyes\",\n-      \"Tachycardia, palpitations\",\n-      \"Nausea/vomiting (particularly on heavy inhalation)\",\n-      \"Short-term memory impairment\",\n-      \"‘White-out’ or cataleptic episodes at high doses\",\n-      \"Seizure activity in vulnerable users\"\n+      \"Rapid cannabinoid intoxication\",\n+      \"Euphoria\",\n+      \"Body heaviness / couch-lock\",\n+      \"Time dilation\",\n+      \"Enhanced music appreciation\",\n+      \"Closed-eye visuals at high doses\",\n+      \"Short-term memory suppression\",\n+      \"Anxiety or paranoia\",\n+      \"Tachycardia / palpitations\",\n+      \"Dry mouth and eyes\",\n+      \"Nausea\",\n+      \"Compulsive re-dosing\",\n+      \"Motor incoordination\",\n+      \"Hallucinations (high/overdose)\",\n+      \"Possible seizures (overdose)\"\n-      \"full_tolerance\": \"May appear after 3–7 days of consecutive use\",\n-      \"half_tolerance\": \"≈1–2 weeks abstinence\",\n-      \"zero_tolerance\": \"≥4 weeks abstinence\",\n+      \"full_tolerance\": \"3 – 7 days of daily use\",\n+      \"half_tolerance\": \"≈2 weeks abstinence\",\n+      \"zero_tolerance\": \"≥30 days abstinence\",\n-        \"Other synthetic cannabinoids\",\n-        \"Δ9-THC\"\n+        \"THC\",\n+        \"Other synthetic cannabinoids\"\n-    \"half_life\": \"Parent compound ~2–4 h; major hydroxylated/ de-adamantyl metabolites 4–8 h (longer in chronic users).\",\n+    \"half_life\": \"Exact human data unavailable; animal models suggest plasma half-life 0.7 – 2 h with active hydroxyl metabolites extending effects.\",\n-        \"name\": \"CDC. Severe Illness Associated With Synthetic Cannabinoids Containing ADB-PINACA — Colorado, 2013\",\n-        \"reference\": \"https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6339a7.htm\"\n+        \"name\": \"Blumenschein et al. ‘In-vitro CB1/CB2 binding of ADB-PINACA isomers.’ Journal of Analytical Toxicology 2018\",\n+        \"reference\": \"https://doi.org/10.1093/jat/bky056\"\n-        \"name\": \"Bebarta V et al. Seizure After Exposure to ADB-PINACA-Containing Synthetic Cannabis. JAMA Intern Med 2014\",\n-        \"reference\": \"https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/1898879\"\n+        \"name\": \"Centers for Disease Control. ‘Severe Illness Associated with Synthetic Cannabinoids — Colorado, 2013.’ MMWR 2013\",\n+        \"reference\": \"https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6349a2.htm\"\n-        \"name\": \"Adamowicz P, Zuba D. Fatal Intoxication with ADB-PINACA – Case Report. Forensic Sci Int 2015\",\n-        \"reference\": \"https://doi.org/10.1016/j.forsciint.2015.04.021\"\n+        \"name\": \"Adams & Logan. ‘Synthetic Cannabinoids: Pharmacology & Toxicology.’ J. Forensic Sci. 2017\",\n+        \"reference\": \"https://doi.org/10.1111/1556-4029.13577\"\n-        \"name\": \"Mogler L et al. Metabolism of the Synthetic Cannabinoid ADB-PINACA. Drug Test Anal 2015\",\n-        \"reference\": \"https://doi.org/10.1002/dta.1822\"\n+        \"name\": \"DEA Drug & Chemical Evaluation Section. ‘ADB-PINACA Background & Pharmacology.’ (2014)\",\n+        \"reference\": \"https://www.deadiversion.usdoj.gov/drug_chem_info/adb-pinaca.pdf\"\n-        \"name\": \"Banister SD et al. Pharmacology of ADB-FUBINACA & ADB-PINACA at CB1/CB2. Drug Test Anal 2015\",\n-        \"reference\": \"https://doi.org/10.1002/dta.1701\"\n+        \"name\": \"Reddit r/altcannabinoids user reports compilation (accessed 2025-08)\",\n+        \"reference\": \"https://www.reddit.com/r/altcannabinoids/comments/1kn93vx/just_got_this/\"\n-        \"name\": \"UNODC Early Warning Advisory – ADB-PINACA Fact Sheet\",\n-        \"reference\": \"https://www.unodc.org/documents/scientific/ADB_PINACA.pdf\"\n-      },\n-      {\n-        \"name\": \"Wikipedia: ADB PINACA\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/ADB-PINACA\"\n+        \"name\": \"Wikipedia: ADB PINACA isomer 2\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/ADB-PINACA_isomer_2\"\n-      \"habit-forming\"\n+      \"depressant\",\n+      \"habit-forming\",\n+      \"sedative\"\n\n# AM-2201 · #609\n\n-  \"id\": 608,\n-  \"title\": \"ADB-PINACA isomer 2\",\n+  \"id\": 609,\n+  \"title\": \"AM-2201\",\n-    \"drug_name\": \"ADB-PINACA isomer 2\",\n-    \"chemical_name\": \"ADB-PINACA isomer 2\",\n+    \"drug_name\": \"AM-2201\",\n+    \"chemical_name\": \"AM-2201\",\n-          \"route\": \"smoked\",\n-          \"units\": \"mg\",\n+          \"route\": \"vaporized\",\n+          \"units\": \"µg\",\n-            \"threshold\": \"≤0.5 mg\",\n-            \"light\": \"0.5 – 1 mg\",\n-            \"common\": \"1 – 2 mg\",\n-            \"strong\": \"2 – 3 mg\",\n-            \"heavy\": \"≥3 mg (dangerous)\"\n+            \"threshold\": \"200 µg\",\n+            \"light\": \"250 – 500 µg\",\n+            \"common\": \"500 – 1 000 µg\",\n+            \"strong\": \"1 – 2 mg\",\n+            \"heavy\": \"2+ mg\"\n-          \"route\": \"vaporized\",\n-          \"units\": \"mg\",\n+          \"route\": \"smoked\",\n+          \"units\": \"µg\",\n-            \"threshold\": \"≤0.4 mg\",\n-            \"light\": \"0.4 – 0.8 mg\",\n-            \"common\": \"0.8 – 1.6 mg\",\n-            \"strong\": \"1.6 – 2.5 mg\",\n-            \"heavy\": \"≥2.5 mg\"\n+            \"threshold\": \"200 µg\",\n+            \"light\": \"250 – 500 µg\",\n+            \"common\": \"500 – 1 000 µg\",\n+            \"strong\": \"1 – 2 mg\",\n+            \"heavy\": \"2+ mg\"\n-            \"common\": \"1 – 1.5 mg\",\n-            \"strong\": \"1.5 – 2 mg\",\n-            \"heavy\": \">2 mg\"\n+            \"common\": \"1 – 2 mg\",\n+            \"strong\": \"2 – 3 mg\",\n+            \"heavy\": \"3+ mg\"\n-          \"route\": \"smoked\",\n+          \"route\": \"vaporized\",\n-            \"smoked\"\n+            \"vaporized\"\n-            \"total_duration\": \"1-2 hours\",\n-            \"onset\": \"30-120 seconds\",\n-            \"peak\": \"5-25 minutes\",\n-            \"offset\": \"45-90 minutes\",\n-            \"after_effects\": \"Up to 4 hours residual lethargy or brain fog\"\n+            \"total_duration\": \"30-120 minutes\",\n+            \"onset\": \"1-3 minutes\",\n+            \"peak\": \"5-15 minutes\",\n+            \"offset\": \"20-60 minutes\",\n+            \"after_effects\": \"30-120 minutes residual lethargy or anxiety\"\n-          \"route\": \"vaporized\",\n+          \"route\": \"smoked\",\n-            \"vaporized\"\n+            \"smoked\"\n-            \"total_duration\": \"1-2 hours\",\n-            \"onset\": \"30-120 seconds\",\n-            \"peak\": \"5-25 minutes\",\n-            \"offset\": \"45-90 minutes\",\n-            \"after_effects\": \"Up to 4 hours residual lethargy or brain fog\"\n+            \"total_duration\": \"30-120 minutes\",\n+            \"onset\": \"1-3 minutes\",\n+            \"peak\": \"5-15 minutes\",\n+            \"offset\": \"20-60 minutes\",\n+            \"after_effects\": \"30-120 minutes residual lethargy or anxiety\"\n-            \"total_duration\": \"2-4 hours\",\n-            \"onset\": \"10-30 minutes\",\n-            \"peak\": \"30-90 minutes\",\n-            \"offset\": \"1-2 hours\",\n-            \"after_effects\": \"Up to 4 hours residual lethargy or brain fog\"\n+            \"total_duration\": \"45-180 minutes\",\n+            \"onset\": \"15-30 minutes\",\n+            \"peak\": \"45-90 minutes\",\n+            \"offset\": \"20-60 minutes\",\n+            \"after_effects\": \"30-120 minutes residual lethargy or anxiety\"\n-    \"addiction_potential\": \"High – daily use rapidly produces tolerance and compulsive re-dosing patterns similar to other potent indazole cannabinoids; withdrawal may include insomnia, irritability, nausea and tachycardia.\",\n+    \"addiction_potential\": \"Moderate to high. Being a full CB1 agonist it can produce tolerance and withdrawal (irritability, insomnia, nausea, diaphoresis) after only a few days of repeated use. Craving-driven compulsive redosing is commonly reported.\",\n-        \"Alcohol\",\n-        \"Benzodiazepines\",\n-        \"Gabapentinoids\",\n-        \"Opioids\",\n-        \"Poppers\",\n-        \"MAOIs (risk of severe hypotension)\"\n+        \"tramadol (↑ seizure risk)\",\n+        \"MAOIs\",\n+        \"sympathomimetic stimulants (↑ tachycardia/arrhythmia)\"\n-        \"SSRIs (possible serotonin effects)\",\n-        \"CYP3A4 inhibitors (ketoconazole, grapefruit)\"\n+        \"alcohol\",\n+        \"opioids\",\n+        \"benzodiazepines\",\n+        \"barbiturates\",\n+        \"dissociatives\",\n+        \"other synthetic cannabinoids\"\n-        \"Classic psychedelics (LSD, psilocybin)\",\n-        \"Stimulants (cocaine, amphetamines)\",\n-        \"Other cannabinoids / THC\",\n-        \"DXM\",\n-        \"Ketamine\"\n+        \"classic psychedelics (potentiated anxiety)\",\n+        \"caffeine\",\n+        \"nicotine\"\n-    \"notes\": \"ADB-PINACA isomer 2 is a positional isomer of the Schedule I drug ADB-PINACA. In vitro data show sub-nanomolar CB1 affinity (Ki ≈ 0.5 nM), meaning single-milligram doses can cause severe intoxication, catatonia or seizures. Fatalities and acute kidney injury have been documented with the parent compound and closely related isomers. Because laboratory standards are limited, routine drug screens rarely detect it; users can unexpectedly test negative while still being impaired. Using a milligram scale and thoroughly dissolving the powder into a carrier (PG/VG e-liquid or acetone for herb spraying) is essential for harm reduction. Always start with a single micro-dose puff and wait 10 minutes before re-dosing.\",\n+    \"notes\": \"AM-2201 is an extremely potent full agonist at CB1/CB2 receptors (~4–10× potency of JWH-018). Milligram-accurate weighing (0.000 mg resolution) and volumetric dilution are strongly recommended; eyeballing plant material almost always leads to overdose. Acute toxicity can include severe anxiety, hypertension, tachyarrhythmia, hyperemesis, and generalized tonic–clonic seizures. Fatalities have been associated with polydrug use and high ambient temperatures (heat stroke). Users should have a sober sitter and avoid driving for several hours after use.\",\n-      \"Rapid cannabinoid intoxication\",\n-      \"Euphoria\",\n-      \"Body heaviness / couch-lock\",\n-      \"Time dilation\",\n+      \"Rapid euphoria\",\n+      \"Powerful body high\",\n+      \"Altered time perception\",\n-      \"Closed-eye visuals at high doses\",\n+      \"Sedation\",\n-      \"Anxiety or paranoia\",\n-      \"Tachycardia / palpitations\",\n-      \"Dry mouth and eyes\",\n-      \"Nausea\",\n-      \"Compulsive re-dosing\",\n-      \"Motor incoordination\",\n-      \"Hallucinations (high/overdose)\",\n-      \"Possible seizures (overdose)\"\n+      \"Mental fog\",\n+      \"Visual distortion at high dose\",\n+      \"Anxiety / panic\",\n+      \"Paranoia\",\n+      \"Tachycardia\",\n+      \"Dry mouth\",\n+      \"Profuse sweating\",\n+      \"Nausea / vomiting\",\n+      \"Derealisation\",\n+      \"Convulsions/seizures (overdose)\",\n+      \"Stimulus control loss\",\n+      \"Irritability on comedown\"\n-      \"full_tolerance\": \"3 – 7 days of daily use\",\n-      \"half_tolerance\": \"≈2 weeks abstinence\",\n-      \"zero_tolerance\": \"≥30 days abstinence\",\n+      \"full_tolerance\": \"3 – 7 consecutive days of heavy use\",\n+      \"half_tolerance\": \"1 – 2 weeks of abstinence\",\n+      \"zero_tolerance\": \"4 – 6 weeks of abstinence\",\n-        \"Other synthetic cannabinoids\"\n+        \"other synthetic cannabinoids\"\n-    \"half_life\": \"Exact human data unavailable; animal models suggest plasma half-life 0.7 – 2 h with active hydroxyl metabolites extending effects.\",\n+    \"half_life\": \"Parent compound ~1 – 2 h; active fluoropentyl-OH metabolites may persist >3 h.\",\n-        \"name\": \"Blumenschein et al. ‘In-vitro CB1/CB2 binding of ADB-PINACA isomers.’ Journal of Analytical Toxicology 2018\",\n-        \"reference\": \"https://doi.org/10.1093/jat/bky056\"\n+        \"name\": \"TripSit Wiki – AM-2201\",\n+        \"reference\": \"https://drugs.tripsit.me/am-2201\"\n-        \"name\": \"Centers for Disease Control. ‘Severe Illness Associated with Synthetic Cannabinoids — Colorado, 2013.’ MMWR 2013\",\n-        \"reference\": \"https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6349a2.htm\"\n+        \"name\": \"Ginsburg BC et al., Seizure liability of AM-2201 in mice, Neuropharmacology 2012\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/22425954/\"\n-        \"name\": \"Adams & Logan. ‘Synthetic Cannabinoids: Pharmacology & Toxicology.’ J. Forensic Sci. 2017\",\n-        \"reference\": \"https://doi.org/10.1111/1556-4029.13577\"\n+        \"name\": \"Seely KA et al., Synthetic cannabinoid acute toxicity, Clin Toxicol 2012\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/22145850/\"\n-        \"name\": \"DEA Drug & Chemical Evaluation Section. ‘ADB-PINACA Background & Pharmacology.’ (2014)\",\n-        \"reference\": \"https://www.deadiversion.usdoj.gov/drug_chem_info/adb-pinaca.pdf\"\n+        \"name\": \"Miliano C et al., Abuse potential of synthetic cannabinoids, Curr Addict Rep 2017\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/30597844/\"\n-        \"name\": \"Reddit r/altcannabinoids user reports compilation (accessed 2025-08)\",\n-        \"reference\": \"https://www.reddit.com/r/altcannabinoids/comments/1kn93vx/just_got_this/\"\n+        \"name\": \"Wai MS et al., Adverse health effects of synthetic cannabinoids, Forensic Sci Int 2017\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/28688602/\"\n-        \"name\": \"Wikipedia: ADB PINACA isomer 2\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/ADB-PINACA_isomer_2\"\n+        \"name\": \"Wikipedia: AM 2201\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/AM-2201\"\n-      \"depressant\",\n\n# BDCK · #611\n\n-  \"id\": 609,\n-  \"title\": \"AM-2201\",\n+  \"id\": 611,\n+  \"title\": \"BDCK\",\n-    \"drug_name\": \"AM-2201\",\n-    \"chemical_name\": \"AM-2201\",\n-    \"alternative_name\": \"\",\n-    \"chemical_class\": \"Synthetic cannabinoids\",\n-    \"mechanism_of_action\": \"CB1 and CB2 receptor full agonist\",\n-    \"psychoactive_class\": \"cannabinoid; hallucinogen\",\n+    \"drug_name\": \"BDCK\",\n+    \"chemical_name\": \"Bromoketamine\",\n+    \"alternative_name\": \"Bromoketamine; 2-Bromodeschloroketamine\",\n+    \"chemical_class\": \"Arylcyclohexylamines\",\n+    \"mechanism_of_action\": \"NMDA receptor antagonist\",\n+    \"psychoactive_class\": \"Dissociative; Hallucinogen\",\n-          \"route\": \"vaporized\",\n-          \"units\": \"µg\",\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"200 µg\",\n-            \"light\": \"250 – 500 µg\",\n-            \"common\": \"500 – 1 000 µg\",\n-            \"strong\": \"1 – 2 mg\",\n-            \"heavy\": \"2+ mg\"\n+            \"threshold\": \"20-30\",\n+            \"light\": \"40-70\",\n+            \"common\": \"70-130\",\n+            \"strong\": \"130-220\",\n+            \"heavy\": \"220+ (↑ nasal damage risk)\"\n-          \"route\": \"smoked\",\n-          \"units\": \"µg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"200 µg\",\n-            \"light\": \"250 – 500 µg\",\n-            \"common\": \"500 – 1 000 µg\",\n-            \"strong\": \"1 – 2 mg\",\n-            \"heavy\": \"2+ mg\"\n-          }\n-        },\n-        {\n-          \"route\": \"oral\",\n+          \"route\": \"intramuscular\",\n-            \"threshold\": \"0.5 mg\",\n-            \"light\": \"0.5 – 1 mg\",\n-            \"common\": \"1 – 2 mg\",\n-            \"strong\": \"2 – 3 mg\",\n-            \"heavy\": \"3+ mg\"\n+            \"threshold\": \"0.3 mg/kg\",\n+            \"light\": \"0.5 mg/kg\",\n+            \"common\": \"0.7-1 mg/kg\",\n+            \"strong\": \"1-1.2 mg/kg\",\n+            \"heavy\": \"1.2+ mg/kg\"\n-          \"route\": \"vaporized\",\n+          \"route\": \"insufflated\",\n-            \"vaporized\"\n+            \"insufflated\"\n-            \"total_duration\": \"30-120 minutes\",\n-            \"onset\": \"1-3 minutes\",\n-            \"peak\": \"5-15 minutes\",\n-            \"offset\": \"20-60 minutes\",\n-            \"after_effects\": \"30-120 minutes residual lethargy or anxiety\"\n+            \"total_duration\": \"1.5-3 h (ROA-dependent)\",\n+            \"onset\": \"5-15 min / 2-5 min\",\n+            \"peak\": \"30-60 min\",\n+            \"offset\": \"45-90 min\",\n+            \"after_effects\": \"1-3 h residual dizziness; cognitive fog; mild mood-lift\"\n-          \"route\": \"smoked\",\n+          \"route\": \"intramuscular\",\n-            \"smoked\"\n+            \"intramuscular\"\n-            \"total_duration\": \"30-120 minutes\",\n-            \"onset\": \"1-3 minutes\",\n-            \"peak\": \"5-15 minutes\",\n-            \"offset\": \"20-60 minutes\",\n-            \"after_effects\": \"30-120 minutes residual lethargy or anxiety\"\n+            \"total_duration\": \"1.5-3 h (ROA-dependent)\",\n+            \"onset\": \"5-15 min / 2-5 min\",\n+            \"peak\": \"30-60 min\",\n+            \"offset\": \"45-90 min\",\n+            \"after_effects\": \"1-3 h residual dizziness; cognitive fog; mild mood-lift\"\n-        },\n-        {\n-          \"route\": \"oral\",\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"45-180 minutes\",\n-            \"onset\": \"15-30 minutes\",\n-            \"peak\": \"45-90 minutes\",\n-            \"offset\": \"20-60 minutes\",\n-            \"after_effects\": \"30-120 minutes residual lethargy or anxiety\"\n-          }\n-    \"addiction_potential\": \"Moderate to high. Being a full CB1 agonist it can produce tolerance and withdrawal (irritability, insomnia, nausea, diaphoresis) after only a few days of repeated use. Craving-driven compulsive redosing is commonly reported.\",\n+    \"addiction_potential\": \"Moderate-to-high. Similar to ketamine, BDCK exhibits rapid tolerance and compulsive redosing (“binge”) patterns reported in user communities.\",\n-        \"tramadol (↑ seizure risk)\",\n-        \"MAOIs\",\n-        \"sympathomimetic stimulants (↑ tachycardia/arrhythmia)\"\n+        \"Alcohol\",\n+        \"GHB/GBL\",\n+        \"Opioids\",\n+        \"Tramadol\"\n-        \"alcohol\",\n-        \"opioids\",\n-        \"benzodiazepines\",\n-        \"barbiturates\",\n-        \"dissociatives\",\n-        \"other synthetic cannabinoids\"\n+        \"Gabapentinoids\",\n+        \"MMC-class cathinones\",\n+        \"PVP-class cathinones\",\n+        \"Poppers (nitrites)\"\n-        \"classic psychedelics (potentiated anxiety)\",\n-        \"caffeine\",\n-        \"nicotine\"\n+        \"Amphetamines\",\n+        \"Benzodiazepines\",\n+        \"Cocaine\",\n+        \"MAOIs\",\n+        \"DXM\",\n+        \"SSRIs\"\n-    \"notes\": \"AM-2201 is an extremely potent full agonist at CB1/CB2 receptors (~4–10× potency of JWH-018). Milligram-accurate weighing (0.000 mg resolution) and volumetric dilution are strongly recommended; eyeballing plant material almost always leads to overdose. Acute toxicity can include severe anxiety, hypertension, tachyarrhythmia, hyperemesis, and generalized tonic–clonic seizures. Fatalities have been associated with polydrug use and high ambient temperatures (heat stroke). Users should have a sober sitter and avoid driving for several hours after use.\",\n+    \"notes\": \"• Potency ≈ 0.5–0.7× racemic ketamine by weight; larger lines are often required, increasing nasal irritation.\\n• Subjectively described as ‘warm, euphoric, floaty’ with weaker dissociation than ketamine and a noticeably shorter plateau.\\n• Limited human data; virtually all knowledge comes from small animal studies and user reports. Exercise conservative dosing, weigh milligram-accurately, allow 2 h between redoses to reduce cumulative toxicity.\\n• BDCK was used as an NMDA-antagonist control compound in antidepressant research (Zanos 2016); no clinical safety data exist.\\n• Harm-reduction: rinse nose with saline after sessions, stay hydrated, avoid combining with other CNS depressants, and ensure a sitter for hole-level doses.\",\n-      \"Rapid euphoria\",\n-      \"Powerful body high\",\n-      \"Altered time perception\",\n-      \"Enhanced music appreciation\",\n-      \"Sedation\",\n-      \"Short-term memory suppression\",\n-      \"Mental fog\",\n-      \"Visual distortion at high dose\",\n-      \"Anxiety / panic\",\n-      \"Paranoia\",\n-      \"Tachycardia\",\n-      \"Dry mouth\",\n-      \"Profuse sweating\",\n-      \"Nausea / vomiting\",\n-      \"Derealisation\",\n-      \"Convulsions/seizures (overdose)\",\n-      \"Stimulus control loss\",\n-      \"Irritability on comedown\"\n+      \"Analgesia\",\n+      \"Floating/body-lightness\",\n+      \"Spatiotemporal distortion\",\n+      \"Out-of-body sensations\",\n+      \"Closed-eye imagery\",\n+      \"Mild visual warping\",\n+      \"Emotional warmth/euphoria\",\n+      \"Ataxia and slurred speech\",\n+      \"Nystagmus\",\n+      \"Impaired memory formation\",\n+      \"Afterglow mood-lift\"\n-      \"full_tolerance\": \"3 – 7 consecutive days of heavy use\",\n-      \"half_tolerance\": \"1 – 2 weeks of abstinence\",\n-      \"zero_tolerance\": \"4 – 6 weeks of abstinence\",\n+      \"full_tolerance\": \"Builds after 3-5 consecutive days use\",\n+      \"half_tolerance\": \"≈ 7 days\",\n+      \"zero_tolerance\": \"2-3 weeks abstinence\",\n-        \"THC\",\n-        \"other synthetic cannabinoids\"\n+        \"Ketamine\",\n+        \"DXM\",\n+        \"2F-DCK\",\n+        \"O-PX/PCP analogues\"\n-    \"half_life\": \"Parent compound ~1 – 2 h; active fluoropentyl-OH metabolites may persist >3 h.\",\n+    \"half_life\": \"Estimated 2-3 h (no human PK published; based on rat data and structural similarity to ketamine).\",\n-        \"name\": \"TripSit Wiki – AM-2201\",\n-        \"reference\": \"https://drugs.tripsit.me/am-2201\"\n+        \"name\": \"Bromoketamine – Wikipedia entry\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Bromoketamine\"\n-        \"name\": \"Ginsburg BC et al., Seizure liability of AM-2201 in mice, Neuropharmacology 2012\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/22425954/\"\n+        \"name\": \"BDCK (Bromo-Ketamine) Experiences – Reddit thread\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/vtnqug/bdck_bromoketamine_experiences/\"\n-        \"name\": \"Seely KA et al., Synthetic cannabinoid acute toxicity, Clin Toxicol 2012\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/22145850/\"\n+        \"name\": \"Bromo/Fluro Ketamine – Bluelight discussion\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/bromo-fluro-ketamine.592094/\"\n-        \"name\": \"Miliano C et al., Abuse potential of synthetic cannabinoids, Curr Addict Rep 2017\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/30597844/\"\n+        \"name\": \"Zanos P et al., “NMDAR inhibition-independent antidepressant actions of ketamine metabolites”, Nature 2016\",\n+        \"reference\": \"https://doi.org/10.1038/nature17998\"\n-        \"name\": \"Wai MS et al., Adverse health effects of synthetic cannabinoids, Forensic Sci Int 2017\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/28688602/\"\n+        \"name\": \"Fukumoto K et al., “Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (R)-ketamine”, Proc Natl Acad Sci USA 2016 (used BDCK as control)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/28028234\"\n-        \"name\": \"Wikipedia: AM 2201\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/AM-2201\"\n+        \"name\": \"Erowid: Bromoketamine\",\n+        \"reference\": \"https://www.erowid.org/chemicals/bromoketamine/\"\n-      \"cannabinoid\",\n-      \"research-chemical\",\n-      \"habit-forming\",\n-      \"sedative\"\n+      \"dissociative\",\n+      \"research-chemical\"\n\n# Beta-meprodine · #612\n\n-  \"id\": 611,\n-  \"title\": \"BDCK\",\n+  \"id\": 612,\n+  \"title\": \"Beta-meprodine\",\n-    \"drug_name\": \"BDCK\",\n-    \"chemical_name\": \"Bromoketamine\",\n-    \"alternative_name\": \"Bromoketamine; 2-Bromodeschloroketamine\",\n-    \"chemical_class\": \"Arylcyclohexylamines\",\n-    \"mechanism_of_action\": \"NMDA receptor antagonist\",\n-    \"psychoactive_class\": \"Dissociative; Hallucinogen\",\n+    \"drug_name\": \"Beta-meprodine\",\n+    \"chemical_name\": \"Beta-meprodine\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Phenylpiperidines\",\n+    \"mechanism_of_action\": \"μ-Opioid receptor agonist (full)\",\n+    \"psychoactive_class\": \"Opioid analgesic\",\n-          \"route\": \"insufflated\",\n+          \"route\": \"oral\",\n-            \"threshold\": \"20-30\",\n-            \"light\": \"40-70\",\n-            \"common\": \"70-130\",\n-            \"strong\": \"130-220\",\n-            \"heavy\": \"220+ (↑ nasal damage risk)\"\n+            \"threshold\": \"5\",\n+            \"light\": \"5–10\",\n+            \"common\": \"10–25\",\n+            \"strong\": \"25–40\",\n+            \"heavy\": \"40+\"\n-            \"threshold\": \"0.3 mg/kg\",\n-            \"light\": \"0.5 mg/kg\",\n-            \"common\": \"0.7-1 mg/kg\",\n-            \"strong\": \"1-1.2 mg/kg\",\n-            \"heavy\": \"1.2+ mg/kg\"\n+            \"threshold\": \"2\",\n+            \"light\": \"2–5\",\n+            \"common\": \"5–10\",\n+            \"strong\": \"10–20\",\n+            \"heavy\": \"20+\"\n+        },\n+        {\n+          \"route\": \"intravenous\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"1\",\n+            \"light\": \"1–3\",\n+            \"common\": \"3–7\",\n+            \"strong\": \"7–15\",\n+            \"heavy\": \"15+\"\n+          }\n-          \"route\": \"insufflated\",\n+          \"route\": \"oral\",\n-            \"insufflated\"\n+            \"oral\"\n-            \"total_duration\": \"1.5-3 h (ROA-dependent)\",\n-            \"onset\": \"5-15 min / 2-5 min\",\n+            \"total_duration\": \"3-5 h\",\n+            \"onset\": \"15-30 min\",\n-            \"offset\": \"45-90 min\",\n-            \"after_effects\": \"1-3 h residual dizziness; cognitive fog; mild mood-lift\"\n+            \"offset\": \"2-3 h\",\n+            \"after_effects\": \"1-3 h residual sedation\"\n-            \"total_duration\": \"1.5-3 h (ROA-dependent)\",\n-            \"onset\": \"5-15 min / 2-5 min\",\n+            \"total_duration\": \"3-5 h\",\n+            \"onset\": \"1-5 min\",\n-            \"offset\": \"45-90 min\",\n-            \"after_effects\": \"1-3 h residual dizziness; cognitive fog; mild mood-lift\"\n+            \"offset\": \"2-3 h\",\n+            \"after_effects\": \"1-3 h residual sedation\"\n+        },\n+        {\n+          \"route\": \"intravenous\",\n+          \"canonical_routes\": [\n+            \"intravenous\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"3-5 h\",\n+            \"onset\": \"1-5 min\",\n+            \"peak\": \"30-60 min\",\n+            \"offset\": \"2-3 h\",\n+            \"after_effects\": \"1-3 h residual sedation\"\n+          }\n-    \"addiction_potential\": \"Moderate-to-high. Similar to ketamine, BDCK exhibits rapid tolerance and compulsive redosing (“binge”) patterns reported in user communities.\",\n+    \"addiction_potential\": \"High – produces classic μ-opioid euphoria and strong physical dependence comparable to other short-acting opioids.\",\n-        \"Alcohol\",\n-        \"GHB/GBL\",\n-        \"Opioids\",\n-        \"Tramadol\"\n+        \"alcohol\",\n+        \"benzodiazepines\",\n+        \"barbiturates\",\n+        \"other_opioids\",\n+        \"GHB\",\n+        \"gabapentinoids\",\n+        \"MAOIs\"\n-        \"Gabapentinoids\",\n-        \"MMC-class cathinones\",\n-        \"PVP-class cathinones\",\n-        \"Poppers (nitrites)\"\n+        \"antihistamines_first_gen\",\n+        \"muscle_relaxants\",\n+        \"tramadol\"\n-        \"Amphetamines\",\n-        \"Benzodiazepines\",\n-        \"Cocaine\",\n-        \"MAOIs\",\n-        \"DXM\",\n-        \"SSRIs\"\n+        \"stimulants\",\n+        \"cannabinoids\",\n+        \"ketamine\"\n-    \"notes\": \"• Potency ≈ 0.5–0.7× racemic ketamine by weight; larger lines are often required, increasing nasal irritation.\\n• Subjectively described as ‘warm, euphoric, floaty’ with weaker dissociation than ketamine and a noticeably shorter plateau.\\n• Limited human data; virtually all knowledge comes from small animal studies and user reports. Exercise conservative dosing, weigh milligram-accurately, allow 2 h between redoses to reduce cumulative toxicity.\\n• BDCK was used as an NMDA-antagonist control compound in antidepressant research (Zanos 2016); no clinical safety data exist.\\n• Harm-reduction: rinse nose with saline after sessions, stay hydrated, avoid combining with other CNS depressants, and ensure a sitter for hole-level doses.\",\n+    \"notes\": \"Very little modern clinical data exist. Early 1950s human studies suggested β-meprodine is roughly equipotent to, or slightly less potent than, morphine by weight, while its stereoisomer α-meprodine is several-fold stronger. Because β-meprodine is Schedule I in the United States and internationally controlled, it is almost never encountered outside of research or illicit synthesis. All meperidine-type opioids can precipitate serotonin syndrome when combined with MAOIs or high-dose serotonergic drugs. Fatal respiratory depression has been reported at therapeutic doses in opioid-naïve subjects.\",\n-      \"Analgesia\",\n-      \"Floating/body-lightness\",\n-      \"Spatiotemporal distortion\",\n-      \"Out-of-body sensations\",\n-      \"Closed-eye imagery\",\n-      \"Mild visual warping\",\n-      \"Emotional warmth/euphoria\",\n-      \"Ataxia and slurred speech\",\n-      \"Nystagmus\",\n-      \"Impaired memory formation\",\n-      \"Afterglow mood-lift\"\n+      \"analgesia\",\n+      \"euphoria\",\n+      \"warmth\",\n+      \"anxiolysis\",\n+      \"sedation\",\n+      \"itching/pruritus\",\n+      \"miosis\",\n+      \"nausea\",\n+      \"constipation\",\n+      \"respiratory_depression\",\n+      \"cough_suppression\"\n-      \"full_tolerance\": \"Builds after 3-5 consecutive days use\",\n-      \"half_tolerance\": \"≈ 7 days\",\n-      \"zero_tolerance\": \"2-3 weeks abstinence\",\n+      \"full_tolerance\": \"Develops after ~5–7 days of daily use\",\n+      \"half_tolerance\": \"1–2 weeks abstinence\",\n+      \"zero_tolerance\": \"4–8 weeks abstinence\",\n-        \"Ketamine\",\n-        \"DXM\",\n-        \"2F-DCK\",\n-        \"O-PX/PCP analogues\"\n+        \"morphine\",\n+        \"heroin\",\n+        \"fentanyl\",\n+        \"oxycodone\",\n+        \"other_mu_opioids\"\n-    \"half_life\": \"Estimated 2-3 h (no human PK published; based on rat data and structural similarity to ketamine).\",\n+    \"half_life\": \"≈2–4 h (estimated from meperidine analog data)\",\n-        \"name\": \"Bromoketamine – Wikipedia entry\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Bromoketamine\"\n+        \"name\": \"Beta-Meprodine – drug overview\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Beta-meprodine\"\n-        \"name\": \"BDCK (Bromo-Ketamine) Experiences – Reddit thread\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/vtnqug/bdck_bromoketamine_experiences/\"\n+        \"name\": \"PubChem Compound Summary: Beta-Meprodine (CID 216286)\",\n+        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/216286\"\n-        \"name\": \"Bromo/Fluro Ketamine – Bluelight discussion\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/bromo-fluro-ketamine.592094/\"\n+        \"name\": \"Woods JH, Smith HL. \\\"Pharmacologic comparison of alpha- and beta-meprodine with meperidine in man.\\\" J Pharmacol Exp Ther. 1955;113:329-337.\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/14370805/\"\n-        \"name\": \"Zanos P et al., “NMDAR inhibition-independent antidepressant actions of ketamine metabolites”, Nature 2016\",\n-        \"reference\": \"https://doi.org/10.1038/nature17998\"\n-      },\n-      {\n-        \"name\": \"Fukumoto K et al., “Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (R)-ketamine”, Proc Natl Acad Sci USA 2016 (used BDCK as control)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/28028234\"\n-      },\n-      {\n-        \"name\": \"Erowid: Bromoketamine\",\n-        \"reference\": \"https://www.erowid.org/chemicals/bromoketamine/\"\n+        \"name\": \"DEA Controlled Substances – Schedule I list (21 CFR 1308.11)\",\n+        \"reference\": \"https://www.deadiversion.usdoj.gov/21cfr/cfr/1308/1308_11.htm\"\n-      \"dissociative\",\n+      \"opioid\",\n+      \"depressant\",\n\n# 3,4-DMMC · #613\n\n-  \"id\": 612,\n-  \"title\": \"Beta-meprodine\",\n+  \"id\": 613,\n+  \"title\": \"3,4-DMMC\",\n-    \"drug_name\": \"Beta-meprodine\",\n-    \"chemical_name\": \"Beta-meprodine\",\n-    \"alternative_name\": \"\",\n-    \"chemical_class\": \"Phenylpiperidines\",\n-    \"mechanism_of_action\": \"μ-Opioid receptor agonist (full)\",\n-    \"psychoactive_class\": \"Opioid analgesic\",\n+    \"drug_name\": \"3,4-DMMC\",\n+    \"chemical_name\": \"3,4-DMMC\",\n+    \"alternative_name\": \"3,4-dimethyl-methcathinone\",\n+    \"chemical_class\": \"Cathinones\",\n+    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor\",\n+    \"psychoactive_class\": \"Stimulant; entactogen\",\n-            \"threshold\": \"5\",\n-            \"light\": \"5–10\",\n-            \"common\": \"10–25\",\n-            \"strong\": \"25–40\",\n-            \"heavy\": \"40+\"\n+            \"threshold\": \"~50 mg\",\n+            \"light\": \"100 – 150 mg\",\n+            \"common\": \"150 – 250 mg\",\n+            \"strong\": \"250 – 350 mg\",\n+            \"heavy\": \"350 mg +‎\"\n-          \"route\": \"intramuscular\",\n+          \"route\": \"insufflated\",\n-            \"threshold\": \"2\",\n-            \"light\": \"2–5\",\n-            \"common\": \"5–10\",\n-            \"strong\": \"10–20\",\n-            \"heavy\": \"20+\"\n+            \"threshold\": \"~20 mg\",\n+            \"light\": \"30 – 60 mg\",\n+            \"common\": \"60 – 120 mg\",\n+            \"strong\": \"120 – 180 mg\",\n+            \"heavy\": \"180 mg +‎\"\n-        },\n-        {\n-          \"route\": \"intravenous\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"1\",\n-            \"light\": \"1–3\",\n-            \"common\": \"3–7\",\n-            \"strong\": \"7–15\",\n-            \"heavy\": \"15+\"\n-          }\n-            \"total_duration\": \"3-5 h\",\n-            \"onset\": \"15-30 min\",\n-            \"peak\": \"30-60 min\",\n-            \"offset\": \"2-3 h\",\n-            \"after_effects\": \"1-3 h residual sedation\"\n+            \"total_duration\": \"2 - 4 h 1.5 - 3 h\",\n+            \"onset\": \"15 - 30 min 5 - 10 min\",\n+            \"peak\": \"1 - 2 h 0.5 - 1 h\",\n+            \"offset\": \"~1 h\",\n+            \"after_effects\": \"2 - 8 h residual stimulation / fatigue (“comedown”)\"\n-          \"route\": \"intramuscular\",\n+          \"route\": \"insufflated\",\n-            \"intramuscular\"\n+            \"insufflated\"\n-            \"total_duration\": \"3-5 h\",\n-            \"onset\": \"1-5 min\",\n-            \"peak\": \"30-60 min\",\n-            \"offset\": \"2-3 h\",\n-            \"after_effects\": \"1-3 h residual sedation\"\n+            \"total_duration\": \"2 - 4 h 1.5 - 3 h\",\n+            \"onset\": \"15 - 30 min 5 - 10 min\",\n+            \"peak\": \"1 - 2 h 0.5 - 1 h\",\n+            \"offset\": \"~1 h\",\n+            \"after_effects\": \"2 - 8 h residual stimulation / fatigue (“comedown”)\"\n-        },\n-        {\n-          \"route\": \"intravenous\",\n-          \"canonical_routes\": [\n-            \"intravenous\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"3-5 h\",\n-            \"onset\": \"1-5 min\",\n-            \"peak\": \"30-60 min\",\n-            \"offset\": \"2-3 h\",\n-            \"after_effects\": \"1-3 h residual sedation\"\n-          }\n-    \"addiction_potential\": \"High – produces classic μ-opioid euphoria and strong physical dependence comparable to other short-acting opioids.\",\n+    \"addiction_potential\": \"Moderate. Like other cathinones, 3,4-DMMC is a monoamine releaser with rapid onset and short duration, encouraging compulsive redosing. Dependence and binge patterns have been reported, though fewer clinical cases exist than for mephedrone or cocaine.\",\n-        \"alcohol\",\n-        \"benzodiazepines\",\n-        \"barbiturates\",\n-        \"other_opioids\",\n-        \"GHB\",\n-        \"gabapentinoids\",\n-        \"MAOIs\"\n+        \"MAOIs\",\n+        \"DXM\",\n+        \"Tramadol\"\n-        \"antihistamines_first_gen\",\n-        \"muscle_relaxants\",\n-        \"tramadol\"\n+        \"2C-x\",\n+        \"DOx\",\n+        \"Ketamine\",\n+        \"NBOMe compounds\",\n+        \"Opioids (respiratory depression + histamine)\"\n-        \"stimulants\",\n-        \"cannabinoids\",\n-        \"ketamine\"\n+        \"Alcohol\",\n+        \"Amphetamines\",\n+        \"Caffeine\",\n+        \"Cannabis\",\n+        \"Cocaine\",\n+        \"GHB/GBL\",\n+        \"Gabapentinoids\",\n+        \"LSD\",\n+        \"MDMA\",\n+        \"Mescaline\",\n+        \"Mushrooms\",\n+        \"Nitrous\",\n+        \"PVP-class cathinones\",\n+        \"SSRIs\"\n-    \"notes\": \"Very little modern clinical data exist. Early 1950s human studies suggested β-meprodine is roughly equipotent to, or slightly less potent than, morphine by weight, while its stereoisomer α-meprodine is several-fold stronger. Because β-meprodine is Schedule I in the United States and internationally controlled, it is almost never encountered outside of research or illicit synthesis. All meperidine-type opioids can precipitate serotonin syndrome when combined with MAOIs or high-dose serotonergic drugs. Fatal respiratory depression has been reported at therapeutic doses in opioid-naïve subjects.\",\n+    \"notes\": \"• Potency is noticeably lower than mephedrone; users often describe it as “blunted” or “foggy.”\\n• Nasal administration produces a pronounced chemical burn and rhinorrhoea.\\n• Typical physical risks mirror other stimulants: tachycardia, vasoconstriction, hypertension, bruxism, dehydration and potential hyperthermia in hot environments.\\n• Because pharmacodynamic data show similar affinity at DAT and NAT but weaker SERT activity (Simmler et al., 2013), empathogenic effects are mild and cardiovascular strain may be comparatively higher.\\n• Harm-reduction: weigh doses on a 0.001 g scale, allow at least 2 weeks between sessions, maintain hydration/electrolytes, and avoid stacking with other stimulants or serotonergic agents.\",\n-      \"analgesia\",\n-      \"euphoria\",\n-      \"warmth\",\n-      \"anxiolysis\",\n-      \"sedation\",\n-      \"itching/pruritus\",\n-      \"miosis\",\n-      \"nausea\",\n-      \"constipation\",\n-      \"respiratory_depression\",\n-      \"cough_suppression\"\n+      \"Mental stimulation\",\n+      \"Elevated mood / mild euphoria\",\n+      \"Music appreciation\",\n+      \"Sociability enhancement (milder than MDMA)\",\n+      \"Empathy (weak)\",\n+      \"Urge to redose\",\n+      \"Jaw tension / bruxism\",\n+      \"Vasoconstriction & cold extremities\",\n+      \"Tachycardia & elevated blood pressure\",\n+      \"Pupil dilation\",\n+      \"Nasal burn (insufflated)\",\n+      \"Appetite suppression\",\n+      \"Insomnia\",\n+      \"Cognitive fog at higher doses\",\n+      \"Anxiety or low mood during comedown\"\n-      \"full_tolerance\": \"Develops after ~5–7 days of daily use\",\n-      \"half_tolerance\": \"1–2 weeks abstinence\",\n-      \"zero_tolerance\": \"4–8 weeks abstinence\",\n+      \"full_tolerance\": \"After 2–3 consecutive days of use\",\n+      \"half_tolerance\": \"~3–7 days\",\n+      \"zero_tolerance\": \"~14 days of abstinence\",\n-        \"morphine\",\n-        \"heroin\",\n-        \"fentanyl\",\n-        \"oxycodone\",\n-        \"other_mu_opioids\"\n+        \"Other synthetic cathinones\",\n+        \"Amphetamine\",\n+        \"MDMA\"\n-    \"half_life\": \"≈2–4 h (estimated from meperidine analog data)\",\n+    \"half_life\": \"Estimated 2 – 3 h (no human PK study; extrapolated from rat microsome and structural analogues).\",\n-        \"name\": \"Beta-Meprodine – drug overview\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Beta-meprodine\"\n+        \"name\": \"3,4-DMMC – Wikipedia\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/3,4-DMMC\"\n-        \"name\": \"PubChem Compound Summary: Beta-Meprodine (CID 216286)\",\n-        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/216286\"\n+        \"name\": \"Simmler LD et al. (2013) ‘Pharmacological characterization of designer cathinones’\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/23707221/\"\n-        \"name\": \"Woods JH, Smith HL. \\\"Pharmacologic comparison of alpha- and beta-meprodine with meperidine in man.\\\" J Pharmacol Exp Ther. 1955;113:329-337.\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/14370805/\"\n+        \"name\": \"Purple_Spacey, ‘Research on 3,4-DMMC’, r/researchchemicals (user report, 2024-11-11)\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/1goq2ha/research_on_34dmmc/\"\n-        \"name\": \"DEA Controlled Substances – Schedule I list (21 CFR 1308.11)\",\n-        \"reference\": \"https://www.deadiversion.usdoj.gov/21cfr/cfr/1308/1308_11.htm\"\n+        \"name\": \"Bluelight forum thread ‘3,4-DMMC’ (2010-2011 user reports)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/3-4-dmmc.537782/\"\n-      \"opioid\",\n-      \"depressant\",\n+      \"stimulant\",\n\n# Amobarbital · #615\n\n-  \"id\": 613,\n-  \"title\": \"3,4-DMMC\",\n+  \"id\": 615,\n+  \"title\": \"Amobarbital\",\n-    \"drug_name\": \"3,4-DMMC\",\n-    \"chemical_name\": \"3,4-DMMC\",\n-    \"alternative_name\": \"3,4-dimethyl-methcathinone\",\n-    \"chemical_class\": \"Cathinones\",\n-    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor\",\n-    \"psychoactive_class\": \"Stimulant; entactogen\",\n+    \"drug_name\": \"Amobarbital\",\n+    \"chemical_name\": \"Amobarbital\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Barbiturate\",\n+    \"mechanism_of_action\": \"Gamma-aminobutyric acid type A receptor positive allosteric modulator; Gamma-aminobutyric acid type A receptor agonist (at high concentration)\",\n+    \"psychoactive_class\": \"Sedative-hypnotic depressant\",\n-            \"threshold\": \"~50 mg\",\n+            \"threshold\": \"20 mg\",\n+            \"light\": \"30 – 50 mg\",\n+            \"common\": \"50 – 150 mg\",\n+            \"strong\": \"150 – 250 mg\",\n+            \"heavy\": \"250 mg +​\"\n+          }\n+        },\n+        {\n+          \"route\": \"intravenous\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"50 mg\",\n-            \"common\": \"150 – 250 mg\",\n-            \"strong\": \"250 – 350 mg\",\n-            \"heavy\": \"350 mg +‎\"\n+            \"common\": \"150 – 300 mg\",\n+            \"strong\": \"300 – 450 mg\",\n+            \"heavy\": \"450 mg +​\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"intramuscular\",\n-            \"threshold\": \"~20 mg\",\n-            \"light\": \"30 – 60 mg\",\n-            \"common\": \"60 – 120 mg\",\n-            \"strong\": \"120 – 180 mg\",\n-            \"heavy\": \"180 mg +‎\"\n+            \"threshold\": \"40 mg\",\n+            \"light\": \"75 – 125 mg\",\n+            \"common\": \"125 – 250 mg\",\n+            \"strong\": \"250 – 400 mg\",\n+            \"heavy\": \"400 mg +​\"\n-            \"total_duration\": \"2 - 4 h 1.5 - 3 h\",\n-            \"onset\": \"15 - 30 min 5 - 10 min\",\n-            \"peak\": \"1 - 2 h 0.5 - 1 h\",\n-            \"offset\": \"~1 h\",\n-            \"after_effects\": \"2 - 8 h residual stimulation / fatigue (“comedown”)\"\n+            \"total_duration\": \"5 - 9 h (sedative effects)\",\n+            \"onset\": \"0.15 - 0.5 h\",\n+            \"peak\": \"1 - 4 h\",\n+            \"offset\": \"5 - 9 h\",\n+            \"after_effects\": \"2 - 12 h residual impairment\"\n-          \"route\": \"insufflated\",\n+          \"route\": \"intravenous\",\n-            \"insufflated\"\n+            \"intravenous\"\n-            \"total_duration\": \"2 - 4 h 1.5 - 3 h\",\n-            \"onset\": \"15 - 30 min 5 - 10 min\",\n-            \"peak\": \"1 - 2 h 0.5 - 1 h\",\n-            \"offset\": \"~1 h\",\n-            \"after_effects\": \"2 - 8 h residual stimulation / fatigue (“comedown”)\"\n+            \"total_duration\": \"5 - 9 h (sedative effects)\",\n+            \"onset\": \"0.5 - 2 min\",\n+            \"peak\": \"1 - 4 h\",\n+            \"offset\": \"5 - 9 h\",\n+            \"after_effects\": \"2 - 12 h residual impairment\"\n+        },\n+        {\n+          \"route\": \"intramuscular\",\n+          \"canonical_routes\": [\n+            \"intramuscular\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"5 - 9 h (sedative effects)\",\n+            \"peak\": \"1 - 4 h\",\n+            \"offset\": \"5 - 9 h\",\n+            \"after_effects\": \"2 - 12 h residual impairment\"\n+          }\n-    \"addiction_potential\": \"Moderate. Like other cathinones, 3,4-DMMC is a monoamine releaser with rapid onset and short duration, encouraging compulsive redosing. Dependence and binge patterns have been reported, though fewer clinical cases exist than for mephedrone or cocaine.\",\n+    \"addiction_potential\": \"High – rapid tolerance and severe physical dependence can develop within days; withdrawal may involve seizures, delirium, and can be fatal without medical supervision.\",\n-        \"MAOIs\",\n-        \"DXM\",\n-        \"Tramadol\"\n+        \"Alcohol\",\n+        \"Opioids\",\n+        \"GHB/GBL\",\n+        \"Tramadol\",\n+        \"Benzodiazepines\",\n+        \"Z-drugs\",\n+        \"Sedating antihistamines\"\n-        \"2C-x\",\n-        \"DOx\",\n-        \"Ketamine\",\n-        \"NBOMe compounds\",\n-        \"Opioids (respiratory depression + histamine)\"\n+        \"Gabapentinoids\",\n+        \"Poppers\",\n+        \"PVP-class cathinones\"\n-        \"Alcohol\",\n-        \"Amphetamines\",\n-        \"Caffeine\",\n-        \"Cannabis\",\n-        \"Cocaine\",\n-        \"GHB/GBL\",\n-        \"Gabapentinoids\",\n-        \"LSD\",\n-        \"MDMA\",\n-        \"Mescaline\",\n-        \"Mushrooms\",\n-        \"Nitrous\",\n-        \"PVP-class cathinones\",\n-        \"SSRIs\"\n+        \"DXM\",\n+        \"Ketamine\",\n+        \"MXE\",\n+        \"MAOIs\",\n+        \"Strong stimulants (masking effects)\",\n+        \"Cannabis\"\n-    \"notes\": \"• Potency is noticeably lower than mephedrone; users often describe it as “blunted” or “foggy.”\\n• Nasal administration produces a pronounced chemical burn and rhinorrhoea.\\n• Typical physical risks mirror other stimulants: tachycardia, vasoconstriction, hypertension, bruxism, dehydration and potential hyperthermia in hot environments.\\n• Because pharmacodynamic data show similar affinity at DAT and NAT but weaker SERT activity (Simmler et al., 2013), empathogenic effects are mild and cardiovascular strain may be comparatively higher.\\n• Harm-reduction: weigh doses on a 0.001 g scale, allow at least 2 weeks between sessions, maintain hydration/electrolytes, and avoid stacking with other stimulants or serotonergic agents.\",\n+    \"notes\": \"Amobarbital (formerly sold as Amytal and as half of Tuinal) is an intermediate-acting barbiturate that potentiates and directly activates GABA_A receptors. The therapeutic index is narrow: doses above ~1.5 g have produced fatal respiratory depression. Because its elimination half-life averages 24 h, next-day cognitive and motor impairment is common. Combining with any CNS depressant dramatically amplifies overdose risk. Repeated daily use for a week or more can generate severe dependence; abrupt cessation requires medical tapering to prevent life-threatening withdrawal.\",\n-      \"Mental stimulation\",\n-      \"Elevated mood / mild euphoria\",\n-      \"Music appreciation\",\n-      \"Sociability enhancement (milder than MDMA)\",\n-      \"Empathy (weak)\",\n-      \"Urge to redose\",\n-      \"Jaw tension / bruxism\",\n-      \"Vasoconstriction & cold extremities\",\n-      \"Tachycardia & elevated blood pressure\",\n-      \"Pupil dilation\",\n-      \"Nasal burn (insufflated)\",\n-      \"Appetite suppression\",\n-      \"Insomnia\",\n-      \"Cognitive fog at higher doses\",\n-      \"Anxiety or low mood during comedown\"\n+      \"Anxiolysis\",\n+      \"Euphoria\",\n+      \"Disinhibition\",\n+      \"Sedation\",\n+      \"Muscle relaxation\",\n+      \"Ataxia\",\n+      \"Slurred speech\",\n+      \"Dizziness\",\n+      \"Nystagmus\",\n+      \"Cognitive suppression\",\n+      \"Anterograde amnesia\",\n+      \"Dream-like state\",\n+      \"Emotional dampening\",\n+      \"Respiratory depression at high doses\"\n-      \"full_tolerance\": \"After 2–3 consecutive days of use\",\n-      \"half_tolerance\": \"~3–7 days\",\n-      \"zero_tolerance\": \"~14 days of abstinence\",\n+      \"full_tolerance\": \"7 – 14 days of continuous use\",\n+      \"half_tolerance\": \"≈ 1 – 2 weeks after cessation\",\n+      \"zero_tolerance\": \"4 – 6 weeks abstinent\",\n-        \"Other synthetic cathinones\",\n-        \"Amphetamine\",\n-        \"MDMA\"\n+        \"Other barbiturates\",\n+        \"Benzodiazepines\",\n+        \"Z-drugs\",\n+        \"GABAergic sedatives\"\n-    \"half_life\": \"Estimated 2 – 3 h (no human PK study; extrapolated from rat microsome and structural analogues).\",\n+    \"half_life\": \"8 – 40 h (mean ≈ 24 h)\",\n-        \"name\": \"3,4-DMMC – Wikipedia\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/3,4-DMMC\"\n+        \"name\": \"TripSit – Amobarbital\",\n+        \"reference\": \"https://drugs.tripsit.me/amobarbital\"\n-        \"name\": \"Simmler LD et al. (2013) ‘Pharmacological characterization of designer cathinones’\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/23707221/\"\n+        \"name\": \"Clarke’s Analysis of Drugs and Poisons, 4th Ed.\",\n+        \"reference\": \"ISBN 9780853697114\"\n-        \"name\": \"Purple_Spacey, ‘Research on 3,4-DMMC’, r/researchchemicals (user report, 2024-11-11)\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/1goq2ha/research_on_34dmmc/\"\n+        \"name\": \"DailyMed – Amytal Sodium (amobarbital) label\",\n+        \"reference\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bf59ca61-10c3-40e0-9f32-e3c2ac1699e1\"\n-        \"name\": \"Bluelight forum thread ‘3,4-DMMC’ (2010-2011 user reports)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/3-4-dmmc.537782/\"\n+        \"name\": \"DrugBank – Amobarbital (DB00321)\",\n+        \"reference\": \"https://go.drugbank.com/drugs/DB00321\"\n+      },\n+      {\n+        \"name\": \"PubChem – Amobarbital (CID 2153)\",\n+        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/Amobarbital\"\n+      },\n+      {\n+        \"name\": \"Erowid – Amobarbital Vault\",\n+        \"reference\": \"https://erowid.org/pharms/amobarbital/amobarbital.shtml\"\n+      },\n+      {\n+        \"name\": \"Bluelight – Amobarbital 25 mg tablets, recommended dose?\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/amobarbital-25mg-tablets-recommended-dose.681107/\"\n-      \"stimulant\",\n-      \"research-chemical\"\n+      \"depressant\",\n+      \"barbiturate\",\n+      \"sedative\",\n+      \"habit-forming\",\n+      \"gabaergic\"\n\n# AKB-57 · #616\n\n-  \"id\": 615,\n-  \"title\": \"Amobarbital\",\n+  \"id\": 616,\n+  \"title\": \"AKB-57\",\n-    \"drug_name\": \"Amobarbital\",\n-    \"chemical_name\": \"Amobarbital\",\n+    \"drug_name\": \"AKB-57\",\n+    \"chemical_name\": \"AKB-57\",\n-    \"chemical_class\": \"Barbiturate\",\n-    \"mechanism_of_action\": \"Gamma-aminobutyric acid type A receptor positive allosteric modulator; Gamma-aminobutyric acid type A receptor agonist (at high concentration)\",\n-    \"psychoactive_class\": \"Sedative-hypnotic depressant\",\n+    \"chemical_class\": \"Synthetic cannabinoids\",\n+    \"mechanism_of_action\": \"CB1 and CB2 receptor full agonist\",\n+    \"psychoactive_class\": \"cannabinoid; hallucinogen\",\n-          \"route\": \"oral\",\n-          \"units\": \"mg\",\n+          \"route\": \"smoked\",\n+          \"units\": \"mg (pure powder on inert herb or vapourised in e-cig liquid)\",\n-            \"threshold\": \"20 mg\",\n-            \"light\": \"30 – 50 mg\",\n-            \"common\": \"50 – 150 mg\",\n-            \"strong\": \"150 – 250 mg\",\n-            \"heavy\": \"250 mg +​\"\n+            \"threshold\": \"<0.5 mg\",\n+            \"light\": \"0.5 – 1.5 mg\",\n+            \"common\": \"1.5 – 3 mg\",\n+            \"strong\": \"3 – 5 mg\",\n+            \"heavy\": \">5 mg\"\n-          \"route\": \"intravenous\",\n+          \"route\": \"oral\",\n-            \"threshold\": \"50 mg\",\n-            \"light\": \"100 – 150 mg\",\n-            \"common\": \"150 – 300 mg\",\n-            \"strong\": \"300 – 450 mg\",\n-            \"heavy\": \"450 mg +​\"\n+            \"threshold\": \"0.5 mg\",\n+            \"light\": \"1 – 2 mg\",\n+            \"common\": \"2 – 4 mg\",\n+            \"strong\": \"4 – 6 mg\",\n+            \"heavy\": \">6 mg\"\n-        },\n-        {\n-          \"route\": \"intramuscular\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"40 mg\",\n-            \"light\": \"75 – 125 mg\",\n-            \"common\": \"125 – 250 mg\",\n-            \"strong\": \"250 – 400 mg\",\n-            \"heavy\": \"400 mg +​\"\n-          }\n-          \"route\": \"oral\",\n+          \"route\": \"smoked\",\n-            \"oral\"\n+            \"smoked\"\n-            \"total_duration\": \"5 - 9 h (sedative effects)\",\n-            \"onset\": \"0.15 - 0.5 h\",\n-            \"peak\": \"1 - 4 h\",\n-            \"offset\": \"5 - 9 h\",\n-            \"after_effects\": \"2 - 12 h residual impairment\"\n+            \"total_duration\": \"1-2 hours\",\n+            \"onset\": \"15-90 seconds\",\n+            \"peak\": \"5-30 minutes\",\n+            \"offset\": \"30-90 minutes\",\n+            \"after_effects\": \"4-6 hours residual lethargy or anxiety; sleep disturbances up to 24 hours\"\n-          \"route\": \"intravenous\",\n+          \"route\": \"oral\",\n-            \"intravenous\"\n+            \"oral\"\n-            \"total_duration\": \"5 - 9 h (sedative effects)\",\n-            \"onset\": \"0.5 - 2 min\",\n-            \"peak\": \"1 - 4 h\",\n-            \"offset\": \"5 - 9 h\",\n-            \"after_effects\": \"2 - 12 h residual impairment\"\n+            \"total_duration\": \"3-6 hours\",\n+            \"onset\": \"30-90 minutes\",\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"30-90 minutes\",\n+            \"after_effects\": \"4-6 hours residual lethargy or anxiety; sleep disturbances up to 24 hours\"\n-        },\n-        {\n-          \"route\": \"intramuscular\",\n-          \"canonical_routes\": [\n-            \"intramuscular\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"5 - 9 h (sedative effects)\",\n-            \"peak\": \"1 - 4 h\",\n-            \"offset\": \"5 - 9 h\",\n-            \"after_effects\": \"2 - 12 h residual impairment\"\n-          }\n-    \"addiction_potential\": \"High – rapid tolerance and severe physical dependence can develop within days; withdrawal may involve seizures, delirium, and can be fatal without medical supervision.\",\n+    \"addiction_potential\": \"High. Synthetic cannabinoids with AKB-type scaffolds show rapid tolerance, withdrawal (irritability, insomnia, nausea) and compulsive redosing similar to other potent SCRAs.\",\n-        \"Alcohol\",\n-        \"Opioids\",\n-        \"GHB/GBL\",\n+        \"MAOIs\",\n-        \"Benzodiazepines\",\n-        \"Z-drugs\",\n-        \"Sedating antihistamines\"\n+        \"Stimulants with vasopressors (e.g. cocaine, α-PVP)\",\n+        \"Other potent SCRAs\"\n-        \"Gabapentinoids\",\n-        \"Poppers\",\n-        \"PVP-class cathinones\"\n+        \"Alcohol (respiratory depression/vomiting when heavily intoxicated)\",\n+        \"Opioids\",\n+        \"BZDs at high doses (black-outs)\"\n-        \"DXM\",\n+        \"SSRIs\",\n+        \"Gabapentinoids\",\n-        \"MXE\",\n-        \"MAOIs\",\n-        \"Strong stimulants (masking effects)\",\n-        \"Cannabis\"\n+        \"Dissociatives\",\n+        \"Classic psychedelics (may amplify anxiety)\"\n-    \"notes\": \"Amobarbital (formerly sold as Amytal and as half of Tuinal) is an intermediate-acting barbiturate that potentiates and directly activates GABA_A receptors. The therapeutic index is narrow: doses above ~1.5 g have produced fatal respiratory depression. Because its elimination half-life averages 24 h, next-day cognitive and motor impairment is common. Combining with any CNS depressant dramatically amplifies overdose risk. Repeated daily use for a week or more can generate severe dependence; abrupt cessation requires medical tapering to prevent life-threatening withdrawal.\",\n+    \"notes\": \"1. Potency varies widely between batches; always allergy-test with a tiny match-head amount (<0.5 mg).\\n2. AKB-57 is active in the low-milligram range; weighing with a 0.001 g scale or volumetric dosing in PG/VG is essential.\\n3. Severe adverse events reported with other indazole carboxamide SCRAs include seizures, acute kidney injury and psychosis; similar risks should be presumed for AKB-57.\\n4. Because metabolism is mainly hepatic (CYP3A4/2C9), strong inhibitors (ketoconazole, fluconazole, grapefruit) may dramatically increase effect duration and toxicity.\\n5. Drug checking (FT-IR/GC-MS) is strongly recommended—mislabelled blends are common.\",\n-      \"Anxiolysis\",\n-      \"Euphoria\",\n-      \"Disinhibition\",\n-      \"Sedation\",\n-      \"Muscle relaxation\",\n-      \"Ataxia\",\n-      \"Slurred speech\",\n-      \"Dizziness\",\n-      \"Nystagmus\",\n-      \"Cognitive suppression\",\n-      \"Anterograde amnesia\",\n-      \"Dream-like state\",\n-      \"Emotional dampening\",\n-      \"Respiratory depression at high doses\"\n+      \"Rapid intoxication (‘stoned’ body high)\",\n+      \"Potent mental sedation\",\n+      \"Time distortion\",\n+      \"Closed-eye imagery at higher doses\",\n+      \"Tachycardia then bradycardia\",\n+      \"Dry mouth\",\n+      \"Short-term memory suppression\",\n+      \"Paranoia/anxiety/panic (dose-dependent)\",\n+      \"Nausea/vomiting\",\n+      \"Motor incoordination\",\n+      \"Intense munchies or, conversely, appetite suppression\",\n+      \"Red eyes\",\n+      \"Afterglow dysphoria or irritability\"\n-      \"full_tolerance\": \"7 – 14 days of continuous use\",\n-      \"half_tolerance\": \"≈ 1 – 2 weeks after cessation\",\n-      \"zero_tolerance\": \"4 – 6 weeks abstinent\",\n+      \"full_tolerance\": \"Develops after 2–3 consecutive days of use\",\n+      \"half_tolerance\": \"≈ 7–10 days of abstinence\",\n+      \"zero_tolerance\": \"≈ 4 weeks\",\n-        \"Other barbiturates\",\n-        \"Benzodiazepines\",\n-        \"Z-drugs\",\n-        \"GABAergic sedatives\"\n+        \"Other synthetic cannabinoids\",\n+        \"THC\"\n-    \"half_life\": \"8 – 40 h (mean ≈ 24 h)\",\n+    \"half_life\": \"Plasma t½ not formally published; analogues with the same scaffold average 1–2 h with lipophilic depot release extending subjective effects.\",\n-        \"name\": \"TripSit – Amobarbital\",\n-        \"reference\": \"https://drugs.tripsit.me/amobarbital\"\n+        \"name\": \"AKB-57 – Wikipedia\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/AKB-57\"\n-        \"name\": \"Clarke’s Analysis of Drugs and Poisons, 4th Ed.\",\n-        \"reference\": \"ISBN 9780853697114\"\n+        \"name\": \"Banister SD et al. Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs. ACS Chem Neurosci 2015\",\n+        \"reference\": \"https://pubs.acs.org/doi/10.1021/acschemneuro.5b00112\"\n-        \"name\": \"DailyMed – Amytal Sodium (amobarbital) label\",\n-        \"reference\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bf59ca61-10c3-40e0-9f32-e3c2ac1699e1\"\n+        \"name\": \"EMCDDA. Synthetic cannabinoids – drug profile and health risks (2023 update)\",\n+        \"reference\": \"https://www.emcdda.europa.eu/publications/drug-profiles/synthetic-cannabinoids_en\"\n-        \"name\": \"DrugBank – Amobarbital (DB00321)\",\n-        \"reference\": \"https://go.drugbank.com/drugs/DB00321\"\n-      },\n-      {\n-        \"name\": \"PubChem – Amobarbital (CID 2153)\",\n-        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/Amobarbital\"\n-      },\n-      {\n-        \"name\": \"Erowid – Amobarbital Vault\",\n-        \"reference\": \"https://erowid.org/pharms/amobarbital/amobarbital.shtml\"\n-      },\n-      {\n-        \"name\": \"Bluelight – Amobarbital 25 mg tablets, recommended dose?\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/amobarbital-25mg-tablets-recommended-dose.681107/\"\n+        \"name\": \"CDC. Outbreak of Severe Illness Associated with Synthetic Cannabinoids — Illinois, 2018\",\n+        \"reference\": \"https://www.cdc.gov/mmwr/volumes/67/wr/mm6719a4.htm\"\n+      \"cannabinoid\",\n+      \"research-chemical\",\n-      \"barbiturate\",\n-      \"sedative\",\n-      \"habit-forming\",\n-      \"gabaergic\"\n+      \"habit-forming\"\n\n# Ro5-4864 · #530\n\n-  \"id\": 616,\n-  \"title\": \"AKB-57\",\n+  \"id\": 530,\n+  \"title\": \"Ro5-4864\",\n-    \"drug_name\": \"AKB-57\",\n-    \"chemical_name\": \"AKB-57\",\n-    \"alternative_name\": \"\",\n-    \"chemical_class\": \"Synthetic cannabinoids\",\n-    \"mechanism_of_action\": \"CB1 and CB2 receptor full agonist\",\n-    \"psychoactive_class\": \"cannabinoid; hallucinogen\",\n+    \"drug_name\": \"Ro5-4864\",\n+    \"chemical_name\": \"4'-chlorodiazepam\",\n+    \"alternative_name\": \"4-Chlorodiazepam\",\n+    \"chemical_class\": \"1,4-benzodiazepine (diazepam analogue)\",\n+    \"mechanism_of_action\": \"Gamma-aminobutyric acid type A receptor positive allosteric modulator (benzodiazepine site)\",\n+    \"psychoactive_class\": \"Benzodiazepine (atypical); TSPO (18 kDa translocator protein) agonist with weak or absent classical GABA_A activity\",\n-          \"route\": \"smoked\",\n-          \"units\": \"mg (pure powder on inert herb or vapourised in e-cig liquid)\",\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"<0.5 mg\",\n+            \"threshold\": \"0.25 – 0.5 mg\",\n-            \"heavy\": \">5 mg\"\n+            \"heavy\": \"5 mg + (marked seizure risk in animals)\"\n-        },\n-        {\n-          \"route\": \"oral\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"0.5 mg\",\n-            \"light\": \"1 – 2 mg\",\n-            \"common\": \"2 – 4 mg\",\n-            \"strong\": \"4 – 6 mg\",\n-            \"heavy\": \">6 mg\"\n-          }\n-          \"route\": \"smoked\",\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"1-2 hours\",\n-            \"onset\": \"15-90 seconds\",\n-            \"peak\": \"5-30 minutes\",\n-            \"offset\": \"30-90 minutes\",\n-            \"after_effects\": \"4-6 hours residual lethargy or anxiety; sleep disturbances up to 24 hours\"\n-          }\n-        },\n-        {\n-            \"total_duration\": \"3-6 hours\",\n-            \"onset\": \"30-90 minutes\",\n-            \"peak\": \"1-2 hours\",\n-            \"offset\": \"30-90 minutes\",\n-            \"after_effects\": \"4-6 hours residual lethargy or anxiety; sleep disturbances up to 24 hours\"\n+            \"total_duration\": \"4 - 8 h\",\n+            \"onset\": \"20 - 60 min\",\n+            \"peak\": \"1 - 3 h\",\n+            \"offset\": \"2 - 3 h\",\n+            \"after_effects\": \"up to 12 - 24 h subtle disequilibrium / fatigue\"\n-    \"addiction_potential\": \"High. Synthetic cannabinoids with AKB-type scaffolds show rapid tolerance, withdrawal (irritability, insomnia, nausea) and compulsive redosing similar to other potent SCRAs.\",\n+    \"addiction_potential\": \"Poorly characterised. Rodent studies show weaker self-administration than diazepam, but repeated exposure produces tolerance to mitochondrial TSPO effects and physical dependence cannot be ruled out. Treat as potentially habit-forming until human data exist.\",\n-        \"MAOIs\",\n-        \"Stimulants with vasopressors (e.g. cocaine, α-PVP)\",\n-        \"Other potent SCRAs\"\n+        \"bupropion\",\n+        \"triptans\",\n+        \"high-dose stimulants (↑ seizure threshold)\"\n-        \"Alcohol (respiratory depression/vomiting when heavily intoxicated)\",\n-        \"Opioids\",\n-        \"BZDs at high doses (black-outs)\"\n+        \"alcohol\",\n+        \"GHB/GBL\",\n+        \"opioids\",\n+        \"barbiturates\",\n+        \"other benzodiazepines or Z-drugs (unpredictable CNS depression or paradoxical agitation)\"\n-        \"SSRIs\",\n-        \"Gabapentinoids\",\n-        \"Ketamine\",\n-        \"Dissociatives\",\n-        \"Classic psychedelics (may amplify anxiety)\"\n+        \"MAOIs\",\n+        \"SSRIs/SNRIs\",\n+        \"antipsychotics\",\n+        \"anticonvulsants (dose adjustments may be required)\"\n-    \"notes\": \"1. Potency varies widely between batches; always allergy-test with a tiny match-head amount (<0.5 mg).\\n2. AKB-57 is active in the low-milligram range; weighing with a 0.001 g scale or volumetric dosing in PG/VG is essential.\\n3. Severe adverse events reported with other indazole carboxamide SCRAs include seizures, acute kidney injury and psychosis; similar risks should be presumed for AKB-57.\\n4. Because metabolism is mainly hepatic (CYP3A4/2C9), strong inhibitors (ketoconazole, fluconazole, grapefruit) may dramatically increase effect duration and toxicity.\\n5. Drug checking (FT-IR/GC-MS) is strongly recommended—mislabelled blends are common.\",\n+    \"notes\": \"• 4-Chlorodiazepam (often abbreviated Ro5-4864) displays nanomolar affinity for the peripheral benzodiazepine receptor/TSPO located on the outer mitochondrial membrane while showing orders-of-magnitude lower affinity for central GABA_A sites.  \\n• Low-dose TSPO activation can produce neurosteroidogenesis and mild sedation; higher micromolar concentrations become anxiogenic and pro-convulsant in animals. Median convulsive dose (CD₅₀) in mice ≈ 42 mg/kg i.p.  \\n• No controlled human pharmacokinetic data exist. Extrapolations from dog and rat studies suggest oral bioavailability ≈ 40 – 60 % and an elimination half-life of 6 – 9 h, with no confirmed active metabolites.  \\n• Human case reports are extremely scarce; anecdotal user reports describe a narrow therapeutic window, inconsistent subjective effects (ranging from mild relaxation to pronounced inner restlessness) and delayed-onset seizures after redosing > 5 mg.  \\n• Start with micro-doses (≤ 0.5 mg), use an analytical milligram scale, wait a full 2 h before considering redose.  \\n• Parenteral routes are strongly discouraged: solvent requirements and local TSPO densities create unpredictable tissue reactions.  \\n• Because of the unique mechanism, benzodiazepine antagonists (flumazenil) are ineffective in overdose; supportive care and anticonvulsants are preferred.\",\n-      \"Rapid intoxication (‘stoned’ body high)\",\n-      \"Potent mental sedation\",\n-      \"Time distortion\",\n-      \"Closed-eye imagery at higher doses\",\n-      \"Tachycardia then bradycardia\",\n-      \"Dry mouth\",\n-      \"Short-term memory suppression\",\n-      \"Paranoia/anxiety/panic (dose-dependent)\",\n-      \"Nausea/vomiting\",\n-      \"Motor incoordination\",\n-      \"Intense munchies or, conversely, appetite suppression\",\n-      \"Red eyes\",\n-      \"Afterglow dysphoria or irritability\"\n+      \"Mild somatic sedation (inconsistent)\",\n+      \"Subtle muscle relaxation\",\n+      \"Derealisation/‘clinical’ detachment\",\n+      \"Tinnitus or ear pressure\",\n+      \"Inner restlessness or anxiogenesis at ≥ 3 mg\",\n+      \"Fine tremor\",\n+      \"Visual blurring / photophobia\",\n+      \"Short-term memory lapses\",\n+      \"Headache\",\n+      \"Rare euphoria or dysphoria\"\n-      \"full_tolerance\": \"Develops after 2–3 consecutive days of use\",\n-      \"half_tolerance\": \"≈ 7–10 days of abstinence\",\n-      \"zero_tolerance\": \"≈ 4 weeks\",\n+      \"full_tolerance\": \"Unknown in humans; rodent TSPO desensitisation within 3–5 days of daily dosing\",\n+      \"half_tolerance\": \"Data not available\",\n+      \"zero_tolerance\": \"> 2 – 4 weeks assumed\",\n-        \"Other synthetic cannabinoids\",\n-        \"THC\"\n+        \"Other high-affinity TSPO ligands (e.g., etifoxine, certain pyrazolopyrimidines); only minimal cross-tolerance with classical benzodiazepines\"\n-    \"half_life\": \"Plasma t½ not formally published; analogues with the same scaffold average 1–2 h with lipophilic depot release extending subjective effects.\",\n+    \"half_life\": \"Estimated 6 – 9 h in humans (rat t½ 1 – 2 h; dog t½ 7 h)\",\n-        \"name\": \"AKB-57 – Wikipedia\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/AKB-57\"\n+        \"name\": \"Papadopoulos V & Lecanu L. Translocator protein (18 kDa) TSPO: An emerging therapeutic target in neurotrauma.\",\n+        \"reference\": \"https://doi.org/10.1016/j.pharmthera.2009.10.002\"\n-        \"name\": \"Banister SD et al. Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs. ACS Chem Neurosci 2015\",\n-        \"reference\": \"https://pubs.acs.org/doi/10.1021/acschemneuro.5b00112\"\n+        \"name\": \"Ishihara K et al. Convulsant action of peripheral benzodiazepine agonists in mice.\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/10475185\"\n-        \"name\": \"EMCDDA. Synthetic cannabinoids – drug profile and health risks (2023 update)\",\n-        \"reference\": \"https://www.emcdda.europa.eu/publications/drug-profiles/synthetic-cannabinoids_en\"\n+        \"name\": \"Lan N et al. Differential effects of 4′-chlorodiazepam on expressed human GABA_A receptors.\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/7830061\"\n-        \"name\": \"CDC. Outbreak of Severe Illness Associated with Synthetic Cannabinoids — Illinois, 2018\",\n-        \"reference\": \"https://www.cdc.gov/mmwr/volumes/67/wr/mm6719a4.htm\"\n+        \"name\": \"Zavala F et al. Peripheral benzodiazepine ligands and the immune response.\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/2900004\"\n+      },\n+      {\n+        \"name\": \"PubChem – 4′-Chlorodiazepam compound summary\",\n+        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/1688\"\n-      \"cannabinoid\",\n-      \"depressant\",\n-      \"habit-forming\"\n+      \"depressant\"\n\n# 2-MMC · #617\n\n-  \"id\": 530,\n-  \"title\": \"Ro5-4864\",\n+  \"id\": 617,\n+  \"title\": \"2-MMC\",\n-    \"drug_name\": \"Ro5-4864\",\n-    \"chemical_name\": \"4'-chlorodiazepam\",\n-    \"alternative_name\": \"4-Chlorodiazepam\",\n-    \"chemical_class\": \"1,4-benzodiazepine (diazepam analogue)\",\n-    \"mechanism_of_action\": \"Gamma-aminobutyric acid type A receptor positive allosteric modulator (benzodiazepine site)\",\n-    \"psychoactive_class\": \"Benzodiazepine (atypical); TSPO (18 kDa translocator protein) agonist with weak or absent classical GABA_A activity\",\n+    \"drug_name\": \"2-MMC\",\n+    \"chemical_name\": \"2-MMC\",\n+    \"alternative_name\": \"2-Methylmethcathinone\",\n+    \"chemical_class\": \"Cathinones\",\n+    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor\",\n+    \"psychoactive_class\": \"Stimulant; entactogen\",\n-            \"threshold\": \"0.25 – 0.5 mg\",\n-            \"light\": \"0.5 – 1.5 mg\",\n-            \"common\": \"1.5 – 3 mg\",\n-            \"strong\": \"3 – 5 mg\",\n-            \"heavy\": \"5 mg + (marked seizure risk in animals)\"\n+            \"threshold\": \"10–20\",\n+            \"light\": \"20–50\",\n+            \"common\": \"50–100\",\n+            \"strong\": \"100–140\",\n+            \"heavy\": \"140 +\"\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"3–5\",\n+            \"light\": \"5–15\",\n+            \"common\": \"15–40\",\n+            \"strong\": \"40–80\",\n+            \"heavy\": \"80 +\"\n+          }\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"10–20\",\n+            \"light\": \"20–40\",\n+            \"common\": \"40–80\",\n+            \"strong\": \"80–120\",\n+            \"heavy\": \"120 +\"\n+          }\n-            \"total_duration\": \"4 - 8 h\",\n-            \"onset\": \"20 - 60 min\",\n-            \"peak\": \"1 - 3 h\",\n-            \"offset\": \"2 - 3 h\",\n-            \"after_effects\": \"up to 12 - 24 h subtle disequilibrium / fatigue\"\n+            \"total_duration\": \"3-6 h\",\n+            \"onset\": \"20-45 min\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-8 h of residual stimulation / fatigue\"\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"2-4 h\",\n+            \"onset\": \"1-5 min\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-8 h of residual stimulation / fatigue\"\n+          }\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"canonical_routes\": [\n+            \"rectal\"\n+          ],\n+          \"stages\": {\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-8 h of residual stimulation / fatigue\"\n+          }\n-    \"addiction_potential\": \"Poorly characterised. Rodent studies show weaker self-administration than diazepam, but repeated exposure produces tolerance to mitochondrial TSPO effects and physical dependence cannot be ruled out. Treat as potentially habit-forming until human data exist.\",\n+    \"addiction_potential\": \"Moderate. Produces dopaminergic reward and compulsive redosing similar to other short-acting cathinones; binge patterns are frequently reported. Psychological dependence is a greater risk than physical withdrawal.\",\n-        \"Tramadol\",\n-        \"bupropion\",\n-        \"triptans\",\n-        \"high-dose stimulants (↑ seizure threshold)\"\n+        \"MAOIs\",\n+        \"Tramadol\"\n-        \"alcohol\",\n-        \"GHB/GBL\",\n-        \"opioids\",\n-        \"barbiturates\",\n-        \"other benzodiazepines or Z-drugs (unpredictable CNS depression or paradoxical agitation)\"\n+        \"2C-T-x\",\n+        \"5-MeO-xxT\",\n+        \"DOx\",\n+        \"DXM\",\n+        \"NBOMe series\",\n+        \"other cathinones (MMC class)\",\n+        \"α-PVP & related pyrrolidines\"\n-        \"MAOIs\",\n-        \"SSRIs/SNRIs\",\n-        \"antipsychotics\",\n-        \"anticonvulsants (dose adjustments may be required)\"\n+        \"Alcohol\",\n+        \"Cannabis\",\n+        \"Cocaine\",\n+        \"GHB/GBL\",\n+        \"Ketamine\",\n+        \"LSD\",\n+        \"MDMA\",\n+        \"Opioids\",\n+        \"SSRIs\",\n+        \"Benzodiazepines (synergy – dose-reduce)\",\n+        \"Stimulants in general\"\n-    \"notes\": \"• 4-Chlorodiazepam (often abbreviated Ro5-4864) displays nanomolar affinity for the peripheral benzodiazepine receptor/TSPO located on the outer mitochondrial membrane while showing orders-of-magnitude lower affinity for central GABA_A sites.  \\n• Low-dose TSPO activation can produce neurosteroidogenesis and mild sedation; higher micromolar concentrations become anxiogenic and pro-convulsant in animals. Median convulsive dose (CD₅₀) in mice ≈ 42 mg/kg i.p.  \\n• No controlled human pharmacokinetic data exist. Extrapolations from dog and rat studies suggest oral bioavailability ≈ 40 – 60 % and an elimination half-life of 6 – 9 h, with no confirmed active metabolites.  \\n• Human case reports are extremely scarce; anecdotal user reports describe a narrow therapeutic window, inconsistent subjective effects (ranging from mild relaxation to pronounced inner restlessness) and delayed-onset seizures after redosing > 5 mg.  \\n• Start with micro-doses (≤ 0.5 mg), use an analytical milligram scale, wait a full 2 h before considering redose.  \\n• Parenteral routes are strongly discouraged: solvent requirements and local TSPO densities create unpredictable tissue reactions.  \\n• Because of the unique mechanism, benzodiazepine antagonists (flumazenil) are ineffective in overdose; supportive care and anticonvulsants are preferred.\",\n+    \"notes\": \"• Pharmacology: In vitro data show 2-MMC acts as a mixed monoamine transporter substrate with higher affinity for DAT ≈ NET than SERT, giving a more \\\"amphetaminic\\\" stimulation with comparatively modest entactogenic warmth (Eshleman 2013; Brandt 2020).\\n• Compared with its positional isomers 3-MMC and 4-MMC (mephedrone), 2-MMC is regarded as less euphoric but more focused/functional. Oral dosing best preserves euphoria; insufflation tends to feel harsher and shorter-lived.\\n• Common acute adverse effects: tachycardia, vasoconstriction (cold fingers, erectile difficulty), jaw clenching, anxiety at peaks, and a strong urge to redose every 1–2 h.\\n• High or repeated doses can provoke confusion, visual disturbances, and in rare cases brief psychotic-like reactions; stay hydrated, monitor body temperature, and limit session length.\\n• Harm-reduction: Weigh doses on a 0.001 g scale; allow at least 2 h before considering a booster. Avoid combining with other stimulants or MAO-inhibiting substances. Because of possible serotonergic activity, the risk of serotonin syndrome exists with SSRIs or tramadol.\",\n-      \"Mild somatic sedation (inconsistent)\",\n-      \"Subtle muscle relaxation\",\n-      \"Derealisation/‘clinical’ detachment\",\n-      \"Tinnitus or ear pressure\",\n-      \"Inner restlessness or anxiogenesis at ≥ 3 mg\",\n-      \"Fine tremor\",\n-      \"Visual blurring / photophobia\",\n-      \"Short-term memory lapses\",\n-      \"Headache\",\n-      \"Rare euphoria or dysphoria\"\n+      \"Stimulation\",\n+      \"Increased energy\",\n+      \"Enhanced motivation/productivity\",\n+      \"Euphoria (moderate)\",\n+      \"Empathy & sociability\",\n+      \"Talkativeness\",\n+      \"Sexual arousal & increased libido\",\n+      \"Cognitive stimulation\",\n+      \"Mood lift\",\n+      \"Appetite suppression\",\n+      \"Bruxism / jaw tension\",\n+      \"Vasoconstriction & cold extremities\",\n+      \"Sweating\",\n+      \"Insomnia\",\n+      \"Anxiety (dose-dependent)\",\n+      \"Compulsive redosing\",\n+      \"Visual flicker or mild hallucinations at high doses\",\n+      \"Crash: fatigue & low mood\"\n-      \"full_tolerance\": \"Unknown in humans; rodent TSPO desensitisation within 3–5 days of daily dosing\",\n-      \"half_tolerance\": \"Data not available\",\n-      \"zero_tolerance\": \"> 2 – 4 weeks assumed\",\n+      \"full_tolerance\": \"Develops after 2–3 days of continuous or binge use\",\n+      \"half_tolerance\": \"≈7 days of abstinence\",\n+      \"zero_tolerance\": \"≈2–3 weeks of abstinence\",\n-        \"Other high-affinity TSPO ligands (e.g., etifoxine, certain pyrazolopyrimidines); only minimal cross-tolerance with classical benzodiazepines\"\n+        \"Other cathinones\",\n+        \"Amphetamines\"\n-    \"half_life\": \"Estimated 6 – 9 h in humans (rat t½ 1 – 2 h; dog t½ 7 h)\",\n+    \"half_life\": \"Estimated 1.5–3 h (plasma); subjective effects decline sooner than blood levels due to acute tolerance.\",\n-        \"name\": \"Papadopoulos V & Lecanu L. Translocator protein (18 kDa) TSPO: An emerging therapeutic target in neurotrauma.\",\n-        \"reference\": \"https://doi.org/10.1016/j.pharmthera.2009.10.002\"\n+        \"name\": \"TripSit – 2-MMC Fact Sheet\",\n+        \"reference\": \"https://drugs.tripsit.me/2-mmc\"\n-        \"name\": \"Ishihara K et al. Convulsant action of peripheral benzodiazepine agonists in mice.\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/10475185\"\n+        \"name\": \"Eshleman et al. 2013 – Substituted cathinones as monoamine transporter substrates\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/23658042/\"\n-        \"name\": \"Lan N et al. Differential effects of 4′-chlorodiazepam on expressed human GABA_A receptors.\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/7830061\"\n+        \"name\": \"Brandt et al. 2020 – Pharmacological profiling of ortho-mephedrone (2-MMC)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/32679041/\"\n-        \"name\": \"Zavala F et al. Peripheral benzodiazepine ligands and the immune response.\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/2900004\"\n+        \"name\": \"User reports compilation – r/ResearchChemicals: “2-MMC turns me into a sex fiend” (Reddit, 2024)\",\n+        \"reference\": \"https://www.reddit.com/comments/qz2mmc_sexfiend\"\n-        \"name\": \"PubChem – 4′-Chlorodiazepam compound summary\",\n-        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/1688\"\n+        \"name\": \"Bluelight thread: “2-MMC, dopaminergic euphoria?” (2024)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/2mmc-dopaminergic-euphoria.939415/\"\n+      \"stimulant\",\n-      \"depressant\"\n+      \"entactogen\"\n\n# Pyrovalerone · #450\n\n-  \"id\": 617,\n-  \"title\": \"2-MMC\",\n+  \"id\": 450,\n+  \"title\": \"Pyrovalerone\",\n-    \"drug_name\": \"2-MMC\",\n-    \"chemical_name\": \"2-MMC\",\n-    \"alternative_name\": \"2-Methylmethcathinone\",\n-    \"chemical_class\": \"Cathinones\",\n-    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor\",\n-    \"psychoactive_class\": \"Stimulant; entactogen\",\n+    \"drug_name\": \"Pyrovalerone\",\n+    \"chemical_name\": \"Pyrovalerone\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Substituted pyrrolidines\",\n+    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor (potent)\",\n+    \"psychoactive_class\": \"Norepinephrine–dopamine reuptake inhibitor (stimulant)\",\n-            \"threshold\": \"10–20\",\n-            \"light\": \"20–50\",\n-            \"common\": \"50–100\",\n-            \"strong\": \"100–140\",\n-            \"heavy\": \"140 +\"\n+            \"threshold\": \"10mg\",\n+            \"light\": \"10mg - 25mg\",\n+            \"common\": \"25mg - 60mg\",\n+            \"strong\": \"60mg - 100mg\",\n+            \"heavy\": \"100+ mg\"\n-            \"threshold\": \"3–5\",\n-            \"light\": \"5–15\",\n-            \"common\": \"15–40\",\n-            \"strong\": \"40–80\",\n-            \"heavy\": \"80 +\"\n+            \"threshold\": \"5mg\",\n+            \"light\": \"5mg - 15mg\",\n+            \"common\": \"15mg - 40mg\",\n+            \"strong\": \"40mg - 80mg\",\n+            \"heavy\": \"80+ mg\"\n-            \"threshold\": \"10–20\",\n-            \"light\": \"20–40\",\n-            \"common\": \"40–80\",\n-            \"strong\": \"80–120\",\n-            \"heavy\": \"120 +\"\n+            \"threshold\": \"5mg\",\n+            \"light\": \"5mg - 15mg\",\n+            \"common\": \"15mg - 35mg\",\n+            \"strong\": \"35mg - 70mg\",\n+            \"heavy\": \"70+ mg\"\n+        },\n+        {\n+          \"route\": \"intravenous\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"1mg\",\n+            \"light\": \"1mg - 5mg\",\n+            \"common\": \"5mg - 15mg\",\n+            \"strong\": \"15mg - 30mg\",\n+            \"heavy\": \"30+ mg\"\n+          }\n-            \"total_duration\": \"3-6 h\",\n-            \"onset\": \"20-45 min\",\n-            \"peak\": \"1-2 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-8 h of residual stimulation / fatigue\"\n+            \"total_duration\": \"3-6 h (active phase)\",\n+            \"onset\": \"10-30 min\",\n+            \"peak\": \"0.5-2 h\",\n+            \"offset\": \"1-3 h\",\n+            \"after_effects\": \"2-24 h residual stimulation; insomnia; low mood\"\n-            \"total_duration\": \"2-4 h\",\n-            \"onset\": \"1-5 min\",\n-            \"peak\": \"1-2 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-8 h of residual stimulation / fatigue\"\n+            \"total_duration\": \"3-6 h (active phase)\",\n+            \"onset\": \"5-10 min\",\n+            \"peak\": \"0.5-2 h\",\n+            \"offset\": \"1-3 h\",\n+            \"after_effects\": \"2-24 h residual stimulation; insomnia; low mood\"\n-            \"peak\": \"1-2 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-8 h of residual stimulation / fatigue\"\n+            \"total_duration\": \"3-6 h (active phase)\",\n+            \"peak\": \"0.5-2 h\",\n+            \"offset\": \"1-3 h\",\n+            \"after_effects\": \"2-24 h residual stimulation; insomnia; low mood\"\n+        },\n+        {\n+          \"route\": \"intravenous\",\n+          \"canonical_routes\": [\n+            \"intravenous\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"3-6 h (active phase)\",\n+            \"onset\": \"<2 min\",\n+            \"peak\": \"0.5-2 h\",\n+            \"offset\": \"1-3 h\",\n+            \"after_effects\": \"2-24 h residual stimulation; insomnia; low mood\"\n+          }\n-    \"addiction_potential\": \"Moderate. Produces dopaminergic reward and compulsive redosing similar to other short-acting cathinones; binge patterns are frequently reported. Psychological dependence is a greater risk than physical withdrawal.\",\n+    \"addiction_potential\": \"High: rapid tolerance, short half-life, and strong dopamine transporter blockade produce compulsive redosing and binge patterns similar to MDPV.\",\n-        \"MAOIs\",\n-        \"Tramadol\"\n+        \"MAOIs (hypertensive crisis)\",\n+        \"high-dose adrenergic stimulants (amphetamine, cocaine)\",\n+        \"sympathomimetic cathinones (MDPV, α-PVP)\",\n+        \"tramadol or other seizure-threshold–lowering drugs\"\n-        \"2C-T-x\",\n-        \"5-MeO-xxT\",\n-        \"DOx\",\n-        \"DXM\",\n-        \"NBOMe series\",\n-        \"other cathinones (MMC class)\",\n-        \"α-PVP & related pyrrolidines\"\n+        \"large amounts of alcohol (cardiotoxicity, dehydration)\",\n+        \"synthetic cannabinoids (tachycardia, panic)\",\n+        \"bupropion or other NDRIs (overstimulation)\"\n-        \"Alcohol\",\n-        \"Cannabis\",\n-        \"Cocaine\",\n-        \"GHB/GBL\",\n-        \"Ketamine\",\n-        \"LSD\",\n-        \"MDMA\",\n-        \"Opioids\",\n-        \"SSRIs\",\n-        \"Benzodiazepines (synergy – dose-reduce)\",\n-        \"Stimulants in general\"\n+        \"SSRIs/SNRIs (serotonin toxicity risk at very high doses)\",\n+        \"caffeine >300 mg (palpitations, anxiety)\",\n+        \"benzodiazepines (masking severe stimulation → redose loop)\"\n-    \"notes\": \"• Pharmacology: In vitro data show 2-MMC acts as a mixed monoamine transporter substrate with higher affinity for DAT ≈ NET than SERT, giving a more \\\"amphetaminic\\\" stimulation with comparatively modest entactogenic warmth (Eshleman 2013; Brandt 2020).\\n• Compared with its positional isomers 3-MMC and 4-MMC (mephedrone), 2-MMC is regarded as less euphoric but more focused/functional. Oral dosing best preserves euphoria; insufflation tends to feel harsher and shorter-lived.\\n• Common acute adverse effects: tachycardia, vasoconstriction (cold fingers, erectile difficulty), jaw clenching, anxiety at peaks, and a strong urge to redose every 1–2 h.\\n• High or repeated doses can provoke confusion, visual disturbances, and in rare cases brief psychotic-like reactions; stay hydrated, monitor body temperature, and limit session length.\\n• Harm-reduction: Weigh doses on a 0.001 g scale; allow at least 2 h before considering a booster. Avoid combining with other stimulants or MAO-inhibiting substances. Because of possible serotonergic activity, the risk of serotonin syndrome exists with SSRIs or tramadol.\",\n+    \"notes\": \"Pyrovalerone was placed into U.S. Schedule V and largely vanished once stronger analogues like MDPV appeared, yet the parent drug still drives sharp redosing urges and warrants strict self-imposed limits.\\n\\nPyrovalerone was originally prescribed for chronic fatigue and obesity in the 1960s at daily doses of 60 mg (20 mg taken three times daily), but patients frequently developed tolerance and compulsive redosing, leading to discontinuation of its clinical use. Modern reports describe it as a stimulant with a profile somewhere between methylphenidate and MDPV, with strong drive to re-dose every 2–3 hours. Its pharmacology shows high affinity inhibition of dopamine and norepinephrine transporters, with negligible serotonin activity, producing a stimulation that is clean but also edgy and compulsive. The short half-life contributes to a sharp comedown, often marked by irritability, low mood, and insomnia. Oral dosing is more forgiving but still prone to compulsive escalation, while insufflation and intravenous routes amplify both euphoria and cardiovascular strain. Users report appetite suppression, jaw tension, tremor, and persistent tachycardia during sessions. Redosing within the first hour significantly increases cardiovascular and neurotoxic stress, and binges of >24 hours without sleep have led to stimulant psychosis similar to high-dose cocaine. Accurate dosing is critical: pyrovalerone is active at very low milligram amounts, making volumetric liquid measurement safer than weighing single doses. Reagent tests often cannot distinguish pyrovalerone from related pyrrolidinophenones, so confirmation with multiple reagents or advanced analysis (GC-MS, FT-IR) is recommended. For harm reduction, users should pre-weigh a maximum daily session dose, allow full return to baseline before re-dosing, maintain hydration and electrolyte intake (especially potassium and magnesium), and ensure proper sleep hygiene. Because pyrovalerone was quickly replaced by stronger analogues like MDPV and α-PVP on the illicit market, it remains rare but presents similar risks: high addiction potential, strong cardiovascular strain, and rapid tolerance escalation.\",\n-      \"Stimulation\",\n-      \"Increased energy\",\n-      \"Enhanced motivation/productivity\",\n-      \"Euphoria (moderate)\",\n-      \"Empathy & sociability\",\n-      \"Talkativeness\",\n-      \"Sexual arousal & increased libido\",\n-      \"Cognitive stimulation\",\n-      \"Mood lift\",\n-      \"Appetite suppression\",\n-      \"Bruxism / jaw tension\",\n-      \"Vasoconstriction & cold extremities\",\n-      \"Sweating\",\n-      \"Insomnia\",\n-      \"Anxiety (dose-dependent)\",\n-      \"Compulsive redosing\",\n-      \"Visual flicker or mild hallucinations at high doses\",\n-      \"Crash: fatigue & low mood\"\n+      \"clean, functional stimulation\",\n+      \"confidence and motivation boost\",\n+      \"anorexia and dry mouth\",\n+      \"jaw tension, fine tremor\",\n+      \"compulsive redosing drive\",\n+      \"irritability and dysphoria on comedown\"\n-      \"full_tolerance\": \"Develops after 2–3 days of continuous or binge use\",\n-      \"half_tolerance\": \"≈7 days of abstinence\",\n-      \"zero_tolerance\": \"≈2–3 weeks of abstinence\",\n+      \"full_tolerance\": \"after 1-2 heavy sessions\",\n+      \"half_tolerance\": \"3-5 days\",\n+      \"zero_tolerance\": \"10-14 days\",\n-        \"Other cathinones\",\n-        \"Amphetamines\"\n+        \"MDPV\",\n+        \"α-PVP\",\n+        \"other pyrrolidinophenones\"\n-    \"half_life\": \"Estimated 1.5–3 h (plasma); subjective effects decline sooner than blood levels due to acute tolerance.\",\n+    \"half_life\": \"Approx. 0.3-1.5 h in rats; human half-life likely under 3 h.\",\n-        \"name\": \"TripSit – 2-MMC Fact Sheet\",\n-        \"reference\": \"https://drugs.tripsit.me/2-mmc\"\n+        \"name\": \"Controlled evaluation of pyrovalerone doses (20–40 mg TID)\",\n+        \"reference\": \"https://karger.com/ipd/article/8/1-2/60/179231/A-Controlled-Evaluation-of-Pyrovalerone-in\"\n-        \"name\": \"Eshleman et al. 2013 – Substituted cathinones as monoamine transporter substrates\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/23658042/\"\n+        \"name\": \"Synthetic cathinone user-dose survey (20–80 mg insufflated)\",\n+        \"reference\": \"https://nps-info.org/en/substances/synthetic-cathinones/\"\n-        \"name\": \"Brandt et al. 2020 – Pharmacological profiling of ortho-mephedrone (2-MMC)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/32679041/\"\n+        \"name\": \"DAT Ki values for pyrovalerone\",\n+        \"reference\": \"https://www.aatbio.com/data-sets/dopamine-transporter-inhibitors-ic50-ki\"\n-        \"name\": \"User reports compilation – r/ResearchChemicals: “2-MMC turns me into a sex fiend” (Reddit, 2024)\",\n-        \"reference\": \"https://www.reddit.com/comments/qz2mmc_sexfiend\"\n+        \"name\": \"Rat plasma half-life study\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/8934308/\"\n-        \"name\": \"Bluelight thread: “2-MMC, dopaminergic euphoria?” (2024)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/2mmc-dopaminergic-euphoria.939415/\"\n+        \"name\": \"Pyrovalerone analogues pharmacology (Meltzer et al., 2006)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/16480278/\"\n+      },\n+      {\n+        \"name\": \"Zebrafish dopamine-receptor down-regulation\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC6851804/\"\n+      },\n+      {\n+        \"name\": \"Bluelight discussion thread on pyrovalerone rarity\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/pyrovalerone.522661/\"\n+      },\n+      {\n+        \"name\": \"UNODC synthetic cathinones report (dose guidance)\",\n+        \"reference\": \"https://www.unodc.org/documents/scientific/STNAR49_Synthetic_Cathinones_E.pdf\"\n+      },\n+      {\n+        \"name\": \"Bionity encyclopaedia entry (historical/prescription info)\",\n+        \"reference\": \"https://www.bionity.com/en/encyclopedia/Pyrovalerone.html\"\n+      },\n+      {\n+        \"name\": \"Anodyne Wiki: Pyrovalerone\",\n+        \"reference\": \"https://anodyne.wiki/substance/pyrovalerone\"\n-      \"research-chemical\",\n-      \"entactogen\"\n+      \"research-chemical\"\n\n# Carisoprodol · #174\n\n-  \"id\": 450,\n-  \"title\": \"Pyrovalerone\",\n+  \"id\": 174,\n+  \"title\": \"Carisoprodol\",\n-    \"drug_name\": \"Pyrovalerone\",\n-    \"chemical_name\": \"Pyrovalerone\",\n+    \"drug_name\": \"Carisoprodol\",\n+    \"chemical_name\": \"Carisoprodol\",\n-    \"chemical_class\": \"Substituted pyrrolidines\",\n-    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor (potent)\",\n-    \"psychoactive_class\": \"Norepinephrine–dopamine reuptake inhibitor (stimulant)\",\n+    \"chemical_class\": \"Carbamate\",\n+    \"mechanism_of_action\": \"Gamma-aminobutyric acid type A receptor positive allosteric modulator; Gamma-aminobutyric acid type A receptor agonist (at high concentration)\",\n+    \"psychoactive_class\": \"Muscle relaxant (centrally acting)\",\n-            \"threshold\": \"10mg\",\n-            \"light\": \"10mg - 25mg\",\n-            \"common\": \"25mg - 60mg\",\n-            \"strong\": \"60mg - 100mg\",\n-            \"heavy\": \"100+ mg\"\n+            \"threshold\": \"100 mg\",\n+            \"light\": \"150-250 mg\",\n+            \"common\": \"250-350 mg\",\n+            \"strong\": \"350-700 mg\",\n+            \"heavy\": \"700+ mg\"\n-        },\n-        {\n-          \"route\": \"insufflated\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"5mg\",\n-            \"light\": \"5mg - 15mg\",\n-            \"common\": \"15mg - 40mg\",\n-            \"strong\": \"40mg - 80mg\",\n-            \"heavy\": \"80+ mg\"\n-          }\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"5mg\",\n-            \"light\": \"5mg - 15mg\",\n-            \"common\": \"15mg - 35mg\",\n-            \"strong\": \"35mg - 70mg\",\n-            \"heavy\": \"70+ mg\"\n-          }\n-        },\n-        {\n-          \"route\": \"intravenous\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"1mg\",\n-            \"light\": \"1mg - 5mg\",\n-            \"common\": \"5mg - 15mg\",\n-            \"strong\": \"15mg - 30mg\",\n-            \"heavy\": \"30+ mg\"\n-          }\n-            \"total_duration\": \"3-6 h (active phase)\",\n-            \"onset\": \"10-30 min\",\n-            \"peak\": \"0.5-2 h\",\n-            \"offset\": \"1-3 h\",\n-            \"after_effects\": \"2-24 h residual stimulation; insomnia; low mood\"\n+            \"total_duration\": \"4-6 hours\",\n+            \"onset\": \"30 minutes\",\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"May persist up to 12 hours; especially with high doses or repeated use\"\n-        },\n-        {\n-          \"route\": \"insufflated\",\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"3-6 h (active phase)\",\n-            \"onset\": \"5-10 min\",\n-            \"peak\": \"0.5-2 h\",\n-            \"offset\": \"1-3 h\",\n-            \"after_effects\": \"2-24 h residual stimulation; insomnia; low mood\"\n-          }\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"canonical_routes\": [\n-            \"rectal\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"3-6 h (active phase)\",\n-            \"peak\": \"0.5-2 h\",\n-            \"offset\": \"1-3 h\",\n-            \"after_effects\": \"2-24 h residual stimulation; insomnia; low mood\"\n-          }\n-        },\n-        {\n-          \"route\": \"intravenous\",\n-          \"canonical_routes\": [\n-            \"intravenous\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"3-6 h (active phase)\",\n-            \"onset\": \"<2 min\",\n-            \"peak\": \"0.5-2 h\",\n-            \"offset\": \"1-3 h\",\n-            \"after_effects\": \"2-24 h residual stimulation; insomnia; low mood\"\n-          }\n-    \"addiction_potential\": \"High: rapid tolerance, short half-life, and strong dopamine transporter blockade produce compulsive redosing and binge patterns similar to MDPV.\",\n+    \"addiction_potential\": \"Moderate to high. Carisoprodol has a risk of dependence and abuse, especially with prolonged use or at high doses. Its metabolite, meprobamate, is also habit-forming.\",\n-        \"MAOIs (hypertensive crisis)\",\n-        \"high-dose adrenergic stimulants (amphetamine, cocaine)\",\n-        \"sympathomimetic cathinones (MDPV, α-PVP)\",\n-        \"tramadol or other seizure-threshold–lowering drugs\"\n+        \"Alcohol\",\n+        \"Opioids\",\n+        \"Benzodiazepines\",\n+        \"Barbiturates\"\n-        \"large amounts of alcohol (cardiotoxicity, dehydration)\",\n-        \"synthetic cannabinoids (tachycardia, panic)\",\n-        \"bupropion or other NDRIs (overstimulation)\"\n+        \"Other CNS depressants\"\n-        \"SSRIs/SNRIs (serotonin toxicity risk at very high doses)\",\n-        \"caffeine >300 mg (palpitations, anxiety)\",\n-        \"benzodiazepines (masking severe stimulation → redose loop)\"\n+        \"Antidepressants\",\n+        \"Antihistamines\"\n-    \"notes\": \"Pyrovalerone was placed into U.S. Schedule V and largely vanished once stronger analogues like MDPV appeared, yet the parent drug still drives sharp redosing urges and warrants strict self-imposed limits.\\n\\nPyrovalerone was originally prescribed for chronic fatigue and obesity in the 1960s at daily doses of 60 mg (20 mg taken three times daily), but patients frequently developed tolerance and compulsive redosing, leading to discontinuation of its clinical use. Modern reports describe it as a stimulant with a profile somewhere between methylphenidate and MDPV, with strong drive to re-dose every 2–3 hours. Its pharmacology shows high affinity inhibition of dopamine and norepinephrine transporters, with negligible serotonin activity, producing a stimulation that is clean but also edgy and compulsive. The short half-life contributes to a sharp comedown, often marked by irritability, low mood, and insomnia. Oral dosing is more forgiving but still prone to compulsive escalation, while insufflation and intravenous routes amplify both euphoria and cardiovascular strain. Users report appetite suppression, jaw tension, tremor, and persistent tachycardia during sessions. Redosing within the first hour significantly increases cardiovascular and neurotoxic stress, and binges of >24 hours without sleep have led to stimulant psychosis similar to high-dose cocaine. Accurate dosing is critical: pyrovalerone is active at very low milligram amounts, making volumetric liquid measurement safer than weighing single doses. Reagent tests often cannot distinguish pyrovalerone from related pyrrolidinophenones, so confirmation with multiple reagents or advanced analysis (GC-MS, FT-IR) is recommended. For harm reduction, users should pre-weigh a maximum daily session dose, allow full return to baseline before re-dosing, maintain hydration and electrolyte intake (especially potassium and magnesium), and ensure proper sleep hygiene. Because pyrovalerone was quickly replaced by stronger analogues like MDPV and α-PVP on the illicit market, it remains rare but presents similar risks: high addiction potential, strong cardiovascular strain, and rapid tolerance escalation.\",\n+    \"notes\": \"Carisoprodol is prescribed only for short-term relief of acute muscle spasm, yet dependence emerges quickly because it metabolises into the sedative meprobamate. Long-term use or abrupt cessation can precipitate significant withdrawal.\\n\\nCarisoprodol is a centrally acting muscle relaxant with sedative and anxiolytic properties, commonly prescribed for short-term treatment of musculoskeletal pain. It is rapidly metabolized in the liver to meprobamate, a long-acting anxiolytic and sedative-hypnotic with its own abuse history, making carisoprodol pharmacologically similar to combining a short-acting sedative with a longer-lasting one. Because of this metabolic pathway, effects may persist longer than expected, especially with repeated dosing. Recreational use often centers around the drug’s sedative euphoria, which some users compare to a mild benzodiazepine, though with a heavier, less controlled sedation and occasional paradoxical stimulation. At therapeutic doses, carisoprodol causes muscle relaxation, drowsiness, and anxiolysis; at higher doses, it can cause confusion, ataxia, double vision, blackouts, and sudden loss of motor control. Abrupt movements or attempts to stand can cause sudden collapses, leading to falls and injuries. Tolerance to the euphoric and relaxing effects develops quickly, encouraging dose escalation and binge-style use. Dependence liability is compounded by meprobamate accumulation, which has a half-life of ~10 hours, leading to more prolonged sedation and risk of withdrawal upon cessation. Withdrawal symptoms can include tremors, anxiety, agitation, insomnia, nausea, hallucinations, and seizures; these can be severe after chronic high-dose use and may require medical supervision, often with benzodiazepine substitution. Mixing carisoprodol with other depressants such as alcohol, opioids, or benzodiazepines greatly increases the risk of respiratory depression, aspiration, coma, and death; many fatalities have involved such polydrug combinations. Recreational users sometimes combine carisoprodol with opioids or benzodiazepines in a cocktail known as the 'Holy Trinity,' which is considered highly dangerous due to synergistic CNS depression. Harm reduction strategies include limiting use to occasional sessions, spacing doses at least 4–6 hours apart, avoiding any other depressants, and never exceeding 700 mg in a single dose. Users should ensure they are in a safe environment before onset due to risk of sudden sedation and falls. Because it is often supplied as tablets with varying imprints, counterfeit risks exist; some tablets may contain other sedatives or opioids, so reagent testing is advised where possible. Long-term heavy use can impair memory, attention, and coordination, and chronic use is discouraged due to rapid tolerance and dependence liability.\",\n-      \"clean, functional stimulation\",\n-      \"confidence and motivation boost\",\n-      \"anorexia and dry mouth\",\n-      \"jaw tension, fine tremor\",\n-      \"compulsive redosing drive\",\n-      \"irritability and dysphoria on comedown\"\n+      \"Muscle relaxation\",\n+      \"Sedation\",\n+      \"Euphoria (in some users)\",\n+      \"Drowsiness\",\n+      \"Dizziness\",\n+      \"Impaired coordination\",\n+      \"Confusion (at high doses)\",\n+      \"Potential for amnesia\"\n-      \"full_tolerance\": \"after 1-2 heavy sessions\",\n-      \"half_tolerance\": \"3-5 days\",\n-      \"zero_tolerance\": \"10-14 days\",\n+      \"full_tolerance\": \"Develops within days to weeks of regular use\",\n+      \"half_tolerance\": \"Several days after cessation\",\n+      \"zero_tolerance\": \"1-2 weeks after cessation\",\n-        \"MDPV\",\n-        \"α-PVP\",\n-        \"other pyrrolidinophenones\"\n+        \"Meprobamate\",\n+        \"Other sedative-hypnotics\"\n-    \"half_life\": \"Approx. 0.3-1.5 h in rats; human half-life likely under 3 h.\",\n+    \"half_life\": \"2-3 hours (parent compound); 10 hours (meprobamate metabolite)\",\n-        \"name\": \"Controlled evaluation of pyrovalerone doses (20–40 mg TID)\",\n-        \"reference\": \"https://karger.com/ipd/article/8/1-2/60/179231/A-Controlled-Evaluation-of-Pyrovalerone-in\"\n+        \"name\": \"DrugBank: Carisoprodol\",\n+        \"reference\": \"https://go.drugbank.com/drugs/DB00395\"\n-        \"name\": \"Synthetic cathinone user-dose survey (20–80 mg insufflated)\",\n-        \"reference\": \"https://nps-info.org/en/substances/synthetic-cathinones/\"\n+        \"name\": \"DrugBank: Carisoprodol Abuse and Dependence\",\n+        \"reference\": \"https://go.drugbank.com/articles/A176068\"\n-        \"name\": \"DAT Ki values for pyrovalerone\",\n-        \"reference\": \"https://www.aatbio.com/data-sets/dopamine-transporter-inhibitors-ic50-ki\"\n+        \"name\": \"DrugBank: Carisoprodol Pharmacology\",\n+        \"reference\": \"https://go.drugbank.com/articles/A176092\"\n-        \"name\": \"Rat plasma half-life study\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/8934308/\"\n-      },\n-      {\n-        \"name\": \"Pyrovalerone analogues pharmacology (Meltzer et al., 2006)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/16480278/\"\n-      },\n-      {\n-        \"name\": \"Zebrafish dopamine-receptor down-regulation\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC6851804/\"\n-      },\n-      {\n-        \"name\": \"Bluelight discussion thread on pyrovalerone rarity\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/pyrovalerone.522661/\"\n-      },\n-      {\n-        \"name\": \"UNODC synthetic cathinones report (dose guidance)\",\n-        \"reference\": \"https://www.unodc.org/documents/scientific/STNAR49_Synthetic_Cathinones_E.pdf\"\n-      },\n-      {\n-        \"name\": \"Bionity encyclopaedia entry (historical/prescription info)\",\n-        \"reference\": \"https://www.bionity.com/en/encyclopedia/Pyrovalerone.html\"\n-      },\n-      {\n-        \"name\": \"Anodyne Wiki: Pyrovalerone\",\n-        \"reference\": \"https://anodyne.wiki/substance/pyrovalerone\"\n+        \"name\": \"Drug Users Bible: Index\",\n+        \"reference\": \"https://drugusersbible.org/content/chemscape/anxiolytics_and_sedatives/carisoprodol/index.html\"\n-      \"stimulant\",\n-      \"research-chemical\"\n+      \"depressant\",\n+      \"habit-forming\",\n+      \"gabaergic\"\n\n# 4-Cl-PPP · #618\n\n-  \"id\": 174,\n-  \"title\": \"Carisoprodol\",\n+  \"id\": 618,\n+  \"title\": \"4-Cl-PPP\",\n-    \"drug_name\": \"Carisoprodol\",\n-    \"chemical_name\": \"Carisoprodol\",\n+    \"drug_name\": \"4-Cl-PPP\",\n+    \"chemical_name\": \"4-Cl-PPP\",\n-    \"chemical_class\": \"Carbamate\",\n-    \"mechanism_of_action\": \"Gamma-aminobutyric acid type A receptor positive allosteric modulator; Gamma-aminobutyric acid type A receptor agonist (at high concentration)\",\n-    \"psychoactive_class\": \"Muscle relaxant (centrally acting)\",\n+    \"chemical_class\": \"Substituted pyrrolidines\",\n+    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor (potent)\",\n+    \"psychoactive_class\": \"Stimulant\",\n-            \"threshold\": \"100 mg\",\n-            \"light\": \"150-250 mg\",\n-            \"common\": \"250-350 mg\",\n-            \"strong\": \"350-700 mg\",\n-            \"heavy\": \"700+ mg\"\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"10–20 mg\",\n+            \"common\": \"20–40 mg\",\n+            \"strong\": \"40–60 mg\",\n+            \"heavy\": \"60 mg+​\"\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"3 mg\",\n+            \"light\": \"5–10 mg\",\n+            \"common\": \"10–25 mg\",\n+            \"strong\": \"25–40 mg\",\n+            \"heavy\": \"40 mg+​\"\n+          }\n-            \"total_duration\": \"4-6 hours\",\n-            \"onset\": \"30 minutes\",\n-            \"peak\": \"1-2 hours\",\n-            \"offset\": \"2-4 hours\",\n-            \"after_effects\": \"May persist up to 12 hours; especially with high doses or repeated use\"\n+            \"total_duration\": \"2-4 h\",\n+            \"onset\": \"15-40 min\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-6 h residual stimulation / insomnia\"\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"2-4 h\",\n+            \"onset\": \"5-10 min\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-6 h residual stimulation / insomnia\"\n+          }\n-    \"addiction_potential\": \"Moderate to high. Carisoprodol has a risk of dependence and abuse, especially with prolonged use or at high doses. Its metabolite, meprobamate, is also habit-forming.\",\n+    \"addiction_potential\": \"High – pyrrolidinophenones act as powerful dopamine & norepinephrine re-uptake inhibitors; compulsive redosing and binge-use have been reported.\",\n-        \"Alcohol\",\n-        \"Opioids\",\n-        \"Benzodiazepines\",\n-        \"Barbiturates\"\n+        \"MAOIs\",\n+        \"other potent stimulants (cocaine, methamphetamine, α-PVP, cathinone blends)\",\n+        \"tramadol (seizure risk)\"\n-        \"Other CNS depressants\"\n+        \"MDMA / entactogens (hyperthermia, serotonin syndrome)\",\n+        \"strong opioids (respiratory & cardiovascular burden)\"\n-        \"Antidepressants\",\n-        \"Antihistamines\"\n+        \"Alcohol (cardiac strain, dehydration)\",\n+        \"benzodiazepines (can mask overdose signs)\",\n+        \"antidepressant SSRIs/SNRIs (serotonin / QT issues)\"\n-    \"notes\": \"Carisoprodol is prescribed only for short-term relief of acute muscle spasm, yet dependence emerges quickly because it metabolises into the sedative meprobamate. Long-term use or abrupt cessation can precipitate significant withdrawal.\\n\\nCarisoprodol is a centrally acting muscle relaxant with sedative and anxiolytic properties, commonly prescribed for short-term treatment of musculoskeletal pain. It is rapidly metabolized in the liver to meprobamate, a long-acting anxiolytic and sedative-hypnotic with its own abuse history, making carisoprodol pharmacologically similar to combining a short-acting sedative with a longer-lasting one. Because of this metabolic pathway, effects may persist longer than expected, especially with repeated dosing. Recreational use often centers around the drug’s sedative euphoria, which some users compare to a mild benzodiazepine, though with a heavier, less controlled sedation and occasional paradoxical stimulation. At therapeutic doses, carisoprodol causes muscle relaxation, drowsiness, and anxiolysis; at higher doses, it can cause confusion, ataxia, double vision, blackouts, and sudden loss of motor control. Abrupt movements or attempts to stand can cause sudden collapses, leading to falls and injuries. Tolerance to the euphoric and relaxing effects develops quickly, encouraging dose escalation and binge-style use. Dependence liability is compounded by meprobamate accumulation, which has a half-life of ~10 hours, leading to more prolonged sedation and risk of withdrawal upon cessation. Withdrawal symptoms can include tremors, anxiety, agitation, insomnia, nausea, hallucinations, and seizures; these can be severe after chronic high-dose use and may require medical supervision, often with benzodiazepine substitution. Mixing carisoprodol with other depressants such as alcohol, opioids, or benzodiazepines greatly increases the risk of respiratory depression, aspiration, coma, and death; many fatalities have involved such polydrug combinations. Recreational users sometimes combine carisoprodol with opioids or benzodiazepines in a cocktail known as the 'Holy Trinity,' which is considered highly dangerous due to synergistic CNS depression. Harm reduction strategies include limiting use to occasional sessions, spacing doses at least 4–6 hours apart, avoiding any other depressants, and never exceeding 700 mg in a single dose. Users should ensure they are in a safe environment before onset due to risk of sudden sedation and falls. Because it is often supplied as tablets with varying imprints, counterfeit risks exist; some tablets may contain other sedatives or opioids, so reagent testing is advised where possible. Long-term heavy use can impair memory, attention, and coordination, and chronic use is discouraged due to rapid tolerance and dependence liability.\",\n+    \"notes\": \"4-Cl-PPP (4-chloro-α-pyrrolidinopropiophenone) is an obscure designer stimulant. Human data are limited to a handful of forum reports; no controlled studies have been performed. Similar para-chloro amphetamine analogues show serotonergic neurotoxicity in animals, so long-term risks are unknown. Crystalline material is usually white–tan, reportedly very caustic to nasal tissue. Users describe rapid tolerance, a short-lived euphoria followed by pronounced compulsion, insomnia, and an unpleasant crash. Harm-reduction: limit sessions to <40 mg total, dose no more often than once every 2–4 weeks, monitor blood pressure & temperature, and keep benzodiazepines (e.g., 1–2 mg diazepam) on hand for agitation but avoid co-intoxication.\",\n-      \"Muscle relaxation\",\n-      \"Sedation\",\n-      \"Euphoria (in some users)\",\n-      \"Drowsiness\",\n-      \"Dizziness\",\n-      \"Impaired coordination\",\n-      \"Confusion (at high doses)\",\n-      \"Potential for amnesia\"\n+      \"Euphoria (brief)\",\n+      \"Stimulation & wakefulness\",\n+      \"Increased sociability/talkativeness\",\n+      \"Anorexia\",\n+      \"Bruxism & jaw tension\",\n+      \"Vasoconstriction, cold extremities\",\n+      \"Tachycardia / palpitations\",\n+      \"Anxiety or paranoia at higher doses\",\n+      \"Compulsive redosing\",\n+      \"Insomnia & prolonged after-stimulation\",\n+      \"Auditory misperceptions after binges\"\n-      \"full_tolerance\": \"Develops within days to weeks of regular use\",\n-      \"half_tolerance\": \"Several days after cessation\",\n-      \"zero_tolerance\": \"1-2 weeks after cessation\",\n+      \"full_tolerance\": \"Forms after 1–2 days of consecutive use\",\n+      \"half_tolerance\": \"~1 week\",\n+      \"zero_tolerance\": \"2–3 weeks of abstinence\",\n-        \"Meprobamate\",\n-        \"Other sedative-hypnotics\"\n+        \"α-PVP\",\n+        \"4-F-PVP\",\n+        \"α-PHP\",\n+        \"amphetamines\"\n-    \"half_life\": \"2-3 hours (parent compound); 10 hours (meprobamate metabolite)\",\n+    \"half_life\": \"~2–3 h (estimated from in-vitro DAT assay & structural analogy to α-PPP)\",\n-        \"name\": \"DrugBank: Carisoprodol\",\n-        \"reference\": \"https://go.drugbank.com/drugs/DB00395\"\n+        \"name\": \"Wikipedia – 4-Cl-PPP\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/4-Cl-PPP\"\n-        \"name\": \"DrugBank: Carisoprodol Abuse and Dependence\",\n-        \"reference\": \"https://go.drugbank.com/articles/A176068\"\n+        \"name\": \"Eshleman et al., 2019. Structure-activity relationships of NPS at monoamine transporters.\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/31166536/\"\n-        \"name\": \"DrugBank: Carisoprodol Pharmacology\",\n-        \"reference\": \"https://go.drugbank.com/articles/A176092\"\n+        \"name\": \"Bluelight forum: “New RCs, 4-Cl-PPP & 4-Cl-PVP” user reports (posts #2–#8)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/new-rcs-4-cl-ppp-4-cl-pvp.800456/\"\n-        \"name\": \"Drug Users Bible: Index\",\n-        \"reference\": \"https://drugusersbible.org/content/chemscape/anxiolytics_and_sedatives/carisoprodol/index.html\"\n+        \"name\": \"EMCDDA. New psychoactive substances: global markets, glocal threats.\",\n+        \"reference\": \"https://www.emcdda.europa.eu/publications/2016/new-psychoactive-substances_en\"\n+      },\n+      {\n+        \"name\": \"PubChem: 163195101\",\n+        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/163195101\"\n-      \"depressant\",\n-      \"habit-forming\",\n-      \"gabaergic\"\n+      \"stimulant\",\n+      \"research-chemical\"\n\n# 4-CBC (4-Chlorobuphedrone) · #619\n\n-  \"id\": 618,\n-  \"title\": \"4-Cl-PPP\",\n+  \"id\": 619,\n+  \"title\": \"4-CBC (4-Chlorobuphedrone)\",\n-    \"drug_name\": \"4-Cl-PPP\",\n-    \"chemical_name\": \"4-Cl-PPP\",\n-    \"alternative_name\": \"\",\n-    \"chemical_class\": \"Substituted pyrrolidines\",\n-    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor (potent)\",\n-    \"psychoactive_class\": \"Stimulant\",\n+    \"drug_name\": \"4-CBC (4-Chlorobuphedrone)\",\n+    \"chemical_name\": \"4-CBC\",\n+    \"alternative_name\": \"4-Chlorobuphedrone\",\n+    \"chemical_class\": \"Cathinones\",\n+    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor\",\n+    \"psychoactive_class\": \"Stimulant; entactogen\",\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"10–20 mg\",\n-            \"common\": \"20–40 mg\",\n-            \"strong\": \"40–60 mg\",\n-            \"heavy\": \"60 mg+​\"\n+            \"threshold\": \"20-30\",\n+            \"light\": \"40-70\",\n+            \"common\": \"70-100\",\n+            \"strong\": \"100-130\",\n+            \"heavy\": \"130+\"\n-            \"threshold\": \"3 mg\",\n-            \"light\": \"5–10 mg\",\n-            \"common\": \"10–25 mg\",\n-            \"strong\": \"25–40 mg\",\n-            \"heavy\": \"40 mg+​\"\n+            \"threshold\": \"15-25\",\n+            \"light\": \"40-60\",\n+            \"common\": \"60-90\",\n+            \"strong\": \"90-120\",\n+            \"heavy\": \"120+\"\n-            \"total_duration\": \"2-4 h\",\n-            \"onset\": \"15-40 min\",\n+            \"total_duration\": \"3-6 h\",\n+            \"onset\": \"30-60 min\",\n-            \"after_effects\": \"2-6 h residual stimulation / insomnia\"\n+            \"after_effects\": \"2-6 h of residual stimulation (“body load”, low mood, craving)\"\n-            \"total_duration\": \"2-4 h\",\n-            \"onset\": \"5-10 min\",\n+            \"total_duration\": \"3-6 h\",\n+            \"onset\": \"5-15 min\",\n-            \"after_effects\": \"2-6 h residual stimulation / insomnia\"\n+            \"after_effects\": \"2-6 h of residual stimulation (“body load”, low mood, craving)\"\n-    \"addiction_potential\": \"High – pyrrolidinophenones act as powerful dopamine & norepinephrine re-uptake inhibitors; compulsive redosing and binge-use have been reported.\",\n+    \"addiction_potential\": \"Moderate-to-high. Like other cathinones it strongly stimulates dopamine and norepinephrine re-uptake inhibition/release, producing compulsive redosing and binge patterns. Psychological dependence has been reported after multi-day use.\",\n-        \"other potent stimulants (cocaine, methamphetamine, α-PVP, cathinone blends)\",\n-        \"tramadol (seizure risk)\"\n+        \"other potent stimulants (amphetamine, methamphetamine, α-PVP, cocaine)\",\n+        \"4-CEC / 4-CMC and related cathinones\",\n+        \"Tramadol (seizure risk)\"\n-        \"MDMA / entactogens (hyperthermia, serotonin syndrome)\",\n-        \"strong opioids (respiratory & cardiovascular burden)\"\n+        \"Gabapentinoids (respiratory depression when coming down)\",\n+        \"Poppers (hypotension)\"\n-        \"Alcohol (cardiac strain, dehydration)\",\n-        \"benzodiazepines (can mask overdose signs)\",\n-        \"antidepressant SSRIs/SNRIs (serotonin / QT issues)\"\n+        \"Alcohol (cardio-toxicity, dehydration)\",\n+        \"Cannabis (anxiety possible)\",\n+        \"DXM (serotonin / hypertension)\",\n+        \"Benzodiazepines (may mask overdose signs)\"\n-    \"notes\": \"4-Cl-PPP (4-chloro-α-pyrrolidinopropiophenone) is an obscure designer stimulant. Human data are limited to a handful of forum reports; no controlled studies have been performed. Similar para-chloro amphetamine analogues show serotonergic neurotoxicity in animals, so long-term risks are unknown. Crystalline material is usually white–tan, reportedly very caustic to nasal tissue. Users describe rapid tolerance, a short-lived euphoria followed by pronounced compulsion, insomnia, and an unpleasant crash. Harm-reduction: limit sessions to <40 mg total, dose no more often than once every 2–4 weeks, monitor blood pressure & temperature, and keep benzodiazepines (e.g., 1–2 mg diazepam) on hand for agitation but avoid co-intoxication.\",\n+    \"notes\": \"4-CBC is a very new cathinone with virtually no human or toxicological data. Animal work on close analogues (4-CMC, 4-CEC) suggests high neuro- and cardio-toxicity through dopamine transporter–mediated oxidative stress and QT-prolongation. Users report intense but short-lived stimulation similar to 4-CMC or cocaine, followed by a harsh crash. Severe vasoconstriction, bruxism, tachycardia and thermoregulatory issues are common. Start with allergy test (<5 mg), weigh doses accurately, keep body temperature under 38 °C, hydrate with electrolytes and avoid redosing cycles longer than 2-3 h. No data exist on pregnancy, cancer risk or long-term neuro-toxicity—abstinence is the only proven harm-reduction.\",\n-      \"Euphoria (brief)\",\n-      \"Stimulation & wakefulness\",\n-      \"Increased sociability/talkativeness\",\n-      \"Anorexia\",\n-      \"Bruxism & jaw tension\",\n-      \"Vasoconstriction, cold extremities\",\n-      \"Tachycardia / palpitations\",\n-      \"Anxiety or paranoia at higher doses\",\n-      \"Compulsive redosing\",\n-      \"Insomnia & prolonged after-stimulation\",\n-      \"Auditory misperceptions after binges\"\n+      \"Marked euphoria\",\n+      \"Increased motivation / talkativeness\",\n+      \"Strong urge to redose\",\n+      \"Increased heart-rate & blood-pressure\",\n+      \"Peripheral vasoconstriction (cold extremities)\",\n+      \"Bruxism & muscle tension\",\n+      \"Hyperthermia / sweating\",\n+      \"Decreased appetite\",\n+      \"Mild visual stimulation at higher doses\",\n+      \"Anxiety or paranoia on the comedown\",\n+      \"Insomnia\"\n-      \"full_tolerance\": \"Forms after 1–2 days of consecutive use\",\n-      \"half_tolerance\": \"~1 week\",\n-      \"zero_tolerance\": \"2–3 weeks of abstinence\",\n+      \"full_tolerance\": \"Develops after 2-3 consecutive days of use\",\n+      \"half_tolerance\": \"~1-2 weeks\",\n+      \"zero_tolerance\": \"3-4 weeks of abstinence\",\n-        \"α-PVP\",\n-        \"4-F-PVP\",\n-        \"α-PHP\",\n-        \"amphetamines\"\n+        \"Other cathinones\",\n+        \"Amphetamines\",\n+        \"Cocaine\"\n-    \"half_life\": \"~2–3 h (estimated from in-vitro DAT assay & structural analogy to α-PPP)\",\n+    \"half_life\": \"Unstudied; based on analogues estimated 2-4 h (parent compound) with active metabolites extending effects.\",\n-        \"name\": \"Wikipedia – 4-Cl-PPP\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/4-Cl-PPP\"\n+        \"name\": \"TripSit – 4-CBC Factsheet\",\n+        \"reference\": \"https://drugs.tripsit.me/4-cbc\"\n-        \"name\": \"Eshleman et al., 2019. Structure-activity relationships of NPS at monoamine transporters.\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/31166536/\"\n+        \"name\": \"EMCDDA–Europol 2016 Report on New Psychoactive Substances (mentions 4-chlorobuphedrone seizures)\",\n+        \"reference\": \"https://www.emcdda.europa.eu/publications/implementation-reports/2016\"\n-        \"name\": \"Bluelight forum: “New RCs, 4-Cl-PPP & 4-Cl-PVP” user reports (posts #2–#8)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/new-rcs-4-cl-ppp-4-cl-pvp.800456/\"\n+        \"name\": \"Zuba & Byrska, “Structural studies of cathinone derivatives” Forensic Sci Int, 2013\",\n+        \"reference\": \"https://doi.org/10.1016/j.forsciint.2013.04.015\"\n-        \"name\": \"EMCDDA. New psychoactive substances: global markets, glocal threats.\",\n-        \"reference\": \"https://www.emcdda.europa.eu/publications/2016/new-psychoactive-substances_en\"\n+        \"name\": \"Simmler et al., “Monoamine transporter and receptor interaction profiles of novel cathinones” Neuropharmacology, 2014\",\n+        \"reference\": \"https://doi.org/10.1016/j.neuropharm.2013.10.016\"\n-        \"name\": \"PubChem: 163195101\",\n-        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/163195101\"\n+        \"name\": \"Reddit /r/researchchemicals – User report: “First time 4-CBC – teeth chatter & crash”, 2023-05-14\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/13hoq2c/first_time_4cbc_report\"\n-      \"research-chemical\"\n+      \"research-chemical\",\n+      \"habit-forming\"\n\n# 4-FPP · #620\n\n-  \"id\": 619,\n-  \"title\": \"4-CBC (4-Chlorobuphedrone)\",\n+  \"id\": 620,\n+  \"title\": \"4-FPP\",\n-    \"drug_name\": \"4-CBC (4-Chlorobuphedrone)\",\n-    \"chemical_name\": \"4-CBC\",\n-    \"alternative_name\": \"4-Chlorobuphedrone\",\n-    \"chemical_class\": \"Cathinones\",\n-    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor\",\n-    \"psychoactive_class\": \"Stimulant; entactogen\",\n+    \"drug_name\": \"4-FPP\",\n+    \"chemical_name\": \"4-FPP\",\n+    \"alternative_name\": \"para-Fluorophenylpiperazine; pFPP\",\n+    \"chemical_class\": \"Piperazines\",\n+    \"mechanism_of_action\": \"Serotonin receptor agonist\",\n+    \"psychoactive_class\": \"empathogen; mild psychedelic\",\n-            \"threshold\": \"20-30\",\n-            \"light\": \"40-70\",\n-            \"common\": \"70-100\",\n-            \"strong\": \"100-130\",\n-            \"heavy\": \"130+\"\n+            \"threshold\": \"10–20\",\n+            \"light\": \"20–40\",\n+            \"common\": \"40–80\",\n+            \"strong\": \"80–150\",\n+            \"heavy\": \"150+\"\n-            \"threshold\": \"15-25\",\n-            \"light\": \"40-60\",\n-            \"common\": \"60-90\",\n-            \"strong\": \"90-120\",\n-            \"heavy\": \"120+\"\n+            \"threshold\": \"5–10\",\n+            \"light\": \"10–20\",\n+            \"common\": \"20–40\",\n+            \"strong\": \"40–70\",\n+            \"heavy\": \"70+\"\n-            \"total_duration\": \"3-6 h\",\n-            \"onset\": \"30-60 min\",\n-            \"peak\": \"1-2 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-6 h of residual stimulation (“body load”, low mood, craving)\"\n+            \"total_duration\": \"4-8 h\",\n+            \"onset\": \"15-45 min\",\n+            \"peak\": \"1-3 h\",\n+            \"offset\": \"2-4 h\",\n+            \"after_effects\": \"2-6 h mild lethargy; headache\"\n-            \"total_duration\": \"3-6 h\",\n-            \"onset\": \"5-15 min\",\n-            \"peak\": \"1-2 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-6 h of residual stimulation (“body load”, low mood, craving)\"\n+            \"total_duration\": \"4-8 h\",\n+            \"onset\": \"15-45 min\",\n+            \"peak\": \"1-3 h\",\n+            \"offset\": \"2-4 h\",\n+            \"after_effects\": \"2-6 h mild lethargy; headache\"\n-    \"addiction_potential\": \"Moderate-to-high. Like other cathinones it strongly stimulates dopamine and norepinephrine re-uptake inhibition/release, producing compulsive redosing and binge patterns. Psychological dependence has been reported after multi-day use.\",\n+    \"addiction_potential\": \"Low. Acts primarily on 5-HT receptors and as a weak serotonin releaser; produces little reinforcement. Psychological habituation possible with frequent use.\",\n-        \"other potent stimulants (amphetamine, methamphetamine, α-PVP, cocaine)\",\n-        \"4-CEC / 4-CMC and related cathinones\",\n-        \"Tramadol (seizure risk)\"\n+        \"Linezolid\",\n+        \"Methylene blue\",\n+        \"Tramadol\",\n+        \"Meperidine\",\n+        \"Ritonavir\"\n-        \"Gabapentinoids (respiratory depression when coming down)\",\n-        \"Poppers (hypotension)\"\n+        \"SSRIs/SNRIs\",\n+        \"other piperazines (mCPP, TFMPP)\",\n+        \"MDMA or other strong releasers\",\n+        \"dextromethorphan\"\n-        \"Alcohol (cardio-toxicity, dehydration)\",\n-        \"Cannabis (anxiety possible)\",\n-        \"DXM (serotonin / hypertension)\",\n-        \"Benzodiazepines (may mask overdose signs)\"\n+        \"stimulants (cathinones, amphetamines)\",\n+        \"other psychedelics\",\n+        \"alcohol (adds sedation & dehydration)\"\n-    \"notes\": \"4-CBC is a very new cathinone with virtually no human or toxicological data. Animal work on close analogues (4-CMC, 4-CEC) suggests high neuro- and cardio-toxicity through dopamine transporter–mediated oxidative stress and QT-prolongation. Users report intense but short-lived stimulation similar to 4-CMC or cocaine, followed by a harsh crash. Severe vasoconstriction, bruxism, tachycardia and thermoregulatory issues are common. Start with allergy test (<5 mg), weigh doses accurately, keep body temperature under 38 °C, hydrate with electrolytes and avoid redosing cycles longer than 2-3 h. No data exist on pregnancy, cancer risk or long-term neuro-toxicity—abstinence is the only proven harm-reduction.\",\n+    \"notes\": \"4-FPP has circulated in many “legal-high” blends and occasionally as an adulterant in MDMA tablets. Effects are often described as a subdued, dreamy empathogen with light closed-eye visuals and a notable sedative ‘body-load’. Nausea and mild vasoconstriction are common above 60 mg. Because it is largely serotonergic, combining with other serotonin-increasing drugs markedly raises the risk of serotonin syndrome. Users report a ceiling effect—doses above ~120 mg add side-effects rather than euphoria. Stay well-hydrated, avoid redosing within the same session, and allow at least two weeks between uses to mitigate tolerance and possible neurochemical depletion.\",\n-      \"Marked euphoria\",\n-      \"Increased motivation / talkativeness\",\n-      \"Strong urge to redose\",\n-      \"Increased heart-rate & blood-pressure\",\n-      \"Peripheral vasoconstriction (cold extremities)\",\n-      \"Bruxism & muscle tension\",\n-      \"Hyperthermia / sweating\",\n-      \"Decreased appetite\",\n-      \"Mild visual stimulation at higher doses\",\n-      \"Anxiety or paranoia on the comedown\",\n-      \"Insomnia\"\n+      \"Warm empathy\",\n+      \"Anxiolysis\",\n+      \"Mild euphoria\",\n+      \"Sedation\",\n+      \"Closed-eye visual patterns\",\n+      \"Color enhancement\",\n+      \"Auditory softness/‘music appreciation’\",\n+      \"Dream-like thought loops\",\n+      \"Pupil dilation\",\n+      \"Jaw tension\",\n+      \"Nausea\",\n+      \"Body heaviness\",\n+      \"Vasoconstriction\",\n+      \"Mild dizziness/headache post-use\"\n-      \"full_tolerance\": \"Develops after 2-3 consecutive days of use\",\n-      \"half_tolerance\": \"~1-2 weeks\",\n-      \"zero_tolerance\": \"3-4 weeks of abstinence\",\n+      \"full_tolerance\": \"After 2–3 consecutive daily uses\",\n+      \"half_tolerance\": \"~7 days\",\n+      \"zero_tolerance\": \"~14–21 days\",\n-        \"Other cathinones\",\n-        \"Amphetamines\",\n-        \"Cocaine\"\n+        \"MDMA\",\n+        \"mCPP\",\n+        \"TFMPP\",\n+        \"classical psychedelics (partial)\"\n-    \"half_life\": \"Unstudied; based on analogues estimated 2-4 h (parent compound) with active metabolites extending effects.\",\n+    \"half_life\": \"Estimated 3–5 h (no formal human PK data; based on animal studies of phenylpiperazines)\",\n-        \"name\": \"TripSit – 4-CBC Factsheet\",\n-        \"reference\": \"https://drugs.tripsit.me/4-cbc\"\n+        \"name\": \"TripSit – 4-FPP profile\",\n+        \"reference\": \"https://drugs.tripsit.me/4-fpp\"\n-        \"name\": \"EMCDDA–Europol 2016 Report on New Psychoactive Substances (mentions 4-chlorobuphedrone seizures)\",\n-        \"reference\": \"https://www.emcdda.europa.eu/publications/implementation-reports/2016\"\n+        \"name\": \"Bluelight discussion: ‘Novel Empathogen: para-Fluorophenylpiperazine’\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/novel-empathogen-para-fluorophenylpiperazine-pfpp-4fpp.821107/\"\n-        \"name\": \"Zuba & Byrska, “Structural studies of cathinone derivatives” Forensic Sci Int, 2013\",\n-        \"reference\": \"https://doi.org/10.1016/j.forsciint.2013.04.015\"\n+        \"name\": \"Erowid Experience ID 61761 – ‘pFPP – 60 mg oral’\",\n+        \"reference\": \"https://erowid.org/experiences/exp.php?ID=61761\"\n-        \"name\": \"Simmler et al., “Monoamine transporter and receptor interaction profiles of novel cathinones” Neuropharmacology, 2014\",\n-        \"reference\": \"https://doi.org/10.1016/j.neuropharm.2013.10.016\"\n+        \"name\": \"Erowid Experience ID 56641 – ‘pFPP + methylone’\",\n+        \"reference\": \"https://erowid.org/experiences/exp.php?ID=56641\"\n-        \"name\": \"Reddit /r/researchchemicals – User report: “First time 4-CBC – teeth chatter & crash”, 2023-05-14\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/13hoq2c/first_time_4cbc_report\"\n+        \"name\": \"EMCDDA. Piperazines – A review of pFPP pharmacology and adverse effects (Technical report, 2010)\",\n+        \"reference\": \"https://www.emcdda.europa.eu/system/files/publications/639/TDS_Piperazines_192995.pdf\"\n-      \"stimulant\",\n+      \"entactogen\",\n-      \"habit-forming\"\n+      \"other entactogens\"\n\n# 4-MEPPP · #621\n\n-  \"id\": 620,\n-  \"title\": \"4-FPP\",\n+  \"id\": 621,\n+  \"title\": \"4-MEPPP\",\n-    \"drug_name\": \"4-FPP\",\n-    \"chemical_name\": \"4-FPP\",\n-    \"alternative_name\": \"para-Fluorophenylpiperazine; pFPP\",\n-    \"chemical_class\": \"Piperazines\",\n-    \"mechanism_of_action\": \"Serotonin receptor agonist\",\n-    \"psychoactive_class\": \"empathogen; mild psychedelic\",\n+    \"drug_name\": \"4-MEPPP\",\n+    \"chemical_name\": \"4-MEPPP\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Substituted pyrrolidines\",\n+    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor\",\n+    \"psychoactive_class\": \"Stimulant (primarily DAT/NET reuptake inhibitor; weak SERT activity)\",\n-            \"threshold\": \"10–20\",\n-            \"light\": \"20–40\",\n-            \"common\": \"40–80\",\n-            \"strong\": \"80–150\",\n-            \"heavy\": \"150+\"\n+            \"threshold\": \"10 mg\",\n+            \"light\": \"10 mg - 30 mg\",\n+            \"common\": \"30 mg - 60 mg\",\n+            \"strong\": \"60 mg - 100 mg\",\n+            \"heavy\": \"100+ mg\"\n-            \"threshold\": \"5–10\",\n-            \"light\": \"10–20\",\n-            \"common\": \"20–40\",\n-            \"strong\": \"40–70\",\n-            \"heavy\": \"70+\"\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"5 mg - 15 mg\",\n+            \"common\": \"15 mg - 40 mg\",\n+            \"strong\": \"40 mg - 60 mg\",\n+            \"heavy\": \"60+ mg\"\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"5 mg - 20 mg\",\n+            \"common\": \"20 mg - 50 mg\",\n+            \"strong\": \"50 mg - 80 mg\",\n+            \"heavy\": \"80+ mg\"\n+          }\n-            \"total_duration\": \"4-8 h\",\n-            \"onset\": \"15-45 min\",\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"2-4 h\",\n-            \"after_effects\": \"2-6 h mild lethargy; headache\"\n+            \"total_duration\": \"2-4 hours (active stimulation); 4-8 hours total including residual\",\n+            \"onset\": \"20-45 min\",\n+            \"peak\": \"0.5-1.5 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"4-12 hours (residual stimulation, appetite suppression, difficulty sleeping)\"\n-            \"total_duration\": \"4-8 h\",\n-            \"onset\": \"15-45 min\",\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"2-4 h\",\n-            \"after_effects\": \"2-6 h mild lethargy; headache\"\n+            \"total_duration\": \"2-4 hours (active stimulation); 4-8 hours total including residual\",\n+            \"onset\": \"1-5 min\",\n+            \"peak\": \"0.5-1.5 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"4-12 hours (residual stimulation, appetite suppression, difficulty sleeping)\"\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"canonical_routes\": [\n+            \"rectal\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"2-4 hours (active stimulation); 4-8 hours total including residual\",\n+            \"onset\": \"5-15 min\",\n+            \"peak\": \"0.5-1.5 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"4-12 hours (residual stimulation, appetite suppression, difficulty sleeping)\"\n+          }\n-    \"addiction_potential\": \"Low. Acts primarily on 5-HT receptors and as a weak serotonin releaser; produces little reinforcement. Psychological habituation possible with frequent use.\",\n+    \"addiction_potential\": \"Moderate to high (stimulant-typical): dopaminergic reinforcement, short duration and redose drive; lower 'fiendishness' than MDPV reported anecdotally but binges still occur.\",\n-        \"MAOIs\",\n-        \"Linezolid\",\n-        \"Methylene blue\",\n-        \"Tramadol\",\n-        \"Meperidine\",\n-        \"Ritonavir\"\n+        \"MAOIs (hypertensive crisis, hyperthermia)\",\n+        \"other potent stimulants (cocaine, amphetamine, α-PVP, MDPV) (tachyarrhythmia, hyperthermia)\",\n+        \"bupropion or other NDRIs at high dose (seizure risk, hypertension)\",\n+        \"tramadol (seizure risk)\"\n-        \"SSRIs/SNRIs\",\n-        \"other piperazines (mCPP, TFMPP)\",\n-        \"MDMA or other strong releasers\",\n-        \"dextromethorphan\"\n+        \"large amounts of alcohol (cardiac strain, dehydration, risk-taking)\",\n+        \"synthetic cannabinoids (panic, tachycardia)\",\n+        \"decongestants with pseudoephedrine/phenylephrine (additive vasoconstriction)\"\n-        \"stimulants (cathinones, amphetamines)\",\n-        \"other psychedelics\",\n-        \"alcohol (adds sedation & dehydration)\"\n+        \"SSRIs/SNRIs (serotonergic load at high doses; monitor for agitation/hyperthermia)\",\n+        \"caffeine >200 mg (palpitations, anxiety)\",\n+        \"antipsychotics (QT prolongation concerns; blunted stimulant effects leading to redose)\"\n-    \"notes\": \"4-FPP has circulated in many “legal-high” blends and occasionally as an adulterant in MDMA tablets. Effects are often described as a subdued, dreamy empathogen with light closed-eye visuals and a notable sedative ‘body-load’. Nausea and mild vasoconstriction are common above 60 mg. Because it is largely serotonergic, combining with other serotonin-increasing drugs markedly raises the risk of serotonin syndrome. Users report a ceiling effect—doses above ~120 mg add side-effects rather than euphoria. Stay well-hydrated, avoid redosing within the same session, and allow at least two weeks between uses to mitigate tolerance and possible neurochemical depletion.\",\n+    \"notes\": \"4-MEPPP, chemically 4-methyl-alpha-pyrrolidinopropiophenone, was designed to mimic classic stimulants. Reports describe SNDRI-like alertness with rapid tolerance and highlight the need for accurate dosing and respect for its abuse potential.\\n\\n4-MEPPP (4-methyl-α-pyrrolidinopropiophenone) is a pyrrolidinophenone stimulant related to α-PPP and more distantly to α-PVP/MDPV. In vitro and in vivo work indicates it behaves primarily as a dopamine>norepinephrine reuptake blocker with minimal serotonin releasing activity, yielding a 'cleaner', more dopaminergic stimulation profile than 4-MEC or mephedrone. Intranasal user reports cluster around 20-40 mg per line with fast onset (1-2 min), modest euphoria, talkativeness, mydriasis, and a relatively short window (about 1-2 h of noticeable effects) followed by a mild comedown; 50+ mg in a single line has been described as too intense/panicky by some. Oral doses are less well-documented but appear higher than intranasal on a milligram basis (common 30-60 mg), with slower onset and smoother peak. Several users note a 'ceiling' effect where repeated lines after the first hour add side effects (tachycardia, anxiety) more than benefits; scheduling gaps of 90+ minutes between trials reduces stacking. Market context matters: 4-MEPPP has been found in mixed 'NRG' products and mis-sold as α-PVP; expect inconsistent potency and possible blends. Use multiple reagents (e.g., Marquis, Mecke, Simon’s) and avoid assuming identity from a single color reaction; ideally verify with FT-IR/GC-MS from a drug-checking service. Start low, use a 0.001 g scale, and consider volumetric dosing to achieve <10 mg accuracy when titrating. Redosing loops and sleep loss are the main acute harm vectors: set a hard session cap (e.g., 60-120 mg total depending on ROA), avoid back-to-back days, and plan a sleep window. Hydration and electrolytes (especially potassium/magnesium) help with jaw tension and tremor; light carbohydrates can blunt post-peak edginess. Avoid strenuous activity and hot environments to limit hyperthermia risk, and monitor pulse/temperature during sessions. Combining with other stimulants or MAOIs significantly increases cardiovascular and neurotoxic risk and should be avoided; alcohol adds cardiovascular strain and disinhibition. Intravenous or vaporized routes are strongly discouraged due to unknown pyrolysis products, rapid spike/crash dynamics, and high complication risk; most reported benefits are achievable with intranasal or oral use at much lower risk. Tolerance rises across a binge but tends to reset substantially after 3-5 days off; repeated multi-day runs increase crash dysphoria and insomnia. Because analytical work shows rapid metabolism and detection via characteristic metabolites, drug screens may miss parent compound; however, this does not imply safety. If anxiety or palpitations escalate, stop redosing, hydrate, cool down, and consider non-sedating de-escalation (quiet environment; avoid benzodiazepines unless medically indicated).\",\n-      \"Warm empathy\",\n-      \"Anxiolysis\",\n-      \"Mild euphoria\",\n-      \"Sedation\",\n-      \"Closed-eye visual patterns\",\n-      \"Color enhancement\",\n-      \"Auditory softness/‘music appreciation’\",\n-      \"Dream-like thought loops\",\n-      \"Pupil dilation\",\n-      \"Jaw tension\",\n-      \"Nausea\",\n-      \"Body heaviness\",\n-      \"Vasoconstriction\",\n-      \"Mild dizziness/headache post-use\"\n+      \"alertness and increased talkativeness\",\n+      \"moderate euphoria (short-lived)\",\n+      \"enhanced focus with low–moderate doses\",\n+      \"mydriasis (large pupils)\",\n+      \"appetite suppression and dry mouth\",\n+      \"jaw tension, fine tremor\",\n+      \"anxiety/panic at high doses\",\n+      \"residual stimulation with difficulty sleeping\"\n-      \"full_tolerance\": \"After 2–3 consecutive daily uses\",\n-      \"half_tolerance\": \"~7 days\",\n-      \"zero_tolerance\": \"~14–21 days\",\n+      \"full_tolerance\": \"after 1-2 heavy sessions or a multi-hour binge\",\n+      \"half_tolerance\": \"3-5 days\",\n+      \"zero_tolerance\": \"10-14 days\",\n-        \"MDMA\",\n-        \"mCPP\",\n-        \"TFMPP\",\n-        \"classical psychedelics (partial)\"\n+        \"α-PPP\",\n+        \"α-PVP/MDPV\",\n+        \"other pyrrolidinophenones\",\n+        \"dopamine-selective stimulants\"\n-    \"half_life\": \"Estimated 3–5 h (no formal human PK data; based on animal studies of phenylpiperazines)\",\n+    \"half_life\": \"2-4 hours (subjective window typical); precise human PK not established\",\n-        \"name\": \"TripSit – 4-FPP profile\",\n-        \"reference\": \"https://drugs.tripsit.me/4-fpp\"\n+        \"name\": \"Bluelight – 4-MePPP thread (intranasal doses, onset, user patterns)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/4-meppp-2-pyrrolidin-1-yl-1-p-tolylpropan-1-one-cas-28117-80-8.604620/\"\n-        \"name\": \"Bluelight discussion: ‘Novel Empathogen: para-Fluorophenylpiperazine’\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/novel-empathogen-para-fluorophenylpiperazine-pfpp-4fpp.821107/\"\n+        \"name\": \"Bluelight – α-PPP discussion (contextual dosing/ROA comparisons within class)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/4-methyl-alpha-pyrrolidinopropiophenone.372855/\"\n-        \"name\": \"Erowid Experience ID 61761 – ‘pFPP – 60 mg oral’\",\n-        \"reference\": \"https://erowid.org/experiences/exp.php?ID=61761\"\n+        \"name\": \"Saha et al., 2015 – 4-MEC vs 4-MePPP transporter pharmacology (DAT blocker, minimal SERT substrate activity for 4-MePPP)\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC4397398/\"\n-        \"name\": \"Erowid Experience ID 56641 – ‘pFPP + methylone’\",\n-        \"reference\": \"https://erowid.org/experiences/exp.php?ID=56641\"\n+        \"name\": \"DEA – Synthetic Cathinones Three-Factor Analysis (4-MePPP animal discrimination/locomotor data)\",\n+        \"reference\": \"https://www.dea.gov/sites/default/files/2020-06/Synthetic%20Cathinones%20-%20Three%20Factor%20Analysis.pdf\"\n-        \"name\": \"EMCDDA. Piperazines – A review of pFPP pharmacology and adverse effects (Technical report, 2010)\",\n-        \"reference\": \"https://www.emcdda.europa.eu/system/files/publications/639/TDS_Piperazines_192995.pdf\"\n+        \"name\": \"Springer et al., 2002 – 4-MePPP metabolism and GC-MS detection (rat urine)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/12015267\"\n+      },\n+      {\n+        \"name\": \"Springer et al., 2003 – CYP identification for 4-MePPP in HLM\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/12867484\"\n+      },\n+      {\n+        \"name\": \"Brandt et al., 2011 – NRG blends analysis (4-MePPP identified in 'NRG-3')\",\n+        \"reference\": \"https://www.drugtestinganalysis.co.uk/10.1002/dta.204\"\n+      },\n+      {\n+        \"name\": \"Wikipedia – 4'-Methyl-α-pyrrolidinopropiophenone (overview, NRG-3 context, references to Springer/Brandt)\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/4%27-Methyl-%CE%B1-pyrrolidinopropiophenone\"\n+      },\n+      {\n+        \"name\": \"Erowid 4-MEPPP vault (general background)\",\n+        \"reference\": \"https://erowid.org/chemicals/4_meppp/4_meppp.shtml\"\n-      \"entactogen\",\n-      \"research-chemical\",\n-      \"other entactogens\"\n+      \"stimulant\",\n+      \"research-chemical\"\n\n# 4-MXP · #622\n\n-  \"id\": 621,\n-  \"title\": \"4-MEPPP\",\n+  \"id\": 622,\n+  \"title\": \"4-MXP\",\n-    \"drug_name\": \"4-MEPPP\",\n-    \"chemical_name\": \"4-MEPPP\",\n+    \"drug_name\": \"4-MXP\",\n+    \"chemical_name\": \"4-MXP\",\n-    \"chemical_class\": \"Substituted pyrrolidines\",\n-    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor\",\n-    \"psychoactive_class\": \"Stimulant (primarily DAT/NET reuptake inhibitor; weak SERT activity)\",\n+    \"chemical_class\": \"Substituted diarylethylamines\",\n+    \"mechanism_of_action\": \"NMDA receptor antagonist\",\n+    \"psychoactive_class\": \"Dissociative; Hallucinogen\",\n-            \"threshold\": \"10 mg\",\n-            \"light\": \"10 mg - 30 mg\",\n-            \"common\": \"30 mg - 60 mg\",\n-            \"strong\": \"60 mg - 100 mg\",\n-            \"heavy\": \"100+ mg\"\n+            \"threshold\": \"15–25\",\n+            \"light\": \"25–50\",\n+            \"common\": \"50–100\",\n+            \"strong\": \"100–150\",\n+            \"heavy\": \"150 +‎\"\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"5 mg - 15 mg\",\n-            \"common\": \"15 mg - 40 mg\",\n-            \"strong\": \"40 mg - 60 mg\",\n-            \"heavy\": \"60+ mg\"\n+            \"threshold\": \"5–10\",\n+            \"light\": \"15–30\",\n+            \"common\": \"30–70\",\n+            \"strong\": \"70–100\",\n+            \"heavy\": \"100 +‎\"\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"5 mg - 20 mg\",\n-            \"common\": \"20 mg - 50 mg\",\n-            \"strong\": \"50 mg - 80 mg\",\n-            \"heavy\": \"80+ mg\"\n-          }\n-            \"total_duration\": \"2-4 hours (active stimulation); 4-8 hours total including residual\",\n-            \"onset\": \"20-45 min\",\n-            \"peak\": \"0.5-1.5 hours\",\n-            \"offset\": \"1-2 hours\",\n-            \"after_effects\": \"4-12 hours (residual stimulation, appetite suppression, difficulty sleeping)\"\n+            \"total_duration\": \"6-12 h\",\n+            \"onset\": \"30-120 min\",\n+            \"peak\": \"2-5 h\",\n+            \"offset\": \"2-3 h\",\n+            \"after_effects\": \"6-24 h residual stimulation; cognitive fog & insomnia\"\n-            \"total_duration\": \"2-4 hours (active stimulation); 4-8 hours total including residual\",\n-            \"onset\": \"1-5 min\",\n-            \"peak\": \"0.5-1.5 hours\",\n-            \"offset\": \"1-2 hours\",\n-            \"after_effects\": \"4-12 hours (residual stimulation, appetite suppression, difficulty sleeping)\"\n+            \"total_duration\": \"6-12 h\",\n+            \"onset\": \"10-45 min\",\n+            \"peak\": \"2-5 h\",\n+            \"offset\": \"2-3 h\",\n+            \"after_effects\": \"6-24 h residual stimulation; cognitive fog & insomnia\"\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"canonical_routes\": [\n-            \"rectal\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"2-4 hours (active stimulation); 4-8 hours total including residual\",\n-            \"onset\": \"5-15 min\",\n-            \"peak\": \"0.5-1.5 hours\",\n-            \"offset\": \"1-2 hours\",\n-            \"after_effects\": \"4-12 hours (residual stimulation, appetite suppression, difficulty sleeping)\"\n-          }\n-    \"addiction_potential\": \"Moderate to high (stimulant-typical): dopaminergic reinforcement, short duration and redose drive; lower 'fiendishness' than MDPV reported anecdotally but binges still occur.\",\n+    \"addiction_potential\": \"Moderate psychological dependence possible. Compulsive redosing and rapid tolerance are frequently reported; physical withdrawal is rare.\",\n-        \"MAOIs (hypertensive crisis, hyperthermia)\",\n-        \"other potent stimulants (cocaine, amphetamine, α-PVP, MDPV) (tachyarrhythmia, hyperthermia)\",\n-        \"bupropion or other NDRIs at high dose (seizure risk, hypertension)\",\n-        \"tramadol (seizure risk)\"\n+        \"alcohol\",\n+        \"opioids\",\n+        \"benzodiazepines\",\n+        \"GHB\",\n+        \"barbiturates\",\n+        \"other dissociatives (ketamine, DXM, PCP analogues)\"\n-        \"large amounts of alcohol (cardiac strain, dehydration, risk-taking)\",\n-        \"synthetic cannabinoids (panic, tachycardia)\",\n-        \"decongestants with pseudoephedrine/phenylephrine (additive vasoconstriction)\"\n+        \"MAO-Is\",\n+        \"tramadol\",\n+        \"gabapentinoids\"\n-        \"SSRIs/SNRIs (serotonergic load at high doses; monitor for agitation/hyperthermia)\",\n-        \"caffeine >200 mg (palpitations, anxiety)\",\n-        \"antipsychotics (QT prolongation concerns; blunted stimulant effects leading to redose)\"\n+        \"stimulants\",\n+        \"psychedelics\",\n+        \"SSRI/SNRI\",\n+        \"antihistamines\"\n-    \"notes\": \"4-MEPPP, chemically 4-methyl-alpha-pyrrolidinopropiophenone, was designed to mimic classic stimulants. Reports describe SNDRI-like alertness with rapid tolerance and highlight the need for accurate dosing and respect for its abuse potential.\\n\\n4-MEPPP (4-methyl-α-pyrrolidinopropiophenone) is a pyrrolidinophenone stimulant related to α-PPP and more distantly to α-PVP/MDPV. In vitro and in vivo work indicates it behaves primarily as a dopamine>norepinephrine reuptake blocker with minimal serotonin releasing activity, yielding a 'cleaner', more dopaminergic stimulation profile than 4-MEC or mephedrone. Intranasal user reports cluster around 20-40 mg per line with fast onset (1-2 min), modest euphoria, talkativeness, mydriasis, and a relatively short window (about 1-2 h of noticeable effects) followed by a mild comedown; 50+ mg in a single line has been described as too intense/panicky by some. Oral doses are less well-documented but appear higher than intranasal on a milligram basis (common 30-60 mg), with slower onset and smoother peak. Several users note a 'ceiling' effect where repeated lines after the first hour add side effects (tachycardia, anxiety) more than benefits; scheduling gaps of 90+ minutes between trials reduces stacking. Market context matters: 4-MEPPP has been found in mixed 'NRG' products and mis-sold as α-PVP; expect inconsistent potency and possible blends. Use multiple reagents (e.g., Marquis, Mecke, Simon’s) and avoid assuming identity from a single color reaction; ideally verify with FT-IR/GC-MS from a drug-checking service. Start low, use a 0.001 g scale, and consider volumetric dosing to achieve <10 mg accuracy when titrating. Redosing loops and sleep loss are the main acute harm vectors: set a hard session cap (e.g., 60-120 mg total depending on ROA), avoid back-to-back days, and plan a sleep window. Hydration and electrolytes (especially potassium/magnesium) help with jaw tension and tremor; light carbohydrates can blunt post-peak edginess. Avoid strenuous activity and hot environments to limit hyperthermia risk, and monitor pulse/temperature during sessions. Combining with other stimulants or MAOIs significantly increases cardiovascular and neurotoxic risk and should be avoided; alcohol adds cardiovascular strain and disinhibition. Intravenous or vaporized routes are strongly discouraged due to unknown pyrolysis products, rapid spike/crash dynamics, and high complication risk; most reported benefits are achievable with intranasal or oral use at much lower risk. Tolerance rises across a binge but tends to reset substantially after 3-5 days off; repeated multi-day runs increase crash dysphoria and insomnia. Because analytical work shows rapid metabolism and detection via characteristic metabolites, drug screens may miss parent compound; however, this does not imply safety. If anxiety or palpitations escalate, stop redosing, hydrate, cool down, and consider non-sedating de-escalation (quiet environment; avoid benzodiazepines unless medically indicated).\",\n+    \"notes\": \"4-MXP (commonly called MXP, Methoxphenidine) is a long-acting dissociative that can take up to two hours to appear orally, leading inexperienced users to redose prematurely. Doses above ~150 mg have produced severe confusion, black-outs, urinary tract irritation similar to ketamine cystitis, and in a few cases hospitalisation. Large crystals are caustic to nasal tissue; oral capsules are preferred. Because of its long half-life, impairment can persist into the following day—avoid driving or safety-critical work for at least 24 h. Always use an accurate milligram scale; potency between batches varies markedly.\",\n-      \"alertness and increased talkativeness\",\n-      \"moderate euphoria (short-lived)\",\n-      \"enhanced focus with low–moderate doses\",\n-      \"mydriasis (large pupils)\",\n-      \"appetite suppression and dry mouth\",\n-      \"jaw tension, fine tremor\",\n-      \"anxiety/panic at high doses\",\n-      \"residual stimulation with difficulty sleeping\"\n+      \"dissociation/floaty body sensation\",\n+      \"analgesia\",\n+      \"mild euphoria or melancholic mood\",\n+      \"time dilation\",\n+      \"vision rippling/warping at higher doses\",\n+      \"auditory enhancement (music sounds “crisp”)\",\n+      \"impaired coordination & slurred speech\",\n+      \"memory gaps/black-outs at high doses\",\n+      \"introspection and emotional catharsis\",\n+      \"tachycardia & mild hypertension\"\n-      \"full_tolerance\": \"after 1-2 heavy sessions or a multi-hour binge\",\n-      \"half_tolerance\": \"3-5 days\",\n-      \"zero_tolerance\": \"10-14 days\",\n+      \"full_tolerance\": \"Develops after 2–4 consecutive days of use\",\n+      \"half_tolerance\": \"1–2 weeks\",\n+      \"zero_tolerance\": \"3–4 weeks of abstinence\",\n-        \"α-PPP\",\n-        \"α-PVP/MDPV\",\n-        \"other pyrrolidinophenones\",\n-        \"dopamine-selective stimulants\"\n+        \"ketamine\",\n+        \"DXM\",\n+        \"MXE\",\n+        \"other diarylethylamines\"\n-    \"half_life\": \"2-4 hours (subjective window typical); precise human PK not established\",\n+    \"half_life\": \"≈ 12–15 h (estimated from limited human and animal data)\",\n-        \"name\": \"Bluelight – 4-MePPP thread (intranasal doses, onset, user patterns)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/4-meppp-2-pyrrolidin-1-yl-1-p-tolylpropan-1-one-cas-28117-80-8.604620/\"\n+        \"name\": \"4-MXP – Wikipedia\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/4-MXP\"\n-        \"name\": \"Bluelight – α-PPP discussion (contextual dosing/ROA comparisons within class)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/4-methyl-alpha-pyrrolidinopropiophenone.372855/\"\n+        \"name\": \"The Big & Dandy Methoxphenidine Thread (user doses & duration)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-methoxphenidine-mxp-thread-part-2-foxphenny-methoxphenny.777635/\"\n-        \"name\": \"Saha et al., 2015 – 4-MEC vs 4-MePPP transporter pharmacology (DAT blocker, minimal SERT substrate activity for 4-MePPP)\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC4397398/\"\n+        \"name\": \"Erowid Experience #108006 – Methoxphenidine 75 mg oral\",\n+        \"reference\": \"https://www.erowid.org/experiences/exp.php?ID=108006\"\n-        \"name\": \"DEA – Synthetic Cathinones Three-Factor Analysis (4-MePPP animal discrimination/locomotor data)\",\n-        \"reference\": \"https://www.dea.gov/sites/default/files/2020-06/Synthetic%20Cathinones%20-%20Three%20Factor%20Analysis.pdf\"\n+        \"name\": \"Wallach et al., Diarylethylamines: Pharmacology of Diphenidine Analogues\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/25224818/\"\n-        \"name\": \"Springer et al., 2002 – 4-MePPP metabolism and GC-MS detection (rat urine)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/12015267\"\n-      },\n-      {\n-        \"name\": \"Springer et al., 2003 – CYP identification for 4-MePPP in HLM\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/12867484\"\n-      },\n-      {\n-        \"name\": \"Brandt et al., 2011 – NRG blends analysis (4-MePPP identified in 'NRG-3')\",\n-        \"reference\": \"https://www.drugtestinganalysis.co.uk/10.1002/dta.204\"\n-      },\n-      {\n-        \"name\": \"Wikipedia – 4'-Methyl-α-pyrrolidinopropiophenone (overview, NRG-3 context, references to Springer/Brandt)\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/4%27-Methyl-%CE%B1-pyrrolidinopropiophenone\"\n-      },\n-      {\n-        \"name\": \"Erowid 4-MEPPP vault (general background)\",\n-        \"reference\": \"https://erowid.org/chemicals/4_meppp/4_meppp.shtml\"\n+        \"name\": \"ACMD Technical Report on Methoxphenidine (UK Home Office, 2016)\",\n+        \"reference\": \"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/535573/ACMD_Report_-_Methoxphenidine.pdf\"\n-      \"stimulant\",\n+      \"dissociative\",\n\n# 5-AEDB · #623\n\n-  \"id\": 622,\n-  \"title\": \"4-MXP\",\n+  \"id\": 623,\n+  \"title\": \"5-AEDB\",\n-    \"drug_name\": \"4-MXP\",\n-    \"chemical_name\": \"4-MXP\",\n+    \"drug_name\": \"5-AEDB\",\n+    \"chemical_name\": \"5-AEDB\",\n-    \"chemical_class\": \"Substituted diarylethylamines\",\n-    \"mechanism_of_action\": \"NMDA receptor antagonist\",\n-    \"psychoactive_class\": \"Dissociative; Hallucinogen\",\n+    \"chemical_class\": \"Benzofurans\",\n+    \"mechanism_of_action\": \"Stimulant (uncertain mechanism)\",\n+    \"psychoactive_class\": \"Entactogen; stimulant\",\n-            \"threshold\": \"15–25\",\n-            \"light\": \"25–50\",\n-            \"common\": \"50–100\",\n-            \"strong\": \"100–150\",\n-            \"heavy\": \"150 +‎\"\n+            \"threshold\": \"25 mg\",\n+            \"light\": \"40–60 mg\",\n+            \"common\": \"60–100 mg\",\n+            \"strong\": \"100–130 mg\",\n+            \"heavy\": \"130 mg + (NOT ADVISED)\"\n-        },\n-        {\n-          \"route\": \"insufflated\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"5–10\",\n-            \"light\": \"15–30\",\n-            \"common\": \"30–70\",\n-            \"strong\": \"70–100\",\n-            \"heavy\": \"100 +‎\"\n-          }\n-            \"total_duration\": \"6-12 h\",\n-            \"onset\": \"30-120 min\",\n-            \"peak\": \"2-5 h\",\n-            \"offset\": \"2-3 h\",\n-            \"after_effects\": \"6-24 h residual stimulation; cognitive fog & insomnia\"\n+            \"total_duration\": \"4-6 h\",\n+            \"onset\": \"45-90 min\",\n+            \"peak\": \"1.5-3 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-6 h of residual stimulation (‘after-glow’ or restlessness)\"\n-        },\n-        {\n-          \"route\": \"insufflated\",\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"6-12 h\",\n-            \"onset\": \"10-45 min\",\n-            \"peak\": \"2-5 h\",\n-            \"offset\": \"2-3 h\",\n-            \"after_effects\": \"6-24 h residual stimulation; cognitive fog & insomnia\"\n-          }\n-    \"addiction_potential\": \"Moderate psychological dependence possible. Compulsive redosing and rapid tolerance are frequently reported; physical withdrawal is rare.\",\n+    \"addiction_potential\": \"Moderate. Like other serotonin–releasing empathogens (e.g. MDMA, 6-APB) it produces euphoria and could encourage redosing. No published cases of physical dependence, but compulsive use has been reported anecdotally.\",\n-        \"alcohol\",\n-        \"opioids\",\n-        \"benzodiazepines\",\n-        \"GHB\",\n-        \"barbiturates\",\n-        \"other dissociatives (ketamine, DXM, PCP analogues)\"\n+        \"MAOIs\",\n+        \"Tramadol\",\n+        \"DXM\",\n+        \"MDMA (↑ risk of serotonin syndrome)\",\n+        \"Stimulant cathinones (↑ cardiovascular stress)\"\n-        \"MAO-Is\",\n-        \"tramadol\",\n-        \"gabapentinoids\"\n+        \"Alcohol (↑ dehydration / overheating)\",\n+        \"Cocaine\"\n-        \"stimulants\",\n-        \"psychedelics\",\n-        \"SSRI/SNRI\",\n-        \"antihistamines\"\n+        \"SSRIs/SNRIs (may blunt effects or precipitate serotonin toxicity)\",\n+        \"Bupropion\",\n+        \"α-2 agonists\",\n+        \"GHB/benzodiazepines (CNS depression when coming down)\"\n-    \"notes\": \"4-MXP (commonly called MXP, Methoxphenidine) is a long-acting dissociative that can take up to two hours to appear orally, leading inexperienced users to redose prematurely. Doses above ~150 mg have produced severe confusion, black-outs, urinary tract irritation similar to ketamine cystitis, and in a few cases hospitalisation. Large crystals are caustic to nasal tissue; oral capsules are preferred. Because of its long half-life, impairment can persist into the following day—avoid driving or safety-critical work for at least 24 h. Always use an accurate milligram scale; potency between batches varies markedly.\",\n+    \"notes\": \"• Practically no human research exists; all parameters are based on scattered user reports of ‘5-AEDB’ sold online between 2019–2024 and extrapolation from related benzofurans (5-APB, 5-APDB).\\n• Potency appears roughly 60-70 % of 5-APB by weight and markedly shorter in duration.\\n• Users frequently report pronounced peripheral stimulation (↑ HR/BP) compared with MDMA, alongside moderate empathogenic warmth and mild visual enhancement.\\n• Severe vasoconstriction (‘purple feet’), bruxism, and nystagmus have been described at doses >100 mg.\\n• Because reagent reactions overlap with 5-APDB and other APBs, professional analysis (FT-IR/GC-MS) is recommended.\\n• Start low, ensure cool environment, hydrate with electrolytes; avoid redosing within 8 h to reduce neuro- and cardiotoxic risk.\",\n-      \"dissociation/floaty body sensation\",\n-      \"analgesia\",\n-      \"mild euphoria or melancholic mood\",\n-      \"time dilation\",\n-      \"vision rippling/warping at higher doses\",\n-      \"auditory enhancement (music sounds “crisp”)\",\n-      \"impaired coordination & slurred speech\",\n-      \"memory gaps/black-outs at high doses\",\n-      \"introspection and emotional catharsis\",\n-      \"tachycardia & mild hypertension\"\n+      \"Euphoria\",\n+      \"Empathy and prosocial feelings\",\n+      \"Anxiolysis\",\n+      \"Stimulation (mental and physical)\",\n+      \"Enhanced tactile sensations\",\n+      \"Slight visual tracers at high doses\",\n+      \"Jaw clenching/bruxism\",\n+      \"Vasoconstriction/cold extremities\",\n+      \"Mydriasis\",\n+      \"Difficulty sleeping for several hours after use\"\n-      \"full_tolerance\": \"Develops after 2–4 consecutive days of use\",\n-      \"half_tolerance\": \"1–2 weeks\",\n-      \"zero_tolerance\": \"3–4 weeks of abstinence\",\n+      \"full_tolerance\": \"After 2–3 consecutive or high-dose sessions\",\n+      \"half_tolerance\": \"~1 week\",\n+      \"zero_tolerance\": \"1–2 months\",\n-        \"ketamine\",\n-        \"DXM\",\n-        \"MXE\",\n-        \"other diarylethylamines\"\n+        \"MDMA\",\n+        \"5-APB\",\n+        \"other serotonergic empathogens\"\n-    \"half_life\": \"≈ 12–15 h (estimated from limited human and animal data)\",\n+    \"half_life\": \"~3–4 h (extrapolated from animal microsome data; human data unavailable)\",\n-        \"name\": \"4-MXP – Wikipedia\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/4-MXP\"\n+        \"name\": \"Test-kit colour reactions for APBs (user ‘snmfmy’).\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/any-tests-to-distinguish-6-apb-from-5-apb-or-other-benzofurans.937517/\"\n-        \"name\": \"The Big & Dandy Methoxphenidine Thread (user doses & duration)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-methoxphenidine-mxp-thread-part-2-foxphenny-methoxphenny.777635/\"\n+        \"name\": \"Anonymous user reports compiled on r/ResearchChemicals (Oct 2021 – Apr 2024).\",\n+        \"reference\": \"https://www.reddit.com/search/?q=5-AEDB\"\n-        \"name\": \"Erowid Experience #108006 – Methoxphenidine 75 mg oral\",\n-        \"reference\": \"https://www.erowid.org/experiences/exp.php?ID=108006\"\n+        \"name\": \"Brandt, S.D. et al. (2010) ‘Analogs of MDMA: structure–activity relationships’. Drug Test. Anal.\",\n+        \"reference\": \"https://doi.org/10.1002/dta.152\"\n-        \"name\": \"Wallach et al., Diarylethylamines: Pharmacology of Diphenidine Analogues\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/25224818/\"\n-      },\n-      {\n-        \"name\": \"ACMD Technical Report on Methoxphenidine (UK Home Office, 2016)\",\n-        \"reference\": \"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/535573/ACMD_Report_-_Methoxphenidine.pdf\"\n+        \"name\": \"Erowid: Other Info6.shtml\",\n+        \"reference\": \"https://erowid.org/chemicals/other/other_info6.shtml#5-AEDB\"\n-      \"dissociative\",\n+      \"stimulant\",\n+      \"entactogen\",\n\n# 5-Cl-AMT · #625\n\n-  \"id\": 623,\n-  \"title\": \"5-AEDB\",\n+  \"id\": 625,\n+  \"title\": \"5-Cl-AMT\",\n-    \"drug_name\": \"5-AEDB\",\n-    \"chemical_name\": \"5-AEDB\",\n+    \"drug_name\": \"5-Cl-AMT\",\n+    \"chemical_name\": \"5-Cl-AMT\",\n-    \"chemical_class\": \"Benzofurans\",\n-    \"mechanism_of_action\": \"Stimulant (uncertain mechanism)\",\n-    \"psychoactive_class\": \"Entactogen; stimulant\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist; monoamine oxidase inhibitor\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-            \"threshold\": \"25 mg\",\n-            \"light\": \"40–60 mg\",\n-            \"common\": \"60–100 mg\",\n-            \"strong\": \"100–130 mg\",\n-            \"heavy\": \"130 mg + (NOT ADVISED)\"\n+            \"threshold\": \"0.5 mg - 1 mg\",\n+            \"light\": \"1 mg - 3 mg\",\n+            \"common\": \"3 mg - 8 mg\",\n+            \"strong\": \"8 mg - 12 mg\",\n+            \"heavy\": \"12+ mg\"\n-            \"total_duration\": \"4-6 h\",\n-            \"onset\": \"45-90 min\",\n-            \"peak\": \"1.5-3 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-6 h of residual stimulation (‘after-glow’ or restlessness)\"\n+            \"total_duration\": \"10-18 hours\",\n+            \"onset\": \"30-120 minutes\",\n+            \"peak\": \"3-6 hours\",\n+            \"offset\": \"6-12 hours\",\n+            \"after_effects\": \"12-24 hours (residual stimulation, insomnia, depletion)\"\n-    \"addiction_potential\": \"Moderate. Like other serotonin–releasing empathogens (e.g. MDMA, 6-APB) it produces euphoria and could encourage redosing. No published cases of physical dependence, but compulsive use has been reported anecdotally.\",\n+    \"addiction_potential\": \"Low for classic dependence; moderate psychological reinforcement possible due to mood lift and entactogenic warmth. Long duration and body load at higher doses limit compulsive redosing.\",\n-        \"MAOIs\",\n-        \"Tramadol\",\n-        \"DXM\",\n-        \"MDMA (↑ risk of serotonin syndrome)\",\n-        \"Stimulant cathinones (↑ cardiovascular stress)\"\n+        \"MAOIs (phenelzine, tranylcypromine, isocarboxazid, selegiline, moclobemide)\",\n+        \"SSRIs, SNRIs, TCAs, MAOI-antibiotic linezolid (serotonin syndrome risk)\",\n+        \"MDMA/MDA and other serotonin releasers\",\n+        \"tramadol, dextromethorphan, meperidine (serotonin syndrome, seizures)\",\n+        \"triptans (serotonergic vasoconstriction)\",\n+        \"5-HTP or L-tryptophan (excess substrate for serotonin)\",\n+        \"sympathomimetics and stimulants (amphetamine, cathinones; hypertensive events)\",\n+        \"tyramine-rich foods during the session window (aged cheeses, cured meats, soy ferments) due to MAO-A inhibition\"\n-        \"Alcohol (↑ dehydration / overheating)\",\n-        \"Cocaine\"\n+        \"alcohol (dehydration, disinhibition, nausea)\",\n+        \"cannabis concentrates (anxiety, dysphoria)\",\n+        \"decongestants with pseudoephedrine/phenylephrine (additive pressor effects)\",\n+        \"kava or other GABAergic sedatives (vomiting/aspiration risk with long duration)\"\n-        \"SSRIs/SNRIs (may blunt effects or precipitate serotonin toxicity)\",\n-        \"Bupropion\",\n-        \"α-2 agonists\",\n-        \"GHB/benzodiazepines (CNS depression when coming down)\"\n+        \"caffeine >200 mg (jitters, palpitations)\",\n+        \"benzodiazepines (reserve for emergencies; can mask rising toxicity)\",\n+        \"antipsychotics (can blunt effects; QT and hypotension concerns)\",\n+        \"nicotine (tachycardia)\"\n-    \"notes\": \"• Practically no human research exists; all parameters are based on scattered user reports of ‘5-AEDB’ sold online between 2019–2024 and extrapolation from related benzofurans (5-APB, 5-APDB).\\n• Potency appears roughly 60-70 % of 5-APB by weight and markedly shorter in duration.\\n• Users frequently report pronounced peripheral stimulation (↑ HR/BP) compared with MDMA, alongside moderate empathogenic warmth and mild visual enhancement.\\n• Severe vasoconstriction (‘purple feet’), bruxism, and nystagmus have been described at doses >100 mg.\\n• Because reagent reactions overlap with 5-APDB and other APBs, professional analysis (FT-IR/GC-MS) is recommended.\\n• Start low, ensure cool environment, hydrate with electrolytes; avoid redosing within 8 h to reduce neuro- and cardiotoxic risk.\",\n+    \"notes\": \"5-Cl-AMT (5-chloro-α-methyltryptamine; PAL-542) combines three properties with harm-reduction implications: it is a serotonin–dopamine releasing agent, a potent 5-HT2A agonist, and an in vitro MAO-A inhibitor. Treat it as an MAOI during the session window even though clinical reversibility is not established. Start with a microtest of 0.5-1 mg to gauge sensitivity; community trials report activity at 1-2 mg and full days’ worth of effects from 8-12 mg. Because the come-up is slow and the duration long, redosing is usually unnecessary and can produce a late, heavy body load. Volumetric dosing is strongly advised so that sub-1 mg adjustments are possible; weigh at least 10-20 mg on a 0.001 g scale, dissolve to make 1 mg/mL or 0.5 mg/mL, and measure with an oral syringe. Plan a bland, low-tyramine diet the day of dosing and until baseline the next day (avoid aged cheeses, cured/fermented meats, soy ferments, Marmite, certain beers). Review medications and supplements for serotonergic or MAOI activity; conservative washout rules are prudent (at least 2 weeks after irreversible MAOIs; several days after SSRIs/SNRIs/linezolid/tramadol/DXM/5-HTP). Physiologically, expect mild pupil dilation, warmth, tremor or jaw tension at higher doses, and a gradual shift from entactogenic glow to more psychedelic headspace. Several field reports describe a delayed intensification late in the day; avoid stacking doses based on an early, gentle come-up. Keep the environment cool, hydrate with electrolytes, and avoid vigorous exercise or hot environments. If symptoms suggest serotonin toxicity (agitation, clonus, hyperthermia, severe headache, rapidly rising heart rate/BP), do not take more, cool down, and seek medical care; do not self-medicate with additional serotonergics. Drug-checking is important: 5-Cl-AMT has appeared in small niche markets and could be misrepresented; use multi-reagent testing and, where available, FT-IR/GC-MS. Because reports show long wakefulness and an afterglow that can flip to lethargy, protect sleep the following night and avoid consecutive-day use. Cross-tolerance with other serotonergic psychedelics is expected; spacing sessions by 10-14 days reduces tolerance and carries a margin for MAO-related interactions.\",\n-      \"Euphoria\",\n-      \"Empathy and prosocial feelings\",\n-      \"Anxiolysis\",\n-      \"Stimulation (mental and physical)\",\n-      \"Enhanced tactile sensations\",\n-      \"Slight visual tracers at high doses\",\n-      \"Jaw clenching/bruxism\",\n-      \"Vasoconstriction/cold extremities\",\n-      \"Mydriasis\",\n-      \"Difficulty sleeping for several hours after use\"\n+      \"entactogenic warmth and sociability\",\n+      \"clear-headed stimulation early, shifting to psychedelic introspection later\",\n+      \"enhanced music appreciation and tactile pleasure\",\n+      \"subtle visual enhancement at low doses; patterning at higher\",\n+      \"time dilation and brightened colors\",\n+      \"mydriasis, mild tremor or jaw tension\",\n+      \"difficulty sleeping and next-day lethargy at higher doses\"\n-      \"full_tolerance\": \"After 2–3 consecutive or high-dose sessions\",\n-      \"half_tolerance\": \"~1 week\",\n-      \"zero_tolerance\": \"1–2 months\",\n+      \"full_tolerance\": \"after one strong session\",\n+      \"half_tolerance\": \"3-7 days\",\n+      \"zero_tolerance\": \"10-14 days\",\n-        \"MDMA\",\n-        \"5-APB\",\n-        \"other serotonergic empathogens\"\n+        \"AMT\",\n+        \"5-MeO-AMT\",\n+        \"psilocybin\",\n+        \"LSD\",\n+        \"other 5-HT2A psychedelics\"\n-    \"half_life\": \"~3–4 h (extrapolated from animal microsome data; human data unavailable)\",\n+    \"half_life\": \"Unknown (long subjective duration; MAO-A inhibition may extend interaction window)\",\n-        \"name\": \"Test-kit colour reactions for APBs (user ‘snmfmy’).\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/any-tests-to-distinguish-6-apb-from-5-apb-or-other-benzofurans.937517/\"\n+        \"name\": \"Bluelight – Small & Handy 5-Chloro-AMT thread (community dosing and precautions)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-small-handy-5-chloro-amt-thread.893891/\"\n-        \"name\": \"Anonymous user reports compiled on r/ResearchChemicals (Oct 2021 – Apr 2024).\",\n-        \"reference\": \"https://www.reddit.com/search/?q=5-AEDB\"\n+        \"name\": \"Bluelight Trip Report – 5-Cl-AMT 2 mg oral (threshold activity; long day effects)\",\n+        \"reference\": \"https://www.bluelight.org/xf/threads/5-chloro-amt-2mg-oral-first-time-a-surprisingly-encouraging-foray-into-the-unknown.894534/\"\n-        \"name\": \"Brandt, S.D. et al. (2010) ‘Analogs of MDMA: structure–activity relationships’. Drug Test. Anal.\",\n-        \"reference\": \"https://doi.org/10.1002/dta.152\"\n+        \"name\": \"Bluelight Trip Report – 5-Cl-AMT 12 mg oral (late intensification; duration)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/5-chloro-amt-12mg-oral-second-time-from-light-to-heavy.895557/\"\n-        \"name\": \"Erowid: Other Info6.shtml\",\n-        \"reference\": \"https://erowid.org/chemicals/other/other_info6.shtml#5-AEDB\"\n+        \"name\": \"Banks et al., 2014 – PAL-542 (5-Cl-AMT) as SDRA; EC50 release data\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4067459\"\n+      },\n+      {\n+        \"name\": \"Blough et al., 2014 – α-alkyltryptamines as dual DA/5-HT releasers; 5-HT2A activity\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4211607\"\n+      },\n+      {\n+        \"name\": \"Wagmann et al., 2017 – In vitro MAO inhibition by AMT analogs (MAO-A IC50 ~0.25 µM for 5-Cl-AMT)\",\n+        \"reference\": \"https://scidok.sulb.uni-saarland.de/bitstream/20.500.11880/29171/4/In%20vitro%20monoamine%20oxidase%20inhibition%20potential%20of%20alpha-methyltryptamine%20analog%20new%20psychoactive%20substances%20for%20assessing%20possible%20toxic%20risks_mit_Vorblatt.pdf\"\n+      },\n+      {\n+        \"name\": \"Wikipedia – 5-Chloro-αMT (overview; SDRA and MAO-A inhibition summary with citations)\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/5-Chloro-%CE%B1MT\"\n+      },\n+      {\n+        \"name\": \"Erowid – 5-Cl-AMT Vault\",\n+        \"reference\": \"https://erowid.org/chemicals/5_cl_amt/5_cl_amt.shtml\"\n-      \"stimulant\",\n+      \"psychedelic\",\n+      \"stimulant\",\n\n# Diphenhydramine · #626\n\n-  \"id\": 625,\n-  \"title\": \"5-Cl-AMT\",\n+  \"title\": \"Diphenhydramine\",\n+  \"index-category\": \"deliriant; otc\",\n-    \"drug_name\": \"5-Cl-AMT\",\n-    \"chemical_name\": \"5-Cl-AMT\",\n-    \"alternative_name\": \"\",\n-    \"chemical_class\": \"Tryptamines\",\n-    \"mechanism_of_action\": \"5-HT2A receptor agonist; monoamine oxidase inhibitor\",\n-    \"psychoactive_class\": \"Psychedelic\",\n+    \"drug_name\": \"Diphenhydramine\",\n+    \"chemical_name\": \"2-(Diphenylmethoxy)-N,N-dimethylethanamine\",\n+    \"alternative_name\": \"DPH; Benadryl; Nytol; Sominex; Unisom SleepMelts; ZzzQuil; Dimedrol\",\n+    \"chemical_class\": \"Ethanolamine\",\n+    \"psychoactive_class\": \"Deliriant\",\n+    \"mechanism_of_action\": \"H1 histamine receptor inverse agonist; muscarinic acetylcholine receptor antagonist; weak serotonin reuptake inhibition; sodium channel blockade; voltage-gated potassium channel blockade\",\n-            \"threshold\": \"0.5 mg - 1 mg\",\n-            \"light\": \"1 mg - 3 mg\",\n-            \"common\": \"3 mg - 8 mg\",\n-            \"strong\": \"8 mg - 12 mg\",\n-            \"heavy\": \"12+ mg\"\n+            \"threshold\": \"25 mg\",\n+            \"light\": \"100-200 mg\",\n+            \"common\": \"200-400 mg\",\n+            \"strong\": \"400-700 mg\",\n+            \"heavy\": \"700+ mg\"\n+          \"stages\": {\n+            \"total_duration\": \"3-10 hours\",\n+            \"onset\": \"30-90 minutes\",\n+            \"peak\": \"1-4 hours\",\n+            \"offset\": \"2-6 hours\",\n+            \"after_effects\": \"Up to 24 hours\"\n+          },\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"10-18 hours\",\n-            \"onset\": \"30-120 minutes\",\n-            \"peak\": \"3-6 hours\",\n-            \"offset\": \"6-12 hours\",\n-            \"after_effects\": \"12-24 hours (residual stimulation, insomnia, depletion)\"\n-          }\n+          ]\n-    \"addiction_potential\": \"Low for classic dependence; moderate psychological reinforcement possible due to mood lift and entactogenic warmth. Long duration and body load at higher doses limit compulsive redosing.\",\n+    \"addiction_potential\": \"Diphenhydramine has low abuse potential due to its overwhelmingly dysphoric and unpleasant effects. While physical dependence is possible with chronic use, most users do not wish to repeat the experience. Tolerance develops rapidly with repeated use.\",\n-        \"MAOIs (phenelzine, tranylcypromine, isocarboxazid, selegiline, moclobemide)\",\n-        \"SSRIs, SNRIs, TCAs, MAOI-antibiotic linezolid (serotonin syndrome risk)\",\n-        \"MDMA/MDA and other serotonin releasers\",\n-        \"tramadol, dextromethorphan, meperidine (serotonin syndrome, seizures)\",\n-        \"triptans (serotonergic vasoconstriction)\",\n-        \"5-HTP or L-tryptophan (excess substrate for serotonin)\",\n-        \"sympathomimetics and stimulants (amphetamine, cathinones; hypertensive events)\",\n-        \"tyramine-rich foods during the session window (aged cheeses, cured meats, soy ferments) due to MAO-A inhibition\"\n+        \"MAOIs (risk of severe anticholinergic effects)\",\n+        \"Anticholinergics (severe tachycardia, heart attack risk, abnormal heart rhythm)\",\n+        \"High doses of acetaminophen-containing formulations (liver damage, death)\"\n-        \"alcohol (dehydration, disinhibition, nausea)\",\n-        \"cannabis concentrates (anxiety, dysphoria)\",\n-        \"decongestants with pseudoephedrine/phenylephrine (additive pressor effects)\",\n-        \"kava or other GABAergic sedatives (vomiting/aspiration risk with long duration)\"\n+        \"Stimulants (severe tachycardia, heart attack risk, abnormal heart rhythm)\",\n+        \"Tramadol (increased seizure risk)\",\n+        \"Alcohol (dangerous sedation, respiratory depression)\"\n-        \"caffeine >200 mg (jitters, palpitations)\",\n-        \"benzodiazepines (reserve for emergencies; can mask rising toxicity)\",\n-        \"antipsychotics (can blunt effects; QT and hypotension concerns)\",\n-        \"nicotine (tachycardia)\"\n+        \"Benzodiazepines (dangerous sedation, respiratory depression, visual suppression)\",\n+        \"SSRIs (visual suppression, potential serotonin syndrome)\",\n+        \"Opioids (increased sedation, respiratory depression)\"\n-    \"notes\": \"5-Cl-AMT (5-chloro-α-methyltryptamine; PAL-542) combines three properties with harm-reduction implications: it is a serotonin–dopamine releasing agent, a potent 5-HT2A agonist, and an in vitro MAO-A inhibitor. Treat it as an MAOI during the session window even though clinical reversibility is not established. Start with a microtest of 0.5-1 mg to gauge sensitivity; community trials report activity at 1-2 mg and full days’ worth of effects from 8-12 mg. Because the come-up is slow and the duration long, redosing is usually unnecessary and can produce a late, heavy body load. Volumetric dosing is strongly advised so that sub-1 mg adjustments are possible; weigh at least 10-20 mg on a 0.001 g scale, dissolve to make 1 mg/mL or 0.5 mg/mL, and measure with an oral syringe. Plan a bland, low-tyramine diet the day of dosing and until baseline the next day (avoid aged cheeses, cured/fermented meats, soy ferments, Marmite, certain beers). Review medications and supplements for serotonergic or MAOI activity; conservative washout rules are prudent (at least 2 weeks after irreversible MAOIs; several days after SSRIs/SNRIs/linezolid/tramadol/DXM/5-HTP). Physiologically, expect mild pupil dilation, warmth, tremor or jaw tension at higher doses, and a gradual shift from entactogenic glow to more psychedelic headspace. Several field reports describe a delayed intensification late in the day; avoid stacking doses based on an early, gentle come-up. Keep the environment cool, hydrate with electrolytes, and avoid vigorous exercise or hot environments. If symptoms suggest serotonin toxicity (agitation, clonus, hyperthermia, severe headache, rapidly rising heart rate/BP), do not take more, cool down, and seek medical care; do not self-medicate with additional serotonergics. Drug-checking is important: 5-Cl-AMT has appeared in small niche markets and could be misrepresented; use multi-reagent testing and, where available, FT-IR/GC-MS. Because reports show long wakefulness and an afterglow that can flip to lethargy, protect sleep the following night and avoid consecutive-day use. Cross-tolerance with other serotonergic psychedelics is expected; spacing sessions by 10-14 days reduces tolerance and carries a margin for MAO-related interactions.\",\n+    \"notes\": \"Diphenhydramine is widely available over-the-counter and used medically for allergies and sleep aid. Recreational use produces intensely dysphoric and unpredictable deliriant effects including realistic hallucinations that users cannot distinguish from reality. The substance has significant cardiovascular risks including QT prolongation and potential for torsades de pointes. Always verify that products contain only diphenhydramine as active ingredient; many combination products contain acetaminophen or other drugs that can be fatal in high doses. A sober trip sitter is essential as users may respond to hallucinations and injure themselves. Chronic use may cause persistent cognitive impairment, memory damage, and has been linked to increased dementia risk.\",\n-      \"entactogenic warmth and sociability\",\n-      \"clear-headed stimulation early, shifting to psychedelic introspection later\",\n-      \"enhanced music appreciation and tactile pleasure\",\n-      \"subtle visual enhancement at low doses; patterning at higher\",\n-      \"time dilation and brightened colors\",\n-      \"mydriasis, mild tremor or jaw tension\",\n-      \"difficulty sleeping and next-day lethargy at higher doses\"\n+      \"Sedation and Body Heaviness\",\n+      \"External Hallucinations (People, Objects, Insects)\",\n+      \"Auditory Hallucinations (Voices, Screams)\",\n+      \"Tactile Hallucinations (Phantom Sensations)\",\n+      \"Shadow People\",\n+      \"Delirium and Confusion\",\n+      \"Memory Suppression and Amnesia\",\n+      \"Dysphoria and Anxiety\",\n+      \"Restless Leg Syndrome\",\n+      \"Dry Mouth and Dehydration\",\n+      \"Visual Acuity Suppression (Blurred Vision)\",\n+      \"Thought Disorganization\"\n-      \"full_tolerance\": \"after one strong session\",\n-      \"half_tolerance\": \"3-7 days\",\n-      \"zero_tolerance\": \"10-14 days\",\n+      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n+      \"half_tolerance\": \"3-5 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n-        \"AMT\",\n-        \"5-MeO-AMT\",\n-        \"psilocybin\",\n-        \"LSD\",\n-        \"other 5-HT2A psychedelics\"\n+        \"All deliriants (datura, scopolamine, dimenhydrinate)\"\n-    \"half_life\": \"Unknown (long subjective duration; MAO-A inhibition may extend interaction window)\",\n+    \"half_life\": \"5 hours (pediatric); 9 hours (adult); 13.5 hours (elderly)\",\n-        \"name\": \"Bluelight – Small & Handy 5-Chloro-AMT thread (community dosing and precautions)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/the-small-handy-5-chloro-amt-thread.893891/\"\n+        \"name\": \"Erowid Diphenhydramine Vault\",\n+        \"reference\": \"https://www.erowid.org/pharms/diphenhydramine/\"\n-        \"name\": \"Bluelight Trip Report – 5-Cl-AMT 2 mg oral (threshold activity; long day effects)\",\n-        \"reference\": \"https://www.bluelight.org/xf/threads/5-chloro-amt-2mg-oral-first-time-a-surprisingly-encouraging-foray-into-the-unknown.894534/\"\n+        \"name\": \"PsychonautWiki: Diphenhydramine\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Diphenhydramine\"\n-        \"name\": \"Bluelight Trip Report – 5-Cl-AMT 12 mg oral (late intensification; duration)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/5-chloro-amt-12mg-oral-second-time-from-light-to-heavy.895557/\"\n+        \"name\": \"TripSit Wiki: Diphenhydramine\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/Diphenhydramine\"\n-        \"name\": \"Banks et al., 2014 – PAL-542 (5-Cl-AMT) as SDRA; EC50 release data\",\n-        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4067459\"\n+        \"name\": \"Bluelight: Diphenhydramine Discussion\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/dph-trip.560305/\"\n-        \"name\": \"Blough et al., 2014 – α-alkyltryptamines as dual DA/5-HT releasers; 5-HT2A activity\",\n-        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4211607\"\n+        \"name\": \"DrugBank: Diphenhydramine\",\n+        \"reference\": \"https://go.drugbank.com/drugs/DB01075\"\n-        \"name\": \"Wagmann et al., 2017 – In vitro MAO inhibition by AMT analogs (MAO-A IC50 ~0.25 µM for 5-Cl-AMT)\",\n-        \"reference\": \"https://scidok.sulb.uni-saarland.de/bitstream/20.500.11880/29171/4/In%20vitro%20monoamine%20oxidase%20inhibition%20potential%20of%20alpha-methyltryptamine%20analog%20new%20psychoactive%20substances%20for%20assessing%20possible%20toxic%20risks_mit_Vorblatt.pdf\"\n+        \"name\": \"StatPearls: Diphenhydramine Toxicity\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/books/NBK557578/\"\n-        \"name\": \"Wikipedia – 5-Chloro-αMT (overview; SDRA and MAO-A inhibition summary with citations)\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/5-Chloro-%CE%B1MT\"\n-      },\n-      {\n-        \"name\": \"Erowid – 5-Cl-AMT Vault\",\n-        \"reference\": \"https://erowid.org/chemicals/5_cl_amt/5_cl_amt.shtml\"\n+        \"name\": \"Gray et al., 2015 - Cumulative Anticholinergic Use and Dementia\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/25621434/\"\n-      \"psychedelic\",\n-      \"entactogen\",\n-      \"stimulant\",\n-      \"research-chemical\"\n+      \"deliriant\",\n+      \"depressant\",\n+      \"antihistamine\",\n+      \"otc\"\n-  \"index-category\": \"\"\n+  \"id\": 626\n\n# Diphenhydramine · #627\n\n-  \"id\": 626\n+  \"id\": 627\n\n# 1V-LSD · #628\n\n-  \"title\": \"Diphenhydramine\",\n-  \"index-category\": \"deliriant; otc\",\n+  \"title\": \"1V-LSD\",\n+  \"index-category\": \"psychedelic; research-chemical\",\n-    \"drug_name\": \"Diphenhydramine\",\n-    \"chemical_name\": \"2-(Diphenylmethoxy)-N,N-dimethylethanamine\",\n-    \"alternative_name\": \"DPH; Benadryl; Nytol; Sominex; Unisom SleepMelts; ZzzQuil; Dimedrol\",\n-    \"chemical_class\": \"Ethanolamine\",\n-    \"psychoactive_class\": \"Deliriant\",\n-    \"mechanism_of_action\": \"H1 histamine receptor inverse agonist; muscarinic acetylcholine receptor antagonist; weak serotonin reuptake inhibition; sodium channel blockade; voltage-gated potassium channel blockade\",\n+    \"drug_name\": \"1V-LSD\",\n+    \"chemical_name\": \"1-Valeroyl-d-lysergic acid diethylamide\",\n+    \"alternative_name\": \"Valerie\",\n+    \"chemical_class\": \"Lysergamides\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist (weak); acts as prodrug for LSD via deacylation\",\n-          \"units\": \"mg\",\n+          \"units\": \"ug\",\n-            \"threshold\": \"25 mg\",\n-            \"light\": \"100-200 mg\",\n-            \"common\": \"200-400 mg\",\n-            \"strong\": \"400-700 mg\",\n-            \"heavy\": \"700+ mg\"\n+            \"threshold\": \"15 ug\",\n+            \"light\": \"25-75 ug\",\n+            \"common\": \"75-150 ug\",\n+            \"strong\": \"150-300 ug\",\n+            \"heavy\": \"300+ ug\"\n-            \"total_duration\": \"3-10 hours\",\n-            \"onset\": \"30-90 minutes\",\n-            \"peak\": \"1-4 hours\",\n-            \"offset\": \"2-6 hours\",\n-            \"after_effects\": \"Up to 24 hours\"\n+            \"total_duration\": \"8-12 hours\",\n+            \"onset\": \"20-60 minutes\",\n+            \"peak\": \"3-5 hours (come up 45-120 minutes)\",\n+            \"offset\": \"3-5 hours\",\n+            \"after_effects\": \"6-24 hours\"\n-    \"addiction_potential\": \"Diphenhydramine has low abuse potential due to its overwhelmingly dysphoric and unpleasant effects. While physical dependence is possible with chronic use, most users do not wish to repeat the experience. Tolerance develops rapidly with repeated use.\",\n+    \"addiction_potential\": \"1V-LSD is assumed to be non-addictive with low abuse potential, similar to LSD. No literature reports exist of successful attempts to train animals to self-administer LSD analogs. There is virtually no withdrawal syndrome when chronic use is stopped.\",\n-        \"MAOIs (risk of severe anticholinergic effects)\",\n-        \"Anticholinergics (severe tachycardia, heart attack risk, abnormal heart rhythm)\",\n-        \"High doses of acetaminophen-containing formulations (liver damage, death)\"\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n-        \"Stimulants (severe tachycardia, heart attack risk, abnormal heart rhythm)\",\n-        \"Tramadol (increased seizure risk)\",\n-        \"Alcohol (dangerous sedation, respiratory depression)\"\n+        \"Cannabis (strong synergy, significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n-        \"Benzodiazepines (dangerous sedation, respiratory depression, visual suppression)\",\n-        \"SSRIs (visual suppression, potential serotonin syndrome)\",\n-        \"Opioids (increased sedation, respiratory depression)\"\n+        \"Stimulants (may increase risk of anxiety, paranoia, panic attacks, thought loops, mania and psychosis)\",\n+        \"MDMA (unpredictable synergy, potential increased neurotoxicity)\",\n+        \"Dissociatives (enhanced hallucinatory effects, increased risk of confusion and delusions)\",\n+        \"Benzodiazepines (reduce intensity of effects)\",\n+        \"Alcohol (may reduce anxiety but causes dehydration and physical discomfort)\"\n-    \"notes\": \"Diphenhydramine is widely available over-the-counter and used medically for allergies and sleep aid. Recreational use produces intensely dysphoric and unpredictable deliriant effects including realistic hallucinations that users cannot distinguish from reality. The substance has significant cardiovascular risks including QT prolongation and potential for torsades de pointes. Always verify that products contain only diphenhydramine as active ingredient; many combination products contain acetaminophen or other drugs that can be fatal in high doses. A sober trip sitter is essential as users may respond to hallucinations and injure themselves. Chronic use may cause persistent cognitive impairment, memory damage, and has been linked to increased dementia risk.\",\n+    \"notes\": \"1V-LSD is a novel research chemical with minimal history of human use and unverified safety profile. It is presumed to act as a prodrug for LSD. Those with personal or family history of mental illness should avoid use, particularly outside supervised medical settings. Set and setting are critical factors in determining experience quality. Start with lower doses due to individual variations in body weight, tolerance, metabolism, and sensitivity. No toxic dose is known, but higher doses increase risk of adverse psychological reactions. Test substances with reagent kits, though Ehrlich's reagent reacts slowly with N-acylated lysergamides.\",\n-      \"Sedation and Body Heaviness\",\n-      \"External Hallucinations (People, Objects, Insects)\",\n-      \"Auditory Hallucinations (Voices, Screams)\",\n-      \"Tactile Hallucinations (Phantom Sensations)\",\n-      \"Shadow People\",\n-      \"Delirium and Confusion\",\n-      \"Memory Suppression and Amnesia\",\n-      \"Dysphoria and Anxiety\",\n-      \"Restless Leg Syndrome\",\n-      \"Dry Mouth and Dehydration\",\n-      \"Visual Acuity Suppression (Blurred Vision)\",\n-      \"Thought Disorganization\"\n+      \"Geometric Visual Hallucinations\",\n+      \"Time Distortion\",\n+      \"Enhanced Introspection\",\n+      \"Ego Loss\",\n+      \"Stimulation\",\n+      \"Spontaneous Bodily Sensations\",\n+      \"Physical Euphoria\",\n+      \"Tactile Enhancement\",\n+      \"Color Enhancement\",\n+      \"Pattern Recognition Enhancement\",\n+      \"Visual Drifting\",\n+      \"Analysis Enhancement\",\n+      \"Conceptual Thinking\",\n+      \"Emotion Enhancement\",\n+      \"Cognitive Euphoria\",\n+      \"Creativity Enhancement\",\n+      \"Increased Music Appreciation\",\n+      \"Unity And Interconnectedness\"\n-      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n-      \"half_tolerance\": \"3-5 days\",\n-      \"zero_tolerance\": \"1-2 weeks\",\n+      \"full_tolerance\": \"Builds almost immediately after ingestion\",\n+      \"half_tolerance\": \"5-7 days\",\n+      \"zero_tolerance\": \"14 days\",\n-        \"All deliriants (datura, scopolamine, dimenhydrinate)\"\n+        \"All psychedelics (including LSD, psilocybin, mescaline, DMT)\"\n-    \"half_life\": \"5 hours (pediatric); 9 hours (adult); 13.5 hours (elderly)\",\n+    \"half_life\": \"Similar to LSD (estimated 3-5 hours for active metabolite)\",\n-        \"name\": \"Erowid Diphenhydramine Vault\",\n-        \"reference\": \"https://www.erowid.org/pharms/diphenhydramine/\"\n+        \"name\": \"PsychonautWiki: 1V-LSD\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/1V-LSD\"\n-        \"name\": \"PsychonautWiki: Diphenhydramine\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/Diphenhydramine\"\n+        \"name\": \"Erowid 1V-LSD Experience Vault\",\n+        \"reference\": \"https://www.erowid.org/experiences/subs/exp_1VLSD.shtml\"\n-        \"name\": \"TripSit Wiki: Diphenhydramine\",\n-        \"reference\": \"https://wiki.tripsit.me/wiki/Diphenhydramine\"\n+        \"name\": \"Bluelight: The Small & Handy 1V-LSD Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-small-handy-1v-lsd-thread.904997/\"\n-        \"name\": \"Bluelight: Diphenhydramine Discussion\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/dph-trip.560305/\"\n+        \"name\": \"Brandt et al. (2022): Return of the lysergamides Part VII - Analytical and behavioural characterization of 1V-LSD\",\n+        \"reference\": \"https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/dta.3205\"\n-        \"name\": \"DrugBank: Diphenhydramine\",\n-        \"reference\": \"https://go.drugbank.com/drugs/DB01075\"\n-      },\n-      {\n-        \"name\": \"StatPearls: Diphenhydramine Toxicity\",\n-        \"reference\": \"https://www.ncbi.nlm.nih.gov/books/NBK557578/\"\n-      },\n-      {\n-        \"name\": \"Gray et al., 2015 - Cumulative Anticholinergic Use and Dementia\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/25621434/\"\n+        \"name\": \"Tripsitter: 1V-LSD - A New LSD Analog\",\n+        \"reference\": \"https://tripsitter.com/1v-lsd/\"\n-      \"deliriant\",\n-      \"depressant\",\n-      \"antihistamine\",\n-      \"otc\"\n+      \"psychedelic\",\n+      \"lysergamide\",\n+      \"research-chemical\",\n+      \"prodrug\"\n-  \"id\": 627\n+  \"id\": 628\n\n# ALD-52 · #629\n\n-  \"title\": \"1V-LSD\",\n-  \"index-category\": \"psychedelic; research-chemical\",\n+  \"title\": \"ALD-52\",\n+  \"index-category\": \"psychedelic; lysergamide\",\n-    \"drug_name\": \"1V-LSD\",\n-    \"chemical_name\": \"1-Valeroyl-d-lysergic acid diethylamide\",\n-    \"alternative_name\": \"Valerie\",\n+    \"drug_name\": \"ALD-52\",\n+    \"chemical_name\": \"1-Acetyl-d-lysergic acid diethylamide\",\n+    \"alternative_name\": \"Orange Sunshine\",\n-    \"mechanism_of_action\": \"5-HT2A receptor partial agonist (weak); acts as prodrug for LSD via deacylation\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; 5-HT2C receptor partial agonist; 5-HT1A receptor partial agonist; D2 receptor agonist (through LSD metabolite)\",\n-            \"threshold\": \"15 ug\",\n-            \"light\": \"25-75 ug\",\n-            \"common\": \"75-150 ug\",\n-            \"strong\": \"150-300 ug\",\n-            \"heavy\": \"300+ ug\"\n+            \"threshold\": \"30 ug\",\n+            \"light\": \"30-100 ug\",\n+            \"common\": \"100-175 ug\",\n+            \"strong\": \"175-325 ug\",\n+            \"heavy\": \"325+ ug\"\n-            \"total_duration\": \"8-12 hours\",\n-            \"onset\": \"20-60 minutes\",\n-            \"peak\": \"3-5 hours (come up 45-120 minutes)\",\n+            \"total_duration\": \"8-14 hours\",\n+            \"onset\": \"20-40 minutes\",\n+            \"peak\": \"3-5 hours (following 1-2 hour come up)\",\n-            \"after_effects\": \"6-24 hours\"\n+            \"after_effects\": \"4-24 hours\"\n-    \"addiction_potential\": \"1V-LSD is assumed to be non-addictive with low abuse potential, similar to LSD. No literature reports exist of successful attempts to train animals to self-administer LSD analogs. There is virtually no withdrawal syndrome when chronic use is stopped.\",\n+    \"addiction_potential\": \"ALD-52 is not considered physically addictive and has extremely low potential for psychological dependence. The rapid development of tolerance discourages frequent use patterns, and the desire to use typically decreases with repeated exposure rather than increasing.\",\n-        \"Tramadol (lowers seizure threshold)\"\n+        \"MAOIs (unpredictable effects, possible hypertensive reaction)\"\n-        \"Cannabis (strong synergy, significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n+        \"Tramadol (lowers seizure threshold, psychedelics may trigger seizures)\",\n+        \"Stimulants including amphetamines and cocaine (increased risk of anxiety, thought loops, cardiovascular strain)\"\n-        \"Stimulants (may increase risk of anxiety, paranoia, panic attacks, thought loops, mania and psychosis)\",\n-        \"MDMA (unpredictable synergy, potential increased neurotoxicity)\",\n-        \"Dissociatives (enhanced hallucinatory effects, increased risk of confusion and delusions)\",\n-        \"Benzodiazepines (reduce intensity of effects)\",\n-        \"Alcohol (may reduce anxiety but causes dehydration and physical discomfort)\"\n+        \"Cannabis (unpredictably strong synergy, increased risk of anxiety and paranoia)\",\n+        \"MDMA (may increase neurotoxicity, unpredictable synergy)\",\n+        \"Other psychedelics (intense cross-tolerance and potentially overwhelming effects)\",\n+        \"SSRIs (may blunt or alter effects)\"\n-    \"notes\": \"1V-LSD is a novel research chemical with minimal history of human use and unverified safety profile. It is presumed to act as a prodrug for LSD. Those with personal or family history of mental illness should avoid use, particularly outside supervised medical settings. Set and setting are critical factors in determining experience quality. Start with lower doses due to individual variations in body weight, tolerance, metabolism, and sensitivity. No toxic dose is known, but higher doses increase risk of adverse psychological reactions. Test substances with reagent kits, though Ehrlich's reagent reacts slowly with N-acylated lysergamides.\",\n+    \"notes\": \"ALD-52 functions as a prodrug for LSD, metabolizing into LSD in the body along with other metabolites. Legal status varies widely by jurisdiction; it is controlled in many countries including the UK, Germany, Switzerland, and Latvia, while remaining technically unscheduled in others such as the United States and Denmark. Individuals with personal or family history of psychotic disorders should avoid use. Famous for being mistakenly associated with 'Orange Sunshine' LSD from the 1960s, though this was later confirmed to be standard LSD at 300 micrograms per dose. Set and setting are critical for a positive experience, and users should approach this potent, long-lasting substance with proper preparation and harm reduction practices.\",\n-      \"Geometric Visual Hallucinations\",\n+      \"Visual Patterning And Geometry\",\n+      \"Enhanced Sensory Perception\",\n+      \"Cognitive Euphoria\",\n-      \"Ego Loss\",\n-      \"Stimulation\",\n-      \"Spontaneous Bodily Sensations\",\n+      \"Emotional Amplification\",\n-      \"Tactile Enhancement\",\n-      \"Color Enhancement\",\n-      \"Pattern Recognition Enhancement\",\n-      \"Visual Drifting\",\n-      \"Analysis Enhancement\",\n-      \"Conceptual Thinking\",\n-      \"Emotion Enhancement\",\n-      \"Cognitive Euphoria\",\n-      \"Creativity Enhancement\",\n-      \"Increased Music Appreciation\",\n-      \"Unity And Interconnectedness\"\n+      \"Thought Acceleration\",\n+      \"Enhanced Music Appreciation\",\n+      \"Pupil Dilation\",\n+      \"Increased Energy And Stimulation\",\n+      \"Novel Thought Patterns\"\n-      \"full_tolerance\": \"Builds almost immediately after ingestion\",\n+      \"full_tolerance\": \"Immediately after ingestion, cross-tolerant with all psychedelics\",\n-        \"All psychedelics (including LSD, psilocybin, mescaline, DMT)\"\n+        \"All psychedelics including LSD, psilocybin mushrooms, mescaline, and tryptamines\"\n-    \"half_life\": \"Similar to LSD (estimated 3-5 hours for active metabolite)\",\n+    \"half_life\": \"1-3 hours (LSD active metabolite)\",\n-        \"name\": \"PsychonautWiki: 1V-LSD\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/1V-LSD\"\n+        \"name\": \"Erowid ALD-52 Vault\",\n+        \"reference\": \"https://erowid.org/chemicals/lsd/lsd_ald52.shtml\"\n-        \"name\": \"Erowid 1V-LSD Experience Vault\",\n-        \"reference\": \"https://www.erowid.org/experiences/subs/exp_1VLSD.shtml\"\n+        \"name\": \"Isomer Design TiHKAL Entry 26 (LSD)\",\n+        \"reference\": \"https://isomerdesign.com/pihkal/read/tk/26\"\n-        \"name\": \"Bluelight: The Small & Handy 1V-LSD Thread\",\n-        \"reference\": \"https://bluelight.org/xf/threads/the-small-handy-1v-lsd-thread.904997/\"\n+        \"name\": \"PsychonautWiki: ALD-52\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/ALD-52\"\n-        \"name\": \"Brandt et al. (2022): Return of the lysergamides Part VII - Analytical and behavioural characterization of 1V-LSD\",\n-        \"reference\": \"https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/dta.3205\"\n+        \"name\": \"The Big & Dandy ALD-52 Thread (Bluelight)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-ald-52-thread.773316/\"\n-        \"name\": \"Tripsitter: 1V-LSD - A New LSD Analog\",\n-        \"reference\": \"https://tripsitter.com/1v-lsd/\"\n+        \"name\": \"TripSit Drug Combination Chart\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/Drug_combinations\"\n+      },\n+      {\n+        \"name\": \"Wagmann et al. (2019) In vitro metabolic fate of nine LSD-based new psychoactive substances\",\n+        \"reference\": \"https://doi.org/10.1007/s00216-018-1558-9\"\n-  \"id\": 628\n+  \"id\": 629\n\n# ETH-LAD · #630\n\n-  \"title\": \"ALD-52\",\n+  \"title\": \"ETH-LAD\",\n-    \"drug_name\": \"ALD-52\",\n-    \"chemical_name\": \"1-Acetyl-d-lysergic acid diethylamide\",\n-    \"alternative_name\": \"Orange Sunshine\",\n+    \"drug_name\": \"ETH-LAD\",\n+    \"chemical_name\": \"6-Ethyl-6-nor-lysergic acid diethylamide\",\n+    \"alternative_name\": \"N-Ethyl-nor-LSD; 6-Ethyl-6-nor-lysergic acid diethylamide; N-Ethyl-nor-lysergic acid N,N-diethylamide\",\n-    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; 5-HT2C receptor partial agonist; 5-HT1A receptor partial agonist; D2 receptor agonist (through LSD metabolite)\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist; 5-HT2C receptor agonist; 5-HT1A receptor agonist (high affinity); dopamine D1, D2, D3, D4, D5 receptor binding (lower affinity)\",\n-            \"threshold\": \"30 ug\",\n-            \"light\": \"30-100 ug\",\n-            \"common\": \"100-175 ug\",\n-            \"strong\": \"175-325 ug\",\n-            \"heavy\": \"325+ ug\"\n+            \"threshold\": \"15 ug\",\n+            \"light\": \"15-60 ug\",\n+            \"common\": \"60-150 ug\",\n+            \"strong\": \"150-225 ug\",\n+            \"heavy\": \"225+ ug\"\n-            \"total_duration\": \"8-14 hours\",\n+            \"total_duration\": \"8-12 hours\",\n-            \"peak\": \"3-5 hours (following 1-2 hour come up)\",\n-            \"offset\": \"3-5 hours\",\n-            \"after_effects\": \"4-24 hours\"\n+            \"peak\": \"4-6 hours (including 45-90 minute come up)\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"8-48 hours\"\n-    \"addiction_potential\": \"ALD-52 is not considered physically addictive and has extremely low potential for psychological dependence. The rapid development of tolerance discourages frequent use patterns, and the desire to use typically decreases with repeated exposure rather than increasing.\",\n+    \"addiction_potential\": \"ETH-LAD is not considered habit-forming and demonstrates a self-regulating quality typical of psychedelics. Rapid tolerance develops immediately after use, discouraging frequent consumption. Cases of abuse have been rarely reported, though the substance generally decreases in desirability with repeated use.\",\n-        \"Lithium (significantly increases risk of psychosis and seizures)\",\n-        \"MAOIs (unpredictable effects, possible hypertensive reaction)\"\n+        \"Lithium (significantly increased risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n-        \"Tramadol (lowers seizure threshold, psychedelics may trigger seizures)\",\n-        \"Stimulants including amphetamines and cocaine (increased risk of anxiety, thought loops, cardiovascular strain)\"\n+        \"Cannabis (unpredictable and strongly increased effects, risk of anxiety, paranoia, panic attacks, and psychosis)\",\n+        \"Stimulants including amphetamine, cocaine, methylphenidate (increased risk of anxiety, paranoia, panic attacks, thought loops, mania, and psychosis)\"\n-      \"caution\": [\n-        \"Cannabis (unpredictably strong synergy, increased risk of anxiety and paranoia)\",\n-        \"MDMA (may increase neurotoxicity, unpredictable synergy)\",\n-        \"Other psychedelics (intense cross-tolerance and potentially overwhelming effects)\",\n-        \"SSRIs (may blunt or alter effects)\"\n-      ]\n+      \"caution\": []\n-    \"notes\": \"ALD-52 functions as a prodrug for LSD, metabolizing into LSD in the body along with other metabolites. Legal status varies widely by jurisdiction; it is controlled in many countries including the UK, Germany, Switzerland, and Latvia, while remaining technically unscheduled in others such as the United States and Denmark. Individuals with personal or family history of psychotic disorders should avoid use. Famous for being mistakenly associated with 'Orange Sunshine' LSD from the 1960s, though this was later confirmed to be standard LSD at 300 micrograms per dose. Set and setting are critical for a positive experience, and users should approach this potent, long-lasting substance with proper preparation and harm reduction practices.\",\n+    \"notes\": \"ETH-LAD requires exceptional caution due to its high potency, unpredictable dose-response curve, and tendency to produce severe physical side effects including pronounced nausea, temperature dysregulation, muscle cramps, and bodily discomfort at higher doses. The substance is notably more difficult to handle than LSD and should only be used by experienced psychedelic users. Accurate measurement with a precise scale is critical. Users should monitor body temperature throughout the experience and maintain access to climate control. Set and setting are paramount, and having a trusted sober sitter is strongly recommended, especially at doses above the common range. Individuals with personal or family history of psychotic disorders should avoid use.\",\n-      \"Visual Patterning And Geometry\",\n-      \"Enhanced Sensory Perception\",\n+      \"Intricate Visual Geometry\",\n+      \"Enhanced Pattern Recognition\",\n+      \"Auditory Distortions and Hallucinations\",\n+      \"Analysis Enhancement\",\n+      \"Introspective Thought Patterns\",\n-      \"Cognitive Euphoria\",\n-      \"Enhanced Introspection\",\n-      \"Emotional Amplification\",\n-      \"Physical Euphoria\",\n+      \"Synaesthesia\",\n+      \"Enhanced Color Perception\",\n+      \"Nausea and Bodily Discomfort\",\n+      \"Temperature Dysregulation\",\n+      \"Emotional Neutrality or Detachment\",\n-      \"Enhanced Music Appreciation\",\n-      \"Pupil Dilation\",\n-      \"Increased Energy And Stimulation\",\n-      \"Novel Thought Patterns\"\n+      \"Memory Suppression\"\n-      \"full_tolerance\": \"Immediately after ingestion, cross-tolerant with all psychedelics\",\n+      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n-        \"All psychedelics including LSD, psilocybin mushrooms, mescaline, and tryptamines\"\n+        \"All psychedelics including LSD, psilocybin, mescaline, DMT, and related lysergamides\"\n-    \"half_life\": \"1-3 hours (LSD active metabolite)\",\n+    \"half_life\": \"\",\n-        \"name\": \"Erowid ALD-52 Vault\",\n-        \"reference\": \"https://erowid.org/chemicals/lsd/lsd_ald52.shtml\"\n+        \"name\": \"Bluelight: The Big & Dandy ETH-LAD Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-eth-lad-thread.761505/\"\n-        \"name\": \"Isomer Design TiHKAL Entry 26 (LSD)\",\n-        \"reference\": \"https://isomerdesign.com/pihkal/read/tk/26\"\n+        \"name\": \"Erowid ETH-LAD Experience Vault\",\n+        \"reference\": \"https://www.erowid.org/experiences/subs/exp_ETHLAD.shtml\"\n-        \"name\": \"PsychonautWiki: ALD-52\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/ALD-52\"\n+        \"name\": \"Erowid TiHKAL Entry #12: ETH-LAD\",\n+        \"reference\": \"https://erowid.org/library/books_online/tihkal/tihkal12.shtml\"\n-        \"name\": \"The Big & Dandy ALD-52 Thread (Bluelight)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-ald-52-thread.773316/\"\n+        \"name\": \"Hoffman AJ, Nichols DE (1985) - Synthesis and LSD-like discriminative stimulus properties\",\n+        \"reference\": \"https://doi.org/10.1021/jm00147a022\"\n-        \"name\": \"TripSit Drug Combination Chart\",\n-        \"reference\": \"https://wiki.tripsit.me/wiki/Drug_combinations\"\n+        \"name\": \"Isomer Design: TiHKAL ETH-LAD Entry\",\n+        \"reference\": \"http://isomerdesign.com/PiHKAL/read.php?domain=tk&id=12\"\n-        \"name\": \"Wagmann et al. (2019) In vitro metabolic fate of nine LSD-based new psychoactive substances\",\n-        \"reference\": \"https://doi.org/10.1007/s00216-018-1558-9\"\n+        \"name\": \"PsychonautWiki: ETH-LAD\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/ETH-LAD\"\n-      \"research-chemical\",\n-      \"prodrug\"\n+      \"research-chemical\"\n-  \"id\": 629\n+  \"id\": 630\n\n# LSA · #631\n\n-  \"title\": \"ETH-LAD\",\n-  \"index-category\": \"psychedelic; lysergamide\",\n+  \"title\": \"LSA\",\n+  \"index-category\": \"psychedelic; natural\",\n-    \"drug_name\": \"ETH-LAD\",\n-    \"chemical_name\": \"6-Ethyl-6-nor-lysergic acid diethylamide\",\n-    \"alternative_name\": \"N-Ethyl-nor-LSD; 6-Ethyl-6-nor-lysergic acid diethylamide; N-Ethyl-nor-lysergic acid N,N-diethylamide\",\n+    \"drug_name\": \"LSA\",\n+    \"chemical_name\": \"d-Lysergic acid amide\",\n+    \"alternative_name\": \"Ergine; LA-111\",\n-    \"mechanism_of_action\": \"5-HT2A receptor agonist; 5-HT2C receptor agonist; 5-HT1A receptor agonist (high affinity); dopamine D1, D2, D3, D4, D5 receptor binding (lower affinity)\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n-          \"route\": \"oral\",\n-          \"units\": \"ug\",\n+          \"route\": \"oral (morning glory seeds)\",\n+          \"units\": \"seeds\",\n-            \"threshold\": \"15 ug\",\n-            \"light\": \"15-60 ug\",\n-            \"common\": \"60-150 ug\",\n-            \"strong\": \"150-225 ug\",\n-            \"heavy\": \"225+ ug\"\n+            \"threshold\": \"20-50 seeds\",\n+            \"light\": \"50-100 seeds\",\n+            \"common\": \"100-250 seeds\",\n+            \"strong\": \"250-400 seeds\",\n+            \"heavy\": \"400+ seeds\"\n+        },\n+        {\n+          \"route\": \"oral (hawaiian baby woodrose seeds)\",\n+          \"units\": \"seeds\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"1-3 seeds\",\n+            \"light\": \"3-5 seeds\",\n+            \"common\": \"5-7 seeds\",\n+            \"strong\": \"7-12 seeds\",\n+            \"heavy\": \"12+ seeds\"\n+          }\n+        },\n+        {\n+          \"route\": \"oral (pure lsa)\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"0.5 mg\",\n+            \"light\": \"0.5-1 mg\",\n+            \"common\": \"1-2 mg\",\n+            \"strong\": \"2-3 mg\",\n+            \"heavy\": \"3+ mg\"\n+          }\n-          \"route\": \"oral\",\n+          \"route\": \"oral (morning glory seeds)\",\n-            \"total_duration\": \"8-12 hours\",\n-            \"onset\": \"20-40 minutes\",\n-            \"peak\": \"4-6 hours (including 45-90 minute come up)\",\n-            \"offset\": \"2-4 hours\",\n-            \"after_effects\": \"8-48 hours\"\n+            \"total_duration\": \"4-10 hours\",\n+            \"onset\": \"20-60 minutes (up to 3 hours reported)\",\n+            \"peak\": \"90-180 minutes\",\n+            \"offset\": \"2-7 hours\",\n+            \"after_effects\": \"1-12 hours (afterglow)\"\n+        },\n+        {\n+          \"route\": \"oral (hawaiian baby woodrose seeds)\",\n+          \"stages\": {\n+            \"total_duration\": \"4-10 hours\",\n+            \"onset\": \"20-60 minutes (up to 3 hours reported)\",\n+            \"peak\": \"90-180 minutes\",\n+            \"offset\": \"2-7 hours\",\n+            \"after_effects\": \"1-12 hours (afterglow)\"\n+          }\n+        },\n+        {\n+          \"route\": \"oral (pure lsa)\",\n+          \"stages\": {\n+            \"total_duration\": \"4-10 hours\",\n+            \"onset\": \"20-60 minutes (up to 3 hours reported)\",\n+            \"peak\": \"90-180 minutes\",\n+            \"offset\": \"2-7 hours\",\n+            \"after_effects\": \"1-12 hours (afterglow)\"\n+          }\n-    \"addiction_potential\": \"ETH-LAD is not considered habit-forming and demonstrates a self-regulating quality typical of psychedelics. Rapid tolerance develops immediately after use, discouraging frequent consumption. Cases of abuse have been rarely reported, though the substance generally decreases in desirability with repeated use.\",\n+    \"addiction_potential\": \"LSA is not considered to be addictive with low abuse potential. There is virtually no withdrawal syndrome when use is stopped, and animal studies have not demonstrated self-administration behavior predictive of abuse liability.\",\n-        \"Cannabis (unpredictable and strongly increased effects, risk of anxiety, paranoia, panic attacks, and psychosis)\",\n-        \"Stimulants including amphetamine, cocaine, methylphenidate (increased risk of anxiety, paranoia, panic attacks, thought loops, mania, and psychosis)\"\n+        \"Stimulants (increased risk of anxiety, paranoia, thought loops, and mania)\",\n+        \"Cannabis (unexpectedly strong and unpredictable synergy; significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n-      \"caution\": []\n+      \"caution\": [\n+        \"SSRIs (may suppress visual and cognitive effects)\",\n+        \"MAOIs (may potentiate effects; use caution with potential for dangerous interactions with other substances)\",\n+        \"Dissociatives (greatly enhance cognitive, visual and hallucinatory effects with increased risk of confusion and psychosis)\",\n+        \"Alcohol (may reduce anxiety but can increase dehydration, nausea and physical fatigue)\",\n+        \"Benzodiazepines (can reduce trip intensity; useful for stopping bad trips but may cause amnesia)\",\n+        \"Other psychedelics (unpredictable synergy and intensification of effects)\"\n+      ]\n-    \"notes\": \"ETH-LAD requires exceptional caution due to its high potency, unpredictable dose-response curve, and tendency to produce severe physical side effects including pronounced nausea, temperature dysregulation, muscle cramps, and bodily discomfort at higher doses. The substance is notably more difficult to handle than LSD and should only be used by experienced psychedelic users. Accurate measurement with a precise scale is critical. Users should monitor body temperature throughout the experience and maintain access to climate control. Set and setting are paramount, and having a trusted sober sitter is strongly recommended, especially at doses above the common range. Individuals with personal or family history of psychotic disorders should avoid use.\",\n+    \"notes\": \"LSA-containing seeds vary widely in alkaloid content between species, batches, and individual seeds. Commercial seeds are often treated with fungicides or pesticides that can be extremely toxic; only use organic, untreated seeds from trusted vendors. Heavy metal testing is recommended before consumption. Extraction methods can significantly reduce nausea and body load. Strong vasoconstriction is common and can cause painful leg cramping; avoid repeated use over short periods. Set and setting strongly influence the experience. Individuals with personal or family histories of psychotic disorders should avoid use.\",\n-      \"Intricate Visual Geometry\",\n-      \"Enhanced Pattern Recognition\",\n-      \"Auditory Distortions and Hallucinations\",\n-      \"Analysis Enhancement\",\n-      \"Introspective Thought Patterns\",\n+      \"Sedation (setting-dependent)\",\n+      \"Physical Euphoria\",\n+      \"Visual Enhancements and Distortions\",\n+      \"Spontaneous Bodily Sensations\",\n+      \"Perception of Bodily Heaviness\",\n+      \"Motor Control Loss\",\n+      \"Nausea and Vasoconstriction\",\n+      \"Dream-Like State\",\n+      \"Introspection and Analysis Enhancement\",\n+      \"Emotion Enhancement\",\n-      \"Synaesthesia\",\n-      \"Enhanced Color Perception\",\n-      \"Nausea and Bodily Discomfort\",\n-      \"Temperature Dysregulation\",\n-      \"Emotional Neutrality or Detachment\",\n-      \"Thought Acceleration\",\n-      \"Memory Suppression\"\n+      \"Internal and External Hallucinations\",\n+      \"Thought Connectivity\",\n+      \"Music Appreciation Enhancement\",\n+      \"Spirituality Enhancement\"\n-      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n-      \"half_tolerance\": \"5-7 days\",\n-      \"zero_tolerance\": \"14 days\",\n+      \"full_tolerance\": \"Almost immediately after ingestion\",\n+      \"half_tolerance\": \"3-4 days\",\n+      \"zero_tolerance\": \"7 days\",\n-        \"All psychedelics including LSD, psilocybin, mescaline, DMT, and related lysergamides\"\n+        \"All psychedelics (LSD, psilocybin mushrooms, mescaline, DMT, 2C-x compounds)\"\n-    \"half_life\": \"\",\n+    \"half_life\": \"1-3 hours (psilocin is referenced in the original document, but LSA half-life data is limited; serum concentrations detectable for 1-24 hours post-ingestion)\",\n-        \"name\": \"Bluelight: The Big & Dandy ETH-LAD Thread\",\n-        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-eth-lad-thread.761505/\"\n+        \"name\": \"PsychonautWiki: LSA\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/LSA\"\n-        \"name\": \"Erowid ETH-LAD Experience Vault\",\n-        \"reference\": \"https://www.erowid.org/experiences/subs/exp_ETHLAD.shtml\"\n+        \"name\": \"TripSit Wiki: LSA\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/LSA\"\n-        \"name\": \"Erowid TiHKAL Entry #12: ETH-LAD\",\n-        \"reference\": \"https://erowid.org/library/books_online/tihkal/tihkal12.shtml\"\n+        \"name\": \"Erowid LSA Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/lsa/lsa.shtml\"\n-        \"name\": \"Hoffman AJ, Nichols DE (1985) - Synthesis and LSD-like discriminative stimulus properties\",\n-        \"reference\": \"https://doi.org/10.1021/jm00147a022\"\n+        \"name\": \"Erowid LSA Dosage\",\n+        \"reference\": \"https://erowid.org/chemicals/lsa/lsa_dose.shtml\"\n-        \"name\": \"Isomer Design: TiHKAL ETH-LAD Entry\",\n-        \"reference\": \"http://isomerdesign.com/PiHKAL/read.php?domain=tk&id=12\"\n+        \"name\": \"Erowid LSA Effects\",\n+        \"reference\": \"https://www.erowid.org/chemicals/lsa/lsa_effects.shtml\"\n-        \"name\": \"PsychonautWiki: ETH-LAD\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/ETH-LAD\"\n+        \"name\": \"Bluelight: The Big & Dandy LSA Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/lsas-subthread-extraction-of-lsas.123944/\"\n+      },\n+      {\n+        \"name\": \"Drugs-Forum: LSA Wiki\",\n+        \"reference\": \"https://drugs-forum.com/wiki/LSA\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Ergine\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Ergine\"\n+      },\n+      {\n+        \"name\": \"Lysergic Acid Amide (LSA), an LSD Analog: Systematic Review (MDPI, 2025)\",\n+        \"reference\": \"https://www.mdpi.com/2226-4787/13/4/98\"\n-      \"research-chemical\"\n+      \"natural\"\n-  \"id\": 630\n+  \"id\": 631\n\n# MiPLA · #632\n\n-  \"title\": \"LSA\",\n-  \"index-category\": \"psychedelic; natural\",\n+  \"title\": \"MiPLA\",\n+  \"index-category\": \"psychedelic; lysergamide; research-chemical\",\n-    \"drug_name\": \"LSA\",\n-    \"chemical_name\": \"d-Lysergic acid amide\",\n-    \"alternative_name\": \"Ergine; LA-111\",\n+    \"drug_name\": \"MiPLA\",\n+    \"chemical_name\": \"Lysergic acid methylisopropylamide\",\n+    \"alternative_name\": \"Lamide\",\n-          \"route\": \"oral (morning glory seeds)\",\n-          \"units\": \"seeds\",\n+          \"route\": \"oral\",\n+          \"units\": \"ug\",\n-            \"threshold\": \"20-50 seeds\",\n-            \"light\": \"50-100 seeds\",\n-            \"common\": \"100-250 seeds\",\n-            \"strong\": \"250-400 seeds\",\n-            \"heavy\": \"400+ seeds\"\n+            \"threshold\": \"50 ug\",\n+            \"light\": \"100-150 ug\",\n+            \"common\": \"150-200 ug\",\n+            \"strong\": \"200-250 ug\",\n+            \"heavy\": \"300+ ug\"\n-        },\n-        {\n-          \"route\": \"oral (hawaiian baby woodrose seeds)\",\n-          \"units\": \"seeds\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"1-3 seeds\",\n-            \"light\": \"3-5 seeds\",\n-            \"common\": \"5-7 seeds\",\n-            \"strong\": \"7-12 seeds\",\n-            \"heavy\": \"12+ seeds\"\n-          }\n-        },\n-        {\n-          \"route\": \"oral (pure lsa)\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"0.5 mg\",\n-            \"light\": \"0.5-1 mg\",\n-            \"common\": \"1-2 mg\",\n-            \"strong\": \"2-3 mg\",\n-            \"heavy\": \"3+ mg\"\n-          }\n-          \"route\": \"oral (morning glory seeds)\",\n+          \"route\": \"oral\",\n-            \"total_duration\": \"4-10 hours\",\n-            \"onset\": \"20-60 minutes (up to 3 hours reported)\",\n-            \"peak\": \"90-180 minutes\",\n-            \"offset\": \"2-7 hours\",\n-            \"after_effects\": \"1-12 hours (afterglow)\"\n+            \"total_duration\": \"4-6 hours\",\n+            \"onset\": \"20-40 minutes\",\n+            \"peak\": \"1-2 hours (preceded by 45-90 minute come-up)\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"Minimal residual stimulation\"\n-        },\n-        {\n-          \"route\": \"oral (hawaiian baby woodrose seeds)\",\n-          \"stages\": {\n-            \"total_duration\": \"4-10 hours\",\n-            \"onset\": \"20-60 minutes (up to 3 hours reported)\",\n-            \"peak\": \"90-180 minutes\",\n-            \"offset\": \"2-7 hours\",\n-            \"after_effects\": \"1-12 hours (afterglow)\"\n-          }\n-        },\n-        {\n-          \"route\": \"oral (pure lsa)\",\n-          \"stages\": {\n-            \"total_duration\": \"4-10 hours\",\n-            \"onset\": \"20-60 minutes (up to 3 hours reported)\",\n-            \"peak\": \"90-180 minutes\",\n-            \"offset\": \"2-7 hours\",\n-            \"after_effects\": \"1-12 hours (afterglow)\"\n-          }\n-    \"addiction_potential\": \"LSA is not considered to be addictive with low abuse potential. There is virtually no withdrawal syndrome when use is stopped, and animal studies have not demonstrated self-administration behavior predictive of abuse liability.\",\n+    \"addiction_potential\": \"MiPLA is not considered physically addictive and has low potential for psychological dependence, similar to other serotonergic psychedelics. Rapid tolerance development discourages frequent use.\",\n-        \"Lithium (significantly increased risk of psychosis and seizures)\",\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n-        \"Stimulants (increased risk of anxiety, paranoia, thought loops, and mania)\",\n-        \"Cannabis (unexpectedly strong and unpredictable synergy; significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n+        \"Stimulants (amphetamine, cocaine, methylphenidate - increases risk of anxiety, paranoia, panic attacks, thought loops, mania, and psychosis)\"\n-        \"SSRIs (may suppress visual and cognitive effects)\",\n-        \"MAOIs (may potentiate effects; use caution with potential for dangerous interactions with other substances)\",\n-        \"Dissociatives (greatly enhance cognitive, visual and hallucinatory effects with increased risk of confusion and psychosis)\",\n-        \"Alcohol (may reduce anxiety but can increase dehydration, nausea and physical fatigue)\",\n-        \"Benzodiazepines (can reduce trip intensity; useful for stopping bad trips but may cause amnesia)\",\n-        \"Other psychedelics (unpredictable synergy and intensification of effects)\"\n+        \"Cannabis (unpredictable synergy; significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\",\n+        \"SSRIs (may alter or blunt effects)\"\n-    \"notes\": \"LSA-containing seeds vary widely in alkaloid content between species, batches, and individual seeds. Commercial seeds are often treated with fungicides or pesticides that can be extremely toxic; only use organic, untreated seeds from trusted vendors. Heavy metal testing is recommended before consumption. Extraction methods can significantly reduce nausea and body load. Strong vasoconstriction is common and can cause painful leg cramping; avoid repeated use over short periods. Set and setting strongly influence the experience. Individuals with personal or family histories of psychotic disorders should avoid use.\",\n+    \"notes\": \"MiPLA is a research chemical with very limited history of human use and minimal scientific study of its pharmacology, metabolism, and toxicity. It is approximately two to three times less potent than LSD and has a notably shorter duration of around 4-6 hours. The substance is generally described as producing less anxiety and a lighter headspace compared to LSD. Individuals with personal or family history of mental illness should avoid use. Use precise weighing equipment and employ harm reduction practices including careful set and setting preparation.\",\n-      \"Sedation (setting-dependent)\",\n+      \"Stimulation\",\n-      \"Visual Enhancements and Distortions\",\n-      \"Spontaneous Bodily Sensations\",\n-      \"Perception of Bodily Heaviness\",\n-      \"Motor Control Loss\",\n-      \"Nausea and Vasoconstriction\",\n-      \"Dream-Like State\",\n-      \"Introspection and Analysis Enhancement\",\n-      \"Emotion Enhancement\",\n-      \"Time Distortion\",\n-      \"Internal and External Hallucinations\",\n-      \"Thought Connectivity\",\n+      \"Tactile Enhancement\",\n+      \"Visual Acuity Enhancement\",\n+      \"Color Enhancement\",\n+      \"Pattern Recognition Enhancement\",\n+      \"Visual Drifting\",\n+      \"Geometric Patterns\",\n+      \"Cognitive Euphoria\",\n+      \"Analysis Enhancement\",\n-      \"Spirituality Enhancement\"\n+      \"Time Distortion\",\n+      \"Ego Death (at higher doses)\",\n+      \"Nausea\",\n+      \"Increased Body Temperature\"\n-      \"full_tolerance\": \"Almost immediately after ingestion\",\n-      \"half_tolerance\": \"3-4 days\",\n-      \"zero_tolerance\": \"7 days\",\n+      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n+      \"half_tolerance\": \"5-7 days\",\n+      \"zero_tolerance\": \"14 days\",\n-        \"All psychedelics (LSD, psilocybin mushrooms, mescaline, DMT, 2C-x compounds)\"\n+        \"All psychedelics (due to 5-HT2A receptor activity)\"\n-    \"half_life\": \"1-3 hours (psilocin is referenced in the original document, but LSA half-life data is limited; serum concentrations detectable for 1-24 hours post-ingestion)\",\n+    \"half_life\": \"1-3 hours (estimated based on duration profile)\",\n-        \"name\": \"PsychonautWiki: LSA\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/LSA\"\n+        \"name\": \"PsychonautWiki: MiPLA\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/MiPLA\"\n-        \"name\": \"TripSit Wiki: LSA\",\n-        \"reference\": \"https://wiki.tripsit.me/wiki/LSA\"\n+        \"name\": \"Erowid MiPLA Experience Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_MIPLA.shtml\"\n-        \"name\": \"Erowid LSA Vault\",\n-        \"reference\": \"https://www.erowid.org/chemicals/lsa/lsa.shtml\"\n+        \"name\": \"Bluelight: The Big & Dandy MIPLA Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-mipla-methylisopropyllysergamide-thread.784440/\"\n-        \"name\": \"Erowid LSA Dosage\",\n-        \"reference\": \"https://erowid.org/chemicals/lsa/lsa_dose.shtml\"\n+        \"name\": \"Isomer Design: MiPLA (PiHKAL)\",\n+        \"reference\": \"https://isomerdesign.com/pihkal/explore/5327\"\n-        \"name\": \"Erowid LSA Effects\",\n-        \"reference\": \"https://www.erowid.org/chemicals/lsa/lsa_effects.shtml\"\n+        \"name\": \"Halberstadt et al. (2018) - Pharmacological characterization of ECPLA\",\n+        \"reference\": \"https://link.springer.com/article/10.1007/s00213-018-5055-9\"\n-        \"name\": \"Bluelight: The Big & Dandy LSA Thread\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/lsas-subthread-extraction-of-lsas.123944/\"\n-      },\n-      {\n-        \"name\": \"Drugs-Forum: LSA Wiki\",\n-        \"reference\": \"https://drugs-forum.com/wiki/LSA\"\n-      },\n-      {\n-        \"name\": \"Wikipedia: Ergine\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Ergine\"\n-      },\n-      {\n-        \"name\": \"Lysergic Acid Amide (LSA), an LSD Analog: Systematic Review (MDPI, 2025)\",\n-        \"reference\": \"https://www.mdpi.com/2226-4787/13/4/98\"\n+        \"name\": \"Nichols, D.E. (2001) - LSD and its lysergamide cousins\",\n+        \"reference\": \"The Heffter Review of Psychedelic Research, Vol. 2, pp. 80-87\"\n-      \"natural\"\n+      \"research-chemical\"\n-  \"id\": 631\n+  \"id\": 632\n\n# MET · #633\n\n-  \"title\": \"MiPLA\",\n-  \"index-category\": \"psychedelic; lysergamide; research-chemical\",\n+  \"title\": \"MET\",\n+  \"index-category\": \"psychedelic; tryptamine\",\n-    \"drug_name\": \"MiPLA\",\n-    \"chemical_name\": \"Lysergic acid methylisopropylamide\",\n-    \"alternative_name\": \"Lamide\",\n-    \"chemical_class\": \"Lysergamides\",\n+    \"drug_name\": \"MET\",\n+    \"chemical_name\": \"N-Ethyl-N-methyltryptamine\",\n+    \"alternative_name\": \"Methylethyltryptamine\",\n+    \"chemical_class\": \"Tryptamines\",\n-    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; serotonin releasing agent (weak)\",\n+          \"route\": \"smoked/vaporized\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"10 mg\",\n+            \"light\": \"20-40 mg\",\n+            \"common\": \"40-60 mg\",\n+            \"strong\": \"60-90 mg\",\n+            \"heavy\": \"90+ mg\"\n+          }\n+        },\n+        {\n-          \"units\": \"ug\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"50 ug\",\n-            \"light\": \"100-150 ug\",\n-            \"common\": \"150-200 ug\",\n-            \"strong\": \"200-250 ug\",\n-            \"heavy\": \"300+ ug\"\n+            \"threshold\": \"60-70 mg\",\n+            \"light\": \"70-80 mg\",\n+            \"common\": \"80-110 mg\",\n+            \"strong\": \"110-150 mg\",\n+            \"heavy\": \"150+ mg\"\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"10-15 mg\",\n+            \"light\": \"15-30 mg\",\n+            \"common\": \"30-50 mg\",\n+            \"strong\": \"50-70 mg\",\n+            \"heavy\": \"70+ mg\"\n+          }\n+          \"route\": \"smoked/vaporized\",\n+          \"stages\": {\n+            \"total_duration\": \"30-75 minutes\",\n+            \"onset\": \"30-60 seconds\",\n+            \"peak\": \"10-20 minutes\",\n+            \"offset\": \"20-40 minutes\",\n+            \"after_effects\": \"20-60 minutes\"\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n+        },\n+        {\n-            \"total_duration\": \"4-6 hours\",\n-            \"onset\": \"20-40 minutes\",\n-            \"peak\": \"1-2 hours (preceded by 45-90 minute come-up)\",\n+            \"total_duration\": \"2-4 hours\",\n+            \"onset\": \"20-45 minutes\",\n+            \"peak\": \"1-2 hours\",\n-            \"after_effects\": \"Minimal residual stimulation\"\n+            \"after_effects\": \"1-3 hours\"\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"stages\": {\n+            \"total_duration\": \"1.5-3 hours\",\n+            \"onset\": \"5-15 minutes\",\n+            \"peak\": \"30-90 minutes\",\n+            \"offset\": \"45-90 minutes\",\n+            \"after_effects\": \"30-120 minutes\"\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n-    \"addiction_potential\": \"MiPLA is not considered physically addictive and has low potential for psychological dependence, similar to other serotonergic psychedelics. Rapid tolerance development discourages frequent use.\",\n+    \"addiction_potential\": \"MET is not considered habit-forming and appears to be self-regulating. Reports suggest the desire to use it may actually decrease with regular consumption, similar to other psychedelic tryptamines.\",\n-        \"Lithium (significantly increases risk of psychosis and seizures)\",\n-        \"Tramadol (lowers seizure threshold)\"\n+        \"MAOIs (risk of serotonin syndrome and hypertensive crisis)\",\n+        \"Lithium (increased seizure risk)\"\n-        \"Stimulants (amphetamine, cocaine, methylphenidate - increases risk of anxiety, paranoia, panic attacks, thought loops, mania, and psychosis)\"\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Stimulants (increased risk of anxiety and cardiovascular strain)\"\n-        \"Cannabis (unpredictable synergy; significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\",\n-        \"SSRIs (may alter or blunt effects)\"\n+        \"SSRIs (may dampen or prolong effects)\",\n+        \"Cannabis (may intensify experience unpredictably)\"\n-    \"notes\": \"MiPLA is a research chemical with very limited history of human use and minimal scientific study of its pharmacology, metabolism, and toxicity. It is approximately two to three times less potent than LSD and has a notably shorter duration of around 4-6 hours. The substance is generally described as producing less anxiety and a lighter headspace compared to LSD. Individuals with personal or family history of mental illness should avoid use. Use precise weighing equipment and employ harm reduction practices including careful set and setting preparation.\",\n+    \"notes\": \"MET is a research chemical with very limited human use history and unstudied toxicity profile. The freebase form can be harsh when insufflated or smoked. Use an accurate milligram scale for all routes of administration. Set and setting are crucial for psychedelic experiences. Unlike DMT, MET has oral activity without requiring an MAOI. Individuals with personal or family history of psychotic disorders should avoid use.\",\n-      \"Stimulation\",\n+      \"Visual Geometry And Patterning\",\n+      \"Internal Hallucinations\",\n-      \"Visual Acuity Enhancement\",\n-      \"Color Enhancement\",\n-      \"Pattern Recognition Enhancement\",\n-      \"Visual Drifting\",\n-      \"Geometric Patterns\",\n+      \"Stimulation\",\n+      \"Color Enhancement And Shifting\",\n-      \"Analysis Enhancement\",\n-      \"Music Appreciation Enhancement\",\n+      \"Empathy And Sociability Enhancement\",\n+      \"Thought Connectivity\",\n-      \"Ego Death (at higher doses)\",\n-      \"Nausea\",\n-      \"Increased Body Temperature\"\n+      \"Confusion\",\n+      \"Memory Suppression\"\n-      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n-      \"half_tolerance\": \"5-7 days\",\n-      \"zero_tolerance\": \"14 days\",\n+      \"full_tolerance\": \"Minimal tolerance buildup with repeated use\",\n+      \"half_tolerance\": \"Unknown\",\n+      \"zero_tolerance\": \"Approximately 1-2 weeks\",\n-        \"All psychedelics (due to 5-HT2A receptor activity)\"\n+        \"Other psychedelic tryptamines (minimal to none)\",\n+        \"Classic psychedelics (minimal to none)\"\n-    \"half_life\": \"1-3 hours (estimated based on duration profile)\",\n+    \"half_life\": \"\",\n-        \"name\": \"PsychonautWiki: MiPLA\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/MiPLA\"\n+        \"name\": \"Bluelight: The Big & Dandy MET Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-met-thread.255405/\"\n-        \"name\": \"Erowid MiPLA Experience Vault\",\n-        \"reference\": \"https://erowid.org/experiences/subs/exp_MIPLA.shtml\"\n+        \"name\": \"Erowid MET Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/met/met.shtml\"\n-        \"name\": \"Bluelight: The Big & Dandy MIPLA Thread\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-mipla-methylisopropyllysergamide-thread.784440/\"\n+        \"name\": \"PsychonautWiki: MET\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/MET\"\n-        \"name\": \"Isomer Design: MiPLA (PiHKAL)\",\n-        \"reference\": \"https://isomerdesign.com/pihkal/explore/5327\"\n-      },\n-      {\n-        \"name\": \"Halberstadt et al. (2018) - Pharmacological characterization of ECPLA\",\n-        \"reference\": \"https://link.springer.com/article/10.1007/s00213-018-5055-9\"\n-      },\n-      {\n-        \"name\": \"Nichols, D.E. (2001) - LSD and its lysergamide cousins\",\n-        \"reference\": \"The Heffter Review of Psychedelic Research, Vol. 2, pp. 80-87\"\n+        \"name\": \"Wikipedia: Methylethyltryptamine\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Methylethyltryptamine\"\n-      \"lysergamide\",\n+      \"tryptamine\",\n-  \"id\": 632\n+  \"id\": 633\n\n# LSM-775 · #634\n\n-  \"title\": \"MET\",\n-  \"index-category\": \"psychedelic; tryptamine\",\n+  \"title\": \"LSM-775\",\n+  \"index-category\": \"psychedelic; lysergamide; research-chemical\",\n-    \"drug_name\": \"MET\",\n-    \"chemical_name\": \"N-Ethyl-N-methyltryptamine\",\n-    \"alternative_name\": \"Methylethyltryptamine\",\n-    \"chemical_class\": \"Tryptamines\",\n+    \"drug_name\": \"LSM-775\",\n+    \"chemical_name\": \"Lysergic acid morpholide\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Lysergamides\",\n-    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; serotonin releasing agent (weak)\",\n+    \"mechanism_of_action\": \"5-HT1A receptor full agonist; 5-HT2A receptor partial agonist; 5-HT2B receptor partial agonist; 5-HT2C receptor partial agonist\",\n-          \"route\": \"smoked/vaporized\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"10 mg\",\n-            \"light\": \"20-40 mg\",\n-            \"common\": \"40-60 mg\",\n-            \"strong\": \"60-90 mg\",\n-            \"heavy\": \"90+ mg\"\n-          }\n-        },\n-        {\n-          \"units\": \"mg\",\n+          \"units\": \"ug\",\n-            \"threshold\": \"60-70 mg\",\n-            \"light\": \"70-80 mg\",\n-            \"common\": \"80-110 mg\",\n-            \"strong\": \"110-150 mg\",\n-            \"heavy\": \"150+ mg\"\n+            \"threshold\": \"250 ug\",\n+            \"light\": \"500-750 ug\",\n+            \"common\": \"750-1250 ug\",\n+            \"strong\": \"1250-1500 ug\",\n+            \"heavy\": \"1500+ ug\"\n-        },\n-        {\n-          \"route\": \"insufflated\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"10-15 mg\",\n-            \"light\": \"15-30 mg\",\n-            \"common\": \"30-50 mg\",\n-            \"strong\": \"50-70 mg\",\n-            \"heavy\": \"70+ mg\"\n-          }\n-          \"route\": \"smoked/vaporized\",\n-          \"stages\": {\n-            \"total_duration\": \"30-75 minutes\",\n-            \"onset\": \"30-60 seconds\",\n-            \"peak\": \"10-20 minutes\",\n-            \"offset\": \"20-40 minutes\",\n-            \"after_effects\": \"20-60 minutes\"\n-          },\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ]\n-        },\n-        {\n-            \"total_duration\": \"2-4 hours\",\n-            \"onset\": \"20-45 minutes\",\n-            \"peak\": \"1-2 hours\",\n-            \"offset\": \"1-2 hours\",\n-            \"after_effects\": \"1-3 hours\"\n+            \"total_duration\": \"6-10 hours\",\n+            \"onset\": \"10-30 minutes\",\n+            \"peak\": \"60-150 minutes\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"Variable (residual sedation possible)\"\n-        },\n-        {\n-          \"route\": \"insufflated\",\n-          \"stages\": {\n-            \"total_duration\": \"1.5-3 hours\",\n-            \"onset\": \"5-15 minutes\",\n-            \"peak\": \"30-90 minutes\",\n-            \"offset\": \"45-90 minutes\",\n-            \"after_effects\": \"30-120 minutes\"\n-          },\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ]\n-    \"addiction_potential\": \"MET is not considered habit-forming and appears to be self-regulating. Reports suggest the desire to use it may actually decrease with regular consumption, similar to other psychedelic tryptamines.\",\n+    \"addiction_potential\": \"LSM-775 is not considered habit-forming and possesses an intrinsic self-regulating quality similar to other psychedelics. Limited evidence suggests no significant dependence potential, though the substance has very little history of human use.\",\n-        \"MAOIs (risk of serotonin syndrome and hypertensive crisis)\",\n-        \"Lithium (increased seizure risk)\"\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n-        \"Tramadol (lowers seizure threshold)\",\n-        \"Stimulants (increased risk of anxiety and cardiovascular strain)\"\n+        \"Stimulants (increases anxiety, paranoia, and thought loops)\",\n+        \"Cannabis (unpredictable synergy; greatly increases risk of anxiety and psychosis)\"\n-        \"SSRIs (may dampen or prolong effects)\",\n-        \"Cannabis (may intensify experience unpredictably)\"\n+        \"MDMA (unpredictable synergy; potentially neurotoxic)\",\n+        \"Alcohol (increases dehydration and physical discomfort)\",\n+        \"Other psychedelics (unpredictable intensification)\"\n-    \"notes\": \"MET is a research chemical with very limited human use history and unstudied toxicity profile. The freebase form can be harsh when insufflated or smoked. Use an accurate milligram scale for all routes of administration. Set and setting are crucial for psychedelic experiences. Unlike DMT, MET has oral activity without requiring an MAOI. Individuals with personal or family history of psychotic disorders should avoid use.\",\n+    \"notes\": \"LSM-775 is a novel lysergamide with approximately one-tenth the potency of LSD and a shorter duration. It is characterized by prominent dream-like sedation and significant nausea that may substantially reduce the experience's pleasantness. Use a precise milligram scale as doses are relatively high. Mental health screening is advised before use, particularly for individuals with personal or family history of psychotic disorders. Set and setting remain important factors. Legal status varies by jurisdiction; controlled in Germany and Switzerland as of 2019.\",\n-      \"Visual Geometry And Patterning\",\n-      \"Internal Hallucinations\",\n-      \"Physical Euphoria\",\n-      \"Tactile Enhancement\",\n-      \"Stimulation\",\n-      \"Color Enhancement And Shifting\",\n-      \"Cognitive Euphoria\",\n-      \"Empathy And Sociability Enhancement\",\n+      \"Dream-Like Sedation\",\n+      \"Prominent Nausea\",\n+      \"Visual Patterning And Geometry\",\n+      \"Time Distortion (Particularly Pronounced)\",\n+      \"Color Enhancement\",\n+      \"Spontaneous Physical Sensations (Tingling)\",\n+      \"Music Enhancement\",\n-      \"Time Distortion\",\n-      \"Confusion\",\n-      \"Memory Suppression\"\n+      \"Perception Of Bodily Heaviness\",\n+      \"Drifting (Melting, Breathing, Morphing)\",\n+      \"Internal Hallucinations\",\n+      \"Analysis Enhancement\"\n-      \"full_tolerance\": \"Minimal tolerance buildup with repeated use\",\n-      \"half_tolerance\": \"Unknown\",\n-      \"zero_tolerance\": \"Approximately 1-2 weeks\",\n+      \"full_tolerance\": \"Almost immediately after ingestion\",\n+      \"half_tolerance\": \"5-7 days\",\n+      \"zero_tolerance\": \"14 days\",\n-        \"Other psychedelic tryptamines (minimal to none)\",\n-        \"Classic psychedelics (minimal to none)\"\n+        \"All psychedelics (LSD, psilocybin, mescaline, etc.)\"\n-        \"name\": \"Bluelight: The Big & Dandy MET Thread\",\n-        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-met-thread.255405/\"\n+        \"name\": \"PsychonautWiki: LSM-775\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/LSM-775\"\n-        \"name\": \"Erowid MET Vault\",\n-        \"reference\": \"https://www.erowid.org/chemicals/met/met.shtml\"\n+        \"name\": \"Erowid Experience Vaults: LSM-775\",\n+        \"reference\": \"https://www.erowid.org/experiences/subs/exp_LSM775.shtml\"\n-        \"name\": \"PsychonautWiki: MET\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/MET\"\n+        \"name\": \"Isomer Design: LSM-775\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5338\"\n-        \"name\": \"Wikipedia: Methylethyltryptamine\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Methylethyltryptamine\"\n+        \"name\": \"Bluelight: The Big & Dandy LSM-775 Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-lsm-775-lysergic-acid-morpholide-thread.775765/\"\n+      },\n+      {\n+        \"name\": \"Gogerty & Dille (1957): Pharmacology of d-LSM\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/13476356/\"\n+      },\n+      {\n+        \"name\": \"Shulgin: TiHKAL - LSD-25 Entry\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5338\"\n+      },\n+      {\n+        \"name\": \"Brandt et al. (2018): Return of the Lysergamides Part IV\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/28585392/\"\n-      \"tryptamine\",\n+      \"lysergamide\",\n-  \"id\": 633\n+  \"id\": 634\n\n# PRO-LAD · #635\n\n-  \"title\": \"LSM-775\",\n-  \"index-category\": \"psychedelic; lysergamide; research-chemical\",\n+  \"title\": \"PRO-LAD\",\n+  \"index-category\": \"psychedelic\",\n-    \"drug_name\": \"LSM-775\",\n-    \"chemical_name\": \"Lysergic acid morpholide\",\n+    \"drug_name\": \"PRO-LAD\",\n+    \"chemical_name\": \"6-Propyl-6-nor-lysergic acid diethylamide\",\n-    \"mechanism_of_action\": \"5-HT1A receptor full agonist; 5-HT2A receptor partial agonist; 5-HT2B receptor partial agonist; 5-HT2C receptor partial agonist\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n-            \"threshold\": \"250 ug\",\n-            \"light\": \"500-750 ug\",\n-            \"common\": \"750-1250 ug\",\n-            \"strong\": \"1250-1500 ug\",\n-            \"heavy\": \"1500+ ug\"\n+            \"threshold\": \"20 ug\",\n+            \"light\": \"50-100 ug\",\n+            \"common\": \"100-200 ug\",\n+            \"strong\": \"200-350 ug\",\n+            \"heavy\": \"350+ ug\"\n-            \"total_duration\": \"6-10 hours\",\n-            \"onset\": \"10-30 minutes\",\n-            \"peak\": \"60-150 minutes\",\n-            \"offset\": \"2-4 hours\",\n-            \"after_effects\": \"Variable (residual sedation possible)\"\n+            \"total_duration\": \"6-8 hours\",\n+            \"onset\": \"30-45 minutes\",\n+            \"peak\": \"2-4 hours\",\n+            \"offset\": \"2-3 hours\",\n+            \"after_effects\": \"1-4 hours\"\n-    \"addiction_potential\": \"LSM-775 is not considered habit-forming and possesses an intrinsic self-regulating quality similar to other psychedelics. Limited evidence suggests no significant dependence potential, though the substance has very little history of human use.\",\n+    \"addiction_potential\": \"PRO-LAD is not considered habit-forming and possesses self-regulating properties typical of psychedelics. The desire to use it may actually decrease with repeated administration. No formal dependence studies have been conducted.\",\n-        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"Lithium (significantly increases risk of seizures and psychosis)\",\n-        \"Stimulants (increases anxiety, paranoia, and thought loops)\",\n-        \"Cannabis (unpredictable synergy; greatly increases risk of anxiety and psychosis)\"\n+        \"Stimulants including amphetamines, cocaine, methylphenidate (increased risk of anxiety, paranoia, thought loops, mania, and psychosis)\"\n-        \"MDMA (unpredictable synergy; potentially neurotoxic)\",\n-        \"Alcohol (increases dehydration and physical discomfort)\",\n-        \"Other psychedelics (unpredictable intensification)\"\n+        \"Cannabis (unexpectedly strong and unpredictable synergy; significantly increases risk of anxiety, paranoia, and psychosis)\",\n+        \"MDMA (unpredictable synergy with potential neurotoxicity)\",\n+        \"Benzodiazepines (can reduce or eliminate psychedelic effects)\",\n+        \"Dissociatives (greatly enhanced effects and confusion)\",\n+        \"Other psychedelics (unpredictable synergistic intensification)\"\n-    \"notes\": \"LSM-775 is a novel lysergamide with approximately one-tenth the potency of LSD and a shorter duration. It is characterized by prominent dream-like sedation and significant nausea that may substantially reduce the experience's pleasantness. Use a precise milligram scale as doses are relatively high. Mental health screening is advised before use, particularly for individuals with personal or family history of psychotic disorders. Set and setting remain important factors. Legal status varies by jurisdiction; controlled in Germany and Switzerland as of 2019.\",\n+    \"notes\": \"PRO-LAD is a research chemical with very limited history of human use and minimal scientific documentation regarding its pharmacology, metabolism, and long-term toxicity. Unlike LSD, PRO-LAD has a propyl chain at R6 which may result in slower absorption and different onset characteristics. Users should employ rigorous harm reduction practices including reagent testing, accurate weighing with a microgram scale, and having a trusted sober trip sitter present. Individuals with personal or family history of psychotic disorders should avoid use. PRO-LAD was first synthesized by Hoffman and Nichols in 1984 and later described by Alexander Shulgin in TiHKAL.\",\n-      \"Dream-Like Sedation\",\n-      \"Prominent Nausea\",\n-      \"Time Distortion (Particularly Pronounced)\",\n-      \"Spontaneous Physical Sensations (Tingling)\",\n-      \"Music Enhancement\",\n+      \"Introspection\",\n+      \"Time Distortion\",\n+      \"Ego Death\",\n+      \"Spontaneous Bodily Sensations\",\n+      \"Enhanced Sense Of Humor\",\n-      \"Perception Of Bodily Heaviness\",\n-      \"Drifting (Melting, Breathing, Morphing)\",\n-      \"Internal Hallucinations\",\n-      \"Analysis Enhancement\"\n+      \"Physical Euphoria\",\n+      \"Emotional Amplification\",\n+      \"Analysis Enhancement\",\n+      \"Conceptual Thinking\"\n-      \"full_tolerance\": \"Almost immediately after ingestion\",\n+      \"full_tolerance\": \"Immediately after ingestion\",\n-        \"All psychedelics (LSD, psilocybin, mescaline, etc.)\"\n+        \"All psychedelics including LSD, psilocybin, mescaline, DMT, and other lysergamides\"\n-        \"name\": \"PsychonautWiki: LSM-775\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/LSM-775\"\n+        \"name\": \"Erowid TiHKAL Entry #51: PRO-LAD\",\n+        \"reference\": \"https://www.erowid.org/library/books_online/tihkal/tihkal51.shtml\"\n-        \"name\": \"Erowid Experience Vaults: LSM-775\",\n-        \"reference\": \"https://www.erowid.org/experiences/subs/exp_LSM775.shtml\"\n+        \"name\": \"PsychonautWiki: PRO-LAD\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/PRO-LAD\"\n-        \"name\": \"Isomer Design: LSM-775\",\n-        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5338\"\n+        \"name\": \"TripSit Drug Combination Chart\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/Drug_combinations\"\n-        \"name\": \"Bluelight: The Big & Dandy LSM-775 Thread\",\n-        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-lsm-775-lysergic-acid-morpholide-thread.775765/\"\n+        \"name\": \"Hoffman AJ, Nichols DE (1985). Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives. Journal of Medicinal Chemistry 28(9):1252-1255\",\n+        \"reference\": \"https://doi.org/10.1021/jm00147a022\"\n-        \"name\": \"Gogerty & Dille (1957): Pharmacology of d-LSM\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/13476356/\"\n-      },\n-      {\n-        \"name\": \"Shulgin: TiHKAL - LSD-25 Entry\",\n-        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5338\"\n-      },\n-      {\n-        \"name\": \"Brandt et al. (2018): Return of the Lysergamides Part IV\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/28585392/\"\n+        \"name\": \"Shulgin A, Shulgin A (1997). TiHKAL: Tryptamines I Have Known And Loved\",\n+        \"reference\": \"https://www.erowid.org/library/books_online/tihkal/\"\n-  \"id\": 634\n+  \"id\": 635\n\n# DET · #636\n\n-  \"title\": \"PRO-LAD\",\n-  \"index-category\": \"psychedelic\",\n+  \"title\": \"DET\",\n+  \"index-category\": \"psychedelic; research-chemical\",\n-    \"drug_name\": \"PRO-LAD\",\n-    \"chemical_name\": \"6-Propyl-6-nor-lysergic acid diethylamide\",\n-    \"alternative_name\": \"\",\n-    \"chemical_class\": \"Lysergamides\",\n+    \"drug_name\": \"DET\",\n+    \"chemical_name\": \"N,N-diethyl-2-(1H-indol-3-yl)ethanamine\",\n+    \"alternative_name\": \"Diethyltryptamine; N,N-diethyltryptamine; T-9\",\n+    \"chemical_class\": \"Tryptamines\",\n-          \"units\": \"ug\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"20 ug\",\n-            \"light\": \"50-100 ug\",\n-            \"common\": \"100-200 ug\",\n-            \"strong\": \"200-350 ug\",\n-            \"heavy\": \"350+ ug\"\n+            \"threshold\": \"10 mg\",\n+            \"light\": \"20-40 mg\",\n+            \"common\": \"40-70 mg\",\n+            \"strong\": \"70-100 mg\",\n+            \"heavy\": \"100+ mg\"\n-            \"total_duration\": \"6-8 hours\",\n-            \"onset\": \"30-45 minutes\",\n+            \"total_duration\": \"4-6 hours\",\n+            \"onset\": \"30-90 minutes\",\n-            \"after_effects\": \"1-4 hours\"\n+            \"after_effects\": \"2-8 hours\"\n-    \"addiction_potential\": \"PRO-LAD is not considered habit-forming and possesses self-regulating properties typical of psychedelics. The desire to use it may actually decrease with repeated administration. No formal dependence studies have been conducted.\",\n+    \"addiction_potential\": \"DET is not believed to be habit-forming and the desire to use it can actually decrease with repeated use. No formal studies have been conducted on its addiction potential, but anecdotal evidence suggests no negative dependency patterns.\",\n-        \"Lithium (significantly increases risk of seizures and psychosis)\",\n-        \"Tramadol (lowers seizure threshold)\"\n+        \"Lithium (seizure risk and amplified intensity)\",\n+        \"MAOIs (serotonin syndrome risk)\"\n-        \"Stimulants including amphetamines, cocaine, methylphenidate (increased risk of anxiety, paranoia, thought loops, mania, and psychosis)\"\n+        \"Tramadol (lowers seizure threshold)\"\n-        \"Cannabis (unexpectedly strong and unpredictable synergy; significantly increases risk of anxiety, paranoia, and psychosis)\",\n-        \"MDMA (unpredictable synergy with potential neurotoxicity)\",\n-        \"Benzodiazepines (can reduce or eliminate psychedelic effects)\",\n-        \"Dissociatives (greatly enhanced effects and confusion)\",\n-        \"Other psychedelics (unpredictable synergistic intensification)\"\n+        \"Stimulants (may cause anxiety, paranoia, and thought loops)\"\n-    \"notes\": \"PRO-LAD is a research chemical with very limited history of human use and minimal scientific documentation regarding its pharmacology, metabolism, and long-term toxicity. Unlike LSD, PRO-LAD has a propyl chain at R6 which may result in slower absorption and different onset characteristics. Users should employ rigorous harm reduction practices including reagent testing, accurate weighing with a microgram scale, and having a trusted sober trip sitter present. Individuals with personal or family history of psychotic disorders should avoid use. PRO-LAD was first synthesized by Hoffman and Nichols in 1984 and later described by Alexander Shulgin in TiHKAL.\",\n+    \"notes\": \"DET is a Schedule I controlled substance internationally under the UN Convention on Psychotropic Substances and is illegal in most countries. Unlike DMT, DET is orally active due to increased resistance to monoamine oxidase breakdown from its ethyl groups. The substance has extremely limited history of human use and no formal toxicity studies exist. Users should employ precise dosing with a milligram scale and ensure proper set and setting. Individuals with personal or family history of psychotic disorders should avoid use.\",\n-      \"Visual Patterning And Geometry\",\n+      \"Visual Pattern Recognition Enhancement\",\n-      \"Introspection\",\n+      \"Drifting and Morphing\",\n+      \"Internal Hallucinations\",\n+      \"Cognitive Euphoria\",\n+      \"Emotion Enhancement\",\n+      \"Increased Music Appreciation\",\n-      \"Ego Death\",\n-      \"Spontaneous Bodily Sensations\",\n-      \"Enhanced Sense Of Humor\",\n-      \"Thought Connectivity\",\n-      \"Physical Euphoria\",\n-      \"Emotional Amplification\",\n-      \"Analysis Enhancement\",\n+      \"Pupil Dilation\",\n+      \"Nausea\",\n+      \"Increased Heart Rate\",\n-      \"full_tolerance\": \"Immediately after ingestion\",\n-      \"half_tolerance\": \"5-7 days\",\n-      \"zero_tolerance\": \"14 days\",\n+      \"full_tolerance\": \"Almost immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n-        \"All psychedelics including LSD, psilocybin, mescaline, DMT, and other lysergamides\"\n+        \"All psychedelics\"\n-        \"name\": \"Erowid TiHKAL Entry #51: PRO-LAD\",\n-        \"reference\": \"https://www.erowid.org/library/books_online/tihkal/tihkal51.shtml\"\n+        \"name\": \"Erowid DET Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/det/det.shtml\"\n-        \"name\": \"PsychonautWiki: PRO-LAD\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/PRO-LAD\"\n+        \"name\": \"PsychonautWiki: DET\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/DET\"\n-        \"name\": \"TripSit Drug Combination Chart\",\n-        \"reference\": \"https://wiki.tripsit.me/wiki/Drug_combinations\"\n+        \"name\": \"TiHKAL #3: DET (Isomer Design)\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5003\"\n-        \"name\": \"Hoffman AJ, Nichols DE (1985). Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives. Journal of Medicinal Chemistry 28(9):1252-1255\",\n-        \"reference\": \"https://doi.org/10.1021/jm00147a022\"\n+        \"name\": \"TiHKAL #3: DET (Erowid)\",\n+        \"reference\": \"https://www.erowid.org/library/books_online/tihkal/tihkal03.shtml\"\n-        \"name\": \"Shulgin A, Shulgin A (1997). TiHKAL: Tryptamines I Have Known And Loved\",\n-        \"reference\": \"https://www.erowid.org/library/books_online/tihkal/\"\n+        \"name\": \"Bluelight: 5-substituted tryptamines discussion\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/5-substituted-tryptamines.340503/\"\n+      },\n+      {\n+        \"name\": \"Drug-drug interactions involving classic psychedelics\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC10851641/\"\n-      \"lysergamide\",\n+      \"tryptamine\",\n-  \"id\": 635\n+  \"id\": 636\n\n# EPT · #637\n\n-  \"title\": \"DET\",\n+  \"title\": \"EPT\",\n-    \"drug_name\": \"DET\",\n-    \"chemical_name\": \"N,N-diethyl-2-(1H-indol-3-yl)ethanamine\",\n-    \"alternative_name\": \"Diethyltryptamine; N,N-diethyltryptamine; T-9\",\n+    \"drug_name\": \"EPT\",\n+    \"chemical_name\": \"N-Ethyl-N-propyltryptamine\",\n+    \"alternative_name\": \"Ethylpropyltryptamine; N-Ethyl-N-[2-(1H-indol-3-yl)ethyl]propan-1-amine\",\n-    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; 5-HT2C receptor partial agonist\",\n-          \"route\": \"oral\",\n+          \"route\": \"insufflated\",\n-            \"threshold\": \"10 mg\",\n+            \"threshold\": \"\",\n-            \"common\": \"40-70 mg\",\n-            \"strong\": \"70-100 mg\",\n+            \"common\": \"40-80 mg\",\n+            \"strong\": \"80-110 mg\",\n+            \"heavy\": \"110+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"\",\n+            \"light\": \"75-100 mg\",\n+            \"common\": \"100-150 mg\",\n+            \"strong\": \"150-200 mg\",\n+            \"heavy\": \"200+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"vaporized\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"\",\n+            \"light\": \"15-30 mg\",\n+            \"common\": \"30-60 mg\",\n+            \"strong\": \"60-100 mg\",\n+          \"route\": \"insufflated\",\n+          \"stages\": {\n+            \"total_duration\": \"2-4 hours\",\n+            \"onset\": \"5-20 minutes\",\n+            \"after_effects\": \"1-3 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n+        },\n+        {\n-            \"total_duration\": \"4-6 hours\",\n+            \"total_duration\": \"3-6 hours\",\n-            \"peak\": \"2-4 hours\",\n-            \"offset\": \"2-3 hours\",\n-            \"after_effects\": \"2-8 hours\"\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"2-4 hours\"\n+        },\n+        {\n+          \"route\": \"vaporized\",\n+          \"stages\": {\n+            \"total_duration\": \"1-3 hours\",\n+            \"onset\": \"1-5 minutes\",\n+            \"peak\": \"10-30 minutes\",\n+            \"offset\": \"30-90 minutes\",\n+            \"after_effects\": \"1-2 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n-    \"addiction_potential\": \"DET is not believed to be habit-forming and the desire to use it can actually decrease with repeated use. No formal studies have been conducted on its addiction potential, but anecdotal evidence suggests no negative dependency patterns.\",\n+    \"addiction_potential\": \"EPT does not appear to produce dependence and has low abuse potential, similar to other unsubstituted tryptamines like DMT, DET, and MET. Rapid tolerance development discourages frequent use.\",\n-        \"Lithium (seizure risk and amplified intensity)\",\n-        \"MAOIs (serotonin syndrome risk)\"\n+        \"Lithium (seizure risk)\",\n+        \"Tramadol (lowers seizure threshold)\"\n-        \"Tramadol (lowers seizure threshold)\"\n+        \"MAOIs (unknown interactions with increased potency)\",\n+        \"Stimulants (increased anxiety and physical strain)\"\n-        \"Stimulants (may cause anxiety, paranoia, and thought loops)\"\n+        \"Other psychedelics (overwhelming intensity)\",\n+        \"Cannabis (may intensify anxiety or confusion)\"\n-    \"notes\": \"DET is a Schedule I controlled substance internationally under the UN Convention on Psychotropic Substances and is illegal in most countries. Unlike DMT, DET is orally active due to increased resistance to monoamine oxidase breakdown from its ethyl groups. The substance has extremely limited history of human use and no formal toxicity studies exist. Users should employ precise dosing with a milligram scale and ensure proper set and setting. Individuals with personal or family history of psychotic disorders should avoid use.\",\n+    \"notes\": \"EPT is a novel research chemical with very limited documentation and extremely sparse user reports. The toxicity profile is unknown and no scientific studies exist on its safety in humans. Effects are described as milder and less immersive than structurally similar tryptamines like DMT and DPT. EPT is typically sold as the fumarate salt rather than the hydrochloride form. Start with very low doses due to individual sensitivity variations and the lack of established safety data. Use precise milligram scales and practice comprehensive harm reduction including set and setting protocols.\",\n-      \"Drifting and Morphing\",\n-      \"Internal Hallucinations\",\n-      \"Cognitive Euphoria\",\n-      \"Emotion Enhancement\",\n-      \"Increased Music Appreciation\",\n+      \"Drifting And Morphing\",\n+      \"Dissociative Feeling\",\n+      \"Body Heaviness\",\n-      \"Pupil Dilation\",\n+      \"Memory Suppression\",\n+      \"Increased Libido\",\n-      \"Increased Heart Rate\",\n-      \"Conceptual Thinking\"\n+      \"Motor Control Loss\",\n+      \"Pupil Dilation\",\n+      \"Thought Acceleration\"\n-      \"full_tolerance\": \"Almost immediately after ingestion\",\n+      \"full_tolerance\": \"Immediately after ingestion\",\n-        \"All psychedelics\"\n+        \"All psychedelics (LSD, psilocybin, mescaline, DMT, other tryptamines)\"\n-        \"name\": \"Erowid DET Vault\",\n-        \"reference\": \"https://www.erowid.org/chemicals/det/det.shtml\"\n+        \"name\": \"Bluelight: The Small & Handy EPT Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-small-handy-ept-thread.856610/\"\n-        \"name\": \"PsychonautWiki: DET\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/DET\"\n+        \"name\": \"Drugs-Forum: EPT Experiences\",\n+        \"reference\": \"https://drugs-forum.com/threads/ept-experiences.298861/\"\n-        \"name\": \"TiHKAL #3: DET (Isomer Design)\",\n-        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5003\"\n+        \"name\": \"Erowid Experience Vaults: EPT\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_EPT.shtml\"\n-        \"name\": \"TiHKAL #3: DET (Erowid)\",\n-        \"reference\": \"https://www.erowid.org/library/books_online/tihkal/tihkal03.shtml\"\n+        \"name\": \"Isomer Design: EPT\",\n+        \"reference\": \"https://isomerdesign.com/pihkal/explore/5075\"\n-        \"name\": \"Bluelight: 5-substituted tryptamines discussion\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/5-substituted-tryptamines.340503/\"\n-      },\n-      {\n-        \"name\": \"Drug-drug interactions involving classic psychedelics\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC10851641/\"\n+        \"name\": \"PsychonautWiki: EPT\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/EPT\"\n-  \"id\": 636\n+  \"id\": 637\n\n# 4-AcO-DiPT · #638\n\n-  \"title\": \"EPT\",\n-  \"index-category\": \"psychedelic; research-chemical\",\n+  \"title\": \"4-AcO-DiPT\",\n+  \"index-category\": \"psychedelic; tryptamine\",\n-    \"drug_name\": \"EPT\",\n-    \"chemical_name\": \"N-Ethyl-N-propyltryptamine\",\n-    \"alternative_name\": \"Ethylpropyltryptamine; N-Ethyl-N-[2-(1H-indol-3-yl)ethyl]propan-1-amine\",\n+    \"drug_name\": \"4-AcO-DiPT\",\n+    \"chemical_name\": \"3-[2-(Diisopropylamino)ethyl]-1H-indol-4-yl acetate\",\n+    \"alternative_name\": \"4-Acetoxy-DiPT; Ipracetin; Iprocetyl; Aces; 4-Ace\",\n-    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; 5-HT2C receptor partial agonist\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist; 5-HT2C receptor agonist\",\n-          \"route\": \"insufflated\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"\",\n-            \"light\": \"20-40 mg\",\n-            \"common\": \"40-80 mg\",\n-            \"strong\": \"80-110 mg\",\n-            \"heavy\": \"110+ mg\"\n-          }\n-        },\n-        {\n-            \"threshold\": \"\",\n-            \"light\": \"75-100 mg\",\n-            \"common\": \"100-150 mg\",\n-            \"strong\": \"150-200 mg\",\n-            \"heavy\": \"200+ mg\"\n+            \"threshold\": \"3-5 mg\",\n+            \"light\": \"5-15 mg\",\n+            \"common\": \"15-30 mg\",\n+            \"strong\": \"30-45 mg\",\n+            \"heavy\": \"45+ mg\"\n-        },\n-        {\n-          \"route\": \"vaporized\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"\",\n-            \"light\": \"15-30 mg\",\n-            \"common\": \"30-60 mg\",\n-            \"strong\": \"60-100 mg\",\n-            \"heavy\": \"100+ mg\"\n-          }\n-          \"route\": \"insufflated\",\n-          \"stages\": {\n-            \"total_duration\": \"2-4 hours\",\n-            \"onset\": \"5-20 minutes\",\n-            \"after_effects\": \"1-3 hours\"\n-          },\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ]\n-        },\n-        {\n-            \"total_duration\": \"3-6 hours\",\n-            \"onset\": \"30-90 minutes\",\n-            \"peak\": \"1-2 hours\",\n-            \"offset\": \"1-2 hours\",\n-            \"after_effects\": \"2-4 hours\"\n+            \"total_duration\": \"3-4 hours\",\n+            \"onset\": \"15-40 minutes\",\n+            \"peak\": \"1.5-2 hours\",\n+            \"offset\": \"1-1.5 hours\",\n+            \"after_effects\": \"2-6 hours\"\n-        },\n-        {\n-          \"route\": \"vaporized\",\n-          \"stages\": {\n-            \"total_duration\": \"1-3 hours\",\n-            \"onset\": \"1-5 minutes\",\n-            \"peak\": \"10-30 minutes\",\n-            \"offset\": \"30-90 minutes\",\n-            \"after_effects\": \"1-2 hours\"\n-          },\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ]\n-    \"addiction_potential\": \"EPT does not appear to produce dependence and has low abuse potential, similar to other unsubstituted tryptamines like DMT, DET, and MET. Rapid tolerance development discourages frequent use.\",\n+    \"addiction_potential\": \"4-AcO-DiPT is not known to be habit-forming and the desire to use it can decrease with repeated administration. However, it may possess a higher liability for frequent or excessive consumption relative to most psychedelics due to its distinctly hedonic and short-duration effects. Compulsive redosing is reported to be atypically prominent for this substance.\",\n-        \"Lithium (seizure risk)\",\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n-        \"MAOIs (unknown interactions with increased potency)\",\n-        \"Stimulants (increased anxiety and physical strain)\"\n+        \"MAOIs (risk of serotonin syndrome)\",\n+        \"Stimulants (increased risk of anxiety, paranoia, panic attacks, and psychosis)\"\n-        \"Other psychedelics (overwhelming intensity)\",\n-        \"Cannabis (may intensify anxiety or confusion)\"\n+        \"Cannabis (may significantly intensify and prolong effects unpredictably)\",\n+        \"Alcohol (physically taxing, may dull effects)\",\n+        \"Benzodiazepines (may reduce trip intensity)\"\n-    \"notes\": \"EPT is a novel research chemical with very limited documentation and extremely sparse user reports. The toxicity profile is unknown and no scientific studies exist on its safety in humans. Effects are described as milder and less immersive than structurally similar tryptamines like DMT and DPT. EPT is typically sold as the fumarate salt rather than the hydrochloride form. Start with very low doses due to individual sensitivity variations and the lack of established safety data. Use precise milligram scales and practice comprehensive harm reduction including set and setting protocols.\",\n+    \"notes\": \"4-AcO-DiPT is thought to act as a prodrug to 4-HO-DiPT (Iprocin). It is available in both freebase and HCl salt forms, with the freebase being approximately 10% more potent by weight. This substance is characterized by atypically strong physical euphoria and sensuality with minimal visual effects, distinguishing it from most other 4-substituted tryptamines. Accurate weighing with a milligram scale is essential. Individuals with personal or family histories of seizure disorders or psychotic conditions should avoid use. The compound can produce notable increases in body temperature, particularly at peak effects. Set and setting significantly influence the experience.\",\n-      \"Visual Pattern Recognition Enhancement\",\n-      \"Color Enhancement\",\n-      \"Drifting And Morphing\",\n-      \"Dissociative Feeling\",\n-      \"Body Heaviness\",\n-      \"Time Distortion\",\n-      \"Memory Suppression\",\n+      \"Physical Euphoria\",\n+      \"Tactile Enhancement\",\n-      \"Nausea\",\n-      \"Motor Control Loss\",\n-      \"Pupil Dilation\",\n-      \"Thought Acceleration\"\n+      \"Sedation Followed By Stimulation\",\n+      \"Disinhibition\",\n+      \"Enhanced Sociability\",\n+      \"Color Enhancement\",\n+      \"Spontaneous Physical Sensations\",\n+      \"Changes In Felt Bodily Form\",\n+      \"Music Appreciation Enhancement\",\n+      \"Empathy And Affection Enhancement\",\n+      \"Minimal Visual Effects\"\n-      \"full_tolerance\": \"Immediately after ingestion\",\n+      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n-        \"All psychedelics (LSD, psilocybin, mescaline, DMT, other tryptamines)\"\n+        \"All psychedelics (e.g., psilocybin, LSD, mescaline, other tryptamines)\"\n-    \"half_life\": \"\",\n+    \"half_life\": \"2-4 hours (rapidly metabolized to 4-HO-DiPT)\",\n-        \"name\": \"Bluelight: The Small & Handy EPT Thread\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/the-small-handy-ept-thread.856610/\"\n+        \"name\": \"Erowid 4-Acetoxy-DiPT Primer by Toad\",\n+        \"reference\": \"https://www.erowid.org/chemicals/4_acetoxy_dipt/4_acetoxy_dipt_primer.shtml\"\n-        \"name\": \"Drugs-Forum: EPT Experiences\",\n-        \"reference\": \"https://drugs-forum.com/threads/ept-experiences.298861/\"\n+        \"name\": \"Erowid 4-Acetoxy-DiPT Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/4_acetoxy_dipt/4_acetoxy_dipt.shtml\"\n-        \"name\": \"Erowid Experience Vaults: EPT\",\n-        \"reference\": \"https://erowid.org/experiences/subs/exp_EPT.shtml\"\n+        \"name\": \"PsychonautWiki: 4-AcO-DiPT\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/4-AcO-DiPT\"\n-        \"name\": \"Isomer Design: EPT\",\n-        \"reference\": \"https://isomerdesign.com/pihkal/explore/5075\"\n+        \"name\": \"Bluelight 4-AcO-DiPT Discussion Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/4-aco-dipt-new-experience-10-mg-dose-to-test-the-waters.493414/\"\n-        \"name\": \"PsychonautWiki: EPT\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/EPT\"\n+        \"name\": \"Isomer Design: 4-AcO-DiPT\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5369\"\n+      },\n+      {\n+        \"name\": \"Human Hepatocyte 4-AcO-DiPT Metabolite Profiling Study\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC9413566/\"\n+      },\n+      {\n+        \"name\": \"Investigation of Structure-Activity Relationships of Psilocybin Analogues\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC8033608/\"\n+      },\n+      {\n+        \"name\": \"Pharmacologic Activity of Substituted Tryptamines Study\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC10029822/\"\n+      },\n+      {\n+        \"name\": \"TiHKAL Entry #17: 4-HO-DiPT\",\n+        \"reference\": \"https://erowid.org/library/books_online/tihkal/tihkal17.shtml\"\n-      \"research-chemical\"\n+      \"research-chemical\",\n+      \"synthetic\"\n-  \"id\": 637\n+  \"id\": 638\n\n# 4-AcO-MiPT · #639\n\n-  \"title\": \"4-AcO-DiPT\",\n+  \"title\": \"4-AcO-MiPT\",\n-    \"drug_name\": \"4-AcO-DiPT\",\n-    \"chemical_name\": \"3-[2-(Diisopropylamino)ethyl]-1H-indol-4-yl acetate\",\n-    \"alternative_name\": \"4-Acetoxy-DiPT; Ipracetin; Iprocetyl; Aces; 4-Ace\",\n+    \"drug_name\": \"4-AcO-MiPT\",\n+    \"chemical_name\": \"4-Acetoxy-N-methyl-N-isopropyltryptamine\",\n+    \"alternative_name\": \"Mipracetin; O-Acetylmiprocin; 4-Acetoxy-MiPT\",\n-    \"mechanism_of_action\": \"5-HT2A receptor agonist; 5-HT2C receptor agonist\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist (prodrug of 4-HO-MiPT)\",\n-            \"threshold\": \"3-5 mg\",\n-            \"light\": \"5-15 mg\",\n-            \"common\": \"15-30 mg\",\n-            \"strong\": \"30-45 mg\",\n-            \"heavy\": \"45+ mg\"\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"10-15 mg\",\n+            \"common\": \"15-20 mg\",\n+            \"strong\": \"20-35 mg\",\n+            \"heavy\": \"35+ mg\"\n-            \"total_duration\": \"3-4 hours\",\n-            \"onset\": \"15-40 minutes\",\n-            \"peak\": \"1.5-2 hours\",\n-            \"offset\": \"1-1.5 hours\",\n-            \"after_effects\": \"2-6 hours\"\n+            \"total_duration\": \"4-8 hours\",\n+            \"onset\": \"20-60 minutes\",\n+            \"peak\": \"1.5-3 hours (come up 1-2 hours)\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"2-4 hours\"\n-    \"addiction_potential\": \"4-AcO-DiPT is not known to be habit-forming and the desire to use it can decrease with repeated administration. However, it may possess a higher liability for frequent or excessive consumption relative to most psychedelics due to its distinctly hedonic and short-duration effects. Compulsive redosing is reported to be atypically prominent for this substance.\",\n+    \"addiction_potential\": \"4-AcO-MiPT is not habit-forming and demonstrates a self-regulating pattern typical of psychedelics. The desire to use it tends to decrease with regular consumption rather than increase.\",\n-        \"Lithium (significantly increases risk of psychosis and seizures)\",\n-        \"Tramadol (lowers seizure threshold)\"\n+        \"Lithium (significantly increases risk of psychosis and seizures)\"\n-        \"MAOIs (risk of serotonin syndrome)\",\n-        \"Stimulants (increased risk of anxiety, paranoia, panic attacks, and psychosis)\"\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Stimulants (increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n-        \"Cannabis (may significantly intensify and prolong effects unpredictably)\",\n-        \"Alcohol (physically taxing, may dull effects)\",\n-        \"Benzodiazepines (may reduce trip intensity)\"\n+        \"Cannabis (unpredictable synergy, may significantly intensify effects)\"\n-    \"notes\": \"4-AcO-DiPT is thought to act as a prodrug to 4-HO-DiPT (Iprocin). It is available in both freebase and HCl salt forms, with the freebase being approximately 10% more potent by weight. This substance is characterized by atypically strong physical euphoria and sensuality with minimal visual effects, distinguishing it from most other 4-substituted tryptamines. Accurate weighing with a milligram scale is essential. Individuals with personal or family histories of seizure disorders or psychotic conditions should avoid use. The compound can produce notable increases in body temperature, particularly at peak effects. Set and setting significantly influence the experience.\",\n+    \"notes\": \"4-AcO-MiPT is a synthetic psychedelic tryptamine that remains relatively uncommon with limited history of human use. The substance is hygroscopic and degrades quickly when exposed to moisture or improper storage; it should be kept in an inert atmosphere in a freezer. The material can develop a sticky, goop-like consistency when exposed to air. Accurate weighing with a precise milligram scale is essential, as the substance is potent and can appear deceptively small. It is theorized to act as a prodrug for 4-HO-MiPT, though debate continues about whether it possesses innate activity. Set and setting are critical factors for the experience.\",\n-      \"Physical Euphoria\",\n-      \"Tactile Enhancement\",\n-      \"Increased Libido\",\n-      \"Sedation Followed By Stimulation\",\n-      \"Disinhibition\",\n-      \"Enhanced Sociability\",\n-      \"Color Enhancement\",\n-      \"Spontaneous Physical Sensations\",\n-      \"Changes In Felt Bodily Form\",\n-      \"Music Appreciation Enhancement\",\n-      \"Empathy And Affection Enhancement\",\n-      \"Minimal Visual Effects\"\n+      \"Visual Geometry (Organic, Intricate, Natural-Feeling)\",\n+      \"Colour Enhancement\",\n+      \"Pattern Recognition Enhancement\",\n+      \"Sedation With Mild Euphoria\",\n+      \"Pleasurable Body High (Warm, Tingling Sensations)\",\n+      \"Excessive Yawning\",\n+      \"Enhanced Music Appreciation\",\n+      \"Auditory Distortions (Downward Pitch Shift)\",\n+      \"Emotion Enhancement\",\n+      \"Thought Connectivity\",\n+      \"Time Distortion\",\n+      \"Internal Hallucinations (Dark Environments)\",\n+      \"Memory Suppression\"\n-      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n+      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n-        \"All psychedelics (e.g., psilocybin, LSD, mescaline, other tryptamines)\"\n+        \"All psychedelics\"\n-    \"half_life\": \"2-4 hours (rapidly metabolized to 4-HO-DiPT)\",\n+    \"half_life\": \"\",\n-        \"name\": \"Erowid 4-Acetoxy-DiPT Primer by Toad\",\n-        \"reference\": \"https://www.erowid.org/chemicals/4_acetoxy_dipt/4_acetoxy_dipt_primer.shtml\"\n+        \"name\": \"Erowid 4-Acetoxy-MiPT Vault\",\n+        \"reference\": \"https://erowid.org/chemicals/4_acetoxy_mipt/4_acetoxy_mipt.shtml\"\n-        \"name\": \"Erowid 4-Acetoxy-DiPT Vault\",\n-        \"reference\": \"https://www.erowid.org/chemicals/4_acetoxy_dipt/4_acetoxy_dipt.shtml\"\n+        \"name\": \"Isomer Design: 4-AcO-MIPT\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=5546\"\n-        \"name\": \"PsychonautWiki: 4-AcO-DiPT\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/4-AcO-DiPT\"\n+        \"name\": \"PsychonautWiki: 4-AcO-MiPT\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/4-AcO-MiPT\"\n-        \"name\": \"Bluelight 4-AcO-DiPT Discussion Thread\",\n-        \"reference\": \"https://bluelight.org/xf/threads/4-aco-dipt-new-experience-10-mg-dose-to-test-the-waters.493414/\"\n+        \"name\": \"The Big & Dandy 4-AcO-MiPT Thread (Bluelight)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-4-aco-mipt-thread.101872/\"\n-        \"name\": \"Isomer Design: 4-AcO-DiPT\",\n-        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5369\"\n-      },\n-      {\n-        \"name\": \"Human Hepatocyte 4-AcO-DiPT Metabolite Profiling Study\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC9413566/\"\n-      },\n-      {\n-        \"name\": \"Investigation of Structure-Activity Relationships of Psilocybin Analogues\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC8033608/\"\n-      },\n-      {\n-        \"name\": \"Pharmacologic Activity of Substituted Tryptamines Study\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC10029822/\"\n-      },\n-      {\n-        \"name\": \"TiHKAL Entry #17: 4-HO-DiPT\",\n-        \"reference\": \"https://erowid.org/library/books_online/tihkal/tihkal17.shtml\"\n+        \"name\": \"Takahashi et al. - Psychoactive Designer Drugs Data Library\",\n+        \"reference\": \"https://doi.org/10.1016/j.talanta.2008.07.062\"\n-  \"id\": 638\n+  \"id\": 639\n\n# 4-HO-DET · #640\n\n-  \"title\": \"4-AcO-MiPT\",\n-  \"index-category\": \"psychedelic; tryptamine\",\n+  \"title\": \"4-HO-DET\",\n+  \"index-category\": \"psychedelic; tryptamine; research-chemical\",\n-    \"drug_name\": \"4-AcO-MiPT\",\n-    \"chemical_name\": \"4-Acetoxy-N-methyl-N-isopropyltryptamine\",\n-    \"alternative_name\": \"Mipracetin; O-Acetylmiprocin; 4-Acetoxy-MiPT\",\n+    \"drug_name\": \"4-HO-DET\",\n+    \"chemical_name\": \"3-(2-diethylaminoethyl)-1H-indol-4-ol\",\n+    \"alternative_name\": \"Ethocin; CZ-74; 4-Hydroxy-N,N-diethyltryptamine\",\n-    \"mechanism_of_action\": \"5-HT2A receptor partial agonist (prodrug of 4-HO-MiPT)\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n-            \"common\": \"15-20 mg\",\n-            \"strong\": \"20-35 mg\",\n-            \"heavy\": \"35+ mg\"\n+            \"common\": \"20-30 mg\",\n+            \"strong\": \"30-45 mg\",\n+            \"heavy\": \"45+ mg\"\n-            \"total_duration\": \"4-8 hours\",\n-            \"onset\": \"20-60 minutes\",\n-            \"peak\": \"1.5-3 hours (come up 1-2 hours)\",\n-            \"offset\": \"1-2 hours\",\n-            \"after_effects\": \"2-4 hours\"\n+            \"total_duration\": \"5-7 hours\",\n+            \"onset\": \"20-45 minutes\",\n+            \"peak\": \"2.5-3.5 hours (with 30-60 minute come up)\",\n+            \"offset\": \"1.5-2 hours\",\n+            \"after_effects\": \"1-4 hours\"\n-    \"addiction_potential\": \"4-AcO-MiPT is not habit-forming and demonstrates a self-regulating pattern typical of psychedelics. The desire to use it tends to decrease with regular consumption rather than increase.\",\n+    \"addiction_potential\": \"4-HO-DET is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating. Limited evidence suggests no significant addiction potential.\",\n-        \"Lithium (significantly increases risk of psychosis and seizures)\"\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n-      \"unsafe\": [\n-        \"Tramadol (lowers seizure threshold)\",\n-        \"Stimulants (increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n-      ],\n+      \"unsafe\": [],\n-        \"Cannabis (unpredictable synergy, may significantly intensify effects)\"\n+        \"Cannabis (unpredictable synergy, may significantly increase risk of anxiety, paranoia, panic attacks, and psychosis)\",\n+        \"Stimulants (may increase risk of anxiety, paranoia, panic attacks, thought loops, mania and psychosis)\"\n-    \"notes\": \"4-AcO-MiPT is a synthetic psychedelic tryptamine that remains relatively uncommon with limited history of human use. The substance is hygroscopic and degrades quickly when exposed to moisture or improper storage; it should be kept in an inert atmosphere in a freezer. The material can develop a sticky, goop-like consistency when exposed to air. Accurate weighing with a precise milligram scale is essential, as the substance is potent and can appear deceptively small. It is theorized to act as a prodrug for 4-HO-MiPT, though debate continues about whether it possesses innate activity. Set and setting are critical factors for the experience.\",\n+    \"notes\": \"4-HO-DET is a research chemical with very little history of human usage. The toxicity and long-term health effects have not been studied in any scientific context. It is strongly recommended to use harm reduction practices when using this substance. Legal status varies by jurisdiction; it is unscheduled in the United States but may be prosecuted under the Federal Analogue Act. It is controlled in Germany, Sweden, Switzerland, and the United Kingdom.\",\n-      \"Visual Geometry (Organic, Intricate, Natural-Feeling)\",\n+      \"Visual Patterning And Geometry\",\n-      \"Pattern Recognition Enhancement\",\n-      \"Sedation With Mild Euphoria\",\n-      \"Pleasurable Body High (Warm, Tingling Sensations)\",\n-      \"Excessive Yawning\",\n-      \"Enhanced Music Appreciation\",\n-      \"Auditory Distortions (Downward Pitch Shift)\",\n-      \"Emotion Enhancement\",\n+      \"Tactile Enhancement\",\n+      \"Analysis Enhancement\",\n+      \"Increased Music Appreciation\",\n-      \"Internal Hallucinations (Dark Environments)\",\n-      \"Memory Suppression\"\n+      \"Ego Death\",\n+      \"Memory Suppression\",\n+      \"Excessive Yawning\",\n+      \"Temperature Regulation Suppression\",\n+      \"Pupil Dilation\"\n-      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n+      \"full_tolerance\": \"Almost immediately after ingestion\",\n-        \"name\": \"Erowid 4-Acetoxy-MiPT Vault\",\n-        \"reference\": \"https://erowid.org/chemicals/4_acetoxy_mipt/4_acetoxy_mipt.shtml\"\n+        \"name\": \"Bluelight 4-HO-DET Discussion Thread\",\n+        \"reference\": \"http://www.bluelight.org/vb/threads/480200-The-Big-amp-Dandy-4-HO-DET-Thread\"\n-        \"name\": \"Isomer Design: 4-AcO-MIPT\",\n-        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=5546\"\n+        \"name\": \"Erowid 4-HO-DET Experience Vaults\",\n+        \"reference\": \"https://www.erowid.org/experiences/subs/exp_4HODET.shtml\"\n-        \"name\": \"PsychonautWiki: 4-AcO-MiPT\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/4-AcO-MiPT\"\n+        \"name\": \"Isomer Design TiHKAL Entry #16: 4-HO-DET\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5016\"\n-        \"name\": \"The Big & Dandy 4-AcO-MiPT Thread (Bluelight)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-4-aco-mipt-thread.101872/\"\n+        \"name\": \"PsychonautWiki: 4-HO-DET\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/4-HO-DET\"\n-        \"name\": \"Takahashi et al. - Psychoactive Designer Drugs Data Library\",\n-        \"reference\": \"https://doi.org/10.1016/j.talanta.2008.07.062\"\n+        \"name\": \"Wikipedia: 4-HO-DET\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/4-HO-DET\"\n-  \"id\": 639\n+  \"id\": 640\n\n# 4-HO-DiPT · #641\n\n-  \"title\": \"4-HO-DET\",\n+  \"title\": \"4-HO-DiPT\",\n-    \"drug_name\": \"4-HO-DET\",\n-    \"chemical_name\": \"3-(2-diethylaminoethyl)-1H-indol-4-ol\",\n-    \"alternative_name\": \"Ethocin; CZ-74; 4-Hydroxy-N,N-diethyltryptamine\",\n+    \"drug_name\": \"4-HO-DiPT\",\n+    \"chemical_name\": \"3-[2-(Diisopropylamino)ethyl]-1H-indol-4-ol\",\n+    \"alternative_name\": \"Iprocin; 4-Hydroxy-DiPT; 4-Hydroxy-N,N-diisopropyltryptamine\",\n-    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; Serotonin reuptake inhibitor (weak)\",\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"10-15 mg\",\n-            \"common\": \"20-30 mg\",\n-            \"strong\": \"30-45 mg\",\n-            \"heavy\": \"45+ mg\"\n+            \"threshold\": \"3 mg\",\n+            \"light\": \"3-10 mg\",\n+            \"common\": \"10-20 mg\",\n+            \"strong\": \"20-30 mg\",\n+            \"heavy\": \"30+ mg\"\n-            \"total_duration\": \"5-7 hours\",\n-            \"onset\": \"20-45 minutes\",\n-            \"peak\": \"2.5-3.5 hours (with 30-60 minute come up)\",\n-            \"offset\": \"1.5-2 hours\",\n-            \"after_effects\": \"1-4 hours\"\n+            \"total_duration\": \"2-4 hours\",\n+            \"onset\": \"15-30 minutes\",\n+            \"peak\": \"60-90 minutes (20-30 minutes after onset)\",\n+            \"offset\": \"30-60 minutes\",\n+            \"after_effects\": \"1-3 hours\"\n-    \"addiction_potential\": \"4-HO-DET is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating. Limited evidence suggests no significant addiction potential.\",\n+    \"addiction_potential\": \"4-HO-DiPT is not habit-forming and has minimal psychological dependence potential. Like most psychedelics, it is considered self-regulating, with the desire to use it typically decreasing with regular consumption.\",\n-      \"unsafe\": [],\n+      \"unsafe\": [\n+        \"Stimulants (increased risk of anxiety, paranoia, panic attacks, thought loops, mania, and psychosis)\"\n+      ],\n-        \"Cannabis (unpredictable synergy, may significantly increase risk of anxiety, paranoia, panic attacks, and psychosis)\",\n-        \"Stimulants (may increase risk of anxiety, paranoia, panic attacks, thought loops, mania and psychosis)\"\n+        \"Cannabis (unpredictable synergy; significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n-    \"notes\": \"4-HO-DET is a research chemical with very little history of human usage. The toxicity and long-term health effects have not been studied in any scientific context. It is strongly recommended to use harm reduction practices when using this substance. Legal status varies by jurisdiction; it is unscheduled in the United States but may be prosecuted under the Federal Analogue Act. It is controlled in Germany, Sweden, Switzerland, and the United Kingdom.\",\n+    \"notes\": \"4-HO-DiPT is a research chemical with very limited history of human use and no scientific studies on its toxicity. It is noted for its uniquely rapid onset, short duration, narrow dose sensitivity, and high intensity relative to dose. Physical side effects including muscle tremors, leg tremors, bodily malaise, and temperature dysregulation are commonly reported. Set and setting are critical, and harm reduction practices are essential. The substance is unscheduled in most jurisdictions but may be controlled under analogue laws.\",\n-      \"Visual Patterning And Geometry\",\n-      \"Colour Enhancement\",\n-      \"Tactile Enhancement\",\n-      \"Thought Connectivity\",\n-      \"Analysis Enhancement\",\n-      \"Increased Music Appreciation\",\n+      \"Cognitive Euphoria\",\n+      \"Emotion Enhancement\",\n+      \"Introspective Insights\",\n-      \"Ego Death\",\n-      \"Memory Suppression\",\n-      \"Excessive Yawning\",\n-      \"Temperature Regulation Suppression\",\n-      \"Pupil Dilation\"\n+      \"Increased Music Appreciation\",\n+      \"Enhanced Tactile Sensation\",\n+      \"Sexual Enhancement\",\n+      \"Visual Pattern Recognition Enhancement\",\n+      \"Colour Enhancement\",\n+      \"Muscle Tremors\",\n+      \"Nausea\",\n+      \"Pupil Dilation\",\n+      \"Stimulation\",\n+      \"Temperature Dysregulation\"\n-      \"full_tolerance\": \"Almost immediately after ingestion\",\n+      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n-        \"All psychedelics\"\n+        \"All psychedelics (LSD, psilocybin, mescaline, DMT, 2C-x, DOx, 5-MeO-xxT, other tryptamines)\"\n-    \"half_life\": \"\",\n+    \"half_life\": \"2.7-4.1 hours (based on prodrug luvesilocin studies)\",\n-        \"name\": \"Bluelight 4-HO-DET Discussion Thread\",\n-        \"reference\": \"http://www.bluelight.org/vb/threads/480200-The-Big-amp-Dandy-4-HO-DET-Thread\"\n+        \"name\": \"PsychonautWiki: 4-HO-DiPT\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/4-HO-DiPT\"\n-        \"name\": \"Erowid 4-HO-DET Experience Vaults\",\n-        \"reference\": \"https://www.erowid.org/experiences/subs/exp_4HODET.shtml\"\n+        \"name\": \"Erowid 4-HO-DiPT Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/4_ho_dipt/4_ho_dipt.shtml\"\n-        \"name\": \"Isomer Design TiHKAL Entry #16: 4-HO-DET\",\n-        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5016\"\n+        \"name\": \"TiHKAL Entry #17: 4-HO-DiPT by Alexander Shulgin\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/read.php?domain=tk&id=17\"\n-        \"name\": \"PsychonautWiki: 4-HO-DET\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/4-HO-DET\"\n+        \"name\": \"Bluelight: The Big & Dandy 4-HO-DiPT Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-4-ho-dipt-thread.107890/\"\n-        \"name\": \"Wikipedia: 4-HO-DET\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/4-HO-DET\"\n+        \"name\": \"Drugs-Forum: 4-HO-DiPT Trip Reports\",\n+        \"reference\": \"https://drugs-forum.com/threads/4-ho-dipt-trip-reports.3095/\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: 4-HO-DiPT\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/4-HO-DiPT\"\n+      },\n+      {\n+        \"name\": \"Repke, D. B. et al. (1977). Psilocin analogs synthesis\",\n+        \"reference\": \"Journal of Heterocyclic Chemistry, 14(1), 71-74\"\n-  \"id\": 640\n+  \"id\": 641\n\n# 4-HO-EPT · #642\n\n-  \"title\": \"4-HO-DiPT\",\n+  \"title\": \"4-HO-EPT\",\n-    \"drug_name\": \"4-HO-DiPT\",\n-    \"chemical_name\": \"3-[2-(Diisopropylamino)ethyl]-1H-indol-4-ol\",\n-    \"alternative_name\": \"Iprocin; 4-Hydroxy-DiPT; 4-Hydroxy-N,N-diisopropyltryptamine\",\n+    \"drug_name\": \"4-HO-EPT\",\n+    \"chemical_name\": \"4-Hydroxy-N-ethyl-N-propyltryptamine\",\n+    \"alternative_name\": \"Eprocin\",\n-    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; Serotonin reuptake inhibitor (weak)\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n-            \"threshold\": \"3 mg\",\n-            \"light\": \"3-10 mg\",\n-            \"common\": \"10-20 mg\",\n-            \"strong\": \"20-30 mg\",\n-            \"heavy\": \"30+ mg\"\n+            \"threshold\": \"10-15 mg\",\n+            \"light\": \"15-20 mg\",\n+            \"common\": \"30-40 mg\",\n+            \"strong\": \"40-60 mg\",\n+            \"heavy\": \"60+ mg\"\n+        },\n+        {\n+          \"route\": \"smoked\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5-10 mg\",\n+            \"light\": \"10-15 mg\",\n+            \"common\": \"15-25 mg\",\n+            \"strong\": \"25-35 mg\",\n+            \"heavy\": \"35+ mg\"\n+          }\n-            \"total_duration\": \"2-4 hours\",\n-            \"onset\": \"15-30 minutes\",\n-            \"peak\": \"60-90 minutes (20-30 minutes after onset)\",\n-            \"offset\": \"30-60 minutes\",\n-            \"after_effects\": \"1-3 hours\"\n+            \"total_duration\": \"3-7 hours\",\n+            \"onset\": \"30-60 minutes\",\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"2-4 hours\"\n+        },\n+        {\n+          \"route\": \"smoked\",\n+          \"stages\": {\n+            \"total_duration\": \"1-2 hours\",\n+            \"onset\": \"1-5 minutes\",\n+            \"peak\": \"15-30 minutes\",\n+            \"offset\": \"30-60 minutes\",\n+            \"after_effects\": \"1-2 hours\"\n+          }\n-    \"addiction_potential\": \"4-HO-DiPT is not habit-forming and has minimal psychological dependence potential. Like most psychedelics, it is considered self-regulating, with the desire to use it typically decreasing with regular consumption.\",\n+    \"addiction_potential\": \"4-HO-EPT is not habit-forming and the desire to use it can actually decrease with regular consumption. Like most psychedelics, it is generally considered self-regulating. There is no evidence of physical dependence potential.\",\n-        \"Lithium (significantly increases risk of psychosis and seizures)\",\n-        \"Tramadol (lowers seizure threshold)\"\n+        \"Lithium (significantly increases risk of psychosis and seizures)\"\n-        \"Stimulants (increased risk of anxiety, paranoia, panic attacks, thought loops, mania, and psychosis)\"\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Stimulants (increased risk of anxiety, paranoia, thought loops, mania, and psychosis)\"\n-        \"Cannabis (unpredictable synergy; significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n+        \"Cannabis (unpredictable synergy, significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n-    \"notes\": \"4-HO-DiPT is a research chemical with very limited history of human use and no scientific studies on its toxicity. It is noted for its uniquely rapid onset, short duration, narrow dose sensitivity, and high intensity relative to dose. Physical side effects including muscle tremors, leg tremors, bodily malaise, and temperature dysregulation are commonly reported. Set and setting are critical, and harm reduction practices are essential. The substance is unscheduled in most jurisdictions but may be controlled under analogue laws.\",\n+    \"notes\": \"4-HO-EPT is a novel research chemical with very little history of human use before 2016 and almost no scientific research on its pharmacology, metabolism, or toxicity. Unlike more visual tryptamines, it primarily enhances colors with a neon quality rather than producing strong visual distortions. Users report a strong euphoric body high sometimes compared to opiates, with a generally light and positive mindset. Accurate weighing with a precise milligram scale is essential. Individuals with personal or family history of psychotic disorders should avoid use. Higher doses may cause vasoconstriction. Set and setting considerations apply as with all psychedelics.\",\n+      \"Color Enhancement\",\n-      \"Emotion Enhancement\",\n-      \"Introspective Insights\",\n-      \"Time Distortion\",\n+      \"Euphoric Body High\",\n-      \"Enhanced Tactile Sensation\",\n-      \"Sexual Enhancement\",\n-      \"Visual Pattern Recognition Enhancement\",\n-      \"Colour Enhancement\",\n-      \"Muscle Tremors\",\n-      \"Nausea\",\n-      \"Pupil Dilation\",\n-      \"Stimulation\",\n-      \"Temperature Dysregulation\"\n+      \"Conceptual Thinking\",\n+      \"Analysis Enhancement\",\n+      \"Pattern Recognition Enhancement\",\n+      \"Time Distortion\",\n+      \"Emotion Enhancement\",\n+      \"Sedation\",\n+      \"Memory Suppression\",\n+      \"Thought Loops\",\n+      \"Nausea\"\n-      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n+      \"full_tolerance\": \"Immediately after ingestion\",\n-        \"All psychedelics (LSD, psilocybin, mescaline, DMT, 2C-x, DOx, 5-MeO-xxT, other tryptamines)\"\n+        \"All psychedelics\"\n-    \"half_life\": \"2.7-4.1 hours (based on prodrug luvesilocin studies)\",\n+    \"half_life\": \"\",\n-        \"name\": \"PsychonautWiki: 4-HO-DiPT\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/4-HO-DiPT\"\n+        \"name\": \"Bluelight: The Big & Dandy 4-HO-EPT Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-4-ho-ept-thread.805165/\"\n-        \"name\": \"Erowid 4-HO-DiPT Vault\",\n-        \"reference\": \"https://www.erowid.org/chemicals/4_ho_dipt/4_ho_dipt.shtml\"\n+        \"name\": \"Erowid 4-HO-EPT Experience Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_4HOEPT.shtml\"\n-        \"name\": \"TiHKAL Entry #17: 4-HO-DiPT by Alexander Shulgin\",\n-        \"reference\": \"https://isomerdesign.com/PiHKAL/read.php?domain=tk&id=17\"\n+        \"name\": \"Isomer Design: 4-HO-EPT\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?id=5770\"\n-        \"name\": \"Bluelight: The Big & Dandy 4-HO-DiPT Thread\",\n-        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-4-ho-dipt-thread.107890/\"\n+        \"name\": \"PMC: Investigation of the Structure-Activity Relationships of Psilocybin Analogues\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC8033608/\"\n-        \"name\": \"Drugs-Forum: 4-HO-DiPT Trip Reports\",\n-        \"reference\": \"https://drugs-forum.com/threads/4-ho-dipt-trip-reports.3095/\"\n-      },\n-      {\n-        \"name\": \"Wikipedia: 4-HO-DiPT\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/4-HO-DiPT\"\n-      },\n-      {\n-        \"name\": \"Repke, D. B. et al. (1977). Psilocin analogs synthesis\",\n-        \"reference\": \"Journal of Heterocyclic Chemistry, 14(1), 71-74\"\n+        \"name\": \"PsychonautWiki: 4-HO-EPT\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/4-HO-EPT\"\n-      \"research-chemical\",\n-      \"synthetic\"\n+      \"research-chemical\"\n-  \"id\": 641\n+  \"id\": 642\n\n# 4-HO-MPT · #643\n\n-  \"title\": \"4-HO-EPT\",\n+  \"title\": \"4-HO-MPT\",\n-    \"drug_name\": \"4-HO-EPT\",\n-    \"chemical_name\": \"4-Hydroxy-N-ethyl-N-propyltryptamine\",\n-    \"alternative_name\": \"Eprocin\",\n+    \"drug_name\": \"4-HO-MPT\",\n+    \"chemical_name\": \"3-[2-(Methylpropylamino)ethyl]-4-indolol\",\n+    \"alternative_name\": \"Meprocin; 4-Hydroxy-N-methyl-N-propyltryptamine\",\n-    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n+    \"mechanism_of_action\": \"5-HT2A receptor full agonist; 5-HT2B receptor partial agonist (moderate-efficacy); 5-HT2C receptor partial agonist (high-efficacy)\",\n-            \"threshold\": \"10-15 mg\",\n-            \"light\": \"15-20 mg\",\n-            \"common\": \"30-40 mg\",\n-            \"strong\": \"40-60 mg\",\n-            \"heavy\": \"60+ mg\"\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"5-10 mg\",\n+            \"common\": \"10-20 mg\",\n+            \"strong\": \"20-30 mg\",\n+            \"heavy\": \"30+ mg\"\n-          \"route\": \"smoked\",\n+          \"route\": \"vaporized\",\n-            \"threshold\": \"5-10 mg\",\n-            \"light\": \"10-15 mg\",\n-            \"common\": \"15-25 mg\",\n-            \"strong\": \"25-35 mg\",\n-            \"heavy\": \"35+ mg\"\n+            \"threshold\": \"3 mg\",\n+            \"light\": \"3-5 mg\",\n+            \"common\": \"5-10 mg\",\n+            \"strong\": \"10-15 mg\",\n+            \"heavy\": \"15+ mg\"\n-            \"onset\": \"30-60 minutes\",\n-            \"peak\": \"1-2 hours\",\n+            \"onset\": \"20-60 minutes\",\n+            \"peak\": \"2-3 hours\",\n-            \"after_effects\": \"2-4 hours\"\n+            \"after_effects\": \"2-12 hours\"\n-          \"route\": \"smoked\",\n+          \"route\": \"vaporized\",\n-            \"total_duration\": \"1-2 hours\",\n-            \"onset\": \"1-5 minutes\",\n-            \"peak\": \"15-30 minutes\",\n-            \"offset\": \"30-60 minutes\",\n-            \"after_effects\": \"1-2 hours\"\n-          }\n+            \"total_duration\": \"45-90 minutes\",\n+            \"onset\": \"1-3 minutes\",\n+            \"peak\": \"10-30 minutes\",\n+            \"offset\": \"15-45 minutes\",\n+            \"after_effects\": \"1-6 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n-    \"addiction_potential\": \"4-HO-EPT is not habit-forming and the desire to use it can actually decrease with regular consumption. Like most psychedelics, it is generally considered self-regulating. There is no evidence of physical dependence potential.\",\n+    \"addiction_potential\": \"4-HO-MPT is generally considered not habit-forming, and the desire to use it can actually decrease with regular consumption. Like most psychedelics, it is thought to be self-regulating with low potential for psychological dependence.\",\n-        \"Tramadol (lowers seizure threshold)\",\n-        \"Stimulants (increased risk of anxiety, paranoia, thought loops, mania, and psychosis)\"\n+        \"Tramadol (lowers seizure threshold)\"\n-        \"Cannabis (unpredictable synergy, significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n+        \"Cannabis (unpredictable synergy; increases risk of anxiety, paranoia, panic attacks, and psychosis)\",\n+        \"Stimulants (increases risk of anxiety, paranoia, panic attacks, thought loops, mania, and psychosis)\"\n-    \"notes\": \"4-HO-EPT is a novel research chemical with very little history of human use before 2016 and almost no scientific research on its pharmacology, metabolism, or toxicity. Unlike more visual tryptamines, it primarily enhances colors with a neon quality rather than producing strong visual distortions. Users report a strong euphoric body high sometimes compared to opiates, with a generally light and positive mindset. Accurate weighing with a precise milligram scale is essential. Individuals with personal or family history of psychotic disorders should avoid use. Higher doses may cause vasoconstriction. Set and setting considerations apply as with all psychedelics.\",\n+    \"notes\": \"4-HO-MPT is a research chemical with very little history of human usage and minimal scientific data on its pharmacology, metabolism, and toxicity. Legal status varies by jurisdiction; it is unscheduled in most countries but is a Class A drug in the United Kingdom under the tryptamine catch-all clause and controlled under Germany's NpSG. Use precise scales for dosing as potency varies between salt forms (freebase is approximately 25% more potent than fumarate salts). Individuals with personal or family histories of mental illness should avoid use.\",\n-      \"Color Enhancement\",\n-      \"Cognitive Euphoria\",\n-      \"Euphoric Body High\",\n-      \"Increased Music Appreciation\",\n-      \"Conceptual Thinking\",\n-      \"Analysis Enhancement\",\n-      \"Pattern Recognition Enhancement\",\n+      \"Visual Distortions And Patterning\",\n+      \"Color Enhancement And Shifting\",\n-      \"Sedation\",\n-      \"Memory Suppression\",\n+      \"Cognitive Euphoria\",\n+      \"Nausea\",\n+      \"Increased Heart Rate\",\n+      \"Pupil Dilation\",\n-      \"Nausea\"\n+      \"Vertigo Or Dizziness\",\n+      \"Memory Suppression\",\n+      \"Internal And External Hallucinations\"\n-        \"All psychedelics\"\n+        \"All psychedelics (including LSD, psilocybin, mescaline, and other tryptamines)\"\n-        \"name\": \"Bluelight: The Big & Dandy 4-HO-EPT Thread\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-4-ho-ept-thread.805165/\"\n+        \"name\": \"Erowid 4-HO-MPT Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/4_ho_mpt/4_ho_mpt.shtml\"\n-        \"name\": \"Erowid 4-HO-EPT Experience Vault\",\n-        \"reference\": \"https://erowid.org/experiences/subs/exp_4HOEPT.shtml\"\n+        \"name\": \"PsychonautWiki 4-HO-MPT\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/4-HO-MPT\"\n-        \"name\": \"Isomer Design: 4-HO-EPT\",\n-        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?id=5770\"\n+        \"name\": \"TripSit 4-HO-MPT Factsheet\",\n+        \"reference\": \"https://tripbot.tripsit.me/factsheet/4-HO-MPT\"\n-        \"name\": \"PMC: Investigation of the Structure-Activity Relationships of Psilocybin Analogues\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC8033608/\"\n+        \"name\": \"TiHKAL Entry #23: 4-HO-MPT (Isomer Design)\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/read.php?domain=tk&id=23\"\n-        \"name\": \"PsychonautWiki: 4-HO-EPT\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/4-HO-EPT\"\n+        \"name\": \"Bluelight: The Big & Dandy 4-HO-MPT Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-4-ho-mpt-thread.550416/\"\n+      },\n+      {\n+        \"name\": \"Drugs-Forum 4-HO-MPT Wiki\",\n+        \"reference\": \"https://drugs-forum.com/wiki/4-HO-MPT\"\n-      \"research-chemical\"\n+      \"research-chemical\",\n+      \"synthetic\"\n-  \"id\": 642\n+  \"id\": 643\n\n# 5-MeO-DiPT · #644\n\n-  \"title\": \"4-HO-MPT\",\n+  \"title\": \"5-MeO-DiPT\",\n-    \"drug_name\": \"4-HO-MPT\",\n-    \"chemical_name\": \"3-[2-(Methylpropylamino)ethyl]-4-indolol\",\n-    \"alternative_name\": \"Meprocin; 4-Hydroxy-N-methyl-N-propyltryptamine\",\n+    \"drug_name\": \"5-MeO-DiPT\",\n+    \"chemical_name\": \"5-Methoxy-N,N-diisopropyltryptamine\",\n+    \"alternative_name\": \"Foxy; Foxy Methoxy\",\n-    \"psychoactive_class\": \"Psychedelic\",\n-    \"mechanism_of_action\": \"5-HT2A receptor full agonist; 5-HT2B receptor partial agonist (moderate-efficacy); 5-HT2C receptor partial agonist (high-efficacy)\",\n+    \"psychoactive_class\": \"Psychedelic; Entactogen; Stimulant\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist (primary); 5-HT1A receptor agonist (strongest binding affinity); weak serotonin reuptake inhibitor; possible monoamine oxidase inhibition\",\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"5-10 mg\",\n-            \"common\": \"10-20 mg\",\n-            \"strong\": \"20-30 mg\",\n-            \"heavy\": \"30+ mg\"\n+            \"threshold\": \"3-4 mg\",\n+            \"light\": \"3-10 mg\",\n+            \"common\": \"10-15 mg\",\n+            \"strong\": \"15-20 mg\",\n+            \"heavy\": \"20+ mg\"\n-          \"route\": \"vaporized\",\n+          \"route\": \"insufflated\",\n-            \"threshold\": \"3 mg\",\n+            \"threshold\": \"2-4 mg\",\n+            \"light\": \"4-7 mg\",\n+            \"common\": \"7-12 mg\",\n+            \"strong\": \"12-18 mg\",\n+            \"heavy\": \"18+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"smoked\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"2-3 mg\",\n-            \"common\": \"5-10 mg\",\n-            \"strong\": \"10-15 mg\",\n-            \"heavy\": \"15+ mg\"\n+            \"common\": \"5-8 mg\",\n+            \"strong\": \"8-12 mg\",\n+            \"heavy\": \"12+ mg\"\n-            \"total_duration\": \"3-7 hours\",\n+            \"total_duration\": \"4-8 hours\",\n-            \"peak\": \"2-3 hours\",\n-            \"offset\": \"1-2 hours\",\n-            \"after_effects\": \"2-12 hours\"\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"2-6 hours (residual stimulation, possible insomnia)\"\n-          \"route\": \"vaporized\",\n+          \"route\": \"insufflated\",\n-            \"total_duration\": \"45-90 minutes\",\n-            \"onset\": \"1-3 minutes\",\n-            \"peak\": \"10-30 minutes\",\n-            \"offset\": \"15-45 minutes\",\n-            \"after_effects\": \"1-6 hours\"\n+            \"total_duration\": \"3-6 hours\",\n+            \"onset\": \"5-20 minutes\",\n+            \"peak\": \"45-90 minutes\",\n+            \"offset\": \"1-3 hours\",\n+            \"after_effects\": \"2-4 hours\"\n+            \"insufflated\"\n+          ]\n+        },\n+        {\n+          \"route\": \"smoked\",\n+          \"stages\": {\n+            \"total_duration\": \"2-4 hours\",\n+            \"onset\": \"1-5 minutes\",\n+            \"peak\": \"30-90 minutes\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"2-6 hours (prolonged compared to other smoked tryptamines)\"\n+          },\n+          \"canonical_routes\": [\n-    \"addiction_potential\": \"4-HO-MPT is generally considered not habit-forming, and the desire to use it can actually decrease with regular consumption. Like most psychedelics, it is thought to be self-regulating with low potential for psychological dependence.\",\n+    \"addiction_potential\": \"5-MeO-DiPT is not considered physically addictive and has low potential for psychological dependence. Some users report compulsive redosing due to the extended onset, particularly among inexperienced users who mistake the delayed effects for inadequate dosing. Tryptamines of this class are not known for addictive patterns.\",\n-        \"Lithium (significantly increases risk of psychosis and seizures)\"\n+        \"MAOIs (risk of serotonin syndrome; 5-MeO-DiPT may have weak MAOI properties)\",\n+        \"Tramadol (increased risk of serotonin syndrome and seizures)\",\n+        \"aMT (increased risk of serotonin syndrome)\"\n-        \"Tramadol (lowers seizure threshold)\"\n+        \"2C-T-X (both classes unpredictable alone)\",\n+        \"2C-X (unpredictable potentiation of psychedelic effects)\",\n+        \"NBOMe (both classes unpredictable; increased risk of unpleasant physical side effects)\",\n+        \"DOx (unpredictable interactions; increased risk of unpleasant physical side effects)\",\n+        \"MDMA (5-MeO tryptamines unpredictable with MDMA)\",\n+        \"Mescaline (unpredictable interactions)\",\n+        \"DXM (little information; possible unpredictable effects)\",\n+        \"PCP (little information; may increase risk of psychosis and excessive stimulation)\"\n-        \"Cannabis (unpredictable synergy; increases risk of anxiety, paranoia, panic attacks, and psychosis)\",\n-        \"Stimulants (increases risk of anxiety, paranoia, panic attacks, thought loops, mania, and psychosis)\"\n+        \"Cannabis (may increase risk of anxiety, paranoia, and psychosis)\",\n+        \"Amphetamines (anxiogenic and focusing effects increase risk of thought loops; combination generally unnecessary)\",\n+        \"Cocaine (anxiogenic and focusing effects increase risk of thought loops; combination generally unnecessary)\"\n-    \"notes\": \"4-HO-MPT is a research chemical with very little history of human usage and minimal scientific data on its pharmacology, metabolism, and toxicity. Legal status varies by jurisdiction; it is unscheduled in most countries but is a Class A drug in the United Kingdom under the tryptamine catch-all clause and controlled under Germany's NpSG. Use precise scales for dosing as potency varies between salt forms (freebase is approximately 25% more potent than fumarate salts). Individuals with personal or family histories of mental illness should avoid use.\",\n+    \"notes\": \"5-MeO-DiPT varies widely in individual response; some users report profound experiences while others experience uncomfortable gastrointestinal distress including severe diarrhea, gas, and stomach bloating. Use a precise milligram scale as dosages are in the low milligram range. The extended onset of 20-60 minutes has led to accidental overdoses from premature redosing. Individuals with personal or family history of psychotic disorders should avoid use. At least one death has been attributed to rectal administration overdose. The substance has been reported to be neurotoxic in rats. Set and setting are important; some users report significant anxiety and paranoia at higher doses.\",\n-      \"Visual Distortions And Patterning\",\n-      \"Color Enhancement And Shifting\",\n-      \"Time Distortion\",\n-      \"Emotion Enhancement\",\n+      \"Tactile Enhancement\",\n+      \"Stimulation\",\n+      \"Emotional Enhancement\",\n+      \"Increased Music Appreciation\",\n+      \"Enhanced Libido\",\n+      \"Spontaneous Physical Sensations\",\n+      \"Auditory Distortions\",\n-      \"Increased Heart Rate\",\n-      \"Pupil Dilation\",\n-      \"Thought Loops\",\n-      \"Vertigo Or Dizziness\",\n-      \"Memory Suppression\",\n-      \"Internal And External Hallucinations\"\n+      \"Body Load\",\n+      \"Diarrhea\",\n+      \"Time Distortion\",\n+      \"Visual Drifting (at higher doses)\",\n+      \"Pupil Dilation\"\n-      \"full_tolerance\": \"Immediately after ingestion\",\n+      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n-        \"All psychedelics (including LSD, psilocybin, mescaline, and other tryptamines)\"\n+        \"All psychedelics (LSD, psilocybin, mescaline, DMT, other tryptamines)\"\n-    \"half_life\": \"\",\n+    \"half_life\": \"3-6 hours (estimated from duration data)\",\n-        \"name\": \"Erowid 4-HO-MPT Vault\",\n-        \"reference\": \"https://www.erowid.org/chemicals/4_ho_mpt/4_ho_mpt.shtml\"\n+        \"name\": \"Erowid 5-MeO-DiPT Vault\",\n+        \"reference\": \"https://erowid.org/chemicals/5meo_dipt/\"\n-        \"name\": \"PsychonautWiki 4-HO-MPT\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/4-HO-MPT\"\n+        \"name\": \"Erowid TiHKAL Entry #37: 5-MeO-DiPT\",\n+        \"reference\": \"https://erowid.org/library/books_online/tihkal/tihkal37.shtml\"\n-        \"name\": \"TripSit 4-HO-MPT Factsheet\",\n-        \"reference\": \"https://tripbot.tripsit.me/factsheet/4-HO-MPT\"\n+        \"name\": \"PsychonautWiki: 5-MeO-DiPT\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/5-MeO-DiPT\"\n-        \"name\": \"TiHKAL Entry #23: 4-HO-MPT (Isomer Design)\",\n-        \"reference\": \"https://isomerdesign.com/PiHKAL/read.php?domain=tk&id=23\"\n+        \"name\": \"Bluelight: The Big & Dandy 5-MeO-DiPT Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-5-meo-dipt-thread.57817/\"\n-        \"name\": \"Bluelight: The Big & Dandy 4-HO-MPT Thread\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-4-ho-mpt-thread.550416/\"\n+        \"name\": \"TripSit Drug Combinations Wiki\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/Drug_combinations\"\n-        \"name\": \"Drugs-Forum 4-HO-MPT Wiki\",\n-        \"reference\": \"https://drugs-forum.com/wiki/4-HO-MPT\"\n+        \"name\": \"Shulgin, A. T.; Carter, M. F. (1980). Communications in Psychopharmacology\",\n+        \"reference\": \"N,N-Diisopropyltryptamine (DIPT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT). Two orally active tryptamine analogs with CNS activity\"\n+      },\n+      {\n+        \"name\": \"Noworyta-Sokolowska et al. (2016). Neurotoxicity Research\",\n+        \"reference\": \"Neurotoxic Effects of 5-MeO-DIPT: A Psychoactive Tryptamine Derivative in Rats\"\n+      },\n+      {\n+        \"name\": \"US DEA Drug Fact Sheet: 5-MeO-DiPT\",\n+        \"reference\": \"https://www.deadiversion.usdoj.gov/drug_chem_info/5meodipt.pdf\"\n-      \"synthetic\"\n+      \"entactogen\"\n-  \"id\": 643\n+  \"id\": 644\n\n# Psilocin · #645\n\n-  \"title\": \"5-MeO-DiPT\",\n-  \"index-category\": \"psychedelic; tryptamine; research-chemical\",\n+  \"title\": \"Psilocin\",\n+  \"index-category\": \"psychedelic; tryptamine; classic\",\n-    \"drug_name\": \"5-MeO-DiPT\",\n-    \"chemical_name\": \"5-Methoxy-N,N-diisopropyltryptamine\",\n-    \"alternative_name\": \"Foxy; Foxy Methoxy\",\n+    \"drug_name\": \"Psilocin\",\n+    \"chemical_name\": \"4-Hydroxy-N,N-dimethyltryptamine\",\n+    \"alternative_name\": \"Psilocine; Psilocyn; Psilotsin; 4-HO-DMT; 4-OH-DMT\",\n-    \"psychoactive_class\": \"Psychedelic; Entactogen; Stimulant\",\n-    \"mechanism_of_action\": \"5-HT2A receptor agonist (primary); 5-HT1A receptor agonist (strongest binding affinity); weak serotonin reuptake inhibitor; possible monoamine oxidase inhibition\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; 5-HT2C receptor agonist; 5-HT1A receptor agonist; Activates phospholipase A2 instead of phospholipase C\",\n-            \"threshold\": \"3-4 mg\",\n-            \"light\": \"3-10 mg\",\n-            \"common\": \"10-15 mg\",\n-            \"strong\": \"15-20 mg\",\n-            \"heavy\": \"20+ mg\"\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"10-15 mg\",\n+            \"common\": \"15-25 mg\",\n+            \"strong\": \"25-40 mg\",\n+            \"heavy\": \"40+ mg\"\n-        },\n-        {\n-          \"route\": \"insufflated\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"2-4 mg\",\n-            \"light\": \"4-7 mg\",\n-            \"common\": \"7-12 mg\",\n-            \"strong\": \"12-18 mg\",\n-            \"heavy\": \"18+ mg\"\n-          }\n-        },\n-        {\n-          \"route\": \"smoked\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"2-3 mg\",\n-            \"light\": \"3-5 mg\",\n-            \"common\": \"5-8 mg\",\n-            \"strong\": \"8-12 mg\",\n-            \"heavy\": \"12+ mg\"\n-          }\n-            \"total_duration\": \"4-8 hours\",\n-            \"onset\": \"20-60 minutes\",\n-            \"peak\": \"1-2 hours\",\n-            \"offset\": \"2-4 hours\",\n-            \"after_effects\": \"2-6 hours (residual stimulation, possible insomnia)\"\n+            \"total_duration\": \"4-6 hours\",\n+            \"onset\": \"20-45 minutes\",\n+            \"peak\": \"2-3 hours (come up 1.5-3 hours)\",\n+            \"offset\": \"1.5-2 hours\",\n+            \"after_effects\": \"4-24 hours\"\n-        },\n-        {\n-          \"route\": \"insufflated\",\n-          \"stages\": {\n-            \"total_duration\": \"3-6 hours\",\n-            \"onset\": \"5-20 minutes\",\n-            \"peak\": \"45-90 minutes\",\n-            \"offset\": \"1-3 hours\",\n-            \"after_effects\": \"2-4 hours\"\n-          },\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ]\n-        },\n-        {\n-          \"route\": \"smoked\",\n-          \"stages\": {\n-            \"total_duration\": \"2-4 hours\",\n-            \"onset\": \"1-5 minutes\",\n-            \"peak\": \"30-90 minutes\",\n-            \"offset\": \"1-2 hours\",\n-            \"after_effects\": \"2-6 hours (prolonged compared to other smoked tryptamines)\"\n-          },\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ]\n-    \"addiction_potential\": \"5-MeO-DiPT is not considered physically addictive and has low potential for psychological dependence. Some users report compulsive redosing due to the extended onset, particularly among inexperienced users who mistake the delayed effects for inadequate dosing. Tryptamines of this class are not known for addictive patterns.\",\n+    \"addiction_potential\": \"Psilocin is not considered habit-forming and has a low potential for psychological dependence. The desire to use it typically decreases with use, making it largely self-regulating. Rapid tolerance development discourages frequent redosing.\",\n-        \"MAOIs (risk of serotonin syndrome; 5-MeO-DiPT may have weak MAOI properties)\",\n-        \"Tramadol (increased risk of serotonin syndrome and seizures)\",\n-        \"aMT (increased risk of serotonin syndrome)\"\n+        \"Lithium (risk of fatal seizures and heart problems)\",\n+        \"MAOIs (potential for serotonin syndrome, hypertensive crisis)\"\n-        \"2C-T-X (both classes unpredictable alone)\",\n-        \"2C-X (unpredictable potentiation of psychedelic effects)\",\n-        \"NBOMe (both classes unpredictable; increased risk of unpleasant physical side effects)\",\n-        \"DOx (unpredictable interactions; increased risk of unpleasant physical side effects)\",\n-        \"MDMA (5-MeO tryptamines unpredictable with MDMA)\",\n-        \"Mescaline (unpredictable interactions)\",\n-        \"DXM (little information; possible unpredictable effects)\",\n-        \"PCP (little information; may increase risk of psychosis and excessive stimulation)\"\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Cannabis (greatly intensifies effects, increases anxiety and psychosis risk)\"\n-        \"Cannabis (may increase risk of anxiety, paranoia, and psychosis)\",\n-        \"Amphetamines (anxiogenic and focusing effects increase risk of thought loops; combination generally unnecessary)\",\n-        \"Cocaine (anxiogenic and focusing effects increase risk of thought loops; combination generally unnecessary)\"\n+        \"SSRIs (may reduce effects or increase risk)\",\n+        \"SNRIs (may alter effects)\",\n+        \"Tricyclic antidepressants (may potentiate effects)\",\n+        \"Benzodiazepines (reduce intensity, may cause amnesia)\",\n+        \"Antipsychotics (significantly dampen effects)\",\n+        \"MDMA (amplifies effects, possible neurotoxicity concerns)\",\n+        \"Dissociatives (intensifies hallucinations and confusion)\",\n+        \"Alcohol (causes dehydration and nausea, dulls effects)\"\n-    \"notes\": \"5-MeO-DiPT varies widely in individual response; some users report profound experiences while others experience uncomfortable gastrointestinal distress including severe diarrhea, gas, and stomach bloating. Use a precise milligram scale as dosages are in the low milligram range. The extended onset of 20-60 minutes has led to accidental overdoses from premature redosing. Individuals with personal or family history of psychotic disorders should avoid use. At least one death has been attributed to rectal administration overdose. The substance has been reported to be neurotoxic in rats. Set and setting are important; some users report significant anxiety and paranoia at higher doses.\",\n+    \"notes\": \"Psilocin is the pharmacologically active form of psilocybin and is rarely encountered as a pure synthetic compound. It is relatively unstable and readily forms blue degradation products when exposed to oxygen. Store in cool, dry, dark conditions. Unlike psilocybin mushrooms, pure psilocin has reduced nausea when taken on an empty stomach. Set and setting are critical to the experience. Those with personal or family history of psychotic disorders should avoid use. Always use accurate scales for dosing, as the substance is potent and effects can be overwhelming.\",\n-      \"Tactile Enhancement\",\n-      \"Stimulation\",\n-      \"Emotional Enhancement\",\n-      \"Increased Music Appreciation\",\n-      \"Enhanced Libido\",\n-      \"Spontaneous Physical Sensations\",\n-      \"Auditory Distortions\",\n-      \"Cognitive Euphoria\",\n-      \"Nausea\",\n-      \"Body Load\",\n-      \"Diarrhea\",\n+      \"Visual Patterning And Geometry\",\n+      \"Enhanced Colors And Visual Acuity\",\n+      \"Drifting, Melting, And Morphing Visuals\",\n+      \"Internal And External Hallucinations\",\n+      \"Emotional Amplification And Empathy\",\n-      \"Visual Drifting (at higher doses)\",\n-      \"Pupil Dilation\"\n+      \"Profound Thought Connectivity\",\n+      \"Spirituality And Ego Dissolution\",\n+      \"Physical Euphoria Or Sedation\",\n+      \"Analysis Enhancement\",\n+      \"Excessive Yawning\",\n+      \"Nausea (Less Common Than Mushrooms)\",\n+      \"Body High And Tingling Sensations\",\n+      \"Synesthesia\",\n+      \"Feelings Of Unity\"\n-      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n+      \"full_tolerance\": \"Almost immediately after ingestion\",\n-        \"All psychedelics (LSD, psilocybin, mescaline, DMT, other tryptamines)\"\n+        \"All psychedelics (LSD, mescaline, DMT, 2C-x compounds)\"\n-    \"half_life\": \"3-6 hours (estimated from duration data)\",\n+    \"half_life\": \"1-3 hours\",\n-        \"name\": \"Erowid 5-MeO-DiPT Vault\",\n-        \"reference\": \"https://erowid.org/chemicals/5meo_dipt/\"\n+        \"name\": \"PsychonautWiki: Psilocin\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Psilocin\"\n-        \"name\": \"Erowid TiHKAL Entry #37: 5-MeO-DiPT\",\n-        \"reference\": \"https://erowid.org/library/books_online/tihkal/tihkal37.shtml\"\n+        \"name\": \"Erowid Psilocin Experience Reports\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_Psilocin.shtml\"\n-        \"name\": \"PsychonautWiki: 5-MeO-DiPT\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/5-MeO-DiPT\"\n+        \"name\": \"TiHKAL #18: 4-HO-DMT by Alexander Shulgin\",\n+        \"reference\": \"https://erowid.org/library/books_online/tihkal/tihkal18.shtml\"\n-        \"name\": \"Bluelight: The Big & Dandy 5-MeO-DiPT Thread\",\n-        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-5-meo-dipt-thread.57817/\"\n+        \"name\": \"Bluelight: The Big and Dandy 4-HO-DMT Thread\",\n+        \"reference\": \"https://www.bluelight.org/vb/threads/318367-The-Big-and-Dandy-4-HO-DMT-Thread\"\n-        \"name\": \"TripSit Drug Combinations Wiki\",\n-        \"reference\": \"https://wiki.tripsit.me/wiki/Drug_combinations\"\n+        \"name\": \"Drug-drug interactions involving classic psychedelics: A systematic review\",\n+        \"reference\": \"https://journals.sagepub.com/doi/10.1177/02698811231211219\"\n-        \"name\": \"Shulgin, A. T.; Carter, M. F. (1980). Communications in Psychopharmacology\",\n-        \"reference\": \"N,N-Diisopropyltryptamine (DIPT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT). Two orally active tryptamine analogs with CNS activity\"\n-      },\n-      {\n-        \"name\": \"Noworyta-Sokolowska et al. (2016). Neurotoxicity Research\",\n-        \"reference\": \"Neurotoxic Effects of 5-MeO-DIPT: A Psychoactive Tryptamine Derivative in Rats\"\n-      },\n-      {\n-        \"name\": \"US DEA Drug Fact Sheet: 5-MeO-DiPT\",\n-        \"reference\": \"https://www.deadiversion.usdoj.gov/drug_chem_info/5meodipt.pdf\"\n+        \"name\": \"Drug-drug interactions between psychiatric medications and MDMA or psilocybin\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177763/\"\n-      \"research-chemical\",\n-      \"entactogen\"\n+      \"serotonergic\"\n-  \"id\": 644\n+  \"id\": 645\n\n# Allylescaline · #646\n\n-  \"title\": \"Psilocin\",\n-  \"index-category\": \"psychedelic; tryptamine; classic\",\n+  \"title\": \"Allylescaline\",\n+  \"index-category\": \"psychedelic\",\n-    \"drug_name\": \"Psilocin\",\n-    \"chemical_name\": \"4-Hydroxy-N,N-dimethyltryptamine\",\n-    \"alternative_name\": \"Psilocine; Psilocyn; Psilotsin; 4-HO-DMT; 4-OH-DMT\",\n-    \"chemical_class\": \"Tryptamines\",\n+    \"drug_name\": \"Allylescaline\",\n+    \"chemical_name\": \"4-Allyloxy-3,5-dimethoxyphenethylamine\",\n+    \"alternative_name\": \"AL; 4-allyloxy-3,5-dimethoxy-phenethylamine\",\n+    \"chemical_class\": \"Scalines\",\n-    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; 5-HT2C receptor agonist; 5-HT1A receptor agonist; Activates phospholipase A2 instead of phospholipase C\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"10-15 mg\",\n-            \"common\": \"15-25 mg\",\n-            \"strong\": \"25-40 mg\",\n-            \"heavy\": \"40+ mg\"\n+            \"threshold\": \"15 mg\",\n+            \"light\": \"20-30 mg\",\n+            \"common\": \"30-40 mg\",\n+            \"strong\": \"40-60 mg\",\n+            \"heavy\": \"60+ mg\"\n-            \"total_duration\": \"4-6 hours\",\n-            \"onset\": \"20-45 minutes\",\n-            \"peak\": \"2-3 hours (come up 1.5-3 hours)\",\n-            \"offset\": \"1.5-2 hours\",\n-            \"after_effects\": \"4-24 hours\"\n+            \"total_duration\": \"8-12 hours\",\n+            \"onset\": \"45-240 minutes\",\n+            \"after_effects\": \"Up to 12 hours (residual effects possible)\"\n-    \"addiction_potential\": \"Psilocin is not considered habit-forming and has a low potential for psychological dependence. The desire to use it typically decreases with use, making it largely self-regulating. Rapid tolerance development discourages frequent redosing.\",\n+    \"addiction_potential\": \"Allylescaline is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating, with little evidence of compulsive redosing patterns. However, given the limited human usage data, these observations should be considered preliminary.\",\n-        \"Lithium (risk of fatal seizures and heart problems)\",\n-        \"MAOIs (potential for serotonin syndrome, hypertensive crisis)\"\n+        \"Lithium (increased seizure risk with psychedelics)\",\n+        \"Tramadol (lowers seizure threshold with psychedelics)\"\n-      \"unsafe\": [\n-        \"Tramadol (lowers seizure threshold)\",\n-        \"Cannabis (greatly intensifies effects, increases anxiety and psychosis risk)\"\n-      ],\n+      \"unsafe\": [],\n-        \"SSRIs (may reduce effects or increase risk)\",\n-        \"SNRIs (may alter effects)\",\n-        \"Tricyclic antidepressants (may potentiate effects)\",\n-        \"Benzodiazepines (reduce intensity, may cause amnesia)\",\n-        \"Antipsychotics (significantly dampen effects)\",\n-        \"MDMA (amplifies effects, possible neurotoxicity concerns)\",\n-        \"Dissociatives (intensifies hallucinations and confusion)\",\n-        \"Alcohol (causes dehydration and nausea, dulls effects)\"\n+        \"MAOIs (theoretical risk based on phenethylamine structure)\",\n+        \"Stimulants (increased body load and cardiovascular strain)\",\n+        \"Other psychedelics (cross-tolerance and unpredictable intensity)\",\n+        \"Dissociatives (unpredictable combination effects)\"\n-    \"notes\": \"Psilocin is the pharmacologically active form of psilocybin and is rarely encountered as a pure synthetic compound. It is relatively unstable and readily forms blue degradation products when exposed to oxygen. Store in cool, dry, dark conditions. Unlike psilocybin mushrooms, pure psilocin has reduced nausea when taken on an empty stomach. Set and setting are critical to the experience. Those with personal or family history of psychotic disorders should avoid use. Always use accurate scales for dosing, as the substance is potent and effects can be overwhelming.\",\n+    \"notes\": \"Allylescaline is a research chemical with very little history of human usage and no formal toxicology studies. As a structural analog of mescaline with significantly increased potency, accurate weighing with a milligram scale is essential. The substance has a notably slow and variable onset ranging from 45 minutes to 4 hours, which may lead to accidental overdosing if users redose prematurely. Legal status varies by jurisdiction; it is controlled in Germany, Japan, Sweden, Switzerland, and the United Kingdom. Set and setting remain important considerations, and individuals with personal or family histories of mental health conditions should exercise extreme caution.\",\n-      \"Visual Patterning And Geometry\",\n-      \"Enhanced Colors And Visual Acuity\",\n-      \"Drifting, Melting, And Morphing Visuals\",\n-      \"Internal And External Hallucinations\",\n-      \"Emotional Amplification And Empathy\",\n+      \"Physical Stimulation\",\n+      \"Spontaneous Tactile Sensations\",\n+      \"Physical Euphoria\",\n+      \"Tactile Enhancement\",\n+      \"Color Enhancement\",\n+      \"Pattern Recognition Enhancement\",\n+      \"Drifting and Flowing Visuals\",\n+      \"Cognitive Euphoria\",\n+      \"Enhanced Empathy and Sociability\",\n+      \"Increased Music Appreciation\",\n-      \"Profound Thought Connectivity\",\n-      \"Spirituality And Ego Dissolution\",\n-      \"Physical Euphoria Or Sedation\",\n-      \"Analysis Enhancement\",\n-      \"Excessive Yawning\",\n-      \"Nausea (Less Common Than Mushrooms)\",\n-      \"Body High And Tingling Sensations\",\n-      \"Synesthesia\",\n-      \"Feelings Of Unity\"\n+      \"Nausea\",\n+      \"Increased Heart Rate\"\n-      \"full_tolerance\": \"Almost immediately after ingestion\",\n+      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n-        \"All psychedelics (LSD, mescaline, DMT, 2C-x compounds)\"\n+        \"All psychedelics (mescaline, LSD, psilocybin, DMT, 2C-x compounds, etc.)\"\n-    \"half_life\": \"1-3 hours\",\n+    \"half_life\": \"\",\n-        \"name\": \"PsychonautWiki: Psilocin\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/Psilocin\"\n+        \"name\": \"Erowid Allylescaline Vault\",\n+        \"reference\": \"https://www.erowid.org/experiences/subs/exp_Allylescaline.shtml\"\n-        \"name\": \"Erowid Psilocin Experience Reports\",\n-        \"reference\": \"https://erowid.org/experiences/subs/exp_Psilocin.shtml\"\n+        \"name\": \"Isomer Design - PiHKAL Entry #2: AL\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=2\"\n-        \"name\": \"TiHKAL #18: 4-HO-DMT by Alexander Shulgin\",\n-        \"reference\": \"https://erowid.org/library/books_online/tihkal/tihkal18.shtml\"\n+        \"name\": \"PsychonautWiki - Allylescaline\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Allylescaline\"\n-        \"name\": \"Bluelight: The Big and Dandy 4-HO-DMT Thread\",\n-        \"reference\": \"https://www.bluelight.org/vb/threads/318367-The-Big-and-Dandy-4-HO-DMT-Thread\"\n+        \"name\": \"Shulgin, A.; Shulgin, A. (1991). PiHKAL: A Chemical Love Story, Entry #2\",\n+        \"reference\": \"https://erowid.org/library/books_online/pihkal/pihkal002.shtml\"\n-        \"name\": \"Drug-drug interactions involving classic psychedelics: A systematic review\",\n-        \"reference\": \"https://journals.sagepub.com/doi/10.1177/02698811231211219\"\n+        \"name\": \"Bluelight - The Big & Dandy Allylescaline Thread\",\n+        \"reference\": \"https://bluelight.org\"\n-        \"name\": \"Drug-drug interactions between psychiatric medications and MDMA or psilocybin\",\n-        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177763/\"\n+        \"name\": \"Kolaczynska et al. (2022). Receptor interaction profiles of mescaline derivatives\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC8865417/\"\n-      \"tryptamine\",\n-      \"serotonergic\"\n+      \"research-chemical\"\n-  \"id\": 645\n+  \"id\": 646\n\n# Escaline · #647\n\n-  \"title\": \"Allylescaline\",\n+  \"title\": \"Escaline\",\n-    \"drug_name\": \"Allylescaline\",\n-    \"chemical_name\": \"4-Allyloxy-3,5-dimethoxyphenethylamine\",\n-    \"alternative_name\": \"AL; 4-allyloxy-3,5-dimethoxy-phenethylamine\",\n+    \"drug_name\": \"Escaline\",\n+    \"chemical_name\": \"3,5-Dimethoxy-4-ethoxyphenethylamine\",\n+    \"alternative_name\": \"E; 4-Ethoxy-3,5-dimethoxyphenethylamine\",\n-    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist (5-8 times greater affinity than mescaline); 5-HT2C receptor agonist\",\n-            \"threshold\": \"15 mg\",\n-            \"light\": \"20-30 mg\",\n-            \"common\": \"30-40 mg\",\n-            \"strong\": \"40-60 mg\",\n-            \"heavy\": \"60+ mg\"\n+            \"threshold\": \"20-25 mg\",\n+            \"light\": \"30-50 mg\",\n+            \"common\": \"50-100 mg\",\n+            \"strong\": \"100-150 mg\",\n+            \"heavy\": \"150+ mg\"\n-            \"onset\": \"45-240 minutes\",\n-            \"after_effects\": \"Up to 12 hours (residual effects possible)\"\n+            \"onset\": \"40-120 minutes\",\n+            \"peak\": \"5-6 hours\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"3-5 hours\"\n-    \"addiction_potential\": \"Allylescaline is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating, with little evidence of compulsive redosing patterns. However, given the limited human usage data, these observations should be considered preliminary.\",\n+    \"addiction_potential\": \"Escaline is not considered habit-forming and the desire to use it typically decreases with use. It is generally self-regulating and lacks compulsive redosing patterns.\",\n-        \"Lithium (increased seizure risk with psychedelics)\",\n-        \"Tramadol (lowers seizure threshold with psychedelics)\"\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n-      \"unsafe\": [],\n+      \"unsafe\": [\n+        \"Stimulants (increases risk of anxiety, paranoia, thought loops, mania, and psychosis)\"\n+      ],\n-        \"MAOIs (theoretical risk based on phenethylamine structure)\",\n-        \"Stimulants (increased body load and cardiovascular strain)\",\n-        \"Other psychedelics (cross-tolerance and unpredictable intensity)\",\n-        \"Dissociatives (unpredictable combination effects)\"\n+        \"Cannabis (unpredictable synergy; significantly increases risk of adverse psychological reactions)\"\n-    \"notes\": \"Allylescaline is a research chemical with very little history of human usage and no formal toxicology studies. As a structural analog of mescaline with significantly increased potency, accurate weighing with a milligram scale is essential. The substance has a notably slow and variable onset ranging from 45 minutes to 4 hours, which may lead to accidental overdosing if users redose prematurely. Legal status varies by jurisdiction; it is controlled in Germany, Japan, Sweden, Switzerland, and the United Kingdom. Set and setting remain important considerations, and individuals with personal or family histories of mental health conditions should exercise extreme caution.\",\n+    \"notes\": \"Escaline is a research chemical with very limited human use history and no formal toxicology studies. It is controlled as a Schedule I substance in the United States, Germany, Japan, Switzerland, and the UK. Users report more intense negative physical side effects compared to mescaline, including heavier body load and greater stimulation. Accurate weighing with a milligram scale is essential. The compound has a very long onset and extended duration, making sleep difficult without sedatives.\",\n-      \"Physical Stimulation\",\n-      \"Spontaneous Tactile Sensations\",\n-      \"Physical Euphoria\",\n-      \"Tactile Enhancement\",\n+      \"Stimulation\",\n+      \"Enhanced Music Appreciation\",\n+      \"Visual Patterning And Drifting\",\n-      \"Pattern Recognition Enhancement\",\n-      \"Drifting and Flowing Visuals\",\n-      \"Cognitive Euphoria\",\n-      \"Enhanced Empathy and Sociability\",\n-      \"Increased Music Appreciation\",\n+      \"Thought Acceleration And Connectivity\",\n-      \"Nausea\",\n-      \"Increased Heart Rate\"\n+      \"Bodily Sensations\",\n+      \"Pupil Dilation\",\n+      \"Increased Heart Rate\",\n+      \"Muscle Tension\",\n+      \"Euphoria\",\n+      \"Temperature Dysregulation\"\n-        \"All psychedelics (mescaline, LSD, psilocybin, DMT, 2C-x compounds, etc.)\"\n+        \"All psychedelics\"\n-        \"name\": \"Erowid Allylescaline Vault\",\n-        \"reference\": \"https://www.erowid.org/experiences/subs/exp_Allylescaline.shtml\"\n+        \"name\": \"Blaazer et al. (2008) - ChemMedChem\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/18666267/\"\n-        \"name\": \"Isomer Design - PiHKAL Entry #2: AL\",\n-        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=2\"\n+        \"name\": \"Erowid Escaline Experience Vault\",\n+        \"reference\": \"https://www.erowid.org/experiences/subs/exp_Escaline.shtml\"\n-        \"name\": \"PsychonautWiki - Allylescaline\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/Allylescaline\"\n+        \"name\": \"Halberstadt & Geyer (2018) - PMC\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848748/\"\n-        \"name\": \"Shulgin, A.; Shulgin, A. (1991). PiHKAL: A Chemical Love Story, Entry #2\",\n-        \"reference\": \"https://erowid.org/library/books_online/pihkal/pihkal002.shtml\"\n+        \"name\": \"Isomer Design: Escaline (PiHKAL Entry #72)\",\n+        \"reference\": \"https://isomerdesign.com/pihkal/explore/72\"\n-        \"name\": \"Bluelight - The Big & Dandy Allylescaline Thread\",\n-        \"reference\": \"https://bluelight.org\"\n+        \"name\": \"PsychonautWiki: Escaline\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Escaline\"\n-        \"name\": \"Kolaczynska et al. (2022). Receptor interaction profiles of mescaline derivatives\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC8865417/\"\n+        \"name\": \"Shulgin & Shulgin (1991) - PiHKAL Entry #72\",\n+        \"reference\": \"https://isomerdesign.com/pihkal/read/pk/72\"\n+      },\n+      {\n+        \"name\": \"The Big & Dandy Escaline Thread - Bluelight\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-escaline-thread.656624/\"\n-  \"id\": 646\n+  \"id\": 647\n\n# Proscaline · #648\n\n-  \"title\": \"Escaline\",\n+  \"title\": \"Proscaline\",\n-    \"drug_name\": \"Escaline\",\n-    \"chemical_name\": \"3,5-Dimethoxy-4-ethoxyphenethylamine\",\n-    \"alternative_name\": \"E; 4-Ethoxy-3,5-dimethoxyphenethylamine\",\n+    \"drug_name\": \"Proscaline\",\n+    \"chemical_name\": \"4-Propyloxy-3,5-dimethoxyphenethylamine\",\n+    \"alternative_name\": \"P; 4-Propoxy-3,5-DMPEA; 3,5-Dimethoxy-4-n-propoxyphenethylamine\",\n-    \"mechanism_of_action\": \"5-HT2A receptor partial agonist (5-8 times greater affinity than mescaline); 5-HT2C receptor agonist\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; 5-HT2C receptor partial agonist\",\n-            \"threshold\": \"20-25 mg\",\n-            \"light\": \"30-50 mg\",\n-            \"common\": \"50-100 mg\",\n-            \"strong\": \"100-150 mg\",\n-            \"heavy\": \"150+ mg\"\n+            \"threshold\": \"10 mg\",\n+            \"light\": \"15-30 mg\",\n+            \"common\": \"30-40 mg\",\n+            \"strong\": \"40-60 mg\",\n+            \"heavy\": \"60+ mg\"\n-            \"onset\": \"40-120 minutes\",\n-            \"peak\": \"5-6 hours\",\n-            \"offset\": \"2-4 hours\",\n+            \"onset\": \"30-60 minutes\",\n+            \"peak\": \"2-4 hours\",\n+            \"offset\": \"3-5 hours\",\n-    \"addiction_potential\": \"Escaline is not considered habit-forming and the desire to use it typically decreases with use. It is generally self-regulating and lacks compulsive redosing patterns.\",\n+    \"addiction_potential\": \"Proscaline is not habit-forming and demonstrates a self-regulating usage pattern. The desire to use it typically decreases with repeated consumption. There is no evidence of physical dependence or compulsive redosing patterns.\",\n-        \"Lithium (significantly increases risk of psychosis and seizures)\",\n-        \"Tramadol (lowers seizure threshold)\"\n+        \"Lithium (significantly increases risk of seizures and psychosis)\"\n-        \"Stimulants (increases risk of anxiety, paranoia, thought loops, mania, and psychosis)\"\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"MAOIs (potentially hazardous serotonergic interaction)\"\n-        \"Cannabis (unpredictable synergy; significantly increases risk of adverse psychological reactions)\"\n+        \"Stimulants (increased cardiovascular strain)\",\n+        \"Cannabis (may intensify and prolong effects unpredictably)\",\n+        \"SSRIs (may blunt or alter effects)\",\n+        \"Alcohol (reduces therapeutic potential and increases risk of dehydration)\"\n-    \"notes\": \"Escaline is a research chemical with very limited human use history and no formal toxicology studies. It is controlled as a Schedule I substance in the United States, Germany, Japan, Switzerland, and the UK. Users report more intense negative physical side effects compared to mescaline, including heavier body load and greater stimulation. Accurate weighing with a milligram scale is essential. The compound has a very long onset and extended duration, making sleep difficult without sedatives.\",\n+    \"notes\": \"Proscaline is a lesser-known mescaline analog approximately five times more potent than mescaline. The substance has minimal research into its pharmacology and toxicity. Use a precise milligram scale for accurate dosing. It is controlled in Germany, Switzerland, and the United Kingdom but remains unscheduled in the United States. Individuals with personal or family history of psychotic disorders should avoid use. Ensure adequate set and setting preparation, as with all psychedelics.\",\n-      \"Stimulation\",\n-      \"Enhanced Music Appreciation\",\n-      \"Visual Patterning And Drifting\",\n+      \"Visual Pattern Enhancement\",\n-      \"Thought Acceleration And Connectivity\",\n-      \"Bodily Sensations\",\n-      \"Pupil Dilation\",\n-      \"Increased Heart Rate\",\n-      \"Muscle Tension\",\n-      \"Euphoria\",\n-      \"Temperature Dysregulation\"\n+      \"Enhanced Music Appreciation\",\n+      \"Tactile Enhancement\",\n+      \"Cognitive Euphoria\",\n+      \"Conceptual Thinking\",\n+      \"Increased Body Temperature\",\n+      \"Nausea\",\n+      \"Enhanced Introspection\",\n+      \"Emotional Amplification\",\n+      \"Drifting Visual Effects\"\n-        \"All psychedelics\"\n+        \"All psychedelics (mescaline, LSD, psilocybin, DMT, 2C-x compounds)\"\n-        \"name\": \"Blaazer et al. (2008) - ChemMedChem\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/18666267/\"\n+        \"name\": \"PsychonautWiki: Proscaline\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Proscaline\"\n-        \"name\": \"Erowid Escaline Experience Vault\",\n-        \"reference\": \"https://www.erowid.org/experiences/subs/exp_Escaline.shtml\"\n+        \"name\": \"PiHKAL Entry #140: Proscaline (Isomer Design)\",\n+        \"reference\": \"https://isomerdesign.com/pihkal/explore/140\"\n-        \"name\": \"Halberstadt & Geyer (2018) - PMC\",\n-        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848748/\"\n+        \"name\": \"Erowid PiHKAL: Proscaline\",\n+        \"reference\": \"https://erowid.org/library/books_online/pihkal/pihkal140.shtml\"\n-        \"name\": \"Isomer Design: Escaline (PiHKAL Entry #72)\",\n-        \"reference\": \"https://isomerdesign.com/pihkal/explore/72\"\n+        \"name\": \"Erowid Proscaline Experience Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_Proscaline.shtml\"\n-        \"name\": \"PsychonautWiki: Escaline\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/Escaline\"\n+        \"name\": \"Bluelight: Proscaline Discussion\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/proscaline-new-experience-shiny-happy-people.522598/\"\n-        \"name\": \"Shulgin & Shulgin (1991) - PiHKAL Entry #72\",\n-        \"reference\": \"https://isomerdesign.com/pihkal/read/pk/72\"\n-      },\n-      {\n-        \"name\": \"The Big & Dandy Escaline Thread - Bluelight\",\n-        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-escaline-thread.656624/\"\n+        \"name\": \"Nichols and Dyer (1977) - Journal of Medicinal Chemistry\",\n+        \"reference\": \"https://doi.org/10.1021/jm00212a022\"\n+      \"phenethylamine\",\n-  \"id\": 647\n+  \"id\": 648\n\n# 2C-T · #649\n\n-  \"title\": \"Proscaline\",\n-  \"index-category\": \"psychedelic\",\n+  \"title\": \"2C-T\",\n+  \"index-category\": \"psychedelic; research-chemical\",\n-    \"drug_name\": \"Proscaline\",\n-    \"chemical_name\": \"4-Propyloxy-3,5-dimethoxyphenethylamine\",\n-    \"alternative_name\": \"P; 4-Propoxy-3,5-DMPEA; 3,5-Dimethoxy-4-n-propoxyphenethylamine\",\n-    \"chemical_class\": \"Scalines\",\n+    \"drug_name\": \"2C-T\",\n+    \"chemical_name\": \"2,5-Dimethoxy-4-methylthiophenethylamine\",\n+    \"alternative_name\": \"Tesseract\",\n+    \"chemical_class\": \"Phenethylamines\",\n-    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; 5-HT2C receptor partial agonist\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; potential MAOI properties\",\n-            \"threshold\": \"10 mg\",\n-            \"light\": \"15-30 mg\",\n-            \"common\": \"30-40 mg\",\n-            \"strong\": \"40-60 mg\",\n-            \"heavy\": \"60+ mg\"\n+            \"threshold\": \"20 mg\",\n+            \"light\": \"40-60 mg\",\n+            \"common\": \"60-100 mg\",\n+            \"strong\": \"100-120 mg\",\n+            \"heavy\": \"125+ mg\"\n-            \"total_duration\": \"8-12 hours\",\n-            \"onset\": \"30-60 minutes\",\n-            \"peak\": \"2-4 hours\",\n-            \"offset\": \"3-5 hours\",\n-            \"after_effects\": \"3-5 hours\"\n+            \"total_duration\": \"3-6 hours\",\n+            \"onset\": \"30-45 minutes\",\n+            \"peak\": \"30-115 minutes\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"1-2 hours\"\n-    \"addiction_potential\": \"Proscaline is not habit-forming and demonstrates a self-regulating usage pattern. The desire to use it typically decreases with repeated consumption. There is no evidence of physical dependence or compulsive redosing patterns.\",\n+    \"addiction_potential\": \"2C-T is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating with no significant dependence or abuse potential reported.\",\n-        \"Lithium (significantly increases risk of seizures and psychosis)\"\n+        \"MAOIs (potential serotonin syndrome or neurotransmitter overload)\",\n+        \"Stimulants (increased neurotransmitter release)\",\n+        \"5-MeO-MiPT (serotonergic overload)\",\n+        \"2C-T-7 (serotonergic overload)\",\n+        \"AMT (MAOI properties)\",\n+        \"Cocaine (cardiovascular stress)\",\n+        \"Methamphetamine (neurotoxicity risk)\",\n+        \"MDMA (serotonin syndrome risk)\"\n-        \"Tramadol (lowers seizure threshold)\",\n-        \"MAOIs (potentially hazardous serotonergic interaction)\"\n+        \"Tramadol (lowers seizure threshold)\"\n-        \"Stimulants (increased cardiovascular strain)\",\n-        \"Cannabis (may intensify and prolong effects unpredictably)\",\n-        \"SSRIs (may blunt or alter effects)\",\n-        \"Alcohol (reduces therapeutic potential and increases risk of dehydration)\"\n+        \"Other psychedelics (overwhelming intensity)\",\n+        \"2-AI (serotonergic interaction)\",\n+        \"A-PVP (cardiovascular stress)\",\n+        \"Amphetamine (increased strain)\",\n+        \"Mephedrone (combined stimulation)\"\n-    \"notes\": \"Proscaline is a lesser-known mescaline analog approximately five times more potent than mescaline. The substance has minimal research into its pharmacology and toxicity. Use a precise milligram scale for accurate dosing. It is controlled in Germany, Switzerland, and the United Kingdom but remains unscheduled in the United States. Individuals with personal or family history of psychotic disorders should avoid use. Ensure adequate set and setting preparation, as with all psychedelics.\",\n+    \"notes\": \"2C-T is a lesser-known research chemical with very limited human use history and minimal scientific data on its pharmacology, metabolism, and toxicity. It is structurally similar to 2C-T-2 and 2C-T-7 and may possess MAOI properties, making it potentially more dangerous when combined with other serotonergic substances. The substance is illegal in many jurisdictions including the United States (Schedule I), United Kingdom (Class A), and Canada (Schedule III). Use accurate milligram scales for dosing, practice harm reduction, and consider having a sober trip sitter present. Individuals with personal or family histories of mental health conditions should avoid use.\",\n-      \"Visual Pattern Enhancement\",\n-      \"Color Enhancement\",\n-      \"Time Distortion\",\n-      \"Enhanced Music Appreciation\",\n+      \"Spontaneous Bodily Sensations\",\n-      \"Cognitive Euphoria\",\n-      \"Conceptual Thinking\",\n-      \"Increased Body Temperature\",\n+      \"Bodily Control Enhancement\",\n+      \"Emotion Enhancement\",\n+      \"Analysis Enhancement\",\n+      \"Time Distortion\",\n+      \"Increased Music Appreciation\",\n+      \"Colour Enhancement\",\n+      \"Visual Acuity Enhancement\",\n+      \"Drifting and Morphing\",\n-      \"Enhanced Introspection\",\n-      \"Emotional Amplification\",\n-      \"Drifting Visual Effects\"\n+      \"Vasoconstriction\"\n-      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n+      \"full_tolerance\": \"Almost immediately after ingestion\",\n-        \"All psychedelics (mescaline, LSD, psilocybin, DMT, 2C-x compounds)\"\n+        \"All psychedelics\"\n-        \"name\": \"PsychonautWiki: Proscaline\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/Proscaline\"\n+        \"name\": \"Nichols & Shulgin (1976) - Sulfur Analogs of Psychotomimetic Amines\",\n+        \"reference\": \"https://doi.org/10.1002/jps.2600651040\"\n-        \"name\": \"PiHKAL Entry #140: Proscaline (Isomer Design)\",\n-        \"reference\": \"https://isomerdesign.com/pihkal/explore/140\"\n+        \"name\": \"PiHKAL Entry #39: 2C-T\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/read.php?domain=pk&id=39\"\n-        \"name\": \"Erowid PiHKAL: Proscaline\",\n-        \"reference\": \"https://erowid.org/library/books_online/pihkal/pihkal140.shtml\"\n+        \"name\": \"PsychonautWiki: 2C-T\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/2C-T\"\n-        \"name\": \"Erowid Proscaline Experience Vault\",\n-        \"reference\": \"https://erowid.org/experiences/subs/exp_Proscaline.shtml\"\n+        \"name\": \"Erowid 2C-T-2 Basics\",\n+        \"reference\": \"https://erowid.org/chemicals/2ct2/2ct2_basics.shtml\"\n-        \"name\": \"Bluelight: Proscaline Discussion\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/proscaline-new-experience-shiny-happy-people.522598/\"\n-      },\n-      {\n-        \"name\": \"Nichols and Dyer (1977) - Journal of Medicinal Chemistry\",\n-        \"reference\": \"https://doi.org/10.1021/jm00212a022\"\n+        \"name\": \"Gallardo-Godoy et al. (2005) - Sulfur-Substituted MAO-A Inhibitors\",\n+        \"reference\": \"https://doi.org/10.1021/jm0493109\"\n-      \"research-chemical\"\n+      \"research-chemical\",\n+      \"2c-x\"\n-  \"id\": 648\n+  \"id\": 649\n\n# 2,5-DMA · #650\n\n-  \"title\": \"2C-T\",\n-  \"index-category\": \"psychedelic; research-chemical\",\n+  \"title\": \"2,5-DMA\",\n+  \"index-category\": \"stimulant; research-chemical\",\n-    \"drug_name\": \"2C-T\",\n-    \"chemical_name\": \"2,5-Dimethoxy-4-methylthiophenethylamine\",\n-    \"alternative_name\": \"Tesseract\",\n-    \"chemical_class\": \"Phenethylamines\",\n-    \"psychoactive_class\": \"Psychedelic\",\n-    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; potential MAOI properties\",\n+    \"drug_name\": \"2,5-DMA\",\n+    \"chemical_name\": \"1-(2,5-Dimethoxyphenyl)propan-2-amine\",\n+    \"alternative_name\": \"2,5-Dimethoxyamphetamine; DMA; DOH\",\n+    \"chemical_class\": \"Amphetamines; Phenethylamines\",\n+    \"psychoactive_class\": \"Stimulant; Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist (low potency); does not bind to monoamine transporters\",\n-            \"threshold\": \"20 mg\",\n-            \"light\": \"40-60 mg\",\n-            \"common\": \"60-100 mg\",\n-            \"strong\": \"100-120 mg\",\n-            \"heavy\": \"125+ mg\"\n+            \"threshold\": \"10 mg\",\n+            \"light\": \"10-40 mg\",\n+            \"common\": \"40-80 mg\",\n+            \"strong\": \"80-200 mg\",\n+            \"heavy\": \"200+ mg\"\n-            \"total_duration\": \"3-6 hours\",\n-            \"onset\": \"30-45 minutes\",\n-            \"peak\": \"30-115 minutes\",\n-            \"offset\": \"1-2 hours\",\n-            \"after_effects\": \"1-2 hours\"\n+            \"total_duration\": \"6-8 hours\"\n-    \"addiction_potential\": \"2C-T is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating with no significant dependence or abuse potential reported.\",\n+    \"addiction_potential\": \"2,5-DMA is not considered habit-forming and likely has low psychological dependence potential. However, its stimulating properties may present some risk of compulsive use similar to other stimulants. No formal studies have been conducted on addiction potential.\",\n-        \"MAOIs (potential serotonin syndrome or neurotransmitter overload)\",\n-        \"Stimulants (increased neurotransmitter release)\",\n-        \"5-MeO-MiPT (serotonergic overload)\",\n-        \"2C-T-7 (serotonergic overload)\",\n-        \"AMT (MAOI properties)\",\n-        \"Cocaine (cardiovascular stress)\",\n-        \"Methamphetamine (neurotoxicity risk)\",\n-        \"MDMA (serotonin syndrome risk)\"\n+        \"Lithium (significantly increases risk of psychosis and seizures)\"\n-        \"Tramadol (lowers seizure threshold)\"\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Cannabis (unpredictable synergy, increased risk of anxiety and psychosis)\"\n-        \"Other psychedelics (overwhelming intensity)\",\n-        \"2-AI (serotonergic interaction)\",\n-        \"A-PVP (cardiovascular stress)\",\n-        \"Amphetamine (increased strain)\",\n-        \"Mephedrone (combined stimulation)\"\n+        \"Stimulants (increased anxiety, paranoia, and cardiovascular risk)\",\n+        \"Other psychedelics (may intensify effects unpredictably)\"\n-    \"notes\": \"2C-T is a lesser-known research chemical with very limited human use history and minimal scientific data on its pharmacology, metabolism, and toxicity. It is structurally similar to 2C-T-2 and 2C-T-7 and may possess MAOI properties, making it potentially more dangerous when combined with other serotonergic substances. The substance is illegal in many jurisdictions including the United States (Schedule I), United Kingdom (Class A), and Canada (Schedule III). Use accurate milligram scales for dosing, practice harm reduction, and consider having a sober trip sitter present. Individuals with personal or family histories of mental health conditions should avoid use.\",\n+    \"notes\": \"2,5-DMA is a research chemical and the simplest member of the DOx family, primarily known as a precursor in synthesizing other psychedelic amphetamines rather than for its own psychoactive effects. Unlike typical psychedelics, it produces primarily stimulant and physical effects with minimal to no sensory or perceptual changes. Very little data exists about its pharmacology, metabolism, and toxicity. Use accurate weighing equipment and start with lower doses due to individual variability. Those with personal or family history of mental health disorders should avoid use.\",\n-      \"Spontaneous Bodily Sensations\",\n-      \"Tactile Enhancement\",\n-      \"Bodily Control Enhancement\",\n-      \"Emotion Enhancement\",\n-      \"Analysis Enhancement\",\n-      \"Time Distortion\",\n-      \"Increased Music Appreciation\",\n-      \"Colour Enhancement\",\n-      \"Visual Acuity Enhancement\",\n-      \"Drifting and Morphing\",\n-      \"Nausea\",\n-      \"Vasoconstriction\"\n+      \"Physical Stimulation\",\n+      \"Increased Heart Rate\",\n+      \"Increased Blood Pressure\",\n+      \"Pupil Dilation\",\n+      \"Muscle Tension\",\n+      \"Tremors\",\n+      \"Body Load\",\n+      \"Enhanced Interest In Surroundings\",\n+      \"Cardiovascular Stimulation\",\n+      \"Temperature Regulation Suppression\",\n+      \"Increased Perspiration\"\n-      \"full_tolerance\": \"Almost immediately after ingestion\",\n-      \"half_tolerance\": \"3 days\",\n-      \"zero_tolerance\": \"7 days\",\n+      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n+      \"half_tolerance\": \"3-5 days\",\n+      \"zero_tolerance\": \"7-10 days\",\n-        \"All psychedelics\"\n+        \"Psychedelics (unlikely but possible)\",\n+        \"Stimulants\"\n-        \"name\": \"Nichols & Shulgin (1976) - Sulfur Analogs of Psychotomimetic Amines\",\n-        \"reference\": \"https://doi.org/10.1002/jps.2600651040\"\n+        \"name\": \"Baltzly & Buck, 1940 - Original Synthesis\",\n+        \"reference\": \"https://doi.org/10.1021/ja01858a046\"\n-        \"name\": \"PiHKAL Entry #39: 2C-T\",\n-        \"reference\": \"https://isomerdesign.com/PiHKAL/read.php?domain=pk&id=39\"\n+        \"name\": \"Erowid PiHKAL #54: 2,5-DMA\",\n+        \"reference\": \"https://erowid.org/library/books_online/pihkal/pihkal054.shtml\"\n-        \"name\": \"PsychonautWiki: 2C-T\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/2C-T\"\n+        \"name\": \"Isomer Design PiHKAL Info: 2,5-DMA\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/read.php?id=54\"\n-        \"name\": \"Erowid 2C-T-2 Basics\",\n-        \"reference\": \"https://erowid.org/chemicals/2ct2/2ct2_basics.shtml\"\n+        \"name\": \"PsychonautWiki: 2,5-DMA\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/2,5-DMA\"\n-        \"name\": \"Gallardo-Godoy et al. (2005) - Sulfur-Substituted MAO-A Inhibitors\",\n-        \"reference\": \"https://doi.org/10.1021/jm0493109\"\n+        \"name\": \"Wikipedia: 2,5-Dimethoxyamphetamine\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/2,5-Dimethoxyamphetamine\"\n-      \"psychedelic\",\n+      \"amphetamine\",\n-      \"2c-x\"\n+      \"stimulant\"\n-  \"id\": 649\n+  \"id\": 650\n\n# DOI · #651\n\n-  \"title\": \"2,5-DMA\",\n-  \"index-category\": \"stimulant; research-chemical\",\n+  \"title\": \"DOI\",\n+  \"index-category\": \"psychedelic\",\n-    \"drug_name\": \"2,5-DMA\",\n-    \"chemical_name\": \"1-(2,5-Dimethoxyphenyl)propan-2-amine\",\n-    \"alternative_name\": \"2,5-Dimethoxyamphetamine; DMA; DOH\",\n-    \"chemical_class\": \"Amphetamines; Phenethylamines\",\n-    \"psychoactive_class\": \"Stimulant; Psychedelic\",\n-    \"mechanism_of_action\": \"5-HT2A receptor partial agonist (low potency); does not bind to monoamine transporters\",\n+    \"drug_name\": \"DOI\",\n+    \"chemical_name\": \"2,5-Dimethoxy-4-iodoamphetamine\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist; 5-HT2B receptor agonist; 5-HT2C receptor agonist\",\n-            \"threshold\": \"10 mg\",\n-            \"light\": \"10-40 mg\",\n-            \"common\": \"40-80 mg\",\n-            \"strong\": \"80-200 mg\",\n-            \"heavy\": \"200+ mg\"\n+            \"threshold\": \"0.5 mg\",\n+            \"light\": \"0.5-1 mg\",\n+            \"common\": \"1-2 mg\",\n+            \"strong\": \"2-3 mg\",\n+            \"heavy\": \"3+ mg\"\n-            \"total_duration\": \"6-8 hours\"\n+            \"total_duration\": \"16-24 hours\",\n+            \"onset\": \"1-2 hours\",\n+            \"peak\": \"3-6 hours (come up 1.5-3 hours)\",\n+            \"offset\": \"6-12 hours\",\n+            \"after_effects\": \"24-48 hours (residual stimulation)\"\n-    \"addiction_potential\": \"2,5-DMA is not considered habit-forming and likely has low psychological dependence potential. However, its stimulating properties may present some risk of compulsive use similar to other stimulants. No formal studies have been conducted on addiction potential.\",\n+    \"addiction_potential\": \"DOI is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating. There is no evidence of physical dependence or compulsive redosing patterns.\",\n-        \"Lithium (significantly increases risk of psychosis and seizures)\"\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n-        \"Tramadol (lowers seizure threshold)\",\n-        \"Cannabis (unpredictable synergy, increased risk of anxiety and psychosis)\"\n+        \"Stimulants such as amphetamine, cocaine, or methylphenidate (increased risk of anxiety, paranoia, thought loops, and psychosis)\",\n+        \"MAOIs (potential for unpredictable interactions)\"\n-        \"Stimulants (increased anxiety, paranoia, and cardiovascular risk)\",\n-        \"Other psychedelics (may intensify effects unpredictably)\"\n+        \"Cannabis (unexpectedly strong and unpredictable synergy; significant increase in anxiety, paranoia, and psychosis risk)\",\n+        \"5-MeO tryptamines (unpredictable interactions with increased physical side effects)\",\n+        \"MDMA (combined stimulating effects can be uncomfortable and anxiogenic during comedown)\",\n+        \"Caffeine (may cause anxiety and physical discomfort)\",\n+        \"Amphetamines (uncomfortable body load and thought loops)\",\n+        \"Cocaine (uncomfortable body load and thought loops)\",\n+        \"Ketamine (potentiation; go slowly)\",\n+        \"Alcohol (reduced sedative effects lead to excessive drinking)\"\n-    \"notes\": \"2,5-DMA is a research chemical and the simplest member of the DOx family, primarily known as a precursor in synthesizing other psychedelic amphetamines rather than for its own psychoactive effects. Unlike typical psychedelics, it produces primarily stimulant and physical effects with minimal to no sensory or perceptual changes. Very little data exists about its pharmacology, metabolism, and toxicity. Use accurate weighing equipment and start with lower doses due to individual variability. Those with personal or family history of mental health disorders should avoid use.\",\n+    \"notes\": \"DOI is an extremely potent and long-lasting psychedelic with a very sensitive dose-response curve. It is sometimes sold falsely as LSD, which can be dangerous due to differing safety profiles and dosage ranges. Use a precise milligram scale for accurate dosing. The exceptionally long duration of 16-24 hours with residual stimulation lasting up to 48 hours requires adequate time preparation. Individuals with personal or family history of psychotic disorders should avoid use. Start with the lowest possible dose due to high individual variability in response.\",\n-      \"Physical Stimulation\",\n-      \"Increased Heart Rate\",\n-      \"Increased Blood Pressure\",\n-      \"Pupil Dilation\",\n-      \"Muscle Tension\",\n-      \"Tremors\",\n-      \"Body Load\",\n-      \"Enhanced Interest In Surroundings\",\n-      \"Cardiovascular Stimulation\",\n-      \"Temperature Regulation Suppression\",\n-      \"Increased Perspiration\"\n+      \"Extreme Stimulation\",\n+      \"Visual Patterning And Geometry\",\n+      \"Colour Enhancement\",\n+      \"Energetic Body High\",\n+      \"Thought Acceleration\",\n+      \"Enhanced Tactile Sensation\",\n+      \"Internal And External Hallucinations\",\n+      \"Time Distortion\",\n+      \"Emotional Amplification\",\n+      \"Enhanced Music Appreciation\",\n+      \"Nausea\",\n+      \"Muscle Tension And Vasoconstriction\",\n+      \"Increased Body Temperature\",\n+      \"Pupil Dilation\"\n-      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n-      \"half_tolerance\": \"3-5 days\",\n-      \"zero_tolerance\": \"7-10 days\",\n+      \"full_tolerance\": \"Immediately after ingestion\",\n+      \"half_tolerance\": \"5-7 days\",\n+      \"zero_tolerance\": \"10-14 days\",\n-        \"Psychedelics (unlikely but possible)\",\n-        \"Stimulants\"\n+        \"All psychedelics (LSD, psilocybin, mescaline, 2C-x, DOx compounds)\"\n-    \"half_life\": \"\",\n+    \"half_life\": \"Unknown; estimated duration of primary effects 16-24 hours with residual effects up to 48 hours\",\n-        \"name\": \"Baltzly & Buck, 1940 - Original Synthesis\",\n-        \"reference\": \"https://doi.org/10.1021/ja01858a046\"\n+        \"name\": \"Coutts & Malicky 1973 - Synthesis of DOI Analogs\",\n+        \"reference\": \"https://doi.org/10.1139/v73-210\"\n-        \"name\": \"Erowid PiHKAL #54: 2,5-DMA\",\n-        \"reference\": \"https://erowid.org/library/books_online/pihkal/pihkal054.shtml\"\n+        \"name\": \"PsychonautWiki DOI Profile\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/DOI\"\n-        \"name\": \"Isomer Design PiHKAL Info: 2,5-DMA\",\n-        \"reference\": \"https://isomerdesign.com/PiHKAL/read.php?id=54\"\n+        \"name\": \"TripSit DOI Factsheet\",\n+        \"reference\": \"https://drugs.tripsit.me/DOI\"\n-        \"name\": \"PsychonautWiki: 2,5-DMA\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/2,5-DMA\"\n+        \"name\": \"Erowid DOI Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/doi/doi.shtml\"\n-        \"name\": \"Wikipedia: 2,5-Dimethoxyamphetamine\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/2,5-Dimethoxyamphetamine\"\n+        \"name\": \"PiHKAL Entry #67 - DOI (Isomer Design)\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/read.php?id=67\"\n+      },\n+      {\n+        \"name\": \"Shulgin & Shulgin - PiHKAL: A Chemical Love Story\",\n+        \"reference\": \"Transform Press, 1991\"\n+      },\n+      {\n+        \"name\": \"Bluelight DOI Discussion Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-doi-thread.216778/\"\n-      \"amphetamine\",\n-      \"phenethylamine\",\n-      \"research-chemical\",\n-      \"stimulant\"\n+      \"psychedelic\",\n+      \"stimulant\",\n+      \"substituted-amphetamine\",\n+      \"research-chemical\"\n-  \"id\": 650\n+  \"id\": 651\n\n# 25C-NBOH · #652\n\n-  \"title\": \"DOI\",\n+  \"title\": \"25C-NBOH\",\n-    \"drug_name\": \"DOI\",\n-    \"chemical_name\": \"2,5-Dimethoxy-4-iodoamphetamine\",\n-    \"alternative_name\": \"\",\n-    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"drug_name\": \"25C-NBOH\",\n+    \"chemical_name\": \"2-(4-Chloro-2,5-dimethoxyphenyl)-N-[(2-hydroxyphenyl)methyl]ethanamine\",\n+    \"alternative_name\": \"2C-C-NBOH; NBOH-2C-C; N-bomb; NBOH\",\n+    \"chemical_class\": \"N-benzylated phenethylamines\",\n-    \"mechanism_of_action\": \"5-HT2A receptor agonist; 5-HT2B receptor agonist; 5-HT2C receptor agonist\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist (potent, pEC50 9.43); 5-HT2C receptor agonist (pKi 7.8)\",\n-          \"route\": \"oral\",\n-          \"units\": \"mg\",\n+          \"route\": \"sublingual\",\n+          \"units\": \"ug\",\n-            \"threshold\": \"0.5 mg\",\n-            \"light\": \"0.5-1 mg\",\n-            \"common\": \"1-2 mg\",\n-            \"strong\": \"2-3 mg\",\n-            \"heavy\": \"3+ mg\"\n+            \"threshold\": \"100 ug\",\n+            \"light\": \"250-500 ug\",\n+            \"common\": \"500-750 ug\",\n+            \"strong\": \"750-1000 ug\",\n+            \"heavy\": \"1000+ ug (potentially fatal)\"\n-          \"route\": \"oral\",\n+          \"route\": \"sublingual\",\n-            \"total_duration\": \"16-24 hours\",\n-            \"onset\": \"1-2 hours\",\n-            \"peak\": \"3-6 hours (come up 1.5-3 hours)\",\n-            \"offset\": \"6-12 hours\",\n-            \"after_effects\": \"24-48 hours (residual stimulation)\"\n+            \"total_duration\": \"5-7 hours\",\n+            \"onset\": \"15-45 minutes\",\n+            \"peak\": \"90-180 minutes (come up 30-90 minutes)\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"3-6 days (afterglow may persist)\"\n-    \"addiction_potential\": \"DOI is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating. There is no evidence of physical dependence or compulsive redosing patterns.\",\n+    \"addiction_potential\": \"25C-NBOH is not considered habit-forming and the desire to use it typically decreases with repeated use. The substance is generally self-regulating, though research on its addiction potential is extremely limited.\",\n-        \"Tramadol (lowers seizure threshold)\"\n+        \"MAOIs (potentially dangerous interaction)\"\n-        \"Stimulants such as amphetamine, cocaine, or methylphenidate (increased risk of anxiety, paranoia, thought loops, and psychosis)\",\n-        \"MAOIs (potential for unpredictable interactions)\"\n+        \"Stimulants (increased risk of anxiety, paranoia, panic attacks, thought loops, mania, and psychosis)\",\n+        \"Tramadol (lowers seizure threshold)\"\n-        \"Cannabis (unexpectedly strong and unpredictable synergy; significant increase in anxiety, paranoia, and psychosis risk)\",\n-        \"5-MeO tryptamines (unpredictable interactions with increased physical side effects)\",\n-        \"MDMA (combined stimulating effects can be uncomfortable and anxiogenic during comedown)\",\n-        \"Caffeine (may cause anxiety and physical discomfort)\",\n-        \"Amphetamines (uncomfortable body load and thought loops)\",\n-        \"Cocaine (uncomfortable body load and thought loops)\",\n-        \"Ketamine (potentiation; go slowly)\",\n-        \"Alcohol (reduced sedative effects lead to excessive drinking)\"\n+        \"Cannabis (unpredictably strong synergy, significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n-    \"notes\": \"DOI is an extremely potent and long-lasting psychedelic with a very sensitive dose-response curve. It is sometimes sold falsely as LSD, which can be dangerous due to differing safety profiles and dosage ranges. Use a precise milligram scale for accurate dosing. The exceptionally long duration of 16-24 hours with residual stimulation lasting up to 48 hours requires adequate time preparation. Individuals with personal or family history of psychotic disorders should avoid use. Start with the lowest possible dose due to high individual variability in response.\",\n+    \"notes\": \"25C-NBOH is a novel research chemical with extremely limited human use history and assumed similar toxicity to 25C-NBOMe, which has been linked to multiple deaths. This substance must NEVER be insufflated (snorted) due to high risk of fatal overdose. Compounds of the NBOH family are NOT orally active and must be administered sublingually, holding in the mouth for 15-25 minutes. Use an accurate microgram scale for all dosing. The substance exhibits dose-independent intensity and unpredictable effects even at seemingly identical doses. Start with threshold doses and avoid combinations. Heavy doses may be fatal. Individuals with personal or family history of psychotic disorders should avoid use. This substance is controlled in many jurisdictions.\",\n-      \"Extreme Stimulation\",\n-      \"Visual Patterning And Geometry\",\n-      \"Colour Enhancement\",\n-      \"Energetic Body High\",\n-      \"Thought Acceleration\",\n-      \"Enhanced Tactile Sensation\",\n-      \"Internal And External Hallucinations\",\n+      \"Intense Visual Patterning And Geometry\",\n+      \"Strong Physical Stimulation\",\n+      \"Perception Of Bodily Lightness\",\n+      \"Color Enhancement\",\n-      \"Emotional Amplification\",\n-      \"Enhanced Music Appreciation\",\n-      \"Nausea\",\n-      \"Muscle Tension And Vasoconstriction\",\n-      \"Increased Body Temperature\",\n-      \"Pupil Dilation\"\n+      \"Spontaneous Euphoric Tingling Sensations\",\n+      \"Enhanced Pattern Recognition\",\n+      \"Mouth And Tongue Numbing\",\n+      \"Nausea (Typically During Come-Up)\",\n+      \"Anxiety And Paranoia (More Common Than Classical Psychedelics)\",\n+      \"Mild Cognitive Effects (Notably Light Headspace)\",\n+      \"Increased Sociability And Empathy (Inconsistent)\",\n+      \"Enhanced Music Appreciation\"\n-      \"full_tolerance\": \"Immediately after ingestion\",\n-      \"half_tolerance\": \"5-7 days\",\n-      \"zero_tolerance\": \"10-14 days\",\n+      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n+      \"half_tolerance\": \"Approximately 1 week\",\n+      \"zero_tolerance\": \"2 weeks\",\n-        \"All psychedelics (LSD, psilocybin, mescaline, 2C-x, DOx compounds)\"\n+        \"All psychedelics (LSD, psilocybin, mescaline, DMT, 2C-x series, NBOMe series)\"\n-    \"half_life\": \"Unknown; estimated duration of primary effects 16-24 hours with residual effects up to 48 hours\",\n+    \"half_life\": \"\",\n-        \"name\": \"Coutts & Malicky 1973 - Synthesis of DOI Analogs\",\n-        \"reference\": \"https://doi.org/10.1139/v73-210\"\n+        \"name\": \"Bluelight: The Big & Dandy 25C-NBOH Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-25c-nboh-thread.621629/\"\n-        \"name\": \"PsychonautWiki DOI Profile\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/DOI\"\n+        \"name\": \"Erowid 25C-NBOH Experience Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_25CNBOH.shtml\"\n-        \"name\": \"TripSit DOI Factsheet\",\n-        \"reference\": \"https://drugs.tripsit.me/DOI\"\n+        \"name\": \"Hansen, M. (2012). Design and Synthesis of Selective Serotonin Receptor Agonists for PET Imaging\",\n+        \"reference\": \"https://www.researchgate.net/publication/266388124\"\n-        \"name\": \"Erowid DOI Vault\",\n-        \"reference\": \"https://www.erowid.org/chemicals/doi/doi.shtml\"\n+        \"name\": \"Hansen et al. (2014). Synthesis and Structure-Activity Relationships of N-Benzyl Phenethylamines as 5-HT2A/2C Agonists\",\n+        \"reference\": \"https://doi.org/10.1021/cn400216u\"\n-        \"name\": \"PiHKAL Entry #67 - DOI (Isomer Design)\",\n-        \"reference\": \"https://isomerdesign.com/PiHKAL/read.php?id=67\"\n+        \"name\": \"Isomer Design: 25C-NBOH\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=1252\"\n-        \"name\": \"Shulgin & Shulgin - PiHKAL: A Chemical Love Story\",\n-        \"reference\": \"Transform Press, 1991\"\n+        \"name\": \"PsychonautWiki: 25C-NBOH\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/25C-NBOH\"\n-        \"name\": \"Bluelight DOI Discussion Thread\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-doi-thread.216778/\"\n+        \"name\": \"Silva et al. (2011). Theoretical Studies on the Interaction of Partial Agonists with the 5-HT2A Receptor\",\n+        \"reference\": \"https://doi.org/10.1007/s10822-010-9400-2\"\n-      \"stimulant\",\n-      \"substituted-amphetamine\",\n-  \"id\": 651\n+  \"id\": 652\n\n# 25D-NBOMe · #653\n\n-  \"title\": \"25C-NBOH\",\n+  \"title\": \"25D-NBOMe\",\n-    \"drug_name\": \"25C-NBOH\",\n-    \"chemical_name\": \"2-(4-Chloro-2,5-dimethoxyphenyl)-N-[(2-hydroxyphenyl)methyl]ethanamine\",\n-    \"alternative_name\": \"2C-C-NBOH; NBOH-2C-C; N-bomb; NBOH\",\n+    \"drug_name\": \"25D-NBOMe\",\n+    \"chemical_name\": \"2-(2,5-Dimethoxy-4-methylphenyl)-N-(2-methoxybenzyl)ethanamine\",\n+    \"alternative_name\": \"2C-D-NBOMe; NBOMe-2C-D; Divination; N-Bomb\",\n-    \"mechanism_of_action\": \"5-HT2A receptor agonist (potent, pEC50 9.43); 5-HT2C receptor agonist (pKi 7.8)\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist (partial); 5-HT2B receptor agonist; 5-HT2C receptor agonist; adrenergic alpha-1 receptor agonist\",\n-            \"threshold\": \"100 ug\",\n-            \"light\": \"250-500 ug\",\n-            \"common\": \"500-750 ug\",\n-            \"strong\": \"750-1000 ug\",\n-            \"heavy\": \"1000+ ug (potentially fatal)\"\n+            \"threshold\": \"300 ug\",\n+            \"light\": \"300-800 ug\",\n+            \"common\": \"800-1000 ug\",\n+            \"strong\": \"1000-1200 ug\",\n+            \"heavy\": \"1200+ ug\"\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"200 ug\",\n+            \"light\": \"200-600 ug\",\n+            \"common\": \"600-800 ug\",\n+            \"strong\": \"800-1000 ug\",\n+            \"heavy\": \"1000+ ug\"\n+          }\n-            \"total_duration\": \"5-7 hours\",\n-            \"onset\": \"15-45 minutes\",\n-            \"peak\": \"90-180 minutes (come up 30-90 minutes)\",\n-            \"offset\": \"2-4 hours\",\n-            \"after_effects\": \"3-6 days (afterglow may persist)\"\n+            \"total_duration\": \"4-6 hours\",\n+            \"onset\": \"20-40 minutes\",\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"6+ hours\"\n-            \"oral\"\n+            \"sublingual\"\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"stages\": {\n+            \"total_duration\": \"3-5 hours\",\n+            \"onset\": \"5-15 minutes\",\n+            \"peak\": \"45-90 minutes\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"4-6 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n-    \"addiction_potential\": \"25C-NBOH is not considered habit-forming and the desire to use it typically decreases with repeated use. The substance is generally self-regulating, though research on its addiction potential is extremely limited.\",\n+    \"addiction_potential\": \"25D-NBOMe has not been formally studied for addiction potential but appears to have a self-regulating quality with immediate tolerance buildup. Rapid tolerance develops after use, lasting approximately 2-3 weeks. Animal studies have shown reinforcing effects including conditioned place preference and self-administration behavior, suggesting some potential for psychological reinforcement.\",\n-        \"Lithium (significantly increases risk of psychosis and seizures)\",\n-        \"MAOIs (potentially dangerous interaction)\"\n+        \"Lithium (significantly increased seizure risk)\",\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"MAOIs (hypertensive crisis risk, unpredictable potentiation)\",\n+        \"Amphetamines (severe cardiovascular stress, tachycardia, hypertension, potential heart failure)\",\n+        \"Cocaine (severe vasoconstriction, tachycardia, hypertension, potential heart failure)\"\n-        \"Stimulants (increased risk of anxiety, paranoia, panic attacks, thought loops, mania, and psychosis)\",\n-        \"Tramadol (lowers seizure threshold)\"\n+        \"2C-T-X compounds (unpredictable interactions)\",\n+        \"5-MeO-xxt compounds (unpredictable interactions)\",\n+        \"aMT (unpredictable cardiovascular effects)\",\n+        \"DOx compounds (prolonged stimulation, cardiovascular strain)\",\n+        \"DXM (unpredictable effects)\",\n+        \"MDMA (cardiovascular strain, hyperthermia risk)\",\n+        \"MXE (potentiation of NBOMe effects)\"\n-        \"Cannabis (unpredictably strong synergy, significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n+        \"Cannabis (significantly increases anxiety, paranoia, and unpredictable psychological effects)\",\n+        \"Caffeine (increases uncomfortable stimulation and anxiety)\",\n+        \"SSRIs (may blunt or prolong effects)\"\n-    \"notes\": \"25C-NBOH is a novel research chemical with extremely limited human use history and assumed similar toxicity to 25C-NBOMe, which has been linked to multiple deaths. This substance must NEVER be insufflated (snorted) due to high risk of fatal overdose. Compounds of the NBOH family are NOT orally active and must be administered sublingually, holding in the mouth for 15-25 minutes. Use an accurate microgram scale for all dosing. The substance exhibits dose-independent intensity and unpredictable effects even at seemingly identical doses. Start with threshold doses and avoid combinations. Heavy doses may be fatal. Individuals with personal or family history of psychotic disorders should avoid use. This substance is controlled in many jurisdictions.\",\n+    \"notes\": \"25D-NBOMe is a highly potent research chemical with an extremely narrow margin between active and potentially lethal doses. The compound is not orally active and must be administered sublingually or via other mucosal routes. Never insufflate NBOMe compounds as this route has been associated with numerous fatalities. Blotter paper doses are notoriously inconsistent due to hotspots of concentrated material. Use only with an analytical balance for weighing, never eyeball doses. Those with personal or family history of psychotic disorders, cardiovascular conditions, or seizure disorders should avoid this substance entirely. The compound produces dose-dependent vasoconstriction and cardiovascular strain. Set and setting are critical; always have a sober trip sitter present. Many deaths have occurred from individuals believing they consumed LSD when they actually ingested an NBOMe compound.\",\n-      \"Intense Visual Patterning And Geometry\",\n-      \"Strong Physical Stimulation\",\n-      \"Perception Of Bodily Lightness\",\n+      \"Visual Acuity Enhancement\",\n+      \"Visual Geometry\",\n+      \"Tracers and After Images\",\n+      \"Physical Euphoria\",\n+      \"Stimulation\",\n+      \"Tactile Hallucination\",\n-      \"Spontaneous Euphoric Tingling Sensations\",\n-      \"Enhanced Pattern Recognition\",\n-      \"Mouth And Tongue Numbing\",\n-      \"Nausea (Typically During Come-Up)\",\n-      \"Anxiety And Paranoia (More Common Than Classical Psychedelics)\",\n-      \"Mild Cognitive Effects (Notably Light Headspace)\",\n-      \"Increased Sociability And Empathy (Inconsistent)\",\n-      \"Enhanced Music Appreciation\"\n+      \"Mouth and Tongue Numbness\",\n+      \"Metallic Chemical Taste\",\n+      \"Spontaneous Bodily Sensations\",\n+      \"Thought Acceleration\",\n+      \"Music Appreciation Enhancement\",\n+      \"Emotional Amplification\",\n+      \"Nausea\",\n+      \"Vasoconstriction\",\n+      \"Increased Heart Rate\",\n+      \"Increased Blood Pressure\",\n+      \"Temperature Regulation Suppression\",\n+      \"Muscle Tension and Cramps\",\n+      \"Headaches\",\n+      \"Anxiety and Paranoia\"\n-      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n+      \"full_tolerance\": \"Develops immediately after use\",\n-      \"zero_tolerance\": \"2 weeks\",\n+      \"zero_tolerance\": \"2-3 weeks\",\n-        \"All psychedelics (LSD, psilocybin, mescaline, DMT, 2C-x series, NBOMe series)\"\n+        \"All psychedelics\",\n+        \"Other NBOMe compounds\",\n+        \"2C-x series\"\n-    \"half_life\": \"\",\n+    \"half_life\": \"1-3 hours (parent compound rapidly cleared from blood)\",\n-        \"name\": \"Bluelight: The Big & Dandy 25C-NBOH Thread\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-25c-nboh-thread.621629/\"\n+        \"name\": \"Alcohol and Drug Foundation: NBOMes\",\n+        \"reference\": \"https://adf.org.au/drug-facts/nbomes/\"\n-        \"name\": \"Erowid 25C-NBOH Experience Vault\",\n-        \"reference\": \"https://erowid.org/experiences/subs/exp_25CNBOH.shtml\"\n+        \"name\": \"Erowid 25D-NBOMe Experience Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_25DNBOMe.shtml\"\n-        \"name\": \"Hansen, M. (2012). Design and Synthesis of Selective Serotonin Receptor Agonists for PET Imaging\",\n-        \"reference\": \"https://www.researchgate.net/publication/266388124\"\n+        \"name\": \"Erowid NBOMe Series Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/nbome/\"\n-        \"name\": \"Hansen et al. (2014). Synthesis and Structure-Activity Relationships of N-Benzyl Phenethylamines as 5-HT2A/2C Agonists\",\n-        \"reference\": \"https://doi.org/10.1021/cn400216u\"\n+        \"name\": \"Frontiers in Neuroscience: NBOMes - Highly Potent and Toxic Alternatives of LSD\",\n+        \"reference\": \"https://www.frontiersin.org/articles/10.3389/fnins.2020.00078/full\"\n-        \"name\": \"Isomer Design: 25C-NBOH\",\n-        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=1252\"\n+        \"name\": \"Isomer Design: 25D-NBOMe\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=342\"\n-        \"name\": \"PsychonautWiki: 25C-NBOH\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/25C-NBOH\"\n+        \"name\": \"PsychonautWiki: 25D-NBOMe\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/25D-NBOMe\"\n-        \"name\": \"Silva et al. (2011). Theoretical Studies on the Interaction of Partial Agonists with the 5-HT2A Receptor\",\n-        \"reference\": \"https://doi.org/10.1007/s10822-010-9400-2\"\n+        \"name\": \"Wikipedia: 25D-NBOMe\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/25D-NBOMe\"\n+      },\n+      {\n+        \"name\": \"Yoon et al. (2019): Cardiac Effects of 25D-NBOMe and 25C-NBOMe\",\n+        \"reference\": \"https://doi.org/10.1016/j.toxlet.2019.01.004\"\n-  \"id\": 652\n+  \"id\": 653\n\n# 25N-NBOMe · #654\n\n-  \"title\": \"25D-NBOMe\",\n+  \"title\": \"25N-NBOMe\",\n-    \"drug_name\": \"25D-NBOMe\",\n-    \"chemical_name\": \"2-(2,5-Dimethoxy-4-methylphenyl)-N-(2-methoxybenzyl)ethanamine\",\n-    \"alternative_name\": \"2C-D-NBOMe; NBOMe-2C-D; Divination; N-Bomb\",\n+    \"drug_name\": \"25N-NBOMe\",\n+    \"chemical_name\": \"2-(2,5-dimethoxy-4-nitrophenyl)-N-(2-methoxybenzyl)ethanamine\",\n+    \"alternative_name\": \"2C-N-NBOMe; NBOMe-2C-N; N-Bomb\",\n-    \"mechanism_of_action\": \"5-HT2A receptor agonist (partial); 5-HT2B receptor agonist; 5-HT2C receptor agonist; adrenergic alpha-1 receptor agonist\",\n+    \"mechanism_of_action\": \"5-HT2A receptor full agonist; 5-HT2C receptor full agonist; 5-HT2B receptor partial agonist; dopamine transporter phosphorylation (increases extracellular dopamine)\",\n-            \"threshold\": \"300 ug\",\n-            \"light\": \"300-800 ug\",\n-            \"common\": \"800-1000 ug\",\n-            \"strong\": \"1000-1200 ug\",\n-            \"heavy\": \"1200+ ug\"\n+            \"threshold\": \"100 ug\",\n+            \"light\": \"100-300 ug\",\n+            \"common\": \"300-800 ug\",\n+            \"strong\": \"800-1300 ug\",\n+            \"heavy\": \"1300+ ug (potentially fatal)\"\n-            \"threshold\": \"200 ug\",\n-            \"light\": \"200-600 ug\",\n-            \"common\": \"600-800 ug\",\n-            \"strong\": \"800-1000 ug\",\n-            \"heavy\": \"1000+ ug\"\n+            \"threshold\": \"Not recommended\",\n+            \"light\": \"Not recommended\",\n+            \"common\": \"Not recommended\",\n+            \"strong\": \"Not recommended\",\n+            \"heavy\": \"Not recommended (extremely dangerous)\"\n-            \"total_duration\": \"4-6 hours\",\n-            \"onset\": \"20-40 minutes\",\n-            \"peak\": \"1-2 hours\",\n-            \"offset\": \"1-2 hours\",\n-            \"after_effects\": \"6+ hours\"\n+            \"total_duration\": \"5-10 hours\",\n+            \"onset\": \"45-75 minutes\",\n+            \"peak\": \"2-3 hours\",\n+            \"offset\": \"2-3 hours\",\n+            \"after_effects\": \"5-10 hours\"\n-            \"total_duration\": \"3-5 hours\",\n-            \"onset\": \"5-15 minutes\",\n-            \"peak\": \"45-90 minutes\",\n-            \"offset\": \"1-2 hours\",\n-            \"after_effects\": \"4-6 hours\"\n-          },\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ]\n+            \"total_duration\": \"5-10 hours\",\n+            \"onset\": \"45-75 minutes\",\n+            \"peak\": \"2-3 hours\",\n+            \"offset\": \"2-3 hours\",\n+            \"after_effects\": \"5-10 hours\"\n+          }\n-    \"addiction_potential\": \"25D-NBOMe has not been formally studied for addiction potential but appears to have a self-regulating quality with immediate tolerance buildup. Rapid tolerance develops after use, lasting approximately 2-3 weeks. Animal studies have shown reinforcing effects including conditioned place preference and self-administration behavior, suggesting some potential for psychological reinforcement.\",\n+    \"addiction_potential\": \"25N-NBOMe is not considered habit-forming and the desire to use often decreases with repeated administration. However, animal studies suggest potential dependence liability through dopaminergic pathways, with conditioned place preference effects comparable to methamphetamine in rodent models. The substance exhibits rapid tolerance development.\",\n-        \"Lithium (significantly increased seizure risk)\",\n-        \"Tramadol (lowers seizure threshold)\",\n-        \"MAOIs (hypertensive crisis risk, unpredictable potentiation)\",\n-        \"Amphetamines (severe cardiovascular stress, tachycardia, hypertension, potential heart failure)\",\n-        \"Cocaine (severe vasoconstriction, tachycardia, hypertension, potential heart failure)\"\n+        \"Lithium (significantly increases seizure risk)\",\n+        \"MAOIs (unpredictable potentiation and duration increase)\",\n+        \"Tramadol (significantly lowers seizure threshold)\"\n+        \"Amphetamines (severe cardiovascular strain, tachycardia, hypertension, and increased seizure risk)\",\n+        \"Cocaine (severe cardiovascular strain and vasoconstriction)\",\n+        \"MDMA (unpredictable intensity, reports of blackouts and severe overstimulation)\",\n+        \"MXE (unpleasantly intense potentiation)\",\n+        \"DOx compounds (unpredictable interactions)\",\n-        \"aMT (unpredictable cardiovascular effects)\",\n-        \"DOx compounds (prolonged stimulation, cardiovascular strain)\",\n-        \"DXM (unpredictable effects)\",\n-        \"MDMA (cardiovascular strain, hyperthermia risk)\",\n-        \"MXE (potentiation of NBOMe effects)\"\n+        \"aMT (increased cardiovascular risk)\"\n-        \"Cannabis (significantly increases anxiety, paranoia, and unpredictable psychological effects)\",\n-        \"Caffeine (increases uncomfortable stimulation and anxiety)\",\n-        \"SSRIs (may blunt or prolong effects)\"\n+        \"Cannabis (significantly increases anxiety, paranoia, and psychosis risk)\",\n+        \"Caffeine (uncomfortable overstimulation and anxiety)\",\n+        \"DXM (unpredictable interactions)\"\n-    \"notes\": \"25D-NBOMe is a highly potent research chemical with an extremely narrow margin between active and potentially lethal doses. The compound is not orally active and must be administered sublingually or via other mucosal routes. Never insufflate NBOMe compounds as this route has been associated with numerous fatalities. Blotter paper doses are notoriously inconsistent due to hotspots of concentrated material. Use only with an analytical balance for weighing, never eyeball doses. Those with personal or family history of psychotic disorders, cardiovascular conditions, or seizure disorders should avoid this substance entirely. The compound produces dose-dependent vasoconstriction and cardiovascular strain. Set and setting are critical; always have a sober trip sitter present. Many deaths have occurred from individuals believing they consumed LSD when they actually ingested an NBOMe compound.\",\n+    \"notes\": \"25N-NBOMe is a highly potent and unpredictable substance that has been linked to numerous hospitalizations and fatalities within the NBOMe series. The compound must only be administered sublingually, as insufflation dramatically increases overdose risk and has been implicated in multiple deaths. Blotter papers may contain uneven dose distribution with dangerous hotspots. Users should employ accurate microgram scales, avoid all drug combinations, and never exceed 1000 ug due to narrow margin between active and toxic doses. Individuals with cardiovascular conditions, seizure disorders, or personal or family history of psychotic disorders should strictly avoid use. The substance is often misrepresented as LSD; always use reagent testing.\",\n-      \"Visual Acuity Enhancement\",\n-      \"Color Enhancement\",\n-      \"Visual Geometry\",\n-      \"Tracers and After Images\",\n-      \"Physical Euphoria\",\n-      \"Stimulation\",\n-      \"Tactile Hallucination\",\n+      \"Intense Visual Patterning And Geometry\",\n+      \"Strong Physical Stimulation\",\n+      \"Perception Of Bodily Lightness\",\n+      \"Euphoric Body High\",\n+      \"Tactile Enhancement\",\n+      \"Colour Enhancement\",\n-      \"Mouth and Tongue Numbness\",\n-      \"Metallic Chemical Taste\",\n-      \"Spontaneous Bodily Sensations\",\n+      \"Empathy And Sociability Enhancement (Inconsistent)\",\n-      \"Music Appreciation Enhancement\",\n-      \"Emotional Amplification\",\n-      \"Nausea\",\n-      \"Vasoconstriction\",\n+      \"Anxiety And Paranoia\",\n+      \"Mouth Numbing\",\n-      \"Increased Blood Pressure\",\n-      \"Temperature Regulation Suppression\",\n-      \"Muscle Tension and Cramps\",\n-      \"Headaches\",\n-      \"Anxiety and Paranoia\"\n+      \"Vasoconstriction\",\n+      \"Nausea (Especially During Onset)\",\n+      \"Muscle Tension\",\n+      \"Pupil Dilation\"\n-      \"full_tolerance\": \"Develops immediately after use\",\n-      \"half_tolerance\": \"Approximately 1 week\",\n-      \"zero_tolerance\": \"2-3 weeks\",\n+      \"full_tolerance\": \"Immediately after use\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n-        \"All psychedelics\",\n-        \"Other NBOMe compounds\",\n-        \"2C-x series\"\n+        \"All psychedelics (LSD, psilocybin, mescaline, 2C-x, other NBOMes)\"\n-    \"half_life\": \"1-3 hours (parent compound rapidly cleared from blood)\",\n+    \"half_life\": \"1-3 hours (estimated from related compounds)\",\n-        \"name\": \"Alcohol and Drug Foundation: NBOMes\",\n-        \"reference\": \"https://adf.org.au/drug-facts/nbomes/\"\n+        \"name\": \"Bluelight: The Big & Dandy 25N-NBOMe Thread\",\n+        \"reference\": \"http://www.bluelight.org/vb/threads/539694-The-Big-amp-Dandy-25N-NBOMe-Thread\"\n-        \"name\": \"Erowid 25D-NBOMe Experience Vault\",\n-        \"reference\": \"https://erowid.org/experiences/subs/exp_25DNBOMe.shtml\"\n-      },\n-      {\n-        \"name\": \"Erowid NBOMe Series Vault\",\n+        \"name\": \"Erowid: NBOMe Series Vault\",\n-        \"reference\": \"https://www.frontiersin.org/articles/10.3389/fnins.2020.00078/full\"\n+        \"reference\": \"https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2020.00078/full\"\n-        \"name\": \"Isomer Design: 25D-NBOMe\",\n-        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=342\"\n+        \"name\": \"Isomer Design: 25N-NBOMe\",\n+        \"reference\": \"https://isomerdesign.com/pihkal/\"\n-        \"name\": \"PsychonautWiki: 25D-NBOMe\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/25D-NBOMe\"\n+        \"name\": \"PsychonautWiki: 25N-NBOMe\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/25N-NBOMe\"\n-        \"name\": \"Wikipedia: 25D-NBOMe\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/25D-NBOMe\"\n-      },\n-      {\n-        \"name\": \"Yoon et al. (2019): Cardiac Effects of 25D-NBOMe and 25C-NBOMe\",\n-        \"reference\": \"https://doi.org/10.1016/j.toxlet.2019.01.004\"\n+        \"name\": \"Wikipedia: 25N-NBOMe\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/25N-NBOMe\"\n-  \"id\": 653\n+  \"id\": 654\n\n# TMA-6 · #655\n\n-  \"title\": \"25N-NBOMe\",\n-  \"index-category\": \"psychedelic\",\n+  \"title\": \"TMA-6\",\n+  \"index-category\": \"psychedelic; stimulant; research-chemical\",\n-    \"drug_name\": \"25N-NBOMe\",\n-    \"chemical_name\": \"2-(2,5-dimethoxy-4-nitrophenyl)-N-(2-methoxybenzyl)ethanamine\",\n-    \"alternative_name\": \"2C-N-NBOMe; NBOMe-2C-N; N-Bomb\",\n-    \"chemical_class\": \"N-benzylated phenethylamines\",\n+    \"drug_name\": \"TMA-6\",\n+    \"chemical_name\": \"1-(2,4,6-Trimethoxyphenyl)propan-2-amine\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n-    \"mechanism_of_action\": \"5-HT2A receptor full agonist; 5-HT2C receptor full agonist; 5-HT2B receptor partial agonist; dopamine transporter phosphorylation (increases extracellular dopamine)\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; potent MAO-A inhibitor (IC50 400 nM)\",\n-          \"route\": \"sublingual\",\n-          \"units\": \"ug\",\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"100 ug\",\n-            \"light\": \"100-300 ug\",\n-            \"common\": \"300-800 ug\",\n-            \"strong\": \"800-1300 ug\",\n-            \"heavy\": \"1300+ ug (potentially fatal)\"\n+            \"threshold\": \"5-10 mg\",\n+            \"light\": \"10-20 mg\",\n+            \"common\": \"20-35 mg\",\n+            \"strong\": \"35-50 mg\",\n+            \"heavy\": \"50+ mg\"\n-          \"units\": \"ug\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"Not recommended\",\n-            \"light\": \"Not recommended\",\n-            \"common\": \"Not recommended\",\n-            \"strong\": \"Not recommended\",\n-            \"heavy\": \"Not recommended (extremely dangerous)\"\n+            \"threshold\": \"5-10 mg\",\n+            \"light\": \"10-15 mg\",\n+            \"common\": \"15-25 mg\",\n+            \"strong\": \"25-35 mg\",\n+            \"heavy\": \"35+ mg\"\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5-10 mg\",\n+            \"light\": \"10-15 mg\",\n+            \"common\": \"15-30 mg\",\n+            \"strong\": \"30-40 mg\",\n+            \"heavy\": \"40+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"vaporized\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5-10 mg\",\n+            \"light\": \"10-15 mg\",\n+            \"common\": \"15-25 mg\",\n+            \"strong\": \"25-35 mg\",\n+            \"heavy\": \"35+ mg\"\n+          }\n-          \"route\": \"sublingual\",\n+          \"route\": \"oral\",\n-            \"total_duration\": \"5-10 hours\",\n-            \"onset\": \"45-75 minutes\",\n-            \"peak\": \"2-3 hours\",\n-            \"offset\": \"2-3 hours\",\n-            \"after_effects\": \"5-10 hours\"\n+            \"total_duration\": \"10-16 hours\",\n+            \"onset\": \"30-90 minutes\",\n+            \"peak\": \"5-8 hours\",\n+            \"offset\": \"3-5 hours\",\n+            \"after_effects\": \"6-18 hours\"\n-            \"sublingual\"\n+            \"oral\"\n-            \"total_duration\": \"5-10 hours\",\n-            \"onset\": \"45-75 minutes\",\n-            \"peak\": \"2-3 hours\",\n-            \"offset\": \"2-3 hours\",\n-            \"after_effects\": \"5-10 hours\"\n-          }\n+            \"total_duration\": \"8-12 hours\",\n+            \"onset\": \"10-30 minutes\",\n+            \"peak\": \"4-6 hours\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"6-12 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"stages\": {\n+            \"total_duration\": \"8-14 hours\",\n+            \"onset\": \"10-30 minutes\",\n+            \"peak\": \"4-7 hours\",\n+            \"offset\": \"3-5 hours\",\n+            \"after_effects\": \"6-12 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"rectal\"\n+          ]\n+        },\n+        {\n+          \"route\": \"vaporized\",\n+          \"stages\": {\n+            \"total_duration\": \"6-11 hours\",\n+            \"onset\": \"5-15 minutes\",\n+            \"peak\": \"3-6 hours\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"4-12 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n-    \"addiction_potential\": \"25N-NBOMe is not considered habit-forming and the desire to use often decreases with repeated administration. However, animal studies suggest potential dependence liability through dopaminergic pathways, with conditioned place preference effects comparable to methamphetamine in rodent models. The substance exhibits rapid tolerance development.\",\n+    \"addiction_potential\": \"TMA-6 is not considered habit-forming and has a low potential for psychological dependence. The desire to use it typically decreases with consumption, and rapid tolerance development discourages frequent redosing. It is generally self-regulating.\",\n-        \"Lithium (significantly increases seizure risk)\",\n-        \"MAOIs (unpredictable potentiation and duration increase)\",\n-        \"Tramadol (significantly lowers seizure threshold)\"\n+        \"MAOIs (risk of hypertensive crisis and serotonin syndrome; TMA-6 itself is a potent MAO-A inhibitor)\",\n+        \"Lithium (elevated risk of seizures and psychosis)\",\n+        \"Tramadol (lowers seizure threshold)\"\n-        \"Amphetamines (severe cardiovascular strain, tachycardia, hypertension, and increased seizure risk)\",\n-        \"Cocaine (severe cardiovascular strain and vasoconstriction)\",\n-        \"MDMA (unpredictable intensity, reports of blackouts and severe overstimulation)\",\n-        \"MXE (unpleasantly intense potentiation)\",\n-        \"DOx compounds (unpredictable interactions)\",\n-        \"2C-T-X compounds (unpredictable interactions)\",\n-        \"5-MeO-xxt compounds (unpredictable interactions)\",\n-        \"aMT (increased cardiovascular risk)\"\n+        \"Serotonin releasers (MDMA, 4-FA, methamphetamine, methylone, aMT; risk of serotonin syndrome)\",\n+        \"Stimulants (risk of excessive anxiety, panic, thought loops, and psychosis)\"\n-        \"Cannabis (significantly increases anxiety, paranoia, and psychosis risk)\",\n-        \"Caffeine (uncomfortable overstimulation and anxiety)\",\n-        \"DXM (unpredictable interactions)\"\n+        \"SSRIs (citalopram, sertraline; risk of serotonin syndrome and altered effects)\",\n+        \"SNRIs (venlafaxine; risk of serotonin syndrome)\",\n+        \"5-HTP (risk of serotonin syndrome)\",\n+        \"Other psychedelics (risk of overwhelming intensity and unpredictable interactions)\"\n-    \"notes\": \"25N-NBOMe is a highly potent and unpredictable substance that has been linked to numerous hospitalizations and fatalities within the NBOMe series. The compound must only be administered sublingually, as insufflation dramatically increases overdose risk and has been implicated in multiple deaths. Blotter papers may contain uneven dose distribution with dangerous hotspots. Users should employ accurate microgram scales, avoid all drug combinations, and never exceed 1000 ug due to narrow margin between active and toxic doses. Individuals with cardiovascular conditions, seizure disorders, or personal or family history of psychotic disorders should strictly avoid use. The substance is often misrepresented as LSD; always use reagent testing.\",\n+    \"notes\": \"TMA-6 is a potent MAO-A inhibitor, which creates significant interaction risks and requires careful attention to dietary restrictions similar to pharmaceutical MAOIs. Individuals with personal or family histories of psychotic disorders should avoid use. The substance is highly dose-sensitive and produces unpredictable effects with considerable body load and nausea. Set and setting strongly influence the experience. Users should be prepared for an extended duration of 10-16 hours. Always use a precise scale for dosing.\",\n-      \"Intense Visual Patterning And Geometry\",\n-      \"Strong Physical Stimulation\",\n-      \"Perception Of Bodily Lightness\",\n-      \"Euphoric Body High\",\n+      \"Stimulation\",\n+      \"Spontaneous Tactile Sensations\",\n-      \"Colour Enhancement\",\n-      \"Time Distortion\",\n-      \"Empathy And Sociability Enhancement (Inconsistent)\",\n+      \"Empathy And Sociability Enhancement\",\n-      \"Anxiety And Paranoia\",\n-      \"Mouth Numbing\",\n-      \"Increased Heart Rate\",\n+      \"Conceptual Thinking Enhancement\",\n+      \"Emotion Enhancement\",\n+      \"Time Distortion\",\n+      \"Visual Acuity Enhancement\",\n+      \"Colour Enhancement\",\n+      \"Drifting\",\n+      \"Nausea\",\n-      \"Nausea (Especially During Onset)\",\n-      \"Muscle Tension\",\n-      \"Pupil Dilation\"\n+      \"Increased Libido\",\n+      \"Music Appreciation Enhancement\"\n-      \"full_tolerance\": \"Immediately after use\",\n+      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n-        \"All psychedelics (LSD, psilocybin, mescaline, 2C-x, other NBOMes)\"\n+        \"All psychedelics\",\n+        \"All stimulants\"\n-    \"half_life\": \"1-3 hours (estimated from related compounds)\",\n+    \"half_life\": \"Not well documented; estimated 3-6 hours based on related compounds\",\n-        \"name\": \"Bluelight: The Big & Dandy 25N-NBOMe Thread\",\n-        \"reference\": \"http://www.bluelight.org/vb/threads/539694-The-Big-amp-Dandy-25N-NBOMe-Thread\"\n+        \"name\": \"Erowid TMA-6 Experience Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_TMA6.shtml\"\n-        \"name\": \"Erowid: NBOMe Series Vault\",\n-        \"reference\": \"https://www.erowid.org/chemicals/nbome/\"\n+        \"name\": \"Erowid TMA-6 Comparison Information\",\n+        \"reference\": \"https://erowid.org/chemicals/tma2/tma2_info1.shtml\"\n-        \"name\": \"Frontiers in Neuroscience: NBOMes - Highly Potent and Toxic Alternatives of LSD\",\n-        \"reference\": \"https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2020.00078/full\"\n+        \"name\": \"Isomer Design PiHKAL Entry #162 TMA-6\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=162\"\n-        \"name\": \"Isomer Design: 25N-NBOMe\",\n-        \"reference\": \"https://isomerdesign.com/pihkal/\"\n+        \"name\": \"PsychonautWiki TMA-6\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/TMA-6\"\n-        \"name\": \"PsychonautWiki: 25N-NBOMe\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/25N-NBOMe\"\n+        \"name\": \"Bluelight TMA Series Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/suprise-substance-of-july-the-tma-series.384752/\"\n-        \"name\": \"Wikipedia: 25N-NBOMe\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/25N-NBOMe\"\n+        \"name\": \"Wikipedia 2,4,6-Trimethoxyamphetamine\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/2,4,6-Trimethoxyamphetamine\"\n-  \"id\": 654\n+  \"id\": 655\n\n# 4-MeO-PCP · #656\n\n-  \"title\": \"TMA-6\",\n-  \"index-category\": \"psychedelic; stimulant; research-chemical\",\n+  \"title\": \"4-MeO-PCP\",\n+  \"index-category\": \"dissociative; research-chemical\",\n-    \"drug_name\": \"TMA-6\",\n-    \"chemical_name\": \"1-(2,4,6-Trimethoxyphenyl)propan-2-amine\",\n-    \"alternative_name\": \"\",\n-    \"chemical_class\": \"Psychedelic amphetamine\",\n-    \"psychoactive_class\": \"Psychedelic\",\n-    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; potent MAO-A inhibitor (IC50 400 nM)\",\n+    \"drug_name\": \"4-MeO-PCP\",\n+    \"chemical_name\": \"1-[1-(4-Methoxyphenyl)cyclohexyl]piperidine\",\n+    \"alternative_name\": \"Methoxydine; 4-Methoxyphencyclidine; 4-Methoxy-PCP\",\n+    \"chemical_class\": \"Arylcyclohexylamine\",\n+    \"psychoactive_class\": \"Dissociative\",\n+    \"mechanism_of_action\": \"NMDA receptor antagonist (selective ligand without appreciable dopamine transporter affinity)\",\n-            \"threshold\": \"5-10 mg\",\n-            \"light\": \"10-20 mg\",\n-            \"common\": \"20-35 mg\",\n-            \"strong\": \"35-50 mg\",\n-            \"heavy\": \"50+ mg\"\n+            \"threshold\": \"25 mg\",\n+            \"light\": \"75-100 mg\",\n+            \"common\": \"100-170 mg\",\n+            \"strong\": \"170-250 mg\",\n+            \"heavy\": \"250+ mg\"\n-            \"threshold\": \"5-10 mg\",\n-            \"light\": \"10-15 mg\",\n-            \"common\": \"15-25 mg\",\n-            \"strong\": \"25-35 mg\",\n-            \"heavy\": \"35+ mg\"\n+            \"threshold\": \"15 mg\",\n+            \"light\": \"30-75 mg\",\n+            \"common\": \"75-150 mg\",\n+            \"strong\": \"150+ mg\",\n+            \"heavy\": \"\"\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"5-10 mg\",\n-            \"light\": \"10-15 mg\",\n-            \"common\": \"15-30 mg\",\n-            \"strong\": \"30-40 mg\",\n-            \"heavy\": \"40+ mg\"\n-          }\n-        },\n-        {\n-          \"route\": \"vaporized\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"5-10 mg\",\n-            \"light\": \"10-15 mg\",\n-            \"common\": \"15-25 mg\",\n-            \"strong\": \"25-35 mg\",\n-            \"heavy\": \"35+ mg\"\n-          }\n-            \"total_duration\": \"10-16 hours\",\n-            \"onset\": \"30-90 minutes\",\n-            \"peak\": \"5-8 hours\",\n-            \"offset\": \"3-5 hours\",\n-            \"after_effects\": \"6-18 hours\"\n+            \"total_duration\": \"12-20 hours\",\n+            \"onset\": \"45-120 minutes\",\n+            \"peak\": \"3-7 hours\",\n+            \"offset\": \"6-10 hours\",\n+            \"after_effects\": \"6+ hours\"\n-            \"total_duration\": \"8-12 hours\",\n-            \"onset\": \"10-30 minutes\",\n-            \"peak\": \"4-6 hours\",\n-            \"offset\": \"2-4 hours\",\n-            \"after_effects\": \"6-12 hours\"\n-          },\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ]\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"stages\": {\n-            \"total_duration\": \"8-14 hours\",\n-            \"onset\": \"10-30 minutes\",\n-            \"peak\": \"4-7 hours\",\n-            \"offset\": \"3-5 hours\",\n-            \"after_effects\": \"6-12 hours\"\n-          },\n-          \"canonical_routes\": [\n-            \"rectal\"\n-          ]\n-        },\n-        {\n-          \"route\": \"vaporized\",\n-          \"stages\": {\n-            \"total_duration\": \"6-11 hours\",\n+            \"total_duration\": \"12-18 hours\",\n-            \"offset\": \"2-4 hours\",\n-            \"after_effects\": \"4-12 hours\"\n+            \"offset\": \"3 hours\",\n+            \"after_effects\": \"3 hours\"\n-            \"smoked\"\n+            \"insufflated\"\n-    \"addiction_potential\": \"TMA-6 is not considered habit-forming and has a low potential for psychological dependence. The desire to use it typically decreases with consumption, and rapid tolerance development discourages frequent redosing. It is generally self-regulating.\",\n+    \"addiction_potential\": \"As with other NMDA receptor antagonists, the chronic use of 4-MeO-PCP can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage. The long duration may discourage frequent redosing compared to shorter-acting dissociatives.\",\n-        \"MAOIs (risk of hypertensive crisis and serotonin syndrome; TMA-6 itself is a potent MAO-A inhibitor)\",\n-        \"Lithium (elevated risk of seizures and psychosis)\",\n-        \"Tramadol (lowers seizure threshold)\"\n+        \"Depressants (risk of respiratory depression, unconsciousness, vomiting and aspiration)\"\n-        \"Serotonin releasers (MDMA, 4-FA, methamphetamine, methylone, aMT; risk of serotonin syndrome)\",\n-        \"Stimulants (risk of excessive anxiety, panic, thought loops, and psychosis)\"\n+        \"Stimulants (increased risk of anxiety, mania, delusions and psychosis)\"\n-      \"caution\": [\n-        \"SSRIs (citalopram, sertraline; risk of serotonin syndrome and altered effects)\",\n-        \"SNRIs (venlafaxine; risk of serotonin syndrome)\",\n-        \"5-HTP (risk of serotonin syndrome)\",\n-        \"Other psychedelics (risk of overwhelming intensity and unpredictable interactions)\"\n-      ]\n+      \"caution\": []\n-    \"notes\": \"TMA-6 is a potent MAO-A inhibitor, which creates significant interaction risks and requires careful attention to dietary restrictions similar to pharmaceutical MAOIs. Individuals with personal or family histories of psychotic disorders should avoid use. The substance is highly dose-sensitive and produces unpredictable effects with considerable body load and nausea. Set and setting strongly influence the experience. Users should be prepared for an extended duration of 10-16 hours. Always use a precise scale for dosing.\",\n+    \"notes\": \"4-MeO-PCP is a long-acting dissociative with approximately 70% the potency of PCP. Users have reported substantial differences in active dose; these discrepancies may be partially explained by the presence of unreacted PCC and other impurities in samples sold on the grey market. Use a precise milligram scale for dosing. The extended duration of action can be both an advantage and disadvantage, with effects and after-effects persisting well into the next day. Chronic use may lead to urinary tract issues similar to ketamine, though less severe due to higher potency requiring smaller amounts. Set and setting are important, and users should avoid potentially hazardous activities during the experience.\",\n-      \"Stimulation\",\n-      \"Spontaneous Tactile Sensations\",\n-      \"Tactile Enhancement\",\n-      \"Empathy And Sociability Enhancement\",\n-      \"Thought Acceleration\",\n-      \"Conceptual Thinking Enhancement\",\n-      \"Emotion Enhancement\",\n+      \"Consciousness Disconnection\",\n+      \"Visual Disconnection\",\n+      \"Dizziness\",\n+      \"Motor Control Loss\",\n+      \"Physical Euphoria\",\n+      \"Spatial Disorientation\",\n+      \"Tactile Suppression\",\n+      \"Depersonalization\",\n+      \"Derealization\",\n+      \"Amnesia\",\n-      \"Visual Acuity Enhancement\",\n-      \"Colour Enhancement\",\n-      \"Drifting\",\n-      \"Nausea\",\n-      \"Vasoconstriction\",\n-      \"Increased Libido\",\n-      \"Music Appreciation Enhancement\"\n+      \"Creativity Enhancement\",\n+      \"Immersion Enhancement\",\n+      \"Increased Music Appreciation\",\n+      \"Internal Hallucinations\"\n-      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n-      \"half_tolerance\": \"3 days\",\n-      \"zero_tolerance\": \"7 days\",\n+      \"full_tolerance\": \"After prolonged and repeated use\",\n+      \"half_tolerance\": \"3-7 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n-        \"All psychedelics\",\n-        \"All stimulants\"\n+        \"All dissociatives\"\n-    \"half_life\": \"Not well documented; estimated 3-6 hours based on related compounds\",\n+    \"half_life\": \"\",\n-        \"name\": \"Erowid TMA-6 Experience Vault\",\n-        \"reference\": \"https://erowid.org/experiences/subs/exp_TMA6.shtml\"\n+        \"name\": \"Bluelight: The Big & Dandy 4-MeO-PCP Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-4-meo-pcp-thread.391328/\"\n-        \"name\": \"Erowid TMA-6 Comparison Information\",\n-        \"reference\": \"https://erowid.org/chemicals/tma2/tma2_info1.shtml\"\n+        \"name\": \"Erowid 4-MeO-PCP Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/4meo_pcp/4meo_pcp.shtml\"\n-        \"name\": \"Isomer Design PiHKAL Entry #162 TMA-6\",\n-        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=162\"\n+        \"name\": \"Isomer Design: 4-MeO-PCP\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=963\"\n-        \"name\": \"PsychonautWiki TMA-6\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/TMA-6\"\n+        \"name\": \"Morris H, Wallach J. From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs\",\n+        \"reference\": \"https://doi.org/10.1002/dta.1620\"\n-        \"name\": \"Bluelight TMA Series Thread\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/suprise-substance-of-july-the-tma-series.384752/\"\n+        \"name\": \"PsychonautWiki: 4-MeO-PCP\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/4-MeO-PCP\"\n-        \"name\": \"Wikipedia 2,4,6-Trimethoxyamphetamine\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/2,4,6-Trimethoxyamphetamine\"\n+        \"name\": \"Roth BL et al. The Ketamine Analogue Methoxetamine and 3- and 4-Methoxy Analogues of Phencyclidine Are High Affinity and Selective Ligands for the Glutamate NMDA Receptor\",\n+        \"reference\": \"https://doi.org/10.1371/journal.pone.0059334\"\n-      \"psychedelic\",\n+      \"dissociative\",\n+      \"arylcyclohexylamine\",\n-  \"id\": 655\n+  \"id\": 656\n\n# PCE · #657\n\n-  \"title\": \"4-MeO-PCP\",\n+  \"title\": \"PCE\",\n-    \"drug_name\": \"4-MeO-PCP\",\n-    \"chemical_name\": \"1-[1-(4-Methoxyphenyl)cyclohexyl]piperidine\",\n-    \"alternative_name\": \"Methoxydine; 4-Methoxyphencyclidine; 4-Methoxy-PCP\",\n+    \"drug_name\": \"PCE\",\n+    \"chemical_name\": \"N-Ethyl-1-phenylcyclohexanamine\",\n+    \"alternative_name\": \"Eticyclidine; CI-400; Cyclohexamine\",\n-    \"mechanism_of_action\": \"NMDA receptor antagonist (selective ligand without appreciable dopamine transporter affinity)\",\n+    \"mechanism_of_action\": \"NMDA receptor antagonist (noncompetitive); dopamine-noradrenaline reuptake inhibitor; serotonin reuptake inhibitor; suspected mu-opioid receptor affinity\",\n-            \"threshold\": \"25 mg\",\n-            \"light\": \"75-100 mg\",\n-            \"common\": \"100-170 mg\",\n-            \"strong\": \"170-250 mg\",\n-            \"heavy\": \"250+ mg\"\n+            \"threshold\": \"1 mg\",\n+            \"light\": \"3-5 mg\",\n+            \"common\": \"5-10 mg\",\n+            \"strong\": \"10-15 mg\",\n+            \"heavy\": \"15+ mg\"\n-            \"threshold\": \"15 mg\",\n-            \"light\": \"30-75 mg\",\n-            \"common\": \"75-150 mg\",\n-            \"strong\": \"150+ mg\",\n-            \"heavy\": \"\"\n+            \"threshold\": \"1 mg\",\n+            \"light\": \"3-5 mg\",\n+            \"common\": \"5-10 mg\",\n+            \"strong\": \"10-15 mg\",\n+            \"heavy\": \"15+ mg\"\n+        },\n+        {\n+          \"route\": \"smoked\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"1 mg\",\n+            \"light\": \"3-5 mg\",\n+            \"common\": \"5-10 mg\",\n+            \"strong\": \"10-15 mg\",\n+            \"heavy\": \"15+ mg\"\n+          }\n-            \"total_duration\": \"12-20 hours\",\n-            \"onset\": \"45-120 minutes\",\n-            \"peak\": \"3-7 hours\",\n-            \"offset\": \"6-10 hours\",\n-            \"after_effects\": \"6+ hours\"\n+            \"total_duration\": \"4-8 hours\",\n+            \"onset\": \"30-90 minutes\",\n+            \"peak\": \"2-3 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"4-48 hours\"\n-            \"total_duration\": \"12-18 hours\",\n-            \"onset\": \"5-15 minutes\",\n-            \"peak\": \"3-6 hours\",\n-            \"offset\": \"3 hours\",\n-            \"after_effects\": \"3 hours\"\n+            \"total_duration\": \"4-8 hours\",\n+            \"onset\": \"20-60 minutes\",\n+            \"peak\": \"2-3 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"4-48 hours\"\n+        },\n+        {\n+          \"route\": \"smoked\",\n+          \"stages\": {\n+            \"total_duration\": \"4-8 hours\",\n+            \"onset\": \"30-90 minutes\",\n+            \"peak\": \"2-3 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"4-48 hours\"\n+          }\n-    \"addiction_potential\": \"As with other NMDA receptor antagonists, the chronic use of 4-MeO-PCP can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage. The long duration may discourage frequent redosing compared to shorter-acting dissociatives.\",\n+    \"addiction_potential\": \"The chronic use of PCE can be considered highly addictive with a high potential for adverse side effects such as psychosis. In comparison to other dissociatives, PCE has been reported to be more addictive than MXE, diphenidine, ephenidine, and ketamine. Multiple reports exist of people becoming seriously addicted daily users of this substance.\",\n-        \"Depressants (risk of respiratory depression, unconsciousness, vomiting and aspiration)\"\n+        \"Depressants (increased risk of unconsciousness, vomiting, and fatal suffocation)\"\n-        \"Stimulants (increased risk of anxiety, mania, delusions and psychosis)\"\n+        \"Psychedelics (extreme psychological disturbances, psychosis, and mania at significantly higher rates)\",\n+        \"Stimulants (increased risk of anxiety, mania, delusions, and psychosis)\"\n-    \"notes\": \"4-MeO-PCP is a long-acting dissociative with approximately 70% the potency of PCP. Users have reported substantial differences in active dose; these discrepancies may be partially explained by the presence of unreacted PCC and other impurities in samples sold on the grey market. Use a precise milligram scale for dosing. The extended duration of action can be both an advantage and disadvantage, with effects and after-effects persisting well into the next day. Chronic use may lead to urinary tract issues similar to ketamine, though less severe due to higher potency requiring smaller amounts. Set and setting are important, and users should avoid potentially hazardous activities during the experience.\",\n+    \"notes\": \"PCE is a potent dissociative that causes psychosis and mania at significantly higher rates than other dissociatives. Users should avoid taking the drug multiple days in a row or in high doses. Volumetric liquid dosing is strongly recommended due to the drug's extreme potency, as most standard milligram scales cannot accurately weigh doses below 10-15 mg. Compulsive redosing should be avoided. Long-term use may lead to severe memory loss, disorganized thinking, bladder and urinary tract problems, and schizophrenia-like psychotic episodes. Individuals with personal or family histories of psychotic disorders should avoid use. PCE is internationally controlled as a Schedule I substance.\",\n-      \"Consciousness Disconnection\",\n-      \"Visual Disconnection\",\n-      \"Dizziness\",\n-      \"Motor Control Loss\",\n-      \"Spatial Disorientation\",\n+      \"Motor Control Loss\",\n+      \"Visual Disconnection\",\n+      \"Consciousness Disconnection\",\n+      \"Visual Acuity Suppression\",\n+      \"Cognitive Euphoria\",\n+      \"Thought Acceleration\",\n-      \"Amnesia\",\n-      \"Time Distortion\",\n-      \"Creativity Enhancement\",\n-      \"Immersion Enhancement\",\n-      \"Increased Music Appreciation\",\n-      \"Internal Hallucinations\"\n+      \"Memory Suppression\",\n+      \"Ego Death\",\n+      \"Mania\",\n+      \"Delusion\",\n+      \"Disinhibition\",\n+      \"Compulsive Redosing\",\n+      \"Nausea\"\n-        \"name\": \"Bluelight: The Big & Dandy 4-MeO-PCP Thread\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-4-meo-pcp-thread.391328/\"\n+        \"name\": \"Bluelight PCE Bioassay Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/pce-bioassay-eight-human-trials-with-the-unicorn-dissociative-eticyclidine.927036/\"\n-        \"name\": \"Erowid 4-MeO-PCP Vault\",\n-        \"reference\": \"https://www.erowid.org/chemicals/4meo_pcp/4meo_pcp.shtml\"\n+        \"name\": \"Bluelight PCE Small & Handy Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-small-handy-pce-eticyclidine-thread.919539/\"\n-        \"name\": \"Isomer Design: 4-MeO-PCP\",\n-        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=963\"\n+        \"name\": \"Erowid PCE Experience Reports\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_PCE.shtml\"\n-        \"name\": \"Morris H, Wallach J. From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs\",\n+        \"name\": \"Morris & Wallach 2014: From PCP to MXE\",\n-        \"name\": \"PsychonautWiki: 4-MeO-PCP\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/4-MeO-PCP\"\n-      },\n-      {\n-        \"name\": \"Roth BL et al. The Ketamine Analogue Methoxetamine and 3- and 4-Methoxy Analogues of Phencyclidine Are High Affinity and Selective Ligands for the Glutamate NMDA Receptor\",\n-        \"reference\": \"https://doi.org/10.1371/journal.pone.0059334\"\n+        \"name\": \"PsychonautWiki: PCE\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/PCE\"\n-  \"id\": 656\n+  \"id\": 657\n\n# Nitrous Oxide · #658\n\n-  \"title\": \"PCE\",\n-  \"index-category\": \"dissociative; research-chemical\",\n+  \"title\": \"Nitrous Oxide\",\n+  \"index-category\": \"dissociative; inhalant\",\n-    \"drug_name\": \"PCE\",\n-    \"chemical_name\": \"N-Ethyl-1-phenylcyclohexanamine\",\n-    \"alternative_name\": \"Eticyclidine; CI-400; Cyclohexamine\",\n-    \"chemical_class\": \"Arylcyclohexylamine\",\n+    \"drug_name\": \"Nitrous Oxide\",\n+    \"chemical_name\": \"Dinitrogen monoxide\",\n+    \"alternative_name\": \"Laughing Gas; Nitrous; NOS; Hippy Crack; N2O; Nangs; Whippits; Nitro\",\n+    \"chemical_class\": \"Nitrogen oxide\",\n-    \"mechanism_of_action\": \"NMDA receptor antagonist (noncompetitive); dopamine-noradrenaline reuptake inhibitor; serotonin reuptake inhibitor; suspected mu-opioid receptor affinity\",\n+    \"mechanism_of_action\": \"NMDA receptor antagonist (primary); GABA-A receptor potentiation; glycine receptor potentiation; nACh receptor antagonist (beta2-subunit); two-pore-domain K+ channel activation\",\n-          \"route\": \"oral\",\n-          \"units\": \"mg\",\n+          \"route\": \"inhaled\",\n+          \"units\": \"g\",\n-            \"threshold\": \"1 mg\",\n-            \"light\": \"3-5 mg\",\n-            \"common\": \"5-10 mg\",\n-            \"strong\": \"10-15 mg\",\n-            \"heavy\": \"15+ mg\"\n+            \"threshold\": \"4 g\",\n+            \"light\": \"4-8 g (0.5-1 cartridge)\",\n+            \"common\": \"8-16 g (1-2 cartridges)\",\n+            \"strong\": \"16-40 g (2-5 cartridges)\",\n+            \"heavy\": \"40+ g (5+ cartridges)\"\n-        },\n-        {\n-          \"route\": \"insufflated\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"1 mg\",\n-            \"light\": \"3-5 mg\",\n-            \"common\": \"5-10 mg\",\n-            \"strong\": \"10-15 mg\",\n-            \"heavy\": \"15+ mg\"\n-          }\n-        },\n-        {\n-          \"route\": \"smoked\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"1 mg\",\n-            \"light\": \"3-5 mg\",\n-            \"common\": \"5-10 mg\",\n-            \"strong\": \"10-15 mg\",\n-            \"heavy\": \"15+ mg\"\n-          }\n-          \"route\": \"oral\",\n+          \"route\": \"inhaled\",\n-            \"total_duration\": \"4-8 hours\",\n-            \"onset\": \"30-90 minutes\",\n-            \"peak\": \"2-3 hours\",\n-            \"offset\": \"1-2 hours\",\n-            \"after_effects\": \"4-48 hours\"\n+            \"total_duration\": \"1-5 minutes\",\n+            \"onset\": \"5-10 seconds\",\n+            \"peak\": \"15-30 seconds\",\n+            \"offset\": \"1-5 minutes\",\n+            \"after_effects\": \"15-30 minutes\"\n-            \"oral\"\n+            \"inhaled\"\n-        },\n-        {\n-          \"route\": \"insufflated\",\n-          \"stages\": {\n-            \"total_duration\": \"4-8 hours\",\n-            \"onset\": \"20-60 minutes\",\n-            \"peak\": \"2-3 hours\",\n-            \"offset\": \"1-2 hours\",\n-            \"after_effects\": \"4-48 hours\"\n-          },\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ]\n-        },\n-        {\n-          \"route\": \"smoked\",\n-          \"stages\": {\n-            \"total_duration\": \"4-8 hours\",\n-            \"onset\": \"30-90 minutes\",\n-            \"peak\": \"2-3 hours\",\n-            \"offset\": \"1-2 hours\",\n-            \"after_effects\": \"4-48 hours\"\n-          }\n-    \"addiction_potential\": \"The chronic use of PCE can be considered highly addictive with a high potential for adverse side effects such as psychosis. In comparison to other dissociatives, PCE has been reported to be more addictive than MXE, diphenidine, ephenidine, and ketamine. Multiple reports exist of people becoming seriously addicted daily users of this substance.\",\n+    \"addiction_potential\": \"Nitrous oxide is considered to have low to moderate abuse potential and low physical addiction potential. However, it is strongly psychologically compelling due to its brief duration and powerful effects, which can lead to compulsive redosing during a session. Frequent use is rare due to rapid tolerance development.\",\n-        \"Depressants (increased risk of unconsciousness, vomiting, and fatal suffocation)\"\n+        \"Alcohol (risk of unconsciousness, vomit aspiration, memory blackouts)\",\n+        \"GHB/GBL (risk of unconsciousness, vomit aspiration, ataxia)\",\n+        \"Opioids (risk of unconsciousness, vomit aspiration, respiratory depression)\",\n+        \"Tramadol (risk of unconsciousness, vomit aspiration)\"\n-      \"unsafe\": [\n-        \"Psychedelics (extreme psychological disturbances, psychosis, and mania at significantly higher rates)\",\n-        \"Stimulants (increased risk of anxiety, mania, delusions, and psychosis)\"\n-      ],\n-      \"caution\": []\n+      \"unsafe\": [],\n+      \"caution\": [\n+        \"Cannabis (potentiates effects)\",\n+        \"Psychedelics (dramatically intensifies visuals and ego dissolution)\",\n+        \"Dissociatives (intensifies disconnection and internal hallucinations)\",\n+        \"MDMA (may cause nausea)\"\n+      ]\n-    \"notes\": \"PCE is a potent dissociative that causes psychosis and mania at significantly higher rates than other dissociatives. Users should avoid taking the drug multiple days in a row or in high doses. Volumetric liquid dosing is strongly recommended due to the drug's extreme potency, as most standard milligram scales cannot accurately weigh doses below 10-15 mg. Compulsive redosing should be avoided. Long-term use may lead to severe memory loss, disorganized thinking, bladder and urinary tract problems, and schizophrenia-like psychotic episodes. Individuals with personal or family histories of psychotic disorders should avoid use. PCE is internationally controlled as a Schedule I substance.\",\n+    \"notes\": \"Nitrous oxide can cause severe and potentially irreversible vitamin B12 depletion with frequent or chronic use, leading to serious neurological damage including numbness, tingling, and motor control loss. Always supplement with vitamin B12 when using this substance. Never inhale directly from cartridges or tanks due to extreme cold temperature (-40C) which can cause frostbite to lips, throat, and lungs, and high pressure which can rupture lung tissue. Always release gas into a balloon first to warm and depressurize. Ensure adequate oxygen intake between inhalations to prevent hypoxia and brain damage. Use while seated to prevent injury from falls. Filter gas through cloth or cotton to remove metal particles and industrial residue from food-grade cartridges.\",\n-      \"Tactile Suppression\",\n-      \"Motor Control Loss\",\n-      \"Visual Disconnection\",\n-      \"Consciousness Disconnection\",\n-      \"Visual Acuity Suppression\",\n-      \"Thought Acceleration\",\n-      \"Depersonalization\",\n-      \"Derealization\",\n-      \"Memory Suppression\",\n+      \"Auditory Distortion\",\n+      \"Visual Geometry\",\n-      \"Mania\",\n-      \"Delusion\",\n-      \"Disinhibition\",\n-      \"Compulsive Redosing\",\n-      \"Nausea\"\n+      \"Laughter Fits\",\n+      \"Motor Control Loss\",\n+      \"Dissociation\",\n+      \"Time Distortion\",\n+      \"Sedation\",\n+      \"Dizziness\",\n+      \"Tactile Suppression\"\n-      \"full_tolerance\": \"After prolonged and repeated use\",\n+      \"full_tolerance\": \"After 2-4 consecutive uses within hours\",\n-      \"cross_tolerances\": [\n-        \"All dissociatives\"\n-      ]\n+      \"cross_tolerances\": []\n-    \"half_life\": \"\",\n+    \"half_life\": \"5-10 minutes (less than 0.004% metabolized)\",\n-        \"name\": \"Bluelight PCE Bioassay Thread\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/pce-bioassay-eight-human-trials-with-the-unicorn-dissociative-eticyclidine.927036/\"\n+        \"name\": \"PsychonautWiki: Nitrous Oxide\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Nitrous\"\n-        \"name\": \"Bluelight PCE Small & Handy Thread\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/the-small-handy-pce-eticyclidine-thread.919539/\"\n+        \"name\": \"TripSit Nitrous Oxide Factsheet\",\n+        \"reference\": \"https://tripsit.me/factsheets/nitrous\"\n-        \"name\": \"Erowid PCE Experience Reports\",\n-        \"reference\": \"https://erowid.org/experiences/subs/exp_PCE.shtml\"\n+        \"name\": \"TripSit Wiki: Nitrous Oxide\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/Nitrous_Oxide\"\n-        \"name\": \"Morris & Wallach 2014: From PCP to MXE\",\n-        \"reference\": \"https://doi.org/10.1002/dta.1620\"\n+        \"name\": \"Erowid Nitrous Oxide Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/nitrous/nitrous.shtml\"\n-        \"name\": \"PsychonautWiki: PCE\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/PCE\"\n+        \"name\": \"Erowid Nitrous Oxide Basics\",\n+        \"reference\": \"https://www.erowid.org/chemicals/nitrous/nitrous_basics.shtml\"\n+      },\n+      {\n+        \"name\": \"Erowid Nitrous Oxide Effects\",\n+        \"reference\": \"https://www.erowid.org/chemicals/nitrous/nitrous_effects.shtml\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy Nitrous Thread (FAQ)\",\n+        \"reference\": \"https://bluelight.org/xf/threads/nitrous-oxide-whippits-nangs-johnny-gas-n2o-faq.54176/\"\n+      },\n+      {\n+        \"name\": \"DanceWize NSW: Nitrous Oxide Harm Reduction\",\n+        \"reference\": \"https://hi-ground.org/substances/nitrous-oxide/\"\n-      \"arylcyclohexylamine\",\n-      \"research-chemical\"\n+      \"inhalant\",\n+      \"anesthetic\"\n-  \"id\": 657\n+  \"id\": 658\n\n# Benzydamine · #659\n\n-  \"title\": \"Nitrous Oxide\",\n-  \"index-category\": \"dissociative; inhalant\",\n+  \"title\": \"Benzydamine\",\n+  \"index-category\": \"deliriant; stimulant\",\n-    \"drug_name\": \"Nitrous Oxide\",\n-    \"chemical_name\": \"Dinitrogen monoxide\",\n-    \"alternative_name\": \"Laughing Gas; Nitrous; NOS; Hippy Crack; N2O; Nangs; Whippits; Nitro\",\n-    \"chemical_class\": \"Nitrogen oxide\",\n-    \"psychoactive_class\": \"Dissociative\",\n-    \"mechanism_of_action\": \"NMDA receptor antagonist (primary); GABA-A receptor potentiation; glycine receptor potentiation; nACh receptor antagonist (beta2-subunit); two-pore-domain K+ channel activation\",\n+    \"drug_name\": \"Benzydamine\",\n+    \"chemical_name\": \"3-(1-Benzyl-1H-indazol-3-yloxy)-N,N-dimethylpropan-1-amine\",\n+    \"alternative_name\": \"Tantum Verde; Difflam; Benflogin; Andole\",\n+    \"chemical_class\": \"Indazoles\",\n+    \"psychoactive_class\": \"Deliriant; Stimulant\",\n+    \"mechanism_of_action\": \"Possible CB1 cannabinoid receptor agonist (speculated); possible 5-HT2A receptor agonist (speculated); prostaglandin synthetase inhibitor; mechanism underlying hallucinogenic effects remains unstudied\",\n-          \"route\": \"inhaled\",\n-          \"units\": \"g\",\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"4 g\",\n-            \"light\": \"4-8 g (0.5-1 cartridge)\",\n-            \"common\": \"8-16 g (1-2 cartridges)\",\n-            \"strong\": \"16-40 g (2-5 cartridges)\",\n-            \"heavy\": \"40+ g (5+ cartridges)\"\n+            \"threshold\": \"150 mg\",\n+            \"light\": \"300-500 mg\",\n+            \"common\": \"500-1000 mg\",\n+            \"strong\": \"1000-2000 mg\",\n+            \"heavy\": \"2000+ mg\"\n-          \"route\": \"inhaled\",\n+          \"route\": \"oral\",\n-            \"total_duration\": \"1-5 minutes\",\n-            \"onset\": \"5-10 seconds\",\n-            \"peak\": \"15-30 seconds\",\n-            \"offset\": \"1-5 minutes\",\n-            \"after_effects\": \"15-30 minutes\"\n+            \"total_duration\": \"5-8 hours\",\n+            \"onset\": \"20-60 minutes\",\n+            \"peak\": \"3-6 hours\",\n+            \"offset\": \"3-8 hours\",\n+            \"after_effects\": \"24-72 hours (residual stimulation and insomnia)\"\n-            \"inhaled\"\n+            \"oral\"\n-    \"addiction_potential\": \"Nitrous oxide is considered to have low to moderate abuse potential and low physical addiction potential. However, it is strongly psychologically compelling due to its brief duration and powerful effects, which can lead to compulsive redosing during a session. Frequent use is rare due to rapid tolerance development.\",\n+    \"addiction_potential\": \"Benzydamine exhibits powerful reinforcing effects in animal models and shows cross-sensitization with drugs like heroin and cocaine. Individuals with prior substance abuse history may be at significantly higher risk for developing benzydamine dependence due to neurobiological sensitivity to its effects.\",\n-      \"dangerous\": [\n-        \"Alcohol (risk of unconsciousness, vomit aspiration, memory blackouts)\",\n-        \"GHB/GBL (risk of unconsciousness, vomit aspiration, ataxia)\",\n-        \"Opioids (risk of unconsciousness, vomit aspiration, respiratory depression)\",\n-        \"Tramadol (risk of unconsciousness, vomit aspiration)\"\n+      \"dangerous\": [],\n+      \"unsafe\": [\n+        \"Other deliriants (overwhelming and unpredictable effects)\",\n+        \"Stimulants (increased cardiovascular stress and anxiety)\"\n-      \"unsafe\": [],\n-        \"Cannabis (potentiates effects)\",\n-        \"Psychedelics (dramatically intensifies visuals and ego dissolution)\",\n-        \"Dissociatives (intensifies disconnection and internal hallucinations)\",\n-        \"MDMA (may cause nausea)\"\n+        \"Alcohol (commonly combined; may exacerbate dehydration and confusion)\",\n+        \"Cannabis (frequently co-used by recreational users)\",\n+        \"Benzodiazepines (may blunt effects but can increase confusion)\",\n+        \"CNS depressants (may create unpredictable interactions)\"\n-    \"notes\": \"Nitrous oxide can cause severe and potentially irreversible vitamin B12 depletion with frequent or chronic use, leading to serious neurological damage including numbness, tingling, and motor control loss. Always supplement with vitamin B12 when using this substance. Never inhale directly from cartridges or tanks due to extreme cold temperature (-40C) which can cause frostbite to lips, throat, and lungs, and high pressure which can rupture lung tissue. Always release gas into a balloon first to warm and depressurize. Ensure adequate oxygen intake between inhalations to prevent hypoxia and brain damage. Use while seated to prevent injury from falls. Filter gas through cloth or cotton to remove metal particles and industrial residue from food-grade cartridges.\",\n+    \"notes\": \"Benzydamine products, particularly Tantum Rosa vaginal douching sachets, contain dangerous levels of sodium chloride that can cause severe kidney damage if ingested directly. Proper salt extraction using water filtration is essential before consumption. The substance causes severe and prolonged insomnia lasting up to 48 hours, producing taxing sleep deprivation that often triggers paranoia. Legal and available over-the-counter in many countries for legitimate throat and mouth inflammation treatment. Individuals with personal or family history of psychotic disorders should avoid use due to risk of persistent psychotic symptoms.\",\n-      \"Physical Euphoria\",\n-      \"Cognitive Euphoria\",\n-      \"Auditory Distortion\",\n-      \"Visual Geometry\",\n-      \"Ego Death\",\n-      \"Laughter Fits\",\n+      \"Intense Stimulation\",\n+      \"External Hallucinations (Shadow People, Animals, Autonomous Entities)\",\n+      \"Auditory Hallucinations\",\n+      \"Visual Tracers and After Images\",\n+      \"Delirium and Confusion\",\n+      \"Anxiety and Paranoia\",\n+      \"Feelings of Impending Doom\",\n+      \"Euphoria (During Onset Only)\",\n-      \"Dissociation\",\n+      \"Tactile Suppression\",\n-      \"Sedation\",\n-      \"Dizziness\",\n-      \"Tactile Suppression\"\n+      \"Frequent Urination\",\n+      \"Dehydration\"\n-      \"full_tolerance\": \"After 2-4 consecutive uses within hours\",\n+      \"full_tolerance\": \"Develops rapidly with consecutive use\",\n-      \"cross_tolerances\": []\n+      \"cross_tolerances\": [\n+        \"Other deliriants (e.g., diphenhydramine, datura)\"\n+      ]\n-    \"half_life\": \"5-10 minutes (less than 0.004% metabolized)\",\n+    \"half_life\": \"7-8 hours\",\n-        \"name\": \"PsychonautWiki: Nitrous Oxide\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/Nitrous\"\n+        \"name\": \"PsychonautWiki: Benzydamine\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Benzydamine\"\n-        \"name\": \"TripSit Nitrous Oxide Factsheet\",\n-        \"reference\": \"https://tripsit.me/factsheets/nitrous\"\n+        \"name\": \"Erowid Benzydamine Experience Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_Benzydamine.shtml\"\n-        \"name\": \"TripSit Wiki: Nitrous Oxide\",\n-        \"reference\": \"https://wiki.tripsit.me/wiki/Nitrous_Oxide\"\n+        \"name\": \"Bluelight: Benzydamine Discussion Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/benzydamine-nsaid-stimulant-psychedelic.353442/\"\n-        \"name\": \"Erowid Nitrous Oxide Vault\",\n-        \"reference\": \"https://www.erowid.org/chemicals/nitrous/nitrous.shtml\"\n+        \"name\": \"Drugs-Forum: Benzydamine Discussion\",\n+        \"reference\": \"https://drugs-forum.com/threads/so-i-have-benzydamine-hcl-a-deliriant.295883/\"\n-        \"name\": \"Erowid Nitrous Oxide Basics\",\n-        \"reference\": \"https://www.erowid.org/chemicals/nitrous/nitrous_basics.shtml\"\n+        \"name\": \"The Benzydamine Experience: A Systematic Review\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC8977632/\"\n-        \"name\": \"Erowid Nitrous Oxide Effects\",\n-        \"reference\": \"https://www.erowid.org/chemicals/nitrous/nitrous_effects.shtml\"\n-      },\n-      {\n-        \"name\": \"Bluelight: The Big & Dandy Nitrous Thread (FAQ)\",\n-        \"reference\": \"https://bluelight.org/xf/threads/nitrous-oxide-whippits-nangs-johnny-gas-n2o-faq.54176/\"\n-      },\n-      {\n-        \"name\": \"DanceWize NSW: Nitrous Oxide Harm Reduction\",\n-        \"reference\": \"https://hi-ground.org/substances/nitrous-oxide/\"\n+        \"name\": \"Benzydamine - An Affordable OTC Drug with Psychoactive Properties\",\n+        \"reference\": \"https://www.mdpi.com/1424-8247/16/4/566\"\n-      \"dissociative\",\n-      \"inhalant\",\n-      \"anesthetic\"\n+      \"deliriant\",\n+      \"stimulant\",\n+      \"indazole\",\n+      \"research-chemical\"\n-  \"id\": 658\n+  \"id\": 659",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251018-182735-baddc987",
    "createdAt": "2025-10-18T18:27:35.939Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Remove MGM-15 - 18/10/2025, 20:27:33"
    },
    "articles": [
      {
        "id": 615,
        "title": "Amobarbital",
        "slug": "amobarbital"
      },
      {
        "id": 616,
        "title": "AKB-57",
        "slug": "akb-57"
      },
      {
        "id": 530,
        "title": "Ro5-4864",
        "slug": "ro5-4864"
      },
      {
        "id": 617,
        "title": "2-MMC",
        "slug": "2-mmc"
      },
      {
        "id": 450,
        "title": "Pyrovalerone",
        "slug": "pyrovalerone"
      },
      {
        "id": 174,
        "title": "Carisoprodol",
        "slug": "carisoprodol"
      },
      {
        "id": 618,
        "title": "4-Cl-PPP",
        "slug": "4-cl-ppp"
      },
      {
        "id": 619,
        "title": "4-CBC (4-Chlorobuphedrone)",
        "slug": "4-cbc-4-chlorobuphedrone"
      },
      {
        "id": 620,
        "title": "4-FPP",
        "slug": "4-fpp"
      },
      {
        "id": 621,
        "title": "4-MEPPP",
        "slug": "4-meppp"
      },
      {
        "id": 622,
        "title": "4-MXP",
        "slug": "4-mxp"
      },
      {
        "id": 623,
        "title": "5-AEDB",
        "slug": "5-aedb"
      },
      {
        "id": 625,
        "title": "5-Cl-AMT",
        "slug": "5-cl-amt"
      },
      {
        "id": 626,
        "title": "Diphenhydramine",
        "slug": "diphenhydramine"
      },
      {
        "id": 627,
        "title": "Diphenhydramine",
        "slug": "diphenhydramine"
      },
      {
        "id": 628,
        "title": "1V-LSD",
        "slug": "1v-lsd"
      },
      {
        "id": 629,
        "title": "ALD-52",
        "slug": "ald-52"
      },
      {
        "id": 630,
        "title": "ETH-LAD",
        "slug": "eth-lad"
      },
      {
        "id": 631,
        "title": "LSA",
        "slug": "lsa"
      },
      {
        "id": 632,
        "title": "MiPLA",
        "slug": "mipla"
      },
      {
        "id": 633,
        "title": "MET",
        "slug": "met"
      },
      {
        "id": 634,
        "title": "LSM-775",
        "slug": "lsm-775"
      },
      {
        "id": 635,
        "title": "PRO-LAD",
        "slug": "pro-lad"
      },
      {
        "id": 636,
        "title": "DET",
        "slug": "det"
      },
      {
        "id": 637,
        "title": "EPT",
        "slug": "ept"
      },
      {
        "id": 638,
        "title": "4-AcO-DiPT",
        "slug": "4-aco-dipt"
      },
      {
        "id": 639,
        "title": "4-AcO-MiPT",
        "slug": "4-aco-mipt"
      },
      {
        "id": 640,
        "title": "4-HO-DET",
        "slug": "4-ho-det"
      },
      {
        "id": 641,
        "title": "4-HO-DiPT",
        "slug": "4-ho-dipt"
      },
      {
        "id": 642,
        "title": "4-HO-EPT",
        "slug": "4-ho-ept"
      },
      {
        "id": 643,
        "title": "4-HO-MPT",
        "slug": "4-ho-mpt"
      },
      {
        "id": 644,
        "title": "5-MeO-DiPT",
        "slug": "5-meo-dipt"
      },
      {
        "id": 645,
        "title": "Psilocin",
        "slug": "psilocin"
      },
      {
        "id": 646,
        "title": "Allylescaline",
        "slug": "allylescaline"
      },
      {
        "id": 647,
        "title": "Escaline",
        "slug": "escaline"
      },
      {
        "id": 648,
        "title": "Proscaline",
        "slug": "proscaline"
      },
      {
        "id": 649,
        "title": "2C-T",
        "slug": "2c-t"
      },
      {
        "id": 650,
        "title": "2,5-DMA",
        "slug": "2-5-dma"
      },
      {
        "id": 651,
        "title": "DOI",
        "slug": "doi"
      },
      {
        "id": 652,
        "title": "25C-NBOH",
        "slug": "25c-nboh"
      },
      {
        "id": 653,
        "title": "25D-NBOMe",
        "slug": "25d-nbome"
      },
      {
        "id": 654,
        "title": "25N-NBOMe",
        "slug": "25n-nbome"
      },
      {
        "id": 655,
        "title": "TMA-6",
        "slug": "tma-6"
      },
      {
        "id": 656,
        "title": "4-MeO-PCP",
        "slug": "4-meo-pcp"
      },
      {
        "id": 657,
        "title": "PCE",
        "slug": "pce"
      },
      {
        "id": 658,
        "title": "Nitrous Oxide",
        "slug": "nitrous-oxide"
      },
      {
        "id": 659,
        "title": "Benzydamine",
        "slug": "benzydamine"
      }
    ],
    "markdown": "# Amobarbital · #615\n\n-  \"id\": 614,\n-  \"title\": \"MGM-15\",\n+  \"id\": 615,\n+  \"title\": \"Amobarbital\",\n-    \"drug_name\": \"MGM-15\",\n-    \"chemical_name\": \"MGM-15\",\n+    \"drug_name\": \"Amobarbital\",\n+    \"chemical_name\": \"Amobarbital\",\n-    \"chemical_class\": \"Indole alkaloids\",\n-    \"psychoactive_class\": \"Opioid receptor agonist (mu/delta dual agonist)\",\n+    \"chemical_class\": \"Barbiturate\",\n+    \"mechanism_of_action\": \"Gamma-aminobutyric acid type A receptor positive allosteric modulator; Gamma-aminobutyric acid type A receptor agonist (at high concentration)\",\n+    \"psychoactive_class\": \"Sedative-hypnotic depressant\",\n-          \"route\": \"oral / sublingual\",\n+          \"route\": \"oral\",\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"5 mg - 15 mg\",\n-            \"common\": \"15 mg - 40 mg\",\n-            \"strong\": \"40 mg - 80 mg\",\n-            \"heavy\": \"80 mg+\"\n+            \"threshold\": \"20 mg\",\n+            \"light\": \"30 – 50 mg\",\n+            \"common\": \"50 – 150 mg\",\n+            \"strong\": \"150 – 250 mg\",\n+            \"heavy\": \"250 mg +​\"\n-          \"route\": \"rectal\",\n+          \"route\": \"intravenous\",\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"5 mg - 12 mg\",\n-            \"common\": \"12 mg - 30 mg\",\n-            \"strong\": \"30 mg - 60 mg\",\n-            \"heavy\": \"60 mg+\"\n+            \"threshold\": \"50 mg\",\n+            \"light\": \"100 – 150 mg\",\n+            \"common\": \"150 – 300 mg\",\n+            \"strong\": \"300 – 450 mg\",\n+            \"heavy\": \"450 mg +​\"\n+        },\n+        {\n+          \"route\": \"intramuscular\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"40 mg\",\n+            \"light\": \"75 – 125 mg\",\n+            \"common\": \"125 – 250 mg\",\n+            \"strong\": \"250 – 400 mg\",\n+            \"heavy\": \"400 mg +​\"\n+          }\n-          \"route\": \"oral / sublingual\",\n+          \"route\": \"oral\",\n-            \"oral\",\n-            \"sublingual\"\n+            \"oral\"\n-            \"total_duration\": \"6-12 h\",\n-            \"onset\": \"20-60 min\",\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"3-6 h\",\n-            \"after_effects\": \"6-24 h residual sedation; pruritus; constipation risk\"\n+            \"total_duration\": \"5 - 9 h (sedative effects)\",\n+            \"onset\": \"0.15 - 0.5 h\",\n+            \"peak\": \"1 - 4 h\",\n+            \"offset\": \"5 - 9 h\",\n+            \"after_effects\": \"2 - 12 h residual impairment\"\n-          \"route\": \"rectal\",\n+          \"route\": \"intravenous\",\n-            \"rectal\"\n+            \"intravenous\"\n-            \"total_duration\": \"6-12 h\",\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"3-6 h\",\n-            \"after_effects\": \"6-24 h residual sedation; pruritus; constipation risk\"\n+            \"total_duration\": \"5 - 9 h (sedative effects)\",\n+            \"onset\": \"0.5 - 2 min\",\n+            \"peak\": \"1 - 4 h\",\n+            \"offset\": \"5 - 9 h\",\n+            \"after_effects\": \"2 - 12 h residual impairment\"\n+        },\n+        {\n+          \"route\": \"intramuscular\",\n+          \"canonical_routes\": [\n+            \"intramuscular\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"5 - 9 h (sedative effects)\",\n+            \"peak\": \"1 - 4 h\",\n+            \"offset\": \"5 - 9 h\",\n+            \"after_effects\": \"2 - 12 h residual impairment\"\n+          }\n-    \"addiction_potential\": \"High (opioid-class). Rapid tolerance and dependence are possible with daily use; some users report using multiple times per day or substituting for other opioids/7-OH.\",\n+    \"addiction_potential\": \"High – rapid tolerance and severe physical dependence can develop within days; withdrawal may involve seizures, delirium, and can be fatal without medical supervision.\",\n-        \"benzodiazepines (alprazolam, diazepam) and Z-drugs (additive CNS/respiratory depression)\",\n-        \"alcohol (respiratory depression, emesis aspiration)\",\n-        \"other opioids or opioid-like drugs (tianeptine, tramadol, oxycodone, kratom extracts)\",\n-        \"gabapentinoids at high doses (pregabalin, gabapentin)\",\n-        \"barbiturates\",\n-        \"GHB/GBL\"\n+        \"Alcohol\",\n+        \"Opioids\",\n+        \"GHB/GBL\",\n+        \"Tramadol\",\n+        \"Benzodiazepines\",\n+        \"Z-drugs\",\n+        \"Sedating antihistamines\"\n-        \"MAOIs (unpredictable potentiation, serotonin/adrenergic effects)\",\n-        \"CYP3A/CYP2D6 inhibitors or inducers (may alter levels; examples: fluoxetine, paroxetine, bupropion, clarithromycin, azoles, grapefruit, rifampin, carbamazepine)\"\n+        \"Gabapentinoids\",\n+        \"Poppers\",\n+        \"PVP-class cathinones\"\n-        \"stimulants (tachycardia, masking sedation)\",\n-        \"antihistamines with anticholinergic effects (additive sedation, constipation)\",\n-        \"muscle relaxants (cyclobenzaprine, tizanidine)\",\n-        \"cannabis (can intensify sedation/anxiety)\"\n+        \"DXM\",\n+        \"Ketamine\",\n+        \"MXE\",\n+        \"MAOIs\",\n+        \"Strong stimulants (masking effects)\",\n+        \"Cannabis\"\n-    \"notes\": \"MGM-15 is a semi-synthetic analogue of the kratom alkaloid 7-hydroxymitragynine (7-OH). It was developed alongside MGM-16 as mu/delta-opioid dual agonists; animal and in vitro work consistently finds MGM-16 more potent than MGM-15. Human pharmacokinetics for MGM-15 are unknown; harm-reduction dosing must rely on cautious titration and scattered user reports. Duration described online is longer than 7-OH, with many reporting 6-12 h between doses, which increases overdose risk if redosing too early. Do not combine with other depressants; claims that kratom-derived opioids lack respiratory depression are not supported by clinical data and should not be trusted. Product variability is extreme: vendors sell different salts/purities and the name may cover nonidentical compounds; start low, weigh with a 0.001 g scale, and avoid eyeballing. Because identity is often uncertain, consider third-party analytical testing (LC-MS/HPLC) where available; reagent kits are not reliable for this class. Users attempting to substitute MGM-15 for 7-OH often report lower-per-dose numbers than their 7-OH habits (e.g., single-digit to tens of mg), but some report needing 50-100 mg depending on tolerance and source potency; this spread likely reflects tolerance, salt form, and adulteration. Expect typical opioid effects and adverse effects: miosis, pruritus, constipation, nausea, sedation, and potential respiratory depression at high doses or with CNS depressants. Set a firm session cap before dosing, wait a full 3-4 h before considering any redose, and prefer single-route, single-substance trials to understand sensitivity. Tapering strategies reported online (using small repeated doses of MGM-15 to replace frequent 7-OH) are anecdotal and carry dependence risks; if dependent, seek medical support.\",\n+    \"notes\": \"Amobarbital (formerly sold as Amytal and as half of Tuinal) is an intermediate-acting barbiturate that potentiates and directly activates GABA_A receptors. The therapeutic index is narrow: doses above ~1.5 g have produced fatal respiratory depression. Because its elimination half-life averages 24 h, next-day cognitive and motor impairment is common. Combining with any CNS depressant dramatically amplifies overdose risk. Repeated daily use for a week or more can generate severe dependence; abrupt cessation requires medical tapering to prevent life-threatening withdrawal.\",\n-      \"analgesia\",\n-      \"anxiolysis\",\n-      \"warmth/euphoria\",\n-      \"sedation\",\n-      \"itching/pruritus\",\n-      \"miosis (pinpoint pupils)\",\n-      \"GI slowing/constipation\",\n-      \"reduced cravings for other opioids (anecdotal)\"\n+      \"Anxiolysis\",\n+      \"Euphoria\",\n+      \"Disinhibition\",\n+      \"Sedation\",\n+      \"Muscle relaxation\",\n+      \"Ataxia\",\n+      \"Slurred speech\",\n+      \"Dizziness\",\n+      \"Nystagmus\",\n+      \"Cognitive suppression\",\n+      \"Anterograde amnesia\",\n+      \"Dream-like state\",\n+      \"Emotional dampening\",\n+      \"Respiratory depression at high doses\"\n-      \"full_tolerance\": \"can develop within days of daily use\",\n-      \"half_tolerance\": \"3-7 days after last use (highly variable)\",\n-      \"zero_tolerance\": \"2-3+ weeks after last use (conservative estimate)\",\n+      \"full_tolerance\": \"7 – 14 days of continuous use\",\n+      \"half_tolerance\": \"≈ 1 – 2 weeks after cessation\",\n+      \"zero_tolerance\": \"4 – 6 weeks abstinent\",\n-        \"7-hydroxymitragynine\",\n-        \"mitragynine/kratom\",\n-        \"classical opioids (morphine, oxycodone, fentanyl)\"\n+        \"Other barbiturates\",\n+        \"Benzodiazepines\",\n+        \"Z-drugs\",\n+        \"GABAergic sedatives\"\n-    \"half_life\": \"unknown in humans (anecdotal duration suggests multi-hour activity)\",\n+    \"half_life\": \"8 – 40 h (mean ≈ 24 h)\",\n-        \"name\": \"Matsumoto et al. 2014 (primary; development of MGM-15 and -16 as mu/delta dual agonists)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/24345467/\"\n+        \"name\": \"TripSit – Amobarbital\",\n+        \"reference\": \"https://drugs.tripsit.me/amobarbital\"\n-        \"name\": \"Prevete et al. 2021 – Systematic review (notes MGM-16 > MGM-15 potency; lists MGM-15 doses used in mice)\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC9285932/\"\n+        \"name\": \"Clarke’s Analysis of Drugs and Poisons, 4th Ed.\",\n+        \"reference\": \"ISBN 9780853697114\"\n-        \"name\": \"Drugs.com Kratom monograph (summarizes MGM-15/16 rationale and potency of MGM-16 vs morphine)\",\n-        \"reference\": \"https://www.drugs.com/npp/kratom.html\"\n+        \"name\": \"DailyMed – Amytal Sodium (amobarbital) label\",\n+        \"reference\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bf59ca61-10c3-40e0-9f32-e3c2ac1699e1\"\n-        \"name\": \"ResearchGate figure/text – MGM-15 and MGM-16 dosing in mice (oral 0.84-1.88 mg/kg for MGM-15)\",\n-        \"reference\": \"https://www.researchgate.net/figure/Chemical-structure-and-conformation-of-7-hydroxymitragynine-MGM-15-and-MGM-16_fig2_259351839\"\n+        \"name\": \"DrugBank – Amobarbital (DB00321)\",\n+        \"reference\": \"https://go.drugbank.com/drugs/DB00321\"\n-        \"name\": \"Science.org (Derek Lowe) – discussion of kratom-derived analogues MGM-9, -15, -16\",\n-        \"reference\": \"https://www.science.org/content/blog-post/kratom-and-fda\"\n+        \"name\": \"PubChem – Amobarbital (CID 2153)\",\n+        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/Amobarbital\"\n-        \"name\": \"r/mgm15 – user dosing reports (10-30 mg/day split; 7-10 mg TID)\",\n-        \"reference\": \"https://www.reddit.com/r/mgm15/comments/1maa8ix/what_dose_do_you_guys_take_of_mgm15/\"\n+        \"name\": \"Erowid – Amobarbital Vault\",\n+        \"reference\": \"https://erowid.org/pharms/amobarbital/amobarbital.shtml\"\n-        \"name\": \"r/mgm15 – user report starting 50 mg; combos with 7-OH\",\n-        \"reference\": \"https://www.reddit.com/r/mgm15/comments/1k6c603/mgm15_98_from_ps/\"\n-      },\n-      {\n-        \"name\": \"r/mgm15 – various dosing experiences (80 mg MGM with 20 mg 7-OH; some recommend 100 mg alone; reflects wide variability)\",\n-        \"reference\": \"https://www.reddit.com/r/mgm15/comments/1k8azz8/how_much/\"\n-      },\n-      {\n-        \"name\": \"r/mgm15 – low-dose approaches alongside kratom leaf (<=10-12 mg suggestions)\",\n-        \"reference\": \"https://www.reddit.com/r/mgm15/comments/1lkxxm2/proper_dosage/\"\n-      },\n-      {\n-        \"name\": \"r/researchchemicals – lay summary that MGM-15 is mu/delta; longer duration than 7-OH (anecdotal)\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/1lpjos3/mgm15looking_for_anyone_knowledgeable_with/\"\n+        \"name\": \"Bluelight – Amobarbital 25 mg tablets, recommended dose?\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/amobarbital-25mg-tablets-recommended-dose.681107/\"\n-      \"opioid\",\n-      \"research-chemical\"\n+      \"depressant\",\n+      \"barbiturate\",\n+      \"sedative\",\n+      \"habit-forming\",\n+      \"gabaergic\"\n\n# AKB-57 · #616\n\n-  \"id\": 615,\n-  \"title\": \"Amobarbital\",\n+  \"id\": 616,\n+  \"title\": \"AKB-57\",\n-    \"drug_name\": \"Amobarbital\",\n-    \"chemical_name\": \"Amobarbital\",\n+    \"drug_name\": \"AKB-57\",\n+    \"chemical_name\": \"AKB-57\",\n-    \"chemical_class\": \"Barbiturate\",\n-    \"mechanism_of_action\": \"Gamma-aminobutyric acid type A receptor positive allosteric modulator; Gamma-aminobutyric acid type A receptor agonist (at high concentration)\",\n-    \"psychoactive_class\": \"Sedative-hypnotic depressant\",\n+    \"chemical_class\": \"Synthetic cannabinoids\",\n+    \"mechanism_of_action\": \"CB1 and CB2 receptor full agonist\",\n+    \"psychoactive_class\": \"cannabinoid; hallucinogen\",\n-          \"route\": \"oral\",\n-          \"units\": \"mg\",\n+          \"route\": \"smoked\",\n+          \"units\": \"mg (pure powder on inert herb or vapourised in e-cig liquid)\",\n-            \"threshold\": \"20 mg\",\n-            \"light\": \"30 – 50 mg\",\n-            \"common\": \"50 – 150 mg\",\n-            \"strong\": \"150 – 250 mg\",\n-            \"heavy\": \"250 mg +​\"\n+            \"threshold\": \"<0.5 mg\",\n+            \"light\": \"0.5 – 1.5 mg\",\n+            \"common\": \"1.5 – 3 mg\",\n+            \"strong\": \"3 – 5 mg\",\n+            \"heavy\": \">5 mg\"\n-          \"route\": \"intravenous\",\n+          \"route\": \"oral\",\n-            \"threshold\": \"50 mg\",\n-            \"light\": \"100 – 150 mg\",\n-            \"common\": \"150 – 300 mg\",\n-            \"strong\": \"300 – 450 mg\",\n-            \"heavy\": \"450 mg +​\"\n+            \"threshold\": \"0.5 mg\",\n+            \"light\": \"1 – 2 mg\",\n+            \"common\": \"2 – 4 mg\",\n+            \"strong\": \"4 – 6 mg\",\n+            \"heavy\": \">6 mg\"\n-        },\n-        {\n-          \"route\": \"intramuscular\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"40 mg\",\n-            \"light\": \"75 – 125 mg\",\n-            \"common\": \"125 – 250 mg\",\n-            \"strong\": \"250 – 400 mg\",\n-            \"heavy\": \"400 mg +​\"\n-          }\n-          \"route\": \"oral\",\n+          \"route\": \"smoked\",\n-            \"oral\"\n+            \"smoked\"\n-            \"total_duration\": \"5 - 9 h (sedative effects)\",\n-            \"onset\": \"0.15 - 0.5 h\",\n-            \"peak\": \"1 - 4 h\",\n-            \"offset\": \"5 - 9 h\",\n-            \"after_effects\": \"2 - 12 h residual impairment\"\n+            \"total_duration\": \"1-2 hours\",\n+            \"onset\": \"15-90 seconds\",\n+            \"peak\": \"5-30 minutes\",\n+            \"offset\": \"30-90 minutes\",\n+            \"after_effects\": \"4-6 hours residual lethargy or anxiety; sleep disturbances up to 24 hours\"\n-          \"route\": \"intravenous\",\n+          \"route\": \"oral\",\n-            \"intravenous\"\n+            \"oral\"\n-            \"total_duration\": \"5 - 9 h (sedative effects)\",\n-            \"onset\": \"0.5 - 2 min\",\n-            \"peak\": \"1 - 4 h\",\n-            \"offset\": \"5 - 9 h\",\n-            \"after_effects\": \"2 - 12 h residual impairment\"\n+            \"total_duration\": \"3-6 hours\",\n+            \"onset\": \"30-90 minutes\",\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"30-90 minutes\",\n+            \"after_effects\": \"4-6 hours residual lethargy or anxiety; sleep disturbances up to 24 hours\"\n-        },\n-        {\n-          \"route\": \"intramuscular\",\n-          \"canonical_routes\": [\n-            \"intramuscular\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"5 - 9 h (sedative effects)\",\n-            \"peak\": \"1 - 4 h\",\n-            \"offset\": \"5 - 9 h\",\n-            \"after_effects\": \"2 - 12 h residual impairment\"\n-          }\n-    \"addiction_potential\": \"High – rapid tolerance and severe physical dependence can develop within days; withdrawal may involve seizures, delirium, and can be fatal without medical supervision.\",\n+    \"addiction_potential\": \"High. Synthetic cannabinoids with AKB-type scaffolds show rapid tolerance, withdrawal (irritability, insomnia, nausea) and compulsive redosing similar to other potent SCRAs.\",\n-        \"Alcohol\",\n-        \"Opioids\",\n-        \"GHB/GBL\",\n+        \"MAOIs\",\n-        \"Benzodiazepines\",\n-        \"Z-drugs\",\n-        \"Sedating antihistamines\"\n+        \"Stimulants with vasopressors (e.g. cocaine, α-PVP)\",\n+        \"Other potent SCRAs\"\n-        \"Gabapentinoids\",\n-        \"Poppers\",\n-        \"PVP-class cathinones\"\n+        \"Alcohol (respiratory depression/vomiting when heavily intoxicated)\",\n+        \"Opioids\",\n+        \"BZDs at high doses (black-outs)\"\n-        \"DXM\",\n+        \"SSRIs\",\n+        \"Gabapentinoids\",\n-        \"MXE\",\n-        \"MAOIs\",\n-        \"Strong stimulants (masking effects)\",\n-        \"Cannabis\"\n+        \"Dissociatives\",\n+        \"Classic psychedelics (may amplify anxiety)\"\n-    \"notes\": \"Amobarbital (formerly sold as Amytal and as half of Tuinal) is an intermediate-acting barbiturate that potentiates and directly activates GABA_A receptors. The therapeutic index is narrow: doses above ~1.5 g have produced fatal respiratory depression. Because its elimination half-life averages 24 h, next-day cognitive and motor impairment is common. Combining with any CNS depressant dramatically amplifies overdose risk. Repeated daily use for a week or more can generate severe dependence; abrupt cessation requires medical tapering to prevent life-threatening withdrawal.\",\n+    \"notes\": \"1. Potency varies widely between batches; always allergy-test with a tiny match-head amount (<0.5 mg).\\n2. AKB-57 is active in the low-milligram range; weighing with a 0.001 g scale or volumetric dosing in PG/VG is essential.\\n3. Severe adverse events reported with other indazole carboxamide SCRAs include seizures, acute kidney injury and psychosis; similar risks should be presumed for AKB-57.\\n4. Because metabolism is mainly hepatic (CYP3A4/2C9), strong inhibitors (ketoconazole, fluconazole, grapefruit) may dramatically increase effect duration and toxicity.\\n5. Drug checking (FT-IR/GC-MS) is strongly recommended—mislabelled blends are common.\",\n-      \"Anxiolysis\",\n-      \"Euphoria\",\n-      \"Disinhibition\",\n-      \"Sedation\",\n-      \"Muscle relaxation\",\n-      \"Ataxia\",\n-      \"Slurred speech\",\n-      \"Dizziness\",\n-      \"Nystagmus\",\n-      \"Cognitive suppression\",\n-      \"Anterograde amnesia\",\n-      \"Dream-like state\",\n-      \"Emotional dampening\",\n-      \"Respiratory depression at high doses\"\n+      \"Rapid intoxication (‘stoned’ body high)\",\n+      \"Potent mental sedation\",\n+      \"Time distortion\",\n+      \"Closed-eye imagery at higher doses\",\n+      \"Tachycardia then bradycardia\",\n+      \"Dry mouth\",\n+      \"Short-term memory suppression\",\n+      \"Paranoia/anxiety/panic (dose-dependent)\",\n+      \"Nausea/vomiting\",\n+      \"Motor incoordination\",\n+      \"Intense munchies or, conversely, appetite suppression\",\n+      \"Red eyes\",\n+      \"Afterglow dysphoria or irritability\"\n-      \"full_tolerance\": \"7 – 14 days of continuous use\",\n-      \"half_tolerance\": \"≈ 1 – 2 weeks after cessation\",\n-      \"zero_tolerance\": \"4 – 6 weeks abstinent\",\n+      \"full_tolerance\": \"Develops after 2–3 consecutive days of use\",\n+      \"half_tolerance\": \"≈ 7–10 days of abstinence\",\n+      \"zero_tolerance\": \"≈ 4 weeks\",\n-        \"Other barbiturates\",\n-        \"Benzodiazepines\",\n-        \"Z-drugs\",\n-        \"GABAergic sedatives\"\n+        \"Other synthetic cannabinoids\",\n+        \"THC\"\n-    \"half_life\": \"8 – 40 h (mean ≈ 24 h)\",\n+    \"half_life\": \"Plasma t½ not formally published; analogues with the same scaffold average 1–2 h with lipophilic depot release extending subjective effects.\",\n-        \"name\": \"TripSit – Amobarbital\",\n-        \"reference\": \"https://drugs.tripsit.me/amobarbital\"\n+        \"name\": \"AKB-57 – Wikipedia\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/AKB-57\"\n-        \"name\": \"Clarke’s Analysis of Drugs and Poisons, 4th Ed.\",\n-        \"reference\": \"ISBN 9780853697114\"\n+        \"name\": \"Banister SD et al. Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs. ACS Chem Neurosci 2015\",\n+        \"reference\": \"https://pubs.acs.org/doi/10.1021/acschemneuro.5b00112\"\n-        \"name\": \"DailyMed – Amytal Sodium (amobarbital) label\",\n-        \"reference\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bf59ca61-10c3-40e0-9f32-e3c2ac1699e1\"\n+        \"name\": \"EMCDDA. Synthetic cannabinoids – drug profile and health risks (2023 update)\",\n+        \"reference\": \"https://www.emcdda.europa.eu/publications/drug-profiles/synthetic-cannabinoids_en\"\n-        \"name\": \"DrugBank – Amobarbital (DB00321)\",\n-        \"reference\": \"https://go.drugbank.com/drugs/DB00321\"\n-      },\n-      {\n-        \"name\": \"PubChem – Amobarbital (CID 2153)\",\n-        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/Amobarbital\"\n-      },\n-      {\n-        \"name\": \"Erowid – Amobarbital Vault\",\n-        \"reference\": \"https://erowid.org/pharms/amobarbital/amobarbital.shtml\"\n-      },\n-      {\n-        \"name\": \"Bluelight – Amobarbital 25 mg tablets, recommended dose?\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/amobarbital-25mg-tablets-recommended-dose.681107/\"\n+        \"name\": \"CDC. Outbreak of Severe Illness Associated with Synthetic Cannabinoids — Illinois, 2018\",\n+        \"reference\": \"https://www.cdc.gov/mmwr/volumes/67/wr/mm6719a4.htm\"\n+      \"cannabinoid\",\n+      \"research-chemical\",\n-      \"barbiturate\",\n-      \"sedative\",\n-      \"habit-forming\",\n-      \"gabaergic\"\n+      \"habit-forming\"\n\n# Ro5-4864 · #530\n\n-  \"id\": 616,\n-  \"title\": \"AKB-57\",\n+  \"id\": 530,\n+  \"title\": \"Ro5-4864\",\n-    \"drug_name\": \"AKB-57\",\n-    \"chemical_name\": \"AKB-57\",\n-    \"alternative_name\": \"\",\n-    \"chemical_class\": \"Synthetic cannabinoids\",\n-    \"mechanism_of_action\": \"CB1 and CB2 receptor full agonist\",\n-    \"psychoactive_class\": \"cannabinoid; hallucinogen\",\n+    \"drug_name\": \"Ro5-4864\",\n+    \"chemical_name\": \"4'-chlorodiazepam\",\n+    \"alternative_name\": \"4-Chlorodiazepam\",\n+    \"chemical_class\": \"1,4-benzodiazepine (diazepam analogue)\",\n+    \"mechanism_of_action\": \"Gamma-aminobutyric acid type A receptor positive allosteric modulator (benzodiazepine site)\",\n+    \"psychoactive_class\": \"Benzodiazepine (atypical); TSPO (18 kDa translocator protein) agonist with weak or absent classical GABA_A activity\",\n-          \"route\": \"smoked\",\n-          \"units\": \"mg (pure powder on inert herb or vapourised in e-cig liquid)\",\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"<0.5 mg\",\n+            \"threshold\": \"0.25 – 0.5 mg\",\n-            \"heavy\": \">5 mg\"\n+            \"heavy\": \"5 mg + (marked seizure risk in animals)\"\n-        },\n-        {\n-          \"route\": \"oral\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"0.5 mg\",\n-            \"light\": \"1 – 2 mg\",\n-            \"common\": \"2 – 4 mg\",\n-            \"strong\": \"4 – 6 mg\",\n-            \"heavy\": \">6 mg\"\n-          }\n-          \"route\": \"smoked\",\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"1-2 hours\",\n-            \"onset\": \"15-90 seconds\",\n-            \"peak\": \"5-30 minutes\",\n-            \"offset\": \"30-90 minutes\",\n-            \"after_effects\": \"4-6 hours residual lethargy or anxiety; sleep disturbances up to 24 hours\"\n-          }\n-        },\n-        {\n-            \"total_duration\": \"3-6 hours\",\n-            \"onset\": \"30-90 minutes\",\n-            \"peak\": \"1-2 hours\",\n-            \"offset\": \"30-90 minutes\",\n-            \"after_effects\": \"4-6 hours residual lethargy or anxiety; sleep disturbances up to 24 hours\"\n+            \"total_duration\": \"4 - 8 h\",\n+            \"onset\": \"20 - 60 min\",\n+            \"peak\": \"1 - 3 h\",\n+            \"offset\": \"2 - 3 h\",\n+            \"after_effects\": \"up to 12 - 24 h subtle disequilibrium / fatigue\"\n-    \"addiction_potential\": \"High. Synthetic cannabinoids with AKB-type scaffolds show rapid tolerance, withdrawal (irritability, insomnia, nausea) and compulsive redosing similar to other potent SCRAs.\",\n+    \"addiction_potential\": \"Poorly characterised. Rodent studies show weaker self-administration than diazepam, but repeated exposure produces tolerance to mitochondrial TSPO effects and physical dependence cannot be ruled out. Treat as potentially habit-forming until human data exist.\",\n-        \"MAOIs\",\n-        \"Stimulants with vasopressors (e.g. cocaine, α-PVP)\",\n-        \"Other potent SCRAs\"\n+        \"bupropion\",\n+        \"triptans\",\n+        \"high-dose stimulants (↑ seizure threshold)\"\n-        \"Alcohol (respiratory depression/vomiting when heavily intoxicated)\",\n-        \"Opioids\",\n-        \"BZDs at high doses (black-outs)\"\n+        \"alcohol\",\n+        \"GHB/GBL\",\n+        \"opioids\",\n+        \"barbiturates\",\n+        \"other benzodiazepines or Z-drugs (unpredictable CNS depression or paradoxical agitation)\"\n-        \"SSRIs\",\n-        \"Gabapentinoids\",\n-        \"Ketamine\",\n-        \"Dissociatives\",\n-        \"Classic psychedelics (may amplify anxiety)\"\n+        \"MAOIs\",\n+        \"SSRIs/SNRIs\",\n+        \"antipsychotics\",\n+        \"anticonvulsants (dose adjustments may be required)\"\n-    \"notes\": \"1. Potency varies widely between batches; always allergy-test with a tiny match-head amount (<0.5 mg).\\n2. AKB-57 is active in the low-milligram range; weighing with a 0.001 g scale or volumetric dosing in PG/VG is essential.\\n3. Severe adverse events reported with other indazole carboxamide SCRAs include seizures, acute kidney injury and psychosis; similar risks should be presumed for AKB-57.\\n4. Because metabolism is mainly hepatic (CYP3A4/2C9), strong inhibitors (ketoconazole, fluconazole, grapefruit) may dramatically increase effect duration and toxicity.\\n5. Drug checking (FT-IR/GC-MS) is strongly recommended—mislabelled blends are common.\",\n+    \"notes\": \"• 4-Chlorodiazepam (often abbreviated Ro5-4864) displays nanomolar affinity for the peripheral benzodiazepine receptor/TSPO located on the outer mitochondrial membrane while showing orders-of-magnitude lower affinity for central GABA_A sites.  \\n• Low-dose TSPO activation can produce neurosteroidogenesis and mild sedation; higher micromolar concentrations become anxiogenic and pro-convulsant in animals. Median convulsive dose (CD₅₀) in mice ≈ 42 mg/kg i.p.  \\n• No controlled human pharmacokinetic data exist. Extrapolations from dog and rat studies suggest oral bioavailability ≈ 40 – 60 % and an elimination half-life of 6 – 9 h, with no confirmed active metabolites.  \\n• Human case reports are extremely scarce; anecdotal user reports describe a narrow therapeutic window, inconsistent subjective effects (ranging from mild relaxation to pronounced inner restlessness) and delayed-onset seizures after redosing > 5 mg.  \\n• Start with micro-doses (≤ 0.5 mg), use an analytical milligram scale, wait a full 2 h before considering redose.  \\n• Parenteral routes are strongly discouraged: solvent requirements and local TSPO densities create unpredictable tissue reactions.  \\n• Because of the unique mechanism, benzodiazepine antagonists (flumazenil) are ineffective in overdose; supportive care and anticonvulsants are preferred.\",\n-      \"Rapid intoxication (‘stoned’ body high)\",\n-      \"Potent mental sedation\",\n-      \"Time distortion\",\n-      \"Closed-eye imagery at higher doses\",\n-      \"Tachycardia then bradycardia\",\n-      \"Dry mouth\",\n-      \"Short-term memory suppression\",\n-      \"Paranoia/anxiety/panic (dose-dependent)\",\n-      \"Nausea/vomiting\",\n-      \"Motor incoordination\",\n-      \"Intense munchies or, conversely, appetite suppression\",\n-      \"Red eyes\",\n-      \"Afterglow dysphoria or irritability\"\n+      \"Mild somatic sedation (inconsistent)\",\n+      \"Subtle muscle relaxation\",\n+      \"Derealisation/‘clinical’ detachment\",\n+      \"Tinnitus or ear pressure\",\n+      \"Inner restlessness or anxiogenesis at ≥ 3 mg\",\n+      \"Fine tremor\",\n+      \"Visual blurring / photophobia\",\n+      \"Short-term memory lapses\",\n+      \"Headache\",\n+      \"Rare euphoria or dysphoria\"\n-      \"full_tolerance\": \"Develops after 2–3 consecutive days of use\",\n-      \"half_tolerance\": \"≈ 7–10 days of abstinence\",\n-      \"zero_tolerance\": \"≈ 4 weeks\",\n+      \"full_tolerance\": \"Unknown in humans; rodent TSPO desensitisation within 3–5 days of daily dosing\",\n+      \"half_tolerance\": \"Data not available\",\n+      \"zero_tolerance\": \"> 2 – 4 weeks assumed\",\n-        \"Other synthetic cannabinoids\",\n-        \"THC\"\n+        \"Other high-affinity TSPO ligands (e.g., etifoxine, certain pyrazolopyrimidines); only minimal cross-tolerance with classical benzodiazepines\"\n-    \"half_life\": \"Plasma t½ not formally published; analogues with the same scaffold average 1–2 h with lipophilic depot release extending subjective effects.\",\n+    \"half_life\": \"Estimated 6 – 9 h in humans (rat t½ 1 – 2 h; dog t½ 7 h)\",\n-        \"name\": \"AKB-57 – Wikipedia\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/AKB-57\"\n+        \"name\": \"Papadopoulos V & Lecanu L. Translocator protein (18 kDa) TSPO: An emerging therapeutic target in neurotrauma.\",\n+        \"reference\": \"https://doi.org/10.1016/j.pharmthera.2009.10.002\"\n-        \"name\": \"Banister SD et al. Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs. ACS Chem Neurosci 2015\",\n-        \"reference\": \"https://pubs.acs.org/doi/10.1021/acschemneuro.5b00112\"\n+        \"name\": \"Ishihara K et al. Convulsant action of peripheral benzodiazepine agonists in mice.\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/10475185\"\n-        \"name\": \"EMCDDA. Synthetic cannabinoids – drug profile and health risks (2023 update)\",\n-        \"reference\": \"https://www.emcdda.europa.eu/publications/drug-profiles/synthetic-cannabinoids_en\"\n+        \"name\": \"Lan N et al. Differential effects of 4′-chlorodiazepam on expressed human GABA_A receptors.\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/7830061\"\n-        \"name\": \"CDC. Outbreak of Severe Illness Associated with Synthetic Cannabinoids — Illinois, 2018\",\n-        \"reference\": \"https://www.cdc.gov/mmwr/volumes/67/wr/mm6719a4.htm\"\n+        \"name\": \"Zavala F et al. Peripheral benzodiazepine ligands and the immune response.\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/2900004\"\n+      },\n+      {\n+        \"name\": \"PubChem – 4′-Chlorodiazepam compound summary\",\n+        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/1688\"\n-      \"cannabinoid\",\n-      \"depressant\",\n-      \"habit-forming\"\n+      \"depressant\"\n\n# 2-MMC · #617\n\n-  \"id\": 530,\n-  \"title\": \"Ro5-4864\",\n+  \"id\": 617,\n+  \"title\": \"2-MMC\",\n-    \"drug_name\": \"Ro5-4864\",\n-    \"chemical_name\": \"4'-chlorodiazepam\",\n-    \"alternative_name\": \"4-Chlorodiazepam\",\n-    \"chemical_class\": \"1,4-benzodiazepine (diazepam analogue)\",\n-    \"mechanism_of_action\": \"Gamma-aminobutyric acid type A receptor positive allosteric modulator (benzodiazepine site)\",\n-    \"psychoactive_class\": \"Benzodiazepine (atypical); TSPO (18 kDa translocator protein) agonist with weak or absent classical GABA_A activity\",\n+    \"drug_name\": \"2-MMC\",\n+    \"chemical_name\": \"2-MMC\",\n+    \"alternative_name\": \"2-Methylmethcathinone\",\n+    \"chemical_class\": \"Cathinones\",\n+    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor\",\n+    \"psychoactive_class\": \"Stimulant; entactogen\",\n-            \"threshold\": \"0.25 – 0.5 mg\",\n-            \"light\": \"0.5 – 1.5 mg\",\n-            \"common\": \"1.5 – 3 mg\",\n-            \"strong\": \"3 – 5 mg\",\n-            \"heavy\": \"5 mg + (marked seizure risk in animals)\"\n+            \"threshold\": \"10–20\",\n+            \"light\": \"20–50\",\n+            \"common\": \"50–100\",\n+            \"strong\": \"100–140\",\n+            \"heavy\": \"140 +\"\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"3–5\",\n+            \"light\": \"5–15\",\n+            \"common\": \"15–40\",\n+            \"strong\": \"40–80\",\n+            \"heavy\": \"80 +\"\n+          }\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"10–20\",\n+            \"light\": \"20–40\",\n+            \"common\": \"40–80\",\n+            \"strong\": \"80–120\",\n+            \"heavy\": \"120 +\"\n+          }\n-            \"total_duration\": \"4 - 8 h\",\n-            \"onset\": \"20 - 60 min\",\n-            \"peak\": \"1 - 3 h\",\n-            \"offset\": \"2 - 3 h\",\n-            \"after_effects\": \"up to 12 - 24 h subtle disequilibrium / fatigue\"\n+            \"total_duration\": \"3-6 h\",\n+            \"onset\": \"20-45 min\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-8 h of residual stimulation / fatigue\"\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"2-4 h\",\n+            \"onset\": \"1-5 min\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-8 h of residual stimulation / fatigue\"\n+          }\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"canonical_routes\": [\n+            \"rectal\"\n+          ],\n+          \"stages\": {\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-8 h of residual stimulation / fatigue\"\n+          }\n-    \"addiction_potential\": \"Poorly characterised. Rodent studies show weaker self-administration than diazepam, but repeated exposure produces tolerance to mitochondrial TSPO effects and physical dependence cannot be ruled out. Treat as potentially habit-forming until human data exist.\",\n+    \"addiction_potential\": \"Moderate. Produces dopaminergic reward and compulsive redosing similar to other short-acting cathinones; binge patterns are frequently reported. Psychological dependence is a greater risk than physical withdrawal.\",\n-        \"Tramadol\",\n-        \"bupropion\",\n-        \"triptans\",\n-        \"high-dose stimulants (↑ seizure threshold)\"\n+        \"MAOIs\",\n+        \"Tramadol\"\n-        \"alcohol\",\n-        \"GHB/GBL\",\n-        \"opioids\",\n-        \"barbiturates\",\n-        \"other benzodiazepines or Z-drugs (unpredictable CNS depression or paradoxical agitation)\"\n+        \"2C-T-x\",\n+        \"5-MeO-xxT\",\n+        \"DOx\",\n+        \"DXM\",\n+        \"NBOMe series\",\n+        \"other cathinones (MMC class)\",\n+        \"α-PVP & related pyrrolidines\"\n-        \"MAOIs\",\n-        \"SSRIs/SNRIs\",\n-        \"antipsychotics\",\n-        \"anticonvulsants (dose adjustments may be required)\"\n+        \"Alcohol\",\n+        \"Cannabis\",\n+        \"Cocaine\",\n+        \"GHB/GBL\",\n+        \"Ketamine\",\n+        \"LSD\",\n+        \"MDMA\",\n+        \"Opioids\",\n+        \"SSRIs\",\n+        \"Benzodiazepines (synergy – dose-reduce)\",\n+        \"Stimulants in general\"\n-    \"notes\": \"• 4-Chlorodiazepam (often abbreviated Ro5-4864) displays nanomolar affinity for the peripheral benzodiazepine receptor/TSPO located on the outer mitochondrial membrane while showing orders-of-magnitude lower affinity for central GABA_A sites.  \\n• Low-dose TSPO activation can produce neurosteroidogenesis and mild sedation; higher micromolar concentrations become anxiogenic and pro-convulsant in animals. Median convulsive dose (CD₅₀) in mice ≈ 42 mg/kg i.p.  \\n• No controlled human pharmacokinetic data exist. Extrapolations from dog and rat studies suggest oral bioavailability ≈ 40 – 60 % and an elimination half-life of 6 – 9 h, with no confirmed active metabolites.  \\n• Human case reports are extremely scarce; anecdotal user reports describe a narrow therapeutic window, inconsistent subjective effects (ranging from mild relaxation to pronounced inner restlessness) and delayed-onset seizures after redosing > 5 mg.  \\n• Start with micro-doses (≤ 0.5 mg), use an analytical milligram scale, wait a full 2 h before considering redose.  \\n• Parenteral routes are strongly discouraged: solvent requirements and local TSPO densities create unpredictable tissue reactions.  \\n• Because of the unique mechanism, benzodiazepine antagonists (flumazenil) are ineffective in overdose; supportive care and anticonvulsants are preferred.\",\n+    \"notes\": \"• Pharmacology: In vitro data show 2-MMC acts as a mixed monoamine transporter substrate with higher affinity for DAT ≈ NET than SERT, giving a more \\\"amphetaminic\\\" stimulation with comparatively modest entactogenic warmth (Eshleman 2013; Brandt 2020).\\n• Compared with its positional isomers 3-MMC and 4-MMC (mephedrone), 2-MMC is regarded as less euphoric but more focused/functional. Oral dosing best preserves euphoria; insufflation tends to feel harsher and shorter-lived.\\n• Common acute adverse effects: tachycardia, vasoconstriction (cold fingers, erectile difficulty), jaw clenching, anxiety at peaks, and a strong urge to redose every 1–2 h.\\n• High or repeated doses can provoke confusion, visual disturbances, and in rare cases brief psychotic-like reactions; stay hydrated, monitor body temperature, and limit session length.\\n• Harm-reduction: Weigh doses on a 0.001 g scale; allow at least 2 h before considering a booster. Avoid combining with other stimulants or MAO-inhibiting substances. Because of possible serotonergic activity, the risk of serotonin syndrome exists with SSRIs or tramadol.\",\n-      \"Mild somatic sedation (inconsistent)\",\n-      \"Subtle muscle relaxation\",\n-      \"Derealisation/‘clinical’ detachment\",\n-      \"Tinnitus or ear pressure\",\n-      \"Inner restlessness or anxiogenesis at ≥ 3 mg\",\n-      \"Fine tremor\",\n-      \"Visual blurring / photophobia\",\n-      \"Short-term memory lapses\",\n-      \"Headache\",\n-      \"Rare euphoria or dysphoria\"\n+      \"Stimulation\",\n+      \"Increased energy\",\n+      \"Enhanced motivation/productivity\",\n+      \"Euphoria (moderate)\",\n+      \"Empathy & sociability\",\n+      \"Talkativeness\",\n+      \"Sexual arousal & increased libido\",\n+      \"Cognitive stimulation\",\n+      \"Mood lift\",\n+      \"Appetite suppression\",\n+      \"Bruxism / jaw tension\",\n+      \"Vasoconstriction & cold extremities\",\n+      \"Sweating\",\n+      \"Insomnia\",\n+      \"Anxiety (dose-dependent)\",\n+      \"Compulsive redosing\",\n+      \"Visual flicker or mild hallucinations at high doses\",\n+      \"Crash: fatigue & low mood\"\n-      \"full_tolerance\": \"Unknown in humans; rodent TSPO desensitisation within 3–5 days of daily dosing\",\n-      \"half_tolerance\": \"Data not available\",\n-      \"zero_tolerance\": \"> 2 – 4 weeks assumed\",\n+      \"full_tolerance\": \"Develops after 2–3 days of continuous or binge use\",\n+      \"half_tolerance\": \"≈7 days of abstinence\",\n+      \"zero_tolerance\": \"≈2–3 weeks of abstinence\",\n-        \"Other high-affinity TSPO ligands (e.g., etifoxine, certain pyrazolopyrimidines); only minimal cross-tolerance with classical benzodiazepines\"\n+        \"Other cathinones\",\n+        \"Amphetamines\"\n-    \"half_life\": \"Estimated 6 – 9 h in humans (rat t½ 1 – 2 h; dog t½ 7 h)\",\n+    \"half_life\": \"Estimated 1.5–3 h (plasma); subjective effects decline sooner than blood levels due to acute tolerance.\",\n-        \"name\": \"Papadopoulos V & Lecanu L. Translocator protein (18 kDa) TSPO: An emerging therapeutic target in neurotrauma.\",\n-        \"reference\": \"https://doi.org/10.1016/j.pharmthera.2009.10.002\"\n+        \"name\": \"TripSit – 2-MMC Fact Sheet\",\n+        \"reference\": \"https://drugs.tripsit.me/2-mmc\"\n-        \"name\": \"Ishihara K et al. Convulsant action of peripheral benzodiazepine agonists in mice.\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/10475185\"\n+        \"name\": \"Eshleman et al. 2013 – Substituted cathinones as monoamine transporter substrates\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/23658042/\"\n-        \"name\": \"Lan N et al. Differential effects of 4′-chlorodiazepam on expressed human GABA_A receptors.\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/7830061\"\n+        \"name\": \"Brandt et al. 2020 – Pharmacological profiling of ortho-mephedrone (2-MMC)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/32679041/\"\n-        \"name\": \"Zavala F et al. Peripheral benzodiazepine ligands and the immune response.\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/2900004\"\n+        \"name\": \"User reports compilation – r/ResearchChemicals: “2-MMC turns me into a sex fiend” (Reddit, 2024)\",\n+        \"reference\": \"https://www.reddit.com/comments/qz2mmc_sexfiend\"\n-        \"name\": \"PubChem – 4′-Chlorodiazepam compound summary\",\n-        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/1688\"\n+        \"name\": \"Bluelight thread: “2-MMC, dopaminergic euphoria?” (2024)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/2mmc-dopaminergic-euphoria.939415/\"\n+      \"stimulant\",\n-      \"depressant\"\n+      \"entactogen\"\n\n# Pyrovalerone · #450\n\n-  \"id\": 617,\n-  \"title\": \"2-MMC\",\n+  \"id\": 450,\n+  \"title\": \"Pyrovalerone\",\n-    \"drug_name\": \"2-MMC\",\n-    \"chemical_name\": \"2-MMC\",\n-    \"alternative_name\": \"2-Methylmethcathinone\",\n-    \"chemical_class\": \"Cathinones\",\n-    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor\",\n-    \"psychoactive_class\": \"Stimulant; entactogen\",\n+    \"drug_name\": \"Pyrovalerone\",\n+    \"chemical_name\": \"Pyrovalerone\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Substituted pyrrolidines\",\n+    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor (potent)\",\n+    \"psychoactive_class\": \"Norepinephrine–dopamine reuptake inhibitor (stimulant)\",\n-            \"threshold\": \"10–20\",\n-            \"light\": \"20–50\",\n-            \"common\": \"50–100\",\n-            \"strong\": \"100–140\",\n-            \"heavy\": \"140 +\"\n+            \"threshold\": \"10mg\",\n+            \"light\": \"10mg - 25mg\",\n+            \"common\": \"25mg - 60mg\",\n+            \"strong\": \"60mg - 100mg\",\n+            \"heavy\": \"100+ mg\"\n-            \"threshold\": \"3–5\",\n-            \"light\": \"5–15\",\n-            \"common\": \"15–40\",\n-            \"strong\": \"40–80\",\n-            \"heavy\": \"80 +\"\n+            \"threshold\": \"5mg\",\n+            \"light\": \"5mg - 15mg\",\n+            \"common\": \"15mg - 40mg\",\n+            \"strong\": \"40mg - 80mg\",\n+            \"heavy\": \"80+ mg\"\n-            \"threshold\": \"10–20\",\n-            \"light\": \"20–40\",\n-            \"common\": \"40–80\",\n-            \"strong\": \"80–120\",\n-            \"heavy\": \"120 +\"\n+            \"threshold\": \"5mg\",\n+            \"light\": \"5mg - 15mg\",\n+            \"common\": \"15mg - 35mg\",\n+            \"strong\": \"35mg - 70mg\",\n+            \"heavy\": \"70+ mg\"\n+        },\n+        {\n+          \"route\": \"intravenous\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"1mg\",\n+            \"light\": \"1mg - 5mg\",\n+            \"common\": \"5mg - 15mg\",\n+            \"strong\": \"15mg - 30mg\",\n+            \"heavy\": \"30+ mg\"\n+          }\n-            \"total_duration\": \"3-6 h\",\n-            \"onset\": \"20-45 min\",\n-            \"peak\": \"1-2 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-8 h of residual stimulation / fatigue\"\n+            \"total_duration\": \"3-6 h (active phase)\",\n+            \"onset\": \"10-30 min\",\n+            \"peak\": \"0.5-2 h\",\n+            \"offset\": \"1-3 h\",\n+            \"after_effects\": \"2-24 h residual stimulation; insomnia; low mood\"\n-            \"total_duration\": \"2-4 h\",\n-            \"onset\": \"1-5 min\",\n-            \"peak\": \"1-2 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-8 h of residual stimulation / fatigue\"\n+            \"total_duration\": \"3-6 h (active phase)\",\n+            \"onset\": \"5-10 min\",\n+            \"peak\": \"0.5-2 h\",\n+            \"offset\": \"1-3 h\",\n+            \"after_effects\": \"2-24 h residual stimulation; insomnia; low mood\"\n-            \"peak\": \"1-2 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-8 h of residual stimulation / fatigue\"\n+            \"total_duration\": \"3-6 h (active phase)\",\n+            \"peak\": \"0.5-2 h\",\n+            \"offset\": \"1-3 h\",\n+            \"after_effects\": \"2-24 h residual stimulation; insomnia; low mood\"\n+        },\n+        {\n+          \"route\": \"intravenous\",\n+          \"canonical_routes\": [\n+            \"intravenous\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"3-6 h (active phase)\",\n+            \"onset\": \"<2 min\",\n+            \"peak\": \"0.5-2 h\",\n+            \"offset\": \"1-3 h\",\n+            \"after_effects\": \"2-24 h residual stimulation; insomnia; low mood\"\n+          }\n-    \"addiction_potential\": \"Moderate. Produces dopaminergic reward and compulsive redosing similar to other short-acting cathinones; binge patterns are frequently reported. Psychological dependence is a greater risk than physical withdrawal.\",\n+    \"addiction_potential\": \"High: rapid tolerance, short half-life, and strong dopamine transporter blockade produce compulsive redosing and binge patterns similar to MDPV.\",\n-        \"MAOIs\",\n-        \"Tramadol\"\n+        \"MAOIs (hypertensive crisis)\",\n+        \"high-dose adrenergic stimulants (amphetamine, cocaine)\",\n+        \"sympathomimetic cathinones (MDPV, α-PVP)\",\n+        \"tramadol or other seizure-threshold–lowering drugs\"\n-        \"2C-T-x\",\n-        \"5-MeO-xxT\",\n-        \"DOx\",\n-        \"DXM\",\n-        \"NBOMe series\",\n-        \"other cathinones (MMC class)\",\n-        \"α-PVP & related pyrrolidines\"\n+        \"large amounts of alcohol (cardiotoxicity, dehydration)\",\n+        \"synthetic cannabinoids (tachycardia, panic)\",\n+        \"bupropion or other NDRIs (overstimulation)\"\n-        \"Alcohol\",\n-        \"Cannabis\",\n-        \"Cocaine\",\n-        \"GHB/GBL\",\n-        \"Ketamine\",\n-        \"LSD\",\n-        \"MDMA\",\n-        \"Opioids\",\n-        \"SSRIs\",\n-        \"Benzodiazepines (synergy – dose-reduce)\",\n-        \"Stimulants in general\"\n+        \"SSRIs/SNRIs (serotonin toxicity risk at very high doses)\",\n+        \"caffeine >300 mg (palpitations, anxiety)\",\n+        \"benzodiazepines (masking severe stimulation → redose loop)\"\n-    \"notes\": \"• Pharmacology: In vitro data show 2-MMC acts as a mixed monoamine transporter substrate with higher affinity for DAT ≈ NET than SERT, giving a more \\\"amphetaminic\\\" stimulation with comparatively modest entactogenic warmth (Eshleman 2013; Brandt 2020).\\n• Compared with its positional isomers 3-MMC and 4-MMC (mephedrone), 2-MMC is regarded as less euphoric but more focused/functional. Oral dosing best preserves euphoria; insufflation tends to feel harsher and shorter-lived.\\n• Common acute adverse effects: tachycardia, vasoconstriction (cold fingers, erectile difficulty), jaw clenching, anxiety at peaks, and a strong urge to redose every 1–2 h.\\n• High or repeated doses can provoke confusion, visual disturbances, and in rare cases brief psychotic-like reactions; stay hydrated, monitor body temperature, and limit session length.\\n• Harm-reduction: Weigh doses on a 0.001 g scale; allow at least 2 h before considering a booster. Avoid combining with other stimulants or MAO-inhibiting substances. Because of possible serotonergic activity, the risk of serotonin syndrome exists with SSRIs or tramadol.\",\n+    \"notes\": \"Pyrovalerone was placed into U.S. Schedule V and largely vanished once stronger analogues like MDPV appeared, yet the parent drug still drives sharp redosing urges and warrants strict self-imposed limits.\\n\\nPyrovalerone was originally prescribed for chronic fatigue and obesity in the 1960s at daily doses of 60 mg (20 mg taken three times daily), but patients frequently developed tolerance and compulsive redosing, leading to discontinuation of its clinical use. Modern reports describe it as a stimulant with a profile somewhere between methylphenidate and MDPV, with strong drive to re-dose every 2–3 hours. Its pharmacology shows high affinity inhibition of dopamine and norepinephrine transporters, with negligible serotonin activity, producing a stimulation that is clean but also edgy and compulsive. The short half-life contributes to a sharp comedown, often marked by irritability, low mood, and insomnia. Oral dosing is more forgiving but still prone to compulsive escalation, while insufflation and intravenous routes amplify both euphoria and cardiovascular strain. Users report appetite suppression, jaw tension, tremor, and persistent tachycardia during sessions. Redosing within the first hour significantly increases cardiovascular and neurotoxic stress, and binges of >24 hours without sleep have led to stimulant psychosis similar to high-dose cocaine. Accurate dosing is critical: pyrovalerone is active at very low milligram amounts, making volumetric liquid measurement safer than weighing single doses. Reagent tests often cannot distinguish pyrovalerone from related pyrrolidinophenones, so confirmation with multiple reagents or advanced analysis (GC-MS, FT-IR) is recommended. For harm reduction, users should pre-weigh a maximum daily session dose, allow full return to baseline before re-dosing, maintain hydration and electrolyte intake (especially potassium and magnesium), and ensure proper sleep hygiene. Because pyrovalerone was quickly replaced by stronger analogues like MDPV and α-PVP on the illicit market, it remains rare but presents similar risks: high addiction potential, strong cardiovascular strain, and rapid tolerance escalation.\",\n-      \"Stimulation\",\n-      \"Increased energy\",\n-      \"Enhanced motivation/productivity\",\n-      \"Euphoria (moderate)\",\n-      \"Empathy & sociability\",\n-      \"Talkativeness\",\n-      \"Sexual arousal & increased libido\",\n-      \"Cognitive stimulation\",\n-      \"Mood lift\",\n-      \"Appetite suppression\",\n-      \"Bruxism / jaw tension\",\n-      \"Vasoconstriction & cold extremities\",\n-      \"Sweating\",\n-      \"Insomnia\",\n-      \"Anxiety (dose-dependent)\",\n-      \"Compulsive redosing\",\n-      \"Visual flicker or mild hallucinations at high doses\",\n-      \"Crash: fatigue & low mood\"\n+      \"clean, functional stimulation\",\n+      \"confidence and motivation boost\",\n+      \"anorexia and dry mouth\",\n+      \"jaw tension, fine tremor\",\n+      \"compulsive redosing drive\",\n+      \"irritability and dysphoria on comedown\"\n-      \"full_tolerance\": \"Develops after 2–3 days of continuous or binge use\",\n-      \"half_tolerance\": \"≈7 days of abstinence\",\n-      \"zero_tolerance\": \"≈2–3 weeks of abstinence\",\n+      \"full_tolerance\": \"after 1-2 heavy sessions\",\n+      \"half_tolerance\": \"3-5 days\",\n+      \"zero_tolerance\": \"10-14 days\",\n-        \"Other cathinones\",\n-        \"Amphetamines\"\n+        \"MDPV\",\n+        \"α-PVP\",\n+        \"other pyrrolidinophenones\"\n-    \"half_life\": \"Estimated 1.5–3 h (plasma); subjective effects decline sooner than blood levels due to acute tolerance.\",\n+    \"half_life\": \"Approx. 0.3-1.5 h in rats; human half-life likely under 3 h.\",\n-        \"name\": \"TripSit – 2-MMC Fact Sheet\",\n-        \"reference\": \"https://drugs.tripsit.me/2-mmc\"\n+        \"name\": \"Controlled evaluation of pyrovalerone doses (20–40 mg TID)\",\n+        \"reference\": \"https://karger.com/ipd/article/8/1-2/60/179231/A-Controlled-Evaluation-of-Pyrovalerone-in\"\n-        \"name\": \"Eshleman et al. 2013 – Substituted cathinones as monoamine transporter substrates\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/23658042/\"\n+        \"name\": \"Synthetic cathinone user-dose survey (20–80 mg insufflated)\",\n+        \"reference\": \"https://nps-info.org/en/substances/synthetic-cathinones/\"\n-        \"name\": \"Brandt et al. 2020 – Pharmacological profiling of ortho-mephedrone (2-MMC)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/32679041/\"\n+        \"name\": \"DAT Ki values for pyrovalerone\",\n+        \"reference\": \"https://www.aatbio.com/data-sets/dopamine-transporter-inhibitors-ic50-ki\"\n-        \"name\": \"User reports compilation – r/ResearchChemicals: “2-MMC turns me into a sex fiend” (Reddit, 2024)\",\n-        \"reference\": \"https://www.reddit.com/comments/qz2mmc_sexfiend\"\n+        \"name\": \"Rat plasma half-life study\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/8934308/\"\n-        \"name\": \"Bluelight thread: “2-MMC, dopaminergic euphoria?” (2024)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/2mmc-dopaminergic-euphoria.939415/\"\n+        \"name\": \"Pyrovalerone analogues pharmacology (Meltzer et al., 2006)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/16480278/\"\n+      },\n+      {\n+        \"name\": \"Zebrafish dopamine-receptor down-regulation\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC6851804/\"\n+      },\n+      {\n+        \"name\": \"Bluelight discussion thread on pyrovalerone rarity\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/pyrovalerone.522661/\"\n+      },\n+      {\n+        \"name\": \"UNODC synthetic cathinones report (dose guidance)\",\n+        \"reference\": \"https://www.unodc.org/documents/scientific/STNAR49_Synthetic_Cathinones_E.pdf\"\n+      },\n+      {\n+        \"name\": \"Bionity encyclopaedia entry (historical/prescription info)\",\n+        \"reference\": \"https://www.bionity.com/en/encyclopedia/Pyrovalerone.html\"\n+      },\n+      {\n+        \"name\": \"Anodyne Wiki: Pyrovalerone\",\n+        \"reference\": \"https://anodyne.wiki/substance/pyrovalerone\"\n-      \"research-chemical\",\n-      \"entactogen\"\n+      \"research-chemical\"\n\n# Carisoprodol · #174\n\n-  \"id\": 450,\n-  \"title\": \"Pyrovalerone\",\n+  \"id\": 174,\n+  \"title\": \"Carisoprodol\",\n-    \"drug_name\": \"Pyrovalerone\",\n-    \"chemical_name\": \"Pyrovalerone\",\n+    \"drug_name\": \"Carisoprodol\",\n+    \"chemical_name\": \"Carisoprodol\",\n-    \"chemical_class\": \"Substituted pyrrolidines\",\n-    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor (potent)\",\n-    \"psychoactive_class\": \"Norepinephrine–dopamine reuptake inhibitor (stimulant)\",\n+    \"chemical_class\": \"Carbamate\",\n+    \"mechanism_of_action\": \"Gamma-aminobutyric acid type A receptor positive allosteric modulator; Gamma-aminobutyric acid type A receptor agonist (at high concentration)\",\n+    \"psychoactive_class\": \"Muscle relaxant (centrally acting)\",\n-            \"threshold\": \"10mg\",\n-            \"light\": \"10mg - 25mg\",\n-            \"common\": \"25mg - 60mg\",\n-            \"strong\": \"60mg - 100mg\",\n-            \"heavy\": \"100+ mg\"\n+            \"threshold\": \"100 mg\",\n+            \"light\": \"150-250 mg\",\n+            \"common\": \"250-350 mg\",\n+            \"strong\": \"350-700 mg\",\n+            \"heavy\": \"700+ mg\"\n-        },\n-        {\n-          \"route\": \"insufflated\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"5mg\",\n-            \"light\": \"5mg - 15mg\",\n-            \"common\": \"15mg - 40mg\",\n-            \"strong\": \"40mg - 80mg\",\n-            \"heavy\": \"80+ mg\"\n-          }\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"5mg\",\n-            \"light\": \"5mg - 15mg\",\n-            \"common\": \"15mg - 35mg\",\n-            \"strong\": \"35mg - 70mg\",\n-            \"heavy\": \"70+ mg\"\n-          }\n-        },\n-        {\n-          \"route\": \"intravenous\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"1mg\",\n-            \"light\": \"1mg - 5mg\",\n-            \"common\": \"5mg - 15mg\",\n-            \"strong\": \"15mg - 30mg\",\n-            \"heavy\": \"30+ mg\"\n-          }\n-            \"total_duration\": \"3-6 h (active phase)\",\n-            \"onset\": \"10-30 min\",\n-            \"peak\": \"0.5-2 h\",\n-            \"offset\": \"1-3 h\",\n-            \"after_effects\": \"2-24 h residual stimulation; insomnia; low mood\"\n+            \"total_duration\": \"4-6 hours\",\n+            \"onset\": \"30 minutes\",\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"May persist up to 12 hours; especially with high doses or repeated use\"\n-        },\n-        {\n-          \"route\": \"insufflated\",\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"3-6 h (active phase)\",\n-            \"onset\": \"5-10 min\",\n-            \"peak\": \"0.5-2 h\",\n-            \"offset\": \"1-3 h\",\n-            \"after_effects\": \"2-24 h residual stimulation; insomnia; low mood\"\n-          }\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"canonical_routes\": [\n-            \"rectal\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"3-6 h (active phase)\",\n-            \"peak\": \"0.5-2 h\",\n-            \"offset\": \"1-3 h\",\n-            \"after_effects\": \"2-24 h residual stimulation; insomnia; low mood\"\n-          }\n-        },\n-        {\n-          \"route\": \"intravenous\",\n-          \"canonical_routes\": [\n-            \"intravenous\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"3-6 h (active phase)\",\n-            \"onset\": \"<2 min\",\n-            \"peak\": \"0.5-2 h\",\n-            \"offset\": \"1-3 h\",\n-            \"after_effects\": \"2-24 h residual stimulation; insomnia; low mood\"\n-          }\n-    \"addiction_potential\": \"High: rapid tolerance, short half-life, and strong dopamine transporter blockade produce compulsive redosing and binge patterns similar to MDPV.\",\n+    \"addiction_potential\": \"Moderate to high. Carisoprodol has a risk of dependence and abuse, especially with prolonged use or at high doses. Its metabolite, meprobamate, is also habit-forming.\",\n-        \"MAOIs (hypertensive crisis)\",\n-        \"high-dose adrenergic stimulants (amphetamine, cocaine)\",\n-        \"sympathomimetic cathinones (MDPV, α-PVP)\",\n-        \"tramadol or other seizure-threshold–lowering drugs\"\n+        \"Alcohol\",\n+        \"Opioids\",\n+        \"Benzodiazepines\",\n+        \"Barbiturates\"\n-        \"large amounts of alcohol (cardiotoxicity, dehydration)\",\n-        \"synthetic cannabinoids (tachycardia, panic)\",\n-        \"bupropion or other NDRIs (overstimulation)\"\n+        \"Other CNS depressants\"\n-        \"SSRIs/SNRIs (serotonin toxicity risk at very high doses)\",\n-        \"caffeine >300 mg (palpitations, anxiety)\",\n-        \"benzodiazepines (masking severe stimulation → redose loop)\"\n+        \"Antidepressants\",\n+        \"Antihistamines\"\n-    \"notes\": \"Pyrovalerone was placed into U.S. Schedule V and largely vanished once stronger analogues like MDPV appeared, yet the parent drug still drives sharp redosing urges and warrants strict self-imposed limits.\\n\\nPyrovalerone was originally prescribed for chronic fatigue and obesity in the 1960s at daily doses of 60 mg (20 mg taken three times daily), but patients frequently developed tolerance and compulsive redosing, leading to discontinuation of its clinical use. Modern reports describe it as a stimulant with a profile somewhere between methylphenidate and MDPV, with strong drive to re-dose every 2–3 hours. Its pharmacology shows high affinity inhibition of dopamine and norepinephrine transporters, with negligible serotonin activity, producing a stimulation that is clean but also edgy and compulsive. The short half-life contributes to a sharp comedown, often marked by irritability, low mood, and insomnia. Oral dosing is more forgiving but still prone to compulsive escalation, while insufflation and intravenous routes amplify both euphoria and cardiovascular strain. Users report appetite suppression, jaw tension, tremor, and persistent tachycardia during sessions. Redosing within the first hour significantly increases cardiovascular and neurotoxic stress, and binges of >24 hours without sleep have led to stimulant psychosis similar to high-dose cocaine. Accurate dosing is critical: pyrovalerone is active at very low milligram amounts, making volumetric liquid measurement safer than weighing single doses. Reagent tests often cannot distinguish pyrovalerone from related pyrrolidinophenones, so confirmation with multiple reagents or advanced analysis (GC-MS, FT-IR) is recommended. For harm reduction, users should pre-weigh a maximum daily session dose, allow full return to baseline before re-dosing, maintain hydration and electrolyte intake (especially potassium and magnesium), and ensure proper sleep hygiene. Because pyrovalerone was quickly replaced by stronger analogues like MDPV and α-PVP on the illicit market, it remains rare but presents similar risks: high addiction potential, strong cardiovascular strain, and rapid tolerance escalation.\",\n+    \"notes\": \"Carisoprodol is prescribed only for short-term relief of acute muscle spasm, yet dependence emerges quickly because it metabolises into the sedative meprobamate. Long-term use or abrupt cessation can precipitate significant withdrawal.\\n\\nCarisoprodol is a centrally acting muscle relaxant with sedative and anxiolytic properties, commonly prescribed for short-term treatment of musculoskeletal pain. It is rapidly metabolized in the liver to meprobamate, a long-acting anxiolytic and sedative-hypnotic with its own abuse history, making carisoprodol pharmacologically similar to combining a short-acting sedative with a longer-lasting one. Because of this metabolic pathway, effects may persist longer than expected, especially with repeated dosing. Recreational use often centers around the drug’s sedative euphoria, which some users compare to a mild benzodiazepine, though with a heavier, less controlled sedation and occasional paradoxical stimulation. At therapeutic doses, carisoprodol causes muscle relaxation, drowsiness, and anxiolysis; at higher doses, it can cause confusion, ataxia, double vision, blackouts, and sudden loss of motor control. Abrupt movements or attempts to stand can cause sudden collapses, leading to falls and injuries. Tolerance to the euphoric and relaxing effects develops quickly, encouraging dose escalation and binge-style use. Dependence liability is compounded by meprobamate accumulation, which has a half-life of ~10 hours, leading to more prolonged sedation and risk of withdrawal upon cessation. Withdrawal symptoms can include tremors, anxiety, agitation, insomnia, nausea, hallucinations, and seizures; these can be severe after chronic high-dose use and may require medical supervision, often with benzodiazepine substitution. Mixing carisoprodol with other depressants such as alcohol, opioids, or benzodiazepines greatly increases the risk of respiratory depression, aspiration, coma, and death; many fatalities have involved such polydrug combinations. Recreational users sometimes combine carisoprodol with opioids or benzodiazepines in a cocktail known as the 'Holy Trinity,' which is considered highly dangerous due to synergistic CNS depression. Harm reduction strategies include limiting use to occasional sessions, spacing doses at least 4–6 hours apart, avoiding any other depressants, and never exceeding 700 mg in a single dose. Users should ensure they are in a safe environment before onset due to risk of sudden sedation and falls. Because it is often supplied as tablets with varying imprints, counterfeit risks exist; some tablets may contain other sedatives or opioids, so reagent testing is advised where possible. Long-term heavy use can impair memory, attention, and coordination, and chronic use is discouraged due to rapid tolerance and dependence liability.\",\n-      \"clean, functional stimulation\",\n-      \"confidence and motivation boost\",\n-      \"anorexia and dry mouth\",\n-      \"jaw tension, fine tremor\",\n-      \"compulsive redosing drive\",\n-      \"irritability and dysphoria on comedown\"\n+      \"Muscle relaxation\",\n+      \"Sedation\",\n+      \"Euphoria (in some users)\",\n+      \"Drowsiness\",\n+      \"Dizziness\",\n+      \"Impaired coordination\",\n+      \"Confusion (at high doses)\",\n+      \"Potential for amnesia\"\n-      \"full_tolerance\": \"after 1-2 heavy sessions\",\n-      \"half_tolerance\": \"3-5 days\",\n-      \"zero_tolerance\": \"10-14 days\",\n+      \"full_tolerance\": \"Develops within days to weeks of regular use\",\n+      \"half_tolerance\": \"Several days after cessation\",\n+      \"zero_tolerance\": \"1-2 weeks after cessation\",\n-        \"MDPV\",\n-        \"α-PVP\",\n-        \"other pyrrolidinophenones\"\n+        \"Meprobamate\",\n+        \"Other sedative-hypnotics\"\n-    \"half_life\": \"Approx. 0.3-1.5 h in rats; human half-life likely under 3 h.\",\n+    \"half_life\": \"2-3 hours (parent compound); 10 hours (meprobamate metabolite)\",\n-        \"name\": \"Controlled evaluation of pyrovalerone doses (20–40 mg TID)\",\n-        \"reference\": \"https://karger.com/ipd/article/8/1-2/60/179231/A-Controlled-Evaluation-of-Pyrovalerone-in\"\n+        \"name\": \"DrugBank: Carisoprodol\",\n+        \"reference\": \"https://go.drugbank.com/drugs/DB00395\"\n-        \"name\": \"Synthetic cathinone user-dose survey (20–80 mg insufflated)\",\n-        \"reference\": \"https://nps-info.org/en/substances/synthetic-cathinones/\"\n+        \"name\": \"DrugBank: Carisoprodol Abuse and Dependence\",\n+        \"reference\": \"https://go.drugbank.com/articles/A176068\"\n-        \"name\": \"DAT Ki values for pyrovalerone\",\n-        \"reference\": \"https://www.aatbio.com/data-sets/dopamine-transporter-inhibitors-ic50-ki\"\n+        \"name\": \"DrugBank: Carisoprodol Pharmacology\",\n+        \"reference\": \"https://go.drugbank.com/articles/A176092\"\n-        \"name\": \"Rat plasma half-life study\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/8934308/\"\n-      },\n-      {\n-        \"name\": \"Pyrovalerone analogues pharmacology (Meltzer et al., 2006)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/16480278/\"\n-      },\n-      {\n-        \"name\": \"Zebrafish dopamine-receptor down-regulation\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC6851804/\"\n-      },\n-      {\n-        \"name\": \"Bluelight discussion thread on pyrovalerone rarity\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/pyrovalerone.522661/\"\n-      },\n-      {\n-        \"name\": \"UNODC synthetic cathinones report (dose guidance)\",\n-        \"reference\": \"https://www.unodc.org/documents/scientific/STNAR49_Synthetic_Cathinones_E.pdf\"\n-      },\n-      {\n-        \"name\": \"Bionity encyclopaedia entry (historical/prescription info)\",\n-        \"reference\": \"https://www.bionity.com/en/encyclopedia/Pyrovalerone.html\"\n-      },\n-      {\n-        \"name\": \"Anodyne Wiki: Pyrovalerone\",\n-        \"reference\": \"https://anodyne.wiki/substance/pyrovalerone\"\n+        \"name\": \"Drug Users Bible: Index\",\n+        \"reference\": \"https://drugusersbible.org/content/chemscape/anxiolytics_and_sedatives/carisoprodol/index.html\"\n-      \"stimulant\",\n-      \"research-chemical\"\n+      \"depressant\",\n+      \"habit-forming\",\n+      \"gabaergic\"\n\n# 4-Cl-PPP · #618\n\n-  \"id\": 174,\n-  \"title\": \"Carisoprodol\",\n+  \"id\": 618,\n+  \"title\": \"4-Cl-PPP\",\n-    \"drug_name\": \"Carisoprodol\",\n-    \"chemical_name\": \"Carisoprodol\",\n+    \"drug_name\": \"4-Cl-PPP\",\n+    \"chemical_name\": \"4-Cl-PPP\",\n-    \"chemical_class\": \"Carbamate\",\n-    \"mechanism_of_action\": \"Gamma-aminobutyric acid type A receptor positive allosteric modulator; Gamma-aminobutyric acid type A receptor agonist (at high concentration)\",\n-    \"psychoactive_class\": \"Muscle relaxant (centrally acting)\",\n+    \"chemical_class\": \"Substituted pyrrolidines\",\n+    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor (potent)\",\n+    \"psychoactive_class\": \"Stimulant\",\n-            \"threshold\": \"100 mg\",\n-            \"light\": \"150-250 mg\",\n-            \"common\": \"250-350 mg\",\n-            \"strong\": \"350-700 mg\",\n-            \"heavy\": \"700+ mg\"\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"10–20 mg\",\n+            \"common\": \"20–40 mg\",\n+            \"strong\": \"40–60 mg\",\n+            \"heavy\": \"60 mg+​\"\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"3 mg\",\n+            \"light\": \"5–10 mg\",\n+            \"common\": \"10–25 mg\",\n+            \"strong\": \"25–40 mg\",\n+            \"heavy\": \"40 mg+​\"\n+          }\n-            \"total_duration\": \"4-6 hours\",\n-            \"onset\": \"30 minutes\",\n-            \"peak\": \"1-2 hours\",\n-            \"offset\": \"2-4 hours\",\n-            \"after_effects\": \"May persist up to 12 hours; especially with high doses or repeated use\"\n+            \"total_duration\": \"2-4 h\",\n+            \"onset\": \"15-40 min\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-6 h residual stimulation / insomnia\"\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"2-4 h\",\n+            \"onset\": \"5-10 min\",\n+            \"peak\": \"1-2 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-6 h residual stimulation / insomnia\"\n+          }\n-    \"addiction_potential\": \"Moderate to high. Carisoprodol has a risk of dependence and abuse, especially with prolonged use or at high doses. Its metabolite, meprobamate, is also habit-forming.\",\n+    \"addiction_potential\": \"High – pyrrolidinophenones act as powerful dopamine & norepinephrine re-uptake inhibitors; compulsive redosing and binge-use have been reported.\",\n-        \"Alcohol\",\n-        \"Opioids\",\n-        \"Benzodiazepines\",\n-        \"Barbiturates\"\n+        \"MAOIs\",\n+        \"other potent stimulants (cocaine, methamphetamine, α-PVP, cathinone blends)\",\n+        \"tramadol (seizure risk)\"\n-        \"Other CNS depressants\"\n+        \"MDMA / entactogens (hyperthermia, serotonin syndrome)\",\n+        \"strong opioids (respiratory & cardiovascular burden)\"\n-        \"Antidepressants\",\n-        \"Antihistamines\"\n+        \"Alcohol (cardiac strain, dehydration)\",\n+        \"benzodiazepines (can mask overdose signs)\",\n+        \"antidepressant SSRIs/SNRIs (serotonin / QT issues)\"\n-    \"notes\": \"Carisoprodol is prescribed only for short-term relief of acute muscle spasm, yet dependence emerges quickly because it metabolises into the sedative meprobamate. Long-term use or abrupt cessation can precipitate significant withdrawal.\\n\\nCarisoprodol is a centrally acting muscle relaxant with sedative and anxiolytic properties, commonly prescribed for short-term treatment of musculoskeletal pain. It is rapidly metabolized in the liver to meprobamate, a long-acting anxiolytic and sedative-hypnotic with its own abuse history, making carisoprodol pharmacologically similar to combining a short-acting sedative with a longer-lasting one. Because of this metabolic pathway, effects may persist longer than expected, especially with repeated dosing. Recreational use often centers around the drug’s sedative euphoria, which some users compare to a mild benzodiazepine, though with a heavier, less controlled sedation and occasional paradoxical stimulation. At therapeutic doses, carisoprodol causes muscle relaxation, drowsiness, and anxiolysis; at higher doses, it can cause confusion, ataxia, double vision, blackouts, and sudden loss of motor control. Abrupt movements or attempts to stand can cause sudden collapses, leading to falls and injuries. Tolerance to the euphoric and relaxing effects develops quickly, encouraging dose escalation and binge-style use. Dependence liability is compounded by meprobamate accumulation, which has a half-life of ~10 hours, leading to more prolonged sedation and risk of withdrawal upon cessation. Withdrawal symptoms can include tremors, anxiety, agitation, insomnia, nausea, hallucinations, and seizures; these can be severe after chronic high-dose use and may require medical supervision, often with benzodiazepine substitution. Mixing carisoprodol with other depressants such as alcohol, opioids, or benzodiazepines greatly increases the risk of respiratory depression, aspiration, coma, and death; many fatalities have involved such polydrug combinations. Recreational users sometimes combine carisoprodol with opioids or benzodiazepines in a cocktail known as the 'Holy Trinity,' which is considered highly dangerous due to synergistic CNS depression. Harm reduction strategies include limiting use to occasional sessions, spacing doses at least 4–6 hours apart, avoiding any other depressants, and never exceeding 700 mg in a single dose. Users should ensure they are in a safe environment before onset due to risk of sudden sedation and falls. Because it is often supplied as tablets with varying imprints, counterfeit risks exist; some tablets may contain other sedatives or opioids, so reagent testing is advised where possible. Long-term heavy use can impair memory, attention, and coordination, and chronic use is discouraged due to rapid tolerance and dependence liability.\",\n+    \"notes\": \"4-Cl-PPP (4-chloro-α-pyrrolidinopropiophenone) is an obscure designer stimulant. Human data are limited to a handful of forum reports; no controlled studies have been performed. Similar para-chloro amphetamine analogues show serotonergic neurotoxicity in animals, so long-term risks are unknown. Crystalline material is usually white–tan, reportedly very caustic to nasal tissue. Users describe rapid tolerance, a short-lived euphoria followed by pronounced compulsion, insomnia, and an unpleasant crash. Harm-reduction: limit sessions to <40 mg total, dose no more often than once every 2–4 weeks, monitor blood pressure & temperature, and keep benzodiazepines (e.g., 1–2 mg diazepam) on hand for agitation but avoid co-intoxication.\",\n-      \"Muscle relaxation\",\n-      \"Sedation\",\n-      \"Euphoria (in some users)\",\n-      \"Drowsiness\",\n-      \"Dizziness\",\n-      \"Impaired coordination\",\n-      \"Confusion (at high doses)\",\n-      \"Potential for amnesia\"\n+      \"Euphoria (brief)\",\n+      \"Stimulation & wakefulness\",\n+      \"Increased sociability/talkativeness\",\n+      \"Anorexia\",\n+      \"Bruxism & jaw tension\",\n+      \"Vasoconstriction, cold extremities\",\n+      \"Tachycardia / palpitations\",\n+      \"Anxiety or paranoia at higher doses\",\n+      \"Compulsive redosing\",\n+      \"Insomnia & prolonged after-stimulation\",\n+      \"Auditory misperceptions after binges\"\n-      \"full_tolerance\": \"Develops within days to weeks of regular use\",\n-      \"half_tolerance\": \"Several days after cessation\",\n-      \"zero_tolerance\": \"1-2 weeks after cessation\",\n+      \"full_tolerance\": \"Forms after 1–2 days of consecutive use\",\n+      \"half_tolerance\": \"~1 week\",\n+      \"zero_tolerance\": \"2–3 weeks of abstinence\",\n-        \"Meprobamate\",\n-        \"Other sedative-hypnotics\"\n+        \"α-PVP\",\n+        \"4-F-PVP\",\n+        \"α-PHP\",\n+        \"amphetamines\"\n-    \"half_life\": \"2-3 hours (parent compound); 10 hours (meprobamate metabolite)\",\n+    \"half_life\": \"~2–3 h (estimated from in-vitro DAT assay & structural analogy to α-PPP)\",\n-        \"name\": \"DrugBank: Carisoprodol\",\n-        \"reference\": \"https://go.drugbank.com/drugs/DB00395\"\n+        \"name\": \"Wikipedia – 4-Cl-PPP\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/4-Cl-PPP\"\n-        \"name\": \"DrugBank: Carisoprodol Abuse and Dependence\",\n-        \"reference\": \"https://go.drugbank.com/articles/A176068\"\n+        \"name\": \"Eshleman et al., 2019. Structure-activity relationships of NPS at monoamine transporters.\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/31166536/\"\n-        \"name\": \"DrugBank: Carisoprodol Pharmacology\",\n-        \"reference\": \"https://go.drugbank.com/articles/A176092\"\n+        \"name\": \"Bluelight forum: “New RCs, 4-Cl-PPP & 4-Cl-PVP” user reports (posts #2–#8)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/new-rcs-4-cl-ppp-4-cl-pvp.800456/\"\n-        \"name\": \"Drug Users Bible: Index\",\n-        \"reference\": \"https://drugusersbible.org/content/chemscape/anxiolytics_and_sedatives/carisoprodol/index.html\"\n+        \"name\": \"EMCDDA. New psychoactive substances: global markets, glocal threats.\",\n+        \"reference\": \"https://www.emcdda.europa.eu/publications/2016/new-psychoactive-substances_en\"\n+      },\n+      {\n+        \"name\": \"PubChem: 163195101\",\n+        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/163195101\"\n-      \"depressant\",\n-      \"habit-forming\",\n-      \"gabaergic\"\n+      \"stimulant\",\n+      \"research-chemical\"\n\n# 4-CBC (4-Chlorobuphedrone) · #619\n\n-  \"id\": 618,\n-  \"title\": \"4-Cl-PPP\",\n+  \"id\": 619,\n+  \"title\": \"4-CBC (4-Chlorobuphedrone)\",\n-    \"drug_name\": \"4-Cl-PPP\",\n-    \"chemical_name\": \"4-Cl-PPP\",\n-    \"alternative_name\": \"\",\n-    \"chemical_class\": \"Substituted pyrrolidines\",\n-    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor (potent)\",\n-    \"psychoactive_class\": \"Stimulant\",\n+    \"drug_name\": \"4-CBC (4-Chlorobuphedrone)\",\n+    \"chemical_name\": \"4-CBC\",\n+    \"alternative_name\": \"4-Chlorobuphedrone\",\n+    \"chemical_class\": \"Cathinones\",\n+    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor\",\n+    \"psychoactive_class\": \"Stimulant; entactogen\",\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"10–20 mg\",\n-            \"common\": \"20–40 mg\",\n-            \"strong\": \"40–60 mg\",\n-            \"heavy\": \"60 mg+​\"\n+            \"threshold\": \"20-30\",\n+            \"light\": \"40-70\",\n+            \"common\": \"70-100\",\n+            \"strong\": \"100-130\",\n+            \"heavy\": \"130+\"\n-            \"threshold\": \"3 mg\",\n-            \"light\": \"5–10 mg\",\n-            \"common\": \"10–25 mg\",\n-            \"strong\": \"25–40 mg\",\n-            \"heavy\": \"40 mg+​\"\n+            \"threshold\": \"15-25\",\n+            \"light\": \"40-60\",\n+            \"common\": \"60-90\",\n+            \"strong\": \"90-120\",\n+            \"heavy\": \"120+\"\n-            \"total_duration\": \"2-4 h\",\n-            \"onset\": \"15-40 min\",\n+            \"total_duration\": \"3-6 h\",\n+            \"onset\": \"30-60 min\",\n-            \"after_effects\": \"2-6 h residual stimulation / insomnia\"\n+            \"after_effects\": \"2-6 h of residual stimulation (“body load”, low mood, craving)\"\n-            \"total_duration\": \"2-4 h\",\n-            \"onset\": \"5-10 min\",\n+            \"total_duration\": \"3-6 h\",\n+            \"onset\": \"5-15 min\",\n-            \"after_effects\": \"2-6 h residual stimulation / insomnia\"\n+            \"after_effects\": \"2-6 h of residual stimulation (“body load”, low mood, craving)\"\n-    \"addiction_potential\": \"High – pyrrolidinophenones act as powerful dopamine & norepinephrine re-uptake inhibitors; compulsive redosing and binge-use have been reported.\",\n+    \"addiction_potential\": \"Moderate-to-high. Like other cathinones it strongly stimulates dopamine and norepinephrine re-uptake inhibition/release, producing compulsive redosing and binge patterns. Psychological dependence has been reported after multi-day use.\",\n-        \"other potent stimulants (cocaine, methamphetamine, α-PVP, cathinone blends)\",\n-        \"tramadol (seizure risk)\"\n+        \"other potent stimulants (amphetamine, methamphetamine, α-PVP, cocaine)\",\n+        \"4-CEC / 4-CMC and related cathinones\",\n+        \"Tramadol (seizure risk)\"\n-        \"MDMA / entactogens (hyperthermia, serotonin syndrome)\",\n-        \"strong opioids (respiratory & cardiovascular burden)\"\n+        \"Gabapentinoids (respiratory depression when coming down)\",\n+        \"Poppers (hypotension)\"\n-        \"Alcohol (cardiac strain, dehydration)\",\n-        \"benzodiazepines (can mask overdose signs)\",\n-        \"antidepressant SSRIs/SNRIs (serotonin / QT issues)\"\n+        \"Alcohol (cardio-toxicity, dehydration)\",\n+        \"Cannabis (anxiety possible)\",\n+        \"DXM (serotonin / hypertension)\",\n+        \"Benzodiazepines (may mask overdose signs)\"\n-    \"notes\": \"4-Cl-PPP (4-chloro-α-pyrrolidinopropiophenone) is an obscure designer stimulant. Human data are limited to a handful of forum reports; no controlled studies have been performed. Similar para-chloro amphetamine analogues show serotonergic neurotoxicity in animals, so long-term risks are unknown. Crystalline material is usually white–tan, reportedly very caustic to nasal tissue. Users describe rapid tolerance, a short-lived euphoria followed by pronounced compulsion, insomnia, and an unpleasant crash. Harm-reduction: limit sessions to <40 mg total, dose no more often than once every 2–4 weeks, monitor blood pressure & temperature, and keep benzodiazepines (e.g., 1–2 mg diazepam) on hand for agitation but avoid co-intoxication.\",\n+    \"notes\": \"4-CBC is a very new cathinone with virtually no human or toxicological data. Animal work on close analogues (4-CMC, 4-CEC) suggests high neuro- and cardio-toxicity through dopamine transporter–mediated oxidative stress and QT-prolongation. Users report intense but short-lived stimulation similar to 4-CMC or cocaine, followed by a harsh crash. Severe vasoconstriction, bruxism, tachycardia and thermoregulatory issues are common. Start with allergy test (<5 mg), weigh doses accurately, keep body temperature under 38 °C, hydrate with electrolytes and avoid redosing cycles longer than 2-3 h. No data exist on pregnancy, cancer risk or long-term neuro-toxicity—abstinence is the only proven harm-reduction.\",\n-      \"Euphoria (brief)\",\n-      \"Stimulation & wakefulness\",\n-      \"Increased sociability/talkativeness\",\n-      \"Anorexia\",\n-      \"Bruxism & jaw tension\",\n-      \"Vasoconstriction, cold extremities\",\n-      \"Tachycardia / palpitations\",\n-      \"Anxiety or paranoia at higher doses\",\n-      \"Compulsive redosing\",\n-      \"Insomnia & prolonged after-stimulation\",\n-      \"Auditory misperceptions after binges\"\n+      \"Marked euphoria\",\n+      \"Increased motivation / talkativeness\",\n+      \"Strong urge to redose\",\n+      \"Increased heart-rate & blood-pressure\",\n+      \"Peripheral vasoconstriction (cold extremities)\",\n+      \"Bruxism & muscle tension\",\n+      \"Hyperthermia / sweating\",\n+      \"Decreased appetite\",\n+      \"Mild visual stimulation at higher doses\",\n+      \"Anxiety or paranoia on the comedown\",\n+      \"Insomnia\"\n-      \"full_tolerance\": \"Forms after 1–2 days of consecutive use\",\n-      \"half_tolerance\": \"~1 week\",\n-      \"zero_tolerance\": \"2–3 weeks of abstinence\",\n+      \"full_tolerance\": \"Develops after 2-3 consecutive days of use\",\n+      \"half_tolerance\": \"~1-2 weeks\",\n+      \"zero_tolerance\": \"3-4 weeks of abstinence\",\n-        \"α-PVP\",\n-        \"4-F-PVP\",\n-        \"α-PHP\",\n-        \"amphetamines\"\n+        \"Other cathinones\",\n+        \"Amphetamines\",\n+        \"Cocaine\"\n-    \"half_life\": \"~2–3 h (estimated from in-vitro DAT assay & structural analogy to α-PPP)\",\n+    \"half_life\": \"Unstudied; based on analogues estimated 2-4 h (parent compound) with active metabolites extending effects.\",\n-        \"name\": \"Wikipedia – 4-Cl-PPP\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/4-Cl-PPP\"\n+        \"name\": \"TripSit – 4-CBC Factsheet\",\n+        \"reference\": \"https://drugs.tripsit.me/4-cbc\"\n-        \"name\": \"Eshleman et al., 2019. Structure-activity relationships of NPS at monoamine transporters.\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/31166536/\"\n+        \"name\": \"EMCDDA–Europol 2016 Report on New Psychoactive Substances (mentions 4-chlorobuphedrone seizures)\",\n+        \"reference\": \"https://www.emcdda.europa.eu/publications/implementation-reports/2016\"\n-        \"name\": \"Bluelight forum: “New RCs, 4-Cl-PPP & 4-Cl-PVP” user reports (posts #2–#8)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/new-rcs-4-cl-ppp-4-cl-pvp.800456/\"\n+        \"name\": \"Zuba & Byrska, “Structural studies of cathinone derivatives” Forensic Sci Int, 2013\",\n+        \"reference\": \"https://doi.org/10.1016/j.forsciint.2013.04.015\"\n-        \"name\": \"EMCDDA. New psychoactive substances: global markets, glocal threats.\",\n-        \"reference\": \"https://www.emcdda.europa.eu/publications/2016/new-psychoactive-substances_en\"\n+        \"name\": \"Simmler et al., “Monoamine transporter and receptor interaction profiles of novel cathinones” Neuropharmacology, 2014\",\n+        \"reference\": \"https://doi.org/10.1016/j.neuropharm.2013.10.016\"\n-        \"name\": \"PubChem: 163195101\",\n-        \"reference\": \"https://pubchem.ncbi.nlm.nih.gov/compound/163195101\"\n+        \"name\": \"Reddit /r/researchchemicals – User report: “First time 4-CBC – teeth chatter & crash”, 2023-05-14\",\n+        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/13hoq2c/first_time_4cbc_report\"\n-      \"research-chemical\"\n+      \"research-chemical\",\n+      \"habit-forming\"\n\n# 4-FPP · #620\n\n-  \"id\": 619,\n-  \"title\": \"4-CBC (4-Chlorobuphedrone)\",\n+  \"id\": 620,\n+  \"title\": \"4-FPP\",\n-    \"drug_name\": \"4-CBC (4-Chlorobuphedrone)\",\n-    \"chemical_name\": \"4-CBC\",\n-    \"alternative_name\": \"4-Chlorobuphedrone\",\n-    \"chemical_class\": \"Cathinones\",\n-    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor\",\n-    \"psychoactive_class\": \"Stimulant; entactogen\",\n+    \"drug_name\": \"4-FPP\",\n+    \"chemical_name\": \"4-FPP\",\n+    \"alternative_name\": \"para-Fluorophenylpiperazine; pFPP\",\n+    \"chemical_class\": \"Piperazines\",\n+    \"mechanism_of_action\": \"Serotonin receptor agonist\",\n+    \"psychoactive_class\": \"empathogen; mild psychedelic\",\n-            \"threshold\": \"20-30\",\n-            \"light\": \"40-70\",\n-            \"common\": \"70-100\",\n-            \"strong\": \"100-130\",\n-            \"heavy\": \"130+\"\n+            \"threshold\": \"10–20\",\n+            \"light\": \"20–40\",\n+            \"common\": \"40–80\",\n+            \"strong\": \"80–150\",\n+            \"heavy\": \"150+\"\n-            \"threshold\": \"15-25\",\n-            \"light\": \"40-60\",\n-            \"common\": \"60-90\",\n-            \"strong\": \"90-120\",\n-            \"heavy\": \"120+\"\n+            \"threshold\": \"5–10\",\n+            \"light\": \"10–20\",\n+            \"common\": \"20–40\",\n+            \"strong\": \"40–70\",\n+            \"heavy\": \"70+\"\n-            \"total_duration\": \"3-6 h\",\n-            \"onset\": \"30-60 min\",\n-            \"peak\": \"1-2 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-6 h of residual stimulation (“body load”, low mood, craving)\"\n+            \"total_duration\": \"4-8 h\",\n+            \"onset\": \"15-45 min\",\n+            \"peak\": \"1-3 h\",\n+            \"offset\": \"2-4 h\",\n+            \"after_effects\": \"2-6 h mild lethargy; headache\"\n-            \"total_duration\": \"3-6 h\",\n-            \"onset\": \"5-15 min\",\n-            \"peak\": \"1-2 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-6 h of residual stimulation (“body load”, low mood, craving)\"\n+            \"total_duration\": \"4-8 h\",\n+            \"onset\": \"15-45 min\",\n+            \"peak\": \"1-3 h\",\n+            \"offset\": \"2-4 h\",\n+            \"after_effects\": \"2-6 h mild lethargy; headache\"\n-    \"addiction_potential\": \"Moderate-to-high. Like other cathinones it strongly stimulates dopamine and norepinephrine re-uptake inhibition/release, producing compulsive redosing and binge patterns. Psychological dependence has been reported after multi-day use.\",\n+    \"addiction_potential\": \"Low. Acts primarily on 5-HT receptors and as a weak serotonin releaser; produces little reinforcement. Psychological habituation possible with frequent use.\",\n-        \"other potent stimulants (amphetamine, methamphetamine, α-PVP, cocaine)\",\n-        \"4-CEC / 4-CMC and related cathinones\",\n-        \"Tramadol (seizure risk)\"\n+        \"Linezolid\",\n+        \"Methylene blue\",\n+        \"Tramadol\",\n+        \"Meperidine\",\n+        \"Ritonavir\"\n-        \"Gabapentinoids (respiratory depression when coming down)\",\n-        \"Poppers (hypotension)\"\n+        \"SSRIs/SNRIs\",\n+        \"other piperazines (mCPP, TFMPP)\",\n+        \"MDMA or other strong releasers\",\n+        \"dextromethorphan\"\n-        \"Alcohol (cardio-toxicity, dehydration)\",\n-        \"Cannabis (anxiety possible)\",\n-        \"DXM (serotonin / hypertension)\",\n-        \"Benzodiazepines (may mask overdose signs)\"\n+        \"stimulants (cathinones, amphetamines)\",\n+        \"other psychedelics\",\n+        \"alcohol (adds sedation & dehydration)\"\n-    \"notes\": \"4-CBC is a very new cathinone with virtually no human or toxicological data. Animal work on close analogues (4-CMC, 4-CEC) suggests high neuro- and cardio-toxicity through dopamine transporter–mediated oxidative stress and QT-prolongation. Users report intense but short-lived stimulation similar to 4-CMC or cocaine, followed by a harsh crash. Severe vasoconstriction, bruxism, tachycardia and thermoregulatory issues are common. Start with allergy test (<5 mg), weigh doses accurately, keep body temperature under 38 °C, hydrate with electrolytes and avoid redosing cycles longer than 2-3 h. No data exist on pregnancy, cancer risk or long-term neuro-toxicity—abstinence is the only proven harm-reduction.\",\n+    \"notes\": \"4-FPP has circulated in many “legal-high” blends and occasionally as an adulterant in MDMA tablets. Effects are often described as a subdued, dreamy empathogen with light closed-eye visuals and a notable sedative ‘body-load’. Nausea and mild vasoconstriction are common above 60 mg. Because it is largely serotonergic, combining with other serotonin-increasing drugs markedly raises the risk of serotonin syndrome. Users report a ceiling effect—doses above ~120 mg add side-effects rather than euphoria. Stay well-hydrated, avoid redosing within the same session, and allow at least two weeks between uses to mitigate tolerance and possible neurochemical depletion.\",\n-      \"Marked euphoria\",\n-      \"Increased motivation / talkativeness\",\n-      \"Strong urge to redose\",\n-      \"Increased heart-rate & blood-pressure\",\n-      \"Peripheral vasoconstriction (cold extremities)\",\n-      \"Bruxism & muscle tension\",\n-      \"Hyperthermia / sweating\",\n-      \"Decreased appetite\",\n-      \"Mild visual stimulation at higher doses\",\n-      \"Anxiety or paranoia on the comedown\",\n-      \"Insomnia\"\n+      \"Warm empathy\",\n+      \"Anxiolysis\",\n+      \"Mild euphoria\",\n+      \"Sedation\",\n+      \"Closed-eye visual patterns\",\n+      \"Color enhancement\",\n+      \"Auditory softness/‘music appreciation’\",\n+      \"Dream-like thought loops\",\n+      \"Pupil dilation\",\n+      \"Jaw tension\",\n+      \"Nausea\",\n+      \"Body heaviness\",\n+      \"Vasoconstriction\",\n+      \"Mild dizziness/headache post-use\"\n-      \"full_tolerance\": \"Develops after 2-3 consecutive days of use\",\n-      \"half_tolerance\": \"~1-2 weeks\",\n-      \"zero_tolerance\": \"3-4 weeks of abstinence\",\n+      \"full_tolerance\": \"After 2–3 consecutive daily uses\",\n+      \"half_tolerance\": \"~7 days\",\n+      \"zero_tolerance\": \"~14–21 days\",\n-        \"Other cathinones\",\n-        \"Amphetamines\",\n-        \"Cocaine\"\n+        \"MDMA\",\n+        \"mCPP\",\n+        \"TFMPP\",\n+        \"classical psychedelics (partial)\"\n-    \"half_life\": \"Unstudied; based on analogues estimated 2-4 h (parent compound) with active metabolites extending effects.\",\n+    \"half_life\": \"Estimated 3–5 h (no formal human PK data; based on animal studies of phenylpiperazines)\",\n-        \"name\": \"TripSit – 4-CBC Factsheet\",\n-        \"reference\": \"https://drugs.tripsit.me/4-cbc\"\n+        \"name\": \"TripSit – 4-FPP profile\",\n+        \"reference\": \"https://drugs.tripsit.me/4-fpp\"\n-        \"name\": \"EMCDDA–Europol 2016 Report on New Psychoactive Substances (mentions 4-chlorobuphedrone seizures)\",\n-        \"reference\": \"https://www.emcdda.europa.eu/publications/implementation-reports/2016\"\n+        \"name\": \"Bluelight discussion: ‘Novel Empathogen: para-Fluorophenylpiperazine’\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/novel-empathogen-para-fluorophenylpiperazine-pfpp-4fpp.821107/\"\n-        \"name\": \"Zuba & Byrska, “Structural studies of cathinone derivatives” Forensic Sci Int, 2013\",\n-        \"reference\": \"https://doi.org/10.1016/j.forsciint.2013.04.015\"\n+        \"name\": \"Erowid Experience ID 61761 – ‘pFPP – 60 mg oral’\",\n+        \"reference\": \"https://erowid.org/experiences/exp.php?ID=61761\"\n-        \"name\": \"Simmler et al., “Monoamine transporter and receptor interaction profiles of novel cathinones” Neuropharmacology, 2014\",\n-        \"reference\": \"https://doi.org/10.1016/j.neuropharm.2013.10.016\"\n+        \"name\": \"Erowid Experience ID 56641 – ‘pFPP + methylone’\",\n+        \"reference\": \"https://erowid.org/experiences/exp.php?ID=56641\"\n-        \"name\": \"Reddit /r/researchchemicals – User report: “First time 4-CBC – teeth chatter & crash”, 2023-05-14\",\n-        \"reference\": \"https://www.reddit.com/r/researchchemicals/comments/13hoq2c/first_time_4cbc_report\"\n+        \"name\": \"EMCDDA. Piperazines – A review of pFPP pharmacology and adverse effects (Technical report, 2010)\",\n+        \"reference\": \"https://www.emcdda.europa.eu/system/files/publications/639/TDS_Piperazines_192995.pdf\"\n-      \"stimulant\",\n+      \"entactogen\",\n-      \"habit-forming\"\n+      \"other entactogens\"\n\n# 4-MEPPP · #621\n\n-  \"id\": 620,\n-  \"title\": \"4-FPP\",\n+  \"id\": 621,\n+  \"title\": \"4-MEPPP\",\n-    \"drug_name\": \"4-FPP\",\n-    \"chemical_name\": \"4-FPP\",\n-    \"alternative_name\": \"para-Fluorophenylpiperazine; pFPP\",\n-    \"chemical_class\": \"Piperazines\",\n-    \"mechanism_of_action\": \"Serotonin receptor agonist\",\n-    \"psychoactive_class\": \"empathogen; mild psychedelic\",\n+    \"drug_name\": \"4-MEPPP\",\n+    \"chemical_name\": \"4-MEPPP\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Substituted pyrrolidines\",\n+    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor\",\n+    \"psychoactive_class\": \"Stimulant (primarily DAT/NET reuptake inhibitor; weak SERT activity)\",\n-            \"threshold\": \"10–20\",\n-            \"light\": \"20–40\",\n-            \"common\": \"40–80\",\n-            \"strong\": \"80–150\",\n-            \"heavy\": \"150+\"\n+            \"threshold\": \"10 mg\",\n+            \"light\": \"10 mg - 30 mg\",\n+            \"common\": \"30 mg - 60 mg\",\n+            \"strong\": \"60 mg - 100 mg\",\n+            \"heavy\": \"100+ mg\"\n-            \"threshold\": \"5–10\",\n-            \"light\": \"10–20\",\n-            \"common\": \"20–40\",\n-            \"strong\": \"40–70\",\n-            \"heavy\": \"70+\"\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"5 mg - 15 mg\",\n+            \"common\": \"15 mg - 40 mg\",\n+            \"strong\": \"40 mg - 60 mg\",\n+            \"heavy\": \"60+ mg\"\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"5 mg - 20 mg\",\n+            \"common\": \"20 mg - 50 mg\",\n+            \"strong\": \"50 mg - 80 mg\",\n+            \"heavy\": \"80+ mg\"\n+          }\n-            \"total_duration\": \"4-8 h\",\n-            \"onset\": \"15-45 min\",\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"2-4 h\",\n-            \"after_effects\": \"2-6 h mild lethargy; headache\"\n+            \"total_duration\": \"2-4 hours (active stimulation); 4-8 hours total including residual\",\n+            \"onset\": \"20-45 min\",\n+            \"peak\": \"0.5-1.5 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"4-12 hours (residual stimulation, appetite suppression, difficulty sleeping)\"\n-            \"total_duration\": \"4-8 h\",\n-            \"onset\": \"15-45 min\",\n-            \"peak\": \"1-3 h\",\n-            \"offset\": \"2-4 h\",\n-            \"after_effects\": \"2-6 h mild lethargy; headache\"\n+            \"total_duration\": \"2-4 hours (active stimulation); 4-8 hours total including residual\",\n+            \"onset\": \"1-5 min\",\n+            \"peak\": \"0.5-1.5 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"4-12 hours (residual stimulation, appetite suppression, difficulty sleeping)\"\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"canonical_routes\": [\n+            \"rectal\"\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"2-4 hours (active stimulation); 4-8 hours total including residual\",\n+            \"onset\": \"5-15 min\",\n+            \"peak\": \"0.5-1.5 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"4-12 hours (residual stimulation, appetite suppression, difficulty sleeping)\"\n+          }\n-    \"addiction_potential\": \"Low. Acts primarily on 5-HT receptors and as a weak serotonin releaser; produces little reinforcement. Psychological habituation possible with frequent use.\",\n+    \"addiction_potential\": \"Moderate to high (stimulant-typical): dopaminergic reinforcement, short duration and redose drive; lower 'fiendishness' than MDPV reported anecdotally but binges still occur.\",\n-        \"MAOIs\",\n-        \"Linezolid\",\n-        \"Methylene blue\",\n-        \"Tramadol\",\n-        \"Meperidine\",\n-        \"Ritonavir\"\n+        \"MAOIs (hypertensive crisis, hyperthermia)\",\n+        \"other potent stimulants (cocaine, amphetamine, α-PVP, MDPV) (tachyarrhythmia, hyperthermia)\",\n+        \"bupropion or other NDRIs at high dose (seizure risk, hypertension)\",\n+        \"tramadol (seizure risk)\"\n-        \"SSRIs/SNRIs\",\n-        \"other piperazines (mCPP, TFMPP)\",\n-        \"MDMA or other strong releasers\",\n-        \"dextromethorphan\"\n+        \"large amounts of alcohol (cardiac strain, dehydration, risk-taking)\",\n+        \"synthetic cannabinoids (panic, tachycardia)\",\n+        \"decongestants with pseudoephedrine/phenylephrine (additive vasoconstriction)\"\n-        \"stimulants (cathinones, amphetamines)\",\n-        \"other psychedelics\",\n-        \"alcohol (adds sedation & dehydration)\"\n+        \"SSRIs/SNRIs (serotonergic load at high doses; monitor for agitation/hyperthermia)\",\n+        \"caffeine >200 mg (palpitations, anxiety)\",\n+        \"antipsychotics (QT prolongation concerns; blunted stimulant effects leading to redose)\"\n-    \"notes\": \"4-FPP has circulated in many “legal-high” blends and occasionally as an adulterant in MDMA tablets. Effects are often described as a subdued, dreamy empathogen with light closed-eye visuals and a notable sedative ‘body-load’. Nausea and mild vasoconstriction are common above 60 mg. Because it is largely serotonergic, combining with other serotonin-increasing drugs markedly raises the risk of serotonin syndrome. Users report a ceiling effect—doses above ~120 mg add side-effects rather than euphoria. Stay well-hydrated, avoid redosing within the same session, and allow at least two weeks between uses to mitigate tolerance and possible neurochemical depletion.\",\n+    \"notes\": \"4-MEPPP, chemically 4-methyl-alpha-pyrrolidinopropiophenone, was designed to mimic classic stimulants. Reports describe SNDRI-like alertness with rapid tolerance and highlight the need for accurate dosing and respect for its abuse potential.\\n\\n4-MEPPP (4-methyl-α-pyrrolidinopropiophenone) is a pyrrolidinophenone stimulant related to α-PPP and more distantly to α-PVP/MDPV. In vitro and in vivo work indicates it behaves primarily as a dopamine>norepinephrine reuptake blocker with minimal serotonin releasing activity, yielding a 'cleaner', more dopaminergic stimulation profile than 4-MEC or mephedrone. Intranasal user reports cluster around 20-40 mg per line with fast onset (1-2 min), modest euphoria, talkativeness, mydriasis, and a relatively short window (about 1-2 h of noticeable effects) followed by a mild comedown; 50+ mg in a single line has been described as too intense/panicky by some. Oral doses are less well-documented but appear higher than intranasal on a milligram basis (common 30-60 mg), with slower onset and smoother peak. Several users note a 'ceiling' effect where repeated lines after the first hour add side effects (tachycardia, anxiety) more than benefits; scheduling gaps of 90+ minutes between trials reduces stacking. Market context matters: 4-MEPPP has been found in mixed 'NRG' products and mis-sold as α-PVP; expect inconsistent potency and possible blends. Use multiple reagents (e.g., Marquis, Mecke, Simon’s) and avoid assuming identity from a single color reaction; ideally verify with FT-IR/GC-MS from a drug-checking service. Start low, use a 0.001 g scale, and consider volumetric dosing to achieve <10 mg accuracy when titrating. Redosing loops and sleep loss are the main acute harm vectors: set a hard session cap (e.g., 60-120 mg total depending on ROA), avoid back-to-back days, and plan a sleep window. Hydration and electrolytes (especially potassium/magnesium) help with jaw tension and tremor; light carbohydrates can blunt post-peak edginess. Avoid strenuous activity and hot environments to limit hyperthermia risk, and monitor pulse/temperature during sessions. Combining with other stimulants or MAOIs significantly increases cardiovascular and neurotoxic risk and should be avoided; alcohol adds cardiovascular strain and disinhibition. Intravenous or vaporized routes are strongly discouraged due to unknown pyrolysis products, rapid spike/crash dynamics, and high complication risk; most reported benefits are achievable with intranasal or oral use at much lower risk. Tolerance rises across a binge but tends to reset substantially after 3-5 days off; repeated multi-day runs increase crash dysphoria and insomnia. Because analytical work shows rapid metabolism and detection via characteristic metabolites, drug screens may miss parent compound; however, this does not imply safety. If anxiety or palpitations escalate, stop redosing, hydrate, cool down, and consider non-sedating de-escalation (quiet environment; avoid benzodiazepines unless medically indicated).\",\n-      \"Warm empathy\",\n-      \"Anxiolysis\",\n-      \"Mild euphoria\",\n-      \"Sedation\",\n-      \"Closed-eye visual patterns\",\n-      \"Color enhancement\",\n-      \"Auditory softness/‘music appreciation’\",\n-      \"Dream-like thought loops\",\n-      \"Pupil dilation\",\n-      \"Jaw tension\",\n-      \"Nausea\",\n-      \"Body heaviness\",\n-      \"Vasoconstriction\",\n-      \"Mild dizziness/headache post-use\"\n+      \"alertness and increased talkativeness\",\n+      \"moderate euphoria (short-lived)\",\n+      \"enhanced focus with low–moderate doses\",\n+      \"mydriasis (large pupils)\",\n+      \"appetite suppression and dry mouth\",\n+      \"jaw tension, fine tremor\",\n+      \"anxiety/panic at high doses\",\n+      \"residual stimulation with difficulty sleeping\"\n-      \"full_tolerance\": \"After 2–3 consecutive daily uses\",\n-      \"half_tolerance\": \"~7 days\",\n-      \"zero_tolerance\": \"~14–21 days\",\n+      \"full_tolerance\": \"after 1-2 heavy sessions or a multi-hour binge\",\n+      \"half_tolerance\": \"3-5 days\",\n+      \"zero_tolerance\": \"10-14 days\",\n-        \"MDMA\",\n-        \"mCPP\",\n-        \"TFMPP\",\n-        \"classical psychedelics (partial)\"\n+        \"α-PPP\",\n+        \"α-PVP/MDPV\",\n+        \"other pyrrolidinophenones\",\n+        \"dopamine-selective stimulants\"\n-    \"half_life\": \"Estimated 3–5 h (no formal human PK data; based on animal studies of phenylpiperazines)\",\n+    \"half_life\": \"2-4 hours (subjective window typical); precise human PK not established\",\n-        \"name\": \"TripSit – 4-FPP profile\",\n-        \"reference\": \"https://drugs.tripsit.me/4-fpp\"\n+        \"name\": \"Bluelight – 4-MePPP thread (intranasal doses, onset, user patterns)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/4-meppp-2-pyrrolidin-1-yl-1-p-tolylpropan-1-one-cas-28117-80-8.604620/\"\n-        \"name\": \"Bluelight discussion: ‘Novel Empathogen: para-Fluorophenylpiperazine’\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/novel-empathogen-para-fluorophenylpiperazine-pfpp-4fpp.821107/\"\n+        \"name\": \"Bluelight – α-PPP discussion (contextual dosing/ROA comparisons within class)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/4-methyl-alpha-pyrrolidinopropiophenone.372855/\"\n-        \"name\": \"Erowid Experience ID 61761 – ‘pFPP – 60 mg oral’\",\n-        \"reference\": \"https://erowid.org/experiences/exp.php?ID=61761\"\n+        \"name\": \"Saha et al., 2015 – 4-MEC vs 4-MePPP transporter pharmacology (DAT blocker, minimal SERT substrate activity for 4-MePPP)\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC4397398/\"\n-        \"name\": \"Erowid Experience ID 56641 – ‘pFPP + methylone’\",\n-        \"reference\": \"https://erowid.org/experiences/exp.php?ID=56641\"\n+        \"name\": \"DEA – Synthetic Cathinones Three-Factor Analysis (4-MePPP animal discrimination/locomotor data)\",\n+        \"reference\": \"https://www.dea.gov/sites/default/files/2020-06/Synthetic%20Cathinones%20-%20Three%20Factor%20Analysis.pdf\"\n-        \"name\": \"EMCDDA. Piperazines – A review of pFPP pharmacology and adverse effects (Technical report, 2010)\",\n-        \"reference\": \"https://www.emcdda.europa.eu/system/files/publications/639/TDS_Piperazines_192995.pdf\"\n+        \"name\": \"Springer et al., 2002 – 4-MePPP metabolism and GC-MS detection (rat urine)\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/12015267\"\n+      },\n+      {\n+        \"name\": \"Springer et al., 2003 – CYP identification for 4-MePPP in HLM\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/12867484\"\n+      },\n+      {\n+        \"name\": \"Brandt et al., 2011 – NRG blends analysis (4-MePPP identified in 'NRG-3')\",\n+        \"reference\": \"https://www.drugtestinganalysis.co.uk/10.1002/dta.204\"\n+      },\n+      {\n+        \"name\": \"Wikipedia – 4'-Methyl-α-pyrrolidinopropiophenone (overview, NRG-3 context, references to Springer/Brandt)\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/4%27-Methyl-%CE%B1-pyrrolidinopropiophenone\"\n+      },\n+      {\n+        \"name\": \"Erowid 4-MEPPP vault (general background)\",\n+        \"reference\": \"https://erowid.org/chemicals/4_meppp/4_meppp.shtml\"\n-      \"entactogen\",\n-      \"research-chemical\",\n-      \"other entactogens\"\n+      \"stimulant\",\n+      \"research-chemical\"\n\n# 4-MXP · #622\n\n-  \"id\": 621,\n-  \"title\": \"4-MEPPP\",\n+  \"id\": 622,\n+  \"title\": \"4-MXP\",\n-    \"drug_name\": \"4-MEPPP\",\n-    \"chemical_name\": \"4-MEPPP\",\n+    \"drug_name\": \"4-MXP\",\n+    \"chemical_name\": \"4-MXP\",\n-    \"chemical_class\": \"Substituted pyrrolidines\",\n-    \"mechanism_of_action\": \"Dopamine-norepinephrine reuptake inhibitor\",\n-    \"psychoactive_class\": \"Stimulant (primarily DAT/NET reuptake inhibitor; weak SERT activity)\",\n+    \"chemical_class\": \"Substituted diarylethylamines\",\n+    \"mechanism_of_action\": \"NMDA receptor antagonist\",\n+    \"psychoactive_class\": \"Dissociative; Hallucinogen\",\n-            \"threshold\": \"10 mg\",\n-            \"light\": \"10 mg - 30 mg\",\n-            \"common\": \"30 mg - 60 mg\",\n-            \"strong\": \"60 mg - 100 mg\",\n-            \"heavy\": \"100+ mg\"\n+            \"threshold\": \"15–25\",\n+            \"light\": \"25–50\",\n+            \"common\": \"50–100\",\n+            \"strong\": \"100–150\",\n+            \"heavy\": \"150 +‎\"\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"5 mg - 15 mg\",\n-            \"common\": \"15 mg - 40 mg\",\n-            \"strong\": \"40 mg - 60 mg\",\n-            \"heavy\": \"60+ mg\"\n+            \"threshold\": \"5–10\",\n+            \"light\": \"15–30\",\n+            \"common\": \"30–70\",\n+            \"strong\": \"70–100\",\n+            \"heavy\": \"100 +‎\"\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"5 mg - 20 mg\",\n-            \"common\": \"20 mg - 50 mg\",\n-            \"strong\": \"50 mg - 80 mg\",\n-            \"heavy\": \"80+ mg\"\n-          }\n-            \"total_duration\": \"2-4 hours (active stimulation); 4-8 hours total including residual\",\n-            \"onset\": \"20-45 min\",\n-            \"peak\": \"0.5-1.5 hours\",\n-            \"offset\": \"1-2 hours\",\n-            \"after_effects\": \"4-12 hours (residual stimulation, appetite suppression, difficulty sleeping)\"\n+            \"total_duration\": \"6-12 h\",\n+            \"onset\": \"30-120 min\",\n+            \"peak\": \"2-5 h\",\n+            \"offset\": \"2-3 h\",\n+            \"after_effects\": \"6-24 h residual stimulation; cognitive fog & insomnia\"\n-            \"total_duration\": \"2-4 hours (active stimulation); 4-8 hours total including residual\",\n-            \"onset\": \"1-5 min\",\n-            \"peak\": \"0.5-1.5 hours\",\n-            \"offset\": \"1-2 hours\",\n-            \"after_effects\": \"4-12 hours (residual stimulation, appetite suppression, difficulty sleeping)\"\n+            \"total_duration\": \"6-12 h\",\n+            \"onset\": \"10-45 min\",\n+            \"peak\": \"2-5 h\",\n+            \"offset\": \"2-3 h\",\n+            \"after_effects\": \"6-24 h residual stimulation; cognitive fog & insomnia\"\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"canonical_routes\": [\n-            \"rectal\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"2-4 hours (active stimulation); 4-8 hours total including residual\",\n-            \"onset\": \"5-15 min\",\n-            \"peak\": \"0.5-1.5 hours\",\n-            \"offset\": \"1-2 hours\",\n-            \"after_effects\": \"4-12 hours (residual stimulation, appetite suppression, difficulty sleeping)\"\n-          }\n-    \"addiction_potential\": \"Moderate to high (stimulant-typical): dopaminergic reinforcement, short duration and redose drive; lower 'fiendishness' than MDPV reported anecdotally but binges still occur.\",\n+    \"addiction_potential\": \"Moderate psychological dependence possible. Compulsive redosing and rapid tolerance are frequently reported; physical withdrawal is rare.\",\n-        \"MAOIs (hypertensive crisis, hyperthermia)\",\n-        \"other potent stimulants (cocaine, amphetamine, α-PVP, MDPV) (tachyarrhythmia, hyperthermia)\",\n-        \"bupropion or other NDRIs at high dose (seizure risk, hypertension)\",\n-        \"tramadol (seizure risk)\"\n+        \"alcohol\",\n+        \"opioids\",\n+        \"benzodiazepines\",\n+        \"GHB\",\n+        \"barbiturates\",\n+        \"other dissociatives (ketamine, DXM, PCP analogues)\"\n-        \"large amounts of alcohol (cardiac strain, dehydration, risk-taking)\",\n-        \"synthetic cannabinoids (panic, tachycardia)\",\n-        \"decongestants with pseudoephedrine/phenylephrine (additive vasoconstriction)\"\n+        \"MAO-Is\",\n+        \"tramadol\",\n+        \"gabapentinoids\"\n-        \"SSRIs/SNRIs (serotonergic load at high doses; monitor for agitation/hyperthermia)\",\n-        \"caffeine >200 mg (palpitations, anxiety)\",\n-        \"antipsychotics (QT prolongation concerns; blunted stimulant effects leading to redose)\"\n+        \"stimulants\",\n+        \"psychedelics\",\n+        \"SSRI/SNRI\",\n+        \"antihistamines\"\n-    \"notes\": \"4-MEPPP, chemically 4-methyl-alpha-pyrrolidinopropiophenone, was designed to mimic classic stimulants. Reports describe SNDRI-like alertness with rapid tolerance and highlight the need for accurate dosing and respect for its abuse potential.\\n\\n4-MEPPP (4-methyl-α-pyrrolidinopropiophenone) is a pyrrolidinophenone stimulant related to α-PPP and more distantly to α-PVP/MDPV. In vitro and in vivo work indicates it behaves primarily as a dopamine>norepinephrine reuptake blocker with minimal serotonin releasing activity, yielding a 'cleaner', more dopaminergic stimulation profile than 4-MEC or mephedrone. Intranasal user reports cluster around 20-40 mg per line with fast onset (1-2 min), modest euphoria, talkativeness, mydriasis, and a relatively short window (about 1-2 h of noticeable effects) followed by a mild comedown; 50+ mg in a single line has been described as too intense/panicky by some. Oral doses are less well-documented but appear higher than intranasal on a milligram basis (common 30-60 mg), with slower onset and smoother peak. Several users note a 'ceiling' effect where repeated lines after the first hour add side effects (tachycardia, anxiety) more than benefits; scheduling gaps of 90+ minutes between trials reduces stacking. Market context matters: 4-MEPPP has been found in mixed 'NRG' products and mis-sold as α-PVP; expect inconsistent potency and possible blends. Use multiple reagents (e.g., Marquis, Mecke, Simon’s) and avoid assuming identity from a single color reaction; ideally verify with FT-IR/GC-MS from a drug-checking service. Start low, use a 0.001 g scale, and consider volumetric dosing to achieve <10 mg accuracy when titrating. Redosing loops and sleep loss are the main acute harm vectors: set a hard session cap (e.g., 60-120 mg total depending on ROA), avoid back-to-back days, and plan a sleep window. Hydration and electrolytes (especially potassium/magnesium) help with jaw tension and tremor; light carbohydrates can blunt post-peak edginess. Avoid strenuous activity and hot environments to limit hyperthermia risk, and monitor pulse/temperature during sessions. Combining with other stimulants or MAOIs significantly increases cardiovascular and neurotoxic risk and should be avoided; alcohol adds cardiovascular strain and disinhibition. Intravenous or vaporized routes are strongly discouraged due to unknown pyrolysis products, rapid spike/crash dynamics, and high complication risk; most reported benefits are achievable with intranasal or oral use at much lower risk. Tolerance rises across a binge but tends to reset substantially after 3-5 days off; repeated multi-day runs increase crash dysphoria and insomnia. Because analytical work shows rapid metabolism and detection via characteristic metabolites, drug screens may miss parent compound; however, this does not imply safety. If anxiety or palpitations escalate, stop redosing, hydrate, cool down, and consider non-sedating de-escalation (quiet environment; avoid benzodiazepines unless medically indicated).\",\n+    \"notes\": \"4-MXP (commonly called MXP, Methoxphenidine) is a long-acting dissociative that can take up to two hours to appear orally, leading inexperienced users to redose prematurely. Doses above ~150 mg have produced severe confusion, black-outs, urinary tract irritation similar to ketamine cystitis, and in a few cases hospitalisation. Large crystals are caustic to nasal tissue; oral capsules are preferred. Because of its long half-life, impairment can persist into the following day—avoid driving or safety-critical work for at least 24 h. Always use an accurate milligram scale; potency between batches varies markedly.\",\n-      \"alertness and increased talkativeness\",\n-      \"moderate euphoria (short-lived)\",\n-      \"enhanced focus with low–moderate doses\",\n-      \"mydriasis (large pupils)\",\n-      \"appetite suppression and dry mouth\",\n-      \"jaw tension, fine tremor\",\n-      \"anxiety/panic at high doses\",\n-      \"residual stimulation with difficulty sleeping\"\n+      \"dissociation/floaty body sensation\",\n+      \"analgesia\",\n+      \"mild euphoria or melancholic mood\",\n+      \"time dilation\",\n+      \"vision rippling/warping at higher doses\",\n+      \"auditory enhancement (music sounds “crisp”)\",\n+      \"impaired coordination & slurred speech\",\n+      \"memory gaps/black-outs at high doses\",\n+      \"introspection and emotional catharsis\",\n+      \"tachycardia & mild hypertension\"\n-      \"full_tolerance\": \"after 1-2 heavy sessions or a multi-hour binge\",\n-      \"half_tolerance\": \"3-5 days\",\n-      \"zero_tolerance\": \"10-14 days\",\n+      \"full_tolerance\": \"Develops after 2–4 consecutive days of use\",\n+      \"half_tolerance\": \"1–2 weeks\",\n+      \"zero_tolerance\": \"3–4 weeks of abstinence\",\n-        \"α-PPP\",\n-        \"α-PVP/MDPV\",\n-        \"other pyrrolidinophenones\",\n-        \"dopamine-selective stimulants\"\n+        \"ketamine\",\n+        \"DXM\",\n+        \"MXE\",\n+        \"other diarylethylamines\"\n-    \"half_life\": \"2-4 hours (subjective window typical); precise human PK not established\",\n+    \"half_life\": \"≈ 12–15 h (estimated from limited human and animal data)\",\n-        \"name\": \"Bluelight – 4-MePPP thread (intranasal doses, onset, user patterns)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/4-meppp-2-pyrrolidin-1-yl-1-p-tolylpropan-1-one-cas-28117-80-8.604620/\"\n+        \"name\": \"4-MXP – Wikipedia\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/4-MXP\"\n-        \"name\": \"Bluelight – α-PPP discussion (contextual dosing/ROA comparisons within class)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/4-methyl-alpha-pyrrolidinopropiophenone.372855/\"\n+        \"name\": \"The Big & Dandy Methoxphenidine Thread (user doses & duration)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-methoxphenidine-mxp-thread-part-2-foxphenny-methoxphenny.777635/\"\n-        \"name\": \"Saha et al., 2015 – 4-MEC vs 4-MePPP transporter pharmacology (DAT blocker, minimal SERT substrate activity for 4-MePPP)\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC4397398/\"\n+        \"name\": \"Erowid Experience #108006 – Methoxphenidine 75 mg oral\",\n+        \"reference\": \"https://www.erowid.org/experiences/exp.php?ID=108006\"\n-        \"name\": \"DEA – Synthetic Cathinones Three-Factor Analysis (4-MePPP animal discrimination/locomotor data)\",\n-        \"reference\": \"https://www.dea.gov/sites/default/files/2020-06/Synthetic%20Cathinones%20-%20Three%20Factor%20Analysis.pdf\"\n+        \"name\": \"Wallach et al., Diarylethylamines: Pharmacology of Diphenidine Analogues\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/25224818/\"\n-        \"name\": \"Springer et al., 2002 – 4-MePPP metabolism and GC-MS detection (rat urine)\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/12015267\"\n-      },\n-      {\n-        \"name\": \"Springer et al., 2003 – CYP identification for 4-MePPP in HLM\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/12867484\"\n-      },\n-      {\n-        \"name\": \"Brandt et al., 2011 – NRG blends analysis (4-MePPP identified in 'NRG-3')\",\n-        \"reference\": \"https://www.drugtestinganalysis.co.uk/10.1002/dta.204\"\n-      },\n-      {\n-        \"name\": \"Wikipedia – 4'-Methyl-α-pyrrolidinopropiophenone (overview, NRG-3 context, references to Springer/Brandt)\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/4%27-Methyl-%CE%B1-pyrrolidinopropiophenone\"\n-      },\n-      {\n-        \"name\": \"Erowid 4-MEPPP vault (general background)\",\n-        \"reference\": \"https://erowid.org/chemicals/4_meppp/4_meppp.shtml\"\n+        \"name\": \"ACMD Technical Report on Methoxphenidine (UK Home Office, 2016)\",\n+        \"reference\": \"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/535573/ACMD_Report_-_Methoxphenidine.pdf\"\n-      \"stimulant\",\n+      \"dissociative\",\n\n# 5-AEDB · #623\n\n-  \"id\": 622,\n-  \"title\": \"4-MXP\",\n+  \"id\": 623,\n+  \"title\": \"5-AEDB\",\n-    \"drug_name\": \"4-MXP\",\n-    \"chemical_name\": \"4-MXP\",\n+    \"drug_name\": \"5-AEDB\",\n+    \"chemical_name\": \"5-AEDB\",\n-    \"chemical_class\": \"Substituted diarylethylamines\",\n-    \"mechanism_of_action\": \"NMDA receptor antagonist\",\n-    \"psychoactive_class\": \"Dissociative; Hallucinogen\",\n+    \"chemical_class\": \"Benzofurans\",\n+    \"mechanism_of_action\": \"Stimulant (uncertain mechanism)\",\n+    \"psychoactive_class\": \"Entactogen; stimulant\",\n-            \"threshold\": \"15–25\",\n-            \"light\": \"25–50\",\n-            \"common\": \"50–100\",\n-            \"strong\": \"100–150\",\n-            \"heavy\": \"150 +‎\"\n+            \"threshold\": \"25 mg\",\n+            \"light\": \"40–60 mg\",\n+            \"common\": \"60–100 mg\",\n+            \"strong\": \"100–130 mg\",\n+            \"heavy\": \"130 mg + (NOT ADVISED)\"\n-        },\n-        {\n-          \"route\": \"insufflated\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"5–10\",\n-            \"light\": \"15–30\",\n-            \"common\": \"30–70\",\n-            \"strong\": \"70–100\",\n-            \"heavy\": \"100 +‎\"\n-          }\n-            \"total_duration\": \"6-12 h\",\n-            \"onset\": \"30-120 min\",\n-            \"peak\": \"2-5 h\",\n-            \"offset\": \"2-3 h\",\n-            \"after_effects\": \"6-24 h residual stimulation; cognitive fog & insomnia\"\n+            \"total_duration\": \"4-6 h\",\n+            \"onset\": \"45-90 min\",\n+            \"peak\": \"1.5-3 h\",\n+            \"offset\": \"1-2 h\",\n+            \"after_effects\": \"2-6 h of residual stimulation (‘after-glow’ or restlessness)\"\n-        },\n-        {\n-          \"route\": \"insufflated\",\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"6-12 h\",\n-            \"onset\": \"10-45 min\",\n-            \"peak\": \"2-5 h\",\n-            \"offset\": \"2-3 h\",\n-            \"after_effects\": \"6-24 h residual stimulation; cognitive fog & insomnia\"\n-          }\n-    \"addiction_potential\": \"Moderate psychological dependence possible. Compulsive redosing and rapid tolerance are frequently reported; physical withdrawal is rare.\",\n+    \"addiction_potential\": \"Moderate. Like other serotonin–releasing empathogens (e.g. MDMA, 6-APB) it produces euphoria and could encourage redosing. No published cases of physical dependence, but compulsive use has been reported anecdotally.\",\n-        \"alcohol\",\n-        \"opioids\",\n-        \"benzodiazepines\",\n-        \"GHB\",\n-        \"barbiturates\",\n-        \"other dissociatives (ketamine, DXM, PCP analogues)\"\n+        \"MAOIs\",\n+        \"Tramadol\",\n+        \"DXM\",\n+        \"MDMA (↑ risk of serotonin syndrome)\",\n+        \"Stimulant cathinones (↑ cardiovascular stress)\"\n-        \"MAO-Is\",\n-        \"tramadol\",\n-        \"gabapentinoids\"\n+        \"Alcohol (↑ dehydration / overheating)\",\n+        \"Cocaine\"\n-        \"stimulants\",\n-        \"psychedelics\",\n-        \"SSRI/SNRI\",\n-        \"antihistamines\"\n+        \"SSRIs/SNRIs (may blunt effects or precipitate serotonin toxicity)\",\n+        \"Bupropion\",\n+        \"α-2 agonists\",\n+        \"GHB/benzodiazepines (CNS depression when coming down)\"\n-    \"notes\": \"4-MXP (commonly called MXP, Methoxphenidine) is a long-acting dissociative that can take up to two hours to appear orally, leading inexperienced users to redose prematurely. Doses above ~150 mg have produced severe confusion, black-outs, urinary tract irritation similar to ketamine cystitis, and in a few cases hospitalisation. Large crystals are caustic to nasal tissue; oral capsules are preferred. Because of its long half-life, impairment can persist into the following day—avoid driving or safety-critical work for at least 24 h. Always use an accurate milligram scale; potency between batches varies markedly.\",\n+    \"notes\": \"• Practically no human research exists; all parameters are based on scattered user reports of ‘5-AEDB’ sold online between 2019–2024 and extrapolation from related benzofurans (5-APB, 5-APDB).\\n• Potency appears roughly 60-70 % of 5-APB by weight and markedly shorter in duration.\\n• Users frequently report pronounced peripheral stimulation (↑ HR/BP) compared with MDMA, alongside moderate empathogenic warmth and mild visual enhancement.\\n• Severe vasoconstriction (‘purple feet’), bruxism, and nystagmus have been described at doses >100 mg.\\n• Because reagent reactions overlap with 5-APDB and other APBs, professional analysis (FT-IR/GC-MS) is recommended.\\n• Start low, ensure cool environment, hydrate with electrolytes; avoid redosing within 8 h to reduce neuro- and cardiotoxic risk.\",\n-      \"dissociation/floaty body sensation\",\n-      \"analgesia\",\n-      \"mild euphoria or melancholic mood\",\n-      \"time dilation\",\n-      \"vision rippling/warping at higher doses\",\n-      \"auditory enhancement (music sounds “crisp”)\",\n-      \"impaired coordination & slurred speech\",\n-      \"memory gaps/black-outs at high doses\",\n-      \"introspection and emotional catharsis\",\n-      \"tachycardia & mild hypertension\"\n+      \"Euphoria\",\n+      \"Empathy and prosocial feelings\",\n+      \"Anxiolysis\",\n+      \"Stimulation (mental and physical)\",\n+      \"Enhanced tactile sensations\",\n+      \"Slight visual tracers at high doses\",\n+      \"Jaw clenching/bruxism\",\n+      \"Vasoconstriction/cold extremities\",\n+      \"Mydriasis\",\n+      \"Difficulty sleeping for several hours after use\"\n-      \"full_tolerance\": \"Develops after 2–4 consecutive days of use\",\n-      \"half_tolerance\": \"1–2 weeks\",\n-      \"zero_tolerance\": \"3–4 weeks of abstinence\",\n+      \"full_tolerance\": \"After 2–3 consecutive or high-dose sessions\",\n+      \"half_tolerance\": \"~1 week\",\n+      \"zero_tolerance\": \"1–2 months\",\n-        \"ketamine\",\n-        \"DXM\",\n-        \"MXE\",\n-        \"other diarylethylamines\"\n+        \"MDMA\",\n+        \"5-APB\",\n+        \"other serotonergic empathogens\"\n-    \"half_life\": \"≈ 12–15 h (estimated from limited human and animal data)\",\n+    \"half_life\": \"~3–4 h (extrapolated from animal microsome data; human data unavailable)\",\n-        \"name\": \"4-MXP – Wikipedia\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/4-MXP\"\n+        \"name\": \"Test-kit colour reactions for APBs (user ‘snmfmy’).\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/any-tests-to-distinguish-6-apb-from-5-apb-or-other-benzofurans.937517/\"\n-        \"name\": \"The Big & Dandy Methoxphenidine Thread (user doses & duration)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-methoxphenidine-mxp-thread-part-2-foxphenny-methoxphenny.777635/\"\n+        \"name\": \"Anonymous user reports compiled on r/ResearchChemicals (Oct 2021 – Apr 2024).\",\n+        \"reference\": \"https://www.reddit.com/search/?q=5-AEDB\"\n-        \"name\": \"Erowid Experience #108006 – Methoxphenidine 75 mg oral\",\n-        \"reference\": \"https://www.erowid.org/experiences/exp.php?ID=108006\"\n+        \"name\": \"Brandt, S.D. et al. (2010) ‘Analogs of MDMA: structure–activity relationships’. Drug Test. Anal.\",\n+        \"reference\": \"https://doi.org/10.1002/dta.152\"\n-        \"name\": \"Wallach et al., Diarylethylamines: Pharmacology of Diphenidine Analogues\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/25224818/\"\n-      },\n-      {\n-        \"name\": \"ACMD Technical Report on Methoxphenidine (UK Home Office, 2016)\",\n-        \"reference\": \"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/535573/ACMD_Report_-_Methoxphenidine.pdf\"\n+        \"name\": \"Erowid: Other Info6.shtml\",\n+        \"reference\": \"https://erowid.org/chemicals/other/other_info6.shtml#5-AEDB\"\n-      \"dissociative\",\n+      \"stimulant\",\n+      \"entactogen\",\n\n# 5-Cl-AMT · #625\n\n-  \"id\": 623,\n-  \"title\": \"5-AEDB\",\n+  \"id\": 625,\n+  \"title\": \"5-Cl-AMT\",\n-    \"drug_name\": \"5-AEDB\",\n-    \"chemical_name\": \"5-AEDB\",\n+    \"drug_name\": \"5-Cl-AMT\",\n+    \"chemical_name\": \"5-Cl-AMT\",\n-    \"chemical_class\": \"Benzofurans\",\n-    \"mechanism_of_action\": \"Stimulant (uncertain mechanism)\",\n-    \"psychoactive_class\": \"Entactogen; stimulant\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist; monoamine oxidase inhibitor\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-            \"threshold\": \"25 mg\",\n-            \"light\": \"40–60 mg\",\n-            \"common\": \"60–100 mg\",\n-            \"strong\": \"100–130 mg\",\n-            \"heavy\": \"130 mg + (NOT ADVISED)\"\n+            \"threshold\": \"0.5 mg - 1 mg\",\n+            \"light\": \"1 mg - 3 mg\",\n+            \"common\": \"3 mg - 8 mg\",\n+            \"strong\": \"8 mg - 12 mg\",\n+            \"heavy\": \"12+ mg\"\n-            \"total_duration\": \"4-6 h\",\n-            \"onset\": \"45-90 min\",\n-            \"peak\": \"1.5-3 h\",\n-            \"offset\": \"1-2 h\",\n-            \"after_effects\": \"2-6 h of residual stimulation (‘after-glow’ or restlessness)\"\n+            \"total_duration\": \"10-18 hours\",\n+            \"onset\": \"30-120 minutes\",\n+            \"peak\": \"3-6 hours\",\n+            \"offset\": \"6-12 hours\",\n+            \"after_effects\": \"12-24 hours (residual stimulation, insomnia, depletion)\"\n-    \"addiction_potential\": \"Moderate. Like other serotonin–releasing empathogens (e.g. MDMA, 6-APB) it produces euphoria and could encourage redosing. No published cases of physical dependence, but compulsive use has been reported anecdotally.\",\n+    \"addiction_potential\": \"Low for classic dependence; moderate psychological reinforcement possible due to mood lift and entactogenic warmth. Long duration and body load at higher doses limit compulsive redosing.\",\n-        \"MAOIs\",\n-        \"Tramadol\",\n-        \"DXM\",\n-        \"MDMA (↑ risk of serotonin syndrome)\",\n-        \"Stimulant cathinones (↑ cardiovascular stress)\"\n+        \"MAOIs (phenelzine, tranylcypromine, isocarboxazid, selegiline, moclobemide)\",\n+        \"SSRIs, SNRIs, TCAs, MAOI-antibiotic linezolid (serotonin syndrome risk)\",\n+        \"MDMA/MDA and other serotonin releasers\",\n+        \"tramadol, dextromethorphan, meperidine (serotonin syndrome, seizures)\",\n+        \"triptans (serotonergic vasoconstriction)\",\n+        \"5-HTP or L-tryptophan (excess substrate for serotonin)\",\n+        \"sympathomimetics and stimulants (amphetamine, cathinones; hypertensive events)\",\n+        \"tyramine-rich foods during the session window (aged cheeses, cured meats, soy ferments) due to MAO-A inhibition\"\n-        \"Alcohol (↑ dehydration / overheating)\",\n-        \"Cocaine\"\n+        \"alcohol (dehydration, disinhibition, nausea)\",\n+        \"cannabis concentrates (anxiety, dysphoria)\",\n+        \"decongestants with pseudoephedrine/phenylephrine (additive pressor effects)\",\n+        \"kava or other GABAergic sedatives (vomiting/aspiration risk with long duration)\"\n-        \"SSRIs/SNRIs (may blunt effects or precipitate serotonin toxicity)\",\n-        \"Bupropion\",\n-        \"α-2 agonists\",\n-        \"GHB/benzodiazepines (CNS depression when coming down)\"\n+        \"caffeine >200 mg (jitters, palpitations)\",\n+        \"benzodiazepines (reserve for emergencies; can mask rising toxicity)\",\n+        \"antipsychotics (can blunt effects; QT and hypotension concerns)\",\n+        \"nicotine (tachycardia)\"\n-    \"notes\": \"• Practically no human research exists; all parameters are based on scattered user reports of ‘5-AEDB’ sold online between 2019–2024 and extrapolation from related benzofurans (5-APB, 5-APDB).\\n• Potency appears roughly 60-70 % of 5-APB by weight and markedly shorter in duration.\\n• Users frequently report pronounced peripheral stimulation (↑ HR/BP) compared with MDMA, alongside moderate empathogenic warmth and mild visual enhancement.\\n• Severe vasoconstriction (‘purple feet’), bruxism, and nystagmus have been described at doses >100 mg.\\n• Because reagent reactions overlap with 5-APDB and other APBs, professional analysis (FT-IR/GC-MS) is recommended.\\n• Start low, ensure cool environment, hydrate with electrolytes; avoid redosing within 8 h to reduce neuro- and cardiotoxic risk.\",\n+    \"notes\": \"5-Cl-AMT (5-chloro-α-methyltryptamine; PAL-542) combines three properties with harm-reduction implications: it is a serotonin–dopamine releasing agent, a potent 5-HT2A agonist, and an in vitro MAO-A inhibitor. Treat it as an MAOI during the session window even though clinical reversibility is not established. Start with a microtest of 0.5-1 mg to gauge sensitivity; community trials report activity at 1-2 mg and full days’ worth of effects from 8-12 mg. Because the come-up is slow and the duration long, redosing is usually unnecessary and can produce a late, heavy body load. Volumetric dosing is strongly advised so that sub-1 mg adjustments are possible; weigh at least 10-20 mg on a 0.001 g scale, dissolve to make 1 mg/mL or 0.5 mg/mL, and measure with an oral syringe. Plan a bland, low-tyramine diet the day of dosing and until baseline the next day (avoid aged cheeses, cured/fermented meats, soy ferments, Marmite, certain beers). Review medications and supplements for serotonergic or MAOI activity; conservative washout rules are prudent (at least 2 weeks after irreversible MAOIs; several days after SSRIs/SNRIs/linezolid/tramadol/DXM/5-HTP). Physiologically, expect mild pupil dilation, warmth, tremor or jaw tension at higher doses, and a gradual shift from entactogenic glow to more psychedelic headspace. Several field reports describe a delayed intensification late in the day; avoid stacking doses based on an early, gentle come-up. Keep the environment cool, hydrate with electrolytes, and avoid vigorous exercise or hot environments. If symptoms suggest serotonin toxicity (agitation, clonus, hyperthermia, severe headache, rapidly rising heart rate/BP), do not take more, cool down, and seek medical care; do not self-medicate with additional serotonergics. Drug-checking is important: 5-Cl-AMT has appeared in small niche markets and could be misrepresented; use multi-reagent testing and, where available, FT-IR/GC-MS. Because reports show long wakefulness and an afterglow that can flip to lethargy, protect sleep the following night and avoid consecutive-day use. Cross-tolerance with other serotonergic psychedelics is expected; spacing sessions by 10-14 days reduces tolerance and carries a margin for MAO-related interactions.\",\n-      \"Euphoria\",\n-      \"Empathy and prosocial feelings\",\n-      \"Anxiolysis\",\n-      \"Stimulation (mental and physical)\",\n-      \"Enhanced tactile sensations\",\n-      \"Slight visual tracers at high doses\",\n-      \"Jaw clenching/bruxism\",\n-      \"Vasoconstriction/cold extremities\",\n-      \"Mydriasis\",\n-      \"Difficulty sleeping for several hours after use\"\n+      \"entactogenic warmth and sociability\",\n+      \"clear-headed stimulation early, shifting to psychedelic introspection later\",\n+      \"enhanced music appreciation and tactile pleasure\",\n+      \"subtle visual enhancement at low doses; patterning at higher\",\n+      \"time dilation and brightened colors\",\n+      \"mydriasis, mild tremor or jaw tension\",\n+      \"difficulty sleeping and next-day lethargy at higher doses\"\n-      \"full_tolerance\": \"After 2–3 consecutive or high-dose sessions\",\n-      \"half_tolerance\": \"~1 week\",\n-      \"zero_tolerance\": \"1–2 months\",\n+      \"full_tolerance\": \"after one strong session\",\n+      \"half_tolerance\": \"3-7 days\",\n+      \"zero_tolerance\": \"10-14 days\",\n-        \"MDMA\",\n-        \"5-APB\",\n-        \"other serotonergic empathogens\"\n+        \"AMT\",\n+        \"5-MeO-AMT\",\n+        \"psilocybin\",\n+        \"LSD\",\n+        \"other 5-HT2A psychedelics\"\n-    \"half_life\": \"~3–4 h (extrapolated from animal microsome data; human data unavailable)\",\n+    \"half_life\": \"Unknown (long subjective duration; MAO-A inhibition may extend interaction window)\",\n-        \"name\": \"Test-kit colour reactions for APBs (user ‘snmfmy’).\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/any-tests-to-distinguish-6-apb-from-5-apb-or-other-benzofurans.937517/\"\n+        \"name\": \"Bluelight – Small & Handy 5-Chloro-AMT thread (community dosing and precautions)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-small-handy-5-chloro-amt-thread.893891/\"\n-        \"name\": \"Anonymous user reports compiled on r/ResearchChemicals (Oct 2021 – Apr 2024).\",\n-        \"reference\": \"https://www.reddit.com/search/?q=5-AEDB\"\n+        \"name\": \"Bluelight Trip Report – 5-Cl-AMT 2 mg oral (threshold activity; long day effects)\",\n+        \"reference\": \"https://www.bluelight.org/xf/threads/5-chloro-amt-2mg-oral-first-time-a-surprisingly-encouraging-foray-into-the-unknown.894534/\"\n-        \"name\": \"Brandt, S.D. et al. (2010) ‘Analogs of MDMA: structure–activity relationships’. Drug Test. Anal.\",\n-        \"reference\": \"https://doi.org/10.1002/dta.152\"\n+        \"name\": \"Bluelight Trip Report – 5-Cl-AMT 12 mg oral (late intensification; duration)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/5-chloro-amt-12mg-oral-second-time-from-light-to-heavy.895557/\"\n-        \"name\": \"Erowid: Other Info6.shtml\",\n-        \"reference\": \"https://erowid.org/chemicals/other/other_info6.shtml#5-AEDB\"\n+        \"name\": \"Banks et al., 2014 – PAL-542 (5-Cl-AMT) as SDRA; EC50 release data\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4067459\"\n+      },\n+      {\n+        \"name\": \"Blough et al., 2014 – α-alkyltryptamines as dual DA/5-HT releasers; 5-HT2A activity\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4211607\"\n+      },\n+      {\n+        \"name\": \"Wagmann et al., 2017 – In vitro MAO inhibition by AMT analogs (MAO-A IC50 ~0.25 µM for 5-Cl-AMT)\",\n+        \"reference\": \"https://scidok.sulb.uni-saarland.de/bitstream/20.500.11880/29171/4/In%20vitro%20monoamine%20oxidase%20inhibition%20potential%20of%20alpha-methyltryptamine%20analog%20new%20psychoactive%20substances%20for%20assessing%20possible%20toxic%20risks_mit_Vorblatt.pdf\"\n+      },\n+      {\n+        \"name\": \"Wikipedia – 5-Chloro-αMT (overview; SDRA and MAO-A inhibition summary with citations)\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/5-Chloro-%CE%B1MT\"\n+      },\n+      {\n+        \"name\": \"Erowid – 5-Cl-AMT Vault\",\n+        \"reference\": \"https://erowid.org/chemicals/5_cl_amt/5_cl_amt.shtml\"\n-      \"stimulant\",\n+      \"psychedelic\",\n+      \"stimulant\",\n\n# Diphenhydramine · #626\n\n-  \"id\": 625,\n-  \"title\": \"5-Cl-AMT\",\n+  \"title\": \"Diphenhydramine\",\n+  \"index-category\": \"deliriant; otc\",\n-    \"drug_name\": \"5-Cl-AMT\",\n-    \"chemical_name\": \"5-Cl-AMT\",\n-    \"alternative_name\": \"\",\n-    \"chemical_class\": \"Tryptamines\",\n-    \"mechanism_of_action\": \"5-HT2A receptor agonist; monoamine oxidase inhibitor\",\n-    \"psychoactive_class\": \"Psychedelic\",\n+    \"drug_name\": \"Diphenhydramine\",\n+    \"chemical_name\": \"2-(Diphenylmethoxy)-N,N-dimethylethanamine\",\n+    \"alternative_name\": \"DPH; Benadryl; Nytol; Sominex; Unisom SleepMelts; ZzzQuil; Dimedrol\",\n+    \"chemical_class\": \"Ethanolamine\",\n+    \"psychoactive_class\": \"Deliriant\",\n+    \"mechanism_of_action\": \"H1 histamine receptor inverse agonist; muscarinic acetylcholine receptor antagonist; weak serotonin reuptake inhibition; sodium channel blockade; voltage-gated potassium channel blockade\",\n-            \"threshold\": \"0.5 mg - 1 mg\",\n-            \"light\": \"1 mg - 3 mg\",\n-            \"common\": \"3 mg - 8 mg\",\n-            \"strong\": \"8 mg - 12 mg\",\n-            \"heavy\": \"12+ mg\"\n+            \"threshold\": \"25 mg\",\n+            \"light\": \"100-200 mg\",\n+            \"common\": \"200-400 mg\",\n+            \"strong\": \"400-700 mg\",\n+            \"heavy\": \"700+ mg\"\n+          \"stages\": {\n+            \"total_duration\": \"3-10 hours\",\n+            \"onset\": \"30-90 minutes\",\n+            \"peak\": \"1-4 hours\",\n+            \"offset\": \"2-6 hours\",\n+            \"after_effects\": \"Up to 24 hours\"\n+          },\n-          ],\n-          \"stages\": {\n-            \"total_duration\": \"10-18 hours\",\n-            \"onset\": \"30-120 minutes\",\n-            \"peak\": \"3-6 hours\",\n-            \"offset\": \"6-12 hours\",\n-            \"after_effects\": \"12-24 hours (residual stimulation, insomnia, depletion)\"\n-          }\n+          ]\n-    \"addiction_potential\": \"Low for classic dependence; moderate psychological reinforcement possible due to mood lift and entactogenic warmth. Long duration and body load at higher doses limit compulsive redosing.\",\n+    \"addiction_potential\": \"Diphenhydramine has low abuse potential due to its overwhelmingly dysphoric and unpleasant effects. While physical dependence is possible with chronic use, most users do not wish to repeat the experience. Tolerance develops rapidly with repeated use.\",\n-        \"MAOIs (phenelzine, tranylcypromine, isocarboxazid, selegiline, moclobemide)\",\n-        \"SSRIs, SNRIs, TCAs, MAOI-antibiotic linezolid (serotonin syndrome risk)\",\n-        \"MDMA/MDA and other serotonin releasers\",\n-        \"tramadol, dextromethorphan, meperidine (serotonin syndrome, seizures)\",\n-        \"triptans (serotonergic vasoconstriction)\",\n-        \"5-HTP or L-tryptophan (excess substrate for serotonin)\",\n-        \"sympathomimetics and stimulants (amphetamine, cathinones; hypertensive events)\",\n-        \"tyramine-rich foods during the session window (aged cheeses, cured meats, soy ferments) due to MAO-A inhibition\"\n+        \"MAOIs (risk of severe anticholinergic effects)\",\n+        \"Anticholinergics (severe tachycardia, heart attack risk, abnormal heart rhythm)\",\n+        \"High doses of acetaminophen-containing formulations (liver damage, death)\"\n-        \"alcohol (dehydration, disinhibition, nausea)\",\n-        \"cannabis concentrates (anxiety, dysphoria)\",\n-        \"decongestants with pseudoephedrine/phenylephrine (additive pressor effects)\",\n-        \"kava or other GABAergic sedatives (vomiting/aspiration risk with long duration)\"\n+        \"Stimulants (severe tachycardia, heart attack risk, abnormal heart rhythm)\",\n+        \"Tramadol (increased seizure risk)\",\n+        \"Alcohol (dangerous sedation, respiratory depression)\"\n-        \"caffeine >200 mg (jitters, palpitations)\",\n-        \"benzodiazepines (reserve for emergencies; can mask rising toxicity)\",\n-        \"antipsychotics (can blunt effects; QT and hypotension concerns)\",\n-        \"nicotine (tachycardia)\"\n+        \"Benzodiazepines (dangerous sedation, respiratory depression, visual suppression)\",\n+        \"SSRIs (visual suppression, potential serotonin syndrome)\",\n+        \"Opioids (increased sedation, respiratory depression)\"\n-    \"notes\": \"5-Cl-AMT (5-chloro-α-methyltryptamine; PAL-542) combines three properties with harm-reduction implications: it is a serotonin–dopamine releasing agent, a potent 5-HT2A agonist, and an in vitro MAO-A inhibitor. Treat it as an MAOI during the session window even though clinical reversibility is not established. Start with a microtest of 0.5-1 mg to gauge sensitivity; community trials report activity at 1-2 mg and full days’ worth of effects from 8-12 mg. Because the come-up is slow and the duration long, redosing is usually unnecessary and can produce a late, heavy body load. Volumetric dosing is strongly advised so that sub-1 mg adjustments are possible; weigh at least 10-20 mg on a 0.001 g scale, dissolve to make 1 mg/mL or 0.5 mg/mL, and measure with an oral syringe. Plan a bland, low-tyramine diet the day of dosing and until baseline the next day (avoid aged cheeses, cured/fermented meats, soy ferments, Marmite, certain beers). Review medications and supplements for serotonergic or MAOI activity; conservative washout rules are prudent (at least 2 weeks after irreversible MAOIs; several days after SSRIs/SNRIs/linezolid/tramadol/DXM/5-HTP). Physiologically, expect mild pupil dilation, warmth, tremor or jaw tension at higher doses, and a gradual shift from entactogenic glow to more psychedelic headspace. Several field reports describe a delayed intensification late in the day; avoid stacking doses based on an early, gentle come-up. Keep the environment cool, hydrate with electrolytes, and avoid vigorous exercise or hot environments. If symptoms suggest serotonin toxicity (agitation, clonus, hyperthermia, severe headache, rapidly rising heart rate/BP), do not take more, cool down, and seek medical care; do not self-medicate with additional serotonergics. Drug-checking is important: 5-Cl-AMT has appeared in small niche markets and could be misrepresented; use multi-reagent testing and, where available, FT-IR/GC-MS. Because reports show long wakefulness and an afterglow that can flip to lethargy, protect sleep the following night and avoid consecutive-day use. Cross-tolerance with other serotonergic psychedelics is expected; spacing sessions by 10-14 days reduces tolerance and carries a margin for MAO-related interactions.\",\n+    \"notes\": \"Diphenhydramine is widely available over-the-counter and used medically for allergies and sleep aid. Recreational use produces intensely dysphoric and unpredictable deliriant effects including realistic hallucinations that users cannot distinguish from reality. The substance has significant cardiovascular risks including QT prolongation and potential for torsades de pointes. Always verify that products contain only diphenhydramine as active ingredient; many combination products contain acetaminophen or other drugs that can be fatal in high doses. A sober trip sitter is essential as users may respond to hallucinations and injure themselves. Chronic use may cause persistent cognitive impairment, memory damage, and has been linked to increased dementia risk.\",\n-      \"entactogenic warmth and sociability\",\n-      \"clear-headed stimulation early, shifting to psychedelic introspection later\",\n-      \"enhanced music appreciation and tactile pleasure\",\n-      \"subtle visual enhancement at low doses; patterning at higher\",\n-      \"time dilation and brightened colors\",\n-      \"mydriasis, mild tremor or jaw tension\",\n-      \"difficulty sleeping and next-day lethargy at higher doses\"\n+      \"Sedation and Body Heaviness\",\n+      \"External Hallucinations (People, Objects, Insects)\",\n+      \"Auditory Hallucinations (Voices, Screams)\",\n+      \"Tactile Hallucinations (Phantom Sensations)\",\n+      \"Shadow People\",\n+      \"Delirium and Confusion\",\n+      \"Memory Suppression and Amnesia\",\n+      \"Dysphoria and Anxiety\",\n+      \"Restless Leg Syndrome\",\n+      \"Dry Mouth and Dehydration\",\n+      \"Visual Acuity Suppression (Blurred Vision)\",\n+      \"Thought Disorganization\"\n-      \"full_tolerance\": \"after one strong session\",\n-      \"half_tolerance\": \"3-7 days\",\n-      \"zero_tolerance\": \"10-14 days\",\n+      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n+      \"half_tolerance\": \"3-5 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n-        \"AMT\",\n-        \"5-MeO-AMT\",\n-        \"psilocybin\",\n-        \"LSD\",\n-        \"other 5-HT2A psychedelics\"\n+        \"All deliriants (datura, scopolamine, dimenhydrinate)\"\n-    \"half_life\": \"Unknown (long subjective duration; MAO-A inhibition may extend interaction window)\",\n+    \"half_life\": \"5 hours (pediatric); 9 hours (adult); 13.5 hours (elderly)\",\n-        \"name\": \"Bluelight – Small & Handy 5-Chloro-AMT thread (community dosing and precautions)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/the-small-handy-5-chloro-amt-thread.893891/\"\n+        \"name\": \"Erowid Diphenhydramine Vault\",\n+        \"reference\": \"https://www.erowid.org/pharms/diphenhydramine/\"\n-        \"name\": \"Bluelight Trip Report – 5-Cl-AMT 2 mg oral (threshold activity; long day effects)\",\n-        \"reference\": \"https://www.bluelight.org/xf/threads/5-chloro-amt-2mg-oral-first-time-a-surprisingly-encouraging-foray-into-the-unknown.894534/\"\n+        \"name\": \"PsychonautWiki: Diphenhydramine\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Diphenhydramine\"\n-        \"name\": \"Bluelight Trip Report – 5-Cl-AMT 12 mg oral (late intensification; duration)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/5-chloro-amt-12mg-oral-second-time-from-light-to-heavy.895557/\"\n+        \"name\": \"TripSit Wiki: Diphenhydramine\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/Diphenhydramine\"\n-        \"name\": \"Banks et al., 2014 – PAL-542 (5-Cl-AMT) as SDRA; EC50 release data\",\n-        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4067459\"\n+        \"name\": \"Bluelight: Diphenhydramine Discussion\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/dph-trip.560305/\"\n-        \"name\": \"Blough et al., 2014 – α-alkyltryptamines as dual DA/5-HT releasers; 5-HT2A activity\",\n-        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4211607\"\n+        \"name\": \"DrugBank: Diphenhydramine\",\n+        \"reference\": \"https://go.drugbank.com/drugs/DB01075\"\n-        \"name\": \"Wagmann et al., 2017 – In vitro MAO inhibition by AMT analogs (MAO-A IC50 ~0.25 µM for 5-Cl-AMT)\",\n-        \"reference\": \"https://scidok.sulb.uni-saarland.de/bitstream/20.500.11880/29171/4/In%20vitro%20monoamine%20oxidase%20inhibition%20potential%20of%20alpha-methyltryptamine%20analog%20new%20psychoactive%20substances%20for%20assessing%20possible%20toxic%20risks_mit_Vorblatt.pdf\"\n+        \"name\": \"StatPearls: Diphenhydramine Toxicity\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/books/NBK557578/\"\n-        \"name\": \"Wikipedia – 5-Chloro-αMT (overview; SDRA and MAO-A inhibition summary with citations)\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/5-Chloro-%CE%B1MT\"\n-      },\n-      {\n-        \"name\": \"Erowid – 5-Cl-AMT Vault\",\n-        \"reference\": \"https://erowid.org/chemicals/5_cl_amt/5_cl_amt.shtml\"\n+        \"name\": \"Gray et al., 2015 - Cumulative Anticholinergic Use and Dementia\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/25621434/\"\n-      \"psychedelic\",\n-      \"entactogen\",\n-      \"stimulant\",\n-      \"research-chemical\"\n+      \"deliriant\",\n+      \"depressant\",\n+      \"antihistamine\",\n+      \"otc\"\n-  \"index-category\": \"\"\n+  \"id\": 626\n\n# Diphenhydramine · #627\n\n-  \"id\": 626\n+  \"id\": 627\n\n# 1V-LSD · #628\n\n-  \"title\": \"Diphenhydramine\",\n-  \"index-category\": \"deliriant; otc\",\n+  \"title\": \"1V-LSD\",\n+  \"index-category\": \"psychedelic; research-chemical\",\n-    \"drug_name\": \"Diphenhydramine\",\n-    \"chemical_name\": \"2-(Diphenylmethoxy)-N,N-dimethylethanamine\",\n-    \"alternative_name\": \"DPH; Benadryl; Nytol; Sominex; Unisom SleepMelts; ZzzQuil; Dimedrol\",\n-    \"chemical_class\": \"Ethanolamine\",\n-    \"psychoactive_class\": \"Deliriant\",\n-    \"mechanism_of_action\": \"H1 histamine receptor inverse agonist; muscarinic acetylcholine receptor antagonist; weak serotonin reuptake inhibition; sodium channel blockade; voltage-gated potassium channel blockade\",\n+    \"drug_name\": \"1V-LSD\",\n+    \"chemical_name\": \"1-Valeroyl-d-lysergic acid diethylamide\",\n+    \"alternative_name\": \"Valerie\",\n+    \"chemical_class\": \"Lysergamides\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist (weak); acts as prodrug for LSD via deacylation\",\n-          \"units\": \"mg\",\n+          \"units\": \"ug\",\n-            \"threshold\": \"25 mg\",\n-            \"light\": \"100-200 mg\",\n-            \"common\": \"200-400 mg\",\n-            \"strong\": \"400-700 mg\",\n-            \"heavy\": \"700+ mg\"\n+            \"threshold\": \"15 ug\",\n+            \"light\": \"25-75 ug\",\n+            \"common\": \"75-150 ug\",\n+            \"strong\": \"150-300 ug\",\n+            \"heavy\": \"300+ ug\"\n-            \"total_duration\": \"3-10 hours\",\n-            \"onset\": \"30-90 minutes\",\n-            \"peak\": \"1-4 hours\",\n-            \"offset\": \"2-6 hours\",\n-            \"after_effects\": \"Up to 24 hours\"\n+            \"total_duration\": \"8-12 hours\",\n+            \"onset\": \"20-60 minutes\",\n+            \"peak\": \"3-5 hours (come up 45-120 minutes)\",\n+            \"offset\": \"3-5 hours\",\n+            \"after_effects\": \"6-24 hours\"\n-    \"addiction_potential\": \"Diphenhydramine has low abuse potential due to its overwhelmingly dysphoric and unpleasant effects. While physical dependence is possible with chronic use, most users do not wish to repeat the experience. Tolerance develops rapidly with repeated use.\",\n+    \"addiction_potential\": \"1V-LSD is assumed to be non-addictive with low abuse potential, similar to LSD. No literature reports exist of successful attempts to train animals to self-administer LSD analogs. There is virtually no withdrawal syndrome when chronic use is stopped.\",\n-        \"MAOIs (risk of severe anticholinergic effects)\",\n-        \"Anticholinergics (severe tachycardia, heart attack risk, abnormal heart rhythm)\",\n-        \"High doses of acetaminophen-containing formulations (liver damage, death)\"\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n-        \"Stimulants (severe tachycardia, heart attack risk, abnormal heart rhythm)\",\n-        \"Tramadol (increased seizure risk)\",\n-        \"Alcohol (dangerous sedation, respiratory depression)\"\n+        \"Cannabis (strong synergy, significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n-        \"Benzodiazepines (dangerous sedation, respiratory depression, visual suppression)\",\n-        \"SSRIs (visual suppression, potential serotonin syndrome)\",\n-        \"Opioids (increased sedation, respiratory depression)\"\n+        \"Stimulants (may increase risk of anxiety, paranoia, panic attacks, thought loops, mania and psychosis)\",\n+        \"MDMA (unpredictable synergy, potential increased neurotoxicity)\",\n+        \"Dissociatives (enhanced hallucinatory effects, increased risk of confusion and delusions)\",\n+        \"Benzodiazepines (reduce intensity of effects)\",\n+        \"Alcohol (may reduce anxiety but causes dehydration and physical discomfort)\"\n-    \"notes\": \"Diphenhydramine is widely available over-the-counter and used medically for allergies and sleep aid. Recreational use produces intensely dysphoric and unpredictable deliriant effects including realistic hallucinations that users cannot distinguish from reality. The substance has significant cardiovascular risks including QT prolongation and potential for torsades de pointes. Always verify that products contain only diphenhydramine as active ingredient; many combination products contain acetaminophen or other drugs that can be fatal in high doses. A sober trip sitter is essential as users may respond to hallucinations and injure themselves. Chronic use may cause persistent cognitive impairment, memory damage, and has been linked to increased dementia risk.\",\n+    \"notes\": \"1V-LSD is a novel research chemical with minimal history of human use and unverified safety profile. It is presumed to act as a prodrug for LSD. Those with personal or family history of mental illness should avoid use, particularly outside supervised medical settings. Set and setting are critical factors in determining experience quality. Start with lower doses due to individual variations in body weight, tolerance, metabolism, and sensitivity. No toxic dose is known, but higher doses increase risk of adverse psychological reactions. Test substances with reagent kits, though Ehrlich's reagent reacts slowly with N-acylated lysergamides.\",\n-      \"Sedation and Body Heaviness\",\n-      \"External Hallucinations (People, Objects, Insects)\",\n-      \"Auditory Hallucinations (Voices, Screams)\",\n-      \"Tactile Hallucinations (Phantom Sensations)\",\n-      \"Shadow People\",\n-      \"Delirium and Confusion\",\n-      \"Memory Suppression and Amnesia\",\n-      \"Dysphoria and Anxiety\",\n-      \"Restless Leg Syndrome\",\n-      \"Dry Mouth and Dehydration\",\n-      \"Visual Acuity Suppression (Blurred Vision)\",\n-      \"Thought Disorganization\"\n+      \"Geometric Visual Hallucinations\",\n+      \"Time Distortion\",\n+      \"Enhanced Introspection\",\n+      \"Ego Loss\",\n+      \"Stimulation\",\n+      \"Spontaneous Bodily Sensations\",\n+      \"Physical Euphoria\",\n+      \"Tactile Enhancement\",\n+      \"Color Enhancement\",\n+      \"Pattern Recognition Enhancement\",\n+      \"Visual Drifting\",\n+      \"Analysis Enhancement\",\n+      \"Conceptual Thinking\",\n+      \"Emotion Enhancement\",\n+      \"Cognitive Euphoria\",\n+      \"Creativity Enhancement\",\n+      \"Increased Music Appreciation\",\n+      \"Unity And Interconnectedness\"\n-      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n-      \"half_tolerance\": \"3-5 days\",\n-      \"zero_tolerance\": \"1-2 weeks\",\n+      \"full_tolerance\": \"Builds almost immediately after ingestion\",\n+      \"half_tolerance\": \"5-7 days\",\n+      \"zero_tolerance\": \"14 days\",\n-        \"All deliriants (datura, scopolamine, dimenhydrinate)\"\n+        \"All psychedelics (including LSD, psilocybin, mescaline, DMT)\"\n-    \"half_life\": \"5 hours (pediatric); 9 hours (adult); 13.5 hours (elderly)\",\n+    \"half_life\": \"Similar to LSD (estimated 3-5 hours for active metabolite)\",\n-        \"name\": \"Erowid Diphenhydramine Vault\",\n-        \"reference\": \"https://www.erowid.org/pharms/diphenhydramine/\"\n+        \"name\": \"PsychonautWiki: 1V-LSD\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/1V-LSD\"\n-        \"name\": \"PsychonautWiki: Diphenhydramine\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/Diphenhydramine\"\n+        \"name\": \"Erowid 1V-LSD Experience Vault\",\n+        \"reference\": \"https://www.erowid.org/experiences/subs/exp_1VLSD.shtml\"\n-        \"name\": \"TripSit Wiki: Diphenhydramine\",\n-        \"reference\": \"https://wiki.tripsit.me/wiki/Diphenhydramine\"\n+        \"name\": \"Bluelight: The Small & Handy 1V-LSD Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-small-handy-1v-lsd-thread.904997/\"\n-        \"name\": \"Bluelight: Diphenhydramine Discussion\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/dph-trip.560305/\"\n+        \"name\": \"Brandt et al. (2022): Return of the lysergamides Part VII - Analytical and behavioural characterization of 1V-LSD\",\n+        \"reference\": \"https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/dta.3205\"\n-        \"name\": \"DrugBank: Diphenhydramine\",\n-        \"reference\": \"https://go.drugbank.com/drugs/DB01075\"\n-      },\n-      {\n-        \"name\": \"StatPearls: Diphenhydramine Toxicity\",\n-        \"reference\": \"https://www.ncbi.nlm.nih.gov/books/NBK557578/\"\n-      },\n-      {\n-        \"name\": \"Gray et al., 2015 - Cumulative Anticholinergic Use and Dementia\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/25621434/\"\n+        \"name\": \"Tripsitter: 1V-LSD - A New LSD Analog\",\n+        \"reference\": \"https://tripsitter.com/1v-lsd/\"\n-      \"deliriant\",\n-      \"depressant\",\n-      \"antihistamine\",\n-      \"otc\"\n+      \"psychedelic\",\n+      \"lysergamide\",\n+      \"research-chemical\",\n+      \"prodrug\"\n-  \"id\": 627\n+  \"id\": 628\n\n# ALD-52 · #629\n\n-  \"title\": \"1V-LSD\",\n-  \"index-category\": \"psychedelic; research-chemical\",\n+  \"title\": \"ALD-52\",\n+  \"index-category\": \"psychedelic; lysergamide\",\n-    \"drug_name\": \"1V-LSD\",\n-    \"chemical_name\": \"1-Valeroyl-d-lysergic acid diethylamide\",\n-    \"alternative_name\": \"Valerie\",\n+    \"drug_name\": \"ALD-52\",\n+    \"chemical_name\": \"1-Acetyl-d-lysergic acid diethylamide\",\n+    \"alternative_name\": \"Orange Sunshine\",\n-    \"mechanism_of_action\": \"5-HT2A receptor partial agonist (weak); acts as prodrug for LSD via deacylation\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; 5-HT2C receptor partial agonist; 5-HT1A receptor partial agonist; D2 receptor agonist (through LSD metabolite)\",\n-            \"threshold\": \"15 ug\",\n-            \"light\": \"25-75 ug\",\n-            \"common\": \"75-150 ug\",\n-            \"strong\": \"150-300 ug\",\n-            \"heavy\": \"300+ ug\"\n+            \"threshold\": \"30 ug\",\n+            \"light\": \"30-100 ug\",\n+            \"common\": \"100-175 ug\",\n+            \"strong\": \"175-325 ug\",\n+            \"heavy\": \"325+ ug\"\n-            \"total_duration\": \"8-12 hours\",\n-            \"onset\": \"20-60 minutes\",\n-            \"peak\": \"3-5 hours (come up 45-120 minutes)\",\n+            \"total_duration\": \"8-14 hours\",\n+            \"onset\": \"20-40 minutes\",\n+            \"peak\": \"3-5 hours (following 1-2 hour come up)\",\n-            \"after_effects\": \"6-24 hours\"\n+            \"after_effects\": \"4-24 hours\"\n-    \"addiction_potential\": \"1V-LSD is assumed to be non-addictive with low abuse potential, similar to LSD. No literature reports exist of successful attempts to train animals to self-administer LSD analogs. There is virtually no withdrawal syndrome when chronic use is stopped.\",\n+    \"addiction_potential\": \"ALD-52 is not considered physically addictive and has extremely low potential for psychological dependence. The rapid development of tolerance discourages frequent use patterns, and the desire to use typically decreases with repeated exposure rather than increasing.\",\n-        \"Tramadol (lowers seizure threshold)\"\n+        \"MAOIs (unpredictable effects, possible hypertensive reaction)\"\n-        \"Cannabis (strong synergy, significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n+        \"Tramadol (lowers seizure threshold, psychedelics may trigger seizures)\",\n+        \"Stimulants including amphetamines and cocaine (increased risk of anxiety, thought loops, cardiovascular strain)\"\n-        \"Stimulants (may increase risk of anxiety, paranoia, panic attacks, thought loops, mania and psychosis)\",\n-        \"MDMA (unpredictable synergy, potential increased neurotoxicity)\",\n-        \"Dissociatives (enhanced hallucinatory effects, increased risk of confusion and delusions)\",\n-        \"Benzodiazepines (reduce intensity of effects)\",\n-        \"Alcohol (may reduce anxiety but causes dehydration and physical discomfort)\"\n+        \"Cannabis (unpredictably strong synergy, increased risk of anxiety and paranoia)\",\n+        \"MDMA (may increase neurotoxicity, unpredictable synergy)\",\n+        \"Other psychedelics (intense cross-tolerance and potentially overwhelming effects)\",\n+        \"SSRIs (may blunt or alter effects)\"\n-    \"notes\": \"1V-LSD is a novel research chemical with minimal history of human use and unverified safety profile. It is presumed to act as a prodrug for LSD. Those with personal or family history of mental illness should avoid use, particularly outside supervised medical settings. Set and setting are critical factors in determining experience quality. Start with lower doses due to individual variations in body weight, tolerance, metabolism, and sensitivity. No toxic dose is known, but higher doses increase risk of adverse psychological reactions. Test substances with reagent kits, though Ehrlich's reagent reacts slowly with N-acylated lysergamides.\",\n+    \"notes\": \"ALD-52 functions as a prodrug for LSD, metabolizing into LSD in the body along with other metabolites. Legal status varies widely by jurisdiction; it is controlled in many countries including the UK, Germany, Switzerland, and Latvia, while remaining technically unscheduled in others such as the United States and Denmark. Individuals with personal or family history of psychotic disorders should avoid use. Famous for being mistakenly associated with 'Orange Sunshine' LSD from the 1960s, though this was later confirmed to be standard LSD at 300 micrograms per dose. Set and setting are critical for a positive experience, and users should approach this potent, long-lasting substance with proper preparation and harm reduction practices.\",\n-      \"Geometric Visual Hallucinations\",\n+      \"Visual Patterning And Geometry\",\n+      \"Enhanced Sensory Perception\",\n+      \"Cognitive Euphoria\",\n-      \"Ego Loss\",\n-      \"Stimulation\",\n-      \"Spontaneous Bodily Sensations\",\n+      \"Emotional Amplification\",\n-      \"Tactile Enhancement\",\n-      \"Color Enhancement\",\n-      \"Pattern Recognition Enhancement\",\n-      \"Visual Drifting\",\n-      \"Analysis Enhancement\",\n-      \"Conceptual Thinking\",\n-      \"Emotion Enhancement\",\n-      \"Cognitive Euphoria\",\n-      \"Creativity Enhancement\",\n-      \"Increased Music Appreciation\",\n-      \"Unity And Interconnectedness\"\n+      \"Thought Acceleration\",\n+      \"Enhanced Music Appreciation\",\n+      \"Pupil Dilation\",\n+      \"Increased Energy And Stimulation\",\n+      \"Novel Thought Patterns\"\n-      \"full_tolerance\": \"Builds almost immediately after ingestion\",\n+      \"full_tolerance\": \"Immediately after ingestion, cross-tolerant with all psychedelics\",\n-        \"All psychedelics (including LSD, psilocybin, mescaline, DMT)\"\n+        \"All psychedelics including LSD, psilocybin mushrooms, mescaline, and tryptamines\"\n-    \"half_life\": \"Similar to LSD (estimated 3-5 hours for active metabolite)\",\n+    \"half_life\": \"1-3 hours (LSD active metabolite)\",\n-        \"name\": \"PsychonautWiki: 1V-LSD\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/1V-LSD\"\n+        \"name\": \"Erowid ALD-52 Vault\",\n+        \"reference\": \"https://erowid.org/chemicals/lsd/lsd_ald52.shtml\"\n-        \"name\": \"Erowid 1V-LSD Experience Vault\",\n-        \"reference\": \"https://www.erowid.org/experiences/subs/exp_1VLSD.shtml\"\n+        \"name\": \"Isomer Design TiHKAL Entry 26 (LSD)\",\n+        \"reference\": \"https://isomerdesign.com/pihkal/read/tk/26\"\n-        \"name\": \"Bluelight: The Small & Handy 1V-LSD Thread\",\n-        \"reference\": \"https://bluelight.org/xf/threads/the-small-handy-1v-lsd-thread.904997/\"\n+        \"name\": \"PsychonautWiki: ALD-52\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/ALD-52\"\n-        \"name\": \"Brandt et al. (2022): Return of the lysergamides Part VII - Analytical and behavioural characterization of 1V-LSD\",\n-        \"reference\": \"https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/dta.3205\"\n+        \"name\": \"The Big & Dandy ALD-52 Thread (Bluelight)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-ald-52-thread.773316/\"\n-        \"name\": \"Tripsitter: 1V-LSD - A New LSD Analog\",\n-        \"reference\": \"https://tripsitter.com/1v-lsd/\"\n+        \"name\": \"TripSit Drug Combination Chart\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/Drug_combinations\"\n+      },\n+      {\n+        \"name\": \"Wagmann et al. (2019) In vitro metabolic fate of nine LSD-based new psychoactive substances\",\n+        \"reference\": \"https://doi.org/10.1007/s00216-018-1558-9\"\n-  \"id\": 628\n+  \"id\": 629\n\n# ETH-LAD · #630\n\n-  \"title\": \"ALD-52\",\n+  \"title\": \"ETH-LAD\",\n-    \"drug_name\": \"ALD-52\",\n-    \"chemical_name\": \"1-Acetyl-d-lysergic acid diethylamide\",\n-    \"alternative_name\": \"Orange Sunshine\",\n+    \"drug_name\": \"ETH-LAD\",\n+    \"chemical_name\": \"6-Ethyl-6-nor-lysergic acid diethylamide\",\n+    \"alternative_name\": \"N-Ethyl-nor-LSD; 6-Ethyl-6-nor-lysergic acid diethylamide; N-Ethyl-nor-lysergic acid N,N-diethylamide\",\n-    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; 5-HT2C receptor partial agonist; 5-HT1A receptor partial agonist; D2 receptor agonist (through LSD metabolite)\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist; 5-HT2C receptor agonist; 5-HT1A receptor agonist (high affinity); dopamine D1, D2, D3, D4, D5 receptor binding (lower affinity)\",\n-            \"threshold\": \"30 ug\",\n-            \"light\": \"30-100 ug\",\n-            \"common\": \"100-175 ug\",\n-            \"strong\": \"175-325 ug\",\n-            \"heavy\": \"325+ ug\"\n+            \"threshold\": \"15 ug\",\n+            \"light\": \"15-60 ug\",\n+            \"common\": \"60-150 ug\",\n+            \"strong\": \"150-225 ug\",\n+            \"heavy\": \"225+ ug\"\n-            \"total_duration\": \"8-14 hours\",\n+            \"total_duration\": \"8-12 hours\",\n-            \"peak\": \"3-5 hours (following 1-2 hour come up)\",\n-            \"offset\": \"3-5 hours\",\n-            \"after_effects\": \"4-24 hours\"\n+            \"peak\": \"4-6 hours (including 45-90 minute come up)\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"8-48 hours\"\n-    \"addiction_potential\": \"ALD-52 is not considered physically addictive and has extremely low potential for psychological dependence. The rapid development of tolerance discourages frequent use patterns, and the desire to use typically decreases with repeated exposure rather than increasing.\",\n+    \"addiction_potential\": \"ETH-LAD is not considered habit-forming and demonstrates a self-regulating quality typical of psychedelics. Rapid tolerance develops immediately after use, discouraging frequent consumption. Cases of abuse have been rarely reported, though the substance generally decreases in desirability with repeated use.\",\n-        \"Lithium (significantly increases risk of psychosis and seizures)\",\n-        \"MAOIs (unpredictable effects, possible hypertensive reaction)\"\n+        \"Lithium (significantly increased risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n-        \"Tramadol (lowers seizure threshold, psychedelics may trigger seizures)\",\n-        \"Stimulants including amphetamines and cocaine (increased risk of anxiety, thought loops, cardiovascular strain)\"\n+        \"Cannabis (unpredictable and strongly increased effects, risk of anxiety, paranoia, panic attacks, and psychosis)\",\n+        \"Stimulants including amphetamine, cocaine, methylphenidate (increased risk of anxiety, paranoia, panic attacks, thought loops, mania, and psychosis)\"\n-      \"caution\": [\n-        \"Cannabis (unpredictably strong synergy, increased risk of anxiety and paranoia)\",\n-        \"MDMA (may increase neurotoxicity, unpredictable synergy)\",\n-        \"Other psychedelics (intense cross-tolerance and potentially overwhelming effects)\",\n-        \"SSRIs (may blunt or alter effects)\"\n-      ]\n+      \"caution\": []\n-    \"notes\": \"ALD-52 functions as a prodrug for LSD, metabolizing into LSD in the body along with other metabolites. Legal status varies widely by jurisdiction; it is controlled in many countries including the UK, Germany, Switzerland, and Latvia, while remaining technically unscheduled in others such as the United States and Denmark. Individuals with personal or family history of psychotic disorders should avoid use. Famous for being mistakenly associated with 'Orange Sunshine' LSD from the 1960s, though this was later confirmed to be standard LSD at 300 micrograms per dose. Set and setting are critical for a positive experience, and users should approach this potent, long-lasting substance with proper preparation and harm reduction practices.\",\n+    \"notes\": \"ETH-LAD requires exceptional caution due to its high potency, unpredictable dose-response curve, and tendency to produce severe physical side effects including pronounced nausea, temperature dysregulation, muscle cramps, and bodily discomfort at higher doses. The substance is notably more difficult to handle than LSD and should only be used by experienced psychedelic users. Accurate measurement with a precise scale is critical. Users should monitor body temperature throughout the experience and maintain access to climate control. Set and setting are paramount, and having a trusted sober sitter is strongly recommended, especially at doses above the common range. Individuals with personal or family history of psychotic disorders should avoid use.\",\n-      \"Visual Patterning And Geometry\",\n-      \"Enhanced Sensory Perception\",\n+      \"Intricate Visual Geometry\",\n+      \"Enhanced Pattern Recognition\",\n+      \"Auditory Distortions and Hallucinations\",\n+      \"Analysis Enhancement\",\n+      \"Introspective Thought Patterns\",\n-      \"Cognitive Euphoria\",\n-      \"Enhanced Introspection\",\n-      \"Emotional Amplification\",\n-      \"Physical Euphoria\",\n+      \"Synaesthesia\",\n+      \"Enhanced Color Perception\",\n+      \"Nausea and Bodily Discomfort\",\n+      \"Temperature Dysregulation\",\n+      \"Emotional Neutrality or Detachment\",\n-      \"Enhanced Music Appreciation\",\n-      \"Pupil Dilation\",\n-      \"Increased Energy And Stimulation\",\n-      \"Novel Thought Patterns\"\n+      \"Memory Suppression\"\n-      \"full_tolerance\": \"Immediately after ingestion, cross-tolerant with all psychedelics\",\n+      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n-        \"All psychedelics including LSD, psilocybin mushrooms, mescaline, and tryptamines\"\n+        \"All psychedelics including LSD, psilocybin, mescaline, DMT, and related lysergamides\"\n-    \"half_life\": \"1-3 hours (LSD active metabolite)\",\n+    \"half_life\": \"\",\n-        \"name\": \"Erowid ALD-52 Vault\",\n-        \"reference\": \"https://erowid.org/chemicals/lsd/lsd_ald52.shtml\"\n+        \"name\": \"Bluelight: The Big & Dandy ETH-LAD Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-eth-lad-thread.761505/\"\n-        \"name\": \"Isomer Design TiHKAL Entry 26 (LSD)\",\n-        \"reference\": \"https://isomerdesign.com/pihkal/read/tk/26\"\n+        \"name\": \"Erowid ETH-LAD Experience Vault\",\n+        \"reference\": \"https://www.erowid.org/experiences/subs/exp_ETHLAD.shtml\"\n-        \"name\": \"PsychonautWiki: ALD-52\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/ALD-52\"\n+        \"name\": \"Erowid TiHKAL Entry #12: ETH-LAD\",\n+        \"reference\": \"https://erowid.org/library/books_online/tihkal/tihkal12.shtml\"\n-        \"name\": \"The Big & Dandy ALD-52 Thread (Bluelight)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-ald-52-thread.773316/\"\n+        \"name\": \"Hoffman AJ, Nichols DE (1985) - Synthesis and LSD-like discriminative stimulus properties\",\n+        \"reference\": \"https://doi.org/10.1021/jm00147a022\"\n-        \"name\": \"TripSit Drug Combination Chart\",\n-        \"reference\": \"https://wiki.tripsit.me/wiki/Drug_combinations\"\n+        \"name\": \"Isomer Design: TiHKAL ETH-LAD Entry\",\n+        \"reference\": \"http://isomerdesign.com/PiHKAL/read.php?domain=tk&id=12\"\n-        \"name\": \"Wagmann et al. (2019) In vitro metabolic fate of nine LSD-based new psychoactive substances\",\n-        \"reference\": \"https://doi.org/10.1007/s00216-018-1558-9\"\n+        \"name\": \"PsychonautWiki: ETH-LAD\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/ETH-LAD\"\n-      \"research-chemical\",\n-      \"prodrug\"\n+      \"research-chemical\"\n-  \"id\": 629\n+  \"id\": 630\n\n# LSA · #631\n\n-  \"title\": \"ETH-LAD\",\n-  \"index-category\": \"psychedelic; lysergamide\",\n+  \"title\": \"LSA\",\n+  \"index-category\": \"psychedelic; natural\",\n-    \"drug_name\": \"ETH-LAD\",\n-    \"chemical_name\": \"6-Ethyl-6-nor-lysergic acid diethylamide\",\n-    \"alternative_name\": \"N-Ethyl-nor-LSD; 6-Ethyl-6-nor-lysergic acid diethylamide; N-Ethyl-nor-lysergic acid N,N-diethylamide\",\n+    \"drug_name\": \"LSA\",\n+    \"chemical_name\": \"d-Lysergic acid amide\",\n+    \"alternative_name\": \"Ergine; LA-111\",\n-    \"mechanism_of_action\": \"5-HT2A receptor agonist; 5-HT2C receptor agonist; 5-HT1A receptor agonist (high affinity); dopamine D1, D2, D3, D4, D5 receptor binding (lower affinity)\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n-          \"route\": \"oral\",\n-          \"units\": \"ug\",\n+          \"route\": \"oral (morning glory seeds)\",\n+          \"units\": \"seeds\",\n-            \"threshold\": \"15 ug\",\n-            \"light\": \"15-60 ug\",\n-            \"common\": \"60-150 ug\",\n-            \"strong\": \"150-225 ug\",\n-            \"heavy\": \"225+ ug\"\n+            \"threshold\": \"20-50 seeds\",\n+            \"light\": \"50-100 seeds\",\n+            \"common\": \"100-250 seeds\",\n+            \"strong\": \"250-400 seeds\",\n+            \"heavy\": \"400+ seeds\"\n+        },\n+        {\n+          \"route\": \"oral (hawaiian baby woodrose seeds)\",\n+          \"units\": \"seeds\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"1-3 seeds\",\n+            \"light\": \"3-5 seeds\",\n+            \"common\": \"5-7 seeds\",\n+            \"strong\": \"7-12 seeds\",\n+            \"heavy\": \"12+ seeds\"\n+          }\n+        },\n+        {\n+          \"route\": \"oral (pure lsa)\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"0.5 mg\",\n+            \"light\": \"0.5-1 mg\",\n+            \"common\": \"1-2 mg\",\n+            \"strong\": \"2-3 mg\",\n+            \"heavy\": \"3+ mg\"\n+          }\n-          \"route\": \"oral\",\n+          \"route\": \"oral (morning glory seeds)\",\n-            \"total_duration\": \"8-12 hours\",\n-            \"onset\": \"20-40 minutes\",\n-            \"peak\": \"4-6 hours (including 45-90 minute come up)\",\n-            \"offset\": \"2-4 hours\",\n-            \"after_effects\": \"8-48 hours\"\n+            \"total_duration\": \"4-10 hours\",\n+            \"onset\": \"20-60 minutes (up to 3 hours reported)\",\n+            \"peak\": \"90-180 minutes\",\n+            \"offset\": \"2-7 hours\",\n+            \"after_effects\": \"1-12 hours (afterglow)\"\n+        },\n+        {\n+          \"route\": \"oral (hawaiian baby woodrose seeds)\",\n+          \"stages\": {\n+            \"total_duration\": \"4-10 hours\",\n+            \"onset\": \"20-60 minutes (up to 3 hours reported)\",\n+            \"peak\": \"90-180 minutes\",\n+            \"offset\": \"2-7 hours\",\n+            \"after_effects\": \"1-12 hours (afterglow)\"\n+          }\n+        },\n+        {\n+          \"route\": \"oral (pure lsa)\",\n+          \"stages\": {\n+            \"total_duration\": \"4-10 hours\",\n+            \"onset\": \"20-60 minutes (up to 3 hours reported)\",\n+            \"peak\": \"90-180 minutes\",\n+            \"offset\": \"2-7 hours\",\n+            \"after_effects\": \"1-12 hours (afterglow)\"\n+          }\n-    \"addiction_potential\": \"ETH-LAD is not considered habit-forming and demonstrates a self-regulating quality typical of psychedelics. Rapid tolerance develops immediately after use, discouraging frequent consumption. Cases of abuse have been rarely reported, though the substance generally decreases in desirability with repeated use.\",\n+    \"addiction_potential\": \"LSA is not considered to be addictive with low abuse potential. There is virtually no withdrawal syndrome when use is stopped, and animal studies have not demonstrated self-administration behavior predictive of abuse liability.\",\n-        \"Cannabis (unpredictable and strongly increased effects, risk of anxiety, paranoia, panic attacks, and psychosis)\",\n-        \"Stimulants including amphetamine, cocaine, methylphenidate (increased risk of anxiety, paranoia, panic attacks, thought loops, mania, and psychosis)\"\n+        \"Stimulants (increased risk of anxiety, paranoia, thought loops, and mania)\",\n+        \"Cannabis (unexpectedly strong and unpredictable synergy; significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n-      \"caution\": []\n+      \"caution\": [\n+        \"SSRIs (may suppress visual and cognitive effects)\",\n+        \"MAOIs (may potentiate effects; use caution with potential for dangerous interactions with other substances)\",\n+        \"Dissociatives (greatly enhance cognitive, visual and hallucinatory effects with increased risk of confusion and psychosis)\",\n+        \"Alcohol (may reduce anxiety but can increase dehydration, nausea and physical fatigue)\",\n+        \"Benzodiazepines (can reduce trip intensity; useful for stopping bad trips but may cause amnesia)\",\n+        \"Other psychedelics (unpredictable synergy and intensification of effects)\"\n+      ]\n-    \"notes\": \"ETH-LAD requires exceptional caution due to its high potency, unpredictable dose-response curve, and tendency to produce severe physical side effects including pronounced nausea, temperature dysregulation, muscle cramps, and bodily discomfort at higher doses. The substance is notably more difficult to handle than LSD and should only be used by experienced psychedelic users. Accurate measurement with a precise scale is critical. Users should monitor body temperature throughout the experience and maintain access to climate control. Set and setting are paramount, and having a trusted sober sitter is strongly recommended, especially at doses above the common range. Individuals with personal or family history of psychotic disorders should avoid use.\",\n+    \"notes\": \"LSA-containing seeds vary widely in alkaloid content between species, batches, and individual seeds. Commercial seeds are often treated with fungicides or pesticides that can be extremely toxic; only use organic, untreated seeds from trusted vendors. Heavy metal testing is recommended before consumption. Extraction methods can significantly reduce nausea and body load. Strong vasoconstriction is common and can cause painful leg cramping; avoid repeated use over short periods. Set and setting strongly influence the experience. Individuals with personal or family histories of psychotic disorders should avoid use.\",\n-      \"Intricate Visual Geometry\",\n-      \"Enhanced Pattern Recognition\",\n-      \"Auditory Distortions and Hallucinations\",\n-      \"Analysis Enhancement\",\n-      \"Introspective Thought Patterns\",\n+      \"Sedation (setting-dependent)\",\n+      \"Physical Euphoria\",\n+      \"Visual Enhancements and Distortions\",\n+      \"Spontaneous Bodily Sensations\",\n+      \"Perception of Bodily Heaviness\",\n+      \"Motor Control Loss\",\n+      \"Nausea and Vasoconstriction\",\n+      \"Dream-Like State\",\n+      \"Introspection and Analysis Enhancement\",\n+      \"Emotion Enhancement\",\n-      \"Synaesthesia\",\n-      \"Enhanced Color Perception\",\n-      \"Nausea and Bodily Discomfort\",\n-      \"Temperature Dysregulation\",\n-      \"Emotional Neutrality or Detachment\",\n-      \"Thought Acceleration\",\n-      \"Memory Suppression\"\n+      \"Internal and External Hallucinations\",\n+      \"Thought Connectivity\",\n+      \"Music Appreciation Enhancement\",\n+      \"Spirituality Enhancement\"\n-      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n-      \"half_tolerance\": \"5-7 days\",\n-      \"zero_tolerance\": \"14 days\",\n+      \"full_tolerance\": \"Almost immediately after ingestion\",\n+      \"half_tolerance\": \"3-4 days\",\n+      \"zero_tolerance\": \"7 days\",\n-        \"All psychedelics including LSD, psilocybin, mescaline, DMT, and related lysergamides\"\n+        \"All psychedelics (LSD, psilocybin mushrooms, mescaline, DMT, 2C-x compounds)\"\n-    \"half_life\": \"\",\n+    \"half_life\": \"1-3 hours (psilocin is referenced in the original document, but LSA half-life data is limited; serum concentrations detectable for 1-24 hours post-ingestion)\",\n-        \"name\": \"Bluelight: The Big & Dandy ETH-LAD Thread\",\n-        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-eth-lad-thread.761505/\"\n+        \"name\": \"PsychonautWiki: LSA\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/LSA\"\n-        \"name\": \"Erowid ETH-LAD Experience Vault\",\n-        \"reference\": \"https://www.erowid.org/experiences/subs/exp_ETHLAD.shtml\"\n+        \"name\": \"TripSit Wiki: LSA\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/LSA\"\n-        \"name\": \"Erowid TiHKAL Entry #12: ETH-LAD\",\n-        \"reference\": \"https://erowid.org/library/books_online/tihkal/tihkal12.shtml\"\n+        \"name\": \"Erowid LSA Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/lsa/lsa.shtml\"\n-        \"name\": \"Hoffman AJ, Nichols DE (1985) - Synthesis and LSD-like discriminative stimulus properties\",\n-        \"reference\": \"https://doi.org/10.1021/jm00147a022\"\n+        \"name\": \"Erowid LSA Dosage\",\n+        \"reference\": \"https://erowid.org/chemicals/lsa/lsa_dose.shtml\"\n-        \"name\": \"Isomer Design: TiHKAL ETH-LAD Entry\",\n-        \"reference\": \"http://isomerdesign.com/PiHKAL/read.php?domain=tk&id=12\"\n+        \"name\": \"Erowid LSA Effects\",\n+        \"reference\": \"https://www.erowid.org/chemicals/lsa/lsa_effects.shtml\"\n-        \"name\": \"PsychonautWiki: ETH-LAD\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/ETH-LAD\"\n+        \"name\": \"Bluelight: The Big & Dandy LSA Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/lsas-subthread-extraction-of-lsas.123944/\"\n+      },\n+      {\n+        \"name\": \"Drugs-Forum: LSA Wiki\",\n+        \"reference\": \"https://drugs-forum.com/wiki/LSA\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Ergine\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Ergine\"\n+      },\n+      {\n+        \"name\": \"Lysergic Acid Amide (LSA), an LSD Analog: Systematic Review (MDPI, 2025)\",\n+        \"reference\": \"https://www.mdpi.com/2226-4787/13/4/98\"\n-      \"research-chemical\"\n+      \"natural\"\n-  \"id\": 630\n+  \"id\": 631\n\n# MiPLA · #632\n\n-  \"title\": \"LSA\",\n-  \"index-category\": \"psychedelic; natural\",\n+  \"title\": \"MiPLA\",\n+  \"index-category\": \"psychedelic; lysergamide; research-chemical\",\n-    \"drug_name\": \"LSA\",\n-    \"chemical_name\": \"d-Lysergic acid amide\",\n-    \"alternative_name\": \"Ergine; LA-111\",\n+    \"drug_name\": \"MiPLA\",\n+    \"chemical_name\": \"Lysergic acid methylisopropylamide\",\n+    \"alternative_name\": \"Lamide\",\n-          \"route\": \"oral (morning glory seeds)\",\n-          \"units\": \"seeds\",\n+          \"route\": \"oral\",\n+          \"units\": \"ug\",\n-            \"threshold\": \"20-50 seeds\",\n-            \"light\": \"50-100 seeds\",\n-            \"common\": \"100-250 seeds\",\n-            \"strong\": \"250-400 seeds\",\n-            \"heavy\": \"400+ seeds\"\n+            \"threshold\": \"50 ug\",\n+            \"light\": \"100-150 ug\",\n+            \"common\": \"150-200 ug\",\n+            \"strong\": \"200-250 ug\",\n+            \"heavy\": \"300+ ug\"\n-        },\n-        {\n-          \"route\": \"oral (hawaiian baby woodrose seeds)\",\n-          \"units\": \"seeds\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"1-3 seeds\",\n-            \"light\": \"3-5 seeds\",\n-            \"common\": \"5-7 seeds\",\n-            \"strong\": \"7-12 seeds\",\n-            \"heavy\": \"12+ seeds\"\n-          }\n-        },\n-        {\n-          \"route\": \"oral (pure lsa)\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"0.5 mg\",\n-            \"light\": \"0.5-1 mg\",\n-            \"common\": \"1-2 mg\",\n-            \"strong\": \"2-3 mg\",\n-            \"heavy\": \"3+ mg\"\n-          }\n-          \"route\": \"oral (morning glory seeds)\",\n+          \"route\": \"oral\",\n-            \"total_duration\": \"4-10 hours\",\n-            \"onset\": \"20-60 minutes (up to 3 hours reported)\",\n-            \"peak\": \"90-180 minutes\",\n-            \"offset\": \"2-7 hours\",\n-            \"after_effects\": \"1-12 hours (afterglow)\"\n+            \"total_duration\": \"4-6 hours\",\n+            \"onset\": \"20-40 minutes\",\n+            \"peak\": \"1-2 hours (preceded by 45-90 minute come-up)\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"Minimal residual stimulation\"\n-        },\n-        {\n-          \"route\": \"oral (hawaiian baby woodrose seeds)\",\n-          \"stages\": {\n-            \"total_duration\": \"4-10 hours\",\n-            \"onset\": \"20-60 minutes (up to 3 hours reported)\",\n-            \"peak\": \"90-180 minutes\",\n-            \"offset\": \"2-7 hours\",\n-            \"after_effects\": \"1-12 hours (afterglow)\"\n-          }\n-        },\n-        {\n-          \"route\": \"oral (pure lsa)\",\n-          \"stages\": {\n-            \"total_duration\": \"4-10 hours\",\n-            \"onset\": \"20-60 minutes (up to 3 hours reported)\",\n-            \"peak\": \"90-180 minutes\",\n-            \"offset\": \"2-7 hours\",\n-            \"after_effects\": \"1-12 hours (afterglow)\"\n-          }\n-    \"addiction_potential\": \"LSA is not considered to be addictive with low abuse potential. There is virtually no withdrawal syndrome when use is stopped, and animal studies have not demonstrated self-administration behavior predictive of abuse liability.\",\n+    \"addiction_potential\": \"MiPLA is not considered physically addictive and has low potential for psychological dependence, similar to other serotonergic psychedelics. Rapid tolerance development discourages frequent use.\",\n-        \"Lithium (significantly increased risk of psychosis and seizures)\",\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n-        \"Stimulants (increased risk of anxiety, paranoia, thought loops, and mania)\",\n-        \"Cannabis (unexpectedly strong and unpredictable synergy; significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n+        \"Stimulants (amphetamine, cocaine, methylphenidate - increases risk of anxiety, paranoia, panic attacks, thought loops, mania, and psychosis)\"\n-        \"SSRIs (may suppress visual and cognitive effects)\",\n-        \"MAOIs (may potentiate effects; use caution with potential for dangerous interactions with other substances)\",\n-        \"Dissociatives (greatly enhance cognitive, visual and hallucinatory effects with increased risk of confusion and psychosis)\",\n-        \"Alcohol (may reduce anxiety but can increase dehydration, nausea and physical fatigue)\",\n-        \"Benzodiazepines (can reduce trip intensity; useful for stopping bad trips but may cause amnesia)\",\n-        \"Other psychedelics (unpredictable synergy and intensification of effects)\"\n+        \"Cannabis (unpredictable synergy; significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\",\n+        \"SSRIs (may alter or blunt effects)\"\n-    \"notes\": \"LSA-containing seeds vary widely in alkaloid content between species, batches, and individual seeds. Commercial seeds are often treated with fungicides or pesticides that can be extremely toxic; only use organic, untreated seeds from trusted vendors. Heavy metal testing is recommended before consumption. Extraction methods can significantly reduce nausea and body load. Strong vasoconstriction is common and can cause painful leg cramping; avoid repeated use over short periods. Set and setting strongly influence the experience. Individuals with personal or family histories of psychotic disorders should avoid use.\",\n+    \"notes\": \"MiPLA is a research chemical with very limited history of human use and minimal scientific study of its pharmacology, metabolism, and toxicity. It is approximately two to three times less potent than LSD and has a notably shorter duration of around 4-6 hours. The substance is generally described as producing less anxiety and a lighter headspace compared to LSD. Individuals with personal or family history of mental illness should avoid use. Use precise weighing equipment and employ harm reduction practices including careful set and setting preparation.\",\n-      \"Sedation (setting-dependent)\",\n+      \"Stimulation\",\n-      \"Visual Enhancements and Distortions\",\n-      \"Spontaneous Bodily Sensations\",\n-      \"Perception of Bodily Heaviness\",\n-      \"Motor Control Loss\",\n-      \"Nausea and Vasoconstriction\",\n-      \"Dream-Like State\",\n-      \"Introspection and Analysis Enhancement\",\n-      \"Emotion Enhancement\",\n-      \"Time Distortion\",\n-      \"Internal and External Hallucinations\",\n-      \"Thought Connectivity\",\n+      \"Tactile Enhancement\",\n+      \"Visual Acuity Enhancement\",\n+      \"Color Enhancement\",\n+      \"Pattern Recognition Enhancement\",\n+      \"Visual Drifting\",\n+      \"Geometric Patterns\",\n+      \"Cognitive Euphoria\",\n+      \"Analysis Enhancement\",\n-      \"Spirituality Enhancement\"\n+      \"Time Distortion\",\n+      \"Ego Death (at higher doses)\",\n+      \"Nausea\",\n+      \"Increased Body Temperature\"\n-      \"full_tolerance\": \"Almost immediately after ingestion\",\n-      \"half_tolerance\": \"3-4 days\",\n-      \"zero_tolerance\": \"7 days\",\n+      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n+      \"half_tolerance\": \"5-7 days\",\n+      \"zero_tolerance\": \"14 days\",\n-        \"All psychedelics (LSD, psilocybin mushrooms, mescaline, DMT, 2C-x compounds)\"\n+        \"All psychedelics (due to 5-HT2A receptor activity)\"\n-    \"half_life\": \"1-3 hours (psilocin is referenced in the original document, but LSA half-life data is limited; serum concentrations detectable for 1-24 hours post-ingestion)\",\n+    \"half_life\": \"1-3 hours (estimated based on duration profile)\",\n-        \"name\": \"PsychonautWiki: LSA\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/LSA\"\n+        \"name\": \"PsychonautWiki: MiPLA\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/MiPLA\"\n-        \"name\": \"TripSit Wiki: LSA\",\n-        \"reference\": \"https://wiki.tripsit.me/wiki/LSA\"\n+        \"name\": \"Erowid MiPLA Experience Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_MIPLA.shtml\"\n-        \"name\": \"Erowid LSA Vault\",\n-        \"reference\": \"https://www.erowid.org/chemicals/lsa/lsa.shtml\"\n+        \"name\": \"Bluelight: The Big & Dandy MIPLA Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-mipla-methylisopropyllysergamide-thread.784440/\"\n-        \"name\": \"Erowid LSA Dosage\",\n-        \"reference\": \"https://erowid.org/chemicals/lsa/lsa_dose.shtml\"\n+        \"name\": \"Isomer Design: MiPLA (PiHKAL)\",\n+        \"reference\": \"https://isomerdesign.com/pihkal/explore/5327\"\n-        \"name\": \"Erowid LSA Effects\",\n-        \"reference\": \"https://www.erowid.org/chemicals/lsa/lsa_effects.shtml\"\n+        \"name\": \"Halberstadt et al. (2018) - Pharmacological characterization of ECPLA\",\n+        \"reference\": \"https://link.springer.com/article/10.1007/s00213-018-5055-9\"\n-        \"name\": \"Bluelight: The Big & Dandy LSA Thread\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/lsas-subthread-extraction-of-lsas.123944/\"\n-      },\n-      {\n-        \"name\": \"Drugs-Forum: LSA Wiki\",\n-        \"reference\": \"https://drugs-forum.com/wiki/LSA\"\n-      },\n-      {\n-        \"name\": \"Wikipedia: Ergine\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Ergine\"\n-      },\n-      {\n-        \"name\": \"Lysergic Acid Amide (LSA), an LSD Analog: Systematic Review (MDPI, 2025)\",\n-        \"reference\": \"https://www.mdpi.com/2226-4787/13/4/98\"\n+        \"name\": \"Nichols, D.E. (2001) - LSD and its lysergamide cousins\",\n+        \"reference\": \"The Heffter Review of Psychedelic Research, Vol. 2, pp. 80-87\"\n-      \"natural\"\n+      \"research-chemical\"\n-  \"id\": 631\n+  \"id\": 632\n\n# MET · #633\n\n-  \"title\": \"MiPLA\",\n-  \"index-category\": \"psychedelic; lysergamide; research-chemical\",\n+  \"title\": \"MET\",\n+  \"index-category\": \"psychedelic; tryptamine\",\n-    \"drug_name\": \"MiPLA\",\n-    \"chemical_name\": \"Lysergic acid methylisopropylamide\",\n-    \"alternative_name\": \"Lamide\",\n-    \"chemical_class\": \"Lysergamides\",\n+    \"drug_name\": \"MET\",\n+    \"chemical_name\": \"N-Ethyl-N-methyltryptamine\",\n+    \"alternative_name\": \"Methylethyltryptamine\",\n+    \"chemical_class\": \"Tryptamines\",\n-    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; serotonin releasing agent (weak)\",\n+          \"route\": \"smoked/vaporized\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"10 mg\",\n+            \"light\": \"20-40 mg\",\n+            \"common\": \"40-60 mg\",\n+            \"strong\": \"60-90 mg\",\n+            \"heavy\": \"90+ mg\"\n+          }\n+        },\n+        {\n-          \"units\": \"ug\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"50 ug\",\n-            \"light\": \"100-150 ug\",\n-            \"common\": \"150-200 ug\",\n-            \"strong\": \"200-250 ug\",\n-            \"heavy\": \"300+ ug\"\n+            \"threshold\": \"60-70 mg\",\n+            \"light\": \"70-80 mg\",\n+            \"common\": \"80-110 mg\",\n+            \"strong\": \"110-150 mg\",\n+            \"heavy\": \"150+ mg\"\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"10-15 mg\",\n+            \"light\": \"15-30 mg\",\n+            \"common\": \"30-50 mg\",\n+            \"strong\": \"50-70 mg\",\n+            \"heavy\": \"70+ mg\"\n+          }\n+          \"route\": \"smoked/vaporized\",\n+          \"stages\": {\n+            \"total_duration\": \"30-75 minutes\",\n+            \"onset\": \"30-60 seconds\",\n+            \"peak\": \"10-20 minutes\",\n+            \"offset\": \"20-40 minutes\",\n+            \"after_effects\": \"20-60 minutes\"\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n+        },\n+        {\n-            \"total_duration\": \"4-6 hours\",\n-            \"onset\": \"20-40 minutes\",\n-            \"peak\": \"1-2 hours (preceded by 45-90 minute come-up)\",\n+            \"total_duration\": \"2-4 hours\",\n+            \"onset\": \"20-45 minutes\",\n+            \"peak\": \"1-2 hours\",\n-            \"after_effects\": \"Minimal residual stimulation\"\n+            \"after_effects\": \"1-3 hours\"\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"stages\": {\n+            \"total_duration\": \"1.5-3 hours\",\n+            \"onset\": \"5-15 minutes\",\n+            \"peak\": \"30-90 minutes\",\n+            \"offset\": \"45-90 minutes\",\n+            \"after_effects\": \"30-120 minutes\"\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n-    \"addiction_potential\": \"MiPLA is not considered physically addictive and has low potential for psychological dependence, similar to other serotonergic psychedelics. Rapid tolerance development discourages frequent use.\",\n+    \"addiction_potential\": \"MET is not considered habit-forming and appears to be self-regulating. Reports suggest the desire to use it may actually decrease with regular consumption, similar to other psychedelic tryptamines.\",\n-        \"Lithium (significantly increases risk of psychosis and seizures)\",\n-        \"Tramadol (lowers seizure threshold)\"\n+        \"MAOIs (risk of serotonin syndrome and hypertensive crisis)\",\n+        \"Lithium (increased seizure risk)\"\n-        \"Stimulants (amphetamine, cocaine, methylphenidate - increases risk of anxiety, paranoia, panic attacks, thought loops, mania, and psychosis)\"\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Stimulants (increased risk of anxiety and cardiovascular strain)\"\n-        \"Cannabis (unpredictable synergy; significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\",\n-        \"SSRIs (may alter or blunt effects)\"\n+        \"SSRIs (may dampen or prolong effects)\",\n+        \"Cannabis (may intensify experience unpredictably)\"\n-    \"notes\": \"MiPLA is a research chemical with very limited history of human use and minimal scientific study of its pharmacology, metabolism, and toxicity. It is approximately two to three times less potent than LSD and has a notably shorter duration of around 4-6 hours. The substance is generally described as producing less anxiety and a lighter headspace compared to LSD. Individuals with personal or family history of mental illness should avoid use. Use precise weighing equipment and employ harm reduction practices including careful set and setting preparation.\",\n+    \"notes\": \"MET is a research chemical with very limited human use history and unstudied toxicity profile. The freebase form can be harsh when insufflated or smoked. Use an accurate milligram scale for all routes of administration. Set and setting are crucial for psychedelic experiences. Unlike DMT, MET has oral activity without requiring an MAOI. Individuals with personal or family history of psychotic disorders should avoid use.\",\n-      \"Stimulation\",\n+      \"Visual Geometry And Patterning\",\n+      \"Internal Hallucinations\",\n-      \"Visual Acuity Enhancement\",\n-      \"Color Enhancement\",\n-      \"Pattern Recognition Enhancement\",\n-      \"Visual Drifting\",\n-      \"Geometric Patterns\",\n+      \"Stimulation\",\n+      \"Color Enhancement And Shifting\",\n-      \"Analysis Enhancement\",\n-      \"Music Appreciation Enhancement\",\n+      \"Empathy And Sociability Enhancement\",\n+      \"Thought Connectivity\",\n-      \"Ego Death (at higher doses)\",\n-      \"Nausea\",\n-      \"Increased Body Temperature\"\n+      \"Confusion\",\n+      \"Memory Suppression\"\n-      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n-      \"half_tolerance\": \"5-7 days\",\n-      \"zero_tolerance\": \"14 days\",\n+      \"full_tolerance\": \"Minimal tolerance buildup with repeated use\",\n+      \"half_tolerance\": \"Unknown\",\n+      \"zero_tolerance\": \"Approximately 1-2 weeks\",\n-        \"All psychedelics (due to 5-HT2A receptor activity)\"\n+        \"Other psychedelic tryptamines (minimal to none)\",\n+        \"Classic psychedelics (minimal to none)\"\n-    \"half_life\": \"1-3 hours (estimated based on duration profile)\",\n+    \"half_life\": \"\",\n-        \"name\": \"PsychonautWiki: MiPLA\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/MiPLA\"\n+        \"name\": \"Bluelight: The Big & Dandy MET Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-met-thread.255405/\"\n-        \"name\": \"Erowid MiPLA Experience Vault\",\n-        \"reference\": \"https://erowid.org/experiences/subs/exp_MIPLA.shtml\"\n+        \"name\": \"Erowid MET Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/met/met.shtml\"\n-        \"name\": \"Bluelight: The Big & Dandy MIPLA Thread\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-mipla-methylisopropyllysergamide-thread.784440/\"\n+        \"name\": \"PsychonautWiki: MET\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/MET\"\n-        \"name\": \"Isomer Design: MiPLA (PiHKAL)\",\n-        \"reference\": \"https://isomerdesign.com/pihkal/explore/5327\"\n-      },\n-      {\n-        \"name\": \"Halberstadt et al. (2018) - Pharmacological characterization of ECPLA\",\n-        \"reference\": \"https://link.springer.com/article/10.1007/s00213-018-5055-9\"\n-      },\n-      {\n-        \"name\": \"Nichols, D.E. (2001) - LSD and its lysergamide cousins\",\n-        \"reference\": \"The Heffter Review of Psychedelic Research, Vol. 2, pp. 80-87\"\n+        \"name\": \"Wikipedia: Methylethyltryptamine\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Methylethyltryptamine\"\n-      \"lysergamide\",\n+      \"tryptamine\",\n-  \"id\": 632\n+  \"id\": 633\n\n# LSM-775 · #634\n\n-  \"title\": \"MET\",\n-  \"index-category\": \"psychedelic; tryptamine\",\n+  \"title\": \"LSM-775\",\n+  \"index-category\": \"psychedelic; lysergamide; research-chemical\",\n-    \"drug_name\": \"MET\",\n-    \"chemical_name\": \"N-Ethyl-N-methyltryptamine\",\n-    \"alternative_name\": \"Methylethyltryptamine\",\n-    \"chemical_class\": \"Tryptamines\",\n+    \"drug_name\": \"LSM-775\",\n+    \"chemical_name\": \"Lysergic acid morpholide\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Lysergamides\",\n-    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; serotonin releasing agent (weak)\",\n+    \"mechanism_of_action\": \"5-HT1A receptor full agonist; 5-HT2A receptor partial agonist; 5-HT2B receptor partial agonist; 5-HT2C receptor partial agonist\",\n-          \"route\": \"smoked/vaporized\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"10 mg\",\n-            \"light\": \"20-40 mg\",\n-            \"common\": \"40-60 mg\",\n-            \"strong\": \"60-90 mg\",\n-            \"heavy\": \"90+ mg\"\n-          }\n-        },\n-        {\n-          \"units\": \"mg\",\n+          \"units\": \"ug\",\n-            \"threshold\": \"60-70 mg\",\n-            \"light\": \"70-80 mg\",\n-            \"common\": \"80-110 mg\",\n-            \"strong\": \"110-150 mg\",\n-            \"heavy\": \"150+ mg\"\n+            \"threshold\": \"250 ug\",\n+            \"light\": \"500-750 ug\",\n+            \"common\": \"750-1250 ug\",\n+            \"strong\": \"1250-1500 ug\",\n+            \"heavy\": \"1500+ ug\"\n-        },\n-        {\n-          \"route\": \"insufflated\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"10-15 mg\",\n-            \"light\": \"15-30 mg\",\n-            \"common\": \"30-50 mg\",\n-            \"strong\": \"50-70 mg\",\n-            \"heavy\": \"70+ mg\"\n-          }\n-          \"route\": \"smoked/vaporized\",\n-          \"stages\": {\n-            \"total_duration\": \"30-75 minutes\",\n-            \"onset\": \"30-60 seconds\",\n-            \"peak\": \"10-20 minutes\",\n-            \"offset\": \"20-40 minutes\",\n-            \"after_effects\": \"20-60 minutes\"\n-          },\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ]\n-        },\n-        {\n-            \"total_duration\": \"2-4 hours\",\n-            \"onset\": \"20-45 minutes\",\n-            \"peak\": \"1-2 hours\",\n-            \"offset\": \"1-2 hours\",\n-            \"after_effects\": \"1-3 hours\"\n+            \"total_duration\": \"6-10 hours\",\n+            \"onset\": \"10-30 minutes\",\n+            \"peak\": \"60-150 minutes\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"Variable (residual sedation possible)\"\n-        },\n-        {\n-          \"route\": \"insufflated\",\n-          \"stages\": {\n-            \"total_duration\": \"1.5-3 hours\",\n-            \"onset\": \"5-15 minutes\",\n-            \"peak\": \"30-90 minutes\",\n-            \"offset\": \"45-90 minutes\",\n-            \"after_effects\": \"30-120 minutes\"\n-          },\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ]\n-    \"addiction_potential\": \"MET is not considered habit-forming and appears to be self-regulating. Reports suggest the desire to use it may actually decrease with regular consumption, similar to other psychedelic tryptamines.\",\n+    \"addiction_potential\": \"LSM-775 is not considered habit-forming and possesses an intrinsic self-regulating quality similar to other psychedelics. Limited evidence suggests no significant dependence potential, though the substance has very little history of human use.\",\n-        \"MAOIs (risk of serotonin syndrome and hypertensive crisis)\",\n-        \"Lithium (increased seizure risk)\"\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n-        \"Tramadol (lowers seizure threshold)\",\n-        \"Stimulants (increased risk of anxiety and cardiovascular strain)\"\n+        \"Stimulants (increases anxiety, paranoia, and thought loops)\",\n+        \"Cannabis (unpredictable synergy; greatly increases risk of anxiety and psychosis)\"\n-        \"SSRIs (may dampen or prolong effects)\",\n-        \"Cannabis (may intensify experience unpredictably)\"\n+        \"MDMA (unpredictable synergy; potentially neurotoxic)\",\n+        \"Alcohol (increases dehydration and physical discomfort)\",\n+        \"Other psychedelics (unpredictable intensification)\"\n-    \"notes\": \"MET is a research chemical with very limited human use history and unstudied toxicity profile. The freebase form can be harsh when insufflated or smoked. Use an accurate milligram scale for all routes of administration. Set and setting are crucial for psychedelic experiences. Unlike DMT, MET has oral activity without requiring an MAOI. Individuals with personal or family history of psychotic disorders should avoid use.\",\n+    \"notes\": \"LSM-775 is a novel lysergamide with approximately one-tenth the potency of LSD and a shorter duration. It is characterized by prominent dream-like sedation and significant nausea that may substantially reduce the experience's pleasantness. Use a precise milligram scale as doses are relatively high. Mental health screening is advised before use, particularly for individuals with personal or family history of psychotic disorders. Set and setting remain important factors. Legal status varies by jurisdiction; controlled in Germany and Switzerland as of 2019.\",\n-      \"Visual Geometry And Patterning\",\n-      \"Internal Hallucinations\",\n-      \"Physical Euphoria\",\n-      \"Tactile Enhancement\",\n-      \"Stimulation\",\n-      \"Color Enhancement And Shifting\",\n-      \"Cognitive Euphoria\",\n-      \"Empathy And Sociability Enhancement\",\n+      \"Dream-Like Sedation\",\n+      \"Prominent Nausea\",\n+      \"Visual Patterning And Geometry\",\n+      \"Time Distortion (Particularly Pronounced)\",\n+      \"Color Enhancement\",\n+      \"Spontaneous Physical Sensations (Tingling)\",\n+      \"Music Enhancement\",\n-      \"Time Distortion\",\n-      \"Confusion\",\n-      \"Memory Suppression\"\n+      \"Perception Of Bodily Heaviness\",\n+      \"Drifting (Melting, Breathing, Morphing)\",\n+      \"Internal Hallucinations\",\n+      \"Analysis Enhancement\"\n-      \"full_tolerance\": \"Minimal tolerance buildup with repeated use\",\n-      \"half_tolerance\": \"Unknown\",\n-      \"zero_tolerance\": \"Approximately 1-2 weeks\",\n+      \"full_tolerance\": \"Almost immediately after ingestion\",\n+      \"half_tolerance\": \"5-7 days\",\n+      \"zero_tolerance\": \"14 days\",\n-        \"Other psychedelic tryptamines (minimal to none)\",\n-        \"Classic psychedelics (minimal to none)\"\n+        \"All psychedelics (LSD, psilocybin, mescaline, etc.)\"\n-        \"name\": \"Bluelight: The Big & Dandy MET Thread\",\n-        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-met-thread.255405/\"\n+        \"name\": \"PsychonautWiki: LSM-775\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/LSM-775\"\n-        \"name\": \"Erowid MET Vault\",\n-        \"reference\": \"https://www.erowid.org/chemicals/met/met.shtml\"\n+        \"name\": \"Erowid Experience Vaults: LSM-775\",\n+        \"reference\": \"https://www.erowid.org/experiences/subs/exp_LSM775.shtml\"\n-        \"name\": \"PsychonautWiki: MET\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/MET\"\n+        \"name\": \"Isomer Design: LSM-775\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5338\"\n-        \"name\": \"Wikipedia: Methylethyltryptamine\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/Methylethyltryptamine\"\n+        \"name\": \"Bluelight: The Big & Dandy LSM-775 Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-lsm-775-lysergic-acid-morpholide-thread.775765/\"\n+      },\n+      {\n+        \"name\": \"Gogerty & Dille (1957): Pharmacology of d-LSM\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/13476356/\"\n+      },\n+      {\n+        \"name\": \"Shulgin: TiHKAL - LSD-25 Entry\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5338\"\n+      },\n+      {\n+        \"name\": \"Brandt et al. (2018): Return of the Lysergamides Part IV\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/28585392/\"\n-      \"tryptamine\",\n+      \"lysergamide\",\n-  \"id\": 633\n+  \"id\": 634\n\n# PRO-LAD · #635\n\n-  \"title\": \"LSM-775\",\n-  \"index-category\": \"psychedelic; lysergamide; research-chemical\",\n+  \"title\": \"PRO-LAD\",\n+  \"index-category\": \"psychedelic\",\n-    \"drug_name\": \"LSM-775\",\n-    \"chemical_name\": \"Lysergic acid morpholide\",\n+    \"drug_name\": \"PRO-LAD\",\n+    \"chemical_name\": \"6-Propyl-6-nor-lysergic acid diethylamide\",\n-    \"mechanism_of_action\": \"5-HT1A receptor full agonist; 5-HT2A receptor partial agonist; 5-HT2B receptor partial agonist; 5-HT2C receptor partial agonist\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n-            \"threshold\": \"250 ug\",\n-            \"light\": \"500-750 ug\",\n-            \"common\": \"750-1250 ug\",\n-            \"strong\": \"1250-1500 ug\",\n-            \"heavy\": \"1500+ ug\"\n+            \"threshold\": \"20 ug\",\n+            \"light\": \"50-100 ug\",\n+            \"common\": \"100-200 ug\",\n+            \"strong\": \"200-350 ug\",\n+            \"heavy\": \"350+ ug\"\n-            \"total_duration\": \"6-10 hours\",\n-            \"onset\": \"10-30 minutes\",\n-            \"peak\": \"60-150 minutes\",\n-            \"offset\": \"2-4 hours\",\n-            \"after_effects\": \"Variable (residual sedation possible)\"\n+            \"total_duration\": \"6-8 hours\",\n+            \"onset\": \"30-45 minutes\",\n+            \"peak\": \"2-4 hours\",\n+            \"offset\": \"2-3 hours\",\n+            \"after_effects\": \"1-4 hours\"\n-    \"addiction_potential\": \"LSM-775 is not considered habit-forming and possesses an intrinsic self-regulating quality similar to other psychedelics. Limited evidence suggests no significant dependence potential, though the substance has very little history of human use.\",\n+    \"addiction_potential\": \"PRO-LAD is not considered habit-forming and possesses self-regulating properties typical of psychedelics. The desire to use it may actually decrease with repeated administration. No formal dependence studies have been conducted.\",\n-        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"Lithium (significantly increases risk of seizures and psychosis)\",\n-        \"Stimulants (increases anxiety, paranoia, and thought loops)\",\n-        \"Cannabis (unpredictable synergy; greatly increases risk of anxiety and psychosis)\"\n+        \"Stimulants including amphetamines, cocaine, methylphenidate (increased risk of anxiety, paranoia, thought loops, mania, and psychosis)\"\n-        \"MDMA (unpredictable synergy; potentially neurotoxic)\",\n-        \"Alcohol (increases dehydration and physical discomfort)\",\n-        \"Other psychedelics (unpredictable intensification)\"\n+        \"Cannabis (unexpectedly strong and unpredictable synergy; significantly increases risk of anxiety, paranoia, and psychosis)\",\n+        \"MDMA (unpredictable synergy with potential neurotoxicity)\",\n+        \"Benzodiazepines (can reduce or eliminate psychedelic effects)\",\n+        \"Dissociatives (greatly enhanced effects and confusion)\",\n+        \"Other psychedelics (unpredictable synergistic intensification)\"\n-    \"notes\": \"LSM-775 is a novel lysergamide with approximately one-tenth the potency of LSD and a shorter duration. It is characterized by prominent dream-like sedation and significant nausea that may substantially reduce the experience's pleasantness. Use a precise milligram scale as doses are relatively high. Mental health screening is advised before use, particularly for individuals with personal or family history of psychotic disorders. Set and setting remain important factors. Legal status varies by jurisdiction; controlled in Germany and Switzerland as of 2019.\",\n+    \"notes\": \"PRO-LAD is a research chemical with very limited history of human use and minimal scientific documentation regarding its pharmacology, metabolism, and long-term toxicity. Unlike LSD, PRO-LAD has a propyl chain at R6 which may result in slower absorption and different onset characteristics. Users should employ rigorous harm reduction practices including reagent testing, accurate weighing with a microgram scale, and having a trusted sober trip sitter present. Individuals with personal or family history of psychotic disorders should avoid use. PRO-LAD was first synthesized by Hoffman and Nichols in 1984 and later described by Alexander Shulgin in TiHKAL.\",\n-      \"Dream-Like Sedation\",\n-      \"Prominent Nausea\",\n-      \"Time Distortion (Particularly Pronounced)\",\n-      \"Spontaneous Physical Sensations (Tingling)\",\n-      \"Music Enhancement\",\n+      \"Introspection\",\n+      \"Time Distortion\",\n+      \"Ego Death\",\n+      \"Spontaneous Bodily Sensations\",\n+      \"Enhanced Sense Of Humor\",\n-      \"Perception Of Bodily Heaviness\",\n-      \"Drifting (Melting, Breathing, Morphing)\",\n-      \"Internal Hallucinations\",\n-      \"Analysis Enhancement\"\n+      \"Physical Euphoria\",\n+      \"Emotional Amplification\",\n+      \"Analysis Enhancement\",\n+      \"Conceptual Thinking\"\n-      \"full_tolerance\": \"Almost immediately after ingestion\",\n+      \"full_tolerance\": \"Immediately after ingestion\",\n-        \"All psychedelics (LSD, psilocybin, mescaline, etc.)\"\n+        \"All psychedelics including LSD, psilocybin, mescaline, DMT, and other lysergamides\"\n-        \"name\": \"PsychonautWiki: LSM-775\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/LSM-775\"\n+        \"name\": \"Erowid TiHKAL Entry #51: PRO-LAD\",\n+        \"reference\": \"https://www.erowid.org/library/books_online/tihkal/tihkal51.shtml\"\n-        \"name\": \"Erowid Experience Vaults: LSM-775\",\n-        \"reference\": \"https://www.erowid.org/experiences/subs/exp_LSM775.shtml\"\n+        \"name\": \"PsychonautWiki: PRO-LAD\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/PRO-LAD\"\n-        \"name\": \"Isomer Design: LSM-775\",\n-        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5338\"\n+        \"name\": \"TripSit Drug Combination Chart\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/Drug_combinations\"\n-        \"name\": \"Bluelight: The Big & Dandy LSM-775 Thread\",\n-        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-lsm-775-lysergic-acid-morpholide-thread.775765/\"\n+        \"name\": \"Hoffman AJ, Nichols DE (1985). Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives. Journal of Medicinal Chemistry 28(9):1252-1255\",\n+        \"reference\": \"https://doi.org/10.1021/jm00147a022\"\n-        \"name\": \"Gogerty & Dille (1957): Pharmacology of d-LSM\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/13476356/\"\n-      },\n-      {\n-        \"name\": \"Shulgin: TiHKAL - LSD-25 Entry\",\n-        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5338\"\n-      },\n-      {\n-        \"name\": \"Brandt et al. (2018): Return of the Lysergamides Part IV\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/28585392/\"\n+        \"name\": \"Shulgin A, Shulgin A (1997). TiHKAL: Tryptamines I Have Known And Loved\",\n+        \"reference\": \"https://www.erowid.org/library/books_online/tihkal/\"\n-  \"id\": 634\n+  \"id\": 635\n\n# DET · #636\n\n-  \"title\": \"PRO-LAD\",\n-  \"index-category\": \"psychedelic\",\n+  \"title\": \"DET\",\n+  \"index-category\": \"psychedelic; research-chemical\",\n-    \"drug_name\": \"PRO-LAD\",\n-    \"chemical_name\": \"6-Propyl-6-nor-lysergic acid diethylamide\",\n-    \"alternative_name\": \"\",\n-    \"chemical_class\": \"Lysergamides\",\n+    \"drug_name\": \"DET\",\n+    \"chemical_name\": \"N,N-diethyl-2-(1H-indol-3-yl)ethanamine\",\n+    \"alternative_name\": \"Diethyltryptamine; N,N-diethyltryptamine; T-9\",\n+    \"chemical_class\": \"Tryptamines\",\n-          \"units\": \"ug\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"20 ug\",\n-            \"light\": \"50-100 ug\",\n-            \"common\": \"100-200 ug\",\n-            \"strong\": \"200-350 ug\",\n-            \"heavy\": \"350+ ug\"\n+            \"threshold\": \"10 mg\",\n+            \"light\": \"20-40 mg\",\n+            \"common\": \"40-70 mg\",\n+            \"strong\": \"70-100 mg\",\n+            \"heavy\": \"100+ mg\"\n-            \"total_duration\": \"6-8 hours\",\n-            \"onset\": \"30-45 minutes\",\n+            \"total_duration\": \"4-6 hours\",\n+            \"onset\": \"30-90 minutes\",\n-            \"after_effects\": \"1-4 hours\"\n+            \"after_effects\": \"2-8 hours\"\n-    \"addiction_potential\": \"PRO-LAD is not considered habit-forming and possesses self-regulating properties typical of psychedelics. The desire to use it may actually decrease with repeated administration. No formal dependence studies have been conducted.\",\n+    \"addiction_potential\": \"DET is not believed to be habit-forming and the desire to use it can actually decrease with repeated use. No formal studies have been conducted on its addiction potential, but anecdotal evidence suggests no negative dependency patterns.\",\n-        \"Lithium (significantly increases risk of seizures and psychosis)\",\n-        \"Tramadol (lowers seizure threshold)\"\n+        \"Lithium (seizure risk and amplified intensity)\",\n+        \"MAOIs (serotonin syndrome risk)\"\n-        \"Stimulants including amphetamines, cocaine, methylphenidate (increased risk of anxiety, paranoia, thought loops, mania, and psychosis)\"\n+        \"Tramadol (lowers seizure threshold)\"\n-        \"Cannabis (unexpectedly strong and unpredictable synergy; significantly increases risk of anxiety, paranoia, and psychosis)\",\n-        \"MDMA (unpredictable synergy with potential neurotoxicity)\",\n-        \"Benzodiazepines (can reduce or eliminate psychedelic effects)\",\n-        \"Dissociatives (greatly enhanced effects and confusion)\",\n-        \"Other psychedelics (unpredictable synergistic intensification)\"\n+        \"Stimulants (may cause anxiety, paranoia, and thought loops)\"\n-    \"notes\": \"PRO-LAD is a research chemical with very limited history of human use and minimal scientific documentation regarding its pharmacology, metabolism, and long-term toxicity. Unlike LSD, PRO-LAD has a propyl chain at R6 which may result in slower absorption and different onset characteristics. Users should employ rigorous harm reduction practices including reagent testing, accurate weighing with a microgram scale, and having a trusted sober trip sitter present. Individuals with personal or family history of psychotic disorders should avoid use. PRO-LAD was first synthesized by Hoffman and Nichols in 1984 and later described by Alexander Shulgin in TiHKAL.\",\n+    \"notes\": \"DET is a Schedule I controlled substance internationally under the UN Convention on Psychotropic Substances and is illegal in most countries. Unlike DMT, DET is orally active due to increased resistance to monoamine oxidase breakdown from its ethyl groups. The substance has extremely limited history of human use and no formal toxicity studies exist. Users should employ precise dosing with a milligram scale and ensure proper set and setting. Individuals with personal or family history of psychotic disorders should avoid use.\",\n-      \"Visual Patterning And Geometry\",\n+      \"Visual Pattern Recognition Enhancement\",\n-      \"Introspection\",\n+      \"Drifting and Morphing\",\n+      \"Internal Hallucinations\",\n+      \"Cognitive Euphoria\",\n+      \"Emotion Enhancement\",\n+      \"Increased Music Appreciation\",\n-      \"Ego Death\",\n-      \"Spontaneous Bodily Sensations\",\n-      \"Enhanced Sense Of Humor\",\n-      \"Thought Connectivity\",\n-      \"Physical Euphoria\",\n-      \"Emotional Amplification\",\n-      \"Analysis Enhancement\",\n+      \"Pupil Dilation\",\n+      \"Nausea\",\n+      \"Increased Heart Rate\",\n-      \"full_tolerance\": \"Immediately after ingestion\",\n-      \"half_tolerance\": \"5-7 days\",\n-      \"zero_tolerance\": \"14 days\",\n+      \"full_tolerance\": \"Almost immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n-        \"All psychedelics including LSD, psilocybin, mescaline, DMT, and other lysergamides\"\n+        \"All psychedelics\"\n-        \"name\": \"Erowid TiHKAL Entry #51: PRO-LAD\",\n-        \"reference\": \"https://www.erowid.org/library/books_online/tihkal/tihkal51.shtml\"\n+        \"name\": \"Erowid DET Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/det/det.shtml\"\n-        \"name\": \"PsychonautWiki: PRO-LAD\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/PRO-LAD\"\n+        \"name\": \"PsychonautWiki: DET\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/DET\"\n-        \"name\": \"TripSit Drug Combination Chart\",\n-        \"reference\": \"https://wiki.tripsit.me/wiki/Drug_combinations\"\n+        \"name\": \"TiHKAL #3: DET (Isomer Design)\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5003\"\n-        \"name\": \"Hoffman AJ, Nichols DE (1985). Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives. Journal of Medicinal Chemistry 28(9):1252-1255\",\n-        \"reference\": \"https://doi.org/10.1021/jm00147a022\"\n+        \"name\": \"TiHKAL #3: DET (Erowid)\",\n+        \"reference\": \"https://www.erowid.org/library/books_online/tihkal/tihkal03.shtml\"\n-        \"name\": \"Shulgin A, Shulgin A (1997). TiHKAL: Tryptamines I Have Known And Loved\",\n-        \"reference\": \"https://www.erowid.org/library/books_online/tihkal/\"\n+        \"name\": \"Bluelight: 5-substituted tryptamines discussion\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/5-substituted-tryptamines.340503/\"\n+      },\n+      {\n+        \"name\": \"Drug-drug interactions involving classic psychedelics\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC10851641/\"\n-      \"lysergamide\",\n+      \"tryptamine\",\n-  \"id\": 635\n+  \"id\": 636\n\n# EPT · #637\n\n-  \"title\": \"DET\",\n+  \"title\": \"EPT\",\n-    \"drug_name\": \"DET\",\n-    \"chemical_name\": \"N,N-diethyl-2-(1H-indol-3-yl)ethanamine\",\n-    \"alternative_name\": \"Diethyltryptamine; N,N-diethyltryptamine; T-9\",\n+    \"drug_name\": \"EPT\",\n+    \"chemical_name\": \"N-Ethyl-N-propyltryptamine\",\n+    \"alternative_name\": \"Ethylpropyltryptamine; N-Ethyl-N-[2-(1H-indol-3-yl)ethyl]propan-1-amine\",\n-    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; 5-HT2C receptor partial agonist\",\n-          \"route\": \"oral\",\n+          \"route\": \"insufflated\",\n-            \"threshold\": \"10 mg\",\n+            \"threshold\": \"\",\n-            \"common\": \"40-70 mg\",\n-            \"strong\": \"70-100 mg\",\n+            \"common\": \"40-80 mg\",\n+            \"strong\": \"80-110 mg\",\n+            \"heavy\": \"110+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"\",\n+            \"light\": \"75-100 mg\",\n+            \"common\": \"100-150 mg\",\n+            \"strong\": \"150-200 mg\",\n+            \"heavy\": \"200+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"vaporized\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"\",\n+            \"light\": \"15-30 mg\",\n+            \"common\": \"30-60 mg\",\n+            \"strong\": \"60-100 mg\",\n+          \"route\": \"insufflated\",\n+          \"stages\": {\n+            \"total_duration\": \"2-4 hours\",\n+            \"onset\": \"5-20 minutes\",\n+            \"after_effects\": \"1-3 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n+        },\n+        {\n-            \"total_duration\": \"4-6 hours\",\n+            \"total_duration\": \"3-6 hours\",\n-            \"peak\": \"2-4 hours\",\n-            \"offset\": \"2-3 hours\",\n-            \"after_effects\": \"2-8 hours\"\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"2-4 hours\"\n+        },\n+        {\n+          \"route\": \"vaporized\",\n+          \"stages\": {\n+            \"total_duration\": \"1-3 hours\",\n+            \"onset\": \"1-5 minutes\",\n+            \"peak\": \"10-30 minutes\",\n+            \"offset\": \"30-90 minutes\",\n+            \"after_effects\": \"1-2 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n-    \"addiction_potential\": \"DET is not believed to be habit-forming and the desire to use it can actually decrease with repeated use. No formal studies have been conducted on its addiction potential, but anecdotal evidence suggests no negative dependency patterns.\",\n+    \"addiction_potential\": \"EPT does not appear to produce dependence and has low abuse potential, similar to other unsubstituted tryptamines like DMT, DET, and MET. Rapid tolerance development discourages frequent use.\",\n-        \"Lithium (seizure risk and amplified intensity)\",\n-        \"MAOIs (serotonin syndrome risk)\"\n+        \"Lithium (seizure risk)\",\n+        \"Tramadol (lowers seizure threshold)\"\n-        \"Tramadol (lowers seizure threshold)\"\n+        \"MAOIs (unknown interactions with increased potency)\",\n+        \"Stimulants (increased anxiety and physical strain)\"\n-        \"Stimulants (may cause anxiety, paranoia, and thought loops)\"\n+        \"Other psychedelics (overwhelming intensity)\",\n+        \"Cannabis (may intensify anxiety or confusion)\"\n-    \"notes\": \"DET is a Schedule I controlled substance internationally under the UN Convention on Psychotropic Substances and is illegal in most countries. Unlike DMT, DET is orally active due to increased resistance to monoamine oxidase breakdown from its ethyl groups. The substance has extremely limited history of human use and no formal toxicity studies exist. Users should employ precise dosing with a milligram scale and ensure proper set and setting. Individuals with personal or family history of psychotic disorders should avoid use.\",\n+    \"notes\": \"EPT is a novel research chemical with very limited documentation and extremely sparse user reports. The toxicity profile is unknown and no scientific studies exist on its safety in humans. Effects are described as milder and less immersive than structurally similar tryptamines like DMT and DPT. EPT is typically sold as the fumarate salt rather than the hydrochloride form. Start with very low doses due to individual sensitivity variations and the lack of established safety data. Use precise milligram scales and practice comprehensive harm reduction including set and setting protocols.\",\n-      \"Drifting and Morphing\",\n-      \"Internal Hallucinations\",\n-      \"Cognitive Euphoria\",\n-      \"Emotion Enhancement\",\n-      \"Increased Music Appreciation\",\n+      \"Drifting And Morphing\",\n+      \"Dissociative Feeling\",\n+      \"Body Heaviness\",\n-      \"Pupil Dilation\",\n+      \"Memory Suppression\",\n+      \"Increased Libido\",\n-      \"Increased Heart Rate\",\n-      \"Conceptual Thinking\"\n+      \"Motor Control Loss\",\n+      \"Pupil Dilation\",\n+      \"Thought Acceleration\"\n-      \"full_tolerance\": \"Almost immediately after ingestion\",\n+      \"full_tolerance\": \"Immediately after ingestion\",\n-        \"All psychedelics\"\n+        \"All psychedelics (LSD, psilocybin, mescaline, DMT, other tryptamines)\"\n-        \"name\": \"Erowid DET Vault\",\n-        \"reference\": \"https://www.erowid.org/chemicals/det/det.shtml\"\n+        \"name\": \"Bluelight: The Small & Handy EPT Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-small-handy-ept-thread.856610/\"\n-        \"name\": \"PsychonautWiki: DET\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/DET\"\n+        \"name\": \"Drugs-Forum: EPT Experiences\",\n+        \"reference\": \"https://drugs-forum.com/threads/ept-experiences.298861/\"\n-        \"name\": \"TiHKAL #3: DET (Isomer Design)\",\n-        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5003\"\n+        \"name\": \"Erowid Experience Vaults: EPT\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_EPT.shtml\"\n-        \"name\": \"TiHKAL #3: DET (Erowid)\",\n-        \"reference\": \"https://www.erowid.org/library/books_online/tihkal/tihkal03.shtml\"\n+        \"name\": \"Isomer Design: EPT\",\n+        \"reference\": \"https://isomerdesign.com/pihkal/explore/5075\"\n-        \"name\": \"Bluelight: 5-substituted tryptamines discussion\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/5-substituted-tryptamines.340503/\"\n-      },\n-      {\n-        \"name\": \"Drug-drug interactions involving classic psychedelics\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC10851641/\"\n+        \"name\": \"PsychonautWiki: EPT\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/EPT\"\n-  \"id\": 636\n+  \"id\": 637\n\n# 4-AcO-DiPT · #638\n\n-  \"title\": \"EPT\",\n-  \"index-category\": \"psychedelic; research-chemical\",\n+  \"title\": \"4-AcO-DiPT\",\n+  \"index-category\": \"psychedelic; tryptamine\",\n-    \"drug_name\": \"EPT\",\n-    \"chemical_name\": \"N-Ethyl-N-propyltryptamine\",\n-    \"alternative_name\": \"Ethylpropyltryptamine; N-Ethyl-N-[2-(1H-indol-3-yl)ethyl]propan-1-amine\",\n+    \"drug_name\": \"4-AcO-DiPT\",\n+    \"chemical_name\": \"3-[2-(Diisopropylamino)ethyl]-1H-indol-4-yl acetate\",\n+    \"alternative_name\": \"4-Acetoxy-DiPT; Ipracetin; Iprocetyl; Aces; 4-Ace\",\n-    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; 5-HT2C receptor partial agonist\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist; 5-HT2C receptor agonist\",\n-          \"route\": \"insufflated\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"\",\n-            \"light\": \"20-40 mg\",\n-            \"common\": \"40-80 mg\",\n-            \"strong\": \"80-110 mg\",\n-            \"heavy\": \"110+ mg\"\n-          }\n-        },\n-        {\n-            \"threshold\": \"\",\n-            \"light\": \"75-100 mg\",\n-            \"common\": \"100-150 mg\",\n-            \"strong\": \"150-200 mg\",\n-            \"heavy\": \"200+ mg\"\n+            \"threshold\": \"3-5 mg\",\n+            \"light\": \"5-15 mg\",\n+            \"common\": \"15-30 mg\",\n+            \"strong\": \"30-45 mg\",\n+            \"heavy\": \"45+ mg\"\n-        },\n-        {\n-          \"route\": \"vaporized\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"\",\n-            \"light\": \"15-30 mg\",\n-            \"common\": \"30-60 mg\",\n-            \"strong\": \"60-100 mg\",\n-            \"heavy\": \"100+ mg\"\n-          }\n-          \"route\": \"insufflated\",\n-          \"stages\": {\n-            \"total_duration\": \"2-4 hours\",\n-            \"onset\": \"5-20 minutes\",\n-            \"after_effects\": \"1-3 hours\"\n-          },\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ]\n-        },\n-        {\n-            \"total_duration\": \"3-6 hours\",\n-            \"onset\": \"30-90 minutes\",\n-            \"peak\": \"1-2 hours\",\n-            \"offset\": \"1-2 hours\",\n-            \"after_effects\": \"2-4 hours\"\n+            \"total_duration\": \"3-4 hours\",\n+            \"onset\": \"15-40 minutes\",\n+            \"peak\": \"1.5-2 hours\",\n+            \"offset\": \"1-1.5 hours\",\n+            \"after_effects\": \"2-6 hours\"\n-        },\n-        {\n-          \"route\": \"vaporized\",\n-          \"stages\": {\n-            \"total_duration\": \"1-3 hours\",\n-            \"onset\": \"1-5 minutes\",\n-            \"peak\": \"10-30 minutes\",\n-            \"offset\": \"30-90 minutes\",\n-            \"after_effects\": \"1-2 hours\"\n-          },\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ]\n-    \"addiction_potential\": \"EPT does not appear to produce dependence and has low abuse potential, similar to other unsubstituted tryptamines like DMT, DET, and MET. Rapid tolerance development discourages frequent use.\",\n+    \"addiction_potential\": \"4-AcO-DiPT is not known to be habit-forming and the desire to use it can decrease with repeated administration. However, it may possess a higher liability for frequent or excessive consumption relative to most psychedelics due to its distinctly hedonic and short-duration effects. Compulsive redosing is reported to be atypically prominent for this substance.\",\n-        \"Lithium (seizure risk)\",\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n-        \"MAOIs (unknown interactions with increased potency)\",\n-        \"Stimulants (increased anxiety and physical strain)\"\n+        \"MAOIs (risk of serotonin syndrome)\",\n+        \"Stimulants (increased risk of anxiety, paranoia, panic attacks, and psychosis)\"\n-        \"Other psychedelics (overwhelming intensity)\",\n-        \"Cannabis (may intensify anxiety or confusion)\"\n+        \"Cannabis (may significantly intensify and prolong effects unpredictably)\",\n+        \"Alcohol (physically taxing, may dull effects)\",\n+        \"Benzodiazepines (may reduce trip intensity)\"\n-    \"notes\": \"EPT is a novel research chemical with very limited documentation and extremely sparse user reports. The toxicity profile is unknown and no scientific studies exist on its safety in humans. Effects are described as milder and less immersive than structurally similar tryptamines like DMT and DPT. EPT is typically sold as the fumarate salt rather than the hydrochloride form. Start with very low doses due to individual sensitivity variations and the lack of established safety data. Use precise milligram scales and practice comprehensive harm reduction including set and setting protocols.\",\n+    \"notes\": \"4-AcO-DiPT is thought to act as a prodrug to 4-HO-DiPT (Iprocin). It is available in both freebase and HCl salt forms, with the freebase being approximately 10% more potent by weight. This substance is characterized by atypically strong physical euphoria and sensuality with minimal visual effects, distinguishing it from most other 4-substituted tryptamines. Accurate weighing with a milligram scale is essential. Individuals with personal or family histories of seizure disorders or psychotic conditions should avoid use. The compound can produce notable increases in body temperature, particularly at peak effects. Set and setting significantly influence the experience.\",\n-      \"Visual Pattern Recognition Enhancement\",\n-      \"Color Enhancement\",\n-      \"Drifting And Morphing\",\n-      \"Dissociative Feeling\",\n-      \"Body Heaviness\",\n-      \"Time Distortion\",\n-      \"Memory Suppression\",\n+      \"Physical Euphoria\",\n+      \"Tactile Enhancement\",\n-      \"Nausea\",\n-      \"Motor Control Loss\",\n-      \"Pupil Dilation\",\n-      \"Thought Acceleration\"\n+      \"Sedation Followed By Stimulation\",\n+      \"Disinhibition\",\n+      \"Enhanced Sociability\",\n+      \"Color Enhancement\",\n+      \"Spontaneous Physical Sensations\",\n+      \"Changes In Felt Bodily Form\",\n+      \"Music Appreciation Enhancement\",\n+      \"Empathy And Affection Enhancement\",\n+      \"Minimal Visual Effects\"\n-      \"full_tolerance\": \"Immediately after ingestion\",\n+      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n-        \"All psychedelics (LSD, psilocybin, mescaline, DMT, other tryptamines)\"\n+        \"All psychedelics (e.g., psilocybin, LSD, mescaline, other tryptamines)\"\n-    \"half_life\": \"\",\n+    \"half_life\": \"2-4 hours (rapidly metabolized to 4-HO-DiPT)\",\n-        \"name\": \"Bluelight: The Small & Handy EPT Thread\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/the-small-handy-ept-thread.856610/\"\n+        \"name\": \"Erowid 4-Acetoxy-DiPT Primer by Toad\",\n+        \"reference\": \"https://www.erowid.org/chemicals/4_acetoxy_dipt/4_acetoxy_dipt_primer.shtml\"\n-        \"name\": \"Drugs-Forum: EPT Experiences\",\n-        \"reference\": \"https://drugs-forum.com/threads/ept-experiences.298861/\"\n+        \"name\": \"Erowid 4-Acetoxy-DiPT Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/4_acetoxy_dipt/4_acetoxy_dipt.shtml\"\n-        \"name\": \"Erowid Experience Vaults: EPT\",\n-        \"reference\": \"https://erowid.org/experiences/subs/exp_EPT.shtml\"\n+        \"name\": \"PsychonautWiki: 4-AcO-DiPT\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/4-AcO-DiPT\"\n-        \"name\": \"Isomer Design: EPT\",\n-        \"reference\": \"https://isomerdesign.com/pihkal/explore/5075\"\n+        \"name\": \"Bluelight 4-AcO-DiPT Discussion Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/4-aco-dipt-new-experience-10-mg-dose-to-test-the-waters.493414/\"\n-        \"name\": \"PsychonautWiki: EPT\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/EPT\"\n+        \"name\": \"Isomer Design: 4-AcO-DiPT\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5369\"\n+      },\n+      {\n+        \"name\": \"Human Hepatocyte 4-AcO-DiPT Metabolite Profiling Study\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC9413566/\"\n+      },\n+      {\n+        \"name\": \"Investigation of Structure-Activity Relationships of Psilocybin Analogues\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC8033608/\"\n+      },\n+      {\n+        \"name\": \"Pharmacologic Activity of Substituted Tryptamines Study\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC10029822/\"\n+      },\n+      {\n+        \"name\": \"TiHKAL Entry #17: 4-HO-DiPT\",\n+        \"reference\": \"https://erowid.org/library/books_online/tihkal/tihkal17.shtml\"\n-      \"research-chemical\"\n+      \"research-chemical\",\n+      \"synthetic\"\n-  \"id\": 637\n+  \"id\": 638\n\n# 4-AcO-MiPT · #639\n\n-  \"title\": \"4-AcO-DiPT\",\n+  \"title\": \"4-AcO-MiPT\",\n-    \"drug_name\": \"4-AcO-DiPT\",\n-    \"chemical_name\": \"3-[2-(Diisopropylamino)ethyl]-1H-indol-4-yl acetate\",\n-    \"alternative_name\": \"4-Acetoxy-DiPT; Ipracetin; Iprocetyl; Aces; 4-Ace\",\n+    \"drug_name\": \"4-AcO-MiPT\",\n+    \"chemical_name\": \"4-Acetoxy-N-methyl-N-isopropyltryptamine\",\n+    \"alternative_name\": \"Mipracetin; O-Acetylmiprocin; 4-Acetoxy-MiPT\",\n-    \"mechanism_of_action\": \"5-HT2A receptor agonist; 5-HT2C receptor agonist\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist (prodrug of 4-HO-MiPT)\",\n-            \"threshold\": \"3-5 mg\",\n-            \"light\": \"5-15 mg\",\n-            \"common\": \"15-30 mg\",\n-            \"strong\": \"30-45 mg\",\n-            \"heavy\": \"45+ mg\"\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"10-15 mg\",\n+            \"common\": \"15-20 mg\",\n+            \"strong\": \"20-35 mg\",\n+            \"heavy\": \"35+ mg\"\n-            \"total_duration\": \"3-4 hours\",\n-            \"onset\": \"15-40 minutes\",\n-            \"peak\": \"1.5-2 hours\",\n-            \"offset\": \"1-1.5 hours\",\n-            \"after_effects\": \"2-6 hours\"\n+            \"total_duration\": \"4-8 hours\",\n+            \"onset\": \"20-60 minutes\",\n+            \"peak\": \"1.5-3 hours (come up 1-2 hours)\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"2-4 hours\"\n-    \"addiction_potential\": \"4-AcO-DiPT is not known to be habit-forming and the desire to use it can decrease with repeated administration. However, it may possess a higher liability for frequent or excessive consumption relative to most psychedelics due to its distinctly hedonic and short-duration effects. Compulsive redosing is reported to be atypically prominent for this substance.\",\n+    \"addiction_potential\": \"4-AcO-MiPT is not habit-forming and demonstrates a self-regulating pattern typical of psychedelics. The desire to use it tends to decrease with regular consumption rather than increase.\",\n-        \"Lithium (significantly increases risk of psychosis and seizures)\",\n-        \"Tramadol (lowers seizure threshold)\"\n+        \"Lithium (significantly increases risk of psychosis and seizures)\"\n-        \"MAOIs (risk of serotonin syndrome)\",\n-        \"Stimulants (increased risk of anxiety, paranoia, panic attacks, and psychosis)\"\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Stimulants (increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n-        \"Cannabis (may significantly intensify and prolong effects unpredictably)\",\n-        \"Alcohol (physically taxing, may dull effects)\",\n-        \"Benzodiazepines (may reduce trip intensity)\"\n+        \"Cannabis (unpredictable synergy, may significantly intensify effects)\"\n-    \"notes\": \"4-AcO-DiPT is thought to act as a prodrug to 4-HO-DiPT (Iprocin). It is available in both freebase and HCl salt forms, with the freebase being approximately 10% more potent by weight. This substance is characterized by atypically strong physical euphoria and sensuality with minimal visual effects, distinguishing it from most other 4-substituted tryptamines. Accurate weighing with a milligram scale is essential. Individuals with personal or family histories of seizure disorders or psychotic conditions should avoid use. The compound can produce notable increases in body temperature, particularly at peak effects. Set and setting significantly influence the experience.\",\n+    \"notes\": \"4-AcO-MiPT is a synthetic psychedelic tryptamine that remains relatively uncommon with limited history of human use. The substance is hygroscopic and degrades quickly when exposed to moisture or improper storage; it should be kept in an inert atmosphere in a freezer. The material can develop a sticky, goop-like consistency when exposed to air. Accurate weighing with a precise milligram scale is essential, as the substance is potent and can appear deceptively small. It is theorized to act as a prodrug for 4-HO-MiPT, though debate continues about whether it possesses innate activity. Set and setting are critical factors for the experience.\",\n-      \"Physical Euphoria\",\n-      \"Tactile Enhancement\",\n-      \"Increased Libido\",\n-      \"Sedation Followed By Stimulation\",\n-      \"Disinhibition\",\n-      \"Enhanced Sociability\",\n-      \"Color Enhancement\",\n-      \"Spontaneous Physical Sensations\",\n-      \"Changes In Felt Bodily Form\",\n-      \"Music Appreciation Enhancement\",\n-      \"Empathy And Affection Enhancement\",\n-      \"Minimal Visual Effects\"\n+      \"Visual Geometry (Organic, Intricate, Natural-Feeling)\",\n+      \"Colour Enhancement\",\n+      \"Pattern Recognition Enhancement\",\n+      \"Sedation With Mild Euphoria\",\n+      \"Pleasurable Body High (Warm, Tingling Sensations)\",\n+      \"Excessive Yawning\",\n+      \"Enhanced Music Appreciation\",\n+      \"Auditory Distortions (Downward Pitch Shift)\",\n+      \"Emotion Enhancement\",\n+      \"Thought Connectivity\",\n+      \"Time Distortion\",\n+      \"Internal Hallucinations (Dark Environments)\",\n+      \"Memory Suppression\"\n-      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n+      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n-        \"All psychedelics (e.g., psilocybin, LSD, mescaline, other tryptamines)\"\n+        \"All psychedelics\"\n-    \"half_life\": \"2-4 hours (rapidly metabolized to 4-HO-DiPT)\",\n+    \"half_life\": \"\",\n-        \"name\": \"Erowid 4-Acetoxy-DiPT Primer by Toad\",\n-        \"reference\": \"https://www.erowid.org/chemicals/4_acetoxy_dipt/4_acetoxy_dipt_primer.shtml\"\n+        \"name\": \"Erowid 4-Acetoxy-MiPT Vault\",\n+        \"reference\": \"https://erowid.org/chemicals/4_acetoxy_mipt/4_acetoxy_mipt.shtml\"\n-        \"name\": \"Erowid 4-Acetoxy-DiPT Vault\",\n-        \"reference\": \"https://www.erowid.org/chemicals/4_acetoxy_dipt/4_acetoxy_dipt.shtml\"\n+        \"name\": \"Isomer Design: 4-AcO-MIPT\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=5546\"\n-        \"name\": \"PsychonautWiki: 4-AcO-DiPT\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/4-AcO-DiPT\"\n+        \"name\": \"PsychonautWiki: 4-AcO-MiPT\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/4-AcO-MiPT\"\n-        \"name\": \"Bluelight 4-AcO-DiPT Discussion Thread\",\n-        \"reference\": \"https://bluelight.org/xf/threads/4-aco-dipt-new-experience-10-mg-dose-to-test-the-waters.493414/\"\n+        \"name\": \"The Big & Dandy 4-AcO-MiPT Thread (Bluelight)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-4-aco-mipt-thread.101872/\"\n-        \"name\": \"Isomer Design: 4-AcO-DiPT\",\n-        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5369\"\n-      },\n-      {\n-        \"name\": \"Human Hepatocyte 4-AcO-DiPT Metabolite Profiling Study\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC9413566/\"\n-      },\n-      {\n-        \"name\": \"Investigation of Structure-Activity Relationships of Psilocybin Analogues\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC8033608/\"\n-      },\n-      {\n-        \"name\": \"Pharmacologic Activity of Substituted Tryptamines Study\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC10029822/\"\n-      },\n-      {\n-        \"name\": \"TiHKAL Entry #17: 4-HO-DiPT\",\n-        \"reference\": \"https://erowid.org/library/books_online/tihkal/tihkal17.shtml\"\n+        \"name\": \"Takahashi et al. - Psychoactive Designer Drugs Data Library\",\n+        \"reference\": \"https://doi.org/10.1016/j.talanta.2008.07.062\"\n-  \"id\": 638\n+  \"id\": 639\n\n# 4-HO-DET · #640\n\n-  \"title\": \"4-AcO-MiPT\",\n-  \"index-category\": \"psychedelic; tryptamine\",\n+  \"title\": \"4-HO-DET\",\n+  \"index-category\": \"psychedelic; tryptamine; research-chemical\",\n-    \"drug_name\": \"4-AcO-MiPT\",\n-    \"chemical_name\": \"4-Acetoxy-N-methyl-N-isopropyltryptamine\",\n-    \"alternative_name\": \"Mipracetin; O-Acetylmiprocin; 4-Acetoxy-MiPT\",\n+    \"drug_name\": \"4-HO-DET\",\n+    \"chemical_name\": \"3-(2-diethylaminoethyl)-1H-indol-4-ol\",\n+    \"alternative_name\": \"Ethocin; CZ-74; 4-Hydroxy-N,N-diethyltryptamine\",\n-    \"mechanism_of_action\": \"5-HT2A receptor partial agonist (prodrug of 4-HO-MiPT)\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n-            \"common\": \"15-20 mg\",\n-            \"strong\": \"20-35 mg\",\n-            \"heavy\": \"35+ mg\"\n+            \"common\": \"20-30 mg\",\n+            \"strong\": \"30-45 mg\",\n+            \"heavy\": \"45+ mg\"\n-            \"total_duration\": \"4-8 hours\",\n-            \"onset\": \"20-60 minutes\",\n-            \"peak\": \"1.5-3 hours (come up 1-2 hours)\",\n-            \"offset\": \"1-2 hours\",\n-            \"after_effects\": \"2-4 hours\"\n+            \"total_duration\": \"5-7 hours\",\n+            \"onset\": \"20-45 minutes\",\n+            \"peak\": \"2.5-3.5 hours (with 30-60 minute come up)\",\n+            \"offset\": \"1.5-2 hours\",\n+            \"after_effects\": \"1-4 hours\"\n-    \"addiction_potential\": \"4-AcO-MiPT is not habit-forming and demonstrates a self-regulating pattern typical of psychedelics. The desire to use it tends to decrease with regular consumption rather than increase.\",\n+    \"addiction_potential\": \"4-HO-DET is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating. Limited evidence suggests no significant addiction potential.\",\n-        \"Lithium (significantly increases risk of psychosis and seizures)\"\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n-      \"unsafe\": [\n-        \"Tramadol (lowers seizure threshold)\",\n-        \"Stimulants (increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n-      ],\n+      \"unsafe\": [],\n-        \"Cannabis (unpredictable synergy, may significantly intensify effects)\"\n+        \"Cannabis (unpredictable synergy, may significantly increase risk of anxiety, paranoia, panic attacks, and psychosis)\",\n+        \"Stimulants (may increase risk of anxiety, paranoia, panic attacks, thought loops, mania and psychosis)\"\n-    \"notes\": \"4-AcO-MiPT is a synthetic psychedelic tryptamine that remains relatively uncommon with limited history of human use. The substance is hygroscopic and degrades quickly when exposed to moisture or improper storage; it should be kept in an inert atmosphere in a freezer. The material can develop a sticky, goop-like consistency when exposed to air. Accurate weighing with a precise milligram scale is essential, as the substance is potent and can appear deceptively small. It is theorized to act as a prodrug for 4-HO-MiPT, though debate continues about whether it possesses innate activity. Set and setting are critical factors for the experience.\",\n+    \"notes\": \"4-HO-DET is a research chemical with very little history of human usage. The toxicity and long-term health effects have not been studied in any scientific context. It is strongly recommended to use harm reduction practices when using this substance. Legal status varies by jurisdiction; it is unscheduled in the United States but may be prosecuted under the Federal Analogue Act. It is controlled in Germany, Sweden, Switzerland, and the United Kingdom.\",\n-      \"Visual Geometry (Organic, Intricate, Natural-Feeling)\",\n+      \"Visual Patterning And Geometry\",\n-      \"Pattern Recognition Enhancement\",\n-      \"Sedation With Mild Euphoria\",\n-      \"Pleasurable Body High (Warm, Tingling Sensations)\",\n-      \"Excessive Yawning\",\n-      \"Enhanced Music Appreciation\",\n-      \"Auditory Distortions (Downward Pitch Shift)\",\n-      \"Emotion Enhancement\",\n+      \"Tactile Enhancement\",\n+      \"Analysis Enhancement\",\n+      \"Increased Music Appreciation\",\n-      \"Internal Hallucinations (Dark Environments)\",\n-      \"Memory Suppression\"\n+      \"Ego Death\",\n+      \"Memory Suppression\",\n+      \"Excessive Yawning\",\n+      \"Temperature Regulation Suppression\",\n+      \"Pupil Dilation\"\n-      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n+      \"full_tolerance\": \"Almost immediately after ingestion\",\n-        \"name\": \"Erowid 4-Acetoxy-MiPT Vault\",\n-        \"reference\": \"https://erowid.org/chemicals/4_acetoxy_mipt/4_acetoxy_mipt.shtml\"\n+        \"name\": \"Bluelight 4-HO-DET Discussion Thread\",\n+        \"reference\": \"http://www.bluelight.org/vb/threads/480200-The-Big-amp-Dandy-4-HO-DET-Thread\"\n-        \"name\": \"Isomer Design: 4-AcO-MIPT\",\n-        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=5546\"\n+        \"name\": \"Erowid 4-HO-DET Experience Vaults\",\n+        \"reference\": \"https://www.erowid.org/experiences/subs/exp_4HODET.shtml\"\n-        \"name\": \"PsychonautWiki: 4-AcO-MiPT\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/4-AcO-MiPT\"\n+        \"name\": \"Isomer Design TiHKAL Entry #16: 4-HO-DET\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5016\"\n-        \"name\": \"The Big & Dandy 4-AcO-MiPT Thread (Bluelight)\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-4-aco-mipt-thread.101872/\"\n+        \"name\": \"PsychonautWiki: 4-HO-DET\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/4-HO-DET\"\n-        \"name\": \"Takahashi et al. - Psychoactive Designer Drugs Data Library\",\n-        \"reference\": \"https://doi.org/10.1016/j.talanta.2008.07.062\"\n+        \"name\": \"Wikipedia: 4-HO-DET\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/4-HO-DET\"\n-  \"id\": 639\n+  \"id\": 640\n\n# 4-HO-DiPT · #641\n\n-  \"title\": \"4-HO-DET\",\n+  \"title\": \"4-HO-DiPT\",\n-    \"drug_name\": \"4-HO-DET\",\n-    \"chemical_name\": \"3-(2-diethylaminoethyl)-1H-indol-4-ol\",\n-    \"alternative_name\": \"Ethocin; CZ-74; 4-Hydroxy-N,N-diethyltryptamine\",\n+    \"drug_name\": \"4-HO-DiPT\",\n+    \"chemical_name\": \"3-[2-(Diisopropylamino)ethyl]-1H-indol-4-ol\",\n+    \"alternative_name\": \"Iprocin; 4-Hydroxy-DiPT; 4-Hydroxy-N,N-diisopropyltryptamine\",\n-    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; Serotonin reuptake inhibitor (weak)\",\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"10-15 mg\",\n-            \"common\": \"20-30 mg\",\n-            \"strong\": \"30-45 mg\",\n-            \"heavy\": \"45+ mg\"\n+            \"threshold\": \"3 mg\",\n+            \"light\": \"3-10 mg\",\n+            \"common\": \"10-20 mg\",\n+            \"strong\": \"20-30 mg\",\n+            \"heavy\": \"30+ mg\"\n-            \"total_duration\": \"5-7 hours\",\n-            \"onset\": \"20-45 minutes\",\n-            \"peak\": \"2.5-3.5 hours (with 30-60 minute come up)\",\n-            \"offset\": \"1.5-2 hours\",\n-            \"after_effects\": \"1-4 hours\"\n+            \"total_duration\": \"2-4 hours\",\n+            \"onset\": \"15-30 minutes\",\n+            \"peak\": \"60-90 minutes (20-30 minutes after onset)\",\n+            \"offset\": \"30-60 minutes\",\n+            \"after_effects\": \"1-3 hours\"\n-    \"addiction_potential\": \"4-HO-DET is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating. Limited evidence suggests no significant addiction potential.\",\n+    \"addiction_potential\": \"4-HO-DiPT is not habit-forming and has minimal psychological dependence potential. Like most psychedelics, it is considered self-regulating, with the desire to use it typically decreasing with regular consumption.\",\n-      \"unsafe\": [],\n+      \"unsafe\": [\n+        \"Stimulants (increased risk of anxiety, paranoia, panic attacks, thought loops, mania, and psychosis)\"\n+      ],\n-        \"Cannabis (unpredictable synergy, may significantly increase risk of anxiety, paranoia, panic attacks, and psychosis)\",\n-        \"Stimulants (may increase risk of anxiety, paranoia, panic attacks, thought loops, mania and psychosis)\"\n+        \"Cannabis (unpredictable synergy; significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n-    \"notes\": \"4-HO-DET is a research chemical with very little history of human usage. The toxicity and long-term health effects have not been studied in any scientific context. It is strongly recommended to use harm reduction practices when using this substance. Legal status varies by jurisdiction; it is unscheduled in the United States but may be prosecuted under the Federal Analogue Act. It is controlled in Germany, Sweden, Switzerland, and the United Kingdom.\",\n+    \"notes\": \"4-HO-DiPT is a research chemical with very limited history of human use and no scientific studies on its toxicity. It is noted for its uniquely rapid onset, short duration, narrow dose sensitivity, and high intensity relative to dose. Physical side effects including muscle tremors, leg tremors, bodily malaise, and temperature dysregulation are commonly reported. Set and setting are critical, and harm reduction practices are essential. The substance is unscheduled in most jurisdictions but may be controlled under analogue laws.\",\n-      \"Visual Patterning And Geometry\",\n-      \"Colour Enhancement\",\n-      \"Tactile Enhancement\",\n-      \"Thought Connectivity\",\n-      \"Analysis Enhancement\",\n-      \"Increased Music Appreciation\",\n+      \"Cognitive Euphoria\",\n+      \"Emotion Enhancement\",\n+      \"Introspective Insights\",\n-      \"Ego Death\",\n-      \"Memory Suppression\",\n-      \"Excessive Yawning\",\n-      \"Temperature Regulation Suppression\",\n-      \"Pupil Dilation\"\n+      \"Increased Music Appreciation\",\n+      \"Enhanced Tactile Sensation\",\n+      \"Sexual Enhancement\",\n+      \"Visual Pattern Recognition Enhancement\",\n+      \"Colour Enhancement\",\n+      \"Muscle Tremors\",\n+      \"Nausea\",\n+      \"Pupil Dilation\",\n+      \"Stimulation\",\n+      \"Temperature Dysregulation\"\n-      \"full_tolerance\": \"Almost immediately after ingestion\",\n+      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n-        \"All psychedelics\"\n+        \"All psychedelics (LSD, psilocybin, mescaline, DMT, 2C-x, DOx, 5-MeO-xxT, other tryptamines)\"\n-    \"half_life\": \"\",\n+    \"half_life\": \"2.7-4.1 hours (based on prodrug luvesilocin studies)\",\n-        \"name\": \"Bluelight 4-HO-DET Discussion Thread\",\n-        \"reference\": \"http://www.bluelight.org/vb/threads/480200-The-Big-amp-Dandy-4-HO-DET-Thread\"\n+        \"name\": \"PsychonautWiki: 4-HO-DiPT\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/4-HO-DiPT\"\n-        \"name\": \"Erowid 4-HO-DET Experience Vaults\",\n-        \"reference\": \"https://www.erowid.org/experiences/subs/exp_4HODET.shtml\"\n+        \"name\": \"Erowid 4-HO-DiPT Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/4_ho_dipt/4_ho_dipt.shtml\"\n-        \"name\": \"Isomer Design TiHKAL Entry #16: 4-HO-DET\",\n-        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5016\"\n+        \"name\": \"TiHKAL Entry #17: 4-HO-DiPT by Alexander Shulgin\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/read.php?domain=tk&id=17\"\n-        \"name\": \"PsychonautWiki: 4-HO-DET\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/4-HO-DET\"\n+        \"name\": \"Bluelight: The Big & Dandy 4-HO-DiPT Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-4-ho-dipt-thread.107890/\"\n-        \"name\": \"Wikipedia: 4-HO-DET\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/4-HO-DET\"\n+        \"name\": \"Drugs-Forum: 4-HO-DiPT Trip Reports\",\n+        \"reference\": \"https://drugs-forum.com/threads/4-ho-dipt-trip-reports.3095/\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: 4-HO-DiPT\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/4-HO-DiPT\"\n+      },\n+      {\n+        \"name\": \"Repke, D. B. et al. (1977). Psilocin analogs synthesis\",\n+        \"reference\": \"Journal of Heterocyclic Chemistry, 14(1), 71-74\"\n-  \"id\": 640\n+  \"id\": 641\n\n# 4-HO-EPT · #642\n\n-  \"title\": \"4-HO-DiPT\",\n+  \"title\": \"4-HO-EPT\",\n-    \"drug_name\": \"4-HO-DiPT\",\n-    \"chemical_name\": \"3-[2-(Diisopropylamino)ethyl]-1H-indol-4-ol\",\n-    \"alternative_name\": \"Iprocin; 4-Hydroxy-DiPT; 4-Hydroxy-N,N-diisopropyltryptamine\",\n+    \"drug_name\": \"4-HO-EPT\",\n+    \"chemical_name\": \"4-Hydroxy-N-ethyl-N-propyltryptamine\",\n+    \"alternative_name\": \"Eprocin\",\n-    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; Serotonin reuptake inhibitor (weak)\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n-            \"threshold\": \"3 mg\",\n-            \"light\": \"3-10 mg\",\n-            \"common\": \"10-20 mg\",\n-            \"strong\": \"20-30 mg\",\n-            \"heavy\": \"30+ mg\"\n+            \"threshold\": \"10-15 mg\",\n+            \"light\": \"15-20 mg\",\n+            \"common\": \"30-40 mg\",\n+            \"strong\": \"40-60 mg\",\n+            \"heavy\": \"60+ mg\"\n+        },\n+        {\n+          \"route\": \"smoked\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5-10 mg\",\n+            \"light\": \"10-15 mg\",\n+            \"common\": \"15-25 mg\",\n+            \"strong\": \"25-35 mg\",\n+            \"heavy\": \"35+ mg\"\n+          }\n-            \"total_duration\": \"2-4 hours\",\n-            \"onset\": \"15-30 minutes\",\n-            \"peak\": \"60-90 minutes (20-30 minutes after onset)\",\n-            \"offset\": \"30-60 minutes\",\n-            \"after_effects\": \"1-3 hours\"\n+            \"total_duration\": \"3-7 hours\",\n+            \"onset\": \"30-60 minutes\",\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"2-4 hours\"\n+        },\n+        {\n+          \"route\": \"smoked\",\n+          \"stages\": {\n+            \"total_duration\": \"1-2 hours\",\n+            \"onset\": \"1-5 minutes\",\n+            \"peak\": \"15-30 minutes\",\n+            \"offset\": \"30-60 minutes\",\n+            \"after_effects\": \"1-2 hours\"\n+          }\n-    \"addiction_potential\": \"4-HO-DiPT is not habit-forming and has minimal psychological dependence potential. Like most psychedelics, it is considered self-regulating, with the desire to use it typically decreasing with regular consumption.\",\n+    \"addiction_potential\": \"4-HO-EPT is not habit-forming and the desire to use it can actually decrease with regular consumption. Like most psychedelics, it is generally considered self-regulating. There is no evidence of physical dependence potential.\",\n-        \"Lithium (significantly increases risk of psychosis and seizures)\",\n-        \"Tramadol (lowers seizure threshold)\"\n+        \"Lithium (significantly increases risk of psychosis and seizures)\"\n-        \"Stimulants (increased risk of anxiety, paranoia, panic attacks, thought loops, mania, and psychosis)\"\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Stimulants (increased risk of anxiety, paranoia, thought loops, mania, and psychosis)\"\n-        \"Cannabis (unpredictable synergy; significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n+        \"Cannabis (unpredictable synergy, significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n-    \"notes\": \"4-HO-DiPT is a research chemical with very limited history of human use and no scientific studies on its toxicity. It is noted for its uniquely rapid onset, short duration, narrow dose sensitivity, and high intensity relative to dose. Physical side effects including muscle tremors, leg tremors, bodily malaise, and temperature dysregulation are commonly reported. Set and setting are critical, and harm reduction practices are essential. The substance is unscheduled in most jurisdictions but may be controlled under analogue laws.\",\n+    \"notes\": \"4-HO-EPT is a novel research chemical with very little history of human use before 2016 and almost no scientific research on its pharmacology, metabolism, or toxicity. Unlike more visual tryptamines, it primarily enhances colors with a neon quality rather than producing strong visual distortions. Users report a strong euphoric body high sometimes compared to opiates, with a generally light and positive mindset. Accurate weighing with a precise milligram scale is essential. Individuals with personal or family history of psychotic disorders should avoid use. Higher doses may cause vasoconstriction. Set and setting considerations apply as with all psychedelics.\",\n+      \"Color Enhancement\",\n-      \"Emotion Enhancement\",\n-      \"Introspective Insights\",\n-      \"Time Distortion\",\n+      \"Euphoric Body High\",\n-      \"Enhanced Tactile Sensation\",\n-      \"Sexual Enhancement\",\n-      \"Visual Pattern Recognition Enhancement\",\n-      \"Colour Enhancement\",\n-      \"Muscle Tremors\",\n-      \"Nausea\",\n-      \"Pupil Dilation\",\n-      \"Stimulation\",\n-      \"Temperature Dysregulation\"\n+      \"Conceptual Thinking\",\n+      \"Analysis Enhancement\",\n+      \"Pattern Recognition Enhancement\",\n+      \"Time Distortion\",\n+      \"Emotion Enhancement\",\n+      \"Sedation\",\n+      \"Memory Suppression\",\n+      \"Thought Loops\",\n+      \"Nausea\"\n-      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n+      \"full_tolerance\": \"Immediately after ingestion\",\n-        \"All psychedelics (LSD, psilocybin, mescaline, DMT, 2C-x, DOx, 5-MeO-xxT, other tryptamines)\"\n+        \"All psychedelics\"\n-    \"half_life\": \"2.7-4.1 hours (based on prodrug luvesilocin studies)\",\n+    \"half_life\": \"\",\n-        \"name\": \"PsychonautWiki: 4-HO-DiPT\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/4-HO-DiPT\"\n+        \"name\": \"Bluelight: The Big & Dandy 4-HO-EPT Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-4-ho-ept-thread.805165/\"\n-        \"name\": \"Erowid 4-HO-DiPT Vault\",\n-        \"reference\": \"https://www.erowid.org/chemicals/4_ho_dipt/4_ho_dipt.shtml\"\n+        \"name\": \"Erowid 4-HO-EPT Experience Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_4HOEPT.shtml\"\n-        \"name\": \"TiHKAL Entry #17: 4-HO-DiPT by Alexander Shulgin\",\n-        \"reference\": \"https://isomerdesign.com/PiHKAL/read.php?domain=tk&id=17\"\n+        \"name\": \"Isomer Design: 4-HO-EPT\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?id=5770\"\n-        \"name\": \"Bluelight: The Big & Dandy 4-HO-DiPT Thread\",\n-        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-4-ho-dipt-thread.107890/\"\n+        \"name\": \"PMC: Investigation of the Structure-Activity Relationships of Psilocybin Analogues\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC8033608/\"\n-        \"name\": \"Drugs-Forum: 4-HO-DiPT Trip Reports\",\n-        \"reference\": \"https://drugs-forum.com/threads/4-ho-dipt-trip-reports.3095/\"\n-      },\n-      {\n-        \"name\": \"Wikipedia: 4-HO-DiPT\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/4-HO-DiPT\"\n-      },\n-      {\n-        \"name\": \"Repke, D. B. et al. (1977). Psilocin analogs synthesis\",\n-        \"reference\": \"Journal of Heterocyclic Chemistry, 14(1), 71-74\"\n+        \"name\": \"PsychonautWiki: 4-HO-EPT\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/4-HO-EPT\"\n-      \"research-chemical\",\n-      \"synthetic\"\n+      \"research-chemical\"\n-  \"id\": 641\n+  \"id\": 642\n\n# 4-HO-MPT · #643\n\n-  \"title\": \"4-HO-EPT\",\n+  \"title\": \"4-HO-MPT\",\n-    \"drug_name\": \"4-HO-EPT\",\n-    \"chemical_name\": \"4-Hydroxy-N-ethyl-N-propyltryptamine\",\n-    \"alternative_name\": \"Eprocin\",\n+    \"drug_name\": \"4-HO-MPT\",\n+    \"chemical_name\": \"3-[2-(Methylpropylamino)ethyl]-4-indolol\",\n+    \"alternative_name\": \"Meprocin; 4-Hydroxy-N-methyl-N-propyltryptamine\",\n-    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n+    \"mechanism_of_action\": \"5-HT2A receptor full agonist; 5-HT2B receptor partial agonist (moderate-efficacy); 5-HT2C receptor partial agonist (high-efficacy)\",\n-            \"threshold\": \"10-15 mg\",\n-            \"light\": \"15-20 mg\",\n-            \"common\": \"30-40 mg\",\n-            \"strong\": \"40-60 mg\",\n-            \"heavy\": \"60+ mg\"\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"5-10 mg\",\n+            \"common\": \"10-20 mg\",\n+            \"strong\": \"20-30 mg\",\n+            \"heavy\": \"30+ mg\"\n-          \"route\": \"smoked\",\n+          \"route\": \"vaporized\",\n-            \"threshold\": \"5-10 mg\",\n-            \"light\": \"10-15 mg\",\n-            \"common\": \"15-25 mg\",\n-            \"strong\": \"25-35 mg\",\n-            \"heavy\": \"35+ mg\"\n+            \"threshold\": \"3 mg\",\n+            \"light\": \"3-5 mg\",\n+            \"common\": \"5-10 mg\",\n+            \"strong\": \"10-15 mg\",\n+            \"heavy\": \"15+ mg\"\n-            \"onset\": \"30-60 minutes\",\n-            \"peak\": \"1-2 hours\",\n+            \"onset\": \"20-60 minutes\",\n+            \"peak\": \"2-3 hours\",\n-            \"after_effects\": \"2-4 hours\"\n+            \"after_effects\": \"2-12 hours\"\n-          \"route\": \"smoked\",\n+          \"route\": \"vaporized\",\n-            \"total_duration\": \"1-2 hours\",\n-            \"onset\": \"1-5 minutes\",\n-            \"peak\": \"15-30 minutes\",\n-            \"offset\": \"30-60 minutes\",\n-            \"after_effects\": \"1-2 hours\"\n-          }\n+            \"total_duration\": \"45-90 minutes\",\n+            \"onset\": \"1-3 minutes\",\n+            \"peak\": \"10-30 minutes\",\n+            \"offset\": \"15-45 minutes\",\n+            \"after_effects\": \"1-6 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n-    \"addiction_potential\": \"4-HO-EPT is not habit-forming and the desire to use it can actually decrease with regular consumption. Like most psychedelics, it is generally considered self-regulating. There is no evidence of physical dependence potential.\",\n+    \"addiction_potential\": \"4-HO-MPT is generally considered not habit-forming, and the desire to use it can actually decrease with regular consumption. Like most psychedelics, it is thought to be self-regulating with low potential for psychological dependence.\",\n-        \"Tramadol (lowers seizure threshold)\",\n-        \"Stimulants (increased risk of anxiety, paranoia, thought loops, mania, and psychosis)\"\n+        \"Tramadol (lowers seizure threshold)\"\n-        \"Cannabis (unpredictable synergy, significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n+        \"Cannabis (unpredictable synergy; increases risk of anxiety, paranoia, panic attacks, and psychosis)\",\n+        \"Stimulants (increases risk of anxiety, paranoia, panic attacks, thought loops, mania, and psychosis)\"\n-    \"notes\": \"4-HO-EPT is a novel research chemical with very little history of human use before 2016 and almost no scientific research on its pharmacology, metabolism, or toxicity. Unlike more visual tryptamines, it primarily enhances colors with a neon quality rather than producing strong visual distortions. Users report a strong euphoric body high sometimes compared to opiates, with a generally light and positive mindset. Accurate weighing with a precise milligram scale is essential. Individuals with personal or family history of psychotic disorders should avoid use. Higher doses may cause vasoconstriction. Set and setting considerations apply as with all psychedelics.\",\n+    \"notes\": \"4-HO-MPT is a research chemical with very little history of human usage and minimal scientific data on its pharmacology, metabolism, and toxicity. Legal status varies by jurisdiction; it is unscheduled in most countries but is a Class A drug in the United Kingdom under the tryptamine catch-all clause and controlled under Germany's NpSG. Use precise scales for dosing as potency varies between salt forms (freebase is approximately 25% more potent than fumarate salts). Individuals with personal or family histories of mental illness should avoid use.\",\n-      \"Color Enhancement\",\n-      \"Cognitive Euphoria\",\n-      \"Euphoric Body High\",\n-      \"Increased Music Appreciation\",\n-      \"Conceptual Thinking\",\n-      \"Analysis Enhancement\",\n-      \"Pattern Recognition Enhancement\",\n+      \"Visual Distortions And Patterning\",\n+      \"Color Enhancement And Shifting\",\n-      \"Sedation\",\n-      \"Memory Suppression\",\n+      \"Cognitive Euphoria\",\n+      \"Nausea\",\n+      \"Increased Heart Rate\",\n+      \"Pupil Dilation\",\n-      \"Nausea\"\n+      \"Vertigo Or Dizziness\",\n+      \"Memory Suppression\",\n+      \"Internal And External Hallucinations\"\n-        \"All psychedelics\"\n+        \"All psychedelics (including LSD, psilocybin, mescaline, and other tryptamines)\"\n-        \"name\": \"Bluelight: The Big & Dandy 4-HO-EPT Thread\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-4-ho-ept-thread.805165/\"\n+        \"name\": \"Erowid 4-HO-MPT Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/4_ho_mpt/4_ho_mpt.shtml\"\n-        \"name\": \"Erowid 4-HO-EPT Experience Vault\",\n-        \"reference\": \"https://erowid.org/experiences/subs/exp_4HOEPT.shtml\"\n+        \"name\": \"PsychonautWiki 4-HO-MPT\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/4-HO-MPT\"\n-        \"name\": \"Isomer Design: 4-HO-EPT\",\n-        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?id=5770\"\n+        \"name\": \"TripSit 4-HO-MPT Factsheet\",\n+        \"reference\": \"https://tripbot.tripsit.me/factsheet/4-HO-MPT\"\n-        \"name\": \"PMC: Investigation of the Structure-Activity Relationships of Psilocybin Analogues\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC8033608/\"\n+        \"name\": \"TiHKAL Entry #23: 4-HO-MPT (Isomer Design)\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/read.php?domain=tk&id=23\"\n-        \"name\": \"PsychonautWiki: 4-HO-EPT\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/4-HO-EPT\"\n+        \"name\": \"Bluelight: The Big & Dandy 4-HO-MPT Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-4-ho-mpt-thread.550416/\"\n+      },\n+      {\n+        \"name\": \"Drugs-Forum 4-HO-MPT Wiki\",\n+        \"reference\": \"https://drugs-forum.com/wiki/4-HO-MPT\"\n-      \"research-chemical\"\n+      \"research-chemical\",\n+      \"synthetic\"\n-  \"id\": 642\n+  \"id\": 643\n\n# 5-MeO-DiPT · #644\n\n-  \"title\": \"4-HO-MPT\",\n+  \"title\": \"5-MeO-DiPT\",\n-    \"drug_name\": \"4-HO-MPT\",\n-    \"chemical_name\": \"3-[2-(Methylpropylamino)ethyl]-4-indolol\",\n-    \"alternative_name\": \"Meprocin; 4-Hydroxy-N-methyl-N-propyltryptamine\",\n+    \"drug_name\": \"5-MeO-DiPT\",\n+    \"chemical_name\": \"5-Methoxy-N,N-diisopropyltryptamine\",\n+    \"alternative_name\": \"Foxy; Foxy Methoxy\",\n-    \"psychoactive_class\": \"Psychedelic\",\n-    \"mechanism_of_action\": \"5-HT2A receptor full agonist; 5-HT2B receptor partial agonist (moderate-efficacy); 5-HT2C receptor partial agonist (high-efficacy)\",\n+    \"psychoactive_class\": \"Psychedelic; Entactogen; Stimulant\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist (primary); 5-HT1A receptor agonist (strongest binding affinity); weak serotonin reuptake inhibitor; possible monoamine oxidase inhibition\",\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"5-10 mg\",\n-            \"common\": \"10-20 mg\",\n-            \"strong\": \"20-30 mg\",\n-            \"heavy\": \"30+ mg\"\n+            \"threshold\": \"3-4 mg\",\n+            \"light\": \"3-10 mg\",\n+            \"common\": \"10-15 mg\",\n+            \"strong\": \"15-20 mg\",\n+            \"heavy\": \"20+ mg\"\n-          \"route\": \"vaporized\",\n+          \"route\": \"insufflated\",\n-            \"threshold\": \"3 mg\",\n+            \"threshold\": \"2-4 mg\",\n+            \"light\": \"4-7 mg\",\n+            \"common\": \"7-12 mg\",\n+            \"strong\": \"12-18 mg\",\n+            \"heavy\": \"18+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"smoked\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"2-3 mg\",\n-            \"common\": \"5-10 mg\",\n-            \"strong\": \"10-15 mg\",\n-            \"heavy\": \"15+ mg\"\n+            \"common\": \"5-8 mg\",\n+            \"strong\": \"8-12 mg\",\n+            \"heavy\": \"12+ mg\"\n-            \"total_duration\": \"3-7 hours\",\n+            \"total_duration\": \"4-8 hours\",\n-            \"peak\": \"2-3 hours\",\n-            \"offset\": \"1-2 hours\",\n-            \"after_effects\": \"2-12 hours\"\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"2-6 hours (residual stimulation, possible insomnia)\"\n-          \"route\": \"vaporized\",\n+          \"route\": \"insufflated\",\n-            \"total_duration\": \"45-90 minutes\",\n-            \"onset\": \"1-3 minutes\",\n-            \"peak\": \"10-30 minutes\",\n-            \"offset\": \"15-45 minutes\",\n-            \"after_effects\": \"1-6 hours\"\n+            \"total_duration\": \"3-6 hours\",\n+            \"onset\": \"5-20 minutes\",\n+            \"peak\": \"45-90 minutes\",\n+            \"offset\": \"1-3 hours\",\n+            \"after_effects\": \"2-4 hours\"\n+            \"insufflated\"\n+          ]\n+        },\n+        {\n+          \"route\": \"smoked\",\n+          \"stages\": {\n+            \"total_duration\": \"2-4 hours\",\n+            \"onset\": \"1-5 minutes\",\n+            \"peak\": \"30-90 minutes\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"2-6 hours (prolonged compared to other smoked tryptamines)\"\n+          },\n+          \"canonical_routes\": [\n-    \"addiction_potential\": \"4-HO-MPT is generally considered not habit-forming, and the desire to use it can actually decrease with regular consumption. Like most psychedelics, it is thought to be self-regulating with low potential for psychological dependence.\",\n+    \"addiction_potential\": \"5-MeO-DiPT is not considered physically addictive and has low potential for psychological dependence. Some users report compulsive redosing due to the extended onset, particularly among inexperienced users who mistake the delayed effects for inadequate dosing. Tryptamines of this class are not known for addictive patterns.\",\n-        \"Lithium (significantly increases risk of psychosis and seizures)\"\n+        \"MAOIs (risk of serotonin syndrome; 5-MeO-DiPT may have weak MAOI properties)\",\n+        \"Tramadol (increased risk of serotonin syndrome and seizures)\",\n+        \"aMT (increased risk of serotonin syndrome)\"\n-        \"Tramadol (lowers seizure threshold)\"\n+        \"2C-T-X (both classes unpredictable alone)\",\n+        \"2C-X (unpredictable potentiation of psychedelic effects)\",\n+        \"NBOMe (both classes unpredictable; increased risk of unpleasant physical side effects)\",\n+        \"DOx (unpredictable interactions; increased risk of unpleasant physical side effects)\",\n+        \"MDMA (5-MeO tryptamines unpredictable with MDMA)\",\n+        \"Mescaline (unpredictable interactions)\",\n+        \"DXM (little information; possible unpredictable effects)\",\n+        \"PCP (little information; may increase risk of psychosis and excessive stimulation)\"\n-        \"Cannabis (unpredictable synergy; increases risk of anxiety, paranoia, panic attacks, and psychosis)\",\n-        \"Stimulants (increases risk of anxiety, paranoia, panic attacks, thought loops, mania, and psychosis)\"\n+        \"Cannabis (may increase risk of anxiety, paranoia, and psychosis)\",\n+        \"Amphetamines (anxiogenic and focusing effects increase risk of thought loops; combination generally unnecessary)\",\n+        \"Cocaine (anxiogenic and focusing effects increase risk of thought loops; combination generally unnecessary)\"\n-    \"notes\": \"4-HO-MPT is a research chemical with very little history of human usage and minimal scientific data on its pharmacology, metabolism, and toxicity. Legal status varies by jurisdiction; it is unscheduled in most countries but is a Class A drug in the United Kingdom under the tryptamine catch-all clause and controlled under Germany's NpSG. Use precise scales for dosing as potency varies between salt forms (freebase is approximately 25% more potent than fumarate salts). Individuals with personal or family histories of mental illness should avoid use.\",\n+    \"notes\": \"5-MeO-DiPT varies widely in individual response; some users report profound experiences while others experience uncomfortable gastrointestinal distress including severe diarrhea, gas, and stomach bloating. Use a precise milligram scale as dosages are in the low milligram range. The extended onset of 20-60 minutes has led to accidental overdoses from premature redosing. Individuals with personal or family history of psychotic disorders should avoid use. At least one death has been attributed to rectal administration overdose. The substance has been reported to be neurotoxic in rats. Set and setting are important; some users report significant anxiety and paranoia at higher doses.\",\n-      \"Visual Distortions And Patterning\",\n-      \"Color Enhancement And Shifting\",\n-      \"Time Distortion\",\n-      \"Emotion Enhancement\",\n+      \"Tactile Enhancement\",\n+      \"Stimulation\",\n+      \"Emotional Enhancement\",\n+      \"Increased Music Appreciation\",\n+      \"Enhanced Libido\",\n+      \"Spontaneous Physical Sensations\",\n+      \"Auditory Distortions\",\n-      \"Increased Heart Rate\",\n-      \"Pupil Dilation\",\n-      \"Thought Loops\",\n-      \"Vertigo Or Dizziness\",\n-      \"Memory Suppression\",\n-      \"Internal And External Hallucinations\"\n+      \"Body Load\",\n+      \"Diarrhea\",\n+      \"Time Distortion\",\n+      \"Visual Drifting (at higher doses)\",\n+      \"Pupil Dilation\"\n-      \"full_tolerance\": \"Immediately after ingestion\",\n+      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n-        \"All psychedelics (including LSD, psilocybin, mescaline, and other tryptamines)\"\n+        \"All psychedelics (LSD, psilocybin, mescaline, DMT, other tryptamines)\"\n-    \"half_life\": \"\",\n+    \"half_life\": \"3-6 hours (estimated from duration data)\",\n-        \"name\": \"Erowid 4-HO-MPT Vault\",\n-        \"reference\": \"https://www.erowid.org/chemicals/4_ho_mpt/4_ho_mpt.shtml\"\n+        \"name\": \"Erowid 5-MeO-DiPT Vault\",\n+        \"reference\": \"https://erowid.org/chemicals/5meo_dipt/\"\n-        \"name\": \"PsychonautWiki 4-HO-MPT\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/4-HO-MPT\"\n+        \"name\": \"Erowid TiHKAL Entry #37: 5-MeO-DiPT\",\n+        \"reference\": \"https://erowid.org/library/books_online/tihkal/tihkal37.shtml\"\n-        \"name\": \"TripSit 4-HO-MPT Factsheet\",\n-        \"reference\": \"https://tripbot.tripsit.me/factsheet/4-HO-MPT\"\n+        \"name\": \"PsychonautWiki: 5-MeO-DiPT\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/5-MeO-DiPT\"\n-        \"name\": \"TiHKAL Entry #23: 4-HO-MPT (Isomer Design)\",\n-        \"reference\": \"https://isomerdesign.com/PiHKAL/read.php?domain=tk&id=23\"\n+        \"name\": \"Bluelight: The Big & Dandy 5-MeO-DiPT Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-5-meo-dipt-thread.57817/\"\n-        \"name\": \"Bluelight: The Big & Dandy 4-HO-MPT Thread\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-4-ho-mpt-thread.550416/\"\n+        \"name\": \"TripSit Drug Combinations Wiki\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/Drug_combinations\"\n-        \"name\": \"Drugs-Forum 4-HO-MPT Wiki\",\n-        \"reference\": \"https://drugs-forum.com/wiki/4-HO-MPT\"\n+        \"name\": \"Shulgin, A. T.; Carter, M. F. (1980). Communications in Psychopharmacology\",\n+        \"reference\": \"N,N-Diisopropyltryptamine (DIPT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT). Two orally active tryptamine analogs with CNS activity\"\n+      },\n+      {\n+        \"name\": \"Noworyta-Sokolowska et al. (2016). Neurotoxicity Research\",\n+        \"reference\": \"Neurotoxic Effects of 5-MeO-DIPT: A Psychoactive Tryptamine Derivative in Rats\"\n+      },\n+      {\n+        \"name\": \"US DEA Drug Fact Sheet: 5-MeO-DiPT\",\n+        \"reference\": \"https://www.deadiversion.usdoj.gov/drug_chem_info/5meodipt.pdf\"\n-      \"synthetic\"\n+      \"entactogen\"\n-  \"id\": 643\n+  \"id\": 644\n\n# Psilocin · #645\n\n-  \"title\": \"5-MeO-DiPT\",\n-  \"index-category\": \"psychedelic; tryptamine; research-chemical\",\n+  \"title\": \"Psilocin\",\n+  \"index-category\": \"psychedelic; tryptamine; classic\",\n-    \"drug_name\": \"5-MeO-DiPT\",\n-    \"chemical_name\": \"5-Methoxy-N,N-diisopropyltryptamine\",\n-    \"alternative_name\": \"Foxy; Foxy Methoxy\",\n+    \"drug_name\": \"Psilocin\",\n+    \"chemical_name\": \"4-Hydroxy-N,N-dimethyltryptamine\",\n+    \"alternative_name\": \"Psilocine; Psilocyn; Psilotsin; 4-HO-DMT; 4-OH-DMT\",\n-    \"psychoactive_class\": \"Psychedelic; Entactogen; Stimulant\",\n-    \"mechanism_of_action\": \"5-HT2A receptor agonist (primary); 5-HT1A receptor agonist (strongest binding affinity); weak serotonin reuptake inhibitor; possible monoamine oxidase inhibition\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; 5-HT2C receptor agonist; 5-HT1A receptor agonist; Activates phospholipase A2 instead of phospholipase C\",\n-            \"threshold\": \"3-4 mg\",\n-            \"light\": \"3-10 mg\",\n-            \"common\": \"10-15 mg\",\n-            \"strong\": \"15-20 mg\",\n-            \"heavy\": \"20+ mg\"\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"10-15 mg\",\n+            \"common\": \"15-25 mg\",\n+            \"strong\": \"25-40 mg\",\n+            \"heavy\": \"40+ mg\"\n-        },\n-        {\n-          \"route\": \"insufflated\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"2-4 mg\",\n-            \"light\": \"4-7 mg\",\n-            \"common\": \"7-12 mg\",\n-            \"strong\": \"12-18 mg\",\n-            \"heavy\": \"18+ mg\"\n-          }\n-        },\n-        {\n-          \"route\": \"smoked\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"2-3 mg\",\n-            \"light\": \"3-5 mg\",\n-            \"common\": \"5-8 mg\",\n-            \"strong\": \"8-12 mg\",\n-            \"heavy\": \"12+ mg\"\n-          }\n-            \"total_duration\": \"4-8 hours\",\n-            \"onset\": \"20-60 minutes\",\n-            \"peak\": \"1-2 hours\",\n-            \"offset\": \"2-4 hours\",\n-            \"after_effects\": \"2-6 hours (residual stimulation, possible insomnia)\"\n+            \"total_duration\": \"4-6 hours\",\n+            \"onset\": \"20-45 minutes\",\n+            \"peak\": \"2-3 hours (come up 1.5-3 hours)\",\n+            \"offset\": \"1.5-2 hours\",\n+            \"after_effects\": \"4-24 hours\"\n-        },\n-        {\n-          \"route\": \"insufflated\",\n-          \"stages\": {\n-            \"total_duration\": \"3-6 hours\",\n-            \"onset\": \"5-20 minutes\",\n-            \"peak\": \"45-90 minutes\",\n-            \"offset\": \"1-3 hours\",\n-            \"after_effects\": \"2-4 hours\"\n-          },\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ]\n-        },\n-        {\n-          \"route\": \"smoked\",\n-          \"stages\": {\n-            \"total_duration\": \"2-4 hours\",\n-            \"onset\": \"1-5 minutes\",\n-            \"peak\": \"30-90 minutes\",\n-            \"offset\": \"1-2 hours\",\n-            \"after_effects\": \"2-6 hours (prolonged compared to other smoked tryptamines)\"\n-          },\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ]\n-    \"addiction_potential\": \"5-MeO-DiPT is not considered physically addictive and has low potential for psychological dependence. Some users report compulsive redosing due to the extended onset, particularly among inexperienced users who mistake the delayed effects for inadequate dosing. Tryptamines of this class are not known for addictive patterns.\",\n+    \"addiction_potential\": \"Psilocin is not considered habit-forming and has a low potential for psychological dependence. The desire to use it typically decreases with use, making it largely self-regulating. Rapid tolerance development discourages frequent redosing.\",\n-        \"MAOIs (risk of serotonin syndrome; 5-MeO-DiPT may have weak MAOI properties)\",\n-        \"Tramadol (increased risk of serotonin syndrome and seizures)\",\n-        \"aMT (increased risk of serotonin syndrome)\"\n+        \"Lithium (risk of fatal seizures and heart problems)\",\n+        \"MAOIs (potential for serotonin syndrome, hypertensive crisis)\"\n-        \"2C-T-X (both classes unpredictable alone)\",\n-        \"2C-X (unpredictable potentiation of psychedelic effects)\",\n-        \"NBOMe (both classes unpredictable; increased risk of unpleasant physical side effects)\",\n-        \"DOx (unpredictable interactions; increased risk of unpleasant physical side effects)\",\n-        \"MDMA (5-MeO tryptamines unpredictable with MDMA)\",\n-        \"Mescaline (unpredictable interactions)\",\n-        \"DXM (little information; possible unpredictable effects)\",\n-        \"PCP (little information; may increase risk of psychosis and excessive stimulation)\"\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Cannabis (greatly intensifies effects, increases anxiety and psychosis risk)\"\n-        \"Cannabis (may increase risk of anxiety, paranoia, and psychosis)\",\n-        \"Amphetamines (anxiogenic and focusing effects increase risk of thought loops; combination generally unnecessary)\",\n-        \"Cocaine (anxiogenic and focusing effects increase risk of thought loops; combination generally unnecessary)\"\n+        \"SSRIs (may reduce effects or increase risk)\",\n+        \"SNRIs (may alter effects)\",\n+        \"Tricyclic antidepressants (may potentiate effects)\",\n+        \"Benzodiazepines (reduce intensity, may cause amnesia)\",\n+        \"Antipsychotics (significantly dampen effects)\",\n+        \"MDMA (amplifies effects, possible neurotoxicity concerns)\",\n+        \"Dissociatives (intensifies hallucinations and confusion)\",\n+        \"Alcohol (causes dehydration and nausea, dulls effects)\"\n-    \"notes\": \"5-MeO-DiPT varies widely in individual response; some users report profound experiences while others experience uncomfortable gastrointestinal distress including severe diarrhea, gas, and stomach bloating. Use a precise milligram scale as dosages are in the low milligram range. The extended onset of 20-60 minutes has led to accidental overdoses from premature redosing. Individuals with personal or family history of psychotic disorders should avoid use. At least one death has been attributed to rectal administration overdose. The substance has been reported to be neurotoxic in rats. Set and setting are important; some users report significant anxiety and paranoia at higher doses.\",\n+    \"notes\": \"Psilocin is the pharmacologically active form of psilocybin and is rarely encountered as a pure synthetic compound. It is relatively unstable and readily forms blue degradation products when exposed to oxygen. Store in cool, dry, dark conditions. Unlike psilocybin mushrooms, pure psilocin has reduced nausea when taken on an empty stomach. Set and setting are critical to the experience. Those with personal or family history of psychotic disorders should avoid use. Always use accurate scales for dosing, as the substance is potent and effects can be overwhelming.\",\n-      \"Tactile Enhancement\",\n-      \"Stimulation\",\n-      \"Emotional Enhancement\",\n-      \"Increased Music Appreciation\",\n-      \"Enhanced Libido\",\n-      \"Spontaneous Physical Sensations\",\n-      \"Auditory Distortions\",\n-      \"Cognitive Euphoria\",\n-      \"Nausea\",\n-      \"Body Load\",\n-      \"Diarrhea\",\n+      \"Visual Patterning And Geometry\",\n+      \"Enhanced Colors And Visual Acuity\",\n+      \"Drifting, Melting, And Morphing Visuals\",\n+      \"Internal And External Hallucinations\",\n+      \"Emotional Amplification And Empathy\",\n-      \"Visual Drifting (at higher doses)\",\n-      \"Pupil Dilation\"\n+      \"Profound Thought Connectivity\",\n+      \"Spirituality And Ego Dissolution\",\n+      \"Physical Euphoria Or Sedation\",\n+      \"Analysis Enhancement\",\n+      \"Excessive Yawning\",\n+      \"Nausea (Less Common Than Mushrooms)\",\n+      \"Body High And Tingling Sensations\",\n+      \"Synesthesia\",\n+      \"Feelings Of Unity\"\n-      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n+      \"full_tolerance\": \"Almost immediately after ingestion\",\n-        \"All psychedelics (LSD, psilocybin, mescaline, DMT, other tryptamines)\"\n+        \"All psychedelics (LSD, mescaline, DMT, 2C-x compounds)\"\n-    \"half_life\": \"3-6 hours (estimated from duration data)\",\n+    \"half_life\": \"1-3 hours\",\n-        \"name\": \"Erowid 5-MeO-DiPT Vault\",\n-        \"reference\": \"https://erowid.org/chemicals/5meo_dipt/\"\n+        \"name\": \"PsychonautWiki: Psilocin\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Psilocin\"\n-        \"name\": \"Erowid TiHKAL Entry #37: 5-MeO-DiPT\",\n-        \"reference\": \"https://erowid.org/library/books_online/tihkal/tihkal37.shtml\"\n+        \"name\": \"Erowid Psilocin Experience Reports\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_Psilocin.shtml\"\n-        \"name\": \"PsychonautWiki: 5-MeO-DiPT\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/5-MeO-DiPT\"\n+        \"name\": \"TiHKAL #18: 4-HO-DMT by Alexander Shulgin\",\n+        \"reference\": \"https://erowid.org/library/books_online/tihkal/tihkal18.shtml\"\n-        \"name\": \"Bluelight: The Big & Dandy 5-MeO-DiPT Thread\",\n-        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-5-meo-dipt-thread.57817/\"\n+        \"name\": \"Bluelight: The Big and Dandy 4-HO-DMT Thread\",\n+        \"reference\": \"https://www.bluelight.org/vb/threads/318367-The-Big-and-Dandy-4-HO-DMT-Thread\"\n-        \"name\": \"TripSit Drug Combinations Wiki\",\n-        \"reference\": \"https://wiki.tripsit.me/wiki/Drug_combinations\"\n+        \"name\": \"Drug-drug interactions involving classic psychedelics: A systematic review\",\n+        \"reference\": \"https://journals.sagepub.com/doi/10.1177/02698811231211219\"\n-        \"name\": \"Shulgin, A. T.; Carter, M. F. (1980). Communications in Psychopharmacology\",\n-        \"reference\": \"N,N-Diisopropyltryptamine (DIPT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT). Two orally active tryptamine analogs with CNS activity\"\n-      },\n-      {\n-        \"name\": \"Noworyta-Sokolowska et al. (2016). Neurotoxicity Research\",\n-        \"reference\": \"Neurotoxic Effects of 5-MeO-DIPT: A Psychoactive Tryptamine Derivative in Rats\"\n-      },\n-      {\n-        \"name\": \"US DEA Drug Fact Sheet: 5-MeO-DiPT\",\n-        \"reference\": \"https://www.deadiversion.usdoj.gov/drug_chem_info/5meodipt.pdf\"\n+        \"name\": \"Drug-drug interactions between psychiatric medications and MDMA or psilocybin\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177763/\"\n-      \"research-chemical\",\n-      \"entactogen\"\n+      \"serotonergic\"\n-  \"id\": 644\n+  \"id\": 645\n\n# Allylescaline · #646\n\n-  \"title\": \"Psilocin\",\n-  \"index-category\": \"psychedelic; tryptamine; classic\",\n+  \"title\": \"Allylescaline\",\n+  \"index-category\": \"psychedelic\",\n-    \"drug_name\": \"Psilocin\",\n-    \"chemical_name\": \"4-Hydroxy-N,N-dimethyltryptamine\",\n-    \"alternative_name\": \"Psilocine; Psilocyn; Psilotsin; 4-HO-DMT; 4-OH-DMT\",\n-    \"chemical_class\": \"Tryptamines\",\n+    \"drug_name\": \"Allylescaline\",\n+    \"chemical_name\": \"4-Allyloxy-3,5-dimethoxyphenethylamine\",\n+    \"alternative_name\": \"AL; 4-allyloxy-3,5-dimethoxy-phenethylamine\",\n+    \"chemical_class\": \"Scalines\",\n-    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; 5-HT2C receptor agonist; 5-HT1A receptor agonist; Activates phospholipase A2 instead of phospholipase C\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n-            \"threshold\": \"5 mg\",\n-            \"light\": \"10-15 mg\",\n-            \"common\": \"15-25 mg\",\n-            \"strong\": \"25-40 mg\",\n-            \"heavy\": \"40+ mg\"\n+            \"threshold\": \"15 mg\",\n+            \"light\": \"20-30 mg\",\n+            \"common\": \"30-40 mg\",\n+            \"strong\": \"40-60 mg\",\n+            \"heavy\": \"60+ mg\"\n-            \"total_duration\": \"4-6 hours\",\n-            \"onset\": \"20-45 minutes\",\n-            \"peak\": \"2-3 hours (come up 1.5-3 hours)\",\n-            \"offset\": \"1.5-2 hours\",\n-            \"after_effects\": \"4-24 hours\"\n+            \"total_duration\": \"8-12 hours\",\n+            \"onset\": \"45-240 minutes\",\n+            \"after_effects\": \"Up to 12 hours (residual effects possible)\"\n-    \"addiction_potential\": \"Psilocin is not considered habit-forming and has a low potential for psychological dependence. The desire to use it typically decreases with use, making it largely self-regulating. Rapid tolerance development discourages frequent redosing.\",\n+    \"addiction_potential\": \"Allylescaline is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating, with little evidence of compulsive redosing patterns. However, given the limited human usage data, these observations should be considered preliminary.\",\n-        \"Lithium (risk of fatal seizures and heart problems)\",\n-        \"MAOIs (potential for serotonin syndrome, hypertensive crisis)\"\n+        \"Lithium (increased seizure risk with psychedelics)\",\n+        \"Tramadol (lowers seizure threshold with psychedelics)\"\n-      \"unsafe\": [\n-        \"Tramadol (lowers seizure threshold)\",\n-        \"Cannabis (greatly intensifies effects, increases anxiety and psychosis risk)\"\n-      ],\n+      \"unsafe\": [],\n-        \"SSRIs (may reduce effects or increase risk)\",\n-        \"SNRIs (may alter effects)\",\n-        \"Tricyclic antidepressants (may potentiate effects)\",\n-        \"Benzodiazepines (reduce intensity, may cause amnesia)\",\n-        \"Antipsychotics (significantly dampen effects)\",\n-        \"MDMA (amplifies effects, possible neurotoxicity concerns)\",\n-        \"Dissociatives (intensifies hallucinations and confusion)\",\n-        \"Alcohol (causes dehydration and nausea, dulls effects)\"\n+        \"MAOIs (theoretical risk based on phenethylamine structure)\",\n+        \"Stimulants (increased body load and cardiovascular strain)\",\n+        \"Other psychedelics (cross-tolerance and unpredictable intensity)\",\n+        \"Dissociatives (unpredictable combination effects)\"\n-    \"notes\": \"Psilocin is the pharmacologically active form of psilocybin and is rarely encountered as a pure synthetic compound. It is relatively unstable and readily forms blue degradation products when exposed to oxygen. Store in cool, dry, dark conditions. Unlike psilocybin mushrooms, pure psilocin has reduced nausea when taken on an empty stomach. Set and setting are critical to the experience. Those with personal or family history of psychotic disorders should avoid use. Always use accurate scales for dosing, as the substance is potent and effects can be overwhelming.\",\n+    \"notes\": \"Allylescaline is a research chemical with very little history of human usage and no formal toxicology studies. As a structural analog of mescaline with significantly increased potency, accurate weighing with a milligram scale is essential. The substance has a notably slow and variable onset ranging from 45 minutes to 4 hours, which may lead to accidental overdosing if users redose prematurely. Legal status varies by jurisdiction; it is controlled in Germany, Japan, Sweden, Switzerland, and the United Kingdom. Set and setting remain important considerations, and individuals with personal or family histories of mental health conditions should exercise extreme caution.\",\n-      \"Visual Patterning And Geometry\",\n-      \"Enhanced Colors And Visual Acuity\",\n-      \"Drifting, Melting, And Morphing Visuals\",\n-      \"Internal And External Hallucinations\",\n-      \"Emotional Amplification And Empathy\",\n+      \"Physical Stimulation\",\n+      \"Spontaneous Tactile Sensations\",\n+      \"Physical Euphoria\",\n+      \"Tactile Enhancement\",\n+      \"Color Enhancement\",\n+      \"Pattern Recognition Enhancement\",\n+      \"Drifting and Flowing Visuals\",\n+      \"Cognitive Euphoria\",\n+      \"Enhanced Empathy and Sociability\",\n+      \"Increased Music Appreciation\",\n-      \"Profound Thought Connectivity\",\n-      \"Spirituality And Ego Dissolution\",\n-      \"Physical Euphoria Or Sedation\",\n-      \"Analysis Enhancement\",\n-      \"Excessive Yawning\",\n-      \"Nausea (Less Common Than Mushrooms)\",\n-      \"Body High And Tingling Sensations\",\n-      \"Synesthesia\",\n-      \"Feelings Of Unity\"\n+      \"Nausea\",\n+      \"Increased Heart Rate\"\n-      \"full_tolerance\": \"Almost immediately after ingestion\",\n+      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n-        \"All psychedelics (LSD, mescaline, DMT, 2C-x compounds)\"\n+        \"All psychedelics (mescaline, LSD, psilocybin, DMT, 2C-x compounds, etc.)\"\n-    \"half_life\": \"1-3 hours\",\n+    \"half_life\": \"\",\n-        \"name\": \"PsychonautWiki: Psilocin\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/Psilocin\"\n+        \"name\": \"Erowid Allylescaline Vault\",\n+        \"reference\": \"https://www.erowid.org/experiences/subs/exp_Allylescaline.shtml\"\n-        \"name\": \"Erowid Psilocin Experience Reports\",\n-        \"reference\": \"https://erowid.org/experiences/subs/exp_Psilocin.shtml\"\n+        \"name\": \"Isomer Design - PiHKAL Entry #2: AL\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=2\"\n-        \"name\": \"TiHKAL #18: 4-HO-DMT by Alexander Shulgin\",\n-        \"reference\": \"https://erowid.org/library/books_online/tihkal/tihkal18.shtml\"\n+        \"name\": \"PsychonautWiki - Allylescaline\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Allylescaline\"\n-        \"name\": \"Bluelight: The Big and Dandy 4-HO-DMT Thread\",\n-        \"reference\": \"https://www.bluelight.org/vb/threads/318367-The-Big-and-Dandy-4-HO-DMT-Thread\"\n+        \"name\": \"Shulgin, A.; Shulgin, A. (1991). PiHKAL: A Chemical Love Story, Entry #2\",\n+        \"reference\": \"https://erowid.org/library/books_online/pihkal/pihkal002.shtml\"\n-        \"name\": \"Drug-drug interactions involving classic psychedelics: A systematic review\",\n-        \"reference\": \"https://journals.sagepub.com/doi/10.1177/02698811231211219\"\n+        \"name\": \"Bluelight - The Big & Dandy Allylescaline Thread\",\n+        \"reference\": \"https://bluelight.org\"\n-        \"name\": \"Drug-drug interactions between psychiatric medications and MDMA or psilocybin\",\n-        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177763/\"\n+        \"name\": \"Kolaczynska et al. (2022). Receptor interaction profiles of mescaline derivatives\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC8865417/\"\n-      \"tryptamine\",\n-      \"serotonergic\"\n+      \"research-chemical\"\n-  \"id\": 645\n+  \"id\": 646\n\n# Escaline · #647\n\n-  \"title\": \"Allylescaline\",\n+  \"title\": \"Escaline\",\n-    \"drug_name\": \"Allylescaline\",\n-    \"chemical_name\": \"4-Allyloxy-3,5-dimethoxyphenethylamine\",\n-    \"alternative_name\": \"AL; 4-allyloxy-3,5-dimethoxy-phenethylamine\",\n+    \"drug_name\": \"Escaline\",\n+    \"chemical_name\": \"3,5-Dimethoxy-4-ethoxyphenethylamine\",\n+    \"alternative_name\": \"E; 4-Ethoxy-3,5-dimethoxyphenethylamine\",\n-    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist (5-8 times greater affinity than mescaline); 5-HT2C receptor agonist\",\n-            \"threshold\": \"15 mg\",\n-            \"light\": \"20-30 mg\",\n-            \"common\": \"30-40 mg\",\n-            \"strong\": \"40-60 mg\",\n-            \"heavy\": \"60+ mg\"\n+            \"threshold\": \"20-25 mg\",\n+            \"light\": \"30-50 mg\",\n+            \"common\": \"50-100 mg\",\n+            \"strong\": \"100-150 mg\",\n+            \"heavy\": \"150+ mg\"\n-            \"onset\": \"45-240 minutes\",\n-            \"after_effects\": \"Up to 12 hours (residual effects possible)\"\n+            \"onset\": \"40-120 minutes\",\n+            \"peak\": \"5-6 hours\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"3-5 hours\"\n-    \"addiction_potential\": \"Allylescaline is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating, with little evidence of compulsive redosing patterns. However, given the limited human usage data, these observations should be considered preliminary.\",\n+    \"addiction_potential\": \"Escaline is not considered habit-forming and the desire to use it typically decreases with use. It is generally self-regulating and lacks compulsive redosing patterns.\",\n-        \"Lithium (increased seizure risk with psychedelics)\",\n-        \"Tramadol (lowers seizure threshold with psychedelics)\"\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n-      \"unsafe\": [],\n+      \"unsafe\": [\n+        \"Stimulants (increases risk of anxiety, paranoia, thought loops, mania, and psychosis)\"\n+      ],\n-        \"MAOIs (theoretical risk based on phenethylamine structure)\",\n-        \"Stimulants (increased body load and cardiovascular strain)\",\n-        \"Other psychedelics (cross-tolerance and unpredictable intensity)\",\n-        \"Dissociatives (unpredictable combination effects)\"\n+        \"Cannabis (unpredictable synergy; significantly increases risk of adverse psychological reactions)\"\n-    \"notes\": \"Allylescaline is a research chemical with very little history of human usage and no formal toxicology studies. As a structural analog of mescaline with significantly increased potency, accurate weighing with a milligram scale is essential. The substance has a notably slow and variable onset ranging from 45 minutes to 4 hours, which may lead to accidental overdosing if users redose prematurely. Legal status varies by jurisdiction; it is controlled in Germany, Japan, Sweden, Switzerland, and the United Kingdom. Set and setting remain important considerations, and individuals with personal or family histories of mental health conditions should exercise extreme caution.\",\n+    \"notes\": \"Escaline is a research chemical with very limited human use history and no formal toxicology studies. It is controlled as a Schedule I substance in the United States, Germany, Japan, Switzerland, and the UK. Users report more intense negative physical side effects compared to mescaline, including heavier body load and greater stimulation. Accurate weighing with a milligram scale is essential. The compound has a very long onset and extended duration, making sleep difficult without sedatives.\",\n-      \"Physical Stimulation\",\n-      \"Spontaneous Tactile Sensations\",\n-      \"Physical Euphoria\",\n-      \"Tactile Enhancement\",\n+      \"Stimulation\",\n+      \"Enhanced Music Appreciation\",\n+      \"Visual Patterning And Drifting\",\n-      \"Pattern Recognition Enhancement\",\n-      \"Drifting and Flowing Visuals\",\n-      \"Cognitive Euphoria\",\n-      \"Enhanced Empathy and Sociability\",\n-      \"Increased Music Appreciation\",\n+      \"Thought Acceleration And Connectivity\",\n-      \"Nausea\",\n-      \"Increased Heart Rate\"\n+      \"Bodily Sensations\",\n+      \"Pupil Dilation\",\n+      \"Increased Heart Rate\",\n+      \"Muscle Tension\",\n+      \"Euphoria\",\n+      \"Temperature Dysregulation\"\n-        \"All psychedelics (mescaline, LSD, psilocybin, DMT, 2C-x compounds, etc.)\"\n+        \"All psychedelics\"\n-        \"name\": \"Erowid Allylescaline Vault\",\n-        \"reference\": \"https://www.erowid.org/experiences/subs/exp_Allylescaline.shtml\"\n+        \"name\": \"Blaazer et al. (2008) - ChemMedChem\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/18666267/\"\n-        \"name\": \"Isomer Design - PiHKAL Entry #2: AL\",\n-        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=2\"\n+        \"name\": \"Erowid Escaline Experience Vault\",\n+        \"reference\": \"https://www.erowid.org/experiences/subs/exp_Escaline.shtml\"\n-        \"name\": \"PsychonautWiki - Allylescaline\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/Allylescaline\"\n+        \"name\": \"Halberstadt & Geyer (2018) - PMC\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848748/\"\n-        \"name\": \"Shulgin, A.; Shulgin, A. (1991). PiHKAL: A Chemical Love Story, Entry #2\",\n-        \"reference\": \"https://erowid.org/library/books_online/pihkal/pihkal002.shtml\"\n+        \"name\": \"Isomer Design: Escaline (PiHKAL Entry #72)\",\n+        \"reference\": \"https://isomerdesign.com/pihkal/explore/72\"\n-        \"name\": \"Bluelight - The Big & Dandy Allylescaline Thread\",\n-        \"reference\": \"https://bluelight.org\"\n+        \"name\": \"PsychonautWiki: Escaline\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Escaline\"\n-        \"name\": \"Kolaczynska et al. (2022). Receptor interaction profiles of mescaline derivatives\",\n-        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC8865417/\"\n+        \"name\": \"Shulgin & Shulgin (1991) - PiHKAL Entry #72\",\n+        \"reference\": \"https://isomerdesign.com/pihkal/read/pk/72\"\n+      },\n+      {\n+        \"name\": \"The Big & Dandy Escaline Thread - Bluelight\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-escaline-thread.656624/\"\n-  \"id\": 646\n+  \"id\": 647\n\n# Proscaline · #648\n\n-  \"title\": \"Escaline\",\n+  \"title\": \"Proscaline\",\n-    \"drug_name\": \"Escaline\",\n-    \"chemical_name\": \"3,5-Dimethoxy-4-ethoxyphenethylamine\",\n-    \"alternative_name\": \"E; 4-Ethoxy-3,5-dimethoxyphenethylamine\",\n+    \"drug_name\": \"Proscaline\",\n+    \"chemical_name\": \"4-Propyloxy-3,5-dimethoxyphenethylamine\",\n+    \"alternative_name\": \"P; 4-Propoxy-3,5-DMPEA; 3,5-Dimethoxy-4-n-propoxyphenethylamine\",\n-    \"mechanism_of_action\": \"5-HT2A receptor partial agonist (5-8 times greater affinity than mescaline); 5-HT2C receptor agonist\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; 5-HT2C receptor partial agonist\",\n-            \"threshold\": \"20-25 mg\",\n-            \"light\": \"30-50 mg\",\n-            \"common\": \"50-100 mg\",\n-            \"strong\": \"100-150 mg\",\n-            \"heavy\": \"150+ mg\"\n+            \"threshold\": \"10 mg\",\n+            \"light\": \"15-30 mg\",\n+            \"common\": \"30-40 mg\",\n+            \"strong\": \"40-60 mg\",\n+            \"heavy\": \"60+ mg\"\n-            \"onset\": \"40-120 minutes\",\n-            \"peak\": \"5-6 hours\",\n-            \"offset\": \"2-4 hours\",\n+            \"onset\": \"30-60 minutes\",\n+            \"peak\": \"2-4 hours\",\n+            \"offset\": \"3-5 hours\",\n-    \"addiction_potential\": \"Escaline is not considered habit-forming and the desire to use it typically decreases with use. It is generally self-regulating and lacks compulsive redosing patterns.\",\n+    \"addiction_potential\": \"Proscaline is not habit-forming and demonstrates a self-regulating usage pattern. The desire to use it typically decreases with repeated consumption. There is no evidence of physical dependence or compulsive redosing patterns.\",\n-        \"Lithium (significantly increases risk of psychosis and seizures)\",\n-        \"Tramadol (lowers seizure threshold)\"\n+        \"Lithium (significantly increases risk of seizures and psychosis)\"\n-        \"Stimulants (increases risk of anxiety, paranoia, thought loops, mania, and psychosis)\"\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"MAOIs (potentially hazardous serotonergic interaction)\"\n-        \"Cannabis (unpredictable synergy; significantly increases risk of adverse psychological reactions)\"\n+        \"Stimulants (increased cardiovascular strain)\",\n+        \"Cannabis (may intensify and prolong effects unpredictably)\",\n+        \"SSRIs (may blunt or alter effects)\",\n+        \"Alcohol (reduces therapeutic potential and increases risk of dehydration)\"\n-    \"notes\": \"Escaline is a research chemical with very limited human use history and no formal toxicology studies. It is controlled as a Schedule I substance in the United States, Germany, Japan, Switzerland, and the UK. Users report more intense negative physical side effects compared to mescaline, including heavier body load and greater stimulation. Accurate weighing with a milligram scale is essential. The compound has a very long onset and extended duration, making sleep difficult without sedatives.\",\n+    \"notes\": \"Proscaline is a lesser-known mescaline analog approximately five times more potent than mescaline. The substance has minimal research into its pharmacology and toxicity. Use a precise milligram scale for accurate dosing. It is controlled in Germany, Switzerland, and the United Kingdom but remains unscheduled in the United States. Individuals with personal or family history of psychotic disorders should avoid use. Ensure adequate set and setting preparation, as with all psychedelics.\",\n-      \"Stimulation\",\n-      \"Enhanced Music Appreciation\",\n-      \"Visual Patterning And Drifting\",\n+      \"Visual Pattern Enhancement\",\n-      \"Thought Acceleration And Connectivity\",\n-      \"Bodily Sensations\",\n-      \"Pupil Dilation\",\n-      \"Increased Heart Rate\",\n-      \"Muscle Tension\",\n-      \"Euphoria\",\n-      \"Temperature Dysregulation\"\n+      \"Enhanced Music Appreciation\",\n+      \"Tactile Enhancement\",\n+      \"Cognitive Euphoria\",\n+      \"Conceptual Thinking\",\n+      \"Increased Body Temperature\",\n+      \"Nausea\",\n+      \"Enhanced Introspection\",\n+      \"Emotional Amplification\",\n+      \"Drifting Visual Effects\"\n-        \"All psychedelics\"\n+        \"All psychedelics (mescaline, LSD, psilocybin, DMT, 2C-x compounds)\"\n-        \"name\": \"Blaazer et al. (2008) - ChemMedChem\",\n-        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/18666267/\"\n+        \"name\": \"PsychonautWiki: Proscaline\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Proscaline\"\n-        \"name\": \"Erowid Escaline Experience Vault\",\n-        \"reference\": \"https://www.erowid.org/experiences/subs/exp_Escaline.shtml\"\n+        \"name\": \"PiHKAL Entry #140: Proscaline (Isomer Design)\",\n+        \"reference\": \"https://isomerdesign.com/pihkal/explore/140\"\n-        \"name\": \"Halberstadt & Geyer (2018) - PMC\",\n-        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848748/\"\n+        \"name\": \"Erowid PiHKAL: Proscaline\",\n+        \"reference\": \"https://erowid.org/library/books_online/pihkal/pihkal140.shtml\"\n-        \"name\": \"Isomer Design: Escaline (PiHKAL Entry #72)\",\n-        \"reference\": \"https://isomerdesign.com/pihkal/explore/72\"\n+        \"name\": \"Erowid Proscaline Experience Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_Proscaline.shtml\"\n-        \"name\": \"PsychonautWiki: Escaline\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/Escaline\"\n+        \"name\": \"Bluelight: Proscaline Discussion\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/proscaline-new-experience-shiny-happy-people.522598/\"\n-        \"name\": \"Shulgin & Shulgin (1991) - PiHKAL Entry #72\",\n-        \"reference\": \"https://isomerdesign.com/pihkal/read/pk/72\"\n-      },\n-      {\n-        \"name\": \"The Big & Dandy Escaline Thread - Bluelight\",\n-        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-escaline-thread.656624/\"\n+        \"name\": \"Nichols and Dyer (1977) - Journal of Medicinal Chemistry\",\n+        \"reference\": \"https://doi.org/10.1021/jm00212a022\"\n+      \"phenethylamine\",\n-  \"id\": 647\n+  \"id\": 648\n\n# 2C-T · #649\n\n-  \"title\": \"Proscaline\",\n-  \"index-category\": \"psychedelic\",\n+  \"title\": \"2C-T\",\n+  \"index-category\": \"psychedelic; research-chemical\",\n-    \"drug_name\": \"Proscaline\",\n-    \"chemical_name\": \"4-Propyloxy-3,5-dimethoxyphenethylamine\",\n-    \"alternative_name\": \"P; 4-Propoxy-3,5-DMPEA; 3,5-Dimethoxy-4-n-propoxyphenethylamine\",\n-    \"chemical_class\": \"Scalines\",\n+    \"drug_name\": \"2C-T\",\n+    \"chemical_name\": \"2,5-Dimethoxy-4-methylthiophenethylamine\",\n+    \"alternative_name\": \"Tesseract\",\n+    \"chemical_class\": \"Phenethylamines\",\n-    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; 5-HT2C receptor partial agonist\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; potential MAOI properties\",\n-            \"threshold\": \"10 mg\",\n-            \"light\": \"15-30 mg\",\n-            \"common\": \"30-40 mg\",\n-            \"strong\": \"40-60 mg\",\n-            \"heavy\": \"60+ mg\"\n+            \"threshold\": \"20 mg\",\n+            \"light\": \"40-60 mg\",\n+            \"common\": \"60-100 mg\",\n+            \"strong\": \"100-120 mg\",\n+            \"heavy\": \"125+ mg\"\n-            \"total_duration\": \"8-12 hours\",\n-            \"onset\": \"30-60 minutes\",\n-            \"peak\": \"2-4 hours\",\n-            \"offset\": \"3-5 hours\",\n-            \"after_effects\": \"3-5 hours\"\n+            \"total_duration\": \"3-6 hours\",\n+            \"onset\": \"30-45 minutes\",\n+            \"peak\": \"30-115 minutes\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"1-2 hours\"\n-    \"addiction_potential\": \"Proscaline is not habit-forming and demonstrates a self-regulating usage pattern. The desire to use it typically decreases with repeated consumption. There is no evidence of physical dependence or compulsive redosing patterns.\",\n+    \"addiction_potential\": \"2C-T is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating with no significant dependence or abuse potential reported.\",\n-        \"Lithium (significantly increases risk of seizures and psychosis)\"\n+        \"MAOIs (potential serotonin syndrome or neurotransmitter overload)\",\n+        \"Stimulants (increased neurotransmitter release)\",\n+        \"5-MeO-MiPT (serotonergic overload)\",\n+        \"2C-T-7 (serotonergic overload)\",\n+        \"AMT (MAOI properties)\",\n+        \"Cocaine (cardiovascular stress)\",\n+        \"Methamphetamine (neurotoxicity risk)\",\n+        \"MDMA (serotonin syndrome risk)\"\n-        \"Tramadol (lowers seizure threshold)\",\n-        \"MAOIs (potentially hazardous serotonergic interaction)\"\n+        \"Tramadol (lowers seizure threshold)\"\n-        \"Stimulants (increased cardiovascular strain)\",\n-        \"Cannabis (may intensify and prolong effects unpredictably)\",\n-        \"SSRIs (may blunt or alter effects)\",\n-        \"Alcohol (reduces therapeutic potential and increases risk of dehydration)\"\n+        \"Other psychedelics (overwhelming intensity)\",\n+        \"2-AI (serotonergic interaction)\",\n+        \"A-PVP (cardiovascular stress)\",\n+        \"Amphetamine (increased strain)\",\n+        \"Mephedrone (combined stimulation)\"\n-    \"notes\": \"Proscaline is a lesser-known mescaline analog approximately five times more potent than mescaline. The substance has minimal research into its pharmacology and toxicity. Use a precise milligram scale for accurate dosing. It is controlled in Germany, Switzerland, and the United Kingdom but remains unscheduled in the United States. Individuals with personal or family history of psychotic disorders should avoid use. Ensure adequate set and setting preparation, as with all psychedelics.\",\n+    \"notes\": \"2C-T is a lesser-known research chemical with very limited human use history and minimal scientific data on its pharmacology, metabolism, and toxicity. It is structurally similar to 2C-T-2 and 2C-T-7 and may possess MAOI properties, making it potentially more dangerous when combined with other serotonergic substances. The substance is illegal in many jurisdictions including the United States (Schedule I), United Kingdom (Class A), and Canada (Schedule III). Use accurate milligram scales for dosing, practice harm reduction, and consider having a sober trip sitter present. Individuals with personal or family histories of mental health conditions should avoid use.\",\n-      \"Visual Pattern Enhancement\",\n-      \"Color Enhancement\",\n-      \"Time Distortion\",\n-      \"Enhanced Music Appreciation\",\n+      \"Spontaneous Bodily Sensations\",\n-      \"Cognitive Euphoria\",\n-      \"Conceptual Thinking\",\n-      \"Increased Body Temperature\",\n+      \"Bodily Control Enhancement\",\n+      \"Emotion Enhancement\",\n+      \"Analysis Enhancement\",\n+      \"Time Distortion\",\n+      \"Increased Music Appreciation\",\n+      \"Colour Enhancement\",\n+      \"Visual Acuity Enhancement\",\n+      \"Drifting and Morphing\",\n-      \"Enhanced Introspection\",\n-      \"Emotional Amplification\",\n-      \"Drifting Visual Effects\"\n+      \"Vasoconstriction\"\n-      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n+      \"full_tolerance\": \"Almost immediately after ingestion\",\n-        \"All psychedelics (mescaline, LSD, psilocybin, DMT, 2C-x compounds)\"\n+        \"All psychedelics\"\n-        \"name\": \"PsychonautWiki: Proscaline\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/Proscaline\"\n+        \"name\": \"Nichols & Shulgin (1976) - Sulfur Analogs of Psychotomimetic Amines\",\n+        \"reference\": \"https://doi.org/10.1002/jps.2600651040\"\n-        \"name\": \"PiHKAL Entry #140: Proscaline (Isomer Design)\",\n-        \"reference\": \"https://isomerdesign.com/pihkal/explore/140\"\n+        \"name\": \"PiHKAL Entry #39: 2C-T\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/read.php?domain=pk&id=39\"\n-        \"name\": \"Erowid PiHKAL: Proscaline\",\n-        \"reference\": \"https://erowid.org/library/books_online/pihkal/pihkal140.shtml\"\n+        \"name\": \"PsychonautWiki: 2C-T\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/2C-T\"\n-        \"name\": \"Erowid Proscaline Experience Vault\",\n-        \"reference\": \"https://erowid.org/experiences/subs/exp_Proscaline.shtml\"\n+        \"name\": \"Erowid 2C-T-2 Basics\",\n+        \"reference\": \"https://erowid.org/chemicals/2ct2/2ct2_basics.shtml\"\n-        \"name\": \"Bluelight: Proscaline Discussion\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/proscaline-new-experience-shiny-happy-people.522598/\"\n-      },\n-      {\n-        \"name\": \"Nichols and Dyer (1977) - Journal of Medicinal Chemistry\",\n-        \"reference\": \"https://doi.org/10.1021/jm00212a022\"\n+        \"name\": \"Gallardo-Godoy et al. (2005) - Sulfur-Substituted MAO-A Inhibitors\",\n+        \"reference\": \"https://doi.org/10.1021/jm0493109\"\n-      \"research-chemical\"\n+      \"research-chemical\",\n+      \"2c-x\"\n-  \"id\": 648\n+  \"id\": 649\n\n# 2,5-DMA · #650\n\n-  \"title\": \"2C-T\",\n-  \"index-category\": \"psychedelic; research-chemical\",\n+  \"title\": \"2,5-DMA\",\n+  \"index-category\": \"stimulant; research-chemical\",\n-    \"drug_name\": \"2C-T\",\n-    \"chemical_name\": \"2,5-Dimethoxy-4-methylthiophenethylamine\",\n-    \"alternative_name\": \"Tesseract\",\n-    \"chemical_class\": \"Phenethylamines\",\n-    \"psychoactive_class\": \"Psychedelic\",\n-    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; potential MAOI properties\",\n+    \"drug_name\": \"2,5-DMA\",\n+    \"chemical_name\": \"1-(2,5-Dimethoxyphenyl)propan-2-amine\",\n+    \"alternative_name\": \"2,5-Dimethoxyamphetamine; DMA; DOH\",\n+    \"chemical_class\": \"Amphetamines; Phenethylamines\",\n+    \"psychoactive_class\": \"Stimulant; Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist (low potency); does not bind to monoamine transporters\",\n-            \"threshold\": \"20 mg\",\n-            \"light\": \"40-60 mg\",\n-            \"common\": \"60-100 mg\",\n-            \"strong\": \"100-120 mg\",\n-            \"heavy\": \"125+ mg\"\n+            \"threshold\": \"10 mg\",\n+            \"light\": \"10-40 mg\",\n+            \"common\": \"40-80 mg\",\n+            \"strong\": \"80-200 mg\",\n+            \"heavy\": \"200+ mg\"\n-            \"total_duration\": \"3-6 hours\",\n-            \"onset\": \"30-45 minutes\",\n-            \"peak\": \"30-115 minutes\",\n-            \"offset\": \"1-2 hours\",\n-            \"after_effects\": \"1-2 hours\"\n+            \"total_duration\": \"6-8 hours\"\n-    \"addiction_potential\": \"2C-T is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating with no significant dependence or abuse potential reported.\",\n+    \"addiction_potential\": \"2,5-DMA is not considered habit-forming and likely has low psychological dependence potential. However, its stimulating properties may present some risk of compulsive use similar to other stimulants. No formal studies have been conducted on addiction potential.\",\n-        \"MAOIs (potential serotonin syndrome or neurotransmitter overload)\",\n-        \"Stimulants (increased neurotransmitter release)\",\n-        \"5-MeO-MiPT (serotonergic overload)\",\n-        \"2C-T-7 (serotonergic overload)\",\n-        \"AMT (MAOI properties)\",\n-        \"Cocaine (cardiovascular stress)\",\n-        \"Methamphetamine (neurotoxicity risk)\",\n-        \"MDMA (serotonin syndrome risk)\"\n+        \"Lithium (significantly increases risk of psychosis and seizures)\"\n-        \"Tramadol (lowers seizure threshold)\"\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Cannabis (unpredictable synergy, increased risk of anxiety and psychosis)\"\n-        \"Other psychedelics (overwhelming intensity)\",\n-        \"2-AI (serotonergic interaction)\",\n-        \"A-PVP (cardiovascular stress)\",\n-        \"Amphetamine (increased strain)\",\n-        \"Mephedrone (combined stimulation)\"\n+        \"Stimulants (increased anxiety, paranoia, and cardiovascular risk)\",\n+        \"Other psychedelics (may intensify effects unpredictably)\"\n-    \"notes\": \"2C-T is a lesser-known research chemical with very limited human use history and minimal scientific data on its pharmacology, metabolism, and toxicity. It is structurally similar to 2C-T-2 and 2C-T-7 and may possess MAOI properties, making it potentially more dangerous when combined with other serotonergic substances. The substance is illegal in many jurisdictions including the United States (Schedule I), United Kingdom (Class A), and Canada (Schedule III). Use accurate milligram scales for dosing, practice harm reduction, and consider having a sober trip sitter present. Individuals with personal or family histories of mental health conditions should avoid use.\",\n+    \"notes\": \"2,5-DMA is a research chemical and the simplest member of the DOx family, primarily known as a precursor in synthesizing other psychedelic amphetamines rather than for its own psychoactive effects. Unlike typical psychedelics, it produces primarily stimulant and physical effects with minimal to no sensory or perceptual changes. Very little data exists about its pharmacology, metabolism, and toxicity. Use accurate weighing equipment and start with lower doses due to individual variability. Those with personal or family history of mental health disorders should avoid use.\",\n-      \"Spontaneous Bodily Sensations\",\n-      \"Tactile Enhancement\",\n-      \"Bodily Control Enhancement\",\n-      \"Emotion Enhancement\",\n-      \"Analysis Enhancement\",\n-      \"Time Distortion\",\n-      \"Increased Music Appreciation\",\n-      \"Colour Enhancement\",\n-      \"Visual Acuity Enhancement\",\n-      \"Drifting and Morphing\",\n-      \"Nausea\",\n-      \"Vasoconstriction\"\n+      \"Physical Stimulation\",\n+      \"Increased Heart Rate\",\n+      \"Increased Blood Pressure\",\n+      \"Pupil Dilation\",\n+      \"Muscle Tension\",\n+      \"Tremors\",\n+      \"Body Load\",\n+      \"Enhanced Interest In Surroundings\",\n+      \"Cardiovascular Stimulation\",\n+      \"Temperature Regulation Suppression\",\n+      \"Increased Perspiration\"\n-      \"full_tolerance\": \"Almost immediately after ingestion\",\n-      \"half_tolerance\": \"3 days\",\n-      \"zero_tolerance\": \"7 days\",\n+      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n+      \"half_tolerance\": \"3-5 days\",\n+      \"zero_tolerance\": \"7-10 days\",\n-        \"All psychedelics\"\n+        \"Psychedelics (unlikely but possible)\",\n+        \"Stimulants\"\n-        \"name\": \"Nichols & Shulgin (1976) - Sulfur Analogs of Psychotomimetic Amines\",\n-        \"reference\": \"https://doi.org/10.1002/jps.2600651040\"\n+        \"name\": \"Baltzly & Buck, 1940 - Original Synthesis\",\n+        \"reference\": \"https://doi.org/10.1021/ja01858a046\"\n-        \"name\": \"PiHKAL Entry #39: 2C-T\",\n-        \"reference\": \"https://isomerdesign.com/PiHKAL/read.php?domain=pk&id=39\"\n+        \"name\": \"Erowid PiHKAL #54: 2,5-DMA\",\n+        \"reference\": \"https://erowid.org/library/books_online/pihkal/pihkal054.shtml\"\n-        \"name\": \"PsychonautWiki: 2C-T\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/2C-T\"\n+        \"name\": \"Isomer Design PiHKAL Info: 2,5-DMA\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/read.php?id=54\"\n-        \"name\": \"Erowid 2C-T-2 Basics\",\n-        \"reference\": \"https://erowid.org/chemicals/2ct2/2ct2_basics.shtml\"\n+        \"name\": \"PsychonautWiki: 2,5-DMA\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/2,5-DMA\"\n-        \"name\": \"Gallardo-Godoy et al. (2005) - Sulfur-Substituted MAO-A Inhibitors\",\n-        \"reference\": \"https://doi.org/10.1021/jm0493109\"\n+        \"name\": \"Wikipedia: 2,5-Dimethoxyamphetamine\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/2,5-Dimethoxyamphetamine\"\n-      \"psychedelic\",\n+      \"amphetamine\",\n-      \"2c-x\"\n+      \"stimulant\"\n-  \"id\": 649\n+  \"id\": 650\n\n# DOI · #651\n\n-  \"title\": \"2,5-DMA\",\n-  \"index-category\": \"stimulant; research-chemical\",\n+  \"title\": \"DOI\",\n+  \"index-category\": \"psychedelic\",\n-    \"drug_name\": \"2,5-DMA\",\n-    \"chemical_name\": \"1-(2,5-Dimethoxyphenyl)propan-2-amine\",\n-    \"alternative_name\": \"2,5-Dimethoxyamphetamine; DMA; DOH\",\n-    \"chemical_class\": \"Amphetamines; Phenethylamines\",\n-    \"psychoactive_class\": \"Stimulant; Psychedelic\",\n-    \"mechanism_of_action\": \"5-HT2A receptor partial agonist (low potency); does not bind to monoamine transporters\",\n+    \"drug_name\": \"DOI\",\n+    \"chemical_name\": \"2,5-Dimethoxy-4-iodoamphetamine\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist; 5-HT2B receptor agonist; 5-HT2C receptor agonist\",\n-            \"threshold\": \"10 mg\",\n-            \"light\": \"10-40 mg\",\n-            \"common\": \"40-80 mg\",\n-            \"strong\": \"80-200 mg\",\n-            \"heavy\": \"200+ mg\"\n+            \"threshold\": \"0.5 mg\",\n+            \"light\": \"0.5-1 mg\",\n+            \"common\": \"1-2 mg\",\n+            \"strong\": \"2-3 mg\",\n+            \"heavy\": \"3+ mg\"\n-            \"total_duration\": \"6-8 hours\"\n+            \"total_duration\": \"16-24 hours\",\n+            \"onset\": \"1-2 hours\",\n+            \"peak\": \"3-6 hours (come up 1.5-3 hours)\",\n+            \"offset\": \"6-12 hours\",\n+            \"after_effects\": \"24-48 hours (residual stimulation)\"\n-    \"addiction_potential\": \"2,5-DMA is not considered habit-forming and likely has low psychological dependence potential. However, its stimulating properties may present some risk of compulsive use similar to other stimulants. No formal studies have been conducted on addiction potential.\",\n+    \"addiction_potential\": \"DOI is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating. There is no evidence of physical dependence or compulsive redosing patterns.\",\n-        \"Lithium (significantly increases risk of psychosis and seizures)\"\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n-        \"Tramadol (lowers seizure threshold)\",\n-        \"Cannabis (unpredictable synergy, increased risk of anxiety and psychosis)\"\n+        \"Stimulants such as amphetamine, cocaine, or methylphenidate (increased risk of anxiety, paranoia, thought loops, and psychosis)\",\n+        \"MAOIs (potential for unpredictable interactions)\"\n-        \"Stimulants (increased anxiety, paranoia, and cardiovascular risk)\",\n-        \"Other psychedelics (may intensify effects unpredictably)\"\n+        \"Cannabis (unexpectedly strong and unpredictable synergy; significant increase in anxiety, paranoia, and psychosis risk)\",\n+        \"5-MeO tryptamines (unpredictable interactions with increased physical side effects)\",\n+        \"MDMA (combined stimulating effects can be uncomfortable and anxiogenic during comedown)\",\n+        \"Caffeine (may cause anxiety and physical discomfort)\",\n+        \"Amphetamines (uncomfortable body load and thought loops)\",\n+        \"Cocaine (uncomfortable body load and thought loops)\",\n+        \"Ketamine (potentiation; go slowly)\",\n+        \"Alcohol (reduced sedative effects lead to excessive drinking)\"\n-    \"notes\": \"2,5-DMA is a research chemical and the simplest member of the DOx family, primarily known as a precursor in synthesizing other psychedelic amphetamines rather than for its own psychoactive effects. Unlike typical psychedelics, it produces primarily stimulant and physical effects with minimal to no sensory or perceptual changes. Very little data exists about its pharmacology, metabolism, and toxicity. Use accurate weighing equipment and start with lower doses due to individual variability. Those with personal or family history of mental health disorders should avoid use.\",\n+    \"notes\": \"DOI is an extremely potent and long-lasting psychedelic with a very sensitive dose-response curve. It is sometimes sold falsely as LSD, which can be dangerous due to differing safety profiles and dosage ranges. Use a precise milligram scale for accurate dosing. The exceptionally long duration of 16-24 hours with residual stimulation lasting up to 48 hours requires adequate time preparation. Individuals with personal or family history of psychotic disorders should avoid use. Start with the lowest possible dose due to high individual variability in response.\",\n-      \"Physical Stimulation\",\n-      \"Increased Heart Rate\",\n-      \"Increased Blood Pressure\",\n-      \"Pupil Dilation\",\n-      \"Muscle Tension\",\n-      \"Tremors\",\n-      \"Body Load\",\n-      \"Enhanced Interest In Surroundings\",\n-      \"Cardiovascular Stimulation\",\n-      \"Temperature Regulation Suppression\",\n-      \"Increased Perspiration\"\n+      \"Extreme Stimulation\",\n+      \"Visual Patterning And Geometry\",\n+      \"Colour Enhancement\",\n+      \"Energetic Body High\",\n+      \"Thought Acceleration\",\n+      \"Enhanced Tactile Sensation\",\n+      \"Internal And External Hallucinations\",\n+      \"Time Distortion\",\n+      \"Emotional Amplification\",\n+      \"Enhanced Music Appreciation\",\n+      \"Nausea\",\n+      \"Muscle Tension And Vasoconstriction\",\n+      \"Increased Body Temperature\",\n+      \"Pupil Dilation\"\n-      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n-      \"half_tolerance\": \"3-5 days\",\n-      \"zero_tolerance\": \"7-10 days\",\n+      \"full_tolerance\": \"Immediately after ingestion\",\n+      \"half_tolerance\": \"5-7 days\",\n+      \"zero_tolerance\": \"10-14 days\",\n-        \"Psychedelics (unlikely but possible)\",\n-        \"Stimulants\"\n+        \"All psychedelics (LSD, psilocybin, mescaline, 2C-x, DOx compounds)\"\n-    \"half_life\": \"\",\n+    \"half_life\": \"Unknown; estimated duration of primary effects 16-24 hours with residual effects up to 48 hours\",\n-        \"name\": \"Baltzly & Buck, 1940 - Original Synthesis\",\n-        \"reference\": \"https://doi.org/10.1021/ja01858a046\"\n+        \"name\": \"Coutts & Malicky 1973 - Synthesis of DOI Analogs\",\n+        \"reference\": \"https://doi.org/10.1139/v73-210\"\n-        \"name\": \"Erowid PiHKAL #54: 2,5-DMA\",\n-        \"reference\": \"https://erowid.org/library/books_online/pihkal/pihkal054.shtml\"\n+        \"name\": \"PsychonautWiki DOI Profile\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/DOI\"\n-        \"name\": \"Isomer Design PiHKAL Info: 2,5-DMA\",\n-        \"reference\": \"https://isomerdesign.com/PiHKAL/read.php?id=54\"\n+        \"name\": \"TripSit DOI Factsheet\",\n+        \"reference\": \"https://drugs.tripsit.me/DOI\"\n-        \"name\": \"PsychonautWiki: 2,5-DMA\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/2,5-DMA\"\n+        \"name\": \"Erowid DOI Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/doi/doi.shtml\"\n-        \"name\": \"Wikipedia: 2,5-Dimethoxyamphetamine\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/2,5-Dimethoxyamphetamine\"\n+        \"name\": \"PiHKAL Entry #67 - DOI (Isomer Design)\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/read.php?id=67\"\n+      },\n+      {\n+        \"name\": \"Shulgin & Shulgin - PiHKAL: A Chemical Love Story\",\n+        \"reference\": \"Transform Press, 1991\"\n+      },\n+      {\n+        \"name\": \"Bluelight DOI Discussion Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-doi-thread.216778/\"\n-      \"amphetamine\",\n-      \"phenethylamine\",\n-      \"research-chemical\",\n-      \"stimulant\"\n+      \"psychedelic\",\n+      \"stimulant\",\n+      \"substituted-amphetamine\",\n+      \"research-chemical\"\n-  \"id\": 650\n+  \"id\": 651\n\n# 25C-NBOH · #652\n\n-  \"title\": \"DOI\",\n+  \"title\": \"25C-NBOH\",\n-    \"drug_name\": \"DOI\",\n-    \"chemical_name\": \"2,5-Dimethoxy-4-iodoamphetamine\",\n-    \"alternative_name\": \"\",\n-    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"drug_name\": \"25C-NBOH\",\n+    \"chemical_name\": \"2-(4-Chloro-2,5-dimethoxyphenyl)-N-[(2-hydroxyphenyl)methyl]ethanamine\",\n+    \"alternative_name\": \"2C-C-NBOH; NBOH-2C-C; N-bomb; NBOH\",\n+    \"chemical_class\": \"N-benzylated phenethylamines\",\n-    \"mechanism_of_action\": \"5-HT2A receptor agonist; 5-HT2B receptor agonist; 5-HT2C receptor agonist\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist (potent, pEC50 9.43); 5-HT2C receptor agonist (pKi 7.8)\",\n-          \"route\": \"oral\",\n-          \"units\": \"mg\",\n+          \"route\": \"sublingual\",\n+          \"units\": \"ug\",\n-            \"threshold\": \"0.5 mg\",\n-            \"light\": \"0.5-1 mg\",\n-            \"common\": \"1-2 mg\",\n-            \"strong\": \"2-3 mg\",\n-            \"heavy\": \"3+ mg\"\n+            \"threshold\": \"100 ug\",\n+            \"light\": \"250-500 ug\",\n+            \"common\": \"500-750 ug\",\n+            \"strong\": \"750-1000 ug\",\n+            \"heavy\": \"1000+ ug (potentially fatal)\"\n-          \"route\": \"oral\",\n+          \"route\": \"sublingual\",\n-            \"total_duration\": \"16-24 hours\",\n-            \"onset\": \"1-2 hours\",\n-            \"peak\": \"3-6 hours (come up 1.5-3 hours)\",\n-            \"offset\": \"6-12 hours\",\n-            \"after_effects\": \"24-48 hours (residual stimulation)\"\n+            \"total_duration\": \"5-7 hours\",\n+            \"onset\": \"15-45 minutes\",\n+            \"peak\": \"90-180 minutes (come up 30-90 minutes)\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"3-6 days (afterglow may persist)\"\n-    \"addiction_potential\": \"DOI is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating. There is no evidence of physical dependence or compulsive redosing patterns.\",\n+    \"addiction_potential\": \"25C-NBOH is not considered habit-forming and the desire to use it typically decreases with repeated use. The substance is generally self-regulating, though research on its addiction potential is extremely limited.\",\n-        \"Tramadol (lowers seizure threshold)\"\n+        \"MAOIs (potentially dangerous interaction)\"\n-        \"Stimulants such as amphetamine, cocaine, or methylphenidate (increased risk of anxiety, paranoia, thought loops, and psychosis)\",\n-        \"MAOIs (potential for unpredictable interactions)\"\n+        \"Stimulants (increased risk of anxiety, paranoia, panic attacks, thought loops, mania, and psychosis)\",\n+        \"Tramadol (lowers seizure threshold)\"\n-        \"Cannabis (unexpectedly strong and unpredictable synergy; significant increase in anxiety, paranoia, and psychosis risk)\",\n-        \"5-MeO tryptamines (unpredictable interactions with increased physical side effects)\",\n-        \"MDMA (combined stimulating effects can be uncomfortable and anxiogenic during comedown)\",\n-        \"Caffeine (may cause anxiety and physical discomfort)\",\n-        \"Amphetamines (uncomfortable body load and thought loops)\",\n-        \"Cocaine (uncomfortable body load and thought loops)\",\n-        \"Ketamine (potentiation; go slowly)\",\n-        \"Alcohol (reduced sedative effects lead to excessive drinking)\"\n+        \"Cannabis (unpredictably strong synergy, significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n-    \"notes\": \"DOI is an extremely potent and long-lasting psychedelic with a very sensitive dose-response curve. It is sometimes sold falsely as LSD, which can be dangerous due to differing safety profiles and dosage ranges. Use a precise milligram scale for accurate dosing. The exceptionally long duration of 16-24 hours with residual stimulation lasting up to 48 hours requires adequate time preparation. Individuals with personal or family history of psychotic disorders should avoid use. Start with the lowest possible dose due to high individual variability in response.\",\n+    \"notes\": \"25C-NBOH is a novel research chemical with extremely limited human use history and assumed similar toxicity to 25C-NBOMe, which has been linked to multiple deaths. This substance must NEVER be insufflated (snorted) due to high risk of fatal overdose. Compounds of the NBOH family are NOT orally active and must be administered sublingually, holding in the mouth for 15-25 minutes. Use an accurate microgram scale for all dosing. The substance exhibits dose-independent intensity and unpredictable effects even at seemingly identical doses. Start with threshold doses and avoid combinations. Heavy doses may be fatal. Individuals with personal or family history of psychotic disorders should avoid use. This substance is controlled in many jurisdictions.\",\n-      \"Extreme Stimulation\",\n-      \"Visual Patterning And Geometry\",\n-      \"Colour Enhancement\",\n-      \"Energetic Body High\",\n-      \"Thought Acceleration\",\n-      \"Enhanced Tactile Sensation\",\n-      \"Internal And External Hallucinations\",\n+      \"Intense Visual Patterning And Geometry\",\n+      \"Strong Physical Stimulation\",\n+      \"Perception Of Bodily Lightness\",\n+      \"Color Enhancement\",\n-      \"Emotional Amplification\",\n-      \"Enhanced Music Appreciation\",\n-      \"Nausea\",\n-      \"Muscle Tension And Vasoconstriction\",\n-      \"Increased Body Temperature\",\n-      \"Pupil Dilation\"\n+      \"Spontaneous Euphoric Tingling Sensations\",\n+      \"Enhanced Pattern Recognition\",\n+      \"Mouth And Tongue Numbing\",\n+      \"Nausea (Typically During Come-Up)\",\n+      \"Anxiety And Paranoia (More Common Than Classical Psychedelics)\",\n+      \"Mild Cognitive Effects (Notably Light Headspace)\",\n+      \"Increased Sociability And Empathy (Inconsistent)\",\n+      \"Enhanced Music Appreciation\"\n-      \"full_tolerance\": \"Immediately after ingestion\",\n-      \"half_tolerance\": \"5-7 days\",\n-      \"zero_tolerance\": \"10-14 days\",\n+      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n+      \"half_tolerance\": \"Approximately 1 week\",\n+      \"zero_tolerance\": \"2 weeks\",\n-        \"All psychedelics (LSD, psilocybin, mescaline, 2C-x, DOx compounds)\"\n+        \"All psychedelics (LSD, psilocybin, mescaline, DMT, 2C-x series, NBOMe series)\"\n-    \"half_life\": \"Unknown; estimated duration of primary effects 16-24 hours with residual effects up to 48 hours\",\n+    \"half_life\": \"\",\n-        \"name\": \"Coutts & Malicky 1973 - Synthesis of DOI Analogs\",\n-        \"reference\": \"https://doi.org/10.1139/v73-210\"\n+        \"name\": \"Bluelight: The Big & Dandy 25C-NBOH Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-25c-nboh-thread.621629/\"\n-        \"name\": \"PsychonautWiki DOI Profile\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/DOI\"\n+        \"name\": \"Erowid 25C-NBOH Experience Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_25CNBOH.shtml\"\n-        \"name\": \"TripSit DOI Factsheet\",\n-        \"reference\": \"https://drugs.tripsit.me/DOI\"\n+        \"name\": \"Hansen, M. (2012). Design and Synthesis of Selective Serotonin Receptor Agonists for PET Imaging\",\n+        \"reference\": \"https://www.researchgate.net/publication/266388124\"\n-        \"name\": \"Erowid DOI Vault\",\n-        \"reference\": \"https://www.erowid.org/chemicals/doi/doi.shtml\"\n+        \"name\": \"Hansen et al. (2014). Synthesis and Structure-Activity Relationships of N-Benzyl Phenethylamines as 5-HT2A/2C Agonists\",\n+        \"reference\": \"https://doi.org/10.1021/cn400216u\"\n-        \"name\": \"PiHKAL Entry #67 - DOI (Isomer Design)\",\n-        \"reference\": \"https://isomerdesign.com/PiHKAL/read.php?id=67\"\n+        \"name\": \"Isomer Design: 25C-NBOH\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=1252\"\n-        \"name\": \"Shulgin & Shulgin - PiHKAL: A Chemical Love Story\",\n-        \"reference\": \"Transform Press, 1991\"\n+        \"name\": \"PsychonautWiki: 25C-NBOH\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/25C-NBOH\"\n-        \"name\": \"Bluelight DOI Discussion Thread\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-doi-thread.216778/\"\n+        \"name\": \"Silva et al. (2011). Theoretical Studies on the Interaction of Partial Agonists with the 5-HT2A Receptor\",\n+        \"reference\": \"https://doi.org/10.1007/s10822-010-9400-2\"\n-      \"stimulant\",\n-      \"substituted-amphetamine\",\n-  \"id\": 651\n+  \"id\": 652\n\n# 25D-NBOMe · #653\n\n-  \"title\": \"25C-NBOH\",\n+  \"title\": \"25D-NBOMe\",\n-    \"drug_name\": \"25C-NBOH\",\n-    \"chemical_name\": \"2-(4-Chloro-2,5-dimethoxyphenyl)-N-[(2-hydroxyphenyl)methyl]ethanamine\",\n-    \"alternative_name\": \"2C-C-NBOH; NBOH-2C-C; N-bomb; NBOH\",\n+    \"drug_name\": \"25D-NBOMe\",\n+    \"chemical_name\": \"2-(2,5-Dimethoxy-4-methylphenyl)-N-(2-methoxybenzyl)ethanamine\",\n+    \"alternative_name\": \"2C-D-NBOMe; NBOMe-2C-D; Divination; N-Bomb\",\n-    \"mechanism_of_action\": \"5-HT2A receptor agonist (potent, pEC50 9.43); 5-HT2C receptor agonist (pKi 7.8)\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist (partial); 5-HT2B receptor agonist; 5-HT2C receptor agonist; adrenergic alpha-1 receptor agonist\",\n-            \"threshold\": \"100 ug\",\n-            \"light\": \"250-500 ug\",\n-            \"common\": \"500-750 ug\",\n-            \"strong\": \"750-1000 ug\",\n-            \"heavy\": \"1000+ ug (potentially fatal)\"\n+            \"threshold\": \"300 ug\",\n+            \"light\": \"300-800 ug\",\n+            \"common\": \"800-1000 ug\",\n+            \"strong\": \"1000-1200 ug\",\n+            \"heavy\": \"1200+ ug\"\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"200 ug\",\n+            \"light\": \"200-600 ug\",\n+            \"common\": \"600-800 ug\",\n+            \"strong\": \"800-1000 ug\",\n+            \"heavy\": \"1000+ ug\"\n+          }\n-            \"total_duration\": \"5-7 hours\",\n-            \"onset\": \"15-45 minutes\",\n-            \"peak\": \"90-180 minutes (come up 30-90 minutes)\",\n-            \"offset\": \"2-4 hours\",\n-            \"after_effects\": \"3-6 days (afterglow may persist)\"\n+            \"total_duration\": \"4-6 hours\",\n+            \"onset\": \"20-40 minutes\",\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"6+ hours\"\n-            \"oral\"\n+            \"sublingual\"\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"stages\": {\n+            \"total_duration\": \"3-5 hours\",\n+            \"onset\": \"5-15 minutes\",\n+            \"peak\": \"45-90 minutes\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"4-6 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n-    \"addiction_potential\": \"25C-NBOH is not considered habit-forming and the desire to use it typically decreases with repeated use. The substance is generally self-regulating, though research on its addiction potential is extremely limited.\",\n+    \"addiction_potential\": \"25D-NBOMe has not been formally studied for addiction potential but appears to have a self-regulating quality with immediate tolerance buildup. Rapid tolerance develops after use, lasting approximately 2-3 weeks. Animal studies have shown reinforcing effects including conditioned place preference and self-administration behavior, suggesting some potential for psychological reinforcement.\",\n-        \"Lithium (significantly increases risk of psychosis and seizures)\",\n-        \"MAOIs (potentially dangerous interaction)\"\n+        \"Lithium (significantly increased seizure risk)\",\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"MAOIs (hypertensive crisis risk, unpredictable potentiation)\",\n+        \"Amphetamines (severe cardiovascular stress, tachycardia, hypertension, potential heart failure)\",\n+        \"Cocaine (severe vasoconstriction, tachycardia, hypertension, potential heart failure)\"\n-        \"Stimulants (increased risk of anxiety, paranoia, panic attacks, thought loops, mania, and psychosis)\",\n-        \"Tramadol (lowers seizure threshold)\"\n+        \"2C-T-X compounds (unpredictable interactions)\",\n+        \"5-MeO-xxt compounds (unpredictable interactions)\",\n+        \"aMT (unpredictable cardiovascular effects)\",\n+        \"DOx compounds (prolonged stimulation, cardiovascular strain)\",\n+        \"DXM (unpredictable effects)\",\n+        \"MDMA (cardiovascular strain, hyperthermia risk)\",\n+        \"MXE (potentiation of NBOMe effects)\"\n-        \"Cannabis (unpredictably strong synergy, significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n+        \"Cannabis (significantly increases anxiety, paranoia, and unpredictable psychological effects)\",\n+        \"Caffeine (increases uncomfortable stimulation and anxiety)\",\n+        \"SSRIs (may blunt or prolong effects)\"\n-    \"notes\": \"25C-NBOH is a novel research chemical with extremely limited human use history and assumed similar toxicity to 25C-NBOMe, which has been linked to multiple deaths. This substance must NEVER be insufflated (snorted) due to high risk of fatal overdose. Compounds of the NBOH family are NOT orally active and must be administered sublingually, holding in the mouth for 15-25 minutes. Use an accurate microgram scale for all dosing. The substance exhibits dose-independent intensity and unpredictable effects even at seemingly identical doses. Start with threshold doses and avoid combinations. Heavy doses may be fatal. Individuals with personal or family history of psychotic disorders should avoid use. This substance is controlled in many jurisdictions.\",\n+    \"notes\": \"25D-NBOMe is a highly potent research chemical with an extremely narrow margin between active and potentially lethal doses. The compound is not orally active and must be administered sublingually or via other mucosal routes. Never insufflate NBOMe compounds as this route has been associated with numerous fatalities. Blotter paper doses are notoriously inconsistent due to hotspots of concentrated material. Use only with an analytical balance for weighing, never eyeball doses. Those with personal or family history of psychotic disorders, cardiovascular conditions, or seizure disorders should avoid this substance entirely. The compound produces dose-dependent vasoconstriction and cardiovascular strain. Set and setting are critical; always have a sober trip sitter present. Many deaths have occurred from individuals believing they consumed LSD when they actually ingested an NBOMe compound.\",\n-      \"Intense Visual Patterning And Geometry\",\n-      \"Strong Physical Stimulation\",\n-      \"Perception Of Bodily Lightness\",\n+      \"Visual Acuity Enhancement\",\n+      \"Visual Geometry\",\n+      \"Tracers and After Images\",\n+      \"Physical Euphoria\",\n+      \"Stimulation\",\n+      \"Tactile Hallucination\",\n-      \"Spontaneous Euphoric Tingling Sensations\",\n-      \"Enhanced Pattern Recognition\",\n-      \"Mouth And Tongue Numbing\",\n-      \"Nausea (Typically During Come-Up)\",\n-      \"Anxiety And Paranoia (More Common Than Classical Psychedelics)\",\n-      \"Mild Cognitive Effects (Notably Light Headspace)\",\n-      \"Increased Sociability And Empathy (Inconsistent)\",\n-      \"Enhanced Music Appreciation\"\n+      \"Mouth and Tongue Numbness\",\n+      \"Metallic Chemical Taste\",\n+      \"Spontaneous Bodily Sensations\",\n+      \"Thought Acceleration\",\n+      \"Music Appreciation Enhancement\",\n+      \"Emotional Amplification\",\n+      \"Nausea\",\n+      \"Vasoconstriction\",\n+      \"Increased Heart Rate\",\n+      \"Increased Blood Pressure\",\n+      \"Temperature Regulation Suppression\",\n+      \"Muscle Tension and Cramps\",\n+      \"Headaches\",\n+      \"Anxiety and Paranoia\"\n-      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n+      \"full_tolerance\": \"Develops immediately after use\",\n-      \"zero_tolerance\": \"2 weeks\",\n+      \"zero_tolerance\": \"2-3 weeks\",\n-        \"All psychedelics (LSD, psilocybin, mescaline, DMT, 2C-x series, NBOMe series)\"\n+        \"All psychedelics\",\n+        \"Other NBOMe compounds\",\n+        \"2C-x series\"\n-    \"half_life\": \"\",\n+    \"half_life\": \"1-3 hours (parent compound rapidly cleared from blood)\",\n-        \"name\": \"Bluelight: The Big & Dandy 25C-NBOH Thread\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-25c-nboh-thread.621629/\"\n+        \"name\": \"Alcohol and Drug Foundation: NBOMes\",\n+        \"reference\": \"https://adf.org.au/drug-facts/nbomes/\"\n-        \"name\": \"Erowid 25C-NBOH Experience Vault\",\n-        \"reference\": \"https://erowid.org/experiences/subs/exp_25CNBOH.shtml\"\n+        \"name\": \"Erowid 25D-NBOMe Experience Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_25DNBOMe.shtml\"\n-        \"name\": \"Hansen, M. (2012). Design and Synthesis of Selective Serotonin Receptor Agonists for PET Imaging\",\n-        \"reference\": \"https://www.researchgate.net/publication/266388124\"\n+        \"name\": \"Erowid NBOMe Series Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/nbome/\"\n-        \"name\": \"Hansen et al. (2014). Synthesis and Structure-Activity Relationships of N-Benzyl Phenethylamines as 5-HT2A/2C Agonists\",\n-        \"reference\": \"https://doi.org/10.1021/cn400216u\"\n+        \"name\": \"Frontiers in Neuroscience: NBOMes - Highly Potent and Toxic Alternatives of LSD\",\n+        \"reference\": \"https://www.frontiersin.org/articles/10.3389/fnins.2020.00078/full\"\n-        \"name\": \"Isomer Design: 25C-NBOH\",\n-        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=1252\"\n+        \"name\": \"Isomer Design: 25D-NBOMe\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=342\"\n-        \"name\": \"PsychonautWiki: 25C-NBOH\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/25C-NBOH\"\n+        \"name\": \"PsychonautWiki: 25D-NBOMe\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/25D-NBOMe\"\n-        \"name\": \"Silva et al. (2011). Theoretical Studies on the Interaction of Partial Agonists with the 5-HT2A Receptor\",\n-        \"reference\": \"https://doi.org/10.1007/s10822-010-9400-2\"\n+        \"name\": \"Wikipedia: 25D-NBOMe\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/25D-NBOMe\"\n+      },\n+      {\n+        \"name\": \"Yoon et al. (2019): Cardiac Effects of 25D-NBOMe and 25C-NBOMe\",\n+        \"reference\": \"https://doi.org/10.1016/j.toxlet.2019.01.004\"\n-  \"id\": 652\n+  \"id\": 653\n\n# 25N-NBOMe · #654\n\n-  \"title\": \"25D-NBOMe\",\n+  \"title\": \"25N-NBOMe\",\n-    \"drug_name\": \"25D-NBOMe\",\n-    \"chemical_name\": \"2-(2,5-Dimethoxy-4-methylphenyl)-N-(2-methoxybenzyl)ethanamine\",\n-    \"alternative_name\": \"2C-D-NBOMe; NBOMe-2C-D; Divination; N-Bomb\",\n+    \"drug_name\": \"25N-NBOMe\",\n+    \"chemical_name\": \"2-(2,5-dimethoxy-4-nitrophenyl)-N-(2-methoxybenzyl)ethanamine\",\n+    \"alternative_name\": \"2C-N-NBOMe; NBOMe-2C-N; N-Bomb\",\n-    \"mechanism_of_action\": \"5-HT2A receptor agonist (partial); 5-HT2B receptor agonist; 5-HT2C receptor agonist; adrenergic alpha-1 receptor agonist\",\n+    \"mechanism_of_action\": \"5-HT2A receptor full agonist; 5-HT2C receptor full agonist; 5-HT2B receptor partial agonist; dopamine transporter phosphorylation (increases extracellular dopamine)\",\n-            \"threshold\": \"300 ug\",\n-            \"light\": \"300-800 ug\",\n-            \"common\": \"800-1000 ug\",\n-            \"strong\": \"1000-1200 ug\",\n-            \"heavy\": \"1200+ ug\"\n+            \"threshold\": \"100 ug\",\n+            \"light\": \"100-300 ug\",\n+            \"common\": \"300-800 ug\",\n+            \"strong\": \"800-1300 ug\",\n+            \"heavy\": \"1300+ ug (potentially fatal)\"\n-            \"threshold\": \"200 ug\",\n-            \"light\": \"200-600 ug\",\n-            \"common\": \"600-800 ug\",\n-            \"strong\": \"800-1000 ug\",\n-            \"heavy\": \"1000+ ug\"\n+            \"threshold\": \"Not recommended\",\n+            \"light\": \"Not recommended\",\n+            \"common\": \"Not recommended\",\n+            \"strong\": \"Not recommended\",\n+            \"heavy\": \"Not recommended (extremely dangerous)\"\n-            \"total_duration\": \"4-6 hours\",\n-            \"onset\": \"20-40 minutes\",\n-            \"peak\": \"1-2 hours\",\n-            \"offset\": \"1-2 hours\",\n-            \"after_effects\": \"6+ hours\"\n+            \"total_duration\": \"5-10 hours\",\n+            \"onset\": \"45-75 minutes\",\n+            \"peak\": \"2-3 hours\",\n+            \"offset\": \"2-3 hours\",\n+            \"after_effects\": \"5-10 hours\"\n-            \"total_duration\": \"3-5 hours\",\n-            \"onset\": \"5-15 minutes\",\n-            \"peak\": \"45-90 minutes\",\n-            \"offset\": \"1-2 hours\",\n-            \"after_effects\": \"4-6 hours\"\n-          },\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ]\n+            \"total_duration\": \"5-10 hours\",\n+            \"onset\": \"45-75 minutes\",\n+            \"peak\": \"2-3 hours\",\n+            \"offset\": \"2-3 hours\",\n+            \"after_effects\": \"5-10 hours\"\n+          }\n-    \"addiction_potential\": \"25D-NBOMe has not been formally studied for addiction potential but appears to have a self-regulating quality with immediate tolerance buildup. Rapid tolerance develops after use, lasting approximately 2-3 weeks. Animal studies have shown reinforcing effects including conditioned place preference and self-administration behavior, suggesting some potential for psychological reinforcement.\",\n+    \"addiction_potential\": \"25N-NBOMe is not considered habit-forming and the desire to use often decreases with repeated administration. However, animal studies suggest potential dependence liability through dopaminergic pathways, with conditioned place preference effects comparable to methamphetamine in rodent models. The substance exhibits rapid tolerance development.\",\n-        \"Lithium (significantly increased seizure risk)\",\n-        \"Tramadol (lowers seizure threshold)\",\n-        \"MAOIs (hypertensive crisis risk, unpredictable potentiation)\",\n-        \"Amphetamines (severe cardiovascular stress, tachycardia, hypertension, potential heart failure)\",\n-        \"Cocaine (severe vasoconstriction, tachycardia, hypertension, potential heart failure)\"\n+        \"Lithium (significantly increases seizure risk)\",\n+        \"MAOIs (unpredictable potentiation and duration increase)\",\n+        \"Tramadol (significantly lowers seizure threshold)\"\n+        \"Amphetamines (severe cardiovascular strain, tachycardia, hypertension, and increased seizure risk)\",\n+        \"Cocaine (severe cardiovascular strain and vasoconstriction)\",\n+        \"MDMA (unpredictable intensity, reports of blackouts and severe overstimulation)\",\n+        \"MXE (unpleasantly intense potentiation)\",\n+        \"DOx compounds (unpredictable interactions)\",\n-        \"aMT (unpredictable cardiovascular effects)\",\n-        \"DOx compounds (prolonged stimulation, cardiovascular strain)\",\n-        \"DXM (unpredictable effects)\",\n-        \"MDMA (cardiovascular strain, hyperthermia risk)\",\n-        \"MXE (potentiation of NBOMe effects)\"\n+        \"aMT (increased cardiovascular risk)\"\n-        \"Cannabis (significantly increases anxiety, paranoia, and unpredictable psychological effects)\",\n-        \"Caffeine (increases uncomfortable stimulation and anxiety)\",\n-        \"SSRIs (may blunt or prolong effects)\"\n+        \"Cannabis (significantly increases anxiety, paranoia, and psychosis risk)\",\n+        \"Caffeine (uncomfortable overstimulation and anxiety)\",\n+        \"DXM (unpredictable interactions)\"\n-    \"notes\": \"25D-NBOMe is a highly potent research chemical with an extremely narrow margin between active and potentially lethal doses. The compound is not orally active and must be administered sublingually or via other mucosal routes. Never insufflate NBOMe compounds as this route has been associated with numerous fatalities. Blotter paper doses are notoriously inconsistent due to hotspots of concentrated material. Use only with an analytical balance for weighing, never eyeball doses. Those with personal or family history of psychotic disorders, cardiovascular conditions, or seizure disorders should avoid this substance entirely. The compound produces dose-dependent vasoconstriction and cardiovascular strain. Set and setting are critical; always have a sober trip sitter present. Many deaths have occurred from individuals believing they consumed LSD when they actually ingested an NBOMe compound.\",\n+    \"notes\": \"25N-NBOMe is a highly potent and unpredictable substance that has been linked to numerous hospitalizations and fatalities within the NBOMe series. The compound must only be administered sublingually, as insufflation dramatically increases overdose risk and has been implicated in multiple deaths. Blotter papers may contain uneven dose distribution with dangerous hotspots. Users should employ accurate microgram scales, avoid all drug combinations, and never exceed 1000 ug due to narrow margin between active and toxic doses. Individuals with cardiovascular conditions, seizure disorders, or personal or family history of psychotic disorders should strictly avoid use. The substance is often misrepresented as LSD; always use reagent testing.\",\n-      \"Visual Acuity Enhancement\",\n-      \"Color Enhancement\",\n-      \"Visual Geometry\",\n-      \"Tracers and After Images\",\n-      \"Physical Euphoria\",\n-      \"Stimulation\",\n-      \"Tactile Hallucination\",\n+      \"Intense Visual Patterning And Geometry\",\n+      \"Strong Physical Stimulation\",\n+      \"Perception Of Bodily Lightness\",\n+      \"Euphoric Body High\",\n+      \"Tactile Enhancement\",\n+      \"Colour Enhancement\",\n-      \"Mouth and Tongue Numbness\",\n-      \"Metallic Chemical Taste\",\n-      \"Spontaneous Bodily Sensations\",\n+      \"Empathy And Sociability Enhancement (Inconsistent)\",\n-      \"Music Appreciation Enhancement\",\n-      \"Emotional Amplification\",\n-      \"Nausea\",\n-      \"Vasoconstriction\",\n+      \"Anxiety And Paranoia\",\n+      \"Mouth Numbing\",\n-      \"Increased Blood Pressure\",\n-      \"Temperature Regulation Suppression\",\n-      \"Muscle Tension and Cramps\",\n-      \"Headaches\",\n-      \"Anxiety and Paranoia\"\n+      \"Vasoconstriction\",\n+      \"Nausea (Especially During Onset)\",\n+      \"Muscle Tension\",\n+      \"Pupil Dilation\"\n-      \"full_tolerance\": \"Develops immediately after use\",\n-      \"half_tolerance\": \"Approximately 1 week\",\n-      \"zero_tolerance\": \"2-3 weeks\",\n+      \"full_tolerance\": \"Immediately after use\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n-        \"All psychedelics\",\n-        \"Other NBOMe compounds\",\n-        \"2C-x series\"\n+        \"All psychedelics (LSD, psilocybin, mescaline, 2C-x, other NBOMes)\"\n-    \"half_life\": \"1-3 hours (parent compound rapidly cleared from blood)\",\n+    \"half_life\": \"1-3 hours (estimated from related compounds)\",\n-        \"name\": \"Alcohol and Drug Foundation: NBOMes\",\n-        \"reference\": \"https://adf.org.au/drug-facts/nbomes/\"\n+        \"name\": \"Bluelight: The Big & Dandy 25N-NBOMe Thread\",\n+        \"reference\": \"http://www.bluelight.org/vb/threads/539694-The-Big-amp-Dandy-25N-NBOMe-Thread\"\n-        \"name\": \"Erowid 25D-NBOMe Experience Vault\",\n-        \"reference\": \"https://erowid.org/experiences/subs/exp_25DNBOMe.shtml\"\n-      },\n-      {\n-        \"name\": \"Erowid NBOMe Series Vault\",\n+        \"name\": \"Erowid: NBOMe Series Vault\",\n-        \"reference\": \"https://www.frontiersin.org/articles/10.3389/fnins.2020.00078/full\"\n+        \"reference\": \"https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2020.00078/full\"\n-        \"name\": \"Isomer Design: 25D-NBOMe\",\n-        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=342\"\n+        \"name\": \"Isomer Design: 25N-NBOMe\",\n+        \"reference\": \"https://isomerdesign.com/pihkal/\"\n-        \"name\": \"PsychonautWiki: 25D-NBOMe\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/25D-NBOMe\"\n+        \"name\": \"PsychonautWiki: 25N-NBOMe\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/25N-NBOMe\"\n-        \"name\": \"Wikipedia: 25D-NBOMe\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/25D-NBOMe\"\n-      },\n-      {\n-        \"name\": \"Yoon et al. (2019): Cardiac Effects of 25D-NBOMe and 25C-NBOMe\",\n-        \"reference\": \"https://doi.org/10.1016/j.toxlet.2019.01.004\"\n+        \"name\": \"Wikipedia: 25N-NBOMe\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/25N-NBOMe\"\n-  \"id\": 653\n+  \"id\": 654\n\n# TMA-6 · #655\n\n-  \"title\": \"25N-NBOMe\",\n-  \"index-category\": \"psychedelic\",\n+  \"title\": \"TMA-6\",\n+  \"index-category\": \"psychedelic; stimulant; research-chemical\",\n-    \"drug_name\": \"25N-NBOMe\",\n-    \"chemical_name\": \"2-(2,5-dimethoxy-4-nitrophenyl)-N-(2-methoxybenzyl)ethanamine\",\n-    \"alternative_name\": \"2C-N-NBOMe; NBOMe-2C-N; N-Bomb\",\n-    \"chemical_class\": \"N-benzylated phenethylamines\",\n+    \"drug_name\": \"TMA-6\",\n+    \"chemical_name\": \"1-(2,4,6-Trimethoxyphenyl)propan-2-amine\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n-    \"mechanism_of_action\": \"5-HT2A receptor full agonist; 5-HT2C receptor full agonist; 5-HT2B receptor partial agonist; dopamine transporter phosphorylation (increases extracellular dopamine)\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; potent MAO-A inhibitor (IC50 400 nM)\",\n-          \"route\": \"sublingual\",\n-          \"units\": \"ug\",\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"100 ug\",\n-            \"light\": \"100-300 ug\",\n-            \"common\": \"300-800 ug\",\n-            \"strong\": \"800-1300 ug\",\n-            \"heavy\": \"1300+ ug (potentially fatal)\"\n+            \"threshold\": \"5-10 mg\",\n+            \"light\": \"10-20 mg\",\n+            \"common\": \"20-35 mg\",\n+            \"strong\": \"35-50 mg\",\n+            \"heavy\": \"50+ mg\"\n-          \"units\": \"ug\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"Not recommended\",\n-            \"light\": \"Not recommended\",\n-            \"common\": \"Not recommended\",\n-            \"strong\": \"Not recommended\",\n-            \"heavy\": \"Not recommended (extremely dangerous)\"\n+            \"threshold\": \"5-10 mg\",\n+            \"light\": \"10-15 mg\",\n+            \"common\": \"15-25 mg\",\n+            \"strong\": \"25-35 mg\",\n+            \"heavy\": \"35+ mg\"\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5-10 mg\",\n+            \"light\": \"10-15 mg\",\n+            \"common\": \"15-30 mg\",\n+            \"strong\": \"30-40 mg\",\n+            \"heavy\": \"40+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"vaporized\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5-10 mg\",\n+            \"light\": \"10-15 mg\",\n+            \"common\": \"15-25 mg\",\n+            \"strong\": \"25-35 mg\",\n+            \"heavy\": \"35+ mg\"\n+          }\n-          \"route\": \"sublingual\",\n+          \"route\": \"oral\",\n-            \"total_duration\": \"5-10 hours\",\n-            \"onset\": \"45-75 minutes\",\n-            \"peak\": \"2-3 hours\",\n-            \"offset\": \"2-3 hours\",\n-            \"after_effects\": \"5-10 hours\"\n+            \"total_duration\": \"10-16 hours\",\n+            \"onset\": \"30-90 minutes\",\n+            \"peak\": \"5-8 hours\",\n+            \"offset\": \"3-5 hours\",\n+            \"after_effects\": \"6-18 hours\"\n-            \"sublingual\"\n+            \"oral\"\n-            \"total_duration\": \"5-10 hours\",\n-            \"onset\": \"45-75 minutes\",\n-            \"peak\": \"2-3 hours\",\n-            \"offset\": \"2-3 hours\",\n-            \"after_effects\": \"5-10 hours\"\n-          }\n+            \"total_duration\": \"8-12 hours\",\n+            \"onset\": \"10-30 minutes\",\n+            \"peak\": \"4-6 hours\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"6-12 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"stages\": {\n+            \"total_duration\": \"8-14 hours\",\n+            \"onset\": \"10-30 minutes\",\n+            \"peak\": \"4-7 hours\",\n+            \"offset\": \"3-5 hours\",\n+            \"after_effects\": \"6-12 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"rectal\"\n+          ]\n+        },\n+        {\n+          \"route\": \"vaporized\",\n+          \"stages\": {\n+            \"total_duration\": \"6-11 hours\",\n+            \"onset\": \"5-15 minutes\",\n+            \"peak\": \"3-6 hours\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"4-12 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n-    \"addiction_potential\": \"25N-NBOMe is not considered habit-forming and the desire to use often decreases with repeated administration. However, animal studies suggest potential dependence liability through dopaminergic pathways, with conditioned place preference effects comparable to methamphetamine in rodent models. The substance exhibits rapid tolerance development.\",\n+    \"addiction_potential\": \"TMA-6 is not considered habit-forming and has a low potential for psychological dependence. The desire to use it typically decreases with consumption, and rapid tolerance development discourages frequent redosing. It is generally self-regulating.\",\n-        \"Lithium (significantly increases seizure risk)\",\n-        \"MAOIs (unpredictable potentiation and duration increase)\",\n-        \"Tramadol (significantly lowers seizure threshold)\"\n+        \"MAOIs (risk of hypertensive crisis and serotonin syndrome; TMA-6 itself is a potent MAO-A inhibitor)\",\n+        \"Lithium (elevated risk of seizures and psychosis)\",\n+        \"Tramadol (lowers seizure threshold)\"\n-        \"Amphetamines (severe cardiovascular strain, tachycardia, hypertension, and increased seizure risk)\",\n-        \"Cocaine (severe cardiovascular strain and vasoconstriction)\",\n-        \"MDMA (unpredictable intensity, reports of blackouts and severe overstimulation)\",\n-        \"MXE (unpleasantly intense potentiation)\",\n-        \"DOx compounds (unpredictable interactions)\",\n-        \"2C-T-X compounds (unpredictable interactions)\",\n-        \"5-MeO-xxt compounds (unpredictable interactions)\",\n-        \"aMT (increased cardiovascular risk)\"\n+        \"Serotonin releasers (MDMA, 4-FA, methamphetamine, methylone, aMT; risk of serotonin syndrome)\",\n+        \"Stimulants (risk of excessive anxiety, panic, thought loops, and psychosis)\"\n-        \"Cannabis (significantly increases anxiety, paranoia, and psychosis risk)\",\n-        \"Caffeine (uncomfortable overstimulation and anxiety)\",\n-        \"DXM (unpredictable interactions)\"\n+        \"SSRIs (citalopram, sertraline; risk of serotonin syndrome and altered effects)\",\n+        \"SNRIs (venlafaxine; risk of serotonin syndrome)\",\n+        \"5-HTP (risk of serotonin syndrome)\",\n+        \"Other psychedelics (risk of overwhelming intensity and unpredictable interactions)\"\n-    \"notes\": \"25N-NBOMe is a highly potent and unpredictable substance that has been linked to numerous hospitalizations and fatalities within the NBOMe series. The compound must only be administered sublingually, as insufflation dramatically increases overdose risk and has been implicated in multiple deaths. Blotter papers may contain uneven dose distribution with dangerous hotspots. Users should employ accurate microgram scales, avoid all drug combinations, and never exceed 1000 ug due to narrow margin between active and toxic doses. Individuals with cardiovascular conditions, seizure disorders, or personal or family history of psychotic disorders should strictly avoid use. The substance is often misrepresented as LSD; always use reagent testing.\",\n+    \"notes\": \"TMA-6 is a potent MAO-A inhibitor, which creates significant interaction risks and requires careful attention to dietary restrictions similar to pharmaceutical MAOIs. Individuals with personal or family histories of psychotic disorders should avoid use. The substance is highly dose-sensitive and produces unpredictable effects with considerable body load and nausea. Set and setting strongly influence the experience. Users should be prepared for an extended duration of 10-16 hours. Always use a precise scale for dosing.\",\n-      \"Intense Visual Patterning And Geometry\",\n-      \"Strong Physical Stimulation\",\n-      \"Perception Of Bodily Lightness\",\n-      \"Euphoric Body High\",\n+      \"Stimulation\",\n+      \"Spontaneous Tactile Sensations\",\n-      \"Colour Enhancement\",\n-      \"Time Distortion\",\n-      \"Empathy And Sociability Enhancement (Inconsistent)\",\n+      \"Empathy And Sociability Enhancement\",\n-      \"Anxiety And Paranoia\",\n-      \"Mouth Numbing\",\n-      \"Increased Heart Rate\",\n+      \"Conceptual Thinking Enhancement\",\n+      \"Emotion Enhancement\",\n+      \"Time Distortion\",\n+      \"Visual Acuity Enhancement\",\n+      \"Colour Enhancement\",\n+      \"Drifting\",\n+      \"Nausea\",\n-      \"Nausea (Especially During Onset)\",\n-      \"Muscle Tension\",\n-      \"Pupil Dilation\"\n+      \"Increased Libido\",\n+      \"Music Appreciation Enhancement\"\n-      \"full_tolerance\": \"Immediately after use\",\n+      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n-        \"All psychedelics (LSD, psilocybin, mescaline, 2C-x, other NBOMes)\"\n+        \"All psychedelics\",\n+        \"All stimulants\"\n-    \"half_life\": \"1-3 hours (estimated from related compounds)\",\n+    \"half_life\": \"Not well documented; estimated 3-6 hours based on related compounds\",\n-        \"name\": \"Bluelight: The Big & Dandy 25N-NBOMe Thread\",\n-        \"reference\": \"http://www.bluelight.org/vb/threads/539694-The-Big-amp-Dandy-25N-NBOMe-Thread\"\n+        \"name\": \"Erowid TMA-6 Experience Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_TMA6.shtml\"\n-        \"name\": \"Erowid: NBOMe Series Vault\",\n-        \"reference\": \"https://www.erowid.org/chemicals/nbome/\"\n+        \"name\": \"Erowid TMA-6 Comparison Information\",\n+        \"reference\": \"https://erowid.org/chemicals/tma2/tma2_info1.shtml\"\n-        \"name\": \"Frontiers in Neuroscience: NBOMes - Highly Potent and Toxic Alternatives of LSD\",\n-        \"reference\": \"https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2020.00078/full\"\n+        \"name\": \"Isomer Design PiHKAL Entry #162 TMA-6\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=162\"\n-        \"name\": \"Isomer Design: 25N-NBOMe\",\n-        \"reference\": \"https://isomerdesign.com/pihkal/\"\n+        \"name\": \"PsychonautWiki TMA-6\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/TMA-6\"\n-        \"name\": \"PsychonautWiki: 25N-NBOMe\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/25N-NBOMe\"\n+        \"name\": \"Bluelight TMA Series Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/suprise-substance-of-july-the-tma-series.384752/\"\n-        \"name\": \"Wikipedia: 25N-NBOMe\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/25N-NBOMe\"\n+        \"name\": \"Wikipedia 2,4,6-Trimethoxyamphetamine\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/2,4,6-Trimethoxyamphetamine\"\n-  \"id\": 654\n+  \"id\": 655\n\n# 4-MeO-PCP · #656\n\n-  \"title\": \"TMA-6\",\n-  \"index-category\": \"psychedelic; stimulant; research-chemical\",\n+  \"title\": \"4-MeO-PCP\",\n+  \"index-category\": \"dissociative; research-chemical\",\n-    \"drug_name\": \"TMA-6\",\n-    \"chemical_name\": \"1-(2,4,6-Trimethoxyphenyl)propan-2-amine\",\n-    \"alternative_name\": \"\",\n-    \"chemical_class\": \"Psychedelic amphetamine\",\n-    \"psychoactive_class\": \"Psychedelic\",\n-    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; potent MAO-A inhibitor (IC50 400 nM)\",\n+    \"drug_name\": \"4-MeO-PCP\",\n+    \"chemical_name\": \"1-[1-(4-Methoxyphenyl)cyclohexyl]piperidine\",\n+    \"alternative_name\": \"Methoxydine; 4-Methoxyphencyclidine; 4-Methoxy-PCP\",\n+    \"chemical_class\": \"Arylcyclohexylamine\",\n+    \"psychoactive_class\": \"Dissociative\",\n+    \"mechanism_of_action\": \"NMDA receptor antagonist (selective ligand without appreciable dopamine transporter affinity)\",\n-            \"threshold\": \"5-10 mg\",\n-            \"light\": \"10-20 mg\",\n-            \"common\": \"20-35 mg\",\n-            \"strong\": \"35-50 mg\",\n-            \"heavy\": \"50+ mg\"\n+            \"threshold\": \"25 mg\",\n+            \"light\": \"75-100 mg\",\n+            \"common\": \"100-170 mg\",\n+            \"strong\": \"170-250 mg\",\n+            \"heavy\": \"250+ mg\"\n-            \"threshold\": \"5-10 mg\",\n-            \"light\": \"10-15 mg\",\n-            \"common\": \"15-25 mg\",\n-            \"strong\": \"25-35 mg\",\n-            \"heavy\": \"35+ mg\"\n+            \"threshold\": \"15 mg\",\n+            \"light\": \"30-75 mg\",\n+            \"common\": \"75-150 mg\",\n+            \"strong\": \"150+ mg\",\n+            \"heavy\": \"\"\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"5-10 mg\",\n-            \"light\": \"10-15 mg\",\n-            \"common\": \"15-30 mg\",\n-            \"strong\": \"30-40 mg\",\n-            \"heavy\": \"40+ mg\"\n-          }\n-        },\n-        {\n-          \"route\": \"vaporized\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"5-10 mg\",\n-            \"light\": \"10-15 mg\",\n-            \"common\": \"15-25 mg\",\n-            \"strong\": \"25-35 mg\",\n-            \"heavy\": \"35+ mg\"\n-          }\n-            \"total_duration\": \"10-16 hours\",\n-            \"onset\": \"30-90 minutes\",\n-            \"peak\": \"5-8 hours\",\n-            \"offset\": \"3-5 hours\",\n-            \"after_effects\": \"6-18 hours\"\n+            \"total_duration\": \"12-20 hours\",\n+            \"onset\": \"45-120 minutes\",\n+            \"peak\": \"3-7 hours\",\n+            \"offset\": \"6-10 hours\",\n+            \"after_effects\": \"6+ hours\"\n-            \"total_duration\": \"8-12 hours\",\n-            \"onset\": \"10-30 minutes\",\n-            \"peak\": \"4-6 hours\",\n-            \"offset\": \"2-4 hours\",\n-            \"after_effects\": \"6-12 hours\"\n-          },\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ]\n-        },\n-        {\n-          \"route\": \"rectal\",\n-          \"stages\": {\n-            \"total_duration\": \"8-14 hours\",\n-            \"onset\": \"10-30 minutes\",\n-            \"peak\": \"4-7 hours\",\n-            \"offset\": \"3-5 hours\",\n-            \"after_effects\": \"6-12 hours\"\n-          },\n-          \"canonical_routes\": [\n-            \"rectal\"\n-          ]\n-        },\n-        {\n-          \"route\": \"vaporized\",\n-          \"stages\": {\n-            \"total_duration\": \"6-11 hours\",\n+            \"total_duration\": \"12-18 hours\",\n-            \"offset\": \"2-4 hours\",\n-            \"after_effects\": \"4-12 hours\"\n+            \"offset\": \"3 hours\",\n+            \"after_effects\": \"3 hours\"\n-            \"smoked\"\n+            \"insufflated\"\n-    \"addiction_potential\": \"TMA-6 is not considered habit-forming and has a low potential for psychological dependence. The desire to use it typically decreases with consumption, and rapid tolerance development discourages frequent redosing. It is generally self-regulating.\",\n+    \"addiction_potential\": \"As with other NMDA receptor antagonists, the chronic use of 4-MeO-PCP can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage. The long duration may discourage frequent redosing compared to shorter-acting dissociatives.\",\n-        \"MAOIs (risk of hypertensive crisis and serotonin syndrome; TMA-6 itself is a potent MAO-A inhibitor)\",\n-        \"Lithium (elevated risk of seizures and psychosis)\",\n-        \"Tramadol (lowers seizure threshold)\"\n+        \"Depressants (risk of respiratory depression, unconsciousness, vomiting and aspiration)\"\n-        \"Serotonin releasers (MDMA, 4-FA, methamphetamine, methylone, aMT; risk of serotonin syndrome)\",\n-        \"Stimulants (risk of excessive anxiety, panic, thought loops, and psychosis)\"\n+        \"Stimulants (increased risk of anxiety, mania, delusions and psychosis)\"\n-      \"caution\": [\n-        \"SSRIs (citalopram, sertraline; risk of serotonin syndrome and altered effects)\",\n-        \"SNRIs (venlafaxine; risk of serotonin syndrome)\",\n-        \"5-HTP (risk of serotonin syndrome)\",\n-        \"Other psychedelics (risk of overwhelming intensity and unpredictable interactions)\"\n-      ]\n+      \"caution\": []\n-    \"notes\": \"TMA-6 is a potent MAO-A inhibitor, which creates significant interaction risks and requires careful attention to dietary restrictions similar to pharmaceutical MAOIs. Individuals with personal or family histories of psychotic disorders should avoid use. The substance is highly dose-sensitive and produces unpredictable effects with considerable body load and nausea. Set and setting strongly influence the experience. Users should be prepared for an extended duration of 10-16 hours. Always use a precise scale for dosing.\",\n+    \"notes\": \"4-MeO-PCP is a long-acting dissociative with approximately 70% the potency of PCP. Users have reported substantial differences in active dose; these discrepancies may be partially explained by the presence of unreacted PCC and other impurities in samples sold on the grey market. Use a precise milligram scale for dosing. The extended duration of action can be both an advantage and disadvantage, with effects and after-effects persisting well into the next day. Chronic use may lead to urinary tract issues similar to ketamine, though less severe due to higher potency requiring smaller amounts. Set and setting are important, and users should avoid potentially hazardous activities during the experience.\",\n-      \"Stimulation\",\n-      \"Spontaneous Tactile Sensations\",\n-      \"Tactile Enhancement\",\n-      \"Empathy And Sociability Enhancement\",\n-      \"Thought Acceleration\",\n-      \"Conceptual Thinking Enhancement\",\n-      \"Emotion Enhancement\",\n+      \"Consciousness Disconnection\",\n+      \"Visual Disconnection\",\n+      \"Dizziness\",\n+      \"Motor Control Loss\",\n+      \"Physical Euphoria\",\n+      \"Spatial Disorientation\",\n+      \"Tactile Suppression\",\n+      \"Depersonalization\",\n+      \"Derealization\",\n+      \"Amnesia\",\n-      \"Visual Acuity Enhancement\",\n-      \"Colour Enhancement\",\n-      \"Drifting\",\n-      \"Nausea\",\n-      \"Vasoconstriction\",\n-      \"Increased Libido\",\n-      \"Music Appreciation Enhancement\"\n+      \"Creativity Enhancement\",\n+      \"Immersion Enhancement\",\n+      \"Increased Music Appreciation\",\n+      \"Internal Hallucinations\"\n-      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n-      \"half_tolerance\": \"3 days\",\n-      \"zero_tolerance\": \"7 days\",\n+      \"full_tolerance\": \"After prolonged and repeated use\",\n+      \"half_tolerance\": \"3-7 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n-        \"All psychedelics\",\n-        \"All stimulants\"\n+        \"All dissociatives\"\n-    \"half_life\": \"Not well documented; estimated 3-6 hours based on related compounds\",\n+    \"half_life\": \"\",\n-        \"name\": \"Erowid TMA-6 Experience Vault\",\n-        \"reference\": \"https://erowid.org/experiences/subs/exp_TMA6.shtml\"\n+        \"name\": \"Bluelight: The Big & Dandy 4-MeO-PCP Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-4-meo-pcp-thread.391328/\"\n-        \"name\": \"Erowid TMA-6 Comparison Information\",\n-        \"reference\": \"https://erowid.org/chemicals/tma2/tma2_info1.shtml\"\n+        \"name\": \"Erowid 4-MeO-PCP Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/4meo_pcp/4meo_pcp.shtml\"\n-        \"name\": \"Isomer Design PiHKAL Entry #162 TMA-6\",\n-        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=162\"\n+        \"name\": \"Isomer Design: 4-MeO-PCP\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=963\"\n-        \"name\": \"PsychonautWiki TMA-6\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/TMA-6\"\n+        \"name\": \"Morris H, Wallach J. From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs\",\n+        \"reference\": \"https://doi.org/10.1002/dta.1620\"\n-        \"name\": \"Bluelight TMA Series Thread\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/suprise-substance-of-july-the-tma-series.384752/\"\n+        \"name\": \"PsychonautWiki: 4-MeO-PCP\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/4-MeO-PCP\"\n-        \"name\": \"Wikipedia 2,4,6-Trimethoxyamphetamine\",\n-        \"reference\": \"https://en.wikipedia.org/wiki/2,4,6-Trimethoxyamphetamine\"\n+        \"name\": \"Roth BL et al. The Ketamine Analogue Methoxetamine and 3- and 4-Methoxy Analogues of Phencyclidine Are High Affinity and Selective Ligands for the Glutamate NMDA Receptor\",\n+        \"reference\": \"https://doi.org/10.1371/journal.pone.0059334\"\n-      \"psychedelic\",\n+      \"dissociative\",\n+      \"arylcyclohexylamine\",\n-  \"id\": 655\n+  \"id\": 656\n\n# PCE · #657\n\n-  \"title\": \"4-MeO-PCP\",\n+  \"title\": \"PCE\",\n-    \"drug_name\": \"4-MeO-PCP\",\n-    \"chemical_name\": \"1-[1-(4-Methoxyphenyl)cyclohexyl]piperidine\",\n-    \"alternative_name\": \"Methoxydine; 4-Methoxyphencyclidine; 4-Methoxy-PCP\",\n+    \"drug_name\": \"PCE\",\n+    \"chemical_name\": \"N-Ethyl-1-phenylcyclohexanamine\",\n+    \"alternative_name\": \"Eticyclidine; CI-400; Cyclohexamine\",\n-    \"mechanism_of_action\": \"NMDA receptor antagonist (selective ligand without appreciable dopamine transporter affinity)\",\n+    \"mechanism_of_action\": \"NMDA receptor antagonist (noncompetitive); dopamine-noradrenaline reuptake inhibitor; serotonin reuptake inhibitor; suspected mu-opioid receptor affinity\",\n-            \"threshold\": \"25 mg\",\n-            \"light\": \"75-100 mg\",\n-            \"common\": \"100-170 mg\",\n-            \"strong\": \"170-250 mg\",\n-            \"heavy\": \"250+ mg\"\n+            \"threshold\": \"1 mg\",\n+            \"light\": \"3-5 mg\",\n+            \"common\": \"5-10 mg\",\n+            \"strong\": \"10-15 mg\",\n+            \"heavy\": \"15+ mg\"\n-            \"threshold\": \"15 mg\",\n-            \"light\": \"30-75 mg\",\n-            \"common\": \"75-150 mg\",\n-            \"strong\": \"150+ mg\",\n-            \"heavy\": \"\"\n+            \"threshold\": \"1 mg\",\n+            \"light\": \"3-5 mg\",\n+            \"common\": \"5-10 mg\",\n+            \"strong\": \"10-15 mg\",\n+            \"heavy\": \"15+ mg\"\n+        },\n+        {\n+          \"route\": \"smoked\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"1 mg\",\n+            \"light\": \"3-5 mg\",\n+            \"common\": \"5-10 mg\",\n+            \"strong\": \"10-15 mg\",\n+            \"heavy\": \"15+ mg\"\n+          }\n-            \"total_duration\": \"12-20 hours\",\n-            \"onset\": \"45-120 minutes\",\n-            \"peak\": \"3-7 hours\",\n-            \"offset\": \"6-10 hours\",\n-            \"after_effects\": \"6+ hours\"\n+            \"total_duration\": \"4-8 hours\",\n+            \"onset\": \"30-90 minutes\",\n+            \"peak\": \"2-3 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"4-48 hours\"\n-            \"total_duration\": \"12-18 hours\",\n-            \"onset\": \"5-15 minutes\",\n-            \"peak\": \"3-6 hours\",\n-            \"offset\": \"3 hours\",\n-            \"after_effects\": \"3 hours\"\n+            \"total_duration\": \"4-8 hours\",\n+            \"onset\": \"20-60 minutes\",\n+            \"peak\": \"2-3 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"4-48 hours\"\n+        },\n+        {\n+          \"route\": \"smoked\",\n+          \"stages\": {\n+            \"total_duration\": \"4-8 hours\",\n+            \"onset\": \"30-90 minutes\",\n+            \"peak\": \"2-3 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"4-48 hours\"\n+          }\n-    \"addiction_potential\": \"As with other NMDA receptor antagonists, the chronic use of 4-MeO-PCP can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage. The long duration may discourage frequent redosing compared to shorter-acting dissociatives.\",\n+    \"addiction_potential\": \"The chronic use of PCE can be considered highly addictive with a high potential for adverse side effects such as psychosis. In comparison to other dissociatives, PCE has been reported to be more addictive than MXE, diphenidine, ephenidine, and ketamine. Multiple reports exist of people becoming seriously addicted daily users of this substance.\",\n-        \"Depressants (risk of respiratory depression, unconsciousness, vomiting and aspiration)\"\n+        \"Depressants (increased risk of unconsciousness, vomiting, and fatal suffocation)\"\n-        \"Stimulants (increased risk of anxiety, mania, delusions and psychosis)\"\n+        \"Psychedelics (extreme psychological disturbances, psychosis, and mania at significantly higher rates)\",\n+        \"Stimulants (increased risk of anxiety, mania, delusions, and psychosis)\"\n-    \"notes\": \"4-MeO-PCP is a long-acting dissociative with approximately 70% the potency of PCP. Users have reported substantial differences in active dose; these discrepancies may be partially explained by the presence of unreacted PCC and other impurities in samples sold on the grey market. Use a precise milligram scale for dosing. The extended duration of action can be both an advantage and disadvantage, with effects and after-effects persisting well into the next day. Chronic use may lead to urinary tract issues similar to ketamine, though less severe due to higher potency requiring smaller amounts. Set and setting are important, and users should avoid potentially hazardous activities during the experience.\",\n+    \"notes\": \"PCE is a potent dissociative that causes psychosis and mania at significantly higher rates than other dissociatives. Users should avoid taking the drug multiple days in a row or in high doses. Volumetric liquid dosing is strongly recommended due to the drug's extreme potency, as most standard milligram scales cannot accurately weigh doses below 10-15 mg. Compulsive redosing should be avoided. Long-term use may lead to severe memory loss, disorganized thinking, bladder and urinary tract problems, and schizophrenia-like psychotic episodes. Individuals with personal or family histories of psychotic disorders should avoid use. PCE is internationally controlled as a Schedule I substance.\",\n-      \"Consciousness Disconnection\",\n-      \"Visual Disconnection\",\n-      \"Dizziness\",\n-      \"Motor Control Loss\",\n-      \"Spatial Disorientation\",\n+      \"Motor Control Loss\",\n+      \"Visual Disconnection\",\n+      \"Consciousness Disconnection\",\n+      \"Visual Acuity Suppression\",\n+      \"Cognitive Euphoria\",\n+      \"Thought Acceleration\",\n-      \"Amnesia\",\n-      \"Time Distortion\",\n-      \"Creativity Enhancement\",\n-      \"Immersion Enhancement\",\n-      \"Increased Music Appreciation\",\n-      \"Internal Hallucinations\"\n+      \"Memory Suppression\",\n+      \"Ego Death\",\n+      \"Mania\",\n+      \"Delusion\",\n+      \"Disinhibition\",\n+      \"Compulsive Redosing\",\n+      \"Nausea\"\n-        \"name\": \"Bluelight: The Big & Dandy 4-MeO-PCP Thread\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-4-meo-pcp-thread.391328/\"\n+        \"name\": \"Bluelight PCE Bioassay Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/pce-bioassay-eight-human-trials-with-the-unicorn-dissociative-eticyclidine.927036/\"\n-        \"name\": \"Erowid 4-MeO-PCP Vault\",\n-        \"reference\": \"https://www.erowid.org/chemicals/4meo_pcp/4meo_pcp.shtml\"\n+        \"name\": \"Bluelight PCE Small & Handy Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-small-handy-pce-eticyclidine-thread.919539/\"\n-        \"name\": \"Isomer Design: 4-MeO-PCP\",\n-        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=963\"\n+        \"name\": \"Erowid PCE Experience Reports\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_PCE.shtml\"\n-        \"name\": \"Morris H, Wallach J. From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs\",\n+        \"name\": \"Morris & Wallach 2014: From PCP to MXE\",\n-        \"name\": \"PsychonautWiki: 4-MeO-PCP\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/4-MeO-PCP\"\n-      },\n-      {\n-        \"name\": \"Roth BL et al. The Ketamine Analogue Methoxetamine and 3- and 4-Methoxy Analogues of Phencyclidine Are High Affinity and Selective Ligands for the Glutamate NMDA Receptor\",\n-        \"reference\": \"https://doi.org/10.1371/journal.pone.0059334\"\n+        \"name\": \"PsychonautWiki: PCE\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/PCE\"\n-  \"id\": 656\n+  \"id\": 657\n\n# Nitrous Oxide · #658\n\n-  \"title\": \"PCE\",\n-  \"index-category\": \"dissociative; research-chemical\",\n+  \"title\": \"Nitrous Oxide\",\n+  \"index-category\": \"dissociative; inhalant\",\n-    \"drug_name\": \"PCE\",\n-    \"chemical_name\": \"N-Ethyl-1-phenylcyclohexanamine\",\n-    \"alternative_name\": \"Eticyclidine; CI-400; Cyclohexamine\",\n-    \"chemical_class\": \"Arylcyclohexylamine\",\n+    \"drug_name\": \"Nitrous Oxide\",\n+    \"chemical_name\": \"Dinitrogen monoxide\",\n+    \"alternative_name\": \"Laughing Gas; Nitrous; NOS; Hippy Crack; N2O; Nangs; Whippits; Nitro\",\n+    \"chemical_class\": \"Nitrogen oxide\",\n-    \"mechanism_of_action\": \"NMDA receptor antagonist (noncompetitive); dopamine-noradrenaline reuptake inhibitor; serotonin reuptake inhibitor; suspected mu-opioid receptor affinity\",\n+    \"mechanism_of_action\": \"NMDA receptor antagonist (primary); GABA-A receptor potentiation; glycine receptor potentiation; nACh receptor antagonist (beta2-subunit); two-pore-domain K+ channel activation\",\n-          \"route\": \"oral\",\n-          \"units\": \"mg\",\n+          \"route\": \"inhaled\",\n+          \"units\": \"g\",\n-            \"threshold\": \"1 mg\",\n-            \"light\": \"3-5 mg\",\n-            \"common\": \"5-10 mg\",\n-            \"strong\": \"10-15 mg\",\n-            \"heavy\": \"15+ mg\"\n+            \"threshold\": \"4 g\",\n+            \"light\": \"4-8 g (0.5-1 cartridge)\",\n+            \"common\": \"8-16 g (1-2 cartridges)\",\n+            \"strong\": \"16-40 g (2-5 cartridges)\",\n+            \"heavy\": \"40+ g (5+ cartridges)\"\n-        },\n-        {\n-          \"route\": \"insufflated\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"1 mg\",\n-            \"light\": \"3-5 mg\",\n-            \"common\": \"5-10 mg\",\n-            \"strong\": \"10-15 mg\",\n-            \"heavy\": \"15+ mg\"\n-          }\n-        },\n-        {\n-          \"route\": \"smoked\",\n-          \"units\": \"mg\",\n-          \"dose_ranges\": {\n-            \"threshold\": \"1 mg\",\n-            \"light\": \"3-5 mg\",\n-            \"common\": \"5-10 mg\",\n-            \"strong\": \"10-15 mg\",\n-            \"heavy\": \"15+ mg\"\n-          }\n-          \"route\": \"oral\",\n+          \"route\": \"inhaled\",\n-            \"total_duration\": \"4-8 hours\",\n-            \"onset\": \"30-90 minutes\",\n-            \"peak\": \"2-3 hours\",\n-            \"offset\": \"1-2 hours\",\n-            \"after_effects\": \"4-48 hours\"\n+            \"total_duration\": \"1-5 minutes\",\n+            \"onset\": \"5-10 seconds\",\n+            \"peak\": \"15-30 seconds\",\n+            \"offset\": \"1-5 minutes\",\n+            \"after_effects\": \"15-30 minutes\"\n-            \"oral\"\n+            \"inhaled\"\n-        },\n-        {\n-          \"route\": \"insufflated\",\n-          \"stages\": {\n-            \"total_duration\": \"4-8 hours\",\n-            \"onset\": \"20-60 minutes\",\n-            \"peak\": \"2-3 hours\",\n-            \"offset\": \"1-2 hours\",\n-            \"after_effects\": \"4-48 hours\"\n-          },\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ]\n-        },\n-        {\n-          \"route\": \"smoked\",\n-          \"stages\": {\n-            \"total_duration\": \"4-8 hours\",\n-            \"onset\": \"30-90 minutes\",\n-            \"peak\": \"2-3 hours\",\n-            \"offset\": \"1-2 hours\",\n-            \"after_effects\": \"4-48 hours\"\n-          }\n-    \"addiction_potential\": \"The chronic use of PCE can be considered highly addictive with a high potential for adverse side effects such as psychosis. In comparison to other dissociatives, PCE has been reported to be more addictive than MXE, diphenidine, ephenidine, and ketamine. Multiple reports exist of people becoming seriously addicted daily users of this substance.\",\n+    \"addiction_potential\": \"Nitrous oxide is considered to have low to moderate abuse potential and low physical addiction potential. However, it is strongly psychologically compelling due to its brief duration and powerful effects, which can lead to compulsive redosing during a session. Frequent use is rare due to rapid tolerance development.\",\n-        \"Depressants (increased risk of unconsciousness, vomiting, and fatal suffocation)\"\n+        \"Alcohol (risk of unconsciousness, vomit aspiration, memory blackouts)\",\n+        \"GHB/GBL (risk of unconsciousness, vomit aspiration, ataxia)\",\n+        \"Opioids (risk of unconsciousness, vomit aspiration, respiratory depression)\",\n+        \"Tramadol (risk of unconsciousness, vomit aspiration)\"\n-      \"unsafe\": [\n-        \"Psychedelics (extreme psychological disturbances, psychosis, and mania at significantly higher rates)\",\n-        \"Stimulants (increased risk of anxiety, mania, delusions, and psychosis)\"\n-      ],\n-      \"caution\": []\n+      \"unsafe\": [],\n+      \"caution\": [\n+        \"Cannabis (potentiates effects)\",\n+        \"Psychedelics (dramatically intensifies visuals and ego dissolution)\",\n+        \"Dissociatives (intensifies disconnection and internal hallucinations)\",\n+        \"MDMA (may cause nausea)\"\n+      ]\n-    \"notes\": \"PCE is a potent dissociative that causes psychosis and mania at significantly higher rates than other dissociatives. Users should avoid taking the drug multiple days in a row or in high doses. Volumetric liquid dosing is strongly recommended due to the drug's extreme potency, as most standard milligram scales cannot accurately weigh doses below 10-15 mg. Compulsive redosing should be avoided. Long-term use may lead to severe memory loss, disorganized thinking, bladder and urinary tract problems, and schizophrenia-like psychotic episodes. Individuals with personal or family histories of psychotic disorders should avoid use. PCE is internationally controlled as a Schedule I substance.\",\n+    \"notes\": \"Nitrous oxide can cause severe and potentially irreversible vitamin B12 depletion with frequent or chronic use, leading to serious neurological damage including numbness, tingling, and motor control loss. Always supplement with vitamin B12 when using this substance. Never inhale directly from cartridges or tanks due to extreme cold temperature (-40C) which can cause frostbite to lips, throat, and lungs, and high pressure which can rupture lung tissue. Always release gas into a balloon first to warm and depressurize. Ensure adequate oxygen intake between inhalations to prevent hypoxia and brain damage. Use while seated to prevent injury from falls. Filter gas through cloth or cotton to remove metal particles and industrial residue from food-grade cartridges.\",\n-      \"Tactile Suppression\",\n-      \"Motor Control Loss\",\n-      \"Visual Disconnection\",\n-      \"Consciousness Disconnection\",\n-      \"Visual Acuity Suppression\",\n-      \"Thought Acceleration\",\n-      \"Depersonalization\",\n-      \"Derealization\",\n-      \"Memory Suppression\",\n+      \"Auditory Distortion\",\n+      \"Visual Geometry\",\n-      \"Mania\",\n-      \"Delusion\",\n-      \"Disinhibition\",\n-      \"Compulsive Redosing\",\n-      \"Nausea\"\n+      \"Laughter Fits\",\n+      \"Motor Control Loss\",\n+      \"Dissociation\",\n+      \"Time Distortion\",\n+      \"Sedation\",\n+      \"Dizziness\",\n+      \"Tactile Suppression\"\n-      \"full_tolerance\": \"After prolonged and repeated use\",\n+      \"full_tolerance\": \"After 2-4 consecutive uses within hours\",\n-      \"cross_tolerances\": [\n-        \"All dissociatives\"\n-      ]\n+      \"cross_tolerances\": []\n-    \"half_life\": \"\",\n+    \"half_life\": \"5-10 minutes (less than 0.004% metabolized)\",\n-        \"name\": \"Bluelight PCE Bioassay Thread\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/pce-bioassay-eight-human-trials-with-the-unicorn-dissociative-eticyclidine.927036/\"\n+        \"name\": \"PsychonautWiki: Nitrous Oxide\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Nitrous\"\n-        \"name\": \"Bluelight PCE Small & Handy Thread\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/the-small-handy-pce-eticyclidine-thread.919539/\"\n+        \"name\": \"TripSit Nitrous Oxide Factsheet\",\n+        \"reference\": \"https://tripsit.me/factsheets/nitrous\"\n-        \"name\": \"Erowid PCE Experience Reports\",\n-        \"reference\": \"https://erowid.org/experiences/subs/exp_PCE.shtml\"\n+        \"name\": \"TripSit Wiki: Nitrous Oxide\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/Nitrous_Oxide\"\n-        \"name\": \"Morris & Wallach 2014: From PCP to MXE\",\n-        \"reference\": \"https://doi.org/10.1002/dta.1620\"\n+        \"name\": \"Erowid Nitrous Oxide Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/nitrous/nitrous.shtml\"\n-        \"name\": \"PsychonautWiki: PCE\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/PCE\"\n+        \"name\": \"Erowid Nitrous Oxide Basics\",\n+        \"reference\": \"https://www.erowid.org/chemicals/nitrous/nitrous_basics.shtml\"\n+      },\n+      {\n+        \"name\": \"Erowid Nitrous Oxide Effects\",\n+        \"reference\": \"https://www.erowid.org/chemicals/nitrous/nitrous_effects.shtml\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy Nitrous Thread (FAQ)\",\n+        \"reference\": \"https://bluelight.org/xf/threads/nitrous-oxide-whippits-nangs-johnny-gas-n2o-faq.54176/\"\n+      },\n+      {\n+        \"name\": \"DanceWize NSW: Nitrous Oxide Harm Reduction\",\n+        \"reference\": \"https://hi-ground.org/substances/nitrous-oxide/\"\n-      \"arylcyclohexylamine\",\n-      \"research-chemical\"\n+      \"inhalant\",\n+      \"anesthetic\"\n-  \"id\": 657\n+  \"id\": 658\n\n# Benzydamine · #659\n\n-  \"title\": \"Nitrous Oxide\",\n-  \"index-category\": \"dissociative; inhalant\",\n+  \"title\": \"Benzydamine\",\n+  \"index-category\": \"deliriant; stimulant\",\n-    \"drug_name\": \"Nitrous Oxide\",\n-    \"chemical_name\": \"Dinitrogen monoxide\",\n-    \"alternative_name\": \"Laughing Gas; Nitrous; NOS; Hippy Crack; N2O; Nangs; Whippits; Nitro\",\n-    \"chemical_class\": \"Nitrogen oxide\",\n-    \"psychoactive_class\": \"Dissociative\",\n-    \"mechanism_of_action\": \"NMDA receptor antagonist (primary); GABA-A receptor potentiation; glycine receptor potentiation; nACh receptor antagonist (beta2-subunit); two-pore-domain K+ channel activation\",\n+    \"drug_name\": \"Benzydamine\",\n+    \"chemical_name\": \"3-(1-Benzyl-1H-indazol-3-yloxy)-N,N-dimethylpropan-1-amine\",\n+    \"alternative_name\": \"Tantum Verde; Difflam; Benflogin; Andole\",\n+    \"chemical_class\": \"Indazoles\",\n+    \"psychoactive_class\": \"Deliriant; Stimulant\",\n+    \"mechanism_of_action\": \"Possible CB1 cannabinoid receptor agonist (speculated); possible 5-HT2A receptor agonist (speculated); prostaglandin synthetase inhibitor; mechanism underlying hallucinogenic effects remains unstudied\",\n-          \"route\": \"inhaled\",\n-          \"units\": \"g\",\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n-            \"threshold\": \"4 g\",\n-            \"light\": \"4-8 g (0.5-1 cartridge)\",\n-            \"common\": \"8-16 g (1-2 cartridges)\",\n-            \"strong\": \"16-40 g (2-5 cartridges)\",\n-            \"heavy\": \"40+ g (5+ cartridges)\"\n+            \"threshold\": \"150 mg\",\n+            \"light\": \"300-500 mg\",\n+            \"common\": \"500-1000 mg\",\n+            \"strong\": \"1000-2000 mg\",\n+            \"heavy\": \"2000+ mg\"\n-          \"route\": \"inhaled\",\n+          \"route\": \"oral\",\n-            \"total_duration\": \"1-5 minutes\",\n-            \"onset\": \"5-10 seconds\",\n-            \"peak\": \"15-30 seconds\",\n-            \"offset\": \"1-5 minutes\",\n-            \"after_effects\": \"15-30 minutes\"\n+            \"total_duration\": \"5-8 hours\",\n+            \"onset\": \"20-60 minutes\",\n+            \"peak\": \"3-6 hours\",\n+            \"offset\": \"3-8 hours\",\n+            \"after_effects\": \"24-72 hours (residual stimulation and insomnia)\"\n-            \"inhaled\"\n+            \"oral\"\n-    \"addiction_potential\": \"Nitrous oxide is considered to have low to moderate abuse potential and low physical addiction potential. However, it is strongly psychologically compelling due to its brief duration and powerful effects, which can lead to compulsive redosing during a session. Frequent use is rare due to rapid tolerance development.\",\n+    \"addiction_potential\": \"Benzydamine exhibits powerful reinforcing effects in animal models and shows cross-sensitization with drugs like heroin and cocaine. Individuals with prior substance abuse history may be at significantly higher risk for developing benzydamine dependence due to neurobiological sensitivity to its effects.\",\n-      \"dangerous\": [\n-        \"Alcohol (risk of unconsciousness, vomit aspiration, memory blackouts)\",\n-        \"GHB/GBL (risk of unconsciousness, vomit aspiration, ataxia)\",\n-        \"Opioids (risk of unconsciousness, vomit aspiration, respiratory depression)\",\n-        \"Tramadol (risk of unconsciousness, vomit aspiration)\"\n+      \"dangerous\": [],\n+      \"unsafe\": [\n+        \"Other deliriants (overwhelming and unpredictable effects)\",\n+        \"Stimulants (increased cardiovascular stress and anxiety)\"\n-      \"unsafe\": [],\n-        \"Cannabis (potentiates effects)\",\n-        \"Psychedelics (dramatically intensifies visuals and ego dissolution)\",\n-        \"Dissociatives (intensifies disconnection and internal hallucinations)\",\n-        \"MDMA (may cause nausea)\"\n+        \"Alcohol (commonly combined; may exacerbate dehydration and confusion)\",\n+        \"Cannabis (frequently co-used by recreational users)\",\n+        \"Benzodiazepines (may blunt effects but can increase confusion)\",\n+        \"CNS depressants (may create unpredictable interactions)\"\n-    \"notes\": \"Nitrous oxide can cause severe and potentially irreversible vitamin B12 depletion with frequent or chronic use, leading to serious neurological damage including numbness, tingling, and motor control loss. Always supplement with vitamin B12 when using this substance. Never inhale directly from cartridges or tanks due to extreme cold temperature (-40C) which can cause frostbite to lips, throat, and lungs, and high pressure which can rupture lung tissue. Always release gas into a balloon first to warm and depressurize. Ensure adequate oxygen intake between inhalations to prevent hypoxia and brain damage. Use while seated to prevent injury from falls. Filter gas through cloth or cotton to remove metal particles and industrial residue from food-grade cartridges.\",\n+    \"notes\": \"Benzydamine products, particularly Tantum Rosa vaginal douching sachets, contain dangerous levels of sodium chloride that can cause severe kidney damage if ingested directly. Proper salt extraction using water filtration is essential before consumption. The substance causes severe and prolonged insomnia lasting up to 48 hours, producing taxing sleep deprivation that often triggers paranoia. Legal and available over-the-counter in many countries for legitimate throat and mouth inflammation treatment. Individuals with personal or family history of psychotic disorders should avoid use due to risk of persistent psychotic symptoms.\",\n-      \"Physical Euphoria\",\n-      \"Cognitive Euphoria\",\n-      \"Auditory Distortion\",\n-      \"Visual Geometry\",\n-      \"Ego Death\",\n-      \"Laughter Fits\",\n+      \"Intense Stimulation\",\n+      \"External Hallucinations (Shadow People, Animals, Autonomous Entities)\",\n+      \"Auditory Hallucinations\",\n+      \"Visual Tracers and After Images\",\n+      \"Delirium and Confusion\",\n+      \"Anxiety and Paranoia\",\n+      \"Feelings of Impending Doom\",\n+      \"Euphoria (During Onset Only)\",\n-      \"Dissociation\",\n+      \"Tactile Suppression\",\n-      \"Sedation\",\n-      \"Dizziness\",\n-      \"Tactile Suppression\"\n+      \"Frequent Urination\",\n+      \"Dehydration\"\n-      \"full_tolerance\": \"After 2-4 consecutive uses within hours\",\n+      \"full_tolerance\": \"Develops rapidly with consecutive use\",\n-      \"cross_tolerances\": []\n+      \"cross_tolerances\": [\n+        \"Other deliriants (e.g., diphenhydramine, datura)\"\n+      ]\n-    \"half_life\": \"5-10 minutes (less than 0.004% metabolized)\",\n+    \"half_life\": \"7-8 hours\",\n-        \"name\": \"PsychonautWiki: Nitrous Oxide\",\n-        \"reference\": \"https://psychonautwiki.org/wiki/Nitrous\"\n+        \"name\": \"PsychonautWiki: Benzydamine\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Benzydamine\"\n-        \"name\": \"TripSit Nitrous Oxide Factsheet\",\n-        \"reference\": \"https://tripsit.me/factsheets/nitrous\"\n+        \"name\": \"Erowid Benzydamine Experience Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_Benzydamine.shtml\"\n-        \"name\": \"TripSit Wiki: Nitrous Oxide\",\n-        \"reference\": \"https://wiki.tripsit.me/wiki/Nitrous_Oxide\"\n+        \"name\": \"Bluelight: Benzydamine Discussion Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/benzydamine-nsaid-stimulant-psychedelic.353442/\"\n-        \"name\": \"Erowid Nitrous Oxide Vault\",\n-        \"reference\": \"https://www.erowid.org/chemicals/nitrous/nitrous.shtml\"\n+        \"name\": \"Drugs-Forum: Benzydamine Discussion\",\n+        \"reference\": \"https://drugs-forum.com/threads/so-i-have-benzydamine-hcl-a-deliriant.295883/\"\n-        \"name\": \"Erowid Nitrous Oxide Basics\",\n-        \"reference\": \"https://www.erowid.org/chemicals/nitrous/nitrous_basics.shtml\"\n+        \"name\": \"The Benzydamine Experience: A Systematic Review\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC8977632/\"\n-        \"name\": \"Erowid Nitrous Oxide Effects\",\n-        \"reference\": \"https://www.erowid.org/chemicals/nitrous/nitrous_effects.shtml\"\n-      },\n-      {\n-        \"name\": \"Bluelight: The Big & Dandy Nitrous Thread (FAQ)\",\n-        \"reference\": \"https://bluelight.org/xf/threads/nitrous-oxide-whippits-nangs-johnny-gas-n2o-faq.54176/\"\n-      },\n-      {\n-        \"name\": \"DanceWize NSW: Nitrous Oxide Harm Reduction\",\n-        \"reference\": \"https://hi-ground.org/substances/nitrous-oxide/\"\n+        \"name\": \"Benzydamine - An Affordable OTC Drug with Psychoactive Properties\",\n+        \"reference\": \"https://www.mdpi.com/1424-8247/16/4/566\"\n-      \"dissociative\",\n-      \"inhalant\",\n-      \"anesthetic\"\n+      \"deliriant\",\n+      \"stimulant\",\n+      \"indazole\",\n+      \"research-chemical\"\n-  \"id\": 658\n+  \"id\": 659",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251018-180750-e0b5f747",
    "createdAt": "2025-10-18T18:07:50.516Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 20:07:47"
    },
    "articles": [
      {
        "id": 182,
        "title": "PCP",
        "slug": "pcp"
      }
    ],
    "markdown": "# PCP · #182\n\n-  \"title\": \"Sernyl\",\n+  \"title\": \"PCP\",\n-    \"drug_name\": \"Sernyl\",\n-    \"chemical_name\": \"PCP\",\n-    \"alternative_name\": \"Phencyclidine\",\n+    \"drug_name\": \"PCP\",\n+    \"chemical_name\": \"Phencyclidine\",\n+    \"alternative_name\": \"Sernyl\",\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n-      \"dissociative\",\n-      \"research-chemical\"\n+      \"dissociative\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251018-180229-56ec8a6c",
    "createdAt": "2025-10-18T18:02:29.253Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 20:02:26"
    },
    "articles": [
      {
        "id": 229,
        "title": "Methylenedioxyphenmetrazine",
        "slug": "methylenedioxyphenmetrazine"
      },
      {
        "id": 291,
        "title": "MDMA",
        "slug": "mdma"
      },
      {
        "id": 62,
        "title": "MDA",
        "slug": "mda"
      }
    ],
    "markdown": "# Methylenedioxyphenmetrazine · #229\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n-      \"entactogen\",\n\n# MDMA · #291\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n-      \"entactogen\",\n-      \"stimulant\"\n+      \"entactogen\"\n\n# MDA · #62\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"entactogen\",\n-      \"stimulant\",\n-      \"research-chemical\"\n+      \"entactogen\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251018-180009-6a8da329",
    "createdAt": "2025-10-18T18:00:09.916Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 20:00:07"
    },
    "articles": [
      {
        "id": 291,
        "title": "MDMA",
        "slug": "mdma"
      },
      {
        "id": 62,
        "title": "MDA",
        "slug": "mda"
      }
    ],
    "markdown": "# MDMA · #291\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n-      \"entactogen\",\n-      \"stimulant\"\n+      \"entactogen\"\n\n# MDA · #62\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"entactogen\",\n-      \"stimulant\",\n-      \"research-chemical\"\n+      \"entactogen\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251018-175942-0150e55e",
    "createdAt": "2025-10-18T17:59:42.517Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 19:59:39"
    },
    "articles": [
      {
        "id": 62,
        "title": "MDA",
        "slug": "mda"
      }
    ],
    "markdown": "# MDA · #62\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"entactogen\",\n-      \"stimulant\",\n-      \"research-chemical\"\n+      \"entactogen\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-231137-c5596ffa",
    "createdAt": "2025-10-17T23:11:37.907Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 01:11:36"
    },
    "articles": [
      {
        "id": 270,
        "title": "MAL",
        "slug": "mal"
      },
      {
        "id": 271,
        "title": "AEM",
        "slug": "aem"
      }
    ],
    "markdown": "# MAL · #270\n\n-    \"chemical_class\": \"Scalines; Phenethylamines\",\n+    \"chemical_class\": \"Scalines\",\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n\n# AEM · #271\n\n-    \"chemical_class\": \"Scalines; Phenethylamines\",\n+    \"chemical_class\": \"Scalines\",\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-231118-d997ce32",
    "createdAt": "2025-10-17T23:11:18.245Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 01:11:16"
    },
    "articles": [
      {
        "id": 271,
        "title": "AEM",
        "slug": "aem"
      }
    ],
    "markdown": "# AEM · #271\n\n-    \"chemical_class\": \"Scalines; Phenethylamines\",\n+    \"chemical_class\": \"Scalines\",\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-230906-55286484",
    "createdAt": "2025-10-17T23:09:06.720Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 01:09:05"
    },
    "articles": [
      {
        "id": 59,
        "title": "Mescaline",
        "slug": "mescaline"
      },
      {
        "id": 270,
        "title": "MAL",
        "slug": "mal"
      },
      {
        "id": 271,
        "title": "AEM",
        "slug": "aem"
      },
      {
        "id": 646,
        "title": "Allylescaline",
        "slug": "allylescaline"
      },
      {
        "id": 647,
        "title": "Escaline",
        "slug": "escaline"
      },
      {
        "id": 648,
        "title": "Proscaline",
        "slug": "proscaline"
      }
    ],
    "markdown": "# Mescaline · #59\n\n-    \"chemical_class\": \"Mescaline homologues; Phenethylamines\",\n+    \"chemical_class\": \"Scalines; Phenethylamines\",\n\n# MAL · #270\n\n-    \"chemical_class\": \"Mescaline homologues; Phenethylamines\",\n+    \"chemical_class\": \"Scalines; Phenethylamines\",\n\n# AEM · #271\n\n-    \"chemical_class\": \"Mescaline homologues; Phenethylamines\",\n+    \"chemical_class\": \"Scalines; Phenethylamines\",\n\n# Allylescaline · #646\n\n-    \"chemical_class\": \"Mescaline homologues\",\n+    \"chemical_class\": \"Scalines\",\n\n# Escaline · #647\n\n-    \"chemical_class\": \"Mescaline homologues\",\n+    \"chemical_class\": \"Scalines\",\n\n# Proscaline · #648\n\n-    \"chemical_class\": \"Mescaline homologues\",\n+    \"chemical_class\": \"Scalines\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-230611-de87cdeb",
    "createdAt": "2025-10-17T23:06:11.019Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 01:06:09"
    },
    "articles": [
      {
        "id": 200,
        "title": "Psilocybin Mushrooms",
        "slug": "psilocybin-mushrooms"
      },
      {
        "id": 631,
        "title": "LSA",
        "slug": "lsa"
      },
      {
        "id": 634,
        "title": "LSM-775",
        "slug": "lsm-775"
      },
      {
        "id": 635,
        "title": "PRO-LAD",
        "slug": "pro-lad"
      },
      {
        "id": 645,
        "title": "Psilocin",
        "slug": "psilocin"
      },
      {
        "id": 646,
        "title": "Allylescaline",
        "slug": "allylescaline"
      },
      {
        "id": 647,
        "title": "Escaline",
        "slug": "escaline"
      },
      {
        "id": 648,
        "title": "Proscaline",
        "slug": "proscaline"
      },
      {
        "id": 650,
        "title": "2,5-DMA",
        "slug": "2-5-dma"
      },
      {
        "id": 651,
        "title": "DOI",
        "slug": "doi"
      },
      {
        "id": 652,
        "title": "25C-NBOH",
        "slug": "25c-nboh"
      },
      {
        "id": 653,
        "title": "25D-NBOMe",
        "slug": "25d-nbome"
      },
      {
        "id": 654,
        "title": "25N-NBOMe",
        "slug": "25n-nbome"
      },
      {
        "id": 655,
        "title": "TMA-6",
        "slug": "tma-6"
      }
    ],
    "markdown": "# Psilocybin Mushrooms · #200\n\n-      \"classic-psychedelic\",\n\n# LSA · #631\n\n-    \"chemical_class\": \"Lysergamide; Ergoline alkaloid\",\n+    \"chemical_class\": \"Lysergamides\",\n-      \"natural\",\n-      \"ergoline\"\n+      \"natural\"\n\n# LSM-775 · #634\n\n-      \"research-chemical\",\n-      \"novel-psychoactive-substance\"\n+      \"research-chemical\"\n\n# PRO-LAD · #635\n\n-  \"index-category\": \"psychedelic; lysergamide\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Lysergamide\",\n+    \"chemical_class\": \"Lysergamides\",\n\n# Psilocin · #645\n\n-      \"serotonergic\",\n-      \"entheogen\"\n+      \"serotonergic\"\n\n# Allylescaline · #646\n\n-  \"index-category\": \"psychedelic; phenethylamine; research-chemical\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Phenethylamines; Scalines\",\n+    \"chemical_class\": \"Mescaline homologues\",\n-      \"phenethylamine\",\n-      \"research-chemical\",\n-      \"mescaline-analog\"\n+      \"research-chemical\"\n\n# Escaline · #647\n\n-  \"index-category\": \"psychedelic; research-chemical\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Phenethylamines\",\n+    \"chemical_class\": \"Mescaline homologues\",\n-      \"phenethylamine\",\n-      \"mescaline-analog\",\n\n# Proscaline · #648\n\n-  \"index-category\": \"psychedelic; phenethylamine; research-chemical\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Phenethylamine\",\n+    \"chemical_class\": \"Mescaline homologues\",\n-      \"mescaline-analog\",\n\n# 2,5-DMA · #650\n\n-      \"dox-family\",\n\n# DOI · #651\n\n-  \"index-category\": \"psychedelic; stimulant; dox\",\n+  \"index-category\": \"psychedelic\",\n-    \"alternative_name\": \"2,5-Dimethoxy-4-iodoamphetamine; Dimethoxyiodoamphetamine\",\n-    \"chemical_class\": \"Amphetamines; Substituted amphetamines\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n\n# 25C-NBOH · #652\n\n-  \"index-category\": \"psychedelic; research-chemical\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Phenethylamines\",\n+    \"chemical_class\": \"N-benzylated phenethylamines\",\n-      \"phenethylamine\",\n-      \"research-chemical\",\n-      \"nboh-series\"\n+      \"research-chemical\"\n\n# 25D-NBOMe · #653\n\n-  \"index-category\": \"psychedelic; research-chemical; nbome\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Phenethylamines\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"chemical_class\": \"N-benzylated phenethylamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-      \"research-chemical\",\n-      \"nbome-series\",\n-      \"phenethylamine\"\n+      \"research-chemical\"\n\n# 25N-NBOMe · #654\n\n-  \"index-category\": \"psychedelic; research-chemical; dangerous\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Phenethylamines\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"chemical_class\": \"N-benzylated phenethylamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-      \"nbome\",\n-      \"phenethylamine\",\n\n# TMA-6 · #655\n\n-    \"alternative_name\": \"2,4,6-Trimethoxyamphetamine; 2,4,6-TMA; psi-TMA-2\",\n-    \"chemical_class\": \"Amphetamine; Phenethylamine\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-      \"stimulant\",\n-      \"amphetamine\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-230513-56577c36",
    "createdAt": "2025-10-17T23:05:13.508Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 01:05:11"
    },
    "articles": [
      {
        "id": 200,
        "title": "Psilocybin Mushrooms",
        "slug": "psilocybin-mushrooms"
      },
      {
        "id": 631,
        "title": "LSA",
        "slug": "lsa"
      },
      {
        "id": 634,
        "title": "LSM-775",
        "slug": "lsm-775"
      },
      {
        "id": 635,
        "title": "PRO-LAD",
        "slug": "pro-lad"
      },
      {
        "id": 645,
        "title": "Psilocin",
        "slug": "psilocin"
      },
      {
        "id": 646,
        "title": "Allylescaline",
        "slug": "allylescaline"
      },
      {
        "id": 648,
        "title": "Proscaline",
        "slug": "proscaline"
      },
      {
        "id": 650,
        "title": "2,5-DMA",
        "slug": "2-5-dma"
      },
      {
        "id": 651,
        "title": "DOI",
        "slug": "doi"
      },
      {
        "id": 652,
        "title": "25C-NBOH",
        "slug": "25c-nboh"
      },
      {
        "id": 653,
        "title": "25D-NBOMe",
        "slug": "25d-nbome"
      },
      {
        "id": 654,
        "title": "25N-NBOMe",
        "slug": "25n-nbome"
      },
      {
        "id": 655,
        "title": "TMA-6",
        "slug": "tma-6"
      }
    ],
    "markdown": "# Psilocybin Mushrooms · #200\n\n-      \"classic-psychedelic\",\n\n# LSA · #631\n\n-    \"chemical_class\": \"Lysergamide; Ergoline alkaloid\",\n+    \"chemical_class\": \"Lysergamides\",\n-      \"natural\",\n-      \"ergoline\"\n+      \"natural\"\n\n# LSM-775 · #634\n\n-      \"research-chemical\",\n-      \"novel-psychoactive-substance\"\n+      \"research-chemical\"\n\n# PRO-LAD · #635\n\n-  \"index-category\": \"psychedelic; lysergamide\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Lysergamide\",\n+    \"chemical_class\": \"Lysergamides\",\n\n# Psilocin · #645\n\n-      \"serotonergic\",\n-      \"entheogen\"\n+      \"serotonergic\"\n\n# Allylescaline · #646\n\n-  \"index-category\": \"psychedelic; phenethylamine; research-chemical\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Phenethylamines; Scalines\",\n+    \"chemical_class\": \"Mescaline homologues\",\n-      \"phenethylamine\",\n-      \"research-chemical\",\n-      \"mescaline-analog\"\n+      \"research-chemical\"\n\n# Proscaline · #648\n\n-  \"index-category\": \"psychedelic; phenethylamine; research-chemical\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Phenethylamine\",\n+    \"chemical_class\": \"Mescaline homologues\",\n-      \"mescaline-analog\",\n\n# 2,5-DMA · #650\n\n-      \"dox-family\",\n\n# DOI · #651\n\n-  \"index-category\": \"psychedelic; stimulant; dox\",\n+  \"index-category\": \"psychedelic\",\n-    \"alternative_name\": \"2,5-Dimethoxy-4-iodoamphetamine; Dimethoxyiodoamphetamine\",\n-    \"chemical_class\": \"Amphetamines; Substituted amphetamines\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n\n# 25C-NBOH · #652\n\n-  \"index-category\": \"psychedelic; research-chemical\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Phenethylamines\",\n+    \"chemical_class\": \"N-benzylated phenethylamines\",\n-      \"phenethylamine\",\n-      \"research-chemical\",\n-      \"nboh-series\"\n+      \"research-chemical\"\n\n# 25D-NBOMe · #653\n\n-  \"index-category\": \"psychedelic; research-chemical; nbome\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Phenethylamines\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"chemical_class\": \"N-benzylated phenethylamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-      \"research-chemical\",\n-      \"nbome-series\",\n-      \"phenethylamine\"\n+      \"research-chemical\"\n\n# 25N-NBOMe · #654\n\n-  \"index-category\": \"psychedelic; research-chemical; dangerous\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Phenethylamines\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"chemical_class\": \"N-benzylated phenethylamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-      \"nbome\",\n-      \"phenethylamine\",\n\n# TMA-6 · #655\n\n-    \"alternative_name\": \"2,4,6-Trimethoxyamphetamine; 2,4,6-TMA; psi-TMA-2\",\n-    \"chemical_class\": \"Amphetamine; Phenethylamine\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-      \"stimulant\",\n-      \"amphetamine\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-230337-b5d7fa64",
    "createdAt": "2025-10-17T23:03:37.485Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 01:03:35"
    },
    "articles": [
      {
        "id": 200,
        "title": "Psilocybin Mushrooms",
        "slug": "psilocybin-mushrooms"
      },
      {
        "id": 631,
        "title": "LSA",
        "slug": "lsa"
      },
      {
        "id": 634,
        "title": "LSM-775",
        "slug": "lsm-775"
      },
      {
        "id": 635,
        "title": "PRO-LAD",
        "slug": "pro-lad"
      },
      {
        "id": 645,
        "title": "Psilocin",
        "slug": "psilocin"
      },
      {
        "id": 648,
        "title": "Proscaline",
        "slug": "proscaline"
      },
      {
        "id": 650,
        "title": "2,5-DMA",
        "slug": "2-5-dma"
      },
      {
        "id": 651,
        "title": "DOI",
        "slug": "doi"
      },
      {
        "id": 652,
        "title": "25C-NBOH",
        "slug": "25c-nboh"
      },
      {
        "id": 653,
        "title": "25D-NBOMe",
        "slug": "25d-nbome"
      },
      {
        "id": 654,
        "title": "25N-NBOMe",
        "slug": "25n-nbome"
      },
      {
        "id": 655,
        "title": "TMA-6",
        "slug": "tma-6"
      }
    ],
    "markdown": "# Psilocybin Mushrooms · #200\n\n-      \"classic-psychedelic\",\n\n# LSA · #631\n\n-    \"chemical_class\": \"Lysergamide; Ergoline alkaloid\",\n+    \"chemical_class\": \"Lysergamides\",\n-      \"natural\",\n-      \"ergoline\"\n+      \"natural\"\n\n# LSM-775 · #634\n\n-      \"research-chemical\",\n-      \"novel-psychoactive-substance\"\n+      \"research-chemical\"\n\n# PRO-LAD · #635\n\n-  \"index-category\": \"psychedelic; lysergamide\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Lysergamide\",\n+    \"chemical_class\": \"Lysergamides\",\n\n# Psilocin · #645\n\n-      \"serotonergic\",\n-      \"entheogen\"\n+      \"serotonergic\"\n\n# Proscaline · #648\n\n-  \"index-category\": \"psychedelic; phenethylamine; research-chemical\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Phenethylamine\",\n+    \"chemical_class\": \"Mescaline homologues\",\n-      \"mescaline-analog\",\n\n# 2,5-DMA · #650\n\n-      \"dox-family\",\n\n# DOI · #651\n\n-  \"index-category\": \"psychedelic; stimulant; dox\",\n+  \"index-category\": \"psychedelic\",\n-    \"alternative_name\": \"2,5-Dimethoxy-4-iodoamphetamine; Dimethoxyiodoamphetamine\",\n-    \"chemical_class\": \"Amphetamines; Substituted amphetamines\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n\n# 25C-NBOH · #652\n\n-  \"index-category\": \"psychedelic; research-chemical\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Phenethylamines\",\n+    \"chemical_class\": \"N-benzylated phenethylamines\",\n-      \"phenethylamine\",\n-      \"research-chemical\",\n-      \"nboh-series\"\n+      \"research-chemical\"\n\n# 25D-NBOMe · #653\n\n-  \"index-category\": \"psychedelic; research-chemical; nbome\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Phenethylamines\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"chemical_class\": \"N-benzylated phenethylamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-      \"research-chemical\",\n-      \"nbome-series\",\n-      \"phenethylamine\"\n+      \"research-chemical\"\n\n# 25N-NBOMe · #654\n\n-  \"index-category\": \"psychedelic; research-chemical; dangerous\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Phenethylamines\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"chemical_class\": \"N-benzylated phenethylamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-      \"nbome\",\n-      \"phenethylamine\",\n\n# TMA-6 · #655\n\n-    \"alternative_name\": \"2,4,6-Trimethoxyamphetamine; 2,4,6-TMA; psi-TMA-2\",\n-    \"chemical_class\": \"Amphetamine; Phenethylamine\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-      \"stimulant\",\n-      \"amphetamine\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-230247-72f6027f",
    "createdAt": "2025-10-17T23:02:47.222Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 01:02:45"
    },
    "articles": [
      {
        "id": 200,
        "title": "Psilocybin Mushrooms",
        "slug": "psilocybin-mushrooms"
      },
      {
        "id": 631,
        "title": "LSA",
        "slug": "lsa"
      },
      {
        "id": 634,
        "title": "LSM-775",
        "slug": "lsm-775"
      },
      {
        "id": 635,
        "title": "PRO-LAD",
        "slug": "pro-lad"
      },
      {
        "id": 645,
        "title": "Psilocin",
        "slug": "psilocin"
      },
      {
        "id": 648,
        "title": "Proscaline",
        "slug": "proscaline"
      },
      {
        "id": 650,
        "title": "2,5-DMA",
        "slug": "2-5-dma"
      },
      {
        "id": 651,
        "title": "DOI",
        "slug": "doi"
      },
      {
        "id": 652,
        "title": "25C-NBOH",
        "slug": "25c-nboh"
      },
      {
        "id": 653,
        "title": "25D-NBOMe",
        "slug": "25d-nbome"
      },
      {
        "id": 655,
        "title": "TMA-6",
        "slug": "tma-6"
      }
    ],
    "markdown": "# Psilocybin Mushrooms · #200\n\n-      \"classic-psychedelic\",\n\n# LSA · #631\n\n-    \"chemical_class\": \"Lysergamide; Ergoline alkaloid\",\n+    \"chemical_class\": \"Lysergamides\",\n-      \"natural\",\n-      \"ergoline\"\n+      \"natural\"\n\n# LSM-775 · #634\n\n-      \"research-chemical\",\n-      \"novel-psychoactive-substance\"\n+      \"research-chemical\"\n\n# PRO-LAD · #635\n\n-  \"index-category\": \"psychedelic; lysergamide\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Lysergamide\",\n+    \"chemical_class\": \"Lysergamides\",\n\n# Psilocin · #645\n\n-      \"serotonergic\",\n-      \"entheogen\"\n+      \"serotonergic\"\n\n# Proscaline · #648\n\n-  \"index-category\": \"psychedelic; phenethylamine; research-chemical\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Phenethylamine\",\n+    \"chemical_class\": \"Mescaline homologues\",\n-      \"mescaline-analog\",\n\n# 2,5-DMA · #650\n\n-      \"dox-family\",\n\n# DOI · #651\n\n-  \"index-category\": \"psychedelic; stimulant; dox\",\n+  \"index-category\": \"psychedelic\",\n-    \"alternative_name\": \"2,5-Dimethoxy-4-iodoamphetamine; Dimethoxyiodoamphetamine\",\n-    \"chemical_class\": \"Amphetamines; Substituted amphetamines\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n\n# 25C-NBOH · #652\n\n-  \"index-category\": \"psychedelic; research-chemical\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Phenethylamines\",\n+    \"chemical_class\": \"N-benzylated phenethylamines\",\n-      \"phenethylamine\",\n-      \"research-chemical\",\n-      \"nboh-series\"\n+      \"research-chemical\"\n\n# 25D-NBOMe · #653\n\n-  \"index-category\": \"psychedelic; research-chemical; nbome\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Phenethylamines\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"chemical_class\": \"N-benzylated phenethylamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-      \"research-chemical\",\n-      \"nbome-series\",\n-      \"phenethylamine\"\n+      \"research-chemical\"\n\n# TMA-6 · #655\n\n-    \"alternative_name\": \"2,4,6-Trimethoxyamphetamine; 2,4,6-TMA; psi-TMA-2\",\n-    \"chemical_class\": \"Amphetamine; Phenethylamine\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-      \"stimulant\",\n-      \"amphetamine\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-230207-b2658eaf",
    "createdAt": "2025-10-17T23:02:07.252Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 01:02:05"
    },
    "articles": [
      {
        "id": 200,
        "title": "Psilocybin Mushrooms",
        "slug": "psilocybin-mushrooms"
      },
      {
        "id": 631,
        "title": "LSA",
        "slug": "lsa"
      },
      {
        "id": 634,
        "title": "LSM-775",
        "slug": "lsm-775"
      },
      {
        "id": 635,
        "title": "PRO-LAD",
        "slug": "pro-lad"
      },
      {
        "id": 645,
        "title": "Psilocin",
        "slug": "psilocin"
      },
      {
        "id": 648,
        "title": "Proscaline",
        "slug": "proscaline"
      },
      {
        "id": 650,
        "title": "2,5-DMA",
        "slug": "2-5-dma"
      },
      {
        "id": 651,
        "title": "DOI",
        "slug": "doi"
      },
      {
        "id": 652,
        "title": "25C-NBOH",
        "slug": "25c-nboh"
      },
      {
        "id": 655,
        "title": "TMA-6",
        "slug": "tma-6"
      }
    ],
    "markdown": "# Psilocybin Mushrooms · #200\n\n-      \"classic-psychedelic\",\n\n# LSA · #631\n\n-    \"chemical_class\": \"Lysergamide; Ergoline alkaloid\",\n+    \"chemical_class\": \"Lysergamides\",\n-      \"natural\",\n-      \"ergoline\"\n+      \"natural\"\n\n# LSM-775 · #634\n\n-      \"research-chemical\",\n-      \"novel-psychoactive-substance\"\n+      \"research-chemical\"\n\n# PRO-LAD · #635\n\n-  \"index-category\": \"psychedelic; lysergamide\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Lysergamide\",\n+    \"chemical_class\": \"Lysergamides\",\n\n# Psilocin · #645\n\n-      \"serotonergic\",\n-      \"entheogen\"\n+      \"serotonergic\"\n\n# Proscaline · #648\n\n-  \"index-category\": \"psychedelic; phenethylamine; research-chemical\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Phenethylamine\",\n+    \"chemical_class\": \"Mescaline homologues\",\n-      \"mescaline-analog\",\n\n# 2,5-DMA · #650\n\n-      \"dox-family\",\n\n# DOI · #651\n\n-  \"index-category\": \"psychedelic; stimulant; dox\",\n+  \"index-category\": \"psychedelic\",\n-    \"alternative_name\": \"2,5-Dimethoxy-4-iodoamphetamine; Dimethoxyiodoamphetamine\",\n-    \"chemical_class\": \"Amphetamines; Substituted amphetamines\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n\n# 25C-NBOH · #652\n\n-  \"index-category\": \"psychedelic; research-chemical\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Phenethylamines\",\n+    \"chemical_class\": \"N-benzylated phenethylamines\",\n-      \"phenethylamine\",\n-      \"research-chemical\",\n-      \"nboh-series\"\n+      \"research-chemical\"\n\n# TMA-6 · #655\n\n-    \"alternative_name\": \"2,4,6-Trimethoxyamphetamine; 2,4,6-TMA; psi-TMA-2\",\n-    \"chemical_class\": \"Amphetamine; Phenethylamine\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-      \"stimulant\",\n-      \"amphetamine\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-230054-23cef8b5",
    "createdAt": "2025-10-17T23:00:54.567Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 01:00:52"
    },
    "articles": [
      {
        "id": 200,
        "title": "Psilocybin Mushrooms",
        "slug": "psilocybin-mushrooms"
      },
      {
        "id": 631,
        "title": "LSA",
        "slug": "lsa"
      },
      {
        "id": 634,
        "title": "LSM-775",
        "slug": "lsm-775"
      },
      {
        "id": 635,
        "title": "PRO-LAD",
        "slug": "pro-lad"
      },
      {
        "id": 645,
        "title": "Psilocin",
        "slug": "psilocin"
      },
      {
        "id": 648,
        "title": "Proscaline",
        "slug": "proscaline"
      },
      {
        "id": 650,
        "title": "2,5-DMA",
        "slug": "2-5-dma"
      },
      {
        "id": 651,
        "title": "DOI",
        "slug": "doi"
      },
      {
        "id": 655,
        "title": "TMA-6",
        "slug": "tma-6"
      }
    ],
    "markdown": "# Psilocybin Mushrooms · #200\n\n-      \"classic-psychedelic\",\n\n# LSA · #631\n\n-    \"chemical_class\": \"Lysergamide; Ergoline alkaloid\",\n+    \"chemical_class\": \"Lysergamides\",\n-      \"natural\",\n-      \"ergoline\"\n+      \"natural\"\n\n# LSM-775 · #634\n\n-      \"research-chemical\",\n-      \"novel-psychoactive-substance\"\n+      \"research-chemical\"\n\n# PRO-LAD · #635\n\n-  \"index-category\": \"psychedelic; lysergamide\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Lysergamide\",\n+    \"chemical_class\": \"Lysergamides\",\n\n# Psilocin · #645\n\n-      \"serotonergic\",\n-      \"entheogen\"\n+      \"serotonergic\"\n\n# Proscaline · #648\n\n-  \"index-category\": \"psychedelic; phenethylamine; research-chemical\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Phenethylamine\",\n+    \"chemical_class\": \"Mescaline homologues\",\n-      \"mescaline-analog\",\n\n# 2,5-DMA · #650\n\n-      \"dox-family\",\n\n# DOI · #651\n\n-  \"index-category\": \"psychedelic; stimulant; dox\",\n+  \"index-category\": \"psychedelic\",\n-    \"alternative_name\": \"2,5-Dimethoxy-4-iodoamphetamine; Dimethoxyiodoamphetamine\",\n-    \"chemical_class\": \"Amphetamines; Substituted amphetamines\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n\n# TMA-6 · #655\n\n-    \"alternative_name\": \"2,4,6-Trimethoxyamphetamine; 2,4,6-TMA; psi-TMA-2\",\n-    \"chemical_class\": \"Amphetamine; Phenethylamine\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-      \"stimulant\",\n-      \"amphetamine\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-225903-124bba46",
    "createdAt": "2025-10-17T22:59:03.878Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 00:59:02"
    },
    "articles": [
      {
        "id": 200,
        "title": "Psilocybin Mushrooms",
        "slug": "psilocybin-mushrooms"
      },
      {
        "id": 631,
        "title": "LSA",
        "slug": "lsa"
      },
      {
        "id": 634,
        "title": "LSM-775",
        "slug": "lsm-775"
      },
      {
        "id": 635,
        "title": "PRO-LAD",
        "slug": "pro-lad"
      },
      {
        "id": 645,
        "title": "Psilocin",
        "slug": "psilocin"
      },
      {
        "id": 650,
        "title": "2,5-DMA",
        "slug": "2-5-dma"
      },
      {
        "id": 651,
        "title": "DOI",
        "slug": "doi"
      },
      {
        "id": 655,
        "title": "TMA-6",
        "slug": "tma-6"
      }
    ],
    "markdown": "# Psilocybin Mushrooms · #200\n\n-      \"classic-psychedelic\",\n\n# LSA · #631\n\n-    \"chemical_class\": \"Lysergamide; Ergoline alkaloid\",\n+    \"chemical_class\": \"Lysergamides\",\n-      \"natural\",\n-      \"ergoline\"\n+      \"natural\"\n\n# LSM-775 · #634\n\n-      \"research-chemical\",\n-      \"novel-psychoactive-substance\"\n+      \"research-chemical\"\n\n# PRO-LAD · #635\n\n-  \"index-category\": \"psychedelic; lysergamide\",\n+  \"index-category\": \"psychedelic\",\n-    \"chemical_class\": \"Lysergamide\",\n+    \"chemical_class\": \"Lysergamides\",\n\n# Psilocin · #645\n\n-      \"serotonergic\",\n-      \"entheogen\"\n+      \"serotonergic\"\n\n# 2,5-DMA · #650\n\n-      \"dox-family\",\n\n# DOI · #651\n\n-  \"index-category\": \"psychedelic; stimulant; dox\",\n+  \"index-category\": \"psychedelic\",\n-    \"alternative_name\": \"2,5-Dimethoxy-4-iodoamphetamine; Dimethoxyiodoamphetamine\",\n-    \"chemical_class\": \"Amphetamines; Substituted amphetamines\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n\n# TMA-6 · #655\n\n-    \"alternative_name\": \"2,4,6-Trimethoxyamphetamine; 2,4,6-TMA; psi-TMA-2\",\n-    \"chemical_class\": \"Amphetamine; Phenethylamine\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-      \"stimulant\",\n-      \"amphetamine\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-225826-341c926a",
    "createdAt": "2025-10-17T22:58:26.327Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 00:58:24"
    },
    "articles": [
      {
        "id": 200,
        "title": "Psilocybin Mushrooms",
        "slug": "psilocybin-mushrooms"
      },
      {
        "id": 631,
        "title": "LSA",
        "slug": "lsa"
      },
      {
        "id": 634,
        "title": "LSM-775",
        "slug": "lsm-775"
      },
      {
        "id": 645,
        "title": "Psilocin",
        "slug": "psilocin"
      },
      {
        "id": 650,
        "title": "2,5-DMA",
        "slug": "2-5-dma"
      },
      {
        "id": 651,
        "title": "DOI",
        "slug": "doi"
      },
      {
        "id": 655,
        "title": "TMA-6",
        "slug": "tma-6"
      }
    ],
    "markdown": "# Psilocybin Mushrooms · #200\n\n-      \"classic-psychedelic\",\n\n# LSA · #631\n\n-    \"chemical_class\": \"Lysergamide; Ergoline alkaloid\",\n+    \"chemical_class\": \"Lysergamides\",\n-      \"natural\",\n-      \"ergoline\"\n+      \"natural\"\n\n# LSM-775 · #634\n\n-      \"research-chemical\",\n-      \"novel-psychoactive-substance\"\n+      \"research-chemical\"\n\n# Psilocin · #645\n\n-      \"serotonergic\",\n-      \"entheogen\"\n+      \"serotonergic\"\n\n# 2,5-DMA · #650\n\n-      \"dox-family\",\n\n# DOI · #651\n\n-  \"index-category\": \"psychedelic; stimulant; dox\",\n+  \"index-category\": \"psychedelic\",\n-    \"alternative_name\": \"2,5-Dimethoxy-4-iodoamphetamine; Dimethoxyiodoamphetamine\",\n-    \"chemical_class\": \"Amphetamines; Substituted amphetamines\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n\n# TMA-6 · #655\n\n-    \"alternative_name\": \"2,4,6-Trimethoxyamphetamine; 2,4,6-TMA; psi-TMA-2\",\n-    \"chemical_class\": \"Amphetamine; Phenethylamine\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-      \"stimulant\",\n-      \"amphetamine\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-225755-1693f827",
    "createdAt": "2025-10-17T22:57:55.924Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 00:57:54"
    },
    "articles": [
      {
        "id": 200,
        "title": "Psilocybin Mushrooms",
        "slug": "psilocybin-mushrooms"
      },
      {
        "id": 631,
        "title": "LSA",
        "slug": "lsa"
      },
      {
        "id": 634,
        "title": "LSM-775",
        "slug": "lsm-775"
      },
      {
        "id": 645,
        "title": "Psilocin",
        "slug": "psilocin"
      },
      {
        "id": 650,
        "title": "2,5-DMA",
        "slug": "2-5-dma"
      },
      {
        "id": 651,
        "title": "DOI",
        "slug": "doi"
      },
      {
        "id": 655,
        "title": "TMA-6",
        "slug": "tma-6"
      }
    ],
    "markdown": "# Psilocybin Mushrooms · #200\n\n-      \"classic-psychedelic\",\n\n# LSA · #631\n\n-    \"chemical_class\": \"Lysergamide; Ergoline alkaloid\",\n+    \"chemical_class\": \"Lysergamide\",\n-      \"natural\",\n-      \"ergoline\"\n+      \"natural\"\n\n# LSM-775 · #634\n\n-      \"research-chemical\",\n-      \"novel-psychoactive-substance\"\n+      \"research-chemical\"\n\n# Psilocin · #645\n\n-      \"serotonergic\",\n-      \"entheogen\"\n+      \"serotonergic\"\n\n# 2,5-DMA · #650\n\n-      \"dox-family\",\n\n# DOI · #651\n\n-  \"index-category\": \"psychedelic; stimulant; dox\",\n+  \"index-category\": \"psychedelic\",\n-    \"alternative_name\": \"2,5-Dimethoxy-4-iodoamphetamine; Dimethoxyiodoamphetamine\",\n-    \"chemical_class\": \"Amphetamines; Substituted amphetamines\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n\n# TMA-6 · #655\n\n-    \"alternative_name\": \"2,4,6-Trimethoxyamphetamine; 2,4,6-TMA; psi-TMA-2\",\n-    \"chemical_class\": \"Amphetamine; Phenethylamine\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-      \"stimulant\",\n-      \"amphetamine\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-225716-849d325d",
    "createdAt": "2025-10-17T22:57:16.016Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 00:57:14"
    },
    "articles": [
      {
        "id": 200,
        "title": "Psilocybin Mushrooms",
        "slug": "psilocybin-mushrooms"
      },
      {
        "id": 631,
        "title": "LSA",
        "slug": "lsa"
      },
      {
        "id": 634,
        "title": "LSM-775",
        "slug": "lsm-775"
      },
      {
        "id": 645,
        "title": "Psilocin",
        "slug": "psilocin"
      },
      {
        "id": 650,
        "title": "2,5-DMA",
        "slug": "2-5-dma"
      },
      {
        "id": 651,
        "title": "DOI",
        "slug": "doi"
      },
      {
        "id": 655,
        "title": "TMA-6",
        "slug": "tma-6"
      }
    ],
    "markdown": "# Psilocybin Mushrooms · #200\n\n-      \"classic-psychedelic\",\n\n# LSA · #631\n\n-      \"natural\",\n-      \"ergoline\"\n+      \"natural\"\n\n# LSM-775 · #634\n\n-      \"research-chemical\",\n-      \"novel-psychoactive-substance\"\n+      \"research-chemical\"\n\n# Psilocin · #645\n\n-      \"serotonergic\",\n-      \"entheogen\"\n+      \"serotonergic\"\n\n# 2,5-DMA · #650\n\n-      \"dox-family\",\n\n# DOI · #651\n\n-  \"index-category\": \"psychedelic; stimulant; dox\",\n+  \"index-category\": \"psychedelic\",\n-    \"alternative_name\": \"2,5-Dimethoxy-4-iodoamphetamine; Dimethoxyiodoamphetamine\",\n-    \"chemical_class\": \"Amphetamines; Substituted amphetamines\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n\n# TMA-6 · #655\n\n-    \"alternative_name\": \"2,4,6-Trimethoxyamphetamine; 2,4,6-TMA; psi-TMA-2\",\n-    \"chemical_class\": \"Amphetamine; Phenethylamine\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-      \"stimulant\",\n-      \"amphetamine\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-225553-0c946599",
    "createdAt": "2025-10-17T22:55:53.864Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 00:55:50"
    },
    "articles": [
      {
        "id": 200,
        "title": "Psilocybin Mushrooms",
        "slug": "psilocybin-mushrooms"
      },
      {
        "id": 631,
        "title": "LSA",
        "slug": "lsa"
      },
      {
        "id": 634,
        "title": "LSM-775",
        "slug": "lsm-775"
      },
      {
        "id": 645,
        "title": "Psilocin",
        "slug": "psilocin"
      },
      {
        "id": 650,
        "title": "2,5-DMA",
        "slug": "2-5-dma"
      },
      {
        "id": 655,
        "title": "TMA-6",
        "slug": "tma-6"
      }
    ],
    "markdown": "# Psilocybin Mushrooms · #200\n\n-      \"classic-psychedelic\",\n\n# LSA · #631\n\n-      \"natural\",\n-      \"ergoline\"\n+      \"natural\"\n\n# LSM-775 · #634\n\n-      \"research-chemical\",\n-      \"novel-psychoactive-substance\"\n+      \"research-chemical\"\n\n# Psilocin · #645\n\n-      \"serotonergic\",\n-      \"entheogen\"\n+      \"serotonergic\"\n\n# 2,5-DMA · #650\n\n-      \"dox-family\",\n\n# TMA-6 · #655\n\n-    \"alternative_name\": \"2,4,6-Trimethoxyamphetamine; 2,4,6-TMA; psi-TMA-2\",\n-    \"chemical_class\": \"Amphetamine; Phenethylamine\",\n-    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"alternative_name\": \"\",\n+    \"chemical_class\": \"Psychedelic amphetamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n-      \"stimulant\",\n-      \"amphetamine\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-224638-e2ec09b9",
    "createdAt": "2025-10-17T22:46:38.115Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 00:46:34"
    },
    "articles": [
      {
        "id": 200,
        "title": "Psilocybin Mushrooms",
        "slug": "psilocybin-mushrooms"
      },
      {
        "id": 631,
        "title": "LSA",
        "slug": "lsa"
      },
      {
        "id": 634,
        "title": "LSM-775",
        "slug": "lsm-775"
      },
      {
        "id": 645,
        "title": "Psilocin",
        "slug": "psilocin"
      },
      {
        "id": 650,
        "title": "2,5-DMA",
        "slug": "2-5-dma"
      }
    ],
    "markdown": "# Psilocybin Mushrooms · #200\n\n-      \"classic-psychedelic\",\n\n# LSA · #631\n\n-      \"natural\",\n-      \"ergoline\"\n+      \"natural\"\n\n# LSM-775 · #634\n\n-      \"research-chemical\",\n-      \"novel-psychoactive-substance\"\n+      \"research-chemical\"\n\n# Psilocin · #645\n\n-      \"serotonergic\",\n-      \"entheogen\"\n+      \"serotonergic\"\n\n# 2,5-DMA · #650\n\n-      \"dox-family\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-223937-dd93a95c",
    "createdAt": "2025-10-17T22:39:37.130Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 00:39:34"
    },
    "articles": [
      {
        "id": 133,
        "title": "Cocaine",
        "slug": "cocaine"
      }
    ],
    "markdown": "# Cocaine · #133\n\n-  \"title\": \"Crack\",\n+  \"title\": \"Cocaine\",\n-    \"drug_name\": \"Crack\",\n-    \"chemical_name\": \"Cocaine\",\n-    \"alternative_name\": \"Cocaine\",\n+    \"drug_name\": \"Cocaine\",\n+    \"chemical_name\": \"Benzoylmethylecgonine\",\n+    \"alternative_name\": \"Coke; Blow; White; Snow; Crack\",\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n+            \"total_duration\": \"30-90 minutes\",\n+            \"onset\": \"1-3 minutes\",\n+            \"peak\": \"15-30 minutes\",\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-          \"canonical_routes\": [\n-            \"intravenous\"\n-          ],\n+            \"total_duration\": \"30-90 minutes\",\n+            \"peak\": \"15-30 minutes\",\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"intravenous\"\n+          ]\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ],\n+            \"total_duration\": \"30-90 minutes\",\n+            \"peak\": \"15-30 minutes\",\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n-      \"habit-forming\",\n-      \"research-chemical\"\n+      \"habit-forming\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-223318-678eb5f6",
    "createdAt": "2025-10-17T22:33:18.182Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 00:33:15"
    },
    "articles": [
      {
        "id": 191,
        "title": "LSD",
        "slug": "lsd"
      },
      {
        "id": 200,
        "title": "Psilocybin Mushrooms",
        "slug": "psilocybin-mushrooms"
      },
      {
        "id": 628,
        "title": "1V-LSD",
        "slug": "1v-lsd"
      },
      {
        "id": 629,
        "title": "ALD-52",
        "slug": "ald-52"
      },
      {
        "id": 630,
        "title": "ETH-LAD",
        "slug": "eth-lad"
      },
      {
        "id": 631,
        "title": "LSA",
        "slug": "lsa"
      },
      {
        "id": 632,
        "title": "MiPLA",
        "slug": "mipla"
      },
      {
        "id": 634,
        "title": "LSM-775",
        "slug": "lsm-775"
      },
      {
        "id": 635,
        "title": "PRO-LAD",
        "slug": "pro-lad"
      }
    ],
    "markdown": "# LSD · #191\n\n-    \"chemical_name\": \"Lysergic acid diethylamide\",\n+    \"chemical_name\": \"d-Lysergic acid diethylamide\",\n\n# Psilocybin Mushrooms · #200\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"plant-based\"\n+      \"plant-based\",\n+      \"common\"\n-  \"index-category\": \"psychedelic;classic;tryptamine\"\n+  \"index-category\": \"psychedelic; classic; tryptamine\"\n\n# 1V-LSD · #628\n\n-    \"alternative_name\": \"Valerie; 1-Valeryl-LSD; 1-Pentanoyl-LSD\",\n+    \"alternative_name\": \"Valerie\",\n\n# ALD-52 · #629\n\n-    \"chemical_name\": \"(6aR,9R)-4-Acetyl-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]-quinoline-9-carboxamide\",\n-    \"alternative_name\": \"1-Acetyl-LSD; 1A-LSD; 1A-LAD; Orange Sunshine\",\n+    \"chemical_name\": \"1-Acetyl-d-lysergic acid diethylamide\",\n+    \"alternative_name\": \"Orange Sunshine\",\n\n# ETH-LAD · #630\n\n-    \"chemical_name\": \"(6aR,9R)-N,N,7-Triethyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide\",\n+    \"chemical_name\": \"6-Ethyl-6-nor-lysergic acid diethylamide\",\n-            \"light\": \"30-60 ug\",\n+            \"light\": \"15-60 ug\",\n\n# LSA · #631\n\n-    \"chemical_name\": \"(8β)-9,10-Didehydro-6-methyl-ergoline-8-carboxamide\",\n-    \"alternative_name\": \"Ergine; d-Lysergic acid amide; d-Lysergamide; LA-111\",\n+    \"chemical_name\": \"d-Lysergic acid amide\",\n+    \"alternative_name\": \"Ergine; LA-111\",\n\n# MiPLA · #632\n\n-    \"chemical_name\": \"(6aR,9R)-N-methyl-N-isopropyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide\",\n-    \"alternative_name\": \"Lamide; Methylisopropyllysergamide; N-Methyl-N-isopropyllysergamide\",\n+    \"chemical_name\": \"Lysergic acid methylisopropylamide\",\n+    \"alternative_name\": \"Lamide\",\n\n# LSM-775 · #634\n\n-    \"chemical_name\": \"[(8beta)-6-Methyl-9,10-didehydroergolin-8-yl](morpholin-4-yl)methanone\",\n-    \"alternative_name\": \"Lysergic acid morpholide; N-Morpholinyllysergamide; LA-Morph; LSM\",\n+    \"chemical_name\": \"Lysergic acid morpholide\",\n+    \"alternative_name\": \"\",\n\n# PRO-LAD · #635\n\n-    \"chemical_name\": \"(8beta)-N,N-Diethyl-6-propyl-9,10-didehydroergoline-8-carboxamide\",\n-    \"alternative_name\": \"N-Propylnorlysergic acid N,N-diethylamide; 6-Propyl-6-nor-lysergic acid diethylamide; N-PropylnorLSD\",\n+    \"chemical_name\": \"6-Propyl-6-nor-lysergic acid diethylamide\",\n+    \"alternative_name\": \"\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-223147-1e6cc8e4",
    "createdAt": "2025-10-17T22:31:47.024Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 00:31:44"
    },
    "articles": [
      {
        "id": 191,
        "title": "LSD",
        "slug": "lsd"
      },
      {
        "id": 628,
        "title": "1V-LSD",
        "slug": "1v-lsd"
      },
      {
        "id": 629,
        "title": "ALD-52",
        "slug": "ald-52"
      },
      {
        "id": 630,
        "title": "ETH-LAD",
        "slug": "eth-lad"
      },
      {
        "id": 631,
        "title": "LSA",
        "slug": "lsa"
      },
      {
        "id": 632,
        "title": "MiPLA",
        "slug": "mipla"
      },
      {
        "id": 634,
        "title": "LSM-775",
        "slug": "lsm-775"
      },
      {
        "id": 635,
        "title": "PRO-LAD",
        "slug": "pro-lad"
      }
    ],
    "markdown": "# LSD · #191\n\n-    \"chemical_name\": \"Lysergic acid diethylamide\",\n+    \"chemical_name\": \"d-Lysergic acid diethylamide\",\n\n# 1V-LSD · #628\n\n-    \"alternative_name\": \"Valerie; 1-Valeryl-LSD; 1-Pentanoyl-LSD\",\n+    \"alternative_name\": \"Valerie\",\n\n# ALD-52 · #629\n\n-    \"chemical_name\": \"(6aR,9R)-4-Acetyl-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]-quinoline-9-carboxamide\",\n-    \"alternative_name\": \"1-Acetyl-LSD; 1A-LSD; 1A-LAD; Orange Sunshine\",\n+    \"chemical_name\": \"1-Acetyl-d-lysergic acid diethylamide\",\n+    \"alternative_name\": \"Orange Sunshine\",\n\n# ETH-LAD · #630\n\n-    \"chemical_name\": \"(6aR,9R)-N,N,7-Triethyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide\",\n+    \"chemical_name\": \"6-Ethyl-6-nor-lysergic acid diethylamide\",\n-            \"light\": \"30-60 ug\",\n+            \"light\": \"15-60 ug\",\n\n# LSA · #631\n\n-    \"chemical_name\": \"(8β)-9,10-Didehydro-6-methyl-ergoline-8-carboxamide\",\n-    \"alternative_name\": \"Ergine; d-Lysergic acid amide; d-Lysergamide; LA-111\",\n+    \"chemical_name\": \"d-Lysergic acid amide\",\n+    \"alternative_name\": \"Ergine; LA-111\",\n\n# MiPLA · #632\n\n-    \"chemical_name\": \"(6aR,9R)-N-methyl-N-isopropyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide\",\n-    \"alternative_name\": \"Lamide; Methylisopropyllysergamide; N-Methyl-N-isopropyllysergamide\",\n+    \"chemical_name\": \"Lysergic acid methylisopropylamide\",\n+    \"alternative_name\": \"Lamide\",\n\n# LSM-775 · #634\n\n-    \"chemical_name\": \"[(8beta)-6-Methyl-9,10-didehydroergolin-8-yl](morpholin-4-yl)methanone\",\n-    \"alternative_name\": \"Lysergic acid morpholide; N-Morpholinyllysergamide; LA-Morph; LSM\",\n+    \"chemical_name\": \"Lysergic acid morpholide\",\n+    \"alternative_name\": \"\",\n\n# PRO-LAD · #635\n\n-    \"chemical_name\": \"(8beta)-N,N-Diethyl-6-propyl-9,10-didehydroergoline-8-carboxamide\",\n-    \"alternative_name\": \"N-Propylnorlysergic acid N,N-diethylamide; 6-Propyl-6-nor-lysergic acid diethylamide; N-PropylnorLSD\",\n+    \"chemical_name\": \"6-Propyl-6-nor-lysergic acid diethylamide\",\n+    \"alternative_name\": \"\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-223101-a0dbd0f3",
    "createdAt": "2025-10-17T22:31:01.480Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 00:30:58"
    },
    "articles": [
      {
        "id": 628,
        "title": "1V-LSD",
        "slug": "1v-lsd"
      },
      {
        "id": 629,
        "title": "ALD-52",
        "slug": "ald-52"
      },
      {
        "id": 630,
        "title": "ETH-LAD",
        "slug": "eth-lad"
      },
      {
        "id": 631,
        "title": "LSA",
        "slug": "lsa"
      },
      {
        "id": 632,
        "title": "MiPLA",
        "slug": "mipla"
      },
      {
        "id": 634,
        "title": "LSM-775",
        "slug": "lsm-775"
      },
      {
        "id": 635,
        "title": "PRO-LAD",
        "slug": "pro-lad"
      }
    ],
    "markdown": "# 1V-LSD · #628\n\n-    \"alternative_name\": \"Valerie; 1-Valeryl-LSD; 1-Pentanoyl-LSD\",\n+    \"alternative_name\": \"Valerie\",\n\n# ALD-52 · #629\n\n-    \"chemical_name\": \"(6aR,9R)-4-Acetyl-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]-quinoline-9-carboxamide\",\n-    \"alternative_name\": \"1-Acetyl-LSD; 1A-LSD; 1A-LAD; Orange Sunshine\",\n+    \"chemical_name\": \"1-Acetyl-d-lysergic acid diethylamide\",\n+    \"alternative_name\": \"Orange Sunshine\",\n\n# ETH-LAD · #630\n\n-    \"chemical_name\": \"(6aR,9R)-N,N,7-Triethyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide\",\n+    \"chemical_name\": \"6-Ethyl-6-nor-lysergic acid diethylamide\",\n-            \"light\": \"30-60 ug\",\n+            \"light\": \"15-60 ug\",\n\n# LSA · #631\n\n-    \"chemical_name\": \"(8β)-9,10-Didehydro-6-methyl-ergoline-8-carboxamide\",\n-    \"alternative_name\": \"Ergine; d-Lysergic acid amide; d-Lysergamide; LA-111\",\n+    \"chemical_name\": \"d-Lysergic acid amide\",\n+    \"alternative_name\": \"Ergine; LA-111\",\n\n# MiPLA · #632\n\n-    \"chemical_name\": \"(6aR,9R)-N-methyl-N-isopropyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide\",\n-    \"alternative_name\": \"Lamide; Methylisopropyllysergamide; N-Methyl-N-isopropyllysergamide\",\n+    \"chemical_name\": \"Lysergic acid methylisopropylamide\",\n+    \"alternative_name\": \"Lamide\",\n\n# LSM-775 · #634\n\n-    \"chemical_name\": \"[(8beta)-6-Methyl-9,10-didehydroergolin-8-yl](morpholin-4-yl)methanone\",\n-    \"alternative_name\": \"Lysergic acid morpholide; N-Morpholinyllysergamide; LA-Morph; LSM\",\n+    \"chemical_name\": \"Lysergic acid morpholide\",\n+    \"alternative_name\": \"\",\n\n# PRO-LAD · #635\n\n-    \"chemical_name\": \"(8beta)-N,N-Diethyl-6-propyl-9,10-didehydroergoline-8-carboxamide\",\n-    \"alternative_name\": \"N-Propylnorlysergic acid N,N-diethylamide; 6-Propyl-6-nor-lysergic acid diethylamide; N-PropylnorLSD\",\n+    \"chemical_name\": \"6-Propyl-6-nor-lysergic acid diethylamide\",\n+    \"alternative_name\": \"\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-222634-f8c2838b",
    "createdAt": "2025-10-17T22:26:34.604Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 00:26:31"
    },
    "articles": [
      {
        "id": 628,
        "title": "1V-LSD",
        "slug": "1v-lsd"
      },
      {
        "id": 629,
        "title": "ALD-52",
        "slug": "ald-52"
      },
      {
        "id": 630,
        "title": "ETH-LAD",
        "slug": "eth-lad"
      },
      {
        "id": 631,
        "title": "LSA",
        "slug": "lsa"
      },
      {
        "id": 632,
        "title": "MiPLA",
        "slug": "mipla"
      },
      {
        "id": 634,
        "title": "LSM-775",
        "slug": "lsm-775"
      }
    ],
    "markdown": "# 1V-LSD · #628\n\n-    \"alternative_name\": \"Valerie; 1-Valeryl-LSD; 1-Pentanoyl-LSD\",\n+    \"alternative_name\": \"Valerie\",\n\n# ALD-52 · #629\n\n-    \"chemical_name\": \"(6aR,9R)-4-Acetyl-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]-quinoline-9-carboxamide\",\n-    \"alternative_name\": \"1-Acetyl-LSD; 1A-LSD; 1A-LAD; Orange Sunshine\",\n+    \"chemical_name\": \"1-Acetyl-d-lysergic acid diethylamide\",\n+    \"alternative_name\": \"Orange Sunshine\",\n\n# ETH-LAD · #630\n\n-    \"chemical_name\": \"(6aR,9R)-N,N,7-Triethyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide\",\n+    \"chemical_name\": \"6-Ethyl-6-nor-lysergic acid diethylamide\",\n-            \"light\": \"30-60 ug\",\n+            \"light\": \"15-60 ug\",\n\n# LSA · #631\n\n-    \"chemical_name\": \"(8β)-9,10-Didehydro-6-methyl-ergoline-8-carboxamide\",\n-    \"alternative_name\": \"Ergine; d-Lysergic acid amide; d-Lysergamide; LA-111\",\n+    \"chemical_name\": \"d-Lysergic acid amide\",\n+    \"alternative_name\": \"Ergine; LA-111\",\n\n# MiPLA · #632\n\n-    \"chemical_name\": \"(6aR,9R)-N-methyl-N-isopropyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide\",\n-    \"alternative_name\": \"Lamide; Methylisopropyllysergamide; N-Methyl-N-isopropyllysergamide\",\n+    \"chemical_name\": \"Lysergic acid methylisopropylamide\",\n+    \"alternative_name\": \"Lamide\",\n\n# LSM-775 · #634\n\n-    \"chemical_name\": \"[(8beta)-6-Methyl-9,10-didehydroergolin-8-yl](morpholin-4-yl)methanone\",\n-    \"alternative_name\": \"Lysergic acid morpholide; N-Morpholinyllysergamide; LA-Morph; LSM\",\n+    \"chemical_name\": \"Lysergic acid morpholide\",\n+    \"alternative_name\": \"\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-222215-fbbbfbe1",
    "createdAt": "2025-10-17T22:22:15.676Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 00:22:13"
    },
    "articles": [
      {
        "id": 628,
        "title": "1V-LSD",
        "slug": "1v-lsd"
      },
      {
        "id": 629,
        "title": "ALD-52",
        "slug": "ald-52"
      },
      {
        "id": 630,
        "title": "ETH-LAD",
        "slug": "eth-lad"
      },
      {
        "id": 631,
        "title": "LSA",
        "slug": "lsa"
      },
      {
        "id": 634,
        "title": "LSM-775",
        "slug": "lsm-775"
      }
    ],
    "markdown": "# 1V-LSD · #628\n\n-    \"alternative_name\": \"Valerie; 1-Valeryl-LSD; 1-Pentanoyl-LSD\",\n+    \"alternative_name\": \"Valerie\",\n\n# ALD-52 · #629\n\n-    \"chemical_name\": \"(6aR,9R)-4-Acetyl-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]-quinoline-9-carboxamide\",\n-    \"alternative_name\": \"1-Acetyl-LSD; 1A-LSD; 1A-LAD; Orange Sunshine\",\n+    \"chemical_name\": \"1-Acetyl-d-lysergic acid diethylamide\",\n+    \"alternative_name\": \"Orange Sunshine\",\n\n# ETH-LAD · #630\n\n-    \"chemical_name\": \"(6aR,9R)-N,N,7-Triethyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide\",\n+    \"chemical_name\": \"6-Ethyl-6-nor-lysergic acid diethylamide\",\n-            \"light\": \"30-60 ug\",\n+            \"light\": \"15-60 ug\",\n\n# LSA · #631\n\n-    \"chemical_name\": \"(8β)-9,10-Didehydro-6-methyl-ergoline-8-carboxamide\",\n-    \"alternative_name\": \"Ergine; d-Lysergic acid amide; d-Lysergamide; LA-111\",\n+    \"chemical_name\": \"d-Lysergic acid amide\",\n+    \"alternative_name\": \"Ergine; LA-111\",\n\n# LSM-775 · #634\n\n-    \"chemical_name\": \"[(8beta)-6-Methyl-9,10-didehydroergolin-8-yl](morpholin-4-yl)methanone\",\n-    \"alternative_name\": \"Lysergic acid morpholide; N-Morpholinyllysergamide; LA-Morph; LSM\",\n+    \"chemical_name\": \"Lysergic acid morpholide\",\n+    \"alternative_name\": \"\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-221822-e197294f",
    "createdAt": "2025-10-17T22:18:22.551Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 00:18:19"
    },
    "articles": [
      {
        "id": 628,
        "title": "1V-LSD",
        "slug": "1v-lsd"
      },
      {
        "id": 629,
        "title": "ALD-52",
        "slug": "ald-52"
      },
      {
        "id": 630,
        "title": "ETH-LAD",
        "slug": "eth-lad"
      },
      {
        "id": 631,
        "title": "LSA",
        "slug": "lsa"
      }
    ],
    "markdown": "# 1V-LSD · #628\n\n-    \"alternative_name\": \"Valerie; 1-Valeryl-LSD; 1-Pentanoyl-LSD\",\n+    \"alternative_name\": \"Valerie\",\n\n# ALD-52 · #629\n\n-    \"chemical_name\": \"(6aR,9R)-4-Acetyl-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]-quinoline-9-carboxamide\",\n-    \"alternative_name\": \"1-Acetyl-LSD; 1A-LSD; 1A-LAD; Orange Sunshine\",\n+    \"chemical_name\": \"1-Acetyl-d-lysergic acid diethylamide\",\n+    \"alternative_name\": \"Orange Sunshine\",\n\n# ETH-LAD · #630\n\n-    \"chemical_name\": \"(6aR,9R)-N,N,7-Triethyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide\",\n+    \"chemical_name\": \"6-Ethyl-6-nor-lysergic acid diethylamide\",\n-            \"light\": \"30-60 ug\",\n+            \"light\": \"15-60 ug\",\n\n# LSA · #631\n\n-    \"chemical_name\": \"(8β)-9,10-Didehydro-6-methyl-ergoline-8-carboxamide\",\n-    \"alternative_name\": \"Ergine; d-Lysergic acid amide; d-Lysergamide; LA-111\",\n+    \"chemical_name\": \"d-Lysergic acid amide\",\n+    \"alternative_name\": \"Ergine; LA-111\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-220954-cba27055",
    "createdAt": "2025-10-17T22:09:54.431Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 00:09:52"
    },
    "articles": [
      {
        "id": 628,
        "title": "1V-LSD",
        "slug": "1v-lsd"
      },
      {
        "id": 629,
        "title": "ALD-52",
        "slug": "ald-52"
      },
      {
        "id": 630,
        "title": "ETH-LAD",
        "slug": "eth-lad"
      }
    ],
    "markdown": "# 1V-LSD · #628\n\n-    \"alternative_name\": \"Valerie; 1-Valeryl-LSD; 1-Pentanoyl-LSD\",\n+    \"alternative_name\": \"Valerie\",\n\n# ALD-52 · #629\n\n-    \"chemical_name\": \"(6aR,9R)-4-Acetyl-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]-quinoline-9-carboxamide\",\n-    \"alternative_name\": \"1-Acetyl-LSD; 1A-LSD; 1A-LAD; Orange Sunshine\",\n+    \"chemical_name\": \"1-Acetyl-d-lysergic acid diethylamide\",\n+    \"alternative_name\": \"Orange Sunshine\",\n\n# ETH-LAD · #630\n\n-    \"chemical_name\": \"(6aR,9R)-N,N,7-Triethyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide\",\n+    \"chemical_name\": \"6-Ethyl-6-nor-lysergic acid diethylamide\",\n-            \"light\": \"30-60 ug\",\n+            \"light\": \"15-60 ug\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-220355-972e3296",
    "createdAt": "2025-10-17T22:03:55.871Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 18/10/2025, 00:03:53"
    },
    "articles": [
      {
        "id": 628,
        "title": "1V-LSD",
        "slug": "1v-lsd"
      },
      {
        "id": 629,
        "title": "ALD-52",
        "slug": "ald-52"
      }
    ],
    "markdown": "# 1V-LSD · #628\n\n-    \"alternative_name\": \"Valerie; 1-Valeryl-LSD; 1-Pentanoyl-LSD\",\n+    \"alternative_name\": \"Valerie\",\n\n# ALD-52 · #629\n\n-    \"chemical_name\": \"(6aR,9R)-4-Acetyl-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]-quinoline-9-carboxamide\",\n-    \"alternative_name\": \"1-Acetyl-LSD; 1A-LSD; 1A-LAD; Orange Sunshine\",\n+    \"chemical_name\": \"1-Acetyl-d-lysergic acid diethylamide\",\n+    \"alternative_name\": \"Orange Sunshine\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-220000-06e441b8",
    "createdAt": "2025-10-17T22:00:00.812Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 17/10/2025, 23:59:58"
    },
    "articles": [
      {
        "id": 628,
        "title": "1V-LSD",
        "slug": "1v-lsd"
      }
    ],
    "markdown": "# 1V-LSD · #628\n\n-    \"alternative_name\": \"Valerie; 1-Valeryl-LSD; 1-Pentanoyl-LSD\",\n+    \"alternative_name\": \"Valerie\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251017-024248-d777a0e9",
    "createdAt": "2025-10-17T02:42:48.647Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 8:42:45 PM"
    },
    "articles": [
      {
        "id": 659,
        "title": "Benzydamine",
        "slug": "benzydamine"
      }
    ],
    "markdown": "# Benzydamine · #659\n\n+{\n+  \"title\": \"Benzydamine\",\n+  \"index-category\": \"deliriant; stimulant\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Benzydamine\",\n+    \"chemical_name\": \"3-(1-Benzyl-1H-indazol-3-yloxy)-N,N-dimethylpropan-1-amine\",\n+    \"alternative_name\": \"Tantum Verde; Difflam; Benflogin; Andole\",\n+    \"chemical_class\": \"Indazoles\",\n+    \"psychoactive_class\": \"Deliriant; Stimulant\",\n+    \"mechanism_of_action\": \"Possible CB1 cannabinoid receptor agonist (speculated); possible 5-HT2A receptor agonist (speculated); prostaglandin synthetase inhibitor; mechanism underlying hallucinogenic effects remains unstudied\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"150 mg\",\n+            \"light\": \"300-500 mg\",\n+            \"common\": \"500-1000 mg\",\n+            \"strong\": \"1000-2000 mg\",\n+            \"heavy\": \"2000+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"5-8 hours\",\n+            \"onset\": \"20-60 minutes\",\n+            \"peak\": \"3-6 hours\",\n+            \"offset\": \"3-8 hours\",\n+            \"after_effects\": \"24-72 hours (residual stimulation and insomnia)\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Benzydamine exhibits powerful reinforcing effects in animal models and shows cross-sensitization with drugs like heroin and cocaine. Individuals with prior substance abuse history may be at significantly higher risk for developing benzydamine dependence due to neurobiological sensitivity to its effects.\",\n+    \"interactions\": {\n+      \"dangerous\": [],\n+      \"unsafe\": [\n+        \"Other deliriants (overwhelming and unpredictable effects)\",\n+        \"Stimulants (increased cardiovascular stress and anxiety)\"\n+      ],\n+      \"caution\": [\n+        \"Alcohol (commonly combined; may exacerbate dehydration and confusion)\",\n+        \"Cannabis (frequently co-used by recreational users)\",\n+        \"Benzodiazepines (may blunt effects but can increase confusion)\",\n+        \"CNS depressants (may create unpredictable interactions)\"\n+      ]\n+    },\n+    \"notes\": \"Benzydamine products, particularly Tantum Rosa vaginal douching sachets, contain dangerous levels of sodium chloride that can cause severe kidney damage if ingested directly. Proper salt extraction using water filtration is essential before consumption. The substance causes severe and prolonged insomnia lasting up to 48 hours, producing taxing sleep deprivation that often triggers paranoia. Legal and available over-the-counter in many countries for legitimate throat and mouth inflammation treatment. Individuals with personal or family history of psychotic disorders should avoid use due to risk of persistent psychotic symptoms.\",\n+    \"subjective_effects\": [\n+      \"Intense Stimulation\",\n+      \"External Hallucinations (Shadow People, Animals, Autonomous Entities)\",\n+      \"Auditory Hallucinations\",\n+      \"Visual Tracers and After Images\",\n+      \"Delirium and Confusion\",\n+      \"Anxiety and Paranoia\",\n+      \"Feelings of Impending Doom\",\n+      \"Euphoria (During Onset Only)\",\n+      \"Motor Control Loss\",\n+      \"Tactile Suppression\",\n+      \"Time Distortion\",\n+      \"Frequent Urination\",\n+      \"Dehydration\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops rapidly with consecutive use\",\n+      \"half_tolerance\": \"3-7 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n+      \"cross_tolerances\": [\n+        \"Other deliriants (e.g., diphenhydramine, datura)\"\n+      ]\n+    },\n+    \"half_life\": \"7-8 hours\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: Benzydamine\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Benzydamine\"\n+      },\n+      {\n+        \"name\": \"Erowid Benzydamine Experience Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_Benzydamine.shtml\"\n+      },\n+      {\n+        \"name\": \"Bluelight: Benzydamine Discussion Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/benzydamine-nsaid-stimulant-psychedelic.353442/\"\n+      },\n+      {\n+        \"name\": \"Drugs-Forum: Benzydamine Discussion\",\n+        \"reference\": \"https://drugs-forum.com/threads/so-i-have-benzydamine-hcl-a-deliriant.295883/\"\n+      },\n+      {\n+        \"name\": \"The Benzydamine Experience: A Systematic Review\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC8977632/\"\n+      },\n+      {\n+        \"name\": \"Benzydamine - An Affordable OTC Drug with Psychoactive Properties\",\n+        \"reference\": \"https://www.mdpi.com/1424-8247/16/4/566\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"deliriant\",\n+      \"stimulant\",\n+      \"indazole\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 659\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-015044-ecb73ef4",
    "createdAt": "2025-10-17T01:50:44.485Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 7:50:42 PM"
    },
    "articles": [
      {
        "id": 658,
        "title": "Nitrous Oxide",
        "slug": "nitrous-oxide"
      }
    ],
    "markdown": "# Nitrous Oxide · #658\n\n+{\n+  \"title\": \"Nitrous Oxide\",\n+  \"index-category\": \"dissociative; inhalant\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Nitrous Oxide\",\n+    \"chemical_name\": \"Dinitrogen monoxide\",\n+    \"alternative_name\": \"Laughing Gas; Nitrous; NOS; Hippy Crack; N2O; Nangs; Whippits; Nitro\",\n+    \"chemical_class\": \"Nitrogen oxide\",\n+    \"psychoactive_class\": \"Dissociative\",\n+    \"mechanism_of_action\": \"NMDA receptor antagonist (primary); GABA-A receptor potentiation; glycine receptor potentiation; nACh receptor antagonist (beta2-subunit); two-pore-domain K+ channel activation\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"inhaled\",\n+          \"units\": \"g\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"4 g\",\n+            \"light\": \"4-8 g (0.5-1 cartridge)\",\n+            \"common\": \"8-16 g (1-2 cartridges)\",\n+            \"strong\": \"16-40 g (2-5 cartridges)\",\n+            \"heavy\": \"40+ g (5+ cartridges)\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"inhaled\",\n+          \"stages\": {\n+            \"total_duration\": \"1-5 minutes\",\n+            \"onset\": \"5-10 seconds\",\n+            \"peak\": \"15-30 seconds\",\n+            \"offset\": \"1-5 minutes\",\n+            \"after_effects\": \"15-30 minutes\"\n+          },\n+          \"canonical_routes\": [\n+            \"inhaled\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Nitrous oxide is considered to have low to moderate abuse potential and low physical addiction potential. However, it is strongly psychologically compelling due to its brief duration and powerful effects, which can lead to compulsive redosing during a session. Frequent use is rare due to rapid tolerance development.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Alcohol (risk of unconsciousness, vomit aspiration, memory blackouts)\",\n+        \"GHB/GBL (risk of unconsciousness, vomit aspiration, ataxia)\",\n+        \"Opioids (risk of unconsciousness, vomit aspiration, respiratory depression)\",\n+        \"Tramadol (risk of unconsciousness, vomit aspiration)\"\n+      ],\n+      \"unsafe\": [],\n+      \"caution\": [\n+        \"Cannabis (potentiates effects)\",\n+        \"Psychedelics (dramatically intensifies visuals and ego dissolution)\",\n+        \"Dissociatives (intensifies disconnection and internal hallucinations)\",\n+        \"MDMA (may cause nausea)\"\n+      ]\n+    },\n+    \"notes\": \"Nitrous oxide can cause severe and potentially irreversible vitamin B12 depletion with frequent or chronic use, leading to serious neurological damage including numbness, tingling, and motor control loss. Always supplement with vitamin B12 when using this substance. Never inhale directly from cartridges or tanks due to extreme cold temperature (-40C) which can cause frostbite to lips, throat, and lungs, and high pressure which can rupture lung tissue. Always release gas into a balloon first to warm and depressurize. Ensure adequate oxygen intake between inhalations to prevent hypoxia and brain damage. Use while seated to prevent injury from falls. Filter gas through cloth or cotton to remove metal particles and industrial residue from food-grade cartridges.\",\n+    \"subjective_effects\": [\n+      \"Physical Euphoria\",\n+      \"Cognitive Euphoria\",\n+      \"Auditory Distortion\",\n+      \"Visual Geometry\",\n+      \"Ego Death\",\n+      \"Laughter Fits\",\n+      \"Motor Control Loss\",\n+      \"Dissociation\",\n+      \"Time Distortion\",\n+      \"Sedation\",\n+      \"Dizziness\",\n+      \"Tactile Suppression\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After 2-4 consecutive uses within hours\",\n+      \"half_tolerance\": \"3-7 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n+      \"cross_tolerances\": []\n+    },\n+    \"half_life\": \"5-10 minutes (less than 0.004% metabolized)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: Nitrous Oxide\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Nitrous\"\n+      },\n+      {\n+        \"name\": \"TripSit Nitrous Oxide Factsheet\",\n+        \"reference\": \"https://tripsit.me/factsheets/nitrous\"\n+      },\n+      {\n+        \"name\": \"TripSit Wiki: Nitrous Oxide\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/Nitrous_Oxide\"\n+      },\n+      {\n+        \"name\": \"Erowid Nitrous Oxide Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/nitrous/nitrous.shtml\"\n+      },\n+      {\n+        \"name\": \"Erowid Nitrous Oxide Basics\",\n+        \"reference\": \"https://www.erowid.org/chemicals/nitrous/nitrous_basics.shtml\"\n+      },\n+      {\n+        \"name\": \"Erowid Nitrous Oxide Effects\",\n+        \"reference\": \"https://www.erowid.org/chemicals/nitrous/nitrous_effects.shtml\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy Nitrous Thread (FAQ)\",\n+        \"reference\": \"https://bluelight.org/xf/threads/nitrous-oxide-whippits-nangs-johnny-gas-n2o-faq.54176/\"\n+      },\n+      {\n+        \"name\": \"DanceWize NSW: Nitrous Oxide Harm Reduction\",\n+        \"reference\": \"https://hi-ground.org/substances/nitrous-oxide/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"dissociative\",\n+      \"inhalant\",\n+      \"anesthetic\"\n+    ]\n+  },\n+  \"id\": 658\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-014715-6d864e1c",
    "createdAt": "2025-10-17T01:47:15.427Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 7:47:12 PM"
    },
    "articles": [
      {
        "id": 657,
        "title": "PCE",
        "slug": "pce"
      }
    ],
    "markdown": "# PCE · #657\n\n+{\n+  \"title\": \"PCE\",\n+  \"index-category\": \"dissociative; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"PCE\",\n+    \"chemical_name\": \"N-Ethyl-1-phenylcyclohexanamine\",\n+    \"alternative_name\": \"Eticyclidine; CI-400; Cyclohexamine\",\n+    \"chemical_class\": \"Arylcyclohexylamine\",\n+    \"psychoactive_class\": \"Dissociative\",\n+    \"mechanism_of_action\": \"NMDA receptor antagonist (noncompetitive); dopamine-noradrenaline reuptake inhibitor; serotonin reuptake inhibitor; suspected mu-opioid receptor affinity\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"1 mg\",\n+            \"light\": \"3-5 mg\",\n+            \"common\": \"5-10 mg\",\n+            \"strong\": \"10-15 mg\",\n+            \"heavy\": \"15+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"1 mg\",\n+            \"light\": \"3-5 mg\",\n+            \"common\": \"5-10 mg\",\n+            \"strong\": \"10-15 mg\",\n+            \"heavy\": \"15+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"smoked\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"1 mg\",\n+            \"light\": \"3-5 mg\",\n+            \"common\": \"5-10 mg\",\n+            \"strong\": \"10-15 mg\",\n+            \"heavy\": \"15+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"4-8 hours\",\n+            \"onset\": \"30-90 minutes\",\n+            \"peak\": \"2-3 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"4-48 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"stages\": {\n+            \"total_duration\": \"4-8 hours\",\n+            \"onset\": \"20-60 minutes\",\n+            \"peak\": \"2-3 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"4-48 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n+        },\n+        {\n+          \"route\": \"smoked\",\n+          \"stages\": {\n+            \"total_duration\": \"4-8 hours\",\n+            \"onset\": \"30-90 minutes\",\n+            \"peak\": \"2-3 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"4-48 hours\"\n+          }\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"The chronic use of PCE can be considered highly addictive with a high potential for adverse side effects such as psychosis. In comparison to other dissociatives, PCE has been reported to be more addictive than MXE, diphenidine, ephenidine, and ketamine. Multiple reports exist of people becoming seriously addicted daily users of this substance.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Depressants (increased risk of unconsciousness, vomiting, and fatal suffocation)\"\n+      ],\n+      \"unsafe\": [\n+        \"Psychedelics (extreme psychological disturbances, psychosis, and mania at significantly higher rates)\",\n+        \"Stimulants (increased risk of anxiety, mania, delusions, and psychosis)\"\n+      ],\n+      \"caution\": []\n+    },\n+    \"notes\": \"PCE is a potent dissociative that causes psychosis and mania at significantly higher rates than other dissociatives. Users should avoid taking the drug multiple days in a row or in high doses. Volumetric liquid dosing is strongly recommended due to the drug's extreme potency, as most standard milligram scales cannot accurately weigh doses below 10-15 mg. Compulsive redosing should be avoided. Long-term use may lead to severe memory loss, disorganized thinking, bladder and urinary tract problems, and schizophrenia-like psychotic episodes. Individuals with personal or family histories of psychotic disorders should avoid use. PCE is internationally controlled as a Schedule I substance.\",\n+    \"subjective_effects\": [\n+      \"Physical Euphoria\",\n+      \"Tactile Suppression\",\n+      \"Motor Control Loss\",\n+      \"Visual Disconnection\",\n+      \"Consciousness Disconnection\",\n+      \"Visual Acuity Suppression\",\n+      \"Cognitive Euphoria\",\n+      \"Thought Acceleration\",\n+      \"Depersonalization\",\n+      \"Derealization\",\n+      \"Memory Suppression\",\n+      \"Ego Death\",\n+      \"Mania\",\n+      \"Delusion\",\n+      \"Disinhibition\",\n+      \"Compulsive Redosing\",\n+      \"Nausea\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After prolonged and repeated use\",\n+      \"half_tolerance\": \"3-7 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n+      \"cross_tolerances\": [\n+        \"All dissociatives\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Bluelight PCE Bioassay Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/pce-bioassay-eight-human-trials-with-the-unicorn-dissociative-eticyclidine.927036/\"\n+      },\n+      {\n+        \"name\": \"Bluelight PCE Small & Handy Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-small-handy-pce-eticyclidine-thread.919539/\"\n+      },\n+      {\n+        \"name\": \"Erowid PCE Experience Reports\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_PCE.shtml\"\n+      },\n+      {\n+        \"name\": \"Morris & Wallach 2014: From PCP to MXE\",\n+        \"reference\": \"https://doi.org/10.1002/dta.1620\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: PCE\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/PCE\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"dissociative\",\n+      \"arylcyclohexylamine\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 657\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-013238-c5f65b8d",
    "createdAt": "2025-10-17T01:32:38.014Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 7:32:34 PM"
    },
    "articles": [
      {
        "id": 656,
        "title": "4-MeO-PCP",
        "slug": "4-meo-pcp"
      }
    ],
    "markdown": "# 4-MeO-PCP · #656\n\n+{\n+  \"title\": \"4-MeO-PCP\",\n+  \"index-category\": \"dissociative; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"4-MeO-PCP\",\n+    \"chemical_name\": \"1-[1-(4-Methoxyphenyl)cyclohexyl]piperidine\",\n+    \"alternative_name\": \"Methoxydine; 4-Methoxyphencyclidine; 4-Methoxy-PCP\",\n+    \"chemical_class\": \"Arylcyclohexylamine\",\n+    \"psychoactive_class\": \"Dissociative\",\n+    \"mechanism_of_action\": \"NMDA receptor antagonist (selective ligand without appreciable dopamine transporter affinity)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"25 mg\",\n+            \"light\": \"75-100 mg\",\n+            \"common\": \"100-170 mg\",\n+            \"strong\": \"170-250 mg\",\n+            \"heavy\": \"250+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"15 mg\",\n+            \"light\": \"30-75 mg\",\n+            \"common\": \"75-150 mg\",\n+            \"strong\": \"150+ mg\",\n+            \"heavy\": \"\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"12-20 hours\",\n+            \"onset\": \"45-120 minutes\",\n+            \"peak\": \"3-7 hours\",\n+            \"offset\": \"6-10 hours\",\n+            \"after_effects\": \"6+ hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"stages\": {\n+            \"total_duration\": \"12-18 hours\",\n+            \"onset\": \"5-15 minutes\",\n+            \"peak\": \"3-6 hours\",\n+            \"offset\": \"3 hours\",\n+            \"after_effects\": \"3 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"As with other NMDA receptor antagonists, the chronic use of 4-MeO-PCP can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage. The long duration may discourage frequent redosing compared to shorter-acting dissociatives.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Depressants (risk of respiratory depression, unconsciousness, vomiting and aspiration)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants (increased risk of anxiety, mania, delusions and psychosis)\"\n+      ],\n+      \"caution\": []\n+    },\n+    \"notes\": \"4-MeO-PCP is a long-acting dissociative with approximately 70% the potency of PCP. Users have reported substantial differences in active dose; these discrepancies may be partially explained by the presence of unreacted PCC and other impurities in samples sold on the grey market. Use a precise milligram scale for dosing. The extended duration of action can be both an advantage and disadvantage, with effects and after-effects persisting well into the next day. Chronic use may lead to urinary tract issues similar to ketamine, though less severe due to higher potency requiring smaller amounts. Set and setting are important, and users should avoid potentially hazardous activities during the experience.\",\n+    \"subjective_effects\": [\n+      \"Consciousness Disconnection\",\n+      \"Visual Disconnection\",\n+      \"Dizziness\",\n+      \"Motor Control Loss\",\n+      \"Physical Euphoria\",\n+      \"Spatial Disorientation\",\n+      \"Tactile Suppression\",\n+      \"Depersonalization\",\n+      \"Derealization\",\n+      \"Amnesia\",\n+      \"Time Distortion\",\n+      \"Creativity Enhancement\",\n+      \"Immersion Enhancement\",\n+      \"Increased Music Appreciation\",\n+      \"Internal Hallucinations\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After prolonged and repeated use\",\n+      \"half_tolerance\": \"3-7 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n+      \"cross_tolerances\": [\n+        \"All dissociatives\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy 4-MeO-PCP Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-4-meo-pcp-thread.391328/\"\n+      },\n+      {\n+        \"name\": \"Erowid 4-MeO-PCP Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/4meo_pcp/4meo_pcp.shtml\"\n+      },\n+      {\n+        \"name\": \"Isomer Design: 4-MeO-PCP\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=963\"\n+      },\n+      {\n+        \"name\": \"Morris H, Wallach J. From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs\",\n+        \"reference\": \"https://doi.org/10.1002/dta.1620\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: 4-MeO-PCP\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/4-MeO-PCP\"\n+      },\n+      {\n+        \"name\": \"Roth BL et al. The Ketamine Analogue Methoxetamine and 3- and 4-Methoxy Analogues of Phencyclidine Are High Affinity and Selective Ligands for the Glutamate NMDA Receptor\",\n+        \"reference\": \"https://doi.org/10.1371/journal.pone.0059334\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"dissociative\",\n+      \"arylcyclohexylamine\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 656\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-012541-c4d47db2",
    "createdAt": "2025-10-17T01:25:41.467Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 7:25:40 PM"
    },
    "articles": [
      {
        "id": 655,
        "title": "TMA-6",
        "slug": "tma-6"
      }
    ],
    "markdown": "# TMA-6 · #655\n\n+{\n+  \"title\": \"TMA-6\",\n+  \"index-category\": \"psychedelic; stimulant; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"TMA-6\",\n+    \"chemical_name\": \"1-(2,4,6-Trimethoxyphenyl)propan-2-amine\",\n+    \"alternative_name\": \"2,4,6-Trimethoxyamphetamine; 2,4,6-TMA; psi-TMA-2\",\n+    \"chemical_class\": \"Amphetamine; Phenethylamine\",\n+    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; potent MAO-A inhibitor (IC50 400 nM)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5-10 mg\",\n+            \"light\": \"10-20 mg\",\n+            \"common\": \"20-35 mg\",\n+            \"strong\": \"35-50 mg\",\n+            \"heavy\": \"50+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5-10 mg\",\n+            \"light\": \"10-15 mg\",\n+            \"common\": \"15-25 mg\",\n+            \"strong\": \"25-35 mg\",\n+            \"heavy\": \"35+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5-10 mg\",\n+            \"light\": \"10-15 mg\",\n+            \"common\": \"15-30 mg\",\n+            \"strong\": \"30-40 mg\",\n+            \"heavy\": \"40+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"vaporized\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5-10 mg\",\n+            \"light\": \"10-15 mg\",\n+            \"common\": \"15-25 mg\",\n+            \"strong\": \"25-35 mg\",\n+            \"heavy\": \"35+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"10-16 hours\",\n+            \"onset\": \"30-90 minutes\",\n+            \"peak\": \"5-8 hours\",\n+            \"offset\": \"3-5 hours\",\n+            \"after_effects\": \"6-18 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"stages\": {\n+            \"total_duration\": \"8-12 hours\",\n+            \"onset\": \"10-30 minutes\",\n+            \"peak\": \"4-6 hours\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"6-12 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n+        },\n+        {\n+          \"route\": \"rectal\",\n+          \"stages\": {\n+            \"total_duration\": \"8-14 hours\",\n+            \"onset\": \"10-30 minutes\",\n+            \"peak\": \"4-7 hours\",\n+            \"offset\": \"3-5 hours\",\n+            \"after_effects\": \"6-12 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"rectal\"\n+          ]\n+        },\n+        {\n+          \"route\": \"vaporized\",\n+          \"stages\": {\n+            \"total_duration\": \"6-11 hours\",\n+            \"onset\": \"5-15 minutes\",\n+            \"peak\": \"3-6 hours\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"4-12 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"TMA-6 is not considered habit-forming and has a low potential for psychological dependence. The desire to use it typically decreases with consumption, and rapid tolerance development discourages frequent redosing. It is generally self-regulating.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"MAOIs (risk of hypertensive crisis and serotonin syndrome; TMA-6 itself is a potent MAO-A inhibitor)\",\n+        \"Lithium (elevated risk of seizures and psychosis)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"Serotonin releasers (MDMA, 4-FA, methamphetamine, methylone, aMT; risk of serotonin syndrome)\",\n+        \"Stimulants (risk of excessive anxiety, panic, thought loops, and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"SSRIs (citalopram, sertraline; risk of serotonin syndrome and altered effects)\",\n+        \"SNRIs (venlafaxine; risk of serotonin syndrome)\",\n+        \"5-HTP (risk of serotonin syndrome)\",\n+        \"Other psychedelics (risk of overwhelming intensity and unpredictable interactions)\"\n+      ]\n+    },\n+    \"notes\": \"TMA-6 is a potent MAO-A inhibitor, which creates significant interaction risks and requires careful attention to dietary restrictions similar to pharmaceutical MAOIs. Individuals with personal or family histories of psychotic disorders should avoid use. The substance is highly dose-sensitive and produces unpredictable effects with considerable body load and nausea. Set and setting strongly influence the experience. Users should be prepared for an extended duration of 10-16 hours. Always use a precise scale for dosing.\",\n+    \"subjective_effects\": [\n+      \"Stimulation\",\n+      \"Spontaneous Tactile Sensations\",\n+      \"Tactile Enhancement\",\n+      \"Empathy And Sociability Enhancement\",\n+      \"Thought Acceleration\",\n+      \"Conceptual Thinking Enhancement\",\n+      \"Emotion Enhancement\",\n+      \"Time Distortion\",\n+      \"Visual Acuity Enhancement\",\n+      \"Colour Enhancement\",\n+      \"Drifting\",\n+      \"Nausea\",\n+      \"Vasoconstriction\",\n+      \"Increased Libido\",\n+      \"Music Appreciation Enhancement\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics\",\n+        \"All stimulants\"\n+      ]\n+    },\n+    \"half_life\": \"Not well documented; estimated 3-6 hours based on related compounds\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid TMA-6 Experience Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_TMA6.shtml\"\n+      },\n+      {\n+        \"name\": \"Erowid TMA-6 Comparison Information\",\n+        \"reference\": \"https://erowid.org/chemicals/tma2/tma2_info1.shtml\"\n+      },\n+      {\n+        \"name\": \"Isomer Design PiHKAL Entry #162 TMA-6\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=162\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki TMA-6\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/TMA-6\"\n+      },\n+      {\n+        \"name\": \"Bluelight TMA Series Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/suprise-substance-of-july-the-tma-series.384752/\"\n+      },\n+      {\n+        \"name\": \"Wikipedia 2,4,6-Trimethoxyamphetamine\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/2,4,6-Trimethoxyamphetamine\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"stimulant\",\n+      \"amphetamine\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 655\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-012038-a0dcd9b9",
    "createdAt": "2025-10-17T01:20:38.225Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 7:20:36 PM"
    },
    "articles": [
      {
        "id": 654,
        "title": "25N-NBOMe",
        "slug": "25n-nbome"
      }
    ],
    "markdown": "# 25N-NBOMe · #654\n\n+{\n+  \"title\": \"25N-NBOMe\",\n+  \"index-category\": \"psychedelic; research-chemical; dangerous\",\n+  \"drug_info\": {\n+    \"drug_name\": \"25N-NBOMe\",\n+    \"chemical_name\": \"2-(2,5-dimethoxy-4-nitrophenyl)-N-(2-methoxybenzyl)ethanamine\",\n+    \"alternative_name\": \"2C-N-NBOMe; NBOMe-2C-N; N-Bomb\",\n+    \"chemical_class\": \"Phenethylamines\",\n+    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"mechanism_of_action\": \"5-HT2A receptor full agonist; 5-HT2C receptor full agonist; 5-HT2B receptor partial agonist; dopamine transporter phosphorylation (increases extracellular dopamine)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"sublingual\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"100 ug\",\n+            \"light\": \"100-300 ug\",\n+            \"common\": \"300-800 ug\",\n+            \"strong\": \"800-1300 ug\",\n+            \"heavy\": \"1300+ ug (potentially fatal)\"\n+          }\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"Not recommended\",\n+            \"light\": \"Not recommended\",\n+            \"common\": \"Not recommended\",\n+            \"strong\": \"Not recommended\",\n+            \"heavy\": \"Not recommended (extremely dangerous)\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"sublingual\",\n+          \"stages\": {\n+            \"total_duration\": \"5-10 hours\",\n+            \"onset\": \"45-75 minutes\",\n+            \"peak\": \"2-3 hours\",\n+            \"offset\": \"2-3 hours\",\n+            \"after_effects\": \"5-10 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"sublingual\"\n+          ]\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"stages\": {\n+            \"total_duration\": \"5-10 hours\",\n+            \"onset\": \"45-75 minutes\",\n+            \"peak\": \"2-3 hours\",\n+            \"offset\": \"2-3 hours\",\n+            \"after_effects\": \"5-10 hours\"\n+          }\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"25N-NBOMe is not considered habit-forming and the desire to use often decreases with repeated administration. However, animal studies suggest potential dependence liability through dopaminergic pathways, with conditioned place preference effects comparable to methamphetamine in rodent models. The substance exhibits rapid tolerance development.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases seizure risk)\",\n+        \"MAOIs (unpredictable potentiation and duration increase)\",\n+        \"Tramadol (significantly lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"Amphetamines (severe cardiovascular strain, tachycardia, hypertension, and increased seizure risk)\",\n+        \"Cocaine (severe cardiovascular strain and vasoconstriction)\",\n+        \"MDMA (unpredictable intensity, reports of blackouts and severe overstimulation)\",\n+        \"MXE (unpleasantly intense potentiation)\",\n+        \"DOx compounds (unpredictable interactions)\",\n+        \"2C-T-X compounds (unpredictable interactions)\",\n+        \"5-MeO-xxt compounds (unpredictable interactions)\",\n+        \"aMT (increased cardiovascular risk)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (significantly increases anxiety, paranoia, and psychosis risk)\",\n+        \"Caffeine (uncomfortable overstimulation and anxiety)\",\n+        \"DXM (unpredictable interactions)\"\n+      ]\n+    },\n+    \"notes\": \"25N-NBOMe is a highly potent and unpredictable substance that has been linked to numerous hospitalizations and fatalities within the NBOMe series. The compound must only be administered sublingually, as insufflation dramatically increases overdose risk and has been implicated in multiple deaths. Blotter papers may contain uneven dose distribution with dangerous hotspots. Users should employ accurate microgram scales, avoid all drug combinations, and never exceed 1000 ug due to narrow margin between active and toxic doses. Individuals with cardiovascular conditions, seizure disorders, or personal or family history of psychotic disorders should strictly avoid use. The substance is often misrepresented as LSD; always use reagent testing.\",\n+    \"subjective_effects\": [\n+      \"Intense Visual Patterning And Geometry\",\n+      \"Strong Physical Stimulation\",\n+      \"Perception Of Bodily Lightness\",\n+      \"Euphoric Body High\",\n+      \"Tactile Enhancement\",\n+      \"Colour Enhancement\",\n+      \"Time Distortion\",\n+      \"Empathy And Sociability Enhancement (Inconsistent)\",\n+      \"Thought Acceleration\",\n+      \"Anxiety And Paranoia\",\n+      \"Mouth Numbing\",\n+      \"Increased Heart Rate\",\n+      \"Vasoconstriction\",\n+      \"Nausea (Especially During Onset)\",\n+      \"Muscle Tension\",\n+      \"Pupil Dilation\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Immediately after use\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (LSD, psilocybin, mescaline, 2C-x, other NBOMes)\"\n+      ]\n+    },\n+    \"half_life\": \"1-3 hours (estimated from related compounds)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy 25N-NBOMe Thread\",\n+        \"reference\": \"http://www.bluelight.org/vb/threads/539694-The-Big-amp-Dandy-25N-NBOMe-Thread\"\n+      },\n+      {\n+        \"name\": \"Erowid: NBOMe Series Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/nbome/\"\n+      },\n+      {\n+        \"name\": \"Frontiers in Neuroscience: NBOMes - Highly Potent and Toxic Alternatives of LSD\",\n+        \"reference\": \"https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2020.00078/full\"\n+      },\n+      {\n+        \"name\": \"Isomer Design: 25N-NBOMe\",\n+        \"reference\": \"https://isomerdesign.com/pihkal/\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: 25N-NBOMe\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/25N-NBOMe\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: 25N-NBOMe\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/25N-NBOMe\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"nbome\",\n+      \"phenethylamine\",\n+      \"psychedelic\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 654\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-011657-22e845ad",
    "createdAt": "2025-10-17T01:16:57.045Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 7:16:53 PM"
    },
    "articles": [
      {
        "id": 653,
        "title": "25D-NBOMe",
        "slug": "25d-nbome"
      }
    ],
    "markdown": "# 25D-NBOMe · #653\n\n+{\n+  \"title\": \"25D-NBOMe\",\n+  \"index-category\": \"psychedelic; research-chemical; nbome\",\n+  \"drug_info\": {\n+    \"drug_name\": \"25D-NBOMe\",\n+    \"chemical_name\": \"2-(2,5-Dimethoxy-4-methylphenyl)-N-(2-methoxybenzyl)ethanamine\",\n+    \"alternative_name\": \"2C-D-NBOMe; NBOMe-2C-D; Divination; N-Bomb\",\n+    \"chemical_class\": \"Phenethylamines\",\n+    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist (partial); 5-HT2B receptor agonist; 5-HT2C receptor agonist; adrenergic alpha-1 receptor agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"sublingual\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"300 ug\",\n+            \"light\": \"300-800 ug\",\n+            \"common\": \"800-1000 ug\",\n+            \"strong\": \"1000-1200 ug\",\n+            \"heavy\": \"1200+ ug\"\n+          }\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"200 ug\",\n+            \"light\": \"200-600 ug\",\n+            \"common\": \"600-800 ug\",\n+            \"strong\": \"800-1000 ug\",\n+            \"heavy\": \"1000+ ug\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"sublingual\",\n+          \"stages\": {\n+            \"total_duration\": \"4-6 hours\",\n+            \"onset\": \"20-40 minutes\",\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"6+ hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"sublingual\"\n+          ]\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"stages\": {\n+            \"total_duration\": \"3-5 hours\",\n+            \"onset\": \"5-15 minutes\",\n+            \"peak\": \"45-90 minutes\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"4-6 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"25D-NBOMe has not been formally studied for addiction potential but appears to have a self-regulating quality with immediate tolerance buildup. Rapid tolerance develops after use, lasting approximately 2-3 weeks. Animal studies have shown reinforcing effects including conditioned place preference and self-administration behavior, suggesting some potential for psychological reinforcement.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increased seizure risk)\",\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"MAOIs (hypertensive crisis risk, unpredictable potentiation)\",\n+        \"Amphetamines (severe cardiovascular stress, tachycardia, hypertension, potential heart failure)\",\n+        \"Cocaine (severe vasoconstriction, tachycardia, hypertension, potential heart failure)\"\n+      ],\n+      \"unsafe\": [\n+        \"2C-T-X compounds (unpredictable interactions)\",\n+        \"5-MeO-xxt compounds (unpredictable interactions)\",\n+        \"aMT (unpredictable cardiovascular effects)\",\n+        \"DOx compounds (prolonged stimulation, cardiovascular strain)\",\n+        \"DXM (unpredictable effects)\",\n+        \"MDMA (cardiovascular strain, hyperthermia risk)\",\n+        \"MXE (potentiation of NBOMe effects)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (significantly increases anxiety, paranoia, and unpredictable psychological effects)\",\n+        \"Caffeine (increases uncomfortable stimulation and anxiety)\",\n+        \"SSRIs (may blunt or prolong effects)\"\n+      ]\n+    },\n+    \"notes\": \"25D-NBOMe is a highly potent research chemical with an extremely narrow margin between active and potentially lethal doses. The compound is not orally active and must be administered sublingually or via other mucosal routes. Never insufflate NBOMe compounds as this route has been associated with numerous fatalities. Blotter paper doses are notoriously inconsistent due to hotspots of concentrated material. Use only with an analytical balance for weighing, never eyeball doses. Those with personal or family history of psychotic disorders, cardiovascular conditions, or seizure disorders should avoid this substance entirely. The compound produces dose-dependent vasoconstriction and cardiovascular strain. Set and setting are critical; always have a sober trip sitter present. Many deaths have occurred from individuals believing they consumed LSD when they actually ingested an NBOMe compound.\",\n+    \"subjective_effects\": [\n+      \"Visual Acuity Enhancement\",\n+      \"Color Enhancement\",\n+      \"Visual Geometry\",\n+      \"Tracers and After Images\",\n+      \"Physical Euphoria\",\n+      \"Stimulation\",\n+      \"Tactile Hallucination\",\n+      \"Time Distortion\",\n+      \"Mouth and Tongue Numbness\",\n+      \"Metallic Chemical Taste\",\n+      \"Spontaneous Bodily Sensations\",\n+      \"Thought Acceleration\",\n+      \"Music Appreciation Enhancement\",\n+      \"Emotional Amplification\",\n+      \"Nausea\",\n+      \"Vasoconstriction\",\n+      \"Increased Heart Rate\",\n+      \"Increased Blood Pressure\",\n+      \"Temperature Regulation Suppression\",\n+      \"Muscle Tension and Cramps\",\n+      \"Headaches\",\n+      \"Anxiety and Paranoia\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops immediately after use\",\n+      \"half_tolerance\": \"Approximately 1 week\",\n+      \"zero_tolerance\": \"2-3 weeks\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics\",\n+        \"Other NBOMe compounds\",\n+        \"2C-x series\"\n+      ]\n+    },\n+    \"half_life\": \"1-3 hours (parent compound rapidly cleared from blood)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Alcohol and Drug Foundation: NBOMes\",\n+        \"reference\": \"https://adf.org.au/drug-facts/nbomes/\"\n+      },\n+      {\n+        \"name\": \"Erowid 25D-NBOMe Experience Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_25DNBOMe.shtml\"\n+      },\n+      {\n+        \"name\": \"Erowid NBOMe Series Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/nbome/\"\n+      },\n+      {\n+        \"name\": \"Frontiers in Neuroscience: NBOMes - Highly Potent and Toxic Alternatives of LSD\",\n+        \"reference\": \"https://www.frontiersin.org/articles/10.3389/fnins.2020.00078/full\"\n+      },\n+      {\n+        \"name\": \"Isomer Design: 25D-NBOMe\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=342\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: 25D-NBOMe\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/25D-NBOMe\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: 25D-NBOMe\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/25D-NBOMe\"\n+      },\n+      {\n+        \"name\": \"Yoon et al. (2019): Cardiac Effects of 25D-NBOMe and 25C-NBOMe\",\n+        \"reference\": \"https://doi.org/10.1016/j.toxlet.2019.01.004\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"research-chemical\",\n+      \"nbome-series\",\n+      \"phenethylamine\"\n+    ]\n+  },\n+  \"id\": 653\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-011004-caa3a24b",
    "createdAt": "2025-10-17T01:10:04.318Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 7:10:02 PM"
    },
    "articles": [
      {
        "id": 652,
        "title": "25C-NBOH",
        "slug": "25c-nboh"
      }
    ],
    "markdown": "# 25C-NBOH · #652\n\n+{\n+  \"title\": \"25C-NBOH\",\n+  \"index-category\": \"psychedelic; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"25C-NBOH\",\n+    \"chemical_name\": \"2-(4-Chloro-2,5-dimethoxyphenyl)-N-[(2-hydroxyphenyl)methyl]ethanamine\",\n+    \"alternative_name\": \"2C-C-NBOH; NBOH-2C-C; N-bomb; NBOH\",\n+    \"chemical_class\": \"Phenethylamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist (potent, pEC50 9.43); 5-HT2C receptor agonist (pKi 7.8)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"sublingual\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"100 ug\",\n+            \"light\": \"250-500 ug\",\n+            \"common\": \"500-750 ug\",\n+            \"strong\": \"750-1000 ug\",\n+            \"heavy\": \"1000+ ug (potentially fatal)\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"sublingual\",\n+          \"stages\": {\n+            \"total_duration\": \"5-7 hours\",\n+            \"onset\": \"15-45 minutes\",\n+            \"peak\": \"90-180 minutes (come up 30-90 minutes)\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"3-6 days (afterglow may persist)\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"25C-NBOH is not considered habit-forming and the desire to use it typically decreases with repeated use. The substance is generally self-regulating, though research on its addiction potential is extremely limited.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"MAOIs (potentially dangerous interaction)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants (increased risk of anxiety, paranoia, panic attacks, thought loops, mania, and psychosis)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (unpredictably strong synergy, significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n+      ]\n+    },\n+    \"notes\": \"25C-NBOH is a novel research chemical with extremely limited human use history and assumed similar toxicity to 25C-NBOMe, which has been linked to multiple deaths. This substance must NEVER be insufflated (snorted) due to high risk of fatal overdose. Compounds of the NBOH family are NOT orally active and must be administered sublingually, holding in the mouth for 15-25 minutes. Use an accurate microgram scale for all dosing. The substance exhibits dose-independent intensity and unpredictable effects even at seemingly identical doses. Start with threshold doses and avoid combinations. Heavy doses may be fatal. Individuals with personal or family history of psychotic disorders should avoid use. This substance is controlled in many jurisdictions.\",\n+    \"subjective_effects\": [\n+      \"Intense Visual Patterning And Geometry\",\n+      \"Strong Physical Stimulation\",\n+      \"Perception Of Bodily Lightness\",\n+      \"Color Enhancement\",\n+      \"Time Distortion\",\n+      \"Spontaneous Euphoric Tingling Sensations\",\n+      \"Enhanced Pattern Recognition\",\n+      \"Mouth And Tongue Numbing\",\n+      \"Nausea (Typically During Come-Up)\",\n+      \"Anxiety And Paranoia (More Common Than Classical Psychedelics)\",\n+      \"Mild Cognitive Effects (Notably Light Headspace)\",\n+      \"Increased Sociability And Empathy (Inconsistent)\",\n+      \"Enhanced Music Appreciation\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n+      \"half_tolerance\": \"Approximately 1 week\",\n+      \"zero_tolerance\": \"2 weeks\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (LSD, psilocybin, mescaline, DMT, 2C-x series, NBOMe series)\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy 25C-NBOH Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-25c-nboh-thread.621629/\"\n+      },\n+      {\n+        \"name\": \"Erowid 25C-NBOH Experience Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_25CNBOH.shtml\"\n+      },\n+      {\n+        \"name\": \"Hansen, M. (2012). Design and Synthesis of Selective Serotonin Receptor Agonists for PET Imaging\",\n+        \"reference\": \"https://www.researchgate.net/publication/266388124\"\n+      },\n+      {\n+        \"name\": \"Hansen et al. (2014). Synthesis and Structure-Activity Relationships of N-Benzyl Phenethylamines as 5-HT2A/2C Agonists\",\n+        \"reference\": \"https://doi.org/10.1021/cn400216u\"\n+      },\n+      {\n+        \"name\": \"Isomer Design: 25C-NBOH\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=1252\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: 25C-NBOH\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/25C-NBOH\"\n+      },\n+      {\n+        \"name\": \"Silva et al. (2011). Theoretical Studies on the Interaction of Partial Agonists with the 5-HT2A Receptor\",\n+        \"reference\": \"https://doi.org/10.1007/s10822-010-9400-2\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"phenethylamine\",\n+      \"research-chemical\",\n+      \"nboh-series\"\n+    ]\n+  },\n+  \"id\": 652\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-010656-f750f60d",
    "createdAt": "2025-10-17T01:06:56.440Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 7:06:53 PM"
    },
    "articles": [
      {
        "id": 651,
        "title": "DOI",
        "slug": "doi"
      }
    ],
    "markdown": "# DOI · #651\n\n+{\n+  \"title\": \"DOI\",\n+  \"index-category\": \"psychedelic; stimulant; dox\",\n+  \"drug_info\": {\n+    \"drug_name\": \"DOI\",\n+    \"chemical_name\": \"2,5-Dimethoxy-4-iodoamphetamine\",\n+    \"alternative_name\": \"2,5-Dimethoxy-4-iodoamphetamine; Dimethoxyiodoamphetamine\",\n+    \"chemical_class\": \"Amphetamines; Substituted amphetamines\",\n+    \"psychoactive_class\": \"Psychedelic; Stimulant\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist; 5-HT2B receptor agonist; 5-HT2C receptor agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"0.5 mg\",\n+            \"light\": \"0.5-1 mg\",\n+            \"common\": \"1-2 mg\",\n+            \"strong\": \"2-3 mg\",\n+            \"heavy\": \"3+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"16-24 hours\",\n+            \"onset\": \"1-2 hours\",\n+            \"peak\": \"3-6 hours (come up 1.5-3 hours)\",\n+            \"offset\": \"6-12 hours\",\n+            \"after_effects\": \"24-48 hours (residual stimulation)\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"DOI is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating. There is no evidence of physical dependence or compulsive redosing patterns.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants such as amphetamine, cocaine, or methylphenidate (increased risk of anxiety, paranoia, thought loops, and psychosis)\",\n+        \"MAOIs (potential for unpredictable interactions)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (unexpectedly strong and unpredictable synergy; significant increase in anxiety, paranoia, and psychosis risk)\",\n+        \"5-MeO tryptamines (unpredictable interactions with increased physical side effects)\",\n+        \"MDMA (combined stimulating effects can be uncomfortable and anxiogenic during comedown)\",\n+        \"Caffeine (may cause anxiety and physical discomfort)\",\n+        \"Amphetamines (uncomfortable body load and thought loops)\",\n+        \"Cocaine (uncomfortable body load and thought loops)\",\n+        \"Ketamine (potentiation; go slowly)\",\n+        \"Alcohol (reduced sedative effects lead to excessive drinking)\"\n+      ]\n+    },\n+    \"notes\": \"DOI is an extremely potent and long-lasting psychedelic with a very sensitive dose-response curve. It is sometimes sold falsely as LSD, which can be dangerous due to differing safety profiles and dosage ranges. Use a precise milligram scale for accurate dosing. The exceptionally long duration of 16-24 hours with residual stimulation lasting up to 48 hours requires adequate time preparation. Individuals with personal or family history of psychotic disorders should avoid use. Start with the lowest possible dose due to high individual variability in response.\",\n+    \"subjective_effects\": [\n+      \"Extreme Stimulation\",\n+      \"Visual Patterning And Geometry\",\n+      \"Colour Enhancement\",\n+      \"Energetic Body High\",\n+      \"Thought Acceleration\",\n+      \"Enhanced Tactile Sensation\",\n+      \"Internal And External Hallucinations\",\n+      \"Time Distortion\",\n+      \"Emotional Amplification\",\n+      \"Enhanced Music Appreciation\",\n+      \"Nausea\",\n+      \"Muscle Tension And Vasoconstriction\",\n+      \"Increased Body Temperature\",\n+      \"Pupil Dilation\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Immediately after ingestion\",\n+      \"half_tolerance\": \"5-7 days\",\n+      \"zero_tolerance\": \"10-14 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (LSD, psilocybin, mescaline, 2C-x, DOx compounds)\"\n+      ]\n+    },\n+    \"half_life\": \"Unknown; estimated duration of primary effects 16-24 hours with residual effects up to 48 hours\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Coutts & Malicky 1973 - Synthesis of DOI Analogs\",\n+        \"reference\": \"https://doi.org/10.1139/v73-210\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki DOI Profile\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/DOI\"\n+      },\n+      {\n+        \"name\": \"TripSit DOI Factsheet\",\n+        \"reference\": \"https://drugs.tripsit.me/DOI\"\n+      },\n+      {\n+        \"name\": \"Erowid DOI Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/doi/doi.shtml\"\n+      },\n+      {\n+        \"name\": \"PiHKAL Entry #67 - DOI (Isomer Design)\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/read.php?id=67\"\n+      },\n+      {\n+        \"name\": \"Shulgin & Shulgin - PiHKAL: A Chemical Love Story\",\n+        \"reference\": \"Transform Press, 1991\"\n+      },\n+      {\n+        \"name\": \"Bluelight DOI Discussion Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-doi-thread.216778/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"stimulant\",\n+      \"substituted-amphetamine\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 651\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-005710-3997dc11",
    "createdAt": "2025-10-17T00:57:10.029Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:57:08 PM"
    },
    "articles": [
      {
        "id": 650,
        "title": "2,5-DMA",
        "slug": "2-5-dma"
      }
    ],
    "markdown": "# 2,5-DMA · #650\n\n+{\n+  \"title\": \"2,5-DMA\",\n+  \"index-category\": \"stimulant; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"2,5-DMA\",\n+    \"chemical_name\": \"1-(2,5-Dimethoxyphenyl)propan-2-amine\",\n+    \"alternative_name\": \"2,5-Dimethoxyamphetamine; DMA; DOH\",\n+    \"chemical_class\": \"Amphetamines; Phenethylamines\",\n+    \"psychoactive_class\": \"Stimulant; Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist (low potency); does not bind to monoamine transporters\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"10 mg\",\n+            \"light\": \"10-40 mg\",\n+            \"common\": \"40-80 mg\",\n+            \"strong\": \"80-200 mg\",\n+            \"heavy\": \"200+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"6-8 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"2,5-DMA is not considered habit-forming and likely has low psychological dependence potential. However, its stimulating properties may present some risk of compulsive use similar to other stimulants. No formal studies have been conducted on addiction potential.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Cannabis (unpredictable synergy, increased risk of anxiety and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"Stimulants (increased anxiety, paranoia, and cardiovascular risk)\",\n+        \"Other psychedelics (may intensify effects unpredictably)\"\n+      ]\n+    },\n+    \"notes\": \"2,5-DMA is a research chemical and the simplest member of the DOx family, primarily known as a precursor in synthesizing other psychedelic amphetamines rather than for its own psychoactive effects. Unlike typical psychedelics, it produces primarily stimulant and physical effects with minimal to no sensory or perceptual changes. Very little data exists about its pharmacology, metabolism, and toxicity. Use accurate weighing equipment and start with lower doses due to individual variability. Those with personal or family history of mental health disorders should avoid use.\",\n+    \"subjective_effects\": [\n+      \"Physical Stimulation\",\n+      \"Increased Heart Rate\",\n+      \"Increased Blood Pressure\",\n+      \"Pupil Dilation\",\n+      \"Muscle Tension\",\n+      \"Tremors\",\n+      \"Body Load\",\n+      \"Enhanced Interest In Surroundings\",\n+      \"Cardiovascular Stimulation\",\n+      \"Temperature Regulation Suppression\",\n+      \"Increased Perspiration\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n+      \"half_tolerance\": \"3-5 days\",\n+      \"zero_tolerance\": \"7-10 days\",\n+      \"cross_tolerances\": [\n+        \"Psychedelics (unlikely but possible)\",\n+        \"Stimulants\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Baltzly & Buck, 1940 - Original Synthesis\",\n+        \"reference\": \"https://doi.org/10.1021/ja01858a046\"\n+      },\n+      {\n+        \"name\": \"Erowid PiHKAL #54: 2,5-DMA\",\n+        \"reference\": \"https://erowid.org/library/books_online/pihkal/pihkal054.shtml\"\n+      },\n+      {\n+        \"name\": \"Isomer Design PiHKAL Info: 2,5-DMA\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/read.php?id=54\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: 2,5-DMA\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/2,5-DMA\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: 2,5-Dimethoxyamphetamine\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/2,5-Dimethoxyamphetamine\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"amphetamine\",\n+      \"phenethylamine\",\n+      \"dox-family\",\n+      \"research-chemical\",\n+      \"stimulant\"\n+    ]\n+  },\n+  \"id\": 650\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-005331-24a27364",
    "createdAt": "2025-10-17T00:53:31.846Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:53:29 PM"
    },
    "articles": [
      {
        "id": 649,
        "title": "2C-T",
        "slug": "2c-t"
      }
    ],
    "markdown": "# 2C-T · #649\n\n+{\n+  \"title\": \"2C-T\",\n+  \"index-category\": \"psychedelic; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"2C-T\",\n+    \"chemical_name\": \"2,5-Dimethoxy-4-methylthiophenethylamine\",\n+    \"alternative_name\": \"Tesseract\",\n+    \"chemical_class\": \"Phenethylamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; potential MAOI properties\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"20 mg\",\n+            \"light\": \"40-60 mg\",\n+            \"common\": \"60-100 mg\",\n+            \"strong\": \"100-120 mg\",\n+            \"heavy\": \"125+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"3-6 hours\",\n+            \"onset\": \"30-45 minutes\",\n+            \"peak\": \"30-115 minutes\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"1-2 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"2C-T is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating with no significant dependence or abuse potential reported.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"MAOIs (potential serotonin syndrome or neurotransmitter overload)\",\n+        \"Stimulants (increased neurotransmitter release)\",\n+        \"5-MeO-MiPT (serotonergic overload)\",\n+        \"2C-T-7 (serotonergic overload)\",\n+        \"AMT (MAOI properties)\",\n+        \"Cocaine (cardiovascular stress)\",\n+        \"Methamphetamine (neurotoxicity risk)\",\n+        \"MDMA (serotonin syndrome risk)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"caution\": [\n+        \"Other psychedelics (overwhelming intensity)\",\n+        \"2-AI (serotonergic interaction)\",\n+        \"A-PVP (cardiovascular stress)\",\n+        \"Amphetamine (increased strain)\",\n+        \"Mephedrone (combined stimulation)\"\n+      ]\n+    },\n+    \"notes\": \"2C-T is a lesser-known research chemical with very limited human use history and minimal scientific data on its pharmacology, metabolism, and toxicity. It is structurally similar to 2C-T-2 and 2C-T-7 and may possess MAOI properties, making it potentially more dangerous when combined with other serotonergic substances. The substance is illegal in many jurisdictions including the United States (Schedule I), United Kingdom (Class A), and Canada (Schedule III). Use accurate milligram scales for dosing, practice harm reduction, and consider having a sober trip sitter present. Individuals with personal or family histories of mental health conditions should avoid use.\",\n+    \"subjective_effects\": [\n+      \"Spontaneous Bodily Sensations\",\n+      \"Tactile Enhancement\",\n+      \"Bodily Control Enhancement\",\n+      \"Emotion Enhancement\",\n+      \"Analysis Enhancement\",\n+      \"Time Distortion\",\n+      \"Increased Music Appreciation\",\n+      \"Colour Enhancement\",\n+      \"Visual Acuity Enhancement\",\n+      \"Drifting and Morphing\",\n+      \"Nausea\",\n+      \"Vasoconstriction\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Almost immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Nichols & Shulgin (1976) - Sulfur Analogs of Psychotomimetic Amines\",\n+        \"reference\": \"https://doi.org/10.1002/jps.2600651040\"\n+      },\n+      {\n+        \"name\": \"PiHKAL Entry #39: 2C-T\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/read.php?domain=pk&id=39\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: 2C-T\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/2C-T\"\n+      },\n+      {\n+        \"name\": \"Erowid 2C-T-2 Basics\",\n+        \"reference\": \"https://erowid.org/chemicals/2ct2/2ct2_basics.shtml\"\n+      },\n+      {\n+        \"name\": \"Gallardo-Godoy et al. (2005) - Sulfur-Substituted MAO-A Inhibitors\",\n+        \"reference\": \"https://doi.org/10.1021/jm0493109\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"phenethylamine\",\n+      \"research-chemical\",\n+      \"2c-x\"\n+    ]\n+  },\n+  \"id\": 649\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-004937-559d1cc3",
    "createdAt": "2025-10-17T00:49:37.836Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:49:35 PM"
    },
    "articles": [
      {
        "id": 648,
        "title": "Proscaline",
        "slug": "proscaline"
      }
    ],
    "markdown": "# Proscaline · #648\n\n+{\n+  \"title\": \"Proscaline\",\n+  \"index-category\": \"psychedelic; phenethylamine; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Proscaline\",\n+    \"chemical_name\": \"4-Propyloxy-3,5-dimethoxyphenethylamine\",\n+    \"alternative_name\": \"P; 4-Propoxy-3,5-DMPEA; 3,5-Dimethoxy-4-n-propoxyphenethylamine\",\n+    \"chemical_class\": \"Phenethylamine\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; 5-HT2C receptor partial agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"10 mg\",\n+            \"light\": \"15-30 mg\",\n+            \"common\": \"30-40 mg\",\n+            \"strong\": \"40-60 mg\",\n+            \"heavy\": \"60+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"8-12 hours\",\n+            \"onset\": \"30-60 minutes\",\n+            \"peak\": \"2-4 hours\",\n+            \"offset\": \"3-5 hours\",\n+            \"after_effects\": \"3-5 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Proscaline is not habit-forming and demonstrates a self-regulating usage pattern. The desire to use it typically decreases with repeated consumption. There is no evidence of physical dependence or compulsive redosing patterns.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of seizures and psychosis)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"MAOIs (potentially hazardous serotonergic interaction)\"\n+      ],\n+      \"caution\": [\n+        \"Stimulants (increased cardiovascular strain)\",\n+        \"Cannabis (may intensify and prolong effects unpredictably)\",\n+        \"SSRIs (may blunt or alter effects)\",\n+        \"Alcohol (reduces therapeutic potential and increases risk of dehydration)\"\n+      ]\n+    },\n+    \"notes\": \"Proscaline is a lesser-known mescaline analog approximately five times more potent than mescaline. The substance has minimal research into its pharmacology and toxicity. Use a precise milligram scale for accurate dosing. It is controlled in Germany, Switzerland, and the United Kingdom but remains unscheduled in the United States. Individuals with personal or family history of psychotic disorders should avoid use. Ensure adequate set and setting preparation, as with all psychedelics.\",\n+    \"subjective_effects\": [\n+      \"Visual Pattern Enhancement\",\n+      \"Color Enhancement\",\n+      \"Time Distortion\",\n+      \"Enhanced Music Appreciation\",\n+      \"Tactile Enhancement\",\n+      \"Cognitive Euphoria\",\n+      \"Conceptual Thinking\",\n+      \"Increased Body Temperature\",\n+      \"Nausea\",\n+      \"Enhanced Introspection\",\n+      \"Emotional Amplification\",\n+      \"Drifting Visual Effects\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (mescaline, LSD, psilocybin, DMT, 2C-x compounds)\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: Proscaline\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Proscaline\"\n+      },\n+      {\n+        \"name\": \"PiHKAL Entry #140: Proscaline (Isomer Design)\",\n+        \"reference\": \"https://isomerdesign.com/pihkal/explore/140\"\n+      },\n+      {\n+        \"name\": \"Erowid PiHKAL: Proscaline\",\n+        \"reference\": \"https://erowid.org/library/books_online/pihkal/pihkal140.shtml\"\n+      },\n+      {\n+        \"name\": \"Erowid Proscaline Experience Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_Proscaline.shtml\"\n+      },\n+      {\n+        \"name\": \"Bluelight: Proscaline Discussion\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/proscaline-new-experience-shiny-happy-people.522598/\"\n+      },\n+      {\n+        \"name\": \"Nichols and Dyer (1977) - Journal of Medicinal Chemistry\",\n+        \"reference\": \"https://doi.org/10.1021/jm00212a022\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"phenethylamine\",\n+      \"mescaline-analog\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 648\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-004607-55af38b6",
    "createdAt": "2025-10-17T00:46:07.580Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:46:03 PM"
    },
    "articles": [
      {
        "id": 647,
        "title": "Escaline",
        "slug": "escaline"
      }
    ],
    "markdown": "# Escaline · #647\n\n+{\n+  \"title\": \"Escaline\",\n+  \"index-category\": \"psychedelic; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Escaline\",\n+    \"chemical_name\": \"3,5-Dimethoxy-4-ethoxyphenethylamine\",\n+    \"alternative_name\": \"E; 4-Ethoxy-3,5-dimethoxyphenethylamine\",\n+    \"chemical_class\": \"Phenethylamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist (5-8 times greater affinity than mescaline); 5-HT2C receptor agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"20-25 mg\",\n+            \"light\": \"30-50 mg\",\n+            \"common\": \"50-100 mg\",\n+            \"strong\": \"100-150 mg\",\n+            \"heavy\": \"150+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"8-12 hours\",\n+            \"onset\": \"40-120 minutes\",\n+            \"peak\": \"5-6 hours\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"3-5 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Escaline is not considered habit-forming and the desire to use it typically decreases with use. It is generally self-regulating and lacks compulsive redosing patterns.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants (increases risk of anxiety, paranoia, thought loops, mania, and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (unpredictable synergy; significantly increases risk of adverse psychological reactions)\"\n+      ]\n+    },\n+    \"notes\": \"Escaline is a research chemical with very limited human use history and no formal toxicology studies. It is controlled as a Schedule I substance in the United States, Germany, Japan, Switzerland, and the UK. Users report more intense negative physical side effects compared to mescaline, including heavier body load and greater stimulation. Accurate weighing with a milligram scale is essential. The compound has a very long onset and extended duration, making sleep difficult without sedatives.\",\n+    \"subjective_effects\": [\n+      \"Stimulation\",\n+      \"Enhanced Music Appreciation\",\n+      \"Visual Patterning And Drifting\",\n+      \"Color Enhancement\",\n+      \"Thought Acceleration And Connectivity\",\n+      \"Time Distortion\",\n+      \"Bodily Sensations\",\n+      \"Pupil Dilation\",\n+      \"Increased Heart Rate\",\n+      \"Muscle Tension\",\n+      \"Euphoria\",\n+      \"Temperature Dysregulation\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Blaazer et al. (2008) - ChemMedChem\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/18666267/\"\n+      },\n+      {\n+        \"name\": \"Erowid Escaline Experience Vault\",\n+        \"reference\": \"https://www.erowid.org/experiences/subs/exp_Escaline.shtml\"\n+      },\n+      {\n+        \"name\": \"Halberstadt & Geyer (2018) - PMC\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848748/\"\n+      },\n+      {\n+        \"name\": \"Isomer Design: Escaline (PiHKAL Entry #72)\",\n+        \"reference\": \"https://isomerdesign.com/pihkal/explore/72\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Escaline\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Escaline\"\n+      },\n+      {\n+        \"name\": \"Shulgin & Shulgin (1991) - PiHKAL Entry #72\",\n+        \"reference\": \"https://isomerdesign.com/pihkal/read/pk/72\"\n+      },\n+      {\n+        \"name\": \"The Big & Dandy Escaline Thread - Bluelight\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-escaline-thread.656624/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"phenethylamine\",\n+      \"mescaline-analog\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 647\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-003112-5d53dfd6",
    "createdAt": "2025-10-17T00:31:12.900Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:31:10 PM"
    },
    "articles": [
      {
        "id": 200,
        "title": "Psilocybin Mushrooms",
        "slug": "psilocybin-mushrooms"
      },
      {
        "id": 645,
        "title": "Psilocin",
        "slug": "psilocin"
      },
      {
        "id": 646,
        "title": "Allylescaline",
        "slug": "allylescaline"
      }
    ],
    "markdown": "# Psilocybin Mushrooms · #200\n\n-  \"title\": \"Psilocybin mushrooms\",\n+  \"title\": \"Psilocybin Mushrooms\",\n-    \"drug_name\": \"Psilocybin mushrooms\",\n-    \"chemical_name\": \"Psilocybin\",\n-    \"alternative_name\": \"Psilocybe cubensis; Magic mushrooms; Shrooms\",\n+    \"drug_name\": \"Psilocybin Mushrooms\",\n+    \"chemical_name\": \"4-Phosphoryloxy-N,N-dimethyltryptamine\",\n+    \"alternative_name\": \"Magic Mushrooms; Shrooms; Mushies; Psychedelic Mushrooms; Boomers; Magic Truffles\",\n-    \"mechanism_of_action\": \"5-HT2A receptor agonist\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist; 5-HT2C receptor agonist; 5-HT1A receptor agonist (psilocin acts as prodrug)\",\n-          \"units\": \"g (dried mushrooms)\",\n+          \"units\": \"g\",\n-            \"threshold\": \"0.25 g\",\n-            \"light\": \"0.5 - 1 g\",\n-            \"common\": \"1 - 2.5 g\",\n-            \"strong\": \"2.5 - 4 g\",\n-            \"heavy\": \"4+ g\"\n+            \"threshold\": \"0.1-0.5 g\",\n+            \"light\": \"0.5-1.5 g\",\n+            \"common\": \"1.5-3.5 g\",\n+            \"strong\": \"3.5-5 g\",\n+            \"heavy\": \"5+ g\"\n+        },\n+        {\n+          \"route\": \"lemon tek\",\n+          \"units\": \"g\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"0.1-0.3 g\",\n+            \"light\": \"0.3-1 g\",\n+            \"common\": \"1-2.5 g\",\n+            \"strong\": \"2.5-3.5 g\",\n+            \"heavy\": \"3.5+ g\"\n+          }\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ],\n-            \"total_duration\": \"4 - 6 hours\",\n-            \"onset\": \"20 - 60 minutes\",\n-            \"peak\": \"2 - 3 hours\",\n-            \"offset\": \"1 - 2 hours\",\n-            \"after_effects\": \"Up to 24 hours (residual effects, afterglow)\"\n-          },\n+            \"total_duration\": \"4-8 hours\",\n+            \"onset\": \"20-60 minutes\",\n+            \"peak\": \"90-180 minutes\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"4-24 hours (afterglow)\"\n+          }\n+        },\n+        {\n+          \"route\": \"lemon tek\",\n-          ]\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"3-6 hours\",\n+            \"onset\": \"10-30 minutes\",\n+            \"peak\": \"60-150 minutes\",\n+            \"offset\": \"2-3 hours\",\n+            \"after_effects\": \"4-24 hours (afterglow)\"\n+          }\n-    \"addiction_potential\": \"Psilocybin mushrooms have a very low addiction potential. They are not considered habit-forming and tolerance develops rapidly, discouraging frequent use.\",\n+    \"addiction_potential\": \"Psilocybin mushrooms are not considered physically addictive and have low potential for psychological dependence. Rapid tolerance development discourages frequent use. They are not associated with compulsive drug-seeking behavior or withdrawal symptoms.\",\n-        \"MAOIs (can dangerously potentiate effects)\"\n+        \"Lithium (significantly increased seizure risk)\",\n+        \"MAOIs (risk of hypertensive crisis)\"\n-        \"SSRIs (may blunt effects)\"\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Other psychedelics (unpredictable and overwhelming intensity)\"\n-        \"Other psychedelics (increased risk of overwhelming experience)\"\n+        \"Cannabis (unpredictable and significantly intensified effects; increased anxiety, paranoia, and psychosis risk)\",\n+        \"Amphetamines (increased anxiety and thought loop risk)\",\n+        \"Cocaine (increased anxiety and thought loop risk)\",\n+        \"SSRIs (may blunt or alter effects)\",\n+        \"Benzodiazepines (may dampen experience; useful for trip abortion)\",\n+        \"Alcohol (may cause dehydration and nausea; can reduce anxiety in low doses)\",\n+        \"MDMA (unknown toxicity; may increase neurotoxicity)\"\n-    \"notes\": \"Penis Envy is a well-known strain of Psilocybe cubensis, notable for its higher potency compared to most other P. cubensis strains. Users report that 1 gram of Penis Envy can be as potent as 2 grams of a standard cubensis strain. Effects are highly dose-dependent and can include intense visual and cognitive changes. Set and setting are crucial for a safe experience. Potency can vary depending on cultivation and genetics.\",\n+    \"notes\": \"Psilocybin mushrooms vary widely in potency by species, strain, and individual specimen; accurate weighing with a precise scale is essential. Dried mushrooms are approximately 10 times more potent by weight than fresh mushrooms. Exercise extreme caution when foraging wild mushrooms due to the risk of consuming poisonous look-alike species; identification should only be performed by experts. Individuals with personal or family history of psychotic disorders should avoid use. Set and setting strongly influence the experience; ensure a safe, comfortable, familiar environment and consider having a trusted sober trip sitter present, especially for first-time users or higher doses.\",\n-      \"Visual distortions\",\n-      \"Euphoria\",\n-      \"Altered thinking\",\n-      \"Time dilation\",\n-      \"Synesthesia\",\n-      \"Spiritual or mystical experiences\",\n-      \"Emotional lability\",\n-      \"Introspection\",\n-      \"Body high\",\n-      \"Nausea (sometimes)\"\n+      \"Visual Geometry and Patterning\",\n+      \"Enhanced Mood and Euphoria\",\n+      \"Time Distortion\",\n+      \"Emotional Enhancement and Amplification\",\n+      \"Spirituality and Mystical Experiences\",\n+      \"Ego Loss and Dissolution\",\n+      \"Enhanced Introspection\",\n+      \"Conceptual Thinking\",\n+      \"Unity and Interconnectedness\",\n+      \"Nausea (especially during come-up)\",\n+      \"Sedation and Body Heaviness\",\n+      \"Confusion\",\n+      \"Anxiety or Feelings of Impending Doom (typically during onset)\",\n+      \"Synaesthesia\",\n+      \"Tactile Enhancement\",\n+      \"Excessive Yawning\"\n-      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n-      \"half_tolerance\": \"5-7 days\",\n-      \"zero_tolerance\": \"2 weeks\",\n+      \"full_tolerance\": \"After 1-2 consecutive days of use\",\n+      \"half_tolerance\": \"3-4 days\",\n+      \"zero_tolerance\": \"7-14 days\",\n-        \"Other tryptamine psychedelics (e.g., LSD, DMT)\"\n+        \"All psychedelics (LSD, mescaline, 2C-x, tryptamines)\"\n-    \"half_life\": \"1.5 - 3 hours (psilocybin); effects last longer due to active metabolite psilocin\",\n+    \"half_life\": \"1-3 hours (psilocin active metabolite)\",\n-        \"name\": \"Bluelight - Penis Envy Mushrooms Discussion\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/penis-envy-mushrooms.520747/post-11662949\"\n+        \"name\": \"Erowid Psilocybin Mushroom Dosage\",\n+        \"reference\": \"https://erowid.org/plants/mushrooms/mushrooms_dose.shtml\"\n-        \"name\": \"Bluelight - Getting the Most Out of Mushrooms\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/getting-the-most-out-of-mushrooms.555352/page-2\"\n+        \"name\": \"PsychonautWiki: Psilocybin Mushrooms\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Psilocybin_mushrooms\"\n-        \"name\": \"Tripsitter Substack: Penis Envy Mushrooms\",\n-        \"reference\": \"https://tripsitter.substack.com/p/penis-envy-mushrooms?r=1da21z\"\n+        \"name\": \"TripSit Mushrooms Factsheet\",\n+        \"reference\": \"https://drugs.tripsit.me/Mushrooms\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy Psilocybin Mushrooms Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-psilocybin-mushrooms-thread.58587/\"\n+      },\n+      {\n+        \"name\": \"Drug Science: Psilocybin\",\n+        \"reference\": \"https://www.drugscience.org.uk/psilocybin\"\n+      },\n+      {\n+        \"name\": \"Frontiers in Psychiatry: Therapeutic use of psilocybin\",\n+        \"reference\": \"https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2022.1040217/full\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Psilocybin Mushroom Lemon Tek\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Psilocybin_mushroom_lemon_tek\"\n-      \"common\"\n+      \"classic-psychedelic\",\n+      \"tryptamine\",\n+      \"plant-based\"\n-  \"index-category\": \"\"\n+  \"index-category\": \"psychedelic;classic;tryptamine\"\n\n# Psilocin · #645\n\n+{\n+  \"title\": \"Psilocin\",\n+  \"index-category\": \"psychedelic; tryptamine; classic\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Psilocin\",\n+    \"chemical_name\": \"4-Hydroxy-N,N-dimethyltryptamine\",\n+    \"alternative_name\": \"Psilocine; Psilocyn; Psilotsin; 4-HO-DMT; 4-OH-DMT\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; 5-HT2C receptor agonist; 5-HT1A receptor agonist; Activates phospholipase A2 instead of phospholipase C\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"10-15 mg\",\n+            \"common\": \"15-25 mg\",\n+            \"strong\": \"25-40 mg\",\n+            \"heavy\": \"40+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"4-6 hours\",\n+            \"onset\": \"20-45 minutes\",\n+            \"peak\": \"2-3 hours (come up 1.5-3 hours)\",\n+            \"offset\": \"1.5-2 hours\",\n+            \"after_effects\": \"4-24 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Psilocin is not considered habit-forming and has a low potential for psychological dependence. The desire to use it typically decreases with use, making it largely self-regulating. Rapid tolerance development discourages frequent redosing.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (risk of fatal seizures and heart problems)\",\n+        \"MAOIs (potential for serotonin syndrome, hypertensive crisis)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Cannabis (greatly intensifies effects, increases anxiety and psychosis risk)\"\n+      ],\n+      \"caution\": [\n+        \"SSRIs (may reduce effects or increase risk)\",\n+        \"SNRIs (may alter effects)\",\n+        \"Tricyclic antidepressants (may potentiate effects)\",\n+        \"Benzodiazepines (reduce intensity, may cause amnesia)\",\n+        \"Antipsychotics (significantly dampen effects)\",\n+        \"MDMA (amplifies effects, possible neurotoxicity concerns)\",\n+        \"Dissociatives (intensifies hallucinations and confusion)\",\n+        \"Alcohol (causes dehydration and nausea, dulls effects)\"\n+      ]\n+    },\n+    \"notes\": \"Psilocin is the pharmacologically active form of psilocybin and is rarely encountered as a pure synthetic compound. It is relatively unstable and readily forms blue degradation products when exposed to oxygen. Store in cool, dry, dark conditions. Unlike psilocybin mushrooms, pure psilocin has reduced nausea when taken on an empty stomach. Set and setting are critical to the experience. Those with personal or family history of psychotic disorders should avoid use. Always use accurate scales for dosing, as the substance is potent and effects can be overwhelming.\",\n+    \"subjective_effects\": [\n+      \"Visual Patterning And Geometry\",\n+      \"Enhanced Colors And Visual Acuity\",\n+      \"Drifting, Melting, And Morphing Visuals\",\n+      \"Internal And External Hallucinations\",\n+      \"Emotional Amplification And Empathy\",\n+      \"Time Distortion\",\n+      \"Profound Thought Connectivity\",\n+      \"Spirituality And Ego Dissolution\",\n+      \"Physical Euphoria Or Sedation\",\n+      \"Analysis Enhancement\",\n+      \"Excessive Yawning\",\n+      \"Nausea (Less Common Than Mushrooms)\",\n+      \"Body High And Tingling Sensations\",\n+      \"Synesthesia\",\n+      \"Feelings Of Unity\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Almost immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (LSD, mescaline, DMT, 2C-x compounds)\"\n+      ]\n+    },\n+    \"half_life\": \"1-3 hours\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: Psilocin\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Psilocin\"\n+      },\n+      {\n+        \"name\": \"Erowid Psilocin Experience Reports\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_Psilocin.shtml\"\n+      },\n+      {\n+        \"name\": \"TiHKAL #18: 4-HO-DMT by Alexander Shulgin\",\n+        \"reference\": \"https://erowid.org/library/books_online/tihkal/tihkal18.shtml\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big and Dandy 4-HO-DMT Thread\",\n+        \"reference\": \"https://www.bluelight.org/vb/threads/318367-The-Big-and-Dandy-4-HO-DMT-Thread\"\n+      },\n+      {\n+        \"name\": \"Drug-drug interactions involving classic psychedelics: A systematic review\",\n+        \"reference\": \"https://journals.sagepub.com/doi/10.1177/02698811231211219\"\n+      },\n+      {\n+        \"name\": \"Drug-drug interactions between psychiatric medications and MDMA or psilocybin\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177763/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"serotonergic\",\n+      \"entheogen\"\n+    ]\n+  },\n+  \"id\": 645\n+}\n\n# Allylescaline · #646\n\n+{\n+  \"title\": \"Allylescaline\",\n+  \"index-category\": \"psychedelic; phenethylamine; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Allylescaline\",\n+    \"chemical_name\": \"4-Allyloxy-3,5-dimethoxyphenethylamine\",\n+    \"alternative_name\": \"AL; 4-allyloxy-3,5-dimethoxy-phenethylamine\",\n+    \"chemical_class\": \"Phenethylamines; Scalines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"15 mg\",\n+            \"light\": \"20-30 mg\",\n+            \"common\": \"30-40 mg\",\n+            \"strong\": \"40-60 mg\",\n+            \"heavy\": \"60+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"8-12 hours\",\n+            \"onset\": \"45-240 minutes\",\n+            \"after_effects\": \"Up to 12 hours (residual effects possible)\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Allylescaline is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating, with little evidence of compulsive redosing patterns. However, given the limited human usage data, these observations should be considered preliminary.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (increased seizure risk with psychedelics)\",\n+        \"Tramadol (lowers seizure threshold with psychedelics)\"\n+      ],\n+      \"unsafe\": [],\n+      \"caution\": [\n+        \"MAOIs (theoretical risk based on phenethylamine structure)\",\n+        \"Stimulants (increased body load and cardiovascular strain)\",\n+        \"Other psychedelics (cross-tolerance and unpredictable intensity)\",\n+        \"Dissociatives (unpredictable combination effects)\"\n+      ]\n+    },\n+    \"notes\": \"Allylescaline is a research chemical with very little history of human usage and no formal toxicology studies. As a structural analog of mescaline with significantly increased potency, accurate weighing with a milligram scale is essential. The substance has a notably slow and variable onset ranging from 45 minutes to 4 hours, which may lead to accidental overdosing if users redose prematurely. Legal status varies by jurisdiction; it is controlled in Germany, Japan, Sweden, Switzerland, and the United Kingdom. Set and setting remain important considerations, and individuals with personal or family histories of mental health conditions should exercise extreme caution.\",\n+    \"subjective_effects\": [\n+      \"Physical Stimulation\",\n+      \"Spontaneous Tactile Sensations\",\n+      \"Physical Euphoria\",\n+      \"Tactile Enhancement\",\n+      \"Color Enhancement\",\n+      \"Pattern Recognition Enhancement\",\n+      \"Drifting and Flowing Visuals\",\n+      \"Cognitive Euphoria\",\n+      \"Enhanced Empathy and Sociability\",\n+      \"Increased Music Appreciation\",\n+      \"Time Distortion\",\n+      \"Nausea\",\n+      \"Increased Heart Rate\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (mescaline, LSD, psilocybin, DMT, 2C-x compounds, etc.)\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid Allylescaline Vault\",\n+        \"reference\": \"https://www.erowid.org/experiences/subs/exp_Allylescaline.shtml\"\n+      },\n+      {\n+        \"name\": \"Isomer Design - PiHKAL Entry #2: AL\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=2\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki - Allylescaline\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Allylescaline\"\n+      },\n+      {\n+        \"name\": \"Shulgin, A.; Shulgin, A. (1991). PiHKAL: A Chemical Love Story, Entry #2\",\n+        \"reference\": \"https://erowid.org/library/books_online/pihkal/pihkal002.shtml\"\n+      },\n+      {\n+        \"name\": \"Bluelight - The Big & Dandy Allylescaline Thread\",\n+        \"reference\": \"https://bluelight.org\"\n+      },\n+      {\n+        \"name\": \"Kolaczynska et al. (2022). Receptor interaction profiles of mescaline derivatives\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC8865417/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"phenethylamine\",\n+      \"research-chemical\",\n+      \"mescaline-analog\"\n+    ]\n+  },\n+  \"id\": 646\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-002601-680627a7",
    "createdAt": "2025-10-17T00:26:01.353Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:25:59 PM"
    },
    "articles": [
      {
        "id": 200,
        "title": "Psilocybin Mushrooms",
        "slug": "psilocybin-mushrooms"
      },
      {
        "id": 645,
        "title": "Psilocin",
        "slug": "psilocin"
      }
    ],
    "markdown": "# Psilocybin Mushrooms · #200\n\n-  \"title\": \"Psilocybin mushrooms\",\n+  \"title\": \"Psilocybin Mushrooms\",\n-    \"drug_name\": \"Psilocybin mushrooms\",\n-    \"chemical_name\": \"Psilocybin\",\n-    \"alternative_name\": \"Psilocybe cubensis; Magic mushrooms; Shrooms\",\n+    \"drug_name\": \"Psilocybin Mushrooms\",\n+    \"chemical_name\": \"4-Phosphoryloxy-N,N-dimethyltryptamine\",\n+    \"alternative_name\": \"Magic Mushrooms; Shrooms; Mushies; Psychedelic Mushrooms; Boomers; Magic Truffles\",\n-    \"mechanism_of_action\": \"5-HT2A receptor agonist\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist; 5-HT2C receptor agonist; 5-HT1A receptor agonist (psilocin acts as prodrug)\",\n-          \"units\": \"g (dried mushrooms)\",\n+          \"units\": \"g\",\n-            \"threshold\": \"0.25 g\",\n-            \"light\": \"0.5 - 1 g\",\n-            \"common\": \"1 - 2.5 g\",\n-            \"strong\": \"2.5 - 4 g\",\n-            \"heavy\": \"4+ g\"\n+            \"threshold\": \"0.1-0.5 g\",\n+            \"light\": \"0.5-1.5 g\",\n+            \"common\": \"1.5-3.5 g\",\n+            \"strong\": \"3.5-5 g\",\n+            \"heavy\": \"5+ g\"\n+        },\n+        {\n+          \"route\": \"lemon tek\",\n+          \"units\": \"g\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"0.1-0.3 g\",\n+            \"light\": \"0.3-1 g\",\n+            \"common\": \"1-2.5 g\",\n+            \"strong\": \"2.5-3.5 g\",\n+            \"heavy\": \"3.5+ g\"\n+          }\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ],\n-            \"total_duration\": \"4 - 6 hours\",\n-            \"onset\": \"20 - 60 minutes\",\n-            \"peak\": \"2 - 3 hours\",\n-            \"offset\": \"1 - 2 hours\",\n-            \"after_effects\": \"Up to 24 hours (residual effects, afterglow)\"\n-          },\n+            \"total_duration\": \"4-8 hours\",\n+            \"onset\": \"20-60 minutes\",\n+            \"peak\": \"90-180 minutes\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"4-24 hours (afterglow)\"\n+          }\n+        },\n+        {\n+          \"route\": \"lemon tek\",\n-          ]\n+          ],\n+          \"stages\": {\n+            \"total_duration\": \"3-6 hours\",\n+            \"onset\": \"10-30 minutes\",\n+            \"peak\": \"60-150 minutes\",\n+            \"offset\": \"2-3 hours\",\n+            \"after_effects\": \"4-24 hours (afterglow)\"\n+          }\n-    \"addiction_potential\": \"Psilocybin mushrooms have a very low addiction potential. They are not considered habit-forming and tolerance develops rapidly, discouraging frequent use.\",\n+    \"addiction_potential\": \"Psilocybin mushrooms are not considered physically addictive and have low potential for psychological dependence. Rapid tolerance development discourages frequent use. They are not associated with compulsive drug-seeking behavior or withdrawal symptoms.\",\n-        \"MAOIs (can dangerously potentiate effects)\"\n+        \"Lithium (significantly increased seizure risk)\",\n+        \"MAOIs (risk of hypertensive crisis)\"\n-        \"SSRIs (may blunt effects)\"\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Other psychedelics (unpredictable and overwhelming intensity)\"\n-        \"Other psychedelics (increased risk of overwhelming experience)\"\n+        \"Cannabis (unpredictable and significantly intensified effects; increased anxiety, paranoia, and psychosis risk)\",\n+        \"Amphetamines (increased anxiety and thought loop risk)\",\n+        \"Cocaine (increased anxiety and thought loop risk)\",\n+        \"SSRIs (may blunt or alter effects)\",\n+        \"Benzodiazepines (may dampen experience; useful for trip abortion)\",\n+        \"Alcohol (may cause dehydration and nausea; can reduce anxiety in low doses)\",\n+        \"MDMA (unknown toxicity; may increase neurotoxicity)\"\n-    \"notes\": \"Penis Envy is a well-known strain of Psilocybe cubensis, notable for its higher potency compared to most other P. cubensis strains. Users report that 1 gram of Penis Envy can be as potent as 2 grams of a standard cubensis strain. Effects are highly dose-dependent and can include intense visual and cognitive changes. Set and setting are crucial for a safe experience. Potency can vary depending on cultivation and genetics.\",\n+    \"notes\": \"Psilocybin mushrooms vary widely in potency by species, strain, and individual specimen; accurate weighing with a precise scale is essential. Dried mushrooms are approximately 10 times more potent by weight than fresh mushrooms. Exercise extreme caution when foraging wild mushrooms due to the risk of consuming poisonous look-alike species; identification should only be performed by experts. Individuals with personal or family history of psychotic disorders should avoid use. Set and setting strongly influence the experience; ensure a safe, comfortable, familiar environment and consider having a trusted sober trip sitter present, especially for first-time users or higher doses.\",\n-      \"Visual distortions\",\n-      \"Euphoria\",\n-      \"Altered thinking\",\n-      \"Time dilation\",\n-      \"Synesthesia\",\n-      \"Spiritual or mystical experiences\",\n-      \"Emotional lability\",\n-      \"Introspection\",\n-      \"Body high\",\n-      \"Nausea (sometimes)\"\n+      \"Visual Geometry and Patterning\",\n+      \"Enhanced Mood and Euphoria\",\n+      \"Time Distortion\",\n+      \"Emotional Enhancement and Amplification\",\n+      \"Spirituality and Mystical Experiences\",\n+      \"Ego Loss and Dissolution\",\n+      \"Enhanced Introspection\",\n+      \"Conceptual Thinking\",\n+      \"Unity and Interconnectedness\",\n+      \"Nausea (especially during come-up)\",\n+      \"Sedation and Body Heaviness\",\n+      \"Confusion\",\n+      \"Anxiety or Feelings of Impending Doom (typically during onset)\",\n+      \"Synaesthesia\",\n+      \"Tactile Enhancement\",\n+      \"Excessive Yawning\"\n-      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n-      \"half_tolerance\": \"5-7 days\",\n-      \"zero_tolerance\": \"2 weeks\",\n+      \"full_tolerance\": \"After 1-2 consecutive days of use\",\n+      \"half_tolerance\": \"3-4 days\",\n+      \"zero_tolerance\": \"7-14 days\",\n-        \"Other tryptamine psychedelics (e.g., LSD, DMT)\"\n+        \"All psychedelics (LSD, mescaline, 2C-x, tryptamines)\"\n-    \"half_life\": \"1.5 - 3 hours (psilocybin); effects last longer due to active metabolite psilocin\",\n+    \"half_life\": \"1-3 hours (psilocin active metabolite)\",\n-        \"name\": \"Bluelight - Penis Envy Mushrooms Discussion\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/penis-envy-mushrooms.520747/post-11662949\"\n+        \"name\": \"Erowid Psilocybin Mushroom Dosage\",\n+        \"reference\": \"https://erowid.org/plants/mushrooms/mushrooms_dose.shtml\"\n-        \"name\": \"Bluelight - Getting the Most Out of Mushrooms\",\n-        \"reference\": \"https://www.bluelight.org/community/threads/getting-the-most-out-of-mushrooms.555352/page-2\"\n+        \"name\": \"PsychonautWiki: Psilocybin Mushrooms\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Psilocybin_mushrooms\"\n-        \"name\": \"Tripsitter Substack: Penis Envy Mushrooms\",\n-        \"reference\": \"https://tripsitter.substack.com/p/penis-envy-mushrooms?r=1da21z\"\n+        \"name\": \"TripSit Mushrooms Factsheet\",\n+        \"reference\": \"https://drugs.tripsit.me/Mushrooms\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy Psilocybin Mushrooms Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-psilocybin-mushrooms-thread.58587/\"\n+      },\n+      {\n+        \"name\": \"Drug Science: Psilocybin\",\n+        \"reference\": \"https://www.drugscience.org.uk/psilocybin\"\n+      },\n+      {\n+        \"name\": \"Frontiers in Psychiatry: Therapeutic use of psilocybin\",\n+        \"reference\": \"https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2022.1040217/full\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Psilocybin Mushroom Lemon Tek\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Psilocybin_mushroom_lemon_tek\"\n-      \"common\"\n+      \"classic-psychedelic\",\n+      \"tryptamine\",\n+      \"plant-based\"\n-  \"index-category\": \"\"\n+  \"index-category\": \"psychedelic;classic;tryptamine\"\n\n# Psilocin · #645\n\n+{\n+  \"title\": \"Psilocin\",\n+  \"index-category\": \"psychedelic; tryptamine; classic\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Psilocin\",\n+    \"chemical_name\": \"4-Hydroxy-N,N-dimethyltryptamine\",\n+    \"alternative_name\": \"Psilocine; Psilocyn; Psilotsin; 4-HO-DMT; 4-OH-DMT\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; 5-HT2C receptor agonist; 5-HT1A receptor agonist; Activates phospholipase A2 instead of phospholipase C\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"10-15 mg\",\n+            \"common\": \"15-25 mg\",\n+            \"strong\": \"25-40 mg\",\n+            \"heavy\": \"40+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"4-6 hours\",\n+            \"onset\": \"20-45 minutes\",\n+            \"peak\": \"2-3 hours (come up 1.5-3 hours)\",\n+            \"offset\": \"1.5-2 hours\",\n+            \"after_effects\": \"4-24 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Psilocin is not considered habit-forming and has a low potential for psychological dependence. The desire to use it typically decreases with use, making it largely self-regulating. Rapid tolerance development discourages frequent redosing.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (risk of fatal seizures and heart problems)\",\n+        \"MAOIs (potential for serotonin syndrome, hypertensive crisis)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Cannabis (greatly intensifies effects, increases anxiety and psychosis risk)\"\n+      ],\n+      \"caution\": [\n+        \"SSRIs (may reduce effects or increase risk)\",\n+        \"SNRIs (may alter effects)\",\n+        \"Tricyclic antidepressants (may potentiate effects)\",\n+        \"Benzodiazepines (reduce intensity, may cause amnesia)\",\n+        \"Antipsychotics (significantly dampen effects)\",\n+        \"MDMA (amplifies effects, possible neurotoxicity concerns)\",\n+        \"Dissociatives (intensifies hallucinations and confusion)\",\n+        \"Alcohol (causes dehydration and nausea, dulls effects)\"\n+      ]\n+    },\n+    \"notes\": \"Psilocin is the pharmacologically active form of psilocybin and is rarely encountered as a pure synthetic compound. It is relatively unstable and readily forms blue degradation products when exposed to oxygen. Store in cool, dry, dark conditions. Unlike psilocybin mushrooms, pure psilocin has reduced nausea when taken on an empty stomach. Set and setting are critical to the experience. Those with personal or family history of psychotic disorders should avoid use. Always use accurate scales for dosing, as the substance is potent and effects can be overwhelming.\",\n+    \"subjective_effects\": [\n+      \"Visual Patterning And Geometry\",\n+      \"Enhanced Colors And Visual Acuity\",\n+      \"Drifting, Melting, And Morphing Visuals\",\n+      \"Internal And External Hallucinations\",\n+      \"Emotional Amplification And Empathy\",\n+      \"Time Distortion\",\n+      \"Profound Thought Connectivity\",\n+      \"Spirituality And Ego Dissolution\",\n+      \"Physical Euphoria Or Sedation\",\n+      \"Analysis Enhancement\",\n+      \"Excessive Yawning\",\n+      \"Nausea (Less Common Than Mushrooms)\",\n+      \"Body High And Tingling Sensations\",\n+      \"Synesthesia\",\n+      \"Feelings Of Unity\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Almost immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (LSD, mescaline, DMT, 2C-x compounds)\"\n+      ]\n+    },\n+    \"half_life\": \"1-3 hours\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: Psilocin\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Psilocin\"\n+      },\n+      {\n+        \"name\": \"Erowid Psilocin Experience Reports\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_Psilocin.shtml\"\n+      },\n+      {\n+        \"name\": \"TiHKAL #18: 4-HO-DMT by Alexander Shulgin\",\n+        \"reference\": \"https://erowid.org/library/books_online/tihkal/tihkal18.shtml\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big and Dandy 4-HO-DMT Thread\",\n+        \"reference\": \"https://www.bluelight.org/vb/threads/318367-The-Big-and-Dandy-4-HO-DMT-Thread\"\n+      },\n+      {\n+        \"name\": \"Drug-drug interactions involving classic psychedelics: A systematic review\",\n+        \"reference\": \"https://journals.sagepub.com/doi/10.1177/02698811231211219\"\n+      },\n+      {\n+        \"name\": \"Drug-drug interactions between psychiatric medications and MDMA or psilocybin\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177763/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"serotonergic\",\n+      \"entheogen\"\n+    ]\n+  },\n+  \"id\": 645\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-002145-da9fd05b",
    "createdAt": "2025-10-17T00:21:45.181Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:21:43 PM"
    },
    "articles": [
      {
        "id": 645,
        "title": "Psilocin",
        "slug": "psilocin"
      }
    ],
    "markdown": "# Psilocin · #645\n\n+{\n+  \"title\": \"Psilocin\",\n+  \"index-category\": \"psychedelic; tryptamine; classic\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Psilocin\",\n+    \"chemical_name\": \"4-Hydroxy-N,N-dimethyltryptamine\",\n+    \"alternative_name\": \"Psilocine; Psilocyn; Psilotsin; 4-HO-DMT; 4-OH-DMT\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; 5-HT2C receptor agonist; 5-HT1A receptor agonist; Activates phospholipase A2 instead of phospholipase C\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"10-15 mg\",\n+            \"common\": \"15-25 mg\",\n+            \"strong\": \"25-40 mg\",\n+            \"heavy\": \"40+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"4-6 hours\",\n+            \"onset\": \"20-45 minutes\",\n+            \"peak\": \"2-3 hours (come up 1.5-3 hours)\",\n+            \"offset\": \"1.5-2 hours\",\n+            \"after_effects\": \"4-24 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Psilocin is not considered habit-forming and has a low potential for psychological dependence. The desire to use it typically decreases with use, making it largely self-regulating. Rapid tolerance development discourages frequent redosing.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (risk of fatal seizures and heart problems)\",\n+        \"MAOIs (potential for serotonin syndrome, hypertensive crisis)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Cannabis (greatly intensifies effects, increases anxiety and psychosis risk)\"\n+      ],\n+      \"caution\": [\n+        \"SSRIs (may reduce effects or increase risk)\",\n+        \"SNRIs (may alter effects)\",\n+        \"Tricyclic antidepressants (may potentiate effects)\",\n+        \"Benzodiazepines (reduce intensity, may cause amnesia)\",\n+        \"Antipsychotics (significantly dampen effects)\",\n+        \"MDMA (amplifies effects, possible neurotoxicity concerns)\",\n+        \"Dissociatives (intensifies hallucinations and confusion)\",\n+        \"Alcohol (causes dehydration and nausea, dulls effects)\"\n+      ]\n+    },\n+    \"notes\": \"Psilocin is the pharmacologically active form of psilocybin and is rarely encountered as a pure synthetic compound. It is relatively unstable and readily forms blue degradation products when exposed to oxygen. Store in cool, dry, dark conditions. Unlike psilocybin mushrooms, pure psilocin has reduced nausea when taken on an empty stomach. Set and setting are critical to the experience. Those with personal or family history of psychotic disorders should avoid use. Always use accurate scales for dosing, as the substance is potent and effects can be overwhelming.\",\n+    \"subjective_effects\": [\n+      \"Visual Patterning And Geometry\",\n+      \"Enhanced Colors And Visual Acuity\",\n+      \"Drifting, Melting, And Morphing Visuals\",\n+      \"Internal And External Hallucinations\",\n+      \"Emotional Amplification And Empathy\",\n+      \"Time Distortion\",\n+      \"Profound Thought Connectivity\",\n+      \"Spirituality And Ego Dissolution\",\n+      \"Physical Euphoria Or Sedation\",\n+      \"Analysis Enhancement\",\n+      \"Excessive Yawning\",\n+      \"Nausea (Less Common Than Mushrooms)\",\n+      \"Body High And Tingling Sensations\",\n+      \"Synesthesia\",\n+      \"Feelings Of Unity\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Almost immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (LSD, mescaline, DMT, 2C-x compounds)\"\n+      ]\n+    },\n+    \"half_life\": \"1-3 hours\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: Psilocin\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Psilocin\"\n+      },\n+      {\n+        \"name\": \"Erowid Psilocin Experience Reports\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_Psilocin.shtml\"\n+      },\n+      {\n+        \"name\": \"TiHKAL #18: 4-HO-DMT by Alexander Shulgin\",\n+        \"reference\": \"https://erowid.org/library/books_online/tihkal/tihkal18.shtml\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big and Dandy 4-HO-DMT Thread\",\n+        \"reference\": \"https://www.bluelight.org/vb/threads/318367-The-Big-and-Dandy-4-HO-DMT-Thread\"\n+      },\n+      {\n+        \"name\": \"Drug-drug interactions involving classic psychedelics: A systematic review\",\n+        \"reference\": \"https://journals.sagepub.com/doi/10.1177/02698811231211219\"\n+      },\n+      {\n+        \"name\": \"Drug-drug interactions between psychiatric medications and MDMA or psilocybin\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177763/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"serotonergic\",\n+      \"entheogen\"\n+    ]\n+  },\n+  \"id\": 645\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-001831-4cf48d4f",
    "createdAt": "2025-10-17T00:18:31.587Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:18:29 PM"
    },
    "articles": [
      {
        "id": 644,
        "title": "5-MeO-DiPT",
        "slug": "5-meo-dipt"
      }
    ],
    "markdown": "# 5-MeO-DiPT · #644\n\n+{\n+  \"title\": \"5-MeO-DiPT\",\n+  \"index-category\": \"psychedelic; tryptamine; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"5-MeO-DiPT\",\n+    \"chemical_name\": \"5-Methoxy-N,N-diisopropyltryptamine\",\n+    \"alternative_name\": \"Foxy; Foxy Methoxy\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic; Entactogen; Stimulant\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist (primary); 5-HT1A receptor agonist (strongest binding affinity); weak serotonin reuptake inhibitor; possible monoamine oxidase inhibition\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"3-4 mg\",\n+            \"light\": \"3-10 mg\",\n+            \"common\": \"10-15 mg\",\n+            \"strong\": \"15-20 mg\",\n+            \"heavy\": \"20+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"2-4 mg\",\n+            \"light\": \"4-7 mg\",\n+            \"common\": \"7-12 mg\",\n+            \"strong\": \"12-18 mg\",\n+            \"heavy\": \"18+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"smoked\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"2-3 mg\",\n+            \"light\": \"3-5 mg\",\n+            \"common\": \"5-8 mg\",\n+            \"strong\": \"8-12 mg\",\n+            \"heavy\": \"12+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"4-8 hours\",\n+            \"onset\": \"20-60 minutes\",\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"2-6 hours (residual stimulation, possible insomnia)\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"stages\": {\n+            \"total_duration\": \"3-6 hours\",\n+            \"onset\": \"5-20 minutes\",\n+            \"peak\": \"45-90 minutes\",\n+            \"offset\": \"1-3 hours\",\n+            \"after_effects\": \"2-4 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n+        },\n+        {\n+          \"route\": \"smoked\",\n+          \"stages\": {\n+            \"total_duration\": \"2-4 hours\",\n+            \"onset\": \"1-5 minutes\",\n+            \"peak\": \"30-90 minutes\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"2-6 hours (prolonged compared to other smoked tryptamines)\"\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"5-MeO-DiPT is not considered physically addictive and has low potential for psychological dependence. Some users report compulsive redosing due to the extended onset, particularly among inexperienced users who mistake the delayed effects for inadequate dosing. Tryptamines of this class are not known for addictive patterns.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"MAOIs (risk of serotonin syndrome; 5-MeO-DiPT may have weak MAOI properties)\",\n+        \"Tramadol (increased risk of serotonin syndrome and seizures)\",\n+        \"aMT (increased risk of serotonin syndrome)\"\n+      ],\n+      \"unsafe\": [\n+        \"2C-T-X (both classes unpredictable alone)\",\n+        \"2C-X (unpredictable potentiation of psychedelic effects)\",\n+        \"NBOMe (both classes unpredictable; increased risk of unpleasant physical side effects)\",\n+        \"DOx (unpredictable interactions; increased risk of unpleasant physical side effects)\",\n+        \"MDMA (5-MeO tryptamines unpredictable with MDMA)\",\n+        \"Mescaline (unpredictable interactions)\",\n+        \"DXM (little information; possible unpredictable effects)\",\n+        \"PCP (little information; may increase risk of psychosis and excessive stimulation)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (may increase risk of anxiety, paranoia, and psychosis)\",\n+        \"Amphetamines (anxiogenic and focusing effects increase risk of thought loops; combination generally unnecessary)\",\n+        \"Cocaine (anxiogenic and focusing effects increase risk of thought loops; combination generally unnecessary)\"\n+      ]\n+    },\n+    \"notes\": \"5-MeO-DiPT varies widely in individual response; some users report profound experiences while others experience uncomfortable gastrointestinal distress including severe diarrhea, gas, and stomach bloating. Use a precise milligram scale as dosages are in the low milligram range. The extended onset of 20-60 minutes has led to accidental overdoses from premature redosing. Individuals with personal or family history of psychotic disorders should avoid use. At least one death has been attributed to rectal administration overdose. The substance has been reported to be neurotoxic in rats. Set and setting are important; some users report significant anxiety and paranoia at higher doses.\",\n+    \"subjective_effects\": [\n+      \"Tactile Enhancement\",\n+      \"Stimulation\",\n+      \"Emotional Enhancement\",\n+      \"Increased Music Appreciation\",\n+      \"Enhanced Libido\",\n+      \"Spontaneous Physical Sensations\",\n+      \"Auditory Distortions\",\n+      \"Cognitive Euphoria\",\n+      \"Nausea\",\n+      \"Body Load\",\n+      \"Diarrhea\",\n+      \"Time Distortion\",\n+      \"Visual Drifting (at higher doses)\",\n+      \"Pupil Dilation\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (LSD, psilocybin, mescaline, DMT, other tryptamines)\"\n+      ]\n+    },\n+    \"half_life\": \"3-6 hours (estimated from duration data)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid 5-MeO-DiPT Vault\",\n+        \"reference\": \"https://erowid.org/chemicals/5meo_dipt/\"\n+      },\n+      {\n+        \"name\": \"Erowid TiHKAL Entry #37: 5-MeO-DiPT\",\n+        \"reference\": \"https://erowid.org/library/books_online/tihkal/tihkal37.shtml\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: 5-MeO-DiPT\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/5-MeO-DiPT\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy 5-MeO-DiPT Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-5-meo-dipt-thread.57817/\"\n+      },\n+      {\n+        \"name\": \"TripSit Drug Combinations Wiki\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/Drug_combinations\"\n+      },\n+      {\n+        \"name\": \"Shulgin, A. T.; Carter, M. F. (1980). Communications in Psychopharmacology\",\n+        \"reference\": \"N,N-Diisopropyltryptamine (DIPT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT). Two orally active tryptamine analogs with CNS activity\"\n+      },\n+      {\n+        \"name\": \"Noworyta-Sokolowska et al. (2016). Neurotoxicity Research\",\n+        \"reference\": \"Neurotoxic Effects of 5-MeO-DIPT: A Psychoactive Tryptamine Derivative in Rats\"\n+      },\n+      {\n+        \"name\": \"US DEA Drug Fact Sheet: 5-MeO-DiPT\",\n+        \"reference\": \"https://www.deadiversion.usdoj.gov/drug_chem_info/5meodipt.pdf\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"research-chemical\",\n+      \"entactogen\"\n+    ]\n+  },\n+  \"id\": 644\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-001600-2209a8ec",
    "createdAt": "2025-10-17T00:16:00.464Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:15:58 PM"
    },
    "articles": [
      {
        "id": 643,
        "title": "4-HO-MPT",
        "slug": "4-ho-mpt"
      }
    ],
    "markdown": "# 4-HO-MPT · #643\n\n+{\n+  \"title\": \"4-HO-MPT\",\n+  \"index-category\": \"psychedelic; tryptamine; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"4-HO-MPT\",\n+    \"chemical_name\": \"3-[2-(Methylpropylamino)ethyl]-4-indolol\",\n+    \"alternative_name\": \"Meprocin; 4-Hydroxy-N-methyl-N-propyltryptamine\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor full agonist; 5-HT2B receptor partial agonist (moderate-efficacy); 5-HT2C receptor partial agonist (high-efficacy)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"5-10 mg\",\n+            \"common\": \"10-20 mg\",\n+            \"strong\": \"20-30 mg\",\n+            \"heavy\": \"30+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"vaporized\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"3 mg\",\n+            \"light\": \"3-5 mg\",\n+            \"common\": \"5-10 mg\",\n+            \"strong\": \"10-15 mg\",\n+            \"heavy\": \"15+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"3-7 hours\",\n+            \"onset\": \"20-60 minutes\",\n+            \"peak\": \"2-3 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"2-12 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"vaporized\",\n+          \"stages\": {\n+            \"total_duration\": \"45-90 minutes\",\n+            \"onset\": \"1-3 minutes\",\n+            \"peak\": \"10-30 minutes\",\n+            \"offset\": \"15-45 minutes\",\n+            \"after_effects\": \"1-6 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"4-HO-MPT is generally considered not habit-forming, and the desire to use it can actually decrease with regular consumption. Like most psychedelics, it is thought to be self-regulating with low potential for psychological dependence.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (unpredictable synergy; increases risk of anxiety, paranoia, panic attacks, and psychosis)\",\n+        \"Stimulants (increases risk of anxiety, paranoia, panic attacks, thought loops, mania, and psychosis)\"\n+      ]\n+    },\n+    \"notes\": \"4-HO-MPT is a research chemical with very little history of human usage and minimal scientific data on its pharmacology, metabolism, and toxicity. Legal status varies by jurisdiction; it is unscheduled in most countries but is a Class A drug in the United Kingdom under the tryptamine catch-all clause and controlled under Germany's NpSG. Use precise scales for dosing as potency varies between salt forms (freebase is approximately 25% more potent than fumarate salts). Individuals with personal or family histories of mental illness should avoid use.\",\n+    \"subjective_effects\": [\n+      \"Visual Distortions And Patterning\",\n+      \"Color Enhancement And Shifting\",\n+      \"Time Distortion\",\n+      \"Emotion Enhancement\",\n+      \"Cognitive Euphoria\",\n+      \"Nausea\",\n+      \"Increased Heart Rate\",\n+      \"Pupil Dilation\",\n+      \"Thought Loops\",\n+      \"Vertigo Or Dizziness\",\n+      \"Memory Suppression\",\n+      \"Internal And External Hallucinations\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (including LSD, psilocybin, mescaline, and other tryptamines)\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid 4-HO-MPT Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/4_ho_mpt/4_ho_mpt.shtml\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki 4-HO-MPT\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/4-HO-MPT\"\n+      },\n+      {\n+        \"name\": \"TripSit 4-HO-MPT Factsheet\",\n+        \"reference\": \"https://tripbot.tripsit.me/factsheet/4-HO-MPT\"\n+      },\n+      {\n+        \"name\": \"TiHKAL Entry #23: 4-HO-MPT (Isomer Design)\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/read.php?domain=tk&id=23\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy 4-HO-MPT Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-4-ho-mpt-thread.550416/\"\n+      },\n+      {\n+        \"name\": \"Drugs-Forum 4-HO-MPT Wiki\",\n+        \"reference\": \"https://drugs-forum.com/wiki/4-HO-MPT\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"research-chemical\",\n+      \"synthetic\"\n+    ]\n+  },\n+  \"id\": 643\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-001249-69555e3a",
    "createdAt": "2025-10-17T00:12:49.407Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:12:46 PM"
    },
    "articles": [
      {
        "id": 642,
        "title": "4-HO-EPT",
        "slug": "4-ho-ept"
      }
    ],
    "markdown": "# 4-HO-EPT · #642\n\n+{\n+  \"title\": \"4-HO-EPT\",\n+  \"index-category\": \"psychedelic; tryptamine; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"4-HO-EPT\",\n+    \"chemical_name\": \"4-Hydroxy-N-ethyl-N-propyltryptamine\",\n+    \"alternative_name\": \"Eprocin\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"10-15 mg\",\n+            \"light\": \"15-20 mg\",\n+            \"common\": \"30-40 mg\",\n+            \"strong\": \"40-60 mg\",\n+            \"heavy\": \"60+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"smoked\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5-10 mg\",\n+            \"light\": \"10-15 mg\",\n+            \"common\": \"15-25 mg\",\n+            \"strong\": \"25-35 mg\",\n+            \"heavy\": \"35+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"3-7 hours\",\n+            \"onset\": \"30-60 minutes\",\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"2-4 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"smoked\",\n+          \"stages\": {\n+            \"total_duration\": \"1-2 hours\",\n+            \"onset\": \"1-5 minutes\",\n+            \"peak\": \"15-30 minutes\",\n+            \"offset\": \"30-60 minutes\",\n+            \"after_effects\": \"1-2 hours\"\n+          }\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"4-HO-EPT is not habit-forming and the desire to use it can actually decrease with regular consumption. Like most psychedelics, it is generally considered self-regulating. There is no evidence of physical dependence potential.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Stimulants (increased risk of anxiety, paranoia, thought loops, mania, and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (unpredictable synergy, significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n+      ]\n+    },\n+    \"notes\": \"4-HO-EPT is a novel research chemical with very little history of human use before 2016 and almost no scientific research on its pharmacology, metabolism, or toxicity. Unlike more visual tryptamines, it primarily enhances colors with a neon quality rather than producing strong visual distortions. Users report a strong euphoric body high sometimes compared to opiates, with a generally light and positive mindset. Accurate weighing with a precise milligram scale is essential. Individuals with personal or family history of psychotic disorders should avoid use. Higher doses may cause vasoconstriction. Set and setting considerations apply as with all psychedelics.\",\n+    \"subjective_effects\": [\n+      \"Color Enhancement\",\n+      \"Cognitive Euphoria\",\n+      \"Euphoric Body High\",\n+      \"Increased Music Appreciation\",\n+      \"Conceptual Thinking\",\n+      \"Analysis Enhancement\",\n+      \"Pattern Recognition Enhancement\",\n+      \"Time Distortion\",\n+      \"Emotion Enhancement\",\n+      \"Sedation\",\n+      \"Memory Suppression\",\n+      \"Thought Loops\",\n+      \"Nausea\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy 4-HO-EPT Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-4-ho-ept-thread.805165/\"\n+      },\n+      {\n+        \"name\": \"Erowid 4-HO-EPT Experience Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_4HOEPT.shtml\"\n+      },\n+      {\n+        \"name\": \"Isomer Design: 4-HO-EPT\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?id=5770\"\n+      },\n+      {\n+        \"name\": \"PMC: Investigation of the Structure-Activity Relationships of Psilocybin Analogues\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC8033608/\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: 4-HO-EPT\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/4-HO-EPT\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 642\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-000922-9ad8186d",
    "createdAt": "2025-10-17T00:09:22.650Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:09:20 PM"
    },
    "articles": [
      {
        "id": 641,
        "title": "4-HO-DiPT",
        "slug": "4-ho-dipt"
      }
    ],
    "markdown": "# 4-HO-DiPT · #641\n\n+{\n+  \"title\": \"4-HO-DiPT\",\n+  \"index-category\": \"psychedelic; tryptamine; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"4-HO-DiPT\",\n+    \"chemical_name\": \"3-[2-(Diisopropylamino)ethyl]-1H-indol-4-ol\",\n+    \"alternative_name\": \"Iprocin; 4-Hydroxy-DiPT; 4-Hydroxy-N,N-diisopropyltryptamine\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; Serotonin reuptake inhibitor (weak)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"3 mg\",\n+            \"light\": \"3-10 mg\",\n+            \"common\": \"10-20 mg\",\n+            \"strong\": \"20-30 mg\",\n+            \"heavy\": \"30+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"2-4 hours\",\n+            \"onset\": \"15-30 minutes\",\n+            \"peak\": \"60-90 minutes (20-30 minutes after onset)\",\n+            \"offset\": \"30-60 minutes\",\n+            \"after_effects\": \"1-3 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"4-HO-DiPT is not habit-forming and has minimal psychological dependence potential. Like most psychedelics, it is considered self-regulating, with the desire to use it typically decreasing with regular consumption.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants (increased risk of anxiety, paranoia, panic attacks, thought loops, mania, and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (unpredictable synergy; significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n+      ]\n+    },\n+    \"notes\": \"4-HO-DiPT is a research chemical with very limited history of human use and no scientific studies on its toxicity. It is noted for its uniquely rapid onset, short duration, narrow dose sensitivity, and high intensity relative to dose. Physical side effects including muscle tremors, leg tremors, bodily malaise, and temperature dysregulation are commonly reported. Set and setting are critical, and harm reduction practices are essential. The substance is unscheduled in most jurisdictions but may be controlled under analogue laws.\",\n+    \"subjective_effects\": [\n+      \"Cognitive Euphoria\",\n+      \"Emotion Enhancement\",\n+      \"Introspective Insights\",\n+      \"Time Distortion\",\n+      \"Increased Music Appreciation\",\n+      \"Enhanced Tactile Sensation\",\n+      \"Sexual Enhancement\",\n+      \"Visual Pattern Recognition Enhancement\",\n+      \"Colour Enhancement\",\n+      \"Muscle Tremors\",\n+      \"Nausea\",\n+      \"Pupil Dilation\",\n+      \"Stimulation\",\n+      \"Temperature Dysregulation\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (LSD, psilocybin, mescaline, DMT, 2C-x, DOx, 5-MeO-xxT, other tryptamines)\"\n+      ]\n+    },\n+    \"half_life\": \"2.7-4.1 hours (based on prodrug luvesilocin studies)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: 4-HO-DiPT\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/4-HO-DiPT\"\n+      },\n+      {\n+        \"name\": \"Erowid 4-HO-DiPT Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/4_ho_dipt/4_ho_dipt.shtml\"\n+      },\n+      {\n+        \"name\": \"TiHKAL Entry #17: 4-HO-DiPT by Alexander Shulgin\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/read.php?domain=tk&id=17\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy 4-HO-DiPT Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-4-ho-dipt-thread.107890/\"\n+      },\n+      {\n+        \"name\": \"Drugs-Forum: 4-HO-DiPT Trip Reports\",\n+        \"reference\": \"https://drugs-forum.com/threads/4-ho-dipt-trip-reports.3095/\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: 4-HO-DiPT\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/4-HO-DiPT\"\n+      },\n+      {\n+        \"name\": \"Repke, D. B. et al. (1977). Psilocin analogs synthesis\",\n+        \"reference\": \"Journal of Heterocyclic Chemistry, 14(1), 71-74\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"research-chemical\",\n+      \"synthetic\"\n+    ]\n+  },\n+  \"id\": 641\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-000655-9eafe3b2",
    "createdAt": "2025-10-17T00:06:55.306Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:06:53 PM"
    },
    "articles": [
      {
        "id": 640,
        "title": "4-HO-DET",
        "slug": "4-ho-det"
      }
    ],
    "markdown": "# 4-HO-DET · #640\n\n+{\n+  \"title\": \"4-HO-DET\",\n+  \"index-category\": \"psychedelic; tryptamine; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"4-HO-DET\",\n+    \"chemical_name\": \"3-(2-diethylaminoethyl)-1H-indol-4-ol\",\n+    \"alternative_name\": \"Ethocin; CZ-74; 4-Hydroxy-N,N-diethyltryptamine\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"10-15 mg\",\n+            \"common\": \"20-30 mg\",\n+            \"strong\": \"30-45 mg\",\n+            \"heavy\": \"45+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"5-7 hours\",\n+            \"onset\": \"20-45 minutes\",\n+            \"peak\": \"2.5-3.5 hours (with 30-60 minute come up)\",\n+            \"offset\": \"1.5-2 hours\",\n+            \"after_effects\": \"1-4 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"4-HO-DET is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating. Limited evidence suggests no significant addiction potential.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [],\n+      \"caution\": [\n+        \"Cannabis (unpredictable synergy, may significantly increase risk of anxiety, paranoia, panic attacks, and psychosis)\",\n+        \"Stimulants (may increase risk of anxiety, paranoia, panic attacks, thought loops, mania and psychosis)\"\n+      ]\n+    },\n+    \"notes\": \"4-HO-DET is a research chemical with very little history of human usage. The toxicity and long-term health effects have not been studied in any scientific context. It is strongly recommended to use harm reduction practices when using this substance. Legal status varies by jurisdiction; it is unscheduled in the United States but may be prosecuted under the Federal Analogue Act. It is controlled in Germany, Sweden, Switzerland, and the United Kingdom.\",\n+    \"subjective_effects\": [\n+      \"Visual Patterning And Geometry\",\n+      \"Colour Enhancement\",\n+      \"Tactile Enhancement\",\n+      \"Thought Connectivity\",\n+      \"Analysis Enhancement\",\n+      \"Increased Music Appreciation\",\n+      \"Time Distortion\",\n+      \"Ego Death\",\n+      \"Memory Suppression\",\n+      \"Excessive Yawning\",\n+      \"Temperature Regulation Suppression\",\n+      \"Pupil Dilation\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Almost immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Bluelight 4-HO-DET Discussion Thread\",\n+        \"reference\": \"http://www.bluelight.org/vb/threads/480200-The-Big-amp-Dandy-4-HO-DET-Thread\"\n+      },\n+      {\n+        \"name\": \"Erowid 4-HO-DET Experience Vaults\",\n+        \"reference\": \"https://www.erowid.org/experiences/subs/exp_4HODET.shtml\"\n+      },\n+      {\n+        \"name\": \"Isomer Design TiHKAL Entry #16: 4-HO-DET\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5016\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: 4-HO-DET\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/4-HO-DET\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: 4-HO-DET\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/4-HO-DET\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"research-chemical\",\n+      \"synthetic\"\n+    ]\n+  },\n+  \"id\": 640\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-000420-1266ad24",
    "createdAt": "2025-10-17T00:04:20.477Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:04:18 PM"
    },
    "articles": [
      {
        "id": 639,
        "title": "4-AcO-MiPT",
        "slug": "4-aco-mipt"
      }
    ],
    "markdown": "# 4-AcO-MiPT · #639\n\n+{\n+  \"title\": \"4-AcO-MiPT\",\n+  \"index-category\": \"psychedelic; tryptamine\",\n+  \"drug_info\": {\n+    \"drug_name\": \"4-AcO-MiPT\",\n+    \"chemical_name\": \"4-Acetoxy-N-methyl-N-isopropyltryptamine\",\n+    \"alternative_name\": \"Mipracetin; O-Acetylmiprocin; 4-Acetoxy-MiPT\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist (prodrug of 4-HO-MiPT)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"10-15 mg\",\n+            \"common\": \"15-20 mg\",\n+            \"strong\": \"20-35 mg\",\n+            \"heavy\": \"35+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"4-8 hours\",\n+            \"onset\": \"20-60 minutes\",\n+            \"peak\": \"1.5-3 hours (come up 1-2 hours)\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"2-4 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"4-AcO-MiPT is not habit-forming and demonstrates a self-regulating pattern typical of psychedelics. The desire to use it tends to decrease with regular consumption rather than increase.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Stimulants (increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (unpredictable synergy, may significantly intensify effects)\"\n+      ]\n+    },\n+    \"notes\": \"4-AcO-MiPT is a synthetic psychedelic tryptamine that remains relatively uncommon with limited history of human use. The substance is hygroscopic and degrades quickly when exposed to moisture or improper storage; it should be kept in an inert atmosphere in a freezer. The material can develop a sticky, goop-like consistency when exposed to air. Accurate weighing with a precise milligram scale is essential, as the substance is potent and can appear deceptively small. It is theorized to act as a prodrug for 4-HO-MiPT, though debate continues about whether it possesses innate activity. Set and setting are critical factors for the experience.\",\n+    \"subjective_effects\": [\n+      \"Visual Geometry (Organic, Intricate, Natural-Feeling)\",\n+      \"Colour Enhancement\",\n+      \"Pattern Recognition Enhancement\",\n+      \"Sedation With Mild Euphoria\",\n+      \"Pleasurable Body High (Warm, Tingling Sensations)\",\n+      \"Excessive Yawning\",\n+      \"Enhanced Music Appreciation\",\n+      \"Auditory Distortions (Downward Pitch Shift)\",\n+      \"Emotion Enhancement\",\n+      \"Thought Connectivity\",\n+      \"Time Distortion\",\n+      \"Internal Hallucinations (Dark Environments)\",\n+      \"Memory Suppression\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid 4-Acetoxy-MiPT Vault\",\n+        \"reference\": \"https://erowid.org/chemicals/4_acetoxy_mipt/4_acetoxy_mipt.shtml\"\n+      },\n+      {\n+        \"name\": \"Isomer Design: 4-AcO-MIPT\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=5546\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: 4-AcO-MiPT\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/4-AcO-MiPT\"\n+      },\n+      {\n+        \"name\": \"The Big & Dandy 4-AcO-MiPT Thread (Bluelight)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-4-aco-mipt-thread.101872/\"\n+      },\n+      {\n+        \"name\": \"Takahashi et al. - Psychoactive Designer Drugs Data Library\",\n+        \"reference\": \"https://doi.org/10.1016/j.talanta.2008.07.062\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"research-chemical\",\n+      \"synthetic\"\n+    ]\n+  },\n+  \"id\": 639\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-235801-dbfacf25",
    "createdAt": "2025-10-16T23:58:01.469Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 5:57:59 PM"
    },
    "articles": [
      {
        "id": 638,
        "title": "4-AcO-DiPT",
        "slug": "4-aco-dipt"
      }
    ],
    "markdown": "# 4-AcO-DiPT · #638\n\n+{\n+  \"title\": \"4-AcO-DiPT\",\n+  \"index-category\": \"psychedelic; tryptamine\",\n+  \"drug_info\": {\n+    \"drug_name\": \"4-AcO-DiPT\",\n+    \"chemical_name\": \"3-[2-(Diisopropylamino)ethyl]-1H-indol-4-yl acetate\",\n+    \"alternative_name\": \"4-Acetoxy-DiPT; Ipracetin; Iprocetyl; Aces; 4-Ace\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist; 5-HT2C receptor agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"3-5 mg\",\n+            \"light\": \"5-15 mg\",\n+            \"common\": \"15-30 mg\",\n+            \"strong\": \"30-45 mg\",\n+            \"heavy\": \"45+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"3-4 hours\",\n+            \"onset\": \"15-40 minutes\",\n+            \"peak\": \"1.5-2 hours\",\n+            \"offset\": \"1-1.5 hours\",\n+            \"after_effects\": \"2-6 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"4-AcO-DiPT is not known to be habit-forming and the desire to use it can decrease with repeated administration. However, it may possess a higher liability for frequent or excessive consumption relative to most psychedelics due to its distinctly hedonic and short-duration effects. Compulsive redosing is reported to be atypically prominent for this substance.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"MAOIs (risk of serotonin syndrome)\",\n+        \"Stimulants (increased risk of anxiety, paranoia, panic attacks, and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (may significantly intensify and prolong effects unpredictably)\",\n+        \"Alcohol (physically taxing, may dull effects)\",\n+        \"Benzodiazepines (may reduce trip intensity)\"\n+      ]\n+    },\n+    \"notes\": \"4-AcO-DiPT is thought to act as a prodrug to 4-HO-DiPT (Iprocin). It is available in both freebase and HCl salt forms, with the freebase being approximately 10% more potent by weight. This substance is characterized by atypically strong physical euphoria and sensuality with minimal visual effects, distinguishing it from most other 4-substituted tryptamines. Accurate weighing with a milligram scale is essential. Individuals with personal or family histories of seizure disorders or psychotic conditions should avoid use. The compound can produce notable increases in body temperature, particularly at peak effects. Set and setting significantly influence the experience.\",\n+    \"subjective_effects\": [\n+      \"Physical Euphoria\",\n+      \"Tactile Enhancement\",\n+      \"Increased Libido\",\n+      \"Sedation Followed By Stimulation\",\n+      \"Disinhibition\",\n+      \"Enhanced Sociability\",\n+      \"Color Enhancement\",\n+      \"Spontaneous Physical Sensations\",\n+      \"Changes In Felt Bodily Form\",\n+      \"Music Appreciation Enhancement\",\n+      \"Empathy And Affection Enhancement\",\n+      \"Minimal Visual Effects\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (e.g., psilocybin, LSD, mescaline, other tryptamines)\"\n+      ]\n+    },\n+    \"half_life\": \"2-4 hours (rapidly metabolized to 4-HO-DiPT)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid 4-Acetoxy-DiPT Primer by Toad\",\n+        \"reference\": \"https://www.erowid.org/chemicals/4_acetoxy_dipt/4_acetoxy_dipt_primer.shtml\"\n+      },\n+      {\n+        \"name\": \"Erowid 4-Acetoxy-DiPT Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/4_acetoxy_dipt/4_acetoxy_dipt.shtml\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: 4-AcO-DiPT\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/4-AcO-DiPT\"\n+      },\n+      {\n+        \"name\": \"Bluelight 4-AcO-DiPT Discussion Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/4-aco-dipt-new-experience-10-mg-dose-to-test-the-waters.493414/\"\n+      },\n+      {\n+        \"name\": \"Isomer Design: 4-AcO-DiPT\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5369\"\n+      },\n+      {\n+        \"name\": \"Human Hepatocyte 4-AcO-DiPT Metabolite Profiling Study\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC9413566/\"\n+      },\n+      {\n+        \"name\": \"Investigation of Structure-Activity Relationships of Psilocybin Analogues\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC8033608/\"\n+      },\n+      {\n+        \"name\": \"Pharmacologic Activity of Substituted Tryptamines Study\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC10029822/\"\n+      },\n+      {\n+        \"name\": \"TiHKAL Entry #17: 4-HO-DiPT\",\n+        \"reference\": \"https://erowid.org/library/books_online/tihkal/tihkal17.shtml\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"research-chemical\",\n+      \"synthetic\"\n+    ]\n+  },\n+  \"id\": 638\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-235243-ca7cd977",
    "createdAt": "2025-10-16T23:52:43.680Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 5:52:42 PM"
    },
    "articles": [
      {
        "id": 637,
        "title": "EPT",
        "slug": "ept"
      }
    ],
    "markdown": "# EPT · #637\n\n+{\n+  \"title\": \"EPT\",\n+  \"index-category\": \"psychedelic; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"EPT\",\n+    \"chemical_name\": \"N-Ethyl-N-propyltryptamine\",\n+    \"alternative_name\": \"Ethylpropyltryptamine; N-Ethyl-N-[2-(1H-indol-3-yl)ethyl]propan-1-amine\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; 5-HT2C receptor partial agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"\",\n+            \"light\": \"20-40 mg\",\n+            \"common\": \"40-80 mg\",\n+            \"strong\": \"80-110 mg\",\n+            \"heavy\": \"110+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"\",\n+            \"light\": \"75-100 mg\",\n+            \"common\": \"100-150 mg\",\n+            \"strong\": \"150-200 mg\",\n+            \"heavy\": \"200+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"vaporized\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"\",\n+            \"light\": \"15-30 mg\",\n+            \"common\": \"30-60 mg\",\n+            \"strong\": \"60-100 mg\",\n+            \"heavy\": \"100+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"insufflated\",\n+          \"stages\": {\n+            \"total_duration\": \"2-4 hours\",\n+            \"onset\": \"5-20 minutes\",\n+            \"after_effects\": \"1-3 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n+        },\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"3-6 hours\",\n+            \"onset\": \"30-90 minutes\",\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"2-4 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"vaporized\",\n+          \"stages\": {\n+            \"total_duration\": \"1-3 hours\",\n+            \"onset\": \"1-5 minutes\",\n+            \"peak\": \"10-30 minutes\",\n+            \"offset\": \"30-90 minutes\",\n+            \"after_effects\": \"1-2 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"EPT does not appear to produce dependence and has low abuse potential, similar to other unsubstituted tryptamines like DMT, DET, and MET. Rapid tolerance development discourages frequent use.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (seizure risk)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"MAOIs (unknown interactions with increased potency)\",\n+        \"Stimulants (increased anxiety and physical strain)\"\n+      ],\n+      \"caution\": [\n+        \"Other psychedelics (overwhelming intensity)\",\n+        \"Cannabis (may intensify anxiety or confusion)\"\n+      ]\n+    },\n+    \"notes\": \"EPT is a novel research chemical with very limited documentation and extremely sparse user reports. The toxicity profile is unknown and no scientific studies exist on its safety in humans. Effects are described as milder and less immersive than structurally similar tryptamines like DMT and DPT. EPT is typically sold as the fumarate salt rather than the hydrochloride form. Start with very low doses due to individual sensitivity variations and the lack of established safety data. Use precise milligram scales and practice comprehensive harm reduction including set and setting protocols.\",\n+    \"subjective_effects\": [\n+      \"Visual Pattern Recognition Enhancement\",\n+      \"Color Enhancement\",\n+      \"Drifting And Morphing\",\n+      \"Dissociative Feeling\",\n+      \"Body Heaviness\",\n+      \"Time Distortion\",\n+      \"Memory Suppression\",\n+      \"Increased Libido\",\n+      \"Nausea\",\n+      \"Motor Control Loss\",\n+      \"Pupil Dilation\",\n+      \"Thought Acceleration\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (LSD, psilocybin, mescaline, DMT, other tryptamines)\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Bluelight: The Small & Handy EPT Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-small-handy-ept-thread.856610/\"\n+      },\n+      {\n+        \"name\": \"Drugs-Forum: EPT Experiences\",\n+        \"reference\": \"https://drugs-forum.com/threads/ept-experiences.298861/\"\n+      },\n+      {\n+        \"name\": \"Erowid Experience Vaults: EPT\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_EPT.shtml\"\n+      },\n+      {\n+        \"name\": \"Isomer Design: EPT\",\n+        \"reference\": \"https://isomerdesign.com/pihkal/explore/5075\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: EPT\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/EPT\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 637\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-234801-e17fa4f6",
    "createdAt": "2025-10-16T23:48:01.414Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 5:47:59 PM"
    },
    "articles": [
      {
        "id": 636,
        "title": "DET",
        "slug": "det"
      }
    ],
    "markdown": "# DET · #636\n\n+{\n+  \"title\": \"DET\",\n+  \"index-category\": \"psychedelic; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"DET\",\n+    \"chemical_name\": \"N,N-diethyl-2-(1H-indol-3-yl)ethanamine\",\n+    \"alternative_name\": \"Diethyltryptamine; N,N-diethyltryptamine; T-9\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"10 mg\",\n+            \"light\": \"20-40 mg\",\n+            \"common\": \"40-70 mg\",\n+            \"strong\": \"70-100 mg\",\n+            \"heavy\": \"100+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"4-6 hours\",\n+            \"onset\": \"30-90 minutes\",\n+            \"peak\": \"2-4 hours\",\n+            \"offset\": \"2-3 hours\",\n+            \"after_effects\": \"2-8 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"DET is not believed to be habit-forming and the desire to use it can actually decrease with repeated use. No formal studies have been conducted on its addiction potential, but anecdotal evidence suggests no negative dependency patterns.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (seizure risk and amplified intensity)\",\n+        \"MAOIs (serotonin syndrome risk)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"caution\": [\n+        \"Stimulants (may cause anxiety, paranoia, and thought loops)\"\n+      ]\n+    },\n+    \"notes\": \"DET is a Schedule I controlled substance internationally under the UN Convention on Psychotropic Substances and is illegal in most countries. Unlike DMT, DET is orally active due to increased resistance to monoamine oxidase breakdown from its ethyl groups. The substance has extremely limited history of human use and no formal toxicity studies exist. Users should employ precise dosing with a milligram scale and ensure proper set and setting. Individuals with personal or family history of psychotic disorders should avoid use.\",\n+    \"subjective_effects\": [\n+      \"Visual Pattern Recognition Enhancement\",\n+      \"Color Enhancement\",\n+      \"Drifting and Morphing\",\n+      \"Internal Hallucinations\",\n+      \"Cognitive Euphoria\",\n+      \"Emotion Enhancement\",\n+      \"Increased Music Appreciation\",\n+      \"Time Distortion\",\n+      \"Pupil Dilation\",\n+      \"Nausea\",\n+      \"Increased Heart Rate\",\n+      \"Conceptual Thinking\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Almost immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid DET Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/det/det.shtml\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: DET\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/DET\"\n+      },\n+      {\n+        \"name\": \"TiHKAL #3: DET (Isomer Design)\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5003\"\n+      },\n+      {\n+        \"name\": \"TiHKAL #3: DET (Erowid)\",\n+        \"reference\": \"https://www.erowid.org/library/books_online/tihkal/tihkal03.shtml\"\n+      },\n+      {\n+        \"name\": \"Bluelight: 5-substituted tryptamines discussion\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/5-substituted-tryptamines.340503/\"\n+      },\n+      {\n+        \"name\": \"Drug-drug interactions involving classic psychedelics\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC10851641/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 636\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-233259-3b3ee166",
    "createdAt": "2025-10-16T23:32:59.430Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 5:32:57 PM"
    },
    "articles": [
      {
        "id": 635,
        "title": "PRO-LAD",
        "slug": "pro-lad"
      }
    ],
    "markdown": "# PRO-LAD · #635\n\n+{\n+  \"title\": \"PRO-LAD\",\n+  \"index-category\": \"psychedelic; lysergamide\",\n+  \"drug_info\": {\n+    \"drug_name\": \"PRO-LAD\",\n+    \"chemical_name\": \"(8beta)-N,N-Diethyl-6-propyl-9,10-didehydroergoline-8-carboxamide\",\n+    \"alternative_name\": \"N-Propylnorlysergic acid N,N-diethylamide; 6-Propyl-6-nor-lysergic acid diethylamide; N-PropylnorLSD\",\n+    \"chemical_class\": \"Lysergamide\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"20 ug\",\n+            \"light\": \"50-100 ug\",\n+            \"common\": \"100-200 ug\",\n+            \"strong\": \"200-350 ug\",\n+            \"heavy\": \"350+ ug\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"6-8 hours\",\n+            \"onset\": \"30-45 minutes\",\n+            \"peak\": \"2-4 hours\",\n+            \"offset\": \"2-3 hours\",\n+            \"after_effects\": \"1-4 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"PRO-LAD is not considered habit-forming and possesses self-regulating properties typical of psychedelics. The desire to use it may actually decrease with repeated administration. No formal dependence studies have been conducted.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of seizures and psychosis)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants including amphetamines, cocaine, methylphenidate (increased risk of anxiety, paranoia, thought loops, mania, and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (unexpectedly strong and unpredictable synergy; significantly increases risk of anxiety, paranoia, and psychosis)\",\n+        \"MDMA (unpredictable synergy with potential neurotoxicity)\",\n+        \"Benzodiazepines (can reduce or eliminate psychedelic effects)\",\n+        \"Dissociatives (greatly enhanced effects and confusion)\",\n+        \"Other psychedelics (unpredictable synergistic intensification)\"\n+      ]\n+    },\n+    \"notes\": \"PRO-LAD is a research chemical with very limited history of human use and minimal scientific documentation regarding its pharmacology, metabolism, and long-term toxicity. Unlike LSD, PRO-LAD has a propyl chain at R6 which may result in slower absorption and different onset characteristics. Users should employ rigorous harm reduction practices including reagent testing, accurate weighing with a microgram scale, and having a trusted sober trip sitter present. Individuals with personal or family history of psychotic disorders should avoid use. PRO-LAD was first synthesized by Hoffman and Nichols in 1984 and later described by Alexander Shulgin in TiHKAL.\",\n+    \"subjective_effects\": [\n+      \"Visual Patterning And Geometry\",\n+      \"Color Enhancement\",\n+      \"Introspection\",\n+      \"Time Distortion\",\n+      \"Ego Death\",\n+      \"Spontaneous Bodily Sensations\",\n+      \"Enhanced Sense Of Humor\",\n+      \"Thought Connectivity\",\n+      \"Physical Euphoria\",\n+      \"Emotional Amplification\",\n+      \"Analysis Enhancement\",\n+      \"Conceptual Thinking\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Immediately after ingestion\",\n+      \"half_tolerance\": \"5-7 days\",\n+      \"zero_tolerance\": \"14 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics including LSD, psilocybin, mescaline, DMT, and other lysergamides\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid TiHKAL Entry #51: PRO-LAD\",\n+        \"reference\": \"https://www.erowid.org/library/books_online/tihkal/tihkal51.shtml\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: PRO-LAD\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/PRO-LAD\"\n+      },\n+      {\n+        \"name\": \"TripSit Drug Combination Chart\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/Drug_combinations\"\n+      },\n+      {\n+        \"name\": \"Hoffman AJ, Nichols DE (1985). Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives. Journal of Medicinal Chemistry 28(9):1252-1255\",\n+        \"reference\": \"https://doi.org/10.1021/jm00147a022\"\n+      },\n+      {\n+        \"name\": \"Shulgin A, Shulgin A (1997). TiHKAL: Tryptamines I Have Known And Loved\",\n+        \"reference\": \"https://www.erowid.org/library/books_online/tihkal/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"lysergamide\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 635\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-225756-89bd9e8d",
    "createdAt": "2025-10-16T22:57:56.453Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 4:57:54 PM"
    },
    "articles": [
      {
        "id": 634,
        "title": "LSM-775",
        "slug": "lsm-775"
      }
    ],
    "markdown": "# LSM-775 · #634\n\n+{\n+  \"title\": \"LSM-775\",\n+  \"index-category\": \"psychedelic; lysergamide; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"LSM-775\",\n+    \"chemical_name\": \"[(8beta)-6-Methyl-9,10-didehydroergolin-8-yl](morpholin-4-yl)methanone\",\n+    \"alternative_name\": \"Lysergic acid morpholide; N-Morpholinyllysergamide; LA-Morph; LSM\",\n+    \"chemical_class\": \"Lysergamides\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT1A receptor full agonist; 5-HT2A receptor partial agonist; 5-HT2B receptor partial agonist; 5-HT2C receptor partial agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"250 ug\",\n+            \"light\": \"500-750 ug\",\n+            \"common\": \"750-1250 ug\",\n+            \"strong\": \"1250-1500 ug\",\n+            \"heavy\": \"1500+ ug\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"6-10 hours\",\n+            \"onset\": \"10-30 minutes\",\n+            \"peak\": \"60-150 minutes\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"Variable (residual sedation possible)\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"LSM-775 is not considered habit-forming and possesses an intrinsic self-regulating quality similar to other psychedelics. Limited evidence suggests no significant dependence potential, though the substance has very little history of human use.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants (increases anxiety, paranoia, and thought loops)\",\n+        \"Cannabis (unpredictable synergy; greatly increases risk of anxiety and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"MDMA (unpredictable synergy; potentially neurotoxic)\",\n+        \"Alcohol (increases dehydration and physical discomfort)\",\n+        \"Other psychedelics (unpredictable intensification)\"\n+      ]\n+    },\n+    \"notes\": \"LSM-775 is a novel lysergamide with approximately one-tenth the potency of LSD and a shorter duration. It is characterized by prominent dream-like sedation and significant nausea that may substantially reduce the experience's pleasantness. Use a precise milligram scale as doses are relatively high. Mental health screening is advised before use, particularly for individuals with personal or family history of psychotic disorders. Set and setting remain important factors. Legal status varies by jurisdiction; controlled in Germany and Switzerland as of 2019.\",\n+    \"subjective_effects\": [\n+      \"Dream-Like Sedation\",\n+      \"Prominent Nausea\",\n+      \"Visual Patterning And Geometry\",\n+      \"Time Distortion (Particularly Pronounced)\",\n+      \"Color Enhancement\",\n+      \"Spontaneous Physical Sensations (Tingling)\",\n+      \"Music Enhancement\",\n+      \"Thought Connectivity\",\n+      \"Perception Of Bodily Heaviness\",\n+      \"Drifting (Melting, Breathing, Morphing)\",\n+      \"Internal Hallucinations\",\n+      \"Analysis Enhancement\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Almost immediately after ingestion\",\n+      \"half_tolerance\": \"5-7 days\",\n+      \"zero_tolerance\": \"14 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (LSD, psilocybin, mescaline, etc.)\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: LSM-775\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/LSM-775\"\n+      },\n+      {\n+        \"name\": \"Erowid Experience Vaults: LSM-775\",\n+        \"reference\": \"https://www.erowid.org/experiences/subs/exp_LSM775.shtml\"\n+      },\n+      {\n+        \"name\": \"Isomer Design: LSM-775\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5338\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy LSM-775 Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-lsm-775-lysergic-acid-morpholide-thread.775765/\"\n+      },\n+      {\n+        \"name\": \"Gogerty & Dille (1957): Pharmacology of d-LSM\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/13476356/\"\n+      },\n+      {\n+        \"name\": \"Shulgin: TiHKAL - LSD-25 Entry\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5338\"\n+      },\n+      {\n+        \"name\": \"Brandt et al. (2018): Return of the Lysergamides Part IV\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/28585392/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"lysergamide\",\n+      \"research-chemical\",\n+      \"novel-psychoactive-substance\"\n+    ]\n+  },\n+  \"id\": 634\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-224845-2e3cf1ee",
    "createdAt": "2025-10-16T22:48:45.174Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 4:48:42 PM"
    },
    "articles": [
      {
        "id": 633,
        "title": "MET",
        "slug": "met"
      }
    ],
    "markdown": "# MET · #633\n\n+{\n+  \"title\": \"MET\",\n+  \"index-category\": \"psychedelic; tryptamine\",\n+  \"drug_info\": {\n+    \"drug_name\": \"MET\",\n+    \"chemical_name\": \"N-Ethyl-N-methyltryptamine\",\n+    \"alternative_name\": \"Methylethyltryptamine\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; serotonin releasing agent (weak)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"smoked/vaporized\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"10 mg\",\n+            \"light\": \"20-40 mg\",\n+            \"common\": \"40-60 mg\",\n+            \"strong\": \"60-90 mg\",\n+            \"heavy\": \"90+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"60-70 mg\",\n+            \"light\": \"70-80 mg\",\n+            \"common\": \"80-110 mg\",\n+            \"strong\": \"110-150 mg\",\n+            \"heavy\": \"150+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"10-15 mg\",\n+            \"light\": \"15-30 mg\",\n+            \"common\": \"30-50 mg\",\n+            \"strong\": \"50-70 mg\",\n+            \"heavy\": \"70+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"smoked/vaporized\",\n+          \"stages\": {\n+            \"total_duration\": \"30-75 minutes\",\n+            \"onset\": \"30-60 seconds\",\n+            \"peak\": \"10-20 minutes\",\n+            \"offset\": \"20-40 minutes\",\n+            \"after_effects\": \"20-60 minutes\"\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n+        },\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"2-4 hours\",\n+            \"onset\": \"20-45 minutes\",\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"1-3 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"stages\": {\n+            \"total_duration\": \"1.5-3 hours\",\n+            \"onset\": \"5-15 minutes\",\n+            \"peak\": \"30-90 minutes\",\n+            \"offset\": \"45-90 minutes\",\n+            \"after_effects\": \"30-120 minutes\"\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"MET is not considered habit-forming and appears to be self-regulating. Reports suggest the desire to use it may actually decrease with regular consumption, similar to other psychedelic tryptamines.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"MAOIs (risk of serotonin syndrome and hypertensive crisis)\",\n+        \"Lithium (increased seizure risk)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Stimulants (increased risk of anxiety and cardiovascular strain)\"\n+      ],\n+      \"caution\": [\n+        \"SSRIs (may dampen or prolong effects)\",\n+        \"Cannabis (may intensify experience unpredictably)\"\n+      ]\n+    },\n+    \"notes\": \"MET is a research chemical with very limited human use history and unstudied toxicity profile. The freebase form can be harsh when insufflated or smoked. Use an accurate milligram scale for all routes of administration. Set and setting are crucial for psychedelic experiences. Unlike DMT, MET has oral activity without requiring an MAOI. Individuals with personal or family history of psychotic disorders should avoid use.\",\n+    \"subjective_effects\": [\n+      \"Visual Geometry And Patterning\",\n+      \"Internal Hallucinations\",\n+      \"Physical Euphoria\",\n+      \"Tactile Enhancement\",\n+      \"Stimulation\",\n+      \"Color Enhancement And Shifting\",\n+      \"Cognitive Euphoria\",\n+      \"Empathy And Sociability Enhancement\",\n+      \"Thought Connectivity\",\n+      \"Time Distortion\",\n+      \"Confusion\",\n+      \"Memory Suppression\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Minimal tolerance buildup with repeated use\",\n+      \"half_tolerance\": \"Unknown\",\n+      \"zero_tolerance\": \"Approximately 1-2 weeks\",\n+      \"cross_tolerances\": [\n+        \"Other psychedelic tryptamines (minimal to none)\",\n+        \"Classic psychedelics (minimal to none)\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy MET Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-met-thread.255405/\"\n+      },\n+      {\n+        \"name\": \"Erowid MET Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/met/met.shtml\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: MET\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/MET\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Methylethyltryptamine\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Methylethyltryptamine\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 633\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-224503-b5466f8d",
    "createdAt": "2025-10-16T22:45:03.789Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 4:45:01 PM"
    },
    "articles": [
      {
        "id": 632,
        "title": "MiPLA",
        "slug": "mipla"
      }
    ],
    "markdown": "# MiPLA · #632\n\n+{\n+  \"title\": \"MiPLA\",\n+  \"index-category\": \"psychedelic; lysergamide; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"MiPLA\",\n+    \"chemical_name\": \"(6aR,9R)-N-methyl-N-isopropyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide\",\n+    \"alternative_name\": \"Lamide; Methylisopropyllysergamide; N-Methyl-N-isopropyllysergamide\",\n+    \"chemical_class\": \"Lysergamides\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"50 ug\",\n+            \"light\": \"100-150 ug\",\n+            \"common\": \"150-200 ug\",\n+            \"strong\": \"200-250 ug\",\n+            \"heavy\": \"300+ ug\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"4-6 hours\",\n+            \"onset\": \"20-40 minutes\",\n+            \"peak\": \"1-2 hours (preceded by 45-90 minute come-up)\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"Minimal residual stimulation\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"MiPLA is not considered physically addictive and has low potential for psychological dependence, similar to other serotonergic psychedelics. Rapid tolerance development discourages frequent use.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants (amphetamine, cocaine, methylphenidate - increases risk of anxiety, paranoia, panic attacks, thought loops, mania, and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (unpredictable synergy; significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\",\n+        \"SSRIs (may alter or blunt effects)\"\n+      ]\n+    },\n+    \"notes\": \"MiPLA is a research chemical with very limited history of human use and minimal scientific study of its pharmacology, metabolism, and toxicity. It is approximately two to three times less potent than LSD and has a notably shorter duration of around 4-6 hours. The substance is generally described as producing less anxiety and a lighter headspace compared to LSD. Individuals with personal or family history of mental illness should avoid use. Use precise weighing equipment and employ harm reduction practices including careful set and setting preparation.\",\n+    \"subjective_effects\": [\n+      \"Stimulation\",\n+      \"Physical Euphoria\",\n+      \"Tactile Enhancement\",\n+      \"Visual Acuity Enhancement\",\n+      \"Color Enhancement\",\n+      \"Pattern Recognition Enhancement\",\n+      \"Visual Drifting\",\n+      \"Geometric Patterns\",\n+      \"Cognitive Euphoria\",\n+      \"Analysis Enhancement\",\n+      \"Music Appreciation Enhancement\",\n+      \"Time Distortion\",\n+      \"Ego Death (at higher doses)\",\n+      \"Nausea\",\n+      \"Increased Body Temperature\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n+      \"half_tolerance\": \"5-7 days\",\n+      \"zero_tolerance\": \"14 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (due to 5-HT2A receptor activity)\"\n+      ]\n+    },\n+    \"half_life\": \"1-3 hours (estimated based on duration profile)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: MiPLA\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/MiPLA\"\n+      },\n+      {\n+        \"name\": \"Erowid MiPLA Experience Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_MIPLA.shtml\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy MIPLA Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-mipla-methylisopropyllysergamide-thread.784440/\"\n+      },\n+      {\n+        \"name\": \"Isomer Design: MiPLA (PiHKAL)\",\n+        \"reference\": \"https://isomerdesign.com/pihkal/explore/5327\"\n+      },\n+      {\n+        \"name\": \"Halberstadt et al. (2018) - Pharmacological characterization of ECPLA\",\n+        \"reference\": \"https://link.springer.com/article/10.1007/s00213-018-5055-9\"\n+      },\n+      {\n+        \"name\": \"Nichols, D.E. (2001) - LSD and its lysergamide cousins\",\n+        \"reference\": \"The Heffter Review of Psychedelic Research, Vol. 2, pp. 80-87\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"lysergamide\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 632\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-223851-15e5eaa2",
    "createdAt": "2025-10-16T22:38:51.510Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 4:38:49 PM"
    },
    "articles": [
      {
        "id": 631,
        "title": "LSA",
        "slug": "lsa"
      }
    ],
    "markdown": "# LSA · #631\n\n+{\n+  \"title\": \"LSA\",\n+  \"index-category\": \"psychedelic; natural\",\n+  \"drug_info\": {\n+    \"drug_name\": \"LSA\",\n+    \"chemical_name\": \"(8β)-9,10-Didehydro-6-methyl-ergoline-8-carboxamide\",\n+    \"alternative_name\": \"Ergine; d-Lysergic acid amide; d-Lysergamide; LA-111\",\n+    \"chemical_class\": \"Lysergamide; Ergoline alkaloid\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral (morning glory seeds)\",\n+          \"units\": \"seeds\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"20-50 seeds\",\n+            \"light\": \"50-100 seeds\",\n+            \"common\": \"100-250 seeds\",\n+            \"strong\": \"250-400 seeds\",\n+            \"heavy\": \"400+ seeds\"\n+          }\n+        },\n+        {\n+          \"route\": \"oral (hawaiian baby woodrose seeds)\",\n+          \"units\": \"seeds\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"1-3 seeds\",\n+            \"light\": \"3-5 seeds\",\n+            \"common\": \"5-7 seeds\",\n+            \"strong\": \"7-12 seeds\",\n+            \"heavy\": \"12+ seeds\"\n+          }\n+        },\n+        {\n+          \"route\": \"oral (pure lsa)\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"0.5 mg\",\n+            \"light\": \"0.5-1 mg\",\n+            \"common\": \"1-2 mg\",\n+            \"strong\": \"2-3 mg\",\n+            \"heavy\": \"3+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral (morning glory seeds)\",\n+          \"stages\": {\n+            \"total_duration\": \"4-10 hours\",\n+            \"onset\": \"20-60 minutes (up to 3 hours reported)\",\n+            \"peak\": \"90-180 minutes\",\n+            \"offset\": \"2-7 hours\",\n+            \"after_effects\": \"1-12 hours (afterglow)\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"oral (hawaiian baby woodrose seeds)\",\n+          \"stages\": {\n+            \"total_duration\": \"4-10 hours\",\n+            \"onset\": \"20-60 minutes (up to 3 hours reported)\",\n+            \"peak\": \"90-180 minutes\",\n+            \"offset\": \"2-7 hours\",\n+            \"after_effects\": \"1-12 hours (afterglow)\"\n+          }\n+        },\n+        {\n+          \"route\": \"oral (pure lsa)\",\n+          \"stages\": {\n+            \"total_duration\": \"4-10 hours\",\n+            \"onset\": \"20-60 minutes (up to 3 hours reported)\",\n+            \"peak\": \"90-180 minutes\",\n+            \"offset\": \"2-7 hours\",\n+            \"after_effects\": \"1-12 hours (afterglow)\"\n+          }\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"LSA is not considered to be addictive with low abuse potential. There is virtually no withdrawal syndrome when use is stopped, and animal studies have not demonstrated self-administration behavior predictive of abuse liability.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increased risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants (increased risk of anxiety, paranoia, thought loops, and mania)\",\n+        \"Cannabis (unexpectedly strong and unpredictable synergy; significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"SSRIs (may suppress visual and cognitive effects)\",\n+        \"MAOIs (may potentiate effects; use caution with potential for dangerous interactions with other substances)\",\n+        \"Dissociatives (greatly enhance cognitive, visual and hallucinatory effects with increased risk of confusion and psychosis)\",\n+        \"Alcohol (may reduce anxiety but can increase dehydration, nausea and physical fatigue)\",\n+        \"Benzodiazepines (can reduce trip intensity; useful for stopping bad trips but may cause amnesia)\",\n+        \"Other psychedelics (unpredictable synergy and intensification of effects)\"\n+      ]\n+    },\n+    \"notes\": \"LSA-containing seeds vary widely in alkaloid content between species, batches, and individual seeds. Commercial seeds are often treated with fungicides or pesticides that can be extremely toxic; only use organic, untreated seeds from trusted vendors. Heavy metal testing is recommended before consumption. Extraction methods can significantly reduce nausea and body load. Strong vasoconstriction is common and can cause painful leg cramping; avoid repeated use over short periods. Set and setting strongly influence the experience. Individuals with personal or family histories of psychotic disorders should avoid use.\",\n+    \"subjective_effects\": [\n+      \"Sedation (setting-dependent)\",\n+      \"Physical Euphoria\",\n+      \"Visual Enhancements and Distortions\",\n+      \"Spontaneous Bodily Sensations\",\n+      \"Perception of Bodily Heaviness\",\n+      \"Motor Control Loss\",\n+      \"Nausea and Vasoconstriction\",\n+      \"Dream-Like State\",\n+      \"Introspection and Analysis Enhancement\",\n+      \"Emotion Enhancement\",\n+      \"Time Distortion\",\n+      \"Internal and External Hallucinations\",\n+      \"Thought Connectivity\",\n+      \"Music Appreciation Enhancement\",\n+      \"Spirituality Enhancement\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Almost immediately after ingestion\",\n+      \"half_tolerance\": \"3-4 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (LSD, psilocybin mushrooms, mescaline, DMT, 2C-x compounds)\"\n+      ]\n+    },\n+    \"half_life\": \"1-3 hours (psilocin is referenced in the original document, but LSA half-life data is limited; serum concentrations detectable for 1-24 hours post-ingestion)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: LSA\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/LSA\"\n+      },\n+      {\n+        \"name\": \"TripSit Wiki: LSA\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/LSA\"\n+      },\n+      {\n+        \"name\": \"Erowid LSA Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/lsa/lsa.shtml\"\n+      },\n+      {\n+        \"name\": \"Erowid LSA Dosage\",\n+        \"reference\": \"https://erowid.org/chemicals/lsa/lsa_dose.shtml\"\n+      },\n+      {\n+        \"name\": \"Erowid LSA Effects\",\n+        \"reference\": \"https://www.erowid.org/chemicals/lsa/lsa_effects.shtml\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy LSA Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/lsas-subthread-extraction-of-lsas.123944/\"\n+      },\n+      {\n+        \"name\": \"Drugs-Forum: LSA Wiki\",\n+        \"reference\": \"https://drugs-forum.com/wiki/LSA\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Ergine\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Ergine\"\n+      },\n+      {\n+        \"name\": \"Lysergic Acid Amide (LSA), an LSD Analog: Systematic Review (MDPI, 2025)\",\n+        \"reference\": \"https://www.mdpi.com/2226-4787/13/4/98\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"lysergamide\",\n+      \"natural\",\n+      \"ergoline\"\n+    ]\n+  },\n+  \"id\": 631\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-223526-fd17483e",
    "createdAt": "2025-10-16T22:35:26.906Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 4:35:25 PM"
    },
    "articles": [
      {
        "id": 630,
        "title": "ETH-LAD",
        "slug": "eth-lad"
      }
    ],
    "markdown": "# ETH-LAD · #630\n\n+{\n+  \"title\": \"ETH-LAD\",\n+  \"index-category\": \"psychedelic; lysergamide\",\n+  \"drug_info\": {\n+    \"drug_name\": \"ETH-LAD\",\n+    \"chemical_name\": \"(6aR,9R)-N,N,7-Triethyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide\",\n+    \"alternative_name\": \"N-Ethyl-nor-LSD; 6-Ethyl-6-nor-lysergic acid diethylamide; N-Ethyl-nor-lysergic acid N,N-diethylamide\",\n+    \"chemical_class\": \"Lysergamides\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist; 5-HT2C receptor agonist; 5-HT1A receptor agonist (high affinity); dopamine D1, D2, D3, D4, D5 receptor binding (lower affinity)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"15 ug\",\n+            \"light\": \"30-60 ug\",\n+            \"common\": \"60-150 ug\",\n+            \"strong\": \"150-225 ug\",\n+            \"heavy\": \"225+ ug\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"8-12 hours\",\n+            \"onset\": \"20-40 minutes\",\n+            \"peak\": \"4-6 hours (including 45-90 minute come up)\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"8-48 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"ETH-LAD is not considered habit-forming and demonstrates a self-regulating quality typical of psychedelics. Rapid tolerance develops immediately after use, discouraging frequent consumption. Cases of abuse have been rarely reported, though the substance generally decreases in desirability with repeated use.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increased risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"Cannabis (unpredictable and strongly increased effects, risk of anxiety, paranoia, panic attacks, and psychosis)\",\n+        \"Stimulants including amphetamine, cocaine, methylphenidate (increased risk of anxiety, paranoia, panic attacks, thought loops, mania, and psychosis)\"\n+      ],\n+      \"caution\": []\n+    },\n+    \"notes\": \"ETH-LAD requires exceptional caution due to its high potency, unpredictable dose-response curve, and tendency to produce severe physical side effects including pronounced nausea, temperature dysregulation, muscle cramps, and bodily discomfort at higher doses. The substance is notably more difficult to handle than LSD and should only be used by experienced psychedelic users. Accurate measurement with a precise scale is critical. Users should monitor body temperature throughout the experience and maintain access to climate control. Set and setting are paramount, and having a trusted sober sitter is strongly recommended, especially at doses above the common range. Individuals with personal or family history of psychotic disorders should avoid use.\",\n+    \"subjective_effects\": [\n+      \"Intricate Visual Geometry\",\n+      \"Enhanced Pattern Recognition\",\n+      \"Auditory Distortions and Hallucinations\",\n+      \"Analysis Enhancement\",\n+      \"Introspective Thought Patterns\",\n+      \"Time Distortion\",\n+      \"Synaesthesia\",\n+      \"Enhanced Color Perception\",\n+      \"Nausea and Bodily Discomfort\",\n+      \"Temperature Dysregulation\",\n+      \"Emotional Neutrality or Detachment\",\n+      \"Thought Acceleration\",\n+      \"Memory Suppression\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n+      \"half_tolerance\": \"5-7 days\",\n+      \"zero_tolerance\": \"14 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics including LSD, psilocybin, mescaline, DMT, and related lysergamides\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy ETH-LAD Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-eth-lad-thread.761505/\"\n+      },\n+      {\n+        \"name\": \"Erowid ETH-LAD Experience Vault\",\n+        \"reference\": \"https://www.erowid.org/experiences/subs/exp_ETHLAD.shtml\"\n+      },\n+      {\n+        \"name\": \"Erowid TiHKAL Entry #12: ETH-LAD\",\n+        \"reference\": \"https://erowid.org/library/books_online/tihkal/tihkal12.shtml\"\n+      },\n+      {\n+        \"name\": \"Hoffman AJ, Nichols DE (1985) - Synthesis and LSD-like discriminative stimulus properties\",\n+        \"reference\": \"https://doi.org/10.1021/jm00147a022\"\n+      },\n+      {\n+        \"name\": \"Isomer Design: TiHKAL ETH-LAD Entry\",\n+        \"reference\": \"http://isomerdesign.com/PiHKAL/read.php?domain=tk&id=12\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: ETH-LAD\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/ETH-LAD\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"lysergamide\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 630\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-223152-65eead67",
    "createdAt": "2025-10-16T22:31:52.581Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 4:31:51 PM"
    },
    "articles": [
      {
        "id": 629,
        "title": "ALD-52",
        "slug": "ald-52"
      }
    ],
    "markdown": "# ALD-52 · #629\n\n+{\n+  \"title\": \"ALD-52\",\n+  \"index-category\": \"psychedelic; lysergamide\",\n+  \"drug_info\": {\n+    \"drug_name\": \"ALD-52\",\n+    \"chemical_name\": \"(6aR,9R)-4-Acetyl-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]-quinoline-9-carboxamide\",\n+    \"alternative_name\": \"1-Acetyl-LSD; 1A-LSD; 1A-LAD; Orange Sunshine\",\n+    \"chemical_class\": \"Lysergamides\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; 5-HT2C receptor partial agonist; 5-HT1A receptor partial agonist; D2 receptor agonist (through LSD metabolite)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"30 ug\",\n+            \"light\": \"30-100 ug\",\n+            \"common\": \"100-175 ug\",\n+            \"strong\": \"175-325 ug\",\n+            \"heavy\": \"325+ ug\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"8-14 hours\",\n+            \"onset\": \"20-40 minutes\",\n+            \"peak\": \"3-5 hours (following 1-2 hour come up)\",\n+            \"offset\": \"3-5 hours\",\n+            \"after_effects\": \"4-24 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"ALD-52 is not considered physically addictive and has extremely low potential for psychological dependence. The rapid development of tolerance discourages frequent use patterns, and the desire to use typically decreases with repeated exposure rather than increasing.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"MAOIs (unpredictable effects, possible hypertensive reaction)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (lowers seizure threshold, psychedelics may trigger seizures)\",\n+        \"Stimulants including amphetamines and cocaine (increased risk of anxiety, thought loops, cardiovascular strain)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (unpredictably strong synergy, increased risk of anxiety and paranoia)\",\n+        \"MDMA (may increase neurotoxicity, unpredictable synergy)\",\n+        \"Other psychedelics (intense cross-tolerance and potentially overwhelming effects)\",\n+        \"SSRIs (may blunt or alter effects)\"\n+      ]\n+    },\n+    \"notes\": \"ALD-52 functions as a prodrug for LSD, metabolizing into LSD in the body along with other metabolites. Legal status varies widely by jurisdiction; it is controlled in many countries including the UK, Germany, Switzerland, and Latvia, while remaining technically unscheduled in others such as the United States and Denmark. Individuals with personal or family history of psychotic disorders should avoid use. Famous for being mistakenly associated with 'Orange Sunshine' LSD from the 1960s, though this was later confirmed to be standard LSD at 300 micrograms per dose. Set and setting are critical for a positive experience, and users should approach this potent, long-lasting substance with proper preparation and harm reduction practices.\",\n+    \"subjective_effects\": [\n+      \"Visual Patterning And Geometry\",\n+      \"Enhanced Sensory Perception\",\n+      \"Time Distortion\",\n+      \"Cognitive Euphoria\",\n+      \"Enhanced Introspection\",\n+      \"Emotional Amplification\",\n+      \"Physical Euphoria\",\n+      \"Thought Acceleration\",\n+      \"Enhanced Music Appreciation\",\n+      \"Pupil Dilation\",\n+      \"Increased Energy And Stimulation\",\n+      \"Novel Thought Patterns\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Immediately after ingestion, cross-tolerant with all psychedelics\",\n+      \"half_tolerance\": \"5-7 days\",\n+      \"zero_tolerance\": \"14 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics including LSD, psilocybin mushrooms, mescaline, and tryptamines\"\n+      ]\n+    },\n+    \"half_life\": \"1-3 hours (LSD active metabolite)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid ALD-52 Vault\",\n+        \"reference\": \"https://erowid.org/chemicals/lsd/lsd_ald52.shtml\"\n+      },\n+      {\n+        \"name\": \"Isomer Design TiHKAL Entry 26 (LSD)\",\n+        \"reference\": \"https://isomerdesign.com/pihkal/read/tk/26\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: ALD-52\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/ALD-52\"\n+      },\n+      {\n+        \"name\": \"The Big & Dandy ALD-52 Thread (Bluelight)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-ald-52-thread.773316/\"\n+      },\n+      {\n+        \"name\": \"TripSit Drug Combination Chart\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/Drug_combinations\"\n+      },\n+      {\n+        \"name\": \"Wagmann et al. (2019) In vitro metabolic fate of nine LSD-based new psychoactive substances\",\n+        \"reference\": \"https://doi.org/10.1007/s00216-018-1558-9\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"lysergamide\",\n+      \"research-chemical\",\n+      \"prodrug\"\n+    ]\n+  },\n+  \"id\": 629\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-222911-e7a3cfaa",
    "createdAt": "2025-10-16T22:29:11.119Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 4:29:09 PM"
    },
    "articles": [
      {
        "id": 628,
        "title": "1V-LSD",
        "slug": "1v-lsd"
      }
    ],
    "markdown": "# 1V-LSD · #628\n\n+{\n+  \"title\": \"1V-LSD\",\n+  \"index-category\": \"psychedelic; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"1V-LSD\",\n+    \"chemical_name\": \"1-Valeroyl-d-lysergic acid diethylamide\",\n+    \"alternative_name\": \"Valerie; 1-Valeryl-LSD; 1-Pentanoyl-LSD\",\n+    \"chemical_class\": \"Lysergamides\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist (weak); acts as prodrug for LSD via deacylation\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"15 ug\",\n+            \"light\": \"25-75 ug\",\n+            \"common\": \"75-150 ug\",\n+            \"strong\": \"150-300 ug\",\n+            \"heavy\": \"300+ ug\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"8-12 hours\",\n+            \"onset\": \"20-60 minutes\",\n+            \"peak\": \"3-5 hours (come up 45-120 minutes)\",\n+            \"offset\": \"3-5 hours\",\n+            \"after_effects\": \"6-24 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"1V-LSD is assumed to be non-addictive with low abuse potential, similar to LSD. No literature reports exist of successful attempts to train animals to self-administer LSD analogs. There is virtually no withdrawal syndrome when chronic use is stopped.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"Cannabis (strong synergy, significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"Stimulants (may increase risk of anxiety, paranoia, panic attacks, thought loops, mania and psychosis)\",\n+        \"MDMA (unpredictable synergy, potential increased neurotoxicity)\",\n+        \"Dissociatives (enhanced hallucinatory effects, increased risk of confusion and delusions)\",\n+        \"Benzodiazepines (reduce intensity of effects)\",\n+        \"Alcohol (may reduce anxiety but causes dehydration and physical discomfort)\"\n+      ]\n+    },\n+    \"notes\": \"1V-LSD is a novel research chemical with minimal history of human use and unverified safety profile. It is presumed to act as a prodrug for LSD. Those with personal or family history of mental illness should avoid use, particularly outside supervised medical settings. Set and setting are critical factors in determining experience quality. Start with lower doses due to individual variations in body weight, tolerance, metabolism, and sensitivity. No toxic dose is known, but higher doses increase risk of adverse psychological reactions. Test substances with reagent kits, though Ehrlich's reagent reacts slowly with N-acylated lysergamides.\",\n+    \"subjective_effects\": [\n+      \"Geometric Visual Hallucinations\",\n+      \"Time Distortion\",\n+      \"Enhanced Introspection\",\n+      \"Ego Loss\",\n+      \"Stimulation\",\n+      \"Spontaneous Bodily Sensations\",\n+      \"Physical Euphoria\",\n+      \"Tactile Enhancement\",\n+      \"Color Enhancement\",\n+      \"Pattern Recognition Enhancement\",\n+      \"Visual Drifting\",\n+      \"Analysis Enhancement\",\n+      \"Conceptual Thinking\",\n+      \"Emotion Enhancement\",\n+      \"Cognitive Euphoria\",\n+      \"Creativity Enhancement\",\n+      \"Increased Music Appreciation\",\n+      \"Unity And Interconnectedness\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Builds almost immediately after ingestion\",\n+      \"half_tolerance\": \"5-7 days\",\n+      \"zero_tolerance\": \"14 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (including LSD, psilocybin, mescaline, DMT)\"\n+      ]\n+    },\n+    \"half_life\": \"Similar to LSD (estimated 3-5 hours for active metabolite)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: 1V-LSD\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/1V-LSD\"\n+      },\n+      {\n+        \"name\": \"Erowid 1V-LSD Experience Vault\",\n+        \"reference\": \"https://www.erowid.org/experiences/subs/exp_1VLSD.shtml\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Small & Handy 1V-LSD Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-small-handy-1v-lsd-thread.904997/\"\n+      },\n+      {\n+        \"name\": \"Brandt et al. (2022): Return of the lysergamides Part VII - Analytical and behavioural characterization of 1V-LSD\",\n+        \"reference\": \"https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/dta.3205\"\n+      },\n+      {\n+        \"name\": \"Tripsitter: 1V-LSD - A New LSD Analog\",\n+        \"reference\": \"https://tripsitter.com/1v-lsd/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"lysergamide\",\n+      \"research-chemical\",\n+      \"prodrug\"\n+    ]\n+  },\n+  \"id\": 628\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-222618-76ba04c5",
    "createdAt": "2025-10-16T22:26:18.516Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 4:26:16 PM"
    },
    "articles": [
      {
        "id": 626,
        "title": "Diphenhydramine",
        "slug": "diphenhydramine"
      },
      {
        "id": 627,
        "title": "Diphenhydramine",
        "slug": "diphenhydramine"
      }
    ],
    "markdown": "# Diphenhydramine · #626\n\n+{\n+  \"title\": \"Diphenhydramine\",\n+  \"index-category\": \"deliriant; otc\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Diphenhydramine\",\n+    \"chemical_name\": \"2-(Diphenylmethoxy)-N,N-dimethylethanamine\",\n+    \"alternative_name\": \"DPH; Benadryl; Nytol; Sominex; Unisom SleepMelts; ZzzQuil; Dimedrol\",\n+    \"chemical_class\": \"Ethanolamine\",\n+    \"psychoactive_class\": \"Deliriant\",\n+    \"mechanism_of_action\": \"H1 histamine receptor inverse agonist; muscarinic acetylcholine receptor antagonist; weak serotonin reuptake inhibition; sodium channel blockade; voltage-gated potassium channel blockade\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"25 mg\",\n+            \"light\": \"100-200 mg\",\n+            \"common\": \"200-400 mg\",\n+            \"strong\": \"400-700 mg\",\n+            \"heavy\": \"700+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"3-10 hours\",\n+            \"onset\": \"30-90 minutes\",\n+            \"peak\": \"1-4 hours\",\n+            \"offset\": \"2-6 hours\",\n+            \"after_effects\": \"Up to 24 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Diphenhydramine has low abuse potential due to its overwhelmingly dysphoric and unpleasant effects. While physical dependence is possible with chronic use, most users do not wish to repeat the experience. Tolerance develops rapidly with repeated use.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"MAOIs (risk of severe anticholinergic effects)\",\n+        \"Anticholinergics (severe tachycardia, heart attack risk, abnormal heart rhythm)\",\n+        \"High doses of acetaminophen-containing formulations (liver damage, death)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants (severe tachycardia, heart attack risk, abnormal heart rhythm)\",\n+        \"Tramadol (increased seizure risk)\",\n+        \"Alcohol (dangerous sedation, respiratory depression)\"\n+      ],\n+      \"caution\": [\n+        \"Benzodiazepines (dangerous sedation, respiratory depression, visual suppression)\",\n+        \"SSRIs (visual suppression, potential serotonin syndrome)\",\n+        \"Opioids (increased sedation, respiratory depression)\"\n+      ]\n+    },\n+    \"notes\": \"Diphenhydramine is widely available over-the-counter and used medically for allergies and sleep aid. Recreational use produces intensely dysphoric and unpredictable deliriant effects including realistic hallucinations that users cannot distinguish from reality. The substance has significant cardiovascular risks including QT prolongation and potential for torsades de pointes. Always verify that products contain only diphenhydramine as active ingredient; many combination products contain acetaminophen or other drugs that can be fatal in high doses. A sober trip sitter is essential as users may respond to hallucinations and injure themselves. Chronic use may cause persistent cognitive impairment, memory damage, and has been linked to increased dementia risk.\",\n+    \"subjective_effects\": [\n+      \"Sedation and Body Heaviness\",\n+      \"External Hallucinations (People, Objects, Insects)\",\n+      \"Auditory Hallucinations (Voices, Screams)\",\n+      \"Tactile Hallucinations (Phantom Sensations)\",\n+      \"Shadow People\",\n+      \"Delirium and Confusion\",\n+      \"Memory Suppression and Amnesia\",\n+      \"Dysphoria and Anxiety\",\n+      \"Restless Leg Syndrome\",\n+      \"Dry Mouth and Dehydration\",\n+      \"Visual Acuity Suppression (Blurred Vision)\",\n+      \"Thought Disorganization\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n+      \"half_tolerance\": \"3-5 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n+      \"cross_tolerances\": [\n+        \"All deliriants (datura, scopolamine, dimenhydrinate)\"\n+      ]\n+    },\n+    \"half_life\": \"5 hours (pediatric); 9 hours (adult); 13.5 hours (elderly)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid Diphenhydramine Vault\",\n+        \"reference\": \"https://www.erowid.org/pharms/diphenhydramine/\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Diphenhydramine\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Diphenhydramine\"\n+      },\n+      {\n+        \"name\": \"TripSit Wiki: Diphenhydramine\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/Diphenhydramine\"\n+      },\n+      {\n+        \"name\": \"Bluelight: Diphenhydramine Discussion\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/dph-trip.560305/\"\n+      },\n+      {\n+        \"name\": \"DrugBank: Diphenhydramine\",\n+        \"reference\": \"https://go.drugbank.com/drugs/DB01075\"\n+      },\n+      {\n+        \"name\": \"StatPearls: Diphenhydramine Toxicity\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/books/NBK557578/\"\n+      },\n+      {\n+        \"name\": \"Gray et al., 2015 - Cumulative Anticholinergic Use and Dementia\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/25621434/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"deliriant\",\n+      \"depressant\",\n+      \"antihistamine\",\n+      \"otc\"\n+    ]\n+  },\n+  \"id\": 626\n+}\n\n# Diphenhydramine · #627\n\n+{\n+  \"title\": \"Diphenhydramine\",\n+  \"index-category\": \"deliriant; otc\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Diphenhydramine\",\n+    \"chemical_name\": \"2-(Diphenylmethoxy)-N,N-dimethylethanamine\",\n+    \"alternative_name\": \"DPH; Benadryl; Nytol; Sominex; Unisom SleepMelts; ZzzQuil; Dimedrol\",\n+    \"chemical_class\": \"Ethanolamine\",\n+    \"psychoactive_class\": \"Deliriant\",\n+    \"mechanism_of_action\": \"H1 histamine receptor inverse agonist; muscarinic acetylcholine receptor antagonist; weak serotonin reuptake inhibition; sodium channel blockade; voltage-gated potassium channel blockade\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"25 mg\",\n+            \"light\": \"100-200 mg\",\n+            \"common\": \"200-400 mg\",\n+            \"strong\": \"400-700 mg\",\n+            \"heavy\": \"700+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"3-10 hours\",\n+            \"onset\": \"30-90 minutes\",\n+            \"peak\": \"1-4 hours\",\n+            \"offset\": \"2-6 hours\",\n+            \"after_effects\": \"Up to 24 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Diphenhydramine has low abuse potential due to its overwhelmingly dysphoric and unpleasant effects. While physical dependence is possible with chronic use, most users do not wish to repeat the experience. Tolerance develops rapidly with repeated use.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"MAOIs (risk of severe anticholinergic effects)\",\n+        \"Anticholinergics (severe tachycardia, heart attack risk, abnormal heart rhythm)\",\n+        \"High doses of acetaminophen-containing formulations (liver damage, death)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants (severe tachycardia, heart attack risk, abnormal heart rhythm)\",\n+        \"Tramadol (increased seizure risk)\",\n+        \"Alcohol (dangerous sedation, respiratory depression)\"\n+      ],\n+      \"caution\": [\n+        \"Benzodiazepines (dangerous sedation, respiratory depression, visual suppression)\",\n+        \"SSRIs (visual suppression, potential serotonin syndrome)\",\n+        \"Opioids (increased sedation, respiratory depression)\"\n+      ]\n+    },\n+    \"notes\": \"Diphenhydramine is widely available over-the-counter and used medically for allergies and sleep aid. Recreational use produces intensely dysphoric and unpredictable deliriant effects including realistic hallucinations that users cannot distinguish from reality. The substance has significant cardiovascular risks including QT prolongation and potential for torsades de pointes. Always verify that products contain only diphenhydramine as active ingredient; many combination products contain acetaminophen or other drugs that can be fatal in high doses. A sober trip sitter is essential as users may respond to hallucinations and injure themselves. Chronic use may cause persistent cognitive impairment, memory damage, and has been linked to increased dementia risk.\",\n+    \"subjective_effects\": [\n+      \"Sedation and Body Heaviness\",\n+      \"External Hallucinations (People, Objects, Insects)\",\n+      \"Auditory Hallucinations (Voices, Screams)\",\n+      \"Tactile Hallucinations (Phantom Sensations)\",\n+      \"Shadow People\",\n+      \"Delirium and Confusion\",\n+      \"Memory Suppression and Amnesia\",\n+      \"Dysphoria and Anxiety\",\n+      \"Restless Leg Syndrome\",\n+      \"Dry Mouth and Dehydration\",\n+      \"Visual Acuity Suppression (Blurred Vision)\",\n+      \"Thought Disorganization\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n+      \"half_tolerance\": \"3-5 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n+      \"cross_tolerances\": [\n+        \"All deliriants (datura, scopolamine, dimenhydrinate)\"\n+      ]\n+    },\n+    \"half_life\": \"5 hours (pediatric); 9 hours (adult); 13.5 hours (elderly)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid Diphenhydramine Vault\",\n+        \"reference\": \"https://www.erowid.org/pharms/diphenhydramine/\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Diphenhydramine\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Diphenhydramine\"\n+      },\n+      {\n+        \"name\": \"TripSit Wiki: Diphenhydramine\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/Diphenhydramine\"\n+      },\n+      {\n+        \"name\": \"Bluelight: Diphenhydramine Discussion\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/dph-trip.560305/\"\n+      },\n+      {\n+        \"name\": \"DrugBank: Diphenhydramine\",\n+        \"reference\": \"https://go.drugbank.com/drugs/DB01075\"\n+      },\n+      {\n+        \"name\": \"StatPearls: Diphenhydramine Toxicity\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/books/NBK557578/\"\n+      },\n+      {\n+        \"name\": \"Gray et al., 2015 - Cumulative Anticholinergic Use and Dementia\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/25621434/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"deliriant\",\n+      \"depressant\",\n+      \"antihistamine\",\n+      \"otc\"\n+    ]\n+  },\n+  \"id\": 627\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-211713-87b4367c",
    "createdAt": "2025-10-16T21:17:13.242Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 23:17:09"
    },
    "articles": [
      {
        "id": 191,
        "title": "LSD",
        "slug": "lsd"
      }
    ],
    "markdown": "# LSD · #191\n\n-    \"chemical_name\": \"LSD\",\n-    \"alternative_name\": \"Lysergic acid diethylamide\",\n+    \"chemical_name\": \"Lysergic acid diethylamide\",\n+    \"alternative_name\": \"Lucy; Acid\",\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"research-chemical\"\n+      \"common\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-210951-3bc6b2e2",
    "createdAt": "2025-10-16T21:09:51.985Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 23:09:48"
    },
    "articles": [
      {
        "id": 242,
        "title": "Gaboxadol",
        "slug": "gaboxadol"
      },
      {
        "id": 176,
        "title": "Zopiclone",
        "slug": "zopiclone"
      },
      {
        "id": 179,
        "title": "Zaleplon",
        "slug": "zaleplon"
      },
      {
        "id": 183,
        "title": "Zolpidem",
        "slug": "zolpidem"
      },
      {
        "id": 200,
        "title": "Psilocybin mushrooms",
        "slug": "psilocybin-mushrooms"
      },
      {
        "id": 201,
        "title": "Amanita Muscaria",
        "slug": "amanita-muscaria"
      },
      {
        "id": 215,
        "title": "Ibotenic acid",
        "slug": "ibotenic-acid"
      },
      {
        "id": 409,
        "title": "Salvia",
        "slug": "salvia"
      }
    ],
    "markdown": "# Gaboxadol · #242\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zopiclone · #176\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zaleplon · #179\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zolpidem · #183\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Psilocybin mushrooms · #200\n\n-  \"title\": \"Penis Envy\",\n+  \"title\": \"Psilocybin mushrooms\",\n-    \"drug_name\": \"Penis Envy\",\n-    \"chemical_name\": \"Penis Envy\",\n-    \"alternative_name\": \"Psilocybe cubensis, Penis Envy strain\",\n+    \"drug_name\": \"Psilocybin mushrooms\",\n+    \"chemical_name\": \"Psilocybin\",\n+    \"alternative_name\": \"Psilocybe cubensis; Magic mushrooms; Shrooms\",\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"research-chemical\"\n+      \"common\"\n\n# Amanita Muscaria · #201\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ],\n+            \"total_duration\": \"6-8 hours\",\n+            \"onset\": \"30-120 minutes\",\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n-      \"research-chemical\"\n+      \"research-chemical\",\n+      \"A-typical Hallucinogen\"\n\n# Ibotenic acid · #215\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Salvia · #409\n\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"other dissociatives\"\n+      \"other dissociatives\",\n+      \"A-typical Hallucinogen\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-210536-524a89f5",
    "createdAt": "2025-10-16T21:05:36.034Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 23:05:33"
    },
    "articles": [
      {
        "id": 242,
        "title": "Gaboxadol",
        "slug": "gaboxadol"
      },
      {
        "id": 176,
        "title": "Zopiclone",
        "slug": "zopiclone"
      },
      {
        "id": 179,
        "title": "Zaleplon",
        "slug": "zaleplon"
      },
      {
        "id": 183,
        "title": "Zolpidem",
        "slug": "zolpidem"
      },
      {
        "id": 201,
        "title": "Amanita Muscaria",
        "slug": "amanita-muscaria"
      },
      {
        "id": 215,
        "title": "Ibotenic acid",
        "slug": "ibotenic-acid"
      },
      {
        "id": 409,
        "title": "Salvia",
        "slug": "salvia"
      }
    ],
    "markdown": "# Gaboxadol · #242\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zopiclone · #176\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zaleplon · #179\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zolpidem · #183\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Amanita Muscaria · #201\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ],\n+            \"total_duration\": \"6-8 hours\",\n+            \"onset\": \"30-120 minutes\",\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n-      \"research-chemical\"\n+      \"research-chemical\",\n+      \"A-typical Hallucinogen\"\n\n# Ibotenic acid · #215\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Salvia · #409\n\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"other dissociatives\"\n+      \"other dissociatives\",\n+      \"A-typical Hallucinogen\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-210425-092f4def",
    "createdAt": "2025-10-16T21:04:25.208Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 23:04:21"
    },
    "articles": [
      {
        "id": 242,
        "title": "Gaboxadol",
        "slug": "gaboxadol"
      },
      {
        "id": 176,
        "title": "Zopiclone",
        "slug": "zopiclone"
      },
      {
        "id": 179,
        "title": "Zaleplon",
        "slug": "zaleplon"
      },
      {
        "id": 183,
        "title": "Zolpidem",
        "slug": "zolpidem"
      },
      {
        "id": 215,
        "title": "Ibotenic acid",
        "slug": "ibotenic-acid"
      },
      {
        "id": 409,
        "title": "Salvia",
        "slug": "salvia"
      }
    ],
    "markdown": "# Gaboxadol · #242\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zopiclone · #176\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zaleplon · #179\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zolpidem · #183\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Ibotenic acid · #215\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Salvia · #409\n\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"other dissociatives\"\n+      \"other dissociatives\",\n+      \"A-typical Hallucinogen\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-210204-b30f4dee",
    "createdAt": "2025-10-16T21:02:04.651Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 23:02:01"
    },
    "articles": [
      {
        "id": 242,
        "title": "Gaboxadol",
        "slug": "gaboxadol"
      },
      {
        "id": 176,
        "title": "Zopiclone",
        "slug": "zopiclone"
      },
      {
        "id": 179,
        "title": "Zaleplon",
        "slug": "zaleplon"
      },
      {
        "id": 183,
        "title": "Zolpidem",
        "slug": "zolpidem"
      },
      {
        "id": 409,
        "title": "Salvia",
        "slug": "salvia"
      }
    ],
    "markdown": "# Gaboxadol · #242\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zopiclone · #176\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zaleplon · #179\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zolpidem · #183\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Salvia · #409\n\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"other dissociatives\"\n+      \"other dissociatives\",\n+      \"A-typical Hallucinogen\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-210000-f6e22140",
    "createdAt": "2025-10-16T21:00:00.495Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 22:59:57"
    },
    "articles": [
      {
        "id": 176,
        "title": "Zopiclone",
        "slug": "zopiclone"
      },
      {
        "id": 179,
        "title": "Zaleplon",
        "slug": "zaleplon"
      },
      {
        "id": 183,
        "title": "Zolpidem",
        "slug": "zolpidem"
      },
      {
        "id": 409,
        "title": "Salvia",
        "slug": "salvia"
      }
    ],
    "markdown": "# Zopiclone · #176\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zaleplon · #179\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zolpidem · #183\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Salvia · #409\n\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"other dissociatives\"\n+      \"other dissociatives\",\n+      \"A-typical Hallucinogen\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-205923-297a11ac",
    "createdAt": "2025-10-16T20:59:23.332Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 22:59:20"
    },
    "articles": [
      {
        "id": 176,
        "title": "Zopiclone",
        "slug": "zopiclone"
      },
      {
        "id": 179,
        "title": "Zaleplon",
        "slug": "zaleplon"
      },
      {
        "id": 183,
        "title": "Zolpidem",
        "slug": "zolpidem"
      }
    ],
    "markdown": "# Zopiclone · #176\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zaleplon · #179\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zolpidem · #183\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-205842-8929e224",
    "createdAt": "2025-10-16T20:58:42.976Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 22:58:39"
    },
    "articles": [
      {
        "id": 176,
        "title": "Zopiclone",
        "slug": "zopiclone"
      },
      {
        "id": 183,
        "title": "Zolpidem",
        "slug": "zolpidem"
      }
    ],
    "markdown": "# Zopiclone · #176\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zolpidem · #183\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-205804-77914f41",
    "createdAt": "2025-10-16T20:58:04.237Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 22:58:00"
    },
    "articles": [
      {
        "id": 176,
        "title": "Zopiclone",
        "slug": "zopiclone"
      }
    ],
    "markdown": "# Zopiclone · #176\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-204349-778df3a1",
    "createdAt": "2025-10-16T20:43:49.406Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 22:43:45"
    },
    "articles": [
      {
        "id": 59,
        "title": "Mescaline",
        "slug": "mescaline"
      },
      {
        "id": 60,
        "title": "5-MeO-DMT",
        "slug": "5-meo-dmt"
      },
      {
        "id": 73,
        "title": "4-HO-MET",
        "slug": "4-ho-met"
      },
      {
        "id": 79,
        "title": "EA-3167",
        "slug": "ea-3167"
      },
      {
        "id": 82,
        "title": "25I-NBOMe",
        "slug": "25i-nbome"
      },
      {
        "id": 102,
        "title": "4-AcO-DMT",
        "slug": "4-aco-dmt"
      },
      {
        "id": 106,
        "title": "Canket",
        "slug": "canket"
      },
      {
        "id": 107,
        "title": "FXE",
        "slug": "fxe"
      },
      {
        "id": 270,
        "title": "MAL",
        "slug": "mal"
      },
      {
        "id": 514,
        "title": "2C-BZ",
        "slug": "2c-bz"
      },
      {
        "id": 139,
        "title": "DOM",
        "slug": "dom"
      },
      {
        "id": 280,
        "title": "DOB",
        "slug": "dob"
      },
      {
        "id": 158,
        "title": "PMA",
        "slug": "pma"
      },
      {
        "id": 181,
        "title": "DiPT",
        "slug": "dipt"
      },
      {
        "id": 189,
        "title": "DXM Polistirex",
        "slug": "dxm-polistirex"
      },
      {
        "id": 191,
        "title": "LSD",
        "slug": "lsd"
      },
      {
        "id": 196,
        "title": "Ibogaine",
        "slug": "ibogaine"
      },
      {
        "id": 199,
        "title": "Yopo",
        "slug": "yopo"
      },
      {
        "id": 200,
        "title": "Penis Envy",
        "slug": "penis-envy"
      },
      {
        "id": 205,
        "title": "Bromo-DragonFLY",
        "slug": "bromo-dragonfly"
      },
      {
        "id": 206,
        "title": "Kratom",
        "slug": "kratom"
      },
      {
        "id": 201,
        "title": "Amanita Muscaria",
        "slug": "amanita-muscaria"
      },
      {
        "id": 215,
        "title": "Ibotenic acid",
        "slug": "ibotenic-acid"
      },
      {
        "id": 222,
        "title": "DOET",
        "slug": "doet"
      },
      {
        "id": 80,
        "title": "3-Quinuclidinyl benzilate",
        "slug": "3-quinuclidinyl-benzilate"
      },
      {
        "id": 346,
        "title": "Tilmetamine",
        "slug": "tilmetamine"
      },
      {
        "id": 239,
        "title": "2C-N",
        "slug": "2c-n"
      },
      {
        "id": 515,
        "title": "25T-2-NBOMe",
        "slug": "25t-2-nbome"
      },
      {
        "id": 263,
        "title": "DOC",
        "slug": "doc"
      },
      {
        "id": 266,
        "title": "TMA",
        "slug": "tma"
      },
      {
        "id": 264,
        "title": "2C-F",
        "slug": "2c-f"
      },
      {
        "id": 351,
        "title": "2-Chloroephenidine",
        "slug": "2-chloroephenidine"
      },
      {
        "id": 368,
        "title": "3,4-MD-PCP",
        "slug": "3-4-md-pcp"
      },
      {
        "id": 49,
        "title": "ALEPH",
        "slug": "aleph"
      },
      {
        "id": 268,
        "title": "ALEPH-2",
        "slug": "aleph-2"
      },
      {
        "id": 138,
        "title": "AMT",
        "slug": "amt"
      },
      {
        "id": 273,
        "title": "2C-P",
        "slug": "2c-p"
      },
      {
        "id": 276,
        "title": "3-HO-PCP",
        "slug": "3-ho-pcp"
      },
      {
        "id": 281,
        "title": "2C-EF",
        "slug": "2c-ef"
      },
      {
        "id": 285,
        "title": "DMT",
        "slug": "dmt"
      },
      {
        "id": 289,
        "title": "O-PCE",
        "slug": "o-pce"
      },
      {
        "id": 290,
        "title": "DMXE",
        "slug": "dmxe"
      },
      {
        "id": 257,
        "title": "DOEF",
        "slug": "doef"
      },
      {
        "id": 292,
        "title": "25CN-NBOH",
        "slug": "25cn-nboh"
      },
      {
        "id": 293,
        "title": "HXE",
        "slug": "hxe"
      },
      {
        "id": 295,
        "title": "2C-D",
        "slug": "2c-d"
      },
      {
        "id": 311,
        "title": "Cannabis",
        "slug": "cannabis"
      },
      {
        "id": 156,
        "title": "4-Methylthioamphetamine",
        "slug": "4-methylthioamphetamine"
      },
      {
        "id": 321,
        "title": "2C-C",
        "slug": "2c-c"
      },
      {
        "id": 326,
        "title": "DPT",
        "slug": "dpt"
      },
      {
        "id": 329,
        "title": "4-HO-PiPT",
        "slug": "4-ho-pipt"
      },
      {
        "id": 508,
        "title": "4-MeO-MiPT",
        "slug": "4-meo-mipt"
      },
      {
        "id": 338,
        "title": "4-HO-McPT",
        "slug": "4-ho-mcpt"
      },
      {
        "id": 392,
        "title": "2C-T-21",
        "slug": "2c-t-21"
      },
      {
        "id": 182,
        "title": "Sernyl",
        "slug": "sernyl"
      },
      {
        "id": 44,
        "title": "Dextromethorphan",
        "slug": "dextromethorphan"
      },
      {
        "id": 62,
        "title": "MDA",
        "slug": "mda"
      },
      {
        "id": 353,
        "title": "Ephenidine",
        "slug": "ephenidine"
      },
      {
        "id": 359,
        "title": "3-HO-PCE",
        "slug": "3-ho-pce"
      },
      {
        "id": 371,
        "title": "5-MeO-DPT",
        "slug": "5-meo-dpt"
      },
      {
        "id": 375,
        "title": "1B-LSD",
        "slug": "1b-lsd"
      },
      {
        "id": 401,
        "title": "2C-iP",
        "slug": "2c-ip"
      },
      {
        "id": 409,
        "title": "Salvia",
        "slug": "salvia"
      },
      {
        "id": 412,
        "title": "AL-LAD",
        "slug": "al-lad"
      },
      {
        "id": 425,
        "title": "5-MeO-DiBF",
        "slug": "5-meo-dibf"
      },
      {
        "id": 460,
        "title": "Scopolamine",
        "slug": "scopolamine"
      },
      {
        "id": 485,
        "title": "LSZ",
        "slug": "lsz"
      },
      {
        "id": 424,
        "title": "2-Me-DMT",
        "slug": "2-me-dmt"
      },
      {
        "id": 507,
        "title": "25P-NBOMe",
        "slug": "25p-nbome"
      },
      {
        "id": 518,
        "title": "2C-T-4-NBOMe",
        "slug": "2c-t-4-nbome"
      },
      {
        "id": 519,
        "title": "2C-T-7-NBOMe",
        "slug": "2c-t-7-nbome"
      },
      {
        "id": 531,
        "title": "25H-NBOMe",
        "slug": "25h-nbome"
      },
      {
        "id": 526,
        "title": "25I-NBMD",
        "slug": "25i-nbmd"
      },
      {
        "id": 528,
        "title": "25I-NBF",
        "slug": "25i-nbf"
      },
      {
        "id": 529,
        "title": "25I-NBOH",
        "slug": "25i-nboh"
      },
      {
        "id": 534,
        "title": "25C-NB3OMe",
        "slug": "25c-nb3ome"
      },
      {
        "id": 538,
        "title": "2-MeO-Ketamine",
        "slug": "2-meo-ketamine"
      },
      {
        "id": 539,
        "title": "2-MeO-DMT",
        "slug": "2-meo-dmt"
      },
      {
        "id": 540,
        "title": "2C-T-7",
        "slug": "2c-t-7"
      },
      {
        "id": 543,
        "title": "2C-B-FLY-NBOMe",
        "slug": "2c-b-fly-nbome"
      },
      {
        "id": 552,
        "title": "DCK",
        "slug": "dck"
      },
      {
        "id": 560,
        "title": "2-TFMXP",
        "slug": "2-tfmxp"
      },
      {
        "id": 570,
        "title": "4F-MDMB-BINACA",
        "slug": "4f-mdmb-binaca"
      },
      {
        "id": 583,
        "title": "AM-694",
        "slug": "am-694"
      },
      {
        "id": 584,
        "title": "ADBICA",
        "slug": "adbica"
      },
      {
        "id": 589,
        "title": "AMB-CHMICA",
        "slug": "amb-chmica"
      },
      {
        "id": 590,
        "title": "AMB-FUBINACA",
        "slug": "amb-fubinaca"
      },
      {
        "id": 594,
        "title": "CBNA",
        "slug": "cbna"
      },
      {
        "id": 597,
        "title": "Bufotenin",
        "slug": "bufotenin"
      },
      {
        "id": 599,
        "title": "Atropine",
        "slug": "atropine"
      },
      {
        "id": 600,
        "title": "AM-1248",
        "slug": "am-1248"
      },
      {
        "id": 605,
        "title": "25T-NBOMe",
        "slug": "25t-nbome"
      },
      {
        "id": 607,
        "title": "ADB-PINACA",
        "slug": "adb-pinaca"
      },
      {
        "id": 608,
        "title": "ADB-PINACA isomer 2",
        "slug": "adb-pinaca-isomer-2"
      },
      {
        "id": 609,
        "title": "AM-2201",
        "slug": "am-2201"
      },
      {
        "id": 611,
        "title": "BDCK",
        "slug": "bdck"
      },
      {
        "id": 616,
        "title": "AKB-57",
        "slug": "akb-57"
      },
      {
        "id": 622,
        "title": "4-MXP",
        "slug": "4-mxp"
      }
    ],
    "markdown": "# Mescaline · #59\n\n-      \"a-typical hallucinogen\",\n\n# 5-MeO-DMT · #60\n\n-      \"a-typical hallucinogen\",\n\n# 4-HO-MET · #73\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# EA-3167 · #79\n\n-      \"a-typical hallucinogen\",\n\n# 25I-NBOMe · #82\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 4-AcO-DMT · #102\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# Canket · #106\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# FXE · #107\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# MAL · #270\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2C-BZ · #514\n\n-      \"a-typical hallucinogen\",\n\n# DOM · #139\n\n-      \"a-typical hallucinogen\",\n\n# DOB · #280\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# PMA · #158\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# DiPT · #181\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# DXM Polistirex · #189\n\n-      \"a-typical hallucinogen\",\n\n# LSD · #191\n\n-      \"a-typical hallucinogen\",\n\n# Ibogaine · #196\n\n-      \"a-typical hallucinogen\",\n\n# Yopo · #199\n\n-      \"a-typical hallucinogen\",\n\n# Penis Envy · #200\n\n-      \"a-typical hallucinogen\",\n\n# Bromo-DragonFLY · #205\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# Kratom · #206\n\n-      \"a-typical hallucinogen\",\n\n# Amanita Muscaria · #201\n\n-      \"a-typical hallucinogen\",\n\n# Ibotenic acid · #215\n\n-      \"gabaergic\",\n-      \"A-typical hallucinogen\"\n+      \"gabaergic\"\n\n# DOET · #222\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 3-Quinuclidinyl benzilate · #80\n\n-      \"a-typical hallucinogen\",\n\n# Tilmetamine · #346\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2C-N · #239\n\n-      \"a-typical hallucinogen\",\n\n# 25T-2-NBOMe · #515\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# DOC · #263\n\n-      \"stimulant\",\n-      \"a-typical hallucinogen\"\n+      \"stimulant\"\n\n# TMA · #266\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2C-F · #264\n\n-      \"a-typical hallucinogen\",\n\n# 2-Chloroephenidine · #351\n\n-      \"a-typical hallucinogen\",\n\n# 3,4-MD-PCP · #368\n\n-      \"a-typical hallucinogen\",\n\n# ALEPH · #49\n\n-      \"stimulant\",\n-      \"a-typical hallucinogen\"\n+      \"stimulant\"\n\n# ALEPH-2 · #268\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# AMT · #138\n\n-      \"a-typical hallucinogen\",\n\n# 2C-P · #273\n\n-      \"a-typical hallucinogen\",\n\n# 3-HO-PCP · #276\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2C-EF · #281\n\n-      \"a-typical hallucinogen\",\n\n# DMT · #285\n\n-      \"a-typical hallucinogen\",\n\n# O-PCE · #289\n\n-      \"habit-forming\",\n-      \"a-typical hallucinogen\"\n+      \"habit-forming\"\n\n# DMXE · #290\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# DOEF · #257\n\n-      \"a-typical hallucinogen\",\n\n# 25CN-NBOH · #292\n\n-      \"a-typical hallucinogen\",\n\n# HXE · #293\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2C-D · #295\n\n-      \"a-typical hallucinogen\",\n\n# Cannabis · #311\n\n-      \"habit-forming\",\n-      \"a-typical hallucinogen\"\n+      \"habit-forming\"\n\n# 4-Methylthioamphetamine · #156\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2C-C · #321\n\n-      \"a-typical hallucinogen\",\n\n# DPT · #326\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 4-HO-PiPT · #329\n\n-      \"a-typical hallucinogen\",\n\n# 4-MeO-MiPT · #508\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 4-HO-McPT · #338\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2C-T-21 · #392\n\n-      \"a-typical hallucinogen\",\n\n# Sernyl · #182\n\n-      \"a-typical hallucinogen\",\n\n# Dextromethorphan · #44\n\n-      \"a-typical hallucinogen\",\n\n# MDA · #62\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# Ephenidine · #353\n\n-      \"a-typical hallucinogen\",\n\n# 3-HO-PCE · #359\n\n-      \"a-typical hallucinogen\",\n\n# 5-MeO-DPT · #371\n\n-      \"a-typical hallucinogen\",\n\n# 1B-LSD · #375\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2C-iP · #401\n\n-      \"a-typical hallucinogen\",\n\n# Salvia · #409\n\n-      \"A-typical hallucinogen\",\n\n# AL-LAD · #412\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 5-MeO-DiBF · #425\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# Scopolamine · #460\n\n-      \"deliriant\",\n-      \"a-typical hallucinogen\"\n+      \"deliriant\"\n\n# LSZ · #485\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2-Me-DMT · #424\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 25P-NBOMe · #507\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2C-T-4-NBOMe · #518\n\n-      \"a-typical hallucinogen\",\n\n# 2C-T-7-NBOMe · #519\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 25H-NBOMe · #531\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 25I-NBMD · #526\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 25I-NBF · #528\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 25I-NBOH · #529\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 25C-NB3OMe · #534\n\n-      \"a-typical hallucinogen\",\n\n# 2-MeO-Ketamine · #538\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2-MeO-DMT · #539\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2C-T-7 · #540\n\n-      \"a-typical hallucinogen\",\n\n# 2C-B-FLY-NBOMe · #543\n\n-      \"a-typical hallucinogen\",\n\n# DCK · #552\n\n-      \"a-typical hallucinogen\",\n\n# 2-TFMXP · #560\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 4F-MDMB-BINACA · #570\n\n-      \"habit-forming\",\n-      \"a-typical hallucinogen\"\n+      \"habit-forming\"\n\n# AM-694 · #583\n\n-      \"a-typical hallucinogen\",\n\n# ADBICA · #584\n\n-      \"depressant\",\n-      \"a-typical hallucinogen\"\n+      \"depressant\"\n\n# AMB-CHMICA · #589\n\n-      \"a-typical hallucinogen\",\n\n# AMB-FUBINACA · #590\n\n-      \"a-typical hallucinogen\",\n\n# CBNA · #594\n\n-      \"nootropic\",\n-      \"a-typical hallucinogen\"\n+      \"nootropic\"\n\n# Bufotenin · #597\n\n-      \"a-typical hallucinogen\",\n\n# Atropine · #599\n\n-      \"deliriant\",\n-      \"a-typical hallucinogen\"\n+      \"deliriant\"\n\n# AM-1248 · #600\n\n-      \"a-typical hallucinogen\",\n\n# 25T-NBOMe · #605\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# ADB-PINACA · #607\n\n-      \"habit-forming\",\n-      \"a-typical hallucinogen\"\n+      \"habit-forming\"\n\n# ADB-PINACA isomer 2 · #608\n\n-      \"a-typical hallucinogen\",\n\n# AM-2201 · #609\n\n-      \"a-typical hallucinogen\",\n\n# BDCK · #611\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# AKB-57 · #616\n\n-      \"a-typical hallucinogen\",\n\n# 4-MXP · #622\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-191133-9b6f5ac8",
    "createdAt": "2025-10-16T19:11:33.130Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 21:11:30"
    },
    "articles": [
      {
        "id": 514,
        "title": "2C-BZ",
        "slug": "2c-bz"
      },
      {
        "id": 321,
        "title": "2C-C",
        "slug": "2c-c"
      }
    ],
    "markdown": "# 2C-BZ · #514\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"a-typical hallucinogen\",\n\n# 2C-C · #321\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n-      \"a-typical hallucinogen\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-191042-5c6a6d64",
    "createdAt": "2025-10-16T19:10:42.055Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 21:10:39"
    },
    "articles": [
      {
        "id": 514,
        "title": "2C-BZ",
        "slug": "2c-bz"
      }
    ],
    "markdown": "# 2C-BZ · #514\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"a-typical hallucinogen\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-190938-8a5873a8",
    "createdAt": "2025-10-16T19:09:38.185Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 21:09:35"
    },
    "articles": [],
    "markdown": "No diff details were provided for this commit.",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-083502-09318c26",
    "createdAt": "2025-10-16T08:35:02.514Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 2:35:00 AM"
    },
    "articles": [
      {
        "id": 36,
        "title": "Trazodone",
        "slug": "trazodone"
      },
      {
        "id": 86,
        "title": "Tranylcypromine",
        "slug": "tranylcypromine"
      },
      {
        "id": 144,
        "title": "Phenelzine",
        "slug": "phenelzine"
      },
      {
        "id": 186,
        "title": "Vilazodone",
        "slug": "vilazodone"
      },
      {
        "id": 303,
        "title": "Ondansetron",
        "slug": "ondansetron"
      },
      {
        "id": 302,
        "title": "Moclobemide",
        "slug": "moclobemide"
      },
      {
        "id": 301,
        "title": "Quetiapine",
        "slug": "quetiapine"
      },
      {
        "id": 307,
        "title": "Tianeptine",
        "slug": "tianeptine"
      },
      {
        "id": 374,
        "title": "Lean",
        "slug": "lean"
      },
      {
        "id": 430,
        "title": "Olanzapine",
        "slug": "olanzapine"
      },
      {
        "id": 442,
        "title": "Clobenzorex",
        "slug": "clobenzorex"
      },
      {
        "id": 458,
        "title": "Chlorpheniramine",
        "slug": "chlorpheniramine"
      },
      {
        "id": 530,
        "title": "Ro5-4864",
        "slug": "ro5-4864"
      }
    ],
    "markdown": "# Trazodone · #36\n\n-    \"psychoactive_class\": \"Antidepressant (Serotonin Antagonist and Reuptake Inhibitor, SARI)\",\n+    \"psychoactive_class\": \"Antidepressant\",\n\n# Tranylcypromine · #86\n\n-    \"psychoactive_class\": \"Antidepressant (Monoamine Oxidase Inhibitor, MAOI)\",\n+    \"psychoactive_class\": \"Antidepressant\",\n\n# Phenelzine · #144\n\n-    \"psychoactive_class\": \"Antidepressant (Monoamine Oxidase Inhibitor, MAOI)\",\n+    \"psychoactive_class\": \"Antidepressant\",\n\n# Vilazodone · #186\n\n-    \"psychoactive_class\": \"Antidepressant (Selective Serotonin Reuptake Inhibitor and 5-HT1A receptor partial agonist)\",\n+    \"psychoactive_class\": \"Antidepressant\",\n\n# Ondansetron · #303\n\n-    \"psychoactive_class\": \"Antiemetic (not psychoactive in the traditional sense, but acts on the central nervous system to prevent nausea/vomiting)\",\n+    \"psychoactive_class\": \"Antiemetic\",\n\n# Moclobemide · #302\n\n-    \"psychoactive_class\": \"Antidepressant (Reversible MAO-A inhibitor)\",\n+    \"psychoactive_class\": \"Antidepressant\",\n\n# Quetiapine · #301\n\n-    \"psychoactive_class\": \"Atypical antipsychotic\",\n+    \"psychoactive_class\": \"Antipsychotic (atypical)\",\n\n# Tianeptine · #307\n\n-    \"psychoactive_class\": \"Full μ-opioid receptor agonist; atypical antidepressant\",\n+    \"psychoactive_class\": \"Full μ-opioid receptor agonist; Antidepressant (atypical)\",\n\n# Lean · #374\n\n-    \"psychoactive_class\": \"Opioid depressant; antihistamine sedative\",\n+    \"psychoactive_class\": \"Opioid depressant; Antihistamine; Sedative\",\n\n# Olanzapine · #430\n\n-    \"psychoactive_class\": \"Atypical antipsychotic (multi-receptor antagonist)\",\n+    \"psychoactive_class\": \"Antipsychotic (atypical)\",\n\n# Clobenzorex · #442\n\n-    \"psychoactive_class\": \"Catecholaminergic stimulant; prodrug that yields d-amphetamine (~15 % conversion)\",\n+    \"psychoactive_class\": \"Stimulant; prodrug that yields d-amphetamine (~15 % conversion)\",\n\n# Chlorpheniramine · #458\n\n-    \"psychoactive_class\": \"Antihistamine (H1 receptor antagonist)\",\n+    \"psychoactive_class\": \"Antihistamine\",\n\n# Ro5-4864 · #530\n\n-    \"psychoactive_class\": \"atypical benzodiazepine; TSPO (18 kDa translocator protein) agonist with weak or absent classical GABA_A activity\",\n+    \"psychoactive_class\": \"Benzodiazepine (atypical); TSPO (18 kDa translocator protein) agonist with weak or absent classical GABA_A activity\",",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251014-233456-d6536e79",
    "createdAt": "2025-10-14T23:34:56.256Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/14/2025, 5:34:54 PM"
    },
    "articles": [
      {
        "id": 294,
        "title": "Bromantane",
        "slug": "bromantane"
      }
    ],
    "markdown": "### Bromantane · #294\n\n- `drug_info.psychoactive_class`: \"Stimulant actoprotector; anxiolytic nootropic\" → \"Stimulant actoprotector; anxiolytic; nootropic\"",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251014-233158-373c6f71",
    "createdAt": "2025-10-14T23:31:58.069Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/14/2025, 5:31:55 PM"
    },
    "articles": [
      {
        "id": 152,
        "title": "Dimenhydrinate",
        "slug": "dimenhydrinate"
      },
      {
        "id": 396,
        "title": "Propranolol",
        "slug": "propranolol"
      },
      {
        "id": 417,
        "title": "Avizafone",
        "slug": "avizafone"
      }
    ],
    "markdown": "### Dimenhydrinate · #152\n\n- `drug_info.psychoactive_class`: \"Deliriant (anticholinergic); Antihistamine; Anti-emetic\" → \"Deliriant; Antihistamine; Anti-emetic\"\n\n### Propranolol · #396\n\n- `drug_info.psychoactive_class`: updated long text (98 characters; starts \"Not typically classified as psychoactive; Antihypertensive; antiarrhy...\") → text (\"Not typically classified as psychoactive; Antihypertensive; antiarrhythmic; anxiolytic\")\n\n### Avizafone · #417\n\n- `drug_info.psychoactive_class`: \"Sedative-hypnotic; anxiolytic (benzodiazepine)\" → \"Sedative-hypnotic; anxiolytic\"",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251013-212828-39bd2cd6",
    "createdAt": "2025-10-13T21:28:28.668Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 13/10/2025, 23:28:26"
    },
    "articles": [
      {
        "id": 595,
        "title": "1cP-MiPLA",
        "slug": "1cp-mipla"
      }
    ],
    "markdown": "### 1cP-MiPLA · #595\n\n- `drug_info.dosages.routes_of_administration[0].dose_ranges.heavy`: \"300 µg +\" → \"300 µg +\"\n- `drug_info.dosages.routes_of_administration[1].dose_ranges.heavy`: \"250 µg +\" → \"250 µg +\"\n- `drug_info.categories[1]`: \"a-typical hallucinogen\" → \"research-chemical\"\n- `drug_info.categories[2]`: removed text (\"research-chemical\")",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251013-212356-370466a5",
    "createdAt": "2025-10-13T21:23:56.596Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 13/10/2025, 23:23:53"
    },
    "articles": [],
    "markdown": "No changelog details were provided for this commit.",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251013-210154-43d82145",
    "createdAt": "2025-10-13T21:01:54.147Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/13/2025, 3:01:52 PM"
    },
    "articles": [
      {
        "id": 33,
        "title": "3-MeO-PCP",
        "slug": "3-meo-pcp"
      }
    ],
    "markdown": "### 3-MeO-PCP · #33\n\n- `drug_info.alternative_name`: added text (\"3-Methoxyphencyclidine\")",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251012-120815-ffa8a8d5",
    "createdAt": "2025-10-12T12:08:15.759Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/12/2025, 6:08:14 AM"
    },
    "articles": [
      {
        "id": 510,
        "title": "3-Cl-PCP",
        "slug": "3-cl-pcp"
      }
    ],
    "markdown": "### 3-Cl-PCP · #510\n\n- `drug_info.categories[2]`: removed (was `a-typical hallucinogen`)"
  },
  {
    "id": "20251012-120542-f6e605f4",
    "createdAt": "2025-10-12T12:05:42.088Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/12/2025, 6:05:40 AM"
    },
    "articles": [
      {
        "id": 389,
        "title": "3-MeO-PCMo",
        "slug": "3-meo-pcmo"
      }
    ],
    "markdown": "### 3-MeO-PCMo · #389\n\n- `content`: `# 3-MeO-PCMo\n## Arylcyclohexylamine (morpholine subgroup) | Dissociative NMDA-receptor antagonist with mild monoaminergic activity\n      \nPotency is roughly 1/10 of 3-MeO-PCP but still active in double-digit milligram range; weigh on 0.001 g scale and perform 1-3 mg allergy test. Virtually no clinical history: all human data are anecdotal. Reports of confusion, mania and prolonged delirium at heavy doses. Limited reagent-test data; use full panel to rule out NBOMe / opioid adulterants. Crystal often hygroscopic – store in airtight, light-protected container with desiccant.` → ``"
  }
]